PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Mutch, WAC; Ellis, MJ; Ryner, LN; Graham, MR; Dufault, B; Gregson, B; Hall, T; Bunge, M; Essig, M; Fisher, JA; Duffin, J; Mikulis, DJ				Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; Graham, M. Ruth; Dufault, Brenden; Gregson, Brian; Hall, Thomas; Bunge, Martin; Essig, Marco; Fisher, Joseph A.; Duffin, James; Mikulis, David J.		Canada North Concussion Network; Univ Hlth Network Cerebrovasc	Brain magnetic resonance imaging CO2 stress testing in adolescent postconcussion syndrome	JOURNAL OF NEUROSURGERY			English	Article						sports-related concussion; adolescent; postconcussion syndrome; magnetic resonance imaging; blood oxygen level-dependent imaging; trauma	CEREBRAL-BLOOD-FLOW; SPORTS-RELATED CONCUSSION; LEVEL-DEPENDENT MRI; CEREBROVASCULAR REACTIVITY; TRANSCRANIAL DOPPLER; WHITE-MATTER; BASE-LINE; DIFFUSION; RECOVERY; INJURY	OBJECTIVE A neuroimaging assessment tool to visualize global and regional impairments in cerebral blood flow (CBF) and cerebrovascular responsiveness in individual patients with concussion remains elusive. Here the authors summarize the safety, feasibility, and results of brain CO, stress testing in adolescents with postconcussion syndrome (PCS) and healthy controls. METHODS This study was approved by the Biomedical Research Ethics Board at the University of Manitoba. Fifteen adolescents with PCS and 17 healthy control subjects underwent anatomical MRI, pseudo-continuous arterial spin labeling MRI, and brain stress testing using controlled CO, challenge and blood oxygen level dependent (BOLD) MRI. Post hoc processing was performed using statistical parametric mapping to determine voxel-by-voxel regional resting CBF and cerebrovascular responsiveness of the brain to the CO, stimulus (increase in BOLD signal) or the inverse (decrease in BOLD signal). Receiver operating characteristic (ROC) curves were generated to compare voxel counts categorized by control (0) or PCS (1). RESULTS Studies were well tolerated without any serious adverse events. Anatomical MRI was normal in all study participants. No differences in CO, stimuli were seen between the 2 participant groups. No group differences in global mean CBF were detected between PCS patients and healthy controls. Patient-specific differences in mean regional CBF and CO, BOLD responsiveness were observed in all PCS patients. The ROC curve analysis for brain regions manifesting a voxel response greater than and less than the control atlas (that is, abnormal voxel counts) produced an area under the curve of 0.87 (p < 0.0001) and 0.80 (p = 0.0003), respectively, consistent with a clinically useful predictive model. CONCLUSIONS Adolescent PCS is associated with patient-specific abnormalities in regional mean CBF and BOLD cerebrovascular responsiveness that occur in the setting of normal global resting CBF. Future prospective studies are warranted to examine the utility of brain MRI CO, stress testing in the longitudinal assessment of acute sports-related concussion and PCS.	[Mutch, W. Alan C.; Graham, M. Ruth; Gregson, Brian] Dept Anesthesia & Perioperat Med, 2nd Fl Harry Medovy House,671 William Ave, Winnipeg, MB R3E 0Z2, Canada; [Ellis, Michael J.] Dept Surg, Winnipeg, MB, Canada; [Ellis, Michael J.] Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Ryner, Lawrence N.; Bunge, Martin; Essig, Marco] Dept Diagnost Imaging, Winnipeg, MB, Canada; [Ellis, Michael J.] Sect Neurosurg, Winnipeg, MB, Canada; [Mutch, W. Alan C.; Ryner, Lawrence N.; Essig, Marco] Hlth Sci Ctr, Winnipeg, MB, Canada; [Ellis, Michael J.] Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.] Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada; [Dufault, Brenden] Community Hlth Sci, Winnipeg, MB, Canada; [Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; Graham, M. Ruth; Dufault, Brenden; Gregson, Brian; Hall, Thomas; Bunge, Martin; Essig, Marco] Univ Manitoba, Winnipeg, MB, Canada; [Fisher, Joseph A.; Duffin, James] Dept Anesthesia, Toronto, ON, Canada; [Fisher, Joseph A.; Duffin, James] Dept Physiol, Toronto, ON, Canada; [Mikulis, David J.] Dept Med Imaging, Toronto, ON, Canada; [Fisher, Joseph A.; Duffin, James; Mikulis, David J.] Univ Toronto, Toronto, ON M5S 1A1, Canada	Mutch, WAC (corresponding author), Dept Anesthesia & Perioperat Med, 2nd Fl Harry Medovy House,671 William Ave, Winnipeg, MB R3E 0Z2, Canada.	wacmutch@shaw.ca	Mikulis, David J/H-5167-2019		Health Sciences Center Foundation; Manitoba Health Research Council, Winnipeg, Manitoba, Canada	All phases of this study were supported by a grant from the Health Sciences Center Foundation and the Manitoba Health Research Council, Winnipeg, Manitoba, Canada.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bewick V, 2005, CRIT CARE, V9, P112, DOI 10.1186/cc3045; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Conklin J, 2011, NEUROLOGY, V77, P431, DOI 10.1212/WNL.0b013e318227b1e7; Conklin J, 2010, STROKE, V41, P1610, DOI 10.1161/STROKEAHA.110.579540; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DAHL A, 1995, STROKE, V26, P2302, DOI 10.1161/01.STR.26.12.2302; Donahue MJ, 2012, STROKE, V43, P903, DOI 10.1161/STROKEAHA.111.635995; Elbin RJ, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0320-7; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P241, DOI 10.3171/2015.1.PEDS14510; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; ELLIS MJ, 2014, CURR RES CONCUSSION, V1, P33; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Fierstra J, 2013, J PHYSIOL-LONDON, V591, P5809, DOI 10.1113/jphysiol.2013.259150; Gardner AJ, 2015, BRIT J SPORT MED, V49, P1050, DOI 10.1136/bjsports-2014-093901; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grossmann WM, 2000, CEREBROVASC DIS, V10, P65, DOI 10.1159/000016027; Han JS, 2008, NAT CLIN PRACT NEURO, V4, P628, DOI 10.1038/ncpneuro0918; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kassner A, 2010, J MAGN RESON IMAGING, V31, P298, DOI 10.1002/jmri.22044; Kim SG, 2012, J CEREBR BLOOD F MET, V32, P1188, DOI 10.1038/jcbfm.2012.23; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mandell DM, 2011, AM J NEURORADIOL, V32, P721, DOI 10.3174/ajnr.A2365; Mandell DM, 2008, STROKE, V39, P2021, DOI 10.1161/STROKEAHA.107.506709; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mikulis DJ, 2005, J NEUROSURG, V103, P347, DOI 10.3171/jns.2005.103.2.0347; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Mutch WAC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057881; Mutch WAC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047443; Regan RE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070751; Saito H, 2011, NEUROL MED-CHIR, V51, P479, DOI 10.2176/nmc.51.479; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Slessarev M, 2007, J PHYSIOL-LONDON, V581, P1207, DOI 10.1113/jphysiol.2007.129395; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sobczyk O, 2014, NEUROIMAGE, V92, P56, DOI 10.1016/j.neuroimage.2014.01.051; Sobczyk O, 2015, J CEREBR BLOOD F MET, V35, P213, DOI 10.1038/jcbfm.2014.184; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484; Tormenti M, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12282; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491	55	44	44	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2016	125	3					648	660		10.3171/2015.6.JNS15972			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DT8YS	WOS:000381782300016	26684777	Bronze			2021-06-18	
J	Haider, HA; Esteller, R; Hahn, CD; Westover, MB; Halford, JJ; Lee, JW; Shafi, MM; Gaspard, N; Herman, ST; Gerard, EE; Hirsch, LJ; Ehrenberg, JA; LaRoche, SM				Haider, Hiba A.; Esteller, Rosana; Hahn, Cecil D.; Westover, M. Brandon; Halford, Jonathan J.; Lee, Jong W.; Shafi, Mouhsin M.; Gaspard, Nicolas; Herman, Susan T.; Gerard, Elizabeth E.; Hirsch, Lawrence J.; Ehrenberg, Joshua A.; LaRoche, Suzette M.		Critical Care EEG Monitoring Res	Sensitivity of quantitative EEG for seizure identification in the intensive care unit	NEUROLOGY			English	Article							AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL FUNCTION MONITOR; CRITICALLY-ILL CHILDREN; DENSITY SPECTRAL ARRAY; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; TERMINOLOGY; CRITERIA; ADULTS	Objective: To evaluate the sensitivity of quantitative EEG (QEEG) for electrographic seizure identification in the intensive care unit (ICU). Methods: Six-hour EEG epochs chosen from 15 patients underwent transformation into QEEG displays. Each epoch was reviewed in 3 formats: raw EEG, QEEG + raw, and QEEG-only. Epochs were also analyzed by a proprietary seizure detection algorithm. Nine neurophysiologists reviewed raw EEGs to identify seizures to serve as the gold standard. Nine other neurophysiologists with experience in QEEG evaluated the epochs in QEEG formats, with and without concomitant raw EEG. Sensitivity and false-positive rates (FPRs) for seizure identification were calculated and median review time assessed. Results: Mean sensitivity for seizure identification ranged from 51% to 67% for QEEG-only and 63%-68% for QEEG + raw. FPRs averaged 1/h for QEEG-only and 0.5/h for QEEG + raw. Mean sensitivity of seizure probability software was 26.2%-26.7%, with FPR of 0.07/h. Epochs with the highest sensitivities contained frequent, intermittent seizures. Lower sensitivities were seen with slow-frequency, low-amplitude seizures and epochs with rhythmic or periodic patterns. Median review times were shorter for QEEG (6 minutes) and QEEG + raw analysis (14.5 minutes) vs raw EEG (19 minutes; p = 0.00003). Conclusions: A panel of QEEG trends can be used by experts to shorten EEG review time for seizure identification with reasonable sensitivity and low FPRs. The prevalence of false detections confirms that raw EEG review must be used in conjunction with QEEG. Studies are needed to identify optimal QEEG trend configurations and the utility of QEEG as a screening tool for non-EEG personnel. Classification of evidence review: This study provides Class II evidence that QEEG + raw interpreted by experts identifies seizures in patients in the ICU with a sensitivity of 63%-68% and FPR of 0.5 seizures per hour.	[Haider, Hiba A.; Ehrenberg, Joshua A.; LaRoche, Suzette M.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Esteller, Rosana] Neuropace Inc, Mountain View, CA USA; [Hahn, Cecil D.] Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Westover, M. Brandon] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA; [Halford, Jonathan J.] Med Univ South Carolina, Dept Neurol, Charleston, SC USA; [Lee, Jong W.; Shafi, Mouhsin M.; Herman, Susan T.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Gaspard, Nicolas] Univ Libre Bruxelles, Brussels, Belgium; [Gerard, Elizabeth E.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Hirsch, Lawrence J.] Yale Univ Hosp, New Haven, CT USA	Haider, HA (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.	hiba.arif@emory.edu	Lee, Jongwoo/AAI-3617-2020; Hahn, Cecil/J-3372-2016; Hahn, Cecil D./F-6218-2011	Hahn, Cecil/0000-0002-0887-8761; Hahn, Cecil D./0000-0002-0887-8761; Haider, Hiba/0000-0001-7118-3690; Halford, Jonathan/0000-0003-1681-6744; Hirsch, Lawrence/0000-0002-6333-832X; Wusthoff, Courtney/0000-0002-1882-5567; gerard, elizabeth/0000-0003-3062-8360	NINDS R25 Research Education Training Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS090900] Funding Source: NIH RePORTER	H. Haider: Supported by an NINDS R25 Research Education Training Grant. R. Esteller, C. Hahn, M. Westover, J. Halford, J. Lee, M. Shafi, N. Gaspard, S. Herman, E. Gerard, L. Hirsch, J. Ehrenberg, and S. LaRoche report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.	Abend NS, 2008, EPILEPSIA, V49, P349, DOI 10.1111/j.1528-1167.2007.01425.x; Akman CI, 2011, EPILEPSY RES, V93, P66, DOI 10.1016/j.eplepsyres.2010.10.018; Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Bourez-Swart MD, 2009, CLIN NEUROPHYSIOL, V120, P1916, DOI 10.1016/j.clinph.2009.08.015; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; El-Dib M, 2009, PEDIATR NEUROL, V41, P315, DOI 10.1016/j.pediatrneurol.2009.05.002; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gaspard N, 2014, EPILEPSIA, V55, P1366, DOI 10.1111/epi.12653; Halford JJ, 2015, CLIN NEUROPHYSIOL, V126, P1661, DOI 10.1016/j.clinph.2014.11.008; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P96, DOI 10.1097/WNP.0000000000000165; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Husain AM, 2013, 4 LOND INNSBR C STAT; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; Mazarati AM, 1998, BRAIN RES, V814, P179, DOI 10.1016/S0006-8993(98)01080-4; Moura LMVR, 2014, NEUROLOGY, V83, P56, DOI 10.1212/WNL.0000000000000537; Nitzschke R, 2011, J CLIN MONIT COMPUT, V25, P329, DOI 10.1007/s10877-011-9312-2; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Pensirikul AD, 2013, J CLIN NEUROPHYSIOL, V30, P371, DOI 10.1097/WNP.0b013e31829de01c; Rennie JM, 2004, ARCH DIS CHILD-FETAL, V89, pF37, DOI 10.1136/fn.89.1.F37; Ronner HE, 2009, SEIZURE-EUR J EPILEP, V18, P257, DOI 10.1016/j.seizure.2008.10.010; Shah DK, 2008, PEDIATRICS, V122, P863, DOI 10.1542/peds.2008-1000; Shellhaas RA, 2007, PEDIATRICS, V120, P770, DOI 10.1542/peds.2007-0514; Stewart CP, 2010, NEUROLOGY, V75, P1501, DOI 10.1212/WNL.0b013e3181f9619e; Toet MC, 2002, PEDIATRICS, V109, P772, DOI 10.1542/peds.109.5.772; Topjian AA, 2015, PEDIATR CRIT CARE ME, V16, P461, DOI 10.1097/PCC.0000000000000352; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williamson CA, 2014, NEUROCRIT CARE, V20, P32, DOI 10.1007/s12028-013-9912-4	33	44	44	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 30	2016	87	9					935	944		10.1212/WNL.0000000000003034			10	Clinical Neurology	Neurosciences & Neurology	DW9LJ	WOS:000383980600020	27466474	Green Published			2021-06-18	
J	Helmy, A; Guilfoyle, MR; Carpenter, KLH; Pickard, JD; Menon, DK; Hutchinson, PJ				Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.			Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Chemokines; brain trauma; microglia; inflammation; neurochemistry	ACUTE ISCHEMIC-STROKE; PHASE-II; MACROPHAGE ACTIVATION; HEAD-INJURY; MICE; POLARIZATION; INFLAMMATION; MCP-1; NEUROINFLAMMATION; NEUTRALIZATION	Interleukin-1 receptor antagonist (IL1ra) has demonstrated efficacy in a wide range of animal models of neuronal injury. We have previously published a randomised controlled study of IL1ra in human severe TBI, with concomitant microdialysis and plasma sampling of 42 cytokines and chemokines. In this study, we have used partial least squares discriminant analysis to model the effects of drug administration and time following injury on the cytokine milieu within the injured brain. We demonstrate that treatment with rhIL1ra causes a brain-specific modification of the cytokine and chemokine response to injury, particularly in samples from the first 48 h following injury. The magnitude of this response is dependent on the concentration of IL1ra achieved in the brain extracellular space. Chemokines related to recruitment of macrophages from the plasma compartment (MCP-1) and biasing towards a M1 microglial phenotype (GM-CSF, IL1) are increased in patient samples in the rhIL1ra-treated patients. In control patients, cytokines and chemokines biased to a M2 microglia phenotype (IL4, IL10, MDC) are relatively increased. This pattern of response suggests that a simple classification of IL1ra as an 'anti-inflammatory' cytokine may not be appropriate and highlights the importance of the microglial response to injury.	[Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge Biomed Campus, Cambridge, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge Biomed Campus, Cambridge, England	Helmy, A (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Hutchinson, Peter/0000-0002-2796-1835	joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowships; Royal College of Surgeons of England Research Fellowship; National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); National Institute for Health Research Senior Investigator Awards; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; National Institute for Health Research Brain Repair Centre Collaborative; National Institute for Health Research Professorship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, 79068]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B, G1002277, G0802251, G0001354, G0601025, G9439390, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2006-14-004, NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: AH is supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (G0802251). AH and MRG are supported by Raymond and Beverly Sackler Fellowships. MRG is supported by the Royal College of Surgeons of England Research Fellowship. KLHC is supported by the National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). DKM and JDP are supported by National Institute for Health Research Senior Investigator Awards. PJH is supported by the Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship, the National Institute for Health Research Brain Repair Centre Collaborative and the National Institute for Health Research Professorship. Study Support was provided by the Medical Research Council (grant number G0600986 ID 79068) and the National Institute for Health Research Brain Repair Centre Collaborative.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Babcock AA, 2003, J NEUROSCI, V23, P7922; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Boulesteix AL, 2007, BRIEF BIOINFORM, V8, P32, DOI 10.1093/bib/bb1016; Cagnin A, 2007, NEUROTHERAPEUTICS, V4, P443, DOI 10.1016/j.nurt.2007.04.006; Chu HX, 2015, STROKE, V46, P1929, DOI 10.1161/STROKEAHA.115.009426; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Desforges Nicole M, 2012, Int J Alzheimers Dis, V2012, P345472, DOI 10.1155/2012/345472; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Eugenin EA, 2003, J NEUROCHEM, V85, P1299, DOI 10.1046/j.1471-4159.2003.01775.x; Eyles JL, 2006, NAT CLIN PRACT RHEUM, V2, P500, DOI 10.1038/ncprheum0291; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gliem M, 2012, ANN NEUROL, V71, P743, DOI 10.1002/ana.23529; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; McLoughlin RM, 2003, J CLIN INVEST, V112, P598, DOI 10.1172/JCI200317129; Miro-Mur F, 2015, BRAIN BEHAV IN PRESS; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Noda M, 2011, J BIOL CHEM, V286, P2308, DOI 10.1074/jbc.M110.169839; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schwartz M, 2009, NEUROSCIENCE, V158, P1133, DOI 10.1016/j.neuroscience.2008.12.013; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Singh N, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-1; Smith CJ, 2015, EXPERT OPIN INV DRUG, V24, P623, DOI 10.1517/13543784.2015.1020110; Soki FN, 2014, J BIOL CHEM, V289, P24560, DOI 10.1074/jbc.M114.571620; Stowe AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-33; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Weiclenbusch M, 2012, J INNATE IMMUN, V4, P463, DOI 10.1159/000336717; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	43	44	46	2	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2016	36	8					1434	1448		10.1177/0271678X15620204			15	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	DU3ED	WOS:000382092700010	26661249	Green Published, Bronze			2021-06-18	
J	Tu, TW; Williams, RA; Lescher, JD; Jikaria, N; Turtzo, LC; Frank, JA				Tu, Tsang-Wei; Williams, Rashida A.; Lescher, Jacob D.; Jikaria, Neekita; Turtzo, L. Christine; Frank, Joseph A.			Radiological-Pathological Correlation of Diffusion Tensor and Magnetization Transfer Imaging in a Closed Head Traumatic Brain Injury Model	ANNALS OF NEUROLOGY			English	Article							FINITE-ELEMENT-ANALYSIS; AXONAL INJURY; MULTIPLE-SCLEROSIS; SPINAL-CORD; MOUSE MODEL; RAT-BRAIN; REMYELINATION; DEMYELINATION; ANISOTROPY; DISEASE	Objective: Metrics of diffusion tensor imaging (DTI) and magnetization transfer imaging (MTI) can detect diffuse axonal injury in traumatic brain injury (TBI). The relationship between the changes in these imaging measures and the underlying pathologies is still relatively unknown. This study investigated the radiological-pathological correlation between these imaging techniques and immunohistochemistry using a closed head rat model of TBI. Methods: TBI was performed on female rats followed longitudinally by magnetic resonance imaging (MRI) out to 30 days postinjury, with a subset of animals selected for histopathological analyses. A MRI-based finite element analysis was generated to characterize the pattern of the mechanical insult and estimate the extent of brain injury to direct the pathological correlation with imaging findings. Results: DTI axial diffusivity and fractional anisotropy (FA) were sensitive to axonal integrity, whereas radial diffusivity showed significant correlation to the myelin compactness. FA was correlated with astrogliosis in the gray matter, whereas mean diffusivity was correlated with increased cellularity. Secondary inflammatory responses also partly affected the changes of these DTI metrics. The magnetization transfer ratio (MTR) at 3.5ppm demonstrated a strong correlation with both axon and myelin integrity. Decrease in MTR at 20ppm correlated with the extent of astrogliosis in both gray and white matter. Interpretation: Although conventional T2-weighted MRI did not detect abnormalities following TBI, DTI and MTI afforded complementary insight into the underlying pathologies reflecting varying injury states over time, and thus may substitute for histology to reveal diffusive axonal injury pathologies in vivo. This correlation of MRI and histology furthers understanding of the microscopic pathology underlying DTI and MTI changes in TBI.	[Tu, Tsang-Wei; Williams, Rashida A.; Lescher, Jacob D.; Jikaria, Neekita; Turtzo, L. Christine; Frank, Joseph A.] NIH, Frank Lab, Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA; [Turtzo, L. Christine] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA	Tu, TW (corresponding author), NIH, Radiol & Imaging Sci, Ctr Clin, Bldg 10,RM B1N256,10 Ctr Dr MSC 1074, Bethesda, MD 20892 USA.	tut@cc.nih.gov	Frank, Joseph/W-2021-2019		Department of Defense through the Center for Neuroscience and Regenerative Medicine (Henry M. Jackson Foundation) [300604-8.01-60855, 305500-8.01-60855]; Intramural Research Programs of the NIH Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); CLINICAL CENTER [ZIACL090020] Funding Source: NIH RePORTER	This work was supported by funding from the Department of Defense through the Center for Neuroscience and Regenerative Medicine (Henry M. Jackson Foundation Award 300604-8.01-60855, J.A.F.; 305500-8.01-60855, L.C.T.) and from the Intramural Research Programs of the NIH Clinical Center and National Institute of Biomedical Imaging and Bioengineering.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2010, P NATL ACAD SCI USA, V107, P14472, DOI 10.1073/pnas.1004841107; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Deloire-Grassin MSA, 2000, J NEUROL SCI, V178, P10, DOI 10.1016/S0022-510X(00)00331-2; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Horsfield MA, 2003, J MAGN RESON IMAGING, V17, P389, DOI 10.1002/jmri.10266; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irfanoglu MO, 2008, LECT NOTES COMPUT SC, V5242, P1014, DOI 10.1007/978-3-540-85990-1_122; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lin M, 2016, MAGN RESON MED, V76, P290, DOI 10.1002/mrm.25816; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maikos JT, 2008, J NEUROTRAUM, V25, P795, DOI 10.1089/neu.2007.0423; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCullough LD, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/s13293-014-0015-5; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Tu TW, 2014, J NEUROPATH EXP NEUR, V73, P1152, DOI 10.1097/NEN.0000000000000140; Tu TW, J NEUROTRAU IN PRESS; Turtzo LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126551; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Ulmer JL, 1996, AM J NEURORADIOL, V17, P805; van de Looij Y, 2012, NMR BIOMED, V25, P93, DOI 10.1002/nbm.1721; van der Flier WM, 2002, ANN NEUROL, V52, P62, DOI 10.1002/ana.10244; van Waesberghe JHTM, 1999, ANN NEUROL, V46, P747; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Wintermark M, 2014, AM J NEURORADIOL, V36, pE1; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Zaaraoui W, 2008, MAGN RESON MATER PHY, V21, P357, DOI 10.1007/s10334-008-0141-3; Zhang LY, 2011, J NEUROSCI METH, V198, P93, DOI 10.1016/j.jneumeth.2011.03.024	61	44	44	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUN	2016	79	6					907	920		10.1002/ana.24641			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DN0ST	WOS:000376775400005	27230970	Green Accepted			2021-06-18	
J	Matuszak, JM; McVige, J; McPherson, J; Willer, B; Leddy, J				Matuszak, Jason M.; McVige, Jennifer; McPherson, Jacob; Willer, Barry; Leddy, John			A Practical Concussion Physical Examination Toolbox: Evidence-Based Physical Examination for Concussion	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; mTBI; physical examination	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; VESTIBULAR REHABILITATION; POSTTRAUMATIC-STRESS; KING-DEVICK; HEAD-INJURY; BALANCE; DEPRESSION; DIZZINESS	Context: With heightened awareness of concussion, there is a need to assess and manage the concussed patient in a consistent manner. Unfortunately, concussion physical examination has not been standardized or supported by evidence. Important questions remain about the physical examination. Evidence Acquisition: Review of ClinicalKey, Cochrane, MEDLINE, and PubMed prior to July 2015 was performed using search terms, including concussion, mTBI, physical examination, mental status, cranial nerves, reflexes, cervical, vestibular, and oculomotor. The references of the pertinent articles were reviewed for other relevant sources. Study Design: Clinical review. Level of Evidence: Level 3. Results: The pertinent physical examination elements for concussion include evaluation of cranial nerves, manual muscle testing, and deep tendon reflexes; inspecting the head and neck for trauma or tenderness and cervical range of motion; Spurling maneuver; a static or dynamic balance assessment; screening ocular examination; and a mental status examination that includes orientation, immediate and delayed recall, concentration, mood, affect, insight, and judgment. Other examination elements to consider, based on signs, symptoms, or clinical suspicion, include testing of upper motor neurons, cervical strength and proprioception, coordination, pupillary reactivity, and visual acuity; examination of the jaw, temporomandibular joint, and thoracic spine; fundoscopic evaluation; orthostatic vital signs; assessment of dynamic visual acuity; and screening for depression, anxiety, substance abuse disorders, and preinjury psychiatric difficulties. Conclusion: Various elements of the physical examination, such as screening ocular examination, cervical musculoskeletal examination, static and/or dynamic balance assessment, and mental status examination, appear to have utility for evaluating concussion; however, data on validity are lacking.	[Matuszak, Jason M.] Excelsior Orthopaed, Amherst, NY USA; [McVige, Jennifer] Dent Neurol, Amherst, NY USA; [McPherson, Jacob] Susan Bennett Phys Therapy, North Tonawanda, NY USA; [Willer, Barry; Leddy, John] Univ Buffalo, Jacobs Sch Med, UBMD Orthopaed & Sports Med, Buffalo, NY USA	Matuszak, JM (corresponding author), Excelsior Orthopaed, Amherst, NY USA.; Matuszak, JM (corresponding author), Excelsior Sports Med, Excelsior Orthopaed, 3925 Sheridan Dr, Amherst, NY 14226 USA.	jmatuszak@excelsiorortho.com					Alsalaheen BA, 2012, THESIS; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Anderson NE, 2005, J NEUROL NEUROSUR PS, V76, P545, DOI 10.1136/jnnp.2004.043679; Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BENOIT BG, 1982, CAN J NEUROL SCI, V9, P321, DOI 10.1017/S0317167100044140; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brandt T, 2005, CLIN NEUROPHYSIOL, V116, P406, DOI 10.1016/j.clinph.2004.08.009; Burgio D L, 1992, J Vestib Res, V2, P221; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; CICERONE CM, 1995, PERCEPT PSYCHOPHYS, V57, P761, DOI 10.3758/BF03206792; Contreras R, 2011, BRAIN RES, V1398, P55, DOI 10.1016/j.brainres.2011.05.004; Cooke J, 2009, QJM-INT J MED, V102, P335, DOI 10.1093/qjmed/hcp020; Crutchfield K, 2014, NEUROLOGY S, V82; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Defense Centers of Excellence for Psychological Traumatic Brain Injury, 2012, ASS MAN DIZZ ASS MIL; Department of Veterans Affairs Department of Defense, 2009, MAN CONC MILD TRAUM; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Faraji F, 2011, OTOL NEUROTOL, V32, P654, DOI 10.1097/MAO.0b013e3182117769; Coello AF, 2010, J NEUROSURG, V113, P547, DOI 10.3171/2010.6.JNS091620; Findling O, 2011, GAIT POSTURE, V34, P473, DOI 10.1016/j.gaitpost.2011.06.021; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Foundation ON, 2013, GUID MILD TRAUM BRAI; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Green W, 2010, OPTOMETRY, V81, P129, DOI 10.1016/j.optm.2009.07.015; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jacobson GP, 2011, EAR HEARING, V32, pE1, DOI 10.1097/AUD.0b013e31822802bb; JOHNSON LN, 1991, J FAM PRACTICE, V33, P381; Kamel H, 2011, NEUROLOGY, V77, P1395, DOI 10.1212/WNL.0b013e3182315249; Kanjwal K, 2010, CARDIOL J, V17, P482; Kardon R, 2014, J NEURO-OPHTHALMOL, V34, pS10, DOI 10.1097/WNO.0000000000000162; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Liu HJ, 2012, ACTA OTO-LARYNGOL, V132, P803, DOI 10.3109/00016489.2012.657359; Longridge NS, 2010, OTOL NEUROTOL, V31, P803, DOI 10.1097/MAO.0b013e3181e3deb2; Martin RM, 2008, CURR REV MUSCULOSKE, V1, P1, DOI 10.1007/s12178-007-9000-5; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mulligan I, 2012, J ORTHOP SPORT PHYS, V42, P625, DOI 10.2519/jospt.2012.3798; Naschitz JE, 2007, POSTGRAD MED J, V83, DOI 10.1136/pgmj.2007.058198; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Page P, 2011, INT J SPORTS PHYS TH, V6, P254; Patel P, 2005, INDIAN J NEUROTRAUM, V2, P27, DOI 10.1016/S0973-0508(05)80007-3; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; SELHORST JB, 1985, NEUROSURGERY, V16, P357, DOI 10.1227/00006123-198503000-00013; Shawkat FS, 2000, BRIT J OPHTHALMOL, V84, P175, DOI 10.1136/bjo.84.2.175; Silverberg ND, SCREENING DEPRESSION; Steffen H, 1996, OPHTHALMOLOGY, V103, P1229, DOI 10.1016/S0161-6420(96)30518-6; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Thiagarajan P, 2014, BRAIN INJURY, V28, P930, DOI 10.3109/02699052.2014.888761; Thiagarajan P, 2014, NEUROREHABILITATION, V34, P129, DOI 10.3233/NRE-131025; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; VARTIAINEN E, 1985, INT J PEDIATR OTORHI, V9, P135, DOI 10.1016/S0165-5876(85)80013-6; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	93	44	44	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAY-JUN	2016	8	3					260	269		10.1177/1941738116641394			10	Sport Sciences	Sport Sciences	EG8CM	WOS:000391283300009	27022058	Green Published			2021-06-18	
J	Black, AM; Macpherson, AK; Hagel, BE; Romiti, MA; Palacios-Derflingher, L; Kang, J; Meeuwisse, WH; Emery, CA				Black, Amanda M.; Macpherson, Alison K.; Hagel, Brent E.; Romiti, Maria A.; Palacios-Derflingher, Luz; Kang, Jian; Meeuwisse, Willem H.; Emery, Carolyn A.			Policy change eliminating body checking in non-elite ice hockey leads to a threefold reduction in injury and concussion risk in 11-and 12-year-old players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Hockey; Risk factor	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; ZURICH	Background In ice hockey, body checking is associated with an increased risk of injury. In 2011, provincial policy change disallowed body checking in non-elite Pee Wee (ages 11-12 years) leagues. Objective To compare the risk of injury and concussion between non-elite Pee Wee ice hockey players in leagues where body checking is permitted (2011-12 Alberta, Canada) and leagues where policy change disallowed body checking (2011-12 Ontario, Canada). Method Non-elite Pee Wee players (lower 70%) from Alberta (n=590) and Ontario (n=281) and elite Pee Wee players (upper 30%) from Alberta (n=294) and Ontario (n=166) were recruited to participate in a cohort study. Baseline information, injury and exposure data was collected using validated injury surveillance. Results Based on multiple Poisson regression analyses (adjusted for clustering by team, exposure hours, year of play, history of injury/concussion, level of play, position and body checking attitude), the incidence rate ratio (IRR) associated with policy allowing body checking was 2.97 (95% CI 1.33 to 6.61) for all game injury and 2.83 (95% CI 1.09 to 7.31) for concussion. There were no differences between provinces in concussion [IRR=1.50 (95% CI 0.84 to 2.68)] or injury risk [IRR=1.22 (95% CI 0.69 to 2.16)] in elite levels of play where both provinces allowed body checking. Conclusions The rate of injury and concussion were threefold greater in non-elite Pee Wee ice hockey players in leagues where body checking was permitted. The rate of injury and concussion did not differ between provinces in elite levels, where body checking was allowed.	[Black, Amanda M.; Hagel, Brent E.; Romiti, Maria A.; Palacios-Derflingher, Luz; Kang, Jian; Meeuwisse, Willem H.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada; [Macpherson, Alison K.] York Univ, Sch Kinesiol & Hlth Sci, Fac Hlth, Toronto, ON M3J 2R7, Canada; [Emery, Carolyn A.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Dept Pediat,Cumming Sch Med, Calgary, AB T2N 1N4, Canada; [Hagel, Brent E.; Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Commun Hlth Sci, Cumming Sch Med, Calgary, AB T2N 1N4, Canada	Black, AM (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada.	ablack@ucalgary.ca	Emery, Carolyn/AAI-2761-2020; Black, Amanda/O-7675-2017; Hagel, Brent/AAK-3319-2020	Black, Amanda/0000-0001-5668-9706; 	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Institute for Child and Maternal Health; Max Bell Foundation; Hotchkiss Brain Institute; Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation; CIHR Chair in Child and Youth Health Services and Policy Research; Alberta Innovates [201201160] Funding Source: researchfish	This study was funded by the Canadian Institutes of Health Research (CIHR), Alberta Children's Hospital Institute for Child and Maternal Health and the Max Bell Foundation. AMB is supported by the Hotchkiss Brain Institute Dr T Chen Fong Doctoral Scholarship in Neuroscience. CAE is supported by an Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation. AKM is supported by a CIHR Chair in Child and Youth Health Services and Policy Research. The role of the sponsors and funding bodies was to provide financial support for this research and the translation of the findings to all community partners.	Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Fraser-Thomas J, 2014, INT J SPORT EXERC PS, V12, P121, DOI 10.1080/1612197X.2013.837091; Hecimovich M, 2004, J AM CHIROPR ASS, V41, P32; Hockey Canada, 2012, HOCK CAN 2012 ANN RE; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Slutzky CB, 2009, PSYCHOL SPORT EXERC, V10, P381, DOI 10.1016/j.psychsport.2008.09.006; Williamson US, 2009, J ASTM INT, V6; Zullig KJ, 2011, APPL RES QUAL LIFE, V6, P277, DOI 10.1007/s11482-010-9129-z	13	44	44	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2016	50	1					55	61		10.1136/bjsports-2015-095103			7	Sport Sciences	Sport Sciences	DA0BW	WOS:000367462700011	26702018				2021-06-18	
J	Smith, CJ; Xiong, GX; Elkind, JA; Putnam, B; Cohen, AS				Smith, Colin J.; Xiong, Guoxiang; Elkind, Jaclynn A.; Putnam, Brendan; Cohen, Akiva S.			Brain Injury Impairs Working Memory and Prefrontal Circuit Function	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; lateral fluid percussion injury; synaptic transmission; intrinsic excitability; medial prefrontal cortex; working memory	EXCITATION/INHIBITION BALANCE; PYRAMIDAL NEURONS; DENTATE GYRUS; CORTEX; HIPPOCAMPAL; DEFICITS; MODEL; DYSFUNCTION; RAT; CONNECTIVITY	More than 2.5 million Americans suffer a traumatic brain injury (TBI) each year. Even mild to moderate TBI causes long-lasting neurological effects. Despite its prevalence, no therapy currently exists to treat the underlying cause of cognitive impairment suffered by TBI patients. Following lateral fluid percussion injury (LFPI), the most widely used experimental model of TBI, we investigated alterations in working memory and excitatory/inhibitory synaptic balance in the prefrontal cortex. LFPI impaired working memory as assessed with a T-maze behavioral task. Field excitatory postsynaptic potentials recorded in the prefrontal cortex were reduced in slices derived from brain-injured mice. Spontaneous and miniature excitatory postsynaptic currents onto layer 2/3 neurons were more frequent in slices derived from LFPI mice, while inhibitory currents onto layer 2/3 neurons were smaller after LFPI. Additionally, an increase in action potential threshold and concomitant decrease in firing rate was observed in layer 2/3 neurons in slices from injured animals. Conversely, no differences in excitatory or inhibitory synaptic transmission onto layer 5 neurons were observed; however, layer 5 neurons demonstrated a decrease in input resistance and action potential duration after LFPI. These results demonstrate synaptic and intrinsic alterations in prefrontal circuitry that may underlie working memory impairment caused by TBI.	[Smith, Colin J.; Xiong, Guoxiang; Elkind, Jaclynn A.; Putnam, Brendan; Cohen, Akiva S.] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA; [Smith, Colin J.] Univ Penn, Sch Med, Neurosci Grad Grp, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	Cohen, AS (corresponding author), Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA.	cohena@email.chop.edu			National Institute of Child Health and human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R37HD059288]; National Institute of Neurological Disease and Stroke at the National Institutes of Health [R01NS069629, 1F31NS083243]	This work was supported by National Institute of Child Health and human Development at the National Institutes of Health (R37HD059288 to AC), and the National Institute of Neurological Disease and Stroke at the National Institutes of Health (R01NS069629 to AC and 1F31NS083243 to CS).	Avesar D, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00012; Axmacher N, 2008, J NEUROSCI, V28, P7304, DOI 10.1523/JNEUROSCI.1778-08.2008; BRITO GNO, 1990, BEHAV BRAIN RES, V36, P127, DOI 10.1016/0166-4328(90)90167-D; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN, P1; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cui YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020312; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Dembrow N, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00054; Dembrow NC, 2010, J NEUROSCI, V30, P16922, DOI 10.1523/JNEUROSCI.3644-10.2010; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Fujisawa S, 2011, NEURON, V72, P153, DOI 10.1016/j.neuron.2011.08.018; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Grady MS, 1994, ANESTHETIC MANAGEMEN; Hearing M, 2013, NEURON, V80, P159, DOI 10.1016/j.neuron.2013.07.019; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Huang YY, 2004, P NATL ACAD SCI USA, V101, P3236, DOI 10.1073/pnas.0308280101; Johnson BN, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00435; Jones MW, 2005, PLOS BIOL, V3, P2187, DOI 10.1371/journal.pbio.0030402; Kalmbach BE, 2013, J NEUROSCI, V33, P13518, DOI 10.1523/JNEUROSCI.2018-13.2013; Kellendonk C, 2006, NEURON, V49, P603, DOI 10.1016/j.neuron.2006.01.023; KRITZER MF, 1995, J COMP NEUROL, V359, P131, DOI 10.1002/cne.903590109; Lee J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00094; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Molnar Z, 2006, NEUROSCI RES, V55, P105, DOI 10.1016/j.neures.2006.02.008; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Morishima M, 2006, J NEUROSCI, V26, P4394, DOI 10.1523/JNEUROSCI.0252-06.2006; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Plenger P, 2016, BRAIN IMAGING BEHAV, V10, P357, DOI 10.1007/s11682-015-9401-9; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schwabe K, 2004, BEHAV BRAIN RES, V153, P21, DOI 10.1016/j.bbr.2003.10.030; Seong HJ, 2012, J NEUROSCI, V32, P10516, DOI 10.1523/JNEUROSCI.1367-12.2012; Shepherd GMG, 2013, NAT REV NEUROSCI, V14, P278, DOI 10.1038/nrn3469; Sigurdsson T, 2010, NATURE, V464, P763, DOI 10.1038/nature08855; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; THOMAS GJ, 1984, BEHAV NEUROSCI, V98, P394, DOI 10.1037/0735-7044.98.3.394; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thuault SJ, 2013, J NEUROSCI, V33, P13583, DOI 10.1523/JNEUROSCI.2427-12.2013; Touzani K, 2007, P NATL ACAD SCI USA, V104, P5632, DOI 10.1073/pnas.0611554104; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Turrigiano G, 2011, ANNU REV NEUROSCI, V34, P89, DOI 10.1146/annurev-neuro-060909-153238; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Wang F, 2011, SCIENCE, V334, P693, DOI 10.1126/science.1209951; Wang M, 2007, CELL, V129, P397, DOI 10.1016/j.cell.2007.03.015; Whiting MD, 2006, J NEUROTRAUM, V23, P1529, DOI 10.1089/neu.2006.23.1529; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360	64	44	46	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	NOV 13	2015	6								240	10.3389/fneur.2015.00240			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DA8YD	WOS:000368092000001	26617569	DOAJ Gold, Green Published			2021-06-18	
J	Balbi, M; Ghosh, M; Longden, TA; Vega, MJ; Gesierich, B; Hellal, F; Lourbopoulos, A; Nelson, MT; Plesnila, N				Balbi, Matilde; Ghosh, Mitrajit; Longden, Thomas A.; Vega, Max Jativa; Gesierich, Benno; Hellal, Farida; Lourbopoulos, Athanasios; Nelson, Mark T.; Plesnila, Nikolaus			Dysfunction of mouse cerebral arteries during early aging	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aging; cerebral blood flow; CO2 reactivity; in vivo microscopy; mice; neurovascular coupling	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; NEURONAL-ACTIVITY; BLOOD-FLOW; ENDOTHELIUM; DILATION; PRESSURE; PROFILE; AGE	Aging leads to a gradual decline in the fidelity of cerebral blood flow (CBF) responses to neuronal activation, resulting in an increased risk for stroke and dementia. However, it is currently unknown when age-related cerebrovascular dysfunction starts or which vascular components and functions are first affected. The aim of this study was to examine the function of microcirculation throughout aging in mice. Microcirculation was challenged by inhalation of 5% and 10% CO2 or by forepaw stimulation in 6-week, 8-month, and 12-month-old FVB/N mice. The resulting dilation of pial vessels and increase in CBF was measured by intravital fluorescence microscopy and laser Doppler fluxmetry, respectively. Neurovascular coupling and astrocytic endfoot Ca2+ were measured in acute brain slices from 18-month-old mice. We did not reveal any changes in CBF after CO2 reactivity up to an age of 12 months. However, direct visualization of pial vessels by in vivo microscopy showed a significant, age-dependent loss of CO2 reactivity starting at 8 months of age. At the same age neurovascular coupling was also significantly affected. These results suggest that aging does not affect cerebral vessel function simultaneously, but starts in pial microvessels months before global changes in CBF are detectable.	[Balbi, Matilde; Ghosh, Mitrajit; Gesierich, Benno; Hellal, Farida; Lourbopoulos, Athanasios; Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res ISD, D-81377 Munich, Germany; [Balbi, Matilde; Vega, Max Jativa; Plesnila, Nikolaus] Univ Munich, Grad Sch Syst Neurosci GSN, D-81377 Munich, Germany; [Longden, Thomas A.; Nelson, Mark T.] Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA; [Plesnila, Nikolaus] Cluster Syst Neurol Synergy, Munich, Germany	Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res ISD, Feodor Lynen Str 17, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Hellal, Farida/D-1834-2015; Plesnila, Nikolaus/T-7522-2019	Hellal, Farida/0000-0002-9344-1846; Longden, Thomas/0000-0002-7950-7677; Nelson, Mark/0000-0002-6608-8784	Solorz-Zaks foundation	This work was supported by Solorz-Zaks foundation.	Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Faraci FM, 1998, PHYSIOL REV, V78, P53; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Filosa JA, 2006, NAT NEUROSCI, V9, P1397, DOI 10.1038/nn1779; Fischer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059952; Friedrich B, 2014, J CEREBR BLOOD F MET, V34, P1422, DOI 10.1038/jcbfm.2014.96; Friedrich B, 2012, J CEREBR BLOOD F MET, V32, P447, DOI 10.1038/jcbfm.2011.154; Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005; Girouard H, 2007, ARTERIOSCL THROM VAS, V27, P303, DOI 10.1161/01.ATV.0000253885.41509.25; Girouard H, 2010, P NATL ACAD SCI USA, V107, P3811, DOI 10.1073/pnas.0914722107; Jennings JR, 2013, STROKE, V44, P2480, DOI 10.1161/STROKEAHA.113.001716; Joutel A, 2010, J CLIN INVEST, V120, P433, DOI 10.1172/JCI39733; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; Kazama K, 2004, CIRC RES, V95, P1019, DOI 10.1161/01.RES.0000148637.85595.c5; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; Koide M, 2012, P NATL ACAD SCI USA, V109, pE1387, DOI 10.1073/pnas.1121359109; Lindauer U, 1999, AM J PHYSIOL-HEART C, V277, pH799; Lindauer U, 2001, AM J PHYSIOL-HEART C, V281, pH1353; Longden TA, 2014, P NATL ACAD SCI USA, V111, P7462, DOI 10.1073/pnas.1401811111; MAYHAN WG, 1990, AM J PHYSIOL, V258, pH1138; MCCARRON JG, 1990, CIRC RES, V67, P1035, DOI 10.1161/01.RES.67.4.1035; Menuet C, 2011, J APPL PHYSIOL, V110, P1572, DOI 10.1152/japplphysiol.00117.2011; Mitchell GF, 2011, BRAIN, V134, P3398, DOI 10.1093/brain/awr253; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Panczel G, 1999, STROKE, V30, P619, DOI 10.1161/01.STR.30.3.619; Park L, 2007, J CEREBR BLOOD F MET, V27, P1908, DOI 10.1038/sj.jcbfm.9600491; Schwarzmaier SM, 2015, J NEUROTRAUM, V32, P731, DOI 10.1089/neu.2014.3650; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Straub SV, 2007, TRENDS CARDIOVAS MED, V17, P183, DOI 10.1016/j.tcm.2007.05.001; Suckow MA, 2001, LAB MOUSE, V8; Terpolilli NA, 2012, CIRC RES, V110, P727, DOI 10.1161/CIRCRESAHA.111.253419; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016	33	44	44	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2015	35	9					1445	1453		10.1038/jcbfm.2015.107			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CQ6BN	WOS:000360689500011	26058694	Green Published, Bronze			2021-06-18	
J	He, Y; Xu, L; Li, B; Guo, ZN; Hu, Q; Guo, ZD; Tang, JJ; Chen, YJ; Zhang, Y; Tang, JP; Zhang, JH				He, Yue; Xu, Liang; Li, Bo; Guo, Zhen-Ni; Hu, Qin; Guo, Zongduo; Tang, Junjia; Chen, Yujie; Zhang, Yang; Tang, Jiping; Zhang, John H.			Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats	STROKE			English	Article						brain injuries; Mincle; subarachnoid hemorrhage; Syk kinase	EARLY BRAIN-INJURY; FACTOR-KAPPA-B; RECEPTOR ANTAGONIST; INFLAMMATION; MINCLE; STROKE; MODEL; ACTIVATION; VASOSPASM; RESPONSES	Background and Purpose-Macrophage-inducible C-type lectin (Mincle, CLEC4E) receptor is reported involved in neuroinflammation in cerebral ischemia and traumatic brain injury. This study was designed to investigate the role of Mincle and its downstream spleen tyrosine kinase (Syk) signal pathway in early brain injury after subarachnoid hemorrhage (SAH) in a rat model. Methods-Two hundred fifteen male Sprague-Dawley rats (280-320 g) were subjected to endovascular perforation model of SAH. SAH grade, neurological score, and brain water content were measured at 24 hours after SAH. Mincle/Syk, as well as CARD9 (a member of the caspase-associated recruitment domain [CARD], involved in innate immune response), interleukin-1 beta, and myeloperoxidase expressions were analyzed by Western blot at 24 hours after SAH. Specific cell types that expressed Mincle were detected with double immunofluorescence staining. Mincle small interfering RNA, recombinant SAP130, and a selective Syk phosphorylation inhibitor piceatannol were used for intervention. Results-Brain water content increased and neurological functions decreased in rats after SAH. The expression of SAP130, Mincle, Syk, and p-Syk increased at 12 hours and peaked at 24 hours after SAH. Mincle small interfering RNA reduced interleukin-1 beta, and infiltration of myeloperoxidase positive cells, decreased brain water content, and improved neurological functions at 24 hours after SAH. Recombinant SAP130 upregulated the expression of p-Syk and CARD9 and increased the levels of interleukin-1 beta and myeloperoxidase, even though it did not increase brain water content nor it deteriorated neurological function at 24 hours after SAH. Syk inhibitor piceatannol reduced brain edema at 24 hours after SAH. Conclusion-Mincle/Syk is involved in early brain injury after SAH, and they may serve as new targets for therapeutic intervention.	[He, Yue; Xu, Liang; Li, Bo; Guo, Zhen-Ni; Hu, Qin; Guo, Zongduo; Tang, Junjia; Chen, Yujie; Zhang, Yang; Tang, Jiping; Zhang, John H.] Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA; [He, Yue; Xu, Liang; Li, Bo; Guo, Zhen-Ni; Hu, Qin; Guo, Zongduo; Tang, Junjia; Chen, Yujie; Zhang, Yang; Tang, Jiping; Zhang, John H.] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92354 USA; [He, Yue] Tong Ji Hosp, Dept Neurosurg, Wuhan, Peoples R China; [Xu, Liang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China; [Li, Bo] Jinan Gen Mil Hosp, Dept Neurosurg, Jinan, Peoples R China; [Chen, Yujie] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China	Zhang, JH (corresponding author), Loma Linda Univ, Sch Med, Dept Anesthesiol, 11041 Campus St,Risley Hall,Room 219, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com	Hu, Qin/N-8930-2017; Zhang, Yang/AAQ-5411-2021	Hu, Qin/0000-0002-2270-8822; Chen, Yujie/0000-0002-9905-9138; zhang, yang/0000-0002-4061-4408	National Institutes HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS081740, NS082184]; Hubei Province Natural Science Foundation of ChinaNatural Science Foundation of Hubei Province [2013CFB1200]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS082184, R01NS081740] Funding Source: NIH RePORTER	This study was supported partially by National Institutes Health NS081740 and NS082184 to Dr Zhang, and 2013CFB1200 from Hubei Province Natural Science Foundation of China to Dr He.	Becker KJ, 1998, NEUROSURG CLIN N AM, V9, P435; Brown GD, 2008, NAT IMMUNOL, V9, P1099, DOI 10.1038/ni1008-1099; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Caner B, 2012, J NEUROCHEM, V123, P12, DOI 10.1111/j.1471-4159.2012.07939.x; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Duris K, 2011, STROKE, V42, P3530, DOI 10.1161/STROKEAHA.111.619965; Friedrich V, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-103; Frontera JA, 2012, J THROMB HAEMOST, V10, P711, DOI 10.1111/j.1538-7836.2012.04651.x; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557; Hasegawa Y, 2011, STROKE, V42, P477, DOI 10.1161/STROKEAHA.110.597344; He ZH, 2012, STROKE, V43, P484, DOI 10.1161/STROKEAHA.111.626432; Ishizuka F, 2013, INVEST OPHTH VIS SCI, V54, P5807, DOI 10.1167/iovs.13-11932; Jimenez-Pacheco A, 2013, EPILEPSIA, V54, P1551, DOI 10.1111/epi.12257; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; Liu F, 2014, STROKE, V45, P3691, DOI 10.1161/STROKEAHA.114.006635; Ma CX, 2009, CHINESE MED J-PEKING, V122, P1575, DOI 10.3760/cma.j.issn.0366-6999.2009.13.019; Manzanero S, 2012, INT J STROKE, V7, P19; Masumoto M, 1999, J IMMUNOL, V163, P5039; Miyake Yasunobu, 2010, Self Nonself, V1, P310, DOI 10.4161/self.1.4.13736; Munoz-Guillen NM, 2013, NEUROLOGIA, V28, P309, DOI 10.1016/j.nrl.2011.10.015; Pamuk ON, 2010, AM J PHYSIOL-GASTR L, V299, pG391, DOI 10.1152/ajpgi.00198.2010; Provencio JJ, 2005, SEMIN NEUROL, V25, P435, DOI 10.1055/s-2005-923537; Prunell GF, 2005, NEUROSURGERY, V56, P1082, DOI 10.1227/01.NEU.0000157966.76590.39; Roth S, 2013, TRENDS IMMUNOL, V34, P243, DOI 10.1016/j.it.2013.02.006; Shichita T, 2012, J NEUROCHEM, V123, P29, DOI 10.1111/j.1471-4159.2012.07941.x; Sugawara T, 2008, J NEUROSCI METH, V167, P327, DOI 10.1016/j.jneumeth.2007.08.004; Suzuki Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03177; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Vaccari JCD, 2015, J NEUROTRAUM, V32, P228, DOI 10.1089/neu.2014.3436; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Yamasaki S, 2013, EUR J IMMUNOL, V43, P3156, DOI 10.1002/eji.201344131; Yan JH, 2013, STROKE, V44, P1410, DOI 10.1161/STROKEAHA.113.678474	36	44	47	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	AUG	2015	46	8					2277	2286		10.1161/STROKEAHA.115.010088			10	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CP6CP	WOS:000359972200053	26138128	Green Accepted			2021-06-18	
J	Shultz, SR; Sun, MJ; Wright, DK; Brady, RD; Liu, SJ; Beynon, S; Schmidt, SF; Kaye, AH; Hamilton, JA; O'Brien, TJ; Grills, BL; McDonald, SJ				Shultz, Sandy R.; Sun, Mujun; Wright, David K.; Brady, Rhys D.; Liu, Shijie; Beynon, Sinead; Schmidt, Shannon F.; Kaye, Andrew H.; Hamilton, John A.; O'Brien, Terence J.; Grills, Brian L.; McDonald, Stuart J.			Tibial fracture exacerbates traumatic brain injury outcomes and neuroinflammation in a novel mouse model of multitrauma	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal model; cytokines; DTI; MRI; polytrauma	CONTROLLED CORTICAL IMPACT; RAT MODEL; ANIMAL-MODEL; HEAD-INJURY; SENSORIMOTOR; HYDROCEPHALUS; INTERLEUKIN-6; POLYTRAUMA; SEVERITY; CORTEX	Multitrauma is a common medical problem worldwide, and often involves concurrent traumatic brain injury (TBI) and bone fracture. Despite the high incidence of combined TBI and fracture, preclinical TBI research commonly employs independent injury models that fail to incorporate the pathophysiologic interactions occurring in multitrauma. Here, we developed a novel mouse model of multitrauma, and investigated whether bone fracture worsened TBI outcomes. Male mice were assigned into four groups: sham-TBI +sham-fracture (SHAM); sham-TBI+fracture (FX); TBI+sham-fracture (TBI); and TBI+fracture (MULTI). The injury methods included a closed-skull weight-drop TBI model and a closed tibial fracture. After a 35-day recovery, mice underwent behavioral testing and magnetic resonance imaging (MRI). MULTI mice displayed abnormal behaviors in the open-field compared with all other groups. On MRI, MULTI mice had enlarged ventricles and diffusion abnormalities compared with all other groups. These changes occurred in the presence of heightened neuroinflammation in MULTI mice at 24 hours and 35 days after injury, and elevated edema and blood-brain barrier disruption at 24 hours after injury. Together, these findings indicate that tibial fracture worsens TBI outcomes, and that exacerbated neuroinflammation may be an important factor that contributes to these effects, which warrants further investigation.	[Shultz, Sandy R.; Sun, Mujun; Liu, Shijie; Beynon, Sinead; Hamilton, John A.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3052, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Brady, Rhys D.; Schmidt, Shannon F.; Grills, Brian L.; McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Melbourne, Vic, Australia; [Kaye, Andrew H.] Univ Melbourne, Dept Surg, Royal Melbourne Hosp, Parkville, Vic 3052, Australia	Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr, Off 1-02, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au		O'Brien, Terence/0000-0002-7198-8621; Kaye, Andrew Henry/0000-0001-5049-8861; Sun, Mujun/0000-0002-9923-9913; McDonald, Stuart/0000-0001-5190-3179	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1062653]; Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); La Trobe University	This study was funded by a grant to SRS from the National Health and Medical Research Council (NHMRC #1062653), a fellowship to SRS from the Canadian Institute of Health Research (CIHR), and grants to SJM and BLG from La Trobe University.	Al-Thani H, 2014, J ENV PUBLIC HLTH, V2014; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Gross T, 2012, ACTA ANAESTH SCAND, V56, P1163, DOI 10.1111/j.1399-6576.2012.02724.x; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Liu NK, 2014, BRAIN RES, V1576, P18, DOI 10.1016/j.brainres.2014.05.042; MacGregor AJ, 2012, INJURY, V43, P1551, DOI 10.1016/j.injury.2011.04.017; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Radu M, 2013, JOVE-J VIS EXP, DOI 10.3791/50062; Schindeler A, 2008, J ORTHOP RES, V26, P1053, DOI 10.1002/jor.20628; Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhuang YF, 2013, ASIAN PAC J TROP MED, V6, P383, DOI 10.1016/S1995-7645(13)60043-7; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	40	44	44	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2015	35	8					1339	1347		10.1038/jcbfm.2015.56			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CN9WN	WOS:000358801300016	25853909	Bronze, Green Published			2021-06-18	
J	Theadom, A; Cropley, M; Parmar, P; Barker-Collo, S; Starkey, N; Jones, K; Feigin, VL				Theadom, Alice; Cropley, Mark; Parmar, Priya; Barker-Collo, Suzanne; Starkey, Nicola; Jones, Kelly; Feigin, Valery L.		BIONIC Res Grp	Sleep difficulties one year following mild traumatic brain injury in a population-based study	SLEEP MEDICINE			English	Article						Epidemiology; Mild traumatic brain injury; Sleep; Recovery; Adult	QUALITY INDEX; HEAD-INJURY; DEPRESSION SCALE; HOSPITAL ANXIETY; DISTURBANCE; DISORDERS; INSOMNIA; VALIDITY; RELIABILITY; EPIDEMIOLOGY	Background: Sleep quality affects all aspects of daily functioning, and it is vital for facilitating recovery from illness and injury. Sleep commonly becomes disrupted following moderate to severe brain injury, yet little is known about the prevalence of sleep disruption over time and how it impacts on recovery following mild injury. Methods: This was a longitudinal study of 346 adults who experienced a mild brain injury (aged >= 16 years) identified within a population-based incidence sample in New Zealand. The prevalence of sleep difficulties was assessed at baseline (within two weeks), one, six and 12 months, alongside other key outcomes. Results: One year post injury, 41.4% of people were identified as having clinically significant sleep difficulties, with 21.0% at a level indicative of insomnia. Poor sleep quality at baseline was significantly predictive of poorer post-concussion symptoms, mood, community integration, and cognitive ability one year post injury. The prevalence of insomnia following mild traumatic brain injury (TBI) was more than three times the rate found in the general population. Of those completing a sleep assessment at six and 12 months, 44.9% of the sample showed improvements in sleep quality, 16.2% remained stable, and 38.9% worsened. Conclusions: Screening for sleep difficulties should occur routinely following a mild brain injury to identify adults potentially at risk of poor recovery. Interventions to improve sleep are needed to facilitate recovery from injury, and to prevent persistent sleep difficulties emerging. (C) 2015 Elsevier B.V. All rights reserved.	[Theadom, Alice; Parmar, Priya; Jones, Kelly; Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland 1142, New Zealand; [Cropley, Mark] Univ Surrey, Sch Psychol, Guildford GU2 5XH, Surrey, England; [Barker-Collo, Suzanne] Univ Auckland, Sch Psychol, Auckland 1, New Zealand; [Starkey, Nicola] Univ Waikato, Sch Psychol, Hamilton, New Zealand	Theadom, A (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Studies, Private Bag 92006, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Jones, Kelly/I-5199-2019; Feigin, Valery/AAF-2313-2019; Cropley, Mark/V-2296-2019; Starkey, Nicola/AAJ-3795-2020	Starkey, Nicola/0000-0002-4370-8186; McPherson, Kathryn/0000-0003-1240-8882; Feigin, Valery L./0000-0002-6372-1740; Ameratunga, Shanthi/0000-0001-8042-2251; Theadom, Alice/0000-0003-0351-6216; Te Ao, Braden/0000-0002-1050-200X; Parmar, Priya/0000-0001-6001-9326; Barber, P Alan/0000-0003-2469-9023; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand [09/063A, 11/192]	This study was funded by the Health Research Council of New Zealand (09/063A, 11/192). We thank the research team for their dedication and performance, in addition to staff at the Coroner's office in Hamilton; New Zealand Accident Compensation Corporation, New Zealand Health Information Service; Waikato District Health Board; Spring Hill Correctional Facility, Waikato University Staff. We thank the many doctors, nurses and rehabilitation professionals and service providers such as ABI Management and administrative staff within and outside Hamilton who referred patients into the study. Additionally, we would like to thank the BIONIC participants and their families and friends. We thank Helen McDonald for her administrative support for the study, and CNS Vital Signs for their support with the neuropsychological assessment.	Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Daley M, 2009, SLEEP MED, V10, P427, DOI 10.1016/j.sleep.2008.04.005; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Grandner Michael A, 2006, Sleep Biol Rhythms, V4, P129, DOI 10.1111/j.1479-8425.2006.00207.x; Grandner MA, 2012, J SLEEP RES, V21, P427, DOI 10.1111/j.1365-2869.2011.00990.x; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Gualtieri CT, 2004, AM NEUR ASS ANN M BA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mollayeva T, 2013, SLEEP MED, V14, P1235, DOI 10.1016/j.sleep.2013.07.009; Novak M, 2004, J PSYCHOSOM RES, V56, P527, DOI 10.1016/j.jpsychores.2004.02.007; Ohayon MM, 1997, J PSYCHIATR RES, V31, P333, DOI 10.1016/S0022-3956(97)00002-2; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Ponsford JL, 2014, PSYCHIAT CLIN N AM, V37, P77, DOI 10.1016/j.psc.2013.10.001; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Smolensky MH, 2011, ACCIDENT ANAL PREV, V43, P533, DOI 10.1016/j.aap.2009.12.004; Sullivan KA, 2015, J NEUROTRAUM, V32, P474, DOI 10.1089/neu.2013.3284; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	44	44	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	AUG	2015	16	8					926	932		10.1016/j.sleep.2015.04.013			7	Clinical Neurology	Neurosciences & Neurology	CN0EO	WOS:000358087000005	26138280				2021-06-18	
J	Beca, J; McSharry, B; Erickson, S; Yung, M; Schibler, A; Slater, A; Wilkins, B; Singhal, A; Williams, G; Sherring, C; Butt, W				Beca, John; McSharry, Brent; Erickson, Simon; Yung, Michael; Schibler, Andreas; Slater, Anthony; Wilkins, Barry; Singhal, Ash; Williams, Gary; Sherring, Claire; Butt, Warwick		Australia New Zealand Intensive Ca	Hypothermia for Traumatic Brain Injury in Children-A Phase II Randomized Controlled Trial	CRITICAL CARE MEDICINE			English	Article						children; pediatric intensive care; randomized controlled trial; therapeutic hypothermia; traumatic brain injury	CLINICAL-TRIALS; MODERATE HYPOTHERMIA; INFORMED-CONSENT; CARDIAC-ARREST; THERAPEUTIC HYPOTHERMIA; UNITED-STATES; MORTALITY; IMPACT; ENCEPHALOPATHY; CARE	Objectives: To perform a pilot study to assess the feasibility of performing a phase III trial of therapeutic hypothermia started early and continued for at least 72 hours in children with severe traumatic brain injury. Design: Multicenter prospective randomized controlled phase II trial. Setting: All eight of the PICUs in Australia and New Zealand and one in Canada. Patients: Children 1-15 years old with severe traumatic brain injury and who could be randomized within 6 hours of injury. Interventions: The control group had strict normothermia to a temperature of 36-37 degrees C for 72 hours. The intervention group had therapeutic hypothermia to a temperature of 32-33 degrees C for 72 hours followed by slow rewarming at a rate compatible with maintaining intracranial pressure and cerebral perfusion pressure. Measurements and Main Results: Of 764 children admitted to PICU with traumatic brain injury, 92 (12%) were eligible and 55 (7.2%) were recruited. There were five major protocol violations (9%): three related to recruitment and consent processes and two to incorrect temperature management. Rewarming took a median of 21.5 hours (16-35hr) and was performed without compromise in the cerebral perfusion pressure. There was no increase in any complications, including infections, bleeding, and arrhythmias. There was no difference in outcomes 12 months after injury; in the therapeutic hypothermia group, four (17%) had a bad outcome (pediatric cerebral performance category, 4-6) and three (13%) died, whereas in the normothermia group, three (12%) had a bad outcome and one (4%) died. Conclusions: Early therapeutic hypothermia in children with severe traumatic brain injury does not improve outcome and should not be used outside a clinical trial. Recruitment rates were lower and outcomes were better than expected. Conventional randomized controlled trials in children with severe traumatic brain injury are unlikely to be feasible. A large international trials group and alternative approaches to trial design will be required to further inform practice.	[Beca, John; McSharry, Brent; Sherring, Claire] Starship Childrens Hosp, Dept Pediat Intens Care, Auckland, New Zealand; [Erickson, Simon] Princess Margaret Hosp, Dept Pediat Intens Care, Perth, WA, Australia; [Yung, Michael] Women & Childrens Hosp, Dept Pediat Intens Care, Adelaide, SA, Australia; [Schibler, Andreas] Univ Queensland, Mater Childrens Hosp, Dept Pediat Intens Care, Brisbane, Qld 4101, Australia; [Slater, Anthony] Royal Childrens Hosp, Dept Pediat Intens Care, Brisbane, Qld, Australia; [Wilkins, Barry] Childrens Hosp Westmead, Dept Pediat Intens Care, Sydney, NSW, Australia; [Singhal, Ash] British Columbia Childrens Hosp, Dept Pediat Neurosurg, Vancouver, BC V6H 3V4, Canada; [Williams, Gary] Sydney Childrens Hosp, Dept Pediat Intens Care, Sydney, NSW, Australia; [Butt, Warwick] Royal Childrens Hosp, Dept Pediat Intens Care, Melbourne, Vic, Australia	Beca, J (corresponding author), Starship Childrens Hosp, Dept Pediat Intens Care, Auckland, New Zealand.	johnbeca@adhb.govt.nz	Jauncey-Cooke, Jacqueline/N-1949-2015; Slater, Anthony/C-4372-2016; Long, Debbie/G-9361-2013	Jauncey-Cooke, Jacqueline/0000-0002-7670-0703; Slater, Anthony/0000-0002-3127-1060; McSharry, Brian/0000-0003-0473-2789; Schibler, Andreas/0000-0002-0791-5938; Singhal, Ash/0000-0002-0061-9570; Long, Debbie/0000-0002-0984-9559	Victorian Transport Accident Commission; Neurotrauma Research Programme of the West Australia Institute for Medical Research; Intensive Care Foundation of Australia and New Zealand; Hospira; Princess Margaret Hospital Foundation; Malaysian Intensive Care Society; Royal Children's Hospital Foundation; Brain Tumor Foundation of Canada; BC Children's Hospital Foundation; Rare Disease Foundation	Supported, in part, by grants from the Victorian Transport Accident Commission, the Neurotrauma Research Programme of the West Australia Institute for Medical Research, and the Intensive Care Foundation of Australia and New Zealand.; Dr. Erickson served as a board member for the Australia and New Zealand Intensive Care Society (ANZICS) (no financial remuneration apart from travel to board meetings or other), consulted for Ikaria, is employed by Princess Margaret Hospital (primary employment), provided expert opinion for medicolegal cases (various legal entities), and received grant support from Hospira and the Princess Margaret Hospital Foundation (unrestricted study grants for other studies). Dr. Slater received support for travel from the Malaysian Intensive Care Society (travel and accommodation to attend the Malaysian Intensive Care Society Annual Scientific Meeting), APLS Australia (travel and accommodation for instructing on courses), and the ANZICS (travel and accommodation for ANZICS core business). His institution received grant support from the Royal Children's Hospital Foundation (grants for hospital equipment and for research projects and innovation grants). Dr. Wilkins is employed by Children's Hospital at Westmead. Dr. Singhal is employed by the University of British Columbia and the British Columbia Children's Hospital and received grant support from Brain Tumor Foundation of Canada, BC Children's Hospital Foundation, and the Rare Disease Foundation (unrelated research). Dr. Williams is employed by the Sydney Children's Hospital	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Bembea MM, 2010, PEDIATR CRIT CARE ME, V11, P723, DOI 10.1097/PCC.0b013e3181dde659; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gaies MG, 2010, PEDIATR CRIT CARE ME, V11, P234, DOI 10.1097/PCC.0b013e3181b806fc; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Meurer WJ, 2012, ANN EMERG MED, V60, P451, DOI 10.1016/j.annemergmed.2012.01.020; Moreau JF, 2013, PEDIATR CRIT CARE ME, V14, P801, DOI 10.1097/PCC.0b013e31828aa71f; Morris MC, 2004, PEDIATRICS, V114, P776, DOI 10.1542/peds.2004-0482; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Roberts I, 2011, LANCET, V377, P1071, DOI 10.1016/S0140-6736(11)60317-6; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013	33	44	48	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2015	43	7					1458	1466		10.1097/CCM.0000000000000947			9	Critical Care Medicine	General & Internal Medicine	CN2XK	WOS:000358285900014	25803648				2021-06-18	
J	Newgard, CD; Meier, EN; Bulger, EM; Buick, J; Sheehan, K; Lin, S; Minei, JR; Barnes-Mackey, RA; Brasel, K				Newgard, Craig D.; Meier, Eric N.; Bulger, Eileen M.; Buick, Jason; Sheehan, Kellie; Lin, Steve; Minei, Joseph R.; Barnes-Mackey, Roxy A.; Brasel, Karen		ROC Investigators	Revisiting the "Golden Hour": An Evaluation of Out-of-Hospital Time in Shock and Traumatic Brain Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							PREHOSPITAL TIME; RESPONSE-TIME; TRIAGE RULE; HYPERTONIC RESUSCITATION; PARAMEDIC JUDGMENT; AMERICAN-COLLEGE; MAJOR TRAUMA; SURVIVAL; IMPACT; CARE	Study objective: We evaluate patients with shock and traumatic brain injury who were previously enrolled in an out-ofhospital clinical trial to test the association between out-of-hospital time and outcome. Methods: This was a secondary analysis of patients with shock and traumatic brain injury who were aged 15 years or older and enrolled in a Resuscitation Outcomes Consortium out-of-hospital clinical trial by 81 emergency medical services agencies transporting to 46 Level I and II trauma centers in 11 sites (May 2006 through May 2009). Inclusion criteria were systolic blood pressure less than or equal to 70 mm Hg or systolic blood pressure 71 to 90 mm Hg with pulse rate greater than or equal to 108 beats/min (shock cohort) and Glasgow Coma Scale score less than or equal to 8 (traumatic brain injury cohort); patients meeting both criteria were placed in the shock cohort. Primary outcomes were 28-day mortality (shock cohort) and 6-month Glasgow Outcome Scale-Extended score less than or equal to 4 (traumatic brain injury cohort). Results: There were 778 patients in the shock cohort (26% 28-day mortality) and 1,239 patients in the traumatic brain injury cohort (53% 6-month Glasgow Outcome Scale-Extended score <4). Out-of-hospital time greater than 60 minutes was not associated with worse outcomes after accounting for important confounders in the shock cohort (adjusted odds ratio [a0R] 1.42; 95% confidence interval [Cl] 0.77 to 2.62) or traumatic brain injury cohort (aOR 0.77; 95% Cl 0.51 to 1.15). However, shock patients requiring early critical hospital resources and arriving after 60 minutes had higher 28day mortality (aOR 2.37; 95% Cl 1.05 to 5.37); this finding was not observed among a similar traumatic brain injury subgroup. Conclusion: Among out-of-hospital trauma patients meeting physiologic criteria for shock and traumatic brain injury, there was no association between time and outcome. However, the subgroup of shock patients requiring early critical resources and arriving after 60 minutes had higher mortality.	[Newgard, Craig D.] Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA; [Meier, Eric N.; Sheehan, Kellie] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Buick, Jason; Lin, Steve] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada; [Minei, Joseph R.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Barnes-Mackey, Roxy A.] Vancouver Fire Dept, Vancouver, WA USA; [Barnes-Mackey, Roxy A.] Providence Med Grp, Happy Valley, OR USA; [Brasel, Karen] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA	Newgard, CD (corresponding author), Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA.	newgardc@ohsu.edu	Lin, Steve/H-3723-2013; Buick, Jason E/K-4816-2013	Lin, Steve/0000-0002-8644-9719; Buick, Jason E/0000-0002-1859-1713	(University of Washington Data Coordinating Center) from the National Heart, Lung, and Blood Institute [5U01 HL077863]; (Medical College of Wisconsin) from the National Heart, Lung, and Blood Institute [HL077866]; (University of Washington) from the National Heart, Lung, and Blood Institute [HL077867]; (University of Pittsburgh) from the National Heart, Lung, and Blood Institute [HL077871]; (St. Michael's Hospital) from the National Heart, Lung, and Blood Institute [HL077872]; (Oregon Health & Science University) from the National Heart, Lung, and Blood Institute [HL077873]; (University of Alabama at Birmingham) from the National Heart, Lung, and Blood Institute [HL077881]; (Ottawa Health Research Institute) from the National Heart, Lung, and Blood Institute [HL077885]; (University of Texas Southwest Medical Center/Dallas) from the National Heart, Lung, and Blood Institute [HL077887]; (University of California San Diego) from the National Heart, Lung, and Blood Institute [HL077908]; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research-Institute of Circulatory and Respiratory HealthCanadian Institutes of Health Research (CIHR); Defence Research and Development Canada; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; American Heart AssociationAmerican Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077863, U01HL077871, U01HL077885, U01HL077872, U01HL077881, U01HL077866, U01HL077887, U01HL077873, U01HL077908, U01HL077867] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: The Resuscitation Outcomes Consortium is supported by a series of cooperative agreements to multiple regional clinical centers and 1 data coordinating center (5U01 HL077863, University of Washington Data Coordinating Center; HL077866, Medical College of Wisconsin; HL077867, University of Washington; HL077871, University of Pittsburgh; HL077872, St. Michael's Hospital; HL077873, Oregon Health & Science University; HL077881, University of Alabama at Birmingham; HL077885, Ottawa Health Research Institute; HL077887, University of Texas Southwest Medical Center/Dallas; and HL077908, University of California San Diego) from the National Heart, Lung, and Blood Institute, in partnership with the US Army Medical Research and Material Command, the Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association.	BAXT WG, 1990, ANN EMERG MED, V19, P1401, DOI 10.1016/S0196-0644(05)82608-3; Becker LR, 2003, ACCIDENT ANAL PREV, V35, P941, DOI 10.1016/S0001-4575(02)00102-1; Blackwell TH, 2002, ACAD EMERG MED, V9, P288, DOI 10.1197/aemj.9.4.288; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P154; Committee on Trauma, 2006, RESOURCES OPTIMAL CA; De Maio VJ, 2003, ANN EMERG MED, V42, P242, DOI 10.1067/mem.2003.266; Di Bartolomeo S, 2007, INJURY, V38, P305, DOI 10.1016/j.injury.2006.10.005; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; Engum SA, 2000, J PEDIATR SURG, V35, P82, DOI 10.1016/S0022-3468(00)80082-2; FRIES GR, 1994, ANN EMERG MED, V24, P885, DOI 10.1016/S0196-0644(94)70207-1; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hannan EL, 2005, J AM COLL SURGEONS, V200, P584, DOI 10.1016/j.jamcollsurg.2004.12.016; Henry MC, 1996, ACAD EMERG MED, V3, P992, DOI 10.1111/j.1553-2712.1996.tb03340.x; Kahn C A, 2001, Prehosp Emerg Care, V5, P261, DOI 10.1080/10903120190939751; Lerner EB, 2014, J TRAUMA ACUTE CARE, V76, P1157, DOI 10.1097/TA.0000000000000189; Lerner EB, 2003, ACAD EMERG MED, V10, P949, DOI 10.1197/S1069-6563(03)00313-0; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Mackersie RC, 2006, PREHOSP EMERG CARE, V10, P287, DOI 10.1080/10903120600721636; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; McCoy CE, 2013, ANN EMERG MED, V61, P167, DOI 10.1016/j.annemergmed.2012.08.026; Newgard CD, 2006, ACAD EMERG MED, V13, P314, DOI 10.1197/j.aem.2005.09.011; Newgard CD, 2005, ACAD EMERG MED, V12, P679, DOI 10.1197/j.aem.2005.03.526; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Newgard CD, 2015, J TRAUMA ACUTE CARE, V78, P342, DOI 10.1097/TA.0000000000000478; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Newgard CD, 2010, J TRAUMA, V68, P452, DOI 10.1097/TA.0b013e3181ae20c9; Osterwalder Joseph J, 2002, Prehosp Disaster Med, V17, P75; PEPE PE, 1987, ANN EMERG MED, V16, P293, DOI 10.1016/S0196-0644(87)80174-9; Petri R W, 1995, Prehosp Disaster Med, V10, P24; PHILLIPS JA, 1993, J TRAUMA, V34, P127, DOI 10.1097/00005373-199301000-00024; Pons PT, 2005, ACAD EMERG MED, V12, P594, DOI 10.1197/j.aem.2005.02.013; Pons PT, 2002, J EMERG MED, V23, P43, DOI 10.1016/S0736-4679(02)00460-2; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; Qazi K, 1998, ACAD EMERG MED, V5, P1002, DOI 10.1111/j.1553-2712.1998.tb02780.x; Rubin DB, 1987, MULTIPLE IMPUTATIN; Sampalis JS, 1999, J TRAUMA, V46, P565, DOI 10.1097/00005373-199904000-00004; SAMPALIS JS, 1993, J TRAUMA, V34, P252, DOI 10.1097/00005373-199302000-00014; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Terkelsen CJ, 2010, JAMA-J AM MED ASSOC, V304, P763, DOI 10.1001/jama.2010.1139; Wang HE, 2008, ANN EMERG MED, V52, P256, DOI 10.1016/j.annemergmed.2008.02.011; Wears RL, 2005, ANN EMERG MED, V46, P253, DOI 10.1016/j.annemergmed.2005.05.007; Wilde ET, 2013, HEALTH ECON, V22, P790, DOI 10.1002/hec.2851; ZECHNICH AD, 1995, ACAD EMERG MED, V2, P1043	48	44	45	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUL	2015	66	1					30	41		10.1016/j.annemergmed.2014.12.004			12	Emergency Medicine	Emergency Medicine	CM3AU	WOS:000357554400009	25596960	Green Accepted			2021-06-18	
J	Potter, DR; Baimukanova, G; Keating, SM; Deng, XT; Chu, JA; Gibb, SL; Peng, ZL; Muench, MO; Fomin, ME; Spinella, PC; Kozar, R; Pati, S				Potter, Daniel R.; Baimukanova, Gail; Keating, Sheila M.; Deng, Xutao; Chu, Jeffrey A.; Gibb, Stuart L.; Peng, Zhanglong; Muench, Marcus O.; Fomin, Marina E.; Spinella, Philip C.; Kozar, Rosemary; Pati, Shibani			Fresh frozen plasma and spray-dried plasma mitigate pulmonary vascular permeability and inflammation in hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	4th Annual Conference on Remote Damage Control Resuscitation (RDCR)	JUN 09-11, 2014	Bergen, NORWAY			Hemorrhagic shock; lung injury; vascular permeability; spray-dried plasma; mice	TRAUMATIC BRAIN-INJURY; DAMAGE CONTROL RESUSCITATION; RED-BLOOD-CELL; LYOPHILIZED PLASMA; BETA-CATENIN; JUNCTIONS; MORTALITY; RATIOS; MODEL; COAGULOPATHY	BACKGROUND: In retrospective and prospective observational studies, fresh frozen plasma (FFP) has been associated with a survival benefit in massively transfused trauma patients. A dry plasma product, such as spray-dried plasma (SDP), offers logistical advantages over FFP. Recent studies on FFP have demonstrated that FFP modulates systemic vascular stability and inflammation. The effect of SDP on these measures has not been previously examined. This study compares SDP with FFP using in vitro assays of endothelial function and in vivo assays of lung injury using a mouse model of hemorrhagic shock (HS) and trauma. METHODS: FFP, SDP, and lactated Ringer's (LR) solution were compared in vitro using assays of endothelial cell (EC) permeability, cytokine production and content, gene expression, as well as tight and adherens junction stability. All resuscitation products were also compared in a murine model of HS. Mean arterial pressures and physiologic measures were assessed. Pulmonary vascular permeability was measured using tagged dextran. Lung tissues were stained for CD68, VE-cadherin, and occludin. RESULTS: Treatment of ECs with FFP and SDP, but not LR, preserved the integrity of EC monolayers in vitro and resulted in similar EC gene expression patterns and cytokine/growth factor production. FFP and SDP also reduced HS-induced pulmonary vascular permeability in vivo to the same extent. In mice with HS, mean arterial pressures and base excess were corrected by both FFP and SDP to levels observed in sham-treated mice. Treatment after HS with FFP and SDP but not LR solution reduce alveolar wall thickening, leukocyte infiltration, and the breakdown of EC junctions, as measured by staining for VE-cadherin, and occludin. CONCLUSION: Both FFP and SDP similarly modulate pulmonary vascular integrity, permeability, and inflammation in vitro and in vivo in a murine model of HS and trauma. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Potter, Daniel R.; Baimukanova, Gail; Keating, Sheila M.; Deng, Xutao; Chu, Jeffrey A.; Gibb, Stuart L.; Muench, Marcus O.; Fomin, Marina E.; Pati, Shibani] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA; [Muench, Marcus O.; Pati, Shibani] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Peng, Zhanglong] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX USA; [Spinella, Philip C.] Washington Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO USA; [Kozar, Rosemary] Univ Maryland, Ctr Shock Trauma, Baltimore, MD 21201 USA	Pati, S (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.	spati@bloodsystems.org	Muench, Marcus O./C-5025-2009	Muench, Marcus O./0000-0001-8946-6605; Keating, Sheila/0000-0002-8324-3694			Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; [Anonymous], 2002, BIOTECHNIQUES; Benest AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070459; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; del Junco DJ, 2013, J TRAUMA ACUTE CARE, V75, pS24, DOI 10.1097/TA.0b013e31828fa3b9; Derouette JP, 2009, ATHEROSCLEROSIS, V206, P69, DOI 10.1016/j.atherosclerosis.2009.02.020; Duan CJ, 2011, SHOCK, V36, P54, DOI 10.1097/SHK.0b013e318214475e; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Li XR, 2001, INT J BIOCHEM CELL B, V33, P421, DOI 10.1016/S1357-2725(01)00027-9; London NR, 2009, ANGIOGENESIS, V12, P149, DOI 10.1007/s10456-009-9130-z; Maegele M, 2008, VOX SANG, V95, P112, DOI 10.1111/j.1423-0410.2008.01074.x; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Martinaud C, 2011, J TRAUMA, V71, P4; Martinaud C, 2011, J TRAUMA, V71, P1761, DOI 10.1097/TA.0b013e31822f1285; Martinaud C, 2011, J TRAUMA, V71, P1091, DOI 10.1097/TA.0b013e31822a8fd5; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Pacurari M, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/689360; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Peng ZL, 2012, SHOCK, V38, P57, DOI 10.1097/SHK.0b013e31825a188a; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Sailliol A, 2013, TRANSFUSION, V53, p65S, DOI 10.1111/trf.12038; Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147; Sawant DA, 2011, J TRAUMA, V70, P481, DOI 10.1097/TA.0b013e31820b3ed7; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Simon TL, 2011, ROSSIS PRINCIPLES TR; Tharakan B, 2012, SHOCK, V37, P306, DOI 10.1097/SHK.0b013e318240b564; Tollofsrud S, 2001, ANESTH ANALG, V93, P823, DOI 10.1097/00000539-200110000-00005; Wataha K, 2013, TRANSFUSION, V53, p80S, DOI 10.1111/trf.12040	49	44	45	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2015	78			1			S7	S17		10.1097/TA.0000000000000630			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DJ7QU	WOS:000374406700003	26002267				2021-06-18	
J	Sun, D; Daniels, TE; Rolfe, A; Waters, M; Hamm, R				Sun, Dong; Daniels, Teresa E.; Rolfe, Andrew; Waters, Michael; Hamm, Robert			Inhibition of Injury-Induced Cell Proliferation in the Dentate Gyrus of the Hippocampus Impairs Spontaneous Cognitive Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						neurogenesis; hippocampus; traumatic brain injury; cognition; Morris water maze; Ara-C	ENDOTHELIAL GROWTH-FACTOR; ADULT NEUROGENESIS; CYTOSINE-ARABINOSIDE; GRANULE CELLS; FOREBRAIN NEUROGENESIS; ENHANCED NEUROGENESIS; CONDITIONAL ABLATION; NEURONS; RATS; MEMORY	Neurogenesis persists throughout life in the neurogenic regions of the mature mammalian brain, and this response is enhanced after traumatic brain injury (TBI). In the hippocampus, adult neurogenesis plays an important role in hippocampal-dependent learning and memory functions and is thought to contribute to the spontaneous cognitive recovery observed after TBI. Utilizing an antimitotic agent, arabinofuranosyl cytidine (Ara-C), the current study investigated the direct association of injury-induced hippocampal neurogenesis with cognitive recovery. In this study, adult rats received a moderate lateral fluid percussion injury followed by a 7-day intraventricular infusion of 2% Ara-C or vehicle. To examine the effect of Ara-C on cell proliferation, animals received intraperitoneal injections of 5-bromo-2-deoxyuridine (BrdU), to label dividing cells, and were sacrificed at 7 days after injury. Brain sections were immunostained for BrdU or doublecortin (DCX), and the total number of BrdU(+) or DCX+ cells in the hippocampus was quantified. To examine the outcome of inhibiting the injury-induced cell proliferative response on cognitive recovery, animals were assessed on Morris water maze (MWM) tasks at 21-25 or 56-60 days postinjury. We found that a 7-day infusion of Ara-C significantly reduced the total number of BrdU(+) and DCX+ cells in the dentate gyrus (DG) in both hemispheres. Moreover, inhibition of the injury-induced cell proliferative response in the DG completely abolished the innate cognitive recovery on MWM performance at 56-60 days postinjury. These results support the causal relationship of injury-induced hippocampal neurogenesis on cognitive functional recovery and suggest the importance of this endogenous repair mechanism on restoration of hippocampal function.	[Sun, Dong; Rolfe, Andrew; Hamm, Robert] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Sun, Dong; Daniels, Teresa E.; Waters, Michael] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia Campus,POB 980631, Richmond, VA 23298 USA.	dsun@vcu.edu		Daniels, Teresa/0000-0002-7826-1556	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086, NS078710]; NIH-NINDS (National Institute of Neurological Disorders and Stroke) center core grant [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055086, R21NS078710, P30NS047463] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health (NIH; grant nos.: NS055086 and NS078710; to D.S.). Microscopy work was performed at the Virginia Commonwealth University Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS (National Institute of Neurological Disorders and Stroke) center core grant 5P30NS047463.	Arruda-Carvalho M, 2011, J NEUROSCI, V31, P15113, DOI 10.1523/JNEUROSCI.3432-11.2011; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Calderon-Martinez D, 2002, J NEUROSCI METH, V114, P1, DOI 10.1016/S0165-0270(01)00493-9; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Hamada A, 2002, CLIN PHARMACOKINET, V41, P705, DOI 10.2165/00003088-200241100-00002; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hernandez-Rabaza V, 2009, NEUROSCIENCE, V159, P59, DOI 10.1016/j.neuroscience.2008.11.054; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; Mizumatsu S, 2003, CANCER RES, V63, P4021; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OORSCHOT DE, 1989, NEUROSCI LETT, V102, P332, DOI 10.1016/0304-3940(89)90101-8; Parent JM, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01631.x; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Singer BH, 2009, J COMP NEUROL, V514, P567, DOI 10.1002/cne.22052; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Suarez-Pereira I, 2015, HIPPOCAMPUS, V25, P51, DOI 10.1002/hipo.22349; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wei YJ, 2009, CELL TISSUE RES, V337, P361, DOI 10.1007/s00441-009-0836-4; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015	55	44	44	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					495	505		10.1089/neu.2014.3545			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400009	25242459	Green Published			2021-06-18	
J	Bouzat, P; Marques-Vidal, P; Zerlauth, JB; Sala, N; Suys, T; Schoettker, P; Bloch, J; Daniel, RT; Levivier, M; Meuli, R; Oddo, M				Bouzat, Pierre; Marques-Vidal, Pedro; Zerlauth, Jean-Baptiste; Sala, Nathalie; Suys, Tamarah; Schoettker, Patrick; Bloch, Jocelyne; Daniel, Roy T.; Levivier, Marc; Meuli, Reto; Oddo, Mauro			Accuracy of Brain Multimodal Monitoring to Detect Cerebral Hypoperfusion After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						brain multimodal monitoring; brain oxygen; cerebral blood flow; intracranial pressure; microdialysis; neuromonitoring; traumatic brain injury	TISSUE OXYGEN-TENSION; SEVERE HEAD TRAUMA; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; MICRODIALYSIS; CT; TOMOGRAPHY; DELIVERY; LACTATE	Objective: To examine the accuracy of brain multimodal monitoring consisting of intracranial pressure, brain tissue Po-2, and cerebral microdialysis in detecting cerebral hypoperfusion in patients with severe traumatic brain injury. Design: Prospective single-center study. Patients: Patients with severe traumatic brain injury. Setting: Medico-surgical ICU, university hospital. Intervention: Intracranial pressure, brain tissue Po-2, and cerebral microdialysis monitoring (right frontal lobe, apparently normal tissue) combined with cerebral blood flow measurements using perfusion CT. Measurements and Main Results: Cerebral blood flow was measured using perfusion CT in tissue area around intracranial monitoring (regional cerebral blood flow) and in bilateral supra-ventricular brain areas (global cerebral blood flow) and was matched to cerebral physiologic variables. The accuracy of intracranial monitoring to predict cerebral hypoperfusion (defined as an oligemic regional cerebral blood flow < 35 mU100g/min) was examined using area under the receiver-operating characteristic curves. Thirty perfusion CT scans (median, 27hr [interquartile range, 20-45] after traumatic brain injury) were performed on 27 patients (age, 39 yr [24-54 yr]; Glasgow Coma Scale, 7 [6-8]; 24/27 [89%] with diffuse injury). Regional cerebral blood flow correlated significantly with global cerebral blood flow (Pearson r = 0.70, p < 0.01). Compared with normal regional cerebral blood flow (n = 16), low regional cerebral blood flow (n = 14) measurements had a higher proportion of samples with intracranial pressure more than 20mm Hg (13% vs 30%), brain tissue Po-2, less than 20mm Hg (9% vs 20%), cerebral microdialysis glucose less than 1 mmol/L (22% vs 57%), and lactate/pyruvate ratio more than 40 (4% vs 14%; all p < 0.05). Compared with intracranial pressure monitoring alone (area under the receiver-operating characteristic curve, 0.74 [95% Cl, 0.61-0.87]), monitoring intracranial pressure + brain tissue Po, (area under the receiver-operating characteristic curve, 0.84 [0.74-0.93]) or intracranial pressure + brain tissue Po-2+ cerebral microdialysis (area under the receiver-operating characteristic curve, 0.88 [0.79-0.96]) was significantly more accurate in predicting low regional cerebral blood flow (both p < 0.05). Conclusion: Brain multimodal monitoring including intracranial pressure, brain tissue- Po-2, and cerebral microdialysis is more accurate than intracranial pressure monitoring alone in detecting cerebral hypoperfusion at the bedside in patients with severe traumatic brain injury and predominantly diffuse injury.	[Bouzat, Pierre; Sala, Nathalie; Suys, Tamarah; Oddo, Mauro] CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, Fac Biol & Med, Lausanne, Switzerland; [Bouzat, Pierre] Univ Grenoble 1, Grenoble, France; [Marques-Vidal, Pedro] CHUV Lausanne Univ Hosp, Dept Internal Med, Fac Biol & Med, Lausanne, Switzerland; [Zerlauth, Jean-Baptiste; Meuli, Reto] CHUV Lausanne Univ Hosp, Fac Biol & Med, Dept Radiol, Lausanne, Switzerland; [Schoettker, Patrick] CHUV Lausanne Univ Hosp, Fac Biol & Med, Dept Anesthesiol, Lausanne, Switzerland; [Bloch, Jocelyne; Daniel, Roy T.; Levivier, Marc] CHUV Lausanne Univ Hosp, Fac Biol & Med, Div Neurosurg, Lausanne, Switzerland	Oddo, M (corresponding author), CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, Fac Biol & Med, Lausanne, Switzerland.	mauro.oddo@chuv.ch	Schoettker, Patrick/AAE-4462-2020; Marques-Vidal, Pedro M/C-9449-2009; Bouzat, Pierre/AAC-4105-2019; Oddo, Mauro/R-3370-2016; Bloch, Jocelyne/A-9668-2017; Bouzat, Pierre/L-6881-2014	Schoettker, Patrick/0000-0001-5370-048X; Marques-Vidal, Pedro M/0000-0002-4548-8500; Bouzat, Pierre/0000-0003-4667-6738; Oddo, Mauro/0000-0002-6155-2525; Bloch, Jocelyne/0000-0002-6405-1590; Levivier, Marc/0000-0002-6273-2595	La Fondation des Gueules Cassees; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Novartis Foundation for Biomedical Research	Dr. Bouzat received research grants from La Fondation des Gueules Cassees. Dr. Oddo received research grants from the Swiss National Science Foundation and the Novartis Foundation for Biomedical Research. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Asgari S, 2013, NEUROCRIT CARE, V19, P56, DOI 10.1007/s12028-013-9821-6; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Carre E, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00146; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dagal A, 2011, CURR OPIN ANESTHESIO, V24, P131, DOI 10.1097/ACO.0b013e3283445898; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Eriksson EA, 2012, CLIN NEUROPHYSIOL, V123, P1255, DOI 10.1016/j.clinph.2011.08.035; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Huang APH, 2014, J NEUROSURG, V120, P473, DOI 10.3171/2013.10.JNS13103; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall RS, 2001, BRAIN, V124, P1208, DOI 10.1093/brain/124.6.1208; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Oddo M, 2012, CURR OPIN CRIT CARE, V18, P111, DOI 10.1097/MCC.0b013e32835132a5; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Valadka AB, 2002, ACT NEUR S, V81, P299; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2001, AM J NEURORADIOL, V22, P905	38	44	45	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					445	452		10.1097/CCM.0000000000000720			8	Critical Care Medicine	General & Internal Medicine	AZ2YX	WOS:000348096200022	25393700				2021-06-18	
J	Yuan, WH; Wade, SL; Babcock, L				Yuan, Weihong; Wade, Shari L.; Babcock, Lynn			Structural Connectivity Abnormality in Children with Acute Mild Traumatic Brain Injury using Graph Theoretical Analysis	HUMAN BRAIN MAPPING			English	Article						acute; mTBI; structural connectivity; graph theoretical analysis; DTI; small-worldness; network	SMALL-WORLD; CORTICAL THICKNESS; FUNCTIONAL NETWORK; COGNITIVE DECLINE; WORKING-MEMORY; ORGANIZATION; ADOLESCENTS; TRACTOGRAPHY; ASSOCIATION; MODERATE	The traumatic biomechanical forces associated with mild traumatic brain injury (mTBI) typically impart diffuse, as opposed to focal, brain injury potentially disrupting the structural connectivity between neural networks. Graph theoretical analysis using diffusion tensor imaging was used to assess injury-related differences in structural connectivity between 23 children (age 11-16 years) with mTBI and 20 age-matched children with isolated orthopedic injuries (OI) scanned within 96 h postinjury. The distribution of hub regions and the associations between alterations in regional network measures and symptom burden, as assessed by the postconcussion symptom scale score (PCSS), were also examined. In comparison to the OI group, the mTBI group was found to have significantly higher small-worldness (P<0.0001), higher normalized clustering coefficients (P<0.0001), higher normalized characteristic path length (P=0.007), higher modularity (P=0.0005), and lower global efficiency (P<0.0001). A series of hub regions in the mTBI group were found to have significant alterations in regional network measures including nodal degree, nodal clustering coefficient, and nodal between-ness centrality. Correlation analysis showed that PCSS total score acquired at the time of imaging was significantly associated with the nodal degree of two hubs, the superior frontal gyrus at orbital section and the middle frontal gyrus. These findings provide new evidence of acute white matter alteration at both global and regional network level following mTBI in children furthering our understanding of underlying mechanisms of acute neurological insult associated with mTBI. Hum Brain Mapp 36:779-792, 2015. (c) 2014 Wiley Periodicals, Inc.	[Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Div Radiol, Cincinnati, OH 45229 USA; [Yuan, Weihong; Wade, Shari L.; Babcock, Lynn] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Babcock, Lynn] Cincinnati Childrens Hosp Med Ctr, Div Pediat Emergency Med, Dept Pediat, Cincinnati, OH 45229 USA	Yuan, WH (corresponding author), Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, 3333 Burnet Ave,ML 5033, Cincinnati, OH 45229 USA.	weihong.yuan@cchmc.org		Babcock, Lynn/0000-0002-2658-6893	KL2 Mentored Career Award from the University of Cincinnati Center for Clinical and Translational Science and Training; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR026315] Funding Source: NIH RePORTER	Contract grant sponsor: KL2 Mentored Career Award (PI: Babcock) from the University of Cincinnati Center for Clinical and Translational Science and Training.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achenbach TM, 1983, MANUAL CHILD BEHAV C; Ajilore O, 2014, AM J GERIAT PSYCHIAT, V22, P102, DOI 10.1016/j.jagp.2013.10.004; Baria AT, 2013, NEUROIMAGE, V73, P144, DOI 10.1016/j.neuroimage.2013.01.072; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Bernhardt BC, 2011, CEREB CORTEX, V21, P2147, DOI 10.1093/cercor/bhq291; Betzel R F, 2013, NETW SCI, V1, P353, DOI [DOI 10.1017/NWS.2013.19, 10.1017/nws.2013.19]; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bullmore ET, 2011, ANNU REV CLIN PSYCHO, V7, P113, DOI 10.1146/annurev-clinpsy-040510-143934; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Cook LG, 2013, J INT NEUROPSYCH SOC, V19, P508, DOI 10.1017/S1355617712001452; Correa DD, 2013, BRAIN IMAGING BEHAV, V7, P478, DOI 10.1007/s11682-013-9221-8; Daianu M, 2013, BRAIN CONNECT, V3, P407, DOI 10.1089/brain.2012.0137; Dennis EL, 2013, NEUROIMAGE, V64, P671, DOI 10.1016/j.neuroimage.2012.09.004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Humphries MD, 2006, P ROY SOC B-BIOL SCI, V273, P503, DOI 10.1098/rspb.2005.3354; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kim DJ, 2011, BRAIN CONNECT, V1, P473, DOI 10.1089/brain.2011.0053; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leunissen I, 2014, HUM BRAIN MAPP, V35, P2459, DOI 10.1002/hbm.22341; Lipszyc J, 2014, ARCH CLIN NEUROPSYCH, V29, P289, DOI 10.1093/arclin/acu004; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048846; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Onoda K, 2013, NEUROSCI LETT, V556, P104, DOI 10.1016/j.neulet.2013.10.023; Ottet MC, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00402; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Reijmer YD, 2013, NEUROLOGY, V80, P1370, DOI 10.1212/WNL.0b013e31828c2ee5; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Shi F, 2012, NEUROIMAGE, V62, P1622, DOI 10.1016/j.neuroimage.2012.05.026; Sporns O, 2013, CURR OPIN NEUROBIOL, V23, P162, DOI 10.1016/j.conb.2012.11.015; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vaessen MJ, 2012, CEREB CORTEX, V22, P2139, DOI 10.1093/cercor/bhr298; van den Heuvel MP, 2013, JAMA PSYCHIAT, V70, P783, DOI 10.1001/jamapsychiatry.2013.1328; van Meer MPA, 2012, J NEUROSCI, V32, P4495, DOI 10.1523/JNEUROSCI.3662-11.2012; Vecchio F, 2014, J ALZHEIMERS DIS, V41, P113, DOI 10.3233/JAD-132087; Wang R, 2007, P INT SOC MAG RESON, V15, P3720; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Yan CG, 2011, CEREB CORTEX, V21, P449, DOI 10.1093/cercor/bhq111; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zalesky A, 2011, BIOL PSYCHIAT, V69, P80, DOI 10.1016/j.biopsych.2010.08.022; Zhang ZQ, 2011, BRAIN, V134, P2912, DOI 10.1093/brain/awr223; Zuo NM, 2012, NEUROSCI BULL, V28, P375, DOI 10.1007/s12264-012-1245-3	64	44	45	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	FEB	2015	36	2					779	792		10.1002/hbm.22664			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AZ7DN	WOS:000348378800029	25363671	Green Published, Green Accepted			2021-06-18	
J	Dennis, EL; Jin, Y; Villalon-Reina, JE; Zhan, L; Kernan, CL; Babikian, T; Mink, RB; Babbitt, CJ; Johnson, JL; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Jin, Yan; Villalon-Reina, Julio E.; Zhan, Liang; Kernan, Claudia L.; Babikian, Talin; Mink, Richard B.; Babbitt, Christopher J.; Johnson, Jeffrey L.; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			White matter disruption in moderate/severe pediatric traumatic brain injury: Advanced tract-based analyses	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Traumatic brain injury; Longitudinal; Pediatric; Tractography	DIFFUSION-TENSOR; AXONAL INJURY; CORPUS-CALLOSUM; CELLULAR EDEMA; MRI; MICROSTRUCTURE; ANISOTROPY; CHILDREN	Traumatic brain injury (TBI) is the leading cause of death and disability in children and can lead to a wide range of impairments. Brain imaging methods such as DTI (diffusion tensor imaging) are uniquely sensitive to the white matter(WM) damage that is common in TBI. However, higher-level analyses using tractography are complicated by the damage and decreased FA (fractional anisotropy) characteristic of TBI, which can result in premature tract endings. We used the newly developed autoMATE (automated multi-atlas tract extraction) method to identify differences in WM integrity. 63 pediatric patients aged 8-19 years with moderate/severe TBI were examined with cross sectional scanning at one or two time points after injury: a post-acute assessment 1-5 months post-injury and a chronic assessment 13-19 months post-injury. A battery of cognitive function tests was performed in the same time periods. 56 children were examined in the first phase, 28 TBI patients and 28 healthy controls. In the second phase 34 children were studied, 17 TBI patients and 17 controls (27 participants completed both post-acute and chronic phases). We did not find any significant group differences in the post-acute phase. Chronically, we found extensive group differences, mainly for mean and radial diffusivity (MD and RD). In the chronic phase, we found higher MD and RD across a wide range of WM. Additionally, we found correlations between these WM integrity measures and cognitive deficits. This suggests a distributed pattern of WM disruption that continues over the first year following a TBI in children. (C) 2015 The Authors. Published by Elsevier Inc.	[Dennis, Emily L.; Jin, Yan; Villalon-Reina, Julio E.; Zhan, Liang; Thompson, Paul M.] Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Imaging Genet Ctr, Los Angeles, CA 90033 USA; [Kernan, Claudia L.; Babikian, Talin; Asarnow, Robert F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Mink, Richard B.] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA; [Mink, Richard B.] Los Angeles BioMed Res Inst, Torrance, CA USA; [Babbitt, Christopher J.] Miller Childrens Hosp, Dept Pediat, Long Beach, CA USA; [Johnson, Jeffrey L.] LAC USC Med Ctr, Dept Pediat, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Div Pediat Neurol, UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Thompson, Paul M.] Univ So Calif, Dept Neurol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Pediat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Psychiat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Radiol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Engn, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA	Thompson, PM (corresponding author), Univ So Calif, Keck Sch Med, 2001 N Soto St, Los Angeles, CA 90033 USA.	pthomp@usc.edu	Thompson, Paul M/C-4194-2018; Dennis, Emily/AAD-5223-2021; Jin, Yan/N-5037-2016	Thompson, Paul M/0000-0002-4720-8867; Jin, Yan/0000-0001-9392-5552; Dennis, Emily/0000-0001-7112-4009	NICHDS [R01 HD061504]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EB008432, R01 AG040060, U54 EB020403, R01 NS080655]; UCLA BIRC [NS027544, NS05489]; Child Neurology Foundation; Jonathan Drown Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922, R01EB008432, U54EB020403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, K99NS096116, R01NS080655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040060] Funding Source: NIH RePORTER	This study was supported by the NICHDS (R01 HD061504). ELD, YJ, JV, LZ, and PT are also supported by NIH grants to PT: R01 EB008432, R01 AG040060, U54 EB020403, and R01 NS080655. CCG is supported by the UCLA BIRC, NS027544, NS05489, Child Neurology Foundation, and the Jonathan Drown Foundation. Scanning was supported by the Staglin IMHRO Center for Cognitive Neuroscience. We gratefully acknowledge the contributions of Alma Martinez and Alma Ramirez in assisting with participant recruitment and study coordination. Finally, the authors thank the participants and their families for contributing their time to this study.	Aganj I, 2011, MED IMAGE ANAL, V15, P414, DOI 10.1016/j.media.2011.01.003; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Catani M., 2012, ATLAS HUMAN BRAIN CO; Catani M, 2007, P NATL ACAD SCI USA, V104, P17163, DOI 10.1073/pnas.0702116104; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Hoogman M., 2014, BRAIN STRUCTURE ADHD; Hua X, 2008, NEUROIMAGE, V43, P458, DOI 10.1016/j.neuroimage.2008.07.013; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jin Y, 2014, NEUROIMAGE, V100, P75, DOI 10.1016/j.neuroimage.2014.04.048; Jin Y, 2013, I S BIOMED IMAGING, P512, DOI 10.1109/isbi.2013.6556524; Jin Yan, 2012, Multimodal Brain Image Anal (2012), V7509, P147, DOI 10.1007/978-3-642-33530-3_12; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinnunen K. M., 2010, BRAIN; Kochunov P, 2012, NEUROBIOL AGING, V33, P9, DOI 10.1016/j.neurobiolaging.2010.01.014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Prasad G., 2011, ATLAS BASED FIBER CL, P1; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Thomason ME, 2011, ANNU REV CLIN PSYCHO, V7, P63, DOI 10.1146/annurev-clinpsy-032210-104507; Wechsler D., 2003, WECHSLER INTELLIGENC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	50	44	45	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	7						493	505		10.1016/j.nicl.2015.02.002			13	Neuroimaging	Neurosciences & Neurology	DI0GE	WOS:000373172600054	25737958	DOAJ Gold, Green Published			2021-06-18	
J	Theodoroff, SM; Lewis, MS; Folmer, RL; Henry, JA; Carlson, KF				Theodoroff, Sarah M.; Lewis, M. Samantha; Folmer, Robert L.; Henry, James A.; Carlson, Kathleen F.			Hearing Impairment and Tinnitus: Prevalence, Risk Factors, and Outcomes in US Service Members and Veterans Deployed to the Iraq and Afghanistan Wars	EPIDEMIOLOGIC REVIEWS			English	Article						hearing loss; prevalence; risk factors; tinnitus; veterans' health	TRAUMATIC BRAIN-INJURY; OPERATION ENDURING FREEDOM; COMBAT WOUNDS; BLAST INJURY; GLOBAL WAR; MECHANISM; TERROR; AIDS	Hearing loss and tinnitus are the 2 most prevalent service-connected disabilities among veterans in the United States. Veterans of Operations Enduring Freedom, Iraqi Freedom, and New Dawn have been exposed to multiple hazards associated with these conditions, such as blasts/explosions, ototoxic chemicals, and most notably high levels of noise. We conducted a systematic literature review of evidence on 1) prevalence of, 2) risk and protective factors for, and 3) functional and quality-of-life outcomes of hearing impairment and tinnitus in US Operations Enduring Freedom, Iraqi Freedom, and New Dawn veterans and military personnel. We identified studies published from 2001 through 2013 using PubMed, PsycINFO, REHABDATA, Cochrane Library, pearling, and expert recommendation. Peer-reviewed English language articles describing studies of 30 or more adults were included if they informed one or more key questions. A total of 839 titles/abstracts were reviewed for relevance by investigators trained in critical analysis of literature; 14 studies met inclusion criteria. Of these, 13 studies presented data on prevalence and 4 on risk/protective factors, respectively. There were no included studies reporting on outcomes. Findings from this systematic review will help inform clinicians, researchers, and policy makers on future resource and research needs pertaining to hearing impairment and tinnitus in this newest generation of veterans.	[Theodoroff, Sarah M.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA	Theodoroff, SM (corresponding author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.	sarah.theodoroff@va.gov	Folmer, Robert L/E-3105-2010		Department of Defense Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PR121146]; Veterans Health Administration Health Services Research and Development ServiceUS Department of Veterans Affairs [CDA 08-025]; National Center for Rehabilitative Auditory Research - VA RR&D at the Portland VA Medical Center [C9230C]	This work was supported, in part, by the Department of Defense Congressionally Directed Medical Research Programs (PR121146 to J. A. H.) and a career development grant from the Veterans Health Administration Health Services Research and Development Service (CDA 08-025 to K. F. C.). Additional support was provided by the National Center for Rehabilitative Auditory Research (funded by VA RR&D grant C9230C) at the Portland VA Medical Center.	[Anonymous], 2012, RS21405 CRS; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Belmont PJ, 2012, J TRAUMA ACUTE CARE, V73, P3, DOI 10.1097/TA.0b013e318250bfb4; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Defense Casualty Analysis System US Department of Defense, 2014, US MIL CAS GWOT CAS; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2014, PRINC WARS WHICH US; Department of Veterans Affairs Office of Research and Development, 2013, TRAUM BRAIN INJ SPOT; Dobie RobertA., 2004, TINNITUS THEORY MANA, P1; Donnelly K, 2008, DEP VET AFF QUERI NA; Dougherty AL, 2013, J REHABIL RES DEV, V50, P893, DOI 10.1682/JRRD.2012.02.0024; Epidemiology Program Post-Deployment Health Group Office of Public Health Veterans Health Administration Department of Veterans Affairs, 2014, AN VA HLTH CAR UT OP; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Folmer RL, 2011, J REHABIL RES DEV, V48, P503, DOI 10.1682/JRRD.2010.07.0138; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Geiling J, 2012, MIL MED, V177, P1235, DOI 10.7205/MILMED-D-12-00031; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Henry James A, 2008, Trends Amplif, V12, P170, DOI 10.1177/1084713808319941; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2014, GULF WAR HLTH, V9; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Mrena R, 2004, ACTA OTO-LARYNGOL, V124, P946, DOI 10.1080/00016480310017045; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Nagorski T, 2010, ABC NEWS; National Research Council, 2006, NOIS MIL SERV IMPL H; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papesh MA, 2014, 37 ANN MIDWINTER M A; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Searchfield GD, 2010, INT J AUDIOL, V49, P574, DOI 10.3109/14992021003777267; Shekhawat GS, 2013, J AM ACAD AUDIOL, V24, P747, DOI 10.3766/jaaa.24.8.11; Surjan G, 1999, INT J MED INFORM, V54, P77, DOI 10.1016/S1386-5056(98)00171-3; U.S. Department of Defense, 1997, MILSTD1474D US DEP D; *US DEP HHS, 2003, DHHS PUBL; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P126, DOI 10.1016/j.jclinepi.2011.08.002; Veterans Benefits Administration US Department of Veterans Affairs, 2014, ANN BEN REPO FISC YE; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Williamson V., 2009, INVISIBLE WOUNDS PSY; Zaugg T. L., 2002, P 7 INT TINN SEM, P226	46	44	45	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0193-936X	1478-6729		EPIDEMIOL REV	Epidemiol. Rev.		2015	37	1					71	85		10.1093/epirev/mxu005			15	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CL3ZX	WOS:000356892800006	25600417	Bronze			2021-06-18	
J	Chevignard, MP; Lind, K				Chevignard, Mathilde P.; Lind, Katia			Long-term outcome of abusive head trauma	PEDIATRIC RADIOLOGY			English	Article						Abusive head trauma; Shaken baby syndrome; Traumatic brain injury; Long-term outcome; Cognitive impairment; Children	SHAKEN-BABY-SYNDROME; BRAIN-INJURY; YOUNG-CHILDREN; IMPACT SYNDROME; FOLLOW-UP; RADIOLOGICAL FINDINGS; SYNDROME GUIDELINES; COGNITIVE SEQUELAE; ROBUST DIAGNOSIS; PREDICTIVE-VALUE	Abusive head trauma is a severe inflicted traumatic brain injury, occurring under the age of 2 years, defined by an acute brain injury (mostly subdural or subarachnoidal haemorrhage), where no history or no compatible history with the clinical presentation is given. The mortality rate is estimated at 20-25% and outcome is extremely poor. High rates of impairments are reported in a number of domains, such as delayed psychomotor development; motor deficits (spastic hemiplegia or quadriplegia in 15-64%); epilepsy, often intractable (11-32%); microcephaly with corticosubcortical atrophy (61-100%); visual impairment (18-48%); language disorders (37-64%), and cognitive, behavioral and sleep disorders, including intellectual deficits, agitation, aggression, tantrums, attention deficits, memory, inhibition or initiation deficits (23-59%). Those combined deficits have obvious consequences on academic achievement, with high rates of special education in the long term. Factors associated with worse outcome include demographic factors (lower parental socioeconomic status), initial severe presentation (e.g., presence of a coma, seizures, extent of retinal hemorrhages, presence of an associated cranial fracture, extent of brain lesions, cerebral oedema and atrophy). Given the high risk of severe outcome, long-term comprehensive follow-up should be systematically performed to monitor development, detect any problem and implement timely adequate rehabilitation interventions, special education and/or support when necessary. Interventions should focus on children as well as families, providing help in dealing with the child's impairment and support with psychosocial issues. Unfortunately, follow-up of children with abusive head trauma has repeatedly been reported to be challenging, with very high attrition rates.	[Chevignard, Mathilde P.] St Maurice Hosp, Rehabil Dept Children Acquired Neurol Injury, F-94410 St Maurice, France; [Chevignard, Mathilde P.] Univ Paris 06, Sorbonne Univ, UMR 7371, UMRS 1146,LIB, Paris, France; [Chevignard, Mathilde P.] CNRS, UMR 7371, LIB, Paris, France; [Chevignard, Mathilde P.] INSERM, UMRS 1146, LIB, Paris, France; [Lind, Katia] Necker Enfants Malades Hosp, Paris, France; [Lind, Katia] Paris Descartes Univ, Paris, France	Chevignard, MP (corresponding author), St Maurice Hosp, Rehabil Dept Children Acquired Neurol Injury, 14 Rue Val Osne, F-94410 St Maurice, France.	m.chevignard@hopitaux-st-maurice.fr					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Ashton R, 2010, J CHILD PSYCHOL PSYC, V51, P967, DOI 10.1111/j.1469-7610.2010.02272.x; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Benayer B, 2000, APRES DEVENIR POPULA, P159; Bonnier C, 2006, ARCH PEDIATRIE, V13, P531, DOI 10.1016/j.arcped.2006.03.113; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; Bourgeois M, 2008, CHILD NERV SYST, V24, P169, DOI 10.1007/s00381-007-0493-4; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chevignard M, 2010, CHILD CARE HLTH DEV, V36, P31, DOI 10.1111/j.1365-2214.2009.00949.x; Chevignard MP, 2010, CURR OPIN NEUROL, V23, P695, DOI 10.1097/WCO.0b013e328340296f; David TJ, 1999, J ROY SOC MED, V92, P556, DOI 10.1177/014107689909201105; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Fanconi M, 2010, EUR J PEDIATR, V169, P1023, DOI 10.1007/s00431-010-1175-x; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; Friedman J, 2012, CHILD ABUSE NEGLECT, V36, P760, DOI 10.1016/j.chiabu.2012.07.008; Greiner MV, 2012, CHILD NERV SYST, V28, P889, DOI 10.1007/s00381-012-1714-z; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Ilves P, 2010, ACTA PAEDIATR, V99, P1329, DOI 10.1111/j.1651-2227.2010.01820.x; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson AR, 2009, DEV DISABIL RES REV, V15, P124, DOI 10.1002/ddrr.63; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Kairys SW, 2001, PEDIATRICS, V108, P206; Kapapa T, 2010, J CHILD NEUROL, V25, P409, DOI 10.1177/0883073809340697; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Laurent-Vannier A., 2011, Annals of Physical and Rehabilitation Medicine, V54, P533, DOI 10.1016/j.rehab.2011.10.003; Laurent-Vannier A., 2011, Annals of Physical and Rehabilitation Medicine, V54, P600, DOI 10.1016/j.rehab.2011.10.002; Laurent-Vannier A, 2009, Ann Phys Rehabil Med, V52, P436, DOI 10.1016/j.rehab.2009.03.001; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Lind K, 2012, BRAIN INJURY, V26, P532; Lo T Y M, 2003, Pediatr Rehabil, V6, P47, DOI 10.1080/1363849031000109516; Minns RA, 2005, CLIN DEV MED, P364; OLIVER JE, 1975, BRIT MED J, V2, P262, DOI 10.1136/bmj.2.5965.262; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Stipanicic A, 2008, CHILD ABUSE NEGLECT, V32, P415, DOI 10.1016/j.chiabu.2007.07.008; Talvik I, 2007, ACTA PAEDIATR, V96, P1164, DOI 10.1111/j.1651-2227.2007.00362.x; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923; Tanoue K, 2013, ACTA PAEDIATR, V102, P805, DOI 10.1111/apa.12281; Tanoue K, 2012, ACTA PAEDIATR, V101, P614, DOI 10.1111/j.1651-2227.2012.02635.x; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Toure H, 2007, DEV NEUROREHABIL, P275; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2003, PEDIATR NEUROSURG, V39, P122, DOI 10.1159/000071648	65	44	45	0	41	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	DEC	2014	44			4	SI		548	558		10.1007/s00247-014-3169-8			11	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	AW4KG	WOS:000346249400004	25501726				2021-06-18	
J	Mondello, S; Buki, A; Barzo, P; Randall, J; Provuncher, G; Hanlon, D; Wilson, D; Kobeissy, F; Jeromin, A				Mondello, Stefania; Buki, Andras; Barzo, Pal; Randall, Jeff; Provuncher, Gail; Hanlon, David; Wilson, David; Kobeissy, Firas; Jeromin, Andreas			CSF and Plasma Amyloid-beta Temporal Profiles and Relationships with Neurological Status and Mortality after Severe Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							COMPUTED-TOMOGRAPHY FINDINGS; CEREBROSPINAL-FLUID; ALZHEIMER-DISEASE; HEAD-INJURY; PROTEIN; BETA-AMYLOID((1-42)); ENCEPHALOPATHY; BIOMARKERS; CORRELATE; DYNAMICS	The role of amyloid-beta (A beta) neuropathology and its significant changes in biofluids after traumatic brain injury (TBI) is still debated. We used ultrasensitive digital ELISA approach to assess amyloid-beta(1-42) (A beta 42) concentrations and time-course in cerebrospinal fluid (CSF) and in plasma of patients with severe TBI and investigated their relationship to injury characteristics, neurological status and clinical outcome. We found decreased CSF A beta 42 levels in TBI patients acutely after injury with lower levels in patients who died 6 months post-injury than in survivors. Conversely, plasma A beta 42 levels were significantly increased in TBI with lower levels in patients who survived. A trend analysis showed that both CSF and plasma A beta 42 levels strongly correlated with mortality. A positive correlation between changes in CSF A beta 42 concentrations and neurological status as assessed by Glasgow Coma Scale (GCS) was identified. Our results suggest that determination of A beta 42 may be valuable to obtain prognostic information in patients with severe TBI as well as in monitoring the response of the brain to injury.	[Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Buki, Andras] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Szeged, Hungary; [Randall, Jeff; Provuncher, Gail; Hanlon, David; Wilson, David; Jeromin, Andreas] Quanterix Corp, Lexington, MA USA; [Kobeissy, Firas] Amer Univ Beirut, Dept Biochem & Mol Biol, Beirut, Lebanon	Mondello, S (corresponding author), Univ Messina, Dept Neurosci, Messina, Italy.	stm_mondello@hotmail.com	Kobeissy, Firas/E-7042-2017; Mondello, Stefania/A-1813-2012	Kobeissy, Firas/0000-0002-5008-6944; Mondello, Stefania/0000-0002-8587-3614	Clinical Neuroscience Image Center of Hungarian Academy of Sciences (HAS) [SROP-4.2.2.A-11/1/KONV-2012-0017]; Hungarian Brain Research Program [KTIA_13_NAP-A-II/8]	This work was supported by Clinical Neuroscience Image Center of Hungarian Academy of Sciences (HAS) (SROP-4.2.2.A-11/1/KONV-2012-0017 and Hungarian Brain Research Program - Grant No. KTIA_13_NAP-A-II/8). We thank the patients and their families for their invaluable contributions.	Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Hansson O, 2010, NEUROBIOL AGING, V31, P357, DOI 10.1016/j.neurobiolaging.2008.03.027; Hernandez-Guillamon M, 2012, NEURODEGENER DIS, V10, P320, DOI 10.1159/000333811; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2013, J NEUROTRAUMA; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marti-Fabregas J, 2014, STROKE, V45, P413, DOI 10.1161/STROKEAHA.113.002838; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mehta PD, 2001, NEUROSCI LETT, V304, P102, DOI 10.1016/S0304-3940(01)01754-2; Mondello S., 2013, NEUROLOGY; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Strozyk D, 2003, NEUROLOGY, V60, P652, DOI 10.1212/01.WNL.0000046581.81650.D0; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263	30	44	44	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 10	2014	4								6446	10.1038/srep06446			6	Multidisciplinary Sciences	Science & Technology - Other Topics	AQ8NG	WOS:000343082100001	25300247	DOAJ Gold, Green Published			2021-06-18	
J	Erdodi, LA; Roth, RM; Kirsch, NL; Lajiness-O'neill, R; Medoff, B				Erdodi, Laszlo A.; Roth, Robert M.; Kirsch, Ned L.; Lajiness-O'neill, Renee; Medoff, Brent			Aggregating Validity Indicators Embedded in Conners' CPT-II Outperforms Individual Cutoffs at Separating Valid from Invalid Performance in Adults with Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						ADHD; Forensic neuropsychology; Performance validity testing; Assessment	MALINGERED NEUROCOGNITIVE DYSFUNCTION; WORD MEMORY TEST; SYMPTOM VALIDITY; RESPONSE BIAS; DIGIT SPAN; NEUROPSYCHOLOGICAL ASSESSMENT; EXAGGERATION; SPECIFICITY; VARIABLES; FAILURE	Continuous performance tests (CPT) provide a useful paradigm to assess vigilance and sustained attention. However, few established methods exist to assess the validity of a given response set. The present study examined embedded validity indicators (EVIs) previously found effective at dissociating valid from invalid performance in relation to well-established performance validity tests in 104 adults with TBI referred for neuropsychological testing. Findings suggest that aggregating EVIs increases their signal detection performance. While individual EVIs performed well at their optimal cutoffs, two specific combinations of these five indicators generally produced the best classification accuracy. A CVI-5A a parts per thousand yen3 had a specificity of .92-.95 and a sensitivity of .45-.54. At a parts per thousand yen4 the CVI-5B had a specificity of .94-.97 and sensitivity of .40-.50. The CVI-5s provide a single numerical summary of the cumulative evidence of invalid performance within the CPT-II. Results support the use of a flexible, multivariate approach to performance validity assessment.	[Erdodi, Laszlo A.] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Erdodi, Laszlo A.] London Hlth Sci Ctr, Univ Hosp, Clin Neuropsychol Serv, London, ON, Canada; [Erdodi, Laszlo A.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Serv, Lebanon, NH 03756 USA; [Kirsch, Ned L.; Medoff, Brent] Univ Michigan, Dept Phys Med & Rehabil, Adult Neurorehabil Day Treatment Program, Ann Arbor, MI 48109 USA; [Lajiness-O'neill, Renee] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA	Erdodi, LA (corresponding author), Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Serv, One Med Ctr Dr, Lebanon, NH 03756 USA.	lerdodi@gmail.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Balint Sara, 2008, Psychiatr Hung, V23, P324; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Conners K. C., 2004, CONNERS CONTINUOUS P; Erdodi LA, 2014, APPL NEUROPSYCH-ADUL, V21, P43, DOI 10.1080/09084282.2012.724036; Erdodi LA, 2010, J ATTEN DISORD, V14, P43, DOI 10.1177/1087054709347199; FEINSTEIN A, 1977, CLIN BIOSTATISTICS; Frederick RI, 2009, J HEAD TRAUMA REHAB, V24, P105, DOI 10.1097/HTR.0b013e31819b1210; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2005, CLIN NEUROPSYCHOL, V19, P121, DOI 10.1080/13854040490516604; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee G.J., 2012, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Leark RA, 2002, ARCH CLIN NEUROPSYCH, V17, P335, DOI 10.1016/S0887-6177(01)00118-4; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003	38	44	45	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2014	29	5					456	466		10.1093/arclin/acu026			11	Psychology, Clinical; Psychology	Psychology	AM6AZ	WOS:000339944200006	24957927	Green Published			2021-06-18	
J	Huang, YY; Nagata, K; Tedford, CE; Hamblin, MR				Huang, Ying-Ying; Nagata, Kazuya; Tedford, Clark E.; Hamblin, Michael R.			Low-level laser therapy (810 nm) protects primary cortical neurons against excitotoxicity in vitro	JOURNAL OF BIOPHOTONICS			English	Article						low-level laser therapy; cultured cortical neurons; excitotoxicity; reactive oxygen species; mitochondrial membrane potential glutamate. NMDA; kainic acid	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; TERM NEUROLOGICAL DEFICITS; NITRIC-OXIDE; CELL-DEATH; CYTOCHROME-C; HIPPOCAMPAL-NEURONS; ISCHEMIC-STROKE; INFRARED LIGHT; SPINAL-CORD	Excitotoxicity describes a pathogenic process whereby death of neurons releases large amounts of the excitatory neurotransmitter glutamate, which then proceeds to activate a set of glutamatergic receptors on neighboring neurons (glutamate, N-methyl-D-aspartate (NMDA), and kainate), opening ion channels leading to an influx of calcium ions producing mitochondrial dysfunction and cell death. Excitotoxicity contributes to brain damage after stroke, traumatic brain injury, and neurodegenerative diseases, and is also involved in spinal cord injury. We tested whether low level laser (light) therapy (LLLT) at 810 nm could protect primary murine cultured cortical neurons against excitotoxicity in vitro produced by addition of glutamate, NMDA or kainate. Although the prevention of cell death was modest but significant, LLLT (3 J/cm(2) delivered at 25 mW/cm(2) over 2 min) gave highly significant benefits in increasing ATP, raising mitochondrial membrane potential, reducing intracellular calcium concentrations, reducing oxidative stress and reducing nitric oxide. The action of LLLT in abrogating excitotoxicity may play a role in explaining its beneficial effects in diverse central nervous system pathologies.	[Huang, Ying-Ying; Nagata, Kazuya; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China; [Nagata, Kazuya] Univ Tokyo, Grad Sch Med, Tokyo 1138654, Japan; [Tedford, Clark E.] Photothera Inc, Carlsbad, CA USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019; Huang, yingying/J-7329-2012; Huang, Yingying/G-3153-2011	Hamblin, Michael R/0000-0001-6431-4605; Huang, yingying/0000-0002-4038-0277; Huang, Yingying/0000-0003-3066-6981	Photothera Inc; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by sponsored research funding from Photothera Inc and by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research (FA9950-04-1-0079).	Albertini R, 2007, J PHOTOCH PHOTOBIO B, V89, P50, DOI 10.1016/j.jphotobiol.2007.08.005; Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Antunes F, 2004, P NATL ACAD SCI USA, V101, P16774, DOI 10.1073/pnas.0405368101; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Calabrese V, 2009, ANTIOXID REDOX SIGN, V11, P2717, DOI [10.1089/ars.2009.2721, 10.1089/ARS.2009.2721]; COOK TM, 1986, NEUROSCIENCE, V18, P79, DOI 10.1016/0306-4522(86)90180-6; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; DUNN KW, 1994, FASEB J, V8, P573; Dutta R, 2011, PROG NEUROBIOL, V93, P1, DOI 10.1016/j.pneurobio.2010.09.005; Codocedo JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057626; Goldstein JC, 2000, NAT CELL BIOL, V2, P156; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 2010, KOREAN J PHYSIOL PHA, V14, P21, DOI 10.4196/kjpp.2010.14.1.21; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Huang Y Y, 2012, J BIOPHOTONICS; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim HJ, 2005, NEUROPHARMACOLOGY, V49, P265, DOI 10.1016/j.neuropharm.2005.03.007; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3; Marks JD, 2005, J NEUROSCI, V25, P6561, DOI 10.1523/JNEUROSCI.1450-05.2005; McGeer E G, 1981, Int Rev Neurobiol, V22, P173, DOI 10.1016/S0074-7742(08)60293-7; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Nakamura T, 2010, MITOCHONDRION, V10, P573, DOI 10.1016/j.mito.2010.04.007; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Palmada Monica, 1998, Frontiers in Bioscience, V3, pD701; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Rochkind S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E8; Schinder AF, 1996, J NEUROSCI, V16, P6125; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Stavrovskaya IG, 2005, FREE RADICAL BIO MED, V38, P687, DOI 10.1016/j.freeradbiomed.2004.11.032; Stout AK, 1998, NAT NEUROSCI, V1, P366; White RJ, 1996, J NEUROSCI, V16, P5688; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729	52	44	45	0	20	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	AUG	2014	7	8					656	664		10.1002/jbio.201300125			9	Biochemical Research Methods; Biophysics; Optics	Biochemistry & Molecular Biology; Biophysics; Optics	AO9VY	WOS:000341708600011	24127337	Green Accepted			2021-06-18	
J	Jadhav, SP; Kamath, SP; Choolani, M; Lu, J; Dheen, ST				Jadhav, Shweta P.; Kamath, Sandhya P.; Choolani, Mahesh; Lu, Jia; Dheen, S. Thameem			microRNA-200b modulates microglia-mediated neuroinflammation via the cJun/MAPK pathway	JOURNAL OF NEUROCHEMISTRY			English	Article						c-Jun; cJun-N terminal kinase; microglia; miRNA-200b; neuroinflammation	KINASE SIGNALING CASCADES; NEURONAL CELL-DEATH; NITRIC-OXIDE; MAP KINASE; PROINFLAMMATORY CYTOKINES; MESENCHYMAL TRANSITION; ACTIVATED MICROGLIA; PARKINSONS-DISEASE; PROTEIN-KINASE; MIR-200 FAMILY	Chronic activation of microglia, the macrophages of the CNS, has been shown to enhance neuronal damage because of excessive release of proinflammatory cytokines and neurotoxic molecules in a number of neurodegenerative diseases. Recent reports showed altered microRNA (miRNA) expression in immune-mediated pathologies, thus suggesting that miRNAs modulate expression of genes involving immune responses. This study demonstrates that miRNA-200b is expressed in microglia and modulates inflammatory response of microglia by regulating mitogen-activated protein kinase pathway. miRNA-200b expression was found to be down-regulated in activated microglia in vivo (traumatic brain injury rat model) and in vitro. A luciferase assay and loss- and gain-of-function studies revealed c-Jun, the transcription factor of cJun-N terminal kinase (JNK) mitogen-activated protein kinase pathway to be the target of miR-200b. Knockdown of miR-200b in microglia increased JNK activity along with an increase in pro-inflammatory cytokines, inducible nitric oxide synthase expression and nitric oxide (NO) production. Conversely, over-expression of miRNA-200b in microglia resulted in a decrease in JNK activity, inducible nitric oxide synthase expression, NO production and migratory potential of activated microglia. Furthermore, miR-200b inhibition resulted in increased neuronal apoptosis after treatment of neuronal cells with conditioned medium obtained from microglial culture. Taken together, these results indicate that miRNA-200b modulates microglial inflammatory process including cytokine secretion, NO production, migration and neuronal survival.	[Jadhav, Shweta P.; Kamath, Sandhya P.; Dheen, S. Thameem] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Choolani, Mahesh] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore 117597, Singapore; [Lu, Jia] DSO Natl Labs, Def Med & Environm Res Inst, Singapore, Singapore	Dheen, ST (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Blk MD10,4 Med Dr, Singapore 117597, Singapore.	antstd@nus.edu.sg	Dheen, S. Thameem/AAU-8627-2020	Dheen, S. Thameem/0000-0001-9600-6789	ASTAR-MINDEF-NUS [09/1/50/19/621, R-181-000-141-305]; NMRC, SingaporeNational Medical Research Council, Singapore [NMRC/EDG/1039/2011, R-181-000-139-275]	This research was supported by the joint ASTAR-MINDEF-NUS grant (09/1/50/19/621 and R-181-000-141-305) and NMRC Exploratory/Developmental Grant (NMRC/EDG/1039/2011; R-181-000-139-275), Singapore. The authors declare no conflict of interest.	Babcock AA, 2003, J NEUROSCI, V23, P7922; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Brecht S, 2005, EUR J NEUROSCI, V21, P363, DOI 10.1111/j.1460-9568.2005.03857.x; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHAO CC, 1992, J IMMUNOL, V149, P2736; Ciesielski-Treska J, 2004, GLIA, V46, P101, DOI 10.1002/glia.10363; Colombo A, 2007, CELL DEATH DIFFER, V14, P1845, DOI 10.1038/sj.cdd.4402202; Deng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036739; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Fiore R, 2008, BBA-GENE REGUL MECH, V1779, P471, DOI 10.1016/j.bbagrm.2007.12.006; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hashimoto Y, 2003, J NEUROCHEM, V84, P864, DOI 10.1046/j.1471-4159.2003.01585.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Juhila J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021495; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mehan S, 2011, J MOL NEUROSCI, V43, P376, DOI 10.1007/s12031-010-9454-6; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mizuno T., 2012, INT J ALZHEIMERS DIS, V2012, P1; Mongroo Perry S, 2010, Cancer biology & therapy, V10, P219; Nayak D, 2010, NEUROSCIENCE, V166, P132, DOI 10.1016/j.neuroscience.2009.12.020; Ouyang YB, 2012, NEUROBIOL DIS, V45, P555, DOI 10.1016/j.nbd.2011.09.012; Park JY, 2008, GLIA, V56, P1215, DOI 10.1002/glia.20691; Phani Sudarshan, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS207, DOI 10.1016/S1353-8020(11)70064-5; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Qi JN, 2012, FEBS LETT, V586, P1201, DOI 10.1016/j.febslet.2012.03.011; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Tuppo EE, 2005, INT J BIOCHEM CELL B, V37, P289, DOI 10.1016/j.biocel.2004.07.009; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wendlandt EB, 2012, INNATE IMMUN-LONDON, V18, P846, DOI 10.1177/1753425912443903; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404	47	44	47	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2014	130	3					388	401		10.1111/jnc.12731			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AL9RU	WOS:000339479200006	24749688	Bronze			2021-06-18	
J	Mackelprang, JL; Bombardier, CH; Fann, JR; Temkin, NR; Barber, JK; Dikmen, SS				Mackelprang, Jessica L.; Bombardier, Charles H.; Fann, Jesse R.; Temkin, Nancy R.; Barber, Jason K.; Dikmen, Sureyya S.			Rates and Predictors of Suicidal Ideation During the First Year After Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							PRIMARY-CARE; RISK-FACTORS; DEPRESSION; PREVALENCE; MORTALITY; VETERANS; REHABILITATION; INDIVIDUALS; ASSOCIATION; BEHAVIORS	Objectives. We examined rates of suicidal ideation (SI) after traumatic brain injury (TBI) and investigated whether demographic characteristics, preinjury psychiatric history, or injury-related factors predicted SI during the first year after injury. Methods. We followed a cohort of 559 adult patients who were admitted to Harborview Medical Center in Seattle, Washington, with a complicated mild to severe TBI between June 2001 and March 2005. Participants completed structured telephone interviews during months 1 through 6, 8, 10, and 12 after injury. We assessed SI using item 9 of the Patient Health Questionnaire (PHQ-9). Results. Twenty-five percent of the sample reported SI during 1 or more assessment points. The strongest predictor of SI was the first PHQ-8 score (i.e., PHQ-9 with item 9 excluded) after injury. Other significant multivariate predictors included a history of a prior suicide attempt, a history of bipolar disorder, and having less than a high school education. Conclusions. Rates of SI among individuals who have sustained a TBI exceed those found among the general population. Increased knowledge of risk factors for SI may assist health care providers in identifying patients who may be vulnerable to SI after TBI.	[Mackelprang, Jessica L.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98122 USA; [Bombardier, Charles H.; Dikmen, Sureyya S.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98122 USA; [Fann, Jesse R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98122 USA; [Temkin, Nancy R.; Barber, Jason K.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98122 USA	Mackelprang, JL (corresponding author), Univ Washington, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98122 USA.	jlmack11@uw.edu		Mackelprang, Jessica/0000-0001-9135-7811	National Center for Medical Rehabilitation Research; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD057822]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD39415]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD057822] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	This study was supported by grants from the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and the National Institutes of Health (to C. H. B. and J. R. F.; R01-HD39415). J. L. Mackelprang received fellowship support from the National Institute of Child Health and Human Development (T32-HD057822) during the preparation of the article.	American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boris NW, 1998, ACAD PSYCHIATR, V22, P21, DOI 10.1007/BF03341440; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2009, BRAIN INJURY, V23, P991, DOI 10.3109/02699050903379362; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Crosby Alex E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dexter-Mazza ET, 2003, SUICIDE LIFE-THREAT, V33, P211, DOI 10.1521/suli.33.2.211.22769; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Misono S, 2008, J CLIN ONCOL, V26, P4731, DOI 10.1200/JCO.2007.13.8941; National Center for Injury Prevention and Control, 2009, CDC INJURY RESEARCH; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Simpson G, 2007, CRISIS, V28, P35, DOI 10.1027/0227-5910.28.1.35; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sudak D, 2007, ACAD PSYCHIATR, V31, P345, DOI 10.1176/appi.ap.31.5.345; Taliaferro LA, 2011, ACAD MED, V86, P342, DOI 10.1097/ACM.0b013e31820984ad; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; Uebelacker Lisa A, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10m01027; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Walker J, 2011, PSYCHOSOMATICS, V52, P424, DOI 10.1016/j.psym.2011.02.003; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013	48	44	44	0	9	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	JUL	2014	104	7					E100	E107		10.2105/AJPH.2013.301794			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AP1EM	WOS:000341809500021	24832143	Green Published			2021-06-18	
J	Pearce, AJ; Hoy, K; Rogers, MA; Corp, DT; Maller, JJ; Drury, HGK; Fitzgerald, PB				Pearce, Alan J.; Hoy, Kate; Rogers, Mark A.; Corp, Daniel T.; Maller, Jerome J.; Drury, Hannah G. K.; Fitzgerald, Paul B.			The Long-Term Effects of Sports Concussion on Retired Australian Football Players: A Study Using Transcranial Magnetic Stimulation	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; motor cortex inhibition; motor execution slowness; sports concussion; TMS	HUMAN MOTOR CORTEX; TRAUMATIC BRAIN-INJURY; INTRACORTICAL INHIBITION; CORTICAL INHIBITION; PARKINSONS-DISEASE; COMMUNITY-LEVEL; HEAD-INJURY; FACILITATION; HUMANS; RESPONSES	This study investigated corticomotor excitability and inhibition, cognitive functioning, and fine motor dexterity in retired elite and amateur Australian football (AF) players who had sustained concussions during their playing careers. Forty male AF players who played at the elite level (n = 20; mean age 49.7 +/- 5.7 years) or amateur level (n = 20; mean age 48.4 +/- 6.9 years), and had sustained on average 3.2 concussions 21.9 years previously, were compared with 20 healthy age-matched male controls (mean age 47.56 +/- 6.85 years). All participants completed assessments of fine dexterity, visuomotor reaction time, spatial working memory (SWM), and associative learning (AL). Transcranial magnetic stimulation (TMS) was used to measure corticospinal excitability: stimulus-response (SR) curves and motor evoked potential (MEP) 125% of active motor threshold (aMT); and intracortical inhibition: cortical silent period (cSP), short-interval intracortical inhibition (SICI), and long-interval intracortical inhibition (LICI). Healthy participants performed better in dexterity (p = 0.003), reaction (p = 0.003), and movement time (p = 0.037) than did both AF groups. Differences between AF groups were found in AL (p = 0.027) and SWM (p = 0.024). TMS measures revealed that both AF groups showed reduced cSP duration at 125% aMT (p > 0.001) and differences in SR curves (p > 0.001) than did healthy controls. Similarly, SICI (p = 0.012) and LICI (p = 0.009) were reduced in both AF groups compared with controls. Regression analyses revealed a significant contribution to differences in motor outcomes with the three measures of intracortical inhibition. The measures of inhibition differed, however, in terms of which performance measure they had a significant and unique predictive relationship with, reflecting the variety of participant concussion injuries. This study is the first to demonstrate differences in motor control and intracortical inhibition in AF players who had sustained concussions during their playing career two decades previously.	[Pearce, Alan J.; Rogers, Mark A.; Corp, Daniel T.; Drury, Hannah G. K.] Deakin Univ, Sch Psychol, Cognit Neurosci Lab, Melbourne, Vic 3125, Australia; [Hoy, Kate; Maller, Jerome J.; Fitzgerald, Paul B.] The Alfred, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Hoy, Kate; Maller, Jerome J.; Fitzgerald, Paul B.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia	Pearce, AJ (corresponding author), Deakin Univ, Sch Psychol, 225 Burwood Highway, Melbourne, Vic 3125, Australia.	alan.pearce@deakin.edu.au	Fitzgerald, Paul B/A-1225-2008; Pearce, Alan J/W-1195-2018; Maller, Jerome J/H-4963-2014	Fitzgerald, Paul B/0000-0003-4217-8096; Pearce, Alan J/0000-0002-9264-9880; Maller, Jerome J/0000-0003-4685-1508; Rogers, Mark/0000-0002-6808-9545; Corp, Daniel/0000-0003-2435-077X; Hoy, Kate/0000-0003-0694-9674	NHMRCNational Health and Medical Research Council of Australia; Cervel Neurotech	Jerome Maller and Paul Fitzgerald are supported by NHMRC fellowships. P. B. F. has received equipment for research from Brainsway, Ltd., Cervel Neurotech, MagVenture A/S, and Medtronic Ltd., and has received funding for research from Cervel Neurotech. The other authors have nothing to disclose.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; AFL Medical Officers Association, 2011, MAN CONC AUSTR FOOTB; Bares M, 2003, EUR J NEUROL, V10, P385, DOI 10.1046/j.1468-1331.2003.00610.x; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Berardelli A, 1996, BRAIN, V119, P71, DOI 10.1093/brain/119.1.71; Berardelli A, 2008, BRAIN STIMUL, V1, P183, DOI 10.1016/j.brs.2008.06.005; Berger MAM, 2009, APPL ERGON, V40, P145, DOI 10.1016/j.apergo.2008.01.014; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Braham R, 2004, J SCI MED SPORT, V7, P451, DOI 10.1016/S1440-2440(04)80263-9; Braham R, 2004, J SCI MED SPORT, V7, P96, DOI 10.1016/S1440-2440(04)80048-3; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; CORLETT EN, 1971, OCCUP PSYCHOL, V45, P57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Espay AJ, 2006, ANN NEUROL, V59, P825, DOI 10.1002/ana.20837; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gabbe B, 2002, J SCI MED SPORT, V5, P149, DOI 10.1016/S1440-2440(02)80036-6; Gilbert F, 2012, MED J AUSTRALIA, V196, P561, DOI 10.5694/mja11.11218; GLOSS DS, 1981, PERCEPT MOTOR SKILL, V53, P659, DOI 10.2466/pms.1981.53.2.659; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harris AW, 2012, CLIN J SPORT MED, V22, P91, DOI 10.1097/JSM.0b013e31823776cb; Jordan BD, 2000, NEUROLOGY, V54, pA410; Kaye AH, 2012, MED J AUSTRALIA, V196, P547, DOI 10.5694/mja12.10539; King T, 2013, J SCI MED SPORT, V16, P302, DOI 10.1016/j.jsams.2012.09.003; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liepert J, 1998, EXP BRAIN RES, V118, P421, DOI 10.1007/s002210050296; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; McGinley M, 2010, EXP GERONTOL, V45, P671, DOI 10.1016/j.exger.2010.04.005; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nowinski Chris, 2013, Cerebrum, V2013, P2; Pearce AJ, 2013, BRAIN STIMUL, V6, P306, DOI 10.1016/j.brs.2012.05.010; Pearce AJ, 2010, J SCI MED SPORT, V13, P167, DOI 10.1016/j.jsams.2008.12.632; Pearce AJ, 2009, J SCI MED SPORT, V12, P280, DOI 10.1016/j.jsams.2007.12.005; Pierantozzi M, 2004, BRAIN RES, V1028, P1, DOI 10.1016/j.brainres.2004.06.009; Poldrack RA, 2006, TRENDS COGN SCI, V10, P59, DOI 10.1016/j.tics.2005.12.004; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; WILSON SA, 1993, NEUROSCI LETT, V154, P52, DOI 10.1016/0304-3940(93)90169-L; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	53	44	44	0	47	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1139	1145		10.1089/neu.2013.3219			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500002	24579780				2021-06-18	
J	Green, REA; Colella, B; Maller, JJ; Bayley, M; Glazer, J; Mikulis, DJ				Green, Robin E. A.; Colella, Brenda; Maller, Jerome J.; Bayley, Mark; Glazer, Joanna; Mikulis, David J.			Scale and pattern of atrophy in the chronic stages of moderate-severe TBI	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						atrophy; chronic; degeneration; traumatic brain injury; progression; MRI	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; DIFFUSION-TENSOR; CORTICAL IMPACT; STRUCTURAL MRI; HEAD-INJURY; RECOVERY; PROGRESSION; PERFORMANCE; NEURONS	Background: Moderate-severe traumatic brain injury (TBI) is increasingly being understood as a progressive disorder, with growing evidence of reduced brain volume and white matter (WM) integrity as well as lesion expansion in the chronic phases of injury. The scale of these losses has yet to be investigated, and pattern of change across structures has received limited attention. Objectives: (1) To measure the percentage of patients in our TBI sample showing atrophy from 5 to 20 months post-injury in the whole brain and in structures with known vulnerability to acute TBI, and (2) To examine relative vulnerability and patterns of volume loss across structures. Methods: Fifty-six TBI patients [complicated mild to severe, with mean Glasgow Coma Scale (GCS) in severe range] underwent MRI at, on average, 5 and 20 months post-injury; 12 healthy controls underwent MRI twice, with a mean gap between scans of 25.4 months. Mean monthly percent volume change was computed for whole brain (ventricle-to-brain ratio; VBR), corpus callosum (CC), and right and left hippocampi (HPC). Results: (1) Using a threshold of 2 z-scores below controls, 96% of patients showed atrophy across time points in at least one region; 75% showed atrophy in at least 3 of the 4 regions measured. (2) There were no significant differences in the proportion of patients who showed atrophy across structures. For those showing decline in VBR, there was a significant association with both the CC and the right HPC (P < 0.05 for both comparisons). There were also significant associations between those showing decline in (i) right and left HPC (P < 0.05); (ii) all combinations of genu, body and splenium of the CC (P < 0.05), and (iii) head and tail of the right HPC (P < 0.05 all sub-structure comparisons). Conclusions: Atrophy in chronic TBI is robust, and the CC, right HPC and left HPC appear equally vulnerable. Significant associations between the right and left HPC, and within substructures of the CC and right HPC, raise the possibility of common mechanisms for these regions, including transneuronal degeneration. Given the 96% incidence rate of atrophy, a genetic explanation is unlikely to explain all findings. Multiple and possibly synergistic mechanisms may explain findings. Atrophy has been associated with poorer functional outcomes, but recent findings suggest there is potential to offset this. A better, understanding of the underlying mechanisms could permit targeted therapy enabling better long-term outcomes.	[Green, Robin E. A.; Colella, Brenda; Bayley, Mark; Glazer, Joanna] Toronto Rehabil Inst, Res Dept, Cognit Neurorehabil Sci Lab, Toronto, ON M5G 2A2, Canada; [Green, Robin E. A.] Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Brain Stimulat & Neuroimaging Lab, Melbourne, Vic, Australia; [Mikulis, David J.] Toronto Western Res Inst, Div Appl & Intervent Res, MRI Lab, Toronto, ON, Canada; [Mikulis, David J.] Univ Toronto, Fac Med, Dept Med Imaging, Toronto, ON, Canada	Green, REA (corresponding author), Toronto Rehabil Inst, 550 Univ Ave,Rm 11-207, Toronto, ON M5G 2A2, Canada.	robin.green@uhn.ca	Maller, Jerome J/H-4963-2014; Mikulis, David J/H-5167-2019	Maller, Jerome J/0000-0003-4685-1508; Green, Robin/0000-0001-9451-3963; Bayley, Mark/0000-0001-7860-9463; Mikulis, David/0000-0003-3956-0892	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians Services Incorporated Foundation; Ontario Neurotrauma Foundation; Canada Research Chairs ProgramCanada Research Chairs	The authors acknowledge the support of the Canadian Institute of Health Research, Physicians Services Incorporated Foundation, Ontario Neurotrauma Foundation and the Canada Research Chairs Program.	Adnan A, 2013, BRAIN INJURY, V27, P1415, DOI 10.3109/02699052.2013.823659; Amaral OB, 2008, PHYSIOL BEHAV, V93, P388, DOI 10.1016/j.physbeh.2007.09.009; Analysisgroup, 2012, FMRIB SOFTW LIB V4 0; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brayne C, 2010, BRAIN, V133, P2210, DOI 10.1093/brain/awq185; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Coulson EJ, 2008, J NEUROSCI, V28, P315, DOI 10.1523/JNEUROSCI.2699-07.2008; Curlik DM, 2013, NEUROPHARMACOLOGY, V64, P506, DOI 10.1016/j.neuropharm.2012.07.027; Curlik DM, 2011, J COGNITIVE NEUROSCI, V23, P2159, DOI 10.1162/jocn.2010.21597; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Draganski B, 2006, J NEUROSCI, V26, P6314, DOI 10.1523/JNEUROSCI.4628-05.2006; Duering M, 2012, NEUROLOGY, V79, P2025, DOI 10.1212/WNL.0b013e3182749f39; Evans J. J., 2008, NEUROPSYCHOL REHABIL, V18, P372, DOI [10.1080/09602010801909153, DOI 10.1080/09602010801909153]; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Frisoni GB, 2010, NAT REV NEUROL, V6, P67, DOI 10.1038/nrneurol.2009.215; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL, DOI [10.1037/10645-000, DOI 10.1037/10645-000]; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Maguire EA, 2006, HIPPOCAMPUS, V16, P1091, DOI 10.1002/hipo.20233; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Miller LS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00506; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Talairach J., 1988, COPLANAR STEREOTAXIC; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Watson C, 1997, ARCH NEUROL-CHICAGO, V54, P67, DOI 10.1001/archneur.1997.00550130049015; Weschler D, 2001, WECHSLER TEST ADULT; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Zijdenbos A, 1998, LECT NOTES COMPUT SC, V1496, P439	63	44	44	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 31	2014	8								67	10.3389/fnhum.2014.00067			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AD9NH	WOS:000333591300001	24744712	DOAJ Gold, Green Published			2021-06-18	
J	Inui, TS; Parina, R; Chang, DC; Inui, TS; Coimbra, R				Inui, Tazo Stowe; Parina, Ralitza; Chang, David C.; Inui, Thomas S.; Coimbra, Raul			Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: A long-term analysis of risk versus benefit	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Warfarin; ground-level fall; head injury; mortality; population outcomes	TRAUMATIC INTRACRANIAL HEMORRHAGE; PREINJURY WARFARIN; BRAIN-INJURY; HEAD-INJURY; OUTCOMES; INTERVENTION; CLOPIDOGREL; ALCOHOL; ASPIRIN; STROKE	BACKGROUND Elderly patients with atrial fibrillation or flutter who experience ground-level falls are at risk for lethal head injuries. Patients on oral anticoagulation (OAC) for thromboprophylaxis may be at higher risk for these head injuries. Trauma surgeons treating these patients face a difficult choice: (1) continue OAC to minimize stroke risk while increasing the risk of a lethal head injury or (2) discontinue OAC to avoid intracranial hemorrhage while increasing the risk of stroke. To inform this choice, we conducted a retrospective cohort study to assess long-term outcomes and risk factors for mortality after presentation with a ground-level fall among patients with and without OAC. METHODS Retrospective analysis of the longitudinal version of the California Office of Statewide Planning and Development database was performed for years 1995 to 2009. Elderly anticoagulated patients (age > 65 years) with known atrial fibrillation or flutter who fell were stratified by CHA(2)DS(2)-VASc score and compared with a nonanticoagulated control cohort. Multivariable logistic regression including patient demographics, stroke risk, injury severity, and hospital type identified risk factors for mortality. RESULTS A total of 377,873 patient records met the inclusion criteria, 42,913 on OAC and 334,960 controls. The mean age was 82.4 and 80.6 years, respectively. Most were female, with CHA(2)DS(2)-VASc scores between 3 and 5. Mortality among OAC patients after a first fall was 6%, compared with 3.1% among non-OAC patients. Patients dying with a head injury constituted 31.6% of deaths within OAC patients compared with 23.8% among controls. Risk of eventual death with head injury exceeded annualized stroke risk for patients with CHA(2)DS(2)-VASc scores of 0 to 2. Predictors for mortality with head injury on the first admission included male sex, Asian ethnicity, a history of stroke, and trauma center admission. CONCLUSION Elderly patients on OAC for atrial fibrillation and/or flutter who fall have a greater risk for mortality compared with controls. Patients with low CHA(2)DS(2)-VASc scores (0-3) at high risk for falls with identified risk factors should speak to their prescribing physicians regarding the risk/benefits of continued use of OAC. LEVEL OF EVIDENCE Epidemiologic/prognostic study, level III.	[Inui, Tazo Stowe; Parina, Ralitza; Chang, David C.; Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Inui, Thomas S.] Indiana Univ, Indianapolis, IN 46204 USA	Inui, TS (corresponding author), Univ Calif San Diego, Dept Surg, 200 W Arbor Dr,Mail Code 8400, San Diego, CA 92103 USA.	tinui@ucsd.edu; rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851	Haemonetics; TEM Systems, Inc.; LFB Biotechnologies	Ernest E. Moore, Editor: PI, research support, Haemonetics; PI, research support, TEM Systems, Inc. Ronald V. Maier, Associate editor: consultant, consulting fee, LFB Biotechnologies. Associate editors: David Hoyt and Steven Shackford have nothing to disclose. Editorial staff: Jennifer Crebs, Jo Fields, and Angela Sauaia have nothing to disclose.	Aguilar M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001925.pub2; Aguilar MI, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001927.pub2; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Bueno-Cavanillas A, 2000, EUR J EPIDEMIOL, V16, P849, DOI 10.1023/A:1007636531965; Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Chu LW, 2005, ANN ACAD MED SINGAP, V34, P60; Claudia C, 2011, J TRAUMA, V70, P906, DOI 10.1097/TA.0b013e3182031ab7; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Coppens M, 2013, EUR HEART J, V34, P170, DOI 10.1093/eurheartj/ehs314; Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031; *FDA, WARF PROD LAB; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017; Gangavati AS, 2009, J AM GERIATR SOC, V57, P1470, DOI 10.1111/j.1532-5415.2009.02344.x; Hori M, 2011, CIRC J, V75, P800, DOI 10.1253/circj.CJ-11-0191; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Inamasu J, 2012, GERIATR GERONTOL INT, V12, P667, DOI 10.1111/j.1447-0594.2012.00838.x; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Johnson JA, 2008, CIRCULATION, V118, P1383, DOI 10.1161/CIRCULATIONAHA.107.704023; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Leukhardt WH, 2010, AM J SURG, V199, P348, DOI 10.1016/j.amjsurg.2009.09.021; Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024; Luchette F, 2010, SURGERY, V148, P729; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Medical Advisory Secretariat, 2008, Ont Health Technol Assess Ser, V8, P1; Meschia JF, 2010, STROKE, V41, P581, DOI 10.1161/STROKEAHA.109.573907; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Moyer TP, 2009, MAYO CLIN PROC, V84, P1079, DOI 10.4065/mcp.2009.0278; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ogawa S, 2010, CIRC J, V74, P2479, DOI 10.1253/circj.CJ-88-0001; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Pernod G, 2013, ARCH CARDIOVASC DIS, V106, P382, DOI 10.1016/j.acvd.2013.04.009; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Schermer CR, 2005, J TRAUMA, V59, pS119, DOI 10.1097/01.ta.0000174679.12567.7c; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Sise MJ, 2005, J TRAUMA, V59, pS112, DOI 10.1097/01.ta.0000176045.95492.01; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	43	44	45	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					642	649		10.1097/TA.0000000000000138			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100021	24553530				2021-06-18	
J	Harpham, JA; Mihalik, JP; Littleton, AC; Frank, BS; Guskiewicz, KM				Harpham, Jacqueline A.; Mihalik, Jason P.; Littleton, Ashley C.; Frank, Barnett S.; Guskiewicz, Kevin M.			The Effect of Visual and Sensory Performance on Head Impact Biomechanics in College Football Players	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Football; Injury prevention; Kinematics; Mild traumatic brain injury; Sports biomechanics; Vision	REACTION-TIME; BRAIN-INJURY; RELIABILITY; CONCUSSION; SYSTEM; EPIDEMIOLOGY; ANTICIPATION; BATTERY	The development of prevention strategies is critical to address the rising prevalence of sport-related concussions. Visual and sensory performance may influence an individual's ability to interpret environmental cues, anticipate opponents' actions, and create appropriate motor responses limiting the severity of an impending head impact. The purpose of this study was to determine the relationship between traditional and visual sensory reaction time measures, and the association between visual and sensory performance and head impact severity in college football players. Thirty-eight collegiate football players participated in the study. We used real-time data collection instrumentation to record head impact biomechanics during games and practices. Our findings reveal no significant correlations between reaction time on traditional and visual sensory measures. We found a significant association between head impact severity and level of visual and sensory performance for multiple assessments, with low visual and sensory performers sustaining a higher number of severe head impacts. Our findings reveal a link between level of visual and sensory performance and head impact biomechanics. Future research will allow clinicians to have the most appropriate testing batteries to identify at-risk athletes and create interventions to decrease their risk of injurious head impacts.	[Harpham, Jacqueline A.; Mihalik, Jason P.; Littleton, Ashley C.; Frank, Barnett S.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Littleton, Ashley/0000-0001-6188-1284; Mihalik, Jason/0000-0001-6085-8322	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Operating Committee on Standards for Athletic Equipment	This study was supported in part by the Centers for Disease Control and Prevention and the National Operating Committee on Standards for Athletic Equipment. None of the authors have any financial interest in any of the systems used for this study. We thank Nike for the provision of equipment used in this study.	Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bracken N., 2007, NCAA SPORTS SPONSORS; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Dick R, 2007, J ATHL TRAINING, V42, P221; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Erickson GB, 2011, OPTOMETRY, V82, P528, DOI 10.1016/j.optm.2011.01.012; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Martell SG, 2004, HUM MOVEMENT SCI, V22, P689, DOI 10.1016/j.humov.2004.02.004; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; National Statistical Institute, 2011, 2010 11 HIGH SCH ATL, P51; Ocwieja K. E., 2011, ANN BIOMED ENG; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Savelsbergh GJP, 2005, ERGONOMICS, V48, P1686, DOI 10.1080/00140130500101346; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; STINE CD, 1982, J AM OPTOM ASSOC, V53, P627; van der Kamp J, 2011, MOTOR CONTROL, V15, P342, DOI 10.1123/mcj.15.3.342; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; WILLIAMS AM, 1994, RES Q EXERCISE SPORT, V65, P127, DOI 10.1080/02701367.1994.10607607; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zimmerman A. B., 2011, EYE CONTACT LENS	32	44	44	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2014	42	1					1	10		10.1007/s10439-013-0881-8			10	Engineering, Biomedical	Engineering	AB7MV	WOS:000331975400001	23918080				2021-06-18	
J	Eakin, K; Li, YZ; Chiang, YH; Hoffer, BJ; Rosenheim, H; Greig, NH; Miller, JP				Eakin, Katharine; Li, Yazhou; Chiang, Yung-Hsiao; Hoffer, Barry J.; Rosenheim, Hilary; Greig, Nigel H.; Miller, Jonathan P.			Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats	PLOS ONE			English	Article							GLUCAGON-LIKE PEPTIDE-1; CONTROLLED CORTICAL IMPACT; TYPE-2 DIABETES-MELLITUS; MORRIS WATER MAZE; ALZHEIMERS-DISEASE; SIGNALING PATHWAY; GENE-EXPRESSION; BINDING-SITES; UNITED-STATES; AMYLOID-BETA	Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic beta-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.	[Eakin, Katharine; Hoffer, Barry J.; Rosenheim, Hilary; Miller, Jonathan P.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Li, Yazhou; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Lab Translat Gerontol, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Chiang, Yung-Hsiao] Taipei Med Univ, Grad Inst Neural Regenerat Med, PhD Program Neural Regenerat Med, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Neurosurg, Taipei, Taiwan	Miller, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.	jonathan.p.miller@case.edu		Miller, Jonathan/0000-0001-5441-1751	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Lincoln Master Clinician in Neurosurgery Award, USPHS [NS070825]; National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC98-2321-B-038-002-MY3]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health; the Lincoln Master Clinician in Neurosurgery Award to Jonathan Miller, USPHS # NS070825; and the National Science Council of Taiwan to Yung-Hsiao Chiang, #NSC98-2321-B-038-002-MY3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Bak AM, 2011, EXPERT OPIN THER TAR, V15, P1153, DOI 10.1517/14728222.2011.600691; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; CDC, 2010, INJURY PREVENTION CO; Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drucker DJ, 2008, LANCET, V372, P1240, DOI 10.1016/S0140-6736(08)61206-4; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Gallwitz B, 2011, DRUGS, V71, P1675, DOI 10.2165/11592810-000000000-00000; Gilman CP, 2003, J NEUROCHEM, V87, P1137, DOI 10.1046/j.1471-4159.2003.02073.x; GOKE R, 1995, NEUROENDOCRINOLOGY, V62, P130, DOI 10.1159/000126997; GOKE R, 1995, EUR J NEUROSCI, V7, P2294, DOI 10.1111/j.1460-9568.1995.tb00650.x; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Holscher C, 2010, VITAM HORM, V84, P331, DOI [10.1016/S0083-6729(10)84005-1, 10.1016/B978-0-12-381517-0.00013-8]; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Li H, 2010, NEUROSCI LETT, V486, P38, DOI 10.1016/j.neulet.2010.09.040; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Lovshin JA, 2009, NAT REV ENDOCRINOL, V5, P262, DOI 10.1038/nrendo.2009.48; Luciani P, 2010, CELL MOL LIFE SCI, V67, P3711, DOI 10.1007/s00018-010-0398-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Rachmany L., 2012, AGE DORDR; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	58	44	45	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2013	8	12							e82016	10.1371/journal.pone.0082016			8	Multidisciplinary Sciences	Science & Technology - Other Topics	265IN	WOS:000327944500114	24312624	DOAJ Gold, Green Published			2021-06-18	
J	Veitch, DP; Friedl, KE; Weiner, MW				Veitch, Dallas P.; Friedl, Karl E.; Weiner, Michael W.			Military Risk Factors for Cognitive Decline, Dementia and Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Alzheimer's disease; armed forces; combat; depression; gulf war illness; post-traumatic stress disorder; risk factors; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; GULF-WAR VETERANS; MENTAL-HEALTH PROBLEMS; QUALITY-OF-LIFE; PERSISTENT ORGANIC POLLUTANTS; AMYLOID PROTEIN DEPOSITION; MAJOR DEPRESSIVE DISORDER; CORONARY-HEART-DISEASE; CHRONIC KIDNEY-DISEASE	Delayed neurological health consequences of environmental exposures during military service have been generally underappreciated. The rapidly expanding understanding of Alzheimer's disease (AD) pathogenesis now makes it possible to quantitate some of the likely long-term health risks associated with military service. Military risk factors for AD include both factors elevated in military personnel such as tobacco use, traumatic brain injury (TBI), depression, and post-traumatic stress disorder (PTSD) and other nonspecific risk factors for AD including, vascular risk factors such as obesity and obesity-related diseases (e.g., metabolic syndrome), education and physical fitness. The degree of combat exposure, Vietnam era Agent Orange exposure and Gulf War Illness may also influence risk for AD. Using available data on the association of AD and specific exposures and risk factors, the authors have conservatively estimated 423,000 new cases of AD in veterans by 2020, including 140,000 excess cases associated with specific military exposures. The cost associated with these excess cases is approximately $5.8 billion to $7.8 billion. Mitigation of the potential impact of military exposures on the cognitive function of veterans and management of modifiable risk factors through specifically designed programs will be instrumental in minimizing the impact of AD in veterans in the future decades.	[Veitch, Dallas P.; Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, Ctr Vet Med, San Francisco, CA 94143 USA; [Friedl, Karl E.] US Army Med Res & Mat Command, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA	Weiner, MW (corresponding author), Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, Ctr Vet Med, San Francisco, CA 94143 USA.	michael.weiner@ucsf.edu	Friedl, Karl/M-1803-2019	Friedl, Karl/0000-0002-3134-8427; Veitch, Dallas/0000-0002-9918-0640			Abouzeid M, 2012, J PSYCHOSOM RES, V72, P33, DOI 10.1016/j.jpsychores.2011.08.002; Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; Ahmadi N, 2011, AM J CARDIOL, V108, P29, DOI 10.1016/j.amjcard.2011.02.340; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Almond N, 2008, MIL MED, V173, P544, DOI 10.7205/MILMED.173.6.544; Ambrus J L, 2004, J Med, V35, P265; Amdur RL, 2009, KIDNEY INT, V76, P1089, DOI 10.1038/ki.2009.332; [Anonymous], 1988, JAMA, V259, P2701; [Anonymous], 1998, JAMA-J AM MED ASSOC, V259, P2708; Apfel BA, 2011, BIOL PSYCHIAT, V69, P541, DOI 10.1016/j.biopsych.2010.09.044; Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Arora P, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-4; Association As, 2011, ALZH DIS FACTS FIG; Babic D, 2007, PSYCHIAT DANUB, V19, P68; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Barber Robert, 2011, Cleve Clin J Med, V78 Suppl 1, pS47, DOI 10.3949/ccjm.78.s1.08; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Bendlin BB, 2010, MATURITAS, V65, P131, DOI 10.1016/j.maturitas.2009.12.014; Bentley S, 1991, SHORT HIST PTSD THER; Beydoun MA, 2008, OBES REV, V9, P204, DOI 10.1111/j.1467-789X.2008.00473.x; Bilbul M, 2011, CAN J NEUROL SCI, V38, P580, DOI 10.1017/S0317167100012129; Blanchard MS, 2006, AM J EPIDEMIOL, V163, P66, DOI 10.1093/aje/kwj008; BOSCARINO JA, 1995, J TRAUMA STRESS, V8, P317, DOI 10.1002/jts.2490080211; Bray R. M., 2009, RTI10940FR; Bremner J. Douglas, 2006, CNS & Neurological Disorders-Drug Targets, V5, P503; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bridger R, 2009, OCCUP MED-OXFORD, V59, P195, DOI 10.1093/occmed/kqp028; Brown DW, 2010, J GEN INTERN MED, V25, P147, DOI 10.1007/s11606-009-1160-0; Buis LR, 2011, J REHABIL RES DEV, V48, P901, DOI 10.1682/JRRD.2010.08.0144; Bunegin L, 2001, TOXICOL IND HEALTH, V17, P128, DOI 10.1191/0748233701th100oa; Bureau USC, 2012, STAT ABSTR; Bureau USC, 2010, CENS 2010; Byers AL, 2012, AM J GERIAT PSYCHIAT, V20, P664, DOI 10.1097/JGP.0b013e31822001c1; Caraci F, 2010, EUR J PHARMACOL, V626, P64, DOI 10.1016/j.ejphar.2009.10.022; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carmelli D, 1998, NEUROLOGY, V50, P1580, DOI 10.1212/WNL.50.6.1580; Carrion-Baralt JR, 2010, J AM GERIATR SOC, V58, P798, DOI 10.1111/j.1532-5415.2010.02789.x; Cataldo JK, 2010, J ALZHEIMERS DIS, V19, P465, DOI 10.3233/JAD-2010-1240; Chang JW, 2010, CHEMOSPHERE, V81, P1027, DOI 10.1016/j.chemosphere.2010.08.050; Chao LDL, 2011, NEUROTOXICOLOGY, V32, P814, DOI 10.1016/j.neuro.2011.06.006; Chao LL, 2010, NEUROTOXICOLOGY, V31, P493, DOI 10.1016/j.neuro.2010.05.006; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cheng D, 2011, DEMENT GERIATR COGN, V31, P424, DOI 10.1159/000324134; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Chwastiak LA, 2011, PSYCHOSOMATICS, V52, P230, DOI 10.1016/j.psym.2010.12.009; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohen BE, 2009, JAMA-J AM MED ASSOC, V302, P489, DOI 10.1001/jama.2009.1084; Coughlin Steven S, 2011, Open Epidemiol J, V4, P140; Coughlin SS, 2011, OPEN CARDIOVASC MED, V5, P164, DOI 10.2174/1874192401105010164; Cranmer M, 2000, TOXICOL SCI, V56, P431, DOI 10.1093/toxsci/56.2.431; Cypel Y, 2010, ANN EPIDEMIOL, V20, P339, DOI 10.1016/j.annepidem.2010.02.003; Das SR, 2005, AM J PREV MED, V28, P291, DOI 10.1016/j.amepre.2004.12.007; David AS, 2002, PSYCHOL MED, V32, P1357, DOI 10.1017/S0033291702006359; Daviglus ML, 2011, ARCH NEUROL-CHICAGO, V68, P1185, DOI 10.1001/archneurol.2011.100; Alves TCDF, 2010, J ALZHEIMERS DIS, V20, P749, DOI 10.3233/JAD-2010-091561; Defense Do, 2012, STATISTICS; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dlugosz LJ, 1999, J CLIN EPIDEMIOL, V52, P1267, DOI 10.1016/S0895-4356(99)00131-6; Dobie DJ, 2004, ARCH INTERN MED, V164, P394, DOI 10.1001/archinte.164.4.394; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Duron E, 2008, VASC HEALTH RISK MAN, V4, P363; Eisen SA, 2005, ANN INTERN MED, V142, P881, DOI 10.7326/0003-4819-142-11-200506070-00005; Enache D, 2011, CURR OPIN PSYCHIATR, V24, P461, DOI 10.1097/YCO.0b013e32834bb9d4; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fiedler N, 2006, BRIT J PSYCHIAT, V188, P453, DOI 10.1192/bjp.188.5.453; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FLESCHJANYS D, 1995, AM J EPIDEMIOL, V142, P1165, DOI 10.1093/oxfordjournals.aje.a117575; Frayne SM, 2006, J GEN INTERN MED, V21, pS40, DOI 10.1111/j.1525-1497.2006.00373.x; Freiberg M, 2010, JAIDS-J ACQ IMM DEF, V53, P247, DOI 10.1097/QAI.0b013e3181c6c4b7; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Gatz M, 1997, J GERONTOL A-BIOL, V52, pM117, DOI 10.1093/gerona/52A.2.M117; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gibson TB, 2009, MIL MED, V174, P936, DOI 10.7205/MILMED-D-03-7808; Gizlice Z., 2002, 133 N CAR CTR HLTH S; Goh C, 2010, PSYCHIAT DANUB, V22, P198; GOLDBERG J, 1990, JAMA-J AM MED ASSOC, V263, P1227, DOI 10.1001/jama.263.9.1227; Goldstein L.E., 2012, SCI TRANSL MED, V4; Graham DI, 1999, ACT NEUR S, V73, P89; Granado NS, 2009, HYPERTENSION, V54, P966, DOI 10.1161/HYPERTENSIONAHA.109.132555; Greenberg N, 2008, Emerg Health Threats J, V1, pe10, DOI 10.3134/ehtj.08.010; Guillamondegui OD, 2011, 11EHC017EF AHRQ; Haddock CK, 2007, MIL MED, V172, P527, DOI 10.7205/MILMED.172.5.527; Haley RW, 2000, RADIOLOGY, V215, P807, DOI 10.1148/radiology.215.3.r00jn48807; Hamilton JD, 1998, J TRAUMA STRESS, V11, P763, DOI 10.1023/A:1024449517730; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hankin CS, 2006, J AMBUL CARE MANAG, V29, P51; Hankin CS, 1999, AM J PSYCHIAT, V156, P1924; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; Health status of Vietnam veterans. III, 1988, JAMA-J AM MED ASSOC, V259, P2715; Heaton KJ, 2007, NEUROTOXICOLOGY, V28, P761, DOI 10.1016/j.neuro.2007.03.006; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Henriksen GL, 1997, EPIDEMIOLOGY, V8, P252, DOI 10.1097/00001648-199705000-00005; Heppner PS, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Huber A, 1993, 2 INT NEUTR S; Humblet O, 2008, ENVIRON HEALTH PERSP, V116, P1443, DOI 10.1289/ehp.11579; Hunt SC, 2006, AM J EPIDEMIOL, V164, DOI 10.1093/aje/kwj297; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Institute of Medicine, 2009, GULF WAR HLTH; Ismail K, 2006, PHILOS T R SOC B, V361, P543, DOI 10.1098/rstb.2006.1815; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Iversen A, 2007, CLIN PSYCHOL REV, V27, P842, DOI 10.1016/j.cpr.2007.07.006; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jakovjevic M, 2007, PSYCHIAT DANUB, V19, P76; Jakovljevic Miro, 2006, Psychiatr Danub, V18, P169; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson AM, 2010, ANN EPIDEMIOL, V20, P143, DOI 10.1016/j.annepidem.2009.10.006; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kang HK, 2006, AM J IND MED, V49, P875, DOI 10.1002/ajim.20385; Kang HK, 2006, ANN EPIDEMIOL, V16, P381, DOI 10.1016/j.annepidem.2005.03.004; Kang HK, 2009, J OCCUP ENVIRON MED, V51, P401, DOI 10.1097/JOM.0b013e3181a2feeb; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kazis Lewis E, 2004, J Ambul Care Manage, V27, P70; Kelsall HL, 2009, AM J EPIDEMIOL, V170, P1048, DOI 10.1093/aje/kwp238; Kern PA, 2004, J CLIN ENDOCR METAB, V89, P4665, DOI 10.1210/jc.2004-0250; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim JS, 2003, IND HEALTH, V41, P149, DOI 10.2486/indhealth.41.149; Kim MJ, 2012, ENVIRON HEALTH PERSP, V120, P508, DOI 10.1289/ehp.1104282; Kimm H, 2011, ARCH GERONTOL GERIAT, V52, pE117, DOI 10.1016/j.archger.2010.09.004; King Brian, 2011, Morbidity and Mortality Weekly Report, V60, P1207; Kizer KW, 2012, JAMA-J AM MED ASSOC, V307, P789, DOI 10.1001/jama.2012.196; Koepsell TD, 2009, PREV MED, V48, P267, DOI 10.1016/j.ypmed.2009.01.008; Kogevinas M, 1997, AM J EPIDEMIOL, V145, P1061, DOI 10.1093/oxfordjournals.aje.a009069; Kopf PG, 2008, CARDIOVASC TOXICOL, V8, P181, DOI 10.1007/s12012-008-9027-x; Kopf PG, 2010, TOXICOL SCI, V117, P537, DOI 10.1093/toxsci/kfq218; Kress AA, 2005, PREV MED, V41, P63, DOI 10.1016/j.ypmed.2004.10.012; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Krishnan LL, 2005, DEMENT GERIATR COGN, V20, P245, DOI 10.1159/000087345; Kubzansky LD, 2007, ARCH GEN PSYCHIAT, V64, P109, DOI 10.1001/archpsyc.64.1.109; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Lahiri DK, 2009, MOL PSYCHIATR, V14, P992, DOI 10.1038/mp.2009.82; Lahiri DK, 2010, EXP GERONTOL, V45, P291, DOI 10.1016/j.exger.2010.01.001; LeardMann CA, 2011, PUBLIC HEALTH REP, V126, P371, DOI 10.1177/003335491112600311; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; Lee HK, 2010, BBA-GEN SUBJECTS, V1800, P282, DOI 10.1016/j.bbagen.2009.11.010; Lee Y, 2010, INT PSYCHOGERIATR, V22, P174, DOI 10.1017/S1041610209991189; Leonard BE, 2007, NEUROCHEM RES, V32, P1749, DOI 10.1007/s11064-007-9385-y; Levine J, 2008, DEPRESS ANXIETY, V25, pE154, DOI 10.1002/da.20400; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Li B, 2011, AM J EPIDEMIOL, V174, P761, DOI 10.1093/aje/kwr154; Lim S, 2010, ANN NY ACAD SCI, V1201, P166, DOI 10.1111/j.1749-6632.2010.05622.x; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Littman AJ, 2009, MED SCI SPORT EXER, V41, P1006, DOI 10.1249/MSS.0b013e3181943826; Luchsinger JA, 2009, J ALZHEIMERS DIS, V16, P693, DOI 10.3233/JAD-2009-1022; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McAuley P, 2007, AM J MED, V120, P518, DOI 10.1016/j.amjmed.2006.07.032; McDonald ML, 2003, ADMIN SCI QUART, V48, P1, DOI 10.2307/3556617; McGraw LK, 2008, J CARDIOVASC NURS, V23, P338, DOI 10.1097/01.JCN.0000317437.75081.e7; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer JS, 1999, INT J GERIATR PSYCH, V14, P1050, DOI 10.1002/(SICI)1099-1166(199912)14:12<1050::AID-GPS56>3.0.CO;2-Z; Milionis HJ, 2008, CNS SPECTRUMS, V13, P606, DOI 10.1017/S1092852900016886; Miller DR, 2004, DIABETES CARE, V27, pB10, DOI 10.2337/diacare.27.suppl_2.B10; Nation DA, 2011, MED HYPOTHESES, V76, P847, DOI 10.1016/j.mehy.2011.02.034; Nelson KM, 2006, J GEN INTERN MED, V21, P915, DOI 10.1007/BF02743137; Newman AB, 2005, J AM GERIATR SOC, V53, P1101, DOI 10.1111/j.1532-5415.2005.53360.x; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; OToole BI, 1996, INT J EPIDEMIOL, V25, P331, DOI 10.1093/ije/25.2.331; Ouseph R, 2007, CLIN NEPHROL, V68, P373; Panza F, 2010, J ALZHEIMERS DIS, V21, P691, DOI 10.3233/JAD-2010-091669; Peckerman A, 2000, PSYCHOSOM MED, V62, P509, DOI 10.1097/00006842-200007000-00009; Pelclova D, 2009, NEUROENDOCRINOL LETT, V30, P219; Peters Ruth, 2008, BMC Geriatr, V8, P36, DOI 10.1186/1471-2318-8-36; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pinder RJ, 2012, INT J EPIDEMIOL, V41, P1272, DOI 10.1093/ije/dyr096; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Proctor SP, 2001, MIL MED, V166, P510; Proctor SP, 2006, NEUROTOXICOLOGY, V27, P931, DOI 10.1016/j.neuro.2006.08.001; Puga A, 2011, TOXICOL SCI, V120, P256, DOI 10.1093/toxsci/kfq393; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Reiber GE, 2004, DIABETES CARE, V27, pB3, DOI 10.2337/diacare.27.suppl_2.B3; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; RICHLIE DG, 1991, ARCH INTERN MED, V151, P1433, DOI 10.1001/archinte.151.7.1433; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Savica R, 2011, PSYCHIAT CLIN N AM, V34, P127, DOI 10.1016/j.psc.2010.11.006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schuff N, 2001, BIOL PSYCHIAT, V50, P952, DOI 10.1016/S0006-3223(01)01245-8; Schuff N, 1997, ANN NY ACAD SCI, V821, P516, DOI 10.1111/j.1749-6632.1997.tb48319.x; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sierksma ASR, 2010, EUR J PHARMACOL, V626, P72, DOI 10.1016/j.ejphar.2009.10.021; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Singh JA, 2005, J AM GERIATR SOC, V53, P108, DOI 10.1111/j.1532-5415.2005.53020.x; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith B, 2008, AM J PREV MED, V35, P539, DOI 10.1016/j.amepre.2008.07.009; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Smith TC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-69; Smith TC, 2009, PUBLIC HEALTH REP, V124, P90, DOI 10.1177/003335490912400112; Sperling W, 2011, J NERV MENT DIS, V199, P196, DOI 10.1097/NMD.0b013e31820c71e0; Spira AP, 2012, AM J GERIAT PSYCHIAT, V20, P1006, DOI 10.1097/JGP.0b013e318235b611; SPIRO A, 1994, PSYCHOL AGING, V9, P17, DOI 10.1037/0882-7974.9.1.17; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, pS69, DOI 10.1097/00002093-200607001-00010; Stimpson NJ, 2003, BRIT J PSYCHIAT, V182, P391, DOI 10.1192/bjp.182.5.391; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Swan GE, 2007, NEUROPSYCHOL REV, V17, P259, DOI 10.1007/s11065-007-9035-9; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas HV, 2006, PSYCHOL MED, V36, P735, DOI 10.1017/S0033291705006975; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tsai J, 2011, PREV CHRONIC DIS, V8; Uemura H, 2009, ENVIRON HEALTH PERSP, V117, P568, DOI 10.1289/ehp.0800012; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Voelker MD, 2002, AM J EPIDEMIOL, V155, P899, DOI 10.1093/aje/155.10.899; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Weiner MW, 2011, MIL MED, V176, P896, DOI 10.7205/MILMED-D-10-00332; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whitmer RA, 2005, NEUROLOGY, V64, P277, DOI 10.1212/01.WNL.0000149519.47454.F2; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Williams John W, 2010, Evid Rep Technol Assess (Full Rep), P1; Wint Dylan, 2011, Cleve Clin J Med, V78 Suppl 1, pS44, DOI 10.3949/ccjm.78.s1.07; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Xu WL, 2009, DIABETES, V58, P71, DOI 10.2337/db08-0586; Yaffe K, 2004, JAMA-J AM MED ASSOC, V292, P2237, DOI 10.1001/jama.292.18.2237; Yaffe K, 2010, J AM GERIATR SOC, V58, P338, DOI 10.1111/j.1532-5415.2009.02670.x; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yoon J, 2011, POPUL HEALTH MANAG, V14, P293, DOI 10.1089/pop.2010.0079; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zunszain PA, 2011, PROG NEURO-PSYCHOPH, V35, P722, DOI 10.1016/j.pnpbp.2010.04.011	251	44	45	1	49	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	NOV	2013	10	9					907	930		10.2174/15672050113109990142			24	Clinical Neurology; Neurosciences	Neurosciences & Neurology	241GO	WOS:000326154600001	23906002				2021-06-18	
J	Truettner, JS; Motti, D; Dietrich, WD				Truettner, Jessie S.; Motti, Dario; Dietrich, W. Dalton			MicroRNA overexpression increases cortical neuronal vulnerability to injury	BRAIN RESEARCH			English	Article						microRNA; Traumatic brain injury; miR-34a; miR-451; miR-874; Transfection	TRAUMATIC BRAIN-INJURY; SUBCELLULAR STRESS-RESPONSE; THERAPEUTIC HYPOTHERMIA; PROTEIN PHOSPHATASE-1; CEREBRAL-ISCHEMIA; EXPRESSION; CELLS; ACTIVATION; CHAPERONES; REGULATORS	Previously we reported that several microRNAs (miRNA) are upregulated following experimentally induced traumatic brain injury (TBI) using both in vivo and in vitro approaches. Specific miRNAs were found to be sensitive to therapeutic hypothermia and may therefore be important targets for neuroprotective strategies. In this study we developed plasmid constructs that overexpress temperature sensitive miRNAs: miR-34a, miR-451, and miR-874. These constructs were transfected into cultured cortical neurons that were subjected to stretch injury using a cell injury controller device. Levels of expression of genes associated with stress, inflammation, apoptosis and transcriptional regulation were measured by qRT-PCR. mRNA levels of cytokines interleukin 1-beta (IL1-beta) and tumor necrosis factor alpha (TNF-alpha) as well as heat shock protein 70 (HSP70) and Caspase 11 were found to be increased up to 24 fold higher than controls in cells overexpressing these miRNAs. After moderate stretch injury, the expression of IL1-beta, TNF-alpha, HSP70 and Caspase 11 all increased over control levels found in uninjured cells suggesting that overexpression of these miRNAs increases cellular vulnerability. miR-34a directly inhibits Bcl2 and XIAP, both anti-apoptotic proteins. The observed increase in Caspase 11 with over-expression of miR-34a indicates that miR-34a may be inducing apoptosis by reducing the levels of antiapoptotic proteins. miR-34a is predicted to inhibit Jun, which was seen to decrease in cells overexpressing this miRNA along with Fos. Over expression of several miRNAs found to be induced by TBI in vivo (miR-34a, miR-451 and miR-874) leads to increased vulnerability in transfected neurons. Therapeutic hypothermia blunts the expression of these miRNAs in vivo and antisense silencing could be a potential therapeutic approach to targeting the consequences of TBI. (C) 2013 Elsevier B.V. All rights reserved.	[Truettner, Jessie S.; Motti, Dario; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA.	ddietrich@miami.edu		Motti, Dario/0000-0002-7714-4040	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS042133, RO1 NS30291]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	The authors wish to thank Doris Nonner for her expertise in isolating and culturing rat primary cortical neurons for this study. The authors have no conflicts of interest to report. This study was supported by grants from NIH: RO1 NS042133 and RO1 NS30291.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876; Becker LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048474; Bijkerk Roel, 2012, Microrna, V1, P2; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; Cohen PTW, 2002, J CELL SCI, V115, P241; Conley YP, 2011, PM&R, V3, pS52, DOI 10.1016/j.pmrj.2011.04.004; Cui QH, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100089; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Duggal Jyoti, 2012, Microrna, V1, P26; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Esau CC, 2007, ADV DRUG DELIVER REV, V59, P101, DOI 10.1016/j.addr.2007.03.007; Fan Q, 2013, CELL BIOCHEM FUNCT, V31, P319, DOI 10.1002/cbf.2902; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Giffard RG, 2008, ANESTHESIOLOGY, V109, P339, DOI 10.1097/ALN.0b013e31817f4ce0; Hsieh C.H., 2012, J BIOMED SCI, V19, P1; Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012; KAUFMAN LM, 1983, SCIENCE, V220, P1394, DOI 10.1126/science.6857258; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; KEANE RW, 1992, TRANSPLANTATION, V54, P520, DOI 10.1097/00007890-199209000-00025; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238-011-1113-3; Nakanishi K, 2010, SPINAL CORD, V48, P192, DOI 10.1038/sc.2009.89; Nohata N, 2011, BRIT J CANCER, V105, P833, DOI 10.1038/bjc.2011.311; Pietrini D, 2012, CURR DRUG TARGETS, V13, P925, DOI 10.2174/138945012800675641; Qureshi IA, 2010, ARCH NEUROL-CHICAGO, V67, P1316, DOI 10.1001/archneurol.2010.275; Rayner KJ, 2013, J LIPID RES, V54, P1174, DOI 10.1194/jlr.R034991; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rosenberger CM, 2012, J IMMUNOL, V189, P5965, DOI 10.4049/jimmunol.1201437; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Truettner JS, 2009, BRAIN RES, V1249, P9, DOI 10.1016/j.brainres.2008.10.032; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Varon J, 2012, AM J EMERG MED, V30, P800, DOI 10.1016/j.ajem.2011.03.007; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang T, 2012, DIGEST DIS SCI, V58, P706; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yablonska Svitlana, 2013, Microrna, V2, P2; Yang S., 2012, ONCOGENE, V24, P1; Zgavc T, 2013, BRAIN RES, V1501, P81, DOI 10.1016/j.brainres.2013.01.034	60	44	47	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 2	2013	1533						122	130		10.1016/j.brainres.2013.08.011			9	Neurosciences	Neurosciences & Neurology	233UL	WOS:000325594900013	23948100	Green Accepted			2021-06-18	
J	Spitz, G; Maller, JJ; O'Sullivan, R; Ponsford, JL				Spitz, Gershon; Maller, Jerome J.; O'Sullivan, Richard; Ponsford, Jennie L.			White Matter Integrity Following Traumatic Brain Injury: The Association with Severity of Injury and Cognitive Functioning	BRAIN TOPOGRAPHY			English	Article						Cognition; MRI; DTI; Traumatic brain injury	DIFFUSE AXONAL INJURY; VOXEL-BASED MORPHOMETRY; SPATIAL NORMALIZATION; EPISODIC MEMORY; REACTION-TIME; ABNORMALITIES; DYSFUNCTION; CONNECTIONS; RECOVERY; AMNESIA	Traumatic brain injury (TBI) frequently results in impairments of memory, speed of information processing, and executive functions that may persist over many years. Diffuse axonal injury is one of the key pathologies following TBI, causing cognitive impairments due to the disruption of cortical white matter pathways. The current study examined the association between injury severity, cognition, and fractional anisotropy (FA) following TBI. Two diffusion tensor imaging techniques-region-of-interest tractography and tract-based spatial statistics-were used to assess the FA of white matter tracts. This study examined the comparability of these two approaches as they relate to injury severity and cognitive performance. Sixty-eight participants with mild-to-severe TBI, and 25 healthy controls, underwent diffusion tensor imaging analysis. A subsample of 36 individuals with TBI also completed cognitive assessment. Results showed reduction in FA values for those with moderate and severe TBI, compared to controls and individuals with mild TBI. Although FA tended to be lower for individuals with mild TBI no significant differences were found compared to controls. Information processing speed and executive abilities were most strongly associated with the FA of white matter tracts. The results highlight similarities and differences between region-of-interest tractography and tract-based spatial statistics approaches, and suggest that they may be used together to explore pathology following TBI.	[Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic, Australia; [Spitz, Gershon; Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3800, Australia; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [O'Sullivan, Richard] Epworth Med Fdn, Healthcare Imaging Serv, Melbourne, Vic, Australia	Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3800, Australia.	gershon.spitz@monash.edu	Spitz, Gershon/H-7755-2014; Maller, Jerome J/H-4963-2014	Spitz, Gershon/0000-0002-7810-1480; Maller, Jerome J/0000-0003-4685-1508			Aggleton JP, 2008, Q J EXP PSYCHOL, V61, P1441, DOI 10.1080/17470210802215335; Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Baddeley A, 1994, DOORS PEOPLE; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton A., 1994, MULTILINGUAL APHASIA; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Bucur B, 2008, NEUROBIOL AGING, V29, P1070, DOI 10.1016/j.neurobiolaging.2007.02.008; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Coughhlan AK, 2007, BIRT MEMORY INFORM P; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fling BW, 2011, NEUROPSYCHOLOGIA, V49, P2564, DOI 10.1016/j.neuropsychologia.2011.05.004; Foxe JJ, 2002, EXP BRAIN RES, V142, P139, DOI 10.1007/s00221-001-0906-7; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Jones DK, 2002, NEUROIMAGE, V17, P592, DOI 10.1006/nimg.2002.1148; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konrad A, 2009, NEUROPSYCHOBIOLOGY, V60, P55, DOI 10.1159/000236445; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Metzler-Baddeley C, 2011, J NEUROSCI, V31, P13236, DOI 10.1523/JNEUROSCI.2317-11.2011; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, P6; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Park HJ, 2003, NEUROIMAGE, V20, P1995, DOI 10.1016/j.neuroimage.2003.08.008; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Povlishock JT, 1994, PATHOBIOLOGY TRAUMAT; Reitan R., 1988, HALSTEAD REITAN NEUR; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shallice, 1997, HAYLING BRIXTON TEST; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith A., 1973, SYMBOL DIGIT MODALIT; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Turken AU, 2008, NEUROIMAGE, V42, P1032, DOI 10.1016/j.neuroimage.2008.03.057; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	73	44	48	0	35	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0896-0267	1573-6792		BRAIN TOPOGR	Brain Topogr.	OCT	2013	26	4					648	660		10.1007/s10548-013-0283-0			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	217AM	WOS:000324328700012	23532465				2021-06-18	
J	Longhi, L; Perego, C; Ortolano, F; Aresi, S; Fumagalli, S; Zanier, ER; Stocchetti, N; De Simoni, MG				Longhi, Luca; Perego, Carlo; Ortolano, Fabrizio; Aresi, Silvia; Fumagalli, Stefano; Zanier, Elisa R.; Stocchetti, Nino; De Simoni, Maria-Grazia			Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; inflammation; microglia; pathophysiology; traumatic brain injury; tumor necrosis factor	CLOSED-HEAD INJURY; CONTROLLED CORTICAL IMPACT; FACTOR-ALPHA; CELL-DEATH; TNF-ALPHA; CONTUSION VOLUME; MICE; BCL-2; ACTIVATION; ISCHEMIA	The role of tumor necrosis factor (TNF) and its receptors after traumatic brain injury (TBI) remains unclear. We evaluated the effects of genetic deletion of either p55 or p75 TNF receptor on neurobehavioral outcome, histopathology, DNA damage and apoptosis-related cell death/survival gene expression (bcl-2/bax), and microglia/macrophage (M/M) activation in wild-type (WT) and knockout mice after TBI. Injured p55 (-/-) mice showed a significant attenuation while p75 (-/-) mice showed a significant worsening of sensorimotor deficits compared with WT mice over 4 weeks postinjury. At the same time point, contusion volume in p55 (-/-) mice (11.1 +/- 3.3 mm(3)) was significantly reduced compared with WT (19.7 +/- 3.4 mm(3)) and p75 (-/-) mice (20.9 +/- 3.2 mm(3)). At 4 hours postinjury, bcl-2/bax ratio mRNA expression was increased in p55 (-/-) compared with p75 (-/-) mice and was associated with reduced DNA damage terminal deoxynucleotidyl transferaseYmediated dUTP nick end labeling (TUNEL-positivity), reduced CD11b expression and increased Ym1 expression at 24 hours postinjury in p55 (-/-) compared with p75 (-/-) mice, indicative of a protective M/M response. These data suggest that TNF may exacerbate neurobehavioral deficits and tissue damage via p55 TNF receptor whose inhibition may represent a specific therapeutic target after TBI.	[Longhi, Luca; Ortolano, Fabrizio; Aresi, Silvia; Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplantat, Neurosurg Intens Care Unit, Fdn IRCCS Osped Maggiore Policlin, Milan, Italy; [Longhi, Luca; Perego, Carlo; Fumagalli, Stefano; Zanier, Elisa R.; De Simoni, Maria-Grazia] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, I-20156 Milan, Italy	De Simoni, MG (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Lab Inflammat & Nervous Syst Dis, I-20156 Milan, Italy.	desimoni@marionegri.it	Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021; Perego, Carlo/AAA-6513-2020; Zanier, Elisa/AAA-8095-2020; De Simoni, Maria Grazia/I-6021-2012; Fumagalli, Stefano/I-3097-2019	Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Perego, Carlo/0000-0002-0259-0003; De Simoni, Maria Grazia/0000-0001-6695-5297; Fumagalli, Stefano/0000-0003-3598-6263; Zanier, Elisa/0000-0002-3011-8718; Ortolano, Fabrizio/0000-0003-1996-948X			Balosso S, 2005, ANN NEUROL, V57, P804, DOI 10.1002/ana.20480; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kitagaki M, 2012, J ATHEROSCLER THROMB, V19, P36, DOI 10.5551/jat.9746; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; RINK A, 1995, AM J PATHOL, V147, P1575; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Soares HD, 1995, J NEUROSCI, V15, P8223; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Taoufik E, 2007, J NEUROSCI, V27, P6633, DOI 10.1523/JNEUROSCI.1091-07.2007; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	56	44	47	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2013	33	8					1182	1189		10.1038/jcbfm.2013.65			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	193OQ	WOS:000322570000007	23611870	Bronze, Green Published			2021-06-18	
J	Finch, CF; Clapperton, AJ; McCrory, P				Finch, Caroline F.; Clapperton, Angela J.; McCrory, Paul			Increasing incidence of hospitalisation for sport-related concussion in Victoria, Australia	MEDICAL JOURNAL OF AUSTRALIA			English	Article							TRAUMATIC BRAIN-INJURY; EPIDEMIOLOGY; FOOTBALL; PLAYERS; HEAD	Objective: To describe trends in hospitalisation for sport-related concussion. Design, setting and patients: Analysis of routinely collected hospital admissions data from all Victorian hospitals (public and private) over the 2002 03 to 2010-11 financial years for patients aged >= 15 years with a diagnosis of concussion and an ICD-10-AM external cause activity code indicating sport. Main outcome measures: Number and cost of hospitalisations; rate of hospitalisation per 100 000 participants overall and for specific sports; and percentage change in frequency and hospitalisation rate per 100 000 participants over 9 years. Results: There were 4745 hospitalisations of people aged 15 years for sport-related concussion, with a total hospital treatment cost of $17 944 799. The frequency of hospitalisation increased by 60.5% (95% CI, 41.7%-77.3%) over the 9 years, but could only partially be explained by increases in sports participation, as the rate per 100 000 participants also increased significantly, by 38.9% (95% CI, 17.5%-61.7%). After adjustment for participation, rates were highest for motor sports, equestrian activities, Australian football, rugby and roller sports. The greatest significant increases in rates were seen in roller sports, rugby, soccer and cycling. Conclusions: The frequency,and participation-adjusted rate of hospitalisation for sport-related concussion, both overall and across several sports, increased significantly over the 9 years: These findings, along with high levels of public concern, make prevention of head injury in sport a population health priority in Australia.	[Finch, Caroline F.] Univ Ballarat, Ctr Hlth & Safe Sport, Ballarat, Vic 3353, Australia; [Clapperton, Angela J.] Monash Univ, Monash Injury Res Inst, Victorian Injury Surveillance Unit, Melbourne, Vic 3004, Australia; [McCrory, Paul] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia	Finch, CF (corresponding author), Univ Ballarat, Ctr Hlth & Safe Sport, Ballarat, Vic 3353, Australia.	c.finch@ballarat.edu.au	McCrory, Paul/Q-8688-2019; Clapperton, Angela/AAN-7862-2020; Clapperton, Angela/AAN-7864-2020	Clapperton, Angela/0000-0002-6129-3404; McCrory, Paul/0000-0003-4850-0568	NHMRCNational Health and Medical Research Council of Australia; Australian Research Council (ARC)Australian Research Council; IOC; International Rugby Board (IRB); Australian Football League Research Board (AFLRB); Australian Rugby Union; SRV; Victorian Health Promotion Foundation (VicHealth); University of MelbourneUniversity of Melbourne; Eastern Health; University of Otago; National Hockey League (US); VicHealth; AFLRB; Royal Australasian College of Surgeons; Australian Sports Commission; Medical Commission of the IOC; Federation Internationale de Football Association (FIFA); American Academy of Neurology; Jockey Club (UK); Axon Sports (US); CogState Inc	Caroline Finch receives, or has previously received, competitive research funding from the following bodies for research into concussion or head injury in sport and its prevention: NHMRC, Australian Research Council (ARC), IOC, International Rugby Board (IRB), Australian Football League Research Board (AFLRB), Australian Rugby Union, SRV and the Victorian Health Promotion Foundation (VicHealth). Paul McCrory currently receives financial research support from the NHMRC, University of Melbourne, IOC, SRV and Eastern Health; his previous competitive grant funding includes the ARC, IRB, University of Melbourne, University of Otago, National Hockey League (US), VicHealth, AFLRB, Royal Australasian College of Surgeons, and the Australian Sports Commission. He has received travel funding from, the Medical Commission of the IOC, the Federation Internationale de Football Association (FIFA), the American Academy of Neurology and the Jockey Club (UK). He receives book royalties from McGraw-Hill and from 2001 to 2008 was employed by the BMJ Publishing Group. He has conducted clinical drug trials on antimigraine (Glaxo Wellcome, Janssen-Cilag, Novartis, Parke-Davis; Schering) and antispasticity drugs (Ipsen) through the Eastern Clinical Research Unit in Melbourne. This drug trial work has not involved any financial payment to him directly. He received consultancy fees in 2010 from Axon Sports (US) for the development of educational material (which was not renewed) and has received support since 2005 from CogState Inc for research costs and the development of educational material. He is a cofounder and shareholder in two biomedical companies (involved in e-health and compression garment technologies) but does not hold any individual shares in any company related to concussion or brain injury assessment or technology. Angela Clapperton has no relevant disclosures.	Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Braham R, 2004, J SCI MED SPORT, V7, P451, DOI 10.1016/S1440-2440(04)80263-9; *CDCP US, 2007, INC TRAUM BRAIN INJ; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finch C., 2007, SPORTS LEISURE INJUR; Finch CF, 2008, INJURY PREV, V14, P202, DOI 10.1136/ip.2007.017251; Gilbert F, 2012, MED J AUSTRALIA, V196, P561, DOI 10.5694/mja11.11218; HELPS Y, 2004, INJURY RES STAT SERI; Hollis SJ, 2011, BRIT J SPORT MED, V45, P997, DOI 10.1136/bjsm.2010.079707; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; National Centre for Classification in Health, 2006, INT STAT CLASS DIS R; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; *STAND COMM RES SP, 2012, PART EX RECR SPORT A; World Health Organization, 2006, NEUR DIS PUBL HLTH C	24	44	44	1	15	AUSTRALASIAN MED PUBL CO LTD	PYRMONT	LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA	0025-729X			MED J AUSTRALIA	Med. J. Aust.	MAY 6	2013	198	8					427	430		10.5694/mja12.11217			4	Medicine, General & Internal	General & Internal Medicine	153RR	WOS:000319620700016	23641993	Bronze			2021-06-18	
J	Olsson, KA; Lloyd, OT; LeBrocque, RM; McKinlay, L; Anderson, VA; Kenardy, JA				Olsson, Katherine A.; Lloyd, Owen T.; LeBrocque, Robyne M.; McKinlay, Lynne; Anderson, Vicki A.; Kenardy, Justin A.			Predictors of child post-concussion symptoms at 6 and 18 months following mild traumatic brain injury	BRAIN INJURY			English	Article						Child; post-concussion; mild traumatic brain injury	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; EVENT SCALE; MODERATE; RECOVERY; OUTCOMES; IMPACT	Background: A proportion of children will experience persistent post-concussion symptoms (PCS) following a mild traumatic brain injury (mTBI). As persistent PCS may be maintained by pathological and psychological factors, this study aimed to describe and evaluate potential pre- and post-injury parent and child predictors of persistent PCS. Methods: A total of 150 children with mTBI and their parents participated. Parents completed measures of their own distress and children's PCS and health-related quality-of-life (HRQoL) at baseline (reflecting pre-injury function). These measures, as well as measures of children's distress and cognitive function were administered at 6 and 18 months post-injury. Results: Children's PCS at 6 months post-injury were predicted by both pre-injury parent distress and children's pre-injury PCS. At 18 months post-injury, children's PCS were predicted by higher levels of parent distress and child PCS at 6 months post-injury, as well as poorer post-injury cognitive functioning. Change in PCS between 6-18 months post-injury was predicted by parent's pre-injury anxiety and children's HRQoL. Conclusions: Children at risk of persistent PCS can be identified by higher levels of pre- and post-injury PCS, parent distress and poorer post-injury cognition. These factors should be addressed by interventions aimed at minimizing the occurrence and impact of child PCS.	[Olsson, Katherine A.; LeBrocque, Robyne M.; Kenardy, Justin A.] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med, Brisbane, Qld 4072, Australia; [Olsson, Katherine A.; Kenardy, Justin A.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia; [Lloyd, Owen T.; McKinlay, Lynne] Royal Childrens Hosp Brisbane, Queensland Paediat Rehabil Serv, Brisbane, Qld, Australia; [Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Kenardy, JA (corresponding author), Royal Brisbane & Womens Hosp, CONROD, Ground Floor,Edith Cavell Bldg, Herston, Qld 4029, Australia.	j.kenardy@uq.edu.au	Kenardy, Justin/F-2085-2010; Le Brocque, Robyne/F-4848-2010; Olsson, Katherine A/K-9957-2016; Kenardy, Justin A/H-6603-2014	Le Brocque, Robyne/0000-0002-4574-1254; Kenardy, Justin A/0000-0001-9475-8450; McKinlay, Lynne/0000-0002-6677-0628	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [301103]	The authors report no conflicts of interest. This study is supported by the National Health and Medical Research Council grant number 301103.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; [Anonymous], 2006, 2006 YB AUSTR; Baumert J, 2004, J AFFECT DISORDERS, V82, P29, DOI 10.1016/j.jad.2003.09.006; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Briere J., 1996, TRAUMA SYMPTOMS CHEC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Field A. P, 2009, DISCOVERING STAT USI; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Goldberg D, 1998, USERS GUIDE GEN HLTH; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirk JW, 2005, DEV NEUROPSYCHOL, V28, P755, DOI 10.1207/s15326942dn2803_2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; Manly T., 1999, TEST EVERYDAY ATTENT; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Olsson KA, 2008, BRAIN INJURY, V22, P595, DOI 10.1080/02699050802132453; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Weiss DS., 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	46	44	44	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2013	27	2					145	157		10.3109/02699052.2012.729286			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	083PX	WOS:000314478500003	23384213				2021-06-18	
J	Siffredi, V; Anderson, V; Leventer, RJ; Spencer-Smith, MM				Siffredi, Vanessa; Anderson, Vicki; Leventer, Richard J.; Spencer-Smith, Megan M.			Neuropsychological Profile of Agenesis of the Corpus Callosum: A Systematic Review	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INTERHEMISPHERIC-TRANSFER; DEVELOPMENTAL DELAY; PRENATAL-DIAGNOSIS; MENTAL-RETARDATION; FETAL AGENESIS; WHITE-MATTER; CHILDREN; DEFICITS; INFORMATION	Developmental absence (agenesis) of the corpus callosum (AgCC) is a common brain malformation that presents in isolation or in association with other conditions. Variability in aspects of neuropsychological functioning has been reported in small samples of individuals. This study aimed to systematically review the literature to characterize the profile and severity of cognitive impairments in individuals with AgCC across development. A mean general intellectual ability was calculated and neuropsychological functioning was qualitatively examined. We discuss methodological limitations of the literature, inherent heterogeneity of the causes and comorbidities of AgCC, and the developmental aspect of AgCC in opposition to split-brain patients.	[Siffredi, Vanessa; Anderson, Vicki; Leventer, Richard J.; Spencer-Smith, Megan M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Leventer, Richard J.] Univ Melbourne, Melbourne, Vic, Australia; [Anderson, Vicki; Leventer, Richard J.] Royal Childrens Hosp, Melbourne, Vic, Australia	Spencer-Smith, MM (corresponding author), Karolinska Inst, Dept Neurosci, Dev Cognit Neurosci Lab, Retzius Vag 8, S-17177 Stockholm, Sweden.	megan.spencer-smith@ki.se	Siffredi, Vanessa/AAA-4866-2020	Siffredi, Vanessa/0000-0002-9137-0730; Spencer-Smith, Megan/0000-0002-1047-0829	Victorian Government; Murdoch Childrens Research Institute	This study was supported by the Victorian Government's Operational Infrastructure Support Program. This research was funded by the Murdoch Childrens Research Institute.	Anderson PJ, 2010, STUD NEUROPSYCHOL NE, P3; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Banich Marie T., 1995, P427; BARKOVICH AJ, 2000, PEDIAT NEUROIMAGING; Barr MS, 2005, NEUROPSYCHOLOGY, V19, P707, DOI 10.1037/0894-4105.19.6.707; Bedeschi MF, 2006, PEDIATR NEUROL, V34, P186, DOI 10.1016/j.pediatrneurol.2005.08.008; Boyd E, 1993, Clin Dysmorphol, V2, P332; Brown WS, 1999, NEUROPSYCHOLOGIA, V37, P1165, DOI 10.1016/S0028-3932(99)00011-1; Brown WS, 2001, J INT NEUROPSYCH SOC, V7, P302, DOI 10.1017/S1355617701733048; Brown WS., 2000, COGN NEUROPSYCHIATRY, V5, P135, DOI [10.1080/135468000395781, DOI 10.1080/135468000395781]; Caille S, 1999, NEUROCASE, V5, P109, DOI 10.1093/neucas/5.2.109; Carroll J. B., 1993, HUMAN COGNITIVE ABIL; Hallak JEC, 2007, ARQ NEURO-PSIQUIAT, V65, P1216, DOI 10.1590/S0004-282X2007000700024; CURATOLO P, 1993, NEUROPEDIATRICS, V24, P77, DOI 10.1055/s-2008-1071518; DAVID AS, 1992, NEUROPSYCHOLOGIA, V30, P161, DOI 10.1016/0028-3932(92)90025-H; de Guise E, 1999, BRAIN, V122, P1049, DOI 10.1093/brain/122.6.1049; Dell'Acqua R, 2005, COGN NEUROPSYCHOL, V22, P1035, DOI 10.1080/02643290442000491; Dennis M., 2006, BRAIN RESERVE CAPACI; Di Stefano M, 1998, NEUROREPORT, V9, P1331; ElAbd S, 1997, DEV MED CHILD NEUROL, V39, P119, DOI 10.1111/j.1469-8749.1997.tb07394.x; Finlay DC, 2000, J CLIN EXP NEUROPSYC, V22, P731, DOI 10.1076/jcen.22.6.731.962; FISCHER M, 1992, ARCH NEUROL-CHICAGO, V49, P271, DOI 10.1001/archneur.1992.00530270085023; Forget J, 2009, EXP BRAIN RES, V192, P443, DOI 10.1007/s00221-008-1602-7; Francesco P, 2006, PEDIATR INT, V48, P298, DOI 10.1111/j.1442-200X.2006.02208.x; Fuchigami T, 1996, ACTA PAEDIATR JAPON, V38, P52; Giedd JN, 1996, DEV BRAIN RES, V91, P274; GOODING CA, 1984, J PEDIATR-US, V104, P509, DOI 10.1016/S0022-3476(84)80538-7; Goodyear PWA, 2001, FETAL DIAGN THER, V16, P139, DOI 10.1159/000053898; Graham JM, 2003, AM J MED GENET A, V123A, P37, DOI 10.1002/ajmg.a.20504; Graham JM, 2008, AM J MED GENET A, V146A, P3011, DOI 10.1002/ajmg.a.32553; GUPTA JK, 1995, PRENATAL DIAG, V15, P301, DOI 10.1002/pd.1970150402; Hannay HJ, 2009, J CLIN EXP NEUROPSYC, V31, P180, DOI 10.1080/13803390802209954; Hetts SW, 2006, AM J ROENTGENOL, V187, P1343, DOI 10.2214/AJR.05.0146; Hines RJ, 2002, NEUROPSYCHOLOGIA, V40, P1804, DOI 10.1016/S0028-3932(02)00032-5; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Huang H, 2009, J NEUROSCI, V29, P4263, DOI 10.1523/JNEUROSCI.2769-08.2009; Huber-Okrainec J, 2005, BRAIN LANG, V93, P349, DOI 10.1016/j.bandl.2004.11.002; Imamura T, 1994, Behav Neurol, V7, P43, DOI 10.3233/BEN-1994-7201; Jancke L, 1997, NEUROPSYCHOLOGIA, V35, P1389, DOI 10.1016/S0028-3932(97)00068-7; Jea A, 2008, CHILD NERV SYST, V24, P685, DOI 10.1007/s00381-008-0626-4; Kamnasaran D, 2005, CLIN INVEST MED, V28, P267; KARNATH HO, 1991, CORTEX, V27, P345, DOI 10.1016/S0010-9452(13)80141-4; Keshavan MS, 2002, LIFE SCI, V70, P1909, DOI 10.1016/S0024-3205(02)01492-3; KESSLER J, 1991, INT J NEUROSCI, V58, P275, DOI 10.3109/00207459108985443; Klaas PA, 1999, J CLIN EXP NEUROPSYC, V21, P837, DOI 10.1076/jcen.21.6.837.851; KOEDA T, 1993, DEV MED CHILD NEUROL, V35, P65; Lamonica DAC, 2009, AM J MED GENET A, V149A, P1041, DOI 10.1002/ajmg.a.32787; LASSONDE M, 1994, ADV BEHAV BIOL, V42, P275; Lawson-Yuen A, 2006, CLIN DYSMORPHOL, V15, P217, DOI 10.1097/01.mcd.0000220609.17284.a9; Lebel C, 2010, NEUROIMAGE, V52, P20, DOI 10.1016/j.neuroimage.2010.03.072; Lee Ying-Ying, 2008, Acta Neurol Taiwan, V17, P194; Lessard N, 2002, BRAIN, V125, P1039, DOI 10.1093/brain/awf096; Lindwall C, 2007, CURR OPIN NEUROBIOL, V17, P3, DOI 10.1016/j.conb.2007.01.008; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Marszal E, 2000, J CHILD NEUROL, V15, P401, DOI 10.1177/088307380001500609; Matlary A, 2004, CLIN DYSMORPHOL, V13, P257, DOI 10.1097/00019605-200410000-00012; Midorikawa A, 2006, CORTEX, V42, P356, DOI 10.1016/S0010-9452(08)70362-9; Motomura N, 2002, PSYCHIAT CLIN NEUROS, V56, P199, DOI 10.1046/j.1440-1819.2002.00944.x; Moutard ML, 2003, CHILD NERV SYST, V19, P471, DOI 10.1007/s00381-003-0781-6; Panos PT, 2001, ARCH CLIN NEUROPSYCH, V16, P507, DOI 10.1016/S0887-6177(00)00061-5; Parraga HC, 2003, INT J PSYCHIAT MED, V33, P107, DOI 10.2190/D4Y1-WNBX-HQW8-HDPL; Paul LK, 2004, ARCH CLIN NEUROPSYCH, V19, P215, DOI 10.1016/S0887-6177(03)00024-6; Paul LK, 2003, BRAIN LANG, V85, P313, DOI 10.1016/S0093-934X(03)00062-2; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Ramelli GP, 2006, SWISS MED WKLY, V136, P404; Raybaud C, 2010, NEURORADIOLOGY, V52, P447, DOI 10.1007/s00234-010-0696-3; Reddy RP, 2010, NEUROPSYCHOL TRENDS, P29, DOI 10.7358/neur-2010-007-redd; Richards LJ, 2004, CLIN GENET, V66, P276, DOI 10.1111/j.1399-0004.2004.00354.x; Schulte T, 2010, NEUROPSYCHOL REV, V20, P174, DOI 10.1007/s11065-010-9130-1; Semrud-Clikeman M., 2009, CHILD NEUROSPYCHOLOG; Shevell MI, 2002, J CHILD NEUROL, V17, P896, DOI 10.1177/08830738020170122601; Simon A, 2008, NEUROPSYCHOBIOLOGY, V58, P118, DOI 10.1159/000170392; Stickles JL., 2002, INT J DISABIL DEV ED, V49, P367, DOI [DOI 10.1080/1034912022000028349, 10.1080/1034912022000028349]; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Symington SH, 2010, SOC NEUROSCI-UK, V5, P296, DOI 10.1080/17470910903462419; Taylor M, 1998, J NEUROL NEUROSUR PS, V64, P131, DOI 10.1136/jnnp.64.1.131; VANASSE M, 1994, ADV BEHAV BIOL, V42, P199; Velek M, 1988, Ala Med, V58, P27	79	44	45	1	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 1	2013	38	1					36	57		10.1080/87565641.2012.721421			22	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	104HX	WOS:000315984000003	23311314				2021-06-18	
J	Sugerman, DE; Xu, LK; Pearson, WS; Faul, M				Sugerman, David E.; Xu, Likang; Pearson, William S.; Faul, Mark			Patients with severe traumatic brain injury transferred to a Level I or II trauma center: United States, 2007 to 2009	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	42nd Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2012	Vail, CO	Western Trauma Assoc		Transfer; traumatic brain injury; death; prehospital transport	DIRECT TRANSPORT; DEFINITIVE CARE; CENTER ACCESS; RURAL TRAUMA; OUTCOMES; IMPACT; GUIDELINES; MANAGEMENT; FACILITIES; MORTALITY	BACKGROUND: Patients with severe traumatic brain injury (TBI), head Abbreviated Injury Scale (AIS) score of 3 or greater, who are indirectly transported from the scene of injury to a nontrauma center can experience delays to definitive neurosurgical management. Transport to a hospital with appropriate initial emergency department treatment and rapid admission has been shown to reduce mortality in a state's trauma system. This study was conducted to see if the same finding holds with a nationally representative sample of patients with severe TBI seen at Level I and II trauma centers. METHODS: This study is based on adult (>= 18 years), severe TBI patients treated in a nationally representative sample of Level I and II trauma centers, submitting data to the National Trauma Databank National Sample Program from 2007 to 2009. We analyzed independent variables including age, sex, primary payer, race, ethnicity, mode of transport, injury type (blunt vs. penetrating), mechanism of injury, trauma center level, head AIS, initial Glasgow Coma Scale (GCS), Injury Severity Score (ISS), and systolic blood pressure by transfer status. The primary outcome variable was inpatient death, with discharge disposition, neurosurgical procedures, and mean hospital, intensive care unit, and ventilator days serving as secondary outcomes. RESULTS: After exclusion criteria were applied (ISS < 16; age < 18 years; GCS motor score = 6; non-head AIS score? 3; head AIS < 3; patients with missing transfer status, and death on arrival), a weighted sample of 51,300 (16%) patients was eligible for analysis. In bivariate analyses, transferred patients were older (>= 60 years), white, insured, less severely injured (head MS score 4, ISS < 25), and less likely to have sustained penetrating trauma (p < 0.001). After controlling for all variables, direct transport, 1 or more comorbidities, advanced age, head AIS score, intracranial hemorrhage, and firearm injury remained significant predictors of death. Being transferred (adjusted odds ratio, 0.79; 95% confidence interval, 0.64-0.96) lowered the risk of death. CONCLUSION: Patients with severe TBI who were transferred to a Level I or II trauma center had lower injury severity, including less penetrating trauma, and, as a result, were less likely to die compared with patients who were directly admitted to a Level I or II trauma center. The results may demonstrate adherence with the current Guidelines for Prehospital Management of Traumatic Brain Injury and Guidelines for Field Triage of Injured Patients, which recommend the direct transport of patients with severe TBI to the highest level trauma center. Patients with severe TBI who cannot be taken to a trauma center should be stabilized at a nontrauma center and then transferred to a Level I or II trauma center. Regional and national trauma databases should consider collecting information on patient outcomes at referral facilities and total transport time after injury, to better address the outcomes of patient triage decisions. (J Trauma Acute Care Surg. 2012;73: 1491-1499. Copyright (C) 2012 by Lippincott Williams & Wilkins) LEVEL OF EVIDENCE: Prognostic study, level III; therapeutic study, level IV.	[Sugerman, David E.; Xu, Likang; Pearson, William S.; Faul, Mark] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA	Sugerman, DE (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 1600 Clifton Rd NE,MS F62, Atlanta, GA 30333 USA.	ggi4@cdc.gov		Faul, Mark/0000-0002-7683-0348			ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; Brain Trauma Foundation, 2000, GUID PREH MAN TRAUM; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; DAY JC, 1993, POPULATION PROJECTIO; Diaz JJ, 2007, SURGERY, V141, P310, DOI 10.1016/j.surg.2007.01.010; Esposito TJ, 2006, J AM COLL SURGEONS, V202, P655, DOI 10.1016/j.jamcollsurg.2005.12.008; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Garwe T, 2011, J TRAUMA, V70, P1118, DOI 10.1097/TA.0b013e3181e243b8; Goble S, 2009, J TRAUMA, V67, P637, DOI 10.1097/TA.0b013e3181b84294; Haas B, 2010, J AM COLL SURGEONS, V211, P804, DOI 10.1016/j.jamcollsurg.2010.08.014; Harrington DT, 2005, ANN SURG, V241, P961, DOI 10.1097/01.sla.0000164178.62726.f1; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hsia R, 2011, ARCH SURG-CHICAGO, V146, P46, DOI 10.1001/archsurg.2010.299; Hsia RY, 2010, J TRAUMA, V68, P217, DOI 10.1097/TA.0b013e3181a0e66d; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kejriwal R, 2009, NEW ZEAL MED J, V122, P40; Lehmann R, 2009, AM J SURG, V197, P571, DOI 10.1016/j.amjsurg.2008.12.037; Lu J, 2005, ACT NEUR S, V95, P281; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Mullins RJ, 2002, J TRAUMA, V52, P1019, DOI 10.1097/00005373-200206000-00002; Newgard CD, 2007, J TRAUMA, V63, P965, DOI 10.1097/TA.0b013e31803c5665; Nirula R, 2010, J TRAUMA, V69, P595, DOI 10.1097/TA.0b013e3181ee6e32; Rivara FP, 2008, J TRAUMA, V64, P1594, DOI 10.1097/TA.0b013e3181493099; Rogers FB, 1999, J TRAUMA, V47, P802, DOI 10.1097/00005373-199910000-00038; RUTLEDGE R, 1993, ANN SURG, V218, P512, DOI 10.1097/00000658-199310000-00011; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sinharay S, 2001, PSYCHOL METHODS, V6, P317, DOI 10.1037//1082-989X.6.4.317; Sollid S, 2003, J NEUROTRAUM, V20, P309, DOI 10.1089/089771503321532897; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Thompson DO, 2011, ANN EMERG MED, V58, P417, DOI 10.1016/j.annemergmed.2011.05.033; Utter GH, 2008, J EMERG MED, V35, P415, DOI 10.1016/j.jemermed.2007.04.021; Wright KD, 1996, INJURY, V27, P719, DOI 10.1016/S0020-1383(96)00119-2; Young JS, 1998, AM SURGEON, V64, P88	40	44	45	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73	6					1491	1499		10.1097/TA.0b013e3182782675			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	058FV	WOS:000312620400021	23188242				2021-06-18	
J	Dobrunz, D; Toma, AC; Tanner, P; Pfohl, T; Palivan, CG				Dobrunz, Dominik; Toma, Adriana C.; Tanner, Pascal; Pfohl, Thomas; Palivan, Cornelia G.			Polymer Nanoreactors with Dual Functionality: Simultaneous Detoxification of Peroxynitrite and Oxygen Transport	LANGMUIR			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; LIPOSOME-ENCAPSULATED HEMOGLOBIN; RESONANCE RAMAN-SPECTROSCOPY; TRIBLOCK COPOLYMER VESICLES; TRAUMATIC BRAIN-INJURY; RED-BLOOD-CELLS; NITRIC-OXIDE; CREATINE-KINASE; METHEMOGLOBIN; OXYHEMOGLOBIN	The design of multifunctional systems is in focus today:is a key. strategy for coping with complex challenges in various domains that include chemistry, medicine, environmental sciences, and technology. Herein, we introduce protein-containing polymer nanoreactors with dual functionality: peroxynitrite degradation and oxygen transport. Vesicles made of poly-(2-methyloxazoline)-poly(dimethylsiloxane)-poly(2-methyloxazoline) successfully encapsulated hemoglobin (Hb), which serves as a model protein because of its dual function in oxygen transport and peroxynitrite degradation. By inserting channel proteins, the polymer membranes of vesicles permitted passage of various compounds that served for the assessment of in situ Hb activity. The requisite conformational changes. in the protein. structure and the. change in oxidation states that took place within the confined space of the vesicle cavity demonstrated that Hb preserved its dual functionality: peroxynitrite degradation and oxygen transport The functionality of our nanoreactor, combined With its simple procedure of production and extensive stability over several months, supports it as a promising system for further medical applications.	[Dobrunz, Dominik; Toma, Adriana C.; Tanner, Pascal; Pfohl, Thomas; Palivan, Cornelia G.] Univ Basel, Dept Chem, CH-4056 Basel, Switzerland	Palivan, CG (corresponding author), Univ Basel, Dept Chem, Klingelbergstr 80, CH-4056 Basel, Switzerland.		Pfohl, Thomas/D-7296-2016	Pfohl, Thomas/0000-0002-7879-5216	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; NCCR Nanoscale ScienceSwiss National Science Foundation (SNSF)European Commission; Forschungsfonds der Universitat Basel	This work was supported by the Swiss National Science Foundation and by NCCR Nanoscale Science, and this is gratefully acknowledged. The authors thank Prof. W. Meier of the University of Basel for providing the block copolymer and for useful discussions. The authors acknowledge Prof. C. Schonenberger from the University of Basel for access to the Raman spectrometer. A.C.T. thanks the "Forschungsfonds der Universitat Basel" for funding and T. Frohlich for support with Raman measurements. D.D. thanks Dr. Ozana Fischer-Onaca for useful discussions. The authors acknowledge Mark Inglin for reading the manuscript.	ABE K, 1979, EUR J BIOCHEM, V101, P423, DOI 10.1111/j.1432-1033.1979.tb19735.x; Arifin DR, 2005, BIOMACROMOLECULES, V6, P2172, DOI 10.1021/bm0501454; Arifin DR, 2005, ARTIF CELL BLOOD SUB, V33, P113, DOI 10.1081/BIO-200055874; Arosio D, 2002, BIOPOLYMERS, V63, P1, DOI 10.1002/bip.1057; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; Ascenzi P, 2009, BIOCHEM BIOPH RES CO, V390, P27, DOI 10.1016/j.bbrc.2009.09.050; Axthelm F, 2008, J PHYS CHEM B, V112, P8211, DOI 10.1021/jp803032w; Balasubramanian V, 2010, EXPERT OPIN DRUG DEL, V7, P63, DOI 10.1517/17425240903394520; Barenholz Y, 2001, CURR OPIN COLLOID IN, V6, P66, DOI 10.1016/S1359-0294(00)00090-X; Bermudez H, 2002, MACROMOLECULES, V35, P8203, DOI 10.1021/ma020669l; Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; Broz P, 2005, J CONTROL RELEASE, V102, P475, DOI 10.1016/j.jconrel.2004.10.014; Centis V, 2011, BIOCHEM ENG J, V55, P162, DOI 10.1016/j.bej.2011.04.001; Chang TMS, 2010, WIRES NANOMED NANOBI, V2, P418, DOI 10.1002/wnan.95; Chang TMS, 2003, ARTIF CELL BLOOD SUB, V31, P231, DOI 10.1081/BIO-120023155; Chen DF, 2007, BIOMED MATER, V2, pS126, DOI 10.1088/1748-6041/2/3/S08; Cohn SM, 1997, ANN MED, V29, P371, DOI 10.3109/07853899708999364; Dairou J, 2004, J BIOL CHEM, V279, P7708, DOI 10.1074/jbc.M311469200; Dhont J. K. G., 1996, INTRO DYNAMICS COLLO, P147; Droege W., 2006, DISEASE AND CANCER, P885; Exner M, 2000, CHEM RES TOXICOL, V13, P287, DOI 10.1021/tx990201k; Faivre B, 1998, ARTIF CELL BLOOD SUB, V26, P17, DOI 10.3109/10731199809118943; Gaoshan Shen, 2008, 2008 2nd International Conference on Bioinformatics and Biomedical Engineering (ICBBE '08), P1476; Graff A, 2002, P NATL ACAD SCI USA, V99, P5064, DOI 10.1073/pnas.062654499; Graff A, 2010, MACROMOL CHEM PHYS, V211, P229, DOI 10.1002/macp.200900517; Grzelakowski M, 2009, SMALL, V5, P2545, DOI 10.1002/smll.200900603; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; Hunt JA, 1997, CHEM BIOL, V4, P845, DOI 10.1016/S1074-5521(97)90117-4; Kumar M, 2007, P NATL ACAD SCI USA, V104, P20719, DOI 10.1073/pnas.0708762104; Li DJ, 2004, ACTA BIOCH BIOPH SIN, V36, P87, DOI 10.1093/abbs/36.2.87; Li JF, 2003, NEUROSCI LETT, V350, P173, DOI 10.1016/S0304-3940(03)00881-4; Li SL, 2005, BIOMATERIALS, V26, P3759, DOI 10.1016/j.biomaterials.2004.09.015; Matsui M, 2006, IEICE T ELECTRON, VE89C, P1741, DOI 10.1093/ietele/e89-c.12.1741; McCool BA, 2004, J NON-CRYST SOLIDS, V333, P143, DOI 10.1016/j.jnoncrysol.2003.09.061; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mihm MJ, 2002, BIOCHIMIE, V84, P1013, DOI 10.1016/S0300-9084(02)00005-6; Nagatomo S, 2011, J AM CHEM SOC, V133, P10101, DOI 10.1021/ja111370f; Nardin C, 2000, CHEM COMMUN, P1433, DOI 10.1039/b004280n; Nardin C, 2000, LANGMUIR, V16, P1035, DOI 10.1021/la990951u; Nauser T, 2002, J PHYS CHEM A, V106, P4084, DOI 10.1021/jp025518z; Onaca O, 2010, MACROMOL BIOSCI, V10, P531, DOI 10.1002/mabi.200900379; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Phillips WT, 1999, J PHARMACOL EXP THER, V288, P665; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1016/S0378-1097(98)00151-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Rameez S, 2008, BIOCONJUGATE CHEM, V19, P1025, DOI 10.1021/bc700465v; Rameez S, 2012, BIOTECHNOL PROGR, V28, P636, DOI 10.1002/btpr.1532; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rigler P, 2006, J AM CHEM SOC, V128, P367, DOI 10.1021/ja056719u; Romero N, 2003, J BIOL CHEM, V278, P44049, DOI 10.1074/jbc.M305895200; Romero N, 2006, IUBMB LIFE, V58, P572, DOI 10.1080/15216540600936549; Sakai H, 2000, BIOCONJUGATE CHEM, V11, P425, DOI 10.1021/bc990173h; Sakai H, 2008, J BIOL CHEM, V283, P1508, DOI 10.1074/jbc.M707660200; Sanders KE, 2002, BLOOD, V100, P299, DOI 10.1182/blood.V100.1.299; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; SPIRO TG, 1972, P NATL ACAD SCI USA, V69, P2622, DOI 10.1073/pnas.69.9.2622; SPIRO TG, 1975, P ROY SOC LOND A MAT, V345, P89, DOI 10.1098/rspa.1975.0127; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Sun J, 2009, LANGMUIR, V25, P13726, DOI 10.1021/la901194k; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Tanner P, 2011, FEBS LETT, V585, P1699, DOI 10.1016/j.febslet.2011.05.003; Tanner P, 2011, CHEM-EUR J, V17, P4552, DOI 10.1002/chem.201002782; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Torres IP, 2008, J APPL PHYSIOL, V104, P1809, DOI 10.1152/japplphysiol.00025.2008; Tsuruga M, 1998, J BIOL CHEM, V273, P8607, DOI 10.1074/jbc.273.15.8607; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; van Dongen SFM, 2009, CHEM-EUR J, V15, P1107, DOI 10.1002/chem.200802114; Wohland T, 2001, BIOPHYS J, V80, P2987, DOI 10.1016/S0006-3495(01)76264-9; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xu HX, 1999, PHYS REV LETT, V83, P4357, DOI 10.1103/PhysRevLett.83.4357; YAMAMOTO T, 1973, J BIOL CHEM, V248, P5211; Zhang XL, 2008, J BIOMED MATER RES B, V87B, P354, DOI 10.1002/jbm.b.31110; Zhao J, 2007, BIOMATERIALS, V28, P1414, DOI 10.1016/j.biomaterials.2006.10.012	74	44	44	1	48	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0743-7463			LANGMUIR	Langmuir	NOV 13	2012	28	45					15889	15899		10.1021/la302724m			11	Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science, Multidisciplinary	Chemistry; Materials Science	038RH	WOS:000311191300016	23083075				2021-06-18	
J	Cheng, JP; Shaw, KE; Monaco, CM; Hoffman, AN; Sozda, CN; Olsen, AS; Kline, AE				Cheng, Jeffrey P.; Shaw, Kaitlyn E.; Monaco, Christina M.; Hoffman, Ann N.; Sozda, Christopher N.; Olsen, Adam S.; Kline, Anthony E.			A Relatively Brief Exposure to Environmental Enrichment after Experimental Traumatic Brain Injury Confers Long-Term Cognitive Benefits	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; environmental enrichment; functional recovery; learning and memory; Morris water maze; traumatic brain injury	MEDIATED FUNCTIONAL IMPROVEMENT; RECEPTOR AGONIST 8-OH-DPAT; TREATMENT REGIMEN; CORTICAL IMPACT; DEFICITS; RECOVERY; HIPPOCAMPUS; ACQUISITION; GROWTH; CORTEX	It is well established that a relatively brief exposure to environmental enrichment (EE) enhances motor and cognitive performance after experimental traumatic brain injury (TBI), but it is not known whether the benefits can be sustained after EE is discontinued. To address this important rehabilitation-relevant concern, anesthetized rats received a controlled cortical impact (CCI) or sham injury, and for phase 1 of the experiment were randomly assigned to either 3 weeks of EE or standard (STD) housing. Neurobehavioral outcome was assessed by established motor and cognitive tests on postoperative days 1-5 and 14-18, respectively. Beam-balance and spatial learning were facilitated in the TBI + EE more than the TBI + STD group (p < 0.0001). In phase 2 of the experiment, half of the rats in EE were transferred to STD conditions (TBI + EE + STD and sham + EE + STD), and neurobehavior was re-assessed once per month for 6 months. The TBI + EE and TBI + EE + STD groups performed markedly better in the water maze than the TBI + STD group (p < 0.0001), and did not differ from one another (p = 0.53). These data replicate those of several studies from our laboratory showing that EE enhances recovery after CCI injury, and extend those findings by demonstrating that the cognitive benefits are maintained for at least 6 months post-rehabilitation. The persistent benefits shown with this paradigm provide further support for EE as a pre-clinical model of rehabilitation that can be further explored, either alone or in combination with pharmacotherapies, for optimal neurorehabilitation after TBI.	[Cheng, Jeffrey P.; Shaw, Kaitlyn E.; Monaco, Christina M.; Hoffman, Ann N.; Sozda, Christopher N.; Olsen, Adam S.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Hoffman, Ann N.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA; [Sozda, Christopher N.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Olsen, Adam S.] Univ Toledo, Coll Med, Toledo, OH 43606 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Olsen, Adam/0000-0003-0957-9867; Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851, R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported in part by National Institutes of Health grants HD043851, HD046700, and NS060005 (to A.E.K.)	BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	28	44	46	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2684	2688		10.1089/neu.2012.2560			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400009	22774771	Green Published			2021-06-18	
J	Geurts, BHJ; Andriessen, TMJC; Goraj, BM; Vos, PE				Geurts, Bram H. J.; Andriessen, Teuntje M. J. C.; Goraj, Bozena M.; Vos, Pieter E.			The reliability of magnetic resonance imaging in traumatic brain injury lesion detection	BRAIN INJURY			English	Article						Traumatic brain injury; magnetic resonance imaging; reliability; Glasgow Coma Scale; Glasgow Outcome Scale	DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; CEREBRAL MICROBLEEDS; CLINICAL-APPLICATIONS; PROGNOSTIC VALUE; MRI; RECOVERY; NEUROPATHOLOGY; CLASSIFICATION; EPIDEMIOLOGY	Objective: This study compares inter-rater-reliability, lesion detection and clinical relevance of T2-weighted imaging (T2WI), Fluid Attenuated Inversion Recovery (FLAIR), T2*-gradient recalled echo (T2*-GRE) and Susceptibility Weighted Imaging (SWI) in Traumatic Brain Injury (TBI). Methods: Three raters retrospectively scored 56 TBI patients' MR images (12-76 years old, median TBI-MRI interval 7 weeks) on number, volume, location and intensity. Punctate lesions (diameter <10mm) were scored separately from large lesions (diameter >= 10 mm). Injury severity was assessed with the Glasgow Coma Scale (GCS), outcome with the Glasgow Outcome Scale-Extended (GOSE). Results: Inter-rater-reliability for lesion volume and punctate lesion count was good (ICC = 0.69-0.94) except for punctate lesion count on T2WI (ICC = 0.19) and FLAIR (ICC = 0.15). SWI showed the highest number of lesions (mean = 30.0), followed by T2*-GRE (mean = 15.4), FLAIR (mean = 3.1) and T2WI (mean = 2.2). Sequences did not differ in detected lesion volume. Punctate lesion count on T2*-GRE (r = -0.53) and SWI (r = -0.49) correlated with the GCS (p < 0.001). Conclusions: T2*-GRE and SWI are more sensitive than T2WI and FLAIR in detecting (haemorrhagic) traumatic punctate lesions. The correlation between number of punctate lesions on T2*-GRE/SWI and the GCS indicates that haemorrhagic lesions are clinically relevant. The considerable inter-rater-disagreement in this study advocates cautiousness in interpretation of punctate lesions using T2WI and FLAIR.	[Geurts, Bram H. J.; Goraj, Bozena M.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; [Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Goraj, Bozena M.] Med Ctr Postgrad Educ, Dept Radiol & Diagnost Imaging, Warsaw, Poland	Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Goraj, B.M./L-4331-2015; Geurts, Bram HJ/G-4493-2016	Geurts, Bram HJ/0000-0002-1960-4491			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; Duckworth JL, 2010, CURR OPIN CRIT CARE, V16, P92, DOI 10.1097/MCC.0b013e3283374900; EDELMAN RR, 1986, AM J NEURORADIOL, V7, P751; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P841, DOI 10.1097/00004728-199211000-00001; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kwee RM, 2007, RADIOGRAPHICS, V27, P1071, DOI 10.1148/rg.274065722; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Manolakaki D, 2009, J TRAUMA, V66, P1008, DOI 10.1097/TA.0b013e31819adba2; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Provenzale J, 2007, EMERG RADIOL, V14, P1, DOI 10.1007/s10140-007-0587-z; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Roob G, 1999, NEUROLOGY, V52, P991, DOI 10.1212/WNL.52.5.991; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Stehling C, 2008, ACAD RADIOL, V15, P895, DOI 10.1016/j.acra.2008.01.013; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thomas B, 2008, NEURORADIOLOGY, V50, P105, DOI 10.1007/s00234-007-0316-z; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tsushima Y, 2006, CURR PROBL DIAGN RAD, V35, P140, DOI 10.1067/j.cpradiol.2006.04.002; Wallace CJ, 1996, SEMIN ULTRASOUND CT, V17, P251, DOI 10.1016/S0887-2171(96)90038-4; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	64	44	46	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2012	26	12					1439	1450		10.3109/02699052.2012.694563			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	022DL	WOS:000309935400005	22731791				2021-06-18	
J	Halpern, AE; Ramig, LO; Matos, CEC; Petska-Cable, JA; Spielman, JL; Pogoda, JM; Gilley, PM; Sapir, S; Bennett, JK; McFarland, DH				Halpern, Angela E.; Ramig, Lorraine O.; Matos, Carlos E. C.; Petska-Cable, Jill A.; Spielman, Jennifer L.; Pogoda, Janice M.; Gilley, Phillip M.; Sapir, Shimon; Bennett, John K.; McFarland, David H.			Innovative Technology for the Assisted Delivery of Intensive Voice Treatment (LSVT (R) LOUD) for Parkinson Disease	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						Parkinson; speech treatment; technology	TRAUMATIC BRAIN-INJURY; TREATMENT LSVT LOUD; SPEECH TREATMENT; NEURAL PLASTICITY; DISORDERED SPEECH; INDIVIDUALS; DYSARTHRIA; THERAPY; REHABILITATION; PERCEPTION	Purpose: To assess the feasibility and effectiveness of a newly developed assistive technology system, Lee Silverman Voice Treatment Companion (LSVT (R) Companion (TM), hereafter referred to as "Companion"), to support the delivery of LSVT (R) LOUD, an efficacious speech intervention for individuals with Parkinson disease (PD). Method: Sixteen individuals with PD were randomized to an immediate (n = 8) or a delayed (n = 8) treatment group. They participated in 9 LSVT LOUD sessions and 7 Companion sessions, independently administered at home. Acoustic, listener perception, and voice and speech rating data were obtained immediately before (pre), immediately after (post), and at 6 months post treatment (follow-up). System usability ratings were collected immediately post treatment. Changes in vocal sound pressure level were compared to data from a historical treatment group of individuals with PD treated with standard, in-person LSVT LOUD. Results: All 16 participants were able to independently use the Companion. These individuals had therapeutic gains in sound pressure level, pre to post and pre to follow-up, similar to those of the historical treatment group. Conclusions: This study supports the use of the Companion as an aid in treatment of hypokinetic dysarthria in individuals with PD. Advantages and disadvantages of the Companion, as well as limitations of the present study and directions for future studies, are discussed.	[Halpern, Angela E.; Ramig, Lorraine O.; Spielman, Jennifer L.; Gilley, Phillip M.; Bennett, John K.] Univ Colorado, Boulder, CO 80309 USA; [Halpern, Angela E.; Ramig, Lorraine O.; Petska-Cable, Jill A.; Spielman, Jennifer L.] Natl Ctr Voice & Speech, Denver, CO USA; [Matos, Carlos E. C.] Fac Ruy Barbosa, Salvador, BA, Brazil; [Pogoda, Janice M.] Univ So Calif, Los Angeles, CA USA; [Sapir, Shimon] Univ Haifa, IL-31999 Haifa, Israel; [McFarland, David H.] Univ Montreal, Quebec City, PQ, Canada; [McFarland, David H.] McGill Univ, Montreal, PQ, Canada	Halpern, AE (corresponding author), Univ Colorado, Boulder, CO 80309 USA.	angela.halpern@lsvtglobal.com			National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21-DC05583]; The Michael J. Fox Foundation; The Coleman Institute for Cognitive Disabilities; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R21DC005583] Funding Source: NIH RePORTER	This research was funded by National Institute on Deafness and Other Communication Disorders and National Institute of Neurological Disorders and Stroke Grant R21-DC05583, The Michael J. Fox Foundation, and The Coleman Institute for Cognitive Disabilities. We thank our research assistants Heather Gustafson and Leslie Mahler. We also express our gratitude to the individuals who volunteered their time to participate in this study.	Adams S, 2006, J MED SPEECH-LANG PA, V14, P221; ADAMS SG, 1992, EUR J DISORDER COMM, V27, P121; Ball LJ, 2004, J COMMUN DISORD, V37, P197, DOI 10.1016/j.jcomdis.2003.09.002; Baumgartner CA, 2001, J VOICE, V15, P105, DOI 10.1016/S0892-1997(01)00010-8; BAYLES KA, 1993, J CLIN EXP NEUROPSYC, V15, P547, DOI 10.1080/01688639308402578; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Benton A., 1994, MULTILINGUAL APHASIA; Boliek C, 2009, MOVEMENT DISORD, V24, pS450; Cariski D, 1999, J MED SPEECH-LANG PA, V7, P315; Cole E., 2006, PAT CTR DESIGN RES S; Constantinescu G, 2011, INT J LANG COMM DIS, V46, P1, DOI 10.3109/13682822.2010.484848; Constantinescu G, 2010, INT J LANG COMM DIS, V45, P630, DOI 10.3109/13682820903470569; Constantinescu GA, 2010, J TELEMED TELECARE, V16, P100, DOI 10.1258/jtt.2009.090306; Countryman S., 1997, AM J SPEECH LANG PAT, V6, P74; DOWNIE AW, 1981, BRIT J DISORD COMMUN, V16, P135; DROMEY C, 1995, J SPEECH HEAR RES, V38, P751, DOI 10.1044/jshr.3804.751; Dykstra A., 2010, ANN CONV AM SPEECH L; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; El Sharkawi A, 2002, J NEUROL NEUROSUR PS, V72, P31; Fairbanks G., 1960, VOICE ARTICULATION D, V, 2nd ed; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox Cynthia M., 2006, Seminars in Speech and Language, V27, P283, DOI 10.1055/s-2006-955118; Fox CM, 2012, J SPEECH LANG HEAR R, V55, P930, DOI 10.1044/1092-4388(2011/10-0235); Greene M C, 1972, J Laryngol Otol, V86, P595, DOI 10.1017/S0022215100075629; Guadagnoli MA, 2002, PARKINSONISM RELAT D, V9, P89, DOI 10.1016/S1353-8020(02)00007-X; HANSON WR, 1980, J SPEECH HEAR DISORD, V45, P268, DOI 10.1044/jshd.4502.268; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HARTELIUS L, 1994, FOLIA PHONIATR LOGO, V46, P9, DOI 10.1159/000266286; Hill AJ, 2006, AM J SPEECH-LANG PAT, V15, P45, DOI 10.1044/1058-0360(2006/006); Hillman RE, 2006, ANN OTO RHINOL LARYN, V115, P795, DOI 10.1177/000348940611501101; Ho AK, 2000, MOVEMENT DISORD, V15, P1125, DOI 10.1002/1531-8257(200011)15:6<1125::AID-MDS1010>3.0.CO;2-R; Ho AK, 1998, BEHAV NEUROL, V11, P131, DOI 10.1155/1999/327643; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Howell S, 2009, INT J LANG COMM DIS, V44, P287, DOI 10.1080/13682820802033968; *ISO, 1999, 134071999E ISO; Jacobson B. H., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI [10.1044/1058-0360.0603.66, DOI 10.1044/1058-0360.0603.66]; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Krause M, 2004, J NEUROL SCI, V219, P119, DOI 10.1016/j.jns.2004.01.004; Liotti M, 2003, NEUROLOGY, V60, P432, DOI 10.1212/WNL.60.3.432; LOGEMANN JA, 1978, J SPEECH HEAR DISORD, V43, P47, DOI 10.1044/jshd.4301.47; Mahler LA, 2009, J MED SPEECH-LANG PA, V17, P165; Mashima PA, 2003, AM J SPEECH-LANG PAT, V12, P432, DOI 10.1044/1058-0360(2003/089); Mashima Pauline A, 2008, Telemed J E Health, V14, P1101, DOI 10.1089/tmj.2008.0080; Massaro DW, 2004, J SPEECH LANG HEAR R, V47, P304, DOI 10.1044/1092-4388(2004/025); Matos C., 2001, THESIS U COLORADO BO; Matos C., 2002, F0 AUTOCORRELA UNPUB; Matos C., 2003, SPL EXTRACTOR UNPUB; McFarland David H., 2006, Seminars in Speech and Language, V27, P300, DOI 10.1055/s-2006-955119; Narayana S, 2010, HUM BRAIN MAPP, V31, P222, DOI 10.1002/hbm.20859; Petska J., 2006, 13 BIENN C MOT SPEEC; Pinto S, 2004, LANCET NEUROL, V3, P547, DOI 10.1016/S1474-4422(04)00854-3; Ramig L. O., 1988, CLIN DYS C SAN DIEG; Ramig LO, 2001, MOVEMENT DISORD, V16, P79, DOI 10.1002/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H; Ramig LO, 2001, J NEUROL NEUROSUR PS, V71, P493, DOI 10.1136/jnnp.71.4.493; RAMIG LO, 1995, J SPEECH HEAR RES, V38, P1232, DOI 10.1044/jshr.3806.1232; Ramig Lorraine Olson, 2004, Seminars in Speech and Language, V25, P169; RASKIN SA, 1992, NEUROPSYCHOLOGIA, V30, P95, DOI 10.1016/0028-3932(92)90018-H; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; RUBOW R, 1985, J SPEECH HEAR DISORD, V50, P178, DOI 10.1044/jshd.5002.178; Sapir S, 2003, AM J SPEECH-LANG PAT, V12, P387, DOI 10.1044/1058-0360(2003/085); Sapir S., 2001, J MED SPEECH-LANG PA, V9, P35; Sapir S, 2007, J SPEECH LANG HEAR R, V50, P899, DOI 10.1044/1092-4388(2007/064); SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SMITH ME, 1995, J VOICE, V9, P453, DOI 10.1016/S0892-1997(05)80210-3; Spielman J., 2010, 15 BIENN C MOT SPEEC; Spielman Jennifer L, 2003, Cogn Behav Neurol, V16, P177, DOI 10.1097/00146965-200309000-00005; Svec Jan G, 2003, Logoped Phoniatr Vocol, V28, P181; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; The RAND Corporation, 2001, PREP AG WORLD POL BR; Theodoros DG, 2006, J TELEMED TELECARE, V12, P88, DOI 10.1258/135763306779380101; ThinkQuest, WORLD AG; Tindall LR, 2008, TELEMED J E-HEALTH, V14, P1070, DOI 10.1089/tmj.2008.0040; Trail M, 2005, NEUROREHABILITATION, V20, P205; Usability First, US METH; Ward EC, 2000, J MED SPEECH-LANG PA, V8, P331; Yorkston KM, 2003, J MED SPEECH-LANG PA, V11, P73	79	44	44	3	50	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	NOV 1	2012	21	4					354	367		10.1044/1058-0360(2012/11-0125)			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	083JY	WOS:000314460700007	23071195				2021-06-18	
J	Soliman, ML; Puig, KL; Combs, CK; Rosenberger, TA				Soliman, Mahmoud L.; Puig, Kendra L.; Combs, Colin K.; Rosenberger, Thad A.			Acetate reduces microglia inflammatory signaling in vitro	JOURNAL OF NEUROCHEMISTRY			English	Article						acetylation; cytokine; histone; MAPK; microglia; neuroinflammation	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-BETA; PROINFLAMMATORY CYTOKINE; EPIGENETIC REGULATION; SELECTIVE MODULATION; HISTONE ACETYLATION; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; KINASE PATHWAYS	Acetate supplementation increases brain acetyl-CoA and histone acetylation and reduces lipopolysaccharide (LPS)-induced neuroglial activation and interleukin (IL)-1 beta expression in vivo. To determine how acetate imparts these properties, we tested the hypothesis that acetate metabolism reduces inflammatory signaling in microglia. To test this, we measured the effect acetate treatment had on cytokine expression, mitogen-activated protein kinase (MAPK) signaling, histone H3 at lysine 9 acetylation, and alterations of nuclear factor-kappa B (NF-kappa B) in primary and BV-2 cultured microglia. We found that treatment induced H3K9 hyperacetylation and reversed LPS-induced H3K9 hypoacetylation similar to that found in vivo. LPS also increased IL-1 beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) mRNA and protein, whereas treatment returned the protein to control levels and only partially attenuated IL-6 mRNA. In contrast, treatment increased mRNA levels of transforming growth factor-beta 1 (TGF-beta 1) and both IL-4 mRNA and protein. LPS increased p38 MAPK and JNK phosphorylation at 4 and 24 h, respectively, whereas treatment reduced p38 MAPK and JNK phosphorylation only at 2 h. In addition, treatment reversed the LPS-induced elevation of NF-kappa B p65 protein and phosphorylation at serine 468 and induced acetylation at lysine 310. These data suggest that acetate metabolism reduces inflammatory signaling and alters histone and non-histone protein acetylation.	[Soliman, Mahmoud L.; Puig, Kendra L.; Combs, Colin K.; Rosenberger, Thad A.] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58203 USA	Rosenberger, TA (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 501 N Columbia Rd,Room 3742, Grand Forks, ND 58203 USA.	thad.rosenberger@med.und.edu		Rosenberger, Thad/0000-0001-6360-4977	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5P20RR017699]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017699] Funding Source: NIH RePORTER	This publication was made possible by Grant Number 5P20RR017699 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). We thank Drs. Othman Ghribi and Joyce Ohm for their technical support and generous use of their equipment. The authors declare no conflict of interests.	Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Ariyannur PS, 2010, J COMP NEUROL, V518, P2952, DOI 10.1002/cne.22373; Arun P, 2010, J INHERIT METAB DIS, V33, P195, DOI 10.1007/s10545-010-9100-z; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Cao WS, 2008, J EXP MED, V205, P1491, DOI 10.1084/jem.20071728; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; da Silva PF, 2012, NEUROSCIENCE, V200, P42, DOI 10.1016/j.neuroscience.2011.10.038; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Dhandapani KM, 2003, CELL BIOCHEM BIOPHYS, V39, P13, DOI 10.1385/CBB:39:1:13; Dhawan G, 2012, NEUROBIOL AGING, V33, P2247, DOI 10.1016/j.neurobiolaging.2011.10.027; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Furlan R, 2000, J NEUROIMMUNOL, V111, P86, DOI 10.1016/S0165-5728(00)00377-5; Galbiati L, 2005, CELL CYCLE, V4, P930, DOI 10.4161/cc.4.7.1784; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Govindarajan N, 2011, J ALZHEIMERS DIS, V26, P187, DOI 10.3233/JAD-2011-110080; Gregio APB, 2009, BIOCHEM BIOPH RES CO, V380, P785, DOI 10.1016/j.bbrc.2009.01.148; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Huang B, 2010, CELL SIGNAL, V22, P1282, DOI 10.1016/j.cellsig.2010.03.017; Ishfaq M, 2012, FEBS LETT, V586, P3236, DOI 10.1016/j.febslet.2012.06.042; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Johnston H, 2011, BIOCHEM SOC T, V39, P886, DOI 10.1042/BST0390886; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kohn DT, 1996, MOL BRAIN RES, V36, P240, DOI 10.1016/0169-328X(95)00239-O; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kraatz J, 1998, J TRAUMA, V45, P684, DOI 10.1097/00005373-199810000-00008; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Ledeboer A, 2000, GLIA, V30, P134, DOI 10.1002/(SICI)1098-1136(200004)30:2<134::AID-GLIA3>3.0.CO;2-3; Lee SB, 2011, BIOCHEM J, V433, P205, DOI 10.1042/BJ20101322; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Li YK, 2003, J NEUROSCI, V23, P1605; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mathew R, 2005, J PHARMACOL EXP THER, V315, P297, DOI 10.1124/jpet.105.087536; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Merson TD, 2010, NEUROMOL MED, V12, P99, DOI 10.1007/s12017-010-8112-z; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Petrova TV, 1999, J BIOL CHEM, V274, P28823, DOI 10.1074/jbc.274.40.28823; Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Reisenauer CJ, 2011, J NEUROCHEM, V117, P264, DOI 10.1111/j.1471-4159.2011.07198.x; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rojanathammanee L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-44; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sadoul K, 2008, BIOCHIMIE, V90, P306, DOI 10.1016/j.biochi.2007.06.009; Saini P, 2009, NATURE, V459, P118, DOI 10.1038/nature08034; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Schumann RR, 1996, BLOOD, V87, P2805, DOI 10.1182/blood.V87.7.2805.bloodjournal8772805; Seo DR, 2004, NEUROREPORT, V15, P1157, DOI 10.1097/00001756-200405190-00015; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Shin JH, 2012, FUNCT INTEGR GENOMIC, V12, P119, DOI 10.1007/s10142-012-0263-6; Soliman ML, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-51; Soliman ML, 2011, MOL CELL BIOCHEM, V352, P173, DOI 10.1007/s11010-011-0751-3; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; Theis M, 2003, P NATL ACAD SCI USA, V100, P9602, DOI 10.1073/pnas.1133424100; Vitkovic L, 2001, NEUROIMMUNOMODULAT, V9, P295, DOI 10.1159/000059387; Vucetic Z, 2011, NEUROPSYCHOPHARMACOL, V36, P1199, DOI 10.1038/npp.2011.4; Wells DG, 2006, J NEUROSCI, V26, P7135, DOI 10.1523/JNEUROSCI.1795-06.2006; Woo MS, 2003, MOL BRAIN RES, V113, P86, DOI 10.1016/S0169-328X(03)00095-0; Zanelli CF, 2006, BIOCHEM BIOPH RES CO, V348, P1358, DOI 10.1016/j.bbrc.2006.07.195; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085	74	44	46	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2012	123	4					555	567		10.1111/j.1471-4159.2012.07955.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	021WU	WOS:000309916900010	22924711	Green Accepted			2021-06-18	
J	Walker, PA; Shah, SK; Jimenez, F; Aroom, KR; Harting, MT; Cox, CS				Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Aroom, Kevin R.; Harting, Matthew T.; Cox, Charles S., Jr.			Bone marrow-derived stromal cell therapy for traumatic brain injury is neuroprotective via stimulation of non-neurologic organ systems	SURGERY			English	Article							GROWTH-FACTOR	Bone marrow-derived mesenchymal stromal cells (MSCs) used as "MSC therapy" after traumatic brain injury act as remote "bioreactors" via stimulation of lung macrophages and augmention of T regulatory cell production by the spleen, leading to systemic increases in circulating anti-inflammatory cytokines and alteration of the locoregional milieu of the central nervous system. The altered intracerebral microenvironment leads to modulation of the resident microglia population, thereby stimulating an increase in the ratio of M2 (anti-inflammatory) macrophage to M1 (proinflammatory) macrophage, and it is this effect that accounts for the observed neuroprotection. (Surgery 2012; 152:790-3.)	[Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Shah, Shinil K.; Aroom, Kevin R.; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Harting, Matthew T.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu		Aroom, Kevin/0000-0003-1504-0585; Harting, Matthew/0000-0002-8929-8311	Texas Higher Education Coordinating Board; Texas Emerging Technology Fund; Children's Memorial Hermann Hospital Foundation; Brown Foundation; Athersys Inc;  [NIH T32 GM 08 79201];  [M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER	Supported by grants NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Texas Emerging Technology Fund; the Children's Memorial Hermann Hospital Foundation; The Brown Foundation; and Athersys Inc.	Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Sahin B., 2011, IMAGE ANAL STEREOL, V20, P9, DOI [10.5566/ias.v20.p9-13, DOI 10.5566/IAS.V20.P9-13]; Stroh M, 2003, BIOPHYS J, V85, P581, DOI 10.1016/S0006-3495(03)74502-0; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017	13	44	47	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2012	152	5					790	793		10.1016/j.surg.2012.06.006			4	Surgery	Surgery	035JY	WOS:000310943900002	22853856				2021-06-18	
J	Lauridsen, E; Hermann, NV; Gerds, TA; Kreiborg, S; Andreasen, JO				Lauridsen, Eva; Hermann, Nuno Vibe; Gerds, Thomas Alexander; Kreiborg, Sven; Andreasen, Jens Ove			Pattern of traumatic dental injuries in the permanent dentition among children, adolescents, and adults	DENTAL TRAUMATOLOGY			English	Article						dental traumal; combination injury; luxation; crown fracture; permanent teeth	AGED 7-18 YEARS; SWEDEN; TEETH; CHILE	Background: Traumatic dental injuries (TDI) comprise six types of luxation and seven types of tooth fractures. The risk of pulp necrosis is increased in teeth with combination injuries where fractures and luxations occur concomitantly. Aim: To report and compare the distributions of luxations and fracture types among children, adolescents, and adults, and to analyze the distribution and prevalence of combination injuries. Material and method: The study group included 4754 patients (3186 men and 1568 women) with 10 166 traumatized permanent incisors treated at Copenhagen University Hospital, Rigshospitalet. Differences in the distributions of trauma types among age groups (children <12 years, adolescents 1220 years, and adults >20 years) and distributions of concomitant crown fractures for each luxation type were analyzed with the Chi-square test. Results: A total of 7464 teeth (73.4%) had suffered a luxation injury and 5914 teeth (58.2%) a fracture. The overall most frequent injuries were crown fractures without pulp exposure (34.9%), concussions (24.2%), and subluxations (22.2%). The relative frequency of crown fractures without pulp exposure decreased across age groups (children 45.2%, adolescents 36.5%, adults 26.3%, P < 0.001), whereas the relative frequencies of other injury types increased across age groups : crownroot fractures (children 1.8%, adolescents 6.3%, adults 9.2%, P < 0.001), root fractures (children 2.5%, adolescents 4.6%, adults 8.7%, P < 0.001), and lateral luxations (children 5.7%, adolescents 10.9%, adults 13.0%, P < 0.001). One-third of the traumatized teeth (n = 3212) had sustained a combination of a fracture and a luxation injury. The luxation types most frequently presenting with a concomitant crown fracture were concussion (57.9%), intrusion (47.2%), and subluxation (33.4%) (P < 0.001). Conclusion: The majority of TDI were minor injuries. The relative frequencies of injury types varied among age groups. Combination injuries were observed in one-third of the traumatized teeth and occurred most frequently in teeth with concussion, intrusion, and subluxation.	[Lauridsen, Eva; Hermann, Nuno Vibe; Kreiborg, Sven] Univ Copenhagen, Sch Dent, Fac Hlth Sci, Dept Pediat Dent & Clin Genet, DK-2200 Copenhagen N, Denmark; [Gerds, Thomas Alexander] Univ Copenhagen, Fac Hlth Sci, Dept Biostat, DK-2200 Copenhagen N, Denmark; [Andreasen, Jens Ove] Copenhagen Univ Hosp, Rigshosp, Ctr Rare Oral Dis, Dept Oral & Maxillofacial Surg, Copenhagen, Denmark	Lauridsen, E (corresponding author), Univ Copenhagen, Sch Dent, Fac Hlth Sci, Dept Pediat Dent & Clin Genet, Norre Alle 20, DK-2200 Copenhagen N, Denmark.	ela@sund.ku.dk		Gerds, Thomas Alexander/0000-0002-5955-816X; Hermann, Nuno Vibe/0000-0002-8079-8571			ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P160; Andreasen J O, 1970, Scand J Dent Res, V78, P329; Andreasen JO, 2011, TRAUMATIC DENT INJUR, P16; Borssen E, 2000, ENDOD DENT TRAUMATOL, V16, P276; Borum M K, 2001, Int J Paediatr Dent, V11, P249; CURREY JD, 1975, J BONE JOINT SURG BR, V57, P810; Diaz JA, 2010, DENT TRAUMATOL, V26, P254, DOI 10.1111/j.1600-9657.2010.00878.x; Fariniuk LF, 2010, J APPL ORAL SCI, V18, P343, DOI 10.1590/S1678-77572010000400004; FORSBERG CM, 1990, SWED DENT J, V14, P115; Glendor U, 1996, SWED DENT J, V20, P15; Glendor U., 2007, TXB COLOR ATLAS TRAU, P217; Hecova H, 2010, DENT TRAUMATOL, V26, P466, DOI 10.1111/j.1600-9657.2010.00924.x; Huang HM, 2006, J DENT, V34, P261, DOI 10.1016/j.jdent.2005.06.007; Lauridsen E, 2012, DENT TRAUMATOL, V28, P371, DOI 10.1111/j.1600-9657.2011.01101.x; Lauridsen E, 2012, DENT TRAUMATOL, V28, P364, DOI 10.1111/j.1600-9657.2011.01102.x; Lauridsen E, 2012, DENT TRAUMATOL, V28, P379, DOI 10.1111/j.1600-9657.2011.01100.x; Mjor IA, 2001, QUINTESSENCE INT, V32, P427; Ohman C, 2011, BONE, V49, P769, DOI 10.1016/j.bone.2011.06.035; ONETTO JE, 1994, ENDOD DENT TRAUMATOL, V10, P223; Robertson A, 1997, Int J Paediatr Dent, V7, P217, DOI 10.1046/j.1365-263X.1997.00046.x; Schatz D, 2001, DENT TRAUMATOL, V17, P167, DOI 10.1034/j.1600-9657.2001.170406.x; SCHATZ JP, 1994, ENDOD DENT TRAUMATOL, V10, P11; Skaare AB, 2003, DENT TRAUMATOL, V19, P67, DOI 10.1034/j.1600-9657.2003.00133.x; Skaare AB, 2003, DENT TRAUMATOL, V19, P304, DOI 10.1046/j.1600-4469.2003.00211.x; Stewart C, 2011, EUR ARCH PAEDIATR DE, V12, P41, DOI 10.1007/BF03262778; VANDERVELDEN U, 1984, J CLIN PERIODONTOL, V11, P281; Viduskalne Ilona, 2010, Stomatologija, V12, P109	27	44	50	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	OCT	2012	28	5					358	363		10.1111/j.1600-9657.2012.01133.x			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	009ZC	WOS:000309063100005	22805514				2021-06-18	
J	Nguyen, DH; Cho, N; Satkunendrarajah, K; Austin, JW; Wang, J; Fehlings, MG				Dung Hoang Nguyen; Cho, Newton; Satkunendrarajah, Kajana; Austin, James W.; Wang, Jian; Fehlings, Michael G.			Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Inflammation; Immuno-modulatory; Immunoglobulin G; Functional recovery	MICROVESSEL ENDOTHELIAL-CELLS; FUNCTIONAL RECOVERY; INFLAMMATORY RESPONSE; NEUROLOGICAL FUNCTION; NEUTROPHIL ELASTASE; MESSENGER-RNA; NITRIC-OXIDE; BRAIN-INJURY; EXPRESSION; METHYLPREDNISOLONE	Background: Evidence suggests that the inflammatory events in the acute phase of spinal cord injury (SCI) exacerbate the initial trauma to the cord leading to poor functional recovery. As a result, minimizing the detrimental aspects of the inflammatory response after SCI is a promising treatment strategy. In this regard, immunoglobulin G (IgG) from pooled human serum is a promising treatment candidate. Due to its putative, though poorly characterized immuno-modulatory effects, IgG has been used clinically to treat neuroinflammatory disorders such as Guillain-Barre syndrome, but its effects in neurotrauma remain largely unexplored. Methods: This study examines the potential neuroprotective effects of IgG in a well-characterized cervical model of SCI. Female Wistar rats were subject to moderate-severe clip compression injury at the C7-T1 level. IgG (0.4 g/kg) or saline was injected intravenously to randomly selected animals at 15 min post SCI. At several time points post SCI, biochemical assays, histology and immunohistochemistry analyses, and neurobehavioral assessments were used to examine the neuroprotective effects of IgG at the molecular, cellular, and neurobehavioral levels. Results: We found that intravenous treatment of IgG following acute clip-compression SCI at C7-T1 significantly reduced two important inflammatory cytokines: interleukin (IL)-1 beta and IL-6. This early reduction in pro-inflammatory signaling was associated with significant reductions in neutrophils in the spinal cord and reductions in the expression of myeloperoxidase and matrix metalloproteinase-9 in the injured spinal cord at 24 h after SCI. These beneficial effects of IgG were associated with enhanced tissue preservation, improved neurobehavioral recovery as measured by the BBB and inclined plane tests, and enhanced electrophysiological evidence of central axonal conduction as determined by motor-evoked potentials. Conclusion: The findings from this study indicate that IgG is a novel immuno-modulatory therapy which shows promise as a potential treatment for SCI.	[Dung Hoang Nguyen; Cho, Newton; Austin, James W.; Wang, Jian; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5T 2S8, Canada; [Dung Hoang Nguyen; Cho, Newton; Satkunendrarajah, Kajana; Austin, James W.; Wang, Jian; Fehlings, Michael G.] Toronto Western Res Inst, Div Genet & Dev, Toronto, ON, Canada; [Wang, Jian; Fehlings, Michael G.] Univ Hlth Network, Krembil Neurosci Ctr, Toronto, ON, Canada; [Wang, Jian; Fehlings, Michael G.] Univ Toronto, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Wang, Jian; Fehlings, Michael G.] Univ Toronto, Neurosci Program, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364	Baxter Healthcare Corporation through Baxter BioScience Grant; Federick Banting and Charles Best Graduate Scholarship	The authors gratefully acknowledge the dedication and support of all members of the Fehlings laboratory in this study. The authors thank Stephanie Hewson for her editorial assistance. We acknowledge Baxter Healthcare Corporation for their financial support through the Baxter BioScience Grant. MGF holds the Gerald and Tootsie Halbert Chair in Neural Repair and Regeneration. DHN holds the Federick Banting and Charles Best Graduate Scholarship.	Abbas A.K., 2000, CELLULAR MOL IMMUNOL; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; BAINTON DF, 1968, J CELL BIOL, V39, P299, DOI 10.1083/jcb.39.2.299; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2008, EXP NEUROL, V214, P160, DOI 10.1016/j.expneurol.2008.09.006; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Cetin A, 2006, EUR SPINE J, V15, P1539, DOI 10.1007/s00586-006-0091-2; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cuzzocrea S, 1999, EUR CYTOKINE NETW, V10, P191; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Ghasemlou N, 2010, BRAIN, V133, P126, DOI 10.1093/brain/awp304; Gok B, 2009, J CLIN NEUROSCI, V16, P549, DOI 10.1016/j.jocn.2008.04.024; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Kwon B.K., 2010, J NEUROTRAUM, V27, P1; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2010, SPINE, V35, pS263, DOI 10.1097/BRS.0b013e3181f3286d; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Penkowa M, 1999, GLIA, V25, P343; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Sorensen PS, 2008, NEURODEGENER DIS, V5, P8, DOI 10.1159/000109932; Stangel M, 2006, J NEUROL, V253, P18, DOI 10.1007/s00415-006-5003-1; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, BRAIN RES, V799, P264, DOI 10.1016/S0006-8993(98)00459-4; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; WONG D, 1995, MICROVASC RES, V49, P325, DOI 10.1006/mvre.1995.1028; Wong D, 1996, J NEUROPATH EXP NEUR, V55, P225, DOI 10.1097/00005072-199602000-00011; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	63	44	48	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	SEP 21	2012	9								224	10.1186/1742-2094-9-224			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	045YV	WOS:000311733600001	22998664	DOAJ Gold, Green Published			2021-06-18	
J	Slobounov, S; Sebastianelli, W; Hallett, M				Slobounov, Semyon; Sebastianelli, Wayne; Hallett, Mark			Residual brain dysfunction observed one year post-mild traumatic brain injury: Combined EEG and balance study	CLINICAL NEUROPHYSIOLOGY			English	Article						EEG; Mild traumatic brain injury; Balance; Center of pressure (COP) area	SPORTS-RELATED CONCUSSION; CEREBRAL CONCUSSION; HEAD-INJURIES; HIGH-SCHOOL; RECOVERY; STABILITY; TASK; OSCILLATIONS; RELIABILITY; PERFORMANCE	Objectives: There is still considerable debate and controversy about whether EEG can be used as a robust clinical tool for assessment of mild traumatic brain injury (MTBI). Nonhomogeneous subject populations, inaccurate assessment of severity of brain injury, time since injury when EEG testing was performed, the lack of EEG research conducted serially and in conjunction with other behavioral measures as injury evolves over time may contribute to the existing controversies. In this study, we implemented a concussion assessment protocol combining a series of EEG and balance measures throughout one year post-injury to document the efficacy of EEG and balance measures as relate to differential recovery of patients suffering from MTBI. Methods: Three hundred and eighty subjects at risk for MTBI were initially recruited for baseline testing. Forty nine from this initial subjects pool subsequently suffered a single episode of concussive blow and were tested on day 7, 15, 30 days, 6 months and 12 months post-injury. EEGs were recorded while sitting, standing on the force plate and then on a foam base of support with eyes open/closed conditions. EEG alpha power (8-12 Hz) and its percent suppression from sitting to standing postures were computed. The center of pressure (COP) measures were obtained from the force platform and analyzed for eyes open and eyes closed conditions. Results: Percent alpha power suppression from sitting to standing postural conditions significantly increased in MTBI subjects shortly after the injury (p < 0.01). Percent alpha power suppression significantly correlated with increased area of COP during standing posture with eye closed (r(2) = 0.53, p < 0.01). The magnitude of alpha power suppression predicted the rate of recovery of this measure in sub-acute and chronic phases of injury (r(2) = 0.609, p < 0.01). Finally, 85% of MTBI subjects who showed more than 20% of alpha power suppression in the acute phase of injury did not return to pre-injury status up to 12 months post-injury. Conclusions: The efficacy of serially implemented EEG measures in conjunction with balance assessment over the course of MTBI evolution to document residual cerebral dysfunction was demonstrated. Specifically, alteration of EEG alpha power dynamics in conjunction with balance data in the acute phase of injury with respect to baseline measures may predict the rate of recovery from a single concussive blow. Significance: Neurophysiological measures are excellent tools to assess the status and prognosis of patients with MTBI. (C) 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Slobounov, Semyon; Sebastianelli, Wayne] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, Semyon; Sebastianelli, Wayne] Penn State Univ, HMC, Dept Orthoped & Med Rehabil, University Pk, PA 16802 USA; [Slobounov, Semyon; Hallett, Mark] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002667, R01NS056227] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury".	Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; BARIN K, 1992, IEEE ENG MED BIOL, V11, P52, DOI 10.1109/51.256960; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Buzsaki G., 2006, RHYTHMS BRAIN CYCLE, P341; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Gevins A, 1997, CEREB CORTEX, V7, P374, DOI 10.1093/cercor/7.4.374; Glaser MA, 1940, W SURG, V48, P6989; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hessen E., 2010, PEDIAT TRAUMATIC BRA, P118; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jasper HH, 1940, ARCH NEURO PSYCHIATR, V44, P328, DOI 10.1001/archneurpsyc.1940.02280080088005; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OKEN BS, 1986, ANN NEUROL, V19, P493, DOI 10.1002/ana.410190511; Palva S, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00204; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pfurtscheller G, 2000, CLIN NEUROPHYSIOL, V111, P1873, DOI 10.1016/S1388-2457(00)00428-4; Pfurtscheller G, 2003, EPILEPSIA, V44, P2, DOI 10.1111/j.0013-9580.2003.12001.x; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rau C, 2003, CLIN NEUROPHYSIOL, V114, P1819, DOI 10.1016/S1388-2457(03)00174-3; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S., 1994, GAIT POSTURE, V2, P85, DOI [10.1016/0966-6362(94)90097-3, DOI 10.1016/0966-6362(94)90097-3]; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	57	44	44	2	31	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	SEP	2012	123	9					1755	1761		10.1016/j.clinph.2011.12.022			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	984IR	WOS:000307183800016	22361265	Green Accepted			2021-06-18	
J	Weaver, AA; Danelson, KA; Stitzel, JD				Weaver, Ashley A.; Danelson, Kerry A.; Stitzel, Joel D.			Modeling Brain Injury Response for Rotational Velocities of Varying Directions and Magnitudes	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Brain; Computational modeling; Computational simulation; Concussion; Finite element model; SIMon; Strain; Traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; PEDIATRIC HEAD-INJURY; HIGH-SCHOOL FOOTBALL; CORPUS-CALLOSUM; IMPACT; DAMAGE; ACCELERATIONS; BIOMECHANICS; CONCUSSIONS	An estimated 1.7 million people in the United States sustain a traumatic brain injury (TBI) annually. To investigate the effects of rotational motions on TBI risk and location, this study modeled rotational velocities of five magnitudes and 26 directions of rotation using the Simulated Injury Monitor finite element brain model. The volume fraction of the total brain exceeding a predetermined strain threshold, the Cumulative Strain Damage Measure (CSDM), was investigated to evaluate global model response. To evaluate regional response, this metric was computed relative to individual brain structures and termed the Structure Cumulative Strain Damage Measure (SCSDM). CSDM increased as input magnitude increased and varied with the direction of rotation. CSDM was 0.55-1.7 times larger in simulations with transverse plane rotation compared to those without transverse plane rotation. The largest SCSDM in the cerebrum and brainstem occurred with rotations in the transverse and sagittal planes, respectively. Velocities causing medial rotation of the cerebellum resulted in the largest SCSDM in this structure. For velocities of the same magnitude, injury risk calculated from CSDM varied from 0 to 97% with variations in the direction of rotation. These findings demonstrate injury risk, as estimated by CSDM and SCSDM, is affected by the direction of rotation and input magnitude, and these may be important considerations for injury prediction.	[Weaver, Ashley A.; Danelson, Kerry A.; Stitzel, Joel D.] Wake Forest Univ, Bowman Gray Sch Med, Virginia Tech Wake Forest Univ Ctr Injury Biomech, Winston Salem, NC 27157 USA	Stitzel, JD (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Virginia Tech Wake Forest Univ Ctr Injury Biomech, Med Ctr Blvd, Winston Salem, NC 27157 USA.	asweaver@wakehealth.edu; kdanelso@wakehealth.edu; jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Danelson, Kerry/0000-0003-1815-8749; Weaver, Ashley/0000-0002-4383-0106			AAAM, 2008, ABBR INJ SCAL 2005; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Atabaki SM, 2007, PEDIATR REV, V28, P215, DOI 10.1542/pir.28-6-215; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F.A, 1994, STAPP CAR CRASH C SO, P145; Bandak F. A., 2001, INT TECHN C ENH SAF; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bhatoe HS, 1999, ACTA NEUROCHIR, V141, P515, DOI 10.1007/s007010050333; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Doya K, 2000, CURR OPIN NEUROBIOL, V10, P732, DOI 10.1016/S0959-4388(00)00153-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; DUMA SM, 2009, EMBC 2009 ANN INT C, P1123; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T.A., 1972, STAPP CAR CRASH J, P296; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hibbeler R., 1998, ENG MECH DYNAMICS; Holbourn AHS, 1943, LANCET, V2, P438; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LESSLEY D, 2004, 2004010288 SAE; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson Steven, 2009, Biomed Sci Instrum, V45, P113; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Takhounts E. G., 2011, 22 ENH SAF VEH C P; Takhounts E. G., 2003, STAPP CAR CRASH J, V47; Takhounts E. G., 2003, STAPP CAR CRASH J, V47; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L. E., 1985, 856022 SAE INT; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	58	44	44	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2012	40	9					2005	2018		10.1007/s10439-012-0553-0			14	Engineering, Biomedical	Engineering	987FB	WOS:000307400900015	22441667				2021-06-18	
J	Wilde, EA; Ayoub, KW; Bigler, ED; Chu, ZD; Hunter, JV; Wu, TC; McCauley, SR; Levin, HS				Wilde, Elisabeth A.; Ayoub, Kareem W.; Bigler, Erin D.; Chu, Zili D.; Hunter, Jill V.; Wu, Trevor C.; McCauley, Stephen R.; Levin, Harvey S.			Diffusion tensor imaging in moderate-to-severe pediatric traumatic brain injury: changes within an 18 month post-injury interval	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Diffusion tensor imaging; Tract-based spatial statistics; Longitudinal; Children	WHITE-MATTER DEVELOPMENT; CORPUS-CALLOSUM; VOXELWISE ANALYSIS; AXONAL INJURY; CHILDREN; MICROSTRUCTURE; ADOLESCENCE; CHILDHOOD; MILD; PERFORMANCE	Traumatic brain injury (TBI) is a leading cause of death and disability in children, yet little is known regarding the pattern of TBI-related microstructural change and its impact on subsequent development. Diffusion tensor imaging (DTI) was used to examine between-group differences at two time points (planned intervals of 3 months and 18 months post-injury) and within-group longitudinal change in a group of children and adolescents aged 7-17 years with moderate-to-severe TBI (n = 20) and a comparison group of children with orthopedic injury (OI) (n = 21). In the 3- and 18-month cross-sectional analyses, tract-based spatial statistics (TBSS) generally revealed decreased fractional anisotropy (FA) and increased apparent diffusion coefficient (ADC) in the TBI group in regions of frontal, temporal, parietal, and occipital white matter as well as several deep subcortical structures, though areas of FA decrease were more prominent at the 3-month assessment, and areas of ADC increase were more prominent at the 18 month assessment, particularly in the frontal regions. In terms of the within-group changes over time, the OI group demonstrated primarily diffuse increases in FA over time, consistent with previous findings of DTI-measured white matter developmental change. The TBI group demonstrated primarily regions of FA decrease and ADC increase over time, consistent with presumed continued degenerative change, though regions of ADC decrease were also appreciated. These results suggest that TBI-related microstructural changes are dynamic in children and continue until at least 18 months post-injury. Understanding the course of these changes in DTI metrics may be important in TBI for facilitating advances in management and intervention.	[Wilde, Elisabeth A.; Ayoub, Kareem W.; Wu, Trevor C.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Ayoub, Kareem W.; Wu, Trevor C.; McCauley, Stephen R.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Chu, Zili D.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Ayoub, Kareem W.] Rice Univ, Dept Bioengn, Houston, TX USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili D.; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). We also acknowledge the generous contribution of Mission Connect of the TIRR Foundation. We gratefully acknowledge the contribution of Ana C. Vasquez, Deleene Menefee, PhD., Summer Lane, Lori Cook, Sandra B. Chapman, PhD., and Gillian Hotz, PhD. in data collection, and Joshua Cooper and Alyssa P. Ibarra in manuscript preparation. We thank the participants and their families for their participation in this research. None of the authors have any financial or other relationship(s) that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashtari M, 2007, NEUROIMAGE, V35, P501, DOI 10.1016/j.neuroimage.2006.10.047; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Clayden J. D., 2011, CEREB CORTE IN PRESS; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; Muetzel RL, 2008, NEUROIMAGE, V39, P1918, DOI 10.1016/j.neuroimage.2007.10.018; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; TEASDALE G, 1974, LANCET, V2, P81; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	54	44	45	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2012	6	3					404	416		10.1007/s11682-012-9150-y			13	Neuroimaging	Neurosciences & Neurology	998MZ	WOS:000308245300006	22399284				2021-06-18	
J	Mayer, AR; Yang, Z; Yeo, RA; Pena, A; Ling, JM; Mannell, MV; Stippler, M; Mojtahed, K				Mayer, Andrew R.; Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Mannell, Maggie V.; Stippler, Martina; Mojtahed, Kasra			A functional MRI study of multimodal selective attention following mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Attention; fMRI; Multimodal	ANTERIOR CINGULATE CORTEX; TASK-INDUCED DEACTIVATION; CROSS-MODAL DISTRACTION; EVENT-RELATED FMRI; WORKING-MEMORY; COGNITIVE CONTROL; RESTING-STATE; DEFAULT-MODE; NEURAL MECHANISMS; CONCUSSION	Previous work suggests that the ability to selectively attend to and resolve conflicting information may be the most enduring cognitive deficit following mild traumatic brain injury (mTBI). The current study used fMRI to evaluate potential differences in hemodynamic activation in 22 mTBI patients and 22 carefully matched healthy controls (HC) during a multimodal selective attention task (numeric Stroop). Behavioral data indicated faster reaction times for congruent versus incongruent trials and for stimuli presented at 0.66 compared to 0.33 Hz across both groups, with minimal differences in behavioral performance across the groups. Similarly, there were no group-wise differences in functional activation within lateral and medial prefrontal cortex during the execution of cognitive control (incongruent versus congruent trials). In contrast, within-group comparisons indicated robust patterns of attention-related modulations (ARM) within the bilateral dorsolateral prefrontal cortex and bilateral visual streams for HC but not mTBI patients. In addition, mTBI patients failed to exhibit task-induced deactivation within the default-mode network (DMN) under conditions of higher attentional load. In summary, in spite of near normal behavioral performance, current results suggest within-group abnormalities during both the top-down allocation of visual attention and in regulating the DMN during the semi-acute stage of mTBI.	[Mayer, Andrew R.; Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Mannell, Maggie V.; Mojtahed, Kasra] Lovelace Biomed & Environm Res, Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Neurol, Sch Med, Albuquerque, NM 87131 USA; [Mayer, Andrew R.; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Stippler, Martina] Univ New Mexico, Neurosurg Dept, Sch Med, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Lovelace Biomed & Environm Res, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE,MSC, Albuquerque, NM 87106 USA.	amayer@mrn.org	He, Hongbo/H-1815-2013; He, Robert/L-9441-2013		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01 S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health [R24-HD050836, R21-NS064464-01A1 and 3 R21 NS064464-01 S1 to A.M.].	Baier B, 2006, J NEUROSCI, V26, P12260, DOI 10.1523/JNEUROSCI.1457-06.2006; Banich MT, 2000, COGNITIVE BRAIN RES, V10, P1, DOI 10.1016/S0926-6410(00)00015-X; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Degerman A, 2007, NEUROIMAGE, V34, P1683, DOI 10.1016/j.neuroimage.2006.11.019; Dhamala M, 2007, NEUROIMAGE, V34, P764, DOI 10.1016/j.neuroimage.2006.07.044; Eichele T, 2008, P NATL ACAD SCI USA, V105, P6173, DOI 10.1073/pnas.0708965105; Eimer M, 2002, J COGNITIVE NEUROSCI, V14, P254, DOI 10.1162/089892902317236885; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson JA, 2005, CEREB CORTEX, V15, P1609, DOI 10.1093/cercor/bhi039; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Liu TS, 2003, CEREB CORTEX, V13, P1334, DOI 10.1093/cercor/bhg080; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mannell MV, 2010, HUM BRAIN MAPP, V31, P424, DOI 10.1002/hbm.20876; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2009, CEREB CORTEX, V19, P993, DOI 10.1093/cercor/bhn148; Mayer A. R., 2011, HUMAN BRAIN MAPPING; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Roberts KL, 2008, J COGNITIVE NEUROSCI, V20, P1063, DOI 10.1162/jocn.2008.20074; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shulman GL, 1997, CEREB CORTEX, V7, P193, DOI 10.1093/cercor/7.3.193; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spence C, 2004, COGN AFFECT BEHAV NE, V4, P148, DOI 10.3758/CABN.4.2.148; Talairach J, 1988, COPLANAR STERIOTAXIC; Talsma D, 2006, INT J PSYCHOPHYSIOL, V62, P249, DOI 10.1016/j.ijpsycho.2006.04.006; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; Weissman DH, 2004, J NEUROSCI, V24, P10941, DOI 10.1523/JNEUROSCI.3669-04.2004; Woodruff PWR, 1996, NEUROREPORT, V7, P1909, DOI 10.1097/00001756-199608120-00007; Yang Z., 2012, J NEUROTRAUMA	67	44	44	1	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557			BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		343	354		10.1007/s11682-012-9178-z			12	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900013	22673802				2021-06-18	
J	Patel, SP; Sullivan, PG; Lyttle, TS; Magnuson, DSK; Rabchevsky, AG				Patel, S. P.; Sullivan, P. G.; Lyttle, T. S.; Magnuson, D. S. K.; Rabchevsky, A. G.			ACETYL-L-CARNITINE TREATMENT FOLLOWING SPINAL CORD INJURY IMPROVES MITOCHONDRIAL FUNCTION CORRELATED WITH REMARKABLE TISSUE SPARING AND FUNCTIONAL RECOVERY	NEUROSCIENCE			English	Article						mitochondrial bioenergetics; L1/L2 SCI; locomotor function; locomotor neuronal circuitry; central pattern generator; neuroprotection	PYRUVATE-DEHYDROGENASE COMPLEX; CENTRAL PATTERN GENERATOR; TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; L-ACETYLCARNITINE; OXIDATIVE STRESS; NEONATAL-RAT; PROPRIOSPINAL NEURONS; HINDLIMB LOCOMOTION; ALZHEIMERS-DISEASE	We have recently documented that treatment with the alternative biofuel, acetyl-L-carnitine (ALC, 300 mg/kg), as late as 1 h after T10 contusion spinal cord injury (SCI), significantly maintained mitochondrial function 24 h after injury. Here we report that after more severe contusion SCI centered on the L1/L2 segments that are postulated to contain lamina X neurons critical for locomotion (the "central pattern generator"), ALC treatment resulted in significant improvements in acute mitochondrial bioenergetics and long-term hind limb function. Although control-injured rats were only able to achieve slight movements of hind limb joints, ALC-treated animals produced consistent weight-supported plantar steps 1 month after injury. Such landmark behavioral improvements were significantly correlated with increased tissue sparing of both gray and white matter proximal to the injury, as well as preservation of choline acetyltransferase (ChAT)-positive neurons in lamina X rostral to the injury site. These findings signify that functional improvements with ALC treatment are mediated, in part, by preserved locomotor circuitry rostral to upper lumbar contusion SCI. Based on beneficial effects of ALC on mitochondrial bioenergetics after injury, our collective evidence demonstrate that preventing mitochondrial dysfunction acutely "promotes" neuroprotection that may be associated with the milestone recovery of plantar, weight-supported stepping. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Patel, S. P.; Sullivan, P. G.; Lyttle, T. S.; Rabchevsky, A. G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Patel, S. P.; Lyttle, T. S.; Rabchevsky, A. G.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; [Sullivan, P. G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Magnuson, D. S. K.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA; [Magnuson, D. S. K.] Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA	Rabchevsky, AG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,Biomed & Biolog Sci Res Bldg,741 S Limestone, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915; Magnuson, David/0000-0003-3816-3676	KSCHIRT [8-13]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS051220, R01NS069633]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS069633] Funding Source: NIH RePORTER	The authors are thankful for the expert technical assistance of Chris R. O'Dell and Khalid C. Eldhan. This study was supported by KSCHIRT #8-13 (A. G. R.), NIH/NINDS R01NS069633 (A. G. R. and P. G. S.), NIH/NINDS P30 NS051220, and a generous donation from the Michael and Helen Schaffer Foundation, Boston, MA, USA.	AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; Arafa HMM, 2009, BASIC CLIN PHARMACOL, V105, P30, DOI 10.1111/j.1742-7843.2009.00399.x; Aureli T, 2000, NEUROCHEM RES, V25, P395, DOI 10.1023/A:1007501306623; Aureli T, 1999, EUR J BIOCHEM, V263, P287, DOI 10.1046/j.1432-1327.1999.00524.x; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Bertrand S, 2002, EUR J NEUROSCI, V16, P1741, DOI 10.1046/j.1460-9568.2002.02233.x; Blass J P, 1978, Adv Neurol, V21, P181; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BONAVITA E, 1986, INT J CLIN PHARM TH, V24, P511; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bracken MB, 2001, SPINE, V26, pS47, DOI 10.1097/00007632-200112151-00010; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; CAZALETS JR, 1995, J NEUROSCI, V15, P4943; Cazalets JR, 1996, J NEUROSCI, V16, P298; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; Cowley KC, 1997, J NEUROPHYSIOL, V77, P247; DEMEIRLEIR L, 1993, PEDIATR NEUROL, V9, P216, DOI 10.1016/0887-8994(93)90088-T; Dhitavat S, 2002, NEUROCHEM RES, V27, P501, DOI 10.1023/A:1019800703683; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; El-Awady EE, 2011, EUR J PHARMACOL, V650, P335, DOI 10.1016/j.ejphar.2010.09.085; Elanchezhian R, 2009, MOL VIS, V15, P1485; FARRELL S, 1986, BIOCHIM BIOPHYS ACTA, V876, P175, DOI 10.1016/0005-2760(86)90332-2; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Hadi B, 2000, J NEUROSURG, V93, P266, DOI 10.3171/spi.2000.93.2.0266; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hao J, 2011, BR J NUTR, V22, P1; Hota KB, 2012, HIPPOCAMPUS, V22, P723, DOI 10.1002/hipo.20934; Hou SP, 2008, J COMP NEUROL, V509, P382, DOI 10.1002/cne.21771; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kido Y, 2001, J NEUROCHEM, V79, P959, DOI 10.1046/j.1471-4159.2001.00621.x; Kjaerulff O, 1996, J NEUROSCI, V16, P5777; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; Kremer E, 1997, J NEUROPHYSIOL, V77, P1155; KSIEZAKREDING H, 1984, MECH AGEING DEV, V26, P67, DOI 10.1016/0047-6374(84)90165-9; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LOWITT S, 1995, METABOLISM, V44, P677, DOI 10.1016/0026-0495(95)90128-0; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Magnuson DSK, 2005, J NEUROTRAUM, V22, P529, DOI 10.1089/neu.2005.22.529; Magnuson DSK, 1998, ANN NY ACAD SCI, V860, P436, DOI 10.1111/j.1749-6632.1998.tb09069.x; Mannelli LDC, 2007, EUR J NEUROSCI, V26, P820, DOI 10.1111/j.1460-9568.2007.05722.x; Mannelli LDC, 2009, J NEUROSCI RES, V87, P200, DOI 10.1002/jnr.21815; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Musicco C, 2011, J PROTEOMICS, V74, P2536, DOI 10.1016/j.jprot.2011.05.041; Ohashi R, 1999, J PHARMACOL EXP THER, V291, P778; ONOFRJ M, 1995, INT J CLIN PHARM RES, V15, P9; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PARADIES G, 1992, BIOCHIM BIOPHYS ACTA, V1103, P324, DOI 10.1016/0005-2736(92)90103-S; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Pettegrew JW, 2000, MOL PSYCHIATR, V5, P616, DOI 10.1038/sj.mp.4000805; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; RAI G, 1990, CURR MED RES OPIN, V11, P638, DOI 10.1185/03007999009112690; Ravikumar R, 2007, J NEUROTRAUM, V24, P1618, DOI 10.1089/neu.2007.0329; Rebouche CJ, 2004, ANN NY ACAD SCI, V1033, P30, DOI 10.1196/annals.1320.003; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; ROSS IB, 1993, NEUROSURGERY, V33, P470; ROSS IB, 1993, SURG NEUROL, V40, P461, DOI 10.1016/0090-3019(93)90048-6; SANO M, 1992, ARCH NEUROL-CHICAGO, V49, P1137, DOI 10.1001/archneur.1992.00530350051019; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; SHEU KFR, 1985, ANN NEUROL, V17, P444; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; SPAGNOLI A, 1991, NEUROLOGY, V41, P1726, DOI 10.1212/WNL.41.11.1726; Springer JE, 2010, J NEUROTRAUM, V27, P139, DOI 10.1089/neu.2009.0952; Steencken ACC, 2010, NEUROSCIENCE, V170, P971, DOI 10.1016/j.neuroscience.2010.06.064; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Swamy-Mruthinti S, 1999, EXP EYE RES, V69, P109, DOI 10.1006/exer.1999.0680; TEMPESTA E, 1987, DRUG EXP CLIN RES, V13, P417; Tufekci O, 2009, CHEMOTHERAPY, V55, P451, DOI 10.1159/000240020; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Virmani Ashraf, 2004, Molecular Aspects of Medicine, V25, P533, DOI 10.1016/j.mam.2004.06.003; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Xiong YQ, 2009, FREE RADICAL RES, V43, P604, DOI 10.1080/10715760902977432; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yu WR, 2009, EUR J NEUROSCI, V29, P114, DOI 10.1111/j.1460-9568.2008.06555.x; Zaidan E, 1998, J NEUROCHEM, V70, P233	106	44	46	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 17	2012	210						296	307		10.1016/j.neuroscience.2012.03.006			12	Neurosciences	Neurosciences & Neurology	951ON	WOS:000304730000029	22445934	Green Accepted			2021-06-18	
J	Wilson, SM; Xiong, W; Wang, Y; Ping, X; Head, JD; Brittain, JM; Gagare, PD; Ramachandran, PV; Jin, X; Khanna, R				Wilson, S. M.; Xiong, W.; Wang, Y.; Ping, X.; Head, J. D.; Brittain, J. M.; Gagare, P. D.; Ramachandran, P. V.; Jin, X.; Khanna, R.			PREVENTION OF POSTTRAUMATIC AXON SPROUTING BY BLOCKING COLLAPSIN RESPONSE MEDIATOR PROTEIN 2-MEDIATED NEURITE OUTGROWTH AND TUBULIN POLYMERIZATION	NEUROSCIENCE			English	Article						epileptogenesis; posttraumatic sprouting; CRMP2; neurite outgrowth; tubulin polymerization; lacosamide	TEMPORAL-LOBE EPILEPSY; V PYRAMIDAL NEURONS; RAT BARREL CORTEX; ANTICONVULSANT LACOSAMIDE; IN-VITRO; SOMATOSENSORY CORTEX; SLOW INACTIVATION; BRAIN-INJURY; MODEL; EPILEPTOGENESIS	Epileptogenesis following traumatic brain injury (TBI) is likely due to a combination of increased excitability, disinhibition, and increased excitatory connectivity via aberrant axon sprouting. Targeting these pathways could be beneficial in the prevention and treatment of posttraumatic epilepsy. Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein. LCM inhibited CRMP2-mediated neurite outgrowth, an effect phenocopied by CRMP2 knockdown. Mutation of LCM-binding sites in CRMP2 reduced the neurite inhibitory effect of LCM by similar to 8-fold. LCM also reduced CRMP2-mediated tubulin polymerization. Thus, LCM selectively impairs CRMP2-mediated microtubule polymerization, which underlies its neurite outgrowth and branching. To determine whether LCM inhibits axon sprouting in vivo, LCM was injected into rats subjected to partial cortical isolation, an animal model of posttraumatic epileptogenesis that exhibits axon sprouting in cortical pyramidal neurons. Two weeks following injury, excitatory synaptic connectivity of cortical layer V pyramidal neurons was mapped using patch clamp recordings and laser scanning photostimulation of caged glutamate. In comparison with injured control animals, there was a significant decrease in the map size of excitatory synaptic connectivity in LCM-treated rats, suggesting that LCM treatment prevented enhanced excitatory synaptic connectivity due to posttraumatic axon sprouting. These findings suggest, for the first time, that LCM's mode of action involves interactions with CRMP2 to inhibit posttraumatic axon sprouting. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wilson, S. M.; Xiong, W.; Ping, X.; Brittain, J. M.; Jin, X.; Khanna, R.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Xiong, W.; Ping, X.; Jin, X.] Indiana Univ Sch Med, Dept Anat, Indianapolis, IN 46202 USA; [Xiong, W.; Ping, X.; Jin, X.] Indiana Univ Sch Med, Dept Cell Biol, Indianapolis, IN 46202 USA; [Xiong, W.; Ping, X.; Jin, X.; Khanna, R.] Indiana Univ Sch Med, Indiana Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Wang, Y.; Khanna, R.] Indiana Univ Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA; [Wang, Y.; Khanna, R.] Indiana Univ Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA; [Head, J. D.] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA; [Gagare, P. D.; Ramachandran, P. V.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Khanna, R (corresponding author), 950 W Walnut St,R2 Room 478, Indianapolis, IN 46202 USA.	xijin@iupui.edu; khanna5@iupui.edu	Jin, Xiaoming/AAH-3555-2020; ping, xingjie/AAW-4597-2020; Jin, Xiaoming/N-8545-2016; Ramachandran, P. Veeraraghavan/AAC-1852-2019	Jin, Xiaoming/0000-0002-8671-8640; Khanna, Rajesh/0000-0002-9066-2969	Larry Kays Fellowship; Project Development Team within the ICTSI NIH/NCRR [RR025761, A70-9-079138]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057940]; Elwert Award in Medicine; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R00NS057940, K99NS057940] Funding Source: NIH RePORTER	We thank members of the SNRI for discussions, Dr. May Khanna (IUSM) for help with Pymol figures, Stephanie Martinez for acquiring some of the confocal images, and Nicole Ashpole for providing some of the cortical neurons. S.M.W. is a Stark Scholar. J.D.H. is supported by an undergraduate Life-Health Sciences Internship. J.M.B. is supported by a Larry Kays Fellowship. This project was supported by a Project Development Team within the ICTSI NIH/NCRR Grant Number RR025761 (A70-9-079138 to R.K.), NIH grant NS057940 (to X.J.), and the Elwert Award in Medicine (to X.J. and R.K.).	Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Bureau I, 2008, J NEUROSCI, V28, P5178, DOI 10.1523/JNEUROSCI.1076-08.2008; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; Chae YC, 2009, CELL SIGNAL, V21, P1818, DOI 10.1016/j.cellsig.2009.07.017; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Chen S, 2005, BRAIN RES, V1057, P88, DOI 10.1016/j.brainres.2005.07.039; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; Choi D, 1996, BIOORGAN MED CHEM, V4, P2105, DOI 10.1016/S0968-0896(96)00225-8; Curia G, 2009, CNS DRUGS, V23, P555, DOI 10.2165/00023210-200923070-00002; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Doty P, 2007, NEUROTHERAPEUTICS, V4, P145, DOI 10.1016/j.nurt.2006.10.002; Errington AC, 2008, MOL PHARMACOL, V73, P157, DOI 10.1124/mol.107.039867; Errington AC, 2006, NEUROPHARMACOLOGY, V50, P1016, DOI 10.1016/j.neuropharm.2006.02.002; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Granacher R, 2003, TRAUMATIC BRAIN INJU; Greenaway C, 2010, THER DRUG MONIT, V32, P448, DOI 10.1097/FTD.0b013e3181dcc5fb; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Harris JA, 2009, ANN PHARMACOTHER, V43, P1809, DOI 10.1345/aph.1M303; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Holtmaat AJGD, 2003, EXP NEUROL, V182, P142, DOI 10.1016/S0014-4886(03)00035-9; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kelemen A, 2010, NEUROPSYCH DIS TREAT, V6, P465; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Lees G, 2006, NEUROPHARMACOLOGY, V50, P98, DOI 10.1016/j.neuropharm.2005.08.016; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Nadler JV, 2003, NEUROCHEM RES, V28, P1649, DOI 10.1023/A:1026004904199; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Park KD, 2009, J MED CHEM, V52, P6897, DOI 10.1021/jm9012054; Perucca E, 2008, NAT REV DRUG DISCOV, V7, P973, DOI 10.1038/nrd2764; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Salin P, 1995, J NEUROSCI, V15, P8234; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Schubert D, 2001, J NEUROSCI, V21, P3580, DOI 10.1523/JNEUROSCI.21-10-03580.2001; Sheets PL, 2008, J PHARMACOL EXP THER, V326, P89, DOI 10.1124/jpet.107.133413; Shepherd GMG, 2003, NEURON, V38, P277, DOI 10.1016/S0896-6273(03)00152-1; SHOLL DA, 1953, J ANAT, V87, P387; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wang YY, 2010, TRANSL NEUROSCI, V1, P106, DOI 10.2478/v10134-010-0025-8; Wang YY, 2011, TRANSL NEUROSCI, V2, P13, DOI 10.2478/s13380-011-0002-9; Wang YY, 2010, J BIOL CHEM, V285, P25296, DOI 10.1074/jbc.M110.128801; Xiong WH, 2011, JOVE-J VIS EXP, DOI 10.3791/2840; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang W, 2012, J NEUROSCI, V32, P1183, DOI 10.1523/JNEUROSCI.5342-11.2012	59	44	46	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 17	2012	210						451	466		10.1016/j.neuroscience.2012.02.038			16	Neurosciences	Neurosciences & Neurology	951ON	WOS:000304730000042	22433297	Green Accepted			2021-06-18	
J	Greer, JE; Povlishock, JT; Jacobs, KM				Greer, John E.; Povlishock, John T.; Jacobs, Kimberle M.			Electrophysiological Abnormalities in Both Axotomized and Nonaxotomized Pyramidal Neurons following Mild Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							DORSAL-ROOT GANGLION; SPINAL SENSORY NEURONS; CORTICAL-NEURONS; NERVE INJURY; ATTENTION DEFICITS; AXONAL INJURY; IN-VITRO; DEPOLARIZATION; MECHANISMS; CORTEX	Mild traumatic brain injury (mTBI) often produces lasting detrimental effects on cognitive processes. The mechanisms underlying neurological abnormalities have not been fully identified, in part due to the diffuse pathology underlying mTBI. Here we employ a mouse model of mTBI that allows for identification of both axotomized and intact neurons in the living cortical slice via neuronal expression of yellow fluorescent protein. Both axotomized and intact neurons recorded within injured cortex are healthy with a normal resting membrane potential, time constant (tau), and input resistance (R-in). In control cortex, 25% of cells show an intrinsically bursting action potential (AP) firing pattern, and the rest respond to injected depolarizing current with a regular-spiking pattern. At 2 d postinjury, intrinsic bursting activity is lost within the intact population. The AP amplitude is increased and afterhyperpolarization duration decreased in axotomized neurons at 1 and 2 d postinjury. In contrast, intact neurons also show these changes at 1 d, but recover by 2 d postinjury. Two measures suggest an initial decrease in excitability in axotomized neurons followed by an increase in excitability within intact neurons. The rheobase is significantly increased in axotomized neurons at 1 d postinjury. The slope of the plot of AP frequency versus injected current is larger for intact neurons at 2 d postinjury. Together, these results demonstrate that intact and axotomized neurons are both affected by mTBI, resulting in different changes in neuronal excitability that may contribute to network dysfunction following TBI.	[Greer, John E.; Povlishock, John T.; Jacobs, Kimberle M.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Jacobs, KM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	kmjacobs@vcu.edu	Greer, John/K-1008-2012; Jacobs, Kimberle/AAW-7526-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675, HD055813, NS047463, NS007288]; NIH-NINDS Center CoreUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077675, T32NS007288, P30NS047463] Funding Source: NIH RePORTER	This work was supported by NIH Grants NS077675, HD055813, NS047463, and NS007288. Microscopy was performed at the Virginia Commonwealth University Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center Core Grant 5P30NS047463-02. We thank Makoto Ezure for help with data analysis and histology.	Abdulla FA, 2001, J NEUROPHYSIOL, V85, P630; Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brumberg JC, 2000, J NEUROSCI, V20, P4829; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Cummins TR, 1997, J NEUROSCI, V17, P3503; ECCLES JC, 1958, J PHYSIOL-LONDON, V143, P11, DOI 10.1113/jphysiol.1958.sp006041; George AL, 2011, BRAIN RES, V1374, P116, DOI 10.1016/j.brainres.2010.12.020; GORDON T, 1987, J PHYSIOL-LONDON, V392, P213, DOI 10.1113/jphysiol.1987.sp016777; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guatteo E, 1996, BRAIN RES, V741, P1, DOI 10.1016/S0006-8993(96)00866-9; GUSTAFSSON B, 1979, J PHYSIOL-LONDON, V293, P197, DOI 10.1113/jphysiol.1979.sp012885; Ishikawa K, 1999, MUSCLE NERVE, V22, P502, DOI 10.1002/(SICI)1097-4598(199904)22:4<502::AID-MUS12>3.0.CO;2-K; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kole MHP, 2011, NEURON, V71, P671, DOI 10.1016/j.neuron.2011.06.024; LAIWAND R, 1988, J PHYSIOL-LONDON, V404, P749, DOI 10.1113/jphysiol.1988.sp017317; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mentis GZ, 2007, J PHYSIOL-LONDON, V582, P1141, DOI 10.1113/jphysiol.2007.133488; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Nishimura Y, 2001, J NEUROPHYSIOL, V86, P771; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Sancini G, 2001, EUR J NEUROSCI, V14, P1065, DOI 10.1046/j.0953-816x.2001.01723.x; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; TAKATA M, 1980, NEUROSCIENCE, V5, P413, DOI 10.1016/0306-4522(80)90116-5; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang W, 2011, ANAT REC, V294, P1406, DOI 10.1002/ar.21437; Wang XJ, 1999, NEUROSCIENCE, V89, P347, DOI 10.1016/S0306-4522(98)00315-7; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466; Williams SR, 1999, J PHYSIOL-LONDON, V521, P467, DOI 10.1111/j.1469-7793.1999.00467.x; YAMUY J, 1992, NEUROBIOL AGING, V13, P231, DOI 10.1016/0197-4580(92)90035-V; Yu JN, 2008, FRONT NEURAL CIRCUIT, V2, DOI 10.3389/neuro.04.006.2008; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	47	44	44	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 9	2012	32	19					6682	6687		10.1523/JNEUROSCI.0881-12.2012			6	Neurosciences	Neurosciences & Neurology	940DL	WOS:000303870100028	22573690	Green Accepted, Bronze, Green Published			2021-06-18	
J	Ramanathan, DM; McWilliams, N; Schatz, P; Hillary, FG				Ramanathan, Deepa M.; McWilliams, Nathan; Schatz, Philip; Hillary, Frank G.			Epidemiological Shifts in Elderly Traumatic Brain Injury: 18-Year Trends in Pennsylvania	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; epidemiology; geriatric brain injury; traumatic brain injury	UNITED-STATES; HEAD-INJURY; POPULATION; OLDER; AGE; MORTALITY; SURVEILLANCE; DISABILITY; ADULTS	Older adults tend to have poorer outcomes compared to younger adults following moderate-to-severe traumatic brain injury (TBI). Currently, there is a need for research focusing on how elderly TBI has changed as the U. S. population shifts. This study provides a statewide account of moderate-to-severe TBI in regard to injury-related variables and incidence rates in the elderly. Data from Pennsylvania accredited trauma centers collected in the Pennsylvania Trauma Outcome Study between 1992 and 2009 were used in the current study. Incidence rates for TBI were calculated using U. S. Census Bureau estimates for individuals aged 65-90 years (separated into three subgroups: ages 65-73, 74-82, and 83-90 years). In addition, we focused on describing the following injury-related variables: mechanism of injury, injury severity, hospital length of stay, and functional status at discharge. The results indicate that the incidence of elderly TBI has approximately doubled in the past 18 years, and that the increase in elderly TBI is greatest for individuals between the ages of 83 and 90. Furthermore, this age group had the poorest outcomes following TBI. Prevention and awareness of TBI in the elderly is imperative in reducing the likelihood of injury and disability. Continued statewide work is needed to demonstrate trends in elderly TBI nationwide to further add to the knowledge base used for prevention and rehabilitation work.	[Ramanathan, Deepa M.; Hillary, Frank G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [McWilliams, Nathan] Penn Trauma Syst Fdn, Mechanicsburg, PA USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, 223 Moore Bldg, University Pk, PA 16802 USA.	fhillary@psu.edu	Hillary, Frank/AAN-8622-2021	Ramanathan-Elion, Deepa/0000-0001-7723-7346; Schatz, Philip/0000-0002-6222-6545			Adekoya N, 2004, PUBLIC HEALTH REP, V119, P486, DOI 10.1016/j.phr.2004.07.006; Anderson GF, 2000, HEALTH AFFAIR, V19, P191, DOI 10.1377/hlthaff.19.3.191; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Centers for Disease Control and Prevention, 2008, PREV FALLS DEV COMM; Colello K, 2007, DO OLDER AM LIVE GEO; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Federal Highway Administration U.S. Department of Transportation, 1999, HIGHW STAT; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murabito JM, 2008, AM J PUBLIC HEALTH, V98, P1256, DOI 10.2105/AJPH.2007.128132; Pennings J.L., 1993, ARCH SURG-CHICAGO, V128, P187; Shrestha L, 2006, CRS REPORT C CHANGIN; Stevens JA, 2001, JAMA-J AM MED ASSOC, V286, P2665, DOI 10.1001/jama.286.21.2665; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 1996, WESTERN J MED, V165, P192; Tieves Kelly S, 2005, WMJ, V104, P22; U.S. Census Bureau, 2009, POP EST PENNS; U. S. Department of Transportation, 2009, HIGHW STAT; Victorino CC, 2005, CAN J AGING, V24, P45, DOI 10.1353/cja.2005.0014; Vincent G. K., 2010, CURR POPULATION REP, P1125	36	44	45	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1371	1378		10.1089/neu.2011.2197			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600011	22150090				2021-06-18	
J	Chatelin, S; Vappou, J; Roth, S; Raul, JS; Willinger, R				Chatelin, S.; Vappou, J.; Roth, S.; Raul, J. S.; Willinger, R.			Towards child versus adult brain mechanical properties	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Brain biomechanics; Viscoelasticity; Child neurotrauma	HEAD IMPACT; TISSUE; INJURY; SHEAR; BEHAVIOR; DEFORMATION; PREVENTION	The characterization of brain tissue mechanical properties is of crucial importance in the development of realistic numerical models of the human head. While the mechanical behavior of the adult brain has been extensively investigated in several studies, there is a considerable paucity of data concerning the influence of age on mechanical properties of the brain. Therefore, the implementation of child and infant head models often involves restrictive assumptions like properties scaling from adult or animal data. The present study presents a step towards the investigation of the effects of age on viscoelastic properties of human brain tissue from a first set of dynamic oscillatory shear experiments. Tests were also performed on three different locations of brain (corona radiata, thalamus and brainstem) in order to investigate regional differences. Despite the limited number of child brain samples a significant increase in both storage and loss moduli occurring between the age of 5 months and the age of 22 months was found, confirmed by statistical Student's t-tests (p = 0.104, 0.038 and 0.054 for respectively corona radiata, thalamus and brain stem samples locations respectively). The adult brain appears to be 3-4 times stiffer than the young child one. Moreover, the brainstem was found to be approximately 2-3 times stiffer than both gray and white matter from corona radiata and thalamus. As a tentative conclusion, this study provides the first rheological data on the human brain at different ages and brain regions. This data could be implemented in numerical models of the human head, especially in models concerning pediatric population. (C) 2011 Elsevier Ltd. All rights reserved.	[Chatelin, S.; Vappou, J.; Roth, S.; Raul, J. S.; Willinger, R.] Univ Strasbourg, IMFS CNRS, F-67000 Strasbourg, France; [Raul, J. S.] Inst Med Legale, F-67085 Strasbourg, France	Willinger, R (corresponding author), Univ Strasbourg, IMFS CNRS, 2Rue Boussingault, F-67000 Strasbourg, France.	Remy.willinger@imfs.u-strasbg.fr	Chatelin, Simon/N-8969-2013	Chatelin, Simon/0000-0001-8999-3608; vappou, jonathan/0000-0002-2156-0619			Arbogast K.B., 1997, STAPP CAR CRASH C P, P293; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Brands D.W.A., 1999, P 43 STAPP CAR CRASH, P313; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; DOBBING J, 1981, SCI FDN PAEDIAT; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Metz H., 1982, P 9 INT C EXP SAF VE; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Roth S, 2007, INT J LEGAL MED, V121, P223, DOI 10.1007/s00414-006-0129-3; Roth S, 2010, COMPUT METH PROG BIO, V99, P25, DOI 10.1016/j.cmpb.2009.10.004; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tsai WC, 2004, J CLIN NEUROSCI, V11, P126, DOI 10.1016/S0967-5868(03)00156-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Viano D, 1997, ACCIDENT ANAL PREV, V29, P811, DOI 10.1016/S0001-4575(97)00050-X	31	44	46	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	FEB	2012	6						166	173		10.1016/j.jmbbm.2011.09.013			8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	905LS	WOS:000301274300020	22301186				2021-06-18	
J	Lin, AY; Kinsella, CR; Rottgers, SA; Smith, DM; Grunwaldt, LJ; Cooper, GM; Losee, JE				Lin, Alexander Y.; Kinsella, Christopher R., Jr.; Rottgers, S. Alex; Smith, Darren M.; Grunwaldt, Lorelei J.; Cooper, Gregory M.; Losee, Joseph E.			Custom Porous Polyethylene Implants for Large-scale Pediatric Skull Reconstruction: Early Outcomes	JOURNAL OF CRANIOFACIAL SURGERY			English	Article						Calvaria; Medpor; alloplastic implant; porous polyethylene	BONE; CHILDREN; CRANIOPLASTY; DEFECTS; REGENERATION; GROWTH; REPAIR; SERIES	Background and Purpose: Some of the most problematic craniofacial injuries in pediatric plastic surgery are large calvarial defects in children who have passed the age of maximal dural osteogenic potential and yet are too young to yield split calvarial grafts. Porous polyethylene (Medpor; Porex) is an alloplastic material that can be customized to precisely match a cranial defect. We present a clinical series that demonstrates successful use of porous polyethylene cranioplasties in large pediatric cranial defects. Methods: From 2007 to 2009, 9 pediatric patients underwent custom-made porous polyethylene cranioplasties for large calvarial defects. Descriptive statistical analyses were performed on the cause of the defects, time to cranioplasty, size of defect, reconstruction technique, and postoperative healing. Results: A total of 5 boys and 4 girls, with a mean age of 6.8 years, underwent 9 cranioplasties incorporating custom porous polyethylene implants. Initial pathologic findings included 7 patients with traumatic brain injuries, 1 patient with intractable seizures, and 1 patient with brain cancer. Initially, each patient had a craniectomy followed by replacement of the frozen bone "flap." All patients experienced either infection or resorption of the bone leading to a permanent defect. The mean defect size was 152 cm(2). The mean delay between the removal of failed bone "flap" and the final implant cranioplasty was 6.8 months. At the last follow-up, which averaged 3.6 months, all patients had stable wounds with acceptable cranial contour. Conclusions: For pediatric large-scale calvarial defects, custom-made porous polyethylene implants can be safely used for cranioplasty. Tissue expansion and acellular dermal matrix were useful tools to help augment the soft tissues of the scalp before cranioplasty to prevent complications of implant extrusion and wound breakdown.	[Lin, Alexander Y.; Kinsella, Christopher R., Jr.; Rottgers, S. Alex; Smith, Darren M.; Grunwaldt, Lorelei J.; Cooper, Gregory M.; Losee, Joseph E.] Univ Pittsburgh, Div Plast Surg, Pittsburgh, PA USA; [Cooper, Gregory M.] Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA USA; [Cooper, Gregory M.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA	Losee, JE (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Pediat Plast Surg, Childrens Hosp Dr,45th & Penn, Pittsburgh, PA 15201 USA.	joseph.losee@chp.edu					Abuzayed B, 2009, J CRANIOFAC SURG, V20, P1245, DOI 10.1097/SCS.0b013e3181acdfaf; Brevi BC, 2010, J PEDIATR SURG, V45, pE17, DOI 10.1016/j.jpedsurg.2010.01.011; Ducic J, 2002, J ORAL MAXIL SURG, V60, P272, DOI 10.1053/joms.2002.30575; Eppley B L, 1990, J Craniofac Surg, V1, P191, DOI 10.1097/00001665-199001040-00008; HOBAR PC, 1993, PLAST RECONSTR SURG, V92, P405; HOCKLEY AD, 1991, PEDIATR NEUROSURG, V16, P271, DOI 10.1159/000120540; KAISER A, 1993, EUR J PEDIATR SURG, V3, P236, DOI 10.1055/s-2008-1063551; Kamdar MR, 2009, PLAST RECONSTR SURG, V124, P2072, DOI 10.1097/PRS.0b013e3181bcefc4; Kinsella CR, 2010, J CRANIOFAC SURG, V21, P605, DOI 10.1097/SCS.0b013e3181d08cee; KLAWITTER JJ, 1976, J BIOMED MATER RES, V10, P311, DOI 10.1002/jbm.820100212; KOENIG WJ, 1995, PLAST RECONSTR SURG, V95, P1; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; MOSSAZ CF, 1981, ACTA ANAT, V109, P321; POCHON JP, 1991, EUR J PEDIATR SURG, V1, P199, DOI 10.1055/s-2008-1042487; Poetker DM, 2004, OTOL NEUROTOL, V25, P604, DOI 10.1097/00129492-200407000-00031; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Romo T, 2009, ANN PLAS SURG, V62, P384, DOI 10.1097/SAP.0b013e31819fae51; RUBIN LR, 1983, BIOMATERIALS RECONST, P474; SPECTOR M, 1979, J BIOMED MATER RES, V13, P677, DOI 10.1002/jbm.820130502; Tabrizi R, 2010, J CRANIOFAC SURG, V21, P1142, DOI 10.1097/SCS.0b013e3181e57241; TOMFORD WW, 1995, J BONE JOINT SURG AM, V77A, P1742, DOI 10.2106/00004623-199511000-00017; Wellisz T, 1992, J Craniofac Surg, V3, P101, DOI 10.1097/00001665-199209000-00009; WELLISZ T, 1993, AESTHET PLAST SURG, V17, P339, DOI 10.1007/BF00437109; Zins JE, 2007, PLAST RECONSTR SURG, V120, P1332, DOI 10.1097/01.prs.0000279557.29134.cd; 홍기선, 2005, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V38, P96	25	44	46	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1049-2275	1536-3732		J CRANIOFAC SURG	J. Craniofac. Surg.	JAN	2012	23	1					67	70		10.1097/SCS.0b013e318240c876			4	Surgery	Surgery	891RS	WOS:000300234900041	22337376				2021-06-18	
J	Schumm, JA; Chard, KM				Schumm, Jeremiah A.; Chard, Kathleen M.			Alcohol and Stress in the Military	ALCOHOL RESEARCH-CURRENT REVIEWS			English	Article						Alcohol consumption; alcohol use and abuse; problematic alcohol use; stress; stress reaction; posttraumatic stress disorder; military personnel; active military; veteran; combat; military sexual trauma; causal pathways; self-medication; genetic vulnerability; co-occurring disorders	SUBSTANCE USE DISORDERS; TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL-INFLUENCES; COMBAT EXPOSURE; BINGE DRINKING; PTSD; IRAQ; PREVALENCE; DEPENDENCE; SYMPTOMS	Although research has independently linked stress experienced by military personnel to both alcohol use and posttraumatic stress disorder, more recently researchers have noted that there also is a significant overlap between stress reactions and alcohol use in veterans and active-duty service members. This overlap seems to be most understood in individuals who have experienced combat or military sexual trauma. This article will provide a brief review of some potential causal mechanisms underlying this relationship, including self-medication and genetic vulnerability models. It also addresses the possible implications for assessment and treatment of military personnel with co-occurring disorders.	[Schumm, Jeremiah A.; Chard, Kathleen M.] Cincinnati Vet Affairs Med Ctr, Posttraumat Stress Disorder & Anxiety Disorders D, Cincinnati, OH USA; [Schumm, Jeremiah A.; Chard, Kathleen M.] Univ Cincinnati, Cincinnati, OH USA	Schumm, JA (corresponding author), Cincinnati Vet Affairs Med Ctr, Posttraumat Stress Disorder & Anxiety Disorders D, Cincinnati, OH USA.		Schumm, Jeremiah/I-9634-2019				Ames G, 2004, ALCOHOL RES HEALTH, V28, P252; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Bremner JD, 1996, AM J PSYCHIAT, V153, P369; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brown PJ, 1999, PSYCHOL ADDICT BEHAV, V13, P115, DOI 10.1037/0893-164X.13.2.115; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Departmental Veterans Affairs, 2009, CONS C PRACT REC TRE; Dickstein BD, 2010, J TRAUMA STRESS, V23, P331, DOI 10.1002/jts.20523; Foa E. B., 2009, EFFECTIVE TREATMENTS; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Ford JD, 2007, J COUNS DEV, V85, P475, DOI 10.1002/j.1556-6678.2007.tb00616.x; FREDMAN S.J., 2010, S 44 ANN CONV ASS CO; Gradus JL, 2008, J STUD ALCOHOL DRUGS, V69, P348, DOI 10.15288/jsad.2008.69.348; Grant B. F., 1999, ADDICTIONS COMPREHEN, P9; Harwood HJ, 2009, MIL MED, V174, P728, DOI 10.7205/MILMED-D-03-9008; Hien DA, 2004, AM J PSYCHIAT, V161, P1426, DOI 10.1176/appi.ajp.161.8.1426; Hien DA, 2009, J CONSULT CLIN PSYCH, V77, P607, DOI 10.1037/a0016227; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Khantzian, 1999, TREATING ADDICTION H; Maguen S, 2011, PSYCHOL TRAUMA-US, V3, P21, DOI 10.1037/a0019897; Maguen S, 2010, J TRAUMA STRESS, V23, P86, DOI 10.1002/jts.20434; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; Messer SC, 2004, SOC PSYCH PSYCH EPID, V39, P419, DOI 10.1007/s00127-004-0757-1; Miller W. R., 2002, MOTIVATIONAL INTERVI; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Najavits L.M., 2002, SEEKING SAFETY TREAT; Ouimette PC, 1999, PSYCHOL ADDICT BEHAV, V13, P105, DOI 10.1037/0893-164X.13.2.105; Scherrer JF, 2008, COMPR PSYCHIAT, V49, P297, DOI 10.1016/j.comppsych.2007.11.001; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Stahre MA, 2009, AM J PREV MED, V36, P208, DOI 10.1016/j.amepre.2008.10.017; Suris A, 2008, TRAUMA VIOLENCE ABUS, V9, P250, DOI 10.1177/1524838008324419; TANELLAN T., 2008, INVISIBLE WOUNDS WAR; Xian H, 2000, DRUG ALCOHOL DEPEN, V61, P95, DOI 10.1016/S0376-8716(00)00127-7	36	44	44	0	21	NATL INST ALCOHOL ABUSE  ALCOHOLISM	ROCKVILLE	6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA	1535-7414	1930-0573		ALCOHOL RES-CURR REV	Alcohol Res.-Curr. Rev.		2012	34	4					401	407					7	Substance Abuse	Substance Abuse	066QB	WOS:000313234200004	23584106				2021-06-18	
J	Di Paola, R; Impellizzeri, D; Trovato-Salinaro, A; Mazzon, E; Bellia, F; Cavallaro, M; Cornelius, C; Vecchio, G; Calabrese, V; Rizzarelli, E; Cuzzocrea, S				Di Paola, Rosanna; Impellizzeri, Daniela; Trovato-Salinaro, Angela; Mazzon, Emanuela; Bellia, Francesco; Cavallaro, Monia; Cornelius, Carolin; Vecchio, Graziella; Calabrese, Vittorio; Rizzarelli, Enrico; Cuzzocrea, Salvatore			Administration of carnosine in the treatment of acute spinal cord injury	BIOCHEMICAL PHARMACOLOGY			English	Article						Carnosine; Spinal cord injury; Inflammation; Apoptosis	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; INHIBITION; STRESS; PATHOPHYSIOLOGY; PEROXYNITRITE; HOMOCARNOSINE; DEGENERATION	L-Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and L-histidine. It acts as a free radical scavenger and possesses antioxidant properties. L-Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), interleukin (IL)-1 and tumor necrosis factor (TNF)-alpha in different experimental settings. In the present study, we investigated the efficacy of L and D-carnosine on the animal model of spinal cord injury (SCI). The spinal cord was exposed via a four-level T5-T8 laminectomy and SCI was produced by extradural compression of the spinal cord at level T6-T7 using an aneurysm clip with a closing force of 24 g. Treatment with D-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI), but not L-carnosine significantly decreased (a) the degree of spinal cord inflammation and tissue injury (histological score), (b) neutrophil infiltration (myeloperoxidase activity), (c) nitrotyrosine formation, inducible NO synthase (iNOS) and Hsp70 expression, (d) proinflammatory cytokines, and (e)apoptosis (TUNEL staining, Fas ligand, Bax, and Bcl-2 expression). Furthermore, D-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI) significantly ameliorated the loss of limb function (evaluated by motor recovery score). Taken together, our results demonstrate the strong difference between L-carnosine and D-carnosine. The result strongly suggests that D-carnosine treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma. (C) 2011 Elsevier Inc. All rights reserved.	[Cuzzocrea, Salvatore] Univ Messina, Dept Clin & Expt Med & Pharmacol, Sch Med, Torre Biol Policlin Univ, I-98100 Messina, Italy; [Di Paola, Rosanna; Mazzon, Emanuela; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, I-98100 Messina, Italy; [Trovato-Salinaro, Angela; Bellia, Francesco; Cavallaro, Monia; Cornelius, Carolin; Vecchio, Graziella; Calabrese, Vittorio; Rizzarelli, Enrico] Univ Catania, Dept Chem Sci, I-95125 Catania, Italy; [Trovato-Salinaro, Angela; Cavallaro, Monia; Cornelius, Carolin; Calabrese, Vittorio; Rizzarelli, Enrico] Interuniv Consortium INBB, Catania, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Dept Clin & Expt Med & Pharmacol, Sch Med, Torre Biol Policlin Univ, Via C Valeria, I-98100 Messina, Italy.	dipaolar@unime.it; danielaimp@hotmail.com; ehazzon@unime.it; fbellia@unict.it; carolin.Cornelius@receptura.de; gr.vecchio@unict.it; calabrese@unict.it; erizzarelli@unict.it; salvator@unime.it	Calabrese, Vittorio/AAC-8157-2021; Mazzon, Emanuela/AAL-4334-2020; Rizzarelli, Enrico/M-6974-2017; Bellia, Francesco/H-2812-2013; di paola, rosanna/U-4356-2019; Vecchio, Graziella/M-2990-2015	Calabrese, Vittorio/0000-0002-0478-985X; Rizzarelli, Enrico/0000-0001-5367-0823; mazzon, emanuela/0000-0002-5073-717X; Impellizzeri, Daniela/0000-0001-9492-3161; Bellia, Francesco/0000-0002-9273-5949; di paola, rosanna/0000-0001-6725-8581; TROVATO SALINARO, Angela/0000-0003-2377-858X; Vecchio, Graziella/0000-0001-8305-081X	MIURMinistry of Education, Universities and Research (MIUR) [2008R23Z7K, F5A3AF005]; FIRBMinistry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB) [RBRN07BMCT]; I.N.B.B.; Fondi Ateneo;  [RBNE08HWLZ001]	We thank Flamma SpA (Bergamo, Italy) for kindly supplying DCar and MIUR (Grants 2008R23Z7K and F5A3AF005) for financial support. Work from the authors' laboratories was supported by grants from MIUR, FIRB RBRN07BMCT, RBNE08HWLZ001, I.N.B.B., and by "Fondi Ateneo" 2008 and 2009.	Ackery A, 2006, J NEUROTRAUM, V23, P604, DOI 10.1089/neu.2006.23.604; ALDINI G, 2005, Patent No. 2005120543; Ambrozaitis Kazys Vytautas, 2006, Medicina (Kaunas), V42, P255; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Beattie MS, 2002, PROG BRAIN RES, V137, P37; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bellia F, 2008, EUR J MED CHEM, V43, P373, DOI 10.1016/j.ejmech.2007.03.038; Bellia F, 2009, ANTIOXID REDOX SIGN, V11, P2759, DOI [10.1089/ars.2009.2738, 10.1089/ARS.2009.2738]; Bertinaria M, 2011, J MED CHEM, V54, P611, DOI 10.1021/jm101394n; Bethea JR, 1998, J NEUROSCI, V18, P3251; Boldyrev A, 2004, COMP BIOCHEM PHYS B, V137, P81, DOI 10.1016/j.cbpc.2003.10.008; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P980, DOI 10.1177/0960327110383625; Calabrese V, 2005, NEUROCHEM RES, V30, P797, DOI 10.1007/s11064-005-6874-8; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Calabrese V, 2010, NEUROCHEM RES, V35, P2208, DOI 10.1007/s11064-010-0304-2; Calabrese V, 2010, NEUROCHEM RES, V35, P1880, DOI 10.1007/s11064-010-0307-z; Calabrese V, 2010, ANTIOXID REDOX SIGN, V13, P1763, DOI 10.1089/ars.2009.3074; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Chez MG, 2002, J CHILD NEUROL, V17, P833, DOI 10.1177/08830738020170111501; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Corona C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017971; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; de Castro R, 2004, EXP NEUROL, V190, P414, DOI 10.1016/j.expneurol.2004.05.046; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Ferrari CKB, 2004, BIOGERONTOLOGY, V5, P275, DOI 10.1007/s10522-004-2566-z; Fontana M, 2002, CELL MOL LIFE SCI, V59, P546, DOI 10.1007/s00018-002-8446-2; Gallant S, 2000, TOHOKU J EXP MED, V191, P85, DOI 10.1620/tjem.191.85; Genovese T, 2006, NEUROSCI LETT, V393, P141, DOI 10.1016/j.neulet.2005.09.060; Genovese T, 2009, PHARMACOL RES, V59, P338, DOI 10.1016/j.phrs.2009.01.018; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hipkiss AR, 2009, ADV FOOD NUTR RES, V57, P87, DOI 10.1016/S1043-4526(09)57003-9; Hobart LJ, 2004, LIFE SCI, V75, P1379, DOI 10.1016/j.lfs.2004.05.002; Kang JH, 2003, MOL CELLS, V15, P87; Kang JH, 2010, BMB REP, V43, P683, DOI [10.3858/BMBRep.2010.43.10.683, 10.5483/BMBRep.2010.43.10.683]; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Lacza Z, 2003, INT J MOL MED, V12, P153; Lanza V, 2011, J INORG BIOCHEM, V105, P181, DOI 10.1016/j.jinorgbio.2010.10.014; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Mullane K, 1989, Prog Clin Biol Res, V301, P39; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Nicoletti VG, 2007, J NEUROSCI RES, V85, P2239, DOI 10.1002/jnr.21365; Perluigi M, 2010, J NEUROSCI RES, V88, P3498, DOI 10.1002/jnr.22500; Petroff OAC, 2001, NEUROLOGY, V56, P709, DOI 10.1212/WNL.56.6.709; Pubill D, 2002, EUR J PHARMACOL, V448, P165, DOI 10.1016/S0014-2999(02)01949-0; QUINN PJ, 1992, MOL ASPECTS MED, V13, P379, DOI 10.1016/0098-2997(92)90006-L; Shen Y, 2010, FREE RADICAL BIO MED, V48, P727, DOI 10.1016/j.freeradbiomed.2009.12.021; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; Skaper SD, 2003, CNS NEUROL DISORD-DR, V2, P279, DOI 10.2174/1568007033482733; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Stvolinsky SL, 1999, CELL MOL NEUROBIOL, V19, P45, DOI 10.1023/A:1006960407008; Szabo Cs., 2003, Acta Physiologica Hungarica, V90, P175, DOI 10.1556/APhysiol.90.2003.3.1; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teufel M, 2003, J BIOL CHEM, V278, P6521, DOI 10.1074/jbc.M209764200; Thiel R, 2005, MED HYPOTHESES, V64, P524, DOI 10.1016/j.mehy.2004.08.020; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323	65	44	44	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	NOV 15	2011	82	10			SI		1478	1489		10.1016/j.bcp.2011.07.074			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	840BX	WOS:000296414400022	21787762				2021-06-18	
J	Chrisman, SP; Schiff, MA; Rivara, FP				Chrisman, Sara P.; Schiff, Melissa A.; Rivara, Frederick P.			Physician Concussion Knowledge and the Effect of Mailing the CDC's "Heads Up" Toolkit	CLINICAL PEDIATRICS			English	Article						brain concussion; physicians; knowledge; practice guidelines as topic	RESPONSE RATES; BRAIN-INJURY; GUIDELINES; SPORTS; IMPACT	Background. The Centers for Disease Control and Prevention's (CDC) "Heads Up" toolkit was designed to educate physicians about concussion, but it has not been well studied. This study proposed to evaluate the effect of receiving the toolkit on physician concussion knowledge. Methods. The authors obtained a sample of physicians from the American Medical Association masterfile and randomly selected half to be mailed the CDC's "Heads Up" toolkit. All physicians were then sent a survey on concussion knowledge. Data were analyzed to evaluate the effect of the toolkit on concussion knowledge. Results. The survey was completed by 414 physicians (183 intervention, 231 control). There were no differences in general concussion knowledge between intervention and control groups, but physicians in the intervention group were significantly less likely to recommend next day return to play after a concussion (adjusted odds ratio = 0.31, 95% confidence interval = 0.12-0.76). Conclusions. Mailing the CDC's "Heads Up" toolkit appears to affect physicians' recommendations regarding returning to play after a concussion.	[Chrisman, Sara P.] Univ Washington, Dept Pediat, Seattle, WA 98145 USA; [Schiff, Melissa A.; Rivara, Frederick P.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Chrisman, SP (corresponding author), Univ Washington, Dept Pediat, POB 5371,M-S CW8-6, Seattle, WA 98145 USA.	sdow@u.washington.edu		Chrisman, Sara/0000-0001-5373-7223	Ruth L. Kirchstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This article was supported in part by a grant from the Ruth L. Kirchstein National Research Service Award.	Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; *CDCP, HEADS BRAIN INJ YOUR; CHOPP F, YOUTH SPORTS HEAD IN; Christakis DA, 1998, PEDIATRICS, V101, P825, DOI 10.1542/peds.101.5.825; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; VanGeest JB, 2007, EVAL HEALTH PROF, V30, P303, DOI 10.1177/0163278707307899	14	44	44	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228			CLIN PEDIATR	Clin. Pediatr.	NOV	2011	50	11					1031	1039		10.1177/0009922811410970			9	Pediatrics	Pediatrics	835FM	WOS:000296020900007	21646251				2021-06-18	
J	Jiang, Q; Qu, CS; Chopp, M; Ding, GL; Nejad-Davarani, SP; Helpern, JA; Jensen, JH; Zhang, ZG; Li, L; Lu, M; Kaplan, D; Hu, JN; Shen, YM; Kou, ZF; Li, QJ; Wang, SY; Mahmood, A				Jiang, Quan; Qu, Changsheng; Chopp, Michael; Ding, Guang Liang; Nejad-Davarani, Siamak P.; Helpern, Joseph A.; Jensen, Jens H.; Zhang, Zheng Gang; Li, Lian; Lu, Mei; Kaplan, David; Hu, Jiani; Shen, Yimin; Kou, Zhifeng; Li, Qingjiang; Wang, Shiyang; Mahmood, Asim			MRI evaluation of axonal reorganization after bone marrow stromal cell treatment of traumatic brain injury	NMR IN BIOMEDICINE			English	Article						MRI; DTI; traumatic brain injury; rat brain	CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; DIFFUSION MRI; STEM-CELLS; THERAPEUTIC BENEFIT; HEAD-INJURY; IN-VIVO; STROKE; RAT; TRANSPLANTATION	We treated traumatic brain injury (TBI) with human bone marrow stromal cells (hMSCs) and evaluated the effect of treatment on white matter reorganization using MRI. We subjected male Wistar rats (n = 17) to controlled cortical impact and either withheld treatment (controls; n = 9) or inserted collagen scaffolds containing hMSCs (n = 8). Six weeks later, the rats were sacrificed and MRI revealed selective migration of grafted neural progenitor cells towards the white matter reorganized boundary of the TBI-induced lesion. Histology confirmed that the white matter had been reorganized, associated with increased fractional anisotropy (FA; p < 0.01) in the recovery regions relative to the injured core region in both treated and control groups. Treatment with hMSCs increased FA in the recovery regions, lowered T-2 in the core region, decreased lesion volume and improved functional recovery relative to untreated controls. Immunoreactive staining showed axonal projections emanating from neurons and extruding from the corpus callosum into the ipsilateral cortex at the boundary of the lesion. Fiber tracking (FT) maps derived from diffusion tensor imaging confirmed the immunohistological data and provided information on axonal rewiring. The apparent kurtosis coefficient (AKC) detected additional axonal remodeling regions with crossing axons, confirmed by immunohistological staining, comparedwith FA. Our data demonstrate that AKC, FA, FTand T-2 can be used to evaluate treatment-induced white matter recovery, which may facilitate restorative therapy in patients with TBI. Copyright (C) 2011 John Wiley & Sons, Ltd.	[Jiang, Quan; Chopp, Michael; Ding, Guang Liang; Nejad-Davarani, Siamak P.; Zhang, Zheng Gang; Li, Lian; Li, Qingjiang; Wang, Shiyang] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; [Qu, Changsheng; Mahmood, Asim] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Jiang, Quan; Chopp, Michael; Zhang, Zheng Gang; Wang, Shiyang] Oakland Univ, Dept Phys, Rochester, MI USA; [Jensen, Jens H.] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA; [Helpern, Joseph A.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA; [Jensen, Jens H.] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY USA; [Lu, Mei] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA; [Kaplan, David] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Hu, Jiani; Shen, Yimin; Kou, Zhifeng] Wayne State Univ, Harper Hosp, MR Ctr, Detroit, MI USA	Jiang, Q (corresponding author), Henry Ford Hosp, Dept Neurol, NMR Lab, 2799 W Grand Blvd, Detroit, MI 48202 USA.		Jensen, Jens H/A-8334-2009; Nejad-Davarani, Siamak/AAH-8399-2021; Wang, Shiyang/C-1729-2012	Jensen, Jens H/0000-0003-3219-4287; Ding, Guangliang/0000-0003-1286-5901; Nejad-Davarani, Siamak/0000-0002-2415-6689	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS38292, RO1 NS43324, RO1 HL64766, PO1 NS23393, R01 AG027852, PO1 NS42345]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, P01NS042345, P50NS023393, R01NS048349, R01NS043324, R01NS064134, R01NS038292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027852] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grants RO1 NS38292, RO1 NS43324, RO1 HL64766, PO1 NS23393, R01 AG027852 and PO1 NS42345.	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Alexander DC, 2005, NEUROIMAGE, V27, P357, DOI 10.1016/j.neuroimage.2005.04.008; Alexander DC, 2005, ANN NY ACAD SCI, V1064, P113, DOI 10.1196/annals.1340.018; Alexander DC, 2002, MAGN RESON MED, V48, P331, DOI 10.1002/mrm.10209; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cramer SC, 2006, STROKE, V37, P111, DOI 10.1161/01.STR.0000195135.70379.1f; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunnett SB, 2001, NAT REV NEUROSCI, V2, P365, DOI 10.1038/35072572; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fok-Seang J, 1998, EUR J NEUROSCI, V10, P2400, DOI 10.1046/j.1460-9568.1998.00251.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Imaizumi T, 2001, No To Shinkei, V53, P632; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; JENSEN JH, 2003, P 11 ANN M ISMRM TOR, P2154; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; Jiang Q, 2002, J CEREBR BLOOD F MET, V22, P559, DOI 10.1097/00004647-200205000-00007; Jiang Q, 2001, J MAGN RESON IMAGING, V13, P178, DOI 10.1002/1522-2586(200102)13:2<178::AID-JMRI1027>3.3.CO;2-4; Jiang Q, 1997, J NEUROL SCI, V145, P15, DOI 10.1016/S0022-510X(96)00286-9; Jiang Q, 2006, NEUROIMAGE, V32, P1080, DOI 10.1016/j.neuroimage.2006.05.025; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lazar M, 2008, MAGN RESON MED, V60, P774, DOI 10.1002/mrm.21725; Li L, 2006, J CEREBR BLOOD F MET, V26, P1366, DOI 10.1038/sj.jcbfm.9600288; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Mahmood A, 2007, NEUROSURGERY, V61, P206, DOI 10.1227/01.neu.0000279914.37559.de; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Napieralski JA, 1996, J COMP NEUROL, V373, P484; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Phinney DG, 2006, STEM CELLS, V24, P186, DOI 10.1634/stemcells.2004-0236; Prockop DJ, 2000, BIOCHEM SOC T, V28, P341, DOI 10.1042/0300-5127:0280341; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SALTHOUSE TN, 1964, STAIN TECHNOL, V39, P123; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; von Bohlen und Halbach O, 1998, J NEUROSCI METH, V81, P169, DOI 10.1016/S0165-0270(98)00026-0; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zheng ZG, 2003, ANN NEUROL, V53, P259, DOI 10.1002/ana.10467	64	44	46	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	NOV	2011	24	9					1119	1128		10.1002/nbm.1667			10	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	840DT	WOS:000296419200012	21432927	Green Accepted			2021-06-18	
J	Rafaels, K; Bass, CR; Salzar, RS; Panzer, MB; Woods, W; Feldman, S; Cummings, T; Capehart, B				Rafaels, Karin; Bass, Cameron R. 'Dale'; Salzar, Robert S.; Panzer, Matthew B.; Woods, William; Feldman, Sanford; Cummings, Thomas; Capehart, Bruce			Survival Risk Assessment for Primary Blast Exposures to the Head	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; injury risk; primary blast; rabbit	BRAIN-INJURY; NEUROTRAUMA	Many soldiers returning from the current conflicts in Iraq and Afghanistan have had at least one exposure to an explosive event and a significant number have symptoms consistent with traumatic brain injury. Although blast injury risk functions have been determined and validated for pulmonary injury, there is little information on the blast levels necessary to cause blast brain injury. Anesthetized male New Zealand White rabbits were exposed to varying levels of shock tube blast exposure focused on the head, while their thoraces were protected. The specimens were euthanized and evaluated when the blast resulted in respiratory arrest that was non-responsive to resuscitation or at 4 h post-exposure. Injury was evaluated by gross examination and histological evaluation. The fatality data from brain injury were then analyzed using Fisher's exact test to determine a brain fatality risk function. Greater blast intensity was associated with post-blast apnea and the need for mechanical ventilation. Gross examination revealed multifocal subdural hemorrhages, most often near the brainstem, at more intense levels of exposure. Histological evaluation revealed subdural and subarachnoid hemorrhages in the non-responsive respiratory-arrested specimens. A fatality risk function from blast exposure to the head was determined for the rabbit specimens with an LD(50) at a peak overpressure of 750 kPa. Scaling techniques were used to predict injury risk at other blast overpressure/duration combinations. The fatality risk function showed that the blast level needed to cause fatality from an overpressure wave exposure to the head was greater than the peak overpressure needed to cause fatality from pulmonary injury. This risk function can be used to guide future research for blast brain injury by providing a realistic fatality risk to guide the design of protection or to evaluate injury.	[Rafaels, Karin; Salzar, Robert S.] Univ Virginia, Ctr Appl Biomech, Charlottesville, VA 22911 USA; [Woods, William] Univ Virginia, Dept Emergency Med, Charlottesville, VA 22911 USA; [Feldman, Sanford] Univ Virginia, Ctr Comparat Med, Charlottesville, VA 22911 USA; [Bass, Cameron R. 'Dale'; Panzer, Matthew B.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Cummings, Thomas] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Capehart, Bruce] Durham VA Med Ctr, Dept Psychiat, Durham, NC USA	Rafaels, K (corresponding author), Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	kar3k@virginia.edu	Feldman, Sanford/AAH-7070-2021				Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bogo V., 1971, 2659 DASA LOV FDN ME; Bowen I., 1968, 2113 DASA LOV FDN ME; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; CLEMEDSON CJ, 1953, AM J PHYSIOL, V174, P316; Clemedson CJ, 1949, ACTA PHYSL SCAND, V18, P1; Cox D. R., 1989, ANAL BINARY DATA, V2nd; EPPINGER RH, 1984, SAE GOVT IND M EXP S; Hooker DR, 1924, AM J PHYSIOL, V67, P219; Hosmer DW, 2004, APPL LOGISTIC REGRES; Hyde DW, 2004, CONWEP 2 1 0 8 CONVE; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; KROHN PL, 1941, 19511249 UK MIN HOM; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Richmond DR, 1962, DASA1335 LOV FDN MED; Rusca F, 1915, Z CHIR, V132, P315; TENNEY SM, 1963, NATURE, V197, P54, DOI 10.1038/197054a0; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Warden DL, 2005, J NEUROTRAUM, V22, P1178; WHITE CS, 1968, ANN NY ACAD SCI, V152, P89, DOI 10.1111/j.1749-6632.1968.tb11969.x; Zhu F, 2010, P STAPP CAR CRASH C; Zuckerman S., 1941, P ROY SOC MED, V34, P171	24	44	44	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2319	2328		10.1089/neu.2009.1207			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600010	21463161				2021-06-18	
J	Logi, F; Pasqualetti, P; Tomaiuolo, F				Logi, Fiammetta; Pasqualetti, Patrizio; Tomaiuolo, Francesco			Predict recovery of consciousness in post-acute severe brain injury: The role of EEG reactivity	BRAIN INJURY			English	Article						Coma; vegetative state; prognosis	SEVERE HEAD-INJURY; CEREBRAL ANOXIA; COMA; PROGNOSIS; PROGNOSTICATION; ARREST; SCALE	Objective: This study tested the hypothesis of electroencephalographic reactivity (EEG-R) as a reliable tool for the prognostic evaluation of consciousness recovery in post-acute brain injury. Methods: EEG was recorded in 50 unconscious patients. All patients had a GCS <= 8 and LCF score <= 2. They suffered from traumatic brain injury, cerebrovascular disease or anoxia. EEG was classified according to Synek classification (1988) as benign, malignant and 'uncertain significance'. EEG-R to painful stimuli was tested. Results: Twenty per cent of patients fulfilled the criteria for benign prognosis, 38% for malignant prognosis, while 42% of them were included in the 'uncertain' category, preventing them from stating a prognosis. EEG-R was detected in 48% of patients classified 'uncertain' and 92% of them recovered consciousness within 5 months from EEG recording. Multivariable analysis indicates that an unconscious patient admitted to the Rehabilitation Unit within 2 months from brain injury, with a LCF score equal to 2 and the presence of EEG-R has a probability of recovery of consciousness higher than 97%. Conclusion: EEG-R is a good positive factor for the prognosis of recovery of consciousness in the post-acute phase of brain injury, with a high specificity (88.9%). Nevertheless, its absence is not invariably associated with a poor prognosis.	[Logi, Fiammetta; Tomaiuolo, Francesco] Multispecialist Rehabil Ctr, Severe Acquired Brain Injury Unit, Auxilium Vitae Volterra, Italy; [Pasqualetti, Patrizio] Fatebenefratelli Assoc Res AFaR, Dept Neurosci, Rome, Italy	Logi, F (corresponding author), Auxilium Vitae Volterra SpA, Unita Gravi Cerebrolesioni Acquisite, Borgo S Lazzaro 5, I-56048 Volterra, Italy.	fiammettal@hotmail.com	Tomaiuolo, Francesco/AAC-1534-2019; Pasqualetti, Patrizio/D-4496-2013	Pasqualetti, Patrizio/0000-0001-5560-1979; Tomaiuolo, Fancesco/0000-0003-1230-2770			Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BRICOLO A, 1979, REV EEG NEUROPHYSIOL, V9, P116, DOI 10.1016/S0370-4475(79)80066-0; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Fischer C., 2002, Annales de Readaptation et de Medecine Physique, V45, P448, DOI 10.1016/S0168-6054(02)00295-7; GUERIT JM, 1999, ELECTROENCEPHALOGR S, V52, P117; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Hagen C., 1979, COGNITIVE ASSESSMENT; HOCKADAY JM, 1965, ELECTROEN CLIN NEURO, V18, P575, DOI 10.1016/0013-4694(65)90075-1; Kaplan PW, 2006, SEMIN NEUROL, V26, P403, DOI 10.1055/s-2006-948321; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; RamachandranNair R, 2005, PEDIATR NEUROL, V33, P345, DOI 10.1016/j.pediatrneurol.2005.05.007; SYNEK VM, 1988, CLIN ELECTROENCEPHAL, V19, P160, DOI 10.1177/155005948801900310; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; TEASDALE G, 1974, LANCET, V2, P81; Thenayan EAL, 2010, J CRIT CARE, V25, P300, DOI 10.1016/j.jcrc.2009.06.049; Young GB, 1997, CAN J NEUROL SCI, V24, P320, DOI 10.1017/S0317167100032996; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	21	44	50	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2011	25	10					972	979		10.3109/02699052.2011.589795			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	801TZ	WOS:000293464800007	21745174				2021-06-18	
J	Zhao, JB; Zhang, Y; Li, GZ; Su, XF; Hang, CH				Zhao, Jin-bing; Zhang, Yang; Li, Guang-zhao; Su, Xing-fen; Hang, Chun-hua			Activation of JAK2/STAT pathway in cerebral cortex after experimental traumatic brain injury of rats	NEUROSCIENCE LETTERS			English	Article						JAK2; STAT1; STAT3; AG490; Traumatic brain injury; Neurological Severity Scores	JAK-STAT PATHWAY; SUBARACHNOID HEMORRHAGE; SIGNALING PATHWAY; APOPTOSIS; ISCHEMIA; INHIBITION; EXPRESSION; PROTEINS; RECEPTOR; CELLS	The janus kinase/signal transducer and activator of transcription (JAK/STAT) is one of the main pathways downstream of cytokine receptors and growth factor receptors by transducing signals from cell surface to the nucleus. In this study, we aimed to survey the role of JAK2/STAT pathway in the progress of TBI. Right parietal cortical contusion in rats was induced by the Feeney free falling model. The activation of JAK2, STAT1 and STAT3 in pericontusional cortex was determined by Western blotting, electrophoretic mobility shift assay (EMSA), immunohistochemistry and immunofluorescence. Moreover, we assessed the neurological recovery (using Neurological Severity Scores (NSS)) of rats under the pretreatment of a JAK2 inhibitor, AG490. Western blotting revealed that expression of p-JAK2, p-STAT1 and p-STAT3 increased immediately, peaked at 3 h after TBI and decreased thereafter, and the activation could be inhibited by AG490. Immunohistochemical study showed that JAK2/STAT pathway was activated in both neurons and astrocytes at 3 h after TBI. STAT3-specific binding activity was obviously enhanced after TBI and down-regulated after AG490 administration. The higher NSS of TBI + AG490 group revealed a worse behavior recovery when compared with TBI + DMSO group. Our results suggest that the JAK2/STAT pathway is activated in pericontusional cortex of rats, and may be involved in the neurological function recovery after TBI. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Zhao, Jin-bing; Zhang, Yang; Su, Xing-fen; Hang, Chun-hua] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China; [Li, Guang-zhao; Hang, Chun-hua] So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hang.neurosurgery@gmail.com			Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2010459]; Nanjing Military Command, China	This study was supported by Natural Science Foundation of Jiangsu Province (BK2010459) and Medical and Health Research Fund of Nanjing Military Command, China.	Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bolli R, 2003, TRENDS CARDIOVAS MED, V13, P72, DOI 10.1016/S1050-1738(02)00230-X; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chen G, 2008, BRAIN RES, V1214, P136, DOI 10.1016/j.brainres.2008.03.085; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De-Fraja C, 1998, J NEUROSCI RES, V54, P320, DOI 10.1002/(SICI)1097-4547(19981101)54:3<320::AID-JNR3>3.0.CO;2-R; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Linnekin D, 1997, LEUKEMIA LYMPHOMA, V27, P439, DOI 10.3109/10428199709058310; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Osuka K, 2006, BRAIN RES, V1072, P1, DOI 10.1016/j.brainres.2005.12.003; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Schindler C, 2008, SEMIN CELL DEV BIOL, V19, P311, DOI 10.1016/j.semcdb.2008.08.010; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Thompson JE, 2005, DRUG NEWS PERSPECT, V18, P305, DOI 10.1358/dnp.2005.18.5.904198; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Xu XL, 1998, CANCER RES, V58, P2832; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	26	44	48	1	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 8	2011	498	2					147	152		10.1016/j.neulet.2011.05.001			6	Neurosciences	Neurosciences & Neurology	788EF	WOS:000292427500010	21596098				2021-06-18	
J	Scott, JC; Woods, SP; Vigil, O; Heaton, RK; Schweinsburg, BC; Ellis, RJ; Grant, I; Marcotte, TD				Scott, J. Cobb; Woods, Steven Paul; Vigil, Ofilio; Heaton, Robert K.; Schweinsburg, Brian C.; Ellis, Ronald J.; Grant, Igor; Marcotte, Thomas D.		San Diego HIV Neurobehav Res Ctr	A Neuropsychological Investigation of Multitasking in HIV Infection: Implications for Everyday Functioning	NEUROPSYCHOLOGY			English	Article						HIV; cognition; neuropsychology; activities of daily living; executive functions	TRAUMATIC BRAIN-INJURY; STRATEGY APPLICATION; ECOLOGICAL VALIDITY; IMPAIRMENT; DAMAGE; PERFORMANCE; DEPENDENCE; PATTERNS	Objective: A subset of individuals with HIV-associated neurocognitive impairment experience related deficits in "real world" functioning (i.e., independently performing instrumental activities of daily living [IADL]). While performance-based tests of everyday functioning are reasonably sensitive to HIV-associated IADL declines, questions remain regarding the extent to which these tests' highly structured nature fully captures the inherent complexities of daily life. The aim of this study was to assess the predictive and ecological validity of a novel multitasking measure in HIV infection. Method: Participants included 60 individuals with HIV infection (HIV+) and 25 demographically comparable seronegative adults (HIV-). Participants were administered a comprehensive neuropsychological battery, questionnaires assessing mood and everyday functioning, and a novel standardized test of multitasking, which involved balancing the demands of four interconnected performance-based functional tasks (i.e., financial management, cooking, medication management, and telephone communication). Results: HIV+ individuals demonstrated significantly worse overall performance, fewer simultaneous task attempts, and increased errors on the multitasking test as compared to the HIV- group. Within the HIV+ sample, multitasking impairments were modestly associated with deficits on standard neuropsychological measures of executive functions, episodic memory, attention/working memory, and information processing speed, providing preliminary evidence for convergent validity. More importantly, multivariate prediction models revealed that multitasking deficits were uniquely predictive of IADL dependence beyond the effects of depression and global neurocognitive impairment, with excellent sensitivity (86%), but modest specificity (57%). Conclusions: Taken together, these data indicate that multitasking ability may play an important role in successful everyday functioning in HIV+ individuals.	[Scott, J. Cobb] San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92182 USA; [Scott, J. Cobb; Woods, Steven Paul; Vigil, Ofilio; Heaton, Robert K.; Schweinsburg, Brian C.; Ellis, Ronald J.; Grant, Igor; Marcotte, Thomas D.] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA; [Schweinsburg, Brian C.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA	Scott, JC (corresponding author), VA Connecticut Healthcare Syst, Clin Neurosci Div 151E, Natl Ctr PTSD, 950 Campbell Ave, West Haven, CT 06516 USA.	cobb.scott@yale.edu	Ellis, Ronald/K-3543-2015	Ellis, Ronald/0000-0003-4931-752X; Scott, J. Cobb/0000-0001-6538-9043; Woods, Steven Paul/0000-0003-0776-4233	American Psychological Foundation [CSPAR-759, MH 62512]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062512] Funding Source: NIH RePORTER	This research was supported by CSPAR-759, MH 62512, and the 2007 Benton-Meier Scholarship from the American Psychological Foundation. Aspects of these data were presented at the 38th annual meeting of the International Neuropsychological Society in Acapulco, Mexico. Authors report no conflicts of interest affecting this article. The HNRC Group includes: Director, Igor Grant; Co-Directors: J. Hampton Atkinson, Ronald J. Ellis, and J. Allen McCutchan; Center Manager: Thomas D. Marcotte; Jennifer Marquie-Beck; Melanie Sherman; Naval Hospital San Diego: Braden R. Hale; Neuromedical Component: Ronald J. Ellis, J. Allen McCutchan, Scott Letendre, Edmund Capparelli, Rachel Schrier, Terry Alexander; Debra Rosario, Shannon LeBlanc; Neurobehavioral Component: Robert K. Heaton, Steven Paul Woods, Mariana Cherner, David J. Moore, Matthew Dawson; Neuroimaging Component: Terry Jernigan, Christine Fennema-Notestine, Sarah L. Archibald, John Hesselink, Jacopo Annese, Michael J. Taylor, Brian C. Schweinsburg; Neurobiology Component: Eliezer Masliah, Ian Everall, Cristian Achim; Neurovirology Component: Douglas Richman, David M. Smith; International Component: J. Allen McCutchan; Developmental Component: Ian Everall, Stuart Lipton; Participant Accrual and Retention Unit: J. Hampton Atkinson, Rodney von Jaeger; Data Management Unit: Anthony C. Gamst, Clint Cushman (Data Systems Manager), Daniel R. Masys (Senior Consultant); Statistics Unit: Ian Abramson, Florin Vaida, Reena Deutsch, and Tanya Wolfson.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Beck AT., 1996, BECK DEPRESSION INVE, V2; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Dawes S, 2008, J CLIN EXP NEUROPSYC, V30, P613, DOI 10.1080/13803390701565225; Dreher JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003227; Everall IP, 2005, NEUROTOX RES, V8, P51, DOI 10.1007/BF03033819; Foerde K, 2006, P NATL ACAD SCI USA, V103, P11778, DOI 10.1073/pnas.0602659103; Giovannetti T, 2007, NEUROPSYCHOLOGY, V21, P448, DOI 10.1037/0894-4105.21.4.448; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; HEATON RK, 1994, PSYCHOSOM MED, V56, P8, DOI 10.1097/00006842-199401000-00001; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; McNair DM, 1981, PROFILE MOOD STATES; Meyer DE, 1997, PSYCHOL REV, V104, P3, DOI 10.1037/0033-295X.104.1.3; Norman DA, 1986, CONSCIOUSNESS SELF R; Ophir E, 2009, P NATL ACAD SCI USA, V106, P15583, DOI 10.1073/pnas.0903620106; Rippeth JD, 2004, J INT NEUROPSYCH SOC, V10, P1, DOI 10.1017/S1355617704101021; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Schwartz MF, 2006, COGN NEUROPSYCHOL, V23, P202, DOI 10.1080/02643290500202623; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Thoma P, 2008, BEHAV BRAIN RES, V194, P214, DOI 10.1016/j.bbr.2008.07.016; Tranel D, 2007, J CLIN EXP NEUROPSYC, V29, P319, DOI 10.1080/13803390600701376; Woods SP, 2006, J CLIN EXP NEUROPSYC, V28, P1030, DOI 10.1080/13803390500350985	32	44	44	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2011	25	4					511	519		10.1037/a0022491			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	787WQ	WOS:000292407800009	21401259	Green Accepted			2021-06-18	
J	Dai, SS; Zhou, YG				Dai, Shuang-Shuang; Zhou, Yuan-Guo			Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury	REVIEWS IN THE NEUROSCIENCES			English	Article						acute neurological injury; adenosine 2A receptor; bidirectional effect; neuroprotection	SPINAL-CORD-INJURY; TUMOR-NECROSIS-FACTOR; CEREBRAL ISCHEMIC-INJURY; EXCITATORY AMINO-ACIDS; BONE-MARROW-CELLS; A(2A) RECEPTOR; INDUCED EXCITOTOXICITY; FACTOR-ALPHA; NEUROLOGICAL DEFICIT; GLUTAMATE RELEASE	This review summarizes recent developments that have contributed to our understanding of how adenosine 2A receptors (A2ARs) modulate brain damage in various animal models of acute neurological injuries, including brain ischemia, traumatic brain injury, spinal cord injury and hemorrhage stroke. The main conclusions are: (1) pharmacological, neurochemical and molecular/genetic approaches to the complex actions of A2AR in different cellular elements suggest that A2AR activation exerts bidirectional effect (detrimental or protective) after brain insults; (2) modulation of glutamate excitotoxicity and neuroinflammation are involved in the protection of A2AR agonists or antagonists, but the bidirectional effect of A2AR is largely due to the bidirectional regulation of neuroinflammation (anti-inflammation or proinflammation) by A2AR on immune cells such as microglia cells and peripheral bone marrow cells; and (3) the bidirectional effect of A2AR on neuroinflammation and brain injury depends on the distinct and sometimes opposite actions of A2AR in various cellular elements and on different injury models and associated pathological conditions. The local glutamate level in the brain injury is one of the crucial factors that contribute to the direction of A2AR effect on neuroinflammation and brain injury outcome. These developments presented here clearly highlight the complexity of using A2AR agents therapeutically in acute neuronal injuries and confirm that A2AR ligands have many promising characteristics that encourage the pursuit of their full therapeutic potential.	[Zhou, Yuan-Guo] Third Mil Med Univ, Inst Surg Res, State Key Lab Trauma Burn & Combined Injury, Ctr Mol Biol, Chongqing 400042, Peoples R China; [Zhou, Yuan-Guo] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China	Zhou, YG (corresponding author), Third Mil Med Univ, Inst Surg Res, State Key Lab Trauma Burn & Combined Injury, Ctr Mol Biol, Chongqing 400042, Peoples R China.	ygzhou@cta.cq.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900587]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]; Science Foundation of Third Military Medical University	We gratefully thank Dr. Jiang-Fan Chen for critical reading and editing the review. The work in the authors' laboratories is supported by grants from the National Natural Science Foundation of China (No. 30900587), Natural Science Foundation of Chongqing, China (No. CSTC2009BB5317) and the Science Foundation of Third Military Medical University (to S.-S.D.).	Aden U, 2003, STROKE, V34, P739, DOI 10.1161/01.STR.0000060204.67672.8B; Bates B, 2002, MOL BRAIN RES, V109, P18, DOI 10.1016/S0169-328X(02)00458-8; Blum D, 2003, J NEUROSCI, V23, P5361; Boison D, 2010, CELL DEATH DIFFER, V17, P1071, DOI 10.1038/cdd.2009.131; Bona E, 1997, NEUROPHARMACOLOGY, V36, P1327, DOI 10.1016/S0028-3908(97)00139-1; Bouma MG, 1997, J IMMUNOL, V158, P5400; Brown J., 1996, THESIS NATL LIB CANA; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Cassada DC, 2002, J VASC SURG, V35, P994, DOI 10.1067/mva.2002.123091; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Chaparro-Huerta V, 2005, J NEUROIMMUNOL, V165, P53, DOI 10.1016/j.jneuroim.2005.04.025; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Chen JF, 2008, CURR PHARM DESIGN, V14, P1490, DOI 10.2174/138161208784480126; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; Chen Jiang-Fan, 2011, Handb Exp Pharmacol, P267, DOI 10.1007/978-3-642-13443-2_10; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5; Cunha GMA, 2006, NEUROSCIENCE, V141, P1775, DOI 10.1016/j.neuroscience.2006.05.024; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dias R. A., 2009, PUR 80 YEARS VER MUC; Dionisotti S, 1997, BRIT J PHARMACOL, V121, P353, DOI 10.1038/sj.bjp.0701119; Duarte JMN, 2006, NEUROCHEM INT, V48, P144, DOI 10.1016/j.neuint.2005.08.008; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fink JS, 2004, J NEUROCHEM, V88, P538, DOI 10.1046/j.1471-4159.2003.02145.x; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731; Frenguelli BG, 2007, J NEUROCHEM, V101, P1400, DOI 10.1111/j.1471-4159.2006.04425.x; GAO Y, 1994, LIFE SCI, V55, pPL61, DOI 10.1016/0024-3205(94)00889-2; Gott VL, 2002, ANN THORAC SURG, V74, P849; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gubitz AK, 1996, J NEUROCHEM, V67, P374; HAGBERG H, 1987, NEUROSCI LETT, V78, P311, DOI 10.1016/0304-3940(87)90379-X; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; Hettinger BD, 2001, J COMP NEUROL, V431, P331, DOI 10.1002/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W; Higashi H, 2002, J NEUROSURG, V96, P117, DOI 10.3171/jns.2002.96.1.0117; Jenner P, 2009, PARKINSONISM RELAT D, V15, pS18, DOI 10.1016/S1353-8020(09)70829-6; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Latini S, 1998, BRAIN RES, V794, P325, DOI 10.1016/S0006-8993(98)00304-7; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Lee YC, 2003, EUR J NEUROSCI, V18, P1786, DOI 10.1046/j.1460-9568.2003.02907.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Li Y, 2006, NEUROSCIENCE, V141, P2029, DOI 10.1016/j.neuroscience.2006.05.014; LIBERT F, 1991, GENOMICS, V11, P225, DOI 10.1016/0888-7543(91)90125-X; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Lin CL, 2007, J NEUROSURG, V106, P436, DOI 10.3171/jns.2007.106.3.436; Manjunath S, 2009, INDIAN J PHARMACOL, V41, P97, DOI 10.4103/0253-7613.55202; Marcoli M, 2004, NEUROPHARMACOLOGY, V47, P884, DOI 10.1016/j.neuropharm.2004.06.022; Marcoli M, 2003, NEUROPHARMACOLOGY, V45, P201, DOI 10.1016/S0028-3908(03)00156-4; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; MATSUMOTO K, 1992, BRAIN RES, V579, P309, DOI 10.1016/0006-8993(92)90066-I; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Meistrell ME, 1997, SHOCK, V8, P341; Melani A, 2006, BRAIN RES, V1073, P470, DOI 10.1016/j.brainres.2005.12.010; Melani A, 2003, BRAIN RES, V959, P243, DOI 10.1016/S0006-8993(02)03753-8; Melani A, 1999, STROKE, V30, P2448, DOI 10.1161/01.STR.30.11.2448; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; Monopoli A, 1998, J PHARMACOL EXP THER, V285, P9; Murphree LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishizaki T, 2002, GLIA, V39, P133, DOI 10.1002/glia.10100; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Okonkwo DO, 2006, J NEUROSURG-SPINE, V4, P64, DOI 10.3171/spi.2006.4.1.64; Ongini E, 1997, ANN NY ACAD SCI, V825, P30, DOI 10.1111/j.1749-6632.1997.tb48412.x; Pedata F, 2005, NEUROL RES, V27, P169, DOI 10.1179/016164105X21913; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; PHILLIS JW, 1994, NEUROCHEM RES, V19, P1387, DOI 10.1007/BF00972467; Pintor A, 2004, J NEUROCHEM, V89, P152, DOI 10.1111/j.1471-4159.2003.02306.x; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; Rebola N, 2005, EPILEPSIA, V46, P159, DOI 10.1111/j.1528-1167.2005.01026.x; Reece TB, 2008, J CARDIOVASC MED, V9, P363, DOI 10.2459/JCM.0b013e3282eee836; Reece TB, 2006, J VASC SURG, V44, P392, DOI 10.1016/j.jvs.2006.04.032; Reece TB, 2006, ANN THORAC SURG, V81, P902, DOI 10.1016/j.athoracsur.2005.09.023; Reece TB, 2004, J THORAC CARDIOV SUR, V128, P925, DOI 10.1016/j.jtcvs.2004.08.019; Revan S, 1996, J BIOL CHEM, V271, P17114, DOI 10.1074/jbc.271.29.17114; Ribeiro JA, 2010, ACTA PHYSIOL, V199, P161, DOI 10.1111/j.1748-1716.2010.02115.x; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Rosin Diane L., 2003, Neurology, V61, pS12; Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x; SCHIFFMANN SN, 1991, J NEUROCHEM, V57, P1062, DOI 10.1111/j.1471-4159.1991.tb08257.x; Skeberdis VA, 2001, NEUROPHARMACOLOGY, V40, P856, DOI 10.1016/S0028-3908(01)00005-3; Svenningsson P, 1999, PROG NEUROBIOL, V59, P355, DOI 10.1016/S0301-0082(99)00011-8; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; Tomimoto H, 1996, ACTA NEUROPATHOL, V92, P281, DOI 10.1007/s004010050519; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; Xu K, 2010, NEUROSCIENCE, V167, P475, DOI 10.1016/j.neuroscience.2010.02.020; Yu LQ, 2008, ANN NEUROL, V63, P338, DOI 10.1002/ana.21313; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	102	44	46	0	4	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	APR	2011	22	2					231	239		10.1515/RNS.2011.020			9	Neurosciences	Neurosciences & Neurology	889QR	WOS:000300088800007	21476942				2021-06-18	
J	Guo, Y; Shin, KY; Hainley, S; Bruera, E; Palmer, JL				Guo, Ying; Shin, Ki Y.; Hainley, Susan; Bruera, Eduardo; Palmer, J. Lynn			Inpatient Rehabilitation Improved Functional Status in Asthenic Patients with Solid and Hematologic Malignancies	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Cancer; Rehabilitation; Asthenia; Functional Independence Measure	STEM-CELL TRANSPLANTATION; SPINAL-CORD COMPRESSION; TRAUMATIC BRAIN-INJURY; ACUTE MYELOID-LEUKEMIA; UNIFORM DATA SYSTEM; CANCER REHABILITATION; INDEPENDENCE MEASURE; INTENSIVE CHEMOTHERAPY; OUTCOMES; TUMORS	Guo Y, Shin KY, Hainley S, Bruera E, Palmer JL: Inpatient rehabilitation improved functional status in asthenic patients with solid and hematologic malignancies. Am J Phys Med Rehabil 2011; 90: 265-271. Objective: The aim of this study was to compare functional outcomes in asthenic patients with hematologic malignancies with those of asthenic patients with solid tumors after inpatient rehabilitation. We hypothesized that asthenic patients with hematologic malignancies are less likely than patients with solid tumors to make functional improvement after rehabilitation. Design: The records of 60 asthenic cancer patients (30 consecutive patients with solid tumors and 30 consecutive patients with hematologic malignancies) who underwent inpatient rehabilitation at a comprehensive cancer center between October 2005 and October 2007 were retrospectively reviewed. Patients with focal neurologic deficits were excluded. All patients admitted to the inpatient rehabilitation unit received 3 hrs of more of therapy per weekday. The main outcomes included total, motor, and cognitive Functional Independence Measure (FIM) scores, hospital and rehabilitation length of stay, and FIM efficiency. Results: The mean total FIM score significantly improved in patients with solid tumors (mean, 15; range, -6 to 38) and in patients with hematologic malignancies (mean, 17; range, -3 to 27); however, between-group differences in FIM scores were not significant (P = 0.31). The solid tumor patients were significantly older than the hematologic malignancy patients (71 +/- 11 vs. 64 +/- 12 yrs; P = 0.02), but the mean rehabilitation lengths of stay were the same for each group (9.5 days; P = 0.82). The mean FIM efficiency in the hematologic malignancy group was higher than that of the solid tumor group (1.9 vs. 1.4; P = 0.049). Conclusions: Asthenic patients with solid tumors or hematologic malignancies could benefit from inpatient rehabilitation and make significant functional gain.	[Guo, Ying] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414, Houston, TX 77030 USA; [Palmer, J. Lynn] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Guo, Y (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Fu, Jack/0000-0002-9397-0668; Guo, Ying/0000-0002-3715-4287	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NR010162-01A1, RO1CA122292-01, RO1CA124481-01]	Supported in part by National Institutes of Health grant numbers RO1NR010162-01A1, RO1CA122292-01, and RO1CA124481-01 (to E.B.).	*AM CANC SOC, 2004, CANC FACTS FIG 2004; Axdorph U, 2002, BRIT J HAEMATOL, V118, P1048, DOI 10.1046/j.1365-2141.2002.03765.x; Cheville AL, 2005, SEMIN ONCOL, V32, P219, DOI 10.1053/j.seminoncol.2004.11.009; Cole RP, 2000, ARCH PHYS MED REHAB, V81, P623, DOI 10.1053/mr.2000.3861; Eriks IE, 2004, SPINAL CORD, V42, P235, DOI 10.1038/sj.sc.3101555; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Evans WJ, 2007, AM J PHYS MED REHAB, V86, pS29, DOI 10.1097/PHM.0b013e31802ba53c; Fouladiun M, 2005, CANCER-AM CANCER SOC, V103, P2189, DOI 10.1002/cncr.21013; Fu JB, 2010, AM J PHYS MED REHAB, V89, P205, DOI 10.1097/PHM.0b013e3181ca2306; Ganz PA, 1999, MAYO CLIN PROC, V74, P939, DOI 10.4065/74.9.939; Garrard P, 2004, NEUROREHAB NEURAL RE, V18, P76, DOI 10.1177/0888439004266306; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Greenberg E, 2006, AM J PHYS MED REHAB, V85, P568, DOI 10.1097/01.phm.0000223218.38152.53; GREY N, 1993, PARAPLEGIA, V31, P457, DOI 10.1038/sc.1993.74; Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11-10-1121; Guo Y, 2005, SUPPORT CARE CANCER, V13, P169, DOI 10.1007/s00520-004-0680-8; Guo Y, 2008, AM J PHYS MED REHAB, V87, P647, DOI 10.1097/PHM.0b013e31817fb94e; Hartvig Per, 2006, J Oncol Pharm Pract, V12, P183, DOI 10.1177/1078155206070776; HARVEY R, 1982, JAMA-J AM MED ASSOC, P2127; Huang ME, 2001, ARCH PHYS MED REHAB, V82, P1540, DOI 10.1053/apmr.2001.26613; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Koistinen P, 2007, EUR J HAEMATOL, V78, P477, DOI 10.1111/j.1600-0609.2007.00846.x; Koreth J, 2007, BIOL BLOOD MARROW TR, V13, P183, DOI 10.1016/j.bbmt.2006.09.010; Lacy MQ, 2007, MAYO CLIN PROC, V82, P1179, DOI 10.4065/82.10.1179; LEHMANN JF, 1978, ARCH PHYS MED REHAB, V59, P410; Mallinson TR, 2008, ARCH PHYS MED REHAB, V89, P2066, DOI 10.1016/j.apmr.2008.05.014; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; Marciniak CM, 2001, ARCH PHYS MED REHAB, V82, P457, DOI 10.1053/apmr.2001.21862; McKinley WO, 2000, AM J PHYS MED REHAB, V79, P138, DOI 10.1097/00002060-200003000-00005; Movsas SB, 2003, ARCH PHYS MED REHAB, V84, P1642, DOI 10.1053/S0003-9993(03)00345-9; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Okamura J, 2007, INT J HEMATOL, V86, P118, DOI 10.1532/IJH97.07070; Parsch D, 2003, SPINAL CORD, V41, P205, DOI 10.1038/sj.sc.3101426; PULLICINO P, 1992, STROKE, V23, P919, DOI 10.1161/str.23.6.919a; Stineman MG, 1998, ARCH PHYS MED REHAB, V79, P497, DOI 10.1016/S0003-9993(98)90062-4; Tang V, 2007, SPINAL CORD, V45, P671, DOI 10.1038/sj.sc.3102024; Tay SS, 2009, ANN ACAD MED SINGAP, V38, P197; Toze CL, 2002, BEST PRACT RES CL HA, V15, P481, DOI 10.1053/beha.2002.0223	40	44	47	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2011	90	4					265	271		10.1097/PHM.0b013e3182063ba6			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	731OI	WOS:000288118600001	21765265				2021-06-18	
J	Knerlich-Lukoschus, F; Noack, M; von der Ropp-Brenner, B; Lucius, R; Mehdorn, HM; Held-Feindt, J				Knerlich-Lukoschus, Friederike; Noack, Malte; von der Ropp-Brenner, Beata; Lucius, Ralph; Mehdorn, Hubertus Maximilian; Held-Feindt, Janka			Spinal Cord Injuries Induce Changes in CB1 Cannabinoid Receptor and C-C Chemokine Expression in Brain Areas Underlying Circuitry of Chronic Pain Conditions	JOURNAL OF NEUROTRAUMA			English	Article						cannabinoid receptor-1; chemokines; central pain; spinal cord injury; transient receptor potential vanilloid receptor 1	CENTRAL NEUROPATHIC PAIN; ACID AMIDE HYDROLASE; IMMUNOHISTOCHEMICAL LOCALIZATION; OPIOID RECEPTORS; RAT-BRAIN; HETEROLOGOUS DESENSITIZATION; ENDOCANNABINOID LEVELS; NEURONAL EXPRESSION; CONTUSION INJURIES; IN-VIVO	Due to their involvement in neuro-modulatory processes, the endogenous cannabinoid system and chemokine network, which were shown to interact which each other, are potential key elements in the cascades underlying central neuropathic pain development after spinal cord injury (SCI). Expression profiles of cannabinoid receptor type-1 (CB1), and of the chemokines chemokine ligand 2 (C-C motif) (CCL2), chemokine ligand 3 (C-C motif) (CCL3), plus their main receptors CCR2 and CCR1, were investigated in brain regions related to pain, emotion, learning, and memory in a rat SCI paradigm of post-traumatic neuropathic pain. Immunoreactivity (IR) was investigated 7 days and 42 days after sham operation, and moderate (100-kdyn), and severe (200-kdyn) thoracic spinal cord contusion lesions. Hippocampal (HC) subregions, amygdaloid complex, anterior cingulate cortex (ACC), periaqueductal gray (PAG), and thalamic nuclei were analyzed. Seven days after lesioning, CB1 IR was induced in thalamic nuclei and HC subregions (CA3 and dentate gyrus), and downregulated in amygdaloid nuclei, ACC, and PAG. On day 42, CB1 IR remained elevated in the HC and thalamic areas, and was induced in ACC after 100-kdyn, but downregulated after 200-kdyn lesions. It remained reduced in the PAG of severely lesioned animals, paralleling their prolonged neuropathic pain-related behavior. Double-labeling revealed partial co-expression of CB1 with the pain-related vanilloid receptor transient receptor potential vanilloid receptor 1 (TRPV1), and chemokines (CCL2 and CCL3). These chemokines were induced in the PAG, thalamus, and HC, especially in the chronic time course after severe SCI. Thus interactions of CB1, C-C chemokines, and TRPV1 likely play a role in SCI-induced plastic changes in the brain, underlying emotional-affective pain responses and central pain development after spinal cord lesions.	[Knerlich-Lukoschus, Friederike; Noack, Malte; von der Ropp-Brenner, Beata; Mehdorn, Hubertus Maximilian; Held-Feindt, Janka] Univ Schleswig Holstein, Med Ctr, Dept Neurosurg, D-24105 Kiel, Germany; [Knerlich-Lukoschus, Friederike; Lucius, Ralph] Univ Kiel, Dept Anat, Kiel, Germany	Held-Feindt, J (corresponding author), Univ Schleswig Holstein, Med Ctr, Dept Neurosurg, Campus Kiel,Arnold Heller Str 3 Geb 41, D-24105 Kiel, Germany.	held-feindtj@nch.uni-kiel.de	Lucius, Ralph/B-1614-2010; Held-Feindt, Janka/E-4690-2010; Knerlich-Lukoschus, Friederike F/J-2895-2016	Knerlich-Lukoschus, Friederike F/0000-0002-6284-0449	Stiftung Neurochirurgische Forschung; Ministry for Science, Commerce, and Transportation of Schleswig-Holstein	We thank Professor Maurice R. Elphick (School of Biological Sciences, Queen Mary, University of London, London, U.K.) who kindly provided the C-terminal CB<INF>1</INF> antibody used in this study. We also greatly appreciate Brigitte Rehmke's, Ute Malcus-Coskun's, and Jorg Krause's excellent technical assistance. This work was funded by Stiftung Neurochirurgische Forschung (F. K. L.), and the Ministry for Science, Commerce, and Transportation of Schleswig-Holstein [Gefordert mit den Mitteln der Fakultatsubergreifenden Forschungsforderung des Medizin-Ausschusses beider Medizinischer Fakultaten in Kiel und Lubeck] (R.L. and J.H.-F.).	Adler MW, 2005, AAPS J, V7, pE865, DOI 10.1208/aapsj070484; Ahmed MM, 2010, SPINE J, V10, P1049, DOI 10.1016/j.spinee.2010.08.015; Baastrup C, 2008, CNS DRUGS, V22, P455, DOI 10.2165/00023210-200822060-00002; Banisadr G, 2005, J COMP NEUROL, V492, P178, DOI 10.1002/cne.20729; Banisadr G, 2005, J COMP NEUROL, V489, P275, DOI 10.1002/cne.20598; Benamar K, 2008, J PHARMACOL EXP THER, V325, P641, DOI 10.1124/jpet.107.135053; Chen XH, 2007, DRUG ALCOHOL DEPEN, V88, P36, DOI 10.1016/j.drugalcdep.2006.09.010; Corasaniti M T, 2006, Cell Death Differ, V13, P534, DOI 10.1038/sj.cdd.4401848; Cristino L, 2006, NEUROSCIENCE, V139, P1405, DOI 10.1016/j.neuroscience.2006.02.074; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Wied D, 1991, Methods Achiev Exp Pathol, V15, P167; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Egertova M, 2000, J COMP NEUROL, V422, P159, DOI 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Farquhar-Smith WP, 2000, MOL CELL NEUROSCI, V15, P510, DOI 10.1006/mcne.2000.0844; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Finnerup NB, 2004, EUR J NEUROL, V11, P73, DOI 10.1046/j.1351-5101.2003.00725.x; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Grimsey NL, 2008, J NEUROSCI METH, V171, P78, DOI 10.1016/j.jneumeth.2008.02.014; Hubscher CH, 2006, EXP NEUROL, V197, P177, DOI 10.1016/j.expneurol.2005.09.007; Hulsebosch CE, 2005, CURR PHARM DESIGN, V11, P1411, DOI 10.2174/1381612053507864; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jalalvand E, 2008, NEUROSCIENCE, V157, P446, DOI 10.1016/j.neuroscience.2008.08.052; Jensen MP, 2007, ARCH PHYS MED REHAB, V88, P638, DOI 10.1016/j.apmr.2007.02.002; Katona I, 2001, J NEUROSCI, V21, P9506, DOI 10.1523/JNEUROSCI.21-23-09506.2001; Katona I, 1999, J NEUROSCI, V19, P4544; KAUER JA, 2008, TINS, V32, P215; Kim SR, 2005, J NEUROSCI, V25, P662, DOI 10.1523/JNEUROSCI.4166-04.2005; Knerlich-Lukoschus F, 2008, J NEUROTRAUM, V25, P427, DOI 10.1089/neu.2007.0431; Knerlich-Lukoschus F, 2010, GLIA, V58, P916, DOI 10.1002/glia.20974; KNERLICHLUKOSCH.F, 2010, J NEUROTRAUMA, V27; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Maione S, 2006, J PHARMACOL EXP THER, V316, P969, DOI 10.1124/jpet.105.093286; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Miller RJ, 2008, J NEUROSCI, V28, P11792, DOI 10.1523/JNEUROSCI.3588-08.2008; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; ONAIVI ES, 1990, J PHARMACOL EXP THER, V253, P1002; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pernia-Andrade AJ, 2009, SCIENCE, V325, P760, DOI 10.1126/science.1171870; Pertwee RG, 2001, PROG NEUROBIOL, V63, P569, DOI 10.1016/S0301-0082(00)00031-9; Petrosino S, 2007, NEUROPHARMACOLOGY, V52, P415, DOI 10.1016/j.neuropharm.2006.08.011; Pettit DAD, 1998, J NEUROSCI RES, V51, P391; Roberts JC, 2004, BRAIN RES, V995, P176, DOI 10.1016/j.brainres.2003.10.001; Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467; Rostene W, 2007, NAT REV NEUROSCI, V8, P895, DOI 10.1038/nrn2255; Sagar DR, 2004, EUR J NEUROSCI, V20, P175, DOI 10.1111/j.1460-9568.2004.03481.x; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Szabo I, 2002, P NATL ACAD SCI USA, V99, P10276, DOI 10.1073/pnas.102327699; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Wolf SA, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-12; Zhang HJ, 2005, BRAIN RES, V1055, P103, DOI 10.1016/j.brainres.2005.06.072; Zhang N, 2004, J IMMUNOL, V173, P594, DOI 10.4049/jimmunol.173.1.594; Zhang N, 2005, P NATL ACAD SCI USA, V102, P4536, DOI 10.1073/pnas.0406030102; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhu CZ, 2009, BRIT J PHARMACOL, V157, P645, DOI 10.1111/j.1476-5381.2009.00184.x	60	44	44	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					619	634		10.1089/neu.2010.1652			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200011	21265596				2021-06-18	
J	Vakili, A; Mojarrad, S; Akhavan, MM; Rashidy-Pour, A				Vakili, Abedin; Mojarrad, Somye; Akhavan, Maziar Mohammad; Rashidy-Pour, Ali			Pentoxifylline attenuates TNF-alpha protein levels and brain edema following temporary focal cerebral ischemia in rats	BRAIN RESEARCH			English	Article						Pentoxifylline; Focal cerebral ischemia; Blood-brain barrier permeability; Brain edema; TNF-alpha; Rat	TUMOR-NECROSIS-FACTOR; SPONTANEOUSLY HYPERTENSIVE-RATS; CLOSED-HEAD INJURY; BARRIER PERMEABILITY; BLOOD-FLOW; ARTERY OCCLUSION; TRANSIENT MODEL; INFARCT VOLUME; MACROPHAGES; INHIBITION	Cerebral edema is the most common cause of neurological deterioration and mortality during acute ischemic stroke. Despite the clinical importance of cerebral ischemia, the underlying mechanisms remain poorly understood. Recent studies suggest a role for TNF-alpha in the brain edema formation. To further investigate whether TNF-alpha would play a role in brain edema formation, we examined the effects of pentoxifylline (PTX, an inhibitor of TNF-alpha synthesis) on the brain edema and TNF-alpha levels in a model of transient focal cerebral ischemia. The right middle cerebral artery (MCA) of rats was occluded for 60 min using the intraluminal filament method. The animals received PTX (60 mg/kg) immediately, 1, 3, or 6 h post-ischemic induction. Twenty-four hours after induction of ischemic injury, permeability of the blood-brain barrier (BBB) and brain edema were determined by in situ brain perfusion of Evans Blue (EB) and wet-to-dry weight ratio, respectively. TNF-alpha protein levels in ischemic cortex were also measured at 1, 4, and 24 h after the beginning of an ischemic stroke by using an enzyme-linked immunosorbent assay method. The administration of PTX up to 6 h after occlusion of the MCA significantly reduced the brain edema. Moreover, PTX significantly reduced the concentration of TNF-alpha in ischemic brain cortex up to 4 h post-transient focal stroke (P<0.002). Finally, treatment by PTX led to a significant decrease in EB extravasations (P<0.001). Our data demonstrate that PTX administration up to 6 h after ischemia can reduce brain edema in a model of transient focal cerebral ischemia. The beneficial effects of PTX may be mediated, at least in part, through a decline in TNF-alpha production and BBB breakdown. (C) 2011 Elsevier B.V. All rights reserved.	[Vakili, Abedin; Mojarrad, Somye] Semnan Univ Med Sci, Sch Med, Lab Cerebrovasc Res, Dept Physiol, Semnan, Iran; [Akhavan, Maziar Mohammad] Shahid Beheshti Univ MC, Shohadae Tajrish Hosp, Skin Res Ctr, Lab Prot & Enzyme, Tehran 1989934148, Iran; [Rashidy-Pour, Ali] Semnan Univ Med Sci, Res Ctr Physiol, Lab Learning & Memory, Semnan, Iran; [Rashidy-Pour, Ali] Semnan Univ Med Sci, Dept Physiol, Lab Learning & Memory, Semnan, Iran; [Vakili, Abedin; Mojarrad, Somye] Semnan Univ Med Sci, Sch Med, Lab Cerebrovasc Res, Res Ctr Physiol, Semnan, Iran	Vakili, A (corresponding author), Semnan Univ Med Sci, Sch Med, Lab Cerebrovasc Res, Dept Physiol, Semnan, Iran.	Abvakili@yahoo.com	Rashidy-Pour, Ali/B-5696-2018	Rashidy-Pour, Ali/0000-0001-5006-1408; Vakili, Abedin/0000-0002-4269-9978	Semnan University of Medical Sciences, Semnan, Iran [243]	This work was financially supported (Grant No. 243) by Semnan University of Medical Sciences, Semnan, Iran. We would like to thank Dr. P. Kokhaei for his critical reading of the manuscript.	Bemeur C, 2010, NEUROCHEM INT, V56, P213, DOI 10.1016/j.neuint.2009.11.010; Bhat VB, 2001, BIOCHEM BIOPH RES CO, V288, P1212, DOI 10.1006/bbrc.2001.5922; BOWTON DL, 1989, STROKE, V20, P1662, DOI 10.1161/01.STR.20.12.1662; FUJIMOTO K, 1976, CHEM PHARM BULL, V24, P1137; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Harada H, 2005, BRAIN RES PROTOC, V14, P165, DOI 10.1016/j.brainresprot.2004.12.007; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Hoie EB, 2004, BIOL PHARM BULL, V27, P1670, DOI 10.1248/bpb.27.1670; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Jacoby D, 2004, DRUGS, V64, P1657, DOI 10.2165/00003495-200464150-00004; JOHANSSON BB, 1989, ACTA NEUROL SCAND, V80, P259, DOI 10.1111/j.1600-0404.1989.tb03872.x; JOHANSSON BB, 1986, STROKE, V17, P744, DOI 10.1161/01.STR.17.4.744; KAMBAYASHI T, 1995, J IMMUNOL, V155, P4909; Kimura H, 2003, BRAIN RES, V990, P148, DOI 10.1016/S0006-8993(03)03450-4; Kondo T, 1997, J NEUROSCI, V17, P4180; KUCUK M, 2002, LIFE SCI, V12, P496; LAUTERBACH R, 1995, BIOL NEONATE, V67, P72; Lecrux C, 2007, STROKE, V38, P3007, DOI 10.1161/STROKEAHA.107.491126; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Marcinkiewicz J, 2000, IMMUNOPHARMACOLOGY, V49, P335, DOI 10.1016/S0162-3109(00)00249-6; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; NATAF S, 1993, ACTA NEUROL SCAND, V88, P97; Nekooeian AA, 2005, IRAN J MED SCI, V30, P169; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rao KVR, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-66; ROCCI ML, 1987, PHARMACEUT RES, V4, P433; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SLIVKA A, 1995, STROKE, V26, P1061, DOI 10.1161/01.STR.26.6.1061; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; TOUNG TJK, 1994, CRIT CARE MED, V22, P273, DOI 10.1097/00003246-199402000-00019; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vakili A, 2007, BRAIN RES, V1170, P97, DOI 10.1016/j.brainres.2007.07.016; Vakili A, 2007, BRAIN RES, V1144, P186, DOI 10.1016/j.brainres.2007.01.096; Watkins LR, 2003, ADV EXP MED BIOL, V521, P1; Yang GY, 1999, MOL BRAIN RES, V69, P135, DOI 10.1016/S0169-328X(99)00007-8; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7	44	44	51	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 4	2011	1377						119	125		10.1016/j.brainres.2011.01.001			7	Neurosciences	Neurosciences & Neurology	733YH	WOS:000288299900012	21219888				2021-06-18	
J	Skardelly, M; Gaber, K; Burdack, S; Scheidt, F; Hilbig, H; Boltze, J; Forschler, A; Schwarz, S; Schwarz, J; Meixensberger, J; Schuhmann, MU				Skardelly, Marco; Gaber, Khaled; Burdack, Swen; Scheidt, Franziska; Hilbig, Heidegard; Boltze, Johannes; Foerschler, Annette; Schwarz, Sigrid; Schwarz, Johannes; Meixensberger, Juergen; Schuhmann, Martin U.			Long-Term Benefit of Human Fetal Neuronal Progenitor Cell Transplantation in a Clinically Adapted Model after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessment; central nervous system injury; stem cells; transplantation; traumatic brain injury	MARROW STROMAL CELLS; NEURAL STEM-CELLS; STEM/PROGENITOR CELLS; NEUROTROPHIC FACTORS; ADULT BRAIN; RATS; STROKE; NEUROPROTECTION; CONTUSION; RECOVERY	Experimental human fetal neural progenitor cell (hfNPC) transplantation has proven to be a promising therapeutic approach after traumatic brain injury (TBI). However, the long-term efficacy and safety, which are both highly important for clinical translation of this approach, have thus far not been investigated. This study investigated the effect of local (L, 1 x 10(5) cells) and systemic (S, 5 x 10(5) cells) administration of PKH-26-labeled pre-differentiated hfNPCs over a period of 12 weeks, beginning 24 h after severe controlled cortical impact TBI in Sprague-Dawley rats. Accelerating rotarod testing revealed a trend toward functional improvement beginning 1 week after transplantation, and persisting until the end of the experiment. The traumatic lesion volume as quantified by magnetic resonance imaging was smaller in both treatment groups compared to control (C) animals (C = 54.50 mm(3), L = 32 mm(3), S = 37.50 mm(3)). Correspondingly, neuronal (NeuN) staining showed increased neuronal survival at the border of the lesion in both transplanted groups (S = 92.4%; L = 87.2%; 72.5%). Histological analysis of the brain compartments revealed transiently increased angiogenesis and reduced astroglial reaction during the first 4 weeks post-transplantation. PKH-26-positive cells were detected exclusively after local transplantation without any evidence of tumor formation. However, graft differentiation was seen only in very rare cases. In conclusion, transplantation of hfNPCs improved the long-term functional outcome after TBI, diminished trauma lesion size, and increased neuronal survival in the border zone of the lesion. This therapeutic effect was not likely due to cell replacement, but was associated with transiently increased angiogenesis and reduced astrogliosis.	[Skardelly, Marco; Gaber, Khaled; Burdack, Swen; Scheidt, Franziska; Meixensberger, Juergen; Schuhmann, Martin U.] Univ Leipzig, Dept Neurosurg, Leipzig, Germany; [Hilbig, Heidegard] Univ Leipzig, Inst Anat, Leipzig, Germany; [Foerschler, Annette] Univ Leipzig, Dept Radiol, Leipzig, Germany; [Schwarz, Sigrid; Schwarz, Johannes] Univ Leipzig, Dept Neurol, Leipzig, Germany; [Boltze, Johannes] Fraunhofer Inst Cell Therapy & Immunol IZI Leipzi, Leipzig, Germany	Skardelly, M (corresponding author), Univ Tubingen, Dept Neurosurg, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	marco.skardelly@med.uni-tuebingen.de	Skardelly, Marco/AAF-8680-2021; Forschler, Annette/O-9390-2015	Boltze, Johannes/0000-0003-3956-4164; Forschler, Annette/0000-0001-9665-5228	Free State of Saxony [1-56]	The authors would like to thank Ingo Roeder for statistical support and Jochen Neuhaus for technical support. This work was supported by funds of the Free State of Saxony, distributed by the University of Leipzig (Formel-1-program, 1-56).	Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; [陈东平 Chen DP], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P10160; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gao Q, 2008, NEUROSCIENCE, V152, P646, DOI 10.1016/j.neuroscience.2007.10.069; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schwarting S, 2008, STROKE, V39, P2867, DOI 10.1161/STROKEAHA.108.513978; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith Quentin R, 2003, Methods Mol Med, V89, P193; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	43	44	44	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					401	414		10.1089/neu.2010.1526			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600006	21083415				2021-06-18	
J	Malhotra, A; Minja, FJ; Crum, A; Burrowes, D				Malhotra, Ajay; Minja, Frank J.; Crum, Alison; Burrowes, Delilah			Ocular Anatomy and Cross-Sectional Imaging of the Eye	SEMINARS IN ULTRASOUND CT AND MRI			English	Article							SURFACE COIL; MRI; CT; RETINOBLASTOMA; ARTIFACTS	Ocular cross-sectional imaging is usually obtained as an adjunct to clinical ophthalmologic examination and ocular ultrasound. Computed tomography/magnetic resonance imaging (CT/MRI) are complimentary for ocular imaging and are performed for evaluation of the vitreous cavity, choroid, retina, sclera, and potential spaces and for the assessment of extension of disease beyond the globe into the orbit or brain. CT has superior spatial resolution aided by the natural contrast between bone, soft tissues, air, and fat. The short scanning time is advantageous to reduce motion effects and the need for sedation. CT is also the modality of choice for evaluation of traumatic injury and for visualization of foreign bodies. Potential clinical indications for MRI include staging of retinoblastoma and other causes of leukocoria, assessment of retinal or choroidal detachments for underlying retinal mass or hemorrhage, uveal melanoma, ocular metastases, choroidal hemangioma, and buphthalmus, staphyloma, and coloboma. Last, but not least, MRI has the advantage of no ionizing radiation. Semin Ultrasound CT MRI 32:2-13 (C) 2011 Published by Elsevier Inc.	[Burrowes, Delilah] Childrens Mem Hosp, Dept Med Imaging, Interim Div Head Neuroradiol, Chicago, IL 60614 USA; [Malhotra, Ajay; Minja, Frank J.] Yale Univ, Dept Radiol, Neuroradiol Sect, New Haven, CT USA; [Crum, Alison] Yale Univ, Sch Med, Dept Ophthalmol, New Haven, CT USA	Burrowes, D (corresponding author), Childrens Mem Hosp, Dept Med Imaging, Interim Div Head Neuroradiol, Box 9,2300 Childrens Plaza, Chicago, IL 60614 USA.	dburrowes@childrensmemorial.org	Malhotra, Ajay/ABC-2951-2020				Atlas SW, 1987, CRANIAL COMPUTED TOM; Belden CJ, 1997, SEMIN ULTRASOUND CT, V18, P413, DOI 10.1016/S0887-2171(97)90003-2; Belden Clifford J, 2002, Magn Reson Imaging Clin N Am, V10, P663, DOI 10.1016/S1064-9689(02)00018-1; Berkowitz BA, 2001, MAGN RESON MED, V46, P412, DOI 10.1002/mrm.1206; Bert RJ, 2006, ACAD RADIOL, V13, P368, DOI 10.1016/j.acra.2005.10.023; Cheng HY, 2006, P NATL ACAD SCI USA, V103, P17525, DOI 10.1073/pnas.0605790103; de Graaf P, 2005, RADIOLOGY, V235, P197, DOI 10.1148/radiol.2351031301; DUKEELDER S, 1961, SYSTEM OPHTHALMOLOGY, P605; GEORGOULI T, 2007, EYE LOND ENGL, V22, P994; Hopper KD, 2001, AM J NEURORADIOL, V22, P1194; Kalra MK, 2004, RADIOLOGY, V233, P649, DOI 10.1148/radiol.2333031150; Lemke AJ, 2006, EUR RADIOL, V16, P1084, DOI 10.1007/s00330-005-0087-z; Lemke AJ, 2007, EUR RADIOL, V17, P49, DOI 10.1007/s00330-006-0197-2; Mafee MF, 2005, NEUROIMAG CLIN N AM, V15, pXI, DOI 10.1016/j.nic.2005.04.001; MAFEE MF, 1987, RADIOL CLIN N AM, V25, pR13; MAFEE MF, 1982, RADIOLOGY, V145, P713, DOI 10.1148/radiology.145.3.7146401; Mafee MF, 2005, IMAGING HEAD NECK, P137; Mafee MF, 2003, HEAD NECK IMAGING, P441; McCaffery S, 2002, ARCH OPHTHALMOL-CHIC, V120, P747; Nakashima E, 2006, HEALTH PHYS, V90, P154, DOI 10.1097/01.HP.0000175442.03596.63; Ortiz O, 1998, SEMIN ULTRASOUND CT, V19, P225, DOI 10.1016/S0887-2171(98)90009-9; PARK ML, 1999, OPHTHALMOLOGY; Schueler AO, 2003, BRIT J OPHTHALMOL, V87, P330, DOI 10.1136/bjo.87.3.330; Smith AB, 2007, AM J NEURORADIOL, V28, P1628, DOI 10.3174/ajnr.A0814; Spencer, 1985, OPHTHALMIC PATHOLOGY; Suzuki S, 2010, AM J NEURORADIOL, V31, P822, DOI 10.3174/ajnr.A1946; Townsend KA, 2008, NMR BIOMED, V21, P997, DOI 10.1002/nbm.1247; YEOMAN LJ, 1992, RADIOLOGY, V184, P113, DOI 10.1148/radiology.184.1.1609066; 1991, ANN ICRP, V21, P1	29	44	47	1	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0887-2171	1558-5034		SEMIN ULTRASOUND CT	Semin. Ultrasound CT MRI	FEB	2011	32	1					2	13		10.1053/j.sult.2010.10.009			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	719QR	WOS:000287224000002	21277487				2021-06-18	
J	Denic, A; Macura, SI; Mishra, P; Gamez, JD; Rodriguez, M; Pirko, I				Denic, Aleksandar; Macura, Slobodan I.; Mishra, Prasanna; Gamez, Jeffrey D.; Rodriguez, Moses; Pirko, Istvan			MRI in Rodent Models of Brain Disorders	NEUROTHERAPEUTICS			English	Article						Small animal MRI; mouse model; rodent model; brain disorders; MRI	RAT SPINAL-CORD; MANGANESE-ENHANCED MRI; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MAGNETIC-RESONANCE-SPECTROSCOPY; SUPERPARAMAGNETIC IRON-OXIDE; CEREBRAL ARTERIOVENOUS-MALFORMATIONS; APPARENT DIFFUSION-COEFFICIENT; ALZHEIMERS AMYLOID PLAQUES; MOTOR-NEURON DEGENERATION	Magnetic resonance imaging (MRI) is a well-established tool in clinical practice and research on human neurological disorders. Translational MRI research utilizing rodent models of central nervous system (CNS) diseases is becoming popular with the increased availability of dedicated small animal MRI systems. Projects utilizing this technology typically fall into one of two categories: 1) true "pre-clinical" studies involving the use of MRI as a noninvasive disease monitoring tool which serves as a biomarker for selected aspects of the disease and 2) studies investigating the pathomechanism of known human MRI findings in CNS disease models. Most small animal MRI systems operate at 4.7-11.7 Tesla field strengths. Although the higher field strength clearly results in a higher signal-to-noise ratio, which enables higher resolution acquisition, a variety of artifacts and limitations related to the specific absorption rate represent significant challenges in these experiments. In addition to standard T1-, T2-, and T2*-weighted MRI methods, all of the currently available advanced MRI techniques have been utilized in experimental animals, including diffusion, perfusion, and susceptibility weighted imaging, functional magnetic resonance imaging, chemical shift imaging, heteronuclear imaging, and H-1 or P-31 MR spectroscopy. Selected MRI techniques are also exclusively utilized in experimental research, including manganese-enhanced MRI, and cell-specific/molecular imaging techniques utilizing negative contrast materials. In this review, we describe technical and practical aspects of small animal MRI and provide examples of different MRI techniques in anatomical imaging and tract tracing as well as several models of neurological disorders, including inflammatory, neurodegenerative, vascular, and traumatic brain and spinal cord injury models, and neoplastic diseases.	[Gamez, Jeffrey D.; Rodriguez, Moses; Pirko, Istvan] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Denic, Aleksandar] Mayo Clin, Dept Neurosci, Rochester, MN 55905 USA; [Macura, Slobodan I.; Mishra, Prasanna] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Pirko, I (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	pirko@mayo.edu		Rodriguez, Moses/0000-0001-6328-6497; Denic, Aleksandar/0000-0001-9157-5405			Ahrens ET, 1998, MAGN RESON MED, V40, P119, DOI 10.1002/mrm.1910400117; Anderson SA, 2004, ANN NEUROL, V55, P654, DOI 10.1002/ana.20066; Andjus RK, 2005, ANN NY ACAD SCI, V1048, P10, DOI 10.1196/annals.1342.003; Angenstein F, 2004, NEUROREPORT, V15, P2271, DOI 10.1097/00001756-200410050-00026; Bakshi R, 2001, J NEUROL SCI, V185, P19, DOI 10.1016/S0022-510X(01)00477-4; Barber PA, 2005, NEUROSCI LETT, V388, P54, DOI 10.1016/j.neulet.2005.06.067; Barth M, 2003, INVEST RADIOL, V38, P409, DOI 10.1097/00004424-200307000-00005; Beckmann N, 2000, MAGNET RESON MED, V44, P252, DOI 10.1002/1522-2594(200008)44:2<252::AID-MRM12>3.0.CO;2-G; Bernstein MA, 2006, J MAGN RESON IMAGING, V24, P735, DOI 10.1002/jmri.20698; Bilgen M, 2005, MAGN RESON IMAGING, V23, P829, DOI 10.1016/j.mri.2005.06.004; Bilgen Mehmet, 2006, BMC Med Imaging, V6, P15, DOI 10.1186/1471-2342-6-15; Bock C, 1998, MAGNET RESON MED, V39, P457, DOI 10.1002/mrm.1910390316; Brinker G, 1999, MAGNET RESON MED, V41, P469, DOI 10.1002/(SICI)1522-2594(199903)41:3<469::AID-MRM7>3.0.CO;2-9; Bucher S, 2007, EUR J NEUROSCI, V26, P1895, DOI 10.1111/j.1460-9568.2007.05831.x; Bulte JWM, 2003, MAGN RESON MED, V50, P201, DOI 10.1002/mrm.10511; Bulte JWM, 2004, METHOD ENZYMOL, V386, P275; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Chamberlain R, 2009, MAGN RESON MED, V61, P1158, DOI 10.1002/mrm.21951; Chen JW, 2006, RADIOLOGY, V240, P473, DOI 10.1148/radiol.2402050994; Choi IY, 2003, NEUROCHEM RES, V28, P987, DOI 10.1023/A:1023370104289; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; Dedeoglu A, 2004, BRAIN RES, V1012, P60, DOI 10.1016/j.brainres.2004.02.079; Dhenain M, 2001, DEV BIOL, V232, P458, DOI 10.1006/dbio.2001.0189; Dousset V, 1999, AM J NEURORADIOL, V20, P223; DRAPEAU P, 1984, J PHYSIOL-LONDON, V348, P493, DOI 10.1113/jphysiol.1984.sp015121; Dreher W, 1998, MAGNET RESON MED, V39, P878, DOI 10.1002/mrm.1910390605; Engberink RDO, 2007, RADIOLOGY, V243, P467, DOI 10.1148/radiol.2432060120; Essig M, 2001, RADIOLOGE, V41, P288, DOI 10.1007/s001170050989; Essig M, 1999, MAGN RESON IMAGING, V17, P1417, DOI 10.1016/S0730-725X(99)00084-3; FRAHM J, 1988, MAGNET RESON MED, V6, P474, DOI 10.1002/mrm.1910060412; Fricke ST, 2004, J NEUROSCI METH, V136, P99, DOI 10.1016/j.jneumeth.2004.01.003; Ge YL, 2001, RADIOLOGY, V220, P606, DOI 10.1148/radiol.2203001776; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Gilissen EP, 1998, AM J PRIMATOL, V45, P291, DOI 10.1002/(SICI)1098-2345(1998)45:3<291::AID-AJP5>3.0.CO;2-R; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GYNGELL ML, 1994, ACTA NEUROCHIR, P350; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2006, Z MED PHYS, V16, P237, DOI 10.1078/0939-3889-00321; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hamans BC, 2006, Z MED PHYS, V16, P269, DOI 10.1078/0939-3889-00325; HANSEN G, 1980, RADIOLOGY, V136, P695, DOI 10.1148/radiology.136.3.7403549; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; HEIDE AC, 1993, MAGNET RESON MED, V29, P478, DOI 10.1002/mrm.1910290409; HENNIG J, 1988, MAGN RESON IMAGING, V6, P391, DOI 10.1016/0730-725X(88)90475-4; Hesselbarth D, 1998, NMR BIOMED, V11, P423, DOI 10.1002/(SICI)1099-1492(199812)11:8<423::AID-NBM538>3.0.CO;2-V; Hirakawa K, 1988, Acta Neurochir Suppl (Wien), V43, P140; Hoehn M, 2001, J MAGN RESON IMAGING, V14, P491, DOI 10.1002/jmri.1213; Howe FA, 2001, NMR BIOMED, V14, P497, DOI 10.1002/nbm.716; Hsu EW, 1998, MAGN RESON MED, V40, P421, DOI 10.1002/mrm.1910400312; Hu TCC, 2001, MAGNET RESON MED, V46, P884, DOI 10.1002/mrm.1273.abs; Illanes S, 2010, BRAIN RES, V1320, P135, DOI 10.1016/j.brainres.2010.01.015; Jack CR, 2007, NEUROSCIENTIST, V13, P38, DOI 10.1177/1073858406295610; Jack CR, 2004, MAGN RESON MED, V52, P1263, DOI 10.1002/mrm.20266; Jacobs RE, 1999, COMPUT MED IMAG GRAP, V23, P15, DOI 10.1016/S0895-6111(98)00059-7; Jacobs RE, 2003, NAT CELL BIOL, pSS10, DOI 10.1038/nrm1195; Jost SC, 2009, INT J RADIAT ONCOL, V75, P527, DOI 10.1016/j.ijrobp.2009.06.007; Kannurpatti SS, 2004, BRAIN RES, V1011, P141, DOI 10.1016/j.brainres.2004.02.076; Kato Y, 2006, MAGN RESON MED, V55, P755, DOI 10.1002/mrm.20831; Kato Y, 2010, NEURO-ONCOLOGY, V12, P71, DOI 10.1093/neuonc/nop006; Keen CL, 2000, MET IONS BIOL SYST, V37, P89; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Knight RA, 2008, STROKE, V39, P2596, DOI 10.1161/STROKEAHA.107.506683; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Ladewig G, 2009, EXP NEUROL, V220, P207, DOI 10.1016/j.expneurol.2009.08.027; Lawrence J, 2004, NEUROIMAGE, V22, P1802, DOI 10.1016/j.neuroimage.2004.04.001; Lawrence J, 2008, MAGN RESON IMAGING, V26, P1, DOI 10.1016/j.mri.2007.05.001; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Lee WT, 2004, PROG NEUROBIOL, V72, P87, DOI 10.1016/j.pneurobio.2004.02.002; Lin WL, 1999, JMRI-J MAGN RESON IM, V10, P118, DOI 10.1002/(SICI)1522-2586(199908)10:2<118::AID-JMRI2>3.0.CO;2-V; Lin YJ, 1997, MAGN RESON MED, V38, P378, DOI 10.1002/mrm.1910380305; Lukasik VM, 2003, NMR BIOMED, V16, P459, DOI 10.1002/nbm.836; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MacKenzie-Graham A, 2004, J ANAT, V204, P93, DOI 10.1111/j.1469-7580.2004.00264.x; MacKenzie-Graham A, 2009, NEUROIMAGE, V48, P637, DOI 10.1016/j.neuroimage.2009.06.073; Majcher K, 2006, EXP NEUROL, V197, P458, DOI 10.1016/j.expneurol.2005.10.012; Malisza KL, 2003, J MAGN RESON IMAGING, V18, P152, DOI 10.1002/jmri.10339; Malisza KL, 2002, J MAGN RESON IMAGING, V16, P553, DOI 10.1002/jmri.10185; Malisza KL, 1999, NMR BIOMED, V12, P31, DOI 10.1002/(SICI)1099-1492(199902)12:1<31::AID-NBM544>3.3.CO;2-D; Mandeville JB, 2001, MAGNET RESON MED, V45, P443, DOI 10.1002/1522-2594(200103)45:3<443::AID-MRM1058>3.0.CO;2-3; Mandeville JB, 1998, MAGNET RESON MED, V39, P615, DOI 10.1002/mrm.1910390415; McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; Metz S, 2004, EUR RADIOL, V14, P1851, DOI 10.1007/s00330-004-2405-2; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Niessen HG, 2006, EXP NEUROL, V201, P293, DOI 10.1016/j.expneurol.2006.04.007; ORDIDGE RJ, 1994, MAGNET RESON MED, V32, P335, DOI 10.1002/mrm.1910320309; Pautler RG, 2002, NEUROIMAGE, V16, P441, DOI 10.1006/nimg.2002.1075; Pautler RG, 2003, MAGNET RESON MED, V50, P33, DOI 10.1002/mrm.10498; Pautler RG, 1998, MAGNET RESON MED, V40, P740, DOI 10.1002/mrm.1910400515; Pedrono E, 2010, J NEUROPATH EXP NEUR, V69, P188, DOI 10.1097/NEN.0b013e3181cd331c; Phuong LK, 2003, CANCER RES, V63, P2462; Pirko I, 2004, NEUROIMAGE, V21, P576, DOI 10.1016/j.neuroimage.2003.09.037; Pirko I, 2004, FRONT BIOSCI-LANDMRK, V9, P1222, DOI 10.2741/1322; Pirko I, 2003, CROAT MED J, V44, P463; Pirko I, 2004, FASEB J, V18, P179, DOI 10.1096/fj.02-1124fje; Pirko I, 2004, FASEB J, V18, P1577, DOI 10.1096/fj.04-2026fje; Pirko I, 2008, RADIOLOGY, V246, P790, DOI 10.1148/radiol.2463070338; Pirko Istvan, 2005, NeuroRx, V2, P250, DOI 10.1602/neurorx.2.2.250; Pirko I, 2009, J NEUROL SCI, V282, P34, DOI 10.1016/j.jns.2008.12.013; Pirko I, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-31; Poduslo JF, 2004, BIOCHEMISTRY-US, V43, P6064, DOI 10.1021/bi0359574; Poduslo JF, 2002, NEUROBIOL DIS, V11, P315, DOI 10.1006/nbdi.2002.0550; Querol M, 2006, J MAGN RESON IMAGING, V24, P971, DOI 10.1002/jmri.20724; Raghunand Natarajan, 2006, Methods Mol Med, V124, P347; Raineteau O, 2002, EUR J NEUROSCI, V16, P1761, DOI 10.1046/j.1460-9568.2002.02243.x; Rausch M, 2003, MAGNET RESON MED, V50, P309, DOI 10.1002/mrm.10541; Reichenbach JR, 2001, NEURORADIOLOGY, V43, P364, DOI 10.1007/s002340000503; Reichenbach JR, 2000, J COMPUT ASSIST TOMO, V24, P949, DOI 10.1097/00004728-200011000-00023; Robb RA, 2002, ST HEAL T, V85, P1; Robb RA, 1999, ANNU REV BIOMED ENG, V1, P377, DOI 10.1146/annurev.bioeng.1.1.377; Robinson KM, 2010, MOL IMAGING BIOL, V12, P240, DOI 10.1007/s11307-009-0272-6; Rosenzweig ES, 2004, CURR OPIN NEUROL, V17, P121, DOI 10.1097/00019052-200404000-00007; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schwarcz A, 2003, MAGNET RESON MED, V49, P822, DOI 10.1002/mrm.10445; Shapiro EM, 2005, MAGNET RESON MED, V53, P329, DOI 10.1002/mrm.20342; STARK DD, 1988, RADIOLOGY, V168, P297, DOI 10.1148/radiology.168.2.3393649; Stieltjes B, 2006, MAGN RESON MED, V55, P1124, DOI 10.1002/mrm.20888; Stoffel M, 2004, J NEUROTRAUM, V21, P733, DOI 10.1089/0897715041269678; Suidan GL, 2006, NEUROL RES, V28, P250, DOI 10.1179/016164106X98116; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tan IL, 2000, AM J NEURORADIOL, V21, P1039; Tatlisumak Turgut, 2004, Current Vascular Pharmacology, V2, P343, DOI 10.2174/1570161043385493; Thorek DLJ, 2008, BIOMATERIALS, V29, P3583, DOI 10.1016/j.biomaterials.2008.05.015; Thu MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007218; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tsai EC, 2001, J HISTOCHEM CYTOCHEM, V49, P1111, DOI 10.1177/002215540104900905; Turner R, 1998, EXP BRAIN RES, V123, P5, DOI 10.1007/s002210050538; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; WEISSLEDER R, 1988, RADIOLOGY, V169, P399, DOI 10.1148/radiology.169.2.3174987; WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474; Wilson JMB, 2004, NEUROIMAGE, V23, P336, DOI 10.1016/j.neuroimage.2004.05.026; Wu EX, 2003, MAGNET RESON MED, V49, P765, DOI 10.1002/mrm.10425; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Wu QZ, 2007, NEUROIMAGE, V37, P1138, DOI 10.1016/j.neuroimage.2007.06.029; Xu JQ, 2008, NMR BIOMED, V21, P928, DOI 10.1002/nbm.1307; Xu S, 1998, J NEUROSCI RES, V52, P549, DOI 10.1002/(SICI)1097-4547(19980601)52:5<549::AID-JNR7>3.0.CO;2-C; Xue R, 1999, MAGNET RESON MED, V42, P1123, DOI 10.1002/(SICI)1522-2594(199912)42:6<1123::AID-MRM17>3.0.CO;2-H; Yang J, 2007, P ANN INT IEEE EMBS, P51, DOI 10.1109/IEMBS.2007.4352220; Yang QX, 1998, MAGNET RESON MED, V39, P402, DOI 10.1002/mrm.1910390310; Yang QX, 1999, MAGNET RESON MED, V41, P423, DOI 10.1002/(SICI)1522-2594(199902)41:2<423::AID-MRM30>3.0.CO;2-M; Zaaraoui W, 2008, MAGN RESON MATER PHY, V21, P357, DOI 10.1007/s10334-008-0141-3; Zang DW, 2004, EUR J NEUROSCI, V20, P1745, DOI 10.1111/j.1460-9568.2004.03648.x; Zhang J, 2004, MAGN RESON MED, V51, P452, DOI 10.1002/mrm.10730	147	44	45	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2011	8	1					3	18		10.1007/s13311-010-0002-4			16	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	750RU	WOS:000289566500003	21274681	Green Published, Bronze			2021-06-18	
S	Gieling, ET; Schuurman, T; Nordquist, RE; van der Staay, FJ		Hagan, JJ		Gieling, Elise T.; Schuurman, Teun; Nordquist, Rebecca E.; van der Staay, F. Josef			The Pig as a Model Animal for Studying Cognition and Neurobehavioral Disorders	MOLECULAR AND FUNCTIONAL MODELS IN NEUROPSYCHIATRY	Current Topics in Behavioral Neurosciences		English	Article; Book Chapter						Animal model; Dementia; Depression - Psychosis; Eating disorders; Magnetic resonance imaging; Neurodegenerative diseases; Pig (Sus scrofa); Positron emission tomography (PET); Translational research	ONE-TRIAL TEST; OXIDE SYNTHASE INHIBITION; CEREBRAL HYPOXIA-ISCHEMIA; TRAUMATIC BRAIN-INJURY; DOMESTIC PIGS; NEWBORN PIGLET; MINIATURE PIG; IN-VIVO; ENVIRONMENTAL ENRICHMENT; BEHAVIORAL-RESPONSE	In experimental animal research, a short phylogenetic distance, i.e., high resemblance between the model species and the species to be modeled is expected to increase the relevance and generalizability of results obtained in the model species. The (mini)pig shows multiple advantageous characteristics that have led to an increase in the use of this species in studies modeling human medical issues, including neurobehavioral (dys)functions. For example, the cerebral cortex of pigs, unlike that of mice or rats, has cerebral convolutions (gyri and sulci) similar to the human neocortex. We expect that appropriately chosen pig models will yield results of high translational value. However, this claim still needs to be substantiated by research, and the area of pig research is still in its infancy. This chapter provides an overview of the pig as a model species for studying cognitive dysfunctions and neurobehavioral disorders and their treatment, along with a discussion of the pros and cons of various tests, as an aid to researchers considering the use of pigs as model animal species in biomedical research.	[Schuurman, Teun] Univ Wageningen & Res Ctr, NL-8200 AB Lelystad, Netherlands; [Gieling, Elise T.; Nordquist, Rebecca E.; van der Staay, F. Josef] Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands; [Gieling, Elise T.; Nordquist, Rebecca E.; van der Staay, F. Josef] Univ Utrecht, Fac Vet, Dept Farm Anim Hlth, Program Emot & Cognit, NL-3508 TD Utrecht, Netherlands	Schuurman, T (corresponding author), Univ Wageningen & Res Ctr, POB 65, NL-8200 AB Lelystad, Netherlands.	Teun.Schuurman@wur.nl	Nordquist, Rebecca E./B-7455-2013; Dilger, Ryan N./E-7031-2010	Nordquist, Rebecca E./0000-0002-8541-5285; Dilger, Ryan N./0000-0003-2538-2845; van der Staay, F. Josef/0000-0002-8704-3366			Aigner B, 2010, J MOL MED, V88, P653, DOI 10.1007/s00109-010-0610-9; Alisky JM, 2006, MED HYPOTHESES, V67, P556, DOI 10.1016/j.mehy.2006.02.043; Alvarez FJ, 2008, PEDIATR RES, V64, P653, DOI 10.1203/PDR.0b013e318186e5dd; Amaral AJ, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-374; Arts JWM, 2009, BEHAV BRAIN RES, V205, P303, DOI 10.1016/j.bbr.2009.06.014; BAILEY J, 2005, BIOGENIC AMINES, V9, P235; BALDWIN BA, 1971, PHYSIOL BEHAV, V10, P267; Bardin L, 2007, BEHAV PHARMACOL, V18, P103, DOI 10.1097/FBP.0b013e3280ae6c96; BARNES RH, 1969, J NUTR, V100, P149; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015; Branchi I, 2003, NEUROSCI BIOBEHAV R, V27, P141, DOI 10.1016/S0149-7634(03)00016-2; Broom DM, 2009, ANIM BEHAV, V78, P1037, DOI 10.1016/j.anbehav.2009.07.027; Brust P, 2003, SYNAPSE, V47, P143, DOI 10.1002/syn.10163; Brust P, 2008, SYNAPSE, V62, P205, DOI 10.1002/syn.20480; Burke C, 2006, BRAIN RES, V1098, P19, DOI 10.1016/j.brainres.2006.04.129; Cady EB, 2008, J NEUROCHEM, V107, P1027, DOI 10.1111/j.1471-4159.2008.05662.x; CHAPUT RL, 1973, LAB ANIM SCI, V23, P711; Chen KF, 2007, INT J BIOL SCI, V3, P153; Cheng Y, 2005, POSTGRAD MED J, V81, P589, DOI 10.1136/pgmj.2004.030114; Cocchi M, 2009, ITAL J ANIM SCI, V8, P691, DOI 10.4081/ijas.2009.691; Croney CC, 2003, APPL ANIM BEHAV SCI, V83, P303, DOI 10.1016/S0168-1591(03)00128-X; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; DALKRATZ.D, 1969, J ANIM SCI, V28, P175; Danielsen EH, 2001, J NEUROSCI METH, V111, P157, DOI 10.1016/S0165-0270(01)00453-8; de Jong IC, 2000, PHYSIOL BEHAV, V68, P571, DOI 10.1016/S0031-9384(99)00212-7; DEGROOT J, 2005, PERINATAL PROGRAMMIN; Dirnagl U, 2006, J CEREBR BLOOD F MET, V26, P1465, DOI 10.1038/sj.jcbfm.9600298; Duhaime AC, 2006, J NEUROSURG, V104, P259, DOI 10.3171/ped.2006.104.4.259; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; ENNACEUR A, 1989, BEHAV BRAIN RES, V33, P197, DOI 10.1016/S0166-4328(89)80051-8; ENNACEUR A, 1992, BEHAV BRAIN RES, V51, P83, DOI 10.1016/S0166-4328(05)80315-8; Ettrup A, 2009, J NUCL MED, V50; Fang MR, 2005, NEUROSIGNALS, V14, P222, DOI 10.1159/000088638; Ferguson SA, 2009, BEHAV PROCESS, V80, P28, DOI 10.1016/j.beproc.2008.08.006; Festing MFW, 2006, ILAR J, V47, P5, DOI 10.1093/ilar.47.1.5; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Gad Shayne C., 2007, P1; GIFFORD AK, 2005, THESIS WASHINGTON ST; Gifford AK, 2007, APPL ANIM BEHAV SCI, V107, P206, DOI 10.1016/j.applanim.2006.10.019; Gizewski ER, 2007, RES VET SCI, V82, P281, DOI 10.1016/j.rvsc.2006.08.004; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; Hagl C, 2005, ANN THORAC SURG, V79, P1307, DOI 10.1016/j.athoracsur.2004.05.067; HAMMELL DL, 1975, J ANIM SCI, V40, P573; Held S, 2005, ANIM COGN, V8, P114, DOI 10.1007/s10071-004-0242-y; Held S, 2001, BEHAVIOUR, V138, P1337, DOI 10.1163/156853901317367627; Held S, 2000, ANIM BEHAV, V59, P569, DOI 10.1006/anbe.1999.1322; HOLMES PV, 2003, CRIT REV NEUROBIOL, V15, P142; HOLTZ W, 2010, UFAW HDB CARE MANAGE; Hoyer D, 2007, CURR OPIN DRUG DISC, V10, P122; *INT ORG STAND, 2002, 109934 ISO; Iwata O, 2008, BRAIN, V131, P2220, DOI 10.1093/brain/awn150; Kaandorp JJ, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-8; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P789, DOI 10.1001/archpsyc.60.8.789; KENNEDY JM, 1972, ANIM BEHAV, V20, P706, DOI 10.1016/S0003-3472(72)80142-8; Klymiuk N, 2010, MOL REPROD DEV, V77, P209, DOI 10.1002/mrd.21127; KOOPMANS SJ, 2009, J DIABETES, V1, pA236; Kornum BR, 2007, BEHAV BRAIN RES, V181, P210, DOI 10.1016/j.bbr.2007.04.007; KORNUM BR, 2007, J CEREB BLOOD FLOW M, V29, P186; Kragh PM, 2009, TRANSGENIC RES, V18, P545, DOI 10.1007/s11248-009-9245-4; KRATZER DD, 1971, J ANIM SCI, V32, P1268; Kristensen HH, 2001, APPL ANIM BEHAV SCI, V72, P321, DOI 10.1016/S0168-1591(00)00209-4; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Laughlin K, 2000, ANIM BEHAV, V60, P403, DOI 10.1006/anbe.2000.1468; Laughlin K, 1999, APPL ANIM BEHAV SCI, V64, P169, DOI 10.1016/S0168-1591(99)00036-2; LEFFLER CW, 1989, AM J PHYSIOL, V257, pH1917; Lind NM, 2007, NEUROSCI BIOBEHAV R, V31, P728, DOI 10.1016/j.neubiorev.2007.02.003; Lind NM, 2005, SCAND J LAB ANIM SCI, V32, P103; Lind NM, 2005, BRAIN RES BULL, V65, P1, DOI 10.1016/j.brainresbull.2004.08.007; Lind NM, 2004, BEHAV BRAIN RES, V155, P217, DOI 10.1016/j.bbr.2004.04.014; Lunney JK, 2007, INT J BIOL SCI, V3, P179, DOI 10.7150/ijbs.3.179; Lyng K, 2006, J PERINAT MED, V34, P226, DOI 10.1515/JPM.2006.041; McGoron Anthony J, 2008, BMC Med Imaging, V8, P4, DOI 10.1186/1471-2342-8-4; McLeman MA, 2005, ANIM BEHAV, V70, P451, DOI 10.1016/j.anbehav.2004.11.013; Mendl M, 1997, ANIM BEHAV, V54, P1491, DOI 10.1006/anbe.1997.0564; Miller I, 2009, RES VET SCI, V86, P362, DOI 10.1016/j.rvsc.2008.05.018; Mortensen JT, 1998, SCAND J LAB ANIM SCI, V25, P77; Moustgaard A, 2005, BEHAV PROCESS, V68, P97, DOI 10.1016/j.beproc.2004.11.002; Moustgaard A, 2004, BEHAV PROCESS, V67, P27, DOI 10.1016/j.beproc.2004.02.002; Moustgaard Anette, 2002, Neural Plasticity, V9, P255, DOI 10.1155/NP.2002.255; Moxon-Lester L, 2007, BRAIN RES, V1179, P79, DOI 10.1016/j.brainres.2007.08.037; Munkeby BH, 2008, ACTA RADIOL, V49, P1049, DOI 10.1080/02841850802334224; Nielsen TR, 2009, BEHAV BRAIN RES, V196, P93, DOI 10.1016/j.bbr.2008.07.019; Niemann H, 2007, REPROD FERT DEVELOP, V19, P762, DOI 10.1071/RD07040; NOBLE M, 1963, J COMP PHYSIOL PSYCH, V56, P215, DOI 10.1037/h0047616; Nordquist RE, 2008, BEHAV PHARMACOL, V19, P518, DOI 10.1097/FBP.0b013e32830cd7f5; Nunoya T., 2007, J TOXICOL PATHOL, V20, P125, DOI [10.1293/tox.20.125, DOI 10.1293/TOX.20.125]; O'Brien FE, 2006, PEDIATRICS, V117, P1549, DOI 10.1542/peds.2005-1649; ODDEN JP, 1989, ACTA PAEDIATR SCAND, P13; Passchier J, 2010, SYNAPSE, V64, P542, DOI 10.1002/syn.20760; Patt JT, 2001, NUCL MED BIOL, V28, P645, DOI 10.1016/S0969-8051(01)00225-6; Patt JT, 1999, NUCL MED BIOL, V26, P165, DOI 10.1016/S0969-8051(98)00084-5; PATT JT, 2005, J LABEL COMP RADIOPH, V48; Peacock L, 1999, NEUROPSYCHOPHARMACOL, V20, P35, DOI 10.1016/S0893-133X(98)00049-9; Peacock L, 1999, PSYCHOPHARMACOLOGY, V144, P189, DOI 10.1007/s002130050993; Peeters-Scholte C, 2002, DEV NEUROSCI-BASEL, V24, P396, DOI 10.1159/000069045; Peeters-Scholte C, 2003, PEDIATR RES, V54, P516, DOI 10.1203/01.PDR.0000081297.53793.C6; Peeters-Scholte C, 2002, STROKE, V33, P2304, DOI 10.1161/01.STR.0000028343.25901.09; Peeters-Scholte C, 2002, EXP BRAIN RES, V147, P200, DOI 10.1007/s00221-002-1182-x; Petersen B, 2009, COMP IMMUNOL MICROB, V32, P91, DOI 10.1016/j.cimid.2007.11.014; Plisson C, 2009, J NUCL MED, V50, P2064, DOI 10.2967/jnumed.109.062919; Prather RS, 2008, BIOTECHNOL GENET ENG, V25, P245; Ramos AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006524; Reynolds LP, 2009, J ANIM SCI, V87, P4181, DOI 10.2527/jas.2009-2102; Roberts RM, 2009, SCIENCE, V324, P468, DOI 10.1126/science.1168521; Robertson NJ, 2007, EARLY HUM DEV, V83, P801, DOI 10.1016/j.earlhumdev.2007.09.015; Rollin BE, 2006, THEOR MED BIOETH, V27, P285, DOI 10.1007/s11017-006-9007-8; Sachs DH, 2009, CURR OPIN ORGAN TRAN, V14, P148, DOI 10.1097/MOT.0b013e3283292549; Salahpour A, 2007, BIOL PSYCHIAT, V61, P65, DOI 10.1016/j.biopsych.2006.03.020; Sauleau P, 2009, ANIMAL, V3, P1138, DOI 10.1017/S1751731109004649; Schook L, 2005, ANIM BIOTECHNOL, V16, P183, DOI 10.1080/10495390500265034; Siegford JM, 2008, APPL ANIM BEHAV SCI, V110, P189, DOI 10.1016/j.applanim.2007.03.022; Sik A, 2003, BEHAV BRAIN RES, V147, P49, DOI 10.1016/S0166-4328(03)00117-7; SKOLD BH, 1966, AM J VET RES, V27, P257; Sneddon IA, 2000, ANIM WELFARE, V9, P373; Souza AS, 2006, APPL ANIM BEHAV SCI, V99, P77, DOI 10.1016/j.applanim.2005.09.008; Spinka M, 1998, APPL ANIM BEHAV SCI, V58, P221, DOI 10.1016/S0168-1591(98)00109-9; Swindle MM, 1998, SCAND J LAB ANIM SCI, V25, P11; Tuggle CK, 2007, INT J BIOL SCI, V3, P132; van der Beek EM, 2004, HIPPOCAMPUS, V14, P688, DOI 10.1002/hipo.10213; Van der Staay FJ, 2007, J VET PHARMACOL THER, V30, P410, DOI 10.1111/j.1365-2885.2007.00884.x; van der Staay FJ, 2006, BRAIN RES REV, V52, P131, DOI 10.1016/j.brainresrev.2006.01.006; van der Staay FJ, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-11; van der Staay FJ, 2010, PHYSIOL BEHAV, V100, P154, DOI 10.1016/j.physbeh.2010.02.020; van der Staay FJ, 2009, PSYCHOPHARMACOLOGY, V206, P715, DOI 10.1007/s00213-009-1599-z; van der Stalay FJ, 2008, PHYSIOL BEHAV, V93, P453, DOI 10.1016/j.physbeh.2007.10.002; van Dijk AJ, 2008, THERIOGENOLOGY, V70, P662, DOI 10.1016/j.theriogenology.2008.04.044; VANDERMEULEN J, 2009, J DIABETES, V1, pA247; Vial F, 2004, MAGN RESON IMAGING, V22, P457, DOI 10.1016/j.mri.2004.01.036; Vodicka P, 2005, ANN NY ACAD SCI, V1049, P161, DOI 10.1196/annals.1334.015; Wainwright PE, 2006, AM J CLIN NUTR, V84, P961; Wang B, 2007, AM J CLIN NUTR, V85, P561; Webster J, 2010, J PHARMACOL TOX MET, V62, P160, DOI 10.1016/j.vascn.2010.05.002; Wheeler MB, 2001, THERIOGENOLOGY, V56, P1345, DOI 10.1016/S0093-691X(01)00635-5; Winter JD, 2009, PEDIATR RES, V65, P181, DOI 10.1203/PDR.0b013e31818f06fb; Witkamp RF, 1998, SCAND J LAB ANIM SCI, V25, P45	139	44	44	0	8	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	1866-3370		978-3-642-19702-4	CURR TOP BEHAV NEURO	Cur. Top. Behav. Neurosci.		2011	7						359	383		10.1007/7854_2010_112	10.1007/978-3-642-19703-1		25	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BVF17	WOS:000291364600012	21287323				2021-06-18	
J	Gould, KR; Ponsford, JL; Johnston, L; Schonberger, M				Gould, Kate Rachel; Ponsford, Jennie Louise; Johnston, Lisa; Schoenberger, Michael			Relationship Between Psychiatric Disorders and 1-Year Psychosocial Outcome Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety disorders; brain injuries; craniocerebral trauma; depression; mental disorders; neuropsychology; outcome; psychosocial; substance-related disorders	SEVERE HEAD-INJURY; MAJOR DEPRESSION; ACUTE PREDICTORS; CHRONIC PAIN; MODERATE; SEVERITY; RETURN; ASSOCIATION; IMPAIRMENT; DISABILITY	Objective: To investigate the relationship of psychiatric functioning with psychosocial functioning at 1 year following traumatic brain injury (TBI), after controlling for relevant demographic, injury-related, and concurrent factors. Design: Prospective 1-year longitudinal study. Participants: Participants were 122 individuals with TBI and 88 proxy informants. Setting: Rehabilitation hospital. MainMeasures: The Structured Clinical Interview for DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders [Fourth Edition, Text Revision]) Axis I Disorders, Hospital Anxiety and Depression Scale, Sydney Psychosocial Reintegration Scale, and Glasgow Outcome Scale-Extended. Results: At 1 year postinjury, occupational activities were the area of most change after TBI followed by interpersonal relationships and independent living skills, according to the Sydney Psychosocial Reintegration Scale. The majority of participants were rated as having moderate disability on the Glasgow Outcome Scale-Extended. After controlling for relevant background factors, preinjury, acute postinjury, and concurrent psychiatric disorders were significantly related to 1-year psychosocial outcome. Conclusion: Screening in the acute postinjury stage for presence of preinjury psychiatric history or current distress may help identify individuals who require more intensive rehabilitation and psychiatric support and more active postdischarge monitoring. Further research exploring potential causal mechanisms for these findings is required.	[Gould, Kate Rachel; Ponsford, Jennie Louise; Johnston, Lisa; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Gould, Kate Rachel; Ponsford, Jennie Louise; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie Louise] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Gould, Kate/AAA-5511-2020	Gould, Kate/0000-0002-3564-7408	Victorian Neurotrauma Initiative	The authors thank the Victorian Neurotrauma Initiative for their support.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Army Individual Test Battery, 1944, MAN DIR SCOR; BABOR TF, 2001, WHOMSDMSB016A DEP ME; BARNETT PA, 1988, PSYCHOL BULL, V104, P97, DOI 10.1037/0033-2909.104.1.97; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; First MB., 2002, STRUCTURED CLIN INTE; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; FREDENBERG E, 1997, COPING SCALE ADULTS; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gould K, 2010, BRAIN INJURY, V24, P337; Gould K, NATURE FREQUEN UNPUB; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hillier SL, 1997, BRAIN INJURY, V11, P661; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kervick RB, 2005, BRAIN INJURY, V19, P881, DOI 10.1080/02699050400025273; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kim JA, 1997, OCCUPATIONAL THERAPY, V4, P180; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nelson HE, 1982, NATL ADULT READING T; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Snaith R.P., 1994, HADS HOSP ANXIETY DE; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	80	44	45	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					79	89		10.1097/HTR.0b013e3182036799			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200008	21209565				2021-06-18	
J	Saljo, A; Mayorga, M; Bolouri, H; Svensson, B; Hamberger, A				Saljo, Annette; Mayorga, Maria; Bolouri, Hayde; Svensson, Berndt; Hamberger, Anders			Mechanisms and pathophysiology of the low-level blast brain injury in animal models	NEUROIMAGE			English	Article						Blast overpressure; Brain injury; Brain edema; Cognitive function; Intracranial pressure; Shock tube	ADULT-RAT BRAIN; IMPULSE NOISE EXPOSURE; CLOSED-HEAD INJURY; INTRACRANIAL-PRESSURE; IMPEDANCE; EDEMA; EXPRESSION; APOPTOSIS; ISCHEMIA; INCREASE	The symptoms of primary blast-induced mTBI, posttraumatic stress disorder and depression overlap. Evidence of an organic basis for these entities has been scarce and controversial. We present a review of animal studies demonstrating that low-level blast causes pathophysiological and functional changes in the brain. We monitor a time period from minutes to approximately 1 week after blast exposure from multiple modes (air, underwater, localized and whole body). The most salient findings observed were (1) the peak pressures (P-max) in the brain, elicited from the blast from the firing of military weapons (P-max 23-45 kPa), have a similar magnitude as that registered in air close to the head. Corresponding measurements during the detonation pulse from explosives under water show a Pmax in the brain, which is only 10% of that in water outside the head. (2) The rise time of the pressure curve is 10 times longer in the brain as compared with the blast in air outside the head during firing of military weapons. (3) The lower frequencies in the blast wave appear to be transmitted more readily to the brain than the higher frequencies. (4) When animals are exposed to low levels of blast, the blast wave appears mostly transmitted directly to the brain during air exposure, not via the thorax or abdomen. (5) Low levels of blast cause brain edema, as indicated by increased bioelectrical impedance, an increase in the intracranial pressure, small brain hemorrhages and impaired cognitive function. Published by Elsevier Inc.	[Saljo, Annette] Univ Gothenburg, Sahlgren Acad, Sect Med Chem & Cell Biol, Inst Biomed,Dept Med Chem & Cell Biol, SE-40530 Gothenburg, Sweden	Saljo, A (corresponding author), Univ Gothenburg, Sahlgren Acad, Sect Med Chem & Cell Biol, Inst Biomed,Dept Med Chem & Cell Biol, POB 440, SE-40530 Gothenburg, Sweden.	annette.saljo@gu.se			Swedish Armed Forces/FMV; Svenska Militarlakareforeningen	The authors want to express their gratitude to Svante Hojer, Samba Sensors AB, Vastra Frolunda, Sweden, for sharing with us his knowledge on pressure sensors and pressure recording. We also thank Torsten Olsson, professor emeritus, Department of Signals and Systems, Chalmers University of Technology, Goteborg, Sweden, for introducing us into the field of electrical impedance and for carrying out experiments with us. The study was supported by grants from the Swedish Armed Forces/FMV and by Svenska Militarlakareforeningen.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ASCHAN, 1954, MED UNDERSOKNINGAR N; CELANDER H, 1954, USE COMPRESSED AIR O; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; CHAVKO M, 2009, TRANSFER ENERGY INSI; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON C J, 1951, Sven Lakartidn, V48, P1337; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; CLEMEDSON CJ, 1954, J APPL PHYSIOL, V7, P38; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Gerhardt KJ, 2000, MIL MED, V165, P153; Harting MT, 2010, J SURG RES, V159, P557, DOI 10.1016/j.jss.2008.10.014; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; KLEIN HC, 1993, NEUROPATH APPL NEURO, V19, P57, DOI 10.1111/j.1365-2990.1993.tb00405.x; Lingwood BE, 2003, BRAIN RES, V969, P160, DOI 10.1016/S0006-8993(03)02295-9; MOBERG AS, 2001, THESIS U GOTHENBURG; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; MOORE DF, 2008, BLAST PHYS CENTRAL N, P243; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsson T, 2006, NEUROSCIENCE, V140, P505, DOI 10.1016/j.neuroscience.2006.02.034; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; TERANISHI K, 2009, BLAST INDUCED NEUROP; VANDEVORD P, 2009, INT STAT SCI M NO IM; VERHEUL B, 1994, NMR BIOMED, V7, P96, DOI 10.1002/nbm.1940070115; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Vink R, 2003, ACT NEUR S, V86, P257; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLIAMS CE, 1991, STROKE, V22, P516, DOI 10.1161/01.STR.22.4.516	40	44	44	1	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S83	S88		10.1016/j.neuroimage.2010.05.050			6	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600012	20580846				2021-06-18	
J	Maric, NP; Doknic, M; Pavlovic, D; Pekic, S; Stojanovic, M; Jasovic-Gasic, M; Popovic, V				Maric, N. P.; Doknic, M.; Pavlovic, D.; Pekic, S.; Stojanovic, M.; Jasovic-Gasic, M.; Popovic, V.			Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						Traumatic brain injury; GH deficiency; GH therapy; psychiatric symptoms; depression	ADULTS; SUBSTITUTION; REPLACEMENT; OUTCOMES; MEMORY	Objective: Traumatic brain injury (TBI) has been recently recognized as a risk factor for cognitive impairment and hypopituitarism, presented most frequently with GH deficiency (GHD). GHD is associated not only with changes in body composition, but also with impaired quality of life, cognitive dysfunctions and some psychiatric sequelae, usually classified as "depression" or "atypical depression". The impact of GH therapy on mental status in TBI patients is still unknown. Design: Psychiatric and cognitive functions were tested in 6 GHD patients at baseline (minimum 3 yr after TBI), reassessed after 6 months of GH therapy as well as 12 months after discontinuation of GH therapy. Psychiatric and cognitive examinations included semi-structured interviews and 3 instruments: Symptom-checklist (SCL-90-R), Zung Depression Inventory, and standard composite neuropsychological battery. Results: Six months of GH therapy in GHD TBI patients improved cognitive abilities (particularly verbal and non-verbal memory) and significantly improved psychiatric functioning. Severity of depression decreased, as well as intensity of interpersonal sensitivity, hostility, paranoid ideation, anxiety, and psychoticism. Somatization, obsessive-compulsive symptoms and phobic anxiety decreased in all except in one patient. In 3 GHD patients who stopped GH therapy for 12 months we registered worsening of the verbal and non-verbal memory, as well symptoms in 3 SCL dimensions: inter-personal sensitivity, anxiety, and paranoid ideation. Conclusion: GH-deficient TBI patients are depressed and have cognitive impairment. GH therapy induced reduction of depression, social dysfunction, and certain cognitive domains. Our preliminary data support the necessity of conducting randomized placebo-controlled trials on the effects of GH therapy on neuropsychological and psychiatric status in GHD TBI patients. (J. Endocrinol. Invest. 33: 770-775, 2010) (C) 2010, Editrice Kurtis	[Maric, N. P.; Jasovic-Gasic, M.] Univ Clin Ctr Belgrade, Inst Psychiat, Belgrade, Serbia; [Maric, N. P.; Doknic, M.; Pavlovic, D.; Pekic, S.; Jasovic-Gasic, M.; Popovic, V.] Univ Belgrade, Sch Med, Belgrade, Serbia; [Doknic, M.; Pekic, S.; Stojanovic, M.; Popovic, V.] Inst Endocrinol Diabet & Metab Dis, Belgrade, Serbia; [Pavlovic, D.] Univ Clin Ctr Belgrade, Inst Neurol, Belgrade, Serbia	Maric, NP (corresponding author), UCC, Inst Psychiat, Pasterova 2, Belgrade 11000, Serbia.	nadjamaric@yahoo.com	Pekic, Sandra/S-7175-2016; Maric, Nadja/AAP-2722-2020	Maric, Nadja/0000-0002-7051-853X	Ministry of Science of Republic of SerbiaMinistry of Science, Serbia [145019]	This study was supported by a grant from the Ministry of Science of Republic of Serbia (Project 145019).	ADEM A, 1989, BRAIN RES, V503, P299, DOI 10.1016/0006-8993(89)91678-8; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Bonne O, 2008, J CLIN PSYCHIAT, V69, P1087, DOI 10.4088/JCP.v69n0707; Clayton P, 2007, GROWTH HORM IGF RES, V17, P369, DOI 10.1016/j.ghir.2007.04.010; Creyghton Wouter M, 2004, Semin Vasc Med, V4, P167, DOI 10.1055/s-2004-835375; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heaton R., 1981, MANUAL WISCONSIN CAR; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Huisman J, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-25; JOHANSSON JO, 1995, NEUROENDOCRINOLOGY, V61, P57, DOI 10.1159/000126813; Kaplan E, 1978, BOSTON NAMING TEST; Lasaite Lina, 2004, Medicina (Kaunas), V40, P740; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069; Nilsson AG, 2007, GROWTH HORM IGF RES, V17, P441, DOI 10.1016/j.ghir.2007.05.005; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Ranganath C, 2005, HIPPOCAMPUS, V15, P997, DOI 10.1002/hipo.20141; Rey A, 1964, EXAMEN CLIN PSYCHOL; Schneider HJ, 2003, EUR J ENDOCRINOL, V149, P377, DOI 10.1530/eje.0.1490377; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Wolfson D., 1993, HALSTEAD REITAN NEUR; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	29	44	46	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0391-4097	1720-8386		J ENDOCRINOL INVEST	J. Endocrinol. Invest.	DEC	2010	33	11					770	775		10.1007/BF03350340			6	Endocrinology & Metabolism	Endocrinology & Metabolism	727HD	WOS:000287787900001	20479569				2021-06-18	
J	Salonia, R; Empey, PE; Poloyac, SM; Wisniewski, SR; Klamerus, M; Ozawa, H; Wagner, AK; Ruppel, R; Bell, MJ; Feldman, K; Adelson, PD; Clark, RSB; Kochanek, PM				Salonia, Rosanne; Empey, Philip E.; Poloyac, Samuel M.; Wisniewski, Stephen R.; Klamerus, Megan; Ozawa, Haishin; Wagner, Amy K.; Ruppel, Randall; Bell, Michael J.; Feldman, Keri; Adelson, P. David; Clark, Robert S. B.; Kochanek, Patrick M.			Endothelin-1 Is Increased in Cerebrospinal Fluid and Associated with Unfavorable Outcomes in Children after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						abusive head trauma; cerebral blood flow; endothelin; hypoperfusion; inflicted childhood neurotrauma; pediatric brain injury; vasospasm	HEAD-INJURY; CEREBRAL AUTOREGULATION; MODERATE HYPOTHERMIA; BLOOD-FLOW; SEVERE TBI; INFANTS; PLASMA; THERAPY; HUMANS; ACID	Severe pediatric traumatic brain injury (TBI) is associated with unfavorable outcomes secondary to injury from activation of the inflammatory cascade, the release of excitotoxic neurotransmitters, and changes in the reactivity of cerebral vessels, causing ischemia. Hypoperfusion of injured brain tissues after TBI is also associated with unfavorable outcomes. Therapeutic hypothermia is an investigational treatment strategy for use in patients with severe TBI that has shown differential effects on various cerebrospinal fluid (CSF) mediators in pediatric patients. Endothelin-1 (ET-1) is a powerful vasoconstrictor that exerts its effects on the cerebrovascular endothelium for sustained periods after TBI. The purpose of this study was to determine if CSF concentrations of ET-1 are increased after severe TBI in children, and if they are associated with demographics and outcomes that are affected by therapeutic hypothermia. This was an ancillary study to a prospective, randomized-controlled trial of early hypothermia in a tertiary care pediatric intensive care unit. Children (n = 34, age 3 months-15 years) suffering from severe TBI were randomized to hypothermia (n = 19) and normothermia (n = 15) as part of the efficacy study. Children undergoing diagnostic lumbar puncture (n = 11) to rule out infection were used as controls. Patients received either mild to moderate hypothermia (32-33 degrees C) or normothermia as part of their treatment protocol. CSF was serially collected during the first 5 days after TBI. ET-1 concentrations were quantitated in patient and control CSF samples by a validated ELISA in duplicate with a limit of quantification of 0.195 pg/mL. CSF ET-1 concentrations were increased by two- to threefold in children after TBI compared to controls, and the increase was sustained for up to 5 days post-TBI. This relationship was not affected by hypothermia, and there were no differences in ET-1 response between children with inflicted and accidental TBI. Group-based trajectory analysis revealed two distinct groups with similar ET-1 levels over time. Univariate analysis showed a significant association between ET-1 levels and Glasgow Outcome Scale (GOS) scores, for which higher ET-1 levels over time were associated with unfavorable outcomes. ET-1 is increased in children with severe TBI and is associated with unfavorable outcomes. This increase in ET-1 may mediate the hypoperfusion or cerebrovascular dysfunction accompanying severe TBI in children. Importantly, hypothermia does not affect the brain's ET-1 response as measured in the CSF.	[Salonia, Rosanne; Ruppel, Randall; Bell, Michael J.; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Empey, Philip E.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Med, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Poloyac, Samuel M.] Univ Pittsburgh, Sch Med, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Biostat, Pittsburgh, PA USA; [Ozawa, Haishin; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Salonia, Rosanne; Empey, Philip E.; Poloyac, Samuel M.; Wagner, Amy K.; Ruppel, Randall; Bell, Michael J.; Feldman, Keri; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Poloyac, Samuel M.; Klamerus, Megan] Univ Pittsburgh, Sch Med, Sch Pharm, Pittsburgh, PA USA; [Adelson, P. David] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA	Salonia, R (corresponding author), Childrens Hosp UPMC, Dept Pediat Crit Care Med, 4401 Penn Ave, Pittsburgh, PA 15213 USA.	saloniar@upmc.edu	Adelson, David/W-2083-2019; Empey, Philip/L-9604-2019; Kochanek, Patrick M/D-2371-2015	Empey, Philip/0000-0001-7474-2339; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD040686-09, NS30318, GM 073031]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM073031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, P20NS030318] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants 5T32HD040686-09 (to R.S. and P.M.K.), NS30318 (to P.M.K.), GM 073031 (to S.M.P.), and National Heart, Lung, and Blood Institute T32HL007820 (to Michael R. Pinsky).	ADELSON DP, 2003, PEDIATR CRIT CARE ME, V4, pS1; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Amin K, 2009, J NEUROTRAUM, V26, pA71; Andresen J, 2006, J APPL PHYSIOL, V100, P318, DOI 10.1152/japplphysiol.00937.2005; Armstead WM, 2004, CURR PHARM DESIGN, V10, P2185, DOI 10.2174/1381612043384178; BA S, 2005, AM J PHYSIOL-GASTR L, V288, pG860; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Gorlach C, 2001, PFLUG ARCH EUR J PHY, V441, P844, DOI 10.1007/s004240000495; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Ho MCY, 2001, FASEB J, V15, P618, DOI 10.1096/fj.99-1022com; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kastner S, 2005, ACTA NEUROCHIR, V147, P1271, DOI 10.1007/s00701-005-0633-0; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Maier B, 2007, SHOCK, V27, P610, DOI 10.1097/shk.0b013e31802f9eaf; MUIZELAAR J, 1992, J NEUROTRAUM, V9, pS333; Nabika S, 2007, PEDIATR NEUROSURG, V43, P312, DOI 10.1159/000103313; Nagin D., 2005, GROUP BASED MODELING; Niyonkuru C, 2009, J NEUROTRAUM, V26, pA16; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; OZAWA H, 2009, PRACTICAL EXAMPLE TR; Ozawa H, 2009, J NEUROTRAUM, V26, pA71; PASAOGLU I, 1993, JPN HEART J, V34, P693; Poloyac SM, 2005, J NEUROSCI METH, V144, P257, DOI 10.1016/j.jneumeth.2004.11.015; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS579; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058	34	44	46	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1819	1825		10.1089/neu.2010.1402			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600006	20684675	Green Published			2021-06-18	
J	Hendricks, HT; Heeren, AH; Vos, PE				Hendricks, H. T.; Heeren, A. H.; Vos, P. E.			Dysautonomia after severe traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						cohort study; diffuse axonal injury; dysautonomia; incidence; traumatic brain injury	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES	Background: Dysautonomia after traumatic brain injury (TBI) is characterized by episodes of increased heart rate, respiratory rate, temperature, blood pressure, muscle tone, decorticate or decerebrate posturing, and profuse sweating. This study addresses the incidence of dysautonomia after severe TBI, the clinical variables that are associated with dysautonomia, and the functional outcome of patients with dysautonomia. Methods: A historic cohort study in patients with severe TBI [Glasgow Coma Scale (GCS) < 8 on admission]. Results: Seventy-six of 119 patients survived and were eligible for follow-up. The incidence of dysautonomia was 11.8%. Episodes of dysautonomia were prevalent during a mean period of 20.1 days (range 3-68) and were often initiated by discomfort. Patients with dysautonomia showed significant longer periods of coma (24.78 vs. 7.99 days) and mechanical ventilation (22.67 vs. 7.21 days). Dysautonomia was associated with diffuse axonal injury (DAI) [relative risk (RR) 20.83, CI 4.92-83.33] and the development of spasticity (RR 16.94, CI 3.96-71.42). Patients with dysautonomia experienced more secondary complications. They tended to have poorer outcome. Conclusions: Dysautonomia occurs in approximately 10% of patients surviving severe TBI and is associated with DAI and the development of spasticity at follow-up. The initiation of dysautonomia by discomfort supports the Excitatory: Inhibitory Ratio model as pathophysiological mechanism.	[Hendricks, H. T.] Rehabil Ctr, Arnhem, Netherlands; [Hendricks, H. T.; Heeren, A. H.] Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [Vos, P. E.] Radboud Univ Nijmegen Med Ctr, Inst Neurol, NL-6500 HB Nijmegen, Netherlands	Hendricks, HT (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, PO 9011, NL-6500 HB Nijmegen, Netherlands.	h.hendricks@reval.umcn.nl	Vos, Pieter/A-6043-2012				American College of Surgeons, 1997, ADV TRAUM LIF SUPP D, V6th ed; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BRATTON SL, 2007, J NEUROTRAUM, V1, pS1; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1994, RADIOLOGY, V191, P1; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	20	44	47	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1351-5101			EUR J NEUROL	Eur. J. Neurol.	SEP	2010	17	9					1172	1177		10.1111/j.1468-1331.2010.02989.x			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	639TG	WOS:000280996800011	20298427				2021-06-18	
J	Kaen, A; Jimenez-Roldan, L; Arrese, I; Delgado, MA; Lopez, PG; Alday, R; Alen, JF; Lagares, A; Lobato, RD				Kaen, Ariel; Jimenez-Roldan, Luis; Arrese, Ignacio; Delgado, Manuel Amosa; Lopez, Pedro Gomez; Alday, Rafael; Alen, Jose Fernandez; Lagares, Alfonso; Lobato, Ramiro D.			The Value of Sequential Computed Tomography Scanning in Anticoagulated Patients Suffering From Minor Head Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Anticoagulation; Outcome; Mild head trauma	TRAUMATIC BRAIN-INJURY; PREINJURY WARFARIN USE; ELDERLY-PATIENTS; COMPLICATIONS; GUIDELINES; MANAGEMENT; ADULTS; RISK; CT	Background: Since 1999, the Italian guidelines have been used at our department for the management of patients with mild head injury (MHI). According to these guidelines, a computed tomography (CT) scan should be obtained in all patients with coagulopathy and these should routinely undergo strict observation during the first 24 hours after injury; in addition they should have a control CT scan before discharge. With the increased use of anticoagulant therapy in the elderly population, admitting patients in such treatment with a MHI to the emergency rooms has become very common. The aim of our study was to evaluate the need of performing a control CT scan in patients on anticoagulation treatment who showed neither intracranial pathology on the first CT-scan nor neurologic worsening during the observation period. Methods: We prospectively analyzed the course of all patients on anticoagulation treatment consecutively admitted to our unit between October 2005 and December 2006 who suffered from a MHI and showed a normal initial CT scan. All patients underwent strict observation during the first 24 hours after admission and had a control CT scan performed before discharge. Results: One hundred thirty-seven patients were included in this study. Only two patients (1.4%) showed hemorrhagic changes. However, neither of them developed concomitant neurologic worsening nor needed admitting or surgery. Conclusion: According with our data, patients on anticoagulation treatment suffering from MHI could be managed with strict neurologic observation without routinely performing a control CT scan that can be reserved for the rare patients showing new clinical symptoms.	[Kaen, Ariel] Hosp 12 Octubre, Serv Neurocirugia, Dept Neurosurg, E-28041 Madrid, Spain	Kaen, A (corresponding author), Hosp 12 Octubre, Serv Neurocirugia, Dept Neurosurg, Avda Cordoba S-N, E-28041 Madrid, Spain.	kaenariel@hotmail.com	ALEN, JOSE A FERNANDEZ/G-4990-2018; Gomez, Pedro/N-5051-2019; Lagares, Alfonso/B-2969-2011; KAEN, ARIEL/F-1338-2015; Jimenez-Roldan, Luis/K-2298-2017; kaen, ariel/G-3786-2015	ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X; Gomez, Pedro/0000-0002-4185-5238; Lagares, Alfonso/0000-0003-3996-0554; Jimenez-Roldan, Luis/0000-0002-9864-0385; Amosa Delgado, Manuel/0000-0003-0748-7627			Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; Gomez PA, 2000, NEUROCIRUGIA, V11, P351; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Karni A, 2001, AM SURGEON, V67, P1098; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Saab M, 1996, J ACCID EMERG MED, V13, P208; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Volans AP, 1998, J ACCID EMERG MED, V15, P159; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	23	44	45	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					895	898		10.1097/TA.0b013e3181b28a76			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	583GY	WOS:000276663100028	20016390				2021-06-18	
J	Atlasz, T; Szabadfi, K; Kiss, P; Tamas, A; Toth, G; Reglodi, D; Gabriel, R				Atlasz, Tamas; Szabadfi, Krisztina; Kiss, Peter; Tamas, Andrea; Toth, Gabor; Reglodi, Dora; Gabriel, Robert			Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration	BRAIN RESEARCH BULLETIN			English	Article						Chronic hypoperfusion; Immunohistochemistry; VGLUT 1; VGAT; Calbindin; Calretinin; Parvalbumin; PKC alpha; GFAP	CYCLASE-ACTIVATING POLYPEPTIDE; CAROTID-ARTERY OCCLUSION; PROTEIN-KINASE-C; VESICULAR GLUTAMATE TRANSPORTERS; AII-AMACRINE CELLS; ADULT-RAT RETINA; MONOSODIUM-GLUTAMATE; INDUCED NEUROTOXICITY; HORIZONTAL CELLS; KAINIC ACID	Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophic and neuroprotective peptide that has been shown to exert protective effects in different neuronal injuries, such as traumatic brain injury, models of neurodegenerative diseases and cerebral ischemia. We have provided evidence that PACAP is neuroprotective in several models of retinal degeneration in vivo. In our previous studies we showed that PACAP treatment significantly ameliorated the damaging effects of permanent bilateral common carotid artery occlusion (BCCAO). In the present study cell-type-specific markers were used in the same models in order to further specify the protective effects of PACAP. In rats BCCAO led to severe degeneration of all retinal layers that was attenuated by PACAP (100 pmol) administered unilaterally immediately following BCCAO into the vitreous body of one eye. Retinas were processed for immunohistochemistry after 3 weeks. Immunolabeling was executed for vesicular glutamate transporter 1 (VGLUT 1), vesicular gamma-aminobutyric acid transporter (VGAT), protein kinase C alpha (PKC alpha), glial fibrillary acidic protein (GFAP) and calcium-binding proteins, such as calbindin, calretinin, parvalbumin. In BCCAO retinas, intensity of immunopositivity for all antisera was dramatically decreased, except in the case of GFAP. In PACAP-treated retinas, immunostaining was similar to that of the control animals. In summary, our study presented immunohistochemical identification of cell types sensitive to chronic retinal hypoperfusion and the protective effects of PACAP. This analysis revealed that the retinoprotective effects of PACAP are not phenotype-specific, but it rather influences general cytoprotective pathways irrespective of the neuronal subtypes in the retina subjected to chronic hypoperfusion. (C) 2009 Elsevier Inc. All rights reserved.	[Atlasz, Tamas] Univ Pecs, Dept Sportbiol, H-7624 Pecs, Hungary; [Atlasz, Tamas; Szabadfi, Krisztina; Gabriel, Robert] Univ Pecs, Dept Expt Zool & Neurobiol, H-7624 Pecs, Hungary; [Kiss, Peter; Tamas, Andrea; Reglodi, Dora] Univ Pecs, Dept Anat, H-7624 Pecs, Hungary; [Toth, Gabor] Univ Szeged, Dept Med Chem, H-6720 Szeged, Hungary	Atlasz, T (corresponding author), Univ Pecs, Dept Sportbiol, Ifjusag Str 6, H-7624 Pecs, Hungary.	attam@gamma.ttk.pte.hu; kriszta.szabadfi@gmail.com; peter.kiss@aok.pte.hu; andrea.tamas@aok.pte.hu; toth@ovrisc.mdche.u-szeged.hu; dora.reglodi@aok.pte.hu; gabriel@ttk.pte.hu	Szabadfi, Krisztina/K-5955-2012	Szabadfi, Krisztina/0000-0002-8390-5408; Atlasz, Tamas/0000-0002-8112-8633	OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [T061766, K72592, CNK78480]; ETT, Bolyai Scholarship and Gedeon Richter Centenary Foundation [F67830];  [GVOP-3.2.1-2004-04-017213.0]	This work was supported by OTKA T061766, K72592, CNK78480; F67830, ETT, Bolyai Scholarship and Gedeon Richter Centenary Foundation. The purchase of Olympus Fluoview FV-1000 laser scanning confocal microscope system was supported by grant GVOP-3.2.1-2004-04-017213.0 to University of Pecs.	Abreu BJ, 2008, NEUROCHEM INT, V53, P155, DOI 10.1016/j.neuint.2008.07.004; Atlasz T, 2007, NEUROTOX RES, V12, P105, DOI 10.1007/BF03033919; Atlasz T, 2007, GEN COMP ENDOCR, V153, P108, DOI 10.1016/j.ygcen.2006.12.022; Atlasz T, 2008, J MOL NEUROSCI, V36, P97, DOI 10.1007/s12031-008-9059-5; Atlasz T, 2009, ANN NY ACAD SCI, V1163, P348, DOI 10.1111/j.1749-6632.2008.03650.x; Babai N, 2005, NEUROTOX RES, V8, P227, DOI 10.1007/BF03033976; Babai N, 2006, ANN NY ACAD SCI, V1070, P149, DOI 10.1196/annals.1317.003; Bagnoli P, 2003, HISTOL HISTOPATHOL, V18, P1219, DOI 10.14670/HH-18.1219; BARNETT NL, 1995, EXP EYE RES, V61, P83, DOI 10.1016/S0014-4835(95)80061-1; Barnett NL, 2001, NEUROCHEM INT, V39, P291, DOI 10.1016/S0197-0186(01)00033-X; BIGNAMI A, 1979, EXP EYE RES, V28, P63; BJORKLUND H, 1985, J NEUROIMMUNOL, V8, P331, DOI 10.1016/S0165-5728(85)80071-0; Borba JC, 2005, DEV BRAIN RES, V156, P193, DOI 10.1016/j.devbrainres.2005.02.016; Bourgault S, 2008, PEPTIDES, V29, P919, DOI 10.1016/j.peptides.2008.01.022; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; Cheon EW, 2002, EXP EYE RES, V75, P591, DOI 10.1006/exer.2002.2051; Chun MH, 1999, NEUROSCI LETT, V260, P125, DOI 10.1016/S0304-3940(98)00973-2; COHEN E, 1986, J COMP NEUROL, V250, P1, DOI 10.1002/cne.902500102; Contini M, 2003, P NATL ACAD SCI USA, V100, P1358, DOI 10.1073/pnas.0337681100; Cueva JG, 2002, J COMP NEUROL, V445, P227, DOI 10.1002/cne.10166; Duarte CB, 1998, GEN PHARMACOL-VASC S, V30, P289, DOI 10.1016/S0306-3623(97)00360-1; Dumoulin A, 1999, J CELL SCI, V112, P811; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Fernandez DC, 2009, INVEST OPHTH VIS SCI, V50, P3922, DOI 10.1167/iovs.08-3344; Fyk-Kolodziej B, 2004, J COMP NEUROL, V475, P518, DOI 10.1002/cne.20199; Gabriel R, 1998, NEUROSCI LETT, V247, P179, DOI 10.1016/S0304-3940(98)00323-1; Gasz B, 2006, PEPTIDES, V27, P87, DOI 10.1016/j.peptides.2005.06.022; Gesslein B, 2009, MOL VIS, V15, P737; Gong J, 2006, BRAIN RES, V1082, P73, DOI 10.1016/j.brainres.2006.01.111; Hannibal J, 2004, NEUROREPORT, V15, P2317, DOI 10.1097/00001756-200410250-00003; HENDRICKSON AE, 1988, J COMP NEUROL, V273, P473, DOI 10.1002/cne.902730404; Kiagiadaki F, 2008, INVEST OPHTH VIS SCI, V49, P3080, DOI 10.1167/iovs.07-1644; Kong L, 2009, NEUROCHEM INT, V54, P172, DOI 10.1016/j.neuint.2008.08.013; Kwon OJ, 2005, MOL CELLS, V19, P382; Langoth N, 2005, INT J PHARMACEUT, V296, P103, DOI 10.1016/j.ijpharm.2005.03.007; Lavinsky D, 2006, GRAEF ARCH CLIN EXP, V244, P199, DOI 10.1007/s00417-005-0006-7; Lenti L, 2009, BRAIN RES, V1283, P50, DOI 10.1016/j.brainres.2009.06.021; Mali RS, 2005, INVEST OPHTH VIS SCI, V46, P2125, DOI 10.1167/iovs.04-1376; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MARC RE, 1985, J COMP NEUROL, V232, P241, DOI 10.1002/cne.902320209; Markhotina N, 2007, IET NANOBIOTECHNOL, V1, P44, DOI 10.1049/iet-nbt:20060019; Mester L, 2009, NEUROTOX RES, V16, P68, DOI 10.1007/s12640-009-9049-6; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; OSBORNE NN, 1995, NEUROPHARMACOLOGY, V34, P1279, DOI 10.1016/0028-3908(95)00097-P; OSBORNE NN, 1991, VISUAL NEUROSCI, V7, P637, DOI 10.1017/S0952523800010427; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Racz B, 2007, NEUROTOX RES, V12, P95, DOI 10.1007/BF03033918; Racz B, 2006, ANN NY ACAD SCI, V1070, P507, DOI 10.1196/annals.1317.070; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Rodrigues LG, 2004, NEUROCHEM INT, V45, P1133, DOI 10.1016/j.neuint.2004.06.011; ROHRENBECK J, 1987, NEUROSCI LETT, V77, P255, DOI 10.1016/0304-3940(87)90508-8; SAHEL JA, 1991, EXP EYE RES, V53, P657, DOI 10.1016/0014-4835(91)90226-5; SCHWARCZ R, 1977, BRAIN RES, V127, P235, DOI 10.1016/0006-8993(77)90538-8; Seki T, 2006, ANN NY ACAD SCI, V1070, P535, DOI 10.1196/annals.1317.043; Seki T, 2000, ANN NY ACAD SCI, V921, P366; Seki T, 1998, ANN NY ACAD SCI, V865, P408, DOI 10.1111/j.1749-6632.1998.tb11205.x; Seki T, 1997, NEUROSCI LETT, V238, P127, DOI 10.1016/S0304-3940(97)00869-0; Seki T, 2006, ANN NY ACAD SCI, V1070, P531, DOI 10.1196/annals.1317.074; Seki T, 2008, J MOL NEUROSCI, V36, P57, DOI 10.1007/s12031-008-9091-5; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Staines DR, 2007, MED HYPOTHESES, V69, P1208, DOI 10.1016/j.mehy.2007.04.004; Stella SL, 2008, BRAIN RES, V1215, P20, DOI 10.1016/j.brainres.2008.03.038; Szabadfi K, 2009, NEUROSCI LETT, V455, P42, DOI 10.1016/j.neulet.2009.03.013; Tamas A, 2004, NEUROSCI LETT, V372, P110, DOI 10.1016/j.neulet.2004.09.021; VANEY DI, 1991, J COMP NEUROL, V310, P154, DOI 10.1002/cne.903100203; Vaudry D, 2000, PHARMACOL REV, V52, P269; VAUGHN JE, 1981, J COMP NEUROL, V197, P113, DOI 10.1002/cne.901970109; Vereczki V, 2006, NEUROSCIENCE, V140, P1089, DOI 10.1016/j.neuroscience.2006.02.081; Vidal-Sanz M, 2000, NEUROTOX RES, V2, P215, DOI 10.1007/BF03033795; Wassle H, 2006, J COMP NEUROL, V496, P544, DOI 10.1002/cne.20942; WASSLE H, 1993, J COMP NEUROL, V332, P407; Wood JPM, 1997, NEUROCHEM INT, V30, P119, DOI 10.1016/S0197-0186(96)00049-6; Yamamoto H, 2006, EXP EYE RES, V82, P767, DOI 10.1016/j.exer.2005.09.019; Yang ZK, 2008, NEUROCHEM INT, V52, P1176, DOI 10.1016/j.neuint.2007.12.008	81	44	46	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	MAR 16	2010	81	4-5					497	504		10.1016/j.brainresbull.2009.09.004			8	Neurosciences	Neurosciences & Neurology	561JP	WOS:000274972800022	19751807				2021-06-18	
J	MacDonald, S; Wiseman-Hakes, C				MacDonald, Sheila; Wiseman-Hakes, Catherine			Knowledge translation in ABI rehabilitation: A model for consolidating and applying the evidence for cognitive-communication interventions	BRAIN INJURY			English	Article						Communication; cognitive-communication; speech-language pathology; speech-language therapy; speech therapy; communication therapy; intervention; treatment evidence; efficacy; evidence based practice; knowledge translation; knowledge transfer	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; PRACTICE GUIDELINES; VERBAL IMPAIRMENT; WORKING-MEMORY; LANGUAGE; DEFICITS; ADOLESCENTS; DISORDERS; CHILDREN	Primary objectives: (1) To propose a model for consolidating and disseminating existing evidence relevant to cognitive-communication interventions after ABI. (2) To present the Cognitive-Communication Intervention Review Framework (CCIRF). (3) To outline future considerations for applying evidence to clinical practice. Research design: Employment of a model for knowledge translation. Methods and procedures: Application of evidence requires synthesis and dissemination of information in an accessible format for end users. A literature search identified 20 systematic reviews (1997-2007) with a complex array of 72 practice recommendations relevant to cognitive-communication interventions. The CCIRF was used to synthesize the evidence within 11 intervention categories. Reviews were analysed according to: organization, population, intervention, comparison and outcome, with a focus on communication outcomes. Main outcomes and results: Consolidated evidence revealed support for interventions relating to: social communication, behavioural regulation, verbal formulation, attention, external memory aids, executive functions and communication partner training. Research gaps were noted in the areas of comprehension (auditory/reading), written expression and vocational communication interventions. Similar recommendations emerge across reviews. Conclusions: Implementation of the growing body of evidence for cognitive-communication interventions is challenged by variability in study populations, interventions, and research focus on communication. The CCIRF provides a means of promoting consistency in knowledge translation and application.	[MacDonald, Sheila] Sheila MacDonald & Associates, Guelph, ON N1H 6J2, Canada; [Wiseman-Hakes, Catherine] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada	MacDonald, S (corresponding author), Sheila MacDonald & Associates, Suite 26,5420 Hwy 6 N, Guelph, ON N1H 6J2, Canada.	sheilamacdonald@rogers.com	Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Ministry of Health and Long-Term Care in OntarioMinistry of Health and Long-Term Care, Ontario	The authors wish to express sincere gratitude to Dr Lyn Turkstra and Dr Mark Ylvisaker for their editorial expertise in reviewing this paper at various stages of its evolution. Appreciation is also extended to Dr Mary Kennedy and Dr Leanne Togher who provided resources during the earlier stages of the paper. The second author gratefully acknowledges the support of the Canadian Institutes for Health Research through a Fellowship in Clinical Research, and the Toronto Rehabilitation Institute who receive funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario. The views expressed do not necessarily reflect those of the Ministry.	*AM SPEECH LANG HE, 2006, ASHA EV BAS PRACT; American Speech-Language-Hearing Association (ASHA), 2005, ROL SPEECH LANG PATH; *ASHA, 2006, STEPS PROC EV BAS PR; *ASHA, 1987, LANG SUBC COGN LANG; Barreca S, 2003, BRAIN INJURY, V17, P1065, DOI 10.1080/0269905031000110535; Beeson PM, 2006, NEUROPSYCHOL REV, V16, P161, DOI 10.1007/s11065-006-9013-7; BIGLER ED, 1988, J LEARN DISABIL, V21, P325, DOI 10.1177/002221948802100602; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Carlson PM, 2006, BRAIN INJURY, V20, P1111, DOI 10.1080/02699050600955337; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CARNEY N, 1999, 2 AG HLTHHC POL RES; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cirrin FM, 2008, LANG SPEECH HEAR SER, V39, pS110, DOI 10.1044/0161-1461(2008/012); Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; COHEN M, NEUROPSYCHO IN PRESS; College of Audiologists, 2002, PREF PRACT GUID COGN; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; Dobbins M, 2002, ONLINE J KNOWL SYN N, V9; Docking K, 1999, BRAIN INJURY, V13, P953; Dodd B, 2007, FOLIA PHONIATR LOGO, V59, P118, DOI 10.1159/000101770; Dolloghan C, 2007, HDB EVIDENCE BASED P; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; GIROLAMETTO L, 1994, J EARLY INTERVENTION, V18, P155, DOI 10.1177/105381519401800204; Glang A, 2008, J HEAD TRAUMA REHAB, V23, P243, DOI 10.1097/01.HTR.0000327256.46504.9f; GOLPER LC, 2001, EVIDENCE BASED PRACT; Graham Ian D, 2007, Healthc Q, V10, P20; GREENER J, 1998, INT J LANGUAGE COM S, V33, P148; HAGEN C, 1986, HDB SPEECH LANGUAGE; Halper AS, 1991, CLIN MANAGEMENT COMM; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); KATZ R, 2002, EVIDENCE BASED PRACT; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824; KUNTZ R, 2008, J CLIN EPIDEMIOL, V61, P207; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; LIPPERT C, 2007, 13 ERABI; LOMAS J, 1997, C971 MCMASTER U CTR; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; Malec JF, 2005, REHABILITATION TRAUM, P176; MARQUARDT TP, 1988, J LEARN DISABIL, V21, P340, DOI 10.1177/002221948802100605; MARSHALL S, 2007, 6 ERABI; Martin Randi C., 2008, Seminars in Speech and Language, V29, P201, DOI 10.1055/s-0028-1082884; MCCORMICK A, 2007, 14 ERABI; MCDONALD S, 2003, BRAIN IMPAIR, V4, P36, DOI DOI 10.1375/brim.4.1.36.27032; MCDONALD S, 2006, BRAIN IMPAIR, V7, P169; Montgomery EB, 2003, J MED SPEECH-LANG PA, V11, pIX; Moran CA, 2006, BRAIN INJURY, V20, P417, DOI 10.1080/02699050500488223; Nail-Chiwetalu BJ, 2006, LANG SPEECH HEAR SER, V37, P157, DOI 10.1044/0161-1461(2006/018); National Reading Panel, 2000, TEACH CHILDR READ EV; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PERDICES M, 2006, BRAIN IMPAIR, V2, P119; *PSYCBITE, PSYCBITE DAT ACQ BRA; Ratner NB, 2006, LANG SPEECH HEAR SER, V37, P257, DOI 10.1044/0161-1461(2006/029); REES L, 2007, 8 ERABI; ROBEY RR, 1994, BRAIN LANG, V47, P582, DOI 10.1006/brln.1994.1060; Robey RR, 1998, J SPEECH LANG HEAR R, V41, P172, DOI 10.1044/jslhr.4101.172; RUSK H, 1969, ARCH PHYS MED REHAB, V67, P400; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SCOLLON J, 2000, PUBLICATION WORKERS; SOHLBERG M, 2007, J MED SPEECH PATHOLO, V15; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Struchen M.A., 2005, REHABILITATION TRAUM, P88; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; TOGHER L, 1999, COMMUNICATION DISORD, P14; TURKIBENALI Y, 2005, PHYSICA E, V26, P222; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra Lyn S, 2005, Semin Speech Lang, V26, P213, DOI 10.1055/s-2005-922100; Turkstra Lyn S., 2001, Seminars in Speech and Language, V22, P147; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Vingilis E, 2003, CAN J PUBLIC HEALTH, V94, P468, DOI 10.1007/BF03405087; WELCHWEST P, 2007, COMMUNICATION DEFICI; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; WISEMANHAKES C, NEUROREHABI IN PRESS; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; YLVISAKER M, 2005, REHABILITATION TRAUM; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI DOI 10.1375/BRIM.7.3.246; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; Zipoli RP, 2005, AM J SPEECH-LANG PAT, V14, P208, DOI 10.1044/1058-0360(2005/021)	103	44	44	1	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2010	24	3					486	508		10.3109/02699050903518118			23	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800005	20184406				2021-06-18	
J	Lanctot, KL; Rapoport, MJ; Chan, F; Rajaram, RD; Strauss, J; Sicard, T; McCullagh, S; Feinstein, A; Kiss, A; Kennedy, JL; Bassett, AS; Herrmann, N				Lanctot, Krista L.; Rapoport, Mark J.; Chan, Florance; Rajaram, Ryan D.; Strauss, John; Sicard, Tricia; McCullagh, Scott; Feinstein, Anthony; Kiss, Alex; Kennedy, James L.; Bassett, Anne S.; Herrmann, Nathan			Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; serotonin receptors; serotonin transporter; brain derived neurotrophic factor (BDNF); methylenetetrahydrofolate reductase (MTHFR); tryptophan hydroxylase (TPH)	NEUROTROPHIC FACTOR BDNF; SEROTONIN TRANSPORTER; MAJOR DEPRESSION; ANTIDEPRESSANT RESPONSE; PROMOTER POLYMORPHISM; VAL66MET POLYMORPHISM; ALLELIC VARIATION; RECEPTOR GENE; ASSOCIATION; DISORDER	Objectives: To determine which serotonergic system-related single nucleotide polymorphisms (SNPs) predicted variation in treatment response to citalopram in depression following a traumatic brain injury (TBI). Methods: Ninety (50 M/40 F, aged 39.9, SD = 18.0 years) post-TBI patients with a major depressive episode (MDE) were recruited into a 6-week open-label study of citalopram (20 mg/day). Six functional SNPs in genes related to the serotonergic system were examined: serotonin transporter (5HTTLPR including rs25531), 5HT1A C-(1019)G and 5HT2A T-(102)C, methylene tetrahydrofolate reductase (MTHFR) C-(677) T, brain-derived neurotrophic factor (BDNF) val66met and tryptophan hydroxylase-2 (TPH2) G-(703)T. Regression analyses were performed using the six SNPs as independent variables: Model 1 with response (percentage Hamilton Depression (HAMD) change from baseline to endpoint) as the dependent variable and Model 2 with adverse event index as the dependent variable (Bonferroni corrected p-value < 0.025). Results: MTHFR and BDNF SNPs predicted greater treatment response (R-2 = 0.098, F = 4.65, p = 0.013). The 5HTTLPR predicted greater occurrence of adverse events (R-2 = 0.069, F = 5.72, p = 0.020). Conclusion: Results suggest that polymorphisms in genes related to the serotonergic system may help predict short-term response to citalopram and tolerability to the medication in patients with MDE following a TBI.	[Lanctot, Krista L.; Rapoport, Mark J.; Chan, Florance; Rajaram, Ryan D.; McCullagh, Scott; Feinstein, Anthony; Herrmann, Nathan] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; [Lanctot, Krista L.; Rapoport, Mark J.; McCullagh, Scott; Feinstein, Anthony; Bassett, Anne S.; Herrmann, Nathan] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Lanctot, Krista L.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; [Rapoport, Mark J.; McCullagh, Scott; Feinstein, Anthony; Bassett, Anne S.; Herrmann, Nathan] Univ Toronto, Dept Med, Toronto, ON, Canada; [Strauss, John; Sicard, Tricia; Kennedy, James L.] Ctr Addict & Mental Hlth, Toronto, ON, Canada	Lanctot, KL (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave,Room FG05, Toronto, ON M4N 3M5, Canada.	krista.lanctot@sunnybrook.ca	Kennedy, James Lowery/AAZ-6947-2020; Lanctot, Krista L./AAY-4820-2020; Rapoport, Mark/AAD-8581-2020	Kennedy, James Lowery/0000-0002-8733-3806; Lanctot, Krista L./0000-0001-7024-6637; 	Ontario Mental Health Foundation	This study was made possible by a grant from the Ontario Mental Health Foundation (KLL, MR, SM, AF, NH). Dr. Lanctot was supported by a Fellowship from the Ontario Mental Health Foundation.	Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Anttila S, 2007, J NEURAL TRANSM, V114, P1065, DOI 10.1007/s00702-007-0705-9; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Aydemir O, 2005, PROG NEURO-PSYCHOPH, V29, P261, DOI 10.1016/j.pnpbp.2004.11.009; Bjelland I, 2003, ARCH GEN PSYCHIAT, V60, P618, DOI 10.1001/archpsyc.60.6.618; Bocchio-Chiavetto L, 2008, NEUROSCI LETT, V437, P130, DOI 10.1016/j.neulet.2008.04.005; BOTTIGLIERI T, 1992, PSYCHOL MED, V22, P871, DOI 10.1017/S0033291700038447; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Choi MJ, 2006, BRAIN RES, V1118, P176, DOI 10.1016/j.brainres.2006.08.012; Daws LC, 2007, J NEUROCHEM, V101, P641, DOI 10.1111/j.1471-4159.2006.04392.x; Denys D, 2007, J CLIN PSYCHIAT, V68, P747, DOI 10.4088/JCP.v68n0512; Dias BG, 2003, NEUROPHARMACOLOGY, V45, P553, DOI 10.1016/S0028-3908(03)00198-9; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; Garriock HA, 2010, BIOL PSYCHIAT, V67, P133, DOI 10.1016/j.biopsych.2009.08.029; Gilbody S, 2007, AM J EPIDEMIOL, V165, P1, DOI 10.1093/aje/kwj347; Gratacos M, 2008, PHARMACOGENOMICS J, V8, P101, DOI 10.1038/sj.tpj.6500460; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Heils A, 1996, J NEUROCHEM, V66, P2621; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hong CJ, 2006, PHARMACOGENOMICS J, V6, P27, DOI 10.1038/sj.tpj.6500340; Hong CJ, 2003, NEUROPSYCHOBIOLOGY, V48, P186, DOI 10.1159/000074636; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Hu XZ, 2006, AM J HUM GENET, V78, P815, DOI 10.1086/503850; Hwang JP, 2006, NEUROBIOL AGING, V27, P1834, DOI 10.1016/j.neurobiolaging.2005.10.013; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kang R, 2009, J PSYCHOPHARMACOLOGY; Kim H, 2006, JAMA-J AM MED ASSOC, V296, P1609, DOI 10.1001/jama.296.13.1609; Kraft JB, 2005, BIOL PSYCHIAT, V58, P374, DOI 10.1016/j.biopsych.2005.04.048; Kraft JB, 2007, BIOL PSYCHIAT, V61, P734, DOI 10.1016/j.biopsych.2006.07.017; Lang UE, 2005, PSYCHOPHARMACOLOGY, V180, P95, DOI 10.1007/s00213-004-2137-7; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lemonde S, 2003, J NEUROSCI, V23, P8788; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Licinio J, 2009, ARCH GEN PSYCHIAT, V66, P488, DOI 10.1001/archgenpsychiatry.2009.38; Markianos M, 1996, ACTA NEUROCHIR, V138, P57, DOI 10.1007/BF01411725; Minov C, 2001, NEUROSCI LETT, V303, P119, DOI 10.1016/S0304-3940(01)01704-9; Morishita S, 2008, HUM PSYCHOPHARM CLIN, V23, P647, DOI 10.1002/hup.969; Murphy GM, 2004, ARCH GEN PSYCHIAT, V61, P1163, DOI 10.1001/archpsyc.61.11.1163; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; Oswald P, 2005, EUR NEUROPSYCHOPHARM, V15, P491, DOI 10.1016/j.euroneuro.2005.01.001; Papakostas GI, 2005, INT J NEUROPSYCHOPH, V8, P523, DOI 10.1017/S1461145705005195; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Perlis RH, 2003, BIOL PSYCHIAT, V54, P879, DOI 10.1016/S0006-3223(03)00424-4; Polesskaya OO, 2006, J NEUROSCI RES, V83, P362, DOI 10.1002/jnr.20732; Pollock BG, 2000, NEUROPSYCHOPHARMACOL, V23, P587, DOI 10.1016/S0893-133X(00)00132-9; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Ribeiro L, 2007, NEUROREPORT, V18, P1291, DOI 10.1097/WNR.0b013e328273bcb0; Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Salomon K, 2009, HEALTH PSYCHOL, V28, P157, DOI 10.1037/a0013001; Sayer N. A., 1993, PSYCHOL ASSESSMENT, V5, P350, DOI [10.1037/1040-3590.5.3.350, DOI 10.1037/1040-3590.5.3.350]; Schumacher J, 2005, BIOL PSYCHIAT, V58, P307, DOI 10.1016/j.biopsych.2005.04.006; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Serretti A, 2007, MOL PSYCHIATR, V12, P247, DOI 10.1038/sj.mp.4001926; Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Strauss J, 2005, MOL PSYCHIATR, V10, P861, DOI 10.1038/sj.mp.4001685; Trivedi Madhukar H, 2008, Dialogues Clin Neurosci, V10, P377; Tsai SJ, 2003, AM J MED GENET B, V123B, P19, DOI 10.1002/ajmg.b.20026; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vermeiden M, 2010, J PSYCHOPHARMACOL, V24, P497, DOI 10.1177/0269881109105137; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Wendland JR, 2006, MOL PSYCHIATR, V11, P224, DOI 10.1038/sj.mp.4001789; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Yoshida K, 2002, PROG NEURO-PSYCHOPH, V26, P383, DOI 10.1016/S0278-5846(01)00287-1; Zill P, 2004, MOL PSYCHIATR, V9, P1030, DOI 10.1038/sj.mp.4001525; Zintzaras E, 2006, PSYCHIAT GENET, V16, P105, DOI 10.1097/01.ypg.0000199444.77291.e2	79	44	48	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	7-8					959	969		10.3109/02699051003789229			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MW	WOS:000279505000005	20515362	Green Accepted			2021-06-18	
J	Moreira, MS; Velasco, IT; Ferreira, LS; Ariga, SKK; Barbeiro, DF; Meneguzzo, DT; Abatepaulo, F; Marques, MM				Moreira, Maria Stella; Velasco, Irineu Tadeu; Ferreira, Leila Soares; Kubo Ariga, Suely Kunimi; Barbeiro, Denise Frediani; Meneguzzo, Daiane Thais; Abatepaulo, Fatima; Marques, Marcia Martins			Effect of phototherapy with low intensity laser on local and systemic immunomodulation following focal brain damage in rat	JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY			English	Article						IL-1 beta; IL-6; IL-10; TNF-alpha; Low power laser; Cryogenic brain injury	PRO-INFLAMMATORY CYTOKINES; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; TERM NEUROLOGICAL DEFICITS; HUMAN ORAL-MUCOSA; TNF-ALPHA; RECEPTOR ANTAGONIST; INTERLEUKIN-1 RECEPTOR; PERIPHERAL-NERVE; THERAPY	Brain injury is responsible for significant morbidity and mortality in trauma patients, but controversy still exists over therapeutic management for these patients. The objective of this study was to analyze the effect of phototherapy with low intensity lasers on local and systemic immunomodulation following cryogenic brain injury. Laser phototherapy was applied (or not-controls) immediately after cryogenic brain injury performed in 51 adult male Wistar rats. The animals were irradiated twice (3 h interval), with continuous diode laser (gallium-aluminum-arsenide (GaAlAs), 780 nm, or indium-gallium-aluminum-phosphide (InGaAlP), 660 nm) in two points and contact mode, 40 mW, spot size 0.042 cm(2), 3 J/cm(2) and 5 J/cm(2) (3 s and 5 s, respectively). The experimental groups were: Control (non-irradiated), RL3 (visible red laser/ 3 J/cm(2)), RL5 (visible red laser/5 J/cm(2)), IRL3 (infrared laser/ 3 J/cm(2)), IRL5 (infrared laser/5 J/cm(2)). The production of interleukin-1IL-1 beta (IL-1 beta), interleukin6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-alpha) was analyzed by enzyme immunoassay technique (ELISA) test in brain and blood samples. The IL-1 beta concentration in brain of the control group ;was significantly reduced in 24 h (p < 0.01). This reduction was also observed in the RL5 and IRL3 groups. The TNF-alpha and IL-6 concentrations increased significantly (p < 0.01 and p < 0.05, respectively) in the blood of all groups, except by the IRL3 group. The IL-6 levels in RL3 group were significantly smaller than in control group in both experimental times. IL-10 concentration was maintained stable in all groups in brain and blood. Under the conditions of this study, it is possible to conclude that the laser phototherapy can affect TNF-alpha, IL-1 beta and IL-6 levels in the brain and in circulation in the first 24 h following cryogenic brain injury. (C) 2009 Elsevier B.V. All rights reserved.	[Marques, Marcia Martins] Univ Sao Paulo, Fac Odontol, Dept Dent, BR-05508000 Sao Paulo, Brazil; [Moreira, Maria Stella; Velasco, Irineu Tadeu; Kubo Ariga, Suely Kunimi; Barbeiro, Denise Frediani; Abatepaulo, Fatima] Univ Sao Paulo, Fac Med, LIM 51, BR-05508000 Sao Paulo, Brazil	Marques, MM (corresponding author), Univ Sao Paulo, Fac Odontol, Dept Dent, Av Prof Lineu Prestes,2227,Cidade Univ, BR-05508000 Sao Paulo, Brazil.	mmmarques@usp.br	Marques, Marcia M/F-3780-2012; Moreira, Maria Stella N A/F-8054-2014; Meneguzzo, Daiane T./ABD-8253-2020	Marques, Marcia M/0000-0002-9398-1252; Moreira, Maria Stella N A/0000-0002-4533-4544; Meneguzzo, Daiane T./0000-0002-8821-3734	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasilia, DF, BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	We thank the staffs of the Labs: LIM51 at the Medicine School and LELO (Special Laboratory of Lasers in Dentistry) at the School of Dentistry, University of Sao Paulo, Brazil. We are also grateful to ours Grants sponsors Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasilia, DF, Brazil.	Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Boschi ES, 2008, LASER SURG MED, V40, P500, DOI 10.1002/lsm.20658; Campana V, 2003, J CLIN LASER MED SUR, V21, P99, DOI 10.1089/104454703765035529; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Damante CA, 2004, LASER SURG MED, V35, P377, DOI 10.1002/lsm.20111; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P1; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; JOYCE DA, 1994, EUR J IMMUNOL, V24, P2699, DOI 10.1002/eji.1830241119; Kandolf-Sekulovic L, 2003, PHOTODERMATOL PHOTO, V19, P203, DOI 10.1034/j.1600-0781.2003.00040.x; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kujawa J, 2004, J CLIN LASER MED SUR, V22, P111, DOI 10.1089/104454704774076163; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MENEGUZZO DT, 2008, P SPIE, V6846; MENEGUZZO DT, 2007, P SPIE, V6428; Mirsky N, 2002, ANTIOXID REDOX SIGN, V4, P785, DOI 10.1089/152308602760598936; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Moriyama Y, 2009, LASER SURG MED, V41, P227, DOI 10.1002/lsm.20745; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Penkowa M, 1999, GLIA, V25, P343; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Sawasaki I, 2009, LASER MED SCI, V24, P113, DOI 10.1007/s10103-007-0531-1; Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1053>3.0.CO;2-9; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Sousa LR, 2009, PHOTOMED LASER SURG, V27, P37, DOI 10.1089/pho.2007.2220; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; TAKAO T, 1993, ENDOCRINOLOGY, V132, P1497, DOI 10.1210/en.132.4.1497; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Unsicker K, 1992, Curr Opin Neurobiol, V2, P671, DOI 10.1016/0959-4388(92)90037-L; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	58	44	44	0	7	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	1011-1344			J PHOTOCH PHOTOBIO B	J. Photochem. Photobiol. B-Biol.	DEC 2	2009	97	3					145	151		10.1016/j.jphotobiol.2009.09.002			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	526TI	WOS:000272316600005	19800810				2021-06-18	
J	Griesdale, DEG; Tremblay, MH; McEwen, J; Chittock, DR				Griesdale, Donald E. G.; Tremblay, Marie-Helene; McEwen, Jonathan; Chittock, Dean R.			Glucose Control and Mortality in Patients with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Glucose; Mortality; Intensive care unit; Hyperglycemia	INTENSIVE INSULIN THERAPY; BLOOD-GLUCOSE; HYPERGLYCEMIA	The optimal glucose range in patients with severe traumatic brain injury (TBI) remains unclear. The goal of this study was to examine the association of serum glucose levels on mortality in patients with severe TBI. As a secondary endpoint, we determined the risk of hyperglycemic and hypoglycemic events, and their association with mortality. We conducted a retrospective cohort study of patients admitted to the ICU between May 2000 and March 2006 with severe TBI (Glasgow Coma Scale a parts per thousand currency sign 8) who survived at least 12 h. Average daily morning glucose levels for the first 10 days of admission were calculated and divided into quintiles. A total of 170 patients were included in the analysis. We found no association between quintiles of mean daily morning glucose and hospital mortality. Episodes of hyperglycemia (a parts per thousand yen11.1 mmol/l or 200 mg/dl) during the first 10 days occurred in 65% of patients (5.4% of all glucose measurements). Using multivariable regression, a single episode of hyperglycemia was associated with 3.6-fold increased risk of hospital mortality (95%CI: 1.2-11.2, P = 0.02). Hypoglycemia (a parts per thousand currency sign4.4 mmol/l or 80 mg/dl) was present in 48% of patients (4.3% of all glucose measurements), and was not associated with mortality. Any episode of hyperglycemia (a parts per thousand yen11.1 mmol/l or 200 mg/dl) was associated with 3.6-fold increased risk of hospital mortality in patients with severe TBI and thus, should be avoided. Maintaining serum glucose a parts per thousand currency sign10 mmol/l appears to be a reasonable balance to avoid extremes of glucose control, but further studies are needed to determine the optimal glucose range.	[Griesdale, Donald E. G.; Chittock, Dean R.] Vancouver Gen Hosp, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Tremblay, Marie-Helene; McEwen, Jonathan] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Tremblay, Marie-Helene; McEwen, Jonathan] Vancouver Gen Hosp, Dept Anesthesia, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Chittock, Dean R.] Univ British Columbia, Dept Med, Div Crit Care Med, Vancouver, BC, Canada	Griesdale, DEG (corresponding author), Vancouver Gen Hosp, Program Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor,855 W 12th, Vancouver, BC V5Z 1M9, Canada.	dgriesdale@post.harvard.edu		Griesdale, Donald/0000-0001-5985-8624			Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P2, DOI 10.1097/ANA.0b013e31818f8a5c; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Griesdale DE, 2005, CMAJ, V112, P1514; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Preiser JC, 2007, INTENS CARE MED, V33, P570, DOI 10.1007/s00134-006-0485-y; Rodbard Helena W, 2007, Endocr Pract, V13 Suppl 1, P1; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vogelzang M, 2004, CRIT CARE, V8, pR122, DOI 10.1186/cc2840; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wass CT, 1996, MAYO CLIN PROC, V71, P801; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	31	44	50	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2009	11	3					311	316		10.1007/s12028-009-9249-1			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	521SH	WOS:000271943800003	19636972				2021-06-18	
J	Kleindienst, A; Brabant, G; Bock, C; Maser-Gluth, C; Buchfelder, M				Kleindienst, Andrea; Brabant, Georg; Bock, Christoph; Maser-Gluth, Christiane; Buchfelder, Michael			Neuroendocrine Function following Traumatic Brain Injury and Subsequent Intensive Care Treatment: A Prospective Longitudinal Evaluation	JOURNAL OF NEUROTRAUMA			English	Article						critical illness; endocrine dysfunction; pituitary; traumatic brain injury	ANTERIOR-PITUITARY INSUFFICIENCY; GROWTH-HORMONE DEFICIENCY; CRITICAL ILLNESS; POSTTRAUMATIC HYPOPITUITARISM; SUBARACHNOID HEMORRHAGE; SELLA TURCICA; ACUTE-PHASE; LONG-TERM; HIGH-RISK; DYSFUNCTION	Neuroendocrine dysfunction following traumatic brain injury (TBI) has been described extensively. However, few studies are longitudinal and most lack subtle radiological, clinical, and repetitive endocrine assessment in the acute phase. Accordingly, we prospectively assessed neuroendocrine function in 71 patients after TBI. Injury was documented by a computed tomography (CT). During the first week, critical clinical data (Glasgow Coma Score, APACHE score), treatment variables such as duration of analgosedation for mechanical ventilation, were related to basal pituitary function. More than 2 years later, a subgroup of patients was re-evaluated using dynamic testing with ACTH and GHRH-arginine tests. The Pearson's correlation analysis and Mann-Whitney rank sum test for group differences were used for statistical analysis. None of the CT findings predicted neuroendocrine dysfunction following TBI. The adaptive response to critical illness with significantly elevated cortisol levels on admission and decreased levels thereafter in patients ventilated for more than 24 h (p < 0.05) was attenuated following severe TBI (p < 0.05). However, the coincidence of low serum cortisol and increased urinary excretion of glucocorticoid metabolites in about 80% of patients challenges the relevance of basal hormone measurements. In ventilated patients, total T3 and free T4 were decreased (p < 0.05), TSH was low on day 3 (p < 0.05), and a gonadotropic insufficiency was present (p < 0.05). The thyrotropic and gonadotropic system recovered completely within the follow-up period. With regard to the somatotropic system, neither brain injury severity nor mechanical ventilation was associated with an insufficiency during the acute phase post-injury. However, initially low GH levels predicted a persistent deficiency (r = 0.731, p < 0.001). We conclude that both severe TBI and prolonged mechanical ventilation result in hormonal disturbances early after injury, suggesting a pathophysiological response to brain injury and subsequent intensive care treatment rather than morphological damage.	[Kleindienst, Andrea; Buchfelder, Michael] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany; [Brabant, Georg] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England; [Bock, Christoph] Univ Gottingen, Dept Neurosurg, Gottingen, Germany; [Maser-Gluth, Christiane] Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany	Kleindienst, A (corresponding author), Univ Erlangen Nurnberg, Dept Neurosurg, Schwabachanlage 6, D-91054 Erlangen, Germany.	andrea.kleindienst@uk-erlangen.de	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; AGHA A, 2005, AM J MED, V188, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Arafah BM, 2006, J CLIN ENDOCR METAB, V91, P3725, DOI 10.1210/jc.2006-0674; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DUSICK JR, 2008, PITUITARY IN PRESS; EDWARDS OM, 1986, MEDICINE, V65, P281; Fliers E, 2001, BEST PRACT RES CL EN, V15, P453, DOI 10.1053/beem.2001.0163; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Gittoes NJL, 1998, CLIN ENDOCRINOL, V48, P331; Jennett B, 1975, Ciba Found Symp, P3; KAPTEIN EM, 1982, J CLIN INVEST, V69, P526, DOI 10.1172/JCI110478; KAWAI K, 1995, J NEUROSURG, V83, P368, DOI 10.3171/jns.1995.83.2.0368; KEELING FP, 1986, CLIN RADIOL, V37, P233, DOI 10.1016/S0009-9260(86)80323-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2008, PITUITARY, V11, P255, DOI 10.1007/s11102-008-0102-x; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koea JB, 2006, ANZ J SURG, V76, P959, DOI 10.1111/j.1445-2197.2006.03944.x; KOJIMA T, 1985, NEUROSURGERY, V16, P225, DOI 10.1227/00006123-198502000-00018; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LILJEDAHL STEN-OTTO, 1961, ACTA CHIR SCAND, V122, P1; Lusk B, 2005, DIMENS CRIT CARE NUR, V24, P25, DOI 10.1097/00003465-200501000-00004; McIver B, 1997, THYROID, V7, P125, DOI 10.1089/thy.1997.7.125; NOMIKOS P, 1997, ANN ENDOCRINOL S, V58; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; SAEZ JMG, 1982, MED CLIN-BARCELONA, V78, P159; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider HJ, 2004, DTSCH ARZTEBL, V101, pA712; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Segal-Lieberman G, 2000, Pituitary, V3, P181, DOI 10.1023/A:1011407910913; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; VandenBerghe G, 1997, CLIN ENDOCRINOL, V47, P599, DOI 10.1046/j.1365-2265.1997.3371118.x; Vanhorebeek I, 2006, NAT CLIN PRACT ENDOC, V2, P20, DOI 10.1038/ncpendmet0071; Vanhorebeek I, 2006, CRIT CARE CLIN, V22, P1, DOI 10.1016/j.ccc.2005.09.004; VOERMAN HJ, 1992, ANN SURG, V216, P648, DOI 10.1097/00000658-199212000-00006; WEST OC, 1993, RADIOLOGY, V188, P329, DOI 10.1148/radiology.188.2.8327674; YOUNG HA, 1980, NEUROSURGERY, V7, P23, DOI 10.1227/00006123-198007000-00004; Zaloga GP, 2001, CRIT CARE CLIN, V17, P25, DOI 10.1016/S0749-0704(05)70150-0	56	44	48	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1435	1446		10.1089/neu.2008.0601			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200001	19459759				2021-06-18	
J	Shandro, JR; Rivara, FP; Wang, J; Jurkovich, GJ; Nathens, AB; MacKenzie, EJ				Shandro, Jamie R.; Rivara, Frederick P.; Wang, Jin; Jurkovich, Gregory J.; Nathens, Avery B.; MacKenzie, Ellen J.			Alcohol and Risk of Mortality in Patients With Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Alcohol; Traumatic brain injury; Intoxication	GLASGOW COMA SCALE; ETHANOL INTOXICATION; MULTIPLE IMPUTATION; MISSING DATA; SEVERITY; ABUSE; SCORE; ASSOCIATION; OUTCOMES; LEVEL	Background: Laboratory and clinical studies demonstrate inconsistent findings on the effect of alcohol on traumatic brain injury (TBI) outcome. The purpose of this study is to use a comprehensive trauma database to determine whether blood alcohol concentration (BAC) is associated with mortality in patients with TBI. Methods. Design: Cohort study. Setting: Eighteen trauma centers and 51 non-trauma centers in the United States. Patients: A total of 1,529 patients aged 18 years to 84 years of age admitted to hospital with TBI between July 2001 and November 2002. Exposure: BAC assessed in the index hospital emergency department. Outcome: Mortality in-hospital, 90 and 365 days after injury. Results. After adjusting for confounding variables, there was no significant difference for in-hospital, 90-day, and 365-day mortality by BAC. Conclusions: When fully adjusted for injury severity, alcohol intoxication is not associated with significantly lower mortality after TBI. The trend toward lower mortality at higher BACs prompts questions about the complex interaction of alcohol and TBI, and warrants further investigation of the possible protective effect of alcohol.	[Shandro, Jamie R.; Rivara, Frederick P.; Wang, Jin; Jurkovich, Gregory J.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Nathens, Avery B.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Nathens, Avery B.] Univ Toronto, Toronto, ON, Canada; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Dept Hlth Policy & Management, Baltimore, MD USA	Shandro, JR (corresponding author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359702, Seattle, WA 98104 USA.	jshandro@u.washington.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01/AG20361] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR316840] Funding Source: Medline		Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; *ASS ADV AUT MED C, 1989, ABBR INJ SCAL 1998 R; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; Gentilello LM, 1999, J TRAUMA, V47, P1131, DOI 10.1097/00005373-199912000-00027; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KLEIN T, 1998, MULTIPLE IMPUTATION; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Raghunathan TE, 2004, ANNU REV PUBL HEALTH, V25, P99, DOI 10.1146/annurev.publhealth.25.102802.124410; Raghunathan TL., 2001, SURV METHODOL, V27, P85; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; Rootman DB, 2007, J TRAUMA, V63, P1370, DOI 10.1097/TA.0b013e31815b837a; Rootman DB, 2007, J TRAUMA, V62, P755, DOI 10.1097/TA.0b013e318031aa7f; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd ed.; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Rubin DB., 1987, MULTIPLE IMPUTATION; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Soderstrom CA, 2001, J TRAUMA, V51, P557, DOI 10.1097/00005373-200109000-00024; Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Subramanian R., 2002, TRANSITIONING MULTIP; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Wacholder S, 1996, EPIDEMIOLOGY, V7, P144, DOI 10.1097/00001648-199603000-00007; Waller PF, 2003, ALCOHOL CLIN EXP RES, V27, P695, DOI 10.1097/01.ALC.0000062758.18918.7C; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461	43	44	46	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1584	1590		10.1097/TA.0b013e318182af96			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	457PN	WOS:000266944500011	19509618				2021-06-18	
J	Tuettenberg, J; Czabanka, M; Horn, P; Woitzik, J; Barth, M; Thome, C; Vajkoczy, P; Schmiedek, P; Muench, E				Tuettenberg, Jochen; Czabanka, Marcus; Horn, Peter; Woitzik, Johannes; Barth, Martin; Thome, Claudius; Vajkoczy, Peter; Schmiedek, Peter; Muench, Elke			Clinical evaluation of the safety and efficacy of lumbar cerebrospinal fluid drainage for the treatment of refractory increased intracranial pressure Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial hypertension; lumbar cerebrospinal fluid drainage; subarachnoid hemorrhage; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; HYPERTENSION; PUNCTURE; TRIAL; VALIDATION; PREDICTORS; MORTALITY	Object. Several approaches have been established for the treatment of intracranial hypertension; however, a considerable number of patients remain unresponsive to even aggressive therapeutic strategies. Lumbar CSF drainage has been contraindicated in the setting of increased intracranial pressure (ICP) because of possible cerebral herniation. The authors of this study investigated the efficacy and safety of controlled lumbar CSF drainage in patients suffering from intracranial hypertension following severe traumatic brain injury (TBI) or aneurysmal subarachnoid hemorrhage (SAH). Methods. The authors prospectively evaluated 100 patients-45 with TBI and 55 with SAH-having a mean age of 43.7 +/- 15.7 years (mean +/- SD) and suffering from refractory intracranial hypertension (ICP > 20 mm Hg). Intracranial pressure and cerebral perfusion pressure (CPP) before and after the initiation of lumbar CSF drainage as well as related complications were documented. Patient Outcomes were assessed 6 months after injury. Results. The application of lumbar CSF drainage led to a significant reduction in 1CP from 32.7 +/- 10.9 to 13.4 +/- 5.9 mm Hg (p < 0.05) and an increase in CPP from 70.6 +/- 18.2 to 86.2 +/- 15.4 mm Hg (p < 0.05). Cerebral herniation with a lethal outcome occurred in 6% of patients. Thirty-six patients had a favorable outcome, 12 were severely disabled, 7 remained in a persistent vegetative state, and 45 died. Conclusions. Lumbar drainage of CSF led to a significant and clinically relevant reduction in ICP. The risk of cerebral herniation can be minimized by performing lumbar drainage only in cases with discernible basal cisterns. (DOI: 10.3171/2008.10.JNS08293)	[Tuettenberg, Jochen] Heidelberg Univ, Univ Hosp Mannheim, Fac Med Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; [Muench, Elke] Heidelberg Univ, Univ Hosp Mannheim, Fac Med Mannheim, Dept Anesthesiol & Intens Care Med, D-68167 Mannheim, Germany; [Czabanka, Marcus; Horn, Peter; Woitzik, Johannes; Vajkoczy, Peter] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany	Tuettenberg, J (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Fac Med Mannheim, Dept Neurosurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	jochen.tuettenberg@nch.ma.uni-heidelberg.de	Barth, Martin/E-8265-2014	Tuettenberg, Jochen/0000-0001-9087-7188			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P537; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Baledent O, 2004, INVEST RADIOL, V39, P45, DOI 10.1097/01.rli.0000100892.87214.49; Baledent O, 2001, INVEST RADIOL, V36, P368, DOI 10.1097/00004424-200107000-00003; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Cushing H, 1909, BOSTON MED SURG J, V161, P71, DOI 10.1056/NEJM190907151610301; Edwards P, 2005, LANCET, V365, P1957; Fremont-Smith F, 1932, J NERV MENT DIS, V76, P261; Fritsch MJ, 1997, ZBL NEUROCHIR, V58, P192; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Hepburn HH, 1938, CAN MED ASSOC J, V39, P449; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hutter BO, 2001, J NEUROSURG, V94, P241, DOI 10.3171/jns.2001.94.2.0241; JENNETT B, 1975, LANCET, V1, P480; Kapadia FN, 1996, BRIT J NEUROSURG, V10, P585; KOREIN J, 1959, NEUROLOGY, V9, P290, DOI 10.1212/WNL.9.4.290; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Munch EC, 2001, CRIT CARE MED, V29, P976; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Quincke H, 1891, BERL KLIN WOCHENSCHR, P929; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Schaller WF, 1933, J NEUROL PSYCHOPATHO, V14, P116; SENCER W, 1956, J Mt Sinai Hosp N Y, V23, P808; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Willemse RB, 1998, ACT NEUR S, V71, P37	39	44	50	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2009	110	6					1200	1208		10.3171/2008.10.JNS08293			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451HH	WOS:000266460800015	19249925				2021-06-18	
J	Slobounov, S; Cao, C; Sebastianelli, W				Slobounov, Semyon; Cao, Cheng; Sebastianelli, Wayne			Differential effect of first versus second concussive episodes on wavelet information quality of EEG	CLINICAL NEUROPHYSIOLOGY			English	Article						MTBI; EEG information quality (EEE-IQ); Wavelet entropy; Differential recovery after MTBI	POSTURAL CONTROL; CEREBRAL CONCUSSION; QUANTITATIVE EEG; BRAIN-INJURY; HIGH-SCHOOL; RECOVERY; ENTROPY; COLLEGIATE; HYPOTHERMIA; FOOTBALL	Objective: Recent reports have suggested that long-term residual brain dysfunctions from mild traumatic brain injury (MTBI) that are often overlooked by clinical criteria may be detected using advanced research methods. The aim of the present study was to examine the feasibility of EEG wavelet information quality measures (EEG-IQ) in monitoring alterations of brain functions as well as to determine the differential rate of recovery between the first and second concussive episodes. Methods: Student-athletes at high risk for MTBI (n = 265) were tested prior to concussive episodes as a baseline. From this subject pool, twenty one athletes who suffered from two concussive episodes within one athletic season and were tested on days 7, 14 and 21 post-first and second injuries using a within-subjects design. Specifically, EEG was recorded and processed using wavelet entropy (EEG-IQ) algorithm along with a battery of neuropsychological (NS) tests. Spatial distribution of EEG-IQ and its dynamics in conjunction with NS data were analyzed prior to and after MTBI. Results: No neuropsychological deficits were present in concussed subjects beyond 7 days post-injury after first and second concussions. However, EEG-IQ measures were significantly reduced primarily at temporal, parietal and the occipital regions (ROIs) after first and especially after second MTBI (p < 0.01) beyond 7 days post-injury. Rate of recovery of EEG-IQ measures was significantly slower after second MTBI compared to those after the first concussion (p < 0.01). Conclusions: EEG-IQ measures may reveal alterations in the brain of concussed individuals that are most often overlooked by current assessment tools. In this regard, EEG-IQ may potentially be a valuable tool for assessing and monitoring residual brain dysfunction in "asymptomatic" MTBI subjects. Significance: The results demonstrate the potential utility of EEG-IQ measures to classify concussed individuals at various stages of recovery. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Slobounov, Semyon; Cao, Cheng] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Sebastianelli, Wayne] Penn State Univ, Athlet Med Clin, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 268 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This study was supported by NIH, NINDS Grant R01 NS056227-01A2.	Al-Nashash HA, 2005, IEEE T BIO-MED ENG, V52, P2119, DOI 10.1109/TBME.2005.857634; Al-Nashash HA, 2003, ANN BIOMED ENG, V31, P653, DOI 10.1114/1.1575757; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hornero R, 2003, SEVENTH INTERNATIONAL SYMPOSIUM ON SIGNAL PROCESSING AND ITS APPLICATIONS, VOL 2, PROCEEDINGS, P5, DOI 10.1109/ISSPA.2003.1224801; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jia XF, 2006, BRAIN RES, V1111, P166, DOI 10.1016/j.brainres.2006.04.121; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Kranczioch C, 2008, CLIN NEUROPHYSIOL, V119, P1419, DOI 10.1016/j.clinph.2008.02.011; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; OKEN BS, 1986, ANN NEUROL, V19, P493, DOI 10.1002/ana.410190511; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rosso OA, 2003, SIGNAL PROCESS, V83, P1275, DOI 10.1016/S0165-1684(03)00054-9; Rosso OA, 2001, J NEUROSCI METH, V105, P65, DOI 10.1016/S0165-0270(00)00356-3; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shin HC, 2006, IEEE T BIO-MED ENG, V53, P1016, DOI 10.1109/TBME.2006.873394; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6	40	44	45	1	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAY	2009	120	5					862	867		10.1016/j.clinph.2009.03.009			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	455JM	WOS:000266755200005	19375981	Green Accepted			2021-06-18	
J	Compagnone, C; d'Avella, D; Servadei, F; Angileri, FF; Brambilla, G; Conti, C; Cristofori, L; Delfini, R; Denaro, L; Ducati, A; Gaini, SM; Stefini, R; Tomei, G; Tagliaferri, F; Trincia, G; Tomasello, F				Compagnone, Christian; d'Avella, Domenico; Servadei, Franco; Angileri, Filippo F.; Brambilla, Gianluigi; Conti, Carlo; Cristofori, Luciano; Delfini, Roberto; Denaro, Luca; Ducati, Alessandro; Gaini, Sergio M.; Stefini, Roberto; Tomei, Giustino; Tagliaferri, Fernanda; Trincia, Giuseppe; Tomasello, Francesco			PATIENTS WITH MODERATE HEAD INJURY: A PROSPECTIVE MULTICENTER STUDY OF 315 PATIENTS	NEUROSURGERY			English	Article						Computed tomographic scan; Moderate head injury; Neuroworsening; Outcome	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; COMPUTERIZED-TOMOGRAPHY; INITIAL MANAGEMENT; MILD; MORTALITY; SEVERITY; ADULTS; TRIAL; SCORE	OBJECTIVE: To analyze the risk factors of worst outcome associated with moderate head injury. METHODS: Data on patients with moderate head injury were collected prospectively in 11 Italian neurosurgical units over a period of 18 months. Patients older than 18 years with blunt head injury and at least one Glasgow Coma Scale (GCS) score between 9 and 13 were enrolled. The outcome was determined at 6 months using the Glasgow Outcome Scale. RESULTS: We analyzed 315 patients. Initial computed tomographic scans showed a diffuse injury type I or 11 in 63%, a mass lesion in 35%, and traumatic subarachnoid hemorrhage in 42% of the patients. The risk of progression toward a mass lesion was 23% when the admission computed tomographic scan showed diffuse injury type I or II. An emergency craniotomy was performed in 22% of the patients, delayed surgery was performed in 14%, and both were performed in 25%. A favorable outcome was obtained in 74% of the patients. When the GCS score was 9 or 10, the predictor of worst outcome was a motor GCS score of 4 or lower (odds ratio [OR], 8.08; 95% confidence interval [CI], 1.22-67.35; P = 0.008), but when the GCS score was 11 to 13, the factors associated with worst outcome were neuroworsening (OR, 3.43; 95% Cl, 1.45-8.17; P = 0.002), seizures (OR, 7.94; 95% Cl, 1.18-64.48; P = 0.02), and medical complications (OR, 4.24; 95% Cl, 1.74-10.33; P = 0.0006). CONCLUSION: There is a high percentage of surgery and worsening on computed tomographic scans in patients with moderate head injury. Neuroworsening, seizures, and medical complications as outcome predictors were more strongly associated with a GCS score of 11 to 13, whereas a low motor GCS score was more outcome-related in patients with GCS scores of 9 and 10.	[d'Avella, Domenico] Univ Padua, Sch Med, Dept Neurosci, I-35128 Padua, Italy; [Compagnone, Christian; Tagliaferri, Fernanda] Bufalini Hosp, Intens Care Unit, Cesena, Italy; [Servadei, Franco] Azienda Osped Univ, Div Neurosurg, Parma, Italy; [Angileri, Filippo F.; Tomasello, Francesco] Univ Messina, Clin Neurochirurg, Messina, Italy; [Brambilla, Gianluigi] IRCCS Policlin S Matteo, Pavia, Italy; [Conti, Carlo; Trincia, Giuseppe] Azienda Osped Mestre, Div Neurosurg, Venice, Italy; [Cristofori, Luciano] Azienda Osped Verona, Dept Neurosurg, Verona, Italy; [Delfini, Roberto] Univ Roma La Sapienza, Dept Neurosurg, Rome, Italy; [Denaro, Luca] Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy; [Ducati, Alessandro] Univ Turin, Clin Neurochirurg, Turin, Italy; [Gaini, Sergio M.] Osped Policlin IRCCS, Clin Neurochirurg, Milan, Italy; [Stefini, Roberto] Univ Brescia, Clin Neurochirurg, Brescia, Italy; [Tomei, Giustino] Univ Insubria Varese, Clin Neurochirurg, Varese, Italy	d'Avella, D (corresponding author), Univ Padua, Sch Med, Dept Neurosci, Via Giustiniani 2, I-35128 Padua, Italy.	domenico.davella@unipd.it	Angileri, Filippo/N-8556-2019; Angileri, Filippo/AAL-4851-2021; Angileri, Filippo Flavio/J-3533-2012	Angileri, Filippo/0000-0002-1107-4115; Angileri, Filippo Flavio/0000-0002-1107-4115; Compagnone, Christian/0000-0001-9951-5503; Servadei, Franco/0000-0002-3595-3464			Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JENNETT B, 1975, LANCET, V1, P480; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER JD, 1985, LANCET, V1, P1141; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Servadei F, 2000, NEUROSURGERY, V46, P70; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1	36	44	45	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2009	64	4					690	696		10.1227/01.NEU.0000340796.18738.F7			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	427MN	WOS:000264783500028	19197220				2021-06-18	
J	Tepas, JJ; Leaphart, CL; Pieper, P; Beaulieu, CL; Spierre, LR; Tuten, JD; Celso, BG				Tepas, Joseph J., III; Leaphart, Cynthia L.; Pieper, Pam; Beaulieu, Cynthia L.; Spierre, Louise R.; Tuten, James D.; Celso, Brian G.			The effect of delay in rehabilitation on outcome of severe traumatic brain injury	JOURNAL OF PEDIATRIC SURGERY			English	Article						Rehabilitation; Outcomes; FIM (functional independence measure); Pediatric trauma	FUNCTIONAL INDEPENDENCE; MORTALITY; CHILDREN; SYSTEM; WEEFIM	Background: Expeditious care within minutes of severe injury improves outcome and is the driving force for development of trauma care systems. Transition from hospital care to rehabilitation is an important step in recovery after trauma-related injury. We hypothesize that delay in the transition from acute care to rehabilitation adversely affects outcome and diminishes recovery after traumatic brain injury (TBI). Methods: After institutional review board approval, the trauma registry of our regional level I pediatric trauma center was queried for all children with severe blunt TBI (initial Glasgow Coma Scale score <= 8) that required inpatient rehabilitation. Records were stratified as severe TBI (Glasgow Coma Scale [GCS] scores 3, 4, 5) and moderate TBI (GSC scores 6, 7, 8). Intensity of acute care was defined by need for mechanical ventilation and length of intensive care unit stay. Outcome was defined by functional independence measurement (FIM) scores at time of transfer to inpatient rehabilitation. Linear regression was used to compare time in days between discharge from intensive care and admission to inpatient rehabilitation (delay) to rehabilitation efficiency (RE), defined as the ratio of FIM score improvement to length of stay for inpatient rehabilitation. Functional improvement was determined by analysis of FIM score improvement (Delta FIM) between initiation and completion of inpatient rehabilitation. Results: Between January 2000 and December 2006, 60 children (38 males, mean age, 11.2 years; 22 females, mean age, 10.6 years) with blunt TBI and an initial GCS score of 8 or lower required resuscitation, comprehensive critical care, and inpatient rehabilitation. Mean length of stay in the intensive care unit was 11.1 +/- 7.4 days. Fifty-two children required an average of 9.4 +/- 6.8 ventilator days. Delay ranged between 0 and 24 days (mean, 4.1 days) and was significantly correlated with RE and Delta FIM (,Correlation coefficient = -0.346, P = .0068). For children with the highest potential for salvage (GCS scores 6, 7, 8), RE correlation increased to -0.457 (P = .011), whereas those with most severe injury (GCS scores 3, 4, 5) demonstrated a weaker correlation that was not significant. For children with most severe injury (GCS scores 3,4,5), the con-elation of Delta FIM was significant (-0.38 P = .035); however, RE was not. Conclusions: These data demonstrate the price of delay of comprehensive rehabilitation, especially for the most vulnerable TBI children with best potential for salvage. The "golden hour," which has become the mantra for continued refinement of systems of emergency and trauma care, must progress without interruption to the "golden clay," during which comprehensive critical care seamlessly transitions to timely and aggressive rehabilitation to effect the greatest functional recovery. (C) 2009 Elsevier Inc. All rights reserved.	[Tepas, Joseph J., III; Leaphart, Cynthia L.; Pieper, Pam] Univ Florida, Coll Med Surg, Jacksonville, FL 32209 USA; [Beaulieu, Cynthia L.; Spierre, Louise R.] Brooks Rehabil Hosp, Jacksonville, FL 32216 USA; [Tuten, James D.] Version2Network, St Augustine, FL 32084 USA; [Celso, Brian G.] Univ Florida, Dept Psychiat, Coll Med, Jacksonville, FL 32209 USA	Tepas, JJ (corresponding author), Univ Florida, Div Pediat Surg, Coll Med Jacksonville, Jacksonville, FL 32209 USA.	jjt@jax.ufl.edu					Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; Gabbe BJ, 2008, ANN SURG, V247, P854, DOI 10.1097/SLA.0b013e3181656d1e; Gabbe BJ, 2007, J TRAUMA, V63, P1374, DOI 10.1097/01.ta.0000240481.55341.38; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Mullins RJ, 1998, J TRAUMA, V44, P17; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Pracht EE, 2008, J PEDIATR SURG, V43, P212, DOI 10.1016/j.jpedsurg.2007.09.047; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Srivastava R, 2007, J HOSP MED, V2, P165, DOI 10.1002/jhm.167; Willis CD, 2006, INJURY, V37, P1185, DOI 10.1016/j.injury.2006.07.011; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	15	44	44	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	FEB	2009	44	2					368	372		10.1016/j.jpedsurg.2008.10.089			5	Pediatrics; Surgery	Pediatrics; Surgery	415MY	WOS:000263939100014	19231536				2021-06-18	
J	Hu, ZG; Wang, HD; Qiao, L; Yan, W; Tan, QF; Yin, HX				Hu, Zhi-Gang; Wang, Han-Dong; Qiao, Liang; Yan, Wei; Tan, Qi-Fu; Yin, Hong-Xia			The protective effect of the ketogenic diet on traumatic brain injury-induced cell death in juvenile rats	BRAIN INJURY			English	Article						ketogenic diet; pediatric; traumatic brain injury; apoptosis	D-BETA-HYDROXYBUTYRATE; KETONE-BODIES; ADULT RATS; CORTICAL CONTUSION; GENE-EXPRESSION; TRANSGENIC MICE; NEURONAL DEATH; BCL-2 FAMILY; APOPTOSIS; ISCHEMIA	Background: The ketogenic diet (the KD) is an effective treatment for intractable epilepsy, especially in the paediatric population, and a growing number of studies have shown the neuroprotective role of the KD. However, few studies focused on the neuroprotective effects of the KD in traumatic brain injury (TBI). The present study aimed to investigate the effects of the KD on TBI. Methods and procedures: Male Sprague-Dawley rats (n = 60) were randomly divided into four groups according to the diet fed (the KD vs normal diet) and whether brain was injured or not. TBI was produced using Feeney weight drop model. Brain oedema was estimated by wet/dry weight ratio; Bax and Bcl-2 mRNA levels were determined by RealTime-PCR; Bax and Bcl-2 protein levels were detected by Western blot. Furthermore, cellular apoptosis in the penumbra area was examined using terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) method. Main outcomes and results: The results indicated that both Bax mRNA and protein levels were significantly elevated 72 hours after TBI and decreased by KD administration. Neither TBI nor the KD affected Bcl-2 mRNA and protein levels. KD administration also reduced brain oedema and cellular apoptosis. Conclusion: These results suggest that the KD might be a useful treatment for children suffering from the consequences of TBI.	[Hu, Zhi-Gang; Wang, Han-Dong; Qiao, Liang; Tan, Qi-Fu; Yin, Hong-Xia] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, Nanjing 210002, Jiangsu Prov, Peoples R China; [Yan, Wei] Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835			Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Cheng BH, 2007, AUTON NEUROSCI-BASIC, V134, P38, DOI 10.1016/j.autneu.2007.02.002; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Eun SH, 2006, BRAIN DEV-JPN, V28, P566, DOI 10.1016/j.braindev.2006.03.011; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; HAWKINS RA, 1979, SCIENCE, V205, P325, DOI 10.1126/science.451608; Hochman A, 1998, J NEUROCHEM, V71, P741; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; Kossoff EH, 2006, EPILEPSIA, V47, P421, DOI 10.1111/j.1528-1167.2006.00438.x; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Papandreou D, 2006, BRIT J NUTR, V95, P5, DOI 10.1079/BJN20051591; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Veech RL, 2001, IUBMB LIFE, V51, P241; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; White FA, 1998, J NEUROSCI, V18, P1428; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YANG J, 1997, SCIENCE, V275, P1132; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	48	44	44	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					459	465	PII 910861424	10.1080/02699050902788469			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700010	19408168				2021-06-18	
J	Lane-Brown, AT; Tate, RL				Lane-Brown, A. T.; Tate, R. L.			Measuring apathy after traumatic brain injury: Psychometric properties of the Apathy Evaluation Scale and the Frontal Systems Behavior Scale	BRAIN INJURY			English	Article						Apathy; traumatic brain injury; measurement	VERBAL-LEARNING TEST; DEPRESSION; RELIABILITY; PREVALENCE; VALIDITY; STRESS; STRATEGIES; FATIGUE; DASS	Objectives: To evaluate the reliability and validity of the Apathy Evaluation Scale (AES) and Apathy sub-scale of the Frontal Systems Behavior Scale (FrSBe-A) for people with traumatic brain injury (TBI). To identify an optimal cut-off score indicating presence of apathy according to the AES. Methods and procedures: A sample of 34 participants with severe TBI currently residing in the community underwent neuropsychological and psychosocial assessment to evaluate reliability, discriminant, convergent and divergent validity. Receiver Operating Characteristic (ROC) curve analysis was undertaken to identify an optimal cut-off score on the AES. Results: AES and FrSBe-A correlated moderately with each other (r=0.71). Both AES and FrSBe-A have good internal consistency and discriminant validity with measures of depression and fatigue. Support for hypothesized correlations with similar and dissimilar constructs was not shown. ROC analysis identified a cut-off score of 37 or higher on AES indicated presence of apathy. Conclusions: AES and FrSBe-A are reliable and valid measures of apathy following TBI. It is suggested that the two scales measure slightly differing aspects of the apathy construct, with AES addressing emotional-affective aspects of apathy more than FrSBe-A, which focuses more heavily on cognitive and behavioral elements of goal-directed behavior.	[Lane-Brown, A. T.; Tate, R. L.] Univ Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia; [Lane-Brown, A. T.; Tate, R. L.] Royal Rehabil Ctr, Sydney, NSW, Australia	Lane-Brown, AT (corresponding author), Univ Sydney, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amandal@med.usyd.edu.au			University of SydneyUniversity of Sydney; Rehabilitation Studies Unit, University of SydneyUniversity of Sydney; Northern Medical Research Foundation; Northern Clinical School, University of SydneyUniversity of Sydney; Australian GovernmentAustralian GovernmentCGIAR	This study was supported by the University of Sydney and funding has been provided by the Rehabilitation Studies Unit, University of Sydney; the Northern Medical Research Foundation and the Northern Clinical School, University of Sydney; and the Australian Government through an Australian Postgraduate Award. The authors thank Regina Schultz for assistance in data collection and for her support.	Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Betz N., 2000, PSYCHOL RES HDB GUID, P239; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; Cohen MJ, 2000, ARCH CLIN NEUROPSYCH, V15, P267, DOI 10.1016/S0887-6177(99)00017-7; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; CROSSEN JR, 1994, J CLIN EXP NEUROPSYC, V16, P190, DOI 10.1080/01688639408402630; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DELANEY RC, 1992, ARCH CLIN NEUROPSYCH, V7, P523, DOI 10.1016/0887-6177(92)90142-A; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Diehl M, 1996, PSYCHOL AGING, V11, P127, DOI 10.1037/0882-7974.11.1.127; Duffy J, 2006, GUIDE NEUROPSYCHIATR, P1; Finset A, 2000, BRAIN INJURY, V14, P887; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kuzis G, 1999, NEUROLOGY, V52, P1403, DOI 10.1212/WNL.52.7.1403; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Marin R.S., 1996, SEMIN CLIN NEUROPSYC, V1, P304, DOI [10.1053/SCNP00100304, DOI 10.1053/SCNP00100304]; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1993, J AFFECT DISORDERS, V28, P7, DOI 10.1016/0165-0327(93)90072-R; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Matud MP, 2004, PERS INDIV DIFFER, V37, P1401, DOI 10.1016/j.paid.2004.01.010; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Norton LE, 2001, AM J GERIAT PSYCHIAT, V9, P41; Rey A, 1964, EXAMEN CLIN PSYCHOL; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; Starkstein SE, 2006, J NEUROL NEUROSUR PS, V77, P8, DOI 10.1136/jnnp.2005.069575; Starkstein SE, 2000, INT PSYCHOGERIATR, V12, P135, DOI 10.1017/S1041610200006918; Starkstein SE, 2006, EUR J PSYCHIAT, V20, P96, DOI 10.4321/s0213-61632006000200005; Stuss DT., 2000, DIFFERENTIATION STAT, P340; Tabachnick BG, 2007, USING MULTIVARIATE S; Tate R.L., 2009, BRAIN IMPAIR, V10, P228; Thurstone L.L., 1962, PRIMARY MENTAL ABILI	45	44	46	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	13-14					999	1007		10.3109/02699050903379347			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	529YR	WOS:000272556000002	19891539				2021-06-18	
J	Li, W; Dai, SS; An, JH; Xiong, RP; Li, PY; Chen, X; Zhao, Y; Liu, P; Wang, H; Zhu, PF; Chen, JF; Zhou, YG				Li, Wei; Dai, Shuangshuang; An, Janhong; Xiong, Renping; Li, Ping; Chen, Xingyun; Zhao, Yan; Liu, Ping; Wang, Hua; Zhu, Peifang; Chen, Jiangfan; Zhou, Yuanguo			Genetic inactivation of adenosine A(2A) receptors attenuates acute traumatic brain injury in the mouse cortical impact model	EXPERIMENTAL NEUROLOGY			English	Article						Adenosine A(2A) receptor; Traumatic brain injury; Cortical impact injury, glutamate; Inflammatory cytokines	MARROW-DERIVED CELLS; INDUCED EXCITOTOXICITY; PARKINSONS-DISEASE; HEAD-INJURY; PROTECTION; NEUROPROTECTION; RAT; ACTIVATION; ISCHEMIA; BLOCKADE	The inactivation of the A(2A) receptor (A(2A)R) has been shown to neuroprotect against brain injury in several animal models of neurological disorders including stroke and Parkinson's disease. However, despite marked elevation of adenosine level, the role of the A(2A) in traumatic brain injury (TBI) remains unclear. In the present study, we investigated the effects of genetic inactivation of A(2A)Rs in the acute stage. The A(2A)R knock-out (KO) mice and their wild-type (WT) littermates Were subjected to cortical impact injury by a dropping weight. The control group Was only craniotomized withoyt TBI. At 24 h post-TBI, the neurological deficit scores of the KO mice were significantly lower than that of WT littermates. Consistent with the behavioral changes, the brain water contents as well as histological changes and the TUNEL-positive cells of the injured cortex of the KO mice were significantly lower than that of WT littermates. Furthermore, the glutamate level in the cerebral spinal fluid (CSF) of the KO mice was also significantly lower than that of WT littermates. In addition, we found that at 12 h post-TBI the mRNA and protein levels of TNF-alpha and IL-1 beta were higher in the KO mice than that in the WT littermates. However, at 24 h post-TBI, the level of TNF-alpha and IL-1 beta continually increased in the WT mice but largely declined in the KO mice. These results suggest that the genetic inactivation of A(2A)R protects against TBI, which is mainly associated with the Suppression of glutamate level. (C) 2008 Elsevier Inc. All rights reserved.	[Chen, Jiangfan] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Li, Wei; Dai, Shuangshuang; An, Janhong; Xiong, Renping; Li, Ping; Chen, Xingyun; Zhao, Yan; Liu, Ping; Wang, Hua; Zhu, Peifang; Zhou, Yuanguo] Third Mil Med Univ, Inst Surg Res, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, Chongqing, Peoples R China; [Li, Wei; Dai, Shuangshuang; An, Janhong; Xiong, Renping; Li, Ping; Chen, Xingyun; Zhao, Yan; Liu, Ping; Wang, Hua; Zhu, Peifang; Zhou, Yuanguo] Third Mil Med Univ, Daping Hosp, Chongqing, Peoples R China	Chen, JF (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St,C329, Boston, MA 02118 USA.	chenjf@bu.edu; ygzhou@cta.cq.cn	Li, ping/J-6507-2019	Chen, Xingyun/0000-0001-7699-4425	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30328015, 30671918]	We thank Mr. Nan Yang for handling the animals. We gratefully acknowledge the proofreading and correcting suggestion for the manuscript of Ms. Eileen Crehan. This work was supported by the grants from National Natural Science Foundation of China (No. 30328015 and No. 30671918).	BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Blum D, 2003, LANCET NEUROL, V2, P366, DOI 10.1016/S1474-4422(03)00411-3; BOLY DL, 1996, ARTHRITIS RHEUM, V39, P923; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cerqueira MD, 2004, AM J CARDIOL, V94, p33D; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; ENGLER RL, 1991, CIRCULATION, V84, P951, DOI 10.1161/01.CIR.84.2.951; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiser SM, 2002, J THORAC CARDIOV SUR, V124, P973, DOI 10.1067/mtc.2002.124886; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Fredholm BB, 2001, DRUG DEVELOP RES, V52, P274, DOI 10.1002/ddr.1124; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Fredholm Bertil B., 2003, Neurology, V61, pS5; GOLDBERG MP, 1988, NEUROSCI LETT, V89, P323, DOI 10.1016/0304-3940(88)90547-2; Huang QY, 2006, J NEUROSCI, V26, P11371, DOI 10.1523/JNEUROSCI.1907-06.2006; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Maddock HL, 2001, J AUTON PHARMACOL, V21, P263, DOI 10.1046/j.1365-2680.2001.00238.x; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Rosin DL, 1998, J COMP NEUROL, V401, P163; Schwarzschild Michael A., 2003, Neurology, V61, pS55; Silva CG, 2007, NEUROBIOL DIS, V27, P182, DOI 10.1016/j.nbd.2007.04.018; Sitkovsky MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/j.it.2005.04.004; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Yu LQ, 2004, BRAIN RES, V1000, P156, DOI 10.1016/j.brainres.2003.11.072	40	44	46	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2009	215	1					69	76		10.1016/j.expneurol.2008.09.012			8	Neurosciences	Neurosciences & Neurology	394QM	WOS:000262462300009	18938161				2021-06-18	
J	Cheng, JP; Hoffman, AN; Zafonte, RD; Kline, AE				Cheng, Jeffrey P.; Hoffman, Ann N.; Zafonte, Ross D.; Kline, Anthony E.			A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning	BEHAVIOURAL BRAIN RESEARCH			English	Article						beam-walking; controlled cortical impact; functional recovery; learning and memory; morris water maze; neurobehavior; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BAY X 3702; WATER MAZE PERFORMANCE; COGNITIVE DEFICITS; METHYLPHENIDATE TREATMENT; NEUROBEHAVIORAL BENEFIT; HALOPERIDOL; MEMORY; WAY-100635; IMPAIRMENT	An early (i.e., 15 min) single systemic administration of the 5-HT1A receptor agonist 8-OH-DPAT enhances behavioral recovery after experimental traumatic brain injury (TBI). However, acute administration of pharmacotherapies after TBI may be clinically challenging and thus the present Study sought to investigate the potential efficacy of a delayed and chronic 8-OH-DPAT treatment regimen. Forty-eight isoflurane-anesthetized adult male rats received either a controlled cortical impact or sham injury and beginning 24 h later were administered 8-OH-DPAT (0.1 or 0.5 mg/kg) or saline vehicle (1.0 mL/kg) intraperitoneally once daily until all behavioral assessments were completed. Neurobehavior was assessed by motor and cognitive tests on post-operative days 1-5 and 14-19, respectively. The lower dose of 8-OH-DPAT (0.1 mg/kg) enhanced motor performance, acquisition of spatial learning, and memory retention vs. both the higher dose (0.5 mg/kg) and vehicle treatment (p < 0.05). These data replicate previous findings from our laboratory showing that 8-OH-DPAT improves neurobehavior after TBI, and extend those results by demonstrating that the benefits can be achieved even when treatment is withheld for 24 h. A delayed and chronic treatment regimen may be more clinically feasible. (C) 2008 Elsevier B.V. All rights reserved.	[Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Cheng, Jeffrey P.; Hoffman, Ann N.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grants HD043851 and HD046700 awarded to AEK.	Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; CARLI M, 1995, BEHAV BRAIN RES, V67, P67, DOI 10.1016/0166-4328(94)00105-O; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Galeotti N, 2000, JPN J PHARMACOL, V84, P418, DOI 10.1254/jjp.84.418; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Helsley S, 1998, PROG NEURO-PSYCHOPH, V22, P1179, DOI 10.1016/S0278-5846(98)00068-2; HOFFMAN AN, LIFE SCI IN PRESS; Kant GJ, 1996, PHARMACOL BIOCHEM BE, V53, P385, DOI 10.1016/0091-3057(95)02038-1; Kant GJ, 1998, PHARMACOL BIOCHEM BE, V59, P729, DOI 10.1016/S0091-3057(97)00553-4; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; KREISS DS, 1992, NEUROPHARMACOLOGY, V31, P1073, DOI 10.1016/0028-3908(92)90110-B; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Luttgen M, 2005, NEUROPHARMACOLOGY, V48, P830, DOI 10.1016/j.neuropharm.2005.01.007; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 2007, BEHAV BRAIN RES, V184, P81, DOI 10.1016/j.bbr.2007.06.026; Misane I, 2003, NEUROPSYCHOPHARMACOL, V28, P253, DOI 10.1038/sj.npp.1300024; Ohman J, 2001, J NEUROTRAUM, V18, P1313, DOI 10.1089/08977150152725614; Pitsikas N, 2003, BRAIN RES, V983, P215, DOI 10.1016/S0006-8993(03)03091-9; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schneider AM, 2003, LEARN MEMORY, V10, P394, DOI 10.1101/lm.54903; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	65	44	44	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 1	2008	194	1					79	85		10.1016/j.bbr.2008.06.025			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	355MM	WOS:000259713000011	18638506	Green Accepted			2021-06-18	
J	Rinder, CS				Rinder, Christine Stowe			Fire safety in the operating room	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						fire triad; monitored anesthesia care liability; operating-room fires; oxygen-enriched atmospheres	MONITORED ANESTHESIA CARE; SURGICAL FIRES; NITROUS-OXIDE; INJURY	Purpose of review Elimination of flammable anesthetic gases has had little effect on operating-room fires except to change their etiology. Electrocautery and lasers, in an oxygen-enriched environment, can ignite even the most fire-resistant materials, including the patient, and the fire triad possibilities in the operating room are nearly limitless. This review will: identify operating room contents capable of acting as ignition/oxidizer/fuel sources, highlight operating room items that are uniquely potent fire triad contributors, and operating room identify settings where fire risk is enhanced by proximity of triad components in time or space. Recent findings Anesthesiologists are cognizant of the risk of airway surgery fires due to laser ignition of the endotracheal tube and/or its contents. Recently, however, head/neck surgery under monitored anesthesia care has emerged as a high-risk setting for operating room fires; burn injuries represent 20% of monitored anesthesia care-related malpractice claims, 95% of which involved head/neck surgery. Summary Operating room fires are infrequent but catastrophic. Operating room fire prevention depends on: (a) understanding how fire triad elements interact to create a fire, (b) recognizing how standard operating-room equipment, materials, and supplemental oxygen can become one of those elements, and (c) vigilance for circumstances that bring fire triad elements into close proximity.	[Rinder, Christine Stowe] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA; [Rinder, Christine Stowe] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA	Rinder, CS (corresponding author), Yale Univ, Sch Med, Dept Anesthesiol, Tompkins 3, New Haven, CT 06520 USA.	christine.rinder@yale.edu					Barker SJ, 2001, ANESTH ANALG, V93, P960, DOI 10.1097/00000539-200110000-00031; Barnes A M, 2000, AANA J, V68, P153; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; *ECRI, 1992, HLTH DEVICES, V21, P3; EHRENWERTH JE, 2006, CLIN ANESTH, P169; GL W, 2000, J CLIN MONITOR COMPU, V16, P237; Goldberg Jessica, 2006, AANA J, V74, P352; *JCAHO, NAT PAT SAF GOALS; Lampotang S, 2005, ANESTH ANALG, V101, P1407, DOI 10.1213/01.ANE.0000180215.50589.02; Meneghetti SC, 2007, PLAST RECONSTR SURG, V120, P1701, DOI 10.1097/01.prs.0000282729.23202.da; NEUMAN GG, 1993, ANESTHESIOLOGY, V78, P875, DOI 10.1097/00000542-199305000-00011; Niskanen M, 2007, ACTA ANAESTH SCAND, V51, P509, DOI 10.1111/j.1399-6576.2007.01280.x; RINDER CS, 2005, ANESTHESIOLOGY S, V105, pC46; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; Smyth ETM, 2005, J HOSP INFECT, V61, P112, DOI 10.1016/j.jhin.2005.02.010; Sommers JR., 1998, SSM, V2, P41; Sosis M B, 1992, J Clin Anesth, V4, P217, DOI 10.1016/0952-8180(92)90069-D; Weber SM, 2005, HEAD NECK-J SCI SPEC, V28, P649; Williams DM, 2006, ACTA ANAESTH SCAND, V50, P505, DOI 10.1111/j.1399-6576.2006.00975.x; WOLF GL, 1987, ANESTHESIOLOGY, V67, P236, DOI 10.1097/00000542-198708000-00014	20	44	44	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0952-7907			CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	DEC	2008	21	6					790	795		10.1097/ACO.0b013e328318693a			6	Anesthesiology	Anesthesiology	398ES	WOS:000262716000017	18997531				2021-06-18	
J	Coats, B; Margulies, SS				Coats, Brittany; Margulies, Susan S.			Potential for head injuries in infants from low-height falls	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						anthropomorphic surrogate; biomechanical study; child abuse; head impact; low-height fall; pediatric head injury	SHAKEN BABY SYNDROME; TRAUMATIC AXONAL INJURY; PROFESSIONAL FOOTBALL; SKULL FRACTURES; CHILDREN; IMPACTS; CONCUSSION; BRAIN	Object. Falls are the most common accident scenario in young children as well as the most common history provided in child abuse cases. Understanding the biomechanics of falls provides clinicians with objective data to aid in their diagnosis of accidental or inflicted trauma. The objective of this study was to determine impact forces and angular accelerations associated with low-height falls in infants. Methods. An instrumented anthropomorphic infant surrogate was created to measure the forces and 3D angular accelerations associated with falls from low heights (0.3-0.9 m) onto a mattress, carpet pad, or concrete. Results. Although height significantly increased peak angular acceleration (alpha(p)), change in peak-to-peak angular velocity, time duration associated with the change in velocity, and peak impact force (F-p) for head-first drops onto a carpet pad or concrete, none of these variables were significantly affected by height when dropped onto a mattress. The ap was not significantly different for drops onto a carpet pad and concrete from 0.6 or 0.9 m due to compression of the carpet pad. Surprisingly, sagittal alpha(p) was equaled or surpassed by axial alpha(p). Conclusions. These are the first 3D angular acceleration and impact force data available for head impact in infants from low-height falls. A future study involving a computational model of the infant head will use the loads measured in this study to predict the probability of occipital skull fracture on impact from head-first low-height falls. Together, these studies will provide data that will aid clinicians in the evaluation of accidental and inflicted head injuries, and will contribute to the design of safer environments for children. (DOI: 10.3171/PED.2008.2.11.321)	[Coats, Brittany; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 210 S 33rd St,Suite 240, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Coats, Brittany/A-4523-2009		NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000411, R01CE001445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39679, R01 NS039679] Funding Source: Medline; NCIPC CDC HHS [R49/CE000411-01, R01 CE001445] Funding Source: Medline		BRETON F, 1990, BIOL PSYCHOL, V31, P57, DOI 10.1016/0301-0511(90)90078-B; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Coats B., 2007, THESIS U PENNSYLVANI; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; GENNARELLI T, 1972, STRAPP CAR CRASH C D; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HALL JR, 1989, J TRAUMA, V29, P1273, DOI 10.1097/00005373-198909000-00015; HELFER RE, 1977, PEDIATRICS, V60, P533; MARGULIES SS, 1999, COMP DIFFUSE BRAIN I; Meaney DF, 1991, THESIS U PENNSYLVANI; Ohman Anna Maria, 2008, Pediatr Phys Ther, V20, P53, DOI 10.1097/PEP.0b013e31815ebb27; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PRANGE M, 2002, THESIS U PENNSYLVANI; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Society of Automotive Engineers (SAE), 1995, SURF VEH REC PRACT J; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; WEBER W, 1985, Z RECHTSMED, V94, P93; WEBER W, 1984, Z RECHTSMED, V92, P87, DOI 10.1007/BF02116216; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; Wolfson DR, 2005, P I MECH ENG H, V219, P63, DOI 10.1243/095441105X9237; ZAR Jh, 2009, BIOSTATISTICAL ANAL	30	44	44	1	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2008	2	5					321	330		10.3171/PED.2008.2.11.321			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	364UX	WOS:000260362000009	18976102				2021-06-18	
J	Ashki, N; Hayes, KC; Bao, F				Ashki, N.; Hayes, K. C.; Bao, F.			The peroxynitrite donor 3-morpholinosydnonimine induces reversible changes in electrophysiological properties of neurons of the guinea-pig spinal cord	NEUROSCIENCE			English	Article						spinal cord injury; neurotrauma; axons; conduction; immuno-fluorescence; nitric oxide	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; CNS WHITE-MATTER; LIPID-PEROXIDATION; AXONAL CONDUCTION; URIC-ACID; MULTIPLE-SCLEROSIS; COMPRESSION INJURY; TYROSINE NITRATION	Elevated concentrations of nitric oxide (NO) and peroxynitrite (ONOO-) are present within the CNS following neurotrauma and are implicated in the pathogenesis of the accompanying neurologic deficits. We tested the hypothesis that elevated extracellular concentrations of ONOO-, introduced by the donor 3-morpholinosydnonimine (SIN-1), induce reversible axonal conduction deficits in neurons of the guinea-pig spinal cord. The compound action potential (CAP) and compound membrane potential (CMP) of excised ventral cord white matter were recorded before, during, and after, bathing the tissue (30 min) in varying concentrations (0.125-2.0 mM) of SIN-1 ( 3.75-60 mu M ONOO-). The principal results were rapid onset, concentration-dependent, reductions in amplitude of the CAP (P<0.05). At a concentration of 0.25 mM of SIN-1 the reduction in CAP amplitude was fully reversible and was not accompanied by any changes in CMP. At higher concentrations of SIN-1 (>= 0.5 mM) the reversibility was incomplete and there was concurrent depolarization of the CMP. These electrophysiological changes were not evident when the donor had been a priori depleted of ONOO- by uric acid or was co-administered with the ONOO- scavenger ebselen (3 mM). Immuno-fluorescence staining for nitrotyrosine (Ntyr) revealed extensive nitration of tyrosine residues in neurons exposed to higher concentrations of SIN-1. These results are the first to demonstrate that ONOO- induces reversible conduction deficits within axons of the spinal cord. The dissociation of CAP and CMP changes at low concentrations of SIN-1, when the CAP changes were reversible and there was no evidence of nitration of tyrosine residues, is consistent with ONOO--induced alteration in Na+ channel conductance in the axolemma. The results support the view that ONOO- contributes to both reversible and non-reversible neurologic deficits following neurotrauma. The reversal of immune-mediated conduction deficits may contribute to spontaneous neurologic deficits following neurotrauma. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Hayes, K. C.] Lawson Hlth Res Inst, London, ON N6C 5J1, Canada; [Ashki, N.; Hayes, K. C.] Univ Western Ontario, Neurosci Program, London, ON, Canada; [Bao, F.] Robarts Res Inst, BioTherapeut Res Grp, London, ON N6A 5C1, Canada	Hayes, KC (corresponding author), Lawson Hlth Res Inst, 801 Commissioners Rd E, London, ON N6C 5J1, Canada.	kchayes@uwo.ca			Rick Hansen Foundation	The authors are grateful to Dr. L. Weaver (Robarts Research Institute) for providing helpful advice and resources for the immuno-fluorescence studies. This work was supported by a grant from the Rick Hansen Foundation.	Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Alvarez MN, 2004, ARCH BIOCHEM BIOPHYS, V432, P222, DOI 10.1016/j.abb.2004.09.015; Ashki N, 2006, J NEUROTRAUM, V23, P1779, DOI 10.1089/neu.2006.23.1779; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Chang HT, 2007, SPINAL CORD, V45, P174, DOI 10.1038/sj.sc.3101910; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Garthwaite G, 2002, NEUROSCIENCE, V109, P145, DOI 10.1016/S0306-4522(01)00447-X; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hosaka N, 2008, EUR SPINE J, V17, P281, DOI 10.1007/s00586-007-0477-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jiang J, 2007, EUR J PHARMACOL, V561, P54, DOI 10.1016/j.ejphar.2006.12.028; Kaegi S, 2002, EUR J NEUROSCI, V16, P249, DOI 10.1046/j.1460-9568.2002.02076.x; Kapoor R, 1999, ANN NY ACAD SCI, V893, P304, DOI 10.1111/j.1749-6632.1999.tb07843.x; KITA Y, 1994, EUR J PHARMACOL, V257, P123, DOI 10.1016/0014-2999(94)90703-X; Kuzkaya N, 2005, BIOCHEM PHARMACOL, V70, P343, DOI 10.1016/j.bcp.2005.05.009; Li MH, 2006, FREE RADICAL BIO MED, V41, P1079, DOI 10.1016/j.freeradbiomed.2006.06.010; Li Z, 1998, NEURON, V20, P1039, DOI 10.1016/S0896-6273(00)80484-5; Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu P, 2000, AM J PHYSIOL-CELL PH, V279, pC1970; Liu XZ, 1997, J NEUROSCI, V17, P5395; Martin-Romero FJ, 2004, J FLUORESC, V14, P17, DOI 10.1023/B:JOFL.0000014655.89256.bd; Meij JTA, 2004, MOL PHARMACOL, V66, P1043, DOI 10.1124/mol.104.001354; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mohiuddin I, 2006, J SURG RES, V133, P143, DOI 10.1016/j.jss.2005.10.008; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Pannu R, 2006, NEUROCHEM INT, V49, P170, DOI 10.1016/j.neuint.2006.04.010; Peluffo RD, 2004, BIOPHYS J, V87, P883, DOI 10.1529/biophysj.103.030643; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Renganathan M, 2002, J NEUROPHYSIOL, V87, P761, DOI 10.1152/jn.00369.2001; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shrager P, 1998, J NEUROPHYSIOL, V79, P529; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; STYS PK, 1992, J NEUROSCI, V12, P430; Stys PK, 1998, NEUROSCIENCE, V82, P21; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Weaver LC, 2001, J NEUROTRAUM, V18, P1107, DOI 10.1089/08977150152693782; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu JH, 2006, NEUROSCI LETT, V399, P210, DOI 10.1016/j.neulet.2006.02.024; Xu LY, 2001, J IMMUNOL, V166, P5810, DOI 10.4049/jimmunol.166.9.5810	59	44	44	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	SEP 22	2008	156	1					107	117		10.1016/j.neuroscience.2008.06.050			11	Neurosciences	Neurosciences & Neurology	352BE	WOS:000259469300011	18662749				2021-06-18	
J	Xiong, Y; Mahmood, A; Lu, DY; Qu, CS; Kazmi, H; Goussev, A; Zhang, ZG; Noguchi, CT; Schallerte, T; Chopp, M				Xiong, Ye; Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Kazmi, Humaira; Goussev, Anton; Zhang, Zheng Gang; Noguchi, Constance T.; Schallerte, Timothy; Chopp, Michael			Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system	BRAIN RESEARCH			English	Article						cell proliferation; erythropoietin receptor null; mouse; sensorimotor; spatial learning; traumatic brain injury	CONTROLLED CORTICAL IMPACT; RECOMBINANT-HUMAN-ERYTHROPOIETIN; NEURAL STEM-CELLS; SUBVENTRICULAR ZONE; SPATIAL MEMORY; POSTTRAUMATIC NEURODEGENERATION; ENHANCES NEUROGENESIS; CALCIUM PRECIPITATION; ADULT NEUROGENESIS; CEREBRAL-CORTEX	Erythropoietin (EPO) and its receptor (EPOR), essential for erythropoiesis, are expressed in the nervous system. Recombinant human EPO treatment promotes functional outcome after traumatic brain injury (TBI) and stroke, suggesting that the endogenous EPO/EPOR system plays an important role in neuroprotection and neurorestoration. This study was designed to investigate effects of the EPOR on histological and functional outcomes after TBI. Experimental TBI was induced in adult EPOR-null and wild-type mice by controlled cortical impact. Neurological function was assessed using the modified Morris Water Maze and footfault tests. Animals were sacrificed 35 days after injury and brain sections stained for immunohistochemistry. As compared to the wild-type injured mice, EPOR-null mice did not exhibit higher susceptibility to TBI as exemplified by tissue loss in the cortex, cell loss in the dentate gyrus, impaired spatial learning, angiogenesis and cell proliferation. We observed that less cortical neurogenesis occurred and that sensorimotor function (i.e., footfault) was more impaired in the EPOR-null mice after TBI. Co-accumulation of amyloid precursor protein (axonal injury marker) and calcium was observed in the ipsilateral thalamus in both EPOR-null and wild-type mice after TBI with more calcium deposits present in the wild-type mice. This study demonstrates for the first time that EPOR null in the nervous system aggravates sensorimotor deficits, impairs cortical neurogenesis and reduces thalamic calcium precipitation after TBI. (C) 2008 Elsevier B.V. All rights reserved.	[Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Xiong, Ye; Mahmood, Asim; Qu, Changsheng; Kazmi, Humaira; Goussev, Anton] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Lu, Dunyue] Suny Downstate Med Ctr, Dept Psychiat, Brooklyn, NY 11203 USA; [Noguchi, Constance T.] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA; [Schallerte, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallerte, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS52280, P01 NS4234S]; NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [ZIADK025061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, P01NS042345] Funding Source: NIH RePORTER	This work was supported by NINDS grants R01 NS52280, P01 NS4234S and NIDDK Intramural Research.	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jin G, 2003, NEUROL RES, V25, P249, DOI 10.1179/016164103101201454; KATO H, 1995, BRAIN RES BULL, V38, P25, DOI 10.1016/0361-9230(95)00067-O; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Keogh CL, 2007, J PHARMACOL EXP THER, V322, P521, DOI 10.1124/jpet.107.121392; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Magavi SS, 2000, NATURE, V405, P951; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Mogensen J, 2008, BEHAV BRAIN RES, V186, P215, DOI 10.1016/j.bbr.2007.08.009; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Ramonet D, 2006, J NEUROSCI RES, V83, P147, DOI 10.1002/jnr.20711; Ramonet D, 2002, J PHYSIOLOGY-PARIS, V96, P307, DOI 10.1016/S0928-4257(02)00020-7; Rodriguez MJ, 2000, INT J DEV NEUROSCI, V18, P299, DOI 10.1016/S0736-5748(99)00098-2; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	53	44	48	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 16	2008	1230						247	257		10.1016/j.brainres.2008.06.127			11	Neurosciences	Neurosciences & Neurology	359BW	WOS:000259962200026	18657521	Green Accepted			2021-06-18	
J	Bottai, D; Madaschi, L; Di Giulio, AM; Gorio, A				Bottai, Daniele; Madaschi, Laura; Di Giulio, Anna M.; Gorio, Alfredo			Viability-dependent promoting action of adult neural precursors in spinal cord injury	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS SURVIVE; CORTICOSPINAL NEURONS; MULTIPLE-SCLEROSIS; MOTOR FUNCTION; IN-VIVO; KAPPA-B; RECOVERY; DIFFERENTIATE; MICE	The aim of the study was the assessment of the effects of adult neural stem cell (INSC) transplantation in a mouse model of spinal cord injury (SCI). The contusion injury was performed by means of the Infinite Horizon Device to allow the generation of reproducible traumatic lesion to the cord. We administered green fluorescent-labeled (GFP-)NSCs either by intravenous (i.v) injection or by direct transplantation into the spinal cord (intraspinal route). We report that NSCs significantly improved recovery of hind limb function and greatly attenuated secondary degeneration. The i.v. route of NSC administration yielded better recovery than the intraspinal route of administration. About 2% of total i.v.-administered NSCs homed to the spinal cord injury site, and survived almost undifferentiated; thus the positive effect of NSC treatment cannot be ascribed to damaged tissue substitution. The NSCs homing to the injury site triggered, within 48 h, a large increase of the expression of neurotrophic factors and chemokines. One wk after transplantation, exogenous GFP-NSCs still retained their proliferation potential and produced neurospheres when recovered from the lesion site and cultured in vitro. At a later time, GFP-NSC were phagocytated by macrophages. We suggest that the process of triggering the recovery of function might be strongly related to the viability of GFP-NSC, still capable ex vivo of producing neurospheres, and their ability to modify the lesion environment in a positive fashion.	[Bottai, Daniele; Madaschi, Laura; Di Giulio, Anna M.; Gorio, Alfredo] Univ Milan, Fac Med, Dept Med Surg & Dent, I-20142 Milan, Italy; [Bottai, Daniele; Gorio, Alfredo] IRCCS Humanitas, Milan, Italy	Gorio, A (corresponding author), Univ Milan, Fac Med, Dept Med Surg & Dent, Via A di Rudini 8, I-20142 Milan, Italy.	alfredo.gorio@unimi.it	Bottai, Daniele/O-2586-2017	Bottai, Daniele/0000-0002-7951-9512; Di Giulio, Anna Maria/0000-0002-5702-4623	The Italian Ministry of Education; Montecatone Foundation, Imola (It)	We acknowledge the continuous support by Drs Guglielmo Brayda, Fabio Colbucci, Mauro Menarini, Roberto Piperno, Maria Taricco, Giulio Cicognani, of the Scientific Advisory Board of the Fondazione Montecatone. We would like to thank Raffaella Adami for the confocal images.; The project was supported by a grant from The Italian Ministry of Education in 2003 and in 2005, and by a generous donation from the Montecatone Foundation, Imola (It) to Alfredo Gorio.	Akerud P, 2002, MOL CELL NEUROSCI, V21, P205, DOI 10.1006/mvne.2002.1171; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2004, NEUROSCIENCE, V125, P179, DOI 10.1016/j.neuroscience.2003.10.046; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Gorio A, 2007, J PHARMACOL EXP THER, V322, P973, DOI 10.1124/jpet.107.123679; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hoffman RM, 2006, CELL CYCLE, V5, P232, DOI 10.4161/cc.5.3.2397; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Huang CJ, 2002, INT J DEV NEUROSCI, V20, P289, DOI 10.1016/S0736-5748(02)00022-9; Kim SS, 2005, J BIOMED MATER RES B, V75B, P369, DOI 10.1002/jbm.b.30302; Liker MA, 2003, BRAIN RES, V971, P168, DOI 10.1016/S0006-8993(03)02337-0; Lu P, 2001, J COMP NEUROL, V436, P456, DOI 10.1002/cne.1080; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Pluchino S, 2004, CURR OPIN NEUROL, V17, P247, DOI 10.1097/00019052-200406000-00003; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reier Paul J, 2004, NeuroRx, V1, P424, DOI 10.1007/BF03206629; Rieske P, 2007, EUR J NEUROSCI, V25, P31, DOI 10.1111/j.1460-9568.2006.05254.x; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Romanko MJ, 2004, J CEREBR BLOOD F MET, V24, P814, DOI 10.1097/01.WCB.0000123906.17746.00; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Sayer FT, 2002, EXP NEUROL, V175, P282, DOI 10.1006/exnr.2002.7901; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schultz SS, 2006, J NEUROSCI METH, V152, P144, DOI 10.1016/j.jneumeth.2005.08.022; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759	41	44	46	1	5	FEINSTEIN INST MED RES	MANHASSET	350 COMMUNITY DR, MANHASSET, NY 11030 USA	1076-1551			MOL MED	Mol. Med.	SEP-OCT	2008	14	9-10					634	644		10.2119/2008-00077.Bottai			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	352YJ	WOS:000259533000013	18654659	DOAJ Gold, Green Published			2021-06-18	
J	Donders, J; Janke, K				Donders, Jacobus; Janke, Kelly			Criterion validity of the Wechsler Intelligence Scale for Children-Fourth Edition after pediatric traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						intelligence; assessment; processing speed; sensitivity; specificity	HEAD-INJURY; WISC-III; SCORES	The performance of 40 children with complicated mild to severe traumatic brain injury on the Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV; Wechsler, 2003) was compared with that of 40 demographically matched healthy controls. Of the four WISC-IV factor index scores, only Processing Speed yielded a statistically significant group difference (p <.001) as well as a statistically significant negative correlation with length of coma (p <.01). Logistic regression, using Processing Speed to classify individual children, yielded a sensitivity of 72.50% and a specificity of 62.50%, with false positive and false negative rates both exceeding 30%. We conclude that Processing Speed has acceptable criterion validity in the evaluation of children with complicated mild to severe traumatic brain injury but that the WISC-IV should be supplemented with other measures to assure sufficient accuracy in the diagnostic process.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; [Janke, Kelly] Calvin Coll, Dept Psychol, Grand Rapids, MI 49506 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					American Educational Research Association American Psychological Association National Council of Measurement in Education Joint Committee on Standards for Educational Psychological Testing (US), 1999, STAND ED PSYCH TEST; Bigler ED, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P415; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Doyle AE, 2000, J CONSULT CLIN PSYCH, V68, P477, DOI [10.1037//0022-006X.68.3.477, 10.1037/0022-006X.68.3.477]; GREEN P, 2003, GREENS WORD MEMORY; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Keith TZ, 2006, SCHOOL PSYCHOL REV, V35, P108; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Naglieri JA, 2005, APPL NEUROPSYCHOL, V12, P208, DOI 10.1207/s15324826an1204_4; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Reinecke MA, 1999, J AM ACAD CHILD PSY, V38, P322, DOI 10.1097/00004583-199903000-00020; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yeates KO., 2005, WISC 4 CLIN USE INTE, P415, DOI [10.1016/B978-012564931-5/50014-1, DOI 10.1016/B978-012564931-5/50014-1]	20	44	44	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2008	14	4					651	655		10.1017/S1355617708080752			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	338VL	WOS:000258537400016	18577295	Bronze			2021-06-18	
J	Tehranian, R; Rose, ME; Vagni, V; Pickrell, AM; Griffith, RP; Liu, H; Clark, RSB; Dixon, CE; Kochanek, PM; Graham, SH				Tehranian, Roya; Rose, Marie E.; Vagni, Vincent; Pickrell, Alicia M.; Griffith, Raymond P.; Liu, Hao; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.; Graham, Steven H.			Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; Bax; TBI; transgenic mice	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; TRANSGENIC MICE; BCL-2 PROTEIN; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; APOPTOSIS; RATS; MITOCHONDRIA; EXPRESSION	Apoptosis contributes to delayed neuronal cell death in traumatic brain injury (TBI). To investigate if Bax plays a role in neuronal cell death and functional outcome after TBI, Bax gene disrupted (null) mice and wild-type (WT) controls were subjected to the controlled cortical impact (CCI) model of TBI. Motor function in WT and Bax null mice was evaluated using the round beam balance and the wire grip test on days 0-5. Spatial memory was assessed using a Morris Water Maze adopted for mice on days 14-18 post-injury. For histopathological analysis, animals were sacrificed 24 h and 21 days post-injury. In all three behavioral tests, the sham and TBI-injured Bax null mice performed significantly worse than their WT sham and TBI-injured counterparts. However, Bax null mice exhibited a higher percentage of surviving neurons in the CA1 and CA3 regions of hippocampus measured at 21 days post-injury. At 24 h after trauma, Bax null mice had fewer TUNEL positive cells in the CA1 and dentate regions of hippocampus as compared to WT mice, suggesting that deletion of the Bax gene ameliorates hippocampal cell death after TBI. Sham-operated Bax null mice had significantly greater brain volume as compared to WT mice. Thus, it is possible that Bax deficiency in the transgenic mice produces developmental behavioral effects, perhaps due to Bax's role in regulating cell death during development.	[Tehranian, Roya; Rose, Marie E.; Pickrell, Alicia M.; Liu, Hao; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA; [Tehranian, Roya; Rose, Marie E.; Liu, Hao; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Griffith, Raymond P.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; [Vagni, Vincent; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA	Graham, SH (corresponding author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, 7108 Highland Dr, Pittsburgh, PA 15206 USA.	sgra@pitt.edu	Kochanek, Patrick M/D-2371-2015; Pickrell, Alicia/B-8494-2018	Kochanek, Patrick M/0000-0002-2627-913X; Pickrell, Alicia/0000-0002-8470-6056	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030318, P50 NS030318-10, NS30318] Funding Source: Medline		Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1992, NEUROCHEMICAL CORREL, P161; Fiskum G, 1983, Am J Emerg Med, V1, P147, DOI 10.1016/0735-6757(83)90082-7; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Hochhauser E, 2003, AM J PHYSIOL-HEART C, V284, pH2351, DOI 10.1152/ajpheart.00783.2002; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OLTVAI ZN, 1993, CELL, V74, P619; Polster BM, 2003, J NEUROSCI, V23, P2735; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young C, 2003, CELL DEATH DIFFER, V10, P1148, DOI 10.1038/sj.cdd.4401277	50	44	52	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					755	767		10.1089/neu.2007.0441			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000004	18627254	Green Accepted, Green Published			2021-06-18	
J	Siman, R; Roberts, VL; McNeil, E; Dang, A; Bavaria, JE; Ramchandren, S; McGarvey, M				Siman, Robert; Roberts, Victoria L.; McNeil, Elizabeth; Dang, Antony; Bavaria, Joseph E.; Ramchandren, Sindhu; McGarvey, Michael			Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest	BRAIN RESEARCH			English	Article						ischemia; acute CNS damage; surrogate marker; calpain; circulation arrest	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; TISSUE-PLASMINOGEN ACTIVATOR; ARTERY-BYPASS-SURGERY; ACUTE ISCHEMIC-STROKE; CEREBROSPINAL-FLUID; SURROGATE MARKERS; CARDIAC-ARREST; RAT-BRAIN; CALPAIN-I	Previously, we identified 14-3-3 beta and zeta isoforms and proteolytic fragments of alpha-spectrin as proteins released from degenerating neurons that also rise markedly in cerebrospinal fluid (CSF) following experimental brain injury or ischemia. in rodents, but these proteins have not been studied before as potential biomarkers for ischemic central nervous system injury in humans. Here we describe longitudinal analysis of these proteins along with the neuron-enriched hypophosphorylated neurofilament H (pNFH) and the deubiquitinating enzyme UCH-L1 in lumbar CSF samples from 19 surgical cases of aortic aneurysm repair, 7 involving cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA). CSF levels of the proteins were near the lower limit of detection by Western blot or enzyme-linked fluorescence immunoassay at the onset of surgical procedures, but increased substantially in a subset of cases, typically within 12-24 h. All cases involving DHCA were characterized by > 3-fold elevations in CSF levels of the two 14-3-3 isoforms, UCH-L1, and pNFH. Six of 7 also exhibited marked increases in alpha-spectrin fragments generated by calpain, a protease known to trigger necrotic neurodegeneration. Among cases involving aortic cross-clamping but not DHCA, the proteins rose in CSF preferentially in the subset experiencing acute neurological complications. Our results suggest the neuron-enriched 14-3-3 beta, 14-3-3 zeta, pNFH, UCH-L1, and calpain-cleaved a-spectrin may serve as a panel of biomarkers with clinical potential for the detection and management of ischemic central nervous system injury, including for mild damage associated with surgically-induced circulation arrest. (c) 2008 Elsevier B.V. All rights reserved.	[Siman, Robert; Roberts, Victoria L.; McNeil, Elizabeth; Dang, Antony] Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Bavaria, Joseph E.] Univ Penn, Sch Med, Div Cardiovasc Surg, Philadelphia, PA 19104 USA; [Ramchandren, Sindhu; McGarvey, Michael] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Ramchandren, Sindhu] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA	Siman, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu	Ramchandren, Sindhu/D-6942-2012	Ramchandren, Sindhu/0000-0002-5201-9200	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS048234, NS048234, R01 NS048234-01A2] Funding Source: Medline		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arrowsmith JE, 2000, BRIT J ANAESTH, V84, P378; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; BETZ D, 1998, CEREBROVASC DIS, P358; Boston P, 1980, BIOCHEM SOC T, V8, P617, DOI 10.1042/bst0080617; Cheung AT, 2005, ANN THORAC SURG, V80, P1280, DOI 10.1016/j.athoracsur.2005.04.027; Cheung AT, 2002, ANN THORAC SURG, V74, P413, DOI 10.1016/S0003-4975(02)03714-1; del Zoppo GJ, 2000, THROMB RES, V98, pV73; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Ergin MA, 1999, ANN THORAC SURG, V67, P1887, DOI 10.1016/S0003-4975(99)00432-4; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Gao L, 2005, CHEST, V128, P3664, DOI 10.1378/chest.128.5.3664; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Jung C, 2000, CELL MOTIL CYTOSKEL, V47, P120, DOI 10.1002/1097-0169(200010)47:2<120::AID-CM3>3.3.CO;2-Y; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; LASEK RJ, 1985, ANN NY ACAD SCI, V455, P462, DOI 10.1111/j.1749-6632.1985.tb50429.x; Lawrence EJ, 2005, RESUSCITATION, V64, P383, DOI 10.1016/j.resuscitation.2004.07.016; LUNDAR T, 1983, SCAND J THORAC CARD, V17, P237, DOI 10.3109/14017438309099358; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; MARTIN H, 1994, J NEUROCHEM, V63, P2259; McGorvey ML, 2007, NEUROCRIT CARE, V6, P35, DOI 10.1385/Neurocrit.Care2007;06:35-39; McKeating EG, 1998, ACT NEUR S, V71, P117; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Newman SP, 2002, LANCET NEUROL, V1, P119, DOI 10.1016/S1474-4422(02)00043-1; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2005, J NEUROTRAUM, V22, P407, DOI 10.1089/neu.2005.22.407; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROCHE GW, 1996, NEW ENGL J MED, V335, P1857; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Selnes OA, 2005, ANN NEUROL, V57, P615, DOI 10.1002/ana.20481; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shiiya N, 2004, ANN THORAC SURG, V77, P2034, DOI 10.1016/j.athoracsur.2003.12.057; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; STERNBERGER LA, 1982, P NATL ACAD SCI-BIOL, V79, P1326, DOI 10.1073/pnas.79.4.1326; Tanaka Y, 2007, BRAIN RES, V1154, P194, DOI 10.1016/j.brainres.2007.03.085; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	58	44	45	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 5	2008	1213						1	11		10.1016/j.brainres.2008.03.034			11	Neurosciences	Neurosciences & Neurology	319TD	WOS:000257186000001	18456245	Green Accepted			2021-06-18	
J	Matsui, T; Kakeda, T				Matsui, Tomohiro; Kakeda, Takahiro			IL-10 production is reduced by hypothermia but augmented by hyperthermia in rat microglia	JOURNAL OF NEUROTRAUMA			English	Article						hyperthermia; hypothermia; interleukin-10; microglia; nitric oxide	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; MILD HYPOTHERMIA; CYTOKINE PRODUCTION; PROTEIN-LEVELS; INTERLEUKIN-10; TEMPERATURE	Pro-inflammatory cytokines and nitric oxide (NO) are considered responsible for exacerbating brain injury. Activated microglia produce these potentially cytotoxic factors during neuron destruction. The beneficial effects of hypothermia on neuroprotection are considered to be due, in part, to suppression of post-injury inflammatory factors by microglia. However, the underlying mechanisms remain unclear. In particular, the hypothermia's role in modulating anti-inflammatory cytokines is unknown. We examined whether altering culture temperature modifies microglial production of cytokines and NO. Microglia isolated from neonatal rats were cultured with 1 mu g/mL lipopolysaccharide (LPS) under hypothermic, normothermic, and hyperthermic conditions for 72 h. Interleukin (IL)-6 and IL-10 levels in supernatants were measured by enzyme-linked immunosorbent assay (ELISA). NO production was analyzed by colorimetric assay of nitrite accumulated in the medium. Compared to normothermia, hypothermia decreased LPS-induced IL-6 production at 6 h of culture. In contrast, hyperthermia reduced IL-6 production throughout culture. IL-10 production was reduced by hypothermia but augmented by hyperthermia at 24-72 h. NO production was reduced by hypothermia throughout culture, while no significant differences in NO production were observed between normothermia and hyperthermia. In this study, hypothermia reduced production of IL-6, IL-10, and NO by LPS-activated microglia, suggesting that the neuroprotective effects of hypothermia might involve not only the inhibition of inflammatory factors, but also anti-inflammatory factor(s). Hyperthermia specifically increased IL-10 production in these cells. These temperature-dependent changes in IL-10 production may imply an important clinical marker for this cytokine in hypothermia-related neuronal protection and in hyperthermia-related neuronal injury.	[Matsui, Tomohiro] Yamaguchi Univ, Grad Sch Med, Dept Lab Sci, Yamaguchi, Japan; [Kakeda, Takahiro] Kawasaki Univ Med Welf, Fac Hlth & Welf, Dept Nursing, Okayama, Japan	Matsui, T (corresponding author), 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	giants-ygc@umin.ac.jp	Kakeda, Takahiro/T-1063-2019		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20791077] Funding Source: KAKEN		Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; FREI K, 1994, J IMMUNOL, V152, P2720; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lancelot E, 1998, NEUROSCI LETT, V242, P131, DOI 10.1016/S0304-3940(98)00095-0; Maekawa S, 2002, CRIT CARE MED, V30, P2700, DOI 10.1097/00003246-200212000-00014; MALEFYT RD, 1991, J EXP MED, V174, P1209; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsui T, 2004, ACTA ANAESTH SCAND, V48, P205, DOI 10.1111/j.0001-5172.2004.00293.x; Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Nakamura Y, 1999, NEUROSCI RES, V35, P95, DOI 10.1016/S0168-0102(99)00071-1; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	35	44	46	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					709	715		10.1089/neu.2007.0482			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900012	18533891				2021-06-18	
J	Grond-Ginsbach, C; Hummel, M; Wiest, T; Horstmann, S; Pfleger, K; Hergenhahn, M; Hollstein, M; Mansmann, U; Grau, AJ; Wagner, S				Grond-Ginsbach, C.; Hummel, M.; Wiest, T.; Horstmann, S.; Pfleger, K.; Hergenhahn, M.; Hollstein, M.; Mansmann, U.; Grau, A. J.; Wagner, S.			Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke	JOURNAL OF NEUROLOGY			English	Article						acute ischemic stroke; acute traumatic brain injury; gene expression; blood	MICROARRAY; BRAIN; INTERLEUKIN-1; NEUTROPHILS; PROFILES; PATTERNS; GENOMICS; INJURY	Background and purpose Ischemic stroke provokes a systemic inflammatory response. The purpose of this study was to characterize this response on the gene expression level in circulating mononuclear leukocytes from acute ischemic stroke (AIS) patients. Methods RNA from peripheral blood mononuclear cells (PBMCs) of AIS patients (24 +/- 2 hours after onset of symptoms) was analyzed with Affymetrix U133A GeneChips using a pooled design. We compared the gene expression signature from AIS patients (n = 20), stroke survivors (n = 15), patients with acute traumatic brain injury (ATBI, n = 15) and healthy control subjects without vascular risk factors (n = 15). Results Expression levels of 9682 probe sets with present calls on each GeneChip were compared. Between AIS patients and stroke survivors or between AIS patients and ATBI patients there were no significant differences in expression values of single genes after correction for multiple testing. However, comparison of the PBMC expression profiles from AIS patients and healthy subjects revealed significantly different expression (p = 0.012) of a single probe set, specific for phosphodiesterase 4 D (PDE4D). In order to detect modest expression differences in multiple genes with a presumed cumulative effect we studied the gene expression of functional groups of genes by global statistical tests. Analysis of 11 gene groups revealed differential expression between AIS patients and healthy subjects for genes involved in the inflammatory response (GeneOntology GO:0006954). Genes encoding the N-formyl peptide receptor-like 1 (FPRL1), interleukin-1 receptor antagonist (IL1RN) and complement component 3a receptor 1 (C3AR1) contributed most to the observed difference. Conclusions This transcriptome analysis did not identify significant changes between circulating mononuclear cells from AIS patients 24 hours after stroke and closely matched stroke survivors. However, comparing AIS patients with healthy control subjects revealed measurable differences in PDE4D and in inflammatory response genes when considered as a set.	[Grond-Ginsbach, C.; Wiest, T.; Horstmann, S.; Pfleger, K.; Wagner, S.] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Hummel, M.; Mansmann, U.] LMU Munchen, Sch Med, IBE, Munich, Germany; [Hergenhahn, M.; Hollstein, M.] German Canc Res Ctr, Dept Genet Alterat Carcinogenesis, D-6900 Heidelberg, Germany; [Grau, A. J.] Klinikum Stadt Ludwigshafen, Dept Neurol, D-6700 Ludwigshafen, Germany	Grond-Ginsbach, C (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Caspar_Grond_Ginsbach@med.uni-heidelberg.de					Baird AE, 2007, STROKE, V38, P694, DOI 10.1161/01.STR.0000250431.99687.7b; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Barnum SR, 2002, GLIA, V38, P169, DOI 10.1002/glia.10069; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Chtanova T, 2005, J IMMUNOL, V175, P7837, DOI 10.4049/jimmunol.175.12.7837; Connolly PH, 2004, J APPL PHYSIOL, V97, P1461, DOI 10.1152/japplphysiol.00316.2004; Cowell RM, 2003, J NEUROSCI, V23, P9459; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Feezor RJ, 2004, PHYSIOL GENOMICS, V19, P247, DOI 10.1152/physiolgenomics.00020.2004; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; GRONDGINSBACH C, 2007, GENE EXPRESSIO UNPUB; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Jolly RA, 2005, PHYSIOL GENOMICS, V22, P346, DOI 10.1152/physiolgenomics.00260.2004; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu J, 2006, J MOL DIAGN, V8, P551, DOI 10.2353/jmoldx.2006.060021; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Mansmann U, 2005, METHOD INFORM MED, V44, P449; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; Moore DF, 2005, CIRCULATION, V111, P212, DOI 10.1161/01.CIR.0000152105.79665.C6; Rosand J, 2006, NAT GENET, V38, P1091, DOI 10.1038/ng1006-1091; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Sebastiani P, 2005, NAT GENET, V37, P435, DOI 10.1038/ng1533; Sharp FR, 2007, STROKE, V38, P691, DOI 10.1161/01.STR.0000247940.27518.38; Sharp FR, 2006, EPILEPSIA, V47, P1603, DOI 10.1111/j.1528-1167.2006.00809.x; Subrahmanyam YVBK, 2001, BLOOD, V97, P2457, DOI 10.1182/blood.V97.8.2457; Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Worrall BB, 2007, STROKE, V38, P1189, DOI 10.1161/01.STR.0000260099.42744.b0; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yue L, 2005, CURR MOL MED, V5, P11, DOI 10.2174/1566524053152906; Zakharkin SO, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-214	35	44	46	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAY	2008	255	5					723	731		10.1007/s00415-008-0784-z			9	Clinical Neurology	Neurosciences & Neurology	311EH	WOS:000256583000017	18465111				2021-06-18	
J	Hawley, CA; Joseph, S				Hawley, Carol A.; Joseph, Stephen			Predictors of positive growth after traumatic brain injury: A longitudinal study	BRAIN INJURY			English	Article						brain injury; outcome; follow-up; post-traumatic growth; trauma	SEVERE HEAD-INJURY; POSTTRAUMATIC GROWTH; FOLLOW-UP; PRACTICAL SCALE; ADJUSTMENT; ADVERSITY; OUTCOMES	Primary objective: To investigate long-term positive psychological growth in individuals with traumatic brain injury (TBI) and to relate growth to injury characteristics and early outcomes. Research design: Longitudinal study. Method and procedure: Long-term follow-up of a group of TBI survivors recruited between 1991-1995. In 2004, 240 of the 563 original participants were invited to take part in a follow-up study. At follow-up, survivors completed the Positive Changes in Outlook Questionnaire (CiOP) along with a structured interview/questionnaire which permitted a Glasgow Outcome Scale (GOSE) score to be assigned. Results: One hundred and sixty-five TBI survivors completed both questionnaire and CiOP. One hundred and three (62%) participants had suffered severe TBI, 24 (15%) moderate and 38 (23%) mild. Mean length of follow-up was 11.5 years post-injury (range 9-25 years). On the GOSE at follow-up, 43 (26%) had severe disability; 72 (44%) moderate disability; and 50 (30%) good recovery. Scores on the CiOP indicated positive psychological growth in over half of the sample, as evidenced by agreement with items such as 'I don't take life for granted anymore' and 'I value my relationships much more now'. CiOP total scores did not correlate with any injury or early outcome variables. However, at long-term follow-up there was a negative correlation between positive growth and anxiety and depression. Conclusion: Survivors of mild, moderate and severe TBI showed evidence of long-term positive changes in outlook.	[Hawley, Carol A.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Joseph, Stephen] Univ Nottingham, CTRG, Sch Sociol & Social Policy, Ctr Social Work, Nottingham NG7 2RD, England	Hawley, CA (corresponding author), Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019	joseph, stephen/0000-0001-7171-3356			ADAMS N, 1996, AUSTR NZ J FAMILY TH, V17, P75; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAWLEY CA, 2000, BRIT J THERAPY REHAB, V7, P116; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOSEPH S, 1993, J TRAUMA STRESS, V6, P271, DOI 10.1007/BF00974121; Joseph S, 2005, PSYCHOL ASSESSMENT, V17, P70, DOI 10.1037/1040-3590.17.1.70; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McGrath J, 2004, CLIN REHABIL, V18, P767, DOI 10.1191/0269215504cr802oa; MCGRATH JC, TRAUMA RECOVERY GROW, P259; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; STEGER MF, IN PRESS J PERSONALI; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; TEASDALE G, 1974, LANCET, V2, P81; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; WHIMALL L, 2006, J NEUROL NEUROSUR PS, V77, P640; *WHO, 1980, INT CLASS IMP DIS HA, P42; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	44	45	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2008	22	5					427	435		10.1080/02699050802064607			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302RH	WOS:000255986500008	18415723				2021-06-18	
J	Hepp, U; Moergeli, H; Buchi, S; Bruchhaus-Steinert, H; Kraemer, B; Sensky, T; Schnyder, U				Hepp, Urs; Moergeli, Hanspeter; Buchi, Stefan; Bruchhaus-Steinert, Helke; Kraemer, Bernd; Sensky, Tom; Schnyder, Ulrich			Post-traumatic stress disorder in serious accidental injury: 3-year follow-up study	BRITISH JOURNAL OF PSYCHIATRY			English	Article							MOTOR-VEHICLE ACCIDENTS; ADMINISTERED PTSD SCALE; TRAUMATIC BRAIN-INJURY; ROAD TRAFFIC ACCIDENT; DEPRESSION SCALE; HOSPITAL ANXIETY; RISK-FACTORS; VICTIMS; ADULTS; PREVALENCE	Background Long-term data on post-traumatic stress disorder (PTSD) following accidents are scarce. Aims To assess and predict PTSD in people 3 years after severe accidental injury. Method Severely injured patients were recruited consecutively from the intensive care unit (n=121) and assessed within 1 month of the trauma. Follow-up interviews were conducted 6 months, 12 months and 36 months later; 90 patients participated in all four interviews. Symptoms were assessed using the Clinician-Administered PTSD Scale. Results Post-traumatic stress disorder was diagnosed in 6% of patients 2 weeks after the accident, in 2% after 1 year and in 4% after 3 years. Robust predictors of later PTSD symptom level were intrusive symptoms shortly after the accident and biographical risk factors. There were individual changes over time between the categories PTSD, sub-threshold PTSD and no PTSD. Whereas PTSD symptom severity was low or decreased for most of the patients, some of them showed an increase or a delayed onset. Patients with persisting PTSD symptoms at 6 months and patients with delayed onset of symptoms are at risk of long-term PTSD. Conclusions The prevalence of PTSD was low over the whole period of 3 years.	[Hepp, Urs] Psychiat Dienste Aargau AG, CH-5401 Baden, Switzerland; [Hepp, Urs; Moergeli, Hanspeter; Buchi, Stefan; Kraemer, Bernd; Schnyder, Ulrich] Univ Zurich Hosp, Dept Psychiat, Zurich, Switzerland; [Bruchhaus-Steinert, Helke] Inst Ecol Syst Therapy, Zurich, Switzerland; [Sensky, Tom] Imperial Coll Sch Med, Div Neurosci & Psychol Med, London, England	Hepp, U (corresponding author), Psychiat Dienste Aargau AG, Haselstr 1, CH-5401 Baden, Switzerland.	Urs.Hepp@pdag.ch		Schnyder, Ulrich/0000-0003-3556-7990			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A., 1987, UNRAVELING MYSTERY H; BAKER WA, 1976, INORG CHIM ACTA, V16, P5, DOI 10.1016/S0020-1693(00)91684-0; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Bisson JI, 1995, BRIT J PSYCHIAT, V167, P718, DOI 10.1192/bjp.167.6.718; Blake D. D., 1990, BEHAV THER, V13, P187; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BOWNES IT, 1991, ACTA PSYCHIAT SCAND, V83, P27, DOI 10.1111/j.1600-0447.1991.tb05507.x; BRESLAU N, 1987, AM J PSYCHIAT, V144, P578; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; Derogatis LR, 1986, SCL 90 R ADM SCORING; Egle UT, 1997, NERVENARZT, V68, P683, DOI 10.1007/s001150050183; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Franke G, 1995, SCL 90 R SYMPTOMCHEC; Frommberger UH, 1998, EUR ARCH PSY CLIN N, V248, P316, DOI 10.1007/s004060050057; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Galea S, 2005, EPIDEMIOL REV, V27, P78, DOI 10.1093/epirev/mxi003; Hardt J, 2003, Z KL PSYCH PSYCHOTH, V32, P41, DOI 10.1026//1616-3443.32.1.41; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Hepp U, 2007, EAT WEIGHT DISORD-ST, V12, pE24; Hepp U, 2006, EUR ARCH PSY CLIN N, V256, P151, DOI 10.1007/s00406-005-0621-7; Hepp U, 2005, PSYCHOTHER PSYCHOSOM, V74, P379, DOI 10.1159/000087786; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2001, HEALTH SERV RES, V36, P987; Koren D, 1999, AM J PSYCHIAT, V156, P367; LEE KA, 1995, AM J PSYCHIAT, V152, P516; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Malt U F, 1992, Psychiatr Med, V10, P117; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; Muthny FA., 1989, FREIBURGER FRAGEBOGE; North CS, 2002, J URBAN HEALTH, V79, P383, DOI 10.1093/jurban/79.3.383; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; Schnyder U, 2002, J TRAUMA STRESS, V15, P487, DOI 10.1023/A:1020922023090; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schnyder U, 2008, PSYCHOTHER PSYCHOSOM, V77, P111, DOI 10.1159/000112888; Schutzwohl M, 1999, J TRAUMA STRESS, V12, P155, DOI 10.1023/A:1024706702133; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; SIEGRIST J, 1983, ZUMA HDB SOCIAL SCI; Sommer I, 2004, J PSYCHOSOM RES, V57, P329, DOI 10.1016/j.jpsychores.2004.01.010; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zlotnick C, 2002, COMPR PSYCHIAT, V43, P413, DOI 10.1053/comp.2002.35900	60	44	44	0	11	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND	0007-1250			BRIT J PSYCHIAT	Br. J. Psychiatry	MAY	2008	192	5					376	383		10.1192/bjp.bp.106.030569			8	Psychiatry	Psychiatry	304JX	WOS:000256106900013	18450664	Bronze			2021-06-18	
J	Minns, RA; Jones, PA; Mok, JYQ				Minns, Robert A.; Jones, Patricia A.; Mok, Jacqueline Y-Q			Incidence and demography of non-accidental head injury in southeast Scotland from a national database	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							RISK-FACTORS; CHILD-ABUSE; INFANTS	Background: This study utilized an existing national database of cases of non-accidental head injury (NAHI; also called inflicted traumatic brain injury [inflicted TBI] and shaken baby syndrome [SBS]) in Scotland to report the incidence, confidence intervals, and demography of such cases in Southeast Scotland. Methods: This prospective population-based study was conducted from January 1998 to September 2006. Data from the Lothian region of Scotland, where there is known full ascertainment of infant head injuries, including NAHI have been used to calculate the incidence rate for this region of Scotland, with government statistics providing the normal annual infant population as the denominator. A new Scottish Index of Multiple Deprivation (SIMD), which assesses a very focused area (data zone population size=750) and provides novel information about social demography for education, housing, employment, health, crime, income, and geographic accessibility to services, was applied to the identified cases of NAHI during this study period. Results: The mean incidence of NAHI in southeast Scotland for 8.75 years was 33.8/100,000 infants per year. The cases of NAHI were mostly located in the lowest 1 (or 2) quintiles for all SIMD domains (education, housing, employment, health, crime, income), although they had good accessibility to medical and other community services. Conclusions: The incidence rates from this prospective study for NAHI are considerably higher than other published UK surveys and are not considered to reflect a cluster effect. The perpetrators in this study fit a strongly skewed profile aggregating to the lowest socioeconomic groups in the community.	[Minns, Robert A.; Jones, Patricia A.; Mok, Jacqueline Y-Q] Univ Edinburgh, Dept Child Life & Hlth, Edinburgh EH9 1UW, Midlothian, Scotland; [Minns, Robert A.; Mok, Jacqueline Y-Q] Lothian Univ Hosp NHS Trust, Royal Hosp Sick Children, Edinburgh, Midlothian, Scotland	Minns, RA (corresponding author), Univ Edinburgh, Dept Child Life & Hlth, 20 Sylvan Pl, Edinburgh EH9 1UW, Midlothian, Scotland.	Robert.Minns@ed.ac.uk					BALLIN JC, 1985, JAMA-J AM MED ASSOC, V254, P796; Barlow KM, 1998, SCOT MED J, V43, P112, DOI 10.1177/003693309804300407; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; DUHAIME AC, 1992, PEDIATRICS, V90, P179; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; HUNTER RS, 1978, PEDIATRICS, V61, P629; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; KAPLUN D, 1976, AM J PSYCHIAT, V133, P809; Keenan H, 2003, INFLICTED CHILDHOOD, P3; Minns RA, 2004, BRIT MED J, V328, P766, DOI 10.1136/bmj.328.7442.766; Minns RA, 2005, CLIN DEV MED, P1; Mok JYQ, 2005, CLIN DEV MED, P415; Nagler J, 2002, CURR OPIN PEDIATR, V14, P251, DOI 10.1097/00008480-200204000-00019; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Rao P, 1999, CLIN RADIOL, V54, P11, DOI 10.1016/S0009-9260(99)91234-5; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; SEDLAK A, 1996, EXECUTIVE SUMMARY, V3; Wu SS, 2004, CHILD ABUSE NEGLECT, V28, P1253, DOI 10.1016/j.chiabu.2004.07.005	19	44	46	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S126	S133		10.1016/j.amepre.2008.01.016			8	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300006	18374262				2021-06-18	
J	Broglio, SP; Ferrara, MS; Sopiarz, K; Kelly, MS				Broglio, Steven P.; Ferrara, Michael S.; Sopiarz, Kay; Kelly, Michael S.			Reliable change of the sensory organization test	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						postural control; concussion; reliable change index	NEUROPSYCHOLOGICAL TEST PROTOCOL; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; COGNITIVE CHANGE; STATISTICAL PROCEDURES; NCAA CONCUSSION; RECOVERY; STATEMENT; SYMPTOMS	Objective: To establish the sensitivity and specificity of the NeuroCom Sensory Organization Test (SOT) and provide practitioners with cut-scores for clinical decision making using estimates of reliable change. Design: Retrospective cohort study. Setting: Research laboratory. Patients: Healthy (n = 66) and concussed (n = 63) young adult participants. Interventions: Postural control assessments on the NeuroCom SOT were completed twice (baseline and follow-up) for both groups. Postconcussion assessments were administered within 24 hours of injury diagnosis. Main Outcome Measurements: The reliable change technique was used to calculated cut-scores for each SOT variable (composite balance; somatosensory visual, and vestibular ratios) at the 95%, 90%, 85%, 80%, 75%, and 70% confidence interval levels. Results: When cut-scores were applied to the post-concussion evaluations, sensitivity and specificity varied with SOT variable and confidence interval. An evaluation for change on one or more SOT variable resulted in the highest combined sensitivity (57%) and specificity (80%) at the 75% confidence interval. Conclusions: Use of reliable change scores to detect significant changes in performance on the SOT resulted in decreased sensitivity and improved specificity compared to a previous report. These findings indicate that some concussed athletes may not show large changes in postconcussion postural control and this postural control evaluation should not be used in exclusion of other assessment techniques. The postural control assessment should be combined with other evaluative measures to gain the highest sensitivity to concussive injuries.	[Broglio, Steven P.; Sopiarz, Kay; Kelly, Michael S.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 1989, MILD HEAD INJURY; Bland JM, 1996, BRIT MED J, V313, P744; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; CANTU R, 2000, NEUROSURG FOCUS, V21, P1; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, 2002, HEADMINDER CONCUSSIO; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maassen GH, 2005, BRIT J SPORT MED, V39, P483, DOI 10.1136/bjsm.2004.015594; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Nashner LM., 1997, HDB BALANCE FUNCTION, P280; *NAT COLL ATHL ASS, 2003, INJ SURV SYST FOOTB; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; VANKAMPEN DA, 2006, AM J SPORT MED, V30, P1; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003	44	44	44	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2008	18	2					148	154		10.1097/JSM.0b013e318164f42a			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	273LQ	WOS:000253932600008	18332690				2021-06-18	
J	Moro, V; Berlucchi, G; Lerch, J; Tomaiuolo, F; Aglioti, SM				Moro, Valentina; Berlucchi, Giouanni; Lerch, Jason; Tomaiuolo, Francesco; Aglioti, Salvatore M.			Selective deficit of mental visual imagery with intact primary visual cortex and visual perception	CORTEX			English	Article						visual imagery and perception; V1; higher order visual cortices; non-visual and motor imagery; brain damaged patients	CORTICAL BLINDNESS; BRAIN; DISSOCIATION; EXTINCTION; AREAS; FMRI	There is a vigorous debate as to whether visual perception and imagery share the same neuronal networks, whether the primary visual cortex is necessarily involved in visual imagery, and whether visual imagery functions are lateralized in the brain. Two patients with brain damage from closed head injury were submitted to tests of mental imagery in the visual, tactile, auditory, gustatory, olfactory and motor domains, as well as to an extensive testing of cognitive functions. A computerized mapping procedure was used to localize the site and to assess the extent of the lesions. One patient showed pure visual mental imagery deficits in the absence of imagery deficits in other sensory domains as well as in the motor domain, while the other patient showed both visual and tactile imagery deficits. Perceptual, language, and memory deficits were conspicuously absent. Computerized analysis of the lesions showed a massive involvement of the left temporal lobe in both patients and a bilateral parietal lesion in one patient. In both patients the calcarine cortex with the primary visual area was bilaterally intact. our study indicates that: (i) visual imagery deficits can occur independently from deficits of visual perception; (ii) visual imagery deficits can occur when the primary visual cortex is intact and (iii) the left temporal lobe plays an important role in visual mental imagery. (C) 2007 Elsevier Masson Srl. All rights reserved.	[Moro, Valentina] Univ Verona, Dept Psychol & Culture Anthropol, I-37122 Verona, VR, Italy; [Berlucchi, Giouanni] Univ Verona, Dept Neurol & Visual Sci, Physiol Sect, I-37122 Verona, VR, Italy; [Tomaiuolo, Francesco; Aglioti, Salvatore M.] IRCCS Fondazione S Lucia, Rome, Italy; [Lerch, Jason] McGill Univ, Brain Imaging Ctr, Montreal Neurol Inst, Montreal, PQ, Canada; [Tomaiuolo, Francesco] Auxilium Vitae Volterra SpA, Pisa, Italy; [Aglioti, Salvatore M.] Univ Roma La Sapienza, Dept Psychol, Rome, Italy	Moro, V (corresponding author), Univ Verona, Dept Psychol & Culture Anthropol, Lung Porta Vittoria 17, I-37122 Verona, VR, Italy.	valentina.moro@univr.it; salvatoremaria.aglioti@uniroma1.it	Tomaiuolo, Francesco/AAC-1534-2019; Aglioti, Salvatore M/E-9829-2012; Moro, Valentina/AAM-2224-2021; Moro, Valentina/K-6464-2016	Moro, Valentina/0000-0002-7119-7264; Moro, Valentina/0000-0002-7119-7264; Tomaiuolo, Fancesco/0000-0003-1230-2770			ARRIGONI G, 1964, CORTEX, V1, P170; Bartolomeo P, 2002, CORTEX, V38, P357, DOI 10.1016/S0010-9452(08)70665-8; BEHRMANN M, 1992, NATURE, V359, P636, DOI 10.1038/359636a0; BENTON AL, 1975, LINE ORIENTATION JUD; Bueti D, 2004, NEUROPSYCHOLOGIA, V42, P1689, DOI 10.1016/j.neuropsychologia.2004.04.005; Chatterjee A, 1995, NEUROLOGY, V45, P2189, DOI 10.1212/WNL.45.12.2189; Driver J, 2001, COGNITION, V79, P39, DOI 10.1016/S0010-0277(00)00124-4; Economo C., 1925, CYTOARCHITEKTONIK HI; FARAH M, 2001, NEUROPSYCHOLOGY, V4, P238; Ganis G, 2004, COGNITIVE BRAIN RES, V20, P226, DOI 10.1016/j.cogbrainres.2004.02.012; GOLDENBERG G, 1995, NEUROPSYCHOLOGIA, V33, P1373, DOI 10.1016/0028-3932(95)00070-J; HUBER W, 1938, AACHENER APHASIE TES; Johnson SH, 2002, J COGNITIVE NEUROSCI, V14, P841, DOI 10.1162/089892902760191072; Kaski D, 2002, PERCEPTION, V31, P717, DOI 10.1068/p3360; Kobayashi M, 2004, NEUROIMAGE, V23, P1271, DOI 10.1016/j.neuroimage.2004.08.002; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; Luzzatti C, 1998, CORTEX, V34, P461, DOI 10.1016/S0010-9452(08)70768-8; Mechelli A, 2004, CEREB CORTEX, V14, P1256, DOI 10.1093/cercor/bhh087; Mellet E, 2000, J COGNITIVE NEUROSCI, V12, P98, DOI 10.1162/08989290051137620; Miceli G, 2001, NAT NEUROSCI, V4, P662, DOI 10.1038/88497; Newman SD, 2005, COGNITIVE BRAIN RES, V23, P235, DOI 10.1016/j.cogbrainres.2004.10.020; Policardi E, 1996, NEUROCASE, V2, P381, DOI 10.1093/neucas/2.5.381; PYLYSHYN ZW, 1973, PSYCHOL BULL, V80, P1, DOI 10.1037/h0034650; Raven J. C., 1954, STANDARD PROGR MATRI; Sack AT, 2005, SCIENCE, V308, P702, DOI 10.1126/science.1107784; Slotnick SD, 2005, CEREB CORTEX, V15, P1570, DOI 10.1093/cercor/bhi035; SMANIA N, 1995, EUROPA MEDICOPHISICA, V31, P169; SPINNLER H, 1987, SCIENCE S8, V6; Talairach J., 1988, COPLANAR STEREOTACTI; TROJANO L, 1994, BRAIN COGNITION, V24, P213, DOI 10.1006/brcg.1994.1012; Warrington E., 1991, VISUAL OBJECT SPACE; Weschler D., 1974, WESCHLER ADULT INTEL; WILSON B, 1985, RIVERMED BEHAV MEMOR; ZATORRE RJ, 1993, NEUROPSYCHOLOGIA, V31, P221, DOI 10.1016/0028-3932(93)90086-F	34	44	46	1	10	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2008	44	2					109	118		10.1016/j.cortex.2006.06.004			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	276OK	WOS:000254151700003	18387540				2021-06-18	
J	Brommeland, T; Rosengren, L; Fridlund, S; Hennig, R; Isaksen, V				Brommeland, T.; Rosengren, L.; Fridlund, S.; Hennig, R.; Isaksen, V.			Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas	ACTA NEUROLOGICA SCANDINAVICA			English	Article						GFAP; glioma; Ki-67; S-100B; tumour marker; tumour volume	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; S-100B PROTEIN; ACUTE STROKE; MARKER; KI-67; S100-BETA; PREDICTOR	Objectives - To investigate serum levels of glial fibrillary acidic protein (GFAP) and S-100B in patients with newly diagnosed high-grade gliomas. Materials and methods - GFAP and S-100B were measured by enzyme-linked immunosorbent assay techniques in preoperative serum from 31 patients with high-grade gliomas. A database with clinical, radiological and histological variables was created for statistical analyses. Results - Mean serum levels of 239 ng/l (range 30-1210 ng/l) for GFAP and 58.3 ng/l (range 22-128 ng/l) for S-100B were found. Of the 31 patients, 16 had elevated levels of GFAP while only two showed increased S-100B concentrations. Tumour size was the only variable significantly associated with serum levels of GFAP (P < 0.0001) with a linear correlation coefficient of 0.67. Conclusions - Serum levels of GFAP demonstrated a linear correlation to tumour volume in patients with high-grade gliomas. GFAP seems to be a more reliable biomarker in patients with high-grade gliomas than the commercially available S-100B.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Gothenburg Univ, Dept Neurol, Sahlgrenska Univ Hosp, Inst Clin Neurosci, Gothenburg, Sweden; Univ Hosp N Norway, Dept Pathol, Tromso, Norway	Brommeland, T (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.	tor.brommeland@unn.no	Brommeland, Tor/AAJ-8483-2020	Rosengren, Lars/0000-0003-0505-8896			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Blennow M, 2001, ACTA PAEDIATR, V90, P1171, DOI 10.1080/080352501317061594; COONS SW, 1993, J NEUROPATH EXP NEUR, V52, P609, DOI 10.1097/00005072-199311000-00008; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Fukuda ME, 2005, CANCER RES, V65, P5190, DOI 10.1158/0008-5472.CAN-04-4134; Haapasalo J, 2005, J CLIN PATHOL, V58, P263, DOI 10.1136/jcp.2004.018606; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; IWA N, 1988, DIAGN CYTOPATHOL, V4, P74, DOI 10.1002/dc.2840040118; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kayaselcuk F, 2002, J NEURO-ONCOL, V57, P115, DOI 10.1023/A:1015739130208; LAMERS KJB, 1995, ACTA NEUROL SCAND, V92, P247; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; Molina R, 2002, TUMOR BIOL, V23, P39, DOI 10.1159/000048687; Moskowitz SI, 2006, J NEURO-ONCOL, V76, P193, DOI 10.1007/s11060-005-5262-1; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Rajendra A, 2004, J NEURO-ONCOL, V67, P345, DOI 10.1023/B:NEON.0000024216.15923.77; ROSENGREN LE, 1995, J NEUROL SCI, V133, P61, DOI 10.1016/0022-510X(95)00152-R; RUUTIAINEN J, 1981, ACTA NEUROL SCAND, V63, P297; Sampath Prakash, 2004, Cancer Control, V11, P174; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sorensen AG, 2001, J CLIN ONCOL, V19, P551, DOI 10.1200/JCO.2001.19.2.551; Tanwar MK, 2002, CANCER RES, V62, P4364; VANDEPOL M, 1994, J NEURO-ONCOL, V19, P149, DOI 10.1007/BF01306456; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Vos MJ, 2004, ANTICANCER RES, V24, P2511; Wakimoto H, 1996, CANCER-AM CANCER SOC, V77, P373, DOI 10.1002/(SICI)1097-0142(19960115)77:2<373::AID-CNCR21>3.0.CO;2-Y; Yoshida S, 2000, J SURG ONCOL, V75, P131, DOI 10.1002/1096-9098(200010)75:2<131::AID-JSO10>3.0.CO;2-L; Zheng PP, 2005, CLIN CANCER RES, V11, P4388, DOI 10.1158/1078-0432.CCR-04-2512	34	44	50	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	DEC	2007	116	6					380	384		10.1111/j.1600-0404.2007.00889.x			5	Clinical Neurology	Neurosciences & Neurology	226VZ	WOS:000250617900006	17986096				2021-06-18	
J	Chau, RMC; Teo, PML; Kam, MKM; Leung, SF; Cheung, KY; Chan, ATC				Chau, Ricky M. C.; Teo, Peter M. L.; Kam, Michael K. M.; Leung, S. F.; Cheung, K. Y.; Chan, Anthony T. C.			Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-STAGE nasopharyngeal carcinoma: To treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord	MEDICAL DOSIMETRY			English	Article						NPC; 2DRT; advanced T-stage; IMRT; DVH; TCP; NTCP	TUMOR-CONTROL PROBABILITY; HONG-KONG EXPERIENCE; NECK CANCERS; RADIOTHERAPY; HEAD; IRRADIATION; MODEL; PLANS	The aim of this study is to evaluate the deficiencies in target coverage and organ protection of 2-dimensional radiation therapy (2DRT) in the treatment of advanced T-stage T3-4) nasopharyngeal carcinoma (NPC), and assess the extent of improvement that could be achieved with intensity modulated radiation therapy IMRT), with special reference to of the dose to the planning organ-at-risk volume (PRV) of the brainstem and spinal cord. A dosimetric study was performed on 10 patients with advanced T-stage (T3-4 and N0-2) NPC. Computer tomography (CT) images of 2.5-mm slice thickness of the head and neck were acquired with the patient immobilized in semi-extended-head position. A 2D plan based on Ho's technique, and an IMRT plan based on a 7-coplanar portals arrangement, were established for each patient. 2DRT was planned with the field borders and shielding drawn on the simulator radiograph with reference to bony landmarks, digitized, and entered into a planning computer for reconstruction of the 3D dose distribution. The 2DRT and IMRT treatment plans were evaluated and compared with respect to the dose-volume histograms (DVHs) of the targets and the organs-at-risk (OARs), tumor control probability (TCP), and normal tissue complication probabilities (NTCPs). With IMRT, the dose coverage of the target was superior to that of 2DRT. The mean minimum dose of the GTV and PTV were increased from 33.7 Gy (2DRT) to 62.6 Gy (IMRT), and 11.9 Gy (2DRT) to 47.8 Gy (IMRT), respectively. The D-95 of the GTV and PTV were also increased from 57.1 Gy (2DRT) to 67 Gy (IMRT), and 45 Gy (2DRT) to 63.6 Gy (IMRT), respectively. The TCP was substantially increased to 78.5% in IMRT. Better protection of the critical normal organs was also achieved with IMRT. The mean maximum dose delivered to the brainstem and spinal cord were reduced significantly from 61.8 Gy (2DRT) to 52.8 Gy IMRT) and 56 Gy (2DRT) to 43.6 Gy IMRT), respectively, which were within the conventional dose limits of 54 Gy for brainstem and of 45 Gy for spinal cord. The mean maximum doses deposited on the PRV of the brainstem and spinal cord were 60.7 Gy and 51.6 Gy respectively, which were above the conventional dose limits. For the chiasm, the mean dose maximum and the dose to 5% of its volume were reduced from 64.3 Gy (2DRT) to 53.7 Gy (IMRT) and from 62.8 Gy (2DRT) to 48.7 Gy IMRT), respectively, and the corresponding NTCP was reduced from 18.4% to 2.1%. For the temporal lobes, the mean dose to 10 % of its volume (about 4.6 cc) was reduced from 63.8 Gy (2DRT) to 55.4 Gy (IMRT) and the NTCP was decreased from 11.7% to 3.4%. The therapeutic ratio for T3-4 NPC tumors can be significantly improved with IMRT treatment technique due to improvement both in target coverage and the sparing of the critical normal organ. Although the maximum doses delivered to the brainstem, and spinal cord in IMRT can be kept at or below their conventional dose limits, the maximum doses deposited on the PRV often exceed these limits due to the close proximity between the target and OARs. In other words, ideal dosimetric considerations cannot be fulfilled in IMRT planning for T34 NPC tumors. A compromise of the maximal dose limit to the PRV of the brainstem and spinal cord would need be accepted if dose coverage to the targets is not to be unacceptably compromised. Dosimetric comparison with 2DRT plans show that these dose limits to PRV were also frequently exceeded in 2DRT plans for locally advanced NPC. A dedicated retrospective study on the incidence of clinical injury to neurological organs in a large seriesof patients with T3-4 NPC treated by 2DRT may provide useful reference data in exploring how far the PRV dose constraints may be relaxed, to maximize the target coverage without compromising the normal organ function. (C) 2007 American Association of Medical Dosimetrists.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China; Sanatorium Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Chau, RMC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.	S033928@mailserv.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018	Chan, Anthony Tak Cheung/0000-0002-6912-8091			BURMAN C, 1991, INT J RADIAT ONCOL, V21, P123, DOI 10.1016/0360-3016(91)90172-Z; Chao KSC, 2000, INT J CANCER, V90, P92, DOI 10.1002/(SICI)1097-0215(20000420)90:2<92::AID-IJC5>3.0.CO;2-9; Chao KSC, 2001, INT J RADIAT ONCOL, V49, P907, DOI 10.1016/S0360-3016(00)01441-3; Chau RMC, 2001, RADIOTHER ONCOL, V58, P143, DOI 10.1016/S0167-8140(00)00336-4; Cheng JCH, 2001, INT J CANCER, V96, P126, DOI 10.1002/ijc.1004; Eisbruch A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3; EMAMI B, 1991, INT J RADIOL ONCOL B, V16, P1623; Ho JH, 1978, INT J RADIAT ONCOL, V4, P183; HO JHC, 1982, TREATMENT CANC, P24; HONORE HB, 2002, INT J RADICOL ONCOL, V53, P638; Hunt MA, 2001, INT J RADIAT ONCOL, V49, P623, DOI 10.1016/S0360-3016(00)01389-4; *INT UN AG CANC UI, 1997, TNM CLASS MAL TUM; International Commission of Radiation Units and Measurements (ICRU), 1999, 50 ICRU; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; LYMAN JT, 1987, INT J RADIAT ONCOL, V13, P103, DOI 10.1016/0360-3016(87)90266-5; NIEMIERKO A, 1993, RADIOTHER ONCOL, V29, P140, DOI 10.1016/0167-8140(93)90239-5; Purdy JA, 2002, SEMIN RADIAT ONCOL, V12, P199, DOI 10.1053/srao.2002.32432; Raaijmakers E, 2002, RADIOTHER ONCOL, V65, P1, DOI 10.1016/S0167-8140(02)00211-6; Sanchez-Nieto B, 1999, INT J RADIAT ONCOL, V44, P369, DOI 10.1016/S0360-3016(99)00029-2; Sultanem K, 2000, INT J RADIAT ONCOL, V48, P711, DOI 10.1016/S0360-3016(00)00702-1; TEO P, 1989, INT J RADIAT ONCOL, V17, P515, DOI 10.1016/0360-3016(89)90102-8; Teo P, 1996, INT J RADIAT ONCOL, V36, P291, DOI 10.1016/S0360-3016(96)00323-9; WEBB S, 1993, PHYS MED BIOL, V38, P653, DOI 10.1088/0031-9155/38/6/001; WONG SM, 2003, J HK COLL RADIOL S, V6, P127; Xia P, 2000, INT J RADIAT ONCOL, V48, P329, DOI 10.1016/S0360-3016(00)00585-X; Zhou JN, 2003, INT J RADIAT ONCOL, V57, P673, DOI 10.1016/S0360-3016(03)00626-6	30	44	59	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0958-3947	1873-4022		MED DOSIM	Med. Dosim.	WIN	2007	32	4					263	270		10.1016/j.meddos.2007.02.006			8	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Oncology; Radiology, Nuclear Medicine & Medical Imaging	233FG	WOS:000251075200005	17980826				2021-06-18	
J	Murphy, B; Dunleavy, M; Shinoda, S; Schindler, C; Meller, R; Bellver-Estelles, C; Hatazaki, S; Dicker, P; Yamamoto, A; Koegel, I; Chu, XP; Wang, WZ; Xiong, ZG; Prehn, J; Simon, R; Henshall, D				Murphy, Brona; Dunleavy, Mark; Shinoda, Sachiko; Schindler, Clara; Meller, Robert; Bellver-Estelles, Carmen; Hatazaki, Seiji; Dicker, Patrick; Yamamoto, Akitaka; Koegel, Ina; Chu, Xiangping; Wang, Weizhen; Xiong, Zhigang; Prehn, Jochen; Simon, Roger; Henshall, David			Bcl-w protects hippocampus during experimental status epilepticus	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EVOKED LIMBIC SEIZURES; INDUCED NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; PROGRAMMED CELL-DEATH; ISCHEMIC BRAIN; DEFICIENT MICE; APOPTOSIS; PROTEINS; EXPRESSION	Experimentally evoked seizures can activate the intrinsic mitochondrial cell death pathway, components of which are modulated in the hippocampus of patients with temporal lobe epilepsy. Bcl-2 family proteins are critical regulators of mitochondrial dysfunction, but their significance in this setting remains primarily untested. Presently, we investigated the mitochondrial pathway and role of anti-apoptotic Bcl-2 proteins using a mouse model of seizure-induced neuronal death. Status epilepticus was evoked in mice by intra-amygdala kainic acid, causing cytochrome c release, processing of caspases 9 and 7, and death of ipsilateral hippocampal pyramidal neurons. Seizures caused a rapid decline in hippocampal Bcl-w levels not seen for either Bcl-2 or Bcl-xl. To test whether endogenous Bcl-w was functionally significant for neuronal survival, we investigated hippocampal injury after seizures in Bcl-w-deficient mice. Seizures induced significantly more hippocampal CA3 neuronal loss and DNA fragmentation in Bcl-w-deficient mice compared with wild-type mice. Quantitative electroencephalography analysis also revealed that Bcl-w-deficient mice display a neurophysiological phenotype whereby there was earlier polyspike seizure onset. Finally, we detected higher levels of Bcl-w in hippocampus from temporal lobe epilepsy patients compared with autopsy controls. These data identify Bcl-w as an endogenous neuroprotectant that may have seizure-suppressive functions.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Legacy Res, Robert S Dow Neurobiol Labs, Portland, OR USA; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan	Henshall, D (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Murphy, Brona/D-4873-2012; Murphy, Brona/P-2544-2019; Dunleavy, Mark/B-4260-2012; Prehn, Jochen HM/A-3928-2010	Murphy, Brona/0000-0002-6740-8858; Murphy, Brona/0000-0002-6740-8858; Dunleavy, Mark/0000-0001-5916-9722; Prehn, Jochen HM/0000-0003-3479-7794; Chu, Xiang-Ping/0000-0002-6781-0468; Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041935, NS39016, R01 NS047622, NS47622, NS41935, R01 NS039016] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [gr076576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047622, R01NS039016, R01NS041935] Funding Source: NIH RePORTER		Araki T, 2002, J NEUROSCI RES, V69, P614, DOI 10.1002/jnr.10356; Briellmann RS, 2000, NEUROLOGY, V55, P1479, DOI 10.1212/WNL.55.10.1479; Cao GD, 2002, J NEUROSCI, V22, P5423; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Fujikawa DG, 2002, J NEUROCHEM, V83, P229, DOI 10.1046/j.1471-4159.2002.01152.x; Hamner S, 1999, NEUROSCIENCE, V91, P673, DOI 10.1016/S0306-4522(98)00642-3; Henshall DC, 2005, J CEREBR BLOOD F MET, V25, P1557, DOI 10.1038/sj.jcbfm.9600149; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2002, NEUROBIOL DIS, V10, P71, DOI 10.1006/nbdi.2002.0505; Henshall DC, 2001, CELL DEATH DIFFER, V8, P1169, DOI 10.1038/sj.cdd.4400921; Henshall DC, 2001, NEUROSCI LETT, V305, P153, DOI 10.1016/S0304-3940(01)01849-3; Hochman A, 1998, J NEUROCHEM, V71, P741; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; Jonas EA, 2003, J NEUROSCI, V23, P8423; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kondratyev A, 2001, MOL BRAIN RES, V91, P1, DOI 10.1016/S0169-328X(01)00099-7; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Tian-Fu, 2005, Shengli Xuebao, V57, P310; Lindsten T, 2006, CELL DEATH DIFFER, V13, P1272, DOI 10.1038/sj.cdd.4401953; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu XM, 2006, J BIOL CHEM, V281, P17432, DOI 10.1074/jbc.M513490200; Meldrum BS, 2002, PROG BRAIN RES, V135, P487; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Pitkanen A, 2002, NEUROLOGY, V59, pS27, DOI 10.1212/WNL.59.9_suppl_5.S27; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Schindler CK, 2004, NEUROSCI LETT, V356, P163, DOI 10.1016/j.neulet.2003.11.048; Shinoda S, 2004, J NEUROSCI RES, V76, P121, DOI 10.1002/jnr.20064; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Sun Y, 2003, GENE THER, V10, P115, DOI 10.1038/sj.gt.3301868; Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508; Weise J, 2005, NEUROBIOL DIS, V18, P582, DOI 10.1016/j.nbd.2004.10.025; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Xiong ZG, 1999, J NEUROSCI, V19; Yamamoto A, 2006, J NEUROPATH EXP NEUR, V65, P217, DOI 10.1097/01.jnen.0000202886.22082.2a; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020	47	44	44	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2007	171	4					1258	1268		10.2353/ajpath.2007.070269			11	Pathology	Pathology	217TJ	WOS:000249969900017	17702891	Green Published			2021-06-18	
J	Gorio, A; Madaschi, L; Zadra, G; Marfia, G; Cavalieri, B; Bertini, R; Di Giulio, AM				Gorio, Alfredo; Madaschi, Laura; Zadra, Giorgia; Marfia, Giovanni; Cavalieri, Barbara; Bertini, Riccardo; Di Giulio, Anna Maria			Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TUMOR NECROSIS FACTOR; TNF-ALPHA; INJURY; METHYLPREDNISOLONE; BRAIN; ERYTHROPOIETIN; ISCHEMIA; NEUTROPHIL; REPERTAXIN; EXPRESSION	It has been shown that the blockade of CXCR1 and CXCR2 receptors prevents ischemia/reperfusion damage in several types of vascular beds. Reparixin is a recently described inhibitor of human CXCR1/R2 and rat CXCR2 receptor activation. We applied reparixin in rats following traumatic spinal cord injury and determined therapeutic temporal and dosages windows. Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells. The observed preservation of the white matter might also be secondary to the enhanced proliferation of NG2-positive cells. The expression of macrophage-inflammatory protein-2, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1 beta was also counteracted, and the proliferation of glial fibrillary acidic protein-positive cells was markedly reduced. These effects resulted in a smaller post-traumatic cavity and in a significantly improved recovery of hind limb function. The best beneficial outcome of reparixin treatment required 7-day administration either by i.p. route (15 mg/kg) or subcutaneous infusion via osmotic pumps (10 mg/kg), reaching a steady blood level of 8 mu g/ml. Methylprednisolone was used as a reference drug; such treatment reduced cytokine production but failed to affect the rate of hind limb recovery.	Univ Milan, Pharmacol Labs, Fac Med, Dept Med Surg & Dent, Milan, Italy; Ist Ric & Cura & Cavattere Sci Humanitas, Milan, Italy; Dompe Pharma SPA, Laquila, Italy	Gorio, A (corresponding author), Dept Med Surg & Dent, Pharmacol Labs, Via A Rydubu 8, I-20142 Milan, Italy.	alfredo.gorio@unimi.it	Marfia, Giovanni/N-4650-2014; Marfia, Giovanni/AAB-8702-2020	Marfia, Giovanni/0000-0002-5849-7000; Marfia, Giovanni/0000-0002-5849-7000; Di Giulio, Anna Maria/0000-0002-5702-4623			BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Boyle EM, 1999, ANN THORAC SURG, V68, P1949, DOI 10.1016/S0003-4975(99)01033-4; Bracken MB, 2002, J NEUROSURG, V96, P140; Cavalieri B, 2005, INT J IMMUNOPATH PH, V18, P475, DOI 10.1177/039463200501800307; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Cugini D, 2005, KIDNEY INT, V67, P1753, DOI 10.1111/j.1523-1755.2005.00272.x; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Fu ES, 2005, J NEUROSURG ANESTH, V17, P82, DOI 10.1097/01.ana.0000163199.10365.38; Garau A, 2005, CYTOKINE, V30, P125, DOI 10.1016/j.cyto.2004.12.014; Gilmont RR, 1996, J SURG RES, V61, P175, DOI 10.1006/jsre.1996.0101; GIULIAN D, 1993, J NEUROSCI, V13, P29; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lankhorst AJ, 2000, BRAIN RES, V859, P334, DOI 10.1016/S0006-8993(00)02025-4; MERCHANT SH, 2003, AM J PHYSIOL, V284, P1260; Merola A, 2002, J ORTHOP TRAUMA, V16, P155, DOI 10.1097/00005131-200203000-00003; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miura M, 2001, AM J PATHOL, V159, P2137, DOI 10.1016/S0002-9440(10)63065-9; Nakashima S, 2004, NEUROREPORT, V15, P2337, DOI 10.1097/00001756-200410250-00007; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; SCHLAYER HJ, 1988, J HEPATOL, V7, P239, DOI 10.1016/S0168-8278(88)80488-4; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; Souza DG, 2004, BRIT J PHARMACOL, V143, P132, DOI 10.1038/sj.bjp.0705862; Souza DG, 2001, BRIT J PHARMACOL, V134, P985, DOI 10.1038/sj.bjp.0704336; Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Vitellaro-Zuccarello L, 2007, NEUROSCIENCE, V144, P865, DOI 10.1016/j.neuroscience.2006.10.023; Willerson J T, 1997, Adv Pharmacol, V39, P291, DOI 10.1016/S1054-3589(08)60074-5; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	41	44	44	0	6	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	SEP	2007	322	3					973	981		10.1124/jpet.107.123679			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	202FM	WOS:000248887400009	17601981				2021-06-18	
J	Beschorner, R; Dietz, K; Schauer, K; Mittelbronn, M; Schluesener, HJ; Trautmann, K; Meyermann, R; Simon, P				Beschorner, R.; Dietz, K.; Schauer, K. N.; Mittelbronn, M.; Schluesener, H. J.; Trautmann, K.; Meyermann, R.; Simon, P.			Expression of EAAT1 reflects a possible neuroprotective function of reactive astrocytes and activated microglia following human traumatic brain injury	HISTOLOGY AND HISTOPATHOLOGY			English	Article						microglial activation; neuroprotection; traumatic brain injury; excitatory amino acid transporters	GLIAL GLUTAMATE TRANSPORTER; AMINO-ACID TRANSPORTER-1; FOCAL CEREBRAL-ISCHEMIA; GLT-1 EXPRESSION; CELL-DEATH; CLINICAL-TRIALS; CORTICAL IMPACT; MICE LACKING; SPINAL-CORD; RAT MODEL	Glutamate-mediated excitotoxicity is known to cause secondary brain damage following stroke and traumatic brain injury (TBI). However, clinical trials using NMDA antagonists failed. Thus, glial excitatory amino acid transporters (EAATs) might be a promising target for therapeutic intervention. Methods and Results. We examined expression of EAAT1 (GLAST) and EAAT2 (Glt-1) in 36 TBI cases by immunohistochemistry. Cortical expression of both EAATs decreased rapidly and widespread throughout the brain (in lesional, adjacent and remote areas) following TBI. In the white matter numbers of EAAT1+ parenchymal cells increased 39-fold within 24h (p < 0.001) and remained markedly elevated till later stages in the lesion (90-fold, p < 0.01) and in peri-lesional regions (86-fold, p < 0.01). In contrast, EAAT2+ parenchymal cells and EAAT1+ or EAAT2+ perivascular cells did not increase significantly. Within the first days following TBI mainly activated microglia and thereafter mainly reactive astrocytes expressed EAAT1. Perivascular monocytes and foamy macrophages lacked EAAT1 immunoreactivity. We conclude that following TBI i) loss of cortical EAATs contributes to secondary brain damage, ii) glial EAAT1 expression reflects a potential neuroprotective function of microglia and astrocytes, iii) microglial EAAT1 expression is restricted to an early stage of activation, iv) blood-derived monocytes do not express EAAT1 and v) pharmacological modification of glial EAAT expression might further limit neuronal damage.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Biometry, D-72076 Tubingen, Germany; Univ Tubingen, Clin Internal Med, Dept Sports Med, D-72076 Tubingen, Germany	Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwestr 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Simon, Perikles D/B-2293-2013; Beschorner, Rudi/M-6397-2014; Simon, Perikles/O-4145-2019; Dietz, Klaus/R-9268-2016	Simon, Perikles D/0000-0002-7996-4034; Simon, Perikles/0000-0002-7996-4034; Dietz, Klaus/0000-0001-8503-9737; Beschorner, Rudi/0000-0003-1109-915X; Mittelbronn, Michel/0000-0002-2998-052X			ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Banner SJ, 2002, NEUROSCIENCE, V109, P27, DOI 10.1016/S0306-4522(01)00437-7; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Bonde C, 2003, NEUROCHEM INT, V43, P371, DOI 10.1016/S0197-0186(03)00024-X; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; Cakir E, 2005, J CLIN NEUROSCI, V12, P923, DOI 10.1016/j.jocn.2005.03.013; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Chretien F, 2002, NEUROPATH APPL NEURO, V28, P410, DOI 10.1046/j.1365-2990.2002.00426.x; Chretien F, 2004, J NEUROPATH EXP NEUR, V63, P1058, DOI 10.1093/jnen/63.10.1058; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Duan SM, 1999, J NEUROSCI, V19, P10193; Eisenstein M, 2005, LAB ANIMAL, V34, P10; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Gras G, 2003, BRAIN PATHOL, V13, P211; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Hurtado O, 2005, NEUROBIOL DIS, V18, P336, DOI 10.1016/j.nbd.2004.10.006; Ikematsu K, 2002, FORENSIC SCI INT, V130, P83, DOI 10.1016/S0379-0738(02)00344-4; Ikematsu K, 2001, FORENSIC SCI INT, V118, P49, DOI 10.1016/S0379-0738(00)00378-9; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Lopez-Bayghen E, 2004, J NEUROCHEM, V91, P200, DOI 10.1111/j.1471-4159.2004.02706.x; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Mori T, 2004, NEUROCHEM INT, V45, P381, DOI 10.1016/j.neuint.2003.06.001; Muir KW, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001244; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Namura S, 2002, NEUROSCI LETT, V324, P117, DOI 10.1016/S0304-3940(02)00193-3; Niederberger E, 2003, NEUROSCIENCE, V116, P81, DOI 10.1016/S0306-4522(02)00547-X; Palacin M, 1998, PHYSIOL REV, V78, P969; Pawlak J, 2005, MOL BRAIN RES, V138, P1, DOI 10.1016/j.molbrainres.2004.10.043; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rimaniol AC, 2000, J IMMUNOL, V164, P5430, DOI 10.4049/jimmunol.164.10.5430; Robelet S, 2004, EUR J NEUROSCI, V20, P1255, DOI 10.1111/j.1460-9568.2004.03591.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rozyczka J, 2004, BRAIN PATHOL, V14, P406; Shimada F, 1999, EUR J PHARMACOL, V386, P263, DOI 10.1016/S0014-2999(99)00735-9; Simantov R, 1999, J NEUROCHEM, V73, P1828; Simantov R, 1999, MOL BRAIN RES, V65, P112, DOI 10.1016/S0169-328X(98)00349-0; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORP R, 1995, EXP BRAIN RES, V103, P51; Umemura K, 1996, STROKE, V27, P1624, DOI 10.1161/01.STR.27.9.1624; Vallat-Decouvelaere AV, 2003, J NEUROPATH EXP NEUR, V62, P475, DOI 10.1093/jnen/62.5.475; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Vera-Portocarrero LP, 2002, BRAIN RES, V927, P104, DOI 10.1016/S0006-8993(01)03329-7; Voutsinos-Porche B, 2003, CEREB CORTEX, V13, P1110, DOI 10.1093/cercor/13.10.1110; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wang CX, 2005, CNS NEUROL DISORD-DR, V4, P143, DOI 10.2174/1568007053544183; Werner P, 2001, ANN NEUROL, V50, P169, DOI 10.1002/ana.1077; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139	76	44	49	0	3	F HERNANDEZ	MURCIA	PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN	0213-3911	1699-5848		HISTOL HISTOPATHOL	Histol. Histopath.	MAY	2007	22	5					515	526					12	Cell Biology; Pathology	Cell Biology; Pathology	145TA	WOS:000244886200005	17330806				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, Cathy; Anderson, Vicki			Recovery in memory function, and its relationship to academic success, at 24 months following pediatric TBI	CHILD NEUROPSYCHOLOGY			English	Article						traumatic brain injury; children; memory; recovery	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; 1ST YEAR; CHILDREN; ADOLESCENTS; CHILDHOOD; SEVERITY	While a number of research papers have reported findings on memory deficits following traumatic brain injury (TBI), only limited studies have monitored the recovery of these skills over time. The present study examined memory ability and its effect on academic success in a group of children who had sustained a mild, moderate, or severe traumatic brain injury (TBI). Results showed that the severe TBI group exhibited greater deficits on memory tasks, irrespective of modality, in the acute, 6-, 12-, and 24-month postinjury stages, in comparison to mild and moderate TBI groups. Performance on academic measures was dependent on both injury severity and task demands. Preinjury academic ability and verbal memory indices best predicted academic success.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au					ANDERSON RL, 1996, CRC HDB LIE GR ANAL, V3, P3; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson V.A., 1997, NEUROPSYCHOLOGICAL A; Baddeley A, 1990, HUMAN MEMORY THEORY; BADDELEY A, 2000, HUMAN MEMORY THEORY; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BARON I, 1996, PEDIAT NEUROPSYCHOLO; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; BJORKLUND DF, 1984, CHILDRENS THINKING D; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHORAZY AJL, 1985, HEAD INJURY REHABILI; COLOMBO M, 1994, BEHAV NEUROSCI, V108, P443, DOI 10.1037/0735-7044.108.3.443; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Cowan Nelson, 1995, ATTENTION MEMORY INT; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harris JR, 1996, J COMMUN DISORD, V29, P79, DOI 10.1016/0021-9924(94)00035-2; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kaufman A. S., 1983, KAUFMAN ASSESSMENT B; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Pressley M, 1997, INTRO MEMORY DEV CHI; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROWE JK, 1995, ROWE BEHAV RATING IN; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Siegler R. S., 1991, CHILDRENS THINKING; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; TEASDALE G, 1974, LANCET, V2, P81; VANZOMERON AH, 1994, CLIN NEUROPSYCHOLOGY; Walsh K., 1994, NEUROPSYCHOLOGY CLIN; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Warschausky S, 2005, NEUROPSYCHOLOGY, V19, P193, DOI 10.1037/0894-4105.19.2.193; Wechsler D., 1991, MANUAL WECHSLER INTE, VIII; WECHSLER D, 1992, WECHSLER INDIVIDUAL; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	63	44	44	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAY	2007	13	3					240	261		10.1080/09297040600837362			22	Clinical Neurology	Neurosciences & Neurology	164BR	WOS:000246208100003	17453832				2021-06-18	
J	Middelkamp, W; Moulaert, VRMP; Verbunt, JA; van Heugten, CM; Bakx, WG; Wade, DT				Middelkamp, Wietske; Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.; van Heugten, Caroline M.; Bakx, Wilbert G.; Wade, Derick T.			Life after survival: long-term daily life functioning and quality of life of patients with hypoxic brain injury as a result of a cardiac arrest	CLINICAL REHABILITATION			English	Article							RESUSCITATION; QUESTIONNAIRE; PARTICIPATION; SEQUELAE; AUTONOMY	Objectives: To determine the level of daily functioning and quality of life of patients with hypoxic brain injury after a cardiac arrest and to investigate the predictive value of the duration of coma and post-traumatic amnesia in long-term functioning. Design: A retrospective cohort study. Setting: A Dutch rehabilitation centre. Subjects: Thirty-two patients with hypoxic brain injury caused by a cardiac arrest 2-7 years ago, who were admitted to a brain injury rehabilitation programme. Main outcome measures: Cognitive Failures Questionnaire (CFQ), Frenchay Activities Index (FAI), Impact on Participation and Autonomy Questionnaire (IPAQ) and Quality of Life after Brain Injury questionnaire (QOLIBRI). Data on duration of coma and post-traumatic amnesia were retrieved from medical files. Results: A significant association was found between duration of coma, complaints of cognitive functioning (r=0.57, P < 0.05) and quality of life after brain injury (r=-0.70, P < 0.01). Duration of post-traumatic amnesia was associated with both daily functioning (r=-0.70, P < 0.01) and quality of life (r=-0.70, P < 0.01). Furthermore complaints of cognitive functioning were associated with both the level of participation in society (r=0.76, P < 0.01) and quality of life (r=0.77,P < 0.01). Conclusions: Long-term outcome of patients with hypoxic brain injury after a cardiac arrest shows that this group is limited in cognitive and daily functioning, participation and quality of life. Based on the duration of coma and post-traumatic amnesia, an estimation of daily life functioning and quality of life 2-7 years after a cardiac arrest can be made.	Rehabil Fdn Limburg, Hoensbroeck Rehabil Ctr, NL-6430 AB Hoensbroek, Netherlands; Maastricht Univ, Fac Hlth Sci, Maastricht, Netherlands; Inst Rehabil Res, Hoensbroek, Netherlands; Oxford Ctr Enablement, Oxford, England	Verbunt, JA (corresponding author), Rehabil Fdn Limburg, Hoensbroeck Rehabil Ctr, POB 88, NL-6430 AB Hoensbroek, Netherlands.	j.verbunt@srl.nl		Wade, Derick/0000-0002-1188-8442			ALEM AP, 2004, AM J CARDIOL, V93, P131; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cardol M, 2001, ARCH PHYS MED REHAB, V82, P210, DOI 10.1053/apmr.2001.18218; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Lundgren-Nilsson A, 2005, RESUSCITATION, V66, P285, DOI 10.1016/j.resuscitation.2005.04.001; PONDS RWH, 1998, THESIS U MAASTRICHT; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sauve M J, 1996, Am J Crit Care, V5, P127; Sibley A, 2006, CLIN REHABIL, V20, P793, DOI 10.1177/0269215506070808; Sullivan M Terry, 2003, Home Healthc Nurse, V21, P197, DOI 10.1097/00004045-200303000-00024; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Waalewijn RA, 1998, RESUSCITATION, V38, P157, DOI 10.1016/S0300-9572(98)00102-6; Wade D T, 1985, Int Rehabil Med, V7, P176; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; *WHO, 2001, INT CLASS FUNCT DISA; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	21	44	46	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	MAY	2007	21	5					425	431		10.1177/0269215507075307			7	Rehabilitation	Rehabilitation	191NB	WOS:000248136800005	17613563				2021-06-18	
J	Kline, AE; Massucci, JL; Zafonte, RD; Dixon, CE; Defeo, JR; Rogers, EH				Kline, Anthony E.; Massucci, Jaime L.; Zafonte, Ross D.; Dixon, C. Edward; DeFeo, Judith R.; Rogers, Emily H.			Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma	CRITICAL CARE MEDICINE			English	Article						beam balance; catecholamines; cognition; controlled cortical impact; functional recovery; Morris water maze; traumatic brain injury	CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; RAT FRONTAL-CORTEX; METHYLPHENIDATE TREATMENT; ATYPICAL ANTIPSYCHOTICS; COGNITIVE DEFICITS; WORKING-MEMORY; INJURY; RECOVERY; DAMAGE	Objectives: Antipsychotics are routinely administered to patients with traumatic brain injury, even though the benefits vs. risks of this approach on behavioral recovery are unclear. To clarify the issue, the present study evaluated the effect of single and multiple administrations of haloperidol and risperidone on functional outcome after traumatic brain injury. Design: Prospective and randomized study in rodents. Setting: Experimental research laboratory at the University of Pittsburgh. Subjects: A total of 60 adult male Sprague-Dawley rats weighing 300-325 g. Interventions: Anesthetized rats received either a cortical impact or sham injury and then were randomly assigned to five traumatic brain injury groups (0.045 mg/kg, 0.45 mg/kg, or 4.5 mg/kg risperidone; 0.5 mg/kg haloperidol; or 1 mL/kg vehicle) or three sham groups (4.5 mg/kg risperidone, 0.5 mg/kg haloperidol, or 1 mL/kg vehicle). The experiment consisted of three phases. In the first phase, a single treatment was provided (intraperitoneally) 24 hrs after surgery, and motor and cognitive function was assessed on postoperative days 1-5 and 14-18, respectively. During the second phase, after completion of the initial behavioral tasks, the same rats were treated once daily for 5 days and behavior was reevaluated. During the third phase, treatments were discontinued, and 3 days later, the rats were assessed one final time. Measurements and Main Results: Time (seconds) to maintain beam balance, traverse an elevated beam, and to locate a submerged platform in a Morris water maze was recorded. Neither motor nor cognitive performance was affected after a single treatment, regardless of group assignment (p > .05). In contrast, both behavioral deficits reoccurred after daily treatments of risperidone (4.5 mg/kg) and haloperidol (p < .05). The cognitive deficits persisted even after a 3-day washout period during the third phase. Conclusions: These data suggest that although single or multiple low doses of risperidone and haloperidol may be innocuous to subsequent recovery after traumatic brain injury, chronic high-dose treatments are detrimental.	Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Kline, AE (corresponding author), Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD043851, R03 HD043851-01, R03 HD043851, R01 HD069620, R01 HD046700-02, R01 HD046700-03, R01 HD046700, HD046770, R01 HD046700-04, R01 HD046700-01A1, R03 HD043851-02] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS060005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER		Alleva E, 1996, PROG NEURO-PSYCHOPH, V20, P483, DOI 10.1016/0278-5846(96)00010-3; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 2004, RESTOR NEUROL NEUROS, V22, P175; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Feeney DM, 1997, ADV NEUROL, V73, P383; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Levy M, 2005, NEUROREHABILITATION, V20, P279; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 1997, BEHAV BRAIN RES, V87, P105, DOI 10.1016/S0166-4328(96)02266-8; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; SCHOTTE A, 1993, BRAIN RES, V631, P191, DOI 10.1016/0006-8993(93)91535-Z; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	39	44	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2007	35	3					919	924		10.1097/01.CCM.0000256722.88854.C0			6	Critical Care Medicine	General & Internal Medicine	139ZE	WOS:000244470800033	17255872	Green Accepted			2021-06-18	
J	Smith, MP; Cass, WA				Smith, Michael P.; Cass, Wayne A.			GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease	NEUROSCIENCE LETTERS			English	Article						GDNF; reactive oxygen species; protein carbonyls; 4-hydroxynonenal; striatum; Sabstantia nigra; dopamine	TRAUMATIC BRAIN-INJURY; RAT SUBSTANTIA-NIGRA; NEUROTROPHIC FACTOR; CELL-LINE; DOPAMINE NEURONS; TIME-COURSE; INTRASTRIATAL 6-HYDROXYDOPAMINE; DISTINCT MECHANISMS; LIPID-PEROXIDATION; SINGLE INJECTION	Many current theories of Parkinson's disease (PD) suggest that oxidative stress is involved in the neurodegenerative process. Potential neuroprotective agents could protect neurons through inherent antioxidant properties or through the Upregulation of the brain's antioxidant defenses. Glial cell line-derived neurotrophic factor (GDNF) has been shown to protect and restore dopamine neurons in experimental models of PD and to improve motor function in human patients. This study was designed to investigate GDNF's effect on oxidative stress in a model of PD. GDNF or vehicle was injected into the right striatum of male Fischer-344 rats. Three days later 6-OHDA or saline was injected into the same striatum. The striatum and substantia nigra from both sides of the brain were removed 24 h after 6-OHDA or saline injection and analyzed for the oxidative stress markers protein carbonyls and 4-hydroxynonenal. Both markers were significantly reduced in GDNF+6-OHDA treated animals compared to vehicle+6-OHDA treated animals. In addition, in animals allowed to recover for 3.5-4 weeks after the 6-OHDA administration, the GDNF led to significant protection against loss of striatal and nigral tissue levels of dopamine. These results suggest that the protective effects of GDNF against 6-OHDA involve a reduction in oxidative stress. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Chandler Med Ctr, Lexington, KY 40536 USA	Cass, WA (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Chandler Med Ctr, MN-225, Lexington, KY 40536 USA.	wacass1@uky.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG17963, T32 AG000242-12, R01 AG017963-05, T32 AG000242, AG00242, R01 AG017963] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242, R01AG017963] Funding Source: NIH RePORTER		Aksenov MY, 2001, NEUROSCI LETT, V305, P5, DOI 10.1016/S0304-3940(01)01786-4; Aoi M, 2000, NEUROSCI RES, V36, P319, DOI 10.1016/S0168-0102(00)00097-3; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Betarbet R, 2005, EXP NEUROL, V191, pS17, DOI 10.1016/j.expneurol.2004.08.021; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; Cass WA, 2004, EXP NEUROL, V187, P205; Cass WA, 2003, BRAIN RES, V984, P133, DOI 10.1016/S0006-8993(03)03122-6; Cass WA, 1996, J NEUROSCI, V16, P8132; Chao CC, 1999, NEUROPHARMACOLOGY, V38, P913, DOI 10.1016/S0028-3908(99)00030-1; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO;2-5; Ding YM, 2004, J NEUROCHEM, V89, P776, DOI 10.1111/j.1471-4159.2004.02415.x; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gong YS, 1999, J ASIAN NAT PROD RES, V1, P153, DOI 10.1080/10286029908039859; Grondin R, 2003, J NEUROSCI, V23, P1974; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Ilic TV, 1999, FUNCT NEUROL, V14, P141; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; JEON BS, 1995, NEURODEGENERATION, V4, P131, DOI 10.1006/neur.1995.0016; Kearns CM, 1997, J NEUROSCI, V17, P7111; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Kikuchi A, 2002, NEUROBIOL DIS, V9, P244, DOI 10.1006/nbdi.2002.0466; Kirik D, 2000, EUR J NEUROSCI, V12, P3871, DOI 10.1046/j.1460-9568.2000.00274.x; Kirik D, 1998, EXP NEUROL, V152, P259, DOI 10.1006/exnr.1998.6848; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Kramer BC, 2004, J NEUROCYTOL, V33, P213, DOI 10.1023/B:NEUR.0000030696.62829.ec; Lotharius J, 1999, J NEUROSCI, V19, P1284; Maguire-Zeiss KA, 2005, MOL BRAIN RES, V134, P18, DOI 10.1016/j.molbrainres.2004.09.014; Mattson MP, 1999, J NEUROSCI RES, V58, P152, DOI 10.1002/(SICI)1097-4547(19991001)58:1<152::AID-JNR15>3.0.CO;2-V; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McGrath LT, 2001, QJM-MON J ASSOC PHYS, V94, P485, DOI 10.1093/qjmed/94.9.485; Patel NK, 2005, ANN NEUROL, V57, P298, DOI 10.1002/ana.20374; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Poon HF, 2004, BRAIN RES, V1018, P86, DOI 10.1016/j.brainres.2004.05.048; Przedborski S, 2005, ANTIOXID REDOX SIGN, V7, P685, DOI 10.1089/ars.2005.7.685; Serra JA, 2001, J NEURAL TRANSM, V108, P1135, DOI 10.1007/s007020170003; Shastry BS, 2001, NEUROSCI RES, V41, P5, DOI 10.1016/S0168-0102(01)00254-1; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Smith MP, 2007, NEUROSCIENCE, V144, P1057, DOI 10.1016/j.neuroscience.2006.10.004; Stadtman ER, 2002, FREE RADICAL BIO MED, V33, P597, DOI 10.1016/S0891-5849(02)00904-8; Theodore S, 2006, NEUROSCIENCE, V137, P925, DOI 10.1016/j.neuroscience.2005.10.056; TOMAC A, 1995, P NATL ACAD SCI USA, V92, P8274, DOI 10.1073/pnas.92.18.8274; Toth G, 2002, J NEUROSCI RES, V69, P622, DOI 10.1002/jnr.10358; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Ugarte SD, 2003, J NEUROSCI RES, V73, P105, DOI 10.1002/jnr.10632; Venero JL, 1997, J NEUROCHEM, V68, P2458; Wang Y, 1997, J NEUROSCI, V17, P4341; Zuch CL, 2000, J COMP NEUROL, V427, P440, DOI 10.1002/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7	49	44	46	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 2	2007	412	3					259	263		10.1016/j.neulet.2006.11.017			5	Neurosciences	Neurosciences & Neurology	138WC	WOS:000244393000015	17125923	Green Accepted			2021-06-18	
J	Iverson, GL; Le Page, J; Koehler, BE; Shojania, K; Badii, M				Iverson, Grant L.; Le Page, Judy; Koehler, Barry E.; Shojania, Kamran; Badii, Maziar			Test of memory malingering (TOMM) scores are not affected by chronic pain or depression in patients with fibromyalgia	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	24th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 17-20, 2004	Seattle, WA	Natl Acad Neuropsychol		chronic pain; depression; effort; malingering; Test of Memory Malingering	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; NEUROPSYCHOLOGICAL TESTS; HEAD-INJURY; COGNITIVELY INTACT; NORMATIVE DATA; RESPONSE BIAS; INVENTORY-II; BACK-PAIN; PERFORMANCE	Neuropsychologists routinely give effort tests, such as the Test of Memory Malingering (TOMM). When a person fails one of these tests, the clinician must try to determine whether the poor performance was due to suboptimal effort or to chronic pain, depression, or other problems. Participants were 54 community-dwelling patients who met American College of Rheumatology criteria for fibromyalgia (FM). In addition to the TOMM, they completed the Beck Depression Inventory-Second Edition, Multidimensional Pain Inventory-Version 1, Oswestry Disability Index-2.0, British Columbia Cognitive Complaints Inventory, and the Fibromyalgia Impact Questionnaire. The majority endorsed at least mild levels of depressive symptoms (72%), and 22% endorsed "severe'' levels of depression. The average scores on the TOMM were 48.8 (SD = 1.9, range = 40-50) for Trial 1, 49.8 (SD = 0.5, range 48-50) for Trial 2, and 49.6 (SD = 0.9, range 45-50) for Retention. Despite relatively high levels of self-reported depression, chronic pain, and disability, not a single patient failed the TOMM. In this study, the TOMM was not affected by chronic pain, depression, or both.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Arthrit Res Ctr Canada, Vancouver, BC, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Allen L.M., 1997, CARB 97 MANUAL COMPU; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arnau RC, 2001, HEALTH PSYCHOL, V20, P112, DOI 10.1037//0278-6133.20.2.112; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Baker DJ, 1989, BACK PAIN NEW APPROA, P174; Beck A., 1996, MANUAL BDI 2; BECK AT, 1979, COGNITIVE THERAPY DE; BERNSTEIN IH, 1995, SPINE, V20, P956, DOI 10.1097/00007632-199504150-00014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Delain SL, 2003, ASSESSMENT, V10, P370, DOI 10.1177/1073191103259156; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Fairbank J C, 1980, Physiotherapy, V66, P271; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Grotle M, 2004, PAIN, V112, P343, DOI 10.1016/j.pain.2004.09.020; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; Hassett AL, 2000, ARTHRITIS RHEUM-US, V43, P2493, DOI 10.1002/1529-0131(200011)43:11<2493::AID-ANR17>3.0.CO;2-W; Hayes JS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P249; Hill SK, 2003, J FORENSIC NEUROPSYC, V3, P1; HOM J, 2003, DETECTION RESPONSE B; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson G. L., 2003, CAN PSYCH ASS HAL NO; Iverson GL, 2005, ARCH CLIN NEUROPSYCH, V20, P882; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P735; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 1999, J COGNITIVE REHABILI, V2, P4; IVERSON GL, 2003, HDB FORENSIC NEUROPS; IVERSON GL, 1998, UNPUB BC COGNITIVE C; Ju D, 2000, Appl Neuropsychol, V7, P201, DOI 10.1207/S15324826AN0704_1; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; King RA, 1999, ARCH CLIN NEUROPSYCH, V14, P651, DOI 10.1016/S0887-6177(99)80063-8; Lousberg R, 1996, J CLIN PSYCHOL, V52, P161, DOI 10.1002/(SICI)1097-4679(199603)52:2<161::AID-JCLP6>3.0.CO;2-X; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Morley S, 2002, PAIN, V99, P289, DOI 10.1016/S0304-3959(02)00137-9; Naugle, 1999, J FORENSIC NEUROPSYC, V1, P5, DOI [10.1300/J151v01n04_02, DOI 10.1300/J151V01N04_02]; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; REYNOLDS C, 1998, DETECTION MALINGERIN; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Rudy TE, 1989, MULTIAXIAL ASSESSMEN; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Suter PB, 2002, PAIN, V100, P249, DOI 10.1016/S0304-3959(02)00238-5; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Thieme K, 2004, PSYCHOSOM MED, V66, P837, DOI 10.1097/01.psy.0000146329.63158.40; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Turk DC, 1996, J RHEUMATOL, V23, P1255; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Viljoen JL, 2003, J CLIN PSYCHOL MED S, V10, P289, DOI 10.1023/A:1026353404839; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Wesley AL, 1999, CLIN J PAIN, V15, P117, DOI 10.1097/00002508-199906000-00008; White KP, 2002, ARTHRIT RHEUM-ARTHR, V47, P260, DOI 10.1002/art.10400; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Wittink H, 2004, CLIN J PAIN, V20, P133, DOI 10.1097/00002508-200405000-00002; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	90	44	45	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2007	21	3					532	546		10.1080/13854040600611392			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	158HA	WOS:000245781200090	17455036				2021-06-18	
J	Lippert-Gruner, M; Maegele, M; Haverkamp, H; Klug, N; Wedekind, C				Lippert-Gruener, Marcela; Maegele, Marc; Haverkamp, Heinz; Klug, Norfrid; Wedekind, Christoph			Health-related quality of life during the first year after severe brain trauma with and without	BRAIN INJURY			English	Article						traumatic brain injury; polytrauma; quality of life; SF-36	SEVERE HEAD-INJURY; SURVEY QUESTIONNAIRE; MULTIPLE TRAUMA; SF-36; RECOMMENDATIONS	Objective: The increasing number of patients surviving severe traumatic brain injury ( sTBI) but with significant sensorimotor and neuropsychological deficits is a challenge to rehabilitation medicine. So far, most research initiatives have focused on mortality rates, physiological or economic parameters to estimate therapeutic effects of rehabilitation strategies. Investigations on health-related quality of life ( HRQoL) after TBI with and without concomitant polytrauma are rare compared to other disorders. Design/patients: A prospective study was conducted to investigate HRQoL using the SF-36 questionnaire in 49 patients with sTBI ( Glasgow Coma Scale < 9 for more than 24 hours) with and without concomitant polytrauma 6 and 12 months after injury. Results: The SF-36 score profiles 6 and 12 months after trauma were similar. Scores 12 months after trauma, however, were higher in 7/8 dimensions indicating an improvement over time. Similar observations were made for physical and mental sum scores. There was no difference in the SF-36 scoring pattern between the patients with isolated TBI and the patients with concomitant polytrauma, except for physical functioning after 12 months. Conclusion: While there is significant overall improvement of HRQoL over time, sTBI appears to bear major influence on post-traumatic HRQoL and outcome.	Univ Cologne, Dept Neurosurg, Cologne, Germany; Klinikum Koln Merheim, Chirurg Klin Kliniken Stadt Koln, Cologne, Germany; Univ Cologne, Coordinating Ctr Clin Trials, Cologne, Germany	Lippert-Gruner, M (corresponding author), Klinikum Univ Koln, Klin Allgemeine Neurochirurg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	marcela.lippert.gruener@medizin.uni-koeln.de		Haverkamp, Heinz/0000-0001-6895-4132			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; BAZIL K, 1992, INT J REHABILITATION, V15, P93; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frowein R A, 1992, Acta Neurochir Suppl (Wien), V55, P72; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Lippert-Gruner M, 2002, ZBL NEUROCHIR, V63, P116, DOI 10.1055/s-2002-35825; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; Lippert-Gruner M, 2001, PHYS MED REHAB KUROR, V11, P233, DOI 10.1055/s-2001-19069; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Thurman DJ, 1996, WESTERN J MED, V165, P192; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005	20	44	46	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	5					451	455		10.1080/02699050701343961			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000001	17522984				2021-06-18	
J	Offen, D; Barhum, Y; Levy, YS; Burshtein, A; Panet, H; Cherlow, T; Melamed, E				Offen, D.; Barhum, Y.; Levy, Y.-S.; Burshtein, A.; Panet, H.; Cherlow, T.; Melamed, E.			Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease	JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT			English	Article						multipotent mesenchymal stromal cells (MSCs); dopamine; dopaminergic neurons; Parkinson's disease (PD); stem cells	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; STROMAL CELLS; DOPAMINERGIC-NEURONS; IN-VITRO; RAT MODEL; SUBSTANTIA-NIGRA; ES CELLS; DIFFERENTIATION; MICE	Strategies of cell therapy for the treatment of Parkinson's disease (PD) are focused on replacing damaged neurons with cells to restore or improve function that is impaired due to cell population damage. In our studies, we used mesenchymal stromal cells (MSCs) from mouse bone marrow. Following our novel neuronal differentiation method, we found that the basic cellular phenotype changed to cells with neural morphology that express specific markers including those characteristic for dopaminergic neurons, such as tyrosine hydroxylase (TH). Intrastriatal transplantation of the differentiated MSCs in 6-hydroxydopamine-lesioned mice led to marked reduction in the amphetamine-induced rotations. Immunohistological analysis of the mice brains four months post transplantation, demonstrated that most of the transplanted cells survived in the striatum and expressed TH. Some of the TH positive cells migrated toward the substantia nigra. In conclusion, transplantation of bone marrow derived stem cells differentiated to dopaminergic-like cells, successfully improved behavior in an animal model of PD suggesting an accessible source of cells that may be used for autotransplantation in patient with PD.	Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsentein Med Res Ctr,Lab Neurosci, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel	Offen, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsentein Med Res Ctr,Lab Neurosci, IL-49100 Petah Tiqwa, Israel.	doffen@post.tau.ac.il		Routtenberg, Tirza/0000-0002-7238-7764			Akerud P, 2001, J NEUROSCI, V21, P8108; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Ben-Hur T, 2004, STEM CELLS, V22, P1246, DOI 10.1634/stemcells.2004-0094; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Blondheim NR, 2006, STEM CELLS DEV, V15, P141, DOI 10.1089/scd.2006.15.141; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P1; Brederlau A, 2006, STEM CELLS, V24, P1433, DOI 10.1634/stemcells.2005-0393; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Carson CT, 2006, NAT MED, V12, P1237, DOI 10.1038/nm1106-1237; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HEFTI F, 1985, NEUROPHARMACOLOGY, V24, P19, DOI 10.1016/0028-3908(85)90090-5; Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097; HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9; Jackson-Lewis V, 2000, BRAIN RES, V866, P197, DOI 10.1016/S0006-8993(00)02243-5; Kan I, 2005, CURR DRUG TARGETS, V6, P31, DOI 10.2174/1389450053344902; Kan I, 2007, J LIPID RES, V48, P513, DOI 10.1194/jlr.C600022-JLR200; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kim DW, 2006, STEM CELLS, V24, P557, DOI 10.1634/stemcells.2005-0233; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levy YS, 2004, J MOL NEUROSCI, V24, P353, DOI 10.1385/JMN:24:3:353; Levy YS, 2003, J MOL NEUROSCI, V21, P121, DOI 10.1385/JMN:21:2:121; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Lindvall Olle, 2004, NeuroRx, V1, P382; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mazzini L, 2006, NEUROL RES, V28, P523, DOI 10.1179/016164106X116791; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Park CH, 2005, J NEUROCHEM, V92, P1265, DOI 10.1111/j.1471-4159.2004.03006.x; Pavon N, 1998, REV NEUROLOGIA, V26, P915, DOI 10.33588/rn.26154.98016; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Sanchez-Pernaute R, 2005, STEM CELLS, V23, P914, DOI 10.1634/stemcells.2004-0172; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Studer L, 1998, NAT NEUROSCI, V1, P290; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; THOMAS J, 1994, EXP NEUROL, V126, P159, DOI 10.1006/exnr.1994.1054; Winkler C, 2005, TRENDS NEUROSCI, V28, P86, DOI 10.1016/j.tins.2004.12.006; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925; Zhang J, 2005, EXP NEUROL, V195, P16, DOI 10.1016/j.expneurol.2005.03.018; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962	66	44	46	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-6995			J NEURAL TRANSM-SUPP	J. Neural Transm.-Suppl.		2007		72					133	143					11	Neurosciences	Neurosciences & Neurology	220XV	WOS:000250191500017	17982886				2021-06-18	
J	Shore, PM; Berger, RP; Varma, S; Janesko, KL; Wisniewski, SR; Clark, RSB; Adelson, PD; Thomas, NJ; Lai, YC; Bayir, H; Kochanek, PM				Shore, Paul M.; Berger, Rachel P.; Varma, Sumeeta; Janesko, Keri L.; Wisniewski, Stephen R.; Clark, Robert S. B.; Adelson, P. David; Thomas, Neal J.; Lai, Yi-Chen; Bayir, Hulya; Kochanek, Patrick M.			Cerebrospinal fluid biomarkers versus Glasgow Coma Scale and Glasgow Outcome Scale in pediatric traumatic brain injury: The role of young age and inflicted injury	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; clinical research; correlation; inflicted traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; CHILD-ABUSE; BIOCHEMICAL MARKERS; PRACTICAL SCALE; PROTEIN S-100B; SERUM; INFANTS; S100B; DAMAGE	The Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) are widely used clinical scoring systems to measure the severity of neurologic injury after traumatic brain injury (TBI), but have recognized limitations in infants and small children. Cerebrospinal fluid (CSF) concentrations of neuron-specific enolase (NSE) and S100B show promise as markers of brain injury. We hypothesized that the initial GCS and 6-month GOS scores would be inversely associated with CSF NSE and/or S100B concentrations after severe pediatric TBI. Using banked CSF obtained during ongoing studies of pediatric TBI, NSE and S100B were determined in CSF collected within 24 h of trauma from 88 infants and children with severe TBI (GCS <= 8) versus 20 non-injured controls. Victims of inflicted (iTBI) and non-inflicted TBI (nTBI) showed similar (> 10-fold) increases in both NSE and S100B versus control. Both markers showed overall significant, inverse correlation with GCS and GOS scores. In subgroup analysis, both markers correlated significantly with GCS and GOS scores only in older (> 4 years) victims of nTBI; no correlation was found for patients <= 4 years old or victims of iTBI. While confirming the overall correlations between GCS/GOS score and CSF NSE and S100B seen in prior studies, we conclude that these clinical and CSF biomarkers of brain injury do not correlate in children <= 4 years of age and/or victims of iTBI. Although further, prospective study is warranted, these findings suggest important limitations in our current ability to assess injury severity in this important population.	Univ Texas, SW Med Ctr, Childrens Med Ctr Dallas, Dept Pediat,Div Crit Care Serv, Dallas, TX 75235 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Penn State Univ, Childrens Hosp, Coll Med, Hershey, PA 17033 USA	Shore, PM (corresponding author), Univ Texas, SW Med Ctr, Childrens Med Ctr Dallas, Dept Pediat,Div Crit Care Serv, 1935 Motor St, Dallas, TX 75235 USA.	paul.shore@childrens.com	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Thomas, Neal/0000-0002-7991-7510; Wisniewski, Stephen/0000-0002-3877-9860; Lai, Yi-Chen/0000-0002-9450-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD 40686] Funding Source: Medline		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; Clark RSB, 1999, FASEB J, V13, P813; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Guan Wei, 2003, Chin J Traumatol, V6, P218; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JENNETT B, 1975, LANCET, V1, P480; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McIntosh TK, 1996, LAB INVEST, V74, P315; McKeating EG, 1998, ACT NEUR S, V71, P117; MOLYNEUX ME, 1989, Q J MED, V71, P441; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Portela LVC, 2002, CLIN CHEM, V48, P950; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Ruppel RA, 2002, NEUROSURG CLIN N AM, V13, P169, DOI 10.1016/S1042-3680(01)00005-5; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SEGATORE M, 1992, HEART LUNG, V21, P548; Shore PM, 2003, CRIT CARE MED, V31, pA91; Shore PM, 2004, J NEUROTRAUM, V21, P1113; SHORE PM, 2003, PEDIATR CRIT CARE ME, V4, pA143; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	58	44	44	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					75	86		10.1089/neu.2006.0062			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100007	17263671				2021-06-18	
J	Scharlach, A; Li, W; Dalvi, TB				Scharlach, Andrew; Li, Wei; Dalvi, Tapashi B.			Family conflict as a mediator of caregiver strain	FAMILY RELATIONS			English	Article						caregiver distress; elder care; family caregiving; family stress	DECISION-MAKING SATISFACTION; TRAUMATIC BRAIN INJURY; GENDER-DIFFERENCES; PSYCHIATRIC MORBIDITY; ALZHEIMERS-DISEASE; STRESS PROCESS; IMPACT; CARE; PERCEPTIONS; PREVALENCE	The present study used structural equation modeling to examine the potential mediating effect of family conflict on caregiver strain in a randomly drawn household sample of 650 adults with primary care responsibility for an adult age 50 or older with a mental disability. Caregiver strain was directly influenced by the conflict, disagreements, and hardships experienced by the caregiver's family. Specifically, family conflict was found to mediate the impact of care recipient mental impairment and caregiver educational level on caregiver strain, and mediate partially the impact of caregiver income and caregiver-care recipient relationship. Findings suggest the importance of considering family-centered approaches when designing interventions to assist family caregivers.	Univ Calif Berkeley, Sch Social Welf, Berkeley, CA 94720 USA; Ctr Responsible Lending, Durham, NC 27701 USA; Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA	Scharlach, A (corresponding author), Univ Calif Berkeley, Sch Social Welf, 120 Haviland, Berkeley, CA 94720 USA.	Scharlach@berkeley.edu; wei.li@responsiblelending.org; tapashi@berkeley.edu					Amirkhanyan AA, 2003, GERONTOLOGIST, V43, P817, DOI 10.1093/geront/43.6.817; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BOSS P, 2004, CONT PERSPECTIVES FA, V4, P207; BRODY EM, 1989, GERONTOLOGIST, V29, P529, DOI 10.1093/geront/29.4.529; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Deimling GT, 2001, J AGING HEALTH, V13, P47, DOI 10.1177/089826430101300103; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fiscella K, 1997, FAM PROCESS, V36, P25, DOI 10.1111/j.1545-5300.1997.00025.x; FISHER L, 1994, FAM PROCESS, V33, P305, DOI 10.1111/j.1545-5300.1994.00305.x; Franks MM, 1996, J GERONTOL B-PSYCHOL, V51, pP43, DOI 10.1093/geronb/51B.1.P43; Fredriksen-Goldsen K. I., 2001, FAMILIES WORK NEW DI; GARWICK AW, 1994, FAM PROCESS, V33, P327, DOI 10.1111/j.1545-5300.1994.00327.x; Gaugler Joseph E, 2003, Am J Alzheimers Dis Other Demen, V18, P300, DOI 10.1177/153331750301800505; Hooker K, 2000, GERONTOLOGIST, V40, P568, DOI 10.1093/geront/40.5.568; Ingersoll-Dayton B, 2003, J MARRIAGE FAM, V65, P201, DOI 10.1111/j.1741-3737.2003.00201.x; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuypers J., 1983, FAM RELAT, P211; Lieberman MA, 1999, GERONTOLOGIST, V39, P159, DOI 10.1093/geront/39.2.159; LIEBERMAN MA, 1995, GERONTOLOGIST, V35, P94, DOI 10.1093/geront/35.1.94; MATTHEWS SH, 1988, J MARRIAGE FAM, V50, P185, DOI 10.2307/352438; McCubbin M. A., 1993, FAMILIES HLTH ILLNES, P20; MILLER B, 1990, J MARRIAGE FAM, V52, P311, DOI 10.2307/353028; MILLER B, 1992, GERONTOLOGIST, V32, P498, DOI 10.1093/geront/32.4.498; MUI AC, 1995, J MARRIAGE FAM, V57, P733, DOI 10.2307/353927; *NAT ALL CAR AM AS, 1997, FAM CAR US FIND NAT; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PENROD JD, 1995, GERONTOLOGIST, V35, P489, DOI 10.1093/geront/35.4.489; Peters-Davis ND, 1999, GERONTOLOGIST, V39, P66, DOI 10.1093/geront/39.1.66; PRUCHNO R, 1998, J AM GERIATR SOC, V37, P697; Pruchno RA, 1997, GERONTOLOGIST, V37, P157, DOI 10.1093/geront/37.2.157; RODRIGUEZ J, 2003, GERONTOLOGIST, V43, P916; *SAS I, 1999, SAS 8 0 COMP SOFTW; Scharlach AE, 2006, J GERONTOL SOC WORK, V47, P133, DOI 10.1300/J083v47n01_09; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; SEMPLE SJ, 1992, GERONTOLOGIST, V32, P648, DOI 10.1093/geront/32.5.648; Smerglia VL, 1997, GERONTOLOGIST, V37, P658, DOI 10.1093/geront/37.5.658; Sobel M.E., 1982, SOCIOL METHODOL, P290, DOI [DOI 10.2307/270723, 10.2307/270723]; Sobel ME, 1986, SOCIOL METHODOL, V16, P159, DOI [DOI 10.2307/270922, 10.2307/270922]; STRAWBRIDGE WJ, 1991, GERONTOLOGIST, V31, P770, DOI 10.1093/geront/31.6.770; TENNSTEDT SL, 1989, GERONTOLOGIST, V29, P677, DOI 10.1093/geront/29.5.677; Weihs K., 2002, FAMILIES SYSTEMS HLT, V20, P7, DOI [10.1037/h0089481, DOI 10.1037/H0089481]; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147	45	44	45	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0197-6664	1741-3729		FAM RELAT	Fam. Relat.	DEC	2006	55	5					625	635		10.1111/j.1741-3729.2006.00431.x			11	Family Studies; Social Work	Family Studies; Social Work	119GC	WOS:000242999800011		Green Published			2021-06-18	
J	da Rocha, AB; Schneider, RF; de Freitas, GR; Andre, C; Grivicich, I; Zanoni, C; Fossa, A; Gehrke, JT; Jotz, GP; Kaufmann, M; Simon, D; Regner, A				da Rocha, Adriana Brondani; Schneider, Rogerio Fett; de Freitas, Gabriel R.; Andre, Charles; Grivicich, Ivana; Zanoni, Caroline; Fossa, Aline; Gehrke, Junia T.; Jotz, Geraldo Pereira; Kaufmann, Mauro; Simon, Daniel; Regner, Andrea			Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						biomarkers; humans; multitrauma; outcome; S100B protein; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; PROTEIN S-100B; CARDIAC-ARREST; DAMAGE; RELEASE; DEATH; ASTROCYTES; S100-BETA; SURGERY	Background: Severe traumatic brain injury (-TBI) is associated with a 30% - 70% mortality rate. S100B has been proposed as a biomarker for indicating outcome after TBI. Nevertheless, controversy has arisen concerning the predictive value of S100B for severe TBI in the context of multitrauma. Therefore, our aim was to determine whether S100B serum levels correlate with primary outcome following isolated severe TBI or multitrauma in males. Methods: Twenty- three consecutive male patients (-age 18 - 65 years), victims of severe TBI [Glasgow Coma Scale (-GCS) 3 - 8x (-10 isolated TBI and 13 multitrauma with TBI) and a control group consisting of eight healthy volunteers were enrolled in this prospective study. Clinical outcome variables of severe TBI comprised: survival, time to intensive care unit (-ICU) discharge, and neurological assessment [Glasgow Outcome Scale (-GOS) at ICU discharge]. Venous blood samples were taken at admission in the ICU (-study entry), 24 h later, and 7 days later. Serum S100B concentration was measured by an immunoluminometric assay. Results: At study entry (mean time 10.9 h after injury), mean S100B concentrations were significantly increased in the patient with TBI (1.448 mu g/ L) compared with the control group (0.037 mu g/L) and patients with fatal outcome had higher mean S100B (2.10 mg/ L) concentrations when compared with survivors (0.85 mg/ L). In fact, there was a significant correlation between higher initial S100B concentrations and fatal outcome (Spearman's =0.485, p=0.019). However, there was no correlation between higher S100B concentrations and the presence of multitrauma. The specificity of S100B in predicting mortality according to the cut- off of 0.79 mg/ L was 73% at study entry. Conclusions: Increased serum S100B levels constitute a valid predictor of unfavourable outcome in severe TBI, regardless of the presence of associated multitrauma.	Univ Luterana Brasil, Lab Marcadores Estresse Celular, Ctr Pesquisa Ciencias Med, BR-92425900 Canoas, RS, Brazil; Univ Luterana Brasil, Programa Posgrad Diagnost Genet & Mol, BR-92425900 Canoas, RS, Brazil; Univ Luterana Brasil, Programa Posgrad Genet & Toxicol Aplicada, BR-92425900 Canoas, RS, Brazil; Univ Luterana Brasil, Curso Med, BR-92425900 Canoas, RS, Brazil; Univ Fed Rio de Janeiro, Dept Neurol, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; Univ Terapia Intens, Hosp Cristo Redentor, Porto Alegre, RS, Brazil; SAMU, Hosp Municipal Pronto Socorro, Porto Alegre, RS, Brazil	Regner, A (corresponding author), Univ Luterana Brasil, Lab Marcadores Estresse Celular, Ctr Pesquisa Ciencias Med, Ave Farroupilha 8001,Pred 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	Simon, Daniel/A-9087-2011; JOTZ, GERALDO P/G-2664-2014; de Freitas, Gabriel R/B-1298-2013; Regner, Andrea/M-2596-2014; Grivicich, Ivana/A-6777-2013	Simon, Daniel/0000-0003-1122-8468; JOTZ, GERALDO P/0000-0001-6289-7827; Regner, Andrea/0000-0002-6657-7991; Grivicich, Ivana/0000-0001-9820-5730			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; DAROCHA AB, 2005, J NEUROTRAUM, V15, P385; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Duff D, 2003, AXONE, V23, P18; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu JR, 1997, J NEUROCHEM, V69, P2294; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2003, RESTOR NEUROL NEUROS, V21, P151; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; KRAUS JF, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Neuwelt EA, 2004, NEUROSURGERY, V54, P131, DOI 10.1227/01.NEU.0000097715.11966.8E; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; PELINKA LE, 2003, EUR J TRAUMA, V5, P316; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; ZAGARA G, 1992, J NEUROSURG SCI, V35, P77	44	44	47	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621	1437-4331		CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	OCT	2006	44	10					1234	1242		10.1515/CCLM.2006.218			9	Medical Laboratory Technology	Medical Laboratory Technology	093TU	WOS:000241193900011	17032136				2021-06-18	
J	Stiefel, MF; Udoetuk, JD; Storm, PB; Sutton, LN; Kim, H; Dominguez, TE; Helfaer, MA; Huh, JW				Stiefel, Michael F.; Udoetuk, Joshua D.; Storm, Phillip B.; Sutton, Leslie N.; Kim, Heakyung; Dominguez, Troy E.; Helfaer, Mark A.; Huh, Jimmy W.			Brain tissue oxygen monitoring in pediatric patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; brain tissue oxygen monitoring; intracranial pressure; cerebral perfusion pressure; pediatric neurosurgery	SEVERE HEAD-INJURY; ELEVATED INTRACRANIAL-PRESSURE; CHILDREN; EXPERIENCE; MANAGEMENT; HYPOXIA; DAMAGE; CARE; HYPOTENSION; METABOLISM	Object. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring are fundamental to the management of severe traumatic brain injury (TBI). In adults, brain tissue oxygen monitoring (specifically PO2) and treatment have been shown to be safe additions to conventional neurocritical care and are associated with improved outcome. Brain tissue oxygen monitoring, however, has not been described in pediatric patients with TBI. In this report, the authors present preliminary experience with the use of ICP and PO2 monitoring in this population. Methods. Pediatric patients (age < 18 years) with severe TBI (Glasgow Coma Scale score < 8) admitted to a Level I trauma center who underwent ICP and PO, monitoring were evaluated. Therapy was directed at maintaining ICP below 20 mm Hg and age-appropriate CPP (>= 40 min Hg). Data obtained in six patients (two girls and four boys ranging in age from 6-16 years) were analyzed. Brain tissue oxygen levels were significantly higher (p < 0.01) at an ICP of less than 20 mm, Hg (PO, 29.29 +/- 7.17 mm Hg) than at an ICP of greater than or equal to 20 mm Hg (PO2 22.83 +/- 13.85 mm Hg). Significant differences (p < 0.01) were also measured when CPP was less than 40 mm Hg (PO2 2.53 +/- 7.98 mm Hg) and greater than or equal to 40 min Hg (PO2 28.97 +/- 7.85 mm Hg). Conclusions. Brain tissue oxygen monitoring may be a safe and useful addition to ICP monitoring in the treatment of pediatric patients with severe TBI.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Crit Care, Philadelphia, PA 19104 USA	Stiefel, MF (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3 Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.	stiefelm@uphs.upenn.edu					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bardt TF, 1998, ACT NEUR S, V71, P153; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOTSCHALL CS, 1995, J NEUROTRAUM, V12, P611, DOI 10.1089/neu.1995.12.611; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JH, 2003, CHILD DEV, V74, P969, DOI 10.1111/1467-8624.00581; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Littlejohns Linda R, 2003, Crit Care Nurse, V23, P17; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	47	44	46	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2006	105	4		S			281	286		10.3171/ped.2006.105.4.281			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	093WO	WOS:000241201200009	17328278				2021-06-18	
J	McCrory, P; Turner, M; LeMasson, B; Bodere, C; Allemandou, A				McCrory, P.; Turner, M.; LeMasson, B.; Bodere, C.; Allemandou, A.			An analysis of injuries resulting from professional horse racing in France during 1991-2001: a comparison with injuries resulting from professional horse racing in Great Britain during 1992-2001	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PEDIATRIC EQUESTRIAN INJURIES; RIDING INJURIES; ACCIDENTS; CHILDREN; HELMETS	Background: It has been previously shown that professional jockeys suffer high rates of fatal and non-fatal injuries in the pursuit of their occupation. Little is known, however, about differences in injury rates between countries. Aim: To determine the rate of fatal and non-fatal injuries in flat and jump jockeys in France and to compare the injury rates with those in Great Britain and Ireland Method: Prospectively collected injury data on professional jockeys were used as the basis of the analysis. Results: Limb fractures occur four times more often in both flat and jump racing in France than in Great Britain. Similarly dislocations are diagnosed 20 times more often in flat and three times more often in jump racing. This difference is surprising given that French jockeys have fewer falls per ride than their British counterparts in flat racing, although they do have more falls than the British in jump racing. Similarly concussion rates seem to be higher in French jockeys, although there may be a difference in the diagnostic methods used in the different countries. By contrast, soft tissue injuries account for a far smaller percentage of injuries than in Great Britain. Conclusion: There are striking differences in injury rates between countries which may be explained in part by a difference in track conditions - for example, harder tracks in France - or different styles of racing for example, larger fields of horses per race in France.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; Univ Melbourne, Inst Brain Res, Parkville, Vic 3052, Australia; Jockey Club, London WC2H 8AL, England; France Gallop, Paris, France; Assoc Format & Act Social Ecuries Courses, Maisons Laffitte, France	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019				ARONSON H, 1993, AM J FOREN MED PATH, V14, P28, DOI 10.1097/00000433-199303000-00006; BARCLAY WR, 1978, JAMA-J AM MED ASSOC, V240, P1892, DOI 10.1001/jama.1978.03290170074037; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; Bernhang A M, 1983, Phys Sportsmed, V11, P90, DOI 10.1080/00913847.1983.11708437; BIXBYHAMMETT D, 1990, SPORTS MED, V9, P36, DOI 10.2165/00007256-199009010-00004; BIXBYHAMMETT DM, 1992, PEDIATRICS, V89, P1173; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BOND GR, 1995, PEDIATRICS, V95, P487; BUCKLEY SM, 1993, AUST J PUBLIC HEALTH, V17, P269; Butterwick DJ, 1996, CLIN J SPORT MED, V6, P171, DOI 10.1097/00042752-199607000-00006; Campbell-Hewson G L, 1999, Eur J Emerg Med, V6, P37; *CDC, 1990, JAMA-J AM MED ASSOC, V264, P18; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; Costa-Paz M, 1999, BRIT J SPORT MED, V33, P329, DOI 10.1136/bjsm.33.5.329; DEBENEDETTE V, 1987, PHYSICIAN SPORTSMED, V15, P237; DEBENEDETTE V, 1989, PHYSICIAN SPORTSMED, V17, P250, DOI 10.1080/00913847.1989.11709748; Douglas B L, 1995, CDS Rev, V88, P28; FOSTER JB, 1976, LANCET, V1, P981; GIEBEL G, 1993, CHIRURG, V64, P938; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; GREISS FC, 1984, AM J OBSTET GYNECOL, V150, P168, DOI 10.1016/S0002-9378(84)80010-1; GROSSMAN JAI, 1978, JAMA-J AM MED ASSOC, V240, P1881, DOI 10.1001/jama.240.17.1881; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; Hobbs Gregory D., 1994, Journal of Emergency Medicine, V12, P143, DOI 10.1016/0736-4679(94)90690-4; HUGHES KM, 1995, AM J EMERG MED, V13, P485, DOI 10.1016/0735-6757(95)90148-5; Hume PA., 1994, NZ J SPORTS MED, V22, P18; INGEMARSON H, 1989, J TRAUMA, V29, P25, DOI 10.1097/00005373-198901000-00005; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; LANDO L, 1976, PHYSICIAN SPORTSMED, V4, P124; Lloyd R G, 1987, Br J Sports Med, V21, P22; MASTERS RG, 1991, CLIN J SPORT MED, V1, P123; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McCrory P, 2005, MED SPORT SCI, V48, P8, DOI 10.1159/000084280; MCGEE C, 1987, BRIT J NEUROSURG, V1, P131; McLatchie G R, 1979, Br J Sports Med, V13, P29; MILLS NJ, 1989, INJURY, V20, P189, DOI 10.1016/0020-1383(89)90108-3; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON DE, 1994, AM J PREV MED, V10, P15; NELSON DE, 1994, PHYSICIAN SPORTSMED, V22, P53, DOI 10.1080/00913847.1994.11710501; OFarrell DA, 1997, BRIT J SPORT MED, V31, P249, DOI 10.1136/bjsm.31.3.249; POUNDER DJ, 1984, MED J AUSTRALIA, V141, P632, DOI 10.5694/j.1326-5377.1984.tb113173.x; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Rathfelder F J, 1995, Sportverletz Sportschaden, V9, P77, DOI 10.1055/s-2007-993429; REEDER AI, 1991, CAN J SPORT SCI, V16, P308; REICH L, 1979, HNO, V27, P416; Sahlin Y, 1990, Br J Sports Med, V24, P40; SCHMIDT B, 1994, UNFALLCHIRURG, V97, P661; Silver J R, 1991, Br J Sports Med, V25, P105; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Whitlock M R, 1987, Br J Sports Med, V21, P25; 1996, MMWR MORB MORTAL WKL, V45, P209	52	44	46	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2006	40	7					614	618		10.1136/bjsm.2006.028449			5	Sport Sciences	Sport Sciences	056OH	WOS:000238533800010	16687479	Green Published			2021-06-18	
J	Feeney, T; Ylvisaker, M				Feeney, Timothy; Ylvisaker, Mark			Context-sensitive cognitive-behavioural supports for young children with TBI: A replication study	BRAIN INJURY			English	Article						behaviour disorders; paediatric rehabilitation; traumatic brain injury; positive behaviour support; cognitive-behavioural intervention; functional assessment; school-based treatment; multi-component intervention; ecological validity	TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE INJURY; CLOSED-HEAD INJURY; SHORT-TERM; FAMILY; ADOLESCENTS; PREDICTORS; REHABILITATION; SEVERITY; RECOVERY	Objective: To replicate an investigation of the effects of a multi-component cognitive-behavioural intervention on the challenging behaviour of two young children with growing behavioural concerns after TBI. Experimental design: Single-subject reversal designs used to document the effects of the combined behavioural, cognitive and executive function intervention on the following dependent variables: frequency and intensity of aggressive behaviours, amount of work accomplished. Participants: Two young children with escalating behaviour problems after TBI. Intervention: Integrated components of positive behaviour supports, cognitive supports ( e. g. graphic organizers) and an executive function routine (goal-plan-do-review). Results: Reduced frequency and intensity of challenging behaviours; increased quantity of work completed. Conclusions: Positive replication of previous single-subject experiments demonstrating the potential for successfully treating behaviour disorders in young children with TBI using a support-oriented intervention that combines behavioural, cognitive and executive function components.	Sch & Community Support Serv, Schenectady, NY USA; Coll St Rose, Sch Educ, Albany, NY USA	Feeney, T (corresponding author), 1171 Van Antwerp Rd, New York 12309, NY USA.	ylvisakm@mail.strose.edu	Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X			Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Barlow D.H., 1984, SINGLE CASE EXPT DES; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BIJOU SW, 1968, J APPL BEHAV ANAL, V1, P175, DOI 10.1901/jaba.1968.1-175; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bogdan R., 1984, INTRO QUALITATIVE RE; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; Bronson MB, 2000, SELF-REGULATION IN EARLY CHILDHOOD, P1; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Carr E.G., 1994, COMMUNICATION BASED; Carr EG, 2002, J POSIT BEHAV INTERV, V4, P4, DOI 10.1177/109830070200400102; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; COSTEFF H, 1985, SCAND J REHABIL MED, P10; DAMASIO AR, 1994, DESCARTES ERRER EMOT; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; DURAND M, 1992, MOTIVATION ASSESSMEN; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P297; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Glesne C., 1992, BECOMING QUALITATIVE; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; HEBB DO, 1947, AM PSYCHOL, V2, P737; KEPPEL G, 1991, DESIGN ANAL INVESTIG; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kolb B., 1995, BRAIN PLASTICITY BEH; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; Mace FC, 1997, J APPL BEHAV ANAL, V30, P1, DOI 10.1901/jaba.1997.30-1; MARLOWE WB, 1990, J CLIN EXP NEUROPSYC, V12, P105; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; McDonald S., 2005, BRAIN IMPAIR, V6, P56, DOI DOI 10.1375/BRIM.6.1.56.65481; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; REICHLE J, 1993, COMMUNICATIVE ALTERN; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Singh N. N., 1994, ABERRANT BEHAV CHECK; Sternberg RJ., 1993, TRANSFER TRIAL INTEL; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, 2005, REHABILITATION TRAUM, P205; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	88	44	44	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					629	645		10.1080/02699050600744194			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100008	16754288				2021-06-18	
J	Goodman, D; Bradley, NL; Paras, B; Williamson, IJ; Bizzochi, J				Goodman, D; Bradley, NL; Paras, B; Williamson, IJ; Bizzochi, J			Video gaming promotes concussion knowledge acquisition in youth hockey players	JOURNAL OF ADOLESCENCE			English	Article						video games; youth; education; concussion	SCHOOL PERFORMANCE; COMPUTER GAMES; LIFE; AGGRESSION; TELEVISION; BEHAVIOR; EXPOSURE; VIOLENCE; HABITS	While the positive uses for video games in an educational setting have also been established, the educational aim is usually made explicit. The goal of this research was to develop a video game wherein the educational aspect was implicitly embedded in the video game, such that the gameing activity remained interesting and relevant. Following a pilot study to confirm the usability of an in-house developed game, two studies were conducted with 11-17 year old hockey players (N-1 = 130, N-2 = 39). Results demonstrated that participants playing the experimental version of the video game scored significantly higher on a concussion symptoms questionnaire, in a significantly faster time, than participants playing the control version of the game. Most participants indicated that they enjoyed the game and would play it again. These results suggest that educational material can be conveyed successfully and in an appealing manner via video game play. (c) 2005 The Association for Professionals in Services for Adolescents. Published by Elsevier Ltd. All rights reserved.	Simon Fraser Univ, Sch Kinesiol, Fac Sci Appl, Burnaby, BC V5A 1S6, Canada	Goodman, D (corresponding author), Simon Fraser Univ, Sch Kinesiol, Fac Sci Appl, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	goodman@sfu.ca					Anderson CA, 2000, J PERS SOC PSYCHOL, V78, P772, DOI 10.1037//0022-3514.78.4.772; Anderson CA, 2004, J ADOLESCENCE, V27, P113, DOI 10.1016/j.adolescence.2003.10.009; Anderson CA, 2004, J ADOLESCENCE, V27, P1, DOI 10.1016/j.adolescence.2003.10.001; Anderson CA, 2001, PSYCHOL SCI, V12, P353, DOI 10.1111/1467-9280.00366; Blumberg FC, 2004, J GEN PSYCHOL, V131, P151, DOI 10.3200/GENP.131.2.151-158; Blumberg FC, 1998, J APPL DEV PSYCHOL, V19, P615, DOI 10.1016/S0193-3973(99)80058-6; Blumberg FC, 2000, J APPL DEV PSYCHOL, V21, P641, DOI 10.1016/S0193-3973(00)00058-7; Brown SJ, 1997, MED INFORM, V22, P77, DOI 10.3109/14639239709089835; Dill KE, 1998, AGGRESS VIOLENT BEH, V3, P407, DOI 10.1016/S1359-1789(97)00001-3; Dustman RE, 1992, J GERONTOL, V47, P168; Funk JB, 2004, J ADOLESCENCE, V27, P23, DOI 10.1016/j.adolescence.2003.10.005; Gentile DA, 2004, J ADOLESCENCE, V27, P5, DOI 10.1016/j.adolescence.2003.10.002; Gentile DA, 2002, J APPL DEV PSYCHOL, V23, P157, DOI 10.1016/S0193-3973(02)00102-8; Hughes R, 1999, FAM RELAT, V48, P5; KOLKO DJ, 1985, J CONSULT CLIN PSYCH, V53, P223, DOI 10.1037/0022-006X.53.2.223; Krahe B, 2004, J ADOLESCENCE, V27, P53, DOI 10.1016/j.adolescence.2003.10.006; Lieberman D A, 2001, J Ambul Care Manage, V24, P26; LIEBERMAN DA, 1997, LEA COMMUN SER, P103; Pope A. T., 1996, CHILD STUDY J, V26, P39; Rieber LP, 1996, ETR&D-EDUC TECH RES, V44, P43, DOI 10.1007/BF02300540; Shewokis PA, 2003, PERCEPT MOTOR SKILL, V97, P581; Shewokis PA, 1997, PERCEPT MOTOR SKILL, V84, P3; Uhlmann E, 2004, J ADOLESCENCE, V27, P41, DOI 10.1016/j.adolescence.2003.10.004; Van Mierlo J, 2004, J ADOLESCENCE, V27, P97, DOI 10.1016/j.adolescence.2003.10.008; VANDENBULCK J, 2004, DREAMING, V14, P43, DOI DOI 10.1037/1053-0797.14.1.43; Vandewater EA, 2004, J ADOLESCENCE, V27, P71, DOI 10.1016/j.adolescence.2003.10.003; VanSchie EGM, 1997, J APPL SOC PSYCHOL, V27, P1175	27	44	45	1	14	ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0140-1971			J ADOLESCENCE	J. Adolesc.	JUN	2006	29	3					351	360		10.1016/j.adolescence.2005.07.004			10	Psychology, Developmental	Psychology	057KQ	WOS:000238595100003	16169584				2021-06-18	
J	Wennersten, A; Holmin, S; Al Nimer, F; Meijer, X; Wahlberg, LU; Mathiesen, T				Wennersten, Andre; Holmin, Staffan; Al Nimer, Faiez; Meijer, Xia; Wahlberg, Lars U.; Mathiesen, Tiit			Sustained survival of xenografted human neural stem/progenitor cells in experimental brain trauma despite discontinuation of immunosuppression	EXPERIMENTAL NEUROLOGY			English	Article						fetal stem cell; traumatic brain injury; immunosuppressed; neural progenitor; immunesuppressed; xenotransplantation; xenogeneic; cyclosporine	CENTRAL-NERVOUS-SYSTEM; EMBRYONIC HUMAN CNS; STEM-CELLS; CYCLOSPORINE-A; PROGENITOR CELLS; FUNCTIONAL RECOVERY; DOPAMINE NEURONS; ADULT RATS; INJURY; TRANSPLANTATION	Neural stein cells have emerged as a promising therapeutic tool in CNS disease and injuries. In the clinical setting, cultured human neural stem/progenitor cells (hNSC) are an attractive possibility for transplantation to the damaged brain. However, transplantation of hNSC requires toxic immunosuppressive treatment to avoid rejection. The aim of the current study was to evaluate if shortening the duration of immuno suppression by cyclosporin A would affect hNSC survival and differentiation after transplantation to the site of a focal brain injury in the rat. hNSC were xenografted to the hippocampus and the medial limit of an experimentally induced cortical contusion. The animals received immumosuppression for either 6 or 3 weeks or no immunosuppression. The status of the grafted human cells was analysed by immunohistochemistry. No statistically significant differences were observed between the two immunosuppressed groups regarding graft survival, migration or proliferation at 6 weeks post-transplantation. In contrast, the graft survival was extremely poor in the non-immunosuppressed group. Furthermore, the expression of the differentiation markers nestin, neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) in the transplanted cells did not differ significantly between the two immunosuppressed groups. Moreover, a fourth group of eight animals that were immunosuppressed for 3 weeks were allowed to survive for 6 months. Five of these rats demonstrated robust graft survival in the hippocampus and scattered cells in the cortex. This study demonstrates the importance of immunosuppression but also the possibility of shortening immunosuppression without impacting on the phenotype of the grafted hNSC. (c) 2006 Elsevier Inc. All rights reserved.	Sect Clin CNS Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden; NS Gene AS, Copenhagen, Denmark	Wennersten, A (corresponding author), Sect Clin CNS Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden.	andre.wennersten@ki.se	Nimer, Faiez Al/ABB-9465-2020	Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919; Al Nimer, Faiez/0000-0003-0937-5995			Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Akhlaghi F, 2002, CLIN PHARMACOKINET, V41, P615, DOI 10.2165/00003088-200241090-00001; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Aleksandrova MA, 2002, DEV BRAIN RES, V134, P143, DOI 10.1016/S0165-3806(02)00273-0; Armstrong RJE, 2001, NEUROSCIENCE, V106, P201, DOI 10.1016/S0306-4522(01)00273-1; Brevig T, 2000, TRENDS NEUROSCI, V23, P337, DOI 10.1016/S0166-2236(00)01605-2; BRUNDIN P, 1989, EXP BRAIN RES, V75, P195; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Castilho RF, 2000, EXP NEUROL, V164, P94, DOI 10.1006/exnr.2000.7405; Chu K, 2003, STROKE, V34, P241; Cicchetti F, 2003, XENOTRANSPLANTATION, V10, P41, DOI 10.1034/j.1399-3089.2003.01130.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; Duan WM, 2002, NEUROSCIENCE, V115, P495, DOI 10.1016/S0306-4522(02)00382-2; Ehtesham M, 2002, CANCER RES, V62, P5657; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ishibashi S, 2004, J NEUROSCI RES, V78, P215, DOI 10.1002/jnr.20246; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Larsson LC, 2003, TRANSPLANTATION, V75, P1448, DOI 10.1097/01.TP.0000058807.45320.A2; Larsson LC, 2000, SCAND J IMMUNOL, V52, P249; Le Belle JE, 2004, J NEUROSCI RES, V76, P174, DOI 10.1002/jnr.20035; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; MATHIESEN T, 1989, CANCER LETT, V44, P151, DOI 10.1016/0304-3835(89)90010-4; Mirza B, 2004, BRAIN RES BULL, V63, P105, DOI 10.1016/j.brainresbull.2004.01.009; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ortega J D, 1992, Cell Transplant, V1, P33; OUREDNIK J, 2002, NAT BIOTECHNOL, V15, P15; PAKZABAN P, 1994, NEUROSCIENCE, V62, P989, DOI 10.1016/0306-4522(94)90338-7; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Snyder EY, 2004, J NEUROSCI RES, V76, P157, DOI 10.1002/jnr.20033; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wennberg L, 2001, TRANSPLANTATION, V71, P1797, DOI 10.1097/00007890-200106270-00016; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y	49	44	46	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2006	199	2					339	347		10.1016/j.expneurol.2005.12.035			9	Neurosciences	Neurosciences & Neurology	063DB	WOS:000238995200014	16490195				2021-06-18	
J	Hamanaka, S; Asukai, N; Kamijo, Y; Hatta, K; Kishimoto, J; Miyaoka, H				Hamanaka, S; Asukai, N; Kamijo, Y; Hatta, K; Kishimoto, J; Miyaoka, H			Acute stress disorder and posttraumatic stress disorder symptoms among patients severely injured in motor vehicle accidents in Japan	GENERAL HOSPITAL PSYCHIATRY			English	Article						motor vehicle accident; acute stress disorder; posttraumatic stress disorder; physical injury severity; physical disability	2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; VICTIMS; SURVIVORS; PREDICTION; PTSD; DEPRESSION; THERAPY; SCALE	Objective: The prevalence of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) in seriously injured survivors of motor vehicle accidents (MVAs) in Japan was investigated. Furthermore, predictive factors in the early stage for development of PTSD were evaluated. Method: Subjects were consecutive samples (N = 100) of patients hospitalized with severe MVA injuries surveyed at two time points: within I month after the MVA and then 6 months later. In the first survey, we conducted the Acute Stress Disorder Interview and compiled results of a self-rating questionnaire; in the second survey, we conducted a structured clinical interview via telephone. Results: The prevalence of ASD and PTSD were 9.0% and 8.5%, respectively. The shift from ASD to PTSD was more pronounced when we included partial diagnoses of ASD and PTSD. Three predictive factors for PTSD were identified through multiple logistic analysis: ASD-positive, presence of persistent physical disability and physical injury severity. Conclusions: Even among severely injured MVA survivors, most acute stress symptoms subside over time. However, having ASD or partial ASD in the early stage, and the presence of physical disability as an aftereffect are strong predictive factors for PTSD. These findings validate the importance of evidence-based intervention for ASD to forestall PTSD. (c) 2006 Elsevier Inc. All rights reserved.	Kitasato Univ, Dept Psychiat, Sch Med, Sagamihara, Kanagawa 2288520, Japan; Tokyo Inst Psychiat, Div Social Psychiat, Tokyo 1568585, Japan; Kitasato Univ, Sch Med, Dept Emergency & Crit Care Med, Sagamihara, Kanagawa 2288520, Japan; Juntendo Univ, Sch Med, Dept Psychiat, Tokyo 1138421, Japan; Univ Tokyo, Sch Med, Dept Clin Bioinformat, Grad Sch Med, Tokyo 1138655, Japan	Hamanaka, S (corresponding author), Kitasato Univ, Dept Psychiat, Sch Med, Sagamihara, Kanagawa 2288520, Japan.	satokohamanaka@ybb.ne.jp	Hatta, Kotaro/AAN-4791-2020				Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; ASUKAI N, 1998, PSYCHIAT CLIN NEUR S, V52, pS75; Asukai N., 2003, JAP J TRAUM STRESS, V1, P47; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bisson JI, 2004, BRIT J PSYCHIAT, V184, P63, DOI 10.1192/bjp.184.1.63; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Blanchard EB, 1997, J TRAUMA STRESS, V10, P215, DOI 10.1023/A:1024826028483; BLANCHARD EB, 1994, BEHAB RES THER, V11, P369; Bryant R.A., 2000, ACUTE STRESS DISORDE; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 2003, AUST NZ J PSYCHIAT, V37, P226, DOI 10.1046/j.1440-1614.2003.01130.x; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Buckley B, 2004, J TRAUMA STRESS, V17, P317, DOI 10.1023/B:JOTS.0000038480.87290.4a; Creamer M, 2004, BEHAV RES THER, V42, P315, DOI 10.1016/S0005-7967(03)00141-4; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; First MB., 1997, STRUCTURED CLIN INTE; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1999, J TRAUMA STRESS, V12, P519, DOI 10.1023/A:1024723205259; HIROHATA S, 2002, SEISHINKEISHI, V104, P549; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holeva V, 2001, J PSYCHOSOM RES, V51, P687, DOI 10.1016/S0022-3999(01)00256-2; ISHII T, 2005, SEISHINKA CHIRYOUGAK, V20, P183; Jeavons S, 2000, BEHAV RES THER, V38, P499, DOI 10.1016/S0005-7967(99)00073-X; KATO H, 2000, B KOBE U FAC MED, V60, P1; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KNAUS WA, 1985, CRITICAL CARE MED, V13, P10; Koren D, 1999, AM J PSYCHIAT, V156, P367; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; MAES M, 2001, PSYCHIAT RES, V15, P1; Marmar C., 2004, ASSESSING PSYCHOL TR; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; MEZZICH JE, 1996, CULTURE PSYCHIAT DIA; Michaels AJ, 1999, J TRAUMA, V47, P867, DOI 10.1097/00005373-199911000-00009; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Veazey CH, 2004, APPL PSYCHOPHYS BIOF, V29, P51, DOI 10.1023/B:APBI.0000017863.35714.a1; Weiss D. S, 2004, ASSESSING PSYCHOL TR, DOI DOI 10.1007/978-0-387-70990-1_10; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	49	44	45	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0163-8343			GEN HOSP PSYCHIAT	Gen. Hosp. Psych.	MAY-JUN	2006	28	3					234	241		10.1016/j.genhosppsych.2006.02.007			8	Psychiatry	Psychiatry	045SE	WOS:000237761700008	16675367				2021-06-18	
J	Smith, C; Graham, DI; Murray, LS; Stewart, J; Nicoll, JAR				Smith, C; Graham, DI; Murray, LS; Stewart, J; Nicoll, JAR			Association of APOE e4 and cerebrovascular pathology in traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							APOLIPOPROTEIN-E GENOTYPE; MISSILE HEAD-INJURY; E-DEFICIENT MICE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL AMYLOID ANGIOPATHY; INCREASED NEURONAL DAMAGE; E POLYMORPHISM; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL-PRESSURE; COGNITIVE DECLINE	Background: Previous studies have found the e4 allele of the apolipoprotein E gene ( APOE e4) is associated with an unfavourable outcome after head injury, but this has not been related to specific pathological features. Objectives: This study tested the postulate that head injured patients with APOE e4, amounting to approximately a third of the population, are selectively predisposed to one or more of the different pathological features that constitute the response to traumatic brain injury (TBI), and that this underlies the association of APOE e4 with poor clinical outcome. Methods: Included in the study were 239 fatal cases of TBI (1987-1999) for which APOE genotypes were determined from archival tissue. For each case, specific pathological features of trauma were recorded by researchers blinded to the APOE e4 status. Of the 239 cases examined, 83 (35%) were APOE e4 carriers and 156 (65%) were non-carriers. Results: Possession of APOE e4 was associated with a greater incidence of moderate or severe contusions (42% v 30% for carriers versus e4 non-carriers; p = 0.05) and there was a trend towards a greater incidence of severe ischaemic brain damage (54% v 42%; p = 0.08). Significant differences were not noted between the other pathological features examined. Conclusions: Possession of APOE e4 is associated with a greater incidence of moderate/severe contusional injury and severe ischaemic brain damage in fatal cases of TBI. This may be relevant to the relatively poor outcome from traumatic brain injury in patients with APOE e4 identified in clinical studies.	Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neruopathol, Glasgow, Lanark, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh, Midlothian, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow, Lanark, Scotland; Univ Southampton, Gen Hosp, Div Clin Neurosci, Southampton, Hants, England	Smith, C (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland.	col.smith@ed.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 1999, J NEUROSCI, V19, P4867; DUNN LT, 2002, STROKE, V33, P548; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Giraud V, 1998, GASTROEN CLIN BIOL, V22, P571; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Leung CHS, 2002, STROKE, V33, P548, DOI 10.1161/hs0202.102326; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Roses AD, 1996, ANN NY ACAD SCI, V777, P146, DOI 10.1111/j.1749-6632.1996.tb34413.x; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097	39	44	49	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2006	77	3					363	366		10.1136/jnnp.2005.074617			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	016WK	WOS:000235651900019	16484645	Green Published			2021-06-18	
J	Schatz, P; Putz, BO				Schatz, Philip; Putz, Brendan O.			Cross-validation of measures used for computer-based assessment of concussion	APPLIED NEUROPSYCHOLOGY			English	Article						concussion testing; computerized neuropsychological assessment	TRAUMATIC BRAIN-INJURY; RELIABLE CHANGE INDEXES; COGNITIVE ASSESSMENT; SPORTS; TESTS; RELIABILITY; PERFORMANCE; RETURN	The purpose of this study was to cross-validate subscales of computerized test batteries developed for the assessment and management of sports-related concussion, as well as to validate these subscales against select long-standing paper-based measures. In order to examine concurrent validity, we administered 3 such computerized measures, CogSport, ImPACT and HeadMinder, along with more established paper-based measures, the Trail Making Tests and the Digit Symbol subtest of the Wechsler scale. Analysis of processing speed indices revealed significant but modest correlations between Trails B and the computer-based measures, ranging ;from -.51 (ImPACT) to .60 (HeadMinder), and for Digit Symbol ranging from -.37 (Headminder) to .53 (ImPACT). Analysis of complex reaction time (CRT) data revealed significant but modest correlations between ImPACT and CogSport (.65), and between ImPACT and HeadMinder (.41), but not between CogSport and HeadMinder No intercorrelations were found between the memory indices from the 3 programs. Our results suggest that these tests share some common variance on constructs such as processing speed and reaction time, but not within the domain of memory. Clinicians obtaining baseline evaluations using I measure should not use the baseline as a basis for post-concussion assessment using another measure.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; BARTRAM D, 1984, J OCCUP PSYCHOL, V57, P221, DOI 10.1111/j.2044-8325.1984.tb00164.x; BORSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651; Brickenkamp R., 1981, TEST D2 AUFMERKSAMKE, V7th; CHARTER RA, 1987, INT J CLIN NEUROPSYC, V9, P28; *COGSTATE, 1999, COGSP COMP SOFTW; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DICK RW, 1999, NCAA INJURY SUREVILL; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Epstein J, 2001, COMPUT HUM BEHAV, V17, P339, DOI 10.1016/S0747-5632(01)00002-4; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Erlanger DM, 1999, CONCUSSION RESOLUTIO; FRENCH CC, 1987, BRIT J CLIN PSYCHOL, V26, P267, DOI 10.1111/j.2044-8260.1987.tb01360.x; Goldstein G, 1989, CLIN NEUROPSYCHOL, V3, P265, DOI DOI 10.1080/13854048908404088; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hopp GA, 1997, J CLIN PSYCHOL, V53, P673, DOI 10.1002/(SICI)1097-4679(199711)53:7<673::AID-JCLP5>3.3.CO;2-8; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 2000, IMPACT IMMEDIATTE PO; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Schatz P, 2002, ARCH CLIN NEUROPSYCH, V17, P851; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Snow W. G., 1988, M INT NEUR SOC NEW O; Spreen O., 1991, COMPENDIUM NEUROPSYC; Vispoel WP, 2000, MEAS EVAL COUNS DEV, V33, P130, DOI 10.1080/07481756.2000.12069005; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; WILSON SL, 1991, MICROCOMPUTERS CLIN, P79	41	44	45	0	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2006	13	3					151	159		10.1207/s15324826an1303_2			9	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	112KG	WOS:000242524000002	17361667				2021-06-18	
J	Longhi, L; Zanier, ER; Royo, N; Stocchetti, N; McIntosh, TK				Longhi, L; Zanier, ER; Royo, N; Stocchetti, N; McIntosh, TK			Stem cell transplantation as a therapeutic strategy for traumatic brain injury	TRANSPLANT IMMUNOLOGY			English	Article						traumatic brain injury; neuroprotection; transplantation; stem cell	MARROW STROMAL CELLS; BONE-MARROW; PROGENITOR CELLS; COGNITIVE FUNCTION; NEURONAL CELLS; RAT MODEL; SURVIVAL; MIGRATION; RECOVERY; DIFFERENTIATION	Stem cell transplantation has enormous potential to be a viable therapeutic approach to replace the lost tissue/cells following traumatic brain injury (TBI). Several types of cell lines such as immortalized progenitors cells, embryonic rodent and human stem cells and bone marrow-derived cells have been successfully transplanted in experimental models of TBI, resulting in reduced neurobehavioral deficits and attenuation of histological damage. To date, it remains unclear whether stem cell are effective following transplantation into the injured brain via either cell replacement, trophic support, or manipulation of the local environment to stimulate endogenous neuroprotection/regeneration. This paper will review the most current and exciting pre-clinical data regarding the utility of cellular transplantation in experimental models of TBI. We believe that further work must continue to better understand the interaction between the host and the transplanted cells as well as the mechanisms regulating their differentiation into mature and functionally active neurons/glia. (C) 2005 Elsevier B.V. All rights reserved.	Univ Milan, Osped Maggiore Policlin, Fdn IRCCS, Dept Anesthesia & Crit Care Med,Neurosurg Intens, I-20100 Milan, Italy; Univ Penn, Dept Neurosurg, Head Injury Lab, Philadelphia, PA 19104 USA	Longhi, L (corresponding author), Univ Milan, Osped Maggiore Policlin, Fdn IRCCS, Dept Anesthesia & Crit Care Med,Neurosurg Intens, Via Sforza 35, I-20100 Milan, Italy.	lucalonghi@policlinico.mi.it	Longhi, Luca/AAF-9903-2021; Zanier, Elisa/AAA-8095-2020; Stocchetti, Nino/O-7444-2017	Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718			Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; EMSLEY JG, 2005, PROG NEUROBIOL; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Jennett B., 1997, HEAD INJURY, P439; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; LE J, 2002, BIODRUGS, V16, P389; Lenzlinger PM, 2002, EXP NEUROL, V175, P421; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lundberg C, 1996, BRAIN RES, V737, P295, DOI 10.1016/0006-8993(96)00923-7; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Seaberg RM, 2003, TRENDS NEUROSCI, V26, P125, DOI 10.1016/S0166-2236(03)00031-6; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Sortwell CE, 2003, FRONT BIOSCI, V8, pS522, DOI 10.2741/1096; Svendsen CN, 2004, NAT MED, V10, P224, DOI 10.1038/nm0304-224; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; ZHANG C, 2005, J NEUROTRAUMA; 2000, J NEUROTRAUMA, V17, P457	48	44	50	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0966-3274	2210-3384		TRANSPL IMMUNOL	Transpl. Immunol.	DEC	2005	15	2					143	148		10.1016/j.trim.2005.09.003			6	Immunology; Transplantation	Immunology; Transplantation	007GM	WOS:000234956800007	16412958				2021-06-18	
J	Aquilani, R; Iadarola, P; Contardi, A; Boselli, M; Verri, M; Pastoris, O; Boschi, F; Arcidiaco, P; Viglio, S				Aquilani, R; Iadarola, P; Contardi, A; Boselli, M; Verri, M; Pastoris, O; Boschi, F; Arcidiaco, P; Viglio, S			Branched-chain amino acids enhance the cognitive recovery of patients with severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amino acids; branched-chain; brain injuries; rehabilitation	P70 S6 KINASE; HEPATIC-ENCEPHALOPATHY; CONTROLLED TRIAL; HUNTINGTONS-DISEASE; DIABETES-MELLITUS; PROTEIN TURNOVER; INSULIN-RECEPTOR; DIETARY-PROTEIN; SKELETAL-MUSCLE; NERVOUS-SYSTEM	Objective: To investigate whether Supplementation with branched-chain amino acids (BCAAs) in patients with severe traumatic brain injury (TBI) improves recovery of cognition and influences plasma concentrations of tyrosine and tryptophan, which are precursors of, respectively, catecholamine and serotonin neurotransmitters in the brain. Design: Forty patients with TBI were randomly assigned to 15 days of intravenous BCAA supplementation (19.6g/d) (n=20) or an isonitrogenous placebo (n=20). Setting: Tertiary care rehabilitation setting in Italy. Participants: Forty men (mean age, 32 +/- 15y) with TBI and 20 healthy subjects (controls) matched for age, sex, and sedentary lifestyle. Intervention: Supplementation with BCAAs. Main Outcome Measures: Disability Rating Scale (DRS) and plasma concentrations of BCAAs, tyrosine, and tryptophan. Results: Fifteen days after admission to the rehabilitation department, the DRS score had improved significantly in both the placebo group (P <.05 vs baseline) and in the BCAA-supplemented group (P <.01 vs baseline). The difference between the 2 groups was significant (P <.004). Plasma tyrosine concentration improved in the group given BCAA supplementation, and tryptophan concentration increased in patients receiving placebo. Conclusions: Supplemental BCAAs enhance the retrieval of DRS without causing negative effects on tyrosine and tryptophan concentration. Key Words: Amino acids, branched-chain; Brain injuries; Rehabilitation.	Univ Pavia, Dipartimento Biochim A Castellani, I-27100 Pavia, Italy; IRCCS, Fdn S Maugeri, Serv Fisiopatol Metab Nutr & Nutr Clin, Pavia, Italy; IRCCS, Fdn S Maugeri, Div Neuroriabilitaz 1, Pavia, Italy; IRCCS, Fdn S Maugeri, Div Neuroriabilitaz, Pavia, Italy; IRCCS, Fdn S Maugeri, IstSci Montescano, Pavia, Italy; Univ Pavia, Dipartimento Sci Fisiol & Farmacol, Sez Farmacol, I-27100 Pavia, Italy; Univ Pavia, Ctr Grandi Strumenti, I-27100 Pavia, Italy	Viglio, S (corresponding author), Univ Pavia, Dipartimento Biochim A Castellani, Via Taramelli 3-B, I-27100 Pavia, Italy.	simona.viglio@unipv.it		Pastoris, Ornella/0000-0003-0273-1010; Viglio, Simona/0000-0001-5020-478X; Boselli, Mirella/0000-0003-4545-5271			Aquilani R, 2003, ARCH PHYS MED REHAB, V84, P1258, DOI 10.1016/S0003-9993(03)00148-5; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1016/S0003-9993(00)90137-0; Banks WA, 1998, PEPTIDES, V19, P883, DOI 10.1016/S0196-9781(98)00018-7; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; BASUN H, 1990, J NEURAL TRANSM-PARK, V2, P295, DOI 10.1007/BF02252924; BERRY HK, 1990, AM J DIS CHILD, V144, P539, DOI 10.1001/archpedi.1990.02150290033020; Bessman SP, 1997, MOL CELL BIOCHEM, V174, P91, DOI 10.1023/A:1006834408181; BISTRIAN BR, 1975, SURG GYNECOL OBSTET, V141, P512; BLACKBURN GL, 1979, SURGERY, V86, P307; Blomstrand E, 1997, ACTA PHYSIOL SCAND, V159, P41, DOI 10.1046/j.1365-201X.1997.547327000.x; BOWER RH, 1986, ANN SURG, V203, P13, DOI 10.1097/00000658-198601000-00003; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CERRA FB, 1985, JPEN-PARENTER ENTER, V9, P288, DOI 10.1177/0148607185009003288; CHAPLIN ER, 1976, J NEUROCHEM, V26, P701, DOI 10.1111/j.1471-4159.1976.tb04440.x; CHIARELLI A, 1990, AM J CLIN NUTR, V51, P1035; Clarke D. D., 1998, BASIC NEUROCHEMISTRY, P637; COTMAN CW, 1981, PHYSIOL REV, V61, P684; Craft S, 1999, ARCH GEN PSYCHIAT, V56, P1135, DOI 10.1001/archpsyc.56.12.1135; CRAFT S, 1993, BEHAV NEUROSCI, V107, P926; DAVIS SN, 1995, J CLIN INVEST, V95, P593, DOI 10.1172/JCI117703; EGBERTS EH, 1985, GASTROENTEROLOGY, V88, P887, DOI 10.1016/S0016-5085(85)80004-4; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ENZI G, 1990, CRIT CARE MED, V18, P719, DOI 10.1097/00003246-199007000-00007; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; FERRANDO AA, 1995, JPEN-PARENTER ENTER, V19, P47, DOI 10.1177/014860719501900147; FIACCADORI F, 1985, ITAL J GASTROENTEROL, V17, P5; FISCHER JE, 1976, SURGERY, V80, P77; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206; Fox HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1232; FREUND H, 1978, SURGERY, V83, P611; FREUND HR, 1981, SURGERY, V90, P237; FULKS RM, 1975, J BIOL CHEM, V250, P290; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; GAMBERINO WC, 1994, J NEUROCHEM, V63, P1392; Gijsman HJ, 2002, PSYCHOPHARMACOLOGY, V160, P192, DOI 10.1007/s00213-001-0970-5; GOLDBERG AL, 1978, FED PROC, V37, P2301; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HASSMEN P, 1994, NUTRITION, V10, P405; HAVRANKOVA J, 1978, P NATL ACAD SCI USA, V75, P5737, DOI 10.1073/pnas.75.11.5737; HENLEY M, 1989, BURNS, V15, P351, DOI 10.1016/0305-4179(89)90098-3; HORST D, 1984, HEPATOLOGY, V4, P279, DOI 10.1002/hep.1840040218; Hoyer S, 1996, ANN NY ACAD SCI, V777, P374, DOI 10.1111/j.1749-6632.1996.tb34448.x; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; JORDAN MK, 1985, DEV MED CHILD NEUROL, V27, P33; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KUHL DE, 1984, ANN NEUROL, V15, pS119; MADSEN DC, 1983, ADV CLIN NUTRITION, P1; MALAISSE WJ, 1968, J LAB CLIN MED, V72, P438; MCGHEE A, 1983, ANN SURG, V197, P288, DOI 10.1097/00000658-198303000-00008; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILNER RDG, 1970, J ENDOCRINOL, V47, P347, DOI 10.1677/joe.0.0470347; Mittleman KD, 1998, MED SCI SPORT EXER, V30, P83, DOI 10.1097/00005768-199801000-00012; MOJA EA, 1991, LIFE SCI, V49, P1121, DOI 10.1016/0024-3205(91)90600-G; MOROO I, 1994, ACTA NEUROPATHOL, V87, P343; Nielsen DH, 1981, CARDIAC REHABILITATI, P11; OBrien RM, 1996, PHYSIOL REV, V76, P1109; ODESSEY R, 1972, AM J PHYSIOL, V223, P1376; Oomura Y, 1976, HUNGER BASIC MECH CL, P145; PALOVCIK RA, 1984, BRAIN RES, V309, P187, DOI 10.1016/0006-8993(84)91028-X; Park CR, 2001, NEUROSCI BIOBEHAV R, V25, P311, DOI 10.1016/S0149-7634(01)00016-1; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PHILLIPS MI, 1989, METHOD ENZYMOL, V168, P129; PLASCHKE K, 1993, INT J DEV NEUROSCI, V11, P477, DOI 10.1016/0736-5748(93)90021-5; PODOLSKY S, 1977, GERONTOLOGY, V23, P55, DOI 10.1159/000212174; PRONCZUK AW, 1970, J NUTR, V100, P1249; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; RICHARDSON JTE, 1990, NEUROSCI BIOBEHAV R, V14, P385, DOI 10.1016/S0149-7634(05)80060-0; RODWELL VW, 1988, HERPES BIOCH, P271; RUDERMAN NB, 1977, AM J PHYSIOL, V233, pE109; SAIDO TC, 1994, FASEB J, V8, P814; SAITOU S, 1993, NEUROSCI LETT, V149, P12, DOI 10.1016/0304-3940(93)90335-I; SCHMIDT GM, 1980, EXP HEMATOL, V8, P506; SHIBATA S, 1986, PHYSIOL BEHAV, V36, P79, DOI 10.1016/0031-9384(86)90077-6; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Stewart R, 1999, DIABETIC MED, V16, P93, DOI 10.1046/j.1464-5491.1999.00027.x; Strauss E., 1986, NUTR SUPP SERVICES, V6, P18; Sweeney G, 1998, MOL CELL BIOCHEM, V182, P121, DOI 10.1023/A:1006805510749; TANAKA K, 1993, J AUTONOM NERV SYST, V42, P225, DOI 10.1016/0165-1838(93)90367-4; VORHEES CV, 1989, PEDIATR RES, V25, P568, DOI 10.1203/00006450-198906000-00002; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; YOKOGOSHI H, 1992, J NUTR, V122, P2210; YOUNG W, 1996, NEUROTRAUMA, P1421	86	44	46	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1729	1735		10.1016/j.apmr.2005.03.022			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	962QM	WOS:000231747300003	16181934				2021-06-18	
J	Gagnon, I; Swaine, B; Friedman, D; Forget, R				Gagnon, I; Swaine, B; Friedman, D; Forget, R			Exploring children's self-efficacy related to physical activity performance after a mild traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	7th Annual Conference of the Euroacademia Multidisciplinaria Neurotraumatologica	JUN, 2002	Newcastle upon Tyne, ENGLAND			adolescents; children; physical activity; self-efficacy; traumatic brain injury	ACTIVITY QUESTIONNAIRE; VALIDATION; PEOPLE; SCALE	Objective: To evaluate children's self-efficacy related to their practice of physical activities prior to and after a mild traumatic brain injury (mTBI), and compare these to those of noninjured children matched for age, sex, and premorbid level of physical activity. Participants and Methods: Thirty-four children (mean age: 12 +/- 3 years) in each group. Children with mTBI were assessed I day postinjury (to document preinjury status) and at 12 weeks post-mTBI using a self-efficacy questionnaire, the Physical Activity Questionnaire, the Athletic Competence subscale of the Self-Perception Profile for Children or Adolescents, and the Rivermead Post-Concussion Symptoms Questionnaire. Noninjured children underwent the same assessments at a corresponding time interval. Results: At 12 weeks postinjury, self-efficacy scores of children with mTBI were significantly lower than initial (ie, pretraumatic) values and those of noninjured children. The children with mTBI had, however, returned to their preinjury level of participation in physical activities and maintained their athletic competence. Conclusions: After mTBI, children appear to lack confidence in their ability to perform during physical activities as compared to before their injury, Intervention strategies such as information or counseling sessions targeting children and their parents may minimize the impact of the mTBI on children's confidence in their performance in physical activities.	McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Fac Med, Ecole Readapt, Montreal, PQ H3H 1P3, Canada; Montreal Metropolitain Site Inst Readapt Montreal, Ctr Rech Interdisciplinaire Readapt, Montreal, PQ, Canada	Gagnon, I (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	Isabelle.gagnon6@sympatico.ca					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bass B. L., 2005, J APPL SPORT PSYCHOL, V78, P155, DOI DOI 10.1080/10413209008406426; Crocker PRE, 1997, MED SCI SPORT EXER, V29, P1344, DOI 10.1097/00005768-199710000-00011; Dilorio C, 1992, J Neurosci Nurs, V24, P9; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; GAGNON I, 2002, ARCH PHYS MED REHAB, V83, P1481; GAGNON I, 2002, NEROREHABIL NEURAL R, V16, P22; HARTER S, 1982, CHILD DEV, V53, P87, DOI 10.2307/1129640; Harter S., 1988, MANUAL SELF PERCEPTI; Harter S., 1984, V3, P219; Harter S., 1985, MANUAL SELF PERCEPTI; Kelly JP, 1997, NEUROLOGY, V48, P581; KILGORE JM, 1998, INVESTIGATION EFFECT; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kowalski KC, 1997, PEDIATR EXERC SCI, V9, P342, DOI 10.1123/pes.9.4.342; Kowalski KC, 1997, PEDIATR EXERC SCI, V9, P174, DOI 10.1123/pes.9.2.174; Levin HS, 1996, NEUROTRAUMA, P749; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; MAIBACH E, 1995, HEALTH EDUC RES, V10, P37, DOI 10.1093/her/10.1.37; SALLIS JF, 1993, MED SCI SPORT EXER, V25, P99, DOI 10.1249/00005768-199301000-00014; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P394, DOI 10.1016/S0003-9993(96)90091-X; Streiner DL, 1989, HLTH MEASUREMENT SCA; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008	27	44	44	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					436	449		10.1097/00001199-200509000-00005			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600006	16170252				2021-06-18	
J	Hang, CH; Shi, JX; Li, JS; Wu, W; Yin, HX				Hang, CH; Shi, JX; Li, JS; Wu, W; Yin, HX			Concomitant upregulation of nuclear factor-kappa B activity, proinflammatory cytokines and ICAM-1 in the injured brain after cortical contusion trauma in a rat model	NEUROLOGY INDIA			English	Article						traumatic brain injury; nuclear factor-kappa B; proinflammatory cytokine; intercellular adhesion molecule-1; inflammation	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; AXONAL INJURY; MESSENGER-RNA; EXPRESSION; TRANSCRIPTION; INFLAMMATION; ACTIVATION; IMPACT; ALPHA	Background: Nuclear factor kappa B (NF-kB), proinflammatory cytokines and intercellular adhesion molecule 1 (ICAM-1) are frequently upregulated in the injured brain after traumatic brain injury (TBI). However, the temporal pattern of upregulation is not well defined. Aims: The current study was undertaken to investigate the temporal profile of the expression of NF-kB, proinflammatory cytokines and ICAM-1 in the injured brain after cortical contusion trauma of the rat brain. Settings and Design: A rat model of cortical contusion was produced by a free-falling weight on the exposed dura of right parietal lobe. The rats were randomly divided into control group and TBI groups at hours 3, 12, 24 and 72, and on day 7. Material and Methods: NF-kB binding activity in the surrounding brain of injured area was studied by electrophoretic mobility shift assay (EMSA). The levels of TNF-alpha and IL-6 were detected using ELISA and ICAM-1 expression studied by immunohistochemistry. Statistical analysis: The data were analyzed by one-way ANOVA followed by Student-Newman-Keuls post hoc test. Relation between variables was analyzed using bivariate correlation with two-tailed test. Results: Compared with that of control group, NF-kB binding activity in the injured brain was significantly increased through 12 h and 7 days postinjury, with the maximum at 72 h. The concentrations of TNF-alpha and IL-6 in the injured brain were significantly increased from 3 h to 7 days and maximal at 24 h postinjury. The number of ICAM-1 immunostained microvessels was significantly increased in the injured brain from 24 h to 7 days postinjury, with its peak at 72 h. Concomitant upregulation of TNF-alpha, IL-6, ICAM-1 and the cytokine mediators NF-kB in the injured brain was observed in the injured brain after cortical contusion, and there was a highly positive relation among these variables. Conclusions: Cortical contusion trauma could induce a concomitant and persistent upregulation of NF-kB binding activity, TNF-alpha, IL-6 and ICAM-1 in the in jured rat brain which might play a central role in the injury-induced immune response of brain.	Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Sch Clin Med, Jinling Hosp, Res Inst Gen Surg, Nanjing 210002, Peoples R China	Hang, CH (corresponding author), Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	hang1965@public1.ptt.js.cn					Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Sullivan PG, 1999, J NEUROSCI, V19, P6248; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Whalen MJ, 1998, ACT NEUR S, V71, P212; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	28	44	57	0	4	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	SEP	2005	53	3					312	317		10.4103/0028-3886.16930			6	Neurosciences	Neurosciences & Neurology	979TG	WOS:000232967100018	16230799				2021-06-18	
J	Clausen, T; Alves, OL; Reinert, M; Doppenberg, E; Zauner, A; Bullock, R				Clausen, T; Alves, OL; Reinert, M; Doppenberg, E; Zauner, A; Bullock, R			Association between elevated brain tissue glycerol levels and poor outcome following severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						glycerol; oxygenation; cerebral perfusion pressure; traumatic brain injury; microdialysis; multimodal monitoring	CEREBRAL PERFUSION-PRESSURE; MEMBRANE PHOSPHOLIPID DEGRADATION; HUMAN HEAD-INJURY; INTERSTITIAL GLYCEROL; FREE-RADICALS; SUBDURAL-HEMATOMA; OXYGEN-TENSION; ACID RELEASE; RAT-BRAIN; MICRODIALYSIS	Object. Glycerol is considered to be a marker of cell membrane degradation and thus cellular lysis. Recently, it has become feasible to measure via microdialysis cerebral extracellular fluid (ECF) glycerol concentrations at the patient's bedside. Therefore the aim of this study was to investigate the ECF concentration and time course of glycerol after severe traumatic brain injury (TBI) and its relationship to patient outcome and other monitoring parameters. Methods. As soon as possible after injury for up to 4 days, 76 severely head-injured patients were monitored using a microdialysis probe (cerebral glycerol) and a Neurotrend sensor (brain tissue PO,) in uninjured brain tissue confirmed by computerized tomography scanning. The mean brain tissue glycerol concentration in all monitored patients decreased significantly from 206 +/- 31 mu mol/L on Day 1 to 9 +/- 3 mu mol/L on Day 4 after injury (p < 0.0001). Note, however, that there was no significant difference in the time course between patients with a favorable outcome (Glasgow Outcome Scale [GOS] Scores 4 and 5) and those with an unfavorable outcome (GOS Scores 1-3). Significantly increased glycerol concentrations were observed when brain tissue PO2 was less than 10 mm Hg or when cerebral perfusion pressure was less than 70 mm Hg. Conclusions. Based on results in the present study one can infer that microdialysate glycerol is a marker of severe tissue damage, as seen immediately after brain injury or during profound tissue hypoxia. Given that brain tissue glycerol levels do not yet add new clinically significant information, however, routine monitoring of this parameter following traumatic brain injury needs further validation.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle Saale, Germany; Univ Porto, Fac Med, Ctr Hosp Gaia, Serv Neurocirurg, Oporto, Portugal; Inselspital Bern, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Miami, Lois Pope Life Ctr, Dept Neurosurg, Miami, FL 33152 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; Alessandri B, 1999, ACT NEUR S, V75, P21; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Berger C, 1999, STROKE, V30, P460, DOI 10.1161/01.STR.30.2.460; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; Chesnut R M, 1995, New Horiz, V3, P366; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Farooqui AA, 2001, BRAIN RES REV, V38, P61, DOI 10.1016/S0169-328X(01)00214-5; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Gasparovic C, 1998, J NEUROCHEM, V71, P1727; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; Lang E W, 1995, New Horiz, V3, P400; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Savers S, 2000, J NEUROTRAUM, V17, P507; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	41	44	45	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2005	103	2					233	238		10.3171/jns.2005.103.2.0233			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	957KI	WOS:000231368300007	16175851				2021-06-18	
J	Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Sauerland, S; Schafer, U; Molcany, M; Lefering, R; Bouillon, B; Neiss, WF; Angelov, DN; Klug, N; McIntosh, TK; Neugebauer, EAM				Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Sauerland, S; Schafer, U; Molcany, M; Lefering, R; Bouillon, B; Neiss, WF; Angelov, DN; Klug, N; McIntosh, TK; Neugebauer, EAM			Reversal of neuromotor and cognitive dysfunction in an enriched environment combined with multimodal early onset stimulation after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cognitive; enriched environment; neuromotor; rat; recovery; stimulation; traumatic brain injury	FLUID-PERCUSSION INJURY; FACTOR MESSENGER-RNA; CEREBRAL-CORTEX; SPATIAL MEMORY; FUNCTIONAL RECOVERY; UNITED-STATES; YOUNG-RATS; HIPPOCAMPAL; INCREASES; LESIONS	This study was designed to investigate the additional benefits of a multimodal early onset stimulation (MEOS) paradigm when combined with enriched environment (EE) versus EE only and standard housing (SH) on the recovery after experimental traumatic brain injury (TBI). Male Sprague-Dawley rats were subjected to moderate lateral fluid percussion (LFP) brain injury (n = 40) or sham operation (n = 6). Thereafter, the injured and sham/EE + MEOS and EE only groups were placed into a complex EE consisting of tunnel-connected wide-bodied cages with various beddings, inclining platforms, and toys. Along with group living and environmental complexity, injured and sham/EE + MEOS animals were additionally exposed to a standardized paradigm of multimodal stimulation including auditory, visual, olfactory, and motor stimuli. In contrast, injured and sham/SH groups were housed individually without stimulation. A standardized composite neuroscore (NS) test was used to assess acute post-traumatic neuromotor deficits (24 h after injury) and recovery on days 7 and 15; recovery of cognitive function was assessed on days 11-15 using the Barnes maze. Neuromotor impairment was comparable in all injured animals at 24 h post-injury, but brain-injured EE + MEOS rats performed significantly better than both brain-injured SH and EE groups when tested on post-injury days 7 and 15 (p = 0.004). Similarly, latencies to locate the hidden box under the Barnes maze platform were significantly shortened in EE + MEOS animals at day 15 (p = 0.003). These results indicate that the reversal of neuromotor and cognitive dysfunction after TBI can be substantially enhanced when MEOS is added to EE.	Univ Cologne, Fac Med, Biochem & Expt Abt, D-51109 Cologne, Germany; Univ Cologne, Neurochirurg Klin, D-5000 Cologne, Germany; Klinikum Koln Merheim, Neurol Klin, Cologne, Germany; Univ Cologne, Inst Anat 1, D-5000 Cologne, Germany; Univ Penn, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA	Maegele, M (corresponding author), Univ Cologne, Fac Med, Biochem & Expt Div, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de		Sauerland, Stefan/0000-0003-1048-796X			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Belayev A, 2003, BRAIN RES, V964, P121, DOI 10.1016/S0006-8993(02)04089-1; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRENNER E, 1983, NEUROSCI LETT, V42, P13, DOI 10.1016/0304-3940(83)90414-7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Czeh B, 1998, HIPPOCAMPUS, V8, P647, DOI 10.1002/(SICI)1098-1063(1998)8:6<647::AID-HIPO7>3.3.CO;2-C; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FERCHMIN PA, 1970, BRAIN RES, V20, P49, DOI 10.1016/0006-8993(70)90153-8; FERCHMIN PA, 1986, DEV PSYCHOBIOL, V19, P511, DOI 10.1002/dev.420190604; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Galani R, 1997, NEUROBIOL LEARN MEM, V67, P43, DOI 10.1006/nlme.1996.3745; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GONZALEZLIMA F, 1994, DEV PSYCHOBIOL, V27, P343, DOI 10.1002/dev.420270603; Greenough W. T., 1992, Brain Dysfunction, V5, P129; Gruner ML, 2000, BRAIN INJURY, V14, P585; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; INGLIS FM, 1995, NEUROSCIENCE, V66, P81, DOI 10.1016/0306-4522(94)00578-S; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LILJEQUIST R, 1993, BEHAV BRAIN RES, V56, P107, DOI 10.1016/0166-4328(93)90027-N; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAEGELE M, 2002, LANGENBECK ARCH SURG, V387, P266; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOHAMMED AK, 1986, BRAIN RES, V398, P6, DOI 10.1016/0006-8993(86)91243-6; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PAYLOR R, 1992, BEHAV BRAIN RES, V52, P49, DOI 10.1016/S0166-4328(05)80324-9; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1996, J NEUROSCI, V16, P1083; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; ROSENZWEIG M R, 1969, Developmental Psychobiology, V2, P87, DOI 10.1002/dev.420020208; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Sosin DM, 1996, BRAIN INJURY, V10, P47; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Young D, 1999, NAT MED, V5, P448	91	44	46	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					772	782		10.1089/neu.2005.22.772			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800005	16004580				2021-06-18	
J	Makoroff, KL; Cecil, LM; Care, M; Ball, WS				Makoroff, KL; Cecil, LM; Care, M; Ball, WS			Elevated lactate as an early marker of brain injury in inflicted traumatic brain injury	PEDIATRIC RADIOLOGY			English	Article						inflicted traumatic brain injury; magnetic resonance spectroscopy; lactate; outcomes	MAGNETIC-RESONANCE SPECTROSCOPY; HEAD; INFANTS; DAMAGE	Background: Traumatic brain injury is a major cause of disability and death in the pediatric population. The metabolic and neurochemical abnormalities that underlie traumatic brain injury remain poorly understood, but hypoxia-ischemic injury might play an important role. Objective: This study evaluated children with inflicted traumatic brain injury using magnetic resonance spectroscopy (MRS). We postulated that children with hypoxic-ischemic injury indicated by elevated lactate in the acute phase of injury will have worse early neurological status and short-term clinical outcomes than those without lactate upon MRS. Materials and methods: This prospective study employed proton MRS to sample bilaterally the frontal lobes and the parasagittal cortex within the parietal and occipital lobes of 11 patients with inflicted traumatic brain injury who were undergoing a clinical MRI examination. Patients' measured clinical course while hospitalized included initial neurological evaluation, presence of seizure activity, need for admission to the pediatric intensive care unit (PICU), number of days hospitalized, presence of retinal hemorrhages and presence of bone fractures. Measurement of outcome was determined using the Pediatric Overall Performance Category Scale (POPCS; 1=good performance; 6=death). Results: Four children demonstrated elevated lactate and diminished N-acetyl aspartate (a neuronal marker) within several regions, indicating global ischemic injury (lactate-positive global group). These four children all had seizure activity and abnormal initial neurological examinations and required admission to the PICU. The mean POPCS for this group was 3.25. In four other children, lactate was detected within at least one region, indicating a focal ischemic injury (lactate-positive focal group); two of these children had seizure activity, and two had an abnormal initial neurological examination. The mean POPCS score was 1.5 for this group. The remaining three children had no evidence of lactate upon MRS (lactate-negative group). These children did not have seizure activity, did not require admission to the PICU, nor did they have initial abnormal neurological examinations. The mean POPCS score was 1.3 for this group. Summary: Patients with inflicted traumatic brain injury and evidence of hypoxic-ischemic injury as indicated by elevated lactate on MRS tend to have worse early neurological status and early outcome scores. Lactate levels as sampled by MRS might predict early clinical outcome in inflicted traumatic brain injury.	Univ Cincinnati, Coll Med, Dept Pediat,Cincinnati Childrens Hosp, Mayerson Ctr Safe & Healthy Children, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Radiol, Imaging Res Ctr,Cincinnati Childrens Hosp Med Ct, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Imaging Res Ctr,Cincinnati Childrens Hosp Med Ct, Cincinnati, OH 45229 USA	Makoroff, KL (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat,Cincinnati Childrens Hosp, Mayerson Ctr Safe & Healthy Children, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kathi.Makoroff@cchmc.org		Cecil, Kim/0000-0001-8233-5485			Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Cecil K M, 2001, Top Magn Reson Imaging, V12, P435, DOI 10.1097/00002142-200112000-00005; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kadri Munaf, 2003, J Perinatol, V23, P181, DOI 10.1038/sj.jp.7210913; LANFERMANN H, 1995, RADIOLOGY, V196, P203, DOI 10.1148/radiology.196.1.7784568; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; WEBB PG, 1994, MAGNET RESON MED, V31, P365, DOI 10.1002/mrm.1910310404	15	44	45	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	JUL	2005	35	7					668	676		10.1007/s00247-005-1441-7			9	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	935SA	WOS:000229802500003	15830194				2021-06-18	
J	McEwen, ML; Springer, JE				McEwen, ML; Springer, JE			A mapping study of caspase-3 activation following acute spinal cord contusion in rats	JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY			English	Article						apoptosis; contusion; myelin; secondary injury; spinal cord injury; central nervous system trauma	TRAUMATIC BRAIN-INJURY; CELL-DEATH; OLIGODENDROCYTE PROGENITORS; INFLAMMATORY RESPONSE; MORPHOLOGICAL-CHANGES; APOPTOTIC CELLS; ENDONUCLEASE-G; EXPRESSION; SURVIVAL; PROTEIN	Spinal cord injury (SCI) initiates a cascade of biochemical changes that results in necrotic and apoptotic cell death. There is evidence that caspase-3 activation and apoptotic cell death occur within hours after SCI. However, the time course and cellular localization of activated caspase-3 has not been examined. Such information is essential because caspase-3-independent apoptotic pathways do exist. In this experiment, we describe the distribution of and cell types containing activated caspase-3 at 4 hr, 1 day, 2 days, 4 days, and 8 days following SCI in rats. Numerous caspase-3-positive cells were observed at 4 hr and 1 day postinjury and colocalized most often with CC1, a marker for oligodendroglia. Both markers disappeared near the injury epicenter over the next several days. Activated caspase-3 was again present in the injured spinal cord on postoperative day 8, which coincided with a reemergence of CC1-positive cells. Many of these CC1-positive cells again colocalized activated caspase-3. NeuN-positive neurons of the dorsal horn were occasionally immunopositive for activated caspase-3 at early time points. OX42-positive microglia/macrophages rarely contained activated caspase-3. The results indicate a biphasic pattern of caspase-3 activation during the first 8 days postinjury, suggesting that at least two mechanisms activate caspase-3 following SCI. This time-course study provides a framework for investigating and understanding the different signaling events contributing to this biphasic pattern of caspase-3 activation.	Univ Kentucky, Med Ctr, Dept Phys Med & Rehabil, Cardinal Hill Rehabil Hosp, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Phys Med & Rehabil, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	McEwen, ML (corresponding author), Univ Kentucky, Med Ctr, Dept Phys Med & Rehabil, Cardinal Hill Rehabil Hosp, 800 Rose St,MN 225, Lexington, KY 40536 USA.	mlmcew2@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046380, R01NS040015] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 00242] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40015, NS 46380] Funding Source: Medline		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bhat RV, 1996, GLIA, V17, P169; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Frei E, 2000, EXP NEUROL, V163, P373, DOI 10.1006/exnr.2000.7379; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Hentze H, 2001, BIOCHEM BIOPH RES CO, V283, P1111, DOI 10.1006/bbrc.2001.4918; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XZ, 1997, J NEUROSCI, V17, P5395; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Nicotera P, 2000, BRAIN PATHOL, V10, P276, DOI 10.1111/j.1750-3639.2000.tb00261.x; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Noyan-Ashraf MH, 2005, GLIA, V49, P588, DOI 10.1002/glia.20140; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Racke MM, 2002, J NEUROCHEM, V80, P1039, DOI 10.1046/j.0022-3042.2002.00787.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schwab ME, 1996, PHYSIOL REV, V76, P319; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	46	44	45	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-1554	1551-5044		J HISTOCHEM CYTOCHEM	J. Histochem. Cytochem.	JUL	2005	53	7					809	819		10.1369/jhc.4A6467.2005			11	Cell Biology	Cell Biology	940OW	WOS:000230154800002	15995139	Bronze			2021-06-18	
J	Sherer, M; Hart, T; Whyte, J; Nick, TG; Yablon, SA				Sherer, M; Hart, T; Whyte, J; Nick, TG; Yablon, SA			Neuroanatomic basis of impaired self-awareness after traumatic brain injury - Findings from early computed tomography	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anosognosia; CT scan; impaired self-awareness; neuroanatomic; traumatic brain injury	DIFFUSE AXONAL INJURY; HEAD-INJURY; MILD; CONSCIOUSNESS; LESIONS	Background: Impaired self-awareness (ISA) is common among patients with severe traumatic brain injury (TBI) and contributes to poorer functional outcome. There is keen interest in improving the understanding of this disorder as the neuroanatomic substrate of posttraumatic ISA is poorly understood. Objective: Determine whether (1) greater number of brain lesions, (2) greater Volume of right hemisphere lesions, or (3) greater volume of frontal lesions is associated with greater levels of ISA after TBI. Design: Prospective, observational study. Participants: Ninety-one TBI admissions to one of 2 National Institute on Disability and Rehabilitation Research TBI Model System (TBIMS) programs. Subjects met TBIMS inclusion criteria plus (1) resolution of posttraumatic amnesia (PTA) prior to rehabilitation discharge and (2) initial postinjury computerized tomography (CT) scan available as a hard copy and as an electronic file. Methods: CT scan lesions outlined by a board-certified neuroradiologist were measured using NIH Image, and resulting calculated lesion volumes/scan variables compared against demographic characteristics, TBI severity variables, and ISA variables measured by the Awareness Questionnaire (AQ) at the time of PTA resolution. Results: Most subjects (78%) had at least 1 lesion on emergent CT, and contusion volumes varied in all regions of interest. Patients rated their functioning as more intact on the AQ than ratings of treating clinicians, consistent with ISA. Greater injury severity was associated with a greater degree of ISA. Multivariable linear regression revealed that, after adjustment for other predictors, the number of brain lesions was predictive of degree of ISA. Right hemisphere contusion or frontal lobe contusion volumes, however, were not predictive of degree of ISA. Conclusions: ISA was significantly associated with the number, but not with location or volume of focal lesions early after TBI. Posttraumatic ISA may reflect disruption in the integrated operation of broadly distributed neural networks, with lesion burden in any specific region being less relevant than disruption across multiple regions. Further imaging research is warranted to confirm these findings and to provide insight into the distributed networks required for-self-awareness.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Ctr Med, Jackson, MS 39216 USA; Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; Cincinnati Childrens Hosp, Ctr Med, Ctr Epidemiol & Biostat, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org		Whyte, John/0000-0002-4381-1474			Anton G., 1893, Z HEILKUNDE, P313; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babinski J., 1914, REV NEUROL-FRANCE, V27, P845; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; HEILMAN KM, 1998, CLIN NEUROLOGY, V2, P1; JACKSON JOHN HUGHLINGS, 1876, ROYAL LONDON OPHTHAL, V8, P434; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kjaer TW, 2002, NEUROIMAGE, V17, P1080, DOI 10.1006/nimg.2002.1230; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1993, HEAD INJURY, P525; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam M., 2000, PRINCIPLES BEHAV COG; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; von Monakow C., 1885, ARCH PSYCHIAT NERVEN, V16, P151, DOI DOI 10.1007/BF02227304; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Weinstein EA, 1955, DENIAL ILLNESS; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016	34	44	44	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					287	300		10.1097/00001199-200507000-00002			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800002	16030437				2021-06-18	
J	Wahlstrom, MR; Olivecrona, M; Koskinen, LOD; Rydenhag, B; Naredi, S				Wahlstrom, MR; Olivecrona, M; Koskinen, LOD; Rydenhag, B; Naredi, S			Severe traumatic brain injury in pediatric patients: treatment and outcome using an intracranial pressure targeted therapy - the Lund concept	INTENSIVE CARE MEDICINE			English	Article						severe traumatic brain injury; children; intracranial pressure; outcome; intracranial pressure targeted therapy	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; CHILDREN; MANAGEMENT; SURVIVAL; SCALE; PERMEABILITY; PRINCIPLES; MUSCLE; LEVEL	Objective: This study evaluated the outcome of treatment according to the Lund concept in children with severe traumatic brain injury and investigated whether the preset goals of the protocol were achieved. Design and setting: A two-center retrospective study in neurointensive care units at university hospitals. Patients: Forty-one children with severe traumatic brain injury from blunt trauma and arriving at hospital within 24 h after injury. Median age was 8.8 years ( range 3 months - 14.2 years), Glasgow Coma Scale 7 ( 3 - 8), and Injury Severity Score 25 ( 16 - 75). All children had pathological findings on initial computed tomography. All developed intracranial hypertension, and survivors required intensive care longer than 72 h. Interventions: Treatment according to the principles of the Lund concept. Measurements and results: Neurosurgery was required in 46% of the children. Survival rate was 93% and favorable outcome ( Glasgow Outcome Score 4 or 5) was 80% at long-term follow-up ( median 12 months postinjury, range 2.5 - 26). The preset physiological and biochemical goals were achieved in over 90% of observations. Conclusions: Treating pediatric patients with severe traumatic brain injury, according to the Lund concept, results in a favorable outcome when the protocol is followed.	Umea Univ Hosp, Dept Anesthesia & Intens Care, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Neurosurg, S-90185 Umea, Sweden; Sahlgrens Univ Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Anesthesia & Intens Care, S-41345 Gothenburg, Sweden	Wahlstrom, MR (corresponding author), Umea Univ Hosp, Dept Anesthesia & Intens Care, S-90185 Umea, Sweden.	marie.rodling@anestesi.umu.se	Koskinen, Lars-Owe/AAQ-8957-2020	Koskinen, Lars-Owe/0000-0003-3528-8502; Naredi, Silvana/0000-0002-4409-6089			ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P567, DOI 10.1007/BF01705723; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney NA, 2003, CRIT CARE MED, V31, pS417, DOI 10.1097/00003246-200306006-00001; Cassidy LD, 2003, J PEDIATR SURG, V38, P482, DOI 10.1053/jpsu.2003.50084; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kongstad L, 1999, ACTA PHYSIOL SCAND, V165, P369; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; REILLY PL, 1988, CHILD NERV SYST, V4, P30; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Steven JM, 1996, SMITHS ANESTHESIA IN, P229; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TODD NV, 1990, ACTA NEUROCHIR WIEN, V51, pS296; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011	41	44	47	1	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2005	31	6					832	839		10.1007/s00134-005-2632-2			8	Critical Care Medicine	General & Internal Medicine	932UC	WOS:000229578000013	15838678				2021-06-18	
J	Coughlan, T; Gibson, C; Murphy, S				Coughlan, T; Gibson, C; Murphy, S			Modulatory effects of progesterone on inducible nitric oxide synthase expression in vivo and in vitro	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; inducible nitric oxide synthase; neuroprotection; progesterone; progesterone response element; transcription	HORMONE REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; BREAST-CANCER CELLS; INTERFERON-GAMMA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; BACTERIAL LIPOPOLYSACCHARIDE; MURINE MACROPHAGES; RECEPTOR ISOFORMS	Nitric oxide (NO) is produced in the CNS following injury-induced expression of inducible nitric oxide synthase (iNOS), yet its role as protective or damaging is unclear. Previous studies investigating the therapeutic potential of female sex steroids in stroke and trauma suggest that NO from this source is harmful, since oestradiol and progesterone decreased the level of iNOS expression in vitro and improved neurological outcome. We investigated the effects of progesterone on stroke-induced expression of iNOS in mice, as well as cytokine-induced expression of iNOS and its transcriptional activators in cells relevant to injury. We observed a significant reduction in stroke-induced iNOS transcript in progesterone-treated mice and in cultured macrophages. In contrast, progesterone significantly amplifed cytokine-induced iNOS mRNA in cultured primary astrocytes, although the expression of protein was decreased. We sequenced upstream of the 1.5 kb reported iNOS promoter region and identified a potential progesterone response element (PRE). Astrocytes transiently transfected with iNOS promoter/CAT reporter gene constructs containing the PRE displayed a significant increase in induction of CAT expression after progesterone treatment, and this was diminished in cells transfected with a construct containing a disrupted PRE. These observations suggest the involvement of iNOS in the neuroprotective effects of progesterone.	Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England	Murphy, S (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Clifton Blvd, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029226] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29226] Funding Source: Medline		Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Bechtel MK, 2001, GYNECOL ONCOL, V82, P127, DOI 10.1021/gyno.2001.6221; Boutin H, 2001, J NEUROSCI, V21, P5528; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bushnell CD, 2001, NEUROLOGY, V56, P1304, DOI 10.1212/WNL.56.10.1304; Camacho-Arroyo I, 1998, NEUROREPORT, V9, P3993, DOI 10.1097/00001756-199812210-00001; Cheng KW, 2001, MOL ENDOCRINOL, V15, P2078, DOI 10.1210/me.15.12.2078; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Garcia-Duran M, 1999, CIRC RES, V85, P1020; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; GIBSON CL, 2004, 34372004 SOC NEUR; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Hayashi T, 1998, J CARDIOVASC PHARM, V31, P292, DOI 10.1097/00005344-199802000-00016; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kassel O, 1998, MOL PHARMACOL, V54, P1073; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kauser K, 1998, BRIT J PHARMACOL, V123, P1089, DOI 10.1038/sj.bjp.0701715; Kohmura Y, 2000, INT J IMMUNOPHARMACO, V22, P765, DOI 10.1016/S0192-0561(00)00038-2; Kouretas D, 1999, CELL MOL BIOL, V45, P219; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Lieb K, 2003, NEUROCHEM INT, V42, P131, DOI 10.1016/S0197-0186(02)00076-1; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Loihl AK, 1999, J BIOL CHEM, V274, P8844, DOI 10.1074/jbc.274.13.8844; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LUSS H, 1994, BIOCHEM BIOPH RES CO, V204, P635, DOI 10.1006/bbrc.1994.2506; Miller L, 1996, J LEUKOCYTE BIOL, V59, P442; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Neugarten J, 1997, J AM SOC NEPHROL, V8, P1240; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Perusquia M, 1996, GEN PHARMACOL, V27, P181, DOI 10.1016/0306-3623(95)00091-7; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rowan BG, 2000, STEROIDS, V65, P545, DOI 10.1016/S0039-128X(00)00112-4; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; Weisz A, 1996, BIOCHEM J, V316, P209, DOI 10.1042/bj3160209; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xu R, 1999, LIFE SCI, V64, P2451, DOI 10.1016/S0024-3205(99)00202-7; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yamamoto T, 2001, MOL CELL ENDOCRINOL, V182, P215, DOI 10.1016/S0303-7207(01)00580-9; Zancan V, 1999, ENDOCRINOLOGY, V140, P2004, DOI 10.1210/en.140.5.2004; Zemojtel T, 2004, TRENDS BIOCHEM SCI, V29, P224, DOI 10.1016/j.tibs.2004.03.005; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	71	44	47	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2005	93	4					932	942		10.1111/j.1471-4159.2005.03068.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	920WB	WOS:000228721200015	15857396				2021-06-18	
J	Zebrack, M; Kadish, H; Nelson, D				Zebrack, M; Kadish, H; Nelson, D			The pediatric hybrid observation unit: An analysis of 6477 consecutive patient encounters	PEDIATRICS			English	Article						emergency department; emergency medicine; hospitalization; pediatric; observation unit	DEPARTMENT OBSERVATION UNIT; OBSERVATION MEDICINE; OBSERVATION WARD; SHORT-STAY; EMERGENCY; MANAGEMENT; DESIGN; CARE	Objectives. Pediatric observation units (OUs) are becoming more common in hospitals throughout the United States, providing physicians with a new disposition option for children who are judged to be too ill for home management. Some OUs function as "hybrid" units, serving both acutely ill and injured observation patients as well as scheduled elective procedure patients. How best to utilize this new resource is not yet defined. We studied the utilization of our pediatric hybrid OU during the first 2 years of operation to determine ( 1) the spectrum and frequency of diagnoses treated, ( 2) diagnoses and procedures most ( and least) likely to attain discharge successfully within 24 hours, and ( 3) whether age was associated with inability to be discharged from the OU within 24 hours. Methods. The study setting was a 20-bed hybrid OU located in a pediatric tertiary care hospital in Salt Lake City, Utah. The records of all patients admitted during the first 2 years of OU operation, from August 1999 through July 2001, were examined retrospectively. Results. There were 6477 OU admissions: 4189 (65%) for acutely ill and injured observation patients and 2288 (35%) for scheduled elective procedure patients. For the observation patients, median age was 2.5 years and median length of stay was 15.5 hours. Common admission diagnoses in these patients included enteritis/dehydration (n = 722), orthopedic injuries ( n = 362), asthma ( n = 327), closed head injury ( n = 289), urgent transfusion/ infusion ( n = 221), bronchiolitis ( n = 212), croup ( n = 207), abdominal pain ( n = 199), cellulitis ( n = 177), and nonfebrile seizure ( n = 98). Overall, 15% of observation patients required subsequent inpatient admission for > 24-hour stay. Observation diagnoses that were most likely to require inpatient admission were hematochezia (60%), viral pneumonia (46%), and bronchiolitis (43%). We demonstrated successful OU discharge rates (> 85%) for several diagnoses not commonly reported: neonatal hyperbilirubinemia, aseptic meningitis, and diabetic ketoacidosis in the patient with known diabetes. Among the scheduled elective procedure patients, median age was 5.0 years and median length of stay was 3.0 hours. Only 1% of these patients required subsequent inpatient admission. In both populations, age <= 30 days was associated with increased need for inpatient admission, with a relative risk of 1.9 (95% confidence interval: 1.4 - 2.6) among the observation patients and 13.9 (95% confidence interval: 3.0 - 65.0) among scheduled procedure patients. Conclusion. Our pediatric hybrid OU played an important role in the treatment of children who were admitted for observation as a result of acute illness or injury, as well as children who required scheduled procedures. For both patient types, we identified diagnoses that are most and least likely to attain successful discharge within 24 hours. The majority (85%) of observation patients were discharged successfully within 24 hours. Successful discharge rates for diagnoses that are not commonly managed in other pediatric OUs were reported. We identified certain age groups within selected diagnoses that may not have been appropriate for the OU.	Univ Utah, Primary Childrens Med Ctr, Div Pediat Emergency Med, Salt Lake City, UT 84113 USA	Zebrack, M (corresponding author), Univ Utah, Primary Childrens Med Ctr, Div Pediat Emergency Med, 100 N Med Dr, Salt Lake City, UT 84113 USA.	michelle.zebrack@hsc.utah.edu					*ACEP PRACT MAN CO, 1994, MAN OBS UN; BOBZIEN WF, 1979, JACEP-J AM COLL EMER, V8, P508, DOI 10.1016/S0361-1124(79)80296-8; Browne GJ, 2000, PEDIATR EMERG CARE, V16, P223, DOI 10.1097/00006565-200008000-00001; DAWSON KP, 1991, NEW ZEAL MED J, V104, P185; DeCoster C, 1996, MANITOBA CTR HLTH PO; FARRELL RG, 1982, ANN EMERG MED, V11, P353, DOI 10.1016/S0196-0644(82)80360-0; HENNEMAN PL, 1989, ANN EMERG MED, V18, P647, DOI 10.1016/S0196-0644(89)80519-0; *HLTH CAR FIN ADM, MED HOSP MAN TRANSM; Holsti M, 2003, ANN EMERG MED, V42, pS85; Johnson ME, 2002, AEROSPACE AM, V40, P76; KLEIN B L, 1991, Emergency Medicine Clinics of North America, V9, P669; Lateef F, 2000, AM J EMERG MED, V18, P629, DOI 10.1053/ajem.2000.9291; Mace SE, 2003, AM J EMERG MED, V21, P529, DOI 10.1016/j.ajem.2003.08.012; Mace SE, 2001, EMERG MED CLIN N AM, V19, P239, DOI 10.1016/S0733-8627(05)70178-4; MACE SE, 1999, OBS MED RED COSTS UN; MALLORY MD, 2003, PED AC SOC ANN M MAY; Miescier MJ, 2003, ANN EMERG MED, V42, pS107; NUMA A, 1991, MED J AUSTRALIA, V155, P395, DOI 10.5694/j.1326-5377.1991.tb101318.x; Rentz AC, 2004, PEDIATR EMERG CARE, V20, P430, DOI 10.1097/01.pec.0000132214.19858.71; Ross MA, 2001, EMERG MED CLIN N AM, V19, P1, DOI 10.1016/S0733-8627(05)70165-6; Ross MA, 2001, ANN EMERG MED, V37, P267, DOI 10.1067/mem.2001.111519; Rydman RJ, 1998, MED CARE, V36, P599, DOI 10.1097/00005650-199804000-00015; Scribano PV, 2001, PEDIATR EMERG CARE, V17, P321, DOI 10.1097/00006565-200110000-00001; Wiley JF, 1998, PEDIATR EMERG CARE, V14, P444, DOI 10.1097/00006565-199812000-00019; Wiley JF, 2001, CLIN PEDIAT EMERG ME, V2, P247; Zebrack MM, 2003, ANN EMERG MED, V42, pS87; ZUN L, 1990, Journal of Emergency Medicine, V8, P485, DOI 10.1016/0736-4679(90)90180-4	27	44	44	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAY	2005	115	5					E535	E542		10.1542/peds.2004-0391			8	Pediatrics	Pediatrics	922JM	WOS:000228833500005	15867018	Bronze			2021-06-18	
J	Lehtonen, S; Stringer, AY; Millis, S; Boake, C; Englander, J; Hart, T; High, W; Macciocchi, S; Meythaler, J; Novack, T; Whyte, J				Lehtonen, S; Stringer, AY; Millis, S; Boake, C; Englander, J; Hart, T; High, W; Macciocchi, S; Meythaler, J; Novack, T; Whyte, J			Neuropsychological outcome and community re-integration following traumatic brain injury: The impact of frontal and non-frontal lesions	BRAIN INJURY			English	Article						TBI; lesion location; neuropsychological outcome; community re-integration	CLOSED-HEAD-INJURY; SORTING TEST-PERFORMANCE; DIFFUSE AXONAL INJURY; PRACTICAL SCALE; FOCAL LESIONS; LOBE DAMAGE; CT; SPECT; MR; SEVERITY	Primary objective: To examine the relationship between cortical lesion location and brain injury outcome. It was hypothesized that focal frontal lesions after traumatic brain injury (TBI) would result in decreased executive and memory functioning and poor community participation outcome. Research design: Three quasi-experimental, prospective studies employed a total of 643 patients with focal frontal, frontotemporal, non-frontal or no lesions in CT scans. Methods and procedures: CT scan analysis, neuropsychological assessment, the Neurobehavioural Functioning Inventory (NFI), the Community Integration Questionnaire (CIQ). Main results: In study 1, frontal and fronto-temporal groups performed worse in executive functioning and better in constructional ability. Study 2 found no differences in neuropsychological and community re-integration measures at 1-year follow-up. Study 3 found comparable neuropsychological test score improvement across groups over 1 year. Conclusions: Results are consistent with previous findings and document the potential for test score improvement with rehabilitation and suggest that lesion location needs to be considered when individual rehabilitation plans are being implemented in the post-acute stage of TBI.	Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Brain Injury Res Ctr, Houston, TX USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Shepherd Ctr, Atlanta, GA USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA	Stringer, AY (corresponding author), Emory Univ, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.	astring@emory.edu		Whyte, John/0000-0002-4381-1474			ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Benton A, 1989, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; De Renzi E., 1982, DISORDERS SPACE EXPL; Delis DC, 2001, DELISKAPLAN EXECUTIV; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; FORMISANO R, 1991, ACTA NEUROCHIR, V109, P1, DOI 10.1007/BF01405688; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; ICHISE M, 1994, J NUCL MED, V35, P217; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P171; LUCAS JA, 1998, CLIN NEUROPSYCHOLOGY, P243; Matthews C, 1964, INSTRUCTION MANUAL A; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Millis S R, 1994, Int J Neurosci, V79, P165; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; MITTL RL, 2000, AM J NEURORADIOL, V15, P808; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; PRAYER L, 1993, ACTA RADIOL, V34, P593; Raininko R K, 1986, Acta Radiol Suppl, V369, P374; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROSENTHAL M, 1993, J HEAD TRAUMA REHABI, V8; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Stringer A. Y., 1996, GUIDE ADULT NEUROPSY; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wechsler, 1981, WAIS R MANUAL; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILSON J T L, 1990, Brain Injury, V4, P349	49	44	47	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					239	256		10.1080/0269905040004310			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400002	15832870				2021-06-18	
J	Blackman, JA; Worley, G; Strittmatter, WJ				Blackman, JA; Worley, G; Strittmatter, WJ			Apolipoprotein E and brain injury: implications for children	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							E-DEFICIENT MICE; INCREASED NEURONAL DAMAGE; GLOBAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; EPSILON 4 ALLELE; E GENOTYPE; ALZHEIMERS-DISEASE; APOE GENOTYPE; APOE-EPSILON-4 ALLELE		Univ Virginia, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, Charlottesville, VA 22903 USA; Duke Univ, Ctr Med, Dept Neurol, Durham, NC USA	Blackman, JA (corresponding author), Univ Virginia, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, 2270 Ivy Rd, Charlottesville, VA 22903 USA.	jab5u@virginia.edu					ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Bartres-Faz D, 2002, J NEUROPSYCH CLIN N, V14, P80, DOI 10.1176/appi.neuropsych.14.1.80; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Berr C, 1996, NEUROSCI LETT, V218, P9, DOI 10.1016/0304-3940(96)13059-7; Blackman JA, 2004, DEV MED CHILD N S100, V46, P26; Bondi MW, 1995, NEUROLOGY, V45, P2203, DOI 10.1212/WNL.45.12.2203; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Buttini M, 1999, J NEUROSCI, V19, P4867; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DelBo R, 1997, J NEUROL SCI, V145, P87, DOI 10.1016/S0022-510X(96)00249-3; DeMattos RB, 2001, J LIPID RES, V42, P976; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Fernandez T, 1999, AM J MED GENET, V88, P211, DOI 10.1002/(SICI)1096-8628(19990416)88:2<211::AID-AJMG20>3.0.CO;2-M; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HANLON CS, 1995, ATHEROSCLEROSIS, V112, P85, DOI 10.1016/0021-9150(94)05402-5; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kerr ME, 1999, ADV EXP MED BIOL, V471, P117; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Masullo C, 2001, NEUROSCI LETT, V303, P87, DOI 10.1016/S0304-3940(01)01673-1; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Morrison KE, 1999, NEUROMUSCULAR DISORD, V9, P372, DOI 10.1016/S0960-8966(99)00036-X; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMEARA ES, 1997, AM J EPIDEMIOL, V8, P707; ORIA RB, 2004, IN PRESS PEDIAT RES; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Raiford KL, 2004, AM J MED GENET B, V125B, P57, DOI 10.1002/ajmg.b.20104; Saito Y, 2002, ANN NEUROL, V52, P351, DOI 10.1002/ana.10266; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Strittmatter WJ, 2002, CURR OPIN LIPIDOL, V13, P119, DOI 10.1097/00041433-200204000-00002; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Ti LK, 2003, J THORAC CARDIOV SUR, V125, P211, DOI 10.1067/mtc.2003.123; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9	79	44	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JAN	2005	47	1					64	70		10.1017/S0012162205000113			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	891UA	WOS:000226605300011	15686292				2021-06-18	
J	Bonny, C; Borsello, T; Zine, A				Bonny, C; Borsello, T; Zine, A			Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases	REVIEWS IN THE NEUROSCIENCES			English	Article						c-Jun N-terminal kinase (JNK); apoptosis; signaling pathways; ischemic damage; hearing loss; JNK inhibition; D-JNKI-1 peptide	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; STRESS-INDUCED APOPTOSIS; PEPTIDE INHIBITOR; SIGNALING PATHWAY; INDUCED COCHLEAR; CEP-1347 KT7515; NOISE EXPOSURE; NEURONAL DEATH; HAIR-CELLS	The c-Jun N-terminal kinases (JNKs) are members of the family of mitogen activated protein kinases (MAPKs). While the functions of the JNKs under physiological conditions are diverse and not completely understood, there is increasing evidence that JNKs are potent effectors of apoptosis in both the brain and the mammalian inner ear following a variety of injuries. The activation of the inducible transcription factor c-Jun by N-terminal phosphorylation is a central event in JNK-mediated neural and inner ear hair cell death. A cell permeable peptide designed specifically to inhibit JNK signaling has proven successful in in vivo models of both neuronal degeneration following cerebral ischemia and auditory hair cell degeneration following exposure to either acoustic trauma or a toxic level of an aminoglycoside antibiotic. Here we discuss the evidence supporting the application of JNK inhibitors to prevent cellular degeneration in several central nervous system (CNS) and peripheral nervous system (PNS) diseases with an emphasis on traumatic ischemic damage to the CNS and acquired deafness in the PNS receptors.	Univ Montpellier I, INSERM, U583, Inst Neurosci Montpellier, F-34091 Montpellier, France; Univ Lausanne, DBCM, Lausanne, Switzerland; Ist Ric Farmacol Mario Negri, Biol Neurodegenerat Disorders Lab, Milan, Italy; Univ Lausanne, Div Med Genet, Lausanne, Switzerland	Zine, A (corresponding author), Univ Montpellier I, INSERM, U583, Inst Neurosci Montpellier, BP 74103, F-34091 Montpellier, France.	zine@montp.inserm.fr	Borsello, Tiziana/ABG-7759-2020; Borsello, Tiziana/J-8232-2016	Borsello, Tiziana/0000-0002-9729-7642			Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Behrens A, 1999, NAT GENET, V21, P326; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Bodmer D, 2002, LARYNGOSCOPE, V112, P2057, DOI 10.1097/00005537-200211000-00028; Borsello T, 2004, TRENDS MOL MED, V10, P239, DOI 10.1016/j.molmed.2004.03.008; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; Carboni S, 2004, J PHARMACOL EXP THER, V310, P25, DOI 10.1124/jpet.103.064246; Conlon BJ, 1999, HEARING RES, V128, P40, DOI 10.1016/S0378-5955(98)00195-6; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FORGE A, 1985, HEARING RES, V19, P171, DOI 10.1016/0378-5955(85)90121-2; Forge A, 2000, HEARING RES, V139, P97, DOI 10.1016/S0378-5955(99)00177-X; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALAZONETIS D, 1998, CELL, V55, P917; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Hu BH, 2002, HEARING RES, V166, P62, DOI 10.1016/S0378-5955(02)00286-1; Huang T, 2000, INT J DEV NEUROSCI, V18, P259, DOI 10.1016/S0736-5748(99)00094-5; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacono AA, 1998, HEARING RES, V117, P31, DOI 10.1016/S0378-5955(97)00214-1; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Ko HW, 1998, J NEUROCHEM, V71, P1390; Kopke R, 1999, ANN NY ACAD SCI, V884, P171, DOI 10.1111/j.1749-6632.1999.tb08641.x; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lefebvre PP, 2002, AUDIOL NEURO-OTOL, V7, P165, DOI 10.1159/000058304; Legos JJ, 2002, EXPERT OPIN INV DRUG, V11, P603; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lynch ED, 2004, LARYNGOSCOPE, V114, P333, DOI 10.1097/00005537-200402000-00029; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Ogita K, 2000, NEUROREPORT, V11, P859, DOI 10.1097/00001756-200003200-00040; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Priuska EM, 1995, BIOCHEM PHARMACOL, V50, P1749, DOI 10.1016/0006-2952(95)02160-4; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Scarpidis U, 2003, OTOL NEUROTOL, V24, P409, DOI 10.1097/00129492-200305000-00011; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Shizuki K, 2002, NEUROSCI LETT, V320, P73, DOI 10.1016/S0304-3940(02)00059-9; STEINBERG GK, 1995, NEUROBIOL DIS, V2, P109, DOI 10.1006/nbdi.1995.0011; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Vago P, 1998, NEUROREPORT, V9, P431, DOI 10.1097/00001756-199802160-00014; Wang J, 2003, J NEUROSCI, V23, P8596; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yamasoba T, 1998, BRAIN RES, V784, P82, DOI 10.1016/S0006-8993(97)01156-6; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Ylikoski J, 2002, HEARING RES, V163, P71, DOI 10.1016/S0378-5955(01)00380-X; Yoshizumi M, 2004, EXP CELL RES, V292, P1, DOI 10.1016/j.yexcr.2003.08.003; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zivin JA, 1998, MG CLIN NEUROSC, V16, P128	59	44	47	0	4	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.		2005	16	1					57	67					11	Neurosciences	Neurosciences & Neurology	911SO	WOS:000228025200004	15810654				2021-06-18	
J	Laatsch, LK; Thulborn, KR; Krisky, CM; Shobat, DM; Sweeney, JA				Laatsch, LK; Thulborn, KR; Krisky, CM; Shobat, DM; Sweeney, JA			Investigating the neurobiological basis of cognitive rehabilitation therapy with fMRI	BRAIN INJURY			English	Article							WORKING-MEMORY; LANGUAGE LATERALIZATION; ACTIVATION; REPRODUCIBILITY; RECOVERY; MAPS	The neurobiological changes occurring during cognitive rehabilitation therapy (CRT) have yet to be systematically studied. In the present study, functional magnetic resonance imaging ( fMRI) was used to demonstrate brain plasticity in response to CRT (n = 5) following mild traumatic brain injury. Neuropsychological tests and two fMRI activation tasks, a visually guided saccades and a reading comprehension task, were employed pre- and post-CRT. CRT was used to systematically address the identified deficits in visual scanning and language processing. As hypothesized, changes in the pattern and extent of activation within expected neuroanatomical areas occurred post-CRT. Changes in fMRI activation are discussed for each subject and related to changes on neuropsychological measures. This study demonstrates how fMRI can illustrate the neurobiological mechanisms of recovery in individual subjects. The variability in subject responses to CRT supports the notion of tailoring rehabilitation strategies to each subject in order to optimize recovery following brain injury.	Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Ctr Magnet Resonance Res, Chicago, IL USA; Univ Illinois, Coll Med, Ctr Cognit Med, Chicago, IL USA	Laatsch, LK (corresponding author), Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL 60607 USA.	llaatsch@ulc.edu	anand, amit/A-7222-2009; Thulborn, Keith Raymond/D-9183-2015	Thulborn, Keith Raymond/0000-0001-6197-4296			BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BRACY O, 1985, SOFT TOOLS COGNITIVE; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Calvert GA, 2000, BRAIN LANG, V71, P391, DOI 10.1006/brln.1999.2272; Carpenter PA, 1999, J COGNITIVE NEUROSCI, V11, P9, DOI 10.1162/089892999563210; Carpenter PA, 1999, NEUROIMAGE, V10, P216, DOI 10.1006/nimg.1999.0465; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DEROGATIS L, 1983, SCL 90R MANUAL; DIKMAN S, 1999, J INT NEUROPSYCH SOC, V51, P346; Eddy WF, 1996, P COMP STAT, P39; Fernandez G, 2003, NEUROLOGY, V60, P969, DOI 10.1212/01.WNL.0000049934.34209.2E; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GIANUTSOS R, 1984, COGNITIVE REHABILITA; GIANUTSOS R, 1990, QUEST COGNITIVE REHA; GLADSOJO J, 1999, NORMS LETT CATEGORY; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Heaton R.K., 1991, COMPREHENSIVE NORMS; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Jastak S, 1984, WIDE RANGE ACHIEVEME; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kiehl KA, 2003, HUM BRAIN MAPP, V18, P42, DOI 10.1002/hbm.10074; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Lewis R.F., 1995, DIGIT VIGILANCE TEST; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Nybakken GE, 2002, NEURORADIOLOGY, V44, P403, DOI 10.1007/s00234-001-0722-6; PRICE C, 2001, HDB FUNCTIONAL NEURO, P1979; Ramsey NF, 1996, HUM BRAIN MAPP, V4, P113, DOI 10.1002/(SICI)1097-0193(1996)4:2<113::AID-HBM3>3.0.CO;2-6; Rees G, 2000, BRAIN, V123, P1624, DOI 10.1093/brain/123.8.1624; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosen HJ, 2000, NEUROLOGY, V55, P1883, DOI 10.1212/WNL.55.12.1883; Rutten GJM, 2002, BRAIN LANG, V80, P421, DOI 10.1006/brln.2001.2600; Small SL, 1998, BRAIN LANG, V62, P298, DOI 10.1006/brln.1998.1951; Sohlberg M. M., 2001, COGNITIVE REHABILITA; THULBORN K, 2001, CURRENT PROTOCOLS MR, P1979; THULBORN K, 1999, MED RADIOLOGY DIAGNO, P337; Thulborn K R, 1999, Top Magn Reson Imaging, V10, P37, DOI 10.1097/00002142-199902000-00004; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Thulborn KR, 2000, AM J NEURORADIOL, V21, P524; Wechsler D, 1997, WAIS 3 ADM SCORING M; Young D, 1999, NAT MED, V5, P448	51	44	46	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					957	974		10.1080/02699050410001672369			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600001	15370896				2021-06-18	
J	Nathoo, N; Narotam, PK; Agrawal, DK; Connolly, CA; Van Dellen, JR; Barnett, GH; Chetty, R				Nathoo, N; Narotam, PK; Agrawal, DK; Connolly, CA; Van Dellen, JR; Barnett, GH; Chetty, R			Influence of apoptosis on neurological outcome following traumatic cerebral contusion	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral contusion; apoptosis; outcome	PROGRAMMED CELL-DEATH; FATAL HEAD-INJURY; BRAIN-INJURY; NEURONAL APOPTOSIS; MOLECULAR MECHANISMS; CEREBROSPINAL-FLUID; PRACTICAL SCALE; TRANSGENIC MICE; FOCAL ISCHEMIA; BCL-2	Object. Apoptosis has increasingly been implicated in the pathobiology of traumatic brain injury (TBI). The present study was undertaken to confirm the presence of apoptosis in the periischemic zone (PIZ) of traumatic cerebral contusions and to determine the role of apoptosis, if any, in neurological outcome. Methods. Brain tissue harvested at Wentworth Hospital from the PIZ in 29 patients with traumatic supratentorial contusions was compared with brain tissue resected in patients with epilepsy. Immunohistochemical analyses were performed on the tissues to see if they contained the apoptosis-related proteins p53, bcl-2, bax, and caspase-3. The findings were then correlated to demographic, clinical, surgical, neuroimaging, and outcome data. In the PIZ significant increases of bax (18-fold; p < 0.005) and caspase-3 (20-fold; p < 0.005) were recorded, whereas bcl-2 was upregulated in only 14 patients (48.3%; 2.9-fold increase) compared with control tissue. Patients in the bcl-2-positive group exhibited improved outcomes at the 18-month follow-up examination despite an older mean age and lower mean admission Glasgow Coma Scale score (p < 0.03). Caspase-3 immunostaining was increased in those patients who died (Glasgow Outcome Scale [GOS] Score 1, 12 patients) when compared with those who experienced a good outcome (GOS Score 4 or 5, 17 patients) (p < 0.005). Regression analysis identified bcl-2-negative status (p < 0.04, odds ratio [OR] 5.5; 95% confidence interval [CI] 1.1-28.4) and caspase-3-positive status (p < 0.01, OR 1.4, 95% Cl 1.1-1.8) as independent predictors of poor outcome. No immunostaining for p53 was recorded in the TBI specimens. Conclusions. The present findings confirm apoptosis in the PIZ of traumatic cerebral contusions and indicate that this form of cell death can influence neurological outcome following a TBI.	Dept Neurosurg, Durban, South Africa; Wentworth Provincial Hosp, Nelson R Mandela Sch Med, Durban, South Africa; Univ KwaZulu Natal, ZA-4001 Durban, South Africa; Med Res Council S Africa, Div Biostat, Durban, South Africa; Cleveland Clin, Brain Tumor Inst, Cleveland, OH 44106 USA; Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA; Creighton Univ, Med Ctr, Dept Neurosurg, Omaha, NE 68178 USA; W London Neurosci Ctr, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Charing Cross Hosp, London SW7 2AZ, England; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Nathoo, N (corresponding author), Cleveland Clin Fdn, Dept Neurosurg S80, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nathoon@ccf.org		Agrawal, Deepak/0000-0002-5499-0746			BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen J, 1997, J NEUROCHEM, V69, P232; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; GOLD R, 1994, LAB INVEST, V71, P219; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JENNETT B, 1975, LANCET, V1, P480; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Maclennan KA, 1990, THEORY PRACTISE HIST, P437; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MAXWELL WL, 1994, ACTA NEUROCHIR, P465; MIYASHITA T, 1995, CELL, V80, P293; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Patel T, 1996, FASEB J, V10, P587; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; ROBINSON G, 1990, THEORY PRACTICE HIST, P413; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; TEASDALE G, 1974, LANCET, V2, P81; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao JS, 2003, CHINESE MED J-PEKING, V116, P1923; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	38	44	52	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	2					233	240		10.3171/jns.2004.101.2.0233			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	842JQ	WOS:000223000600010	15309913				2021-06-18	
J	Goetz, P; Blamire, A; Rajagopalan, B; Cadoux-Hudson, T; Young, D; Styles, P				Goetz, P; Blamire, A; Rajagopalan, B; Cadoux-Hudson, T; Young, D; Styles, P			Increase in apparent diffusion coefficient in normal appearing white matter following human traumatic brain injury correlates with injury severity	JOURNAL OF NEUROTRAUMA			English	Article						ADC; diffuse axonal injury; diffusion weighted imaging; T1 relaxation; T2 relaxation; traumatic brain injury; white matter	CLOSED-HEAD-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; AMYLOID PRECURSOR PROTEIN; CEREBRAL BLOOD-VOLUME; AXONAL INJURY; WEIGHTED MR; WALLERIAN DEGENERATION; WATER-DIFFUSION; TIME-COURSE; T2-WEIGHTED MRI	Following diffuse traumatic brain injury, there may be persistent functional or psychological deficits despite the presence of normal conventional MR images. Previous experimental animal and human studies have shown diffusion abnormalities following focal brain injury. Our aim was to quantify changes in apparent diffusion coefficient (ADC) and absolute relaxation times of normal appearing white matter (NAWM) in humans following traumatic brain injury. Twenty-three patients admitted with a diagnosis of head injury (nine mild, eight moderate, and six severe) were scanned an average of 7.6 days after injury using a quantitative echo planar imaging acquisition to obtain co-registered T1, T2, and ADC parametric maps. Mean NAWM values were compared with a control group (n = 13). The patient group showed a small but significant increase in ADC in NAWM, with no significant change in T1 or T2 relaxation times. There was a correlation between injury severity and increasing ADC (p = 0.03) but no correlation with either T1 or T2, suggesting that ADC is a sensitive and independent marker of diffuse white matter tissue damage following traumatic insult. None of the patients had a reduced ADC, making ischaemia unlikely in this cohort. Pathophysiological mechanisms that may explain diffusely raised ADC include vasogenic edema, chronic ischemic phenomena, or changes in tissue cytoarchitecture or neurofilament alignment.	John Radcliffe Hosp, MRC Biochem & Clin Magnet Resonance Unit, Oxford 0X3 9DU, England; Radcliffe Infirm, Dept Neurosurg, NHS Trust, Oxford OX2 6HE, England; John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 9DU, England	Goetz, P (corresponding author), John Radcliffe Hosp, MRC Biochem & Clin Magnet Resonance Unit, Oxford 0X3 9DU, England.	pgoetz@bioch.ox.ac.uk	Young, John D/M-9756-2016	Blamire, Andrew/0000-0002-8749-1257; Young, John Duncan/0000-0002-6838-4835			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Anderson AW, 1996, MAGN RESON MED, V35, P162, DOI 10.1002/mrm.1910350206; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Blamire AM, 2000, J NEUROSCI, V20, P8153; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Helenius J, 2002, AM J NEURORADIOL, V23, P194; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.1080/10618600.1996.10474713]; Karibe H, 2000, J NEUROSURG, V92, P58, DOI 10.3171/jns.2000.92.1.0058; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; MURTAGH F, 1983, COMPUT J, V26, P354, DOI 10.1093/comjnl/26.4.354; Naganawa S, 2003, EUR RADIOL, V13, P6, DOI 10.1007/s00330-002-1549-1; NOMURA Y, 1994, AM J NEURORADIOL, V15, P231; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rousseeuw P. J., 1987, ROBUST REGRESSION OU; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sawlani V, 1997, J NEUROL SCI, V146, P103, DOI 10.1016/S0022-510X(96)00299-7; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Sibson NR, 2002, BRAIN, V125, P2446, DOI 10.1093/brain/awf256; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; STONE JR, 2000, RESTOR NEUROL NEUROS, V16, P304; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Venables W.N., 2002, MODERN APPL STAT S; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135	53	44	47	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					645	654		10.1089/0897715041269731			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600001	15253793				2021-06-18	
J	Byrd, DA; Touradji, P; Tang, MX; Manly, JJ				Byrd, DA; Touradji, P; Tang, MX; Manly, JJ			Cancellation test performance, in African American, Hispanic, and White elderly	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						cancellation tests; cognitive style; ethnicity differences	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; VISUAL-SEARCH; STIMULUS; ATTENTION; NEGLECT; SPEED; AGE; EDUCATION; MEMORY	Shape and letter cancellation test performance was investigated among large samples of African American, Hispanic, and White non-demented elders. Ethnic minority elders took significantly longer to complete both tasks compared to Whites. An index of task efficiency, which simultaneously measures time and accuracy, suggested that slower time by minority elders was not related to a measurable effort to achieve greater accuracy. The frequency of commission errors was greater in our sample than in previous reports, especially among ethnic minority elders. Although significant differences were observed between the ethnic groups when matched for years of education, equating for literacy level eliminated all performance differences between African Americans and Whites on both cancellation tasks.	Columbia Univ, Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Cognit Neurosci Div, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY USA	Manly, JJ (corresponding author), Columbia Univ, Coll Phys & Surg, GH Sergievsky Ctr, 630 W 168th St P & S Box 16, New York, NY 10032 USA.	jjm71@columbia.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG07232, T32 AG000261, AG16206] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016206, P01AG007232, T32AG000261] Funding Source: NIH RePORTER		Aglioti S, 1997, BRAIN COGNITION, V34, P388, DOI 10.1006/brcg.1997.0915; Amieva H, 1999, BRAIN COGNITION, V40, P26; Baddeley AD, 2001, BRAIN, V124, P1492, DOI 10.1093/brain/124.8.1492; BENTON AL, 1955, VISUAL RETENTION TES; Berry J. W., 2002, CROSS CULTURAL PSYCH; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DELLASALA S, 1992, PSYCHOL MED, V22, P805; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; Filley C M, 1994, Appl Neuropsychol, V1, P29, DOI 10.1207/s15324826an0101&2_6; FOLDI NS, 1992, J GERONTOL B-PSYCHOL, V47, P146; Foster JK, 1995, AGING COGNITION, V2, P279, DOI 10.1080/13825589508256604; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; Geldmacher DS, 1999, NEUROPSY NEUROPSY BE, V12, P28; Geldmacher DS, 2000, AGING NEUROPSYCHOL C, V7, P194, DOI 10.1076/1382-5585(200009)7:3;1-Q;FT194; GELDMACHER DS, 1995, NEUROPSY NEUROPSY BE, V8, P259; Geldmacher DS, 1998, BRAIN COGNITION, V36, P346, DOI 10.1006/brcg.1997.0978; Heaton R.K., 1991, COMPREHENSIVE NORMS; HELMS JE, 1992, AM PSYCHOL, V47, P1083, DOI 10.1037/0003-066X.47.9.1083; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; Jacobs DM, 1997, J CLIN EXP NEUROPSYC, V19, P331, DOI 10.1080/01688639708403862; JONES J, 1998, SOCIAL PSYCHOL TIME, P21; KELLAND DZ, 1996, CLIN NEUROPSYCHOLOGY, V11, P339; KLINEBERG O, 1928, ARCH PSYCHOL; Levine R., 1997, GEOGRAPHY TIME TEMPO; Lewis RF., 1979, MANUAL REPEATABLE CO; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LLABRE MM, 1987, J EXP EDUC, V55, P137, DOI 10.1080/00220973.1987.10806446; LLABRE MM, 1991, ASSESSMENT ACCESS HI, P95; Lockwood KA, 2001, J CLIN EXP NEUROPSYC, V23, P317, DOI 10.1076/jcen.23.3.317.1179; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; MARSHALL JC, 1989, COGNITIVE NEUROPSYCH, V6, P403, DOI 10.1080/02643298908253290; Mennemeier M, 1998, BRAIN COGNITION, V37, P439, DOI 10.1006/brcg.1998.1007; MILLER EN, 1993, J CLIN EXP NEUROPSYC, V15, P66; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Perry RJ, 2000, NEUROPSYCHOLOGIA, V38, P252, DOI 10.1016/S0028-3932(99)00079-2; SANO M, 1984, ATTENTION DEFICITS A; SHOR RE, 1971, J GEN PSYCHOL, V85, P187, DOI 10.1080/00221309.1971.9920672; *SPSS INC, 1998, SPSS WIND REL 9 0 0; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; *US BUR CENS, 1991, CENS POP HOUS 1990 S; WEINTRAUB S, 1988, J NEUROL NEUROSUR PS, V51, P1481, DOI 10.1136/jnnp.51.12.1481; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014; WILKINSON GS, 1993, WIDE RANGE ACHIEVEMN; Willis M., 1989, J BLACK PSYCHOL, V16, P47, DOI 10.1177/009579848901600105	45	44	46	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2004	10	3					401	411		10.1017/S1355617704103081			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	817MB	WOS:000221180500010	15147598				2021-06-18	
J	Kleindienst, A; Harvey, HB; Rice, AC; Muller, C; Hamm, RJ; Gaab, MR; Bullock, MR				Kleindienst, A; Harvey, HB; Rice, AC; Muller, C; Hamm, RJ; Gaab, MR; Bullock, MR			Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; NSE; rat; S100B protein; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID; S-100 PROTEIN; NEURITE EXTENSION; GROWTH-FACTOR; SERUM-LEVELS; HEAD-INJURY; RELEASE	Elevated serum S100B levels have been shown to be a predictor of poor outcome after traumatic brain injury (TBI). Experimental data, on the other hand, demonstrate a neuroprotective and neurotrophic effect of this calcium-binding protein. The purpose of this study was to examine the role of increased S100B levels on functional outcome after TBI. Following lateral fluid percussion or sham injury in male Sprague Dawley rats (n = 56), we infused S100B (50 ng/h) or vehicle into the cerebrospinal fluid of the ipsilateral ventricle for 7 days using an osmotic mini-pump. Assessment of cognitive performance by the Morris water maze on days 30-34 after injury revealed an improved performance of injured animals after S100B infusion (P < 0.05), when compared to vehicle infusion. Blood samples for analysis of clinical markers of brain damage, S100B and neuron specific enolase, taken at 30 min, 3 h, 4 h, 2 days, or 5 days showed a typical peak 3 h after injury (P < 0.01), and higher serum levels correlated significantly with an impaired cognitive recovery (p < 0.01). The correlation of higher serum S100B levels with poor water maze performance may result from injury induced opening of the blood-brain barrier, allowing the passage of S100B into serum. Thus while higher serum levels of S100B seem to reflect the degree of blood-brain barrier opening and severity of injury, a beneficial effect of intraventricular S100B administration on long-term functional recovery after TBI has been demonstrated for the first time. The exact mechanism by which S100B exerts its neuroprotective or neurotrophic influence remains unknown and needs to be elucidated by further investigation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Humboldt Univ, Charite, Inst Lab Med & Pathobiochem, Berlin, Germany; Univ Greifswald, Dept Neurosurg, Greifswald, Germany	Kleindienst, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, 1101 E Marshall St,Box 980508, Richmond, VA 23298 USA.	akleindienst@vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587-26] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Agelink MW, 2001, J NEUROL NEUROSUR PS, V71, P394, DOI 10.1136/jnnp.71.3.394; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DONATO R, 1976, J NEUROCHEM, V27, P439, DOI 10.1111/j.1471-4159.1976.tb12266.x; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, V1, P86; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KRAGH J, 1993, BIOL PSYCHIAT, V33, P794, DOI 10.1016/0006-3223(93)90020-E; Li YK, 1998, J NEUROCHEM, V71, P1421; MATSUTANI T, 1985, NEUROCHEM RES, V10, P1155, DOI 10.1007/BF00965889; Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197-0186(01)00048-1; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; RICKMANN M, 1995, BRAIN RES, V688, P8, DOI 10.1016/0006-8993(95)00495-C; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	39	44	47	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					541	547		10.1089/089771504774129874			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900005	15165362				2021-06-18	
J	Aitken, ME; Mele, N; Barrett, KW				Aitken, ME; Mele, N; Barrett, KW			Recovery of injured children: Parent perspectives on family needs	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Pediatric-Academic-Society	MAY   05, 2003	Seattle, WA	Pediat Acad Soc		family; injuries; pediatrics; rehabilitation; support groups	TRAUMATIC BRAIN INJURY; PEDIATRIC TRAFFIC INJURY; STRESS-DISORDER; ADOLESCENTS; MORBIDITY; SUPPORT; QUALITY; LIFE	Objective: To study the broader impact of emotional and financial burdens of injury in children on their families, along with solutions to these problems. Design: Focus groups were conducted to reveal the needs of parents and children after injury. Audiotaped semistructured interviews were conducted by a team of qualitative researchers. Setting: Tertiary care children's hospital. Participants: Mothers of children who had sustained traumatic injury. Interventions: Not applicable. Main Outcome Measures: Summary of reported themes of experience and suggested interventions. Data were analyzed by using content analysis software. Results: Overall satisfaction with care was high. Parents expressed concerns with communication, access to care, and the transition both within the phases of medical care and from medical care into the community. Consistent financial and social stressors were voiced, along with the need for peer support during all phases of care. Conclusions: Parents provided valuable insight into their needs after their child's injury. Attention to constructive communication, clarification of the system of care, continued family-centered care, and development of peer support programs may meet the needs of caregivers and therefore facilitate improvement in pediatric injury recovery.	Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pediat, Fayetteville, AR 72701 USA; Univ Memphis, Loewenberg Sch Nursing, Memphis, TN 38152 USA	Aitken, ME (corresponding author), Arkansas Childrens Hosp, Dept Pediat, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	AitkenMaryE@uams.edu		Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH054003-01-0] Funding Source: Medline		Ainbinder JG, 1998, J PEDIATR PSYCHOL, V23, P99, DOI 10.1093/jpepsy/23.2.99; Aitken ME, 2002, PEDIATRICS, V110, P337, DOI 10.1542/peds.110.2.337; Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; Crabtree B.F., 1999, DOING QUALITATIVE RE; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; JAFFE KM, 1992, PEDIATR ANN, V21, P438, DOI 10.3928/0090-4481-19920701-09; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Montgomery V, 2002, J TRAUMA, V52, P1121, DOI 10.1097/00005373-200206000-00016; Morgan D.L., 1998, FOCUS GROUP KIT; Osberg JS, 1997, BRAIN INJURY, V11, P11; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Strauss A., 1990, BASICS QUALITATIVE R; Taylor S, 1995, CLIN PSYCHOL REV, V15, P721, DOI 10.1016/0272-7358(95)00043-7; WALAND P, 1988, J HEAD TRAUMA REHAB, V3, P51; WELLS N, 2000, WHAT DO FAMILIES SAY; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	25	44	44	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4					567	573		10.1016/j.apmr.2003.06.018			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	810MM	WOS:000220708400006	15083431				2021-06-18	
J	Shore, PM; Jackson, EK; Wisniewski, SR; Clark, RSB; Adelson, PD; Kochanek, PM				Shore, PM; Jackson, EK; Wisniewski, SR; Clark, RSB; Adelson, PD; Kochanek, PM			Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children	NEUROSURGERY			English	Article						adenosine; angiogenesis; child abuse; head injury; head trauma; pediatrics; purine; regeneration	HYPOXIA-RESPONSE ELEMENT; VEGF EXPRESSION; IN-VITRO; ADENOSINE; ANGIOGENESIS; BARRIER; INTERLEUKIN-6; PERMEABILITY; INFUSION; RECEPTOR	OBJECTIVE: Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis, the formation of which is triggered by hypoxia, cytokines, and growth factors and is also induced by activation of the adenosine 2B receptor. VEGF is neuroprotective in several models of experimental brain injury and is increased in brain after traumatic brain injury (TBI) in humans and experimental animals. Adenosine is a neuroprotective purine metabolite that increases in cerebrospinal fluid (CSF) after clinical TBI in children. We hypothesized that VEGF levels would 1) be increased in CSF after TBI in infants and children, and 2) be preceded by increases in CSF adenosine. To test this hypothesis, we designed a case-control study to compare the CSF of infants and children after severe TBI with that of uninjured children. METHODS: Using an Institutional Review Board-approved protocol, we compared CSF concentrations of VEGF (by enzyme-linked immunosorbent assay) and adenosine (by high-performance liquid chromatography) in 73 samples from 14 infants and children with severe TBI (Glasgow Coma Scale score less than or equal to8) with those in CSF from 5 noninjured control subjects. Patients received standard neurointensive care. RESULTS: Mean VEGF levels were increased after TBI versus control (39.8 +/- 6.2 versus 14.9 +/- 1.5 ng/dl, mean +/- standard error of the mean, P = 0.0002) and peaked at 91.6 +/- 26.4 ng/dl, approximately 6 times control (P = 0.001). Peak VEGF occurred at 22.4 hours after injury. There was a trend toward increased adenosine concentration after TBI versus control (18.3 +/- 3.5 versus 11.5 +/- 2.3 nmol/L), but this did not reach statistical significance. A multivariate regression model showed an independent, significant association between the concentrations of VEGF and adenosine. CONCLUSION: VEGF is increased in CSF after pediatric TBI, and this increase is associated with an increase in CSF adenosine. These results may imply that a component of the vascular regenerative response of the brain is initiated rapidly after TBI and continues for several days after injury. Further investigation is warranted to determine 1) whether this association is causative, 2) the role of adenosine in triggering the increase in CSF VEGF concentration, and 3) the exact role VEGF that plays after injury.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave,Hill Bldg,Suite 201, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, P20NS030318, R01NS038087] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30318, NS-38087] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; BERNINI JC, 1995, LANCET, V345, P544, DOI 10.1016/S0140-6736(95)90464-6; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Conklin BS, 2002, J SURG RES, V102, P13, DOI 10.1006/jsre.2001.6295; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; DeWitt DS, 2001, MO CL BI CC, P71; Dobolyi A, 1998, NEUROCHEM INT, V32, P247, DOI 10.1016/S0197-0186(97)00090-9; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grant MB, 2001, INVEST OPHTH VIS SCI, V42, P2068; Gu JW, 1999, AM J PHYSIOL-HEART C, V277, pH595; Harrigan MR, 2002, NEUROSURGERY, V50, P589, DOI 10.1097/00006123-200203000-00030; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Jackson EK, 1996, J PHARMACOL EXP THER, V279, P1250; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2001, HEAD TRAUMA, P141; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Matsuzaki H, 2001, FASEB J, V15, P1218; MEYER R, 2002, CRIT CARE, V6, pP57; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PHILLIS JW, 1987, J CEREBR BLOOD F MET, V7, P679, DOI 10.1038/jcbfm.1987.122; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Salhia B, 2000, BRAIN RES, V883, P87, DOI 10.1016/S0006-8993(00)02825-0; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Taub PJ, 2000, PLAST RECONSTR SURG, V105, P1034, DOI 10.1097/00006534-200003000-00031; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; VANWYLEN DGL, 1989, J CEREBR BLOOD F MET, V9, P556, DOI 10.1038/jcbfm.1989.79; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	55	44	48	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2004	54	3					605	611		10.1227/01.NEU.0000108642.88724.DB			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500025	15028134				2021-06-18	
J	Hellmich, HL; Frederickson, CJ; DeWitt, DS; Saban, R; Parsley, MO; Stephenson, R; Velasco, M; Uchida, T; Shimamura, M; Prough, DS				Hellmich, HL; Frederickson, CJ; DeWitt, DS; Saban, R; Parsley, MO; Stephenson, R; Velasco, M; Uchida, T; Shimamura, M; Prough, DS			Protective effects of zinc chelation in traumatic brain injury correlate with upregulation of neuroprotective genes in rat brain	NEUROSCIENCE LETTERS			English	Article						zinc; traumatic brain injury; gene expression; neuroprotection; apoptosis	SYNAPTICALLY-RELEASED ZINC; HIPPOCAMPUS; DEATH	Chelation of excessive neuronal zinc ameliorates zinc neurotoxicity and reduces subsequent neuronal injury. To clarify the molecular mechanisms of this neuroprotective effect, we used a focused cDNA array of stress-response genes with zinc chelation (calcium EDTA) in our rat model of fluid percussion brain injury at 2 h, 24 h, and 7 days after injury. In parallel experiments, we compared neuronal cell death in TUNEL-stained brain sections in traumatized rats with and without calcium EDTA treatment. Zinc chelation induced the expression of several neuroprotective genes; neuroprotective gene expression correlated with substantially decreased numbers of TUNEL-positive cells. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Yokohama City Univ, Sch Med, Dept Neurol, Yokohama, Kanagawa 232, Japan; Univ Texas, Med Branch, Dept Biostat, Galveston, TX 77550 USA; Vel Lab Res, Houston, TX USA; Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA; Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77550 USA; Univ Texas, Med Branch, Ctr Biomed Engn, Galveston, TX 77550 USA	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	De Velasco, Marco/R-1022-2019; Prough, Donald S/G-5793-2013	De Velasco, Marco/0000-0002-4011-6572; Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42882, NS40215, NS19355, NS38585] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS040215, R21NS042882, R01NS038585, R01NS019355] Funding Source: NIH RePORTER		BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Conover WJ, 1999, PRACTICAL NONPARAMET, V3rd, P288; Conti AC, 1998, J NEUROSCI, V18, P5663; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; Inguaggiato P, 2001, KIDNEY INT, V60, P2181, DOI 10.1046/j.1523-1755.2001.00046.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Manzanares D, 2001, J PROTEIN CHEM, V20, P181, DOI 10.1023/A:1010996528884; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Pan W, 2002, BIOINFORMATICS, V18, P546, DOI 10.1093/bioinformatics/18.4.546; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rubio E, 2002, EUR J NEUROSCI, V15, P1646, DOI 10.1046/j.1460-9568.2002.01998.x; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3	21	44	45	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 30	2004	355	3					221	225		10.1016/j.neulet.2003.10.074			5	Neurosciences	Neurosciences & Neurology	766VQ	WOS:000188396500017	14732471				2021-06-18	
J	Bush, BA; Novack, TA; Malec, JF; Stringer, AY; Millis, SR; Madan, A				Bush, BA; Novack, TA; Malec, JF; Stringer, AY; Millis, SR; Madan, A			Validation of a model for evaluating outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome assessment (health care); rehabilitation; validation studies [publication type]	HEAD-INJURY; DISABILITY	Objective: To validate a model that examines the contribution of premorbid variables, injury severity, and functional and cognitive status to outcome 1 year after traumatic brain injury (TBI). Design: Cross-validation study using a larger, national, prospective, longitudinal sample. Setting: Acute inpatient rehabilitation hospitals at Traumatic Brain Injury Model Systems centers. Participants: Two sample populations followed through acute rehabilitation to 1 year after TBI. The original sample included 107 patients, and the cross-validation sample included 294 patients. Participants were predominately young men who had experienced moderate to severe TBI in motor vehicle crashes. Interventions: Acute medical and rehabilitation care. Main Outcome Measures: Disability Rating Scale, Community Integration Questionnaire, and return to employment. Results: Structural equation modeling was used to compare the fit of the data to a path analysis developed through clinical use and previous research. Both samples provided adequate goodness of fit, supporting the model's validity. Injury severity affected cognitive and functional status, and cognitive and functional status significantly influenced 1-year outcome. Premorbid factors and injury severity did not directly influence outcome. Conclusions: Both samples supported the proposed model, which was cross-validated. Injury severity indirectly influences outcome through its effects on cognitive and functional status. Although treatment to decrease injury severity is obviously important, concentrated rehabilitation interventions aimed at improving patients' cognitive and functional status may have a more significant impact on 1-year outcome and should be the focus of future research.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; Mayo Med Ctr, Dept Phys Med & Rehabil, Rochester, MN USA; Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Kessler Med Rehabil Res & Educ Corp, Res Dept, W Orange, NJ USA	Bush, BA (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1530 3rd Ave S,CPM253, Birmingham, AL 35294 USA.	babush@uobmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A 980010] Funding Source: Medline; ODCDC CDC HHS [R49/CCR 40364] Funding Source: Medline		BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Benton AL, 1983, MULTILINGUAL APHASIA; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bollen K.A., 1993, TESTING STRUCTURAL E; BOLLEN KA, 1989, SOCIOL METHOD RES, V17, P303, DOI 10.1177/0049124189017003004; BOLLEN KA, 1986, PSYCHOMETRIKA, V51, P375, DOI 10.1007/BF02294061; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Byrne B.M., 1989, PRIMER LISREL BASIC; Carmines E. G., 1981, SOCIAL MEASUREMENT P, P65; Delis DC, 1987, CALIFORNIA VERBAL LE; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Long JS., 1983, CONFIRMATORY FACTOR; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	22	44	44	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2003	84	12					1803	1807		10.1016/S0003-9993(03)00367-8			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	751JY	WOS:000187064400012	14669187				2021-06-18	
J	Baldo, V; Marcolongo, A; Floreani, A; Majori, S; Cristofoletti, M; Dal Zotto, A; Vazzoler, G; Trivello, R				Baldo, V; Marcolongo, A; Floreani, A; Majori, S; Cristofoletti, M; Dal Zotto, A; Vazzoler, G; Trivello, R			Epidemiological aspect of traumatic brain injury in Northeast Italy	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Article						epidemiology; prevention; traumatic brain injuries	MORTALITY	Background: Traumatic brain injuries ( TBIs) remain an important public health problem in developed countries. Hospital records were reviewed to ascertain the epidemiology of TBIs in Northeast Italy. Methods: The annual rates of TBI-associated hospitalisation were estimated by analysing data collected from hospital records from 1996 to 2000. TBIs were identified according to the Centers for Disease Control and Prevention definition and the ICDMAP-90 was used to assess their severity. Findings: 55,368 TBIs were collected between 1996 and 2000, with an overall 29.4% decline in the number of cases. As for severity, moderate TBIs dropped by 34.1%, whereas a less conspicuous decline was observed for mild injuries. Severe injuries remained stable between 1996 and 1999, but rose in 2000, when the unclassified injuries were better distributed. Concerning outcome, fatal TBIs dropped slightly, but only in 2000. Causes of TBI were recorded in 59.2% of cases: 48.5% were motor vehicle accidents, 8.8% occurred at work and 12.2% at home. There were more males than females in all age groups. The highest number of cases per 100,000 person of motor vehicle accidents was recorded among 16 - 25 year-old and 36.5% occurred at weekends. Domestic accidents showed two age peaks, in children and the elderly. Occupational accidents occurred at all working ages, tending to decline with older age. Interpretation: Better health care and educational campaigns may have contributed to the declining rate of TBI-associated hospitalisation. Special efforts should be made to further reduce the motor vehicle accidents involving young people and welfare programs are needed to limit the risk of falls and contain functional impairment in the elderly.	Univ Padua, Inst Hyg, Dept Environm Med & Publ Hlth, I-35131 Padua, Italy; Hosp & Ambulatory Care, Planning Dept, Venice, Italy; Univ Verona, Inst Hyg, Dept Med & Publ Hlth, I-37100 Verona, Italy; Univ Padua, Dept Surg & Gastroenterol Sci, I-35100 Padua, Italy	Baldo, V (corresponding author), Univ Padua, Inst Hyg, Dept Environm Med & Publ Hlth, Via Loredan 18, I-35131 Padua, Italy.		Baldo, Vincenzo/V-4005-2019; Vincenzo, Baldo/D-7822-2018	Baldo, Vincenzo/0000-0001-6012-9453; Vincenzo, Baldo/0000-0001-6012-9453			AA W, 2001, EUR J EPIDEMIOL, V17, P437; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Ferrando J, 2000, Inj Prev, V6, P184, DOI 10.1136/ip.6.3.184; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Poidevin P, 2000, ANN FR ANESTH, V19, P282; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1997, INT CLASS DIS; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wong E, 2002, J EMERG MED, V22, P139, DOI 10.1016/S0736-4679(01)00455-3	16	44	46	0	6	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990			EUR J EPIDEMIOL	Eur. J. Epidemiol.	NOV	2003	18	11					1059	1063		10.1023/A:1026192020963			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	730YK	WOS:000185857600007	14620940				2021-06-18	
J	Van Damme, P; Callewaert, G; Eggermont, J; Robberecht, W; Van Den Bosch, L				Van Damme, P; Callewaert, G; Eggermont, J; Robberecht, W; Van Den Bosch, L			Chloride influx aggravates Ca2+-dependent AMPA receptor-mediated motoneuron death	JOURNAL OF NEUROSCIENCE			English	Article						AMPA receptor; calcium; motoneuron; chloride; excitotoxicity; amyotrophic lateral sclerosis	RAT SPINAL-CORD; AMINO-ACID NEUROTRANSMITTERS; ARTERY ENDOTHELIAL-CELLS; PATCH-CLAMP TECHNIQUE; MOTOR-NEURON DEATH; CEREBRAL-ISCHEMIA; SELECTIVE VULNERABILITY; INTRACELLULAR CHLORIDE; CL; EXCITOTOXICITY	AMPA receptor-mediated excitotoxicity has been implicated in the pathogenesis of stroke, neurotrauma, epilepsy, and many neurodegenerative diseases such as motoneuron disease. We studied the role of Cl- in AMPA receptor-mediated Ca2+-dependent excitotoxicity in cultured rat spinal motoneurons. Using the gramicidin perforated patch-clamp technique, the intracellular Cl- concentration could be calculated from the reversal potential of the GABA-induced current. The membrane depolarization caused by AMPA receptor stimulation resulted in Cl- influx through 5-nitro-2(3-phenylpropyl-amino) benzoic acid- and niflumic acid-sensitive Cl- channels. Cl- influx during AMPA receptor stimulation aggravated excitotoxic motoneuron death by two mechanisms: an increase of AMPA receptor conductance and an elevation of the Ca2+ driving force through a partial repolarization. The Cl- influx during AMPA receptor stimulation was enhanced by coadministration of GABA. This resulted in an increased Ca2+ influx and an enhanced cell death, suggesting that concomitant GABAergic stimulation may aggravate excitotoxic motoneuron death.	Catholic Univ Louvain, Dept Neurobiol, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Physiol, B-3000 Louvain, Belgium	Robberecht, W (corresponding author), Dept Neurol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Van Den Bosch, Ludo/B-7258-2012; Van Damme, Philip/A-6464-2009	Van Damme, Philip/0000-0002-4010-2357; Van Den Bosch, Ludo/0000-0003-0104-4067; Eggermont, Jan/0000-0002-8497-1159			ABE Y, 1994, J NEUROPHYSIOL, V72, P1530; AKAIKE N, 1994, JPN J PHYSIOL, V44, pS113; Al-Noori S, 2000, NEUROSCIENCE, V101, P337, DOI 10.1016/S0306-4522(00)00384-5; BOSLEY TM, 1983, J NEUROCHEM, V40, P189, DOI 10.1111/j.1471-4159.1983.tb12670.x; Canton T, 2001, J PHARMACOL EXP THER, V299, P314; CARLTON SM, 1990, J COMP NEUROL, V300, P162, DOI 10.1002/cne.903000203; Carriedo SG, 1996, J NEUROSCI, V16, P4069; CHOI DW, 1987, J NEUROSCI, V7, P369; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Ehrlich I, 1999, J PHYSIOL-LONDON, V520, P121, DOI 10.1111/j.1469-7793.1999.00121.x; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; Gulyas AI, 2001, EUR J NEUROSCI, V13, P2205, DOI 10.1046/j.0953-816x.2001.01600.x; Hasbani MJ, 2001, J NEUROSCI, V21, P2393; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Inglefield JR, 1998, J NEUROCHEM, V71, P1396; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kakazu Y, 1999, J NEUROSCI, V19, P2843; KYROZIS A, 1995, J NEUROSCI METH, V57, P27, DOI 10.1016/0165-0270(94)00116-X; LANIUS RA, 1993, MOL BRAIN RES, V20, P192, DOI 10.1016/0169-328X(93)90041-M; Lapchak PA, 2000, STROKE, V31, P1953, DOI 10.1161/01.STR.31.8.1953; LERMA J, 1992, MOL PHARMACOL, V41, P217; Li YX, 1998, J PHYSIOL-LONDON, V509, P847, DOI 10.1111/j.1469-7793.1998.847bm.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MADDEN KP, 1994, STROKE, V25, P2271, DOI 10.1161/01.STR.25.11.2271; MAGOUL R, 1987, NEUROSCIENCE, V20, P1001, DOI 10.1016/0306-4522(87)90258-2; MRSULJA BB, 1978, J NEURAL TRANSM    S, V14, P23; Muimo R, 1998, AM J RESP CELL MOL, V18, P270, DOI 10.1165/ajrcmb.18.2.2850; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; OWEN DG, 1986, J NEUROPHYSIOL, V55, P1115; OWEN DG, 1984, NATURE, V311, P567, DOI 10.1038/311567a0; PLAITAKIS A, 1991, ADV NEUROL, V56, P319; PRICE DL, 1976, J CELL BIOL, V68, P389, DOI 10.1083/jcb.68.2.389; RHEE JS, 1994, J NEUROPHYSIOL, V72, P1103; Rivera C, 1999, NATURE, V397, P251; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; Singer JH, 1998, J NEUROPHYSIOL, V80, P2608; TERHARNE KJ, 1994, AM J PHYSIOL, V267, pL592; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Van Damme P, 2003, NEUROSCI LETT, V343, P81, DOI 10.1016/S0304-3940(03)00314-8; Van Damme P, 2002, J NEUROPHYSIOL, V88, P1279, DOI 10.1152/jn.2002.88.3.1279; Van Damme P, 2002, J NEUROPHYSIOL, V88, P965, DOI 10.1152/jn.2002.88.2.965; Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7; Van den Bosch L, 2000, BRAIN RES BULL, V53, P383, DOI 10.1016/S0361-9230(00)00371-3; Van den Bosch L, 2002, NEUROPHARMACOLOGY, V42, P706, DOI 10.1016/S0028-3908(02)00010-2; Vandenberghe W, 1998, BRAIN RES, V807, P1, DOI 10.1016/S0006-8993(98)00569-1; Voets T, 1996, J PHYSIOL-LONDON, V497, P95, DOI 10.1113/jphysiol.1996.sp021752; Yamada KA, 1998, NEUROBIOL DIS, V5, P67, DOI 10.1006/nbdi.1998.0190; ZORUMSKI CF, 1990, NEURON, V5, P61, DOI 10.1016/0896-6273(90)90033-C	55	44	44	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 15	2003	23	12					4942	4950					9	Neurosciences	Neurosciences & Neurology	696MY	WOS:000183891700019	12832516				2021-06-18	
J	D'Arcy, RCN; Marchand, Y; Eskes, GA; Harrison, ER; Phillips, SJ; Major, A; Connolly, JF				D'Arcy, RCN; Marchand, Y; Eskes, GA; Harrison, ER; Phillips, SJ; Major, A; Connolly, JF			Electrophysiological assessment of language function following stroke	CLINICAL NEUROPHYSIOLOGY			English	Article						N400; phonological mismatch negativity; stroke; event-related brain potentials; language; neuropsychological assessment	BRAIN POTENTIALS; RECEPTIVE VOCABULARY; WORD RECOGNITION; APHASIA; SPEECH; COMPREHENSION; VALIDATION; SCALE; FORM	Objective: Event-related brain potentials (ERPs) were used to assess language function after stroke and demonstrate that it is possible to adapt neuropsychological tests to evaluate neurocognitive function using ERPs. Prior ERP assessment work has focused on language in both healthy individuals and case studies of aphasic neurotrauma patients. The objective of the current study was to evaluate left-hemisphere stroke patients who had varying degrees of receptive language impairment. It was hypothesized that ERPs would assess receptive language function accurately and correlate highly with the neuropsychological data. Methods: Data were collected from 10 left-hemisphere stroke patients; all were undergoing rehabilitation at the time of testing. Each patient received a battery of neuropsychological tests including the Peabody Picture Vocabulary Test-Revised (PPVT-R; Minnesota: American Guidance Service, 1981). ERPs were recorded during a computerized PPVT-R, in which pictures are presented followed by digitized spoken words that are either congruent or incongruent with the pictures. Results and conclusion: Incongruent spoken words within an individual's vocabulary level elicited well-known ERP components. One of the components (the N400) could be utilized as a marker of intact semantic processing. The ERP results were subsequently quantified and N400 derivative scores correlated highly with the neuropsychological findings. The results provided a clear demonstration of the efficacy of ERP-based assessment in a neurological patient group. Significance: Language function in stroke patients can be evaluated, independent of behavior, using electrophysiological measures that correlate highly with traditional neuropsychological test scores. (C) 2003 International Federation of Clinical Neurophysiology. Published by Elsevier Science Ireland Ltd. All rights reserved.	Dalhousie Univ, Dept Psychol, Cognit Clin Neurosci Unit, Winnipeg, MB R3B 1Y6, Canada; CNR, Inst Biodiagnost Atlantic, Halifax, NS, Canada; Queen Elizabeth 2 Hlth Sci Ctr, Nova Scotia Rehabil Ctr, Halifax, NS, Canada; Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada; Queen Elizabeth 2 Hlth Sci Ctr, Halifax Infirm, Dept Med, Div Neurol, Halifax, NS, Canada; Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada	D'Arcy, RCN (corresponding author), CNR, Inst Biodiagnost, 435 Ellice Ave, Winnipeg, MB R3B 1Y6, Canada.	ryan.d'arcy@nrc-cnrc.gc.ca		Connolly, John/0000-0001-8869-5369; Marchand, Yannick/0000-0003-3902-0466; Eskes, Gail/0000-0001-5867-9616			Benton AL, 1983, MULTILINGUAL APHASIA; Byrne JM, 1995, CHILD NEUROPSYCHOL, V1, P211, DOI 10.1080/09297049508400226; BYRNE JM, 1995, J CLIN EXP NEUROPSYC, V17, P9, DOI 10.1080/13803399508406576; Chiappa K.H., 1997, EVOKED POTENTIALS CL; Coltheart, 1992, PSYCHOLINGUISTIC ASS; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V37, P31, DOI 10.1016/S0167-8760(00)00093-3; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V38, P55, DOI 10.1016/S0167-8760(00)00130-6; Connolly JF, 1999, J CLIN EXP NEUROPSYC, V21, P444, DOI 10.1076/jcen.21.4.444.879; CONNOLLY JF, 1995, J CLIN EXP NEUROPSYC, V17, P548, DOI 10.1080/01688639508405145; Connolly JF, 1999, ARCH PHYS MED REHAB, V80, P1309, DOI 10.1016/S0003-9993(99)90035-7; CONNOLLY JF, 1995, ELECTROEN CLIN NEURO, V94, P276, DOI 10.1016/0013-4694(95)98479-R; Connolly JF, 2001, NEUROREPORT, V12, P237, DOI 10.1097/00001756-200102120-00012; CONNOLLY JF, 1994, J COGNITIVE NEUROSCI, V6, P256, DOI 10.1162/jocn.1994.6.3.256; D'Arcy RCN, 1999, NEUROPSYCHOLOGIA, V37, P1477, DOI 10.1016/S0028-3932(99)00057-3; D'Arcy RCN, 2000, J INT NEUROPSYCH SOC, V6, P556, DOI 10.1017/S1355617700655054; Dehaene-Lambertz G, 2000, J COGNITIVE NEUROSCI, V12, P635, DOI 10.1162/089892900562390; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Dunn L., 1981, PEABODY PICTURE VOCA; Enderby P, 1987, Int Rehabil Med, V8, P162; ENDERBY P, 1986, BRIT J DISORD COMMUN, V21, P151; Fountoulakis KN, 1999, AGING-CLIN EXP RES, V11, P367, DOI 10.1007/BF03339814; Friederici AD, 1999, BRAIN, V122, P1033, DOI 10.1093/brain/122.6.1033; GOODGLASS H, 1987, ASSESSMENT APHASIA R; GREENHOUSE SW, 1959, PSYCHOMETRIKA, V24, P95, DOI 10.1007/BF02289823; Haan H, 2000, HUM BRAIN MAPP, V11, P178; Hagoort P, 2000, NEUROPSYCHOLOGIA, V38, P1518, DOI 10.1016/S0028-3932(00)00052-X; Helenius P, 1998, BRAIN, V121, P1133, DOI 10.1093/brain/121.6.1133; Helenius P, 2002, J NEUROSCI, V22, P2936, DOI 10.1523/JNEUROSCI.22-07-02936.2002; HOLCOMB PJ, 1990, LANG COGNITIVE PROC, V5, P281, DOI 10.1080/01690969008407065; Kaplan E., 1983, BOSTON NAMING TEST; KNIGHT RT, 1997, BEHAV NEUROLOGY NEUR, P101; KUTAS M, 1994, HDB PSYCHOLINGUISTIC, P83, DOI DOI 10.1016/8978-012369374-7/50018-3; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Marchand Y, 2002, CLIN NEUROPHYSIOL, V113, P1715, DOI 10.1016/S1388-2457(02)00224-9; MARQUARDSEN J, 1969, ACTA NEUROL SCAND  S, V38, P67; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; MORSE PA, 1992, CLIN SYNDROMES ADULT, P86; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; PRAAMSTRA P, 1993, COGNITIVE BRAIN RES, V1, P73, DOI 10.1016/0926-6410(93)90013-U; Spreen O., 1998, COMPENDIUM NEUROPSYC; van den Brink D, 2001, J COGNITIVE NEUROSCI, V13, P967, DOI 10.1162/089892901753165872; WADE DT, 1986, J NEUROL NEUROSUR PS, V49, P11, DOI 10.1136/jnnp.49.1.11; Wechsler D, 1987, MEMORY SCALE REVISED; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	45	44	47	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2003	114	4					662	672		10.1016/S1388-2457(03)00007-5			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	671AG	WOS:000182442000010	12686275				2021-06-18	
J	Kraus, JF; Rice, TM; Peek-Asa, C; McArthur, DL				Kraus, JF; Rice, TM; Peek-Asa, C; McArthur, DL			Facial trauma and the risk of intracranial injury in motorcycle riders	ANNALS OF EMERGENCY MEDICINE			English	Article							FRACTURES; IMPACT; HEAD; FACE	Study objective: We describe the associations among facial fracture, helmet use, skull fracture, and traumatic brain injury in injured motorcycle riders. Methods: The study population consisted of 5,790 motorcycle riders who sustained an injury from a crash in 1991, 1992, or 1993 and were identified from emergency department or hospital records in 28 hospitals in 11 California counties. Diagnostic information was abstracted from ED or hospital records and coded to the 1990 Abbreviated Injury Scale. The risk of traumatic brain injury was examined by using odds ratios and 95% confidence intervals. Logistic regression analysis was used to examine the associations among helmet use, skull fracture, facial fracture, and traumatic brain injury. Results: Facial injury was diagnosed in 24.4% of all injured riders, including 411 with one or more facial fractures. The odds of traumatic brain injury were 3.5 times greater with than without a facial injury and 6.5 times greater with a facial fracture than with no facial injury. Significantly increased odds of traumatic brain injury were observed for fracture of all bones of the face, but the highest odds of traumatic brain injury were found in riders with fractures to bones of the upper face. Helmet use status and the presence of skull fracture were found to be significant effect modifiers. Facial fracture with concurrent skull fracture increased the risk of traumatic brain injury dramatically. Facial fractures are more strongly associated with traumatic brain injury in helmeted riders. Conclusion: The presence of facial fractures increases the risk of traumatic brain injury. Riders with facial fractures should be screened for brain injury, regardless of helmet use status.	Univ Calif Los Angeles, Sch Publ Hlth, So Calif Injury Prevent Res Ctr, Los Angeles, CA 90024 USA	Kraus, JF (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, So Calif Injury Prevent Res Ctr, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90024 USA.	jfkraus@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	ODCDC CDC HHS [R49/CCR903622] Funding Source: Medline		*ASS ADV AUT MED, 1990, ABBR INJ SCAL; ASSAEL LA, 1993, RADIOL CLIN N AM, V31, P209; Bisson JI, 1997, J TRAUMA, V43, P496, DOI 10.1097/00005373-199709000-00018; BJORNSTIG U, 1992, J TRAUMA, V33, P887; CANNELL H, 1982, BRIT J ORAL SURG, V20, P183, DOI 10.1016/S0007-117X(82)80036-X; CANNELL H, 1993, BR J ORAL MAXILLOFAC, V46, P207; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; Down KE, 1995, INT J ORAL MAX SURG, V24, P409, DOI 10.1016/S0901-5027(05)80469-2; Gassner R, 1999, SPORTS MED, V27, P127, DOI 10.2165/00007256-199927020-00005; Gopalakrishna G, 1998, ANN EMERG MED, V32, P425, DOI 10.1016/S0196-0644(98)70170-2; GRUSS JS, 1989, BRIT J PLAST SURG, V42, P385, DOI 10.1016/0007-1226(89)90003-9; HAMPSON D, 1995, J BIOMECH, V28, P1; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; JOHNSON RM, 1995, J TRAUMA, V38, P876, DOI 10.1097/00005373-199506000-00008; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; KOOREY AJ, 1992, INT J ORAL MAX SURG, V21, P77, DOI 10.1016/S0901-5027(05)80535-1; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LEE MC, 1995, INJURY, V26, P467, DOI 10.1016/0020-1383(95)00071-G; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; NAKHGEVANY KB, 1994, AM J EMERG MED, V12, P160, DOI 10.1016/0735-6757(94)90237-2; SASTRY SM, 1995, PLAST RECONSTR SURG, V95, P196, DOI 10.1097/00006534-199501000-00039; VAUGHAN RG, 1977, MED J AUSTRALIA, V1, P125, DOI 10.5694/j.1326-5377.1977.tb130562.x	25	44	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2003	41	1					18	26		10.1067/mem.2003.1			9	Emergency Medicine	Emergency Medicine	634YC	WOS:000180369200003	12514678				2021-06-18	
J	Litvan, I				Litvan, I			Update on epidemiological aspects of progressive supranuclear palsy	MOVEMENT DISORDERS			English	Article; Proceedings Paper	Workshop on Parkinsonism and Dementia	MAY 09-11, 2002	ISTANBUL, TURKEY	Movement Disorder Soc, European Sect		parkinsonism; tau; genetic factors; epidemiology	RICHARDSON-OLSZEWSKI-SYNDROME; MULTIPLE SYSTEM ATROPHY; NINDS NEUROPATHOLOGIC CRITERIA; PARKINSONISM-DEMENTIA COMPLEX; ALZHEIMERS-DISEASE; CORTICOBASAL DEGENERATION; NATURAL-HISTORY; FRONTOTEMPORAL DEMENTIA; ENDOGENOUS AMINE; RISK-FACTORS	The cause of progressive supranuclear palsy (PSP), the most common form of the atypical parkinsonian disorders, is unknown. PSP is characterized by four-repeat tau aggregates in neurons (neurofibrillary tangles) and glia in specific basal ganglia and brainstem areas. A thorough literature review led us to hypothesize that genetic and/or environmental factors contribute to its development. It is likely that inheritance of the H1/H1 tau genotype represents a predisposition to develop PSP requiring other environmental or genetic factors. Less likely, a relatively rare mutation with low penetrance could contribute to the abnormal tau aggregation present in this disorder. The possible role of chemicals in the diet or occupation, hypertension, traumatic brain injury, coffee, and inflammation or oxidative injury are reviewed. (C) 2003 Movement Disorder Society.	Univ Louisville, Sch Med, Dept Neurol, Movement Disorder Program, Louisville, KY 40202 USA	Litvan, I (corresponding author), Univ Louisville, Sch Med, Dept Neurol, Movement Disorder Program, A Bldg,Room 113,500 S Preston, Louisville, KY 40202 USA.	i.litvan@louisville.edu	Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445			Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bhatt M, 2000, MOVEMENT DISORD, V15, P313, DOI 10.1002/1531-8257(200003)15:2<313::AID-MDS1017>3.0.CO;2-P; Bird TD, 1999, BRAIN, V122, P741, DOI 10.1093/brain/122.4.741; Boeve BF, 2003, ANN NEUROL, V54, pS15, DOI 10.1002/ana.10570; Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; Bugiani O, 1999, J NEUROPATH EXP NEUR, V58, P667, DOI 10.1097/00005072-199906000-00011; Caparros-Lefebvre D, 1999, LANCET, V354, P281, DOI 10.1016/S0140-6736(98)10166-6; CAPARROSLEFEBVR.D, 2001, MOVEMENT DISORD, V16, P394; Chambers CB, 1999, ANN NEUROL, V46, P325, DOI 10.1002/1531-8249(199909)46:3<325::AID-ANA8>3.0.CO;2-V; COBUZZI RJ, 1994, J NEUROCHEM, V62, P1503; COLLINS MA, 1992, ANN NY ACAD SCI, V648, P263, DOI 10.1111/j.1749-6632.1992.tb24551.x; COLLINS SJ, 1995, J NEUROL NEUROSUR PS, V58, P167, DOI 10.1136/jnnp.58.2.167; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; DAVIS PH, 1988, NEUROLOGY, V38, P1546, DOI 10.1212/WNL.38.10.1546; Di Maria E, 2000, ANN NEUROL, V47, P374, DOI 10.1002/1531-8249(200003)47:3<374::AID-ANA15>3.0.CO;2-8; Diamond M. C., 1988, ENRICHING HEREDITY I; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935, DOI 10.1093/jnen/61.11.935; Dickson DW, 1999, J NEUROL, V246, P6; Drache B, 1997, J NEUROSCI RES, V47, P98; DRUCKER G, 1990, BRAIN RES, V509, P125, DOI 10.1016/0006-8993(90)90318-6; DUBINSKY RM, 1987, NEUROLOGY, V37, P570, DOI 10.1212/WNL.37.4.570; Fabbrini G, 1998, ARCH NEUROL-CHICAGO, V55, P1153, DOI 10.1001/archneur.55.8.1153; Friedrich MR, 1999, JAMA-J AM MED ASSOC, V282, P2200, DOI 10.1001/jama.282.23.2200; GEARING M, 1994, NEUROLOGY, V44, P1015, DOI 10.1212/WNL.44.6.1015; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gerhard A, 2001, NEUROLOGY, V56, pA270; Ghika J, 1997, ARCH NEUROL-CHICAGO, V54, P1104, DOI 10.1001/archneur.1997.00550210038010; GOETZ CG, 1992, NEUROL CLIN, V10, P907; Golbe LI, 1996, NEUROLOGY, V47, P148, DOI 10.1212/WNL.47.1.148; Golbe LI, 2000, LANCET, V356, P870, DOI 10.1016/S0140-6736(00)02672-6; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hallett M, 2000, MOVEMENT DISORD, V15, P436, DOI 10.1002/1531-8257(200005)15:3<436::AID-MDS1003>3.0.CO;2-L; Halliday G, 2000, CLIN EXP PHARMACOL P, V27, P1, DOI 10.1046/j.1440-1681.2000.03200.x; Halliday GM, 2000, ARCH NEUROL-CHICAGO, V57, P831, DOI 10.1001/archneur.57.6.831; HAUW JJ, 1994, NEUROLOGY, V44, P2015, DOI 10.1212/WNL.44.11.2015; Houlden H, 2001, NEUROLOGY, V56, P1702, DOI 10.1212/WNL.56.12.1702; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iijima M, 1999, NEUROREPORT, V10, P497, DOI 10.1097/00001756-199902250-00010; Ishizawa K, 2001, J NEUROPATH EXP NEUR, V60, P647, DOI 10.1093/jnen/60.6.647; Kawai H, 1998, J NEUROCHEM, V70, P745; Kawas CH, 1999, ALZ DIS ASSOC DIS, V13, P124, DOI 10.1097/00002093-199907000-00002; KIKUCHI K, 1991, DRUG METAB DISPOS, V19, P257; KOTAKE Y, 1995, J NEUROCHEM, V65, P2633; Kotake Y, 1996, NEUROSCI LETT, V217, P69; Kuhn W, 1996, J NEURAL TRANSM, V103, P1435, DOI 10.1007/BF01271257; Lannuzel A., 2000, MOV DISORD S3, V13, P28; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Letenneur L, 2000, AM J EPIDEMIOL, V151, P1064, DOI 10.1093/oxfordjournals.aje.a010149; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; Lippa CF, 1995, NEURODEGENERATION, V4, P425, DOI 10.1006/neur.1995.0051; Lippa CF, 1998, NEUROBIOL AGING, V19, P527, DOI 10.1016/S0197-4580(98)00089-X; Litvan I, 1997, NEUROLOGY, V48, P119, DOI 10.1212/WNL.48.1.119; Litvan I, 1996, J NEUROL NEUROSUR PS, V60, P615, DOI 10.1136/jnnp.60.6.615; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Litvan I, 1996, NEUROLOGY, V46, P922, DOI 10.1212/WNL.46.4.922; Litvan I, 2001, SEMIN NEUROL, V21, P41, DOI 10.1055/s-2001-13118; Litvan I, 2001, NEUROLOGY, V57, P138, DOI 10.1212/WNL.57.1.138; Lopez OL, 1999, NEUROLOGY, V53, P1292, DOI 10.1212/WNL.53.6.1292; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Mackenzie IRA, 2000, NEUROLOGY, V54, P732, DOI 10.1212/WNL.54.3.732; MAHER ER, 1986, NEUROLOGY, V36, P1005, DOI 10.1212/WNL.36.7.1005; MAKINO Y, 1990, J NEUROCHEM, V55, P963, DOI 10.1111/j.1471-4159.1990.tb04585.x; MAKINO Y, 1988, LIFE SCI, V43, P373, DOI 10.1016/0024-3205(88)90115-4; MASTAGLIA F L, 1973, Proceedings of the Australian Association of Neurologists, V10, P35; Matsubara K, 1998, EUR J PHARMACOL, V348, P77, DOI 10.1016/S0014-2999(98)00131-9; MCCRANK E, 1989, CAN J PSYCHIAT, V34, P934, DOI 10.1177/070674378903400916; MCCRANK E, 1990, NEUROLOGY, V40, P1637, DOI 10.1212/WNL.40.10.1637-a; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; Mortiner J.A., 1988, ETIOLOGY DEMENTIA AL, P39; Muller J, 2001, ARCH NEUROL-CHICAGO, V58, P259, DOI 10.1001/archneur.58.2.259; NAGATSU T, 1988, NEUROSCI LETT, V87, P178, DOI 10.1016/0304-3940(88)90166-8; Nath U, 2003, NEUROLOGY, V60, P910, DOI 10.1212/01.WNL.0000052991.70149.68; Nath U, 2001, BRAIN, V124, P1438, DOI 10.1093/brain/124.7.1438; NEAFSEY EJ, 1989, NEUROSCI LETT, V105, P344, DOI 10.1016/0304-3940(89)90645-9; Nee L E, 1991, Clin Auton Res, V1, P9, DOI 10.1007/BF01826052; NEFZGER MD, 1968, AM J EPIDEMIOL, V88, P149, DOI 10.1093/oxfordjournals.aje.a120874; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; NIWA T, 1989, J CHROMATOGR-BIOMED, V491, P397, DOI 10.1016/S0378-4347(00)82857-1; NIWA T, 1988, J CHROMATOGR, V452, P85, DOI 10.1016/S0021-9673(01)81439-4; NIWA T, 1989, J CHROMATOGR-BIOMED, V493, P347, DOI 10.1016/S0378-4347(00)82740-1; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PEZZOLI G, 1989, LANCET, V2, P874, DOI 10.1016/S0140-6736(89)93050-X; PEZZOLI G, 1990, BRAIN RES, V531, P355, DOI 10.1016/0006-8993(90)90801-H; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Santacruz P, 1998, NEUROLOGY, V50, P1637, DOI 10.1212/WNL.50.6.1637; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Schrag A, 1999, LANCET, V354, P1771, DOI 10.1016/S0140-6736(99)04137-9; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Soto-Otero R, 2001, NEUROSCI LETT, V298, P187, DOI 10.1016/S0304-3940(00)01746-8; SPENCER PS, 1991, NEUROLOGY, V41, P62, DOI 10.1212/WNL.41.5_Suppl_2.62; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; TASAKI Y, 1991, J NEUROCHEM, V57, P1940, DOI 10.1111/j.1471-4159.1991.tb06407.x; TETRUD JW, 1994, NEUROLOGY, V44, P1051, DOI 10.1212/WNL.44.6.1051; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I; Vanacore N, 2000, NEUROLOGY, V54, P114, DOI 10.1212/WNL.54.1.114; Wenning GK, 1998, J NEUROL NEUROSUR PS, V64, P184, DOI 10.1136/jnnp.64.2.184; WINIKATES J, 1994, J NEURAL TRANSM-SUPP, P189; YAMADA T, 1994, ACTA NEUROL SCAND, V89, P42; YOSHIDA M, 1990, NEUROSCI LETT, V119, P109, DOI 10.1016/0304-3940(90)90768-5; ZHANG ZX, 1990, ARCH NEUROL-CHICAGO, V47, P1019, DOI 10.1001/archneur.1990.00530090097019; ZHANG ZX, 1990, ARCH NEUROL-CHICAGO, V47, P1069, DOI 10.1001/archneur.1990.00530100031010	112	44	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.		2003	18			6			S43	S50		10.1002/mds.10562			8	Clinical Neurology	Neurosciences & Neurology	724XW	WOS:000185514400007	14502655				2021-06-18	
J	McKeever, CK; Schatz, P				McKeever, CK; Schatz, P			Current issues in the identification, assessment, and management of concussions in sports-related injuries	APPLIED NEUROPSYCHOLOGY			English	Article						concussion; sports-related injury; mild traumatic brain injury; neuropsychological assessment; athletes; computerized assessment; baseline assessment; sideline assessment	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; STANDARDIZED ASSESSMENT; HIGH-SCHOOL; FOOTBALL	The recent literature has focused on the need for appropriate identification, assessment, and management of sports-related concussion. This article addresses current issues in the prevalence and assessment of sports-related concussion. Despite a paucity of research on female athletes and youth athletes, there is evidence that female athletes are at higher risk for injury than males and that concussions may affect children and young adolescents differently than older adolescents and adults. Sideline, baseline, and postconcussion assessments have become prevalent in documenting preinjury and postinjury performance, tracking recovery rates, and assisting return-to-play decisions. New computerized assessment procedures are growing in popularity and use. Future directions in the assessment and management of sports-related concussion include increased research on prevalence rates and effects of concussions for females and youth athletes, educating parents of youth athletes as well as family physicians on the importance of baseline and postconcussion cognitive assessments, and further validation of computerized assessment measures.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			ALVES WM, 1987, CLIN SPORT MED, V6, P211; Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT, 1989, MILD HEAD INJURY; Bernhardt DT, 2000, PEDIATR ANN, V29, P172, DOI 10.3928/0090-4481-20000301-11; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; *COGSTATE LTD, 1999, COGSP COMP SOFTW; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DICK RW, 1999, NCAA INJURY SURVEILL; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ECHEMENDIA RJ, 1997, NEUROPSYCHOLOGICAL A; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hatfield L, 2001, ARCH CLIN NEUROPSYCH, V16, P828; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 2000, IMMEDIATE POST CONCU; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2001, J ATHL TRAINING, V36, P288; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; Schatz P, 2001, ARCH CLIN NEUROPSYCH, V16, P746; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8	38	44	46	1	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					4	11		10.1207/S15324826AN1001_2			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900002	12734070				2021-06-18	
J	Kline, AE; Yu, JY; Massucci, JL; Zafonte, RD; Dixon, CE				Kline, AE; Yu, JY; Massucci, JL; Zafonte, RD; Dixon, CE			Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats	NEUROSCIENCE LETTERS			English	Article						8-hydroxy-2-(di-n-propylamino)tetralin; controlled cortical impact; Morris water maze; recovery; spatial learning and memory	GLUTAMATE RELEASE; HIPPOCAMPUS; 8-OH-DPAT	To further investigate the efficacy of 5-HT1A receptor agonism on functional and histological outcome in traumatically-brain injured (TBI) rats, a single intraperitoneal injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.1, 0.5, or 1.0 mg/kg) or vehicle was given 15 min after controlled cortical impact or sham injury. Function was assessed by established motor and cognitive tests on post-operative days 1-5 and 14-18, respectively. Cortical lesion volume and hippocampal CA(1)/CA(3) cell survival were quantified at 4 weeks. The administration of 8-OH-DPAT (0.5 mg/kg) attenuated spatial acquisition deficits and reduced hippocampal CA(3) cell loss vs. vehicle (P < 0.05). These data augment published reports that 5-HT1A receptor agonists confer neuroprotective effects after experimental TBI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 201 Lillian Kaufmann Bldg, Pittsburgh, PA 15260 USA.	klineae@msx.upmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 33150, NS 40125, NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS033150, R01NS040125, P01NS030318, P20NS030318] Funding Source: NIH RePORTER		ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fujii T, 1997, BRAIN RES, V761, P244, DOI 10.1016/S0006-8993(97)00325-9; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Koyama T, 1999, NEUROSCI LETT, V265, P33, DOI 10.1016/S0304-3940(99)00200-1; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	17	44	47	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 29	2002	333	3					179	182	PII S0304-3940(02)01101-1	10.1016/S0304-3940(02)01101-1			4	Neurosciences	Neurosciences & Neurology	619MR	WOS:000179480200007	12429377				2021-06-18	
J	Paolin, A; Nardin, L; Gaetani, P; Baena, RRY; Pansarasa, O; Marzatico, F				Paolin, A; Nardin, L; Gaetani, P; Baena, RRY; Pansarasa, O; Marzatico, F			Oxidative damage after severe head injury and its relationship to neurological outcome	NEUROSURGERY			English	Article						Glasgow Outcomes Scale; malonylaldehyde; oxidative damage; severe brain injury; superoxide dismutase; vitamin E	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; VITAMIN-E; ALPHA-TOCOPHEROL; FREE-RADICALS; SUPEROXIDE-DISMUTASE; TIRILAZAD MESYLATE; PREDICTIVE-VALUE; BLOOD-FLOW	OBJECTIVE: We sought to establish the time course of reactive oxygen species after severe head injuries in humans and to investigate the relationship with clinical outcomes. METHODS: Both the markers of oxidative damage-malonylaldehyde (MDA) and the enzymatic and nonenzymatic antioxidant defenses (i.e., superoxide dismutase [SOD] and vitamin E [VE], respectively)-were studied. To assess the time course of MDA, SOD, and VE, jugular bulb (JB) and peripheral venous blood samples were obtained from 30 patients within 8 hours of severe head trauma onset (T-0) and 6 (T-1), 12 (T-2), 24(T-3), and 48 hours (T-4) after trauma onset. Patients were divided into good and poor outcome groups according to their 6-month neurological outcome as determined on the basis of their Glasgow Outcome Scale scores and biochemical profiles. RESULTS: In JB samples, MDA levels increased significantly at T-2 and T-3 as compared with T-0; and VE levels decreased significantly at T-1, T-2, and T-3 as compared with T-0. The same variables did not change significantly over time in peripheral venous blood samples. Moreover, the MDA levels and SOD activity detected in JB samples were significantly higher in the poor outcome at T-1 and T-2. No significant difference in VE levels was observed between the two outcome groups. CONCLUSION: Reactive oxygen species-mediated oxidative damage can play an important role in determining the prognosis of severe brain injury in humans.	Gen Hosp Treviso, Neurosurg Intens Care Unit, Treviso, Italy; Humanitas Clin, Dept Neurosurg, Rozzano, MI, Italy; Univ Pavia, Dept Pharmacol & Physiol Sci, Pharmacol Sect, I-27100 Pavia, Italy	Paolin, A (corresponding author), Osped Ca Foncello, Anesthesiol & Intens Care Med, P Osped 1, I-31100 Treviso, Italy.	apaolin@ulss.tv.it	Pansarasa, Orietta/A-2012-2019	Gaetani, Paolo/0000-0003-0662-5872			BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUSTO R, 1984, ANN NEUROL, V15, P441, DOI 10.1002/ana.410150507; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CATIGNANI GL, 1986, METHOD ENZYMOL, V123, P215, DOI 10.1016/S0076-6879(86)23025-6; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ikeda Y, 2000, ACT NEUR S, V76, P343; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; JOHNSON D, 1993, BRIT J NEUROSURG, V7, P53, DOI 10.3109/02688699308995056; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KIRSCH JR, 1992, J NEUROTRAUM, V9, pS157; KNIGHT JA, 1993, ANN CLIN LAB SCI, V23, P51; Koc PK, 1999, RES EXP MED, V199, P21, DOI 10.1007/s004330050129; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Layton ME, 1997, NEUROSCI LETT, V236, P63, DOI 10.1016/S0304-3940(97)00765-9; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; STRAW RN, 1995, PRELIMINARY EFFICACY; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	47	44	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2002	51	4					949	954		10.1227/01.NEU.0000027881.33381.3F			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	598ZV	WOS:000178308500027	12234402				2021-06-18	
J	Yang, JY; Tsai, FC; Chana, JS; Chuang, SS; Chang, SY; Huang, WC				Yang, JY; Tsai, FC; Chana, JS; Chuang, SS; Chang, SY; Huang, WC			Use of free thin anterolateral thigh flaps combined with cervicoplasty for reconstruction of postburn anterior cervical contractures	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							NECK DEFECTS; HEAD	Free thin anterolateral thigh flaps combined with cervicoplasty were used in a series of seven patients undergoing reconstruction for previous burn injury from September of 2000 to May of 2001 at Chang Gung Memorial Hospital. This method uses a suprafascial dissection technique to provide a thin flap to improve cervical contour. Neck contractures had resulted from flame burns in six patients and from a chemical burn in one patient. The mean age was 32.7 years (range, 22 to 45 years). The size of excised scar ranged from 10 x 2 cm to 26 x 5 cm (mean, 19.7 x 3.3 cm). The size of flaps ranged from 11 x 5 cm to 26 x 8 cm (mean, 21.3 xd 6.5 cm). Average operative time was 6 hours. Average hospital stay was 10 days. All flaps survived, with one flap sustaining partial marginal loss. The donor site was closed primarily in five cases and by using a split-thickness skin graft in two cases. At a mean follow-up time of 5 months, the functional improvement was measured as follows; a mean increase in extension of 30 degrees (preoperatively, 95 degrees; postoperatively, 125 degrees), a mean increase in rotation of 18 degrees (preoperatively, 59 degrees; postoperatively, 77 degrees), and a mean increase in lateral flexion of 12.5 degrees (preoperatively, 26.5 degrees; postoperatively, 39 degrees). The average cervicomandibular angle was improved by 25 degrees (preoperatively, 145 degrees; postoperatively, 120 degrees). This series demonstrates that the use of free thin anterolateral thigh flaps combined with cervicoplasty provides a one-stage reconstruction with a thin, pliable flap that achieves good cervical contour with low donor-site morbidity.	Chang Gung Mem Hosp, Dept Plast Surg, LinKou Burn Ctr, Tao Yuan, Taiwan	Yang, JY (corresponding author), Chang Gung Mem Hosp, Dept Plast Surg, LinKou Burn Ctr, Taipei 5,Fu Hsin St, Tao Yuan, Taiwan.						BAKER TJ, 1977, PLAST RECONSTR SURG, V59, P24, DOI 10.1097/00006534-197701000-00004; BALAKRISHNAN C, 1991, PLAST RECONSTR SURG, V88, P171, DOI 10.1097/00006534-199107000-00040; DECASTRO CC, 1980, ANN PLAST SURG, V4, P370; EDLICH RF, 1984, OTOLARYNG CLIN N AM, V17, P361; ELLENBOGEN R, 1980, PLAST RECONSTR SURG, V66, P826, DOI 10.1097/00006534-198012000-00003; FELDMAN JJ, 1990, PLAST RECONSTR SURG, V85, P333, DOI 10.1097/00006534-199003000-00001; FELDMAN JJ, 1984, PEDIAT PLASTIC SURG, V1; Guerrero-Santos J, 1978, Clin Plast Surg, V5, P29; HYAKUSOKU H, 1994, BRIT J PLAST SURG, V47, P465, DOI 10.1016/0007-1226(94)90028-0; Iwuagwu FC, 1999, PLAST RECONSTR SURG, V103, P1198, DOI 10.1097/00006534-199904040-00015; KENNEY J G, 1990, Journal of Burn Care and Rehabilitation, V11, P443, DOI 10.1097/00004630-199009000-00012; Kimata Y, 1997, ARCH OTOLARYNGOL, V123, P1325; Kimata Y, 1998, PLAST RECONSTR SURG, V102, P1517, DOI 10.1097/00006534-199810000-00026; Knipper P, 1997, ANN PLAS SURG, V39, P566, DOI 10.1097/00000637-199712000-00002; KOBUS K, 1985, ANN PLAS SURG, V15, P14, DOI 10.1097/00000637-198507000-00003; Kobus K, 1988, EUR J PLAST SURG, V11, P126; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P411, DOI 10.1097/00006534-199309000-00004; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P421, DOI 10.1097/00006534-199309000-00005; LAITUNG JKG, 1990, ANN PLAS SURG, V25, P205, DOI 10.1097/00000637-199009000-00010; MARINO H, 1963, Plast Reconstr Surg, V31, P45, DOI 10.1097/00006534-196301000-00005; MASSALSKI TB, 1990, BINARY ALLOY PHASE D, V1, P295; MILLARD DR, 1968, PLAST RECONSTR SURG, V41, P513, DOI 10.1097/00006534-196806000-00001; NEALE HW, 1993, PLAST RECONSTR SURG, V91, P624, DOI 10.1097/00006534-199304000-00009; PETERSON R, 1978, S SURGERY AGING FACE, P115; SONG YG, 1984, BRIT J PLAST SURG, V37, P149, DOI 10.1016/0007-1226(84)90002-X; Vistnes L M, 1979, Ann Plast Surg, V2, P381, DOI 10.1097/00000637-197905000-00004; VOINCHET V, 1995, BURNS, V21, P143, DOI 10.1016/0305-4179(95)92141-X	27	44	46	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0032-1052			PLAST RECONSTR SURG	Plast. Reconstr. Surg.	JUL	2002	110	1					39	46		10.1097/00006534-200207000-00009			8	Surgery	Surgery	565YW	WOS:000176399000009	12087229				2021-06-18	
J	Loop, T; Liu, ZH; Humar, M; Hoetzel, A; Benzing, A; Pahl, HL; Geiger, KK; Pannen, BHJ				Loop, T; Liu, ZH; Humar, M; Hoetzel, A; Benzing, A; Pahl, HL; Geiger, KK; Pannen, BHJ			Thiopental inhibits the activation of nuclear factor kappa B	ANESTHESIOLOGY			English	Article; Proceedings Paper	48th Annual Meeting of the German-Society-of-Anesthesiology-and-Intensive-Care-Medicine	JUN 13-16, 2001	NEURNBERG, GERMANY	German Soc Anesthesiol & Intens Care Med			TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURIES; IN-VITRO; TRANSCRIPTION FACTOR; UNITED-STATES; KINASE; RESPONSES; ALPHA; COMPLEX; PHOSPHORYLATION	Background: Thiopental is frequently used for the treatment of intracranial hypertension after severe head injury. Its longterm administration increases the incidence of nosocomial infections, which contributes to the high mortality rate of these patients. However, the mechanism of its immunosuppressing effect remains unknown. Methods: The effect of thiopental (200-1000 mug/ml) on the activation of the nuclear transcription factor kappaB (NF-kappaB; electrophoretic mobility shift assays), on NF-kappaB-driven reporter gene activity (transient transfection assays), on the expression of NF-kappaB target genes (enzyme-linked immunoassays), on T-cell activation (How cytometric analyses of CD69 expression), and on the content of the NF-kappaB inhibitor IkappaB-alpha (Western blotting) was studied in human T lymphocytes in vitro. Results: Thiopental inhibited the activation of the transcription factor NF-kappaB but did not alter the activity of the cyclic adenosine monophosphate response element binding protein. Other barbiturates (methohexital), anesthetics (etomidate, propofol, ketamine), or opioids (fentanyl, morphine) did not affect NF-kappaB activation. Thiopental-mediated suppression of NF-kappaB could be observed in Jurkat cells and in primary CD3(+) lymphocytes from healthy volunteers, was time- and concentration-dependent, occurred at concentrations that are clinically achieved, and persisted for hours after the incubation. It was associated with an inhibition of NF-kappaB-driven reporter gene activity, of the expression of interleukin-2, -6, and -8, and interferon gamma, and of the activation of CD3(+) lymphocytes. Suppression of NY-kappaB appeared to involve reduced degradation of IkappaB-1alpha. Conclusion: The results demonstrate that thiopental inhibits the activation of NF-kappaB and may thus provide a molecular mechanism for some of the immunosuppressing effects associated with thiopental therapy.	Univ Hosp Freiburg, Dept Anesthesiol, Freiburg, Germany; Univ Hosp Freiburg, Dept Anesthesiol & Crit Care Med, Freiburg, Germany; Univ Hosp Freiburg, Dept Expt Anesthesiol, Freiburg, Germany	Pannen, BHJ (corresponding author), Univ Freiburg, Anasthesiol Klin, Hugstetter Str 55, D-79106 Freiburg, Germany.	pannen@nz.ukl.uni-freiburg.de		Benzing, Albert/0000-0003-3979-6467			Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9; De Deyne C, 2000, EUR J ANAESTH, V17, P3; DONEGAN JH, 1985, AM J PHYSIOL, V249, pH421; EBERHARDT KEW, 1992, INFECTION, V20, P12, DOI 10.1007/BF01704886; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Heine J, 1996, BRIT J ANAESTH, V77, P387; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hofbauer R, 1998, INTENS CARE MED, V24, P973, DOI 10.1007/s001340050698; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KRESS HG, 1989, ACTA ANAESTH SCAND, V33, P122, DOI 10.1111/j.1399-6576.1989.tb02873.x; KRUMHOLZ W, 1995, EUR J ANAESTH, V12, P141; Larsen B, 1998, ANESTHESIOLOGY, V89, P1218, DOI 10.1097/00000542-199811000-00023; Manna SK, 1999, J IMMUNOL, V163, P6800; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOHLER H, 1988, EUR J ANAESTH, P15; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nadal P, 1995, Eur J Emerg Med, V2, P14, DOI 10.1097/00063110-199503000-00004; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; Nishina K, 1998, ANESTH ANALG, V86, P159, DOI 10.1097/00000539-199801000-00032; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pannen B H, 1995, New Horiz, V3, P183; ROBERTS I, 2001, BARBITURATES ACUTE T; Salman H, 1998, LIFE SCI, V63, P2221, DOI 10.1016/S0024-3205(98)00506-2; Salo M, 1997, ANAESTHESIA, V52, P341, DOI 10.1111/j.1365-2044.1997.95-pz0084.x; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tian J, 1999, J NEUROIMMUNOL, V96, P21, DOI 10.1016/S0165-5728(98)00264-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YASUDA T, 1993, INT J LEGAL MED, V105, P239, DOI 10.1007/BF01642801; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	44	52	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2002	96	5					1202	1213		10.1097/00000542-200205000-00025			12	Anesthesiology	Anesthesiology	547EU	WOS:000175320700024	11981162				2021-06-18	
J	Stamatakis, EA; Wilson, JTL; Hadley, DM; Wyper, DJ				Stamatakis, EA; Wilson, JTL; Hadley, DM; Wyper, DJ			SPECT imaging in head injury interpreted with statistical parametric mapping	JOURNAL OF NUCLEAR MEDICINE			English	Article						SPECT; regional cerebral blood flow; head injury; statistical parametric mapping	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; ANTERIOR CINGULATE CORTEX; CEREBRAL-BLOOD-FLOW; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; CT; MILD; MRI; DISEASE	This study investigated regional cerebral blood flow in head-injured patients using statistical parametric mapping (SPM) to detect hypoperfusion on Tc-99m-hexamethylpropyleneamine oxime (HMPAO) SPECT scans. Methods: Acute and follow-up SPECT and MRI scans from 61 patients who were admitted to a regional neurosurgical unit were examined. Patients had acute MRI and SPECT at 2-18 d after injury and on follow-up between 130 and 366 d after injury. Thirty-two scans from non-head-injured patients were used as a SPECT control group. The SPECT images were first aligned to the Talairach-Tournoux atlas and then analzed statistically with SPM. Results: SPECT detected more extensive abnormality than MRI in acute and follow-up stages. This effect was more pronounced on follow-up of patients with diffuse injury. Examination of a focal injury group indicated the involvement of frontal and temporal lobes and the anterior cingulate. Blood flow abnormalities persist, to a lesser extent, on follow-up scans, The diffuse group displayed low blood flow in the frontal and temporal lobes, including cingulate involvement, which persists at follow-up with additional involvement of the thalamus. Conclusion: SPM has a role in SPECT image interpretation because it allows better visualization than other methods of quantitative analysis of the spatial distribution of abnormalities in focal and diffuse head injury. Frontal lobe blood flow abnormality (particulary anterofrontal regions and mesiofrontal areas) is common after head injury.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neuroradiol, Glasgow, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow, Lanark, Scotland	Stamatakis, EA (corresponding author), Univ Cambridge, Ctr Speech & Language, Dept Expt Psychol, Cambridge CB2 3BE, England.	emmanuel@csl.psychol.cam.ac.uk	Wilson, Lindsay/O-8883-2019; Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; BULLOCK R, 1990, ACT NEUR S, V51, P286; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; COSTA DC, 1988, J CEREBR BLOOD F MET, V8, pS109, DOI 10.1038/jcbfm.1988.40; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston K.J., 1994, FUNCTIONAL NEUROIMAG, P79; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; HADLEY DM, 1988, CLIN RADIOL, V39, P131; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Johnson LS, 1999, J NUCL MED, V40, p270P; KARBE H, 1994, NEURORADIOLOGY, V36, P1, DOI 10.1007/BF00599183; Lee JS, 1999, J NUCL MED, V40, p276P; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PRAYER L, 1993, ACTA RADIOL, V34, P593; ROPER SN, 1991, J NUCL MED, V32, P1684; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Stamatakis EA, 1999, NEUROIMAGE, V10, P397, DOI 10.1006/nimg.1999.0477; Stamatakis EA, 2001, NEUROIMAGE, V14, P844, DOI 10.1006/nimg.2001.0884; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Tikofsky RS, 1999, J NUCL MED, V40, p272P; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON JTL, 1997, SPECT IMAGING BRAIN	39	44	46	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	APR	2002	43	4					476	483					8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	540BA	WOS:000174907300013	11937590				2021-06-18	
J	Choi, SC; Clifton, GL; Marmarou, A; Miller, ER				Choi, SC; Clifton, GL; Marmarou, A; Miller, ER			Misclassification and treatment effect on primary outcome measures in clinical trials of severe neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						clinical trials; interobserver variability; misclassifications; number of outcome categories; power; primary outcome measures	DISABILITY RATING-SCALE; HEAD; RECOVERY	The power of clinical trials depends mainly on the choice of the primary outcome measure, the statistical test, and the sample size. The most widely used outcome measure has been the five-category Glasgow Outcome Scale (GOS). Contrary to intuition, we show that more categories do not necessarily increase the power of a trial and actually can decrease power. This is so for two reasons. The more categories of outcome measure used, the more the likelihood for misclassifications. The effect of 0 %, 10 %, and 20 % misclassification rate upon power is illustrated. Misclassification rates in two completed trials are examined based on comparative overlap in GOS and Disability Rating Scale (DRS) categories. The outcome results of the "National Acute Brain Injury Study: Hypothermia" indicate that the ideal number of categories also depends upon the effect of study treatment. In the recently completed hypothermia trial, the use of a dichotomized GOS (good recovery/moderate disability versus severe disability/vegetative/dead) is shown to be more sensitive than use of three or more categories of the GOS. The results point to the importance of training study investigators who will collect the outcome data. The results also indicate that the number of categories should be carefully determined using the pilot data or the data from phase II trials.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Choi, SC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Box 980032, Richmond, VA 23298 USA.	choi@hsc.vcu.edu					Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; JENNETT B, 1975, LANCET, V1, P480; LEHMAN EL, 1976, NONPARAMETRICS STAT; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Marmarou A, 2001, HEAD TRAUMA, P371; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	13	44	44	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2002	19	1					17	22		10.1089/089771502753460204			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	517LD	WOS:000173611300002	11852975				2021-06-18	
J	Robertson, CL; Bell, MJ; Kochanek, PM; Adelson, PD; Ruppel, RA; Carcillo, JA; Wisniewski, SR; Mi, ZC; Janesko, KL; Clark, RSB; Marion, DW; Graham, SH; Jackson, EK				Robertson, CL; Bell, MJ; Kochanek, PM; Adelson, PD; Ruppel, RA; Carcillo, JA; Wisniewski, SR; Mi, ZC; Janesko, KL; Clark, RSB; Marion, DW; Graham, SH; Jackson, EK			Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: Association with severity of injury and excitotoxicity	CRITICAL CARE MEDICINE			English	Article						head injury; purine; pediatrics; Glasgow Coma Scale; glutamate; shaken baby syndrome; child abuse	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; AMINO-ACID RELEASE; GLUTAMATE-EVOKED RELEASE; ENDOGENOUS ADENOSINE; INTERSTITIAL ADENOSINE; RECEPTOR STIMULATION; NMDA RECEPTORS; FOCAL ISCHEMIA; RAT STRIATUM	Objectives. To measure adenosine concentration in the cerebrospinal fluid of infants and children after severe traumatic brain injury and to evaluate the contribution of patient age, Glasgow Coma Scale score, mechanism of injury, Glasgow Outcome Score, and time after injury to cerebrospinal fluid adenosine concentrations. To evaluate the relationship between cerebrospinal fluid adenosine and glutamate concentrations in this population. Design. Prospective survey. Setting. Pediatric intensive care unit in a university-based children's hospital. Patients: Twenty-seven critically ill infants and children who had severe traumatic brain injury (Glasgow Coma Scale <8), who required placement of an intraventricular catheter and drainage of cerebrospinal fluid as part of their neurointensive care. Interventions. None. Measurements and Main Results: Patients ranged in age from 2 months to 14 yrs. Cerebrospinal fluid samples (n = 304) were collected from 27 patients during the first 7 days after traumatic brain injury. Control cerebrospinal fluid samples were obtained from lumbar puncture on 21 infants and children without traumatic brain injury or meningitis. Adenosine concentration was measured by using high-pressure liquid chromatography. Adenosine concentration was increased markedly in cerebrospinal fluid of children after traumatic brain injury vs. controls (p < .001). The increase in cerebrospinal fluid adenosine was independently associated with Glasgow Coma Scale less than or equal to4 vs. >4 and time after injury (both p < .005). Cerebrospinal fluid adenosine concentration was not independently associated with either age (less than or equal to4 vs. >4 yrs), mechanism of injury (abuse vs. other), or Glasgow Outcome Score (good/moderately disabled vs. severely disabled, vegetative, or dead). Of the 27 patients studied, 18 had cerebrospinal fluid glutamate concentration previously quantified by high-pressure liquid chromatography. There was a strong association between increases in cerebrospinal fluid adenosine and glutamate concentrations (p < .005) after injury. Conclusions: Cerebrospinal fluid adenosine concentration is increased in a time- and severity-dependent manner in infants and children after severe head injury. The association between cerebrospinal fluid adenosine and glutamate concentrations may reflect an endogenous attempt at neuroprotection against excitotoxicity after severe traumatic brain injury.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA; Va Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Gen Clin Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Injury Control & Res, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@anes.upmc.edu	Marion, Donald/AAR-5749-2021; Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ARANDA JV, 1989, DEV PHARMACOL THERAP, V13, P96, DOI 10.1159/000457590; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bona E, 1997, NEUROPHARMACOLOGY, V36, P1327, DOI 10.1016/S0028-3908(97)00139-1; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BUCHLI R, 1994, PEDIATR RES, V35, P431, DOI 10.1203/00006450-199404000-00009; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; CHEN Y, 1992, BRIT J PHARMACOL, V106, P632, DOI 10.1111/j.1476-5381.1992.tb14387.x; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Delaney SM, 1998, J PHARMACOL EXP THER, V285, P561; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DUNWIDDIE TV, 1990, ADENOSINE ADENOSINE, P143; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; GAO Y, 1994, LIFE SCI, V55, pPL61, DOI 10.1016/0024-3205(94)00889-2; Geiger Jonathan D., 1997, P55; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HERON A, 1994, BRAIN RES, V641, P217, DOI 10.1016/0006-8993(94)90149-X; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HOEHN K, 1990, J NEUROCHEM, V54, P1716, DOI 10.1111/j.1471-4159.1990.tb01226.x; Jackson EK, 1996, J PHARMACOL EXP THER, V279, P1250; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM YB, 1994, J NEUROSURG, V81, P877, DOI 10.3171/jns.1994.81.6.0877; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Latini S, 1999, BRIT J PHARMACOL, V128, P1035, DOI 10.1038/sj.bjp.0702888; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MATSUMOTO K, 1992, BRAIN RES, V579, P309, DOI 10.1016/0006-8993(92)90066-I; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Miller LP, 1999, STROKE THERAPY, P131; MILLER LP, 1992, J NEUROTRAUM, V9, pS563; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEWBY AC, 1991, PURINE PYRIMIDINE ME, P265; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OREGAN MH, 1992, NEUROSCI LETT, V138, P169, DOI 10.1016/0304-3940(92)90498-V; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; SIMPSON RE, 1992, J NEUROCHEM, V58, P1683, DOI 10.1111/j.1471-4159.1992.tb10041.x; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V365, P9, DOI 10.1016/S0014-2999(98)00788-2; von Lubitz DKJE, 1999, ANN NY ACAD SCI, V890, P93; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; WINN HR, 1981, AM J PHYSIOL, V241, pH235; WINN HR, 1980, AM J PHYSIOL, V239, pH636; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; Zauner A, 1996, ACT NEUR S, V67, P40	67	44	46	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2001	29	12					2287	2293		10.1097/00003246-200112000-00009			7	Critical Care Medicine	General & Internal Medicine	505HN	WOS:000172907500009	11801827				2021-06-18	
J	Suehiro, E; Singleton, RH; Stone, JR; Povlishock, JT				Suehiro, E; Singleton, RH; Stone, JR; Povlishock, JT			The immunophilin ligand FK506 attenuates the axonal damage associated with rapid rewarming following posttraumatic hypothermia	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; hypothermia; rewarming; FK506; beta-amyloid precursor protein (APP); RMO-14	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; CYCLOSPORINE-A; AXOLEMMAL PERMEABILITY; HEAD-INJURY; PHOSPHORYLATION; MODEL; RATS; PROTEOLYSIS; CALCINEURIN	Our laboratory has shown that traumatically induced axonal injury (TAI) is significantly reduced by posttraumatic hypothermia followed by slow rewarming. Further, TAI can be exacerbated by rapid rewarming, and the damaging consequences of rapid rewarming can be reversed by cyclosporin A, which is believed to protect via blunting mitochondrial permeability transition (MPT). In this communication, we continue investigating the damaging consequences of rapid posthypothermic rewarming and the protective role of immunophilin ligands using another member of the immunophilin family, FK506, which does not affect MPT but rather inhibits calcineurin. Rats were subjected to impact-acceleration brain injury followed by the induction of hypothermia with subsequent rapid or slow posthypothermic rewarming. During rewarming, animals received either FK506 or its vehicle. Three hours postinjury, animals were prepared for the visualization of TAI via antibodies targeting impaired axoplasmic transport (APP) and/or overt neurofilament alteration (RMO-14). Rapid rewarming exacerbated TAI, which was attenuated by FK506. This protection was statistically significant for the APP-immunoreactive fibers but not for the RMO-14-positive fibers. Combined labeling, using one chromagen to visualize both axonal changes, suggested that these two immunoreactive profiles revealed two distinct pathologies not occurring along the same axon. Collectively, these studies confirmed previous observations identifying the adverse consequences of rapid rewarming while also showing the complexity of the pathobiology of TAL Additionally, the demonstration that FK506 is protective suggests that calcineurin may be a major target for neuroprotection. (C) 2001 Academic Press.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi 7558505, Japan	Suehiro, E (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980709, Richmond, VA 23298 USA.		Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kaplan B, 1996, TRANSPLANTATION, V62, P1174, DOI 10.1097/00007890-199610270-00025; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOIZUMI H, 2001, IN PRESS BRAIN RES; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Lee RKK, 1999, J NEUROSCI, V19, P940; LEE VMY, 1987, J NEUROSCI, V7, P3474; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lote CJ, 2000, CLIN SCI, V99, P285, DOI 10.1042/CS20000076; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin R, 1999, NEUROSCIENCE, V88, P327, DOI 10.1016/S0306-4522(98)00244-9; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pijak DS, 1996, J COMP NEUROL, V368, P569; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; POVLISHOCK JT, 2001, HEAD TRAUMA BASIC PR; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197	38	44	45	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	NOV	2001	172	1					199	210		10.1006/exnr.2001.7765			12	Neurosciences	Neurosciences & Neurology	491BH	WOS:000172087800017	11681852				2021-06-18	
J	Lees-Haley, PR; Fox, DD; Courtney, JC				Lees-Haley, PR; Fox, DD; Courtney, JC			A comparison of complaints by mild brain injury claimants and other claimants describing subjective experiences immediately following their injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; postconcussive symptoms	BASE RATES; SYNDROME QUESTIONNAIRE; SYMPTOMS; HEAD	This study compares the rate of postconcussive (PCS) symptoms at the time of injury for mild traumatic brain injury (MTBI; N=24) claimants and claimants reporting other forms of injury (OI; N=66). On checklists surveying their complaints immediately after their injury, MTBI and OI claimants reported similar levels of many PCS complaints, e.g., dazed, confused, dizzy, disoriented, trouble concentrating, numbness or loss of sensation, and loss of memory for some of what happened. One in four of the OI samples reported partial loss of consciousness (LOC), and one-third reported loss of memory for some of what happened. About 67% of the MTBI sample reported being confused and 71% dazed, but so did many of the OI sample (52% dazed, 65% confused). The authors suggest that classical PCS complaints experienced immediately after an injury are so nonspecific that they have little diagnostic specificity. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Lees Haley Psychol Corp, Woodland Hills, CA 91364 USA; Clin Neuropsychol PC, Mishawaka, IN USA	Lees-Haley, PR (corresponding author), Lees Haley Psychol Corp, 21331 Costanso St, Woodland Hills, CA 91364 USA.						Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86	12	44	45	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	OCT	2001	16	7					689	695		10.1016/S0887-6177(00)00092-5			7	Psychology, Clinical; Psychology	Psychology	473RK	WOS:000171061700006	14589787	Bronze			2021-06-18	
J	Rovlias, A; Kotsou, S				Rovlias, A; Kotsou, S			The blood leukocyte count and its prognostic significance in severe head injury	SURGICAL NEUROLOGY			English	Article						head injury; leukocytosis; neurological outcome; severity of injury	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN INJURY; SUBARACHNOID HEMORRHAGE; CEREBRAL-ISCHEMIA; REPERFUSION INJURY; MYOCARDIAL INJURY; SKELETAL-MUSCLE; PLASMA; CATECHOLAMINES; INTERLEUKIN-1	BACKGROUND Head injury is associated with increased blood levels of catecholamines and cortisol. Catecholamines release neutrophil stores, and corticosteroids cause a decrease in the egress of neutrophils from the circulation. The acute-phase response is also characterized by a leukocytosis upon admission. Therefore, it is possible that an increase in the white blood cell (WBC) count might serve as an additional diagnostic and prognostic indicator in head injury. METHODS We prospectively studied 624 patients with severe, moderate, or minor head injury who were admitted to the neurosurgical department of Asclepeion Hospital in Athens between December 1997 and March 1999. In all cases, WBC count was obtained on admission to the emergency department. Factors that might influence WBC were excluded from this study. RESULTS Patients with severe head injury had significantly higher white blood cell counts than did those with moderate or minor injury (p < 0.001). Among the patients with severe head injury, a significant relationship was found between WBC counts and Glasgow Coma Scale score, pupillary reaction, and presence of subarachnoid hemorrhage (p < 0.001). In the same group of patients, WBC counts were significantly higher in those with an unfavorable outcome (p < 0.001). Multivariate analysis also showed that WBC counts were an independent predictor of outcome. CONCLUSIONS WBC counts on admission could serve as a significant parameter of severity of injury and as an additional predictor of neurological outcome in patients with severe head injury. (C) 2001 by Elsevier Science Inc.	Asclepeion Gen Hosp, Dept Neurosurg, Athens, Greece	Rovlias, A (corresponding author), 55 Erasinidou Str, Athens 17237, Greece.						Bednar MM, 1997, NEUROL RES, V19, P588; BOGGS DANE R., 1967, SEMINAR HEMATOL, V4, P359; Bouzarth NF, 1986, SURG GYNECOL OBSTET, V126, P995; CAPPS JA, 1896, AM J MED SCI, V3, P650; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COCHRANE CG, 1966, J EXP MED, V124, P733, DOI 10.1084/jem.124.4.733; CRUICKSHANK J M, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P634; CRUICKSHANK JM, 1972, J OBSTET GYN BR COMM, V79, P450; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Dale DC, 1991, PRINCIPLES INTERNAL, P359; DEKABAN A, 1952, AMA ARCH NEUROL PSY, V67, P641, DOI 10.1001/archneurpsyc.1952.02320170059008; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ENGLER RL, 1983, AM J PATHOL, V111, P98; FANTONE JC, 1982, AM J PATHOL, V107, P397; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARLAN JM, 1985, BLOOD, V65, P513; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, P699; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HUGHES WL, 1963, ARCH INTERN MED, V111, P338, DOI 10.1001/archinte.1963.03620270064010; JACKSON IJ, 1949, ARCH NEURO PSYCHIATR, V62, P572, DOI 10.1001/archneurpsyc.1949.02310170047004; JANOFF A, 1965, J EXP MED, V122, P841, DOI 10.1084/jem.122.5.841; JENNETT B, 1975, LANCET, V1, P480; JOLLY SR, 1983, CIRCULATION, V68, P185; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KAKARIEKA A, 1995, CEREBROVASC DIS, V5, P403, DOI 10.1159/000107892; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KORTHUIS RJ, 1988, AM J PHYSIOL, V254, pH823; KSIEZYCKA E, 1983, CIRCULATION, V68, P185; LUCCHESI BR, 1986, ANNU REV PHARMACOL, V26, P201, DOI 10.1146/annurev.pa.26.040186.001221; MARCUS AJ, 1983, STROKE, V14, P475, DOI 10.1161/01.STR.14.4.475; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McLaurin RL, 1974, HDB CLIN NEUROLOGY, V23, P109; Metchnikoff E., 1887, ANN I PASTEUR, V1, P321; MISSORI P, 1997, CLIN NEUROLOGY NEU S, V99, pS79; MOUFARRIJ NA, 1984, J NEUROSURG, V61, P1107, DOI 10.3171/jns.1984.61.6.1107; NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; Pentelenyi T, 1992, Acta Neurochir Suppl (Wien), V55, P21; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; POZZILLI C, 1985, ACTA NEUROL SCAND, V71, P396; RAO PS, 1983, CIRCULATION, V68, P185; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SCHMIDSCHONBEIN GW, 1987, FASEB J, V46, P2397; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Smith RR, 1988, CEREBRAL VASOSPASM; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; SUVAL WD, 1987, AM J SURG, V154, P211, DOI 10.1016/0002-9610(87)90181-4; TEASDALE G, 1974, LANCET, V2, P81; VASTHARE US, 1990, SURG NEUROL, V33, P261, DOI 10.1016/0090-3019(90)90046-R; VONHOLST H, 1982, ACTA NEUROCHIR, V62, P177, DOI 10.1007/BF01403622; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YAMAKAWA T, 1987, CIRC SHOCK, V22, P323	64	44	57	0	5	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	APR	2001	55	4					190	196		10.1016/S0090-3019(01)00414-1			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	433WQ	WOS:000168784000001	11358584				2021-06-18	
J	Wheeler, MA; McMillan, CT				Wheeler, Mark A.; McMillan, Corey T.			Focal retrograde amnesia and the episodic-semantic distinction	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article							TEMPORAL-LOBE PATHOLOGY; CLOSED-HEAD INJURY; AUTOBIOGRAPHICAL EVENTS; MEMORY-DEFICIT; RETRIEVAL; PATIENT; RECOVERY; SELF; CONSOLIDATION; DISSOCIATION	This article reports a review of focal retrograde amnesia (FRA), or the phenomenon of organically based severe memory loss restricted to retrograde, or pretraumatic, memory. Cases of FRA are classified according to the type of memory loss: episodic, semantic, or both. A few different clusters of the disorder were identified. Lesions to either the anterior temporal lobes or the posterior/visual cortex can result in an FRA that devastates retrograde episodic memory, while having smaller effects on semantic memory. A number of left-hemisphere patients have FRA confined to semantic memory. There are several additional examples of FRA following minor cerebral trauma that disrupts either episodic memory alone or both episodic and semantic memory that are not accompanied by evidence of structural brain lesions. We discuss these different profiles of FRA and their implications for the understanding of memory retrieval.	[Wheeler, Mark A.; McMillan, Corey T.] Temple Univ, Philadelphia, PA 19122 USA	Wheeler, MA (corresponding author), Temple Univ, Dept Psychol, Weiss Hall, Philadelphia, PA 19122 USA.	mwheeler@nimbus.temple.edu	McMillan, Corey/M-3228-2013	McMillan, Corey/0000-0002-7581-6405			BROWN JW, 1995, APHASIOLOGY, V9, P163, DOI 10.1080/02687039508248703; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; Carlesimo GA, 1998, CORTEX, V34, P449, DOI 10.1016/S0010-9452(08)70767-6; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; CROVITZ HF, 1976, B PSYCHONOMIC SOC, V7, P61, DOI 10.3758/BF03337122; CROVITZ HF, 1974, B PSYCHONOMIC SOC, V4, P517; Dalla Barba G, 1998, CORTEX, V34, P547; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DeRenzi E, 1997, NEUROPSYCHOLOGIA, V35, P781, DOI 10.1016/S0028-3932(97)00018-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; Evans JJ, 1996, NEUROCASE, V2, P1; Fink GR, 1996, J NEUROSCI, V16, P4275; Fujii T, 1999, CORTEX, V35, P599, DOI 10.1016/S0010-9452(08)70822-0; Galton F., 1879, BRAIN, V2, P148, DOI DOI 10.1093/BRAIN/2.2.149; Glenberg AM, 1997, BEHAV BRAIN SCI, V20, P1, DOI 10.1017/S0140525X97470012; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; HODGES JR, 1993, BRAIN, V116, P921, DOI 10.1093/brain/116.4.921; HOKKANEN L, 1995, PSYCHOL MED, V25, P203, DOI 10.1017/S0033291700028245; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; KAPUR N, 1994, NEUROPSYCHOLOGIA, V32, P23, DOI 10.1016/0028-3932(94)90066-3; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; Kapur N, 1996, J COGNITIVE NEUROSCI, V8, P416, DOI 10.1162/jocn.1996.8.5.416; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; KIHLSTROM JF, 1995, HDB MEMORY DISORDERS, P337; Klein SB, 1996, J EXP PSYCHOL GEN, V125, P250, DOI 10.1037/0096-3445.125.3.250; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Maguire EA, 1999, HIPPOCAMPUS, V9, P54, DOI 10.1002/(SICI)1098-1063(1999)9:1<54::AID-HIPO6>3.0.CO;2-O; Maravita A, 1995, CORTEX, V31, P653, DOI 10.1016/S0010-9452(13)80018-4; Markowitsch HJ, 1999, CORTEX, V35, P243, DOI 10.1016/S0010-9452(08)70797-4; MARKOWITSCH HJ, 1985, J COMP NEUROL, V242, P425, DOI 10.1002/cne.902420310; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P947, DOI 10.1080/01688639308402610; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Nyberg L, 1995, NEUROREPORT, V7, P249, DOI 10.1097/00001756-199512000-00060; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; PANDYA DN, 1987, FRONTAL LOBES REVISI, P159; Reinvang I, 1998, NEUROPSYCHOLOGIA, V36, P1335, DOI 10.1016/S0028-3932(98)00021-9; ROMANCAMPOS G, 1980, CORTEX, V16, P509, DOI 10.1016/S0010-9452(80)80053-0; Rubin DC, 1998, P NATL ACAD SCI USA, V95, P5413, DOI 10.1073/pnas.95.9.5413; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; Snowden JS., 1996, FRONTOTEMPORAL LOBAR; STRACCIARI A, 1994, CORTEX, V30, P459, DOI 10.1016/S0010-9452(13)80341-3; STUSS DT, 1988, BRAIN COGNITION, V8, P21, DOI 10.1016/0278-2626(88)90036-X; Tanaka Y, 1999, NEUROLOGY, V53, P344, DOI 10.1212/WNL.53.2.344; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; TULVING E, 1984, BEHAV BRAIN SCI, V7, P223, DOI 10.1017/S0140525X0004440X; Tulving E, 1983, ELEMENTS EPISODIC ME; Viskontas IV, 2000, J NEUROSCI, V20, P5853; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; WILLIAMS M, 1954, J NEUROL NEUROSUR PS, V17, P173, DOI 10.1136/jnnp.17.3.173; Yasuda K, 1997, CORTEX, V33, P623, DOI 10.1016/S0010-9452(08)70721-4; YONEDA Y, 1992, EUR NEUROL, V32, P340, DOI 10.1159/000116857	66	44	46	0	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	MAR	2001	1	1					22	36		10.3758/CABN.1.1.22			15	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	V32LU	WOS:000208953500004	12467101	Bronze			2021-06-18	
J	Bell, MJ; Robertson, CS; Kochanek, PM; Goodman, JC; Gopinath, SP; Carcillo, JA; Clark, RSB; Marion, DW; Mi, ZC; Jackson, EK				Bell, MJ; Robertson, CS; Kochanek, PM; Goodman, JC; Gopinath, SP; Carcillo, JA; Clark, RSB; Marion, DW; Mi, ZC; Jackson, EK			Interstitial brain adenosine and xanthine increase during jugular venous oxygen desaturations in humans after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	27th Annual Meeting of the Society-of-Neuroscience	OCT 25-30, 1997	NEW ORLEANS, LA	Soc Neurosci		adenosine; humans; jugular venous oxygen desaturation; microdialysis; xanthine; head injury	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; CORTICAL-NEURONS; RAT; MICRODIALYSIS; ISCHEMIA; METABOLISM; RELEASE; THEOPHYLLINE; RECEPTOR	Objective: Adenosine decreases the cerebral metabolic rate for oxygen and increases cerebral blood flow, and it may play an important role in cerebrometabolic and cerebrovascular responses to hypoperfusion after traumatic brain injury. Jugular venous oxygen saturation is monitored after traumatic brain injury to assess brain oxygen extraction, and desaturations may reflect secondary brain insults. We hypothesized that brain interstitial adenosine and related purine metabolites would be increased during jugular venous oxygen saturation desaturations (<50%) and determined associations between the purines, lactate, and glucose to assess the role of adenosine during secondary insults in humans. Design: Study of critically ill adults with severe traumatic brain injury, Setting: Adult neurointensive care unit. Patients: We prospectively defined periods of normal saturation and desaturation in six patients after severe traumatic brain injury. Interventions: During these periods, cerebral microdialysis samples of brain interstitial fluid were collected, and adenosine and purine metabolites were measured by high-pressure liquid chromatography, Measurements and Main Results: Adenosine increased 3.1-fold and xanthine increased 2.5-fold during desaturation periods (both p <.05 vs. normal saturation period, signed rank). Adenosine, xanthine, hypoxanthine, and cyclic-adenosine monophosphate correlated with lactate over both study periods (r(2) =.32, .14, .31, .07, and .26, respectively, all p < .05, Pearson product moment correlation). Conclusion: The marked increases in interstitial brain adenosine that occur during jugular venous oxygen desaturations suggest that adenosine may play an important role during periods of secondary insults after traumatic brain injury. The correlation of these metabolites with lactate further suggests that adenosine is increased during periods of enhanced glycolytic metabolism.	Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Bell, MJ (corresponding author), Safar Ctr Resuscitat Res, Pittsburgh, PA USA.		Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, P01NS030318, P50NS030318, P01NS027616, P20NS030318, P50NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS38087, NS27616] Funding Source: Medline		ANGELLO DA, 1991, AM J PHYSIOL, V260, pH193; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; DONAGHY KM, 1994, BRAIN RES, V656, P174, DOI 10.1016/0006-8993(94)91380-3; FLEISCHER AS, 1977, J NEUROSURG, V47, P517, DOI 10.3171/jns.1977.47.4.0517; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; Geiger Jonathan D., 1997, P55; GIDDAY JM, 1995, PEDIATR RES, V38, P306, DOI 10.1203/00006450-199509000-00006; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Goodman JC, 1996, ACT NEUR S, V67, P37; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HYLLAND P, 1994, J CEREBR BLOOD F MET, V14, P877, DOI 10.1038/jcbfm.1994.110; KIM YB, 1994, J NEUROSURG, V81, P877, DOI 10.3171/jns.1994.81.6.0877; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; LAUDIGNON N, 1990, J APPL PHYSIOL, V68, P1534; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; MI ZC, 1995, J PHARMACOL EXP THER, V273, P728; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MORI M, 1992, NEUROSCIENCE, V46, P301, DOI 10.1016/0306-4522(92)90052-4; MORII S, 1987, AM J PHYSIOL, V253, pH165; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PHILLIS JW, 1975, EUR J PHARMACOL, V30, P125, DOI 10.1016/0014-2999(75)90214-9; PINARD E, 1990, BRAIN RES, V511, P303, DOI 10.1016/0006-8993(90)90175-B; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; vonLubitz DKJE, 1997, ANN NY ACAD SCI, V825, P49; WINN HR, 1981, AM J PHYSIOL, V241, pH235; WINN HR, 1979, CIRC RES, V45, P486, DOI 10.1161/01.RES.45.4.486; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU L, 1991, BRAIN RES, V540, P307, DOI 10.1016/0006-8993(91)90525-Z; Zauner A, 1996, ACT NEUR S, V67, P40	43	44	45	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2001	29	2					399	404		10.1097/00003246-200102000-00033			6	Critical Care Medicine	General & Internal Medicine	405UR	WOS:000167179400027	11246323				2021-06-18	
J	Marklund, N; Clausen, F; Lewen, A; Hovda, DA; Olsson, Y; Hillered, L				Marklund, N; Clausen, F; Lewen, A; Hovda, DA; Olsson, Y; Hillered, L			alpha-Phenyl-tert-N-butyl nitrone (PBN) improves functional and morphological outcome after cortical contusion injury in the rat	ACTA NEUROCHIRURGICA			English	Article						MAP-2; Morris Water Maze; PBN; radical; rat; scavenger; TBI	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; SPATIAL MEMORY PERFORMANCE; EXPERIMENTAL HEAD-INJURY; SPIN-TRAPPING AGENT; CEREBRAL BLOOD-FLOW; FLUID-PERCUSSION; SUPEROXIDE-DISMUTASE; FREE-RADICALS; LIPID-PEROXIDATION	alpha -Phenyl-tert-N-butyl nitrone (BBN), a potent reactive oxygen species (ROS) scavenger, has shown robust neuroprotective properties in several models of acute brain injury, although not previously evaluated in traumatic brain injury (TBI). In this study, we assessed the potential efficacy of PEN in a weight drop model producing a controlled cortical contusion. Sham operation, mild or severe injury was induced in intubated and ventilated rats and functional and morphological outcome was used as end-points at two weeks postinjury. In the trauma groups, saline or PEN (30 mg/kg) was injected as an intravenous bolus 30 minutes prior to injury. At day 11-15 post-injury, cognitive disturbance was assessed using the Morris Water Maze (MWM) and estimation of lesion volume and hemispheric loss of tissue was made. No change in MWM performance were found in either of the mildly traumatized groups as compared to uninjured controls. In contrast, a significant decrease in total mean latency and increase in path length in the severely traumatized rats were found. PEN-treatment significantly improved MWM performance as compared to saline treatment at the severe injury level (p < 0.05). The mild injury level caused a discrete atrophy of the ipsilateral cortex with no effect of PEN treatment. The severe injury caused a substantial loss of ipsilateral hemispheric tissue and a large cortical cavitation. PEN pre-treatment significantly reduced the lesion volume and reduced hemispheric loss of tissue at this injury level (p < 0.05). Our results support the involvement of ROS in the injury process contributing to the tissue loss and cognitive disturbance after TBI. The potential clinical utility of PEN will have to be assessed using a post-injury dosing regime.	Univ Uppsala Hosp, Dept Neurosurg, Uppsala, Sweden; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			AU AM, 1985, J CELL BIOCHEM, V27, P449, DOI 10.1002/jcb.240270413; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; CHEN GM, 1990, FREE RADICAL BIO MED, V9, P93, DOI 10.1016/0891-5849(90)90110-5; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CLAUSEN F, 1999, SOC NEUR ABSTR, V29, P822; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Conti AC, 1998, J NEUROSCI, V18, P5663; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Farooque M, 1997, J NEUROTRAUM, V14, P469, DOI 10.1089/neu.1997.14.469; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferger B, 1998, J NEUROCHEM, V70, P276; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hensley K, 1998, J NEUROCHEM, V71, P2549; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; INANAMI O, 1995, FREE RADICAL RES, V23, P33, DOI 10.3109/10715769509064017; Kawamata T, 1997, ACT NEUR S, V70, P191; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marshall L F, 1995, New Horiz, V3, P573; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Sack CA, 1996, NEUROSCI LETT, V205, P181, DOI 10.1016/0304-3940(96)12417-4; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	68	44	44	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2001	143	1					73	81		10.1007/s007010170141			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	402CA	WOS:000166967400031	11345721				2021-06-18	
J	Irazuzta, JE; Pretzlaff, R; Rowin, M; Milam, K; Zemlan, FP; Zingarelli, B				Irazuzta, JE; Pretzlaff, R; Rowin, M; Milam, K; Zemlan, FP; Zingarelli, B			Hypothermia as an adjunctive treatment for severe bacterial meningitis	BRAIN RESEARCH			English	Article						meningitis; hypothermia; intracranial pressure; cerebral perfusion pressure; inflammation; cleaved tau protein	TRAUMATIC BRAIN INJURY; NITRIC-OXIDE SYNTHASE; CEREBRAL PERFUSION-PRESSURE; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; RAT-BRAIN; MYELOPEROXIDASE ACTIVITY; NEUTROPHIL ACCUMULATION; HEAD-INJURY	Brain injury due to bacterial meningitis results in a high mortality rate and significant neurologic sequelae in survivors. The objective of this study was to determine if the application of moderate hypothermia shortly after the administration of antibiotics would attenuate the inflammatory response and increase in intracranial pressure that occurs in meningitis. For this study we used a rabbit model of severe Group B streptococcal meningitis. The first component of this study evaluated the effects of hypothermia on blood-brain barrier function and markers of inflammation in meningitic animals. The second part of the study evaluated the effects of hypothermia on intracranial pressure, cerebral perfusion pressure and brain edema. This study demonstrates that the use of hypothermia preserves CSF/serum glucose ratio, decreases CSF protein and nitric oxide and attenuates myeloperoxidase activity in brain tissue. In the second part of this study we show a decrease in intracranial pressure, an improvement in cerebral perfusion pressure and a decrease in cerebral edema in hypothermic meningitic animals. We conclude that in the treatment of severe bacterial meningitis, the application of moderate hypothermia initiated shortly after antibiotic therapy improves short-term physiologic measures associated with brain injury. (C) 2000 Elsevier Science B.V. All rights reserved.	Childrens Hosp, Med Ctr, Div Crit Care, Cincinnati, OH 45229 USA; Marshall Univ, Huntington, WV USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Irazuzta, JE (corresponding author), Div Crit Care, 1 Childrens Plaza, Dayton, OH 45404 USA.	irazuzta@aol.com					AMAEE FR, 1995, ACTA OTO-LARYNGOL, V115, P386, DOI 10.3109/00016489509139334; Angstwurm K, 2000, J CEREBR BLOOD F MET, V20, P834, DOI 10.1097/00004647-200005000-00010; ARDITI M, 1989, J INFECT DIS, V160, P1005, DOI 10.1093/infdis/160.6.1005; Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BERING EA, 1961, AM J PHYSIOL, V200, P417; Black SM, 1995, NEUROBIOL DIS, V2, P145, DOI 10.1006/nbdi.1995.0016; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4; BURYAKOVA AV, 1975, ARCH NEUROL-CHICAGO, V32, P28, DOI 10.1001/archneur.1975.00490430050007; BUSTER BL, 1995, INFECT IMMUN, V63, P3835, DOI 10.1128/IAI.63.10.3835-3839.1995; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CANEVARY L, 1999, BRAIN RES, V817, P341; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hansbrough JF, 1996, J SURG RES, V61, P17, DOI 10.1006/jsre.1996.0074; HOROWITZ L, 1997, AM J PHYSIOL, V272, pH614; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; Irazuzta JE, 2000, LIFE SCI, V67, P365, DOI 10.1016/S0024-3205(00)00637-8; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; KELLY BJ, 1993, CHEST, V103, P1246, DOI 10.1378/chest.103.4.1246; KILPI T, 1993, PEDIATR INFECT DIS J, V12, P184, DOI 10.1097/00006454-199303000-00002; Kim YS, 1996, INFECT IMMUN, V64, P3148, DOI 10.1128/IAI.64.8.3148-3153.1996; KIM YS, 1995, J NEUROPATH EXP NEUR, V54, P531, DOI 10.1097/00005072-199507000-00007; Koedel U, 1999, BRAIN PATHOL, V9, P57; Kornelisse RF, 1996, J INFECT DIS, V174, P120, DOI 10.1093/infdis/174.1.120; Lahrtz F, 1998, J NEUROIMMUNOL, V85, P33, DOI 10.1016/S0165-5728(97)00267-1; LEBEL MH, 1989, PEDIATRICS, V83, P161; Marion DW, 1997, J INTENSIVE CARE MED, V12, P239, DOI 10.1177/088506669701200504; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; Moller K, 2000, CRIT CARE MED, V28, P1027, DOI 10.1097/00003246-200004000-00019; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUSTAFA MM, 1989, J CLIN INVEST, V84, P1253, DOI 10.1172/JCI114292; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; RENNICK G, 1993, BRIT MED J, V306, P953, DOI 10.1136/bmj.306.6883.953; RISCHBIETH R. H., 1960, MED JOUR AUSTRALIA I, V47, P578; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; Rowin ME, 1999, PEDIATR RES, V45, p173A, DOI 10.1203/00006450-199904020-01028; ROWIN ME, 2000, INFLAMMATION, V23, P23; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SWARTZ MN, 1984, NEW ENGL J MED, V14, P912; TAUBER MG, 1987, J INFECT DIS, V156, P456, DOI 10.1093/infdis/156.3.456; Tucci S, 1998, CLIN BIOCHEM, V31, P143, DOI 10.1016/S0009-9120(98)00003-4; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whalen MJ, 1997, ACT NEUR S, V70, P260; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; ZEMLAN FP, 1997, NEUR ABSTR, V23, P2220; ZEMLAN FP, 2000, IN PRESS CHARACTERIZ; Zingarelli B, 1996, J IMMUNOL, V156, P350	66	44	48	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 20	2000	881	1					88	97		10.1016/S0006-8993(00)02894-8			10	Neurosciences	Neurosciences & Neurology	366ZQ	WOS:000090036500012	11033098				2021-06-18	
J	Kirkwood, M; Janusz, J; Yeates, KO; Taylor, HG; Wade, SL; Stancin, T; Drotar, D				Kirkwood, M; Janusz, J; Yeates, KO; Taylor, HG; Wade, SL; Stancin, T; Drotar, D			Prevalence and correlates of depressive symptoms following traumatic brain injuries in children	CHILD NEUROPSYCHOLOGY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB 09-12, 2000	DENVER, CO	Int Neuropsychol Soc			PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; HEAD-INJURY; ADOLESCENTS; RECOVERY; RELIABILITY; CHILDHOOD; SEVERITY; VALIDITY; STRESS	The prevalence and correlates of depressive symptoms following childhood traumatic brain injuries (TBI), were examined using data drawn from a prospective longitudinal study. Participants included 38 children with severe TBI, 51 with moderate TBI, and 55 with orthopedic injuries (OI). Assessments occurred shortly after injury (baseline) and at 6- and 12-month follow-ups. Children completed the Child Depression Inventory (CDI). Parents rated depressive symptoms using the Child Behavior Checklist (CBC); with baseline ratings reflecting premorbid status. Assessments also included measures of children's neurocognitive functioning and the family environment. The three groups did not differ overall in self-reported symptoms on the CDI, but did display different trends over time. The three groups did not differ on parent ratings of premorbid depressive symptoms on the CBC, but parents reported more depressive symptoms in the TBI groups than in the OI group at 6- and 12-month follow-ups. Child and parent reports were correlated for children in the TBI groups, but not for those in the OI group. Depressive symptoms were related to socioeconomic status in all groups. Socioeconomic status also was a significant moderator of group differences, such that the effects of TBI were exacerbated in children from more disadvantaged homes. Although self-reports of depressive symptoms were related inconsistently to children's verbal memory, parent reports of depressive symptoms were unrelated to IQ or verbal memory. The findings suggest that TBI increases the risk of depressive symptoms, especially among more socially disadvantaged children, and that depressive symptoms are not strongly related to post-injury neurocognitive deficits.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Univ Cincinnati, Dept Phys Med & Rehabil Med, Cincinnati, OH USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Cleveland, OH USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Janusz, Jennifer/0000-0002-6877-0947; Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 RO1 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENNETT DS, 1994, J PEDIATR PSYCHOL, V19, P149, DOI 10.1093/jpepsy/19.2.149; BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cole DA, 2000, PSYCHOL ASSESSMENT, V12, P174, DOI 10.1037//1040-3590.12.2.174; CRAIGHEAD WE, 1995, PSYCHOL ASSESSMENT, V7, P171, DOI 10.1037/1040-3590.7.2.171; DELIS D, 1986, CALIFORNIA VERBAL LE; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEDEROFF JP, 1993, DEPRESSION NEUROLOGI, P139; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GORE S, 1992, J HEALTH SOC BEHAV, V33, P97, DOI 10.2307/2137249; HODGES K, 1990, PSYCHOL ASSESSMENT J, V2, P489, DOI DOI 10.1037/1040-3590.2.4.489; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KASLOW NJ, 1984, J ABNORM CHILD PSYCH, V12, P605, DOI 10.1007/BF00916853; KENDALL PC, 1989, COGNITIVE THER RES, V13, P109, DOI 10.1007/BF01173268; Kovacs M., 1992, CHILDRENS DEPRESSION; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LARSON RW, 1990, J ABNORM PSYCHOL, V99, P92, DOI 10.1037/0021-843X.99.1.92; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; REINHERZ HZ, 1993, J AM ACAD CHILD PSY, V32, P1155, DOI 10.1097/00004583-199311000-00007; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Sattler J. M., 1992, ASSESSMENT CHILDREN; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wechsler D., 1991, WECHSLER INTELLIGENC; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, IN PRESS J PEDIAT PS	54	44	44	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	SEP	2000	6	3					195	208		10.1076/chin.6.3.195.3157			14	Clinical Neurology	Neurosciences & Neurology	437EU	WOS:000168978600004	11402397				2021-06-18	
J	Cornwall, R; Radomisli, TE				Cornwall, R; Radomisli, TE			Nerve injury in traumatic dislocation of the hip	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							MAGNETIC-RESONANCE NEUROGRAPHY; BRACHIAL-PLEXUS; DIAGNOSIS	Neurologic injury often accompanies traumatic dislocation and fracture-dislocation of the hip. A review of the literature reveals an incidence of approximately 10% in adults and 5% in children. The sciatic nerve, usually the peroneal branch, is most often injured, and this complication can be seen after all types of posterior fracture-dislocations and simple posterior dislocations. The sciatic nerve can be acutely lacerated, stretched, or compressed, or later encased in heterotopic ossification. Neurologic examination at the time of injury often is difficult but is extremely important. Once a nerve injury is discovered, prompt closed reduction must be attempted to relieve distortion of the nerve from a dislocated femoral head or displaced acetabular fracture. Considerable controversy surrounds the recommendations for additional treatment of nerve injury once the hip has been reduced. At least partial recovery of nerve function occurs in 60% to 70% of patients, with no clear correlation with injury or treatment type. Rehabilitation of patients with sciatic nerve injury must begin as early as possible and should focus on the prevention of an equinus foot deformity. Magnetic resonance neurography may become useful in the future for initial evaluation of patients with this injury.	Mt Sinai Hosp, Mt Sinai Sch Med, Dept Orthopaed Surg, New York, NY 10029 USA	Radomisli, TE (corresponding author), Mt Sinai Hosp, Mt Sinai Sch Med, Dept Orthopaed Surg, 5 E 98th St,Box 1188, New York, NY 10029 USA.						Aagaard B D, 1998, Magn Reson Imaging Clin N Am, V6, P179; ARMSTRONG JR, 1948, J BONE JOINT SURG BR, V30, P430; BARQUET A, 1979, ACTA ORTHOP SCAND, V50, P549, DOI 10.3109/17453677908989803; Beaton LE, 1937, ANAT REC, V70, P1, DOI 10.1002/ar.1090700102; BROMBERG E, 1977, SOUTHERN MED J, V70, P8, DOI 10.1097/00007611-197701000-00005; Carvalho GA, 1997, ORTHOPADE, V26, P599, DOI 10.1007/PL00003417; COLLINS JD, 1988, J NATL MED ASSOC, V81, P129; DELEE JC, 1996, ROCKWOOD GREENS FRAC, V2, P1659; DERIAN PS, 1974, SOUTH MED J, V67, P209, DOI 10.1097/00007611-197402000-00020; DREINHOFER KE, 1994, J BONE JOINT SURG BR, V76B, P6; EISENBERG KS, 1972, J BONE JOINT SURG AM, VA 54, P1083, DOI 10.2106/00004623-197254050-00016; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; FASSLER R, 1993, J BONE JOINT SURG AM, V75, P1157; Filler AG, 1996, J NEUROSURG, V85, P299, DOI 10.3171/jns.1996.85.2.0299; FILLER AG, 1993, LANCET, V341, P659, DOI 10.1016/0140-6736(93)90422-D; GLASS A, 1961, J BONE JOINT SURG BR, V43, P29; GREGORY CF, 1973, INSTR COURSE LECT, V22, P105; Hart VL, 1942, J BONE JOINT SURG, V24, P458; HAW DWM, 1965, BRIT MED J, V1, P1111, DOI 10.1136/bmj.1.5442.1111; HIRASAWA Y, 1977, CLIN ORTHOP RELAT R, P172; Hoenig LJ, 1997, SEMIN ARTHRITIS RHEU, V26, P684, DOI 10.1016/S0049-0172(97)80004-2; HOWE FA, 1992, MAGNET RESON MED, V28, P328, DOI 10.1002/mrm.1910280215; HUNTER G A, 1969, Journal of Bone and Joint Surgery British Volume, V51, P38; JACOB JR, 1987, CLIN ORTHOP RELAT R, P249; KLEIMAN SG, 1971, J BONE JOINT SURG AM, VA 53, P781, DOI 10.2106/00004623-197153040-00019; LAORR A, 1995, SKELETAL RADIOL, V24, P239; Larson C, 1973, CLIN ORTHOP RELAT R, V92, P147; LEVIN P, 1998, SKELETAL TRAUMA, V2, P1713; McCarthy M, 1996, LANCET, V348, P674, DOI 10.1016/S0140-6736(05)65085-4; NERUBAY J, 1973, J TRAUMA, V13, P1050, DOI 10.1097/00005373-197312000-00003; OCHI M, 1994, J HAND SURG-BRIT EUR, V19B, P55, DOI 10.1016/0266-7681(94)90050-7; OFFIERSKI CM, 1981, J BONE JOINT SURG BR, V63, P194; PATTERSON FP, 1973, J TRAUMA, V12, P1013; PEARSON DE, 1973, CLIN ORTHOP RELAT R, P189; PIGGOT J, 1961, J BONE JOINT SURG BR, V43, P38; PLATTNER P, 1993, SURG FOOT ANKLE, V2, P805; POGGI JJ, 1995, CLIN ORTHOP RELAT R, P249; PROCTOR H, 1973, INJURY, V5, P1, DOI 10.1016/S0020-1383(73)80002-6; RAPOPORT S, 1988, RADIOLOGY, V167, P161, DOI 10.1148/radiology.167.1.3347719; ROGER B, 1988, CLIN ORTHOP RELAT R, P57; SCHLONSKY J, 1973, J BONE JOINT SURG AM, VA 55, P1057, DOI 10.2106/00004623-197355050-00015; Seddon HJ., 1972, SURG DISORDERS PERIP; Steinke CR, 1914, ANN SURG, V60, P617, DOI 10.1097/00000658-191411000-00008; STEWART MJ, 1954, J BONE JOINT SURG AM, V36-A, P315, DOI 10.2106/00004623-195436020-00010; STEWART MJ, 1975, ACTA ORTHOP SCAND, V46, P507; Sunderland S., 1978, NERVE NERVE INJURIES; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548; WILCHINSKY ME, 1985, J PEDIATR ORTHOPED, V5, P534, DOI 10.1097/01241398-198509000-00005; WILSON JN, 1960, P ROY SOC MED, V53, P941, DOI 10.1177/003591576005301111; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	53	44	47	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	2000		377					84	91					8	Orthopedics; Surgery	Orthopedics; Surgery	340WM	WOS:000088559100013	10943188				2021-06-18	
J	Knoblach, SM; Susan, MKC				Knoblach, SM; Susan, MKC			Cortical interleukin-1 beta elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery	NEUROSCIENCE LETTERS			English	Article						interleukin-1; interleukin-1 receptor antagonist; soluble receptors; expression; neurological dysfunction; brain injury	TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; MESSENGER-RNA; HEAD-INJURY; EXPRESSION; CONTRIBUTES; APOPTOSIS; INCREASE; DAMAGE	Interleukin-1 is an inflammatory cytokine implicated in secondary responses to traumatic brain injury. We utilized a specific IL-beta enzyme-linked immunoadsorbant assay to examine the expression of IL-beta after lateral fluid percussion brain injury in the rat. IL-beta was significantly elevated in the ipsilateral injured cortex at 4 h after injury. Increased levels of IL-beta were also observed at 12, 24 and 72 h after injury, although such changes did not reach statistical significance. To determine whether injury-induced IL-beta expression may contribute to subsequent neurological impairment, we treated rats with either of two structurally different, selective IL-1 antagonists and monitored neurological recovery 1,7 and 14 days later. Intracerebroventricular treatment with either the endogenous interleukin-1 receptor antagonist (10 mu g) at 15 min, 2, 4, 6, and 8 h after injury or soluble IL-1 receptors (10 mu g) at 15 min, 4 and 8 h after injury did not significantly alter outcome in a series of motor tasks. These data suggest that cortical elevations of IL-beta follow traumatic brain injury, but they may not contribute to subsequent neurological impairment. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol, Washington, DC 20007 USA	Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, 3970 Reservoir Rd, Washington, DC 20007 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007459] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07459] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR30664-07] Funding Source: Medline		Bagetta G, 1999, NEUROSCIENCE, V89, P1051, DOI 10.1016/S0306-4522(98)00363-7; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FREIDLANDER RM, 1996, J EXP MED, V184, P717; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; JACOBS CA, 1993, INT REV EXP PATHOL, V34, P123; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rothwell NJ, 1997, INT REV NEUROBIOL, V40, P281; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	19	44	45	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 28	2000	289	1					5	8		10.1016/S0304-3940(00)01263-5			4	Neurosciences	Neurosciences & Neurology	339EZ	WOS:000088465800002	10899395				2021-06-18	
J	Boone, KB; Lu, P; Sherman, D; Palmer, B; Back, C; Shamieh, E; Warner-Chacon, K; Berman, NG				Boone, KB; Lu, P; Sherman, D; Palmer, B; Back, C; Shamieh, E; Warner-Chacon, K; Berman, NG			Validation of a new technique to detect malingering of cognitive symptoms: The b Test	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							FEIGNED MEMORY IMPAIRMENT; DIGIT RECOGNITION TEST; CLOSED-HEAD INJURY; PREMORBID INTELLIGENCE; PERFORMANCE; DEFICITS; AMNESIA; IDENTIFICATION; PATTERN; ABILITY	We administered the b Test, a new measure to identify malingering requiring recognition of overlearned information, to 34 suspected malingerers and to 161 subjects in various clinical groups (moderate to severe head injury, elderly depressed learning disability, schizophrenia, right and left CVA, and elderly normals). Comparisons of groups revealed more commission and omission errors in the suspected mn(malingerers relative to all groups except the right stroke patients. In addition, suspected malingerers rook longer lo complete the task than all groups except right and left stroke patients and normal elderly. A cutoff of >2 commission errors produced a sensitivity of 76.5% mid specificity for all comparison groups combined of 82.6%. Lower sensitivity rates were documented for omissions (58.8 using cutoff of >40) and time (57.6% using cutoff of >12 minutes), brit specificity remained high at 85.1% and 83.9%, respectively. Thus, the b Test shows considerable potential as a malingering detection tool. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA; Pepperdine Univ, Malibu, CA 90265 USA	Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, Box 495,ABPP ABCN,1000 W Carson St,Bldg F-9, Torrance, CA 90509 USA.		Palmer, Barton/ABA-7519-2020	Palmer, Barton/0000-0002-7618-3144			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Arnett PA, 1997, ARCH CLIN NEUROPSYCH, V12, P513; ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; BACK C, 1994, DISS ABSTR INT, V55, P582; Back C., 1996, ASSESSMENT, V3, P449, DOI [10.1177/107319119600300411, DOI 10.1177/107319119600300411, DOI 10.1016/S0887-6177(01)00166-4]; BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BARRASH J, 1998, J INT NEUROPSYCH SOC, V4, P27; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BERNARD LC, 1993, ARCH CLIN NEUROPSYCH, V8, P539, DOI 10.1016/0887-6177(93)90054-5; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BLACK FW, 1986, J CLIN PSYCHOL, V42, P770, DOI 10.1002/1097-4679(198609)42:5<770::AID-JCLP2270420516>3.0.CO;2-P; Bowen M, 1997, CLIN NEUROPSYCHOL, V11, P433, DOI 10.1080/13854049708400474; Chouinard M J, 1997, J Int Neuropsychol Soc, V3, P545; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1992, BRIT J PSYCHIAT, V161, P69, DOI 10.1192/bjp.161.1.69; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; Davis HP, 1997, ARCH CLIN NEUROPSYCH, V12, P145, DOI 10.1016/S0887-6177(96)00011-X; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; Griffin GAE, 1997, J CLIN PSYCHOL, V53, P757, DOI 10.1002/(SICI)1097-4679(199711)53:7<757::AID-JCLP14>3.0.CO;2-K; GUDJONSSON GH, 1986, BRIT J CLIN PSYCHOL, V25, P35, DOI 10.1111/j.2044-8260.1986.tb00668.x; HAYS JR, 1993, PERCEPT MOTOR SKILL, V76, P1331, DOI 10.2466/pms.1993.76.3c.1331; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Martin RC, 1998, CLIN NEUROPSYCHOL, V12, P84, DOI 10.1076/clin.12.1.84.1722; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NELSON HE, 1975, BRIT J SOC CLIN PSYC, V14, P259, DOI 10.1111/j.2044-8260.1975.tb00178.x; Osimani A, 1997, J NEUROL NEUROSUR PS, V62, P617, DOI 10.1136/jnnp.62.6.617; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Paul D. S., 1992, INT J CLIN NEUROPSYC, V14, P1; PHILPOTT LM, 1993, DISS ABSTR INT, V53, P5001; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Ray EC, 1997, ARCH CLIN NEUROPSYCH, V12, P491; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; RUBINSKY EW, 1986, BEHAVIORAL SCI LAW, V4, P27; RUDDLE HV, 1982, BRIT J CLIN PSYCHOL, V21, P159, DOI 10.1111/j.2044-8260.1982.tb00548.x; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SCHRETLEN D, 1992, PSYCHOL ASSESSMENT, V14, P77; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	60	44	44	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2000	15	3					227	241		10.1016/S0887-6177(99)00014-1			15	Psychology, Clinical; Psychology	Psychology	288UF	WOS:000085582300003	14590550	Bronze			2021-06-18	
J	Copland, DA; Chenery, HJ; Murdoch, BE				Copland, DA; Chenery, HJ; Murdoch, BE			Persistent deficits in complex language function following dominant nonthalamic subcortical lesions	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							CLOSED-HEAD-INJURY; LEFT BASAL GANGLIA; STROKE PATIENTS; APHASIA; HEMORRHAGE; INFARCTION; IMPAIRMENT; SUBSEQUENT; THALAMUS; PROFILES	The language abilities of 14 subjects with chronic nonthalamic subcortical (NS) lesions following stroke was assessed using a test battery probing a broad range of language functions. The language battery included the Boston Naming Test (BNT), the Western Aphasia Battery (WAB), and subtests from the Test of language Competence-Expanded Edition, the Test of Word Knowledge, and The Word Test-Revised. The performance of the subjects with NS lesions did not differ significantly from a group of matched non-neurologically impaired subjects on most aspects of the WAB, whereas subjects with NS lesions evidenced deficits on the BNT and in word-list generation, recreating sentences, interpreting ambiguous or figurative passages, and in providing definitions, synonyms, and antonyms. These results suggest that standard aphasia batteries may be largely insensitive to subtle deficits in more cognitively demanding aspects of language function which can occur following NS lesions. The implications of these findings are considered in terms of current theories of subcortical language function.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia	Copland, DA (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.		Copland, David A/F-1409-2010; Murdoch, Bruce E/C-1397-2012; Copland, David/AAE-5334-2020; Chenery, Helen J/F-5194-2010	Copland, David A/0000-0002-2257-4270; Copland, David/0000-0002-2257-4270; 			Aglioti S, 1997, J NEUROLINGUIST, V10, P255, DOI 10.1016/S0911-6044(97)00020-1; Alexander M., 1989, HDB NEUROPSYCHOLOGY, V2, P47; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ALEXANDER MP, 1987, BRAIN, V110, P961, DOI 10.1093/brain/110.4.961; ALEXANDER MP, 1980, NEUROLOGY, V30, P1193, DOI 10.1212/WNL.30.11.1193; ALEXANDER MP, 1992, NEUROPSYCHOLOGICAL D, P455; ARAM DM, 1990, DEV NEUROPSYCHOL, V6, P301, DOI 10.1080/87565649009540469; ARAM DM, 1989, DEV DYSLEXIA DYSPHAS; BOCK JK, 1982, PSYCHOL REV, V89, P1, DOI 10.1037/0033-295X.89.1.1; Bowey J., 1984, METALINGUISTIC AWARE, V15, P73; BRUNNER RJ, 1982, BRAIN LANG, V16, P281, DOI 10.1016/0093-934X(82)90087-6; CAPLAN LR, 1990, ARCH NEUROL-CHICAGO, V47, P133, DOI 10.1001/archneur.1990.00530020029011; CAPPA SF, 1983, CORTEX, V19, P227, DOI 10.1016/S0010-9452(83)80016-1; CARAMAZZA A, 1989, BRAIN COGNITION, V10, P256, DOI 10.1016/0278-2626(89)90056-0; CROSSON B, 1985, BRAIN LANG, V25, P257, DOI 10.1016/0093-934X(85)90085-9; Crosson B, 1997, J NEUROLINGUIST, V10, P277, DOI 10.1016/S0911-6044(97)00018-3; Crosson B., 1992, SUBCORTICAL FUNCTION; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DESPOSITO M, 1995, NEUROLOGY, V45, P38, DOI 10.1212/WNL.45.1.38; DUBOIS B, 1995, ADV NEUROLOGY, V65; Fabbro F, 1996, PERCEPT MOTOR SKILL, V82, P1291, DOI 10.2466/pms.1996.82.3c.1291; FLICKER C, 1987, BRAIN LANG, V31, P187, DOI 10.1016/0093-934X(87)90069-1; FRAZIER L, 1989, LEXICAL REPRESENTATI, P505; FROMM D, 1985, ARCH NEUROL-CHICAGO, V42, P943, DOI 10.1001/archneur.1985.04060090025009; GODEFROY O, 1994, J NEUROL NEUROSUR PS, V57, P480, DOI 10.1136/jnnp.57.4.480; Gold M, 1997, BRAIN LANG, V57, P374, DOI 10.1006/brln.1997.1750; GURD JM, 1988, NEUROPSYCHOLOGIA, V26, P237, DOI 10.1016/0028-3932(88)90077-2; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Huisingh R, 1990, WORD TEST REVISED; Kaplan E., 1983, BOSTON NAMING TEST; KENNEDY M, 1993, BRAIN LANG, V44, P284, DOI 10.1006/brln.1993.1019; KENNEDY M, 1989, APHASIOLOGY, V3, P221, DOI 10.1080/02687038908248997; Keppel G, 1992, DESIGN ANAL RES HDB; Kertesz A., 1982, W APHASIA BATTERY; KIRKEVOLD M, 1994, SCAND J CARING SCI, V8, P1; Lethlean JB, 1997, APHASIOLOGY, V11, P39, DOI 10.1080/02687039708248454; Lewis FM, 1998, APHASIOLOGY, V12, P193, DOI 10.1080/02687039808249446; MACDONALD MC, 1994, PSYCHOL REV, V101, P676, DOI 10.1037/0033-295X.101.4.676; MAZZOCCHI F, 1979, CORTEX, V15, P627, DOI 10.1016/S0010-9452(79)80051-9; MEGA MS, 1994, NEUROLOGY, V44, P1824, DOI 10.1212/WNL.44.10.1824; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; METTER EJ, 1988, ARCH NEUROL-CHICAGO, V45, P1229, DOI 10.1001/archneur.1988.00520350067018; MOHR JP, 1975, BRAIN LANG, V2, P3, DOI 10.1016/S0093-934X(75)80050-2; MURDOCH BE, 1986, AUSTR J HUMAN COMMUN, V14, P5; Nadeau SE, 1997, BRAIN LANG, V58, P355, DOI 10.1006/brln.1997.1707; NAESER MA, 1982, ARCH NEUROL-CHICAGO, V39, P2, DOI 10.1001/archneur.1982.00510130004002; NICHOLAS LE, 1989, APHASIOLOGY, V3, P569, DOI 10.1080/02687038908249023; PERFETTI CA, 1990, COMPREHENSION PROCESSES IN READING, P205; PUEL M, 1984, REV NEUROL-FRANCE, V140, P695; Raymer AM, 1997, NEUROPSYCHOLOGIA, V35, P211, DOI 10.1016/S0028-3932(96)00069-3; ROBIN DA, 1990, J SPEECH HEAR DISORD, V55, P90, DOI 10.1044/jshd.5501.90; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Secord, 1989, TEST LANGUAGE COMPET; SKYHOJOLSEN T, 1986, BRAIN, V109, P393; Stuss D.T., 1986, FRONTAL LOBES; TANRIDAG O, 1987, APHASIOLOGY, V1, P107; VALLAR G, 1988, APHASIOLOGY, V2, P463, DOI 10.1080/02687038808248953; WALLESCH CW, 1983, BRAIN LANG, V20, P286, DOI 10.1016/0093-934X(83)90046-9; WALLESCH CW, 1985, BRAIN LANG, V25, P357, DOI 10.1016/0093-934X(85)90090-2; Wallesch CW, 1997, J NEUROLINGUIST, V10, P267, DOI 10.1016/S0911-6044(97)00019-5; Wallesch CW, 1988, APHASIA, P256; WEILLER C, 1993, BRAIN, V116, P1509, DOI 10.1093/brain/116.6.1509; Wiig E, 1992, TEST WORD KNOWLEDGE; Winner E., 1988, POINT WORDS CHILDREN; YANG BJ, 1989, BRAIN LANG, V37, P145, DOI 10.1016/0093-934X(89)90105-3	66	44	44	0	4	SINGULAR PUBLISHING GROUP INC	SAN DIEGO	401 WEST A ST, STE 325, SAN DIEGO, CA 92101-7904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	MAR	2000	8	1					1	14					14	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	290LH	WOS:000085677400002					2021-06-18	
J	Matsushita, Y; Shima, K; Nawashiro, H; Wada, K				Matsushita, Y; Shima, K; Nawashiro, H; Wada, K			Real-time monitoring of glutamate following fluid percussion brain injury with hypoxia in the rat	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; biosensor; dialysis electrode; glutamate; lateral fluid percussion; TBI; TTC	APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; BLOOD-FLOW; DIALYSIS ELECTRODE; CEREBRAL-ISCHEMIA; CYTOCHROME-C; RELEASE; NEURONS; CHLORIDE; STAIN	In the present study, extracellular glutamate (Glu) was monitored in real time using an enzyme electrode biosensor following traumatic brain injury (TBI) either with or without inducing hypoxia in the rat. We also measured the cortical contusion volume at 3 days after insult by staining with 2,3,5-triphenyltetrazolium chloride (TTC). Male Sprague-Dawley rats (300-400g) were anesthetized and then subjected to lateral fluid percussion (FP) brain injury of moderate severity (3.5-4.0 atm), using the Dragonfly device model (no. HPD-1700). The experimental animals mere divided into four groups. Group 1 (n = 10) was subjected to TBI only, group 2 (n = 10) to TBI followed by 20 min of moderate hypoxia (FiO2: 10%), group 3 (n = 4) to 20 min of moderate hypoxia without TBI, and group 4 (n = 4) to sham. Seventy-two hours after the insults, the animals were sacrificed, their brains were stained with TTC, and the lesion volumes were calculated. A surge in the extracellular Glu concentration occurred immediately after TBI in groups 1 and 2. There was no significant difference between the two groups. Group 2 showed a prolonged efflux of Glu during hypoxia (p < 0.05). In group 3, Glu continued to show a mild increase. The cortical contusion volume in group 2 was significantly larger than that in group 1. To evaluate the possible involvement of apoptosis in groups 1 and 2, separate rats were sacrificed under the same procedures after 1, 6, 24, and 72 h after insult (n = 2/group). Immunohistochemical analysis demonstrated an increased number of both the cysteine protease caspase-3-positive cells at 24 h and TUNEL-positive cells at 72 h in group 2. These results suggest that TBI with moderate hypoxia induced the prolonged efflux of Glu, which thus resulted in more cortical damage due to necrosis and apoptosis.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan	Shima, K (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	shima@ndmc.jp					Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COLE DJ, 1990, ACTA NEUROPATHOL, V80, P152, DOI 10.1007/BF00308918; Conti AC, 1998, J NEUROSCI, V18, P5663; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Harada J, 1997, BRAIN RES, V753, P251, DOI 10.1016/S0006-8993(97)00011-5; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kharlamov A, 1996, BRAIN RES, V734, P1; KITA H, 1994, ACTA NEUROCHIR, P452; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu Z, 1997, NEUROREPORT, V8, P2019, DOI 10.1097/00001756-199705260-00043; Long JB, 1996, J NEUROTRAUM, V13, P149, DOI 10.1089/neu.1996.13.149; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; RINK A, 1995, AM J PATHOL, V147, P1575; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tenneti L, 1998, J NEUROCHEM, V71, P946; WALKER MC, 1995, J NEUROCHEM, V65, P725; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Zhao H, 1997, NEUROREPORT, V8, P2389, DOI 10.1097/00001756-199707070-00057	50	44	50	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					143	153		10.1089/neu.2000.17.143			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800004	10709872				2021-06-18	
J	Tate, RL; Pfaff, A; Jurjevic, L				Tate, RL; Pfaff, A; Jurjevic, L			Resolution of disorientation and amnesia during post-traumatic amnesia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						brain injuries; post-traumatic amnesia; confusion; cognition disorders	CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; ORIENTATION; RECOVERY; MEMORY	Objectives-Despite the growing number of instruments for the prospective measurement of post-traumatic amnesia (PTA) after traumatic brain injury, fundamental issues about the natural history of its resolution and methods of examination remain unresolved. The aims of the present study were to: (1) examine the sequence of resolution of disorientation and amnesia, and (2) determine if the method of measuring the memory component affected the duration of PTA. Methods-The sample comprised 31 severely injured patients admitted to a brain injury rehabilitation unit who were examined daily until they emerged from PTA. They were administered a composite PTA scale, covering orientation and memory items from standard PTA scales. Patients were consecutively allocated to one of two groups according to the method of measuring the memory component. Each group was administered identical materials with a different procedure. Results-The most common sequence for resolution of disorientation in both groups was person, followed by place, then time. Overall, amnesia resolved before disorientation in 94% of cases. Correlation coefficients between return of components of orientation and memory were all highly significant, ranging from r=0.81 to 0.93. Significant variability occurred in the number of days to emerge from PTX according to the scale used. There was evidence that the method of measuring memory influenced the patient's capacity to consistently sustain criterion scores on the scale. Conclusions-These results are contrary to findings in mildly injured patients, in whom orientation usually returns before memory They also demonstrate that the duration of PTA will be dictated by the method used. These findings raise validity issues with respect to the prospective measurement of PTA, and in particular determining when an individual patient has emerged from PTA, which require further investigation.	Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Tate, RL (corresponding author), Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au					ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1984, ARCH PHYS MED REHAB, V65, P652; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; FORRESTER G, 1995, J FARR SERVICES POST; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HORN S, 1991, J CLIN EXP NEUROPSYC, V13, P19; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jennett B, 1981, MANAGEMENT HEAD INJU; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SISLER G, 1975, CAN PSYCHIAT ASSOC J, V20, P333, DOI 10.1177/070674377502000502; Tabachnick BG, 2013, USING MULTIVARIATE S; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TEASDALE G, 1974, LANCET, V2, P81; Wilson B.A., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [10.1080/09602019208401410, DOI 10.1080/09602019208401410]	28	44	45	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2000	68	2					178	185		10.1136/jnnp.68.2.178			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	279DM	WOS:000085029000012	10644784	Green Published, Bronze			2021-06-18	
J	Ter Minassian, A; Poirier, N; Pierrot, M; Menei, P; Granry, JC; Ursino, M; Beydon, L				Ter Minassian, A; Poirier, N; Pierrot, M; Menei, P; Granry, JC; Ursino, M; Beydon, L			Correlation between cerebral oxygen saturation measured by near-infrared spectroscopy and jugular oxygen saturation in patients with severe closed head injury	ANESTHESIOLOGY			English	Article						brain; hemodynamics; spectroscopy; transcranial Doppler	BLOOD-FLOW; HUMANS; BRAIN; HYPERTENSION; HYPOTENSION; ISCHEMIA; HYPOXIA; LIGHT; BULB	Background: Near-infrared spectroscopy has been used to monitor cerebral oxygen saturation during cerebral circulatory arrest and carotid damping, However, its utility has not been demonstrated in more complex situations, such as in patients with head injuries. The authors tested this method during conditions that may alter the arteriovenous partition of cerebral blood in different ways. Methods: The authors compared changes in measured cerebral oxygen saturation and other hemodynamic parameters, including jugular venous oxygen saturation, in nine patients with severe closed head injury during manipulation of arterial carbon dioxide partial pressure and after mean arterial pressure was altered by vasopressors. Results: The Bland and Altman representation of cerebral oxygen saturation versus jugular oxygen saturation showed a uniform scatter. Values for changing arterial carbon dioxide partial pressure were: bias = 1.1%, 2 SD = +/- 21%, absolute value; and those for alterations in mean arterial pressure: bias = 3.7%, 2 SD = +/- 24%, absolute value. However, a Bland and Altman plot of changes in cerebral oxygen saturation versus changes in jugular oxygen saturation had a negative slope (alteration in arterial carbon dioxide partial pressure: bias = 2.4%, 2 SD = +/- 17%, absolute value; alteration in mean arterial pressure: bias = -4.9%, 2 SD = +/- 31%, absolute value). Regression analysis showed that changes in cerebral oxygen saturation were positively correlated with changes in jugular venous oxygen saturation during the carbon dioxide challenge, whereas correlation was negative during the arterial pressure challenge, Conclusions: Cerebral oxygen saturation assessed by near-infrared spectroscopy does not adequately reflect changes in jugular venous oxygen saturation in patients with severe head injury. Changes in arteriovenous partitioning, infrared-spectroscopy contamination by extracerebral signal, algorithm errors, and dissimilar tissue sampling may explain these findings.	CHU Larrey, Dept Anesthesia, F-49033 Angers, France; Univ Bologna, Bologna, Italy	Ter Minassian, A (corresponding author), CHU Larrey, Dept Anesthesia, F-49033 Angers, France.		MENEI, Philippe/L-6860-2015	Ursino, Mauro/0000-0002-0911-0308; menei, philippe/0000-0002-2794-1316			AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AUER LM, 1984, CEREBRAL VENOUS SYST, P169; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; DAVIDSON D, 1986, J APPL PHYSIOL, V60, P1230; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; HAMPSON NB, 1990, J APPL PHYSIOL, V69, P907; HONGO K, 1995, NEUROL RES, V17, P89, DOI 10.1080/01616412.1995.11740293; KIRKPATRICK PJ, 1995, J NEUROSURG, V83, P963, DOI 10.3171/jns.1995.83.6.0963; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Kurth CD, 1997, ANESTH ANALG, V84, P1297, DOI 10.1097/00000539-199706000-00023; LEVY WJ, 1995, ANESTHESIOLOGY, V83, P738, DOI 10.1097/00000542-199510000-00013; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; MCCORMICK PW, 1992, J NEUROSURG, V76, P315, DOI 10.3171/jns.1992.76.2.0315; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; Okada E, 1995, PROC SPIE, V2626, P2, DOI 10.1117/12.228651; OwenReece H, 1996, BRIT J ANAESTH, V76, P43; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SMITH DS, 1990, ANESTHESIOLOGY, V73, P12, DOI 10.1097/00000542-199007000-00003; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; TATEISHI A, 1995, CRIT CARE MED, V23, P1734, DOI 10.1097/00003246-199510000-00019	22	44	45	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	OCT	1999	91	4					985	990					6	Anesthesiology	Anesthesiology	241PR	WOS:000082892200014	10519501				2021-06-18	
J	Tellier, A; Della Malva, LC; Cwinn, A; Grahovac, S; Morrish, W; Brennan-Barnes, M				Tellier, A; Della Malva, LC; Cwinn, A; Grahovac, S; Morrish, W; Brennan-Barnes, M			Mild head injury: a misnomer	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CEREBRAL PERFUSION; CT; SEQUELAE; RISK; CLASSIFICATION; TOMOGRAPHY; SPECT; MRI	Despite controversy surrounding the concept of mild head injury (MHI), it is becoming evident that even a head trauma termed 'mild' may result in significant behavioural sequelae. The present study was an attempt at documenting structural cerebral damage, by way of computerized tomography, in a group of patients having suffered a MHI as defined by the Glasgow Coma Scale (GCS) score. A 1-year retrospective chart review identified 80 MHI patients who presented to the Emergency department of a lead hospital for trauma. Sixty-six per cent of these MHI patients were scanned. Evidence of intracranial abnormalities was obtained in 31% of the overall sample. Patients with a lower GCS score had a higher percentage of abnormal scans than those with a GCS score of either 14 or 15. The present findings suggest that a MHI can be associated with significant morbidity, and that a MHI group does not constitute a homogeneous pool of patients.	Ottawa Hosp, Dept Psychol, Neuropsychol Serv, Ottawa, ON K1H 8L6, Canada; Ottawa Hosp, Trauma Serv, Ottawa, ON K1H 8L6, Canada; Ottawa Hosp, Dept Radiol, Ottawa, ON K1H 8L6, Canada; Rehabil Ctr, Psychol Serv, Ottawa, ON, Canada	Tellier, A (corresponding author), Ottawa Hosp, Dept Psychol, Neuropsychol Serv, Module Q,Gen Campus,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Ardila A, 1989, NEUROPSYCHOLOGY, V3, P23, DOI 10.1037//0894-4105.3.1.23; Bailey B. N., 1989, TXB HEAD INJURY, P308; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT., 1989, MILD HEAD INJURY, P257; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BINDER LM, 1994, 22 ANN M INT NEUR SO; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Colohan A. R. T., 1986, J HEAD TRAUMA REHAB, V1, P13; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GEVINS A, 1992, J HEAD TRAUMA REHAB, V7, P78; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRAY C, 1992, EARTH ISL J, V7, P33; HAAS DC, 1988, J NEUROSURG, V68, P181, DOI 10.3171/jns.1988.68.2.0181; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; ICHISE M, 1994, J NUCL MED, V35, P217; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jennett B, 1981, MANAGEMENT HEAD INJU; JOSEPH R, 1990, NEUROPSYCHOLOGY NEUR, P277; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Lidvall H., 1974, ACTA NEUROL SCAND, V50, P3; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Newberg AB, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199612000-00009; NEWTON MR, 1989, NUCL MED COMMUN, V10, P254; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; RUFF RM, 1990, NEUROPSYCHOLOGICAL F, P161; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; TEASDALE G, 1974, LANCET, V2, P81; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	59	44	44	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1999	13	7					463	475					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	215GT	WOS:000081374100001	10462145				2021-06-18	
J	Watt, KJ; O'Carroll, RE				Watt, KJ; O'Carroll, RE			Evaluating methods for estimating premorbid intellectual ability in closed head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						NART; CCRT; STW; assessment; cognitive; premorbid	CONTEXTUAL READING TEST; DEMOGRAPHIC-VARIABLES; BRAIN INJURY; UK SAMPLE; INTELLIGENCE; DEPRESSION; PERFORMANCE; DEMENTIA; IQ	Objectives-The present study examines the utility of three measures of premorbid intellectual functioning in closed head injury, the National adult reading test (NART), the Cambridge contextual reading test (CCRT), and the spot the word test (STW). Methods-In the first experiment, a group of 25 patients with closed head injury were compared with 50 healthy controls and 20 orthopaedic trauma controls. In the second experiment, the strength of correlation between the premorbid measures and current intellectual level were assessed in 114 healthy adults. Results-The head injured group performed significantly more poorly than both control groups on measures of current intellectual ability. However, no significant differences emerged between the groups on any of the premorbid measures. In the large control sample, both the NART and the CCRT accounted for about 50% of the variance in current verbal intelligence. However, by contrast, the STW only accounted for 29% of the variability in verbal intelligence. Adding demographic variables to the prediction of current intellectual level increased the amount of variance explained to 60% for the NART, 62% for the CCRT, but only 41% for the STW. Conclusion-The results provide supportive evidence for the use of the CCRT and NART in estimating premorbid intellectual functioning in patients who have sustained closed head injuries, but suggest caution when employing the STW.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; St Johns Hosp, Dept Clin Psychol, Livingston EH54 6PP, West Lothian, Scotland	O'Carroll, RE (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.		O'Carroll, Ronan E/A-5040-2009	O'Carroll, Ronan E/0000-0002-5130-291X			AUSTIN MP, 1992, J AFFECT DISORDERS, V25, P21, DOI 10.1016/0165-0327(92)90089-O; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; BEARDSALL L, 1994, J CLIN EXP NEUROPSYC, V16, P232, DOI 10.1080/01688639408402634; Benton AL, 1978, MULTILINGUAL APHASIA; Conway SC, 1997, BRIT J CLIN PSYCHOL, V36, P623, DOI 10.1111/j.2044-8260.1997.tb01267.x; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC, P21; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; CRAWFORD JR, 1989, BRIT J CLIN PSYCHOL, V28, P275, DOI 10.1111/j.2044-8260.1989.tb01377.x; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1992, BRIT J CLIN PSYCHOL, V31, P327, DOI 10.1111/j.2044-8260.1992.tb00999.x; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; CRAWFORD JR, 1988, BRIT J CLIN PSYCHOL, V27, P181, DOI 10.1111/j.2044-8260.1988.tb00770.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HART S, 1986, BRIT J CLIN PSYCHOL, V25, P119, DOI 10.1111/j.2044-8260.1986.tb00680.x; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Leber W., 1988, STROOP NEUROPSYCHOLO; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; Nelson H., 1991, REVISED NATL ADULT R; NELSON HA, 1978, CORTEX, V14, P233; NELSON HE, 1975, BRIT J SOC CLIN PSYC, V14, P259, DOI 10.1111/j.2044-8260.1975.tb00178.x; Nelson HE, 1982, NATL ADULT READING T; OCarroll R, 1995, NEUROCASE, V1, P83, DOI 10.1080/13554799508402350; Perez SA, 1996, ARCH CLIN NEUROPSYCH, V11, P491; SHARPE K, 1991, BRIT J CLIN PSYCHOL, V30, P381, DOI 10.1111/j.2044-8260.1991.tb00962.x; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; Williams JM, 1997, ARCH CLIN NEUROPSYCH, V12, P745, DOI 10.1016/S0887-6177(97)00048-6; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	44	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1999	66	4					474	479		10.1136/jnnp.66.4.474			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	181TA	WOS:000079457400011	10201419	Green Published, Bronze			2021-06-18	
J	Krishnappa, IK; Contant, CF; Robertson, CS				Krishnappa, IK; Contant, CF; Robertson, CS			Regional changes in cerebral extracellular glucose and lactate concentrations following severe cortical impact injury and secondary ischemia in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; glucose; lactate; microdialysis; traumatic brain injury	TRAUMATIC BRAIN INJURY; COMPRESSION CONTUSION TRAUMA; ENERGY PHOSPHATE-METABOLISM; FLUID-PERCUSSION INJURY; BLOOD-FLOW; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; LACTIC-ACIDOSIS; OXYGEN DELIVERY	Traumatic brain injury (TBI) causes the brain to be more susceptible to secondary insults, and the occurrence of a secondary insult after trauma increases the damage that develops in the brain. To study the synergistic effect of trauma and ischemia on brain energy metabolites, regional changes in the extracellular concentrations of glucose and lactate following a severe cortical impact injury were measured employing a microdialysis technique. Three microdialysis probes were placed in center of the impact site, in an area adjacent to the impact site, and in the contralateral parietal cortex, and perfused with artificial cerebrospinal fluid (CSF) at 2 mu l/min. Rats were assigned to one of the following experimental groups (n = 7 per group): (1) combined impact injury and secondary insult, (2) impact injury with sham secondary insult, (3) sham impact with secondary insult, or (4) sham impact and sham secondary insult. The impact injury was produced with a pneumatic impactor (5 m/sec, 3-mm deformation). One hour following the impact injury, a secondary insult was produced by bilateral carotid occclusion for 1 h. The impact injury resulted in a three- to fivefold global increase in dialysate lactate concentrations, with a corresponding fall in dialysate glucose concentration by 50% compared to no change in lactate or glucose concentrations in sham-injured animals (p < .0001 for both lactate and glucose). The secondary insult resulted in a second increase in dialysate lactate and decrease in dialysate glucose concentration that was significantly greater in the animals that had suffered the impact injury than in the sham-injured animals. Ischemia and traumatic injury have synergistic effects on lactate accumulation and on glucose depletion in the brain that probably reflects persisting ischemia, but may also indicate mitochondrial abnormalities and inhibition of oxidative metabolism.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Krishnappa, IK (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	Indrak@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Goodman J. C., 1995, Journal of Neurotrauma, V12, P371; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Scremin OU, 1997, J NEUROTRAUM, V14, P573, DOI 10.1089/neu.1997.14.573; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zauner A, 1996, ACT NEUR S, V67, P40	43	44	49	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1999	16	3					213	224		10.1089/neu.1999.16.213			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	178QQ	WOS:000079277800003	10195469				2021-06-18	
J	Martelli, MF; Grayson, RL; Zasler, ND				Martelli, MF; Grayson, RL; Zasler, ND			Posttraumatic headache: Neuropsychological and psychological effects and treatment implications	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic pain; head trauma; neuropsychological tests; posttraumatic headache; treatment	CHRONIC PAIN; TEMPOROMANDIBULAR DISORDERS; STRESS-DISORDER; INJURY PATIENTS; CERVICAL-SPINE; ATTENTION; WHIPLASH; DEFICITS; MIGRAINE; TRAUMA	Posttraumatic headache (PTHA) is a frequent occurrence following trauma to the head, brain, and/or neck. Estimates of persistence for 6 months are as high as 44%. Review of available studies examining the effect of headache on neuropsychological test findings reveals that chronic headache pain, and chronic pain generally, exerts a significant and negative effect that poses a challenge to differential diagnostic efforts in the evaluation of mild brain injury. Given that PTHA is the most common postconcussive symptom and most frequent type of posttraumatic pain associated with mild traumatic brain injury (TBI), it follows that resolution of the postconcussion syndrome, and successful posttraumatic adaptation, may frequently rely on success in coping with PTHA symptomatology. Viewing PTHA from a biopsychosocial perspective, a general outline is offered for improving both assessment and treatment of PTHA. In addition, the most promising psychology-based treatment interventions are reviewed.	Concuss Care Ctr Virginia, Glen Allen, VA 23060 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Dept Psychiat, Richmond, VA 23298 USA; Malcolm Grow Med Ctr, Andrews AFB, MD USA; Tree Life, Glenn Allen, VA USA	Martelli, MF (corresponding author), Concuss Care Ctr Virginia, 10120 W Broad St,Suites G& H, Glen Allen, VA 23060 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDRASIK F, 1990, NEUROL CLIN, V8, P961, DOI 10.1016/S0733-8619(18)30329-3; ANDRASIK F, 1987, BIOFEEDBACK STUDIES; ARENA JG, 1997, ELECTROMYOGRAPHY APP; Auerbach S. M., 1998, STRESS MANAGEMENT PS; BAKAL D, 1982, PSYCHOBIOLOGY CHRONI; Bennett TL, 1988, COGNITIVE REHABILIAT, V6, P34; BLANCHARD EB, 1994, HDB PSYCHOTHERAPY BE; DALY E, 1987, BRIT J MED PSYCHOL, V60, P85; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DeBoever JA, 1996, J ORAL REHABIL, V23, P91; DEVORE JR, 1998, PHYSICAL MED REHABIL, V12, P111; Di Stefano G, 1993, Z Unfallchir Versicherungsmed, V86, P97; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; DUCKRO PN, 1985, HEADAHCE, V25, P180; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; Epstein J B, 1992, J Can Dent Assoc, V58, P488; FLOR H, 1985, J CONSULT CLIN PSYCH, V53, P354, DOI 10.1037/0022-006X.53.3.354; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Goldberg Michael B., 1996, Journal of Orofacial Pain, V10, P126; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; Gramling SE, 1996, J BEHAV THER EXP PSY, V27, P245, DOI 10.1016/S0005-7916(96)00027-4; GRAYSON EL, 1997, ASS ADV BEH THER AAB; GREEN R, 1991, DYNAMICS HLTH WELLNE; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; HAAS DC, 1993, HEADACHES; Ham LP, 1996, BIOFEEDBACK SELF-REG, V21, P93, DOI 10.1007/BF02284689; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; HINNANT DW, 1994, HDB CHRONIC PAIN MAN; HOLROYD KA, 1978, J CONSULT CLIN PSYCH, V46, P1036; JARVIS P, 1998, B NATL ACAD NEUROPSY, V14, P7; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; Karlsborg M, 1997, ACTA NEUROL SCAND, V95, P65, DOI 10.1111/j.1600-0404.1997.tb00071.x; KAY T, 1992, REHABILITATION POSTC; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; LASKIN DM, 1969, J AM DENT ASSOC, V79, P147, DOI 10.14219/jada.archive.1969.0234; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MARTELLI MF, IN PRESS GUIDE FUNCT; Martin P. R., 1993, PSYCHOL MANAGEMENT C; MEDINA JL, 1992, HEADACHE, V32, P180, DOI 10.1111/j.1526-4610.1992.hed3204180.x; Miller L., 1993, PSYCHOTHERAPY BRAIN; MOSS RA, 1987, J CRANIOMANDIB PRACT, V5, P196; MOUNTZ JM, 1995, ARTHRITIS RHEUM, V38, P926, DOI 10.1002/art.1780380708; Mountz JM, 1998, AM J MED SCI, V315, P385, DOI 10.1097/00000441-199806000-00007; MUSE M, 1986, PAIN, V25, P389, DOI 10.1016/0304-3959(86)90243-5; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P40, DOI 10.1055/s-2008-1041057; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; PARKER RS, 1995, J COGNITIVE REHABILI, V13, P14; PENZIEN DB, 1993, HEADACHE DIAGNOSIS T; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1992, ACTA NEUROL SCAND, V85, P358; Rudy TE, 1989, MULTIAXIAL ASSESSMEN; SCHIFFMAN E, 1995, HEADACHE, V35, P121, DOI 10.1111/j.1526-4610.1995.hed3503121.x; SCHREIBER S, 1993, PAIN, V54, P107, DOI 10.1016/0304-3959(93)90105-X; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; Sendrowski DP, 1997, OPTOMETRY VISION SCI, V74, P660, DOI 10.1097/00006324-199708000-00027; TOBIN DL, 1988, COGNITIVE THER RES, V12, P325, DOI 10.1007/BF01173301; Todd D., 1998, COGNIPHOBIA SCALE C, pdomain; Todd D, 1998, FORENSIC EXAMINER, V7, P14; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; Tsushima WT, 1996, HEADACHE, V36, P613, DOI 10.1046/j.1526-4610.1996.3610613.x; TURK DC, 1990, PAIN, V43, P27, DOI 10.1016/0304-3959(90)90047-H; TURK DC, 1986, PAIN MANAGEMENT HDB; TURK DC, 1978, COGNITIVE BEHAV THER; ZEIGLER DK, 1995, ARCH NEUROL-CHICAGO, V52, P602; 1995, BEHAV THER RES, V33, P391	72	44	45	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1999	14	1					49	69		10.1097/00001199-199902000-00007			21	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	165LT	WOS:000078523100007	9949246				2021-06-18	
J	Dearden, NM				Dearden, NM			Mechanisms and prevention of secondary brain damage during intensive care	CLINICAL NEUROPATHOLOGY			English	Article						secondary brain damage, prevention; secondary insults, systemic and intracranial, mechanisms	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURED PATIENTS; VENOUS OXYGEN-SATURATION; BLOOD-FLOW; MANAGEMENT	The injured brain map be damaged by primary impact, secondary injury from secondary damage due to initiation of destructive inflammatory and biochemical cascades by the primary injury or secondary ischemic injury following secondary insults that initiate or augment these immunological and biochemical cascades. Cerebral ischemia will arise whenever delivery of oxygen and substrates to the brain fall below metabolic needs. Many factors lead to the development of secondary insults to the injured brain during initial resuscitation, transport, surgery, and subsequent intensive care. Continuous monitoring of cerebral oxygenation (jugular oximetry, brain tissue PO2) and cerebral blood flow velocity (transcranial Doppler ultrasonography) in patients with brain trauma reveals multiple episodes of transient hypoperfusion with an adverse relationship between incidence and outcome. Secondary brain insults arise through systemic or intracranial mechanisms that reduce cerebral blood flow from compromised CPP, vascular distortion or cerebrovascular narrowing or lower oxygen delivery from hypoxemia associated with airway obstruction, pulmonary pathology, or anemia. Secondary brain ischemia remains a common pathway to secondary brain damage in most critically ill neurosurgical patients. In the future prevention of secondary brain injury may well hinge on giving a cocktail of novel agents that modify destructive biochemical and inflammatory pathways, each having a potential therapeutic window possibly in a subgroup of patients. To date, phase 3 clinical trials of several agents including PEGSOD and tyrilizad mesylate have failed to show relevant efficacy after brain trauma or subarachnoid hemorrhage. The therapeutic role of calcium channel blockers in traumatic subarachnoid hemorrhage is currently under investigation following the results of subgroup metaanalysis. Several phase 3, NMDA receptor antagonist studies are underway in brain trauma with results expected soon. Although we know that secondary insults promote excitotoxic secondary brain damage there is currently no pharmacological intervention with proven efficacy and, therefore, detection and correction of secondary insults appear to offer the best therapeutic strategy. After brain trauma, systemic hypotension, compromised CPP, raised ICP, elevated temperature, hypoxemia, and jugular bulb venous desaturation are associated with poor prognosis. Clinical trials of moderate hypothermia following brain trauma are ongoing. Following adult brain trauma maintenance of CPP above at least 65 mmHg (probably > 40 mmHg in children below 8 years) seems important to improve outcome indicating the need for continuous ICP monitoring during intensive care of brain-injured patients.	Univ Leeds, Gen Infirm, Dept Anaesthesia, Leeds LS1 3EX, W Yorkshire, England	Dearden, NM (corresponding author), Univ Leeds, Gen Infirm, Dept Anaesthesia, Great George St, Leeds LS1 3EX, W Yorkshire, England.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; CHAMBERS R, 1996, JD MILL S 16 18 OCT; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; deDeyne C, 1996, ACTA NEUROCHIR, V138, P1409, DOI 10.1007/BF01411119; GENTLEMAN D, 1992, INT SURG, V77, P297; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; JONES PA, 1996, JD MILL S 16 18 OCT; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAAS AIR, 1996, JD MILL S 16 18 OCT; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; ROBERTS WJ, 1992, APS J, V1, P12; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCHETTI N, 1996, JD MILL S 16 18 OCT	26	44	47	0	0	DUSTRI-VERLAG DR KARL FEISTLE	MUNCHEN-DEISENHOFEN	BAHNHOFSTRABE 9 POSTFACH 49, W-8024 MUNCHEN-DEISENHOFEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JUL-AUG	1998	17	4					221	228					8	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	100QF	WOS:000074826300009	9707338				2021-06-18	
J	Spain, DA; McIlvoy, LH; Fix, SE; Carrillo, EH; Boaz, PW; Harpring, JE; Raque, GH; Miller, FB				Spain, DA; McIlvoy, LH; Fix, SE; Carrillo, EH; Boaz, PW; Harpring, JE; Raque, GH; Miller, FB			Effect of a clinical pathway for severe traumatic brain injury on resource utilization	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 1997	WAIKOLOA, HAWAII	Amer Assoc Surg Trauma		traumatic brain injury; multiple injuries; clinical pathway	HEAD-INJURY; TRACHEOSTOMY; MANAGEMENT; ARTHROPLASTY; GASTROSTOMY; MORBIDITY; KNEE; CARE; RISK; HIP	Background: The usefulness of clinical pathways for the complex trauma patient is unclear. We analyzed the effect of a clinical pathway for severe traumatic brain injury (TBI) on resource utilization. Methods: A clinical pathway for severe TBI (Glasgow Coma Scale (GCS) score less than or equal to 8 at 24 hours) was developed by a multidisciplinary team and used for all patients with severe TBI, Data were gathered prospectively for 15 months and compared with data from historical controls from the previous year. Patients who survived < 48 hours were excluded. Results: The clinical pathway was used for 84 patients with severe TBI and compared with 49 historical controls. No differences in Injury Severity Scores (27 vs. 27) or GCS scores at 24 hours (6.2 vs. 6.5) existed between control or pathway patients. There was an overall increase in the mortality rate of pathway patients (from 12.2 to 21.4%), but this was entirely attributable to withdrawal of care that was initiated by family members in patients with an average age of 71 years, an average GCS score of 4.7, and an average Injury Severity Score of 29, Among survivors, pathway patients had a significant decrease in ventilator days (11.5 +/- 0.9 vs. 14.6 +/- 1.2; p < 0.05), intensive care unit days (16.7 +/- 1.0 vs. 21.2 +/- 1.4; p < 0.05), and hospital days (23.4 +/- 1.2 vs. 31.0 +/- 3.0; p < 0.05). There were no differences in the incidence of complications or functional outcomes. Conclusion: The use of a clinical pathway for severe TBI resulted in a significant reduction in resource utilization. This study suggests that clinical pathways may be a useful component of patient care after blunt trauma. Key Words: Traumatic brain injury, Multiple injuries, Clinical pathway.	Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville Hosp, Trauma Inst, Louisville, KY USA; Univ Louisville Hosp, Dept Nursing, Louisville, KY USA; Vet Adm Med Ctr, Louisville, KY 40202 USA	Spain, DA (corresponding author), Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA.						*AM ASS NEUR SURG, 1996, GUID MAN SEV HEAD IN; Amadio PC, 1996, MAYO CLIN PROC, V71, P127, DOI 10.4065/71.2.127; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Brothers TE, 1997, AM SURGEON, V63, P213; Calligaro KD, 1995, J VASC SURG, V22, P649, DOI 10.1016/S0741-5214(95)70055-2; CARRILLO EH, 1997, SURG ENDOSC-ULTRAS, V11, P210; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; DAMELIO LF, 1994, AM SURGEON, V60, P180; DAVIS JT, 1995, ANN THORAC SURG, V59, P1074, DOI 10.1016/0003-4975(95)00001-2; FORKNER DJ, 1996, NURSING MANAGEMENT, V27, P35; Gadacz TR, 1997, AM SURGEON, V63, P107; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; GIBBS BF, 1995, ANN VASC SURG, V9, P423, DOI 10.1007/BF02143853; GRANGER CV, 1994, GUIDE USE UNIFORM DA; Gregor C, 1996, JOINT COMM J QUAL IM, V22, P617, DOI 10.1016/S1070-3241(16)30269-3; Griffen F D, 1997, Bull Am Coll Surg, V82, P29; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Katterhagen G, 1996, Oncology (Williston Park), V10, P113; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Korpiel Michael R., 1995, Journal of Burn Care and Rehabilitation, V16, P191, DOI 10.1097/00004630-199503001-00003; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Millaire A, 1996, CARDIOVASC DRUG THER, V10, P11, DOI 10.1007/BF00051125; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; Morton J R, 1995, Bull Am Coll Surg, V80, P30; Muluk SC, 1997, J VASC SURG, V25, P84, DOI 10.1016/S0741-5214(97)70324-0; Nikas DJ, 1996, SOUTHERN MED J, V89, P1074, DOI 10.1097/00007611-199611000-00009; QUIGLEY MR, 1997, J TRAUMA, V41, P7; RHODES M, 1996, AM J SURG, V173, P35; RODRIGUEZ JL, 1990, SURGERY, V108, P655; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015	33	44	44	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1998	45	1					101	104		10.1097/00005373-199807000-00022			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	101TA	WOS:000074883200025	9680020				2021-06-18	
J	Koller, H; Allert, N; Oel, D; Stoll, G; Siebler, M				Koller, H; Allert, N; Oel, D; Stoll, G; Siebler, M			TNF alpha induces a protein kinase C-dependent reduction in astroglial K+ conductance	NEUROREPORT			English	Article						astrocytes; cell culture; cytokine; electrophysiology; inflammatory brain diseases; neuroimmunology; TNF alpha	TUMOR-NECROSIS-FACTOR; PRIMARY CULTURES; GLUTAMATE UPTAKE; RAT-BRAIN; ASTROCYTES; MEMBRANE; EXPRESSION; DEMENTIA; CELLS	INCUBATION of cultured cortical astrocytes with tumor necrosis factor alpha (TNF alpha) led to a marked reduction of membrane potential. Here we report that this depolarization depends on activation of protein kinase C (PKC), since it could be blocked by the PKC antagonists staurosporine and H7 and it could be mimicked by direct activation of PKC using the phorbol ester phorbol 12-myristate 13 acetate (PMA). Analyses of whole cell currents revealed a reduction of inwardly rectifying K+ currents whereas K+ outward currents were not affected. We conclude that TNF alpha induces changes of basic electrophysiological properties of astrocytes which are similar to those induced by proliferation or an in vitro model of traumatic injury. (C) 1998 Rapid Science Ltd.	Heinrich Heine Univ, Dept Neurol, D-40001 Dusseldorf, Germany	Koller, H (corresponding author), Heinrich Heine Univ, Dept Neurol, POB 101007, D-40001 Dusseldorf, Germany.						AKERMAN KEO, 1988, NEUROSCI LETT, V92, P265, DOI 10.1016/0304-3940(88)90600-3; BALLANYI K, 1987, J PHYSIOL-LONDON, V382, P159, DOI 10.1113/jphysiol.1987.sp016361; BALLESTAS ME, 1995, GLIA, V14, P267, DOI 10.1002/glia.440140404; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; Francke M, 1997, GLIA, V20, P210, DOI 10.1002/(SICI)1098-1136(199707)20:3<210::AID-GLIA5>3.0.CO;2-B; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; Janigro D, 1997, J NEUROSCI, V17, P2813; Koller H, 1997, J NEUROIMMUNOL, V76, P185, DOI 10.1016/S0165-5728(97)00056-8; Koller H, 1996, BRAIN, V119, P2021, DOI 10.1093/brain/119.6.2021; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; Largo C, 1996, J NEUROSCI, V16, P1219; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; MACVICAR BA, 1987, NATURE, V329, P242, DOI 10.1038/329242a0; MURPHY HS, 1994, AM J PHYSIOL, V267, pL145; NORRIS JG, 1994, J IMMUNOL, V152, P841; RANSOM CB, 1995, J NEUROPHYSIOL, V73, P333; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHARIEF MK, 1992, J INFECT DIS, V166, P350, DOI 10.1093/infdis/166.2.350; WALZ W, 1984, BRAIN RES, V292, P367, DOI 10.1016/0006-8993(84)90772-8; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Ye ZC, 1996, NEUROREPORT, V7, P2181, DOI 10.1097/00001756-199609020-00025	24	44	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0959-4965			NEUROREPORT	Neuroreport	MAY 11	1998	9	7					1375	1378					4	Neurosciences	Neurosciences & Neurology	ZR650	WOS:000074000000025	9631432				2021-06-18	
J	Xiong, Y; Peterson, PL; Muizelaar, JP; Lee, CP				Xiong, Y; Peterson, PL; Muizelaar, JP; Lee, CP			Amelioration of mitochondrial function by a novel antioxidant U-101033E following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						antioxidants; brain mitochondria; calcium; oxidative phosphorylation; rats; traumatic brain injury	SEVERE HEAD-INJURY; NERVOUS-SYSTEM TRAUMA; FACIAL MOTOR-NEURONS; LIPID-PEROXIDATION; FOREBRAIN MITOCHONDRIA; ISCHEMIA; TRIAL; MULTICENTER; INHIBITION; AXOTOMY	In the present study, a severe traumatic brain injury (TBI) was produced over the right parietal cortex of rats using the controlled cortical impact injury (CCII) model, TBI perturbed calcium homeostasis and impaired electron transfer and energy coupling activities of forebrain mitochondria isolated from injured hemispheres with a maximal injury at 12-72 h, Efficacy of the blood-brain barrier penetrating antioxidant U-101033E on TBI-induced mitochondrial impairment was evaluated, In the dose-response experiment, two i.v. boluses (vehicle or 1-10 mg/kg of U-101033E) were administered at 5 min and 2h post-TBI, Forebrain mitochondria from each hemisphere were examined at 12 h post-injury, With respect to forebrain mitochondrial dysfunction, the drug showed a bell-shaped dose-response curve with an optimal dose of 3 mg/kg (n = 5, p < 0.05 vs, vehicle), In the time-course experiment, two i.v. boluses of 3 mg U-101033E/kg (the optimal dose) were given at 5 min and 2 h post-injury and forebrain mitochondria were examined at 6 h-14 days post-injury, U-101033E significantly restored electron transfer, energy coupling capacity, and Ca2(+) transport capacity during 6 h to 14 days post-injury, Our data indicate that the antioxidant U-101033E administered post-injury at proper dosage can effectively restore TBI-induced mitochondrial dysfunction and support the contention that oxidative stress plays an important role in the pathogenesis of TBI.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA	Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.			Xiong, Ye/0000-0001-9770-6031			CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; ERNSTER L, 1993, ACTIVE OXYGENS, LIPID PEROXIDES, AND ANTIOXIDANTS, P1; ForsmarkAndree P, 1997, FREE RADICAL BIO MED, V22, P391, DOI 10.1016/S0891-5849(96)00330-9; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1996, J NEUROSCI RES, V44, P293, DOI 10.1002/(SICI)1097-4547(19960501)44:3<293::AID-JNR10>3.0.CO;2-6; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1994, ACTA NEUROCHIR, P521; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lee C. P., 1993, V2, P41; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINN F, 1987, EXP NEUROL, V96, P321, DOI 10.1016/0014-4886(87)90050-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1995, J HEAD TRAUMA REHAB, V10, P1; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; PETERSON PL, 1997, 65 ANN M AM ASS NEUR, P260; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Smith SL, 1996, EXP NEUROL, V141, P304, DOI 10.1006/exnr.1996.0165; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WITTING PK, 1995, FEBS LETT, V375, P45, DOI 10.1016/0014-5793(95)01172-B; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 1997, FASEB J, V11, pA955; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	46	44	45	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1997	14	12					907	917		10.1089/neu.1997.14.907			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YU127	WOS:000071685000003	9475372				2021-06-18	
J	Brouwer, WH; Withaar, FK				Brouwer, WH; Withaar, FK			Fitness to drive after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; DAMAGE; PERFORMANCE; PREDICTION; SAFETY; SKILLS	This paper deals with the issue of fitness to drive in patients suffering from traumatic brain injury (TBI). Guidelines for assessment are proposed and three types of studies are reviewed: studies about impairments of attention and information processing, studies of driving competence, and driver selection studies, applying and evaluating the procedures for assessing fitness to drive. From these reviews a relicensing rate emerges of slightly over 50% for very severe TBI patients. Failures in relicensing particularly occur in patients with a very long duration of post-traumatic amnesia (exceeding 1 month), and with severe impairments of perception and judgement. Furthermore, a review of studies describing training of driving competence in traumatically brain-injured patients is presented. It is argued that graded procedures for (re)training should be developed and assessment should extend to training advice and prediction of training success. When expanding assessments according to this suggestion, evaluation procedures should not only focus on operational capacities, but should include measures of executive functions and learning potential as well.	UNIV GRONINGEN HOSP, DEPT NEUROPSYCHOL, CMCI 3, NL-9700 RB GRONINGEN, NETHERLANDS							Bardach J L, 1971, Arch Phys Med Rehabil, V52, P328; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer W H, 1994, Disabil Rehabil, V16, P149; BROUWER WH, 1990, TRAUMATIC BRAIN INJU, P89; BROUWER WH, 1988, ROAD USER BEHAV THEO, P296; Engum E., 1988, COGNITIVE REMEDI SEP, P34; ENGUM ES, 1990, COGNITIVE REHABI MAR, P20; ENGUM ES, 1989, COGNITIVE REHABI JUL, P22; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; GURGOLD GD, 1978, AM J OCCUP THER, V32, P41; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER, P307; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KEWMAN DG, 1985, REHABIL PSYCHOL, V30, P11; Klebelsberg D., 1982, VERKEHRSPSYCHOLOGIE; KORTELING H, 1988, ROAD USER BEHAV THEO, P319; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lambert EW, 1992, COGNITIVE REHABI MAY, V10, P32; ODENHEIMER GL, 1994, J GERONTOL, V49, pM153, DOI 10.1093/geronj/49.4.M153; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; SCHMIDT IW, 1996, APPL NEUROPSYCHOLOGY; SHORE D, 1980, ARCH PHYSICAL MED RE, V62, P163; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357	37	44	47	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL	1997	7	3					177	193		10.1080/713755536			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	XL513	WOS:A1997XL51300001					2021-06-18	
J	Reitan, RM; Wolfson, D				Reitan, RM; Wolfson, D			Emotional disturbances and their interaction with neuropsychological deficits	NEUROPSYCHOLOGY REVIEW			English	Article						emotional disturbance; neuropsychological deficits; neuropsychological tests; tests of personality and emotional status; brain damage	FRONTAL-SUBCORTICAL CIRCUITS; CLOSED-HEAD-INJURY; TEST-PERFORMANCE; BASE RATES; MOOD DISORDERS; DEPRESSION; MMPI; SYMPTOMS; OUTPATIENTS; VARIABLES	The interaction and relationships between neuropsychological tests (which are principally oriented to intellectual and cognitive abilities) and tests of personality and emotional status are complex, but nevertheless important in the clinical assessment of brain-damaged persons. Are indications of emotional disturbances to be expected as a direct consequence of brain damage? If so, how can the indications of emotional disturbances be differentiated from results obtained with psychiatrically disturbed (non-brain-damaged) subjects? Some authors have presumed that emotional disturbances, such as depression, acute anxiety, etc., in their own right cause impaired performances on neuropsychological tests, whereas other authors have proposed that brain damage predisposes the individual to demonstrate evidence of emotional disturbances. If emotional disturbances cause impairment on neuropsychological tests, why is it that so many emotionally disturbed persons without brain damage tend to perform normally on neuropsychological tests? This review of relevant publications considers (1) different general approaches to these questions and their implications for neuropsychology, (2) evidence of differential sensitivity to brain damage of neuropsychological and emotional instruments, (3) the sensitivity and specificity of self-assessments and complaints of head-injured subjects, (4) MMPI findings among head-injured subjects and in interaction with neuropsychological measurements, and (5) principles and guidelines that may be of value in clinical application of findings reported in the literature.		Reitan, RM (corresponding author), REITAN NEUROPSYCHOL LAB,2920 S 4TH AVE,TUCSON,AZ 85713, USA.						Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; ALVAREZ RR, 1962, PERCEPT MOTOR SKILL, V14, P91; ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; Beck A.T., 1987, BECK DEPRESSION INVE; BIELIAUSKAS LA, 1993, J CLIN EXP NEUROPSYC, V15, P119, DOI 10.1080/01688639308407223; BIELIAUSKAS LA, 1991, J CLIN EXP NEUROPSYC, V13, P433; BIELIAUSKAS LA, 1991, J CLIN EXP NEUROPSYC, V13, P101; BIELIAUSKAS LA, 1991, CLIN NEUROPSYCHOL, V5, P252; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Butcher J. N., 1989, MANUAL RESTANDARDIZE; BYRNE DG, 1977, J PSYCHIAT RES, V13, P185, DOI 10.1016/0022-3956(77)90008-5; CAINE ED, 1986, NEUROPSYCHOLOGICAL A, P221; CASSILETH BR, 1987, CANCER, V60, P547, DOI 10.1002/1097-0142(19870801)60:3+<547::AID-CNCR2820601518>3.0.CO;2-W; COHEN RM, 1982, ARCH GEN PSYCHIAT, V39, P593; CULLUM CM, 1988, J NERV MENT DIS, V176, P332, DOI 10.1097/00005053-198806000-00002; CUMMINGS JL, 1993, J CLIN PSYCHIAT, V54, P14; CUMMINGS JL, 1994, PSYCHIAT ANN, V24, P525, DOI 10.3928/0048-5713-19941001-10; CUMMINGS JL, 1992, AM J PSYCHIAT, V149, P443; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1974, PERCEPT MOTOR SKILL, V39, P831, DOI 10.2466/pms.1974.39.2.831; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; Dikmen S, 1976, Trans Am Neurol Assoc, V101, P72; DIKMEN S, 1974, J ABNORM PSYCHOL, V83, P675, DOI 10.1037/h0037473; DOEHRING DG, 1960, J CLIN PSYCHOL, V16, P307; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FOX DD, 1993, ANN M NAT AC NEUR PH; GASS CS, 1990, PSYCHOL REP, V67, P435, DOI 10.2466/PR0.67.6.435-438; GASS CS, 1992, ARCH CLIN NEUROPSYCH, V7, P17, DOI 10.1016/0887-6177(92)90015-F; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1992, J CLIN PSYCHOL, V48, P493, DOI 10.1002/1097-4679(199207)48:4<493::AID-JCLP2270480409>3.0.CO;2-P; GASS CS, 1991, J CLIN PSYCHOL, V47, P100, DOI 10.1002/1097-4679(199101)47:1<100::AID-JCLP2270470116>3.0.CO;2-H; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P628; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HENRY GM, 1973, AM J PSYCHIAT, V130, P966, DOI 10.1176/ajp.130.9.966; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; KAUFMAN AS, 1994, J PSYCHOEDUC ASSESS, V12, P112, DOI 10.1177/073428299401200201; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; MALEC JF, 1990, J CLIN PSYCHOL, V46, P551, DOI 10.1002/1097-4679(199009)46:5<551::AID-JCLP2270460502>3.0.CO;2-M; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MAYBERG HS, 1988, AM J PSYCHIAT, V145, P937; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MEYERINK LH, 1988, J CLIN PSYCHOL, V44, P764, DOI 10.1002/1097-4679(198809)44:5<764::AID-JCLP2270440517>3.0.CO;2-Y; NEWMAN B, 1992, NEW YORK U MED CTR R, V4, P3; PAOLO AM, 1991, J CLIN PSYCHOL, V47, P529, DOI 10.1002/1097-4679(199107)47:4<529::AID-JCLP2270470409>3.0.CO;2-I; POPE KS, 1993, MMPI MMPI2 MMPIA COU; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; Reiker P., 1985, J CLIN ONCOL, V3, P1117; REITAN R M, 1955, AMA Arch Neurol Psychiatry, V73, P28; REITAN RM, 1955, ARCH NEURO PSYCHIATR, V73, P530, DOI 10.1001/archneurpsyc.1955.02330110046005; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Ruff R.M., 1989, MILD HEAD INJURY, P176; Spielberger CD, 1970, STATE TRAIT ANXIETY; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STOUDEMIRE A, 1995, PSYCHOL FACTORS AFFE; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VINGERHOETS G, 1995, CLIN NEUROPSYCHOL, V9, P198, DOI 10.1080/13854049508401603; WILSON SR, 1990, J CLIN PSYCHOL, V46, P565, DOI 10.1002/1097-4679(199009)46:5<565::AID-JCLP2270460504>3.0.CO;2-3; Wolfson D., 1993, HALSTEAD REITAN NEUR	67	44	44	0	8	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	MAR	1997	7	1					3	19		10.1007/BF02876970			17	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	XK494	WOS:A1997XK49400001	9243528				2021-06-18	
J	Gonul, E; Baysefer, A; Kahraman, S; Ciklatekerlioglu, O; Gezen, F; Yayla, O; Seber, N				Gonul, E; Baysefer, A; Kahraman, S; Ciklatekerlioglu, O; Gezen, F; Yayla, O; Seber, N			Causes of infections and management results in penetrating craniocerebral injuries	NEUROSURGICAL REVIEW			English	Article						craniocerebral injury; penetrating wound; retained bone fragments; surgical infection	INTRACRANIAL BONE FRAGMENTS; MISSILE WOUNDS; LEBANESE CONFLICT; HEAD WOUNDS; BRAIN; VIETNAM	From February 1992 to December 1994, 148 patients with penetrating craniocerebral injuries were treated surgically with primary and secondary debridement including repair of dural defects and removal of retained intracranial bone and metal fragments. Dural defects were closed primarily or with temporalis fascia, pericranium, and cadaver graft. Cerebrospinal fluid fistulas were observed in 11 (7.3 %) patients: 7 of these were infected. Central nervous system (CNS) infection was seen in 2 patients without CSF fistula. Excluding those 11 patients with CSF fistula, CNS infection was shown in 2 of the 137 cases (1.5 %). All patients underwent CT scans periodically In 51 (34 %) of 148 patients, bone and metal fragments were determined on control CT scans. During this time, 12 patients died (8 %). Most of deaths were caused by the direct effect of brain injury and occured within the first month after injury. Fragments retained after first debridement were followed periodically by CT scan. Surgery was not performed until infection developed. Retained fragments did not increase the infection risk, but high rates of infection did occur in cases with CSF fistula.		Gonul, E (corresponding author), GATA,FAC MED,DEPT NEUROSURG,ANKARA,TURKEY.		Kahraman, Serdar/K-4658-2019	Kahraman, Serdar/0000-0003-2489-3854			AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1989, NEUROSURGERY, V25, P923, DOI 10.1227/00006123-198912000-00011; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MYERS PW, 1989, J NEUROSURG, V70, P319; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007	16	44	45	0	1	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0344-5607			NEUROSURG REV	Neurosurg. Rev.		1997	20	3					177	181		10.1007/BF01105561			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XT017	WOS:A1997XT01700003	9297719				2021-06-18	
J	Asikainen, I; Kaste, M; Sarna, S				Asikainen, I; Kaste, M; Sarna, S			Patients with traumatic brain injury referred to a rehabilitation and re-employment programme: Social and professional outcome for 508 Finnish patients 5 or more years after injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; POPULATION; MANAGEMENT; DISABILITY; PROGNOSIS; SURVIVAL; FEATURES; COUNTY; SCALE	We studied influence of age and educational level before injury on the social and vocational outcome among a group of traumatic brain injury (TBI) patients with post-injury problems in their education and employment. Patients with TBI, followed up for at least 5 years, and who were admitted to a rehabilitation and re-employment programme, were selected for evaluation of long-term outcome. We used the Glasgow Coma Scale (GCS) scores at the time of emergency admission to the hospital to measure brain injury severity. Age at the time of TBI and educational status before TBI were correlated with the outcome measures at the end of follow-up separately in each category of brain injury severity. The study was carried out at the Kauniala outpatient neurological clinic, which specializes in brain injuries in Finland; it works closely with the Departments of Neurology and Neurosurgery at the Helsinki University Central Hospital. Main outcome measures were functional outcome measured by the Glasgow Outcome Scale (GOS), the educational level reached, and postinjury occupation, as well as the incapacity for work at the end of follow-up. In the severe category of brain injuries, children 7 years or younger at the time of injury suffered severe disability as measured by the GOS scores more often than did the older age groups (p = 0.010, chi(2)). They were less often capable of independent employment (p = 0.011, chi(2)) than the children injured at the age of 8-16. Patients with a higher education usually had a better outcome. In the category of mild brain injuries the majority of the patients, regardless of age, recovered well according to the GOS, and were capable of independent employment at the end of follow-up. Our patients were selected from the TBI population as survivors with problems in education and re-employment. Those with severe injury sustained early in life (childhood and early teens) coupled with poor educational attainment had relatively worse social and vocational outcome; better outcomes were enjoyed by those severely injured individuals whose injuries were sustained later Gate teens or early adulthood). In the groups of patients with moderate and mild br;un injuries such a relationship was not found between age or pre-injury education and outcome.	UNIV HELSINKI,DEPT NEUROL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT HLTH,HELSINKI,FINLAND	Asikainen, I (corresponding author), KAUNIALA HOSP,DEPT NEUROL,KYLPYLANTIE 19,KAUNIAINEN 02700,FINLAND.			Sarna, Seppo/0000-0003-3458-1627; Kaste, Markku/0000-0001-6557-6412			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHRISTENSEN AL, 1992, SCAND J REHABIL MED, P34; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Clifton GL, 1993, NEUROSURGERY, V33, P8; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GUATIERI CT, 1988, BRAIN INJURY, V2, P101; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HAGEL KH, 1982, UNFALLHEILKUNDE, V85, P192; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1987, HEAD INJURY, P1; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCKENZIE EJ, 1981, MARYLAND MED J, V38, P725; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PARENTE R, 1990, COMMUNITY INTEGRATIO, P216; Parente R., 1989, J HEAD TRAUMA REHAB, V4, P55; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P793; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUCKERT RF, 1985, UNFALLCHIRURG, V88, P99; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1993, HEAD INJURY, P553; Vollmer DG, 1991, NEUROSURGERY, V75, P37; WEHMAN P, 1990, COMMUNITY INTEGRATIO, P110; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHEATLY C, 1989, WORK PROGR OCCUPATIO, P141; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	48	44	46	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	DEC	1996	10	12					883	899		10.1080/026990596123864			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VU408	WOS:A1996VU40800003	8939307				2021-06-18	
J	Childers, MK; Stacy, M; Cooke, DL; Stonnington, HH				Childers, MK; Stacy, M; Cooke, DL; Stonnington, HH			Comparison of two injection techniques using botulinum toxin in spastic hemiplegia	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						botulinum toxin; spasticity; hemiplegia; gait	CEREBRAL-PALSY; A TOXIN	This study sought to test the hypothesis that injections of botulinum toxin type A (BTX-A) at the mid belly of the gastrocnemius muscle in spastic hemiplegic adults produce superior clinical results to proximal injections directed toward the muscular origin. We designed a randomized, double-blind, placebo-controlled intervention study at a university tertiary care setting. Seventeen subjects with chronic spastic hemiplegic gait were enrolled from a volunteer community sample; time range from acute neurologic insult was 0.75 to 31 yr; age range was 19 to 71 yr; gender consisted of 11 men and 4 women; diagnoses were 12 patients with stroke, 2 with traumatic brain injuries, and 1 with a brain tumor, Two subjects were withdrawn from the study because of (1) acute vascular occlusion before intervention and (2) noncompliance with follow-up visits. After baseline measurements, subjects were injected with 50 units of BTX-A (volume, 0.5 cc) into the medial or lateral gastrocnemius: (1) proximally at one site near the muscular origin; (2) distally at three sites along the mid belly. We measured outcome using the Fugl-Meyer score, Ashworth scale, ankle range of motion, and a timed 50-ft fastest walk. No outcome measures showed a significant effect attributable to site of injections. Confounding variables included physical therapy and varying duration of illness in the study cohort. We conclude that the results failed to support the hypothesis that BTX-A injections at the mid belly of the gastrocnemius produced superior functional improvements to injections located near the muscular origin using localization techniques described. Additional research comparing more precise localization methods for BTX-A injections might Further establish the importance of electromyographic guidance using BTX-A in management of spasticity.	ST JOSEPHS HOSP,BARROW NEUROL INST,PHOENIX,AZ; MEM MED CTR,DEPT PHYS MED & REHABIL,SAVANNAH,GA	Childers, MK (corresponding author), UNIV MISSOURI,DEPT PHYS MED & REHABIL,501 RUSK REHABIL CTR,COLUMBIA,MO 65212, USA.			Childers, Martin/0000-0003-4754-0883	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133P10011] Funding Source: Medline		AGANA BT, 1994, ARCH PHYS MED REHAB, V75, P1063; ASHWORTH B, 1964, PRACTITIONER, V192, P540; AWAD EA, 1993, INJECTION TECHNIQUES; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; BORODIC GE, 1994, MOVEMENT DISORD, V9, P31, DOI 10.1002/mds.870090106; Coers C, 1959, INNERVATION MUSCLE; COERS C, 1958, AM J PHYS MED REHABI, V38, P166; Daniel W. W., 1990, APPLIED NONPARAMETRI; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; DYKSTRA DD, 1990, ARCH PHYS MED REHAB, V71, P24; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KONSTANZER A, 1992, MOV DISORD, V7, P416; MEMIN B, 1992, REV NEUROL, V148, P212; NOORT S, 1990, NEUROLOGY, V40, P1332; NORKIN CC, 1994, MEASUREMENT JOINT MO; OBRIEN CF, 1996, NEUROLOGY, V46, P1306; PIERSON SH, 1994, NEUROLOGY, V44, P15; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; SHAARI CM, 1993, MUSCLE NERVE, V16, P964, DOI 10.1002/mus.880160913; SINGH B, 1994, ANN NEUROL, V36, P513; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; WIEGAND H, 1976, N-S ARCH PHARMACOL, V292, P161, DOI 10.1007/BF00498587	29	44	44	0	11	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1996	75	6					462	469		10.1097/00002060-199611000-00013			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WA783	WOS:A1996WA78300010	8985111				2021-06-18	
J	Cifu, DX; Kaelin, DL; Wall, BE				Cifu, DX; Kaelin, DL; Wall, BE			Deep venous thrombosis: Incidence on admission to a brain injury rehabilitation program	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							VEIN THROMBOSIS; INTRACEREBRAL HEMORRHAGE; PULMONARY-EMBOLISM; THROMBOEMBOLISM; STROKE; PROPHYLAXIS; COMPRESSION	Objective: To determine the incidence of deep venous thrombosis (DVT) in brain injured individuals at time of admission to a brain injury (BI) rehabilitation program. Design: Prospective study, sequential case series. Setting: University tertiary care BI rehabilitation center. Data Set: Eighty-two traumatic brain injury (TBI) and 71 atraumatic brain injury (ABI) patients were consecutively admitted to our BI unit over a 12-month period and screened within 24 hours of admission for a lower extremity DVT with color flow duplex Doppler ultrasonography. All patients had been prophylaxed with either subcutaneous heparin anticoagulation therapy or intermittent compression devices, and all patients were within 2 months of the original BI. Main Outcome Measure: Evidence of intrinsic venous occlusion by duplex Doppler. Results: DVTs were detected and treated prior to rehabilitation admission in three patients (2%), and these persisted at rehabilitation admission. New DVTs were detected at time of rehabilitation admission in 17 patients (11%). All were occult DVTs; none of the 17 patients had clinical findings indicative of acute DVT. No significant differences were noted in the TBI group when age, highest 24-hour Glasgow Coma Scale score, length of acute hospitalization, type of DVT prophylaxis, or presence of an extremity fracture were compared for individuals with and without DVT. No significant differences were noted in the ABI group when age, length of acute hospitalization, and type of DVT prophylaxis were compared for individuals with and without DVT. Conclusion: The overall incidence of DVTs was 13% and the incidence of occult DVT was 11%. Individuals with TBI had an overall incidence of DVTs of 20% and an occult DVT incidence of 18%. Individuals with ABI had an overall incidence of DVT's of 6% and an occult DVT incidence of 4%. These findings indicate the importance of baseline screening for DVT in this patient population. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298; INDIANA UNIV,DEPT PHYS MED & REHABIL,BLOOMINGTON,IN 47405				Cifu, David/0000-0003-1600-9387			BLACK PM, 1986, NEUROSURGERY, V18, P25, DOI 10.1227/00006123-198601000-00005; BRANDSTATER ME, 1992, ARCH PHYS MED REHAB, V73, pS379; COPE C, 1973, RADIOLOGY, V109, P581, DOI 10.1148/109.3.581; DESMUKH M, 1991, AM J PHYS MED REHAB, V70, P313; DICKMANN U, 1988, KLIN WOCHENSCHR, V66, P1182, DOI 10.1007/BF01727666; FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P1121; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; HIRSH J, 1982, HEMOSTASIS THROMBOSI, P831; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL R, 1982, HAEMOSTASIS THROMBOS, P844; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; LACHMANN EA, 1992, ARCH PHYS MED REHAB, V73, P482; LANDI G, 1992, ARCH NEUROL-CHICAGO, V49, P279, DOI 10.1001/archneur.1992.00530270093024; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; MIYAMOTO AT, 1980, ARCH PHYS MED REHAB, V61, P584; *OFF MED APPL RES, 1986, JAMA-J AM MED ASSOC, V256, P744; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; RENTSCH HP, 1987, SCHWEIZ MED WSCHR, V117, P1853; SIOSON ER, 1988, ARCH PHYS MED REHAB, V69, P183; SKILLMAN JJ, 1978, SURGERY, V83, P554; STEINBURG DP, 1993, ARCH PHYS MED REHAB, V74, P1243; Subbarao J, 1984, IMJ Ill Med J, V165, P328; TEASDALE G, 1974, LANCET, V2, P81; WARLOW C, 1976, BRIT MED J, V1, P1178, DOI 10.1136/bmj.1.6019.1178; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; WHEELER HB, 1986, CHEST, V89, pS407, DOI 10.1378/chest.89.5_Supplement.407S; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921	30	44	44	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1996	77	11					1182	1185		10.1016/S0003-9993(96)90145-8			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VR820	WOS:A1996VR82000017	8931533				2021-06-18	
J	Miller, RD; Monsul, NT; Vender, JR; Lehmann, JC				Miller, RD; Monsul, NT; Vender, JR; Lehmann, JC			NMDA- and endothelin-1-induced increases in blood-brain barrier permeability quantitated with Lucifer yellow	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						blood-brain barrier; cerebrovasculature; excitatory amino acid; N-Methyl-D-aspartate; endothelin-1 (ET-I); selfotel; Lucifer yellow	D-ASPARTATE; RECEPTORS; CGS-19755; CELLS	At 48 h following intrastriatal injection of N-methyl-D-aspartate (NMDA; 100 nmol/mu l) or endothelin-1 (ET-1; 143 pmol/mu l), significant increases in brain penetration of the highly polar, fluorescent tracer Lucifer yellow were observed. The competitive NMDA receptor antagonist selfotel (CGS-19755; 30 nmol/mu l, i.c.) significantly reduced the NMDA-induced increases in blood-brain barrier permeability, but not those induced by ET-1. These results suggest that NMDA receptors can mediate increases in blood-brain barrier permeability but do not primarily mediate increases in blood-brain barrier permeability caused by ET-1. This is the first study to our knowledge investigating the relationship between excitotoxicity and disruption of the blood-brain barrier, a major pathophysiological event in stroke and traumatic brain injury.	MED COLL PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,PHILADELPHIA,PA 19102; MED COLL PENN,DEPT PHYSIOL & BIOPHYS,PHILADELPHIA,PA 19102					NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 49898] Funding Source: Medline		ALTURA BM, 1991, STROKE, V23, P153; BEART PM, 1988, J CEREBR BLOOD F MET, V8, P879, DOI 10.1038/jcbfm.1988.146; BOAST CA, 1988, BRAIN RES, V442, P345, DOI 10.1016/0006-8993(88)91522-3; DIRNAGL U, 1993, PROG BRAIN RES, V96, P49; DUX E, 1991, J CEREB BLOOD FLO S2, V11, pS105; FUXE K, 1991, METHODS NEUROSCIENCE, V7, P256; HARDEBO JE, 1989, ACTA PHYSIOL SCAND, V136, P483, DOI 10.1111/j.1748-1716.1989.tb08690.x; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; KOHZUKI M, 1991, NEUROSCIENCE, V42, P245, DOI 10.1016/0306-4522(91)90162-H; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LEHMANN J, 1988, J PHARMACOL EXP THER, V246, P65; LIN WW, 1990, BIOCHEM BIOPH RES CO, V167, P593, DOI 10.1016/0006-291X(90)92066-9; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIMOTO S, 1990, BRAIN RES, V508, P283, DOI 10.1016/0006-8993(90)90407-3	15	44	44	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAR	1996	136	1-2					37	40		10.1016/0022-510X(95)00309-P			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	UC708	WOS:A1996UC70800006	8815176				2021-06-18	
J	Soares, HD; Sinson, GP; McIntosh, TK				Soares, HD; Sinson, GP; McIntosh, TK			Fetal hippocampal transplants attenuate CA3 pyramidal cell death resulting from fluid percussion brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; fetal neural transplants; hippocampus	NERVE GROWTH-FACTOR; INTRACEREBRAL NEURAL IMPLANTS; NEUROTROPHIC FACTOR PREVENTS; MOTOR NEURONS; NEOCORTICAL TRANSPLANTS; CORTICAL TRANSPLANTS; MEMORY DEFICITS; GRAFTS; CORTEX; DEGENERATION	Transplantation of fetal neural tissue has been demonstrated to prevent neuronal loss in a number of CNS injury models including spinal cord contusion, However, no studies have examined the neuroprotective role of fetal transplants in models of traumatic brain injury, The present study examined the ability of fetal neural grafts to attenuate neuronal loss resulting from lateral fluid percussion (FP) brain injury in the rat, Lateral FP in the rat elicits a focal contusion within the parietal/temporal cortex and induces cell death in a subset of hippocampal CA3 pyramidal neurons, To examine potential neuroprotective effects of fetal neural grafts, either E16 fetal hippocampus, E16 fetal cortex, or sterile lactated Ringers was stereotaxically transplanted directly into contused cortex 2 days after FP brain injury, The effects of fetal transplants upon adjacent injured hippocampal CA3 regions were then assessed at 4 weeks after grafting utilizing quantitative image analysis, Both fetal cortex and hippocampal grafts survived within contused cortex, Fetal hippocampal grafts significantly attenuated CA3 cell death resulting from lateral fluid percussion, while fetal cortical transplants induced a small, but nonsignificant, amelioration of CA3 pyramidal loss, Thus, neuroprotection by fetal grafts appeared to be tissue specific with hippocampal, but not cortical, fetal transplants significantly reducing posttraumatic CA3 loss, In summary, fetal neural transplantation can ameliorate hippocampal cell death following experimental brain injury.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, P01NS008803, R01NS026818, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		ARENDT T, 1988, NATURE, V332, P448, DOI 10.1038/332448a0; BARTH TM, 1994, CEREB CORTEX, V4, P271, DOI 10.1093/cercor/4.3.271; BJORKLUND A, 1987, TRENDS NEUROSCI, V10, P509, DOI 10.1016/0166-2236(87)90131-7; BJORKLUND A, 1984, ANNU REV NEUROSCI, V7, P279, DOI 10.1146/annurev.ne.07.030184.001431; BRAUGHLER JM, 1991, J NEUROTRAUM, V8, P51; BREGMAN BS, 1986, J COMP NEUROL, V244, P86, DOI 10.1002/cne.902440107; CIRCIRATA F, 1992, ARCH ITAL BIOL, V130, P101; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAS GD, 1980, AM J ANAT, V158, P135, DOI 10.1002/aja.1001580204; DUNNETT S, 1991, TRENDS NEUROSCI, V14, P371, DOI 10.1016/0166-2236(91)90166-R; Dunnett S. B., 1992, NEURAL TRANSPLANTATI, P1; ESCOBAR M, 1989, BRAIN RES, V478, P368, DOI 10.1016/0006-8993(89)91519-9; FLOETER MK, 1984, J NEUROSCI, V4, P141; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GONZALEZ MF, 1988, EXP NEUROL, V99, P154, DOI 10.1016/0014-4886(88)90135-5; Graham D.I., 1993, HEAD INJURY, P91; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAUN F, 1984, DEV BRAIN RES, V15, P290, DOI 10.1016/0165-3806(84)90108-1; HAUN F, 1987, J COMP NEUROL, V256, P561, DOI 10.1002/cne.902560408; HEFTI F, 1986, J NEUROSCI, V6, P2155; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUDSON JL, 1994, J NEUROSCI, V14, P283; JAEGER CB, 1979, BRAIN RES, V165, P338, DOI 10.1016/0006-8993(79)90566-3; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; LU SY, 1993, J NEURAL TRANSP PLAS, V4, P279, DOI 10.1155/NP.1993.279; LYETH GS, 1972, BRAIN RES, V42, P311; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; PAULABARBOSA MM, 1991, ALCOHOL ALCOHOLISM, V26, P177, DOI 10.1093/oxfordjournals.alcalc.a045099; PERRI BR, 1995, UNPUB J CEREB BLOOD; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; RIDLEY RM, 1993, ANN NY ACAD SCI, V695, P274, DOI 10.1111/j.1749-6632.1993.tb23066.x; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SHARRARD WJW, 1986, REV CHIR ORTHOP, V72, P247; SIEVERS J, 1989, J COMP NEUROL, V281, P267; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; SORENSEN JC, 1992, EXP BRAIN RES, V92, P299; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Witter M. P., 1989, HIPPOCAMPUS NEW VIST, P53; WOODRUFF ML, 1993, PHYSIOL BEHAV, V54, P579, DOI 10.1016/0031-9384(93)90253-C; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YOUNG W, 1992, J NEUROTRAUMA S, V1, pS9	51	44	45	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1059	1067		10.1089/neu.1995.12.1059			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800006	8742134				2021-06-18	
J	SUN, FY; FADEN, AI				SUN, FY; FADEN, AI			PRETREATMENT WITH ANTISENSE OLIGODEOXYNUCLEOTIDES DIRECTED AGAINST THE NMDA-R1 RECEPTOR ENHANCES SURVIVAL AND BEHAVIORAL RECOVERY FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	BRAIN RESEARCH			English	Article						N-METHYL-D-ASPARTATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; NEUROPROTECTION; TRAUMATIC BRAIN INJURY; MORTALITY; BEHAVIORAL RECOVERY; ASTROCYTIC REACTION	EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; CEREBRAL-ISCHEMIA; MOLECULAR DIVERSITY; TRANSPORT SITES; GLUTAMATE; ANTAGONISTS; CHANNEL; NEURONS; HIPPOCAMPUS	Treatment with N-methyl-D-aspartate (NMDA) receptor antagonists limits tissue damage following CNS ischemia or trauma, supporting the hypothesis that NMDA receptors participate in the pathophysiology of such injuries. An alternative approach for evaluating this hypothesis is to examine the effects of selective inhibition of NMDA receptor synthesis, using antisense oligodeoxynucleotides. In the present studies, the effects of antisense oligodeoxynucleotides directed at NMDA-R1 receptor subunit, administered intracerebroventricularly (i.c.v.) prior to injury, were evaluated in a well-defined traumatic brain injury model in rats. Outcome measures included survival, motor recovery, and histological changes. Administration of antisense oligodeoxynucleotides (15 nmol/ml twice daily X 2 days) did not alter physiological variables or motor function prior to trauma. However, such treatment significantly decreased mortality and improved behavioral recovery at 2 weeks after trauma as compared to animals treated with the corresponding sense oligodeoxynucleotides. Although cell counts in hippocampus did not differ between treatment groups, astrocyte activation as reflected by glial fibrillary astrocytic protein (GFAP) immunocytochemistry was significantly reduced in antisense treated animals. These findings provide additional evidence that NMDA receptors contribute to secondary injury after brain trauma and may suggest an alternative treatment approach.	GEORGETOWN UNIV,MED CTR,SCH MED,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,SCH MED,DEPT PHARMACOL,WASHINGTON,DC 20007					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 306634] Funding Source: Medline		ALBERS GW, 1990, CLIN NEUROPHARMACOL, V13, P177, DOI 10.1097/00002826-199006000-00001; ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; ANDERSON KJ, 1993, BRAIN RES, V622, P93, DOI 10.1016/0006-8993(93)90806-X; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; BULLER AL, 1994, J NEUROSCI, V14, P5471; FADDIS BT, 1988, AM J ANAT, V183, P316, DOI 10.1002/aja.1001830405; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; ISHII T, 1993, J BIOL CHEM, V268, P2836; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P25; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Paxinos G, 1986, RAT BRAIN STEREOTAXI; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHARPIR AY, 1990, J NEUROTRAUM, V7, P131; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0	41	44	47	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 25	1995	693	1-2					163	168		10.1016/0006-8993(95)00731-5			6	Neurosciences	Neurosciences & Neurology	RX133	WOS:A1995RX13300019	8653404				2021-06-18	
J	BERRYHILL, P; LILLY, MA; LEVIN, HS; HILLMAN, GR; MENDELSOHN, D; BRUNDER, DG; FLETCHER, JM; KUFERA, J; KENT, TA; YEAKLEY, J; BRUCE, D; EISENBERG, HM				BERRYHILL, P; LILLY, MA; LEVIN, HS; HILLMAN, GR; MENDELSOHN, D; BRUNDER, DG; FLETCHER, JM; KUFERA, J; KENT, TA; YEAKLEY, J; BRUCE, D; EISENBERG, HM			FRONTAL-LOBE CHANGES AFTER SEVERE DIFFUSE CLOSED-HEAD INJURY IN CHILDREN - A VOLUMETRIC STUDY OF MAGNETIC-RESONANCE-IMAGING	NEUROSURGERY			English	Article						CHILDREN; CLOSED HEAD INJURY; MAGNETIC RESONANCE IMAGING	COMA DATA-BANK; BRAIN MORPHOLOGY; ADOLESCENTS; SEQUELAE; MRI; SPECT; CT	IN VIEW OF the pathophysiology and biomechanics of severe closed head injury (CHI) in children, we postulated that the frontal lobes sustain diffuse injury, even in the absence of focal brain lesions detected by magnetic resonance imaging (MRI). This study quantitated the morphological effects of CHI on the frontal lobes in children who sustained head trauma of varying severity. The MRI findings of 14 children who had sustained severe CHIs (Glasgow Coma Scale score of less than or equal to 8) were compared with the findings in a matched group of 14 children having sustained mild head injuries (Glasgow Coma Scale score of 13-15). The patients ranged in age from 5 to 15 years at the time of their MRIs, which were acquired at least 3 months postinjury. MRI findings revealed no focal areas of abnormal signal in the frontal lobes. Volumetric analysis disclosed that the total prefrontal cerebrospinal fluid increased and the gray matter volume decreased in the patients with severe CHI, relative to the mildly injured comparison group. Gray matter volume was also reduced in the orbitofrontal and dorsolateral regions of the brains of children with severe CHI, relative to the children who sustained mild head trauma. These volumetric findings indicate that prefrontal tissue loss occurs after severe CHI in children, even in the absence of focal brain lesions in this area. Nearly two-thirds of the children who sustained severe CHIs were moderately disabled after an average postinjury interval of 3 years or more, whereas 12 of the 14 patients with mild CHIs attained a good recovery (2 were moderately disabled) by the time of study. Although this initial study of brain morphometry after CHI in children was not designed to isolate the contribution of frontal lobe damage to residual disability, further research involving a larger sample is in progress to address this issue.	UNIV MARYLAND MED SYST,DIV NEUROSURG,BALTIMORE,MD 21201; UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT COMP SCI,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,SW MED CTR,ALGUR H MEADOWS DIAGNOST IMAGING CTR,DALLAS,TX 75230; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DIV RADIOL,HOUSTON,TX 77225; PEDIAT ASSOCIATES,NEUROSURGEONS CHILDRENS,DALLAS,TX			Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019	Kent, Thomas/0000-0002-9877-7584	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1980, J NEUROSURG, V62, P194; BERNARDI B, 1993, TOP MAGN RESON IMAG, V5, P161; BIJUR PE, 1990, PEDIATRICS, V86, P337; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Filipek Pauline A., 1992, V6, P301; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; JENNETT B, 1975, LANCET, V1, P480; JERNIGAN T L, 1989, Neurology, V39, P138; JERNIGAN TL, 1990, DEV MED CHILD NEUROL, V32, P379; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PRAYER L, 1993, ACTA RADIOL, V34, P593; REISS AL, 1993, ANN NEUROL, V34, P228; SCHNITZLEIN HN, 1990, IMAGING ANATOMY HEAD; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TEASDALE G, 1974, LANCET, V2, P81	33	44	44	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1995	37	3					392	399		10.1227/00006123-199509000-00004			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RU161	WOS:A1995RU16100009	7501101				2021-06-18	
J	FULTON, RL; VOIGT, WJ; HILAKOS, AS				FULTON, RL; VOIGT, WJ; HILAKOS, AS			CONFUSION SURROUNDING THE TREATMENT OF TRAUMATIC CARDIAC-ARREST	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							THORACOTOMY; RESUSCITATION; HEMORRHAGE	BACKGROUND: To delineate the most reasonable approach to patients with traumatic cardiac arrest we studied the experience at our level 1 trauma center. STUDY DESIGN: Patients with life-threatening trauma admitted during a 41-month period were screened to identify 245 patients who suffered cardiac arrest. Mechanisms of injury, location of arrest, length of arrest, transport methods, treatment rendered, neurologic state, outcomes, and cost of treatment were determined. RESULTS: Six (2.4 percent) patients survived. Mechanism of injury, location of arrest, and age did not correlate with survival. Arrest time longer than ten minutes and loss of neurologic function were associated with mortality. Cost of care was not excessive. CONCLUSIONS: Patients with traumatic cardiac arrest with intact neurologic function should receive treatment. Resuscitation should not be attempted in patients who also have severe brain injury or prolonged time of cardiac arrest.	UNIV LOUISVILLE HOSP,INST TRAUMA,LOUISVILLE,KY	FULTON, RL (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT SURG,LOUISVILLE,KY 40292, USA.						APRAHAMIAN C, 1985, ANN EMERG MED, V14, P95; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BOYD M, 1992, J TRAUMA, V33, P714, DOI 10.1097/00005373-199211000-00021; BUCKBERG GD, 1979, J THORAC CARDIOV SUR, V77, P803; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; CUE JI, 1990, J TRAUMA, V30, P1007, DOI 10.1097/00005373-199008000-00010; DURHAM LA, 1992, J TRAUMA, V32, P775, DOI 10.1097/00005373-199206000-00019; ESPOSITO TJ, 1991, J TRAUMA, V31, P881, DOI 10.1097/00005373-199107000-00001; EVANS J, 1979, ANN SURG, V189, P777, DOI 10.1097/00000658-197906000-00015; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; FULTON RL, 1993, SURG GYNECOL OBSTET, V176, P327; LORENZ HP, 1992, J TRAUMA, V32, P780, DOI 10.1097/00005373-199206000-00020; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; Richardson J D, 1985, Curr Surg, V42, P361; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; WALPOLE RE, 1989, PROBABILITY STATISTI; WEIDLER DJ, 1974, STROKE, V5, P759, DOI 10.1161/01.STR.5.6.759; WRIGHT SW, 1989, ANN EMERG MED, V18, P721, DOI 10.1016/S0196-0644(89)80003-4; 1993, ADV TRAUMA LIFE SUPP; 1994, TXB ADV CARDIAC LIFE	22	44	44	0	0	AMER COLL SURGEONS	CHICAGO	54 EAST ERIE ST, CHICAGO, IL 60611	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	1995	181	3					A209	A214					6	Surgery	Surgery	RT205	WOS:A1995RT20500003	7670679				2021-06-18	
J	BOAKE, C; FREELAND, JC; RINGHOLZ, GM; NANCE, ML; EDWARDS, KE				BOAKE, C; FREELAND, JC; RINGHOLZ, GM; NANCE, ML; EDWARDS, KE			AWARENESS OF MEMORY LOSS AFTER SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							EVERYDAY MEMORY	This study investigated unawareness of memory loss in 48 severe closed-head injury patients. Awareness was measured as the correlation of patients' memory test scores with their self-ratings on the Everyday Memory Questionnaire (EMQ). Patients who endorsed atypical memory failures on the EMQ were classified as invalid responders. Invalid responders had poorer memory test performances and a higher rate of focal left hemispheric lesions, but did not report greater emotional symptoms. Correlations between memory test scores and memory self-ratings were weaker among invalid responders or those classified as depressed, and stronger among valid responders, especially those classified as non-depressed. The results indicate that the validity of memory self-reports is influenced by both neurogenic and psychogenic factors, and suggest that invalid responding is an important problem with self-reports by brain-injured patients.	INST REHABIL & RES, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; CASA COLINA CTR REHABIL, POMONA, CA USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; DALLAS CTY MENTAL HLTH & MENTAL RETARDAT CTR, DALLAS, TX USA							ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DAHLSTROM WG, 1975, MMPI HDB GUIDE USE C, V1; DAHLSTROM WG, 1975, MMPI HDB GUIDE USE C, V2; Delis DC, 1987, CALIFORNIA VERBAL LE; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Wade DT, 1992, MEASUREMENT NEUROLOG; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WILSON B, 1985, RIVERMEAD BEHAVIOURA; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	24	44	46	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1995	9	3					273	283		10.3109/02699059509008198			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QR499	WOS:A1995QR49900005	7606238				2021-06-18	
J	SCHNEIDER, GH; VONHELDEN, A; LANKSCH, WR; UNTERBERG, A				SCHNEIDER, GH; VONHELDEN, A; LANKSCH, WR; UNTERBERG, A			CONTINUOUS MONITORING OF JUGULAR BULB OXYGEN-SATURATION IN COMATOSE PATIENTS - THERAPEUTIC IMPLICATIONS	ACTA NEUROCHIRURGICA			English	Article; Proceedings Paper	Joint Meeting of the Belgian, Dutch, and German Neurosurgical Societies on Modern Trends and Innovative Techniques in Clinical Neurosurgery in Adults	FEB 11-13, 1993	MAASTRICHT, NETHERLANDS			JUGULAR VENOUS OXYGEN SATURATION; HYPERVENTILATION; CEREBRAL PERFUSION PRESSURE; DESATURATION EPISODE	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; HYPERVENTILATION; METABOLISM; PRESSURE; INSULTS	Comatose patients run a high risk of developing cerebral ischaemia which may considerably influence final outcome. It would therefore be extremely useful if one could monitor cerebral blood flow in these patients. Since there is a close correlation between the arteriovenous difference of oxygen and cerebral blood flow, it was a logical step to place a fiberoptic catheter in the jugular bulb for continuous measurement of cerebrovenous oxygen saturation. We have monitored cerebral oxygenation in 54 patients, comatose because of severe head injury, intracerebral haemorrhage or subarachnoid haemorrhage. Normal jugular venous oxygen saturation (SJVO(2)) ranges between 60 and 90%. A decline to below 50% is considered indicative of cerebral ischaemia. Spontaneous episodes of desaturation (SJVO(2) < 50% for at least 15 min) were frequent during the acute phase of these insults. Many of these desaturation episodes could be attributed to hyperventilation, even though considered moderate. Likewise, insufficient cerebral perfusion pressure and severe vasospasm were found to be important causes of desaturation episodes. In many instances, tailoring of ventilation or induced hypervolaemia and hypertension were capable of reversing these low flow states. The new method of continuous cerebrovenous oximetry is expected to contribute to a better outcome by enabling timely detection and treatment of insufficient cerebral perfusion.	FREE UNIV BERLIN,RUDOLF VIRCHOW MED CTR,DEPT NEUROSURG,W-1000 BERLIN,GERMANY							ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAETHMANN A, 1986, MECHANISMS SECONDARY; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1985, CRIT CARE MED, V4, P284; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Miller JD, 1987, CEREBRAL BLOOD FLOW, P119; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; PATEL PM, 1993, J NEUROSURG ANESTH, V5, P62; PRAKASH S, 1992, J NEUROSURG, V76, pA398; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SCHEINBERG M, 1992, J NEUROSURG, V76, P212; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; von Helden A, 1993, Acta Neurochir Suppl (Wien), V59, P102	18	44	45	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	134	1-2					71	75		10.1007/BF01428507			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QZ277	WOS:A1995QZ27700014	7668132				2021-06-18	
J	MOREHEAD, M; BARTUS, RT; DEAN, RL; MIOTKE, JA; MURPHY, S; SALL, J; GOLDMAN, H				MOREHEAD, M; BARTUS, RT; DEAN, RL; MIOTKE, JA; MURPHY, S; SALL, J; GOLDMAN, H			HISTOPATHOLOGIC CONSEQUENCES OF MODERATE CONCUSSION IN AN ANIMAL-MODEL - CORRELATIONS WITH DURATION OF UNCONSCIOUSNESS	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; LESIONS; RATS; MEMORY; VULNERABILITY; HIPPOCAMPUS; ANTERIOR; THALAMUS; DEFICIT	Although duration of unconsciousness is commonly used as a prognostic index following traumatic brain injury (TBI), few controlled studies have statistically evaluated the relationship between unconsciousness and histologic pathology, particularly after moderate head injury, Using a pendulum-striker concussive device, a reproducible model of TBI in rats was developed. This model is uncomplicated by skull fractures, contusions, or experimenter-induced craniotomies. In the present study, the severity of the histopathology observed in this model of moderate closed-head injury at 48 h posttrauma is linearly related to the duration of unconsciousness (p < 0.0001), The pathology, assessed with a silver stain for neurodegeneration, is particularly striking if unconsciousness persists for 4 minutes or more, These data suggest that the initial period of unconsciousness may be a useful predictor of clinical brain histopathology associated with moderate closed-head injury, predicting either the degree of pathology and/or the rate it progresses if left untreated.	WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201; TUFTS UNIV,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BOSTON,MA 02111; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92717	MOREHEAD, M (corresponding author), ALKERMES INC,NEUROBIOL,64 SIDNEY ST,4TH FLOOR,CAMBRIDGE,MA 02139, USA.						AGGLETON JP, 1991, BEHAV BRAIN RES, V44, P151, DOI 10.1016/S0166-4328(05)80020-8; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BERACOCHEA DJ, 1989, BEHAV NEURAL BIOL, V51, P364, DOI 10.1016/S0163-1047(89)91000-5; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; GALLYAS F, 1980, STAIN TECHNOL, V55, P299, DOI 10.3109/10520298009067258; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDMAN H, 1993, ANN EMERG MED, V22, P1035, DOI 10.1016/S0196-0644(05)82747-7; GOLDMAN H, 1993, J NEUROTRAUM, V10, P385, DOI 10.1089/neu.1993.10.385; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAROON JC, 1992, PHYSICIAN SPORTSMED, V20, P37, DOI 10.1080/00913847.1992.11710269; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOREHEAD M, 1991, ALCOHOL POTENTIATES; MOREHEAD M, 1993, APR AM NEUR M; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SQUIRE LR, 1981, J NEUROSCI, V1, P635; STOKES KA, 1990, BEHAV NEURAL BIOL, V53, P334, DOI 10.1016/0163-1047(90)90198-F; TEASDALE G, 1984, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; WINOCUR G, 1985, BEHAV BRAIN RES, V16, P135, DOI 10.1016/0166-4328(85)90088-9	33	44	44	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1994	11	6					657	667		10.1089/neu.1994.11.657			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QD215	WOS:A1994QD21500003	7723065				2021-06-18	
J	CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR				CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR			STAIRWAY-RELATED INJURIES IN CHILDREN	PEDIATRICS			English	Article						STAIRS; STAIRWAY; CHILDREN; INJURY CONTROL; CHILDHOOD INJURIES; HEAD INJURIES	TRAUMA	Objective. To identify the pattern and severity of injury associated with stairway-related falls in children. Methods. During a 2-year period, all children less than 5 years of age presenting to the University of Virginia Pediatric Emergency Department with a stairway-related injury were prospectively studied. At the time of the emergency department visit, demographic and epidemiologic information was obtained. Injuries were assigned E codes and N codes. A Modified Injury Severity Scale (MISS) score was calculated for each child. Excluded from the study were children with suspected intentional trauma and children with walker-related stairway injuries. Results. Sixty-nine children were enrolled in the study. The median age was 2 years. Head and neck injuries occurred in 90% of the patients, extremity injuries in 6%, and truncal injuries in 4%. Injury to more than one body region did not occur. The majority of injuries were minor. Ninety-six percent had a total MISS score less than or equal to 2. Fifteen patients (22%) suffered significant injuries, including concussion in 11 (16%), skull fracture in 5 (7%), cerebral contusion in 2 (3%), subdural hematoma in 1 (1%), and a C-2 fracture in 1 (1%). Conclusions. The majority of stairway-related injuries are minor. Injuries to the head and neck region predominate. Injuries to multiple body regions are rare. However, significant stairway-related injuries may be more common than previously reported.		CHIAVIELLO, CT (corresponding author), UNIV VIRGINIA,DEPT PEDIAT,DIV EMERGENCY MED,CHARLOTTESVILLE,VA 22908, USA.						Baker SP, 1992, THE INJURY FACT BOOK; BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; JOFFE M, 1988, PEDIATRICS, V82, P457; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; 1964, CLIN NEUROSURG, V12, P386; 1980, INT CLASSIFICATION D, V1	9	44	47	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	NOV	1994	94	5					679	681					3	Pediatrics	Pediatrics	PN912	WOS:A1994PN91200005	7936895				2021-06-18	
J	DUNNMEYNELL, A; PAN, SJ; LEVIN, BE				DUNNMEYNELL, A; PAN, SJ; LEVIN, BE			FOCAL TRAUMATIC BRAIN INJURY CAUSES WIDESPREAD REDUCTIONS IN RAT-BRAIN NOREPINEPHRINE TURNOVER FROM 6 TO 24 H	BRAIN RESEARCH			English	Article						BRAIN INJURY; HEAD TRAUMA; RECOVERY OF FUNCTION; PLASTICITY; CATECHOLAMINE	SENSORIMOTOR CORTEX INJURY; CEREBRAL OXIDATIVE-METABOLISM; LOCUS COERULEUS; MOTOR RECOVERY; BEAM-WALKING; CEREBELLAR NOREPINEPHRINE; GLUCOSE-UTILIZATION; CORTICAL INJURY; BARREL CORTEX; AMPHETAMINE	The effect of right sensorimotor traumatic brain injury (TBI) in male Sprague-Dawley rats on brain norepinephrine (NE) turnover was assessed by measuring the decline of endogenous NE levels following tyrosine hydroxylase inhibition produced with alpha-methyl-p-tyrosine. Right sensorimotor cortex contusions were produced by a pneumatically driven piston which depressed the dural surface by 2 mm at 3.2 m/s. TBI rats were compared to uninjured, anesthetized controls at 6 h and 24 h after surgery. While NE turnover was not affected at the lesion site at 6 h after TBI, it was either abolished or decreased by 33-75% bilaterally in the hypothalamus and in the cerebral cortex surrounding and rostral to the lesion site. In the cortex caudal to the lesion site, NE turnover was completely abolished. NE turnover in cerebral cortex opposite the lesion site and in the contralateral cerebellum was decreased by 51 and 43%, respectively, at 6 h. At 24 h, NE turnover was either abolished or decreased bilaterally by 45-92% in all cortical areas, in the hypothalamus, cerebellum, locus coeruleus and medulla. Thus, right sensorimotor cortex contusion causes a marked, early and widespread depression of brain NE turnover. Since amphetamine increases NE turnover, this may explain the dramatic improvement in behavioral deficits which occurs following amphetamine administration at 24 h after such lesions.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	DUNNMEYNELL, A (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,385 TREMONT AVE,E ORANGE,NJ 07018, USA.						BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1993, PHARMACOL BIOCHEM BE, V44, P297, DOI 10.1016/0091-3057(93)90465-6; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BRODIE BB, 1966, J PHARMACOL EXP THER, V154, P493; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CRAIK RL, 1987, BRAIN RES BULL, V19, P495, DOI 10.1016/0361-9230(87)90154-7; DIETRICH WD, 1990, STROKE S, V3, P147; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FULHAM MJ, 1992, NEUROLOGY, V42, P2267, DOI 10.1212/WNL.42.12.2267; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1993, RESTOR NEUROL NEUROS, V5, P371, DOI 10.3233/RNN-1993-55608; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GUSTAFSON I, 1989, J CEREBR BLOOD F MET, V9, P171, DOI 10.1038/jcbfm.1989.25; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; KATAYAMA Y, 1981, BRAIN RES, V21, P173; LAMANNA JC, 1981, BRAIN RES, V204, P87, DOI 10.1016/0006-8993(81)90654-5; LEVIN BE, 1983, BRAIN RES, V289, P205, DOI 10.1016/0006-8993(83)90021-5; LEVIN BE, 1991, EXP NEUROL, V113, P237, DOI 10.1016/0014-4886(91)90180-K; LEVIN BE, IN PRESS RESTOR NEUR; LEVITT P, 1979, J COMP NEUROL, V186, P505, DOI 10.1002/cne.901860402; LOUGHLIN SE, 1982, BRAIN RES BULL, V9, P287, DOI 10.1016/0361-9230(82)90142-3; LOWRY O, 1934, J BIOL CHEM, P265; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; MOURADIAN RD, 1991, BRAIN RES, V546, P83, DOI 10.1016/0006-8993(91)91162-T; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; ROBINSON RG, 1980, BRAIN RES, V188, P63, DOI 10.1016/0006-8993(80)90557-0; SLUKA KA, 1992, BRAIN RES, V579, P67, DOI 10.1016/0006-8993(92)90742-R; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1993, J NEUROTRAUM, V10, pS181; Ungerstedt U, 1971, ACTA PHYSIOL SC S367, V82, P1; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	49	44	45	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 10	1994	660	1					88	95		10.1016/0006-8993(94)90842-7			8	Neurosciences	Neurosciences & Neurology	PJ969	WOS:A1994PJ96900011	7828006				2021-06-18	
J	CHRISTEY, GL; NELSON, DE; RIVARA, FP; SMITH, SM; CONDIE, C				CHRISTEY, GL; NELSON, DE; RIVARA, FP; SMITH, SM; CONDIE, C			HORSEBACK RIDING INJURIES AMONG CHILDREN AND YOUNG-ADULTS	JOURNAL OF FAMILY PRACTICE			English	Article						SPORTS; ATHLETIC INJURIES; HEAD INJURIES; ACCIDENT PREVENTION; HEAD PROTECTIVE DEVICES	EQUESTRIAN INJURIES; ACCIDENTS; SPORTS	Background. Horseback riding injuries are responsible for an estimated 2300 hospital admissions annually among persons younger than 25 years of age in the United States, but injury rates, patterns of injury, and risk factors for this population have not been well studied. Methods. Study participants were selected from a list provided by a national mail-order company that sells riding equipment. A total of 557 persons younger than 25 years of age who rode horses at least six times a year completed survey questionnaires. Results. Among the study participants, 34 (6.1%) had been hospitalized at least once because of a riding injury and 153 (27.5%) had been treated by a physician within the previous 2 years for such an injury. The overall injury rate was 0.6 per 1000 riding hours. Among those injured, sprains or strains (41.8%), lacerations or bruises (40.0%), and fractures or dislocations (33.3%) were the most common types of injury. A total of 27.5% of those injured sustained concussions or other head injuries. Riding 15 to 24 hours per month (odds ratio [OR]=2.04), being female (OR=1.81), and riding English style (OR=1.77) were the characteristics most strongly correlated with injury. Conclusions. Horseback riding injuries among participants in this study tended to be serious. Family physicians should inform their patients who ride horses about the risks associated with equestrian activities and should emphasize helmet use.	CTR DIS CONTROL & PREVENT, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, BEHAV SURVEILLANCE BRANCH, ATLANTA, GA 30341 USA; CHRISTCHURCH SCH MED, CHRISTCHURCH, NEW ZEALAND; CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, ATLANTA, GA USA; HARBORVIEW INJURY PREVENT CTR, SEATTLE, WA USA; UNIV WASHINGTON, SCH PUBL HLTH, SEATTLE, WA 98195 USA; UNIV CANBERRA, FAC MANAGEMENT, BELCONNEN, AUSTRALIA					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 002570] Funding Source: Medline		BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; Bernhang A M, 1983, Phys Sportsmed, V11, P90, DOI 10.1080/00913847.1983.11708437; BIXBYHAMMETT D, 1990, SPORTS MED, V9, P36, DOI 10.2165/00007256-199009010-00004; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BIXBYHAMMETT DM, 1985, PHYSICIAN SPORTSMED, V13, P105, DOI 10.1080/00913847.1985.11708882; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; DANIELSSON LG, 1973, ACTA ORTHOP SCAND, V44, P597, DOI 10.3109/17453677308989097; EASTWOOD FR, 1969, NEW ENGL J MED, V271, P411; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; INGEMARSON H, 1989, J TRAUMA, V29, P25, DOI 10.1097/00005373-198901000-00005; MAHALEY MS, 1976, 18TH P AMA C MED ASP, P37; McGhee C N, 1987, Br J Neurosurg, V1, P131, DOI 10.3109/02688698709034348; McLatchie G R, 1979, Br J Sports Med, V13, P29; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON DE, 1994, AM J PREV MED, V10, P15; POUNDER DJ, 1984, MED J AUSTRALIA, V141, P632, DOI 10.5694/j.1326-5377.1984.tb113173.x; WILLIAMS LP, 1975, 103RD P ANN APHA M W; ZARICZNYJ B, 1980, AM J SPORT MED, V8, P318, DOI 10.1177/036354658000800504; 1990, MMWR-MORBID MORTAL W, V39, P329; 1988, ANN BOOK ASTM STANDA; 1990, 1990 91 HORSE IND DI; 1992, DHHS PHS921232 PUBL; 1992, MMWR-MORBID MORTAL W, V41, P335; 1984, P HOUSE DELEGATES, P360; 1992, PEDIATRICS, V89, P512	26	44	44	0	9	DOWDEN HEALTH MEDIA	MONTVALE	110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA	0094-3509			J FAM PRACTICE	J. Fam. Pract.	AUG	1994	39	2					148	152					5	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	PB544	WOS:A1994PB54400013	8057065				2021-06-18	
J	HALLETT, JD; ZASLER, ND; MAURER, P; CASH, S				HALLETT, JD; ZASLER, ND; MAURER, P; CASH, S			ROLE CHANGE AFTER TRAUMATIC BRAIN INJURY IN ADULTS	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						DISABILITY EVALUATION; SOCIAL ADJUSTMENT	SEVERE HEAD-INJURY; SOCIAL RECOVERY; COMMUNITY; SCALE; COMA	Objectives. The purpose of this study was to gather information regarding changes in adult life roles following severe traumatic brain injury. Method. The Role Checklist and a semistructured interview were administered to 28 adults with traumatic brain injury who bad been in the community for at least 8 months prior to the study. All 28 subjects reported role changes in their lives Results. The majority of the role changes were losses (71%). More than 64% percent of the subjects reported three or four role losses. The losses were in major organizing roles such as worker, hobbyist, and friend. Most role gains were seen in the roles of home maintainer, family member, and religious participant. Almost 40% of all roles were reported as changed (loss or gain), while more than 60% of roles were reported as unchanged (continuous or absent). The participants' subjective impressions concerning the role changes and why they occurred were elicited. Conclusion. With a better understanding of possible role change after traumatic brain injury, rehabilitation professionals can target the development of specific skills necessary for the continuation of valued roles.	NATL NEUROREHABIL CONSORTIUM INC,RICHMOND,VA; VIRGINIA COMMONWEALTH UNIV,DEPT OCCUPAT THERAPY,RICHMOND,VA 23284	HALLETT, JD (corresponding author), PUNXSUTAWNEY AREA HOSP,DEPT OCCUPAT THERAPY,PUNXSUTAWNEY,PA 15767, USA.						BERMANN D, 1988, HEAD INJURY GUIDE FU, P35; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; GLOAG D, 1985, BRIT MED J, V290, P913, DOI 10.1136/bmj.290.6472.913; HEARD C, 1977, AM J OCCUP THER, V31, P243; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOORHEAD L, 1969, AM J OCCUP THER, V23, P329; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; OAKLEY F, 1982, THESIS VIRGINIA COMM; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PEZZULI TW, 1988, THESIS VIRGINIA COMM; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; World Health Organization, 1991, WORLD HLTH STAT ANN	21	44	45	0	6	AMER OCCUPATION THERAPY ASSN	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAR	1994	48	3					241	246		10.5014/ajot.48.3.241			6	Rehabilitation	Rehabilitation	MW828	WOS:A1994MW82800007	8178918				2021-06-18	
J	HENRIKSSON, R; FROJD, O; GUSTAFSSON, H; JOHANSSON, S; YIQING, C; FRANZEN, L; BJERMER, L				HENRIKSSON, R; FROJD, O; GUSTAFSSON, H; JOHANSSON, S; YIQING, C; FRANZEN, L; BJERMER, L			INCREASE IN MAST-CELLS AND HYALURONIC-ACID CORRELATES TO RADIATION-INDUCED DAMAGE AND LOSS OF SEROUS ACINAR-CELLS IN SALIVARY-GLANDS - THE PAROTID AND SUBMANDIBULAR GLANDS DIFFER IN RADIATION SENSITIVITY	BRITISH JOURNAL OF CANCER			English	Article							BREAST-CANCER PATIENTS; BRONCHOALVEOLAR LAVAGE; IRRADIATION; SMOKING; INJURY; LUNG; RADIOSENSITIVITY; AMYLASE	The detailed mechanisms which can explain the inherent radiosensitivity of salivary glands remain to be elucidated. Although DNA is the most plausible critical target for the lethal effects of irradiation, interactions with other constituents, such as cell membrane and neuropeptides, have been suggested to cause important physiological changes. Moreover, mast cells seem to be closely linked to radiation-induced pneumonitis. Therefore, in the present study the effects of fractionated irradiation on salivary glands have been assessed with special regard to the appearance of mast cells and its correlation with damage to gland parenchyma. Sprague-Dawley strain rats were unilaterally irradiated to the head and neck with the salivary glands within the radiation field. The irradiation was delivered once daily for 5 days to a total dose of 20, 35 and 45 Gy. The contralateral parotid and submandibular glands served as intra-animal controls and parallel analysis of glands was performed 2, 4, IO or 180 days following the last radiation treatment. Morphological analysis revealed no obvious changes up to 10 days after the irradiation. At 180 days a radiation dose-dependent loss of gland parenchyma was seen, especially with regard to serous acinar cells in parotid gland and acinar cells and serous CGT (convoluted granular tubule) cells in the submandibular gland. These changes displayed a close correlation with a concomitant dose-dependent enhanced density of mast cells and staining for hyaluronic acid. This cell population seems to conform with the features of the connective tissue mast cell type. The parotid seems to be more sensitive to irradiation than the submandibular gland. Thus, the present results further strengthen the role of and the potential interaction of mast cells with radiation-induced tissue injury and alterations in normal tissue integrity.	UNIV HOSP UMEA,DEPT OTO RHINO LARYNGOL,S-90187 UMEA,SWEDEN; UNIV HOSP TRONDHEIM,DEPT LUNG MED,TRONDHEIM,NORWAY	HENRIKSSON, R (corresponding author), UNIV HOSP UMEA,DEPT ONCOL,S-90187 UMEA,SWEDEN.		Bjermer, Leif H/I-4899-2014	Bjermer, Leif H/0000-0002-3441-8099			ABOK K, 1984, VIRCHOWS ARCH B, V45, P443, DOI 10.1007/BF02889885; Alper T, 1977, Adv Exp Med Biol, V84, P139; BJERMER L, 1990, CANCER RES, V50, P2027; BJERMER L, 1992, EUR RESPIR J, V5, P785; CREASY NA, 1960, BIOCHIM BIOPHYS ACTA, V38, P181; DESAI ID, 1964, BIOCHIM BIOPHYS ACTA, V86, P277, DOI 10.1016/0304-4165(64)90054-6; ELMOFTY SK, 1981, INT J RADIAT BIOL, V39, P55, DOI 10.1080/09553008114550071; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; Enerback L., 1986, P405; ENEROTH CM, 1972, CANCER, V30, P1147, DOI 10.1002/1097-0142(197211)30:5<1147::AID-CNCR2820300502>3.0.CO;2-0; FORSGREN S, 1992, NEUROSCIENCE, V46, P233, DOI 10.1016/0306-4522(92)90023-U; FRANZEN L, 1991, LAB INVEST, V64, P279; FRANZEN L, 1989, INT J RADIAT BIOL, V56, P721, DOI 10.1080/09553008914551961; FRANZEN L, 1993, CELL TISSUE RES, V271, P529, DOI 10.1007/BF02913737; GRAHAM MM, 1990, INT J RADIAT ONCOL, V19, P329, DOI 10.1016/0360-3016(90)90541-Q; HENRIKSSON R, 1982, AM J PHYSIOL, V242, pG481; JUNGLEE D, 1986, CLIN CHEM, V32, P609; MIRA JG, 1982, ACTA RADIOL ONCOL, V21, P151, DOI 10.3109/02841868209133999; NETTELBLAD O, 1989, AM REV RESPIR DIS, V139, P756; NILSSON K, 1990, AM J RESP CELL MOL, V2, P199, DOI 10.1165/ajrcmb/2.2.199; NILSSON K, 1992, IN PRESS INT J RAD B; READE PC, 1985, J BIOL BUCCALE, V13, P307; Rubin P., 1972, FRONT RAD THER ONCOL, V6, P1; SHANNON IL, 1978, P SOC EXP BIOL MED, V157, P50; STEPHENS LC, 1986, AM J PATHOL, V124, P469; STEPHENS LC, 1986, RADIOTHER ONCOL, V7, P165; SUTHERLAND RM, 1967, INT J RADIAT BIOL RE, V12, P551, DOI 10.1080/09553006714551161; Weibel E.R., 1979, STEREOLOGICAL METHOD, V1	28	44	46	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-0920			BRIT J CANCER	Br. J. Cancer	FEB	1994	69	2					320	326		10.1038/bjc.1994.58			7	Oncology	Oncology	MU507	WOS:A1994MU50700019	8297728	Bronze, Green Published			2021-06-18	
J	YANG, KY; TAFT, WC; DIXON, CE; TODARO, CA; YU, RK; HAYES, RL				YANG, KY; TAFT, WC; DIXON, CE; TODARO, CA; YU, RK; HAYES, RL			ALTERATIONS OF PROTEIN-KINASE-C IN RAT HIPPOCAMPUS FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-ISCHEMIA; REDISTRIBUTION; DISSOCIATION; ACTIVATION	Calcium-dependent excitotoxic processes contribute significantly to pathologic responses to traumatic brain injury (TBI). TBI causes neuronal depolarization and excessive excitatory neurotransmitter release, which may lead to increases in intracellular calcium levels. However, responses of calcium-dependent enzymes such as protein kinase C (PKC) following TBI are poorly understood. Since PKC plays an important role in signal transduction and maintenance of normal neuronal function, we investigated changes in PKC activity and protein levels following fluid percussion brain injury in rats. We observed a 23.1% increase in PKC activity 1 h postinjury and 80.7% increase in PKC activity 3 h postinjury. There was no statistically significant change in PKC activity 5 min and 24 h after injury. PKC immunolabelling studies detected a significant increase in PKC levels in membrane fractions 3 h but not 1 h after injury. Thus PKC activation is transiently increased following TBI and may play an important role in pathophysiologic responses to TBI.	UNIV MESSINA,NEUROCHIRURG CLIN,I-98100 MESSINA,ITALY; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM,RICHMOND,VA 23298; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER		CARDELL M, 1990, NEUROSCI LETT, V119, P228, DOI 10.1016/0304-3940(90)90840-6; CRUMRINE RC, 1990, J NEUROCHEM, V55, P2001, DOI 10.1111/j.1471-4159.1990.tb05788.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASLIAH E, 1991, J NEUROSCI, V11, P2759; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1990, NEUROCHEM RES, V15, P515, DOI 10.1007/BF00966209; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Prasad M. R., 1992, Society for Neuroscience Abstracts, V18, P174; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; SHAPIRA Y, 1989, Neurological Research, V11, P169; SMITH M, 1990, 8TH P ANN M SOC NEUR; Taft W. C., 1992, Society for Neuroscience Abstracts, V18, P174; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WIELOCH T, 1991, J NEUROCHEM, V56, P1227, DOI 10.1111/j.1471-4159.1991.tb11415.x; Yang K., 1992, Society for Neuroscience Abstracts, V18, P173; YU RK, 1990, TROPHIC FACTORS NERV, P175	25	44	44	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FAL	1993	10	3					287	295		10.1089/neu.1993.10.287			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	MC021	WOS:A1993MC02100005	8258841				2021-06-18	
J	MICHAUD, LJ; DUHAIME, AC; BATSHAW, ML				MICHAUD, LJ; DUHAIME, AC; BATSHAW, ML			TRAUMATIC BRAIN INJURY IN CHILDREN	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article							SEVERE HEAD-INJURIES; YOUNG-ADULTS; CHILDHOOD; MOTOR; ADOLESCENTS; SEQUELAE; COMA		UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV CHILD DEV,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV REHABIL MED,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DEPT REHABIL MED,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DEPT NEUROSURG,PHILADELPHIA,PA	MICHAUD, LJ (corresponding author), CHILDRENS SEASHORE HOUSE,3405 CIV CTR BLVD,PHILADELPHIA,PA, USA.						AGRAN P, 1990, AM J DIS CHILD, V144, P653, DOI 10.1001/archpedi.1990.02150300051017; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CARNEY J, 1990, Pediatrician, V17, P222; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHRISTOFFEL KK, 1992, PEDIATR ANN, V21, P430, DOI 10.3928/0090-4481-19920701-08; Comninos S C, 1979, Acta Neurochir Suppl (Wien), V28, P144; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DEPOMPEI R, 1991, NEUROREHABILITATION, V1, P29; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P86, DOI 10.1001/jama.1961.03040020012003; DUHAIME AC, 1992, PEDIATRICS, V90, P179; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GENNARELLI TA, 1985, NEUROSURGERY, P1531; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAUFMAN HH, 1985, NEUROSURGERY, V16, P754, DOI 10.1227/00006123-198506000-00002; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARGOLIS LH, 1988, AM J DIS CHILD, V142, P1099, DOI 10.1001/archpedi.1988.02150100093035; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; OLDS DL, 1986, PEDIATRICS, V78, P65; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WALKER M L, 1985, P84; Ylvisaker M, 1989, J HEAD TRAUMA REHAB, V4, P51; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48; 1990, AM J DIS CHILD, V144, P627; 1992, PEDIATRICS, V89, P512	45	44	44	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0031-3955			PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	JUN	1993	40	3					553	565					13	Pediatrics	Pediatrics	LD173	WOS:A1993LD17300008	8493065				2021-06-18	
J	PHILLIPS, LL; BELARDO, ET				PHILLIPS, LL; BELARDO, ET			EXPRESSION OF C-FOS IN THE HIPPOCAMPUS FOLLOWING MILD AND MODERATE FLUID PERCUSSION BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; DENTATE GYRUS; ORNITHINE DECARBOXYLASE; UNANESTHETIZED RATS; INDUCED SEIZURES; MAMMALIAN BRAIN; GENE-EXPRESSION; NMDA RECEPTORS; MESSENGER-RNA	An oncoprotein mediator of gene expression, c-fos, was evaluated in the central fluid percussion model of traumatic brain injury (TBI). Since hippocampal CA1 neurons are particularly vulnerable to TBI, we hypothesized that TBI may produce pathobiologic changes in CA1, in part, by alterations in gene expression through c-fos. Sprague-Dawley rats were subjected to mild (1.0 atm) or moderate (2.1 atm) fluid percussion TBI or sham injury. At 15 min, 1 h, and 24 h after injury (or sham injury), sections from middorsal hippocampus were immunostained with antibodies to c-fos, and c-fos-positive CA1 neurons were counted. As predicted, c-fos was localized in the nuclei of CA1 pyramidal neurons. However, the intensity of label was not equal over all CA1 neurons. Cells with high-intensity c-fos label were more prevalent after mild TBI. The number of c-fos-labeled CA1 neurons was increased at 15 min after both mild and moderate TBI relative to paired sham controls. Counts of c-fos-positive neurons remained significantly elevated at 1 h postinjury only after mild TBI. By 24 h postinjury, the number of c-fos-positive cells at both injury levels was not different from sham controls. No difference was observed between the number of c-fos-positive cells in naive and sham controls. However, label intensity was slightly less in the naive cases. These results suggest that the pathobiologic changes at early intervals following mild or moderate TBI may involve c-fos alteration of gene expression and that c-fos expression may be differentially regulated as a function of injury level.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298	PHILLIPS, LL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19550, NS21458, NS27225] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027225, R01NS019550, R01NS021458] Funding Source: NIH RePORTER		BELT BS, 1989, IMMUNOCYTOCHEMICAL T, P90; CHIARUGI VP, 1989, NEUROCHEM INT, V14, P1, DOI 10.1016/0197-0186(89)90002-8; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HAYES RL, 1992, CENTRAL NERVOUS SYST, P173; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; JEFFERY KJ, 1990, MOL BRAIN RES, V8, P267, DOI 10.1016/0169-328X(90)90039-G; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; POPOVICI T, 1990, BRAIN RES, V536, P183, DOI 10.1016/0006-8993(90)90024-6; RAYTER SI, 1989, ONCOGENES, P113; SAITOH T, 1991, LAB INVEST, V64, P596; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; VENDRELL M, 1991, BRAIN RES, V544, P291, DOI 10.1016/0006-8993(91)90067-6; WESSEL TC, 1991, BRAIN RES, V567, P231, DOI 10.1016/0006-8993(91)90800-B; ZAWIA NH, 1990, MOL BRAIN RES, V7, P243, DOI 10.1016/0169-328X(90)90034-B	34	44	48	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					323	333		10.1089/neu.1992.9.323			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300002	1291692				2021-06-18	
J	MENDELSOHN, DB; LEVIN, HS; HARWARD, H; BRUCE, D				MENDELSOHN, DB; LEVIN, HS; HARWARD, H; BRUCE, D			CORPUS-CALLOSUM LESIONS AFTER CLOSED HEAD-INJURY IN CHILDREN - MRI, CLINICAL-FEATURES AND OUTCOME	NEURORADIOLOGY			English	Article						BRAIN; MAGNETIC RESONANCE IMAGING; TRAUMA; CORPUS CALLOSUM	DIFFUSE AXONAL INJURY; BRAIN-DAMAGE; TRAUMA	Thirty-four children who sustained moderate to severe closed head injury underwent magnetic resonance imaging (MRI). Eight (24%) had MRI evidence of corpus callosum injury, most commonly within the posterior body and splenium. In contradistinction to reports in adults, there was no definite relationship between callosal injury and lower initial Glasgow Coma Scale scores, nor was there a significantly higher incidence of primary brain-stem lesions, diffuse axonal shear injury or intraventricular hemorrhage. In none of these 8 children did the initial admission computed tomography show evidence of callosal injury. Callosal injuries on MRI are not necessarily a poor prognostic finding, the majority of the 8 children showing good functional recovery.	UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75230; GREENERY REHABIL CTR,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75230; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; GENNARELLI TA, 1982, ANN NEUROL, V12, P546; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; JENNETT B, 1975, LANCET, V1, P480; LINDENBERG R, 1955, AM J PATHOL, V31, P297; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862	11	44	44	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0028-3940			NEURORADIOLOGY	Neuroradiology	OCT	1992	34	5					384	388		10.1007/BF00596495			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	JQ585	WOS:A1992JQ58500004	1407515				2021-06-18	
J	SABATES, NR; GONCE, MA; FARRIS, BK				SABATES, NR; GONCE, MA; FARRIS, BK			NEUROOPHTHALMOLOGICAL FINDINGS IN CLOSED HEAD TRAUMA	JOURNAL OF CLINICAL NEURO-OPHTHALMOLOGY			English	Article						CLOSED HEAD TRAUMA; TUNNEL VISUAL FIELDS; CRANIAL NERVE PALSY; BASILAR SKULL FRACTURE	INJURY; NERVE; DISABILITY; COUNTY	Visual abnormalities following closed head trauma are common and can affect any part of the visual pathway. We reviewed 181 consecutive patients referred with visual complaints following closed head trauma. A motor vehicle accident was the most common etiology of trauma in 57% of cases, direct trauma to the head in 15%, and injuries sustained from a fall in 13%. Sixty-three percent of patients lost consciousness and 26% suffered a skull fracture. Thirty-five percent of all patients had visual field defects with functional (tunnel) fields the most common. Over 88% of eyes had 20/20 or better visual acuity. Thirty-three percent of patients suffered a cranial nerve palsy, with 75% resolving without intervention. The severity of head injury was directly related to the lack of proper seat belt and helmet use. Most visual complaints were improved with a simple refraction. Most binocular diplopia cleared with time, with only 15 cases requiring surgical correction.	UNIV OKLAHOMA,HLTH SCI CTR,DEAN A MCGEE EYE INST,DEPT OPHTHALMOL,608 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104; MASSACHUSETTS EYE & EAR HOSP,BOSTON,MA 02114; TULANE UNIV,NEW ORLEANS,LA 70118; RETINA ASSOCIATES,BOSTON,MA	FARRIS, BK (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEAN A MCGEE EYE INST,DEPT OPHTHALMOL,608 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104, USA.						ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BURGER LJ, 1970, BRAIN, V93, P567, DOI 10.1093/brain/93.3.567; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; ELISEVICH KV, 1984, SURG NEUROL, V22, P565, DOI 10.1016/0090-3019(84)90433-6; Evans R W, 1987, Tex Med, V83, P49; HARLEY RD, 1980, OPHTHALMOLOGY, V87, P24; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KEANE JR, 1989, ARCH NEUROL-CHICAGO, V46, P761, DOI 10.1001/archneur.1989.00520430055017; KHAWAM E, 1967, ARCH OPHTHALMOL-CHIC, V77, P761, DOI 10.1001/archopht.1967.00980020763009; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; LAMBERT WG, 1985, BR J CLIN PRAC, V10, P41; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUCKER CW, 1958, AM J OPHTHALMOL, V46, P787, DOI 10.1016/0002-9394(58)90989-9; RUCKER CW, 1966, AM J OPHTHALMOL, V61, P1293, DOI 10.1016/0002-9394(66)90258-3; RUSH JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P76, DOI 10.1001/archopht.1981.03930010078006; SARINO PJ, 1980, NEUROLOGY, V30, P963; SCHIEMANN DA, 1987, FEMS MICROBIOL LETT, V41, P19; SMACHI J, 1970, JPN J OPHTHALMOL, V12, P70; SOSIN DM, 1990, JAMA-J AM MED ASSOC, P2395; Turner JWA, 1943, BRAIN, V66, P140; WALSH FB, 1969, CLIN NEUROOPHTHALMOL, P2381; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; ZETTAS FP, 1979, J TRAUMA, V19, P833	27	44	44	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0272-846X			J CLIN NEURO-OPHTHAL		DEC	1991	11	4					273	277					5	Neurosciences; Ophthalmology	Neurosciences & Neurology; Ophthalmology	GU126	WOS:A1991GU12600011	1838548				2021-06-18	
J	VINK, R; PORTOGHESE, PS; FADEN, AI				VINK, R; PORTOGHESE, PS; FADEN, AI			KAPPA-OPIOID ANTAGONIST IMPROVES CELLULAR BIOENERGETICS AND RECOVERY AFTER TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						NUCLEAR MAGNETIC RESONANCE; ENERGY METABOLISM; MAGNESIUM	MAGNETIC-RESONANCE SPECTROSCOPY; INTRACELLULAR FREE MG-2+; P-31 NMR-SPECTROSCOPY; SPINAL-CORD INJURY; NOR-BINALTORPHIMINE; FREE MAGNESIUM; RAT; NALOXONE; PH; ISCHEMIA	Treatment with opioid receptor antagonists improves outcome after experimental brain trauma, although the mechanisms underlying the protective actions of these compounds remain speculative. We have proposed that endogenous opioids contribute to the pathophysiology of traumatic brain injury through actions at kappa-opioid receptors, possibly by affecting cellular bioenergetic state. In the present study, the effects of the kappa-selective opioid-receptor antagonist nor-binaltorphimine (nor-BNI) were examined after fluid percussion brain injury in rats. Metabolic changes were evaluated by P-31 magnetic resonance spectroscopy; the same animals were subsequently followed over 2 wk to evaluate neurological recovery. Nor-BNI, administered intravenously as a 10 or 20 mg/kg bolus at 30 min after injury, significantly improved neurological outcome at 2 wk posttrauma compared with controls. Animals treated with nor-BNI showed significantly greater recovery of intracellular free magnesium concentrations and cytosolic phosphorylation potentials during the first 4 h after injury compared with saline-treated controls. The improvement in cytosolic phosphorylation potential was significantly correlated to neurological outcome. These data support the hypothesis that kappa-opioid receptors mediate pathophysiological changes after traumatic brain injury and that the beneficial effects of opioid-receptor antagonists may result from improvement of posttraumatic cellular bioenergetics.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; VET ADM MED CTR, CTR NEURAL INJURY, SAN FRANCISCO, CA 94121 USA; UNIV MINNESOTA, COLL PHARM, DEPT MED CHEM, MINNEAPOLIS, MN 55455 USA	VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DEPT CHEM & BIOCHEM, TOWNSVILLE, QLD 4811, AUSTRALIA.		Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667			BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1988, PHYSL BASIS FUNCTION, P531; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; STOKES BT, 1984, BRAIN RES, V290, P187, DOI 10.1016/0006-8993(84)90753-4; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	31	44	46	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	DEC	1991	261	6	2				R1527	R1532					6	Physiology	Physiology	GX687	WOS:A1991GX68700087					2021-06-18	
J	WOLF, G; FISCHER, S; HASS, P; ABICHT, K; KEILHOFF, G				WOLF, G; FISCHER, S; HASS, P; ABICHT, K; KEILHOFF, G			MAGNESIUM-SULFATE SUBCUTANEOUSLY INJECTED PROTECTS AGAINST KAINATE-INDUCED CONVULSIONS AND NEURODEGENERATION - INVIVO STUDY ON THE RAT HIPPOCAMPUS	NEUROSCIENCE			English	Article							EXCITATORY AMINO-ACIDS; GLUTAMATE NEUROTOXICITY; CALCIUM-CONCENTRATION; NERVOUS-SYSTEM; BRAIN INJURY; ASPARTATE; INVITRO; NEURONS; RECEPTOR; DEPENDENCE	Kainate, an agonist of a unique subclass of glutamate receptors (kainate receptor), was injected intracerebroventricularly in rats to induce convulsive reactions and hippocampal damage in order to model glutamate-mediated brain injury. Rats treated with magnesium sulfate (subcutaneously injected, up to 600 mg/kg) were found to be protected from kainate neurotoxicity depending on the dose and time of application. Results were largely consistent with those obtained previously by using quinolinate as an excitotoxic N-methyl-D-asparate-receptor agonist. Magnesium is discussed as being a natural and relatively safe therapeutic in cases of glutamate-induced (hypoxic, ischemic, traumatic, or convulsive) disorders of the brain.	MED ACAD MAGDEBURG,INST CLIN CHEM,O-3034 MAGDEBURG,GERMANY; MED ACAD MAGDEBURG,DIAGNOST LAB,O-3034 MAGDEBURG,GERMANY	WOLF, G (corresponding author), MED ACAD MAGDEBURG,INST BIOL,ERICH WEINERT STR 3,O-3034 MAGDEBURG,GERMANY.		Hass, Peter/AAP-8768-2021	Hass, Peter/0000-0003-0164-5284			ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; ASHTON D, 1989, BRAIN RES, V487, P402, DOI 10.1016/0006-8993(89)90850-0; BERDICHEVSKY E, 1987, BRAIN RES, V423, P213, DOI 10.1016/0006-8993(87)90842-0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; HONORE T, 1989, MED RES REV, V9, P1, DOI 10.1002/med.2610090102; KASS IS, 1982, J PHYSIOL-LONDON, V332, P459, DOI 10.1113/jphysiol.1982.sp014424; KEILHOFF G, 1990, NEUROSCIENCE, V34, P235, DOI 10.1016/0306-4522(90)90317-W; LEHMANN A, 1990, NEUROSCI RES COMMUN, V76, P27; MCCASLIN PP, 1988, EUR J PHARMACOL, V152, P341, DOI 10.1016/0014-2999(88)90729-7; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MELDRUM B, 1989, CEREBROVASC DIS, P47; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; PRITCHARD JA, 1975, AM J OBSTET GYNECOL, V123, P543, DOI 10.1016/0002-9378(75)90042-3; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; SCHMIDT W, 1990, METAB BRAIN DIS, V5, P19, DOI 10.1007/BF00996975; Schwarcz R., 1987, P19; STONE TW, 1985, NEUROSCIENCE, V15, P597, DOI 10.1016/0306-4522(85)90063-6; WATKINS JC, 1989, NMDA RECEPTOR; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; WOLF G, 1990, NEUROSCI LETT, V117, P207, DOI 10.1016/0304-3940(90)90145-Y	26	44	44	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience		1991	43	1					31	34		10.1016/0306-4522(91)90413-I			4	Neurosciences	Neurosciences & Neurology	FV809	WOS:A1991FV80900004	1833668				2021-06-18	
J	BAKSHI, R; NEWMAN, AH; FADEN, AI				BAKSHI, R; NEWMAN, AH; FADEN, AI			DYNORPHIN-A-(1-17) INDUCES ALTERATIONS IN FREE FATTY-ACIDS, EXCITATORY AMINO-ACIDS, AND MOTOR FUNCTION THROUGH AN OPIATE-RECEPTOR-MEDIATED MECHANISM	JOURNAL OF NEUROSCIENCE			English	Article							SPINAL-CORD INJURY; KAPPA-OPIOID RECEPTOR; RAT-BRAIN; BINDING-SITES; LIQUID-CHROMATOGRAPHY; INTRATHECAL INJECTION; NOR-BINALTORPHIMINE; TRAUMATIC INJURY; IMPACT TRAUMA; BLOOD-FLOW	The endogenous opioid dynorphin A-(1-17) (Dyn A) has been implicated as a mediator of tissue damage after traumatic spinal cord injury (TSCI) and causes hindlimb paralysis when administered intrathecally. Motor impairment following intrathecal Dyn A is attenuated by antagonists of excitatory amino acids (EAAs); where opioid receptors mediate such injury has been questioned. TSCI causes various biochemical changes associated with secondary tissue damage, including alterations in tissue amino acids, phospholipids, and fatty acids. Such changes reflect injury severity and correlate with motor dysfunction. The present studies examined whether dynorphin administration causes similar biochemical alterations and whether effects of Dyn A can be modified by treatment with opioid-receptor antagonists. At 24 hr after intrathecal Dyn A, there were significant declines in tissue levels of glutamate, aspartate, and glycine. Increase in total free fatty acids were found at 2 and 24 hr, reflecting changes in both saturated and unsaturated components, which were associated with significant decreases in tissue cholesterol and phospholipid phosphorus at the earlier time point. Each of these neurochemical changes, as well as corresponding motor deficits, were limited by pretreatment with the opioid antagonist nalmefene. In separate experiments, both nalmefene and the selective kappa-opioid antagonist nor-binaltorphimine (nor-BNI) limited dynorphin-induced motor dysfunction; effects of nor-BNI were dose related, and those of nalmefene were stereospecific. Therefore, behavioral and neurochemical consequences of Dyn A administration are mediated in part through opiate receptors, most likely kappa-receptors. These studies indicate that phospholipid hydrolysis and release of EAAs may contribute to dynorphin-induced tissue damage, suggesting for the first time a potential linkage among opioid, excitotoxin, and membrane lipid mechanisms of secondary injury after neurotrauma.	DEPT VET AFFAIRS, NEUROL SERV 127, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CTR NEURAL INJURY, DEPT NEUROL, SAN FRANCISCO, CA 94121 USA; WALTER REED ARMY MED CTR, DEPT APPL BIOCHEM, WASHINGTON, DC 20307 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS23422] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023422] Funding Source: NIH RePORTER		AGARDH CD, 1981, J NEUROCHEM, V36, P490, DOI 10.1111/j.1471-4159.1981.tb01619.x; ALLEN KG, 1984, J CHROMATOGR, V309, P33, DOI 10.1016/0378-4347(84)80003-1; ALLISON LA, 1984, ANAL CHEM, V56, P1089, DOI 10.1021/ac00271a010; ARIAS MJ, 1985, SURG NEUROL, V23, P440, DOI 10.1016/0090-3019(85)90226-5; ATTALI B, 1982, NEUROPEPTIDES, V3, P53, DOI 10.1016/0143-4179(82)90065-8; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BLOK MC, 1977, BIOCHIM BIOPHYS ACTA, V464, P509, DOI 10.1016/0005-2736(77)90026-8; BOWMAN RE, 1962, CLIN CHEM, V8, P302; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CAUDLE RM, 1987, BRAIN RES, V435, P1, DOI 10.1016/0006-8993(87)91579-4; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHOI D W, 1989, Society for Neuroscience Abstracts, V15, P1113; CHOI DW, 1988, J NEUROSCI, V8, P185; CZLONKOWSKI A, 1983, BRAIN RES, V267, P392, DOI 10.1016/0006-8993(83)90897-1; DANYSZ W, 1989, BRAIN RES, V479, P270, DOI 10.1016/0006-8993(89)91628-4; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; ERECINSKA M, 1984, BRAIN RES, V304, P9, DOI 10.1016/0006-8993(84)90857-6; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1985, REGUL PEPTIDES, V11, P35, DOI 10.1016/0167-0115(85)90029-1; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GARDINER M, 1981, J NEUROCHEM, V36, P1500, DOI 10.1111/j.1471-4159.1981.tb00592.x; GOUARDERES C, 1985, NEUROPEPTIDES, V6, P331, DOI 10.1016/0143-4179(85)90006-X; GOUARDERES C, 1984, NEUROPEPTIDES, V5, P113, DOI 10.1016/0143-4179(84)90040-4; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HAN JS, 1982, LIFE SCI, V31, P1781, DOI 10.1016/0024-3205(82)90209-0; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; Houslay MD, 1982, DYNAMICS BIOL MEMBRA, P71; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; INOUE Y, 1986, Journal of the Japanese Orthopaedic Association, V60, P777; IYENGAR S, 1985, Journal of Neurochemistry, V44, pS89; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JONES M, 1982, J CHROMATOGR, V237, P522, DOI 10.1016/S0021-9673(00)97644-1; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LAZAREWICZ JW, 1972, B ACAD POL SCI BIOL, V20, P599; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LEMKE M, 1990, IN PRESS MOL CHEM NE; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; LONG JB, 1989, J NEUROTRAUM, V6, P59; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; LUCY JA, 1970, NATURE, V227, P815, DOI 10.1038/227815a0; MACK KJ, 1984, LIFE SCI, V34, P281, DOI 10.1016/0024-3205(84)90600-3; MASSARDIER D, 1989, EUR J PHARMACOL, V170, P125, DOI 10.1016/0014-2999(89)90149-0; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MICHEL ME, 1985, METHOD FIND EXP CLIN, V7, P175; NOCK B, 1988, EUR J PHARMACOL, V154, P27, DOI 10.1016/0014-2999(88)90359-7; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; RAZ A, 1973, BIOCHIM BIOPHYS ACTA, V311, P222, DOI 10.1016/0005-2736(73)90269-1; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RHOADS DE, 1982, J NEUROCHEM, V38, P1255, DOI 10.1111/j.1471-4159.1982.tb07898.x; RICE KC, 1986, TOTAL SYNTHESIS NORT; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAUNDERS RD, 1984, ANAL BIOCHEM, V143, P71, DOI 10.1016/0003-2697(84)90559-1; SEGLERSTAHL K, 1985, NEUROCHEM RES, V10, P563, DOI 10.1007/BF00964658; SPAMPINATO S, 1985, EUR J PHARMACOL, V110, P21, DOI 10.1016/0014-2999(85)90024-X; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; THORNHILL JA, 1989, BRAIN RES, V490, P174, DOI 10.1016/0006-8993(89)90447-2; TRAYNOR JR, 1982, LIFE SCI, V31, P1377, DOI 10.1016/0024-3205(82)90385-X; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YOSHIDA S, 1982, BRAIN RES, V245, P307, DOI 10.1016/0006-8993(82)90813-7; YOSHIMURA K, 1982, J PHARMACOL EXP THER, V222, P71; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	86	44	44	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC	1990	10	12					3793	3800					8	Neurosciences	Neurosciences & Neurology	EP042	WOS:A1990EP04200004	1980130				2021-06-18	
J	FISHER, RG; ORIA, RA; MATTOX, KL; WHIGHAM, CJ; PICKARD, LR				FISHER, RG; ORIA, RA; MATTOX, KL; WHIGHAM, CJ; PICKARD, LR			CONSERVATIVE MANAGEMENT OF AORTIC LACERATIONS DUE TO BLUNT TRAUMA	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							ARTERIAL INJURIES; AORTOGRAPHY	Three patients with angiographically documented thoracic aortic lacerations were managed conservatively over 8 years due to the nonthreatening appearance of the injuries in two and the presence of an associated major closed head injury in a third. The lesion(s) resolved in one, diminished in another, and remained unchanged in the third. At least ten other cases managed similarly are recorded in the literature. In certain selected circumstances this approach may represent a viable alternative to the current standard of immediate surgical correction of aortic injuries.	BAYLOR UNIV,DEPT SURG,HOUSTON,TX 77030	FISHER, RG (corresponding author), BAYLOR UNIV,DEPT RADIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.						AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; CONN JH, 1971, J TRAUM, V11, P167, DOI 10.1097/00005373-197102000-00007; COWLEY RA, 1989, 69TH M AM ASS THOR S; FLECKENSTEIN JL, 1987, CARDIOVASC INTER RAD, V10, P194, DOI 10.1007/BF02593868; FRYKBERG ER, 1989, J TRAUMA, V29, P577, DOI 10.1097/00005373-198905000-00006; KOURY WC, 1975, RADIOLOGY, V116, P23, DOI 10.1148/116.1.23; KUBOTA RT, 1985, CT-J COMPUT TOMOGR, V9, P237, DOI 10.1016/0149-936X(85)90068-2; MATTOX JL, 1987, VASCULAR SURGICAL EM, P341; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; PEZZELLA AT, 1978, AM SURGEON, V44, P699; STAIN SC, 1989, ARCH SURG-CHICAGO, V124, P1136; Wheat M W Jr, 1980, World J Surg, V4, P563	12	44	44	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1990	30	12					1562	1566		10.1097/00005373-199012000-00022			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EP971	WOS:A1990EP97100022	2258973				2021-06-18	
J	VINK, R; MCINTOSH, TK; YAMAKAMI, I; FADEN, AI				VINK, R; MCINTOSH, TK; YAMAKAMI, I; FADEN, AI			P-31 NMR CHARACTERIZATION OF GRADED TRAUMATIC BRAIN INJURY IN RATS	MAGNETIC RESONANCE IN MEDICINE			English	Article									VET ADM MED CTR,SAN FRANCISCO,CA 94121	VINK, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143, USA.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ALBIN MS, 1969, J TRAUM, V9, P1000, DOI 10.1097/00005373-196912000-00004; BOTTOMLEY PA, 1984, RADIOLOGY, V150, P441, DOI 10.1148/radiology.150.2.6691099; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; COURTEN-MYERS G M, 1985, Stroke, V16, P1016; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVELHOCH JL, 1985, MAGNET RESON MED, V2, P410, DOI 10.1002/mrm.1910020409; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GADIAN DG, 1982, NUCLEAR MAGNETIC RES; GONZALEZMENDEZ R, 1985, J CEREBR BLOOD F MET, V5, P512, DOI 10.1038/jcbfm.1985.77; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; KIM SH, 1985, J CEREB BLOOD FLOW M, V5, P423; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LITT L, 1985, J CEREBR BLOOD F MET, V5, P537, DOI 10.1038/jcbfm.1985.81; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, IN PRESS NEUROSCIENC; MOON RB, 1973, J BIOL CHEM, V248, P7276; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; PETROFF OAC, 1984, ANN NEUROL, V16, P169, DOI 10.1002/ana.410160203; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SATO M, 1984, J CEREBR BLOOD F MET, V4, P173, DOI 10.1038/jcbfm.1984.25; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWANSON PD, 1969, ARCH NEUROL-CHICAGO, V20, P653, DOI 10.1001/archneur.1969.00480120099010; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHIDA S, 1985, J CEREBR BLOOD F MET, V5, P490, DOI 10.1038/jcbfm.1985.75	34	44	44	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0740-3194			MAGNET RESON MED	Magn.Reson.Med.	JAN	1988	6	1					37	48		10.1002/mrm.1910060105			12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	L8880	WOS:A1988L888000004	3352504				2021-06-18	
J	TORNHEIM, PA; MCLAURIN, RL				TORNHEIM, PA; MCLAURIN, RL			ACUTE CHANGES IN REGIONAL BRAIN WATER-CONTENT FOLLOWING EXPERIMENTAL CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article									UNIV CINCINNATI,COLL MED,DIV NEUROSURG,CINCINNATI,OH 45267	TORNHEIM, PA (corresponding author), UNIV CINCINNATI,COLL MED,DEPT ANAT,CINCINNATI,OH 45267, USA.						BRUCE DA, 1979, NEURAL TRAUMA, P155; CANCILLA PA, 1972, LAB INVEST, V26, P376; CLASEN RA, 1957, SURG GYNECOL OBSTET, V104, P591; CLASEN RA, 1962, J NEUROPATH EXP NEUR, V21, P579, DOI 10.1097/00005072-196210000-00006; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; CORALES RL, 1980, INTRACRANIAL PRESSUR, V4, P280; DICK AR, 1976, J NEUROSURG, V45, P141, DOI 10.3171/jns.1976.45.2.0141; FUJIMOTO T, 1976, DYNAMICS BRAIN EDEMA, P171; GAZENDAM J, 1979, J NEUROSURG, V51, P70, DOI 10.3171/jns.1979.51.1.0070; GENNARELLI TA, 1980, INTRACRANIAL PRESSUR, V4, P28; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hossman K, 1976, DYNAMICS BRAIN EDEMA, P219; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Klatzo I, 1965, Prog Brain Res, V15, P73; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LEE JC, 1966, ARCH NEUROL-CHICAGO, V14, P36, DOI 10.1001/archneur.1966.00470070040005; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; NELSON SR, 1974, J NEUROSURG, V41, P193, DOI 10.3171/jns.1974.41.2.0193; PAPPIUS HM, 1969, ARCH NEUROL-CHICAGO, V20, P207, DOI 10.1001/archneur.1969.00480080107013; RAPOPORT SI, 1979, NEURAL TRAUMA, P51; Tornheim P A, 1976, Surg Neurol, V5, P171; WAGA S, 1979, SURG NEUROL, V11, P191	24	44	44	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1981	55	3					407	413		10.3171/jns.1981.55.3.0407			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MC924	WOS:A1981MC92400010	7264732				2021-06-18	
J	SHAW, CM; ALVORD, EC				SHAW, CM; ALVORD, EC			INJURY OF BASILAR ARTERY ASSOCIATED WITH CLOSED HEAD TRAUMA	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																Birley JL, 1928, BRAIN, V51, P184, DOI 10.1093/brain/51.2.184; BOTS G. T. A. M., 1964, ACTA NEUROPATHOL, V3, P416; BRASS K, 1957, Frankf Z Pathol, V68, P254; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAIRNS H, 1942, LISBOA MED, V19, P375; CALDWELL HW, 1948, ANN INTERN MED, V28, P1132, DOI 10.7326/0003-4819-28-6-1132; CARMICHAEL R, 1950, J PATHOL BACTERIOL, V62, P1, DOI 10.1002/path.1700620102; CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V16, P285, DOI 10.1016/0013-4694(64)90111-7; CLARKE PRR, 1955, BRIT J SURG, V43, P215, DOI 10.1002/bjs.18004317816; De Veer JA, 1942, J NEUROPATH EXP NEUR, V1, P24; DRATZ HM, 1947, J NEUROPATH EXP NEUR, V6, P286, DOI 10.1097/00005072-194707000-00009; Forbus WD, 1930, B JOHNS HOPKINS HOSP, V47, P239; FORD FR, 1956, B JOHNS HOPKINS HOSP, V98, P37; Glynn LE, 1940, J PATHOL BACTERIOL, V51, P213, DOI 10.1002/path.1700510206; GRECO T, 1935, ARCH ITAL CHIR, V39, P757; GURDJIAN ES, 1963, J NEUROSURG, V20, P418, DOI 10.3171/jns.1963.20.5.0418; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; HOCKADAY TDR, 1959, J NEUROL NEUROSUR PS, V22, P229, DOI 10.1136/jnnp.22.3.229; HOUCK WS, 1964, ANN SURG, V159, P219, DOI 10.1097/00000658-196402000-00006; HUGHES JT, 1968, J NEUROL NEUROSUR PS, V31, P307, DOI 10.1136/jnnp.31.4.307; HUMPHREY JG, 1960, BRAIN, V83, P565, DOI 10.1093/brain/83.4.565; Kleyn AD, 1933, DTSCH Z NERVENHEILK, V132, P157; KUNKLE EC, 1952, ANN INTERN MED, V36, P1329, DOI 10.7326/0003-4819-36-5-1329; LINDENBERG R, 1955, J NEUROPATH EXP NEUR, V14, P223, DOI 10.1097/00005072-195507000-00001; LINDENBERG R, 1966, J NEUROSURG, V24, P908, DOI 10.3171/jns.1966.24.5.0908; LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219; LOOP JW, 1964, RADIOLOGY, V83, P36, DOI 10.1148/83.1.36; MASTAGLIA FL, 1969, J NEUROL NEUROSUR PS, V32, P383, DOI 10.1136/jnnp.32.5.383; MILLER JDR, 1967, RADIOLOGY, V89, P95, DOI 10.1148/89.1.95; MURRAY DS, 1957, BRIT J SURG, V44, P556, DOI 10.1002/bjs.18004418803; NORTHCROFT GB, 1945, BRITISH J SURGERY, V32, P105; PITNER SE, 1966, NEW ENGL J MED, V274, P764, DOI 10.1056/NEJM196604072741403; PRATTTHOMAS HR, 1947, JAMA-J AM MED ASSOC, V133, P600, DOI 10.1001/jama.1947.02880090022005; RANEY AA, 1948, ARCH NEURO PSYCHIATR, V60, P425, DOI 10.1001/archneurpsyc.1948.02310050002001; SCHNEIDER RC, 1952, J NEUROSURG, V9, P495, DOI 10.3171/jns.1952.9.5.0495; SEDZIMIR CB, 1955, J NEUROL NEUROSUR PS, V18, P293, DOI 10.1136/jnnp.18.4.293; SHAW CM, 1968, J NEUROSURG, V28, P475, DOI 10.3171/jns.1968.28.5.0475; SIGHTS WP, 1968, J NEUROSURG, V28, P588, DOI 10.3171/jns.1968.28.6.0588; SMITH DE, 1961, 7 ANN SCIENT M HOUST, P367; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; THERKELSEN J, 1963, CIRCULATION, V28, P101, DOI 10.1161/01.CIR.28.1.101; THOMSON JLG, 1963, BRIT J RADIOL, V36, P840, DOI 10.1259/0007-1285-36-431-840; TOAKLEY G, 1965, Aust N Z J Surg, V34, P261, DOI 10.1111/j.1445-2197.1965.tb04371.x; VERBIEST H, 1959, Folia Psychiatr Neurol Neurochir Neerl, V62, P371; VERNEUIL, 1972, B ACADEMIE MEDICIN 2, V1, P45; WALTON JN, 1956, SUBARCHNOID HAEMORRH; WINTERNITZ MC, 1938, BIOLOGY ARTERIOSCLER	48	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1972	35	2					247	&		10.1136/jnnp.35.2.247			0	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	M4206	WOS:A1972M420600017	5037036	Green Published, Bronze			2021-06-18	
J	TORRES, F; SHAPIRO, SK				TORRES, F; SHAPIRO, SK			ELECTROENCEPHALOGRAMS IN WHIPLASH INJURY - A COMPARISON OF ELECTROENCEPHALOGRAPHIC ABNORMALITIES WITH THOSE PRESENT IN CLOSED HEAD INJURIES	ARCHIVES OF NEUROLOGY			English	Article												Torres, Ferran/D-1296-2011	Torres, Ferran/0000-0002-7355-7913			COBB WA, 1950, SVA; DENKER PG, 1954, NEUROLOGY, V4, P912, DOI 10.1212/WNL.4.12.912; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FRANKEL CJ, 1959, JAMA-J AM MED ASSOC, V169, P216, DOI 10.1001/jama.1959.03000200014004; Gibbs FA, 1943, ARCH NEURO PSYCHIATR, V50, P111, DOI 10.1001/archneurpsyc.1943.02290200011001; HOEFER PF, 1943, ECHIISBSC; LEWIS RC, 1956, MISSOURI MED, V53, P1059; NIELSEN J M, 1959, Bull Los Angel Neuro Soc, V24, P27; SELETZ E, 1958, JAMA-J AM MED ASSOC, V168, P1750, DOI 10.1001/jama.1958.03000130016005; SHAPIRO SK, 1960, MINN MED, V43, P473; TORRES F, 1959, NEUROLOGY, V9, P147; TORRES F, UPSNCUM; Walter WG, 1942, J MENT SCI, V88, P110; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P257, DOI 10.1136/jnnp.4.3-4.257; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P131, DOI 10.1136/jnnp.4.2.131	16	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1961	5	1					28	&		10.1001/archneur.1961.00450130030005			0	Clinical Neurology	Neurosciences & Neurology	5677A	WOS:A19615677A00013	13777563				2021-06-18	
J	Liu, W; Rong, YL; Wang, JX; Zhou, Z; Ge, XH; Ji, CY; Jiang, DD; Gong, FY; Li, LW; Chen, J; Zhao, SJ; Kong, FQ; Gu, CJ; Fan, J; Cai, WH				Liu, Wei; Rong, Yuluo; Wang, Jiaxing; Zhou, Zheng; Ge, Xuhui; Ji, Chengyue; Jiang, Dongdong; Gong, Fangyi; Li, Linwei; Chen, Jian; Zhao, Shujie; Kong, Fanqi; Gu, Changjiang; Fan, Jin; Cai, Weihua			Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Exosomes; Hypoxia; Microglia polarization; miR-216a-5p; TLR4 axis	CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; FUNCTIONAL RECOVERY; EXTRACELLULAR VESICLES; DELIVERY VEHICLES; THERAPY; PROMOTE; RAT; INFLAMMATION; PROTECTION	Background Spinal cord injury (SCI) can lead to severe motor and sensory dysfunction with high disability and mortality. In recent years, mesenchymal stem cell (MSC)-secreted nano-sized exosomes have shown great potential for promoting functional behavioral recovery following SCI. However, MSCs are usually exposed to normoxia in vitro, which differs greatly from the hypoxic micro-environment in vivo. Thus, the main purpose of this study was to determine whether exosomes derived from MSCs under hypoxia (HExos) exhibit greater effects on functional behavioral recovery than those under normoxia (Exos) following SCI in mice and to seek the underlying mechanism. Methods Electron microscope, nanoparticle tracking analysis (NTA), and western blot were applied to characterize differences between Exos and HExos group. A SCI model in vivo and a series of in vitro experiments were performed to compare the therapeutic effects between the two groups. Next, a miRNA microarray analysis was performed and a series of rescue experiments were conducted to verify the role of hypoxic exosomal miRNA in SCI. Western blot, luciferase activity, and RNA-ChIP were used to investigate the underlying mechanisms. Results Our results indicate that HExos promote functional behavioral recovery by shifting microglial polarization from M1 to M2 phenotype in vivo and in vitro. A miRNA array showed miR-216a-5p to be the most enriched in HExos and potentially involved in HExos-mediated microglial polarization. TLR4 was identified as the target downstream gene of miR-216a-5p and the miR-216a-5p/TLR4 axis was confirmed by a series of gain- and loss-of-function experiments. Finally, we found that TLR4/NF-kappa B/PI3K/AKT signaling cascades may be involved in the modulation of microglial polarization by hypoxic exosomal miR-216a-5p. Conclusion Hypoxia preconditioning represents a promising and effective approach to optimize the therapeutic actions of MSC-derived exosomes and a combination of MSC-derived exosomes and miRNAs may present a minimally invasive method for treating SCI.	[Liu, Wei; Rong, Yuluo; Wang, Jiaxing; Zhou, Zheng; Ge, Xuhui; Ji, Chengyue; Jiang, Dongdong; Gong, Fangyi; Li, Linwei; Chen, Jian; Zhao, Shujie; Kong, Fanqi; Gu, Changjiang; Fan, Jin; Cai, Weihua] Nanjing Med Univ, Dept Orthopaed, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China	Cai, WH (corresponding author), Nanjing Med Univ, Dept Orthopaed, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.	caiwhsubmission@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81974335]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20181490]; Jiangsu Province Six Talents Peak [TD-SWYY-010]; Wu Jieping Medical Foundation	This work was sponsored by the National Natural Science Foundation of China (Grant No.81974335), the Natural Science Foundation of Jiangsu Province (Grant No. BK20181490), the Jiangsu Province Six Talents Peak (Grant No. TD-SWYY-010), and the Wu Jieping Medical Foundation (Grant No.320-2745-16-117).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18; Ailawadi S, 2015, BBA-MOL BASIS DIS, V1852, P1, DOI 10.1016/j.bbadis.2014.10.008; Anderson JD, 2016, STEM CELLS, V34, P601, DOI 10.1002/stem.2298; Andras IE, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2015.1131804; Anson CA, 1996, INT J REHABIL RES, V19, P55, DOI 10.1097/00004356-199603000-00006; Assinck P, 2017, NAT NEUROSCI, V20, P637, DOI 10.1038/nn.4541; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bhanot Y, 2011, BRIT J NEUROSURG, V25, P516, DOI 10.3109/02688697.2010.550658; Boriachek K, 2018, SMALL, V14, DOI 10.1002/smll.201702153; Capiralla H, 2012, J NEUROCHEM, V120, P461, DOI 10.1111/j.1471-4159.2011.07594.x; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Crain JM, 2013, J NEUROSCI RES, V91, P1143, DOI 10.1002/jnr.23242; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; EL Andaloussi S, 2013, ADV DRUG DELIVER REV, V65, P391, DOI 10.1016/j.addr.2012.08.008; Fan J, 2014, BRAIN RES, V1562, P76, DOI 10.1016/j.brainres.2014.03.019; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Francos-Quijorna I, 2016, GLIA, V64, P2079, DOI 10.1002/glia.23041; Gong Z, 2020, CURR STEM CELL RES T, V15, P321, DOI 10.2174/1574888X14666190823144424; Guo SC, 2017, THERANOSTICS, V7, P81, DOI 10.7150/thno.16803; Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001; Haney MJ, 2015, J CONTROL RELEASE, V207, P18, DOI 10.1016/j.jconrel.2015.03.033; Heiman A, 2014, BRAIN BEHAV IMMUN, V42, P232, DOI 10.1016/j.bbi.2014.06.203; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hu XY, 2016, CIRC RES, V118, P970, DOI 10.1161/CIRCRESAHA.115.307516; Hu XY, 2014, STEM CELLS, V32, P2702, DOI 10.1002/stem.1784; Hu XY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-303; Hua F, 2007, J IMMUNOL, V178, P7317, DOI 10.4049/jimmunol.178.11.7317; Huang JH, 2017, J NEUROTRAUM, V34, P3388, DOI 10.1089/neu.2017.5063; Huang RQ, 2019, AGING-US, V11, P7996, DOI 10.18632/aging.102314; Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250; Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Katsuda T, 2013, PROTEOMICS, V13, P1637, DOI 10.1002/pmic.201200373; Kawabata S, 2016, STEM CELL REP, V6, P1, DOI 10.1016/j.stemcr.2015.11.013; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kawikova I, 2015, BRAIN RES, V1617, P63, DOI 10.1016/j.brainres.2014.09.070; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kishk NA, 2010, NEUROREHAB NEURAL RE, V24, P702, DOI 10.1177/1545968310369801; Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41; Lankford KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190358; Li LW, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12689; Li Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0648-5; Liu W, 2020, ACTA BIOMATER, V103, P196, DOI 10.1016/j.actbio.2019.12.020; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Liu ZX, 2019, BIOCHEM BIOPH RES CO, V512, P367, DOI 10.1016/j.bbrc.2019.03.002; Lou GH, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.63; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029; Noelker C, 2013, SCI REP-UK, V3, DOI 10.1038/srep01393; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Nori S, 2011, P NATL ACAD SCI USA, V108, P16825, DOI 10.1073/pnas.1108077108; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Periyasamy P, 2018, MOL NEUROBIOL, V55, P3196, DOI 10.1007/s12035-017-0584-5; Qian DF, 2019, CELL CYCLE, V18, P3010, DOI 10.1080/15384101.2019.1667189; Qiu GG, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1069-9; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Rong YL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1571-8; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375; Sun GD, 2018, MAT SCI ENG C-MATER, V89, P194, DOI 10.1016/j.msec.2018.04.006; Tanaka T, 2015, GLIA, V63, P595, DOI 10.1002/glia.22770; Thind A, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.31292; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Varma AK, 2013, NEUROCHEM RES, V38, P895, DOI 10.1007/s11064-013-0991-6; Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Wang CY, 2019, FASEB J, V33, P5440, DOI 10.1096/fj.201801821R; Wood MJA, 2011, THER DELIV, V2, P1095, DOI 10.4155/TDE.11.83; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Xiao CC, 2018, CIRC RES, V123, P564, DOI 10.1161/CIRCRESAHA.118.312758; Xiao Q, 2017, NEUROSCIENCE, V355, P61, DOI 10.1016/j.neuroscience.2017.04.050; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y; Yang XD, 2017, BRAIN BEHAV IMMUN, V64, P162, DOI 10.1016/j.bbi.2017.03.003; Yang Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.140; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Zhao JX, 2019, CARDIOVASC RES, V115, P1205, DOI 10.1093/cvr/cvz040; Zhou X, 2014, NEURAL REGEN RES, V9, P1787, DOI 10.4103/1673-5374.143423; Zhou Y, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt194; Zhu JY, 2018, ARTIF CELL NANOMED B, V46, P1659, DOI 10.1080/21691401.2017.1388249; Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164	93	43	44	14	29	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 4	2020	17	1							47	10.1186/s12974-020-1726-7			22	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	KW6WO	WOS:000521323400001	32019561	DOAJ Gold, Green Published	Y	Y	2021-06-18	
J	Jaunmuktane, Z; Quaegebeur, A; Taipa, R; Viana-Baptista, M; Barbosa, R; Koriath, C; Sciot, R; Mead, S; Brandner, S				Jaunmuktane, Zane; Quaegebeur, Annelies; Taipa, Ricardo; Viana-Baptista, Miguel; Barbosa, Raquel; Koriath, Carolin; Sciot, Raf; Mead, Simon; Brandner, Sebastian			Evidence of amyloid-beta cerebral amyloid angiopathy transmission through neurosurgery	ACTA NEUROPATHOLOGICA			English	Article						Cerebral amyloid angiopathy; CAA; Transmission; Prion diseases; Proteopathic seeding; Amyloid-beta; A beta; Neurosurgery; Decontamination; Intracerebral haemorrhage; Head trauma; Traumatic brain injury; TBI	CHRONIC TRAUMATIC ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; ALZHEIMERS ASSOCIATION GUIDELINES; INTRACEREBRAL HEMORRHAGE; NEUROPATHOLOGIC ASSESSMENT; BRAIN-INJURY; NATIONAL INSTITUTE; CODING VARIANTS; PRION DISEASES; HEAD TRAUMA	Amyloid-beta (A beta) is a peptide deposited in the brain parenchyma in Alzheimer's disease and in cerebral blood vessels, causing cerebral amyloid angiopathy (CAA). A beta pathology is transmissible experimentally in animals and through medical procedures in humans, such as contaminated growth hormone or dura mater transplantation in the context of iatrogenic prion disease. Here, we present four patients who underwent neurosurgical procedures during childhood or teenage years and presented with intracerebral haemorrhage approximately three decades later, caused by severe CAA. None of these patients carried pathogenic mutations associated with early A beta pathology development. In addition, we identified in the literature four patients with a history of neurosurgical intervention and subsequent development of CAA. These findings raise the possibility that A beta pathology may be transmissible, as prion disease is, through neurosurgical procedures.	[Jaunmuktane, Zane; Quaegebeur, Annelies; Brandner, Sebastian] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England; [Jaunmuktane, Zane] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England; [Taipa, Ricardo] Ctr Hosp Univ Porto, Dept Neurosci, Neuropathol Unit, Portuguese Brain Bank, P-4099001 Porto, Portugal; [Viana-Baptista, Miguel; Barbosa, Raquel] Ctr Hosp Lisboa Ocidental, Dept Neurol, Hosp Egas Moniz, P-1449005 Lisbon, Portugal; [Koriath, Carolin; Brandner, Sebastian] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England; [Sciot, Raf] Univ Leuven, Dept Imaging & Pathol, B-3000 Louvain, Belgium; [Mead, Simon] UCL, Med Res Council, Prion Unit, UCL Inst Prion Dis, Queen Sq, London WC1N 3BG, England; [Mead, Simon] UCL Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Natl Prion Clin, Queen Sq, London WC1N 3BG, England	Brandner, S (corresponding author), Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England.; Brandner, S (corresponding author), UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England.	s.brandner@ucl.ac.uk	Jaunmuktane, Zane/ABC-9039-2020; Viana-Baptista, Miguel/AAW-6791-2020; Taipa, Ricardo/R-7472-2017; Brandner, Sebastian/J-4562-2014	Jaunmuktane, Zane/0000-0001-7738-8881; Viana-Baptista, Miguel/0000-0001-6166-2073; Taipa, Ricardo/0000-0002-9260-0227; Brandner, Sebastian/0000-0002-9821-0342; Mead, Simon/0000-0002-4326-1468; Quaegebeur, Annelies/0000-0001-5357-9341; Koriath, Carolin Anna Maria/0000-0003-1066-4938	National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research CentreNational Institute for Health Research (NIHR); Dementia Biomedical Research Unit; MRC Prion Unit at UCLUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Brain UK, a virtual brain bank [16/006]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U123160651] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0617-10175] Funding Source: researchfish	This work was funded by the National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre and Dementia Biomedical Research Unit (SB). Simon Mead and genetic analyses were supported by core funding of the MRC Prion Unit at UCL. We are grateful to all patients and their relatives and carers for their participation and for consent to autopsy and use of tissues for this research. We thank all physicians who contributed information. We are thankful for the support from Brain UK, a virtual brain bank (Ref 16/006). We also thank Francesca Launchbury and Angela Richard-Loendt from the UCL IQPath Histology facility and staff at the Division of Neuropathology, NHNN for excellent technical support, and Ron Sinclair and Chi-Wah Lok for support with post-mortem examination at UCLH.	BAKER HF, 1994, MOL NEUROBIOL, V8, P25, DOI 10.1007/BF02778005; Beck J, 2014, NEUROBIOL AGING, V35, P261, DOI 10.1016/j.neurobiolaging.2013.07.017; Biffi A, 2010, ANN NEUROL, V68, P934, DOI 10.1002/ana.22134; Bonda DJ, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS15126; Bonfield CM, 2014, J NEUROSURG-PEDIATR, V14, P205, DOI 10.3171/2014.5.PEDS13414; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Cali I, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-017-0503-z; Campbell DM, 2008, J NEUROL, V255, P597, DOI 10.1007/s00415-008-0742-9; Carpenter AM, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.226; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Duyckaerts C, 2018, ACTA NEUROPATHOL, V135, P201, DOI 10.1007/s00401-017-1791-x; Edgeworth JA, 2011, J GEN VIROL, V92, P718, DOI 10.1099/vir.0.027201-0; Ehling R, 2012, EUR J NEUROL, V19, pe29, DOI 10.1111/j.1468-1331.2011.03624.x; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Eisele YS, 2009, P NATL ACAD SCI USA, V106, P12926, DOI 10.1073/pnas.0903200106; Frontzek K, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14287; GIBBS CJ, 1994, J NEUROL NEUROSUR PS, V57, P757, DOI 10.1136/jnnp.57.6.757; Hamaguchi T, 2016, ACTA NEUROPATHOL, V132, P313, DOI 10.1007/s00401-016-1588-3; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Jin SC, 2014, HUM MOL GENET, V23, P5838, DOI 10.1093/hmg/ddu277; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Knudsen KA, 2001, NEUROLOGY, V56, P537, DOI 10.1212/WNL.56.4.537; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P911, DOI 10.1007/s00401-016-1565-x; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Love Seth, 2014, Am J Neurodegener Dis, V3, P19; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nakayama Y, 2017, ACTA NEUROCHIR, V159, P15, DOI 10.1007/s00701-016-3004-0; Pletnikova O, 2015, COGN BEHAV NEUROL, V28, P144, DOI 10.1097/WNN.0000000000000071; Pottier C, 2013, J ALZHEIMERS DIS, V35, P45, DOI 10.3233/JAD-122311; Purrucker JC, 2013, AMYLOID, V20, P45, DOI 10.3109/13506129.2012.746937; Ritchie DL, 2017, ACTA NEUROPATHOL, V134, P221, DOI 10.1007/s00401-017-1703-0; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Shively SB, 2017, ACTA NEUROPATHOL, V133, P353, DOI 10.1007/s00401-016-1649-7; Sims R, 2017, NAT GENET, V49, P1373, DOI 10.1038/ng.3916; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Thomzig A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0151-5; Trefan L, 2016, ARCH DIS CHILD, V101, P527, DOI 10.1136/archdischild-2015-308424; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; WONG MP, 1991, CLIN NEUROL NEUROSUR, V93, P133, DOI 10.1016/0303-8467(91)90054-S	49	43	43	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2018	135	5					671	679		10.1007/s00401-018-1822-2			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	GD1VF	WOS:000430288700002	29450646	Green Published, Other Gold			2021-06-18	
J	Bharadwaj, VN; Nguyen, DT; Kodibagkar, VD; Stabenfeldt, SE				Bharadwaj, Vimala N.; Nguyen, Duong T.; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.			Nanoparticle-Based Therapeutics for Brain Injury	ADVANCED HEALTHCARE MATERIALS			English	Article						blood-brain barrier; cerebral ischemia; nanoparticles; therapeutic nanoparticle delivery; traumatic brain injury	LIPOSOME-ENCAPSULATED HEMOGLOBIN; POLYMER HYBRID NANOPARTICLES; RECEPTOR-MEDIATED TRANSCYTOSIS; ISCHEMIA-REPERFUSION INJURY; TARGETED DRUG-DELIVERY; CEREBRAL-ISCHEMIA; GOLD NANOPARTICLES; OXIDATIVE STRESS; RAT MODEL; POLY(ETHYLENE GLYCOL)	Brain injuries affect a large patient population with major physical and emotional suffering for patients and their relatives; at a significant cost to the society. Effective diagnostic and therapeutic options available for brain injuries are limited by the complex brain injury pathology involving blood-brain barrier (BBB). Brain injuries, including ischemic stroke and brain trauma, initiate BBB opening for a short period of time, which is followed by a second reopening for an extended time. The leaky BBB and/or the alterations in the receptor expression on BBB may provide opportunities for therapeutic delivery via nanoparticles (NPs). The approaches for therapeutic interventions via NP delivery are aimed at salvaging the pericontusional/penumbra area for possible neuroprotection and neurovascular unit preservation. The focus of this progress report is to provide a survey of NP strategies employed in cerebral ischemia and brain trauma and finally provide insights for improved NP-based diagnostic/treatment approaches.	[Bharadwaj, Vimala N.; Nguyen, Duong T.; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, POB 879709, Tempe, AZ 85287 USA	Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, POB 879709, Tempe, AZ 85287 USA.	sarah.stabenfeldt@asu.edu			NSF CBETNational Science Foundation (NSF) [1454282]; NIH NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1DP2HD084067]; Flinn Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER	The authors would like to thank Amanda Witten and Cat Braithwaite for artistic rendering of the figures and the following funding sources: NSF CBET (1454282; SES), NIH NICHD (1DP2HD084067; SES), and Flinn Foundation (1976; VDK and SES).	Addington CP, 2016, ANN BIOMED ENG, V44, P816, DOI 10.1007/s10439-015-1514-1; Adibhatla Rao Muralikrishna, 2013, Nat Rev Neurol, V9, P173, DOI 10.1038/nrneurol.2012.166-c1; Adibhatla RM, 2005, BRAIN RES, V1058, P193, DOI 10.1016/j.brainres.2005.07.067; Agarwal A, 2009, CURR PHARM DESIGN, V15, P917, DOI 10.2174/138161209787582057; Agulla J, 2014, THERANOSTICS, V4, P90, DOI 10.7150/thno.7088; Ahmad N, 2016, INT J BIOL MACROMOL, V91, P640, DOI 10.1016/j.ijbiomac.2016.06.001; Ahmad N, 2016, INT J BIOL MACROMOL, V88, P320, DOI 10.1016/j.ijbiomac.2016.03.019; Ahmad N, 2013, PROTOPLASMA, V250, P1327, DOI 10.1007/s00709-013-0516-9; Aktas Y, 2005, BIOCONJUGATE CHEM, V16, P1503, DOI 10.1021/bc050217o; Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5; Alvarez XA, 2013, FUTUR NEUROL, V8, P175, DOI 10.2217/FNL.12.95; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; AMES A, 1968, AM J PATHOL, V52, P437; Anselmo AC, 2016, BIOENG TRANSL MED, V1, P10, DOI 10.1002/btm2.10003; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011; Bharadwaj VN, 2016, SCI REP-UK, V6, DOI 10.1038/srep29988; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Bogoslovsky T., 2016, NEW THERAPEUTICS TRA, pCh; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Cabezon I, 2015, MOL PHARMACEUT, V12, P4137, DOI 10.1021/acs.molpharmaceut.5b00597; Chaturbedy P, 2015, J CONTROL RELEASE, V217, P151, DOI 10.1016/j.jconrel.2015.08.043; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576; Chen H, 2012, STROKE, V43, P884, DOI 10.1161/STROKEAHA.111.637090; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; Cohen-Sela E, 2009, J PHARM SCI-US, V98, P1452, DOI 10.1002/jps.21527; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cox D. P. M., 2000, BRAIN, V123, P847; Cruz LJ, 2016, NANO RES, V9, P1276, DOI 10.1007/s12274-016-1023-z; Curic A, 2017, EUR J PHARM BIOPHARM, V114, P175, DOI 10.1016/j.ejpb.2017.01.014; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Di Martino A, 2017, INT J PHARMACEUT, V526, P380, DOI 10.1016/j.ijpharm.2017.04.061; Digicaylioglu M, 2010, EXPERT OPIN BIOL TH, V10, P937, DOI 10.1517/14712598.2010.481435; Du JZ, 2004, ANGEW CHEM INT EDIT, V43, P5084, DOI 10.1002/anie.200454244; Dutta D, 2016, J BIOMED MATER RES A, V104, P688, DOI 10.1002/jbm.a.35608; Ernsting MJ, 2013, J CONTROL RELEASE, V172, P782, DOI 10.1016/j.jconrel.2013.09.013; Euliss LE, 2006, CHEM SOC REV, V35, P1095, DOI 10.1039/b600913c; Feigin VL, 2010, BEST PRACT RES-CLIN, V24, P485, DOI 10.1016/j.bpa.2010.10.006; Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011; FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206; FRESTA M, 1995, PHARMACEUT RES, V12, P1769, DOI 10.1023/A:1016234226404; Fricker G., 2014, BLOOD BRAIN BARRIER; GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B; Gadhvi V., 2013, RES J PHARM TECHNOL, V6, P454; Gao XH, 2014, ACS NANO, V8, P3678, DOI 10.1021/nn5003375; Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/nnano.2014.274, 10.1038/NNANO.2014.274]; Geelen T, 2013, CONTRAST MEDIA MOL I, V8, P117, DOI 10.1002/cmmi.1501; Gilmore JL, 2008, J NEUROIMMUNE PHARM, V3, P83, DOI 10.1007/s11481-007-9099-6; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Grabrucker A. M., 2013, BLOOD BRAIN BARRIER, P71; Gulaka PK, 2011, NMR BIOMED, V24, P1226, DOI 10.1002/nbm.1678; Gustafson HH, 2015, NANO TODAY, V10, P487, DOI 10.1016/j.nantod.2015.06.006; Hadinoto K, 2013, EUR J PHARM BIOPHARM, V85, P427, DOI 10.1016/j.ejpb.2013.07.002; Han L, 2016, NANOMED-NANOTECHNOL, V12, P1833, DOI 10.1016/j.nano.2016.03.005; Han LA, 2011, BIOMATERIALS, V32, P2989, DOI 10.1016/j.biomaterials.2011.01.005; Hanada S, 2014, INT J MOL SCI, V15, P1812, DOI 10.3390/ijms15021812; Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1; Harnisch S, 2000, EUR J PHARM BIOPHARM, V49, P41, DOI 10.1016/S0939-6411(99)00064-8; Hartmann A., 2012, CEREBRAL ISCHEMIA BA; Herd H, 2013, ACS NANO, V7, P1961, DOI 10.1021/nn304439f; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Honary S, 2013, TROP J PHARM RES, V12, P7, DOI 10.4314/tjpr.v12i1.2; Hong HY, 2008, J CONTROL RELEASE, V131, P167, DOI 10.1016/j.jconrel.2008.07.020; Huang ZG, 1999, CAN J NEUROL SCI, V26, P298, DOI 10.1017/S0317167100000421; Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009; Ishii T, 2012, J CONTROL RELEASE, V160, P81, DOI 10.1016/j.jconrel.2012.02.004; Jo DH, 2015, NANOMED-NANOTECHNOL, V11, P1603, DOI 10.1016/j.nano.2015.04.015; Johnson BM, 2002, AAPS PHARMSCI, V4; Johnsson M, 2003, BIOPHYS J, V85, P3839, DOI 10.1016/S0006-3495(03)74798-5; Joo J, 2016, NANOSCALE HORIZ, V1, P407, DOI [10.1039/c6nh00082g, 10.1039/C6NH00082G]; Kakkar V, 2013, EUR J PHARM BIOPHARM, V85, P339, DOI 10.1016/j.ejpb.2013.02.005; Kanekar SG, 2012, AM J ROENTGENOL, V198, P63, DOI 10.2214/AJR.10.7312; Kanwar JR, 2012, NANOMED-NANOTECHNOL, V8, P399, DOI 10.1016/j.nano.2011.08.006; Karatas H, 2009, J NEUROSCI, V29, P13761, DOI 10.1523/JNEUROSCI.4246-09.2009; Karchemski F, 2012, J CONTROL RELEASE, V160, P339, DOI 10.1016/j.jconrel.2011.12.037; Karve I. P., 2016, BRIT J PHARM; Kawaguchi AT, 2017, ARTIF ORGANS, V41, P336, DOI 10.1111/aor.12905; Kawaguchi AT, 2010, J PHARMACOL EXP THER, V332, P429, DOI 10.1124/jpet.109.160051; Kawaguchi AT, 2009, ARTIF ORGANS, V33, P153, DOI 10.1111/j.1525-1594.2008.00700.x; Kazmaier P., 2011, MRS BULL, V25, P30; Khalin I, 2016, DRUG DELIV, V23, P3520, DOI 10.1080/10717544.2016.1199609; Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780; Kim SJ, 2013, J STROKE, V15, P27, DOI 10.5853/jos.2013.15.1.27; Kochanek P. M., 2012, ADENOSINE KEY LINK M, P307; Koffie RM, 2011, P NATL ACAD SCI USA, V108, P18837, DOI 10.1073/pnas.1111405108; Kolhar P, 2013, P NATL ACAD SCI USA, V110, P10753, DOI 10.1073/pnas.1308345110; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2007, INT J PHARMACEUT, V331, P1, DOI 10.1016/j.ijpharm.2006.10.021; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levchenko TS, 2002, INT J PHARMACEUT, V240, P95, DOI 10.1016/S0378-5173(02)00129-1; Li M, 2017, AAPS J, V19, P26, DOI 10.1208/s12248-016-0010-3; Li QY, 2013, BIOMATERIALS, V34, P4982, DOI 10.1016/j.biomaterials.2013.03.030; Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w; Li Y, 2012, BIOMATERIALS, V33, P4965, DOI 10.1016/j.biomaterials.2012.03.044; Li Y, 2015, NANOSCALE, V7, P16631, DOI 10.1039/c5nr02970h; Liang F, 2010, CURR MED CHEM, V17, P10, DOI 10.2174/092986710789957742; Lin Y, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/16/165101; LIU DX, 1992, BIOCHIM BIOPHYS ACTA, V1104, P95, DOI 10.1016/0005-2736(92)90136-A; Liu WY, 2012, CNS NEUROSCI THER, V18, P609, DOI 10.1111/j.1755-5949.2012.00340.x; Liu X, 2013, BIOMATERIALS, V34, P817, DOI 10.1016/j.biomaterials.2012.10.017; Liu ZX, 2013, J BIOMED NANOTECHNOL, V9, P1017, DOI 10.1166/jbn.2013.1597; Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295; Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936; Lu W, 2006, CANCER RES, V66, P11878, DOI 10.1158/0008-5472.CAN-06-2354; Lu WL, 2004, J PHARMACOL SCI, V95, P381, DOI 10.1254/jphs.FPJ04001X; Lu YM, 2014, BIOMATERIALS, V35, P530, DOI 10.1016/j.biomaterials.2013.09.093; Lusardi TA, 2009, CURR NEUROPHARMACOL, V7, P228, DOI 10.2174/157015909789152137; Lv LY, 2016, MOL PHARMACEUT, V13, P3506, DOI 10.1021/acs.molpharmaceut.6b00523; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macdonald RL, 1998, NEUROL MED-CHIR, V38, P1, DOI 10.2176/nmc.38.1; MacKay RJ, 2004, VET CLIN N AM-EQUINE, V20, P199, DOI 10.1016/j.cveq.2003.11.006; Mandal B, 2013, NANOMED-NANOTECHNOL, V9, P474, DOI 10.1016/j.nano.2012.11.010; Mann AP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11980; Marpu S, 2015, J PHYS CHEM C, V119, P12551, DOI 10.1021/acs.jpcc.5b00119; Masserini Massimo, 2013, ISRN Biochem, V2013, P238428, DOI 10.1155/2013/238428; McCall R. L., 2013, JOVE-J VIS EXP, P1; McCall RL, 2014, TISSUE BARRIERS, V2, DOI 10.4161/21688362.2014.944449; Mdzinarishvili A, 2013, DRUG DELIV TRANSL RE, V3, P309, DOI 10.1007/s13346-012-0117-8; Menon JU, 2012, THERANOSTICS, V2, P1199, DOI 10.7150/thno.4812; Meshkini A., 2017, J INJ VIOLENCE RES, V9, P41; Mohanraj V. J., 2006, Tropical Journal of Pharmaceutical Research, V5, P561; Mudshinge SR, 2011, SAUDI PHARM J, V19, P129, DOI 10.1016/j.jsps.2011.04.001; Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6; Nagai N, 2015, INT J MOL SCI, V16, P29329, DOI 10.3390/ijms161226166; Nga BL, 2014, J EXP MED, V211, P233, DOI 10.1084/jem.20131660; Nicolay K., 2013, GD CONTAINING NANOPA; Niewoehner J, 2014, NEURON, V81, P49, DOI 10.1016/j.neuron.2013.10.061; Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010; Pardridge William M, 2005, NeuroRx, V2, P3; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285; Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016; Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j.jconrel.2006.10.015; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Polo E, 2017, ACS NANO, V11, P2397, DOI 10.1021/acsnano.7b01197; Price L., 2015, BLOOD BRAIN BARRIER, pCh; Puri A, 2009, CRIT REV THER DRUG, V26, P523, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Rezaei Y., 2014, NEUROPSYCH DIS TREAT, V10, P2299; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Ruozi B, 2015, MOL NEUROBIOL, V52, P899, DOI 10.1007/s12035-015-9235-x; Sadzuka Y, 1998, CANCER LETT, V127, P99, DOI 10.1016/S0304-3835(98)00031-7; Saenger AK, 2010, CLIN CHEM, V56, P21, DOI 10.1373/clinchem.2009.133801; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Saraiva C, 2016, J CONTROL RELEASE, V235, P34, DOI 10.1016/j.jconrel.2016.05.044; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Schnyder Anita, 2005, NeuroRx, V2, P99; Scott MD, 1998, CURR PHARM DESIGN, V4, P423; Sharpe E., 2011, ARTIFICIAL NANOPARTI; Shen MW, 2010, NANOSCALE, V2, P1596, DOI 10.1039/c0nr00072h; Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c; Shilo M, 2014, NANOSCALE, V6, P2146, DOI 10.1039/c3nr04878k; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Silva GA, 2005, SURG NEUROL, V63, P301, DOI 10.1016/j.surneu.2004.06.008; Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4; Stutzmann J. M., 1997, CNS DRUG REV, V3, P83; Takamiya M, 2012, NEUROSCIENCE, V221, P47, DOI 10.1016/j.neuroscience.2012.06.060; Thompson Brandon J, 2014, Adv Pharmacol, V71, P165, DOI 10.1016/bs.apha.2014.06.013; Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011; TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5; Truong TT, 2007, LANGMUIR, V23, P2898, DOI 10.1021/la062981k; Tu H, 2010, FASEB J, V24, P2281, DOI 10.1096/fj.09-143487; Verma SK, 2016, ACS APPL MATER INTER, V8, P19716, DOI 10.1021/acsami.6b01776; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wang J, 2014, REGEN MED RES, V2, DOI 10.1186/2050-490X-2-3; Wang JJ, 2011, INT J NANOMED, V6, P765, DOI 10.2147/IJN.S17296; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Wiley DT, 2013, P NATL ACAD SCI USA, V110, P8662, DOI 10.1073/pnas.1307152110; Williams-Karnesky RL, 2009, CURR NEUROPHARMACOL, V7, P217, DOI 10.2174/157015909789152209; Wohlfart S, 2012, J CONTROL RELEASE, V161, P264, DOI 10.1016/j.jconrel.2011.08.017; Xu JL, 2016, ADV FUNCT MATER, V26, P4124, DOI 10.1002/adfm.201504416; Yang RSH, 2010, J NANOSCI NANOTECHNO, V10, P8482, DOI 10.1166/jnn.2010.2687; Zhang B, 2016, J NEUROTRAUM, V33, pA14; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r; Zhang YN, 2016, J CONTROL RELEASE, V240, P332, DOI 10.1016/j.jconrel.2016.01.020; Zhang YY, 2011, ANN BIOMED ENG, V39, P414, DOI 10.1007/s10439-010-0151-y; Zhao LX, 2013, BIOL PHARM BULL, V36, P1263, DOI 10.1248/bpb.b12-00769; Zhao Y, 2016, J CONTROL RELEASE, V233, P64, DOI 10.1016/j.jconrel.2016.04.038; Zhou ZK, 2010, ACS NANO, V4, P5003, DOI 10.1021/nn100578b	198	43	43	7	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2192-2640	2192-2659		ADV HEALTHC MATER	Adv. Healthc. Mater.	JAN 10	2018	7	1							1700668	10.1002/adhm.201700668			16	Engineering, Biomedical; Nanoscience & Nanotechnology; Materials Science, Biomaterials	Engineering; Science & Technology - Other Topics; Materials Science	FS3IO	WOS:000419674600007	29034608	Bronze, Green Accepted			2021-06-18	
J	Struck, AF; Ustun, B; Ruiz, AR; Lee, JW; LaRoche, SM; Hirsch, LJ; Gilmore, EJ; Vlachy, J; Haider, HA; Rudin, C; Westover, MB				Struck, Aaron F.; Ustun, Berk; Ruiz, Andres Rodriguez; Lee, Jong Woo; LaRoche, Suzette M.; Hirsch, Lawrence J.; Gilmore, Emily J.; Vlachy, Jan; Haider, Hiba Arif; Rudin, Cynthia; Westover, M. Brandon			Association of an Electroencephalography-Based Risk Score With Seizure Probability in Hospitalized Patients	JAMA NEUROLOGY			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; EEG	IMPORTANCE Continuous electroencephalography (EEG) use in critically ill patients is expanding. There is no validated method to combine risk factors and guide clinicians in assessing seizure risk.& para;& para;OBJECTIVE To use seizure risk factors from EEG and clinical history to create a simple scoring system associated with the probability o f seizures in patients with acute illness.& para;& para;DESIGN, SETTING, AND PARTICIPANTS We used a prospective multicenter (Emory University Hospital, Brigham and Women's Hospital, and Yale University Hospital) database containing clinical and electrographic variables on 5427 continuous EEG sessions from eligible patients if they had continuous EEG for clinical indications, excluding epilepsy monitoring unit admissions. We created a scoring system model to estimate seizure risk in acutely ill patients undergoing continuous EEG, The model was built using a new machine learning method (Risks LI M) that is designed to produce accurate, risk-calibrated scoring systems with a limited number of variables and small integer weights. We validated the accuracy and risk calibration of our model using cross-validation and compared its performance with models built with state-of-the-art logistic regression methods. The database was developed by the Critical Care EEG Research Consortium and used data collected over 3 years. The EEG variables were interpreted using standardized terminology by certified reviewers.& para;& para;EXPOSURES All patients had more than 6 hours o f uninterrupted EEG recordings.& para;& para;MAIN OUTCOMES AND MEASURES The main outcome was the average risk calibration error.& para;& para;RESULTS There were 5427 continuous EEGs performed on 4772 participants (2868 men, 49.9%; median age, 61 years) performed at 3 institutions, without further demographic stratification. Our final model, 2HELPS2B, had an area under the curve o f 0.819 and average calibration error of 2.7% (95% Cl, 2.0%-3.6%). It included 6 variables with the following point assignments; (1) brief (ictal) rhythmic discharges (B[l]RDs) (2 points); (2) presence of lateralized periodic discharges, lateralized rhythmic delta activity, or bilateral independent periodic discharges (1 point); (3) prior seizure (1 point); (4) sporadic epileptiform discharges (1 point); (5) frequency greater than 2.0 Hz for any periodic or rhythmic pattern (1 point); and (6) presence o f "plus" features (superimposed, rhythmic, sharp, or fast activity) (1 point). The probable seizure risk of each score was 5% for a score of 0,12% for a score of 1,27% for a score of 2,50% for a score of 3,73% for a score of 4,88% for a score of 5, and greater than 95% for a score of 6 or 7.& para;& para;CONCLUSIONS AND RELEVANCE The 2HELPS2B model is a quick accurate tool to aid clinical judgment of the risk of seizures in critically ill patients.	[Struck, Aaron F.] Univ Wisconsin, Dept Neurol, 7131 MFCB,1685 Highland Ave, Madison, WI 53705 USA; [Ustun, Berk] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Ruiz, Andres Rodriguez; LaRoche, Suzette M.; Haider, Hiba Arif] Emory Univ, Sch Med, Atlanta, GA USA; [Lee, Jong Woo] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [LaRoche, Suzette M.] Mission Hlth, Asheville, NC USA; [Hirsch, Lawrence J.; Gilmore, Emily J.] Yale Univ, Sch Med, New Haven, CT USA; [Vlachy, Jan] Georgia Inst Technol, Atlanta, GA 30332 USA; [Rudin, Cynthia] Duke Univ, Dept Comp Sci, Durham, NC 27706 USA; [Rudin, Cynthia] Duke Univ, Dept Elect & Comp Engn, Durham, NC USA; [Westover, M. Brandon] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Struck, AF (corresponding author), Univ Wisconsin, Dept Neurol, 7131 MFCB,1685 Highland Ave, Madison, WI 53705 USA.	afstruck@wisc.edu	Lee, Jongwoo/AAI-3617-2020; Struck, Aaron/AAP-7908-2021	Struck, Aaron/0000-0002-9103-1798; Hirsch, Lawrence/0000-0002-6333-832X; Rodriguez Ruiz, Andres/0000-0002-1425-9035; Ustun, Berk/0000-0001-5188-3155; Haider, Hiba/0000-0001-7118-3690	Epilepsy Foundation; American Epilepsy Society; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS090900] Funding Source: NIH RePORTER	This study was supported by a Research Infrastructure Award from the American Epilepsy Society and the Epilepsy Foundation.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Bianca Z, 2002, P 8 ACMSIGKDD INT C, P649; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93; Gaspard N, 2014, EPILEPSIA, V55, P1366, DOI 10.1111/epi.12653; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Lee JW, 2016, J CLIN NEUROPHYSIOL, V33, P133, DOI 10.1097/WNP.0000000000000230; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Ruiz AR, 2017, JAMA NEUROL, V74, P181, DOI 10.1001/jamaneurol.2016.4990; Shafi MM, 2012, NEUROLOGY, V79, P1796, DOI 10.1212/WNL.0b013e3182703fbc; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Ustun B, 2015, METHODS MODELS INTER; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Westover MB, 2015, CLIN NEUROPHYSIOL, V126, P463, DOI 10.1016/j.clinph.2014.05.037; Young GB, 1996, NEUROLOGY, V47, P83	22	43	46	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	DEC	2017	74	12					1419	1424		10.1001/jamaneurol.2017.2459			6	Clinical Neurology	Neurosciences & Neurology	FP4YK	WOS:000417622700007	29052706	Green Accepted, Green Published			2021-06-18	
J	Sun, B; Dalvi, P; Abadjian, L; Tang, N; Pulliam, L				Sun, Bing; Dalvi, Pranjali; Abadjian, Linda; Tang, Norina; Pulliam, Lynn			Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV	AIDS			English	Article						aging; biomarker; exosomes; HIV-associated neurocognitive disorder; HIV; neurological impairment	PRECLINICAL ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; CEREBROSPINAL-FLUID; ACTIVATION; EXPRESSION; PROTEINS; CELLS; NEURODEGENERATION; ACCUMULATION	Objective: To investigate proteins associated with neuronal damage in plasma neuronderived exosomes (NDE) of HIV-infected study participants as a liquid biomarker for cognitive impairment. Methods: Plasma NDE were isolated using precipitation and immunoadsorption with antibody to a cell surface-specific neuronal marker. Total exosomes and NDE were enumerated, characterized, and proteins extracted and targets quantified by ELISA. Results: Plasma NDE from 23 HIV seropositive individuals of which 11 had mild cognitive impairment, and 12 HIV seronegative controls of which three had cognitive impairment were isolated. NDE were enriched for the neuronal markers neurofilament light (NF-L) and synaptophysin (SYP). Neuropsychologically impaired individuals had fewer NDE compared with neuropsychologically normal study participants. NDE from neuropsychologically impaired study participants had significantly higher levels of high-mobility group box 1 (HMGB1), NF-L, and amyloid b proteins compared with neuropsychologically normal individuals. NDE HMGB1 protein significantly decreased with age in HIV-infected individuals. Conclusion: Plasma NDE were altered in several ways in HIV infection. Elevated HMGB1, NF-L, and amyloid beta proteins could distinguish cognitive impairment. NDE contents reflect neuronal health in 'real time' and may be useful for following cognitive impairment and response to therapy in HIV infection. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.	[Sun, Bing; Dalvi, Pranjali; Abadjian, Linda; Tang, Norina; Pulliam, Lynn] Univ Calif San Francisco, Vet Affairs Med Ctr, San Francisco, CA 94143 USA; [Pulliam, Lynn] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Pulliam, Lynn] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Pulliam, L (corresponding author), Univ Calif San Francisco, Dept Lab Med, Vet Affairs Med Ctr, 4150 Clement St,113A, San Francisco, CA 94143 USA.	lynn.pulliam@ucsf.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01MH085538, R21MH112483]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH112483, R01MH085538] Funding Source: NIH RePORTER	The authors thank all the blood donors for their participation. The authors also thank Edward J. Goetzl (UCSF) for providing NDE isolation protocols and helpful discussions and Archana Gupta (SBI) for exosome technical support. This study was supported by the National Institute of Health awards R01MH085538 and R21MH112483 (LP). L.P. and B.S. designed the study. B.S. performed the study and analyzed the data. N.T. setup NanoSight parameters and P.D. performed analysis. L. A. performed neuropsychological tests. B.S. and N.T. refined exosome isolation procedure. L.P. and B.S. wrote the manuscript and all authors revised.	Achim CL, 2009, J NEUROIMMUNE PHARM, V4, P190, DOI 10.1007/s11481-009-9152-8; Andras IE, 2017, MOL CELL NEUROSCI, V79, P12, DOI 10.1016/j.mcn.2016.12.006; Banigan MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0048814; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brew BJ, 2005, NEUROLOGY, V65, P1490, DOI 10.1212/01.wnl.0000183293.95787.b7; Brew BJ, 2009, J NEUROIMMUNE PHARM, V4, P163, DOI 10.1007/s11481-008-9143-1; Calcagno A, 2016, J NEUROVIROL, V22, P88, DOI 10.1007/s13365-015-0371-x; Carroll Antonia, 2017, F1000Res, V6, P312, DOI 10.12688/f1000research.10651.1; Clifford DB, 2009, NEUROLOGY, V73, P1982, DOI 10.1212/WNL.0b013e3181c5b445; Eitan E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01386-z; Enokido Y, 2008, BIOCHEM BIOPH RES CO, V376, P128, DOI 10.1016/j.bbrc.2008.08.108; Fang P, 2012, MOL NEUROBIOL, V45, P499, DOI 10.1007/s12035-012-8264-y; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gisslen M, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-63; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Gougeon ML, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00245; Gray LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090620; Gupta A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-68; Hamlett ED, 2017, ALZHEIMERS DEMENT, V13, P541, DOI 10.1016/j.jalz.2016.08.012; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Jeon AHW, 2013, J BIOL CHEM, V288, P15352, DOI 10.1074/jbc.M112.441840; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Lachenal G, 2011, MOL CELL NEUROSCI, V46, P409, DOI 10.1016/j.mcn.2010.11.004; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; McGuire JL, 2015, J NEUROVIROL, V21, P439, DOI 10.1007/s13365-015-0333-3; Mullins RJ, 2017, HUM BRAIN MAPP, V38, P1933, DOI 10.1002/hbm.23494; Peluso MJ, 2013, J INFECT DIS, V207, P1703, DOI 10.1093/infdis/jit088; Peterson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116081; Pulliam L, 2015, DNA CELL BIOL, V34, P459, DOI 10.1089/dna.2015.2884; Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004; Seipold L, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00037; Seipold L, 2017, BBA-MOL CELL RES, V1864, P217, DOI 10.1016/j.bbamcr.2016.11.003; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Sun B, 2013, JAIDS-J ACQ IMM DEF, V62, P190, DOI 10.1097/QAI.0b013e31827b61f1; Takata K, 2003, BIOCHEM BIOPH RES CO, V301, P699, DOI 10.1016/S0006-291X(03)00024-X; Tang N, 2016, FASEB J, V30, P3097, DOI 10.1096/fj.201600368RR; Thali M, 2011, BIOCHEM SOC T, V39, P529, DOI 10.1042/BST0390529; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery C, 2006, CURR PROTOC CELL BIO; Thierry S, 2007, AIDS, V21, P283, DOI 10.1097/QAD.0b013e3280115b50; Venegas C, 2017, J LEUKOCYTE BIOL, V101, P87, DOI 10.1189/jlb.3MR0416-204R; Wakabayashi T, 2009, NAT CELL BIOL, V11, P1340, DOI 10.1038/ncb1978; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001	52	43	44	2	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0269-9370	1473-5571		AIDS	Aids	SEP 10	2017	31	14					F9	F17		10.1097/QAD.0000000000001595			9	Immunology; Infectious Diseases; Virology	Immunology; Infectious Diseases; Virology	FF2FU	WOS:000408714100001	28692534	Green Accepted			2021-06-18	
J	Geisler, JG; Marosi, K; Halpern, J; Mattson, MP				Geisler, John G.; Marosi, Krisztina; Halpern, Joshua; Mattson, Mark P.			DNP, mitochondrial uncoupling, and neuroprotection: A little dab'll do ya	ALZHEIMERS & DEMENTIA			English	Article						BDNF; CREB; DNP; Hormesis; Mitochondrial uncoupling; Parkinson's disease; Synaptic plasticity	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; DIETARY RESTRICTION; HIPPOCAMPAL-NEURONS; ENERGY-METABOLISM; OXIDATIVE STRESS; PERMEABILITY TRANSITION; DOPAMINERGIC-NEURONS; PROTEIN-2 PROTECTS	Recent findings have elucidated roles for mitochondrial uncoupling proteins (UCPs) in neuronal plasticity and resistance to metabolic and oxidative stress. UCPs are induced by bioenergetic challenges such as caloric restriction and exercise and may protect neurons against dysfunction and degeneration. The pharmacological uncoupler 2,4-dinitrophenol (DNP), which was once prescribed to >100,000 people as a treatment for obesity, stimulates several adaptive cellular stress-response signaling pathways in neurons including those involving the brain-derived neurotrophic factor (BDNF), the transcription factor cyclic AMP response element-binding protein (CREB), and autophagy. Preclinical data show that low doses of DNP can protect neurons and improve functional outcome in animal models of Alzheimer's and Parkinson's diseases, epilepsy, and cerebral ischemic stroke. Repurposing of DNP and the development of novel uncoupling agents with hormetic mechanisms of action provide opportunities for new breakthrough therapeutic interventions in a range of acute and chronic insidious neurodegenerative/neuromuscular conditions, all paradoxically at body weight-preserving doses. Published by Elsevier Inc. on behalf of the Alzheimer's Association.	[Geisler, John G.] Mitochon Pharmaceut Inc, Radnor, PA USA; [Marosi, Krisztina; Halpern, Joshua; Mattson, Mark P.] NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; [Mattson, Mark P.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Mattson, MP (corresponding author), NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.; Mattson, MP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	mark.mattson@nih.gov			Intramural Research Program of the National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Mitochon Pharmaceuticals; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000331, ZIAAG000313, ZIAAG000312, ZIAAG000314] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Program of the National Institute on Aging and by Mitochon Pharmaceuticals.	Akinyemi RO, 2013, CURR ALZHEIMER RES, V10, P642; Alemzadeh R, 2008, METABOLISM, V57, P1597, DOI 10.1016/j.metabol.2008.06.017; Alirezaei M, 2010, AUTOPHAGY, V6, P702, DOI 10.4161/auto.6.6.12376; Andrews ZB, 2005, NAT REV NEUROSCI, V6, P829, DOI 10.1038/nrn1767; Arumugam TV, 2010, ANN NEUROL, V67, P41, DOI 10.1002/ana.21798; Barnard ND, 2014, NEUROBIOL AGING, V35, pS74, DOI 10.1016/j.neurobiolaging.2014.03.033; Bengtson CP, 2012, ADV EXP MED BIOL, V970, P377, DOI 10.1007/978-3-7091-0932-8_17; Bernardi P, 1999, PHYSIOL REV, V79, P1127; Bondarenko AI, 2015, PFLUG ARCH EUR J PHY, V467, P2509, DOI 10.1007/s00424-015-1727-z; Brennan JP, 2006, CARDIOVASC RES, V72, P313, DOI 10.1016/j.cardiores.2006.07.019; Calabrese EJ, 2007, TOXICOL APPL PHARM, V222, P122, DOI 10.1016/j.taap.2007.02.015; Chan SL, 2006, J BIOL CHEM, V281, P37391, DOI 10.1074/jbc.M605552200; Charlson F, 2009, PHARMACOEPIDEM DR S, V18, P93, DOI 10.1002/pds.1694; Cheng AW, 2016, CELL METAB, V23, P128, DOI 10.1016/j.cmet.2015.10.013; Cheng AW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2238; Chu ACY, 2009, FREE RADICAL BIO MED, V46, P810, DOI 10.1016/j.freeradbiomed.2008.12.015; Cohen SM, 2015, BIOCHEM BIOPH RES CO, V460, P88, DOI 10.1016/j.bbrc.2015.02.146; Conti B, 2005, J NEUROCHEM, V93, P493, DOI 10.1111/j.1471-4159.2005.03052.x; Cutting WC, 1933, J AMER MED ASSOC, V101, P193, DOI 10.1001/jama.1933.02740280013006; da Silva CCC, 2008, AGING CELL, V7, P552, DOI 10.1111/j.1474-9726.2008.00407.x; Davis LM, 2008, EPILEPSIA, V49, P117, DOI 10.1111/j.1528-1167.2008.01854.x; De Felice FG, 2006, IUBMB LIFE, V58, P185, DOI 10.1080/15216540600702198; Dietrich MO, 2008, J NEUROSCI, V28, P10766, DOI 10.1523/JNEUROSCI.2744-08.2008; Dirnagl U, 2008, NEUROPHARMACOLOGY, V55, P334, DOI 10.1016/j.neuropharm.2008.02.017; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Formentini L, 2014, EMBO J, V33, P762, DOI 10.1002/embj.201386392; Geisler JG, 2011, DIABETOLOGIA, V54, P237, DOI 10.1007/s00125-010-1932-4; Ghosh N, 2011, FREE RADICAL RES, V45, P888, DOI 10.3109/10715762.2011.574290; Giralt M, 2016, CURR DIABETES REV; Goldgof M, 2014, J BIOL CHEM, V289, P19341, DOI 10.1074/jbc.M114.568204; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Hausenloy D, 2004, CIRCULATION, V109, P1714, DOI 10.1161/01.CIR.0000126294.81407.7D; HOLMES RW, 1952, JAMA-J AM MED ASSOC, V148, P935, DOI 10.1001/jama.1952.62930110003013a; Holmuhamedov EL, 2004, FEBS LETT, V568, P167, DOI 10.1016/j.febslet.2004.05.031; Hongpaisan J, 2004, J NEUROSCI, V24, P10878, DOI 10.1523/JNEUROSCI.3278-04.2004; Horner W D, 1941, Trans Am Ophthalmol Soc, V39, P405; Hwang RD, 2014, NEUROBIOL DIS, V69, P180, DOI 10.1016/j.nbd.2014.05.032; Jabbar SB, 2013, AM J FOREN MED PATH, V34, P321, DOI 10.1097/PAF.0000000000000058; JARVIK LF, 1962, EUGEN QUART, V9, P95, DOI 10.1080/19485565.1962.9987510; Jones CM, 2015, AM J PREV MED, V49, P493, DOI 10.1016/j.amepre.2015.03.040; Kashiwaya Y, 2013, NEUROBIOL AGING, V34, P1530, DOI 10.1016/j.neurobiolaging.2012.11.023; Korde AS, 2005, J NEUROCHEM, V94, P1676, DOI 10.1111/j.1471-4159.2005.03328.x; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Kwok KHH, 2010, FREE RADICAL BIO MED, V49, P1023, DOI 10.1016/j.freeradbiomed.2010.06.017; Lee J, 1999, J NEUROSCI RES, V57, P48, DOI 10.1002/(SICI)1097-4547(19990701)57:1<48::AID-JNR6>3.0.CO;2-L; Li Z, 2011, J NEUROSCI, V31, P1114, DOI 10.1523/JNEUROSCI.5387-10.2011; LINK KP, 1959, CIRCULATION, V19, P97, DOI 10.1161/01.CIR.19.1.97; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Liu D, 2006, NEUROMOL MED, V8, P389, DOI 10.1385/NMM:8:3:389; Liu D, 2015, J NEUROCHEM, V134, P677, DOI 10.1111/jnc.13176; Liu D, 2010, J ALZHEIMERS DIS, V22, P443, DOI 10.3233/JAD-2010-101017; Liu Yajun, 2009, BMC Physiology, V9, P17, DOI 10.1186/1472-6793-9-17; da Costa RFM, 2010, J NEUROTRAUM, V27, P829, DOI 10.1089/neu.2009.1189; Marosi K, 2014, TRENDS ENDOCRIN MET, V25, P89, DOI 10.1016/j.tem.2013.10.006; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 2015, AGEING RES REV, V20, P37, DOI 10.1016/j.arr.2014.12.011; Mattson MP, 2012, CELL METAB, V16, P706, DOI 10.1016/j.cmet.2012.08.012; Mattson MP, 2008, NEURON, V60, P748, DOI 10.1016/j.neuron.2008.10.010; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; Meyer R, 2014, POPUL HEALTH MANAG, V17, P372, DOI 10.1089/pop.2013.0098; Minners J, 2000, CARDIOVASC RES, V47, P68, DOI 10.1016/S0008-6363(00)00069-9; Morrison RS, 1996, J NEUROSCI, V16, P1337; Nicholls D G, 1978, Experientia Suppl, V32, P89; Pallanck LJ, 2010, J CELL BIOL, V191, P1225, DOI 10.1083/jcb.201011068; Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood-2007-10-117457; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Perkins R. G, 1919, PUBLIC HLTH REPORTS, V34, P2335; Perry RJ, 2015, SCIENCE, V347, P1253, DOI 10.1126/science.aaa0672; Perry RJ, 2013, CELL METAB, V18, P740, DOI 10.1016/j.cmet.2013.10.004; Petroczi A, 2015, SUBST ABUSE TREAT PR, V10, DOI 10.1186/s13011-015-0034-1; Ploughman M, 2007, EUR J NEUROSCI, V25, P3453, DOI 10.1111/j.1460-9568.2007.05591.x; POLLOCK BE, 1955, JAMA-J AM MED ASSOC, V159, P1094, DOI 10.1001/jama.1955.02960280016004; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Righi V, 2013, FASEB J, V27, P2521, DOI 10.1096/fj.12-220764; Rim JS, 2002, J BIOL CHEM, V277, P34589, DOI 10.1074/jbc.M108866200; Rolfe DFS, 1996, AM J PHYSIOL-CELL PH, V271, pC1380; Sebollela A, 2010, NEUROTOX RES, V18, P112, DOI 10.1007/s12640-009-9133-y; Stranahan AM, 2012, NAT REV NEUROSCI, V13, P209, DOI 10.1038/nrn3151; Stutzmann GE, 2011, PHARMACOL REV, V63, P700, DOI 10.1124/pr.110.003814; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Tainter ML, 1934, AM J PUBLIC HEALTH N, V24, P1045, DOI 10.2105/AJPH.24.10.1045; Tapia-Rojas C, 2016, BRAIN PATHOL, V26, P62, DOI 10.1111/bpa.12255; Varela L, 2016, NEUROBIOL DIS, V90, P68, DOI 10.1016/j.nbd.2016.01.004; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726; Wasilewska-Sampaio AP, 2005, FASEB J, V19, P1627, DOI 10.1096/fj.05-3812com; Weisova P, 2012, BBA-BIOENERGETICS, V1817, P744, DOI 10.1016/j.bbabio.2012.01.016; Wu YN, 2011, BRAIN RES, V1395, P86, DOI 10.1016/j.brainres.2011.04.032; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yaffe K, 2014, ALZHEIMERS DEMENT, V10, pS111, DOI 10.1016/j.jalz.2014.04.010; Yang JL, 2014, NEUROMOL MED, V16, P161, DOI 10.1007/s12017-013-8270-x; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2; Yuede CM, 2009, NEUROBIOL DIS, V35, P426, DOI 10.1016/j.nbd.2009.06.002; Zigmond Michael J, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS123, DOI 10.1016/S1353-8020(13)70030-0	101	43	45	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	MAY	2017	13	5					582	591		10.1016/j.jalz.2016.08.001			10	Clinical Neurology	Neurosciences & Neurology	ET8MV	WOS:000400554400009	27599210	Green Accepted			2021-06-18	
J	Edwards, G; Moreno-Gonzalez, I; Soto, C				Edwards, George, III; Moreno-Gonzalez, Ines; Soto, Claudio			Amyloid-beta and tau pathology following repetitive mild traumatic brain injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Repetitive mild traumatic brain injury; Alzheimer's disease; Chronic traumatic encephalopathy; Amyloid-beta; Neurofibrillary tangles; Protein misfolding	HEAD-INJURY; MOUSE MODEL; NEUROBEHAVIORAL CHANGES; PROTEIN DEPOSITION; ANIMAL-MODELS; NEURODEGENERATION; DISEASE; NEUROINFLAMMATION; ACCUMULATION; IMPAIRMENT	Neurodegenerative diseases are characterized by distinctive neuropathological alterations, including the cerebral accumulation of misfolded protein aggregates, neuroinflammation, synaptic dysfunction, and neuronal loss, along with behavioral impairments. Traumatic brain injury (TBI) is believed to be an important risk factor for certain neurodegenerative diseases, such as Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE). TBI represents a ubiquitous problem in the world and could play a major role in the pathogenesis and etiology of AD or CTE later in life. TBI events appear to trigger and exacerbate some of the pathological processes in these diseases, in particular, the formation and accumulation of misfolded protein aggregates composed of amyloid-beta (A(3) and tau. Here, we describe the relationship between repetitive mild TBI and the development of A beta and tau pathology in patients affected by AD or CTE on the basis of epidemiological and pathological studies in human cases, and a thorough overview of data obtained in experimental animal models. We also discuss the possibility that TBI may contribute to initiate the formation of misfolded oligomeric species that may subsequently spread the pathology through a prion-like process of seeding of protein misfolding. (C) 2016 Elsevier Inc. All rights reserved.	[Edwards, George, III; Moreno-Gonzalez, Ines; Soto, Claudio] Univ Texas Houston, Sch Med, Mitchell Ctr Alzheimers Dis & Related Brain Disor, Dept Neurol, Houston, TX 77004 USA	Soto, C (corresponding author), Univ Texas Houston, Sch Med, Mitchell Ctr Alzheimers Dis & Related Brain Disor, Dept Neurol, Houston, TX 77004 USA.	Claudio.Soto@uth.tmc.edu	Moreno-Gonzalez, Ines/AAA-2222-2019; Moreno-Gonzalez, Ines/AAO-1694-2021	Moreno-Gonzalez, Ines/0000-0003-3875-0889; Edwards III, George/0000-0001-8795-5851	UT Brain Initiative [364831]	We would like to thank Dr Charles Mays for critically reading this article and offering valuable suggestions. This work was funded in part by a pilot grant for the UT Brain Initiative (grant 364831) to C.S.	Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham DI, 1996, ACT NEUR S, V66, P96; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kelly J., 1997, MMWR-MORBID MORTAL W, V46, P224; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lehman EJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt188; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morales R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003537; Moreno-Gonzalez I, 2011, SEMIN CELL DEV BIOL, V22, P482, DOI 10.1016/j.semcdb.2011.04.002; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Prusiner SB, 2012, SCIENCE, V336, P1511, DOI 10.1126/science.1222951; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; RISLING M, 2012, FRONT NEUROL, V3, P1; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Soto C, 2006, TRENDS BIOCHEM SCI, V31, P150, DOI 10.1016/j.tibs.2006.01.002; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Soto C, 2012, CELL, V149, P968, DOI 10.1016/j.cell.2012.05.007; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134	60	43	43	2	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	FEB 19	2017	483	4			SI		1137	1142		10.1016/j.bbrc.2016.07.123			6	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	EP6IK	WOS:000397481700019	27492070				2021-06-18	
J	Zemek, RL; Grool, AM; Duque, DR; DeMatteo, C; Rothman, L; Benchimol, EI; Guttmann, A; Macpherson, AK				Zemek, Roger L.; Grool, Anne M.; Duque, Daniel Rodriguez; DeMatteo, Carol; Rothman, Linda; Benchimol, Eric I.; Guttmann, Astrid; Macpherson, Alison K.			Annual and Seasonal Trends in Ambulatory Visits for Pediatric Concussion in Ontario between 2003 and 2013	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURIES; EMERGENCY-DEPARTMENTS; SPORTS; CHILDREN; EPIDEMIOLOGY; STATEMENT; SYMPTOMS; SCHOOL; RISK; HEAD	Objective To investigate annual and seasonal trends in physician office and emergency department (ED) visit rates for pediatric concussion in Ontario between 2003 and 2013. Study design A retrospective, population-based study was conducted using linked health administrative data from all concussion-related visits to ED and physician office by children aged 5 through 18 years. Time series analysis was used to assess whether periodic components exist in the monthly number of concussion-related visits. Results Over the 11-year study period, there were 176 685 pediatric visits for concussion in EDs and physician offices in Ontario. Standardized concussion-related visits showed a 4.4-fold (95% CI 4.37-4.45) increase per 100 000 from 2003 to 2013, with nearly 35 000 total visits in 2013. Concussion-related visits demonstrated a steep increase from 2010 onward. The greatest increases in standardized visits were in females (6.3-fold, 95% CI 6.236.46 vs 3.6-fold, 95% CI 3.56-3.64 in males) and 13-18.99 year olds (5.0-fold, 95% CI 4.93-5.08 vs 4.1- fold, 95% CI 3.99-4.27 in 9-12 years and 2.3-fold, 95% CI 2.23-2.42 in 5-8 years). A strong seasonal variability (R(2)autoreg = 0.87, P < .01) in the number of concussion-related visits was present, with most occurring in fall and winter. Conclusions Pediatric concussion-related ED and physician office visit rates have greatly increased in the last decade, particularly since 2010. Prevention strategies may be targeted at those most at risk and at seasonalrelated activities carrying the greatest risk of concussion.	[Zemek, Roger L.] Univ Ottawa, Dept Pediat, Div Pediat Emergency Med, Ottawa, ON, Canada; [Zemek, Roger L.; Grool, Anne M.; Benchimol, Eric I.] Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada; [Duque, Daniel Rodriguez; Benchimol, Eric I.; Guttmann, Astrid; Macpherson, Alison K.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [DeMatteo, Carol] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [Rothman, Linda; Macpherson, Alison K.] York Univ, Fac Hlth, Sch Kinesiol & Hlth Sci, Toronto, ON, Canada; [Benchimol, Eric I.] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Ottawa, ON, Canada; [Guttmann, Astrid] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON, Canada	Zemek, RL (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	rzemek@cheo.on.ca	Benchimol, Eric/A-7711-2010; Zemek, Roger/H-1039-2018	Benchimol, Eric/0000-0001-8855-3598; 	CIHRCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Benchimol EI, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001885, 10.1016/j.zefq.2016.07.010]; BEST DJ, 1974, ROY STAT SOC C-APP, V23, P98; Carroll L J, 2011, CONCUSSION CRISIS AN; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Fralick M, 2016, CAN MED ASSOC J, V188, P497, DOI 10.1503/cmaj.150790; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lowrey KM, 2014, J LAW MED ETHICS, V42, P290, DOI 10.1111/jlme.12146; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod A. I., 2011, KENDALL KENDALL RANK; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Moineddin R., 2003, POPUL HEALTH METR, V1, P10, DOI [10.1186/1478-7954-1-10, DOI 10.1186/1478-7954-1-10]; Morrissey D, 2014, J TRAUMA ACUTE CARE, V77, pS8, DOI 10.1097/TA.0000000000000331; Murray IR, 2015, CLIN J SPORT MED, V25, P75, DOI 10.1097/JSM.0000000000000134; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Osborn D.R., 2001, ECONOMETRIC ANAL SEA; Taylor AM, 2015, J PEDIATR-US, V167, P738, DOI 10.1016/j.jpeds.2015.05.036; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zemek R., 2014, GUIDELINES DIAGNOSIN; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	30	43	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	2017	181						222	+		10.1016/j.jpeds.2016.10.067			9	Pediatrics	Pediatrics	EN8KL	WOS:000396249200035	27843008				2021-06-18	
J	Erdodi, LA; Jongsma, KA; Issa, M				Erdodi, Laszlo A.; Jongsma, Katherine A.; Issa, Meriam			The 15-item version of the Boston Naming Test as an index of English proficiency	CLINICAL NEUROPSYCHOLOGIST			English	Article						Boston Naming Test; limited English proficiency; neuropsychological testing; bilingualism; cross-cultural competence	TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; LANGUAGE; BILINGUALS; VALIDITY; ACCULTURATION; INDIVIDUALS; RECOGNITION; NORMS	Objective: The present study was designed to examine the potential of the Boston Naming Test - Short Form (BNT-15) to provide an objective estimate of English proficiency. A secondary goal was to examine the effect of limited English proficiency (LEP) on neuropsychological test performance. Method: A brief battery of neuropsychological tests was administered to 79 bilingual participants (40.5% male, M-Age=26.9, M-Education=14.2). The majority (n=56) were English dominant (EN), and the rest were Arabic dominant (AR). The BNT-15 was further reduced to 10 items that best discriminated between EN and AR (BNT-10). Participants were divided into low, intermediate, and high English proficiency subsamples based on BNT-10 scores (6, 7-8, and 9). Performance across groups was compared on neuropsychological tests with high and low verbal mediation. Results: The BNT-15 and BNT-10 respectively correctly identified 89 and 90% of EN and AR participants. Level of English proficiency had a large effect (partial (2)=.12-.34; Cohen's d=.67-1.59) on tests with high verbal mediation (animal fluency, sentence comprehension, word reading), but no effect on tests with low verbal mediation (auditory consonant trigrams, clock drawing, digit-symbol substitution). Conclusions: The BNT-15 and BNT-10 can function as indices of English proficiency and predict the deleterious effect of LEP on neuropsychological tests with high verbal mediation. Interpreting low scores on such measures as evidence of impairment in examinees with LEP would likely overestimate deficits.	[Erdodi, Laszlo A.; Jongsma, Katherine A.; Issa, Meriam] Univ Windsor, Dept Psychol, Windsor, ON, Canada	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, Windsor, ON, Canada.	lerdodi@gmail.com			Faculty of Arts, Humanities and Social Sciences at the University of Windsor	This research was supported by the Dean of the Faculty of Arts, Humanities and Social Sciences at the University of Windsor.	Akamatsu N, 1999, READ WRIT, V11, P381, DOI 10.1023/A:1008053520326; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P355, DOI 10.1016/j.acn.2007.01.010; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Erdodi L, 2012, HUMOR, V25, P459, DOI 10.1515/humor-2012-0024; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P828, DOI 10.1076/jcen.20.6.828.1105; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Gollan TH, 2007, J INT NEUROPSYCH SOC, V13, P197, DOI 10.1017/S1355617707070038; Gollan TH, 2012, BILING-LANG COGN, V15, P594, DOI 10.1017/S1366728911000332; Gollan TH, 2002, NEUROPSYCHOLOGY, V16, P562, DOI 10.1037//0894-4105.16.4.562; Harris J. G., 2003, CLIN INTERPRETATION, P343, DOI DOI 10.1016/B978-012703570-3/50015-8; Heaton R.K., 2009, NEUROPSYCHOLOGICAL A, P127; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kaplan E., 2001, Boston naming test; Li P, 2006, BEHAV RES METHODS, V38, P202, DOI 10.3758/BF03192770; MACK WJ, 1992, J GERONTOL, V47, pP154, DOI 10.1093/geronj/47.3.P154; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mindt MR, 2008, NEUROPSYCHOL REV, V18, P255, DOI 10.1007/s11065-008-9069-7; Pearson NCS., 2009, ADV CLIN SOLUTIONS W; Ponton M. O, 2001, NEUROPSYCHOLOGY HISP, P39; Razani J, 2007, CLIN NEUROPSYCHOL, V21, P776, DOI 10.1080/13854040701437481; Razani J, 2007, ARCH CLIN NEUROPSYCH, V22, P333, DOI 10.1016/j.acn.2007.01.008; Rey A, 1964, EXAMEN CLIN PSYCHOL; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Roberts P.M., 2002, APHASIOLOGY, V16, P635, DOI [10.1080/02687030244000220, DOI 10.1080/02687030244000220]; Robles L, 2015, J CLIN EXP NEUROPSYC, V37, P614, DOI 10.1080/13803395.2015.1039961; ROULEAU I, 1992, BRAIN COGNITION, V18, P70, DOI 10.1016/0278-2626(92)90112-Y; Salazar X. F., 2007, ASSESSMENT FEIGNED C, P405; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Shin H. B, 2011, FED FOR C WASH DC; Sotelo-Dynega M, 2013, PSYCHOL SCHOOLS, V50, P781, DOI 10.1002/pits.21706; Statistics Canada, 2011, 2011 CEN HDB; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; U.S. Census Bureau, 2013, 2009 2013 AM COMM SU; Walker AJ, 2010, AUST PSYCHOL, V45, P112, DOI 10.1080/00050060903428210; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde MC, 2006, CLIN NEUROPSYCHOL, V20, P702, DOI 10.1080/13854040500246901; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th	44	43	43	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					168	178		10.1080/13854046.2016.1224392			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300010	27556291				2021-06-18	
J	Grabowski, P; Wilson, J; Walker, A; Enz, D; Wang, SJ				Grabowski, Patrick; Wilson, John; Walker, Alyssa; Enz, Dan; Wang, Sijian			Multimodal impairment-based physical therapy for the treatment of patients with post-concussion syndrome: A retrospective analysis on safety and feasibility	PHYSICAL THERAPY IN SPORT			English	Article						Concussion; Mild traumatic brain injury; Physical therapy; Cardiovascular exercise	SPORT-RELATED CONCUSSION; PREDICT PROTRACTED RECOVERY; TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; EXERCISE; REHABILITATION; SYMPTOMS; EPIDEMIOLOGY; METABOLISM; INACTIVITY	Objective: Demonstrate implementation, safety and feasibility of multimodal, impairment-based physical therapy (PT) combining vestibular/oculomotor and cervical rehabilitation with sub-symptom threshold exercise for the treatment of patients with post-concussion syndrome (PCS). Setting: University hospital outpatient sports medicine facility. Participants: Twenty-five patients (12-20 years old) meeting World Health Organization criteria for PCS following sport-related concussion referred for supervised PT consisting of sub-symptom cardiovascular exercise, vestibular/oculomotor and cervical spine rehabilitation. Design: Retrospective cohort. Main measures: Post-Concussion Symptom Scale (PCSS) total score, maximum symptom-free heart rate (SFHR) during graded exercise testing (GXT), GXT duration, balance error scoring system (BESS) score, and number of adverse events. Results: Patients demonstrated a statistically significant decreasing trend (p < 0.01) for total PCSS scores (pre-PT M = 18.2 (SD = 14.2), post -PT M = 9.1 (SD = 10.8), n = 25). Maximum SFHR achieved on GXT increased 23% (p < 0.01, n = 14), and BESS errors decreased 52% (p<0.01, n = 13). Two patients reported mild symptom exacerbation with aerobic exercise at home, attenuated by adjustment of the home exercise program. Conclusions: Multimodal, impairment-based PT is safe and associated with diminishing PCS symptoms. This establishes feasibility for future clinical trials to determine viable treatment approaches to reduce symptoms and improve function while avoiding negative repercussions of physical inactivity and premature return to full activity. (C) 2016 Elsevier Ltd. All rights reserved.	[Grabowski, Patrick; Enz, Dan] Univ Wisconsin Hosp & Clin, 621 Sci Dr, Madison, WI 53711 USA; [Grabowski, Patrick] Univ Wisconsin, Phys Therapy Program, 1725 State St, La Crosse, WI 54601 USA; [Wilson, John; Walker, Alyssa] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA; [Wang, Sijian] Univ Wisconsin, Dept Biostat, 600 Highland Ave, Madison, WI 53705 USA	Grabowski, P (corresponding author), Univ Wisconsin, Phys Therapy Program, 1725 State St, La Crosse, WI 54601 USA.	pgrabowski@uwlax.edu			Herman and Gwendolyn Shapiro Foundation	Author AW was supported by a research grant from the Herman and Gwendolyn Shapiro Foundation. The foundation had no role in the study.	Alosco ML, 2012, HEALTH PSYCHOL, V31, P754, DOI 10.1037/a0028711; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ariza-Garcia A, 2013, EUR J CANCER CARE, V22, P738, DOI 10.1111/ecc.12101; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bogdanis GC, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00142; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Browne GJ, 2006, BRIT J SPORT MED, V40, P68, DOI 10.1136/bjsm.2005.020636; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Childs JD, 2008, J ORTHOP SPORT PHYS, V38, pA1, DOI 10.2519/jospt.2008.0303; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Davies R, 2005, BRAIN INJURY, V19, P941, DOI 10.1080/02699050400000565; Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McDonnell MN, 2013, J APPL PHYSIOL, V114, P1174, DOI 10.1152/japplphysiol.01378.2012; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Nishijima T, 2013, BEHAV BRAIN RES, V245, P34, DOI 10.1016/j.bbr.2013.02.009; Page P, 2011, INT J SPORTS PHYS TH, V6, P254; Reddy CC, 2011, PM&R, V3, pS396, DOI 10.1016/j.pmrj.2011.07.012; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Rose SC, 2015, BRAIN INJURY, V29, P798, DOI 10.3109/02699052.2015.1004756; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Seifert T, 2011, PROG NEUROBIOL, V95, P406, DOI 10.1016/j.pneurobio.2011.09.008; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Zhang PY, 2013, INT J MOL SCI, V14, P6074, DOI 10.3390/ijms14036074	59	43	43	0	26	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1466-853X			PHYS THER SPORT	Phys. Ther. Sport	JAN	2017	23						22	30		10.1016/j.ptsp.2016.06.001			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EJ5ML	WOS:000393262200004	27665247				2021-06-18	
J	Cordingley, D; Girardin, R; Reimer, K; Ritchie, L; Leiter, J; Russell, K; Ellis, MJ				Cordingley, Dean; Girardin, Richard; Reimer, Karen; Ritchie, Lesley; Leiter, Jeff; Russell, Kelly; Ellis, Michael J.			Graded aerobic treadmill testing in pediatric sports-related concussion: safety, clinical use, and patient outcomes	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; trauma; post-concussion syndrome; physiological post-concussion disorder; pediatric; graded aerobic treadmill testing; multidisciplinary	CEREBRAL-BLOOD-FLOW; POSTCONCUSSION SYNDROME; ACTIVE REHABILITATION; EXERCISE; ADOLESCENTS; CHILDREN; RECOVERY; HEAD; RELIABILITY; MANAGEMENT	OBJECTIVE The objectives of this study were 2-fold: 1) to evaluate the safety, tolerability, and clinical use of graded aerobic treadmill testing in pediatric patients with sports-related concussion (SRC), and 2) to evaluate the clinical outcomes of treatment with a submaximal aerobic exercise program in patients with physiological post-concussion disorder (PCD). METHODS The authors conducted a retrospective chart review of pediatric patients (age < 20 years) with SRC who were referred to a multidisciplinary pediatric concussion program and underwent graded aerobic treadmill testing between October 9, 2014, and February 11, 2016. Clinical assessments were carried out by a single neurosurgeon and included clinical history taking, physical examination, and recording specific patient-reported concussion-related symptoms using the Post-Concussion Symptom Scale (PCSS). Graded aerobic treadmill testing using a modified Balke protocol for incremental increases in intensity was used as a diagnostic tool to assess physiological recovery, classify post-concussion syndrome (PCS) subtype, and reassess patients following treatment. Patients with a symptom-limited threshold on treadmill testing (physiological PCD) were treated with an individually tailored submaximal exercise prescription and multidisciplinary targeted therapies. RESULTS One hundred six patients (mean age 15.1 years, range 11-19 years) with SRC underwent a total of 141 treadmill tests. There were no serious complications related to treadmill testing in this study. Overall, 138 (97.9%) of 141 tests were well tolerated and contributed valuable clinical information. Treadmill testing confirmed physiological recovery in 63 (96.9%) of 65 patients tested, allowing successful return to play in 61 (93.8%). Treadmill testing was used to diagnose physiological PCD in 58 patients and cervicogenic PCD in 1 patient. Of the 41 patients with physiological PCD who had complete follow-up and were treated with tailored submaximal exercise prescription, 37 (90.2%) were classified as clinically improved and 33 (80.5%) successfully returned to sporting activities. Patients who did not respond or experienced an incomplete response to submaximal aerobic exercise treatment included 7 patients with migraine headaches and 1 patient with a postinjury psychiatric disorder. CONCLUSIONS Graded aerobic treadmill testing is a safe, tolerable, and clinically valuable tool that can assist in the evaluation and management of pediatric SRC. Future research is needed to confirm the clinical value of this tool in return-to-play decision making. Studies are also needed to understand the pathophysiology of physiological PCD and the effects of targeted treatment.	[Cordingley, Dean; Girardin, Richard; Reimer, Karen; Ritchie, Lesley; Leiter, Jeff; Ellis, Michael J.] Univ Manitoba, Pan Am Concuss Program, Coll Rehabil Sci, Winnipeg, MB, Canada; [Cordingley, Dean; Girardin, Richard; Reimer, Karen; Ritchie, Lesley; Leiter, Jeff; Russell, Kelly; Ellis, Michael J.] Univ Manitoba, Canada North Concuss Network, Coll Rehabil Sci, Winnipeg, MB, Canada; [Ritchie, Lesley] Univ Manitoba, Dept Clin Hlth Psychol, Coll Rehabil Sci, Winnipeg, MB, Canada; [Leiter, Jeff; Ellis, Michael J.] Univ Manitoba, Dept Surg, Coll Rehabil Sci, Winnipeg, MB, Canada; [Russell, Kelly; Ellis, Michael J.] Univ Manitoba, Dept Pediat & Child Hlth, Coll Rehabil Sci, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Coll Rehabil Sci, Winnipeg, MB, Canada; [Reimer, Karen] Univ Manitoba, Sect Phys Therapy, Coll Rehabil Sci, Winnipeg, MB, Canada; [Russell, Kelly; Ellis, Michael J.] Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada	Ellis, MJ (corresponding author), Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com		Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation; Winnipeg Jets True North Foundation	All phases of this study were supported by a grant from the Pan Am Clinic Foundation, Winnipeg Jets True North Foundation, and a generous donation by Leonard and Susan Asper.	Alsalaheen B, 2016, J HEAD TRAUMA REHAB, V31, P242, DOI 10.1097/HTR.0000000000000175; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15600; Ellis MJ, 2016, CURR SPORT MED REP, V15, P27, DOI 10.1249/JSR.0000000000000223; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; ELLIS MJ, 2014, CURR RES CONCUSSION, V1, P33; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	40	43	43	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2016	18	6					693	702		10.3171/2016.5.PEDS16139			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	ED3YA	WOS:000388783200008	27620871	Bronze			2021-06-18	
J	Gabler, LF; Crandall, JR; Panzer, MB				Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.			Assessment of Kinematic Brain Injury Metrics for Predicting Strain Responses in Diverse Automotive Impact Conditions	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Brain injury criteria; Head kinematics; Translational; Rotational; Finite element modeling	DIFFUSE AXONAL INJURY; HEAD; CONCUSSION; MODEL; SIMON	Numerous injury criteria have been developed to predict brain injury using the kinematic response of the head during impact. Each criterion utilizes a metric that is some mathematical combination of the velocity and/or acceleration components of translational and/or rotational head motion. Early metrics were based on linear acceleration of the head, but recent injury criteria have shifted towards rotational-based metrics. Currently, there is no universally accepted metric that is suitable for a diverse range of head impacts. In this study, we assessed the capability of fifteen existing kinematic-based metrics for predicting strain-based brain response using four different automotive impact conditions. Tissue-level strains were obtained through finite element model simulation of 660 head impacts including occupant and pedestrian crash tests, and pendulum head impacts. Correlations between head kinematic metrics and predicted brain strain-based metrics were evaluated. Correlations between brain strain and metrics based on angular velocity were highest among those evaluated, while metrics based on linear acceleration were least correlative. BrIC and RVCI were the kinematic metrics with the highest overall correlation; however, each metric had limitations in certain impact conditions. The results of this study suggest that rotational head kinematics are the most important parameters for brain injury criteria.	[Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.] Univ Virginia, Dept Mech & Aerosp Engn, Ctr Appl Biomechan, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA	Panzer, MB (corresponding author), Univ Virginia, Dept Mech & Aerosp Engn, Ctr Appl Biomechan, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	mbp2q@virginia.edu			Partnership for Dummy Technology and Biomechanics (PDB)	The authors thank the Partnership for Dummy Technology and Biomechanics (PDB) for support and funding for this research. We also thank Dr. Erik Takhounts, Vikas Hasija, and Daniel Parent of NHTSA, and David Zuby, Becky Mueller, and Anna MacAlister of IIHS for their help in obtaining head kinematic data from the NHTSA and IIHS databases, respectively.	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F, 2001, P INT TECHN C ENH SA, P7; BANDAK FA, 1995, J NEUROTRAUM, V12, P635, DOI 10.1089/neu.1995.12.635; Crandall J., 2013, INJURY CRITERIA DEV; Crandall J., 2014, ATD THORACIC RESPONS; Forman Jason L, 2013, Stapp Car Crash J, V57, P343; Gadd C.W., 1966, SAE TECHNICAL PAPER; Gennarelli T, 1971, P 15 STAPP CAR CRASH; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1979, P 23 STAPP CAR CRASH, P563; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kerrigan J, 2012, INT J CRASHWORTHINES, V17, P243, DOI 10.1080/13588265.2011.648517; Kerrigan JR, 2008, STAPP CAR C, V52, P527; Kimpara H., 2011, INT J AUTOMOT ENG, V2, P13; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laituri T. R., 2015, SAE TECHNICAL PAPER; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mueller B., 2015, P 24 INT TECHN C ENH; National Operating Committee on the Standards for Athletic Equipment (NOCSAE), 2012, STAND TEST METH EQ U; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman J.A, 1986, P 1986 INT IRCOBI C; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, DTIC DOCUMENT; Ono K, 1980, SAE TECHNICAL PAPER; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Panzer MB, 2016, INT J AUTOMOT ENG, V7, P37, DOI 10.20485/jsaeijae.7.1_37; Patrick L. M., 1963, P AM ASS AUT MED ANN, V7; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; SAE, 1995, TECHNICAL REPORT; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Subit D., 2008, P INT RES COUNC BIOM; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts E. G., 2011, P 22 ENH SAF VEH C; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L. E., 1990, INT IRCOBI C BIOM IM; Versace J, 1971, REV SEVERITY INDEX; Yanaoka T., 2015, SAE TECHNICAL PAPER; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	52	43	43	1	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2016	44	12					3705	3718		10.1007/s10439-016-1697-0			14	Engineering, Biomedical	Engineering	EC4MB	WOS:000388103900022	27436295				2021-06-18	
J	Byrne, JP; Mason, SA; Gomez, D; Hoeft, C; Subacius, H; Xiong, W; Neal, M; Pirouzmand, F; Nathens, AB				Byrne, James P.; Mason, Stephanie A.; Gomez, David; Hoeft, Christopher; Subacius, Haris; Xiong, Wei; Neal, Melanie; Pirouzmand, Farhad; Nathens, Avery B.			Timing of Pharmacologic Venous Thromboembolism Prophylaxis in Severe Traumatic Brain Injury: A Propensity-Matched Cohort Study	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; INTRACRANIAL HEMORRHAGE; AMERICAN-COLLEGE; HEAD TRAUMA; CHEMOPROPHYLAXIS; ANTICOAGULATION; PROGRESSION; PREDICTORS; PREVENTION	BACKGROUND: Patients with severe traumatic brain injury (sTBI) are at high risk for developing venous thromboembolism (VTE). Nonetheless, pharmacologic VTE prophylaxis is often delayed out of concern for precipitating extension of intracranial hemorrhage (ICH). The purpose of this study was to compare the effectiveness of early vs late VTE prophylaxis in patients with sTBI, and to characterize the risk of subsequent ICH-related complication. STUDY DESIGN: Adults with isolated sTBI (head Abbreviated Injury Scale score >= 3 and total Glasgow Coma Scale score <= 8) who received VTE prophylaxis with low-molecular-weight or unfractionated heparin were derived from the American College of Surgeons Trauma Quality Improvement Program (2012 to 2014). Patients were divided into EP (<72 hours) or LP (>= 72 hours) groups. Propensity score matching was used to minimize selection bias. The primary end point was VTE (pulmonary embolism or deep vein thrombosis). Secondary outcomes were defined as late neurosurgical intervention (>= 72 hours) or death. RESULTS: We identified 3,634 patients with sTBI. Early prophylaxis was given in 43% of patients. Higher head injury severity, presence of ICH, and early neurosurgery were associated with late prophylaxis. Propensity score matching yielded a well-balanced cohort of 2,468 patients. Early prophylaxis was associated with lower rates of both pulmonary embolism (odds ratio = 0.48; 95% CI, 0.25-0.91) and deep vein thrombosis (odds ratio = 0.51; 95% CI, 0.36-0.72), but no increase in risk of late neurosurgical intervention or death. CONCLUSIONS: In this observational study of patients with sTBI, early initiation of VTE prophylaxis was associated with decreased risk of pulmonary embolism and deep vein thrombosis, but no increase in risk of late neurosurgical intervention or death. Early prophylaxis may be safe and should be the goal for each patient in the context of appropriate risk stratification. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.)	[Byrne, James P.; Mason, Stephanie A.; Xiong, Wei; Pirouzmand, Farhad; Nathens, Avery B.] Univ Toronto, Sunnybrook Res Inst, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Byrne, James P.; Mason, Stephanie A.; Nathens, Avery B.] Univ Toronto, Clin Epidemiol Program, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Byrne, James P.; Mason, Stephanie A.; Gomez, David; Nathens, Avery B.] Univ Toronto, Div Gen Surg, Toronto, ON, Canada; [Pirouzmand, Farhad; Nathens, Avery B.] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Hoeft, Christopher; Subacius, Haris; Xiong, Wei; Neal, Melanie; Nathens, Avery B.] Amer Coll Surg, Trauma Qual Improvement Program, Chicago, IL USA	Byrne, JP (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, 2075 Bayview Ave,Room D-574, Toronto, ON M4N 3M5, Canada.	jpbyrne@gmail.com		Byrne, James/0000-0002-3760-8509; Gomez, David/0000-0002-0926-2547	De Souza Chair in Trauma Research	Dr Nathens is supported by funds from the De Souza Chair in Trauma Research.	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; American College of Surgeons, TRAUM QUAL IMPR PROG; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Barrera LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008303.pub2; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Chelladurai Yohalakshmi, 2013, F1000Res, V2, P132, DOI 10.12688/f1000research.2-132.v1; Depew AJ, 2008, AM SURGEON, V74, P906; Dietch ZC, 2015, SURGERY, V158, P379, DOI 10.1016/j.surg.2015.03.052; Farooqui A, 2013, J NEUROSURG, V119, P1576, DOI 10.3171/2013.8.JNS13424; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Haut ER, 2011, J TRAUMA, V70, P27, DOI 10.1097/TA.0b013e3182077d55; Haut ER, 2009, J TRAUMA, V66, P994, DOI 10.1097/TA.0b013e3181991adc; Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6; Hubbard AE, 2010, EPIDEMIOLOGY, V21, P467, DOI 10.1097/EDE.0b013e3181caeb90; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Li SJ, 2016, J TRAUMA ACUTE CARE, V80, P381, DOI 10.1097/TA.0000000000000935; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nickele CM, 2013, NEUROCRIT CARE, V18, P184, DOI 10.1007/s12028-012-9786-x; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, P1434, DOI 10.1097/TA.0b013e31825ac49e; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Rogers SO, 2007, J TRAUMA, V62, P562; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rubin DB, 2010, AM J OPHTHALMOL, V149, P7, DOI 10.1016/j.ajo.2009.08.024; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saadeh Y, 2012, J TRAUMA ACUTE CARE, V73, P426, DOI 10.1097/TA.0b013e31825a758b; Scales DC, 2010, CRIT CARE, V14, DOI 10.1186/cc8980; Shackford SR, 2004, ANN SURG, V240, P496; Shafi S, 2009, J AM COLL SURGEONS, V209, P521, DOI 10.1016/j.jamcollsurg.2009.07.001; Singh S, 2013, 13EHC0821 AG HEALTHC; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004	41	43	44	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2016	223	4					621	+		10.1016/j.jamcollsurg.2016.06.382			16	Surgery	Surgery	DX9FC	WOS:000384698000012	27453296				2021-06-18	
J	Wu, HJ; Shao, AW; Zhao, MF; Chen, S; Yu, J; Zhou, JY; Liang, F; Shi, LG; Dixon, BJ; Wang, Z; Ling, CH; Hong, Y; Zhang, JM				Wu, Haijian; Shao, Anwen; Zhao, Mingfei; Chen, Sheng; Yu, Jun; Zhou, Jingyi; Liang, Feng; Shi, Ligen; Dixon, Brandon J.; Wang, Zhen; Ling, Chenhan; Hong, Yuan; Zhang, Jianmin			Melatonin attenuates neuronal apoptosis through up-regulation of K+-Cl- cotransporter KCC2 expression following traumatic brain injury in rats	JOURNAL OF PINEAL RESEARCH			English	Article						K+-Cl- cotransporter-2; melatonin; neuronal apoptosis; neuroprotection; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; CATION-CHLORIDE COTRANSPORTERS; OXIDATIVE STRESS; POSSIBLE INVOLVEMENT; NEUROPATHIC PAIN; DOWN-REGULATION; BDNF; PATHWAY; TRANSCRIPTION	Traumatic brain injury (TBI) initiates a complex cascade of neurochemical and signaling changes that leads to neuronal apoptosis, which contributes to poor outcomes for patients with TBI. The neuron-specific K+-Cl- cotransporter-2 (KCC2), the principal Cl- extruder in adult neurons, plays an important role in Cl- homeostasis and neuronal function. This present study was designed to investigate the expression pattern of KCC2 following TBI and to evaluate whether or not melatonin is able to prevent neuronal apoptosis by modulating KCC2 expression in a Sprague Dawley rat controlled cortical impact model of TBI. The time course study showed decreased mRNA and protein expression of KCC2 in the ipsilateral peri-core parietal cortex after TBI. Double immunofluorescence staining demonstrated that KCC2 is located in the plasma membrane of neurons. In addition, melatonin (10mg/kg) was injected intraperitoneally at 5minutes and repeated at 1, 2, 3, and 4hours after brain trauma, and brain samples were extracted 24hours after TBI. Compared to the vehicle group, melatonin treatment altered the down-regulation of KCC2 expression in both mRNA and protein levels after TBI. Also, melatonin treatment increased the protein levels of brain-derived neurotrophic factor (BDNF) and phosphorylated extracellular signal-regulated kinase (p-ERK). Simultaneously, melatonin administration ameliorated cortical neuronal apoptosis, reduced brain edema, and attenuated neurological deficits after TBI. In conclusion, our findings suggested that melatonin restores KCC2 expression, inhibits neuronal apoptosis and attenuates secondary brain injury after TBI, partially through activation of BDNF/ERK pathway.	[Wu, Haijian; Shao, Anwen; Zhao, Mingfei; Chen, Sheng; Yu, Jun; Zhou, Jingyi; Liang, Feng; Shi, Ligen; Wang, Zhen; Ling, Chenhan; Hong, Yuan; Zhang, Jianmin] Zhejiang Univ, Dept Neurosurg, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Wu, Haijian] Zhejiang Univ, Dept Neurosurg, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Dixon, Brandon J.] Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA USA; [Zhang, Jianmin] Zhejiang Univ, Brain Res Inst, Hangzhou, Zhejiang, Peoples R China; [Zhang, Jianmin] Zhejiang Univ, Collaborat Innovat Ctr Brain Sci, Hangzhou, Zhejiang, Peoples R China	Hong, Y; Zhang, JM (corresponding author), Zhejiang Univ, Dept Neurosurg, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China.	hy0904@live.cn; zjm135@vip.sina.com	Shao, Anwen/L-4860-2019; 邵, 安文/R-9023-2019	Shao, Anwen/0000-0001-5616-0394; Shao, Anwen/0000-0001-9986-6290	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371433, 81371369]; Research Fund for the Doctoral Program of Higher Education of ChinaResearch Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20120101120030]; Zhejiang Provincial Medical Science and Technology Planning Project [2012RCA030, 2013KYA088]; Zhejiang Provincial Education Planning Project [Y201226287]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [Y13H090007, LY13H090002]	This work was supported by National Natural Science Foundation of China (grant 81371433 and 81371369), Research Fund for the Doctoral Program of Higher Education of China (20120101120030), Zhejiang Provincial Medical Science and Technology Planning Project (2012RCA030 and 2013KYA088), Zhejiang Provincial Education Planning Project (Y201226287) and Zhejiang Provincial Natural Science Foundation of China (Y13H090007, and LY13H090002).	Aguado F, 2003, DEVELOPMENT, V130, P1267, DOI 10.1242/dev.00351; Ali T, 2015, J PINEAL RES, V58, P71, DOI 10.1111/jpi.12194; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chen JY, 2014, J PINEAL RES, V57, P340, DOI 10.1111/jpi.12173; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dong YS, 2016, J PINEAL RES, V60, P253, DOI 10.1111/jpi.12300; Gagnon M, 2013, NAT MED, V19, P1524, DOI 10.1038/nm.3356; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Jaenisch N, 2010, STROKE, V41, pE151, DOI 10.1161/STROKEAHA.109.570424; Juan WS, 2014, J PINEAL RES, V56, P213, DOI 10.1111/jpi.12114; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Kahle KT, 2014, JAMA NEUROL, V71, P640, DOI 10.1001/jamaneurol.2014.21; Kaila K, 2014, NAT REV NEUROSCI, V15, P637, DOI 10.1038/nrn3819; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li HY, 2014, J PINEAL RES, V57, P110, DOI 10.1111/jpi.12148; Ludwig A, 2011, J NEUROSCI, V31, P644, DOI 10.1523/JNEUROSCI.2006-10.2011; Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 2002, J CELL BIOL, V159, P747, DOI 10.1083/jcb.200209011; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; Shao AW, 2016, MOL NEUROBIOL, V53, P18, DOI 10.1007/s12035-014-8986-0; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; Tongjaroenbuangam W, 2013, NEUROCHEM INT, V63, P482, DOI 10.1016/j.neuint.2013.08.011; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Uvarov P, 2006, J NEUROSCI, V26, P13463, DOI 10.1523/JNEUROSCI.4731-06.2006; Wang X, 2013, MOL NEUROBIOL, V47, P373, DOI 10.1007/s12035-012-8355-9; Wang Z, 2013, J PINEAL RES, V55, P399, DOI 10.1111/jpi.12087; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woo NS, 2002, HIPPOCAMPUS, V12, P258, DOI 10.1002/hipo.10014; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu C, 2013, BIOCHEM BIOPH RES CO, V437, P469, DOI 10.1016/j.bbrc.2013.06.107; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang Y, 2014, J PINEAL RES, V57, P357, DOI 10.1111/jpi.12175; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3; Zhang L, 2013, BEHAV BRAIN RES, V256, P72, DOI 10.1016/j.bbr.2013.07.051; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254	50	43	44	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2016	61	2					241	250		10.1111/jpi.12344			10	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	DS6OK	WOS:000380901300011	27159133				2021-06-18	
J	Buckley, TA; Munkasy, BA; Clouse, BP				Buckley, Thomas A.; Munkasy, Barry A.; Clouse, Brandy P.			Acute Cognitive and Physical Rest May Not Improve Concussion Recovery Time	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rest; concussion; mild traumatic brain injury; physical rest; recovery	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; ERROR SCORING SYSTEM; HIGH-SCHOOL; NCAA CONCUSSION; HEAD-INJURY; BED REST; SYMPTOMS; PERFORMANCE; MANAGEMENT	Objective: To evaluate the effectiveness of an acute period of cognitive and physical rest on concussion. Participants: Fifty consecutive patients with a diagnosis of concussions. Design: Participants were evaluated before (n = 25) and after (n = 25) a policy change that incorporated cognitive and physical rest. Patients in the rest group were withheld from activities, including classes, for the remainder of the injury day and the following day, whereas patients in the no-rest group were not provided any postinjury accommodations. Main Measures: Patients were evaluated on a graded symptom checklist, Balance Error Scoring System, Standard Assessment of Concussion, and computerized neuropsychological tests. The number of days until each test achieved baseline values was compared between groups with independent-samples t test. Results: The no-rest group achieved asymptomatic status sooner than the rest group (5.2 +/- 2.9 days and 3.9 +/- 1.9 days, respectively; P = .047). There were no differences between groups for time to baseline values on the Balance Error Scoring System, Standard Assessment of Concussion, computerized neuropsychological tests, or time to clinical recovery. Conclusion: A prescribed day of cognitive and physical rest was not effective in reducing postconcussion recovery time. These results agree with a previous study and suggest that light activity postconcussion may not be deleterious to the concussion recovery process.	[Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA; [Munkasy, Barry A.] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA USA; [Clouse, Brandy P.] Georgia Southern Univ, Dept Intercollegiate Athlet, Statesboro, GA USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Human Performance Lab 144, 541 South Coll Ave, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS070744]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	This project was funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (1R15NS070744). The funding agency had no role in the development of the manuscript or the decision to submit to the Journal of Head Trauma Rehabilitation.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ouyang L, 2011, NEURAL REGEN RES, V6, P2617, DOI 10.3969/j.issn.1673-5374.2011.33.010; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Reynolds Erin, 2014, Neurosurgery, V75 Suppl 4, pS71, DOI 10.1227/NEU.0000000000000471; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smorawinski J, 2001, J APPL PHYSIOL, V91, P249; Solomon GS, 2007, J NEUROPSYCH CLIN N, V19, P195, DOI 10.1176/appi.neuropsych.19.2.195; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569	46	43	43	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2016	31	4					233	241		10.1097/HTR.0000000000000165			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FW	WOS:000379789000008	26394292	Green Accepted			2021-06-18	
J	Grubenhoff, JA; Currie, D; Comstock, RD; Juarez-Colunga, E; Bajaj, L; Kirkwood, MW				Grubenhoff, Joseph A.; Currie, Dustin; Comstock, R. Dawn; Juarez-Colunga, Elizabeth; Bajaj, Lalit; Kirkwood, Michael W.			Psychological Factors Associated with Delayed Symptom Resolution in Children with Concussion	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; MILD; RECOVERY; PATHOPHYSIOLOGY; PSYCHOGENESIS; PHYSIOGENESIS; PREDICTORS; RISK; REST	Objective To characterize the psychological factors associated with persistent symptoms after pediatric concussion. Study design Longitudinal cohort study of 179 children with concussion 8-18 years old evaluated in a pediatric emergency department. Participants were followed for 1 month for delayed symptom resolution, defined as >= 3 symptoms that were new/worse than preinjury symptoms measured by the use of graded symptom inventory. Preinjury psychological traits were measured by parental report on subscales of the Personality Inventory for Children-2 (maladjustment, cognitive abilities, somatization). Child report of postinjury anxiety and injury perception were measured with the State-Trait Anxiety Inventory for Children and Children's Illness Perception Questionnaire. Psychological instrument scores were compared between those with and without delayed symptom resolution via a Kruskal-Wallis test. Associations between psychological traits and delayed symptom resolution were investigated by the use of logistic regression. Results Delayed symptom resolution occurred in 21% of participants. Score distributions were significantly worse on the State-Trait Anxiety Inventory for Children (38 [IQR 33-40] vs 35 [IQR 31-39]; P = .04) and somatization sub-scale (1 [IQR 0-3] vs 1 [IQR 0-1]; P = .01) among children with delayed symptom resolution compared with children with early symptom resolution. Somatization was associated with delayed symptom resolution (aOR 1.35, 95% CI 1.08-1.69). The proportion of children with abnormal somatization scores was significantly greater in the delayed symptom resolution group (34.2%) than the early symptom resolution group (12.8%; P < .01). Other psychological measures were not different between groups. Conclusion Somatization is associated with delayed symptom resolution in this cohort of children with concussion. Postconcussive symptoms lasting at least 1 month may warrant referral to a neuropsychologist familiar with postconcussion care.	[Grubenhoff, Joseph A.; Comstock, R. Dawn; Bajaj, Lalit] Univ Colorado, Sch Med, Sect Pediat Emergency Med, Aurora, CO USA; [Grubenhoff, Joseph A.; Bajaj, Lalit; Kirkwood, Michael W.] Univ Colorado, Childrens Hosp Colorado, Aurora, CO USA; [Currie, Dustin; Comstock, R. Dawn; Juarez-Colunga, Elizabeth] Univ Colorado, Sch Med, Colorado Sch Publ Hlth, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA	Grubenhoff, JA (corresponding author), 13123 E 16th Ave,B-251, Aurora, CO 80045 USA.	Joe.grubenhoff@childrenscolorado.org		Grubenhoff, Joseph/0000-0001-5072-4064; Juarez-Colunga, Elizabeth/0000-0002-6369-2353	Thrasher Research Fund Early Career Award; National Institutes of Health/National Center for Advancing Translational Sciences through Colorado Clinical & Translational Science Institute [UL1 TR000154]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000154, UL1TR001082] Funding Source: NIH RePORTER	J.G. received salary support from the Thrasher Research Fund Early Career Award to conduct the study and the National Institutes of Health/National Center for Advancing Translational Sciences through Colorado Clinical & Translational Science Institute (UL1 TR000154 [REDCap]). The authors declare no conflicts of interest.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Clarke LA, 2012, BRAIN INJURY, V26, P298, DOI 10.3109/02699052.2012.654588; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirkwood MW, 2016, J PEDIATR-US, V169, P244, DOI 10.1016/j.jpeds.2015.10.014; Lachar D., 2001, PERSONALITY INVENTOR; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Peterson RL, 2015, J NEUROPSYCH CLIN N, V27, P280, DOI 10.1176/appi.neuropsych.14120373; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Spielberger CD, 1970, STATE TRAIT ANXIETY; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Walker C, 2006, Psychol Health Med, V11, P100; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wojcik SM, 2014, BRAIN INJURY, V28, P422, DOI 10.3109/02699052.2014.884241; Wood RL, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/HTR.0b013e31827eabba; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	39	43	43	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JUL	2016	174						27	+		10.1016/j.jpeds.2016.03.027			7	Pediatrics	Pediatrics	DP6PX	WOS:000378620800008	27079963	Green Accepted			2021-06-18	
J	Xu, K; Di Luca, DG; Orru, M; Xu, Y; Chen, JF; Schwarzschild, MA				Xu, K.; Di Luca, D. G.; Orru, M.; Xu, Y.; Chen, J. -F.; Schwarzschild, M. A.			NEUROPROTECTION BY CAFFEINE IN THE MPTP MODEL OF PARKINSON'S DISEASE AND ITS DEPENDENCE ON ADENOSINE A(2A) RECEPTORS	NEUROSCIENCE			English	Article						adenosine A(2A) receptors; MPTP; caffeine; neuroprotection; parkinson's disease	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ANIMAL-MODELS; RISK; RAT; INACTIVATION; TOXICITY; A(1); ANTAGONISTS; DOPAMINE	Considerable epidemiological and laboratory data have suggested that caffeine, a nonselective adenosine receptor antagonist, may protect against the underlying neurodegeneration of parkinson's disease (PD). Although both caffeine and more specific antagonists of the A(2A) subtype of adenosine receptor (A(2A)R) have been found to confer protection in animal models of PD, the dependence of caffeine's neuroprotective effects on the A(2A)R is not known. To definitively determine its A(2A)R dependence, the effect of caffeine on 1-methyl-4-phenyl-1,2,3,6 tetra-hydropyridine (MPTP) neurotoxicity was compared in wild-type (WT) and A(2A)R gene global knockout (A(2A) KO) mice, as well as in central nervous system (CNS) cell type-specific (conditional) A(2A)R knockout (cKO) mice that lack the receptor either in postnatal forebrain neurons or in astrocytes. In WT and in heterozygous A(2A)R KO mice caffeine pretreatment (25 mg/kg ip) significantly attenuated MPTP-induced depletion of striatal dopamine. By contrast in homozygous A(2A)R global KO mice caffeine had no effect on MPTP toxicity. In forebrain neuron A(2A)R cKO mice, caffeine lost its locomotor stimulant effect, whereas its neuroprotective effect was mostly preserved. In astrocytic A(2A)R cKO mice, both caffeine's locomotor stimulant and protective properties were undiminished. Taken together, these results indicate that neuroprotection by caffeine in the MPTP model of PD relies on the A(2A)R, although the specific cellular localization of these receptors remains to be determined. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Xu, K.; Di Luca, D. G.; Orru, M.; Xu, Y.; Schwarzschild, M. A.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Mol Neurobiol Lab, Charlestown, MA 02129 USA; [Xu, K.; Di Luca, D. G.; Orru, M.; Xu, Y.; Schwarzschild, M. A.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Chen, J. -F.] Boston Univ, Sch Med, Dept Neurol, 715 Albany St,C314, Boston, MA 02118 USA	Schwarzschild, MA (corresponding author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Mol Neurobiol Lab, Charlestown, MA 02129 USA.; Schwarzschild, MA (corresponding author), Harvard Univ, Sch Med, Charlestown, MA 02129 USA.	kuixu@hotmail.com; dilucadaniel@gmail.com; orrumarco@gmail.com; xuy@helix.mgh.harvard.edu; chenjf@bu.edu; michaels@helix.mgh.harvard.edu	Di Luca, Daniel Garbin/T-6211-2018	Di Luca, Daniel Garbin/0000-0002-1356-4919	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01ES010804, 5K24NS60991]; DOD grant [W81XWH-11-1-0150]; parkinson's disease Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES010804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS060991] Funding Source: NIH RePORTER	Source of support: This work is supported by NIH grants 5R01ES010804 and 5K24NS60991 and DOD grant W81XWH-11-1-0150. The parkinson's disease Foundation has provided funding supporting to Daniel Garbin Di Luca as a summer research fellow.	Antoniou K, 2005, PSYCHOPHARMACOLOGY, V183, P154, DOI 10.1007/s00213-005-0173-6; Ascherio A, 2004, AM J EPIDEMIOL, V160, P977, DOI 10.1093/aje/kwh312; Ascherio A, 2003, NEUROLOGY, V60, P790, DOI 10.1212/01.WNL.0000046523.05125.87; Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bastia E, 2005, NEUROPSYCHOPHARMACOL, V30, P891, DOI 10.1038/sj.npp.1300630; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Bockamp E, 2002, PHYSIOL GENOMICS, V11, P115, DOI 10.1152/physiolgenomics.00067.2002; Brambilla R, 2003, GLIA, V43, P190, DOI 10.1002/glia.10243; Brothers HM, 2010, NEUROSCI LETT, V480, P97, DOI 10.1016/j.neulet.2010.06.013; Carta AR, 2009, J NEUROCHEM, V111, P1478, DOI 10.1111/j.1471-4159.2009.06425.x; Chen JF, 2002, J BIOL CHEM, V277, P36040, DOI 10.1074/jbc.M206830200; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, P NATL ACAD SCI USA, V98, P1970, DOI 10.1073/pnas.98.4.1970; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Cunha RA, 2001, NEUROCHEM INT, V38, P107, DOI 10.1016/S0197-0186(00)00034-6; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Fernandez-Duenas V, 2014, ACS CHEM BIOL, V9, P2496, DOI 10.1021/cb5005383; Ferre S, 2008, J NEUROCHEM, V105, P1067, DOI 10.1111/j.1471-4159.2007.05196.x; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fisone G, 2004, CELL MOL LIFE SCI, V61, P857, DOI 10.1007/s00018-003-3269-3; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; Fredholm BB, 1996, ADV NEUROL, V71, P469; Fredholm BB, 1999, EUR J PHARMACOL, V380, P197, DOI 10.1016/S0014-2999(99)00533-6; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; Hirsch E C, 1999, Adv Neurol, V80, P9; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; Joghataie MT, 2004, PARKINSONISM RELAT D, V10, P465, DOI 10.1016/j.parkreldis.2004.06.004; Kachroo A, 2007, SOC NEUR ANN M SAN D; Karcz-Kubicha M, 2003, EUR J NEUROSCI, V18, P296, DOI 10.1046/j.1460-9568.2003.02747.x; Kelsey JE, 2009, PSYCHOPHARMACOLOGY, V201, P529, DOI 10.1007/s00213-008-1319-0; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; LANGSTON JW, 1984, BRAIN RES, V292, P390; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Liu R, 2012, AM J EPIDEMIOL, V175, P1200, DOI 10.1093/aje/kwr451; Lopes LV, 2004, BRIT J PHARMACOL, V141, P1006, DOI 10.1038/sj.bjp.0705692; Matos M, 2015, BIOL PSYCHIAT, V78, P763, DOI 10.1016/j.biopsych.2015.02.026; Matos M, 2012, GLIA, V60, P702, DOI 10.1002/glia.22290; Meredith GE, 2011, J PARKINSON DIS, V1, P19, DOI 10.3233/JPD-2011-11023; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; Nishizaki T, 2004, J PHARMACOL SCI, V94, P100, DOI 10.1254/jphs.94.100; Okusa MD, 1999, AM J PHYSIOL-RENAL, V277, pF404; Orru M, 2013, NEUROPHARMACOLOGY, V67, P476, DOI 10.1016/j.neuropharm.2012.11.029; Palacios N, 2012, MOVEMENT DISORD, V27, P1276, DOI 10.1002/mds.25076; Pierri M, 2005, NEUROPHARMACOLOGY, V48, P517, DOI 10.1016/j.neuropharm.2004.11.009; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; Ran H, 2015, J NEUROPATH EXP NEUR, V74, P305, DOI 10.1097/NEN.0000000000000174; Rebola N, 2005, NEUROSCIENCE, V132, P893, DOI 10.1016/j.neuroscience.2005.01.014; Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x; RICAURTE GA, 1987, BRAIN RES, V403, P43, DOI 10.1016/0006-8993(87)90120-X; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x; Schwarzschild MA, 2006, TRENDS NEUROSCI, V29, P647, DOI 10.1016/j.tins.2006.09.004; Shen HY, 2008, J NEUROSCI, V28, P2970, DOI 10.1523/JNEUROSCI.5255-07.2008; Sonsalla PK, 2012, EXP NEUROL, V234, P482, DOI 10.1016/j.expneurol.2012.01.022; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Sullivan GW, 1998, DRUG DEVELOP RES, V45, P103, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<103::AID-DDR4>3.0.CO;2-W; Aguiar LMV, 2006, PHARMACOL BIOCHEM BE, V84, P415, DOI 10.1016/j.pbb.2006.05.027; Xu K, 2006, J NEUROSCI, V26, P535, DOI 10.1523/JNEUROSCI.3008-05.2006; Xu K, 2002, NEUROSCI LETT, V322, P13, DOI 10.1016/S0304-3940(02)00069-1; Xu K, 2010, NEUROSCIENCE, V167, P475, DOI 10.1016/j.neuroscience.2010.02.020; Yu LQ, 2008, ANN NEUROL, V63, P338, DOI 10.1002/ana.21313; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	65	43	44	0	43	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 13	2016	322						129	137		10.1016/j.neuroscience.2016.02.035			9	Neurosciences	Neurosciences & Neurology	DG8QX	WOS:000372349800012	26905951	Green Accepted, Bronze			2021-06-18	
J	Carr, W; Stone, JR; Walilko, T; Young, LA; Snook, TL; Paggi, ME; Tsao, JW; Jankosky, CJ; Parish, RV; Ahlers, ST				Carr, Walter; Stone, James R.; Walilko, Tim; Young, Lee Ann; Snook, Tianlu Li; Paggi, Michelle E.; Tsao, Jack W.; Jankosky, Christopher J.; Parish, Robert V.; Ahlers, Stephen T.			Repeated Low-Level Blast Exposure: A Descriptive Human Subjects Study	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health System Research Symposium	AUG 17-21, 2014	Fort Lauderdale, FL				TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; FUNCTIONAL MRI; MILD; PERFORMANCE; CONCUSSION; SAMPLE	The relationship between repeated exposure to blast overpressure and neurological function was examined in the context of breacher training at the U.S. Marine Corps Weapons Training Battalion Dynamic Entry School. During this training, Students are taught to apply explosive charges to achieve rapid ingress into secured buildings. For this study, both Students and Instructors participated in neurobehavioral testing, blood toxin screening, vestibular/auditory testing, and neuroimaging. Volunteers wore instrumentation during training to allow correlation of human response measurements and blast overpressure exposure. The key findings of this study were from high-memory demand tasks and were limited to the Instructors. Specific tests showing blast-related mean differences were California Verbal Learning Test II, Automated Neuropsychological Assessment Metrics subtests (Match-to-Sample, Code Substitution Delayed), and Delayed Matching-to-Sample 10-second delay condition. Importantly, apparent deficits were paralleled with functional magnetic resonance imaging using the n-back task. The findings of this study are suggestive, but not conclusive, owing to small sample size and effect. The observed changes yield descriptive evidence for potential neurological alterations in the subset of individuals with occupational history of repetitive blast exposure. This is the first study to integrate subject instrumentation for measurement of individual blast pressure exposure, neurocognitive testing, and neuroimaging.	[Carr, Walter] Walter Reed Army Inst Res, Dept Behav Biol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Stone, James R.; Snook, Tianlu Li] Univ Virginia Hlth Syst, 480 Ray C Hunt Dr,Room 281,Box 801339, Charlottesville, VA 22903 USA; [Walilko, Tim] Appl Res Associates Inc, 7921 Shaffer Pkwy, Littleton, CO 80127 USA; [Young, Lee Ann] Appl Res Associates Inc, 950 Isom Rd, San Antonio, TX 78216 USA; [Paggi, Michelle E.] Weill Cornell Med Coll, 21 Bloomingdale Rd, White Plains, NY 10605 USA; [Tsao, Jack W.] US Navy, Bur Med & Surg, Traumat Brain Injury Programs, 2300 East St Northwest, Washington, DC 20372 USA; [Jankosky, Christopher J.] Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Parish, Robert V.] MEDCOM Irwin Army Community Hosp, 600 Caisson Hill Rd, Ft Riley, KS 66442 USA; [Ahlers, Stephen T.] US Navy, Med Res Ctr, Operat & Undersea Med, 503 Robert Grant Ave, Silver Spring, MD 20910 USA	Carr, W (corresponding author), Walter Reed Army Inst Res, Dept Behav Biol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.			Paggi, Michelle/0000-0002-6157-9787			Ahlers ST, 1994, FOOD COMPONENTS ENHA, P301; Baker AJ, 2011, J TRAUMA, V71, pS472, DOI 10.1097/TA.0b013e318232e7da; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Carr W, 2015, J HEAD TRAUMA REHAB, V30, P47, DOI 10.1097/HTR.0000000000000064; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dricot L, 2008, NEUROIMAGE, V40, P318, DOI 10.1016/j.neuroimage.2007.11.012; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; Fine EM, 2008, J CLIN EXP NEUROPSYC, V30, P463, DOI 10.1080/13803390701531912; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS3, DOI 10.1016/j.acn.2006.10.001; Kelley A, 201016 US ARM AER RE; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Needham CE, 2010, SHOCK WAVE HIGH PRES, P37, DOI 10.1007/978-3-642-05288-0_5; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Ruff RM, 1999, BRAIN INJURY, V13, P943; St Onge Paul, 2011, US Army Med Dep J, P97; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; THOMAS JR, 1989, AVIAT SPACE ENVIR MD, V60, P1063; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836	20	43	43	1	7	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	MAY	2016	181	5		S			28	39		10.7205/MILMED-D-15-00137			12	Medicine, General & Internal	General & Internal Medicine	DW5LJ	WOS:000383686400007	27168550	Bronze			2021-06-18	
J	Huber, BR; Meabon, JS; Hoffer, ZS; Zhang, J; Hoekstra, JG; Pagulayan, KF; McMillan, PJ; Mayer, CL; Banks, WA; Kraemer, BC; Raskind, MA; McGavern, DB; Peskind, ER; Cook, DG				Huber, B. R.; Meabon, J. S.; Hoffer, Z. S.; Zhang, J.; Hoekstra, J. G.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Banks, W. A.; Kraemer, B. C.; Raskind, M. A.; McGavern, D. B.; Peskind, E. R.; Cook, D. G.			BLAST EXPOSURE CAUSES DYNAMIC MICROGLIAL/MACROPHAGE RESPONSES AND MICRODOMAINS OF BRAIN MICROVESSEL DYSFUNCTION	NEUROSCIENCE			English	Article						blood-brain barrier; two-photon microscopy; neuropathology; microglia; macrophages	CHRONIC TRAUMATIC ENCEPHALOPATHY; IN-VIVO; MICROGLIAL ACTIVATION; WHITE-MATTER; MOUSE MODEL; INJURY; BLOOD; BARRIER; CORTEX; IMPACT	Exposure to blast overpressure (BOP) is associated with behavioral, cognitive, and neuroimaging abnormalities. We investigated the dynamic responses of cortical vasculature and its relation to microglia/macrophage activation in mice using intravital two-photon microscopy following mild blast exposure. We found that blast caused vascular dysfunction evidenced by microdomains of aberrant vascular permeability. Microglial/macrophage activation was specifically associated with these restricted microdomains, as evidenced by rapid microglial process retraction, increased ameboid morphology, and escape of blood-borne Q-dot tracers that were internalized in microglial/macrophage cell bodies and phagosome-like compartments. Microdomains of cortical vascular disruption and microglial/macrophage activation were also associated with aberrant tight junction morphology that was more prominent after repetitive (3 x) blast exposure. Repetitive, but not single, BOPs also caused TNF alpha elevation two weeks post-blast. In addition, following a single BOP we found that aberrantly phosphorylated tau rapidly accumulated in perivascular domains, but cleared within four hours, suggesting it was removed from the perivascular area, degraded, and/or dephosphorylated. Taken together these findings argue that mild blast exposure causes an evolving CNS insult that is initiated by discrete disturbances of vascular function, thereby setting the stage for more protracted and more widespread neuro-inflammatory responses. Published by Elsevier Ltd. on behalf of IBRO.	[Huber, B. R.] Boston Univ, VA Jamaica Plain, Dept Neurol, Sch Med, Jamaica Plain, MA USA; [Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] VA Puget Sound Healthcare Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA; [Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA; [Hoffer, Z. S.] US Army, Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA USA; [Zhang, J.; Hoekstra, J. G.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98108 USA; [Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA; [Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA; [McGavern, D. B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Cook, D. G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98108 USA	Cook, DG (corresponding author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, 1660 South Columbian Way, Seattle, WA 98108 USA.	dgcook@u.washington.edu	Pagulayan, Kati/AAR-9225-2020; Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619; Hoekstra, Jake/0000-0001-6597-5878	Department of Veterans Affairs Office of Research and Development Medical Research ServiceUS Department of Veterans Affairs; VA Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; University of Washington Royalty Research FundUniversity of Washington [R01AG046619]; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 AG000258]; VA CSR&D Career Development Award [IK2 CX00516]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000258, R01AG046619, P50AG005136] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002619, I01BX002311, I01RX000521, IK2CX000516, I01RX001612] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (D.G.C., B.C.K.), VA Rehabilitation Research and Development Service (E.R.P.), University of Washington Royalty Research Fund (D.G.C.); R01AG046619 (W.A.B.); Northwest Network Mental Illness Research, Education and Clinical Center (E.R.P., B.R.H., J.S.M., K.F.P., P.J.M., C.L.M.), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258 (J.S.M.), VA CSR&D Career Development Award Program #IK2 CX00516 (K.F.P.). We thank Dr. Gerard Schellenberg (Univ. Pennsylvania) for providing Tau knock-out samples.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jiao Y, 1999, J NEUROSCI METH, V93, P149, DOI 10.1016/S0165-0270(99)00142-9; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kim HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088924; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McPherson CA, 2014, NEUROTOX RES, V25, P45, DOI 10.1007/s12640-013-9422-3; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu HT, 2007, NAT NEUROSCI, V10, P549, DOI 10.1038/nn1883; Yang G, 2010, NAT PROTOC, V5, P201, DOI 10.1038/nprot.2009.222; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V	41	43	43	0	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 5	2016	319						206	220		10.1016/j.neuroscience.2016.01.022			15	Neurosciences	Neurosciences & Neurology	DD9RD	WOS:000370262400019	26777891	Green Accepted			2021-06-18	
J	Yi, LZ; Shi, ST; Wang, Y; Huang, W; Xia, ZA; Xing, ZH; Peng, WJ; Wang, Z				Yi, Lunzhao; Shi, Shuting; Wang, Yang; Huang, Wei; Xia, Zi-an; Xing, Zhihua; Peng, Weijun; Wang, Zhe			Serum Metabolic Profiling Reveals Altered Metabolic Pathways in Patients with Post-traumatic Cognitive Impairments	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; MOUSE MODEL; HEAD-INJURY; RISK-FACTOR; D-SERINE; PLASMA; BIOMARKERS; ACID	Cognitive impairment, the leading cause of traumatic brain injury (TBI)-related disability, adversely affects the quality of life of TBI patients, and exacts a personal and economic cost that is difficult to quantify. The underlying pathophysiological mechanism is currently unknown, and an effective treatment of the disease has not yet been identified. This study aimed to advance our understanding of the mechanism of disease pathogenesis; thus, metabolomics based on gas chromatography/mass spectrometry (GC-MS), coupled with multivariate and univariate statistical methods were used to identify potential biomarkers and the associated metabolic pathways of post-TBI cognitive impairment. A biomarker panel consisting of nine serum metabolites (serine, pyroglutamic acid, phenylalanine, galactose, palmitic acid, arachidonic acid, linoleic acid, citric acid, and 2,3,4-trihydroxybutyrate) was identified to be able to discriminate between TBI patients with cognitive impairment, TBI patients without cognitive impairment and healthy controls. Furthermore, associations between these metabolite markers and the metabolism of amino acids, lipids and carbohydrates were identified. In conclusion, our study is the first to identify several serum metabolite markers and investigate the altered metabolic pathway that is associated with post-TBI cognitive impairment. These markers appear to be suitable for further investigation of the disease mechanisms of post-TBI cognitive impairment.	[Yi, Lunzhao] Kunming Univ Sci & Technol, Yunnan Food Safety Res Inst, Kunming 650500, Peoples R China; [Shi, Shuting] Cent S Univ, Coll Chem & Chem Engn, Res Ctr Modernizat Tradit Chinese Med, Changsha 410083, Peoples R China; [Wang, Yang; Huang, Wei; Xia, Zi-an; Xing, Zhihua] Cent S Univ, Xiangya Hosp, Inst Integrated Med, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun; Wang, Zhe] Cent S Univ, Xiangya Hosp 2, Dept Integrated Chinese & Western Med, Changsha 410011, Hunan, Peoples R China	Peng, WJ; Wang, Z (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Integrated Chinese & Western Med, Changsha 410011, Hunan, Peoples R China.	pengweijun1987@gmail.com; ericwangzhe@126.com			Young Scientists Fund of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21465016]	This study was financially supported by the Young Scientists Fund of the National Natural Science Foundation of China (Grant No. 81303074) and the National Natural Science Foundation of China (Grant No. 21465016).	Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Bales KR, 2010, NEUROPHARMACOLOGY, V59, P295, DOI 10.1016/j.neuropharm.2010.01.005; Chen YR, 2015, J CANCER RES CLIN, V141, P705, DOI 10.1007/s00432-014-1846-5; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Drago F, 1988, Funct Neurol, V3, P137; Ellis JK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-61; Fisher DR, 2017, NUTR NEUROSCI, V20, P103, DOI 10.1179/1476830514Y.0000000150; Glenn Thomas C, 2013, Acta Neurochir Suppl, V118, P115, DOI 10.1007/978-3-7091-1434-6_20; Gonzalez-Dominguez R, 2015, J PHARMACEUT BIOMED, V107, P75, DOI 10.1016/j.jpba.2014.10.010; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hashimoto K, 2004, PROG NEURO-PSYCHOPH, V28, P385, DOI 10.1016/j.pnpbp.2003.11.009; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iuliano L, 2013, J ALZHEIMERS DIS, V36, P545, DOI 10.3233/JAD-122224; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Li NJ, 2015, J CHROMATOGR B, V985, P54, DOI 10.1016/j.jchromb.2015.01.016; Lin Z, 2014, ANAL CHIM ACTA, V827, P22, DOI [10.1016/j.aca.2014.04.008, 10.1016/j.aca.2014.04.039]; Liu S, 2015, BIOCHEM BIOPH RES CO, V461, P186, DOI 10.1016/j.bbrc.2015.04.031; Louin G, 2007, NITRIC OXIDE-BIOL CH, V17, P91, DOI 10.1016/j.niox.2007.05.006; Madeira C, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.52; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Maitre L, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-110; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Norup A, 2011, NEUROPSYCHOL REHABIL, V21, P306, DOI 10.1080/09602011.2011.558766; Patil S, 2006, NEUROSCI LETT, V406, P55, DOI 10.1016/j.neulet.2006.07.015; Peng WJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/261409; PEPEU G, 1989, PROG NEURO-PSYCHOPH, V13, pS77, DOI 10.1016/0278-5846(89)90112-7; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plassman Brenda L, 2015, Handb Clin Neurol, V128, P711, DOI 10.1016/B978-0-444-63521-1.00044-3; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Robertson CL, 2013, J NEUROTRAUM, V30, P2066, DOI 10.1089/neu.2013.3007; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Sanchez-Mejia RO, 2010, BBA-MOL CELL BIOL L, V1801, P784, DOI 10.1016/j.bbalip.2010.05.013; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Teul J, 2011, J PHARMACEUT BIOMED, V56, P343, DOI 10.1016/j.jpba.2011.05.020; Trushina E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063644; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang G, 2014, J PROTEOME RES, V13, P2649, DOI 10.1021/pr5000895; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang HL, 2014, J ALZHEIMERS DIS, V39, P841, DOI 10.3233/JAD-131463; Wang JH, 2010, SEMIN NEPHROL, V30, P500, DOI 10.1016/j.semnephrol.2010.07.007; Wang ZY, 2015, BIOL PHARM BULL, V38, P1049, DOI 10.1248/bpb.b15-00147; Weng R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11864; Wissmann P, 2013, J NEUROL SCI, V329, P29, DOI 10.1016/j.jns.2013.03.007; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Xu XH, 2012, NEUROSCI BULL, V28, P641, DOI 10.1007/s12264-012-1272-0; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442; Yi LZ, 2014, RSC ADV, V4, P59094, DOI 10.1039/c4ra09860a	57	43	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 17	2016	6								21320	10.1038/srep21320			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DD9GN	WOS:000370233800001	26883691	DOAJ Gold, Green Published			2021-06-18	
J	Kanaan, NM; Cox, K; Alvarez, VE; Stein, TD; Poncil, S; Mckee, AC				Kanaan, Nicholas M.; Cox, Kristine; Alvarez, Victor E.; Stein, Thor D.; Poncil, Sharra; Mckee, Ann C.			Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer disease; Chronic traumatic encephalopathy; Dementia; Oligomers; Phosphatase-activating domain; Tauopathy; Traumatic brain injury	PROGRESSIVE SUPRANUCLEAR PALSY; DEPENDENT AXONAL-TRANSPORT; MILD COGNITIVE IMPAIRMENT; REPETITIVE HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; BRAIN-INJURY; POTENTIAL TARGETS; CASPASE-CLEAVAGE; NEURODEGENERATIVE DISORDERS	Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy that develops after repetitive head injury. Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD). Additionally, phosphorylation at serine 422 in tau occurs early and correlates with cognitive decline in patients with Alzheimer disease (AD). We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE. Notably, the TauC3 epitope, which is abundant in AD, was relatively sparse in CTE. Together, these results provide the first description of PAD exposure, TOC1 reactive oligomers, phosphorylation of S422, and TauC3 truncation in the tau pathology of CTE.	[Kanaan, Nicholas M.; Cox, Kristine; Poncil, Sharra] Michigan State Univ, Coll Human Med, Dept Translat Sci & Mol Med, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA; [Kanaan, Nicholas M.] Mercy Hlth St Marys, Hauenstein Neurosci Ctr, Grand Rapids, MI USA; [Alvarez, Victor E.; Stein, Thor D.; Mckee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [Alvarez, Victor E.; Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, CTE Program, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02215 USA	Kanaan, NM (corresponding author), Michigan State Univ, Coll Human Med, Dept Translat Sci & Mol Med, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	Nicholas.kanaan@hc.msu.edu	Kanaan, Nicholas M./J-3428-2016	Kanaan, Nicholas M./0000-0002-4362-2593; Stein, Thor/0000-0001-6954-4477	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AG044372, R01 NS082730]; BrightFocus FoundationBrightFocus Foundation [A2013364S]; Department of Veterans AffairsUS Department of Veterans Affairs; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study [AG1649]; Alzheimer's AssociationAlzheimer's Association [NIRG-305779]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Disorders and Stroke (National Brain and Tissue Resource for Parkinson's Disease and Related Disorders) [U24 NS072026]; National Institute on Aging (Arizona Alzheimer's Disease Core Center)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG19610]; Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; Alzheimer's Disease Core Center grant from the National Institute on Aging [P30 AG013854]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, R01NS082730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG044372, P30AG013846, P30AG019610] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by NIH grants R01 AG044372 and R01 NS082730 (NMK), the BrightFocus Foundation (A2013364S, NMK), the Department of Veterans Affairs (ACM); National Institute of Neurological Diseases and Stroke 1U01NS086659-01 (ACM), National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846; supplement 0572063345-5, ACM]; National Institute of Aging Boston University Framingham Heart Study R01 [AG1649, ACM]; Alzheimer's Association (NIRG-305779, TDS); Sports Legacy Institute (ACM); National Operating Committee on Standards for Athletic Equipment (ACM); the Veterans Affairs Biorepository (CSP 501, ACM); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C, ACM), unrestricted gifts from the National Football League, the Andlinger Foundation and the World Wrestling Entertainment, Inc. (WWE) (ACM), the Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, and 1001 to the Arizona Parkinson's Disease Consortium), the Michael J. Fox Foundation for Parkinson's Research, and the Alzheimer's Disease Core Center grant (P30 AG013854) from the National Institute on Aging to Northwestern University, Chicago Illinois.	Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bancher C, 1989, Prog Clin Biol Res, V317, P837; Beach TG, 2015, NEUROPATHOLOGY, V35, P354, DOI 10.1111/neup.12189; Berry RW, 2004, J NEUROCYTOL, V33, P287, DOI 10.1023/B:NEUR.0000044190.96426.b9; Berry RW, 2001, NEUROCHEM INT, V39, P469, DOI 10.1016/S0197-0186(01)00054-7; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Castillo-Carranza DL, 2014, J ALZHEIMERS DIS, V40, pS97, DOI 10.3233/JAD-132477; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cardenas-Aguayo MD, 2014, ACS CHEM NEUROSCI, V5, P1178, DOI 10.1021/cn500148z; Dickson DW, 1999, J NEUROL, V246, P6; DUONG T, 1993, BRAIN RES, V603, P74, DOI 10.1016/0006-8993(93)91301-8; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Flores-Rodriguez P, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00033; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Garcia-Sierra F, 2000, ACTA NEUROPATHOL, V100, P29, DOI 10.1007/s004010051189; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guillozet-Bongaarts AL, 2006, J NEUROCHEM, V97, P1005, DOI 10.1111/j.1471-4159.2006.03784.x; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; Guillozet-Bongaarts AL, 2007, ACTA NEUROPATHOL, V113, P513, DOI 10.1007/s00401-007-0209-6; Guzman-Martinez L, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00167; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jeganathan S, 2008, J BIOL CHEM, V283, P32066, DOI 10.1074/jbc.M805300200; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kanaan NM, 2008, GLIA, V56, P1199, DOI 10.1002/glia.20690; Kanaan NM, 2007, J COMP NEUROL, V502, P683, DOI 10.1002/cne.21333; Kanaan NM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.06.006; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Kanaan NM, 2010, NEUROBIOL AGING, V31, P937, DOI 10.1016/j.neurobiolaging.2008.07.006; Kandan NM, 2013, EXP NEUROL, V246, P44, DOI 10.1016/j.expneurol.2012.06.003; Kiernan PT, 2015, SEMIN NEUROL, V35, P20, DOI 10.1055/s-0035-1545080; Kokjohn TA, 2013, J NEUROTRAUM, V30, P981, DOI 10.1089/neu.2012.2699; Kuchibhotla KV, 2014, P NATL ACAD SCI USA, V111, P510, DOI 10.1073/pnas.1318807111; LaPointe NE, 2009, J NEUROSCI RES, V87, P440, DOI 10.1002/jnr.21850; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Ling H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-24; Luna-Munoz J, 2005, J ALZHEIMERS DIS, V8, P29; Luna-Munoz J, 2007, J ALZHEIMERS DIS, V12, P365; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Mondragon-Rodriguez S, 2014, NEUROPATH APPL NEURO, V40, P121, DOI 10.1111/nan.12084; Mondragon-Rodriguez S, 2008, INT J EXP PATHOL, V89, P81, DOI 10.1111/j.1365-2613.2007.00568.x; Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Mufson EJ, 2014, NEURODEGENER DIS, V13, P151, DOI 10.1159/000353687; Patterson KR, 2011, BIOCHEMISTRY-US, V50, P10300, DOI 10.1021/bi2009147; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Sahara N, 2008, CURR ALZHEIMER RES, V5, P591, DOI 10.2174/156720508786898442; Sahara N, 2014, J ALZHEIMERS DIS, V40, pS91, DOI 10.3233/JAD-132429; Gadad BS, 2011, J ALZHEIMERS DIS, V24, P223, DOI 10.3233/JAD-2011-110182; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Tian Huilai, 2013, Int J Cell Biol, V2013, P260787, DOI 10.1155/2013/260787; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Vana L, 2011, AM J PATHOL, V179, P2533, DOI 10.1016/j.ajpath.2011.07.044; Ward SM, 2014, NEUROBIOL DIS, V67, P37, DOI 10.1016/j.nbd.2014.03.002; Ward SM, 2013, J ALZHEIMERS DIS, V37, P593, DOI 10.3233/JAD-131235; Ward SM, 2012, BIOCHEM SOC T, V40, P667, DOI 10.1042/BST20120134; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	72	43	43	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JAN	2016	75	1					19	34		10.1093/jnen/nlv001			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DK9DJ	WOS:000375230400003	26671985	Bronze, Green Accepted, Green Published			2021-06-18	
J	Meizoso, JP; Valle, EJ; Allen, CJ; Ray, JJ; Jouria, JM; Teisch, LF; Shatz, DV; Namias, N; Schulman, CI; Proctor, KG				Meizoso, Jonathan P.; Valle, Evan J.; Allen, Casey J.; Ray, Juliet J.; Jouria, Jassin M.; Teisch, Laura F.; Shatz, David V.; Namias, Nicholas; Schulman, Carl I.; Proctor, Kenneth G.			Decreased mortality after prehospital interventions in severely injured trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 09-13, 2014	Philadelphia, PA	Amer Assoc Surg Trauma		Prehospital; interventions; lifesaving; scoop and run; stay and play	SEVERE HEAD-INJURY; FLUID RESUSCITATION; INTUBATION; ASSOCIATION; MANAGEMENT; GUIDELINE; SURVIVAL; OUTCOMES; SYSTEM	BACKGROUND We test the hypothesis that prehospital interventions (PHIs) performed by skilled emergency medical service providers during ground or air transport adversely affect outcome in severely injured trauma patients. METHODS Consecutive trauma activations (March 2012 to June 2013) transported from the scene by air or ground emergency medical service providers were reviewed. PHI was defined as intubation, needle decompression, tourniquet, cricothyroidotomy, or advanced cardiac life support. RESULTS In 3,733 consecutive trauma activations (71% blunt, 25% penetrating, 4% burns), age was 39 years, 74% were male, Injury Severity Score (ISS) was 5, and Glasgow Coma Score (GCS) was 15, with 32% traumatic brain injury (TBI) and 7% overall mortality. Those who received PHI (n = 130, 3.5% of the trauma activations) were more severely injured: ISS (26 vs. 5), GCS (3 vs. 15), TBI (57% vs. 31%), Revised Trauma Score (RTS, 5.45 vs. 7.84), Trauma and Injury Severity Score (TRISS, 1.32 vs. 4.89), and mortality (56% vs. 5%) were different (all p < 0.05) than those who received no PHI. Air crews transported 22% of the patients; more had TBI, blunt injury, high ISS, and long prehospital times (all p < 0.05), but mortality was similar to those transported by ground. In the most severely injured patients with signs of life who received a PHI, the ISS, prehospital times, and proportions of TBI, blunt trauma, and air transport were similar, but mortality was significantly lower (43% vs. 23%, p= 0.021). CONCLUSION In our urban trauma system, PHIs are associated with a lower incidence of mortality in severely injured trauma patients and do not delay transport to definitive care. LEVEL OF EVIDENCE Prognostic/epidemiologic study, level III; therapeutic study, level IV.	[Meizoso, Jonathan P.; Valle, Evan J.; Allen, Casey J.; Ray, Juliet J.; Jouria, Jassin M.; Teisch, Laura F.; Namias, Nicholas; Schulman, Carl I.; Proctor, Kenneth G.] Univ Miami, Leonard M Miller Sch Med, DeWitt Daughtry Family Dept Surg, Div Trauma Surg Crit Care & Burns, Miami, FL 33136 USA; [Shatz, David V.] UC Davis Hlth Syst, Div Trauma Acute Care Surg & Surg Crit Care, Sacramento, CA USA	Proctor, KG (corresponding author), Univ Miami, Leonard M Miller Sch Med, Ryder Trauma Ctr, Div Trauma,DeWitt Daughtry Family Dept Surg, 1800 NW 10th Ave,Suite T-215 D-40, Miami, FL 33136 USA.	kproctor@miami.edu; kproctor@miami.edu	Schulman, Carl/AAE-7448-2021; Meizoso, Jonathan/AAF-5777-2019	Meizoso, Jonathan/0000-0002-6616-6682; Schulman, Carl/0000-0001-8899-4350; Namias, Nicholas/0000-0001-7021-2250	Office of Naval ResearchOffice of Naval Research [N140610670]; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [09078015]	This study was supported in part by Grants #N140610670 from the Office of Naval Research and #09078015 from US Army Medical Research and Materiel Command.	Ball CG, 2010, CAN J SURG, V53, P184; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BORDER JR, 1983, J TRAUMA, V23, P708, DOI 10.1097/00005373-198308000-00005; Bulger EM, 2014, PREHOSP EMERG CARE, V18, P163, DOI 10.3109/10903127.2014.896962; Bulger EM, 2012, J TRAUMA ACUTE CARE, V72, P567, DOI 10.1097/TA.0b013e31824baddf; Cotton BA, 2009, J TRAUMA, V67, P389, DOI 10.1097/TA.0b013e3181a8b26f; Davis DP, 2010, J TRAUMA, V69, P294, DOI 10.1097/TA.0b013e3181dc6c7f; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Hampton DA, 2013, J TRAUMA ACUTE CARE, V75, pS9, DOI 10.1097/TA.0b013e318290cd52; Johnson NJ, 2013, AM J EMERG MED, V31, P275, DOI 10.1016/j.ajem.2012.07.023; Karamanos E, 2014, PREHOSP DISASTER MED, V29, P32, DOI 10.1017/S1049023X13008947; Mayglothling J, 2012, J TRAUMA ACUTE CARE, V73, pS333, DOI 10.1097/TA.0b013e31827018a5; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Papa L, 2006, J TRAUMA, V61, P261, DOI 10.1097/01.ta.0000221789.53864.ba; Taghavi S, 2014, AM SURGEON, V80, P9; Talving P, 2009, WORLD J SURG, V33, P2469, DOI 10.1007/s00268-009-0185-1; Warner KJ, 2008, PREHOSP EMERG CARE, V12, P162, DOI 10.1080/10903120801907299; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	18	43	44	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2015	79	2					227	231		10.1097/TA.0000000000000748			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CS2II	WOS:000361892800010	26218690				2021-06-18	
J	Zonfrillo, MR; Kim, KH; Arbogast, KB				Zonfrillo, Mark R.; Kim, Konny H.; Arbogast, Kristy B.			Emergency Department Visits and Head Computed Tomography Utilization for Concussion Patients From 2006 to 2011	ACADEMIC EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; UNITED-STATES; MANAGEMENT	ObjectivesConcussion is the most common type of mild traumatic brain injury for which patients present to the emergency department (ED). It is critical to understand the contemporary epidemiology of concussion and rates of head computed tomography (CT) use in head-injured patients to inform education of evidence-based clinical practice guidelines to emergency medicine providers. MethodsThis was a cross-sectional analysis of the Nationwide Emergency Department Sample (NEDS) for years 2006 to 2011, representing a stratified probability sample of all U.S. hospital-based EDs. Patients of all ages with concussion diagnoses were included, and those with intracranial hemorrhages or prolonged loss of consciousness were excluded. Descriptive and bivariate statistics were summarized for patient demographics, injury mechanism, Injury Severity Scores (ISS), and concussion incidence rates, based on U.S. Census Bureau population estimates. ResultsThere were 756,214,762 (weighted) ED visits in the NEDS between 2006 and 2011, of which 0.5% received diagnoses of concussion. The national incidence rate of concussion visits increased 22.6% from 195 visits per 100,000 person-years in 2006 to 239 visits per 100,000 person-years in 2011. The incidence of concussion visits increased by 28.1% from 2006 to 2011 overall (580,573 to 743,994) and within all age group categories. The rate of head CT use in patients diagnosed with concussion increased 35.7% (range= 34.5% to 46.8%) for the entire group from 2006 to 2011 (p<0.0001). The injury severity of patients' injuries decreased over time (66.4% ISS<5 in 2006 and 75% in 2011; p<0.0001), while the proportion of discharged patients increased over time (78.1% in 2006 and 86.6% in 2011; p<0.0001). ConclusionsED visits for concussions have increased over time, with a corresponding increase in head CT utilization despite a decrease in injury severity. Increased visits may be due to more concussion awareness and recognition of subtle injuries. Evidence-based clinical practice guidelines for neuroimaging in head-injured patients and management of concussion should be reinforced to emergency medicine providers.	[Zonfrillo, Mark R.; Kim, Konny H.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Arbogast, Kristy B.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA.	Mark_Zonfrillo@brown.edu	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Arbogast, Kristy/0000-0002-1694-4562	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER	This publication was supported by the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, grant K08HD073241 (MRZ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, 2013, INTR HCUP NAT EM DEP; Association for the Advancement of Automotive Medicine (AAAM), 2008, ABBR INJ SCAL AIS 20; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Tavender EJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-8	10	43	43	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUL	2015	22	7					872	877		10.1111/acem.12696			6	Emergency Medicine	Emergency Medicine	CM8JV	WOS:000357947400015	26111921	Bronze, Green Accepted			2021-06-18	
J	Takahashi, M; Miyata, H; Kametani, F; Nonaka, T; Akiyama, H; Hisanaga, S; Hasegawa, M				Takahashi, Muneaki; Miyata, Haruka; Kametani, Fuyuki; Nonaka, Takashi; Akiyama, Haruhiko; Hisanaga, Shin-ichi; Hasegawa, Masato			Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau	ACTA NEUROPATHOLOGICA			English	Article						Tau; Amyloid precursor protein; Propagation; Alzheimer's disease; Down's syndrome	AMYLOID PRECURSOR PROTEIN; PATHOLOGICAL ALPHA-SYNUCLEIN; TRAUMATIC BRAIN-INJURY; FAMILIAL ALZHEIMERS-DISEASE; LOCUS DUPLICATION; DOWNS-SYNDROME; CEREBROSPINAL-FLUID; MOUSE-BRAIN; RAT; PHOSPHORYLATION	Alzheimer's disease (AD) is characterized by extracellular amyloid beta (A beta) deposition and intracellular tau aggregation. Many studies have indicated some association between these processes, but it remains unknown how the two pathologies are linked. In this study, we investigated whether expression of amyloid precursor protein (APP) influences extracellular seed-dependent intracellular tau accumulation in cultured cells. Treatment of tau-expressing SH-SY5Y cells with A beta fibrils did not induce intracellular tau aggregation. On the other hand, in cells expressing both tau and APP, treatment with tau fibrils or Sarkosyl-insoluble tau from AD brains induced intracellular tau aggregation. The seed-dependent intracellular tau aggregation was not induced by expression of APP lacking the extracellular domain. The amount of phosphorylated tau aggregates in cultured cells was dose dependently elevated in response to increased levels of APP on the cell membrane. Our results indicate that the extracellular region of APP is involved in uptake of tau fibrils into cells, raising the possibility that APP, but not A beta, influences cell-to-cell spreading of tau pathologies in AD by serving as a receptor of abnormal tau aggregates.	[Takahashi, Muneaki; Miyata, Haruka; Kametani, Fuyuki; Nonaka, Takashi; Akiyama, Haruhiko; Hasegawa, Masato] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Setagaya Ku, Tokyo 1568506, Japan; [Takahashi, Muneaki; Hisanaga, Shin-ichi] Tokyo Metropolitan Univ, Lab Mol Neurosci, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan	Hasegawa, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Setagaya Ku, Tokyo 1568506, Japan.	hasegawa-ms@igakuken.or.jp	Kametani, Fuyuki/G-4752-2011; Nonaka, Takashi/L-8572-2017	Kametani, Fuyuki/0000-0001-9125-7001; Nonaka, Takashi/0000-0002-0830-9403	MEXT KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26117005, 23240050, 24111556]; MHLWMinistry of Health, Labour and Welfare, Japan [12946221]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26111730, 26117005, 24500429, 26117004, 15H02356] Funding Source: KAKEN	This work was supported by MEXT KAKENHI Grant Numbers 26117005, 23240050 (to MH), 24111556 (to TN) and MHLW Grant ID Number 12946221 (to MH).	BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2013, ACTA NEUROPATHOL, V126, P631, DOI [10.1007/s00401-013-1139-0, 10.1007/s00401-013-1153-2]; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Frost B, 2009, J BIOL CHEM, V284, P3546, DOI 10.1074/jbc.M805627200; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Guyant-Marechal L, 2008, NEUROLOGY, V71, P1925, DOI 10.1212/01.wnl.0000339400.64213.56; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Holmes BB, 2013, P NATL ACAD SCI USA, V110, pE3138, DOI 10.1073/pnas.1301440110; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; Kandalepas PC, 2012, J NEUROCHEM, V120, P55, DOI 10.1111/j.1471-4159.2011.07512.x; Kasuga K, 2009, J NEUROL NEUROSUR PS, V80, P1050, DOI 10.1136/jnnp.2008.161703; Kfoury N, 2012, J BIOL CHEM, V287, P19440, DOI 10.1074/jbc.M112.346072; Kume H, 2006, BIOCHEM BIOPH RES CO, V349, P1356, DOI 10.1016/j.bbrc.2006.08.181; Lannfelt L, 2014, J INTERN MED, V275, P284, DOI 10.1111/joim.12168; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Luk KC, 2012, J EXP MED, V209, P975, DOI 10.1084/jem.20112457; Mairet-Coello G, 2013, NEURON, V78, P94, DOI 10.1016/j.neuron.2013.02.003; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Masuda-Suzukake M, 2013, BRAIN, V136, P1128, DOI 10.1093/brain/awt037; McNaughton Daniel, 2012, Neurobiol Aging, V33, DOI 10.1016/j.neurobiolaging.2010.10.010; Michel CH, 2014, J BIOL CHEM, V289, P956, DOI 10.1074/jbc.M113.515445; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mougenot AL, 2012, NEUROBIOL AGING, V33, P2225, DOI 10.1016/j.neurobiolaging.2011.06.022; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Nonaka T, 2010, J BIOL CHEM, V285, P34885, DOI 10.1074/jbc.M110.148460; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierrot N, 2013, EMBO MOL MED, V5, P608, DOI 10.1002/emmm.201202215; Purushothuman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059740; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rovelet-Lecrux A, 2007, J NEUROL NEUROSUR PS, V78, P1158, DOI 10.1136/jnnp.2006.113514; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Simon D, 2012, FEBS LETT, V586, P47, DOI 10.1016/j.febslet.2011.11.022; Sleegers K, 2006, BRAIN, V129, P2977, DOI 10.1093/brain/awl203; Song YL, 2014, PROTEIN SCI, V23, P1, DOI 10.1002/pro.2385; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Wilcock DM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-84; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528	61	43	45	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2015	129	6					895	907		10.1007/s00401-015-1415-2			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CI4GO	WOS:000354706600009	25869641	Green Published, Other Gold			2021-06-18	
J	Storzbach, D; O'Neil, ME; Roost, SM; Kowalski, H; Iverson, GL; Binder, LM; Fann, JR; Huckans, M				Storzbach, Daniel; O'Neil, Maya Elin; Roost, Saw-Myo; Kowalski, Halina; Iverson, Grant L.; Binder, Laurence M.; Fann, Jesse R.; Huckans, Marilyn			Comparing the Neuropsychological Test Performance of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans with and without Blast Exposure, Mild Traumatic Brain Injury, and Posttraumatic Stress Symptoms	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injuries; Blast injuries; Explosions; Military personnel; Combat disorders; Stress disorders; Post-traumatic; Cognitive symptoms	OUTCOMES; SOLDIERS; HEALTH	To compare neuropsychological test performance of Veterans with and without mild traumatic brain injury (MTBI), blast exposure, and posttraumatic stress disorder (PTSD) symptoms. We compared the neuropsychological test performance of 49 Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans diagnosed with MTBI resulting from combat blast-exposure to that of 20 blast-exposed OEF/OIF Veterans without history of MTBI, 23 OEF/OIF Veterans with no blast exposure or MTBI history, and 40 matched civilian controls. Comparison of neuropsychological test performance across all four participant groups showed a complex pattern of mixed significant and mostly nonsignificant results, with omnibus tests significant for measures of attention, spatial abilities, and executive function. The most consistent pattern was the absence of significant differences between blast-exposed Veterans with MTBI history and blast-exposed Veterans without MTBI history. When blast-exposed Veteran groups with and without MTBI history were aggregated and compared to non-blast-exposed Veterans, there were significant differences for some measures of learning and memory, spatial abilities, and executive function. However, covariation for severity of PTSD symptoms eliminated all significant omnibus neuropsychological differences between Veteran groups. Our results suggest that, although some mild neurocognitive effects were associated with blast exposure, these neurocognitive effects might be better explained by PTSD symptom severity rather than blast exposure or MTBI history alone.	[Storzbach, Daniel; O'Neil, Maya Elin; Roost, Saw-Myo; Kowalski, Halina; Huckans, Marilyn] Portland VA Med Ctr, Portland, OR USA; [Storzbach, Daniel; O'Neil, Maya Elin; Binder, Laurence M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Storzbach, Daniel; Binder, Laurence M.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [O'Neil, Maya Elin] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	O'Neil, ME (corresponding author), Portland VA Med Ctr R&D 66, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	maya.oneil@va.gov		Iverson, Grant/0000-0001-7348-9570	VA Merit Review Award from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [B5060R]; Veterans Affairs Health Services Research and Development Center of Innovation grant; Center to Improve Veteran Involvement in Care [CIN 13-404]; Agency for Healthcare Research QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1 K12 HS019456 01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS019456, K12HS022981] Funding Source: NIH RePORTER	This work was supported by VA Merit Review Award #B5060R to D.S. from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development, a Veterans Affairs Health Services Research and Development Center of Innovation grant, Center to Improve Veteran Involvement in Care, Award #CIN 13-404, and an Agency for Healthcare Research & Quality-funded PCOR K12 award to MEO (#1 K12 HS019456 01). This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, Oregon. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. All authors declare no conflicts of interests involved in the research presented in the manuscript. The corresponding author (M.E.O.) declares she had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. D. Storzbach and M. O'Neil contributed equally to this work.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Murphy KR, 2004, STAT POWER ANAL; Nelson N. W., 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S1355617711001548; Reynolds C. R., 2003, REYNOLDS INTELLECTUA; Sheehan D. V., 2006, MINI INT NEUROPSYCHI; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2011, J INT NEUROPSYCH SOC, V17, P1, DOI 10.1017/S1355617710001116; Verfaellie M., 2009, POSTTRAUMATIC STRESS, V1, P1; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Weathers F., 1996, MEASUREMENT STRESS T, P250; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Wechsler D., 2001, WECHSLER TEST ADULT	25	43	43	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2015	21	5					353	363		10.1017/S1355617715000326			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	CL9QK	WOS:000357313000004	26029852	Bronze			2021-06-18	
J	Lindley, RI; Wardlaw, JM; Whiteley, WN; Cohen, G; Blackwell, L; Murray, GD; Sandercock, PAG				Lindley, Richard I.; Wardlaw, Joanna M.; Whiteley, William N.; Cohen, Geoff; Blackwell, Lisa; Murray, Gordon D.; Sandercock, Peter A. G.		IST-3 Collaborative Grp	Alteplase for Acute Ischemic Stroke Outcomes by Clinically Important Subgroups in the Third International Stroke Trial	STROKE			English	Article						alteplase; intracranial hemorrhages; stroke; thrombolytic therapy; treatment outcome	TISSUE-PLASMINOGEN ACTIVATOR; TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS THROMBOLYSIS; STATISTICAL-ANALYSIS; 6 H; IST-3; METAANALYSIS; IMPACT; SCALE	Background and Purpose-Our aim was to identify whether particular subgroups of patients had an unacceptably high risk of symptomatic intracranial hemorrhage or low chance of benefit when treated with alteplase (recombinant tissue-type plasminogen activator). Methods-Third International Stroke Trial was an international randomized trial of the intravenous (IV) recombinant plasminogen activator alteplase (0.9 mg/kg) versus control in 3035 (1515 versus 1520) patients. We analyzed the effect of recombinant tissue-type plasminogen activator on 6-month functional outcome, early death, and symptomatic intracranial hemorrhage (both <= 7 days). We tested for any differences in treatment effect between subgroups by a test of interaction. Our 13 protocol prespecified subgroups were time to randomization, age, sex, stroke subtype, atrial fibrillation, early ischemic change (clinician and expert panel), prior antiplatelet use, stroke severity, diastolic and systolic blood pressure at randomization, center's thrombolysis experience, and trial phase. Analyses were adjusted for key baseline prognostic factors. Results-There were no significant interactions in the subgroups analyzed that were consistent across all 3 outcomes. Treatment with recombinant tissue-type plasminogen activator increased the odds of symptomatic intracranial hemorrhage by a greater amount in patients taking prior antiplatelets than those who were not (P=0.019 for test of interaction), but had no clear detrimental effect on functional outcome at 6 months in this group (P=0.781 for test of interaction). Conclusions-Among the types of patient in the Third International Stroke Trial, this secondary analysis did not identify any subgroups for whom treatment should be avoided. Given the limitations of the analysis, we found no clear evidence to avoid treatment in patients with prior ischemic stroke, diabetes mellitus, or hypertension.	[Lindley, Richard I.] Univ Sydney, Sydney, NSW 2006, Australia; [Wardlaw, Joanna M.; Whiteley, William N.; Cohen, Geoff; Murray, Gordon D.; Sandercock, Peter A. G.] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Blackwell, Lisa] Univ Oxford, Oxford, England	Lindley, RI (corresponding author), Westmead Hosp, Sydney Med Sch, Dept Geriatr Med, Sydney, NSW 2006, Australia.	richard.lindley@sydney.edu.au	Hankey, Graeme J/H-4968-2014; Lueck, Christian J/O-4031-2016; Muir, Keith W/A-7670-2011; Wardlaw, Joanna/Y-3456-2019; Armit, Chris/AAZ-5613-2020; Lindley, Richard/B-8148-2013	Hankey, Graeme J/0000-0002-6044-7328; Lueck, Christian J/0000-0003-1537-7612; Muir, Keith W/0000-0001-9535-022X; Wardlaw, Joanna/0000-0002-9812-6642; Armit, Chris/0000-0002-9952-8141; Whiteley, William/0000-0002-4816-8991; Tyrrell, Pippa/0000-0001-9609-1231; Lindley, Richard/0000-0002-0104-5679; Engelter, Stefan/0000-0003-3855-6234; celani, maria grazia/0000-0002-0739-4140	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0400069, G0902303] Funding Source: Medline; Chief Scientist Office Funding Source: Medline		BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Frank B, 2013, STROKE, V44, P727, DOI 10.1161/STROKEAHA.112.674622; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Lindley Richard I, 2004, J Stroke Cerebrovasc Dis, V13, P235, DOI 10.1016/j.jstrokecerebrovasdis.2004.03.003; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; Lyden PD, 2012, STROKE, V43, P1691, DOI 10.1161/STROKEAHA.112.656876; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mishra NK, 2011, NEUROLOGY, V77, P1866, DOI 10.1212/WNL.0b013e318238ee42; Mishra NK, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6046; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sandercock P, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-252; Sandercock P, 2012, INT J STROKE, V7, P186, DOI 10.1111/j.1747-4949.2012.00782.x; Sandercock P, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-37; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Whiteley W, 2006, INT J STROKE, V1, P172, DOI 10.1111/j.1747-4949.2006.00043.x; Whiteley WN, 2012, STROKE, V43, P2904, DOI 10.1161/STROKEAHA.112.665331	25	43	44	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAR	2015	46	3					746	756		10.1161/STROKEAHA.114.006573			11	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CC3XP	WOS:000350284900035	25613308	Bronze			2021-06-18	
J	Baugh, CM; Kroshus, E; Daneshvar, DH; Filali, NA; Hiscox, MJ; Glantz, LH				Baugh, Christine M.; Kroshus, Emily; Daneshvar, Daniel H.; Filali, Naji A.; Hiscox, Michael J.; Glantz, Leonard H.			Concussion Management in United States College Sports Compliance With National Collegiate Athletic Association Concussion Policy and Areas for Improvement	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; NCAA; health policy; college	CHRONIC TRAUMATIC ENCEPHALOPATHY; FOOTBALL PLAYERS; NCAA CONCUSSION; HEAD-INJURY; PROFILE; DISEASE; RETURN; RISK	Background: In 2010, the National Collegiate Athletic Association (NCAA) adopted its Concussion Policy and Legislation, which applies to more than 450,000 collegiate athletes annually. To date, there has been no examination of school-level compliance with the NCAA Concussion Policy. Purpose: To examine whether stakeholders at NCAA schools report that their school has a concussion management plan and whether existing plans are consistent with the NCAA policy. Also examined were stakeholders' perceptions regarding concussion management at their institution and possible areas for improvement. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Surveys were sent by e-mail to coaches, sports medicine clinicians, and compliance administrators at all 1066 NCAA member institutions. Surveys asked population-specific questions about institutional concussion management. Individuals (N = 2880) from 907 unique schools participated in this survey. Results: Most respondents (n = 2607; 92.7%) indicated their school had a concussion management plan. Most schools had all (82.1%) or some (15.2%) respondents indicate a concussion management plan was present. When asked to indicate all individuals who could have final responsibility for returning athletes to play after a concussion, 83.4% selected team doctor, 72.8% athletic trainer, 31.0% specialist physician, 6.8% coach, and 6.6% athlete. Most respondents (76.1%) indicated that their institution had a process for annual athlete concussion education; 91.2% required athletes to acknowledge their responsibility to report concussion symptoms. Nearly all respondents (98.8%) thought their school's concussion management plan protected athletes well or very well. Top categories suggested for improvement included better coach education (39.7%), increasing sports medicine staffing (37.2%), and better athlete education (35.2%). Conclusion: Although a large majority of respondents indicated that their school has a concussion management plan, improvement is needed. Compliance with specified components (eg, annual athlete education) lags behind the presence of the plan itself, and stakeholders had suggestions for areas in which improvements are needed. Increasing scientific evidence supporting the seriousness of concussion underscores the need for the NCAA to use its regulatory capabilities to ensure that athletes' brains are safe.	Boston Univ, Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Baugh, CM (corresponding author), Harvard Univ, Interfac Initiat Hlth Policy, 14 Story St,4th Floor, Cambridge, MA 02138 USA.	cbaugh@g.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	Edmond J. Safra Center for Ethics	One or more of the authors has declared the following potential conflict of interest or source of funding: C.M.B. received funding from the Edmond J. Safra Center for Ethics for the conduct of this study. Material support in the form of an e-mail distribution list and service was provided by the NCAA Sport Science Institute (SSI). The SSI contributed to the design and conduct of the study. E.K. received the NCAA Graduate Student Research Grant for 2012-2013 and was funded as a postdoctoral research fellow by the NCAA Sports Science Institute as of June 2014.	Baugh CM, J LAW MED, V42, P297; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chinn NR, 2013, COMMUNITY COLL J RES, V37, P409, DOI 10.1080/10668926.2012.710127; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Donaldson A, 2016, AM J LIFESTYLE MED, V10, P120, DOI 10.1177/1559827614538751; Fenno N, 2010, THE WASHINGTON TIMES; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Luke AC, 2007, CLIN J SPORT MED, V17, P488, DOI 10.1097/JSM.0b013e31815889f2; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Collegiate Athletic Association, 2013, 2013 2014 DIV 1 HDB; National Collegiate Athletic Association, 2014, CONC GUID DIAGN MAN; NCAA, 2012 2013 NCAA SPORT; Partridge B, 2014, J BIOETHIC INQ, V11, P65, DOI 10.1007/s11673-013-9491-2; Poulos RG, 2013, BRIT J SPORT MED, V47, P974; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Sanchez LT, 2013, COMMUNICATION; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Soligard T, 2010, BRIT J SPORT MED, V44, P787, DOI 10.1136/bjsm.2009.070672; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	30	43	43	0	48	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2015	43	1					47	56		10.1177/0363546514553090			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AX8KW	WOS:000347159300005	25336600				2021-06-18	
J	Ji, SB; Zhao, W; Li, ZG; McAllister, TW				Ji, Songbai; Zhao, Wei; Li, Zhigang; McAllister, Thomas W.			Head impact accelerations for brain strain-related responses in contact sports: a model-based investigation	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; Contact sports; Concussion; Finite element model; Rotational acceleration; Linear acceleration; Dartmouth Head Injury Model	HIGH-SCHOOL; INJURY; FOOTBALL; CONCUSSIONS; PREDICTORS; EXPOSURE; SIMON	Both linear and rotational accelerations contribute to head impacts on the field in contact sports; however, they are often isolated in injury studies. It is critical to evaluate the feasibility of estimating brain responses using isolated instead of full degrees-of-freedom (DOFs) accelerations. In this study, we investigated the sensitivities of regional brain strain-related responses to resultant and as well as the relative contributions of these acceleration components to the responses via random sampling and linear regression using parameterized, triangulated head impacts with kinematic variable values based on on-field measurements. Two independently established and validated finite element models of the human head were employed to evaluate model-consistency and dependency in results: the Dartmouth Head Injury Model and Simulated Injury Monitor. For the majority of the brain, volume-weighted regional peak strain, strain rate, and von Mises stress accumulated from the simulation significantly correlated with the product of the magnitude and duration of , or effectively, the rotational velocity, but not to . Responses from -only were comparable to the full-DOF counterparts especially when normalized by injury-causing thresholds (e.g., volume fractions of large differences virtually diminished (i.e., 1 %) at typical difference percentage levels of 1-4 % on average). These model-consistent results support the inclusion of both rotational acceleration magnitude and duration into kinematics-based injury metrics and demonstrate the feasibility of estimating strain-related responses from isolated for analyses of strain-induced injury relevant to contact sports without significant loss of accuracy, especially for the cerebrum.	[Ji, Songbai; Zhao, Wei] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ji, Songbai] Dartmouth Coll, Geisel Sch Med, Dept Surg, Lebanon, NH 03766 USA; [Li, Zhigang] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Lebanon, NH 03766 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Ji, SB (corresponding author), Dartmouth Coll, Geisel Sch Med, Dept Surg, Lebanon, NH 03766 USA.	Songbai.Ji@Dartmouth.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS078607]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088781, R21NS078607] Funding Source: NIH RePORTER	This work was sponsored, in part, by the NIH Grant R21 NS078607. The authors would like to thank Dr. Keith D. Paulsen from Thayer School of Engineering, Dartmouth College, Hanover, NH, USA, and Dr. Richard M. Greenwald, Mr. Jonathan G. Beckwith, and Dr. Richard P. Bolander from Simbex, LLC, Lebanon, NH, USA, for their helpful comments on this manuscript.	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; de Lange Ronald, 2005, Stapp Car Crash J, V49, P457; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; HAMBY DM, 1994, ENVIRON MONIT ASSESS, V32, P135, DOI 10.1007/BF00547132; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ji S, 2014, GROUP WISE IN PRESS; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Knudson D, 2007, FUNDAMENTALS BIOMECH; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Morrison B, 2011, STUD MECHANOBIOL TIS, V3, P247, DOI 10.1007/8415_2011_79; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J, 2000, 44 STAPP CAR CRASH C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Trosseille X., 1992, P 36 STAPP CAR CRASH; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao W, 2012, INT J VEH SAF, V6, P91	47	43	44	0	33	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	OCT	2014	13	5					1121	1136		10.1007/s10237-014-0562-z			16	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AP0VF	WOS:000341782900015	24610384	Green Accepted			2021-06-18	
J	Wen, JF; Qian, SK; Yang, QF; Deng, L; Mo, Y; Yu, YF				Wen, Jianfeng; Qian, Suokai; Yang, Qifan; Deng, Lei; Mo, Ye; Yu, Yuefei			Overexpression of netrin-1 increases the expression of tight junction-associated proteins, claudin-5, occludin, and ZO-1, following traumatic brain injury in rats	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						traumatic brain injury; blood-brain barrier; tight junctions; netrin-1	BARRIER PERMEABILITY; CEREBRAL EDEMA; CELLS	The function of the blood-brain barrier (BBB) depends on the integrity of tight junction (TJ)-associated proteins. Netrin-1 is known to promote angiogenesis and may also regulate the BBB. To understand the association between netrin-1 and the TJ-associated proteins, the expression levels of proteins involved in maintaining the integrity of the BBB, including netrin-1, claudin-5, occludin and zonula occluden (ZO)-1, were investigated in the present study using quantitative polymerase chain reaction, western blot analysis and immunofluorescence, The aim of the present study was to determine the changes in BBB permeability and whether pZsGreen1-N1 mediated overexpression of netrin-1 increased the expression of the TJ-associated proteins following traumatic brain injury (TB!). The results demonstrated that the levels of mRNA transcription and protein expression of the TJ-associated proteins, claudin-5, occludin and ZO-1, were significantly reduced following TBI. Furthermore, the changes in the expression of these three TJ proteins were consistent with the changes in the BBB permeability, indicating that weakening intercellular junctions leads to BBB opening. The present study also demonstrated that netrin-1 significantly increased the downregulation of claudin-5, occludin and ZO-1 expression levels induced by TBI, which provided a basis for further investigation on the role of netrin-1 in the integrity of TJs and proper functioning of the BBB.	[Wen, Jianfeng; Yu, Yuefei] Nanchang Univ, Changcheng Sub Hosp, Dept Neurosurg, Nanchang 330002, Jiangxi, Peoples R China; [Wen, Jianfeng; Qian, Suokai; Yang, Qifan; Deng, Lei] 94th Hosp PLA, Dept Neurosurg, Nanchang 330002, Jiangxi, Peoples R China; [Mo, Ye] 94th Hosp PLA, Dept Nursing, Nanchang 330002, Jiangxi, Peoples R China; [Yu, Yuefei] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA	Yu, YF (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, 3,601 4th St, Lubbock, TX 79430 USA.	yfyu1963@gmail.com			Medical Research Subject of the 11th Five-Year Plan of Nanjing Military Region [06MA76]	The study was supported by a grant from the Medical Research Subject of the 11th Five-Year Plan of Nanjing Military Region (no. 06MA76).	ANDERSON JM, 1995, BIOCHEM SOC T, V23, P470, DOI 10.1042/bst0230470; Bamforth SD, 1999, J CELL SCI, V112, P1879; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Fan YF, 2008, J CEREBR BLOOD F MET, V28, P1543, DOI 10.1038/jcbfm.2008.39; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hirase T, 1997, J CELL SCI, V110, P1603; Honda M, 2006, CELL MOL NEUROBIOL, V26, P109, DOI 10.1007/s10571-006-9028-x; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Liu N, 2011, NEUROSCIENCE, V194, P349, DOI 10.1016/j.neuroscience.2011.07.037; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Park KW, 2004, P NATL ACAD SCI USA, V101, P16210, DOI 10.1073/pnas.0405984101; Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704; Zeng Y, 2013, HEAD NECK ONCOL, V5, P6	22	43	47	1	11	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	SEP	2014	8	3					881	886		10.3892/etm.2014.1818			6	Medicine, Research & Experimental	Research & Experimental Medicine	AN8KZ	WOS:000340854400035	25120618	Bronze, Green Published			2021-06-18	
J	Gupta, PK; Sayed, N; Ding, K; Agostini, MA; Van Ness, PC; Yablon, S; Madden, C; Mickey, B; D'Ambrosio, R; Diaz-Arrastia, R				Gupta, Puneet K.; Sayed, Nasreen; Ding, Kan; Agostini, Mark A.; Van Ness, Paul C.; Yablon, Stuart; Madden, Christopher; Mickey, Bruce; D'Ambrosio, Raimondo; Diaz-Arrastia, Ramon			Subtypes of Post-Traumatic Epilepsy: Clinical, Electrophysiological, and Imaging Features	JOURNAL OF NEUROTRAUMA			English	Article						EEG; post-traumatic epilepsy; seizure; surgical resection; traumatic brain injury	TRAUMATIC BRAIN-INJURY; COMPLEX PARTIAL SEIZURES; UNITED-STATES; HEAD-INJURY; EPILEPTOGENESIS; CYTOKINES; MODERATE; ORIGIN; ADULTS	Post-traumatic epilepsy (PTE) is a consequence of traumatic brain injury (TBI), occurring in 10-25% of patients with moderate to severe injuries. The development of animal models for testing antiepileptogenic therapies and validation of biomarkers to follow epileptogenesis in humans necessitates sophisticated understanding of the subtypes of PTE, which is the objective of this study. In this study, retrospective review was performed of patients with moderate to severe TBI with subsequent development of medically refractory epilepsy referred for video-electroencephalography (EEG) monitoring at a single center over a 10-year period. Information regarding details of injury, neuroimaging studies, seizures, video-EEG, and surgery outcomes were collected and analyzed. There were 123 patients with PTE identified, representing 4.3% of all patients evaluated in the epilepsy monitoring unit. Most of them had localization-related epilepsy, of which 57% had temporal lobe epilepsy (TLE), 35% had frontal lobe epilepsy (FLE), and 3% each had parietal and occipital lobe epilepsy. Of patients with TLE, 44% had mesial temporal sclerosis (MTS), 26% had temporal neocortical lesions, and 30% were nonlesional. There was no difference in age at injury between the different PTE subtypes. Twenty-two patients, 13 of whom had MTS, proceeded to surgical resection. At a mean follow-up of 2.5 years, Engel Class I outcomes were seen in 69% of those with TLE and 33% of those with FLE. Our findings suggest PTE is a heterogeneous condition, and careful evaluation with video-EEG monitoring and high resolution MRI can identify distinct syndromes. These results have implications for the design of clinical trials of antiepileptogenic therapies for PTE.	[Gupta, Puneet K.; Sayed, Nasreen; Ding, Kan; Agostini, Mark A.; Van Ness, Paul C.; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Madden, Christopher; Mickey, Bruce] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA; [Yablon, Stuart] Baylor Hlth Care Syst, Baylor Inst Rehabil, Dallas, TX USA; [D'Ambrosio, Raimondo] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Sayed, Nasreen] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Yablon, Stuart] Univ Alberta, Div Phys Med & Rehabil, Edmonton, AB, Canada; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA	Diaz-Arrastia, R (corresponding author), 12725 Twinbrook Pkwy, Rockville, MD 20851 USA.	Ramon.Diaz-Arrastia@usuhs.edu		, Kan/0000-0003-3485-8200; Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD78179, U01 HD42652]; NIDRR [H133 A0205206]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER	This study was sponsored by NIH R01 HD78179, U01 HD42652, NIDRR H133 A0205206.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Grant PE, 2005, EPILEPSIA, V46, P7, DOI 10.1111/j.1528-1167.2005.00303.x; Hartzfeld P, 2008, BRIT J NEUROSURG, V22, P224, DOI 10.1080/02688690701818901; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; Melvin JW, 2002, ACCIDENTAL INJURY BI, P277, DOI [10.1007/978-0-387-21787-1_13, DOI 10.1007/978-0-387-21787-1_13]; Rao RS, 2009, INDIAN J EXP BIOL, V47, P625; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; Williamson P D, 1992, Adv Neurol, V57, P289; WILLIAMSON PD, 1986, EPILEPSIA, V27, pS46, DOI 10.1111/j.1528-1157.1986.tb05740.x; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413	29	43	46	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2014	31	16					1439	1443		10.1089/neu.2013.3221			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4DB	WOS:000340536700007	24693960	Green Published			2021-06-18	
J	Fraas, MR; Coughlan, GE; Hart, EC; McCarthy, C				Fraas, Michael R.; Coughlan, Garrett E.; Hart, Emily C.; McCarthy, Conor			Concussion history and reporting rates in elite Irish rugby union players	PHYSICAL THERAPY IN SPORT			English	Article						Head injury; Epidemiology; Ireland; Rugby union; Concussion reporting rates	FOOTBALL PLAYERS; RECURRENT CONCUSSION; PERFORMANCE PROJECT; CONSENSUS STATEMENT; RISK-FACTORS; INJURIES; EPIDEMIOLOGY; SCHOOL; HEAD; KNOWLEDGE	Objectives: To determine the self-reported, seasonal rates of concussion and the reporting practices among Irish rugby union players. Design: Descriptive epidemiology study. Setting: The study was conducted at the training grounds of four professional Irish rugby union clubs. Participants: One hundred seventy-two players (24.97 +/- 4.11 years of age, 13.49 +/- 5.79 years playing experience) gave consent to participate. Main outcome measures: Number of concussions reported during the 2010-2011 season, reasons for not reporting, and positions of concussed players. Results: Forty-five percent of players reported at least one concussion during the 2010-2011 season, but only 46.6% of these presented to medical staff. The reasons for not reporting their concussions included, not thinking the injury was serious enough, and not wanting to be removed from the game. The relative proportion of concussions was higher for backs than forwards; however, the severity of injury was greater for forwards. Scrum-halves (12.0%) and flankers (10.9%) accounted for the majority of concussions reported. Conclusions: The self-reported rate of concussion in elite rugby union players in Ireland is higher than reported in other countries or other sports. Many concussions remain unreported and, therefore, unmanaged. However, recent changes in concussion management guidelines by the International Rugby Board may impact future reporting practices of players. (C) 2013 Elsevier Ltd. All rights reserved.	[Fraas, Michael R.] Western Washington Univ, Dept Commun Sci & Disorders, Bellingham, WA 98225 USA; [Fraas, Michael R.; Hart, Emily C.] Elmhurst Coll, Dept Commun Arts & Sci, Chicago, IL USA; [Coughlan, Garrett E.; McCarthy, Conor] Irish Rugby Football Union, Dept Med, Dublin, Ireland; [McCarthy, Conor] Chicago Sch, Dept Psychol, Chicago, IL USA	Fraas, MR (corresponding author), Western Washington Univ, Dept Commun Sci & Disorders, 516 High St, Bellingham, WA 98225 USA.	fraasm@gmail.com					Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; CIOMS, 2002, INT ETH GUID BIOM RE; Coughlan GF, 2011, J ORTHOP SPORT PHYS, V41, P600, DOI 10.2519/jospt.2011.3508; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Holtzhausen LJ, 2006, SAMJ S AFR MED J, V96, P1260; IRB, 2010, LAWS GAM RUGB UN 201; IRFU, 2011, IR RUGB FOOTB UN ANN; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	34	43	43	0	36	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1466-853X			PHYS THER SPORT	Phys. Ther. Sport	AUG	2014	15	3					136	142		10.1016/j.ptsp.2013.08.002			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AL3NL	WOS:000339035300002	24035483				2021-06-18	
J	Williams, MW; Rapport, LJ; Millis, SR; Hanks, RA				Williams, Michael W.; Rapport, Lisa J.; Millis, Scott R.; Hanks, Robin A.			Psychosocial Outcomes After Traumatic Brain Injury: Life Satisfaction, Community Integration, and Distress	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; life satisfaction; emotional distress; community integration; confirmatory factor analysis	QUALITY-OF-LIFE; 1ST 5 YEARS; HEALTH; INDIVIDUALS; DEPRESSION; VALIDITY; RELIABILITY; VALIDATION; PREDICTORS; SEQUELAE	Objective: To examine the relationship between life satisfaction, community integration, and emotional distress in adults with traumatic brain injury (TBI). Method: This was an archival study of a longitudinal data set on the outcome and recovery process of persons with TBI. Participants were 253 consecutive adults with mild complicated, moderate, and severe TBI who were enrolled in a large, longitudinal study of persons with TBI. Main measures included the Satisfaction with Life Scale, the Positive Affective and Negative Affective Schedule, the Craig Hospital Assessment and Reporting Technique Short-Form, the Community Integration Measure, and the Brief Symptom Inventory-18. Results: The three-factor model adequately fit the data, and a higher-order model did not necessarily improve model fit but revealed significant relationships with first-order constructs and one second-order construct. Conclusions: Life satisfaction, community integration, and emotional distress were found to be related yet unique concepts in persons with TBI. Life satisfaction was positively related to community involvement and inversely related to emotional distress. Community integration was inversely related to emotional distress. In addition, these concepts are related to a higher-order concept of psychosocial status, a global representation of subjective and objective functioning. These findings demonstrate the interrelated and dynamic nature of psychosocial well-being after brain injury and highlight the need for integrative and holistic treatment plans.	[Williams, Michael W.; Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Millis, Scott R.; Hanks, Robin A.] Wayne State Univ, Sch Medicine, Dept Phys Med & Rehabil, Detroit, MI 48202 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave,7th Floor, Detroit, MI 48202 USA.	Rapport@wayne.edu					BARRERA M, 1986, AM J COMMUN PSYCHOL, V14, P413, DOI 10.1007/BF00922627; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Braden CA, 2012, BRAIN INJURY, V26, P1315, DOI 10.3109/02699052.2012.706351; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Griffen JA, 2010, REHABIL PSYCHOL, V55, P292, DOI 10.1037/a0020503; Griffen JA, 2009, TOP STROKE REHABIL, V16, P212, DOI 10.1310/tsr1603-212; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Jewkes R, 1996, SOC SCI MED, V43, P555, DOI 10.1016/0277-9536(95)00439-4; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jones TG, 2003, CLIN NEUROPSYCHOL, V17, P3, DOI 10.1076/clin.17.1.3.15626; Joreskog K.G., 2006, LISREL 8 80 WINDOWS; KAPLAN S, 1991, CLIN NEUROPSYCHOL, V5, P360, DOI DOI 10.1080/13854049108404103; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Mellick D., 2000, CRAIG HANDICAP ASSES; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Rapport LJ, 2008, ARCH PHYS MED REHAB, V89, P922, DOI 10.1016/j.apmr.2008.01.009; Raykov T., 2000, 1 COURSE STRUCTURAL; Reistetter TA, 2005, NEUROREHABILITATION, V20, P139; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Roebuck-Spencer T., 2008, TXB CLIN NEUROPSYCHO, P411; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063	47	43	43	1	22	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2014	59	3					298	305		10.1037/a0037164			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	AN2RH	WOS:000340432500006	25019312				2021-06-18	
J	Simkin, DR; Thatcher, RW; Lubar, J				Simkin, Deborah R.; Thatcher, Robert W.; Lubar, Joel			Quantitative EEG and Neurofeedback in Children and Adolescents Anxiety Disorders, Depressive Disorders, Comorbid Addiction and Attention-deficit/Hyperactivity Disorder, and Brain Injury	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Quantitative EEG; Neurofeedback; LORETA; Anxiety disorders; Depression; Addiction; ADHD; Brain injury in children and adolescents	DEFICIT HYPERACTIVITY DISORDER; RESOLUTION ELECTROMAGNETIC TOMOGRAPHY; ELECTROENCEPHALOGRAPHIC BIOFEEDBACK; MARIJUANA USE; HEAD-INJURY; WISC-R; QEEG; ADHD; THERAPY; LONG	This article explores the science surrounding neurofeedbdck. Both surface neurofeedback (using 2-4 electrodes) and newer interventions, such as real-time z-score neurofeedback (electroencephalogram [EEG] biofeedback) and low-resolution electromagnetic tomography neurofeedback, are reviewed. The limited literature on neurofeedback research in children and adolescents is discussed regarding treatment of anxiety, mood, addiction (with comorbid attention-deficit/hyperactivity disorder), and traumatic brain injury. Future potential applications, the use of quantitative EEG for determining which patients will be responsive to medications, the role of randomized controlled studies in neurofeedback research, and sensible clinical guidelines are considered.	[Simkin, Deborah R.] Amer Acad Child & Adolescent Psychiat, Memory & Cognit Ctr, Comm Integrat Med, Destin, FL 32541 USA; [Simkin, Deborah R.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA; [Thatcher, Robert W.] Appl Neurosci Res Inst, Neuroimaging Lab, Seminole, FL 33772 USA; [Lubar, Joel] Univ Tennessee, Knoxville, TN USA; [Lubar, Joel] Southeastern Neurofeedback Inst Inc, Pompano Beach, FL 33062 USA	Simkin, DR (corresponding author), 4641 Gulfstarr Dr,Suite 106, Destin, FL 32541 USA.	deb62288@aol.com					ABRAHAM HD, 1989, AM J PSYCHIAT, V146, P947; Adolphs RJ, 2004, PRINCIPLES PRACTICE, P451; Arnold LE, 2013, J ATTEN DISORD, V17, P420, DOI 10.1177/1087054713482580; Arnold LE, 2012, J ATTEN DISORD, V17, P1; Arns M, 2014, BIOL PSYCHOL, V95, P108, DOI 10.1016/j.biopsycho.2013.11.013; Arns M, 2013, AM J PSYCHIAT, V170, P799, DOI 10.1176/appi.ajp.2013.13020208; Arns M, 2012, APPL PSYCHOPHYS BIOF, V37, P171, DOI 10.1007/s10484-012-9191-4; Arns M, 2009, CLIN EEG NEUROSCI, V40, P180, DOI 10.1177/155005940904000311; AYERS M, 1995, BIOFEEDBACK SELF-REG, V20, P318; Bares M, 2012, J PSYCHIATR RES, V46, P219, DOI 10.1016/j.jpsychires.2011.09.006; Bauer LO, 2001, NEUROPSYCHOPHARMACOL, V25, P332, DOI 10.1016/S0893-133X(01)00236-6; Beauregard M, 2006, APPL PSYCHOPHYSIOL B, V31; Bosch-Bayard J, 2001, CLIN ELECTROENCEPHAL, V32, P47, DOI 10.1177/155005940103200203; Brodmann K., 1909, VERGLEICHENDE LOKALI; Brodmann VK, 1909, LOCALIZATION CEREBRA; BUCHSBAUM MS, 1985, BIOL PSYCHIAT, V20, P832, DOI 10.1016/0006-3223(85)90208-2; Buckholtz JW, 2012, NEURON, V74, P990, DOI 10.1016/j.neuron.2012.06.002; Buzsaki G., 2006, RHYTHMS BRAIN; Cannon RL, 2012, LOW RESOLUTION BRAIN, P3; Canterberry M, 2013, NICOTINE TOB RES, V15, P2120, DOI 10.1093/ntr/ntt122; Chabot RJ, 2005, CHILD ADOL PSYCH CL, V14, P21, DOI 10.1016/j.chc.2004.07.005; Chabot RJ, 2001, J NEUROPSYCH CLIN N, V13, P171, DOI 10.1176/appi.neuropsych.13.2.171; Chabot RJ, 1996, CLIN ELECTROENCEPHAL, V27, P26, DOI 10.1177/155005949602700105; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Clarke AR, 2001, PSYCHIAT RES, V103, P205, DOI 10.1016/S0165-1781(01)00277-3; Collura T., 2010, J NEUROTHERAPY, V14, P22, DOI [DOI 10.1080/10874200903543963, 10.1080/10874200903543963]; Collura TF, 2008, INTRO QEEG NEUROFEED, P123; Cook IA, 2002, NEUROPSYCHOPHARMACOL, V27, P120, DOI 10.1016/S0893-133X(02)00294-4; Coutin-Churchman P, 2003, CLIN NEUROPHYSIOL, V114, P2294, DOI 10.1016/S1388-2457(03)00228-1; CZOBOR P, 1991, BIOL PSYCHIAT, V30, P927, DOI 10.1016/0006-3223(91)90006-8; DeBoer P, 1996, J PHARMACOL EXP THER, V277, P775; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; DUFFY FH, 1994, CLIN ELECTROENCEPHAL, V25, pR6, DOI 10.1177/155005949402500403; Earnest C., 1999, J NEUROTHER, V3, P28; Egner T, 2003, NEUROREPORT, V14, P1221, DOI 10.1097/00001756-200307010-00006; Eismont EV, 2011, NEUROPHYSIOLOGY+, V43, P53, DOI 10.1007/s11062-011-9185-5; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; Foster D, 2013, INT SOC NEUR RES C D; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hajek T, 2013, AM AC CHILD AD PSYCH; Hammond D.C., 2011, J NEUROTHER, V15, P305, DOI [DOI 10.1080/10874208.2011.623090, 10.1080/10874208.2011.623090]; Hammond DC, 2008, J NEUROTHERAPY, V12, P79, DOI DOI 10.1080/10874200802219947; Hansen ES, 2003, CLIN ELECTROENCEPHAL, V34, P70, DOI 10.1177/155005940303400205; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Huang-Storms L, 2006, J NEUROTHERAPY, V10, P3, DOI DOI 10.1300/J184V10N04_; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Hughes SW, 2007, INT J PSYCHOPHYSIOL, V64, P3, DOI 10.1016/j.ijpsycho.2006.08.004; Hunter AM, 2010, ACTA PSYCHIAT SCAND, V122, P461, DOI 10.1111/j.1600-0447.2010.01560.x; Hunter AM, 2007, PSYCHIAT CLIN N AM, V30, P105, DOI 10.1016/j.psc.2006.12.002; Hwang K, 2012, CEREBRAL CORTEX; Ikarashi Y, 1997, NEUROCHEM INT, V30, P191, DOI 10.1016/S0197-0186(96)00024-1; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; JENIKE MA, 1984, J CLIN PSYCHIAT, V45, P122; Jiang L, 2011, NEUROSCI LETT, V505, P160, DOI 10.1016/j.neulet.2011.10.011; John E. R., 1993, ELECTROENCEPHALOGRAP, P989; John ER, 2005, PROG BRAIN RES, V150, P143, DOI 10.1016/S0079-6123(05)50011-6; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1983, PROG NEUROBIOL, V21, P239, DOI 10.1016/0301-0082(83)90014-X; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kentgen LM, 2000, J ABNORM PSYCHOL, V109, P797, DOI 10.1037/0021-843X.109.4.797; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Leuchter AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032508; Levesque J, 2006, NEUROSCI LETT, V394, P216, DOI 10.1016/j.neulet.2005.10.100; LEVY F, 1991, AUST NZ J PSYCHIAT, V25, P277, DOI 10.3109/00048679109077746; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; Lubar JF, 1981, ARCH NEUROL-CHICAGO, V38, P699; LUBAR JO, 1984, BIOFEEDBACK SELF-REG, V9, P1, DOI 10.1007/BF00998842; Michel CM., 2009, ELECT NEUROIMAGING; Monastra VJ, 2005, APPL PSYCHOPHYS BIOF, V30, P95, DOI 10.1007/s10484-005-4305-x; Monastra VJ, 2005, CHILD ADOL PSYCH CL, V14, P55, DOI 10.1016/j.chc.2004.07.004; Monastra VJ, 2002, APPL PSYCHOPHYS BIOF, V27, P231, DOI 10.1023/A:1021018700609; Nazari M.A., 2012, NEUROSCI MED, V2, P78, DOI [DOI 10.4236/NM.2011.22012, 10.4236/nm.2011.22012]; Niedermeyer E, 1997, CLIN ELECTROENCEPHAL, V28, P130, DOI 10.1177/155005949702800303; NUNEZ P, 1994, NEOCORTICAL DYNAMICS; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 2003, CLIN NEUROPHYSIOL, V114, P2225, DOI 10.1016/S1388-2457(03)00310-9; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Pascual-Marqui RD, 1999, PSYCHIAT RES-NEUROIM, V90, P169, DOI 10.1016/S0925-4927(99)00013-X; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Peniston EG, 1991, MED PSYCHOTHERAPY, V2, P37; Peniston EG, 1991, MED PSYCHOTHERAPY, V4, P47; Phillips ML, 2013, AM AC CHILD AD PSYCH; Power JD, 2010, NEURON, V67, P735, DOI 10.1016/j.neuron.2010.08.017; Prichep L, 1996, RES MONOGRAPH, V162, P142; PRICHEP L S, 1992, Brain Topography, V4, P249, DOI 10.1007/BF01135562; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Prichep LS, 2002, CLIN ELECTROENCEPHAL, V33, P8, DOI 10.1177/155005940203300104; PRICHEP LS, 1993, PSYCHIAT RES-NEUROIM, V50, P25; PRICHEP LS, 1986, BRAIN ELECTRICAL POT, P223; Raymond J, 2005, COGNITIVE BRAIN RES, V23, P287, DOI 10.1016/j.cogbrainres.2004.10.023; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROEMER RA, 1991, NEUROPSYCHOBIOLOGY, V24, P121; RUSSELL V, 1995, BRAIN RES, V676, P343, DOI 10.1016/0006-8993(95)00135-D; Sherlin L, 2010, J NEUROTHERAPY, V14, P66, DOI DOI 10.1080/10874201003773880; Small JG, 1993, ELECTROENCEPHALOGRAP, P581; Sonuga-Barke EJS, 2013, AM J PSYCHIAT, V170, P275, DOI 10.1176/appi.ajp.2012.12070991; Struve FA, 1998, CLIN ELECTROENCEPHAL, V29, P31, DOI 10.1177/155005949802900110; STRUVE FA, 1994, CLIN ELECTROENCEPHAL, V25, P63, DOI 10.1177/155005949402500207; SUFFIN SC, 1995, CLIN ELECTROENCEPHAL, V26, P76, DOI 10.1177/155005949502600204; Sunrmeli T, 2007, J NEUROTHERAPY, V11, P63, DOI DOI 10.1300/J184v11n01_07; Surmeli T, 2010, CLIN EEG NEUROSCI, V41, P32, DOI 10.1177/155005941004100108; TALAIRACH J, 1998, CO PLANAR STEREOTAXI; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher R. W., 2003, Journal of Neurotherapy, V7, P87, DOI 10.1300/J184v07n03_05; Thatcher RW, 2011, NEUROPSYCHIATRY-LOND, V1, P495, DOI 10.2217/npy.11.45; Thatcher RW, 2012, HUM BRAIN MAPP, V33, P1062, DOI 10.1002/hbm.21271; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P1, DOI 10.1177/155005940503600103; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thatcher RW, 2008, INTRO QEEG NEUROFEED; Thatcher RW, 2012, HDB QUANTITATIVE ELE, P10; THATCHER RW, 1994, FUNCTIONAL NEUROIMAG, P269; Thatcher RW, 1996, DEV NEUROIMAGING MAP; Thornton KE, 2008, APPL PSYCHOPHYS BIOF, V33, P101, DOI 10.1007/s10484-008-9056-z; Thornton KE, 2009, APPL PSYCHOPHYS BIOF, V34, P59, DOI 10.1007/s10484-009-9075-4; Tiesinga PH, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00196; Tomarken AJ, 2004, BIOL PSYCHOL, V67, P77, DOI 10.1016/j.biopsycho.2004.03.011; VALDES P, 1992, Brain Topography, V4, P259, DOI 10.1007/BF01135563; van Dongen-Boomsma M, 2013, J CLIN PSYCHIAT, V74, P821, DOI 10.4088/JCP.12m08321; Walker J.E., 2007, HDB NEUROFEEDBACK, P341; Walker JE, 2005, CHILD ADOL PSYCH CL, V14, P163, DOI 10.1016/j.chc.2004.07.009; WANG B, 1994, FUNCTIONAL NEUROIMAG, P251; WHEELER RE, 1993, PSYCHOPHYSIOLOGY, V30, P82, DOI 10.1111/j.1469-8986.1993.tb03207.x	126	43	44	4	79	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1056-4993	1558-0490		CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	JUL	2014	23	3					427	+		10.1016/j.chc.2014.03.001			39	Psychiatry	Psychiatry	AL8TH	WOS:000339411900002	24975621				2021-06-18	
J	Wang, Y; Yue, XY; Kiesewetter, DO; Niu, G; Teng, GJ; Chen, XY				Wang, Yu; Yue, Xuyi; Kiesewetter, Dale O.; Niu, Gang; Teng, Gaojun; Chen, Xiaoyuan			PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						Traumatic brain injury (TBI); Translocator protein (TSPO); [F-18]DPA-714; PET; Molecular imaging	PERIPHERAL BENZODIAZEPINE-RECEPTOR; POSITRON-EMISSION-TOMOGRAPHY; TRANSLOCATOR PROTEIN; IN-VIVO; ACTIVATED MICROGLIA; NERVOUS-SYSTEM; ASTROCYTES; EXPRESSION; ALZHEIMERS; DISEASE	Purpose The inflammatory response in injured brain parenchyma after traumatic brain injury (TBI) is crucial in the pathological process. In order to follow microglia activation and neuroinflammation after TBI, we performed PET imaging in a rat model of TBI using F-18-labeled DPA-714, a ligand of the 18-kDa translocator protein (TSPO). Methods TBI was induced in male SD rats by a controlled cortical impact. The success of the TBI model was confirmed by MRI. [F-18]DPA-714 was synthesized using a slightly modified TRACERLab FX-FN module and an automated procedure. In vivo PET imaging was performed at different time points after surgery using an Inveon small-animal PET scanner. The specificity of [F-18]DPA-714 was confirmed by a displacement study with an unlabeled competitive TSPO ligand, PK11195. Ex vivo autoradiography as well as immunofluorescence staining was carried out to confirm the in vivo PET results. Results Both in vivo T-2-weighted MR images and ex vivo TTC staining results revealed successful establishment of the TBI model. Compared with the sham-treated group, [F-18]DPA-714 uptake was significantly higher in the injured brain area on PET images. Increased lesion-to-normal ratios of [F-18]DPA-714 were observed in the brain of TBI rats on day 2 after surgery. Ratios peaked around day 6 (2.65 +/- 0.36) and then decreased gradually to nearly normal levels on day 28. The displacement study using PK11195 confirmed the specific binding of [F-18]DPA-714 to TSPO. The results of ex vivo autoradiography were consistent with in vivo PET results. Immunofluorescence staining showed the time course of TSPO expression after TBI and the temporal and the spatial distribution of microglia in the damaged brain area. Conclusion TSPO-targeted PET using [F-18]DPA-714 as the imaging probe can be used to dynamically monitor the inflammatory response after TBI in a noninvasive manner. This method will not only facilitate a better understanding of the inflammatory process after TBI, but also provide a useful in vivo monitoring strategy for antiinflammation therapy of TBI.	[Wang, Yu; Teng, Gaojun] Southeast Univ, Jiangsu Key Lab Mol Imaging & Funct Imaging, Dept Radiol, Zhongda Hosp,Med Sch, Nanjing 210009, Jiangsu, Peoples R China; [Wang, Yu; Yue, Xuyi; Kiesewetter, Dale O.; Niu, Gang; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA	Teng, GJ (corresponding author), 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.	niug@mail.nih.gov; gjteng@vip.sina.com; shawn.chen@nih.gov	yue, xuyi/AAE-9006-2020; Chen, Xiaoyuan/D-1860-2014	yue, xuyi/0000-0002-3783-6392; Chen, Xiaoyuan/0000-0002-9622-0870	National Basic Research Program of China (973 program)National Basic Research Program of China [2013CB733803, 2013CB733802]; Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073] Funding Source: NIH RePORTER	This work was supported by the National Basic Research Program of China (973 program, 2013CB733803, 2013CB733802), and the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH).	Arlicot N, 2012, NUCL MED BIOL, V39, P570, DOI 10.1016/j.nucmedbio.2011.10.012; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boutin H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056441; Cai WB, 2009, STROKE, V40, P270, DOI 10.1161/STROKEAHA.108.517474; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chauveau F, 2009, J NUCL MED, V50, P468, DOI 10.2967/jnumed.108.058669; Chen DL, 2004, AM J PHYSIOL-LUNG C, V286, pL834, DOI 10.1152/ajplung.00339.2003; Chen MK, 2004, BRAIN, V127, P1379, DOI 10.1093/brain/awh161; Council NR, 2010, GUIDE CARE USE LAB A; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; GALAN X, 1993, BIOL NEONATE, V64, P295; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; James ML, 2008, J NUCL MED, V49, P814, DOI 10.2967/jnumed.107.046151; James ML, 2006, CURR MED CHEM, V13, P1991, DOI 10.2174/092986706777584979; Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008; Kuhnast B, 2012, APPL RADIAT ISOTOPES, V70, P489, DOI 10.1016/j.apradiso.2011.10.015; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Martin A, 2010, J CEREBR BLOOD F MET, V30, P230, DOI 10.1038/jcbfm.2009.205; Radu CG, 2007, P NATL ACAD SCI USA, V104, P1937, DOI 10.1073/pnas.0610544104; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Tardy M, 1990, Adv Exp Med Biol, V265, P41; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Venneti S, 2009, NEUROBIOL AGING, V30, P1217, DOI 10.1016/j.neurobiolaging.2007.11.005; Winkeler A, 2012, EUR J NUCL MED MOL I, V39, P811, DOI 10.1007/s00259-011-2041-4; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196	34	43	44	1	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1619-7070	1619-7089		EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	JUL	2014	41	7					1440	1449		10.1007/s00259-014-2727-5			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AI9UR	WOS:000337286200020	24615467	Green Accepted			2021-06-18	
J	Dayan, PS; Holmes, JF; Atabaki, S; Hoyle, J; Tunik, MG; Lichenstein, R; Alpern, E; Miskin, M; Kuppermann, N				Dayan, Peter S.; Holmes, James F.; Atabaki, Shireen; Hoyle, John, Jr.; Tunik, Michael G.; Lichenstein, Richard; Alpern, Elizabeth; Miskin, Michelle; Kuppermann, Nathan		Traumatic Brain Injury Study Grp	Association of Traumatic Brain Injuries With Vomiting in Children With Blunt Head Trauma	ANNALS OF EMERGENCY MEDICINE			English	Article							DECISION RULE; INTRACRANIAL INJURY; COMPUTED-TOMOGRAPHY; PREDICTION; CONSCIOUSNESS; VARIABLES; RISK	Study objective: We aimed to determine the prevalence of traumatic brain injuries in children who vomit after minor blunt head trauma, particularly when the vomiting occurs without other-findings suggestive of traumatic brain injury (ie, isolated vomiting). We also aimed to determine the relationship between the timing and degree of vomiting and traumatic brain injury prevalence. Methods: This was a secondary analysis of children younger than 18 years with minor blunt head trauma. Clinicians assessed for history and characteristics of vomiting at the initial evaluation. We assessed for the prevalence of clinically important traumatic brain injury and traumatic brain injury on computed tomography (CT). Results: Of 42,112 children enrolled, 5,557 (13.2%) had a history of vomiting, of whom 815 of 5,392 (15.1%) with complete data had isolated vomiting. Clinically important traumatic brain injury Occurred in 2 of 815 patients (0.2%; 95% confidence interval [Cl] 0% to 0.9%) with isolated vomiting compared with 114 Of 4,577 (2.5%; 95% Cl 2.1% to 3.0%) with nonisolated vomiting (difference -2.3%, 95% Cl -2.8% to -1.5%). Of patients with isolated vomiting for whom CT was performed, traumatic brain injury on CT occurred in 5 of 298 (1.7%; 95% Cl 0.5% to 3.9%) compared with 211 of 3,284 (6.4%; 95% Cl 5.6% to 7.3%) with nonisolated vomiting (difference -4.7%; 95% Cl -6.0% to -2.4%). We found no significant independent associations between prevalence of clinically important traurhatic brain injury and traumatic brain injury on CT with either the timing of onset or time since the last episode of vomiting. Conclusion: Traumatic brain injury on CT is uncommon and clinically important traumatic brain injury is very uncommon in children with minor blunt head trauma when vomiting is their only sign or symptom. Observation in the emergency department before determining the need for CT appears appropriate for many of these children.	[Dayan, Peter S.] Columbia Univ, Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Pediat Emergency Med, New York, NY 10027 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Davis Sch Med, Dept Emergency Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Davis Sch Med, Dept Pediat, Davis, CA 95616 USA; [Atabaki, Shireen] George Washington Univ, Sch Med, Dept Pediat, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Atabaki, Shireen] George Washington Univ, Sch Med, Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC USA; [Hoyle, John, Jr.] Helen DeVos Childrens Hosp, Div Emergency Med, Grand Rapids, MI USA; [Tunik, Michael G.] NYU, Sch Med, Dept Pediat, New York, NY USA; [Tunik, Michael G.] NYU, Sch Med, Dept Emergency Med, New York, NY USA; [Lichenstein, Richard] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Alpern, Elizabeth] Univ Penn, Sch Med, Div Emergency Med, Philadelphia, PA 19104 USA; [Miskin, Michelle] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA	Dayan, PS (corresponding author), Columbia Univ, Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Pediat Emergency Med, New York, NY 10027 USA.	psd6@columbia.edu		Holubkov, Richard/0000-0003-0431-3381; Alpern, Elizabeth/0000-0001-7887-3563; Tunik, Michael/0000-0002-2368-5933; Tsung, James/0000-0002-4718-8325	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U03MC00006, U03MC00008, U03MC00007, R40MC02461, U03MC00001, U03MC00003] Funding Source: Medline		Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; National Center for Injury Prevention and Control, TRAUM BRAIN INJ US; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Quayle KS, 1997, PEDIATRICS, V9, pE1; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Sun BC, 2007, ANN EMERG MED, V49, P325, DOI 10.1016/j.annemergmed.2006.08.032	22	43	44	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	2014	63	6					657	665		10.1016/j.annemergmed.2014.01.009			9	Emergency Medicine	Emergency Medicine	AI7XA	WOS:000337115100006	24559605				2021-06-18	
J	Karimi, A; Navidbakhsh, M; Razaghi, R				Karimi, Alireza; Navidbakhsh, Mandi; Razaghi, Reza			An experimental-finite element analysis on the kinetic energy absorption capacity of polyvinyl alcohol sponge	MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS			English	Article						Polyvinyl alcohol sponge; Helmet; Finite element; Kinetic energy absorption; Energy loss	UNIAXIAL MECHANICAL-PROPERTIES; PLAQUE VULNERABILITY; PVA HYDROGEL; HELMET; HEALTHY; FOAMS; MODEL	Polyvinyl alcohol (PVA) sponge is in widespread use for biomedical and tissue engineering applications owing to its biocompatibility, availability, relative cheapness, and excellent mechanical properties. This study reports a novel concept of design in energy absorbing materials which consist in the use of PVA sponge as an alternative reinforcement material to enhance the energy loss of impact loads. An experimental study is carried out to measure the mechanical properties of the PVA sponge under uniaxial loading. The kinetic energy absorption capacity of the PVA sponge is computed by a hexahedral finite element (FE) model of the steel ball and bullet through the LS-DYNA code under impact load at three different thicknesses (5, 10, 15 mm). The results show that a higher sponge thickness invokes a higher energy loss of the steel ball and bullet. The highest energy loss of the steel ball and bullet is observed for the thickest sponge with 160 and 35J, respectively. The most common type of traumatic brain injury in which the head subject to impact load causes the brain to move within the skull and consequently brain hemorrhaging. These results suggest the application of the PVA sponge as a great kinetic energy absorber material compared to commonly used expanded polystyrene foams (EPS) to absorb most of the impact energy and reduces the transmitted load. The results might have implications not only for understanding of the mechanical properties of PVA sponge but also for use as an alternative reinforcement material in helmet and packaging material design. (C) 2014 Elsevier B.V. All rights reserved.	[Navidbakhsh, Mandi] Iran Univ Sci & Technol, Sch Mech Engn, Tehran 16846, Iran; Iran Univ Sci & Technol, Sch Mech Engn, Tissue Engn & Biol Syst Res Lab, Tehran 16846, Iran	Navidbakhsh, M (corresponding author), Iran Univ Sci & Technol, Sch Mech Engn, Tehran 16846, Iran.	mnavid@iust.ac.ir	Razaghi, Reza/S-7173-2019; Navidbakhsh/S-9351-2018	Razaghi, Reza/0000-0002-9563-7535; 	Iran University of Science and Technology	The authors acknowledge the funding supports of this work by the Iran University of Science and Technology.	Caserta GD, 2011, COMPOS STRUCT, V93, P2748, DOI 10.1016/j.compstruct.2011.05.029; Chen YB, 2010, J BIOMECH, V43, P1131, DOI 10.1016/j.jbiomech.2009.12.009; Corkhill P H, 1990, Proc Inst Mech Eng H, V204, P147, DOI 10.1243/PIME_PROC_1990_204_249_02; Di Landro L, 2002, POLYM TEST, V21, P217, DOI 10.1016/S0142-9418(01)00073-3; DiTizio V, 1998, BIOMATERIALS, V19, P1877, DOI 10.1016/S0142-9612(98)00096-9; Faturechi R, 2014, J BIOMATER TISS ENG, V4, P189, DOI 10.1166/jbt.2014.1156; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Karimi A, 2014, MATER TECHNOL, V29, P90, DOI 10.1179/1753555713Y.0000000115; Karimi A, 2014, PERFUSION-UK, V29, P178, DOI 10.1177/0267659113502835; Karimi A., 2014, INT J DAMAGE MECH; Karimi A., 2014, INT J MATER RES, V105, P1; Karimi A., 2013, CHARACTERIZING MECH, V18, P221; Karimi A., 2014, ARTERY RES; Karimi A, 2014, J THERMOPLAST COMPOS, DOI 0892705714533377; Karimi A, 2014, PERFUSION, DOI 0267659114536761.; Karimi A, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40257; Karimi A, 2014, TISSUE CELL, V46, P97, DOI 10.1016/j.tice.2013.12.004; Karimi A, 2014, BIOMED ENG-APP BAS C, V26, DOI 10.4015/S1016237214500136; Karimi A, 2014, J BIOMATER TISS ENG, V4, P46, DOI 10.1166/jbt.2014.1134; Karimi A, 2013, P I MECH ENG H, V227, P609, DOI 10.1177/0954411913476779; Karimi A, 2013, MAT SCI ENG C-MATER, V33, P2550, DOI 10.1016/j.msec.2013.02.016; Karimi A, 2013, P I MECH ENG H, V227, P148, DOI 10.1177/0954411912461239; Kobayashi H, 2004, MAT SCI ENG C-BIO S, V24, P729, DOI 10.1016/j.msec.2004.08.038; Korteweg W., 2004, [No title captured], Patent No. [US 6711879B2, 6711879]; Lee CT, 2005, CARBOHYD POLYM, V61, P348, DOI 10.1016/j.carbpol.2005.06.018; Lee SY, 2009, ACTA BIOMATER, V5, P1919, DOI 10.1016/j.actbio.2009.02.014; Liu DS, 2003, ENG FAIL ANAL, V10, P581, DOI 10.1016/S1350-6307(03)00040-2; Liu LF, 2012, WATER RES, V46, P1969, DOI 10.1016/j.watres.2012.01.017; MILLS NJ, 1991, ACCIDENT ANAL PREV, V23, P153, DOI 10.1016/0001-4575(91)90045-7; Moscato S, 2008, MICRON, V39, P569, DOI 10.1016/j.micron.2007.06.016; Pinnoji PK, 2010, MATER DESIGN, V31, P3716, DOI 10.1016/j.matdes.2010.03.011; Setiawan L, 2012, J MEMBRANE SCI, V394, P80, DOI 10.1016/j.memsci.2011.12.026; Shi Y, 2013, WEAR, V305, P280, DOI 10.1016/j.wear.2012.12.020; Shuaeib FM, 2002, J MATER PROCESS TECH, V123, P422, DOI 10.1016/S0924-0136(02)00047-X; Stammen JA, 2001, BIOMATERIALS, V22, P799, DOI 10.1016/S0142-9612(00)00242-8; Thali MJ, 2002, FORENSIC SCI INT, V125, P178, DOI 10.1016/S0379-0738(01)00637-5; Young CD, 1998, BIOMATERIALS, V19, P1745, DOI 10.1016/S0142-9612(98)00083-0; Zhang DK, 2012, J BIONIC ENG, V9, P234, DOI 10.1016/S1672-6529(11)60116-9; Zhang JY, 2005, J NEUROTRAUM, V22, P1335, DOI 10.1089/neu.2005.22.1335	39	43	44	2	37	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-4931	1873-0191		MAT SCI ENG C-MATER	Mater. Sci. Eng. C-Mater. Biol. Appl.	JUN 1	2014	39						253	258		10.1016/j.msec.2014.03.009			6	Materials Science, Biomaterials	Materials Science	AS0DS	WOS:000343949200034	24863223				2021-06-18	
J	Koenig, CJ; Maguen, S; Monroy, JD; Mayott, L; Seal, KH				Koenig, Christopher J.; Maguen, Shira; Monroy, Jose D.; Mayott, Lindsay; Seal, Karen H.			Facilitating culture-centered communication between health care providers and veterans transitioning from military deployment to civilian life	PATIENT EDUCATION AND COUNSELING			English	Article						Patient-centered care; Health communication; Culture; Post-deployment health; Readjustment experience; Military veterans; USA	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; AFGHANISTAN VETERANS; MENTAL-HEALTH; DISCOURSE ANALYSIS; COMBAT; BARRIERS; WOMEN; IRAQ; HOME	Objective: To describe returning veterans' transition experience from military to civilian life and to educate health care providers about culture-centered communication that promotes readjustment to civilian life. Methods: Qualitative, in-depth, semi-structured interviews with 17 male and 14 female Iraq and Afghanistan veterans were audio recorded, transcribed verbatim, and analyzed using Grounded Practical Theory. Results: Veterans described disorientation when returning to civilian life after deployment. Veterans' experiences resulted from an underlying tension between military and civilian identities consistent with reverse culture shock. Participants described challenges and strategies for managing readjustment stress across three domains: intrapersonal, professional/educational, and interpersonal. Conclusions: To provide patient-centered care to returning Iraq and Afghanistan veterans, health care providers must be attuned to medical, psychological, and social challenges of the readjustment experience, including reverse culture shock. Cultufe-centered communication may help veterans integrate positive aspects of military and civilian identities, which may promote full reintegration into civilian life. Practice implications: Health care providers may promote culture-centered interactions by asking veterans to reflect about their readjustment experiences. By actively eliciting challenges and helping veterans' to identify possible solutions, health care providers may help veterans integrate military and civilian identities through an increased therapeutic alliance and social support throughout the readjustment process. Published by Elsevier Ireland Ltd.	[Koenig, Christopher J.; Maguen, Shira; Monroy, Jose D.; Mayott, Lindsay; Seal, Karen H.] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA; [Koenig, Christopher J.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA; [Maguen, Shira; Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Koenig, Christopher J.; Mayott, Lindsay; Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Monroy, Jose D.] San Francisco State Univ, Dept Psychol, San Francisco, CA 94132 USA	Koenig, CJ (corresponding author), San Francisco Vet Adm Med Ctr, Dept Med, 4150 Clement St,111-A1, San Francisco, CA 94121 USA.	Christopher.Koenig@va.gov	Koenig, Christopher J./AAA-2831-2020	Koenig, Christopher J./0000-0003-0884-4120	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0106]	Department of Defense award W81XWH-08-2-0106 funded this study. The funders had no role in the design, data analysis, writing or approval of the manuscript.	Abramson CM, 2012, J THEOR SOC BEHAV, V42, P155, DOI 10.1111/j.1468-5914.2011.00484.x; ADLER PS, 1975, J HUMANIST PSYCHOL, V15, P13; Ames GM, 2007, J STUD ALCOHOL DRUGS, V68, P336, DOI 10.15288/jsad.2007.68.336; Anderson LM, 2003, AM J PREV MED, V24, P68, DOI 10.1016/S0749-3797(02)00657-8; Arthur N., 2000, CAN J COUNS, V34, P204; Beder J, 2011, SOC WORK HEALTH CARE, V50, P515, DOI 10.1080/00981389.2011.554279; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Berntsen D, 2006, BEHAV RES THER, V44, P219, DOI 10.1016/j.brat.2005.01.009; Brown WV, 2011, J CLIN LIPIDOL, V5, P1, DOI 10.1016/j.jacl.2010.11.010; Butler CW, 2010, SOC PSYCHOL QUART, V73, P265, DOI 10.1177/0190272510379838; Chretien JP, 2013, J GEN INTERN MED, V28, P953, DOI 10.1007/s11606-013-2359-7; Coll JE, 2011, SOC WORK HEALTH CARE, V50, P487, DOI 10.1080/00981389.2010.528727; Crabtree B.F., 1999, DOING QUALITATIVE RE; CRAIG RT, 1995, COMMUN THEOR, V5, P248, DOI 10.1111/j.1468-2885.1995.tb00108.x; Cuber BJF, 2012, MARRIAGE FAM LIVING, V7, P28; Demers A, 2011, J LOSS TRAUMA, V16, P160, DOI 10.1080/15325024.2010.519281; Dutta MJ, 2007, COMMUN THEOR, V17, P304, DOI 10.1111/j.1468-2885.2007.00297.x; FAULKNER RR, 1977, URBAN LIFE, V6, P303, DOI 10.1177/089124167700600303; GALBRAITH H M, 1945, J Okla State Med Assoc, V38, P481; Gaw KF, 2000, INT J INTERCULT REL, V24, P83, DOI 10.1016/S0147-1767(99)00024-3; Goldsmith DJ, 1997, HUM COMMUN RES, V23, P454, DOI 10.1111/j.1468-2958.1997.tb00406.x; Halfon N, 2002, MILBANK Q, V80, P433, DOI 10.1111/1468-0009.00019; Hall LK, 2011, SOC WORK HEALTH CARE, V50, P4, DOI 10.1080/00981389.2010.513914; Heritage J, 1992, DILEMMAS ADVICE ASPE, P359; Hinojosa R, 2010, J AM BOARD FAM MED, V23, P770, DOI 10.3122/jabfm.2010.06.100094; Hobbs K, 2008, AAOHN J, V56, P337, DOI 10.3928/08910162-20080801-07; Koenig CJ, 2012, HEALTH COMMUN, V27, P818, DOI 10.1080/10410236.2011.651708; Kuehner CA, 2013, J AM ACAD NURSE PRAC, V25, P77, DOI 10.1111/j.1745-7599.2012.00810.x; Kvale S, 2009, INTERVIEWS LEARNING; Lannin DR, 2002, AM J SURG, V184, P418, DOI 10.1016/S0002-9610(02)01009-7; Lapp CA, 2010, J FAM NURS, V16, P45, DOI 10.1177/1074840709357347; Lomsky-Feder E, 2008, ARMED FORCES SOC, V34, P593, DOI 10.1177/0095327X07312090; Maguen S, 2006, J LOSS TRAUMA, V11, P373, DOI 10.1080/15325020600672004; Maguen S, 2010, PROF PSYCHOL-RES PR, V41, P135, DOI 10.1037/a0018835; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; Muhr T, 1999, ATLAS TI 6 X; Nayback AM, 2008, J PSYCHOSOC NURS MEN, V46, P43; Ouimette P, 2011, PSYCHOL SERV, V8, P212, DOI 10.1037/a0024360; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ray SL, 2011, J PSYCHIATR MENT HLT, V18, P198, DOI 10.1111/j.1365-2850.2010.01652.x; Roberts C, 2005, MED EDUC, V39, P632, DOI 10.1111/j.1365-2929.2005.02171.x; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Saha S, 2008, J NATL MED ASSOC, V100, P1275, DOI 10.1016/S0027-9684(15)31505-4; Sayer NA, 2009, PSYCHIATRY, V72, P238, DOI 10.1521/psyc.2009.72.3.238; Sayers SL, 2009, J CLIN PSYCHIAT, V8, pe1; Schegloff EA, 2005, SOC PROBL, V52, P449, DOI 10.1525/sp.2005.52.4.449; Schuetz A, 1945, AM J SOCIOL, V50, P369, DOI 10.1086/219654; Seal KH, 2011, J GEN INTERN MED, V26, P1160, DOI 10.1007/s11606-011-1746-1; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Sewell WH, 1999, STUD HIST SOC CULT, V34, P35; Shaw SE, 2009, FAM PRACT, V26, P413, DOI 10.1093/fampra/cmp038; Shuy RW, 2002, IN PERSON VERSUS TEL, P537; Silverstein R, 1996, J GENET PSYCHOL, V157, P169, DOI 10.1080/00221325.1996.9914855; SOLOMON Z, 1988, PSYCHIATRY, V51, P323, DOI 10.1080/00332747.1988.11024407; Sorsdahl MN, 2010, REENTRY TRANSITION F; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Stachyra A., 2011, BEING BECOMING US IR; Strauss A., 1998, BASICS QUALITATIVE R; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Teal CR, 2009, SOC SCI MED, V68, P533, DOI 10.1016/j.socscimed.2008.10.015; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Walsh JME, 2004, J GEN INTERN MED, V19, P156, DOI 10.1111/j.1525-1497.2004.30263.x; Westwood M. J., 2002, CANADIAN J COUNSELLI, V36, P221; WOLFE J, 1993, J TRAUMA STRESS, V6, P179, DOI 10.1002/jts.2490060203	66	43	44	0	41	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0738-3991			PATIENT EDUC COUNS	Patient Educ. Couns.	JUN	2014	95	3					414	420		10.1016/j.pec.2014.03.016			7	Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary	Public, Environmental & Occupational Health; Social Sciences - Other Topics	AI3QD	WOS:000336776100017	24742536				2021-06-18	
J	Naidoo, J; De Jesus-Cortes, H; Huntington, P; Estill, S; Morlock, LK; Starwalt, R; Mangano, TJ; Williams, NS; Pieper, AA; Ready, JM				Naidoo, Jacinth; De Jesus-Cortes, Hector; Huntington, Paula; Estill, Sandi; Morlock, Lorraine K.; Starwalt, Ruth; Mangano, Thomas J.; Williams, Noelle S.; Pieper, Andrew A.; Ready, Joseph M.			Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with Improved Druglike Properties	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							MOUSE MODEL; AMINOPROPYL CARBAZOLES; PARKINSONS-DISEASE; DERIVATIVES; MPTP; NEUROTOXIN; EFFICACY	(-)-P7C3-S243 is a neuroprotective aminopropyl carbazole with improved druglike properties compared with previously reported compounds in the P7C3 class. It protects developing neurons in a mouse model of hippocampal neurogenesis and protects mature neurons within the substantia nigra in a mouse model of Parkinson's disease. A short, enantioselective synthesis provides the neuroprotective agent in optically pure form. It is nontoxic, orally bioavailable, metabolically stable, and able to cross the blood-brain barrier. As such, it represents a valuable lead compound for the development of drugs to treat neurodegenerative diseases and traumatic brain injury.	[Naidoo, Jacinth; Huntington, Paula; Estill, Sandi; Morlock, Lorraine K.; Starwalt, Ruth; Williams, Noelle S.; Ready, Joseph M.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector] Univ Texas SW Med Ctr Dallas, Dept Neurosci, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [De Jesus-Cortes, Hector; Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA; [De Jesus-Cortes, Hector; Pieper, Andrew A.] Univ Iowa, Dept Vet Affairs, Carver Coll Med, Iowa City, IA 52242 USA; [Mangano, Thomas J.] Univ N Carolina, NIMH, Psychoact Drug Screening Program, Chapel Hill, NC 27599 USA	Pieper, AA (corresponding author), Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu; joseph.ready@utsouthwestern.edu	Pieper, Andrew A/R-5552-2016; De Jesus-Cortes, Hector/ABC-9091-2020	De Jesus-Cortes, Hector/0000-0001-6983-6963; Pieper, Andrew/0000-0001-6299-6577; Starwalt-Lee, Ruth/0000-0001-7196-012X	Edward N. and Della C. Thome Memorial Foundation; Welch FoundationThe Welch Foundation [I-1612]; NSFNational Science Foundation (NSF) [2012140236-02]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH087986]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH087986] Funding Source: NIH RePORTER	We thank Prof. Jef De Brabander (UT Southwestern) for helpful discussions regarding Cu-catalyzed amination and the NIH's Psychoactive Drug Screening Program at the University of North Carolina. Funding was provided by the Edward N. and Della C. Thome Memorial Foundation and the Welch Foundation (I-1612) (to J.M.R.) and the NSF (2012140236-02) (to H.D.J.-C.). Additional support was received from the NIH (R01 MH087986) to A.A.P. and an unrestricted endowment provided to Steven L. McKnight by an anonymous donor.	Asai-Coakwell M, 2013, HUM MOL GENET, V22, P1432, DOI 10.1093/hmg/dds560; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Bombrun A, 2003, J MED CHEM, V46, P4365, DOI 10.1021/jm034107j; Bordet T, 2010, PHARMACEUTICALS, V3, P345, DOI 10.3390/ph3020345; DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808; Das P, 2014, TETRAHEDRON, V70, P1017, DOI 10.1016/j.tet.2013.12.021; Das P, 2013, TETRAHEDRON, V69, P7646, DOI 10.1016/j.tet.2013.04.128; De Brabander J. K., COMMUNICATION; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Elmkaddem MK, 2010, CHEM COMMUN, V46, P925, DOI 10.1039/b916569j; Fukuda T, 2001, NEUROPATHOLOGY, V21, P323, DOI 10.1046/j.1440-1789.2001.00402.x; Hebert LE, 2004, NEUROLOGY, V62, P1645, DOI 10.1212/01.WNL.0000123018.01306.10; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KLUNDER JM, 1989, J ORG CHEM, V54, P1295, DOI 10.1021/jo00267a014; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; McKnight S. L., 2013, U.S. Patent, Patent No. [8,604,074, 8604074]; McKnight S. L., 2013, U.S. Pat., Patent No. [8,362,277, 8362277]; Naidoo J, 2013, TETRAHEDRON LETT, V54, P4429, DOI 10.1016/j.tetlet.2013.06.024; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Struk L, 2012, SYNTHESIS-STUTTGART, V44, P735, DOI 10.1055/s-0031-1289687; Sunyach C, 2012, NEUROPHARMACOLOGY, V62, P2346, DOI 10.1016/j.neuropharm.2012.02.013; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Walker A.K., 2014, MOL PSYCHIA IN PRESS; Wang CG, 2013, J PHARMACEUT BIOMED, V75, P112, DOI 10.1016/j.jpba.2012.11.018; Zhao XQ, 2009, SYNLETT, P779, DOI 10.1055/s-0028-1087931	28	43	44	1	19	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	MAY 8	2014	57	9					3746	3754		10.1021/jm401919s			9	Chemistry, Medicinal	Pharmacology & Pharmacy	AH1KN	WOS:000335879100012	24697290	Green Published, Bronze, Green Accepted			2021-06-18	
J	Moore, E; Indig, D; Haysom, L				Moore, Elizabeth; Indig, Devon; Haysom, Leigh			Traumatic Brain Injury, Mental Health, Substance Use, and Offending Among Incarcerated Young People	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						psychological factors; alcohol-related disorders; juvenile delinquency; traumatic brain injury (TBI); cannabis-related disorders	AGE-CHILDREN-PRESENT; AFFECTIVE-DISORDERS; POPULATION; VALIDITY; RELIABILITY; TBI; IDENTIFICATION; SCHIZOPHRENIA; PREVALENCE; PRISONERS	Objective: Despite being at high risk, little is known about traumatic brain injuries (TBIs) among incarcerated young people. This study aims to describe the prevalence of TBI among incarcerated young people and assess the association with mental health, substance use, and offending behaviors. Setting: The 2009 NSW Young People in Custody Health Survey was conducted in 9 juvenile detention centers. Participants: A total of 361 young people agreed to participate, representing 80% of all incarcerated young people. Main Measures: Young people were asked if they ever had a head injury where they became unconscious or "blacked-out." The survey used the Kiddie Schedule for Affective Disorders for Children to assess for psychiatric disorders, the Alcohol Use Disorder Identification Test, and the Severity of Dependence Scale to measure problematic substance use. Results: The sample comprised 88% man, 48% Aboriginal, with an average age of 17 years. One-third (32%) of young people reported ever experiencing a TBI, and 13% reported multiple TBIs. The majority (92%) of "most serious" TBIs were defined as mild, and the most common cause was an assault (62% woman, 34% man). Young people who reported a history of TBI (compared with those reporting no TBI) were significantly more likely to be diagnosed with a mental health disorder, psychological distress, a history of bullying, problematic substance use, participation in fights, and offending behaviors. Reporting multiple (>2) TBIs conferred a higher risk of psychological disorders and problematic substance use. Conclusions: Incarcerated young people have high rates of TBI. Enhanced detection of TBI among incarcerated young people will assist clinicians in addressing the associated psychosocial sequelae.	[Moore, Elizabeth; Indig, Devon] Justice Hlth, Ctr Hlth Res Criminal Justice, Sydney, NSW, Australia; [Haysom, Leigh] Justice Hlth, Adolescent Hlth, Sydney, NSW, Australia; [Indig, Devon] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia	Moore, E (corresponding author), Justice Hlth, Ctr Hlth Res Criminal Justice, Sydney, NSW, Australia.	elizabeth.moore@justicehealth.nsw.gov.au		Indig, Devon/0000-0002-6741-5062	Juvenile Justice; Justice Health; Centre for Aboriginal Health in the New South Wales Ministry of Health; Centre for Aboriginal Health in the New South Wales Ministry of Health, Australia	The authors thank the research team members from Juvenile Justice and Justice Health, and to those other staff who provided operational support for the 2009 Young People in Custody Health Survey (2009 YPICHS). They also thank Juvenile Justice, Justice Health, and Centre for Aboriginal Health in the New South Wales Ministry of Health for funding the study, and to the young people who kindly participated in the YPICHS study.; The study was funded by Juvenile Justice, Justice Health, and Centre for Aboriginal Health in the New South Wales Ministry of Health, Australia.	Australian Bureau of Statistics, 2011, AUSTR NZ STAND OFF C; Axelson D, 2009, SCHEDULE AFFECTIVE D; Bernstein D., 1998, CHILDHOOD TRAUMA QUE; Bernstein DP, 1997, J AM ACAD CHILD PSY, V36, P340, DOI 10.1097/00004583-199703000-00012; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Helps Y., 2008, INJURY RES STAT SERI, V45; Hux D, 1998, BRAIN INJURY, V12, P667; IBM, 2010, SPSS STAT VERS 19; Indig D., 2011, 2009 NSW YOUNG PEOPL; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kenny DT, 2007, CRIME JUSTICE B, P107; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lauth B, 2010, NORD J PSYCHIAT, V64, P409, DOI 10.3109/08039481003777484; Martin G, 2006, DRUG ALCOHOL DEPEN, V83, P90, DOI 10.1016/j.drugalcdep.2005.10.014; National Institute of Health Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury, 1998, JAMA-J AM MED ASSOC, V282, P974; Oswald SH, 2010, J PEDIATR PSYCHOL, V35, P462, DOI 10.1093/jpepsy/jsp114; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Richards K, 2010, AUSTR I CRIMINOLOGY, P12; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Tasca M, 2012, VIOLENCE AGAINST WOM, V18, P672, DOI 10.1177/1077801212453985; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Williams H, 2010, TLS-TIMES LIT SUPPL, P20; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697	41	43	43	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					239	247		10.1097/HTR.0b013e31828f9876			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100012	23656964				2021-06-18	
J	Ilie, G; Mann, RE; Boak, A; Adlaf, EM; Hamilton, H; Asbridge, M; Rehm, J; Cusimano, MD				Ilie, Gabriela; Mann, Robert E.; Boak, Angela; Adlaf, Edward M.; Hamilton, Hayley; Asbridge, Mark; Rehm, Juergen; Cusimano, Michael D.			Suicidality, Bullying and Other Conduct and Mental Health Correlates of Traumatic Brain Injury in Adolescents	PLOS ONE			English	Article							RISK BEHAVIOR; CHILDREN; SCHOOL; QUESTIONNAIRE-12; CONCUSSION; SYMPTOMS; VALIDITY	Objective: Our knowledge on the adverse correlates of traumatic brain injuries (TBI), including non-hospitalized cases, among adolescents is limited to case studies. We report lifetime TBI and adverse mental health and conduct behaviours associated with TBI among adolescents from a population-based sample in Ontario. Method and Findings: Data were derived from 4,685 surveys administered to adolescents in grades 7 through 12 as part of the 2011 population-based cross-sectional Ontario Student Drug Use and Health Survey (OSDUHS). Lifetime TBI was defined as head injury that resulted in being unconscious for at least 5 minutes or being retained in the hospital for at least one night, and was reported by 19.5% (95% CI: 17.3,21.9) of students. When holding constant sex, grade, and complex sample design, students with TBI had significantly greater odds of reporting elevated psychological distress (AOR = 1.52), attempting suicide (AOR = 3.39), seeking counselling through a crisis help-line (AOR = 2.10), and being prescribed medication for anxiety, depression, or both (AOR = 2.45). Moreover, students with TBI had higher odds of being victimized through bullying at school (AOR = 1.70), being cyber-bullied (AOR = 2.05), and being threatened with a weapon at school (AOR = 2.90), compared with students who did not report TBI. Students with TBI also had higher odds of victimizing others and engaging in numerous violent as well as nonviolent conduct behaviours. Conclusions: Significant associations between TBI and adverse internalizing and externalizing behaviours were found in this large population-based study of adolescents. Those who reported lifetime TBI were at a high risk for experiencing mental and physical health harms in the past year than peers who never had a head injury. Primary physicians should be vigilant and screen for potential mental heath and behavioural harms in adolescent patients with TBI. Efforts to prevent TBI during adolescence and intervene at an early stage may reduce injuries and comorbid problems in this age group.	[Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; [Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Mann, Robert E.; Boak, Angela; Adlaf, Edward M.; Hamilton, Hayley; Rehm, Juergen] Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Adlaf, Edward M.; Hamilton, Hayley; Rehm, Juergen; Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Mann, Robert E.; Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada; [Mann, Robert E.; Asbridge, Mark] Dalhousie Univ, Dept Emergency Med, Halifax, NS, Canada	Ilie, G (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	ilieg@smh.ca	Ilie, Gabriela/AAM-9122-2021; Cusimano, Michael/X-4059-2019		Canadian Institute of Health Research (CIHR)'s Team Grant in Traumatic Brain Injury and ViolenceCanadian Institutes of Health Research (CIHR) [FRN: 103946]; Ontario Neurotrauma Foundation; AUTO21, a member of the Networks of Centres of Excellence program; Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada (NSERC); Social Sciences and Humanities Research CouncilSocial Sciences and Humanities Research Council of Canada (SSHRC); Industry Canada; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	This work was financially supported by the Canadian Institute of Health Research (CIHR)'s Team Grant in Traumatic Brain Injury and Violence (FRN: 103946) and by the Ontario Neurotrauma Foundation. Additional funding was obtained from a grant from AUTO21, a member of the Networks of Centres of Excellence program that is administered and funded by the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, in partnership with Industry Canada, and ongoing funding support from the Ontario Ministry of Health and Long-Term Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, JAMA-J AM MED ASSOC, V308, P2327; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Dicker BG, 1989, HEAD TRAUMA REHABIL, V4, P73; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Due P, 2005, EUR J PUBLIC HEALTH, V15, P128, DOI 10.1093/eurpub/cki105; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Frances A, 2000, DSM 4 CLASSIFICATION; French DJ, 2004, EUR CHILD ADOLES PSY, V13, P1, DOI 10.1007/s00787-004-0345-7; Gainer RB, ATTEMPTED SUICIDE IS; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hux D, 1998, BRAIN INJURY, V12, P667; Ilie G, MENTAL HLTH SU UNPUB; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Laird RD, 2005, DEV PSYCHOPATHOL, V17, P127, DOI 10.1017/S0954579405050078; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; May A, 2011, ASSESSMENT, V18, P379, DOI 10.1177/1073191110374285; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Paglia-Boak A., 2011, CAMH RES DOCUMENT SE, V32; Pickett W, 2002, ARCH PEDIAT ADOL MED, V156, P786, DOI 10.1001/archpedi.156.8.786; Public Health Canada, 2011, BULL PREV SCH; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Tait RJ, 2003, AUST NZ J PSYCHIAT, V37, P374, DOI 10.1046/j.1440-1614.2003.01133.x; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Tate RL, 2004, BRAIN INJURY OUTCOME; Tonks J, 2010, NEUROPSYCHOL REHABIL, V20, P922, DOI 10.1080/09602011.2010.519209; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017	37	43	43	3	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2014	9	4							e94936	10.1371/journal.pone.0094936			6	Multidisciplinary Sciences	Science & Technology - Other Topics	AI5PW	WOS:000336922600110	24736613	DOAJ Gold, Green Published			2021-06-18	
J	Guo, J; Lin, P; Zhao, X; Zhang, J; Wei, X; Wang, Q; Wang, C				Guo, J.; Lin, P.; Zhao, X.; Zhang, J.; Wei, X.; Wang, Q.; Wang, C.			ETAZOLATE ABROGATES THE LIPOPOLYSACCHARIDE (LPS)-INDUCED DOWNREGULATION OF THE cAMP/pCREB/BDNF SIGNALING, NEUROINFLAMMATORY RESPONSE AND DEPRESSIVE-LIKE BEHAVIOR IN MICE	NEUROSCIENCE			English	Article						lipopolysaccharide (LPS); etazolate; depression; phosphodiesterase-4 (PDE4); cyclic adenosine monophosphate (cAMP); interleukin-1 beta (IL-1 beta)	PHOSPHODIESTERASE-4 INHIBITOR ROLIPRAM; ELEMENT-BINDING PROTEIN; TRAUMATIC BRAIN-INJURY; ANTIDEPRESSANT-LIKE; HIPPOCAMPAL NEUROGENESIS; CYTOKINE EXPRESSION; NEUROTROPHIC FACTOR; SICKNESS BEHAVIOR; 5-HT7 RECEPTOR; MESSENGER-RNA	Increasing evidence has indicated that immune challenge by bacterial lipopolysaccharide (LPS) induces depressive-like behavior, neuroinflammatory response and upregulates phosphodiesterase-4 (PDE4), an enzyme that specifically hydrolyzes cyclic adenosine monophosphate (cAMP). However, whether the potential PDE4 inhibitor etazolate prevents the LPS-induced depressive-like behavior remains unclear. Here using a model of depression induced by the repeated administration of LPS during 16 days, and then investigated the influence of LPS on the expression of PDE4, interleukin-1 beta (IL-1 beta) and antidepressant action of etazolate in mice through forced swimming, novelty suppressed feeding, sucrose preference and open-field tests. Our results showed that etazolate pretreatment facilitated the recovery from weight loss and prevented the depressive-like behavior induced by repeated LPS administration. Moreover, the antidepressant action of etazolate was paralleled by significantly reducing the expression levels of PDE4A, PDE4B, PDE4D and IL-1 beta and up-regulating the cAMP/phosphorylated cAMP response-element binding protein (pCREB)/brain-derived neurotrophic factor (BDNF) signaling in the hippocampus and prefrontal cortex of mice. These results indicate that the effects of etazolate on the depressive-like behavior induced by repeated LPS treatment may partially depend on the inhibition of PDE4 subtypes, the activation of the cAMP/pCREB/BDNF signaling and the anti-inflammatory responses in the hippocampus and prefrontal cortex. Crown Copyright (C) 2014 Published by Elsevier Ltd. on behalf of IBRO. All rights reserved.	Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China; [Wang, Q.] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Ningbo 315211, Zhejiang, Peoples R China	Wang, C (corresponding author), Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China.	wangqinwen@nbu.edu.cn; wangchuang@nbu.edu.cn	Wei, Xiaofei/V-5512-2019	Wei, Xiaofei/0000-0002-1173-4734	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201050, 30901802, 81100822]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LQ12H09001, LY12H09002]; Natural Science Foundation of Ningbo [2012A610249, 2011A610064]; Natural Science Foundation of Ningbo University [XKL11D2111]; Ningbo University	This work was supported by National Natural Science Foundation of China (No. 81201050 to Dr. Chuang Wang; No. 30901802 to Dr. Xin Zhao; No. 81100822 to Dr. Xiaowei Chen); Natural Science Foundation of Zhejiang Province (No. LQ12H09001 to Chuang Wang and No. LY12H09002 to Dr. Xin Zhao); Natural Science Foundation of Ningbo (No. 2012A610249 to Dr. Chuang Wang and No. 2011A610064 to Dr. Xiaowei Chen); Natural Science Foundation of Ningbo University (No. XKL11D2111 to Dr. Chuang Wang) and Student Research and Innovation Program (SRIP) of Ningbo University. This project also sponsored by K. C. Wong Magna funded at Ningbo University.	Anderson GM, 2005, PSYCHOPHARMACOLOGY, V178, P339, DOI 10.1007/s00213-004-2011-7; Bekris S, 2005, BEHAV BRAIN RES, V161, P45, DOI 10.1016/j.bbr.2005.01.005; Breuillaud L, 2012, BIOL PSYCHIAT, V72, P528, DOI 10.1016/j.biopsych.2012.04.011; Cheng YF, 2010, PSYCHOPHARMACOLOGY, V212, P181, DOI 10.1007/s00213-010-1943-3; Ching S, 2007, J NEUROSCI, V27, P10476, DOI 10.1523/JNEUROSCI.3357-07.2007; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; Dagyte G, 2011, J NEUROSCI RES, V89, P1646, DOI 10.1002/jnr.22697; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2006, NEUROL CLIN, V24, P441, DOI 10.1016/j.ncl.2006.03.003; Dantzer R, 2012, BIOL PSYCHIAT, V71, P4, DOI 10.1016/j.biopsych.2011.10.025; Drott J, 2010, EUR J PHARMACOL, V634, P95, DOI 10.1016/j.ejphar.2010.02.036; Dworkin S, 2009, STEM CELLS, V27, P1347, DOI 10.1002/stem.56; Dyke HJ, 2002, EXPERT OPIN INV DRUG, V11, P1; Fan LW, 2013, NEUROSCIENCE, V240, P27, DOI 10.1016/j.neuroscience.2013.02.041; Fujimaki K, 2000, NEUROPSYCHOPHARMACOL, V22, P42, DOI 10.1016/S0893-133X(99)00084-6; Fuller-Thomson E, 2006, INFLAMM BOWEL DIS, V12, P697, DOI 10.1097/00054725-200608000-00005; Galecki P, 2012, J AFFECT DISORDERS, V138, P360, DOI 10.1016/j.jad.2012.01.016; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Gobejishvili L, 2013, J PHARMACOL EXP THER, V347, P80, DOI 10.1124/jpet.113.204933; Goltser-Dubner T, 2010, ISR J PSYCHIATR REL, V47, P72; Hasler G, 2010, WORLD PSYCHIATRY, V9, P155; Hedayati SS, 2010, JAMA-J AM MED ASSOC, V303, P1946, DOI 10.1001/jama.2010.619; Hedlund PB, 2005, BIOL PSYCHIAT, V58, P831, DOI 10.1016/j.biopsych.2005.05.012; Ji WW, 2013, PHARM BIOCH BEHAV; Jindal A, 2012, EUR J PHARMACOL, V689, P125, DOI 10.1016/j.ejphar.2012.05.051; Kentner AC, 2010, ENDOCRINOLOGY, V151, P2689, DOI 10.1210/en.2009-1101; KREISS DS, 1995, J PHARMACOL EXP THER, V274, P866; Krogh J, 2013, BRAIN BEHAV IMMUN; Lawson MA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-87; Leonard B, 2012, NEUROSCI BIOBEHAV R, V36, P764, DOI 10.1016/j.neubiorev.2011.12.005; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Li YF, 2009, NEUROPSYCHOPHARMACOL, V34, P2404, DOI 10.1038/npp.2009.66; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P287; Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P664, DOI 10.1016/j.pnpbp.2010.06.014; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Manji H K, 2001, Psychopharmacol Bull, V35, P5; Marsden WN, 2013, PROG NEURO-PSYCHOPH, V43, P168, DOI 10.1016/j.pnpbp.2012.12.012; Miro X, 2002, SYNAPSE, V45, P259, DOI 10.1002/syn.10100; MOORE AR, 1995, CLIN EXP IMMUNOL, V101, P387; Moreau M, 2005, J INFECT DIS, V192, P537, DOI 10.1086/431603; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Nemeroff Charles B, 2007, Expert Rev Neurother, V7, pS11, DOI 10.1586/14737175.7.11s.S11; Niciu MJ, 2013, CNS SPECTRUMS, P1; O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148; O'Donnell JM, 1999, PHARMACOL BIOCHEM BE, V63, P185, DOI 10.1016/S0091-3057(98)00267-6; Park SE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-12; Patki G, 2013, BRAIN RES, VS0006-8993; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Reneerkens OAH, 2009, PSYCHOPHARMACOLOGY, V202, P419, DOI 10.1007/s00213-008-1273-x; Richter W, 2013, EXPERT OPIN THER TAR, V17, P1011, DOI 10.1517/14728222.2013.818656; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; Robichaud A, 2001, NEUROPHARMACOLOGY, V40, P262, DOI 10.1016/S0028-3908(00)00142-8; RUTTER JJ, 1994, NEUROSCI LETT, V171, P183, DOI 10.1016/0304-3940(94)90635-1; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sarkisyan G, 2010, BEHAV BRAIN RES, V209, P99, DOI 10.1016/j.bbr.2010.01.022; Shalaby AM, 2012, J PHARMACOL PHARMACO, V3, P132, DOI 10.4103/0976-500X.95509; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Rojas PS, 2011, PSYCHIAT RES, V189, P239, DOI 10.1016/j.psychres.2011.04.032; Sumegi Andras, 2008, Neuropsychopharmacol Hung, V10, P131; Takano K, 2012, J PHARMACOL SCI, V120, P176, DOI 10.1254/jphs.12039FP; Tonelli LH, 2008, NEUROPSYCHOPHARMACOL, V33, P1038, DOI 10.1038/sj.npp.1301488; Vellas B, 2011, CURR ALZHEIMER RES, V8, P203, DOI 10.2174/156720511795256053; Wang C, 2012, INT J NEUROPSYCHOPH, V15, P749, DOI 10.1017/S1461145711000836; Wang P, 1997, BIOCHEM BIOPH RES CO, V234, P320, DOI 10.1006/bbrc.1997.6636; Wang ZZ, 2013, BRIT J PHARMACOL, V168, P1001, DOI 10.1111/j.1476-5381.2012.02225.x; Wolfe F, 2009, ARTHRIT RHEUM-ARTHR, V61, P667, DOI 10.1002/art.24428; Zeugmann S, 2013, PSYCHIAT DANUB, V25, P227; Zhang HT, 2009, CURR PHARM DESIGN, V15, P1688, DOI 10.2174/138161209788168092; Zhang HT, 2002, NEUROPSYCHOPHARMACOL, V27, P587; Zhang HT, 2006, PSYCHOPHARMACOLOGY, V186, P209, DOI 10.1007/s00213-006-0369-4; Zhang JF, 2013, BEHAV BRAIN RES, V250, P230, DOI 10.1016/j.bbr.2013.05.017; Zhang KYJ, 2005, EXPERT OPIN THER TAR, V9, P1283, DOI 10.1517/14728222.9.6.1283	74	43	47	2	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 28	2014	263						1	14		10.1016/j.neuroscience.2014.01.008			14	Neurosciences	Neurosciences & Neurology	AC3GF	WOS:000332403400001	24434771				2021-06-18	
J	Brooks, BL; Kadoura, B; Turley, B; Crawford, S; Mikrogianakis, A; Barlow, KM				Brooks, Brian L.; Kadoura, Basil; Turley, Brenda; Crawford, Susan; Mikrogianakis, Angelo; Barlow, Karen M.			Perception of Recovery After Pediatric Mild Traumatic Brain Injury Is Influenced by the "Good Old Days" Bias: Tangible Implications for Clinical Practice and Outcomes Research	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Children; Bias; Symptom; Post-concussion syndrome; Recovery	POSTCONCUSSION-SYNDROME; CONCUSSION; EXPECTATION; SYMPTOMS	Recovery from mild traumatic brain injury (mTBI) is primarily based on the resolution of post-concussive symptoms back to a premorbid level. However, the "good old days" bias means fewer premorbid symptoms are retrospectively recalled, thus skewing the determination of recovery relative to pre-injury. The objectives of this study were to investigate the "good old days" bias in pediatric mTBI and demonstrate the implications of this bias on perceived recovery. Children and adolescents 2-18 years old (mean 10.9, SD 4.4, N 412) were recruited after sustaining an mTBI. Ratings of premorbid symptoms were provided: (a) in the Emergency Department (ED; by parents), (b) retrospectively at a 1-month follow-up (by parents and adolescents), and (c) retrospectively at a 3-month follow-up (by parents and adolescents). Parent ratings of premorbid symptoms decreased by 80% from the ED to 1-month post-injury (p < .001) but were stable from 1 to 3 months post-injury (p < .05). Adolescents premorbid ratings declined from 1 to 3 months post-injury. Slow recovery did not have a differential impact on premorbid reporting. Using premorbid ratings obtained in the ED, instead of retrospective symptom reporting at the time of follow-up, suggests that a significant minority of patients believed to be "not recovered" actually have the "same or lower" symptom ratings at 1 (29%) and 3 months (41%) post-injury compared with before the injury. The "good old days" bias is present in pediatric mTBI by 1-month post-injury, influences retrospective symptom reporting, and has measureable implications for determining recovery in research and clinical practice.	[Brooks, Brian L.; Turley, Brenda; Crawford, Susan; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Mikrogianakis, Angelo; Barlow, Karen M.] Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.; Crawford, Susan; Mikrogianakis, Angelo; Barlow, Karen M.] Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB, Canada; [Kadoura, Basil] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Mikrogianakis, Angelo] Alberta Childrens Prov Gen Hosp, Dept Emergency Med, Calgary, AB T3B 6A8, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507	Alberta Children's Hospital Foundation [10000779]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	Funding for this study provided by an Alberta Children's Hospital Foundation project grant (grant #10000779) awarded to AM and KMB, and a summer studentship from the Canadian Institutes of Health Research training program to BK. None of the funding sources were involved in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glass K.L., 2005, ANN M INT NEUR SOC S; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heilbronner R.L., 2008, NEUROPSYCHOLOGY COUR, P243; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Krol AL, 2011, BRAIN INJURY, V25, P1300, DOI 10.3109/02699052.2011.624571; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Langlois JA, 2006, TRAUMATIC BRAIN INJU; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Panayiotou A, 2011, AUST PSYCHOL, V46, P210, DOI 10.1111/j.1742-9544.2010.00018.x; Sullivan KA, 2012, BRAIN INJURY, V26, P1098, DOI 10.3109/02699052.2012.666367	18	43	43	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2014	29	2					186	193		10.1093/arclin/act083			8	Psychology, Clinical; Psychology	Psychology	AB8FY	WOS:000332026800007	24196003	Bronze			2021-06-18	
J	Ferrada, P; Evans, D; Wolfe, L; Anand, RJ; Vanguri, P; Mayglothling, J; Whelan, J; Malhotra, A; Goldberg, S; Duane, T; Aboutanos, M; Ivatury, RR				Ferrada, Paula; Evans, David; Wolfe, Luke; Anand, Rahul J.; Vanguri, Poornima; Mayglothling, Julie; Whelan, James; Malhotra, Ajai; Goldberg, Stephanie; Duane, Therese; Aboutanos, Michel; Ivatury, Rao R.			Findings of a randomized controlled trial using limited transthoracic echocardiogram (LTTE) as a hemodynamic monitoring tool in the trauma bay	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Hemodynamic monitoring in the trauma bay; echocardiogram in the trauma bay; inferior vena cava as a hemodynamic parameter in trauma patients; echocardiogram in trauma; echocardiogram for fluid status management	INFERIOR VENA-CAVA; SURGEON-PERFORMED ULTRASOUND; GOAL-DIRECTED RESUSCITATION; EARLY FLUID RESUSCITATION; HEMORRHAGIC-SHOCK; SONOGRAPHIC MEASUREMENT; HYPOVOLEMIC SHOCK; VOLUME STATUS; BRAIN-INJURY; HEART-RATE	BACKGROUND: We hypothesize that limited transthoracic echocardiogram (LTTE) is a useful tool to guide therapy during the initial phase of resuscitation in trauma patients. METHODS: All highest-level alert patients with at least one measurement of systolic blood pressure less than 100 mm Hg, a mean arterial pressure less than 60 mm Hg, and/or a heart rate greater than 120 beats per minute who arrived to the trauma bay (TB) were randomized to have either LTTE performed (LTTEp) or not performed (non-LTTE) as part of their initial evaluation. Images were stored, and results were reported regarding contractility (good vs. poor), fluid status (empty inferior vena cava [hypovolemic] vs. full inferior vena cava [not hypovolemic]), and pericardial effusion (present vs. absent). Time from TB to operating room, intravenous fluid administration, blood product requirement, intensive care unit admission, and mortality were examined in both groups. RESULTS: A total of 240 patients were randomized. Twenty-five patients were excluded since they died upon arrival to the TB, leaving 215 patients in the study. Ninety-two patients were in the LTTEp group with 123 patients in the non-LTTE group. The LTTEp and non-LTTE groups were similar in age (38 years vs. 38.8 years, p = 0.75), Injury Severity Score (ISS) (19.2 vs. 19.0, p = 0.94), Revised Trauma Score (RTS) (5.5 vs. 6.0, p = 0.09), lactate (4.2 vs. 3.6, p = 0.14), and mechanism of injury (p = 0.44). Strikingly, LTTEp had significantly less intravenous fluid than non-LTTE patients (1.5 L vs. 2.5 L, p < 0.0001), less time from TB to operating room (35.6 minutes vs. 79.1 min, p = 0.0006), higher rate of intensive care unit admission (80.4% vs. 67.2%, p = 0.04), and a lower mortality rate (11% vs. 19.5%, p = 0.09). Mortality differences were particularly evident in the traumatic brain injury patients (14.7% in LTTEp vs. 39.5% in non-LTTE, p = 0.03). CONCLUSION: LTTE is a useful guide for therapy in hypotensive trauma patients during the early phase of resuscitation. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Ferrada, Paula; Evans, David; Wolfe, Luke; Anand, Rahul J.; Vanguri, Poornima; Mayglothling, Julie; Whelan, James; Malhotra, Ajai; Goldberg, Stephanie; Duane, Therese; Aboutanos, Michel; Ivatury, Rao R.] Virginia Commonwealth Univ, Richmond, VA 23298 USA	Ferrada, P (corresponding author), Virginia Commonwealth Univ, West Hosp, 15th Floor East,1200 E Broad St,POB 980454, Richmond, VA 23298 USA.	pferrada@mcvh-vcu.edu	Ivatury, Rao R./H-2922-2019				Abbasi S, 2012, EUR J EMERG MED; Akilli B, 2010, ULUS TRAVMA ACIL CER, V16, P113; Alam HB, 2005, MIL MED, V170, P63, DOI 10.7205/MILMED.170.1.63; Bahner DP, 2012, ACAD MED; Balogh Z, 2002, AM J SURG, V184, P538, DOI 10.1016/S0002-9610(02)01050-4; BICKELL WH, 1991, SURGERY, V110, P529; Bruttig SP, 2005, SHOCK, V24, P92, DOI 10.1097/01.shk.0000168872.37660.d2; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Dipti A, 2012, AM J EMERG MED, V30, P1414, DOI 10.1016/j.ajem.2011.10.017; Duchesne JC, 2012, AM SURGEON, V78, P962; Duke MD, 2012, J TRAUMA ACUTE CARE, V73, P674, DOI 10.1097/TA.0b013e318265ce1f; Ferrada P, 2013, J TRAUMA ACUTE CARE, V74, P220, DOI 10.1097/TA.0b013e318278918a; Ferrada P, 2012, AM SURGEON, V78, P1396; Ferrada P, 2012, AM SURGEON, V78, P468; Ferrada P, 2011, J TRAUMA, V71, P1327, DOI 10.1097/TA.0b013e3182318574; Ferrada P, 2011, J TRAUMA, V70, P56, DOI 10.1097/TA.0b013e318207e6ee; Gunst M, 2008, J TRAUMA, V65, P509, DOI 10.1097/TA.0b013e3181825bc5; Harris T, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5752; Holley A, 2012, EMERG MED AUSTRALAS, V24, P127, DOI 10.1111/j.1742-6723.2011.01515.x; Holley A, 2012, EMERG MED AUSTRALAS, V24, P14, DOI 10.1111/j.1742-6723.2011.01516.x; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kasotakis G, 2013, J TRAUMA ACUTE CARE, V74, P1215, DOI 10.1097/TA.0b013e3182826e13; King DR, 2009, J TRAUMA, V67, P436, DOI 10.1097/TA.0b013e3181ad67de; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; McNeer Richard R, 2013, Anesthesiol Clin, V31, P179, DOI 10.1016/j.anclin.2012.11.005; Nucifora G, 2011, MINERVA CARDIOANGIOL, V59, P519; Opreanu RC, 2010, AM SURGEON, V76, P296; ROZYCKI GS, 1995, J TRAUMA, V39, P492; Rozycki GS, 1998, ANN SURG, V228, P557, DOI 10.1097/00000658-199810000-00012; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sisley AC, 1998, J TRAUMA, V44, P291, DOI 10.1097/00005373-199802000-00009; Soller BR, 2012, J TRAUMA ACUTE CARE, V73, pS106, DOI 10.1097/TA.0b013e318260a928; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Yanagawa Y, 2005, J TRAUMA, V58, P825, DOI 10.1097/01.TA.0000145085.42116.A7; Yanagawa Y, 2007, J TRAUMA, V63, P1245, DOI 10.1097/TA.0b013e318068d72b; Zengin S, 2013, AM J EMERG MED	38	43	45	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					31	37		10.1097/TA.0b013e3182a74ad9			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200008	24368354				2021-06-18	
J	Lin, P; Correa, D; Kean, TJ; Awadallah, A; Dennis, JE; Caplan, AI				Lin, Paul; Correa, Diego; Kean, Thomas J.; Awadallah, Amad; Dennis, James E.; Caplan, Arnold I.			Serial Transplantation and Long-term Engraftment of Intra-arterially Delivered Clonally Derived Mesenchymal Stem Cells to Injured Bone Marrow	MOLECULAR THERAPY			English	Article							IN-VIVO DISTRIBUTION; H-2K(B)-TSA58 TRANSGENIC MOUSE; TRAUMATIC BRAIN-INJURY; VERSUS-HOST-DISEASE; STROMAL CELLS; MYOCARDIAL-INFARCTION; PROGENITOR CELLS; DIFFERENTIATION; GROWTH; MICE	It has been hypothesized that mesenchymal stem cells (MSCs) home to sites of injury. Nevertheless, efficient delivery of MSCs to target organs and description of their ultimate fate remain major challenges. We provide evidence that intra-arterially (IA) injected MSCs selectively engraft from the circulation as perivascular cells in the bone marrow (BM) after a localized radiation injury. Luciferase-expressing MSCs, derived from a conditionally immortalized clone (BMC-9) representing a pure population of cells, were arterially delivered into mice irradiated in one leg. Cell distribution was measured by bioluminescent imaging and final destination assessed by luciferase immunolocalization. IA injections resulted in engraftment only in the irradiated leg where cells localize and proliferate abluminal to the BM vasculature, a phenomenon not replicated with intravenous injections or with IA injections of kidney cells harvested from the same donor used for MSCs. Furthermore, MSCs harvested from the engrafted marrow and serially transplanted retain the ability to selectively engraft at sites of injury. This study demonstrates that MSCs can serially engraft at sites of injury from the circulation, that they reside in the perivascular space, and that arterial delivery is more efficient than venous delivery for cell engraftment.	[Lin, Paul] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; [Lin, Paul; Correa, Diego; Awadallah, Amad; Caplan, Arnold I.] Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA; [Kean, Thomas J.; Dennis, James E.] Benaroya Res Inst, Seattle, WA USA	Lin, P (corresponding author), Case Western Reserve Univ, Millis Sci Ctr, Rm 113C,2080 Adelbert Rd, Cleveland, OH 44106 USA.	pxl57@case.edu	Kean, Thomas/AAI-8010-2021	Kean, Thomas/0000-0001-6844-3404; Caplan, Arnold/0000-0002-8677-6621	L. David and E. Virginia Baldwin Foundation; NIH/NIAMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR049785]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM007250]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR049785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007250] Funding Source: NIH RePORTER	The authors acknowledge the assistance of Margie Harris for isolating the MSCs, Lori Duesler for help with the animal experiments, Mark Schluchter for his assistance with the statistical analysis, Fred Allen and Lan Wang from the Case Mouse Metabolic Phenotyping Center for help with the animal surgeries, and John Mulvihill from the Radiation Resources Core of CWRU for assistance with irradiating the mice. This research was supported by the L. David and E. Virginia Baldwin Foundation (A.I.C.) and NIH/NIAMS, R01AR049785 (J.E.D.). P.L. was supported in part by NIH T32 GM007250. Equity interest in Biotime, Inc. (J.E.D. and A.I.C.)	Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Belema-Bedada F, 2008, CELL STEM CELL, V2, P566, DOI 10.1016/j.stem.2008.03.003; Bexell D, 2009, MOL THER, V17, P183, DOI 10.1038/mt.2008.229; BIANCO P, 2004, HDB ADULT FETAL STEM, P415, DOI DOI 10.1016/B978-012436643-5/50129-2; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Chapel A, 2003, J GENE MED, V5, P1028, DOI 10.1002/jgm.452; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700; Dennis JE, 1996, J CELL PHYSIOL, V167, P523, DOI 10.1002/(SICI)1097-4652(199606)167:3<523::AID-JCP16>3.3.CO;2-E; Dennis JE, 1996, CONNECT TISSUE RES, V35, P93, DOI 10.3109/03008209609029179; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Fouillard L, 2007, LEUKEMIA, V21, P568, DOI 10.1038/sj.leu.2404550; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Iso Y, 2007, BIOCHEM BIOPH RES CO, V354, P700, DOI 10.1016/j.bbrc.2007.01.045; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KIRKEBY OJ, 1991, J ORTHOPAED RES, V9, P862, DOI 10.1002/jor.1100090612; Ko IK, 2010, MOL THER, V18, P1365, DOI 10.1038/mt.2010.54; Kyriakou C, 2008, HAEMATOL-HEMATOL J, V93, P1457, DOI 10.3324/haematol.12553; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Li HH, 2006, CELL TISSUE RES, V326, P725, DOI 10.1007/s00441-006-0270-9; Lin P, 2012, STEM CELL TRANSL MED, V1, P886, DOI 10.5966/sctm.2012-0086; Lu SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054963; Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365-2141.2003.04669.x; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Meyerrose TE, 2007, STEM CELLS, V25, P220, DOI 10.1634/stemcells.2006-0243; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Rajkumar VS, 2006, AM J PATHOL, V169, P2254, DOI 10.2353/ajpath.2006.060196; Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Schenk S, 2007, STEM CELLS, V25, P245, DOI 10.1634/stemcells.2006-0293; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Sorrell JM, 2009, TISSUE ENG PT A, V15, P1751, DOI 10.1089/ten.tea.2008.0254; Togel F, 2008, AM J PHYSIOL-RENAL, V295, pF315, DOI 10.1152/ajprenal.00098.2008; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wang CH, 2008, ARTERIOSCL THROM VAS, V28, P54, DOI 10.1161/ATVBAHA.107.147256; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Westfall PH, 2001, J STAT PLAN INFER, V99, P25, DOI 10.1016/S0378-3758(01)00077-5	48	43	45	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	JAN	2014	22	1					160	168		10.1038/mt.2013.221			9	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	282ZI	WOS:000329213500019	24067545	Other Gold, Green Published			2021-06-18	
J	Mobashsher, AT; Abbosh, AM				Mobashsher, A. T.; Abbosh, A. M.			Three-Dimensional Human Head Phantom With Realistic Electrical Properties and Anatomy	IEEE ANTENNAS AND WIRELESS PROPAGATION LETTERS			English	Article						Brain stroke diagnosis; head imaging; head phantom; head tomography; microwave imaging; mobile communication; traumatic brain injury diagnosis	MICROWAVE; MODELS	An anatomically realistic human head phantom as a potential mean of experimentally validating microwave-based head imaging systems and other prominent applications is reported. Using an MRI-derived model, the phantom is 3-D-printed using a laser sintering material to represent the external tissue layers starting from the skull. The skull cavity is filled with the help of 3-D-printed molds with tissue-mimicking mixtures that are formed using low-cost ingredients. The included tissues are gray matter, white matter, Dura, CSF, eye, cerebellum, spinal cord, and blood. Our measurements indicate that the properties of the fabricated tissues are stable with time and agree with the real properties with less than 5% variation across the band 0.5-4 GHz, which is widely utilized in various imaging and mobile applications.	[Mobashsher, A. T.; Abbosh, A. M.] Univ Queensland, Sch ITEE, Brisbane, Qld 4072, Australia	Mobashsher, AT (corresponding author), Univ Queensland, Sch ITEE, Brisbane, Qld 4072, Australia.	a.mobashsher@uq.edu.au	Mobashsher, Ahmed Toaha/H-6341-2019; Abbosh, Amin/C-3944-2009	Mobashsher, Ahmed Toaha/0000-0002-6351-8136; Abbosh, Amin/0000-0002-8015-5883	ARCAustralian Research Council [DP120101214]	This work was supported by the ARC Discovery Grant DP120101214.	Akyalcin S, 2013, HEAD FACE MED, V9, DOI 10.1186/1746-160X-9-28; Burfeindt MJ, 2012, IEEE ANTENN WIREL PR, V11, P1610, DOI 10.1109/LAWP.2012.2236293; Chandra R, 2013, IEEE T ANTENN PROPAG, V61, P6180, DOI 10.1109/TAP.2013.2283270; Gabriel S, 1996, PHYS MED BIOL, V41, P2271, DOI 10.1088/0031-9155/41/11/003; Iida H, 2013, ANN NUCL MED, V27, P25, DOI 10.1007/s12149-012-0655-7; Ireland D, 2013, IET MICROW ANTENNA P, V7, P909, DOI 10.1049/iet-map.2013.0054; Ireland D, 2013, IEEE T ANTENN PROPAG, V61, P2352, DOI 10.1109/TAP.2013.2242037; JOFRE L, 1990, IEEE T BIO-MED ENG, V37, P303, DOI 10.1109/10.52331; Karathanasis KT, 2010, IEEE T INF TECHNOL B, V14, P657, DOI 10.1109/TITB.2010.2040749; Li CH, 2012, IEEE T ANTENN PROPAG, V60, P1066, DOI 10.1109/TAP.2011.2173102; Looi CK, 2005, MICROW OPT TECHN LET, V47, P163, DOI 10.1002/mop.21113; Mobashsher AT, 2014, ELECTRON LETT, V50, P850, DOI 10.1049/el.2014.0616; Mobashsher AT, 2013, P IEEE MTT S INT MIC, P1, DOI DOI 10.1109/IMWS-BIO.2013.6756149; Mohammed B, 2012, CAIRO INT BIOM ENG, P191, DOI 10.1109/CIBEC.2012.6473320; Mohammed BJ, 2014, MICROW OPT TECHN LET, V56, P979, DOI 10.1002/mop.28229; Mohammed BJ, 2014, IEEE T INSTRUM MEAS, V63, P117, DOI 10.1109/TIM.2013.2277562; Mojabi P, 2009, IEEE ANTENN WIREL PR, V8, P645, DOI 10.1109/LAWP.2009.2023602; Mustafa S, 2013, IEEE ANTENN WIREL PR, V12, P460, DOI 10.1109/LAWP.2013.2255095	18	43	43	2	11	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1536-1225	1548-5757		IEEE ANTENN WIREL PR	IEEE Antennas Wirel. Propag. Lett.		2014	13									10.1109/LAWP.2014.2340409			4	Engineering, Electrical & Electronic; Telecommunications	Engineering; Telecommunications	AN2XQ	WOS:000340449700001					2021-06-18	
J	Jalloh, I; Helmy, A; Shannon, RJ; Gallagher, CN; Menon, DK; Carpenter, KLH; Hutchinson, PJ				Jalloh, Ibrahim; Helmy, Adel; Shannon, Richard J.; Gallagher, Clare N.; Menon, David K.; Carpenter, Keri L. H.; Hutchinson, Peter J.			Lactate Uptake by the Injured Human Brain: Evidence from an Arteriovenous Gradient and Cerebral Microdialysis Study	JOURNAL OF NEUROTRAUMA			English	Article						metabolism; microdialysis; traumatic brain injury (human)	MONOCARBOXYLATE TRANSPORTER-2 EXPRESSION; PENTOSE-PHOSPHATE PATHWAY; TRICARBOXYLIC-ACID CYCLE; COGNITIVE DEFICITS; GLUCOSE; BLOOD; METABOLISM; FLUX; RAT; DYSFUNCTION	Lactate has been regarded as a waste product of anaerobic metabolism of glucose. Evidence also suggests, however, that the brain may use lactate as an alternative fuel. Our aim was to determine the extent of lactate uptake from the circulation into the brain after traumatic brain injury (TBI) and to compare it with levels of lactate in the brain extracellular fluid. We recruited 19 patients with diffuse TBI, monitored with cerebral microdialysis and jugular bulb catheters. Serial arteriovenous (AV) concentration differences of glucose and lactate were calculated from arterial and jugular blood samples, providing a measure of net uptake or export by the brain. Microdialysis was used to measure brain extracellular glucose and lactate. In 17/19 patients studied for 5 days post-injury, there were periods of net lactate uptake into the brain, most frequently on day 3 after injury. Brain microdialysate lactate had a median (interquartile range [IQR]) concentration of 2.5 (1.5-3.2) mmol/L during lactate uptake and 2.2 (1.7-3.0) mmol/L during lactate export. Lactate uptake into the brain occurred at a median (IQR) arterial lactate concentration of 1.6 (1.0-2.2) mmol/L. Lactate uptake was associated with significantly higher AV difference in glucose values with a median (IQR) of 0.4 (0.03-0.7) mmol/L during uptake and 0.1 (-0.2-0.3) mmol/L during lactate export (Mann-Whitney U p=0.003). Despite relatively high brain lactate compared with arterial lactate concentrations, the brain appears to up-regulate lactate transport into the brain after TBI. This may serve to satisfy greater demands for energy substrate from the brain after TBI.	[Jalloh, Ibrahim; Helmy, Adel; Shannon, Richard J.; Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Gallagher, Clare N.] Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB, Canada; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England	Jalloh, I (corresponding author), Univ Cambridge, Sch Clin Med, Div Neurosurg, Dept Clin Neurosci, Box 167 Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	ij232@cam.ac.uk	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Hutchinson, Peter/0000-0002-2796-1835; Carpenter, Keri/0000-0001-8236-7727	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID79068, G1002277 ID98489]; National Institute for Health Research Biomedical Research Centre CambridgeNational Institute for Health Research (NIHR); Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowship; National Institute for Health Research Flexibility and Sustainability Fund; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001354B, G1000183B, G0802251, G0600986, G1002277, G0001354] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004, NF-SI-0512-10090] Funding Source: researchfish	We thank Mr. M. Guilfoyle for statistical advice. We gratefully acknowledge financial support as follows. Study support: Medical Research Council (Grant Nos. G0600986 ID79068 and G1002277 ID98489) and National Institute for Health Research Biomedical Research Centre Cambridge. Authors' support: I.J. - Medical Research Council (Grant no. G1002277 ID 98489) and National Institute for Health Research Biomedical Research Centre Cambridge; A. H. - Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (Grant no. G0802251) and Raymond and Beverly Sackler Fellowship; K. L. H. C. - National Institute for Health Research Biomedical Research Centre Cambridge; RJS - National Institute for Health Research Flexibility and Sustainability Fund; P.J.H. - Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and National Institute for Health Research Biomedical Research Centre Cambridge.	Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Beards SC, 1998, ANAESTHESIA, V53, P627; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; CMA Microdialysis AB, 2008, TECHN MAN ISCUS FLEX, P16; DAGER SR, 1992, LIFE SCI, V51, P973, DOI 10.1016/0024-3205(92)90404-D; Dalsgaard MK, 2006, J CEREBR BLOOD F MET, V26, P731, DOI 10.1038/sj.jcbfm.9600256; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; Espenell AEG, 2010, CAN J ANESTH, V57, P903, DOI 10.1007/s12630-010-9356-7; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gibbs EL, 1942, J BIOL CHEM, V144, P325; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Leegsma-Vogt G, 2001, J NEUROSCI RES, V66, P795, DOI 10.1002/jnr.10046; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pierre K, 2003, J NEUROCHEM, V86, P1468, DOI 10.1046/j.1471-4159.2003.01964.x; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Sun FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034525; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	43	43	45	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2031	2037		10.1089/neu.2013.2947			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500004	23968221	Green Published			2021-06-18	
J	Schonfeld, D; Fitz, BM; Nigrovic, LE				Schonfeld, Deborah; Fitz, Brianna M.; Nigrovic, Lise E.			Effect of the Duration of Emergency Department Observation on Computed Tomography Use in Children With Minor Blunt Head Trauma	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Meeting of the Pediatric-Academic-Societies	MAY, 2013	Washington, DC	Pediat Acad Soc			RADIATION-EXPOSURE; UNITED-STATES; PEDIATRIC CT; MANAGEMENT; INJURY; CANCER; RISKS	Study objective: We determine the effect of the duration of emergency department (ED) observation on computed tomography (CT) rate for children with minor blunt head trauma. Methods: We performed a prospective cohort study of children with blunt head trauma and a Glasgow Coma Scale score greater than 14. We defined time from injury as the time from head injury to initial physician (emergency attending physician or fellow) assessment. For children who were observed in the ED before CT decisionmaking, we defined ED observation time as time from initial physician assessment to the decision whether to obtain a CT. After adjusting for time from injury, patient age, sex, physician type, and study month, we measured the effect of ED observation time on CT rate in each of the 3 Pediatric Emergency Care Applied Research Network Traumatic Brain Injury risk groups. Results: Of the 1,605 eligible patients, we enrolled 1,381 (86%). Of the enrolled patients, 676 (49%) were observed in the ED and 272 (20%) had a CT performed. After adjustment, every hour of ED observation time was associated with a decrease in CT rate for children in all 3 traumatic brain injury risk groups: high risk (adjusted odds ratio [OR] 0.11; 95% confidence interval [Cl] 0.05 to 0.24), intermediate risk (adjusted OR 0.28; 95% Cl 0.21 to 0.36), and low. risk (adjusted OR 0.47; 95% Cl 0.31. to 0.73). All 8 children with a significant traumatic brain injury had an immediate CT. Conclusion: For children with minor blunt head trauma, ED observation time was associated with a time-dependent reduction in cranial CT rate, with no delay in the diagnosis of a significant traumatic brain injury.	[Schonfeld, Deborah; Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Fitz, Brianna M.] Boston Coll, Dept Psychol, Boston, MA USA	Nigrovic, LE (corresponding author), Boston Childrens Hosp, Div Emergency Med, Boston, MA USA.	lise.nigrovic@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997			[Anonymous], 2011, STAT DAT AN VERS 12; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Boutis K, 2013, PEDIATRICS; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Broder J, 2007, EMERG RADIOL, V14, P227, DOI 10.1007/s10140-007-0618-9; Choosing Wisely, AM AC PED 5 THINGS P; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Hostetler MA, 2007, PEDIATR EMERG CARE, V23, P507, DOI 10.1097/01.pec.0000280518.36408.74; IBM Corp, 2012, PASW STAT 21 VERS 21; Karpas A, 2013, PEDIATR EMERG CARE, V29, P30, DOI 10.1097/PEC.0b013e31827b5090; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983	24	43	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	DEC	2013	62	6					597	603		10.1016/j.annemergmed.2013.06.020			7	Emergency Medicine	Emergency Medicine	268PY	WOS:000328184200013	23910481				2021-06-18	
J	Tjarks, BJ; Dorman, JC; Valentine, VD; Munce, TA; Thompson, PA; Kindt, SL; Bergeron, MF				Tjarks, B. Joel; Dorman, Jason C.; Valentine, Verle D.; Munce, Thayne A.; Thompson, Paul A.; Kindt, Shanna L.; Bergeron, Michael F.			Comparison and utility of King-Devick and ImPACT (R) composite scores in adolescent concussion patients	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Diffuse axonal injury; Neuropsychological tests; Oculomotor dysfunction; Post-concussion syndrome; Return to play; Traumatic brain injury; Visual-motor deficits	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; AMYLOID PRECURSOR PROTEIN; RECREATION ACTIVITIES; AXONAL DAMAGE; EYE-MOVEMENTS; UNITED-STATES; HEAD-INJURY; MILD	The King-Devick (ICD) oculomotor test has recently been advocated for sideline diagnosis of concussion. Although visual processing and performance are often impaired in concussion patients, the utility of KD as a concussion diagnostic tool is not validated. Purpose: To examine the diagnostic value of KD, by comparing KD with post-concussion symptom scale (PCSS) and ImPACT (R) composite scores. We hypothesized that KD would be correlated with visual motor speed/memory (VMS, VIS) and reaction time (RI'), because all require cognitive visual processing. We also expected parallel changes in KD and PCSS across recovery. Methods: Thirty-five concussed individuals (12-19 y; 18 females, 17 males) were evaluated with PCSS, ImPACT composite and KD scores over four clinical visits (V). Results: LCD times improved with each visit (Delta V1-V2: 7.86 +/- 11.82; Delta V2-V3: 9.17 +/- 11.07; Delta V3-V4: 5.30 +/- 7.87 s) and paralleled improvements in PCSS (Delta V1-V2: 8.97 +/- 20.27; Delta V2-V3: 8.69 14.70; Delta V3-V4: 6.31 +/- 7.71), RT (Delta V1-V2: 0.05 +/- 021; Delta V2-V3: 0.09 +/- 0.19; Delta V3-V4 0.03 +/- 0.07) and VMS (Delta V1-V2: -5.27 +/- 6.98; Delta V2-V3: 2.61 +/- 6.48; Delta V3-V4: 2.35 +/- 5.22). Longer KD times were associated with slower RT (r = 0.67; P < 0.0001) and lower VMS (r = 0.70; P < 0.0001), respectively. Conclusion: Cognitive visual performance testing using KD has utility in concussion evaluation. Validation would further establish KD as an effective ancillary tool in longitudinal concussion management and research. (C) 2013 Elsevier B.V. All rights reserved.	[Tjarks, B. Joel] Univ S Dakota, Sanford Sch Med, Sioux Falls, SD 57105 USA; [Dorman, Jason C.; Munce, Thayne A.; Bergeron, Michael F.] Natl Inst Athlet Hlth & Performance, Sioux Falls, SD 57104 USA; [Valentine, Verle D.; Kindt, Shanna L.] Sanford Orthoped & Sports Med, Sioux Falls, SD 57104 USA; [Munce, Thayne A.; Bergeron, Michael F.] Univ S Dakota, Sanford Sch Med, Dept Pediat, Sioux Falls, SD 57105 USA; [Thompson, Paul A.] Methodol & Data Anal Ctr, Sioux Falls, SD 57104 USA; [Bergeron, Michael F.] Natl Youth Sports Hlth Safety Inst, Sioux Falls, SD 57104 USA	Tjarks, BJ (corresponding author), Univ S Dakota, Sanford Sch Med, 1400 W 22nd St, Sioux Falls, SD 57105 USA.	Brian.Tjarics@usd.edu	Meijer, Anna/K-5118-2016				Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GLASS I, 1995, BRAIN INJURY, V9, P769, DOI 10.3109/02699059509008233; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; Lieberman S, 1983, J Am Optom Assoc, V54, P631; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Resch J, 2010, THESIS U GEORGIA ATH; Richman J E, 1983, J Am Optom Assoc, V54, P617; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	36	43	43	0	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	NOV 15	2013	334	1-2					148	153		10.1016/j.jns.2013.08.015			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	261OP	WOS:000327674800027	24007870				2021-06-18	
J	Caeyenberghs, K; Leemans, A; Leunissen, I; Michiels, K; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Leunissen, Inge; Michiels, Karla; Swinnen, Stephan P.			Topological correlations of structural and functional networks in patients with traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						functional connectivity; structural connectivity; brain networks; graph theoretical analysis; brain injury	WHITE-MATTER INTEGRITY; GRAPH-THEORETICAL ANALYSIS; HUMAN CEREBRAL-CORTEX; BEHAVIOR RELATIONSHIPS; EXECUTIVE FUNCTIONS; COGNITIVE CONTROL; MRI DATA; CONNECTIVITY; TRACTOGRAPHY; ORGANIZATION	Despite an increasing amount of specific correlation studies between structural and functional connectivity, there is still a need for combined studies, especially in pathological conditions. Impairments of brain white matter (WM) and diffuse axonal injuries are commonly suspected to be responsible for the disconnection hypothesis in traumatic brain injury (TBI) patients. Moreover, our previous research on TBI patients shows a strong relationship between abnormalities in topological organization of brain networks and behavioral deficits. In this study, we combined task-related functional connectivity (using event-related fMRI) with structural connectivity (derived from fiber tractography using diffusion MRI data) estimates in the same participants (17 adults with TBI and 16 controls), allowing for direct comparison between graph metrics of the different imaging modalities. Connectivity matrices were computed covering the switching motor network, which includes the basal ganglia, anterior cingulate cortex/supplementary motor area, and anterior insula/inferior frontal gyrus. The edges constituting this network consisted of the partial correlations between the fMRI time series from each node of the switching motor network. The interregional anatomical connections between the switching-related areas were determined using the fiber tractography results. We found that graph metrics and hubs obtained showed no agreement in both groups. The topological properties of brain functional networks could not be solely accounted for by the properties of the underlying structural networks. However, combining complementary information from both imaging modalities could improve accuracy in prediction of switching performance. Direct comparison between functional task-related and anatomical structural connectivity, presented here for the first time in TBI patients, links two powerful approaches to map the patterns of brain connectivity that may underlie behavioral deficits in brain-injured patient	[Caeyenberghs, Karen] Univ Ghent, Fac Med & Hlth Sci, Dept Phys Therapy & Motor Rehabil, B-9000 Ghent, Belgium; [Caeyenberghs, Karen] Univ Ghent, Fac Med & Hlth Sci, Dept Movement & Sport Sci, B-9000 Ghent, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, PROVIDI Lab, Utrecht, Netherlands; [Leunissen, Inge; Swinnen, Stephan P.] Katholieke Univ Leuven, Grp Biomed Sci, Movement Control & Neuroplast Res Grp, Louvain, Belgium; [Michiels, Karla] Katholieke Univ Leuven Hosp, Dept Phys Med & Rehabil, Louvain, Belgium	Caeyenberghs, K (corresponding author), Univ Ghent, Campus Heymans 1B3,De Pintelaan 185, B-9000 Ghent, Belgium.	karen.caeyenberghs@ugent.be	Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Caeyenberghs, Karen/0000-0001-7009-6843; Leunissen, Inge/0000-0002-3977-3620	Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office [P7/11]; Research Fund KU LeuvenKU Leuven [OT/11/071]; FWO VlaanderenFWO [G.0482.10, G.A114.11, G.0483.10, G.0721.12]	This research was supported by the Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office (P7/11). Additional funding was obtained by the Research Fund KU Leuven (OT/11/071) and FWO Vlaanderen (G.0482.10, G.A114.11, G.0483.10; G.0721.12).	Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Beaulieu C, 2005, NEUROIMAGE, V25, P1266, DOI 10.1016/j.neuroimage.2004.12.053; Bosma I, 2008, J NEURO-ONCOL, V88, P77, DOI 10.1007/s11060-008-9535-3; Bullmore ET, 2012, NAT REV NEUROSCI, V13, P336, DOI 10.1038/nrn3214; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K., 2012, BRAIN STRUCT FUNCT, DOI [10.1007/s00429-012-0494-2, DOI 10.1007/S00429-012-0494-2.[]; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Cheng H, 2012, NEUROIMAGE, V61, P1153, DOI 10.1016/j.neuroimage.2012.03.036; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Damoiseaux JS, 2009, BRAIN STRUCT FUNCT, V213, P525, DOI 10.1007/s00429-009-0208-6; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Griffa A, 2013, NEUROIMAGE, V80, P515, DOI 10.1016/j.neuroimage.2013.04.056; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Heitger MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062133; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Leemans A., 2009, 17 ANN M INT SOC MAG, P3537; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Leunissen I., 2013, HUM BRAIN MAPP, DOI [10.1002/hbm.22341, DOI 10.1002/HBM.22341.[]; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Li YH, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000395; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Lowe MJ, 2008, HUM BRAIN MAPP, V29, P818, DOI 10.1002/hbm.20576; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori T, 2007, PSYCHIAT RES-NEUROIM, V154, P133, DOI 10.1016/j.pscychresns.2006.09.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Rocca MA, 2007, NEUROLOGY, V69, P2136, DOI 10.1212/01.wnl.0000295504.92020.ca; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Skudlarski P, 2010, BIOL PSYCHIAT, V68, P61, DOI 10.1016/j.biopsych.2010.03.035; Skudlarski P, 2008, NEUROIMAGE, V43, P554, DOI 10.1016/j.neuroimage.2008.07.063; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; TEASDALE G, 1974, LANCET, V2, P81; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vaessen MJ, 2012, CEREB CORTEX, V22, P2139, DOI 10.1093/cercor/bhr298; van den Heuvel M, 2008, J NEUROSCI, V28, P10844, DOI 10.1523/JNEUROSCI.2964-08.2008; van den Heuvel MP, 2010, J NEUROSCI, V30, P15915, DOI 10.1523/JNEUROSCI.2874-10.2010; Veraart J., 2012, MAGN RESON MED, DOI [10.1002/mrm.24529, DOI 10.1002/MRM.24529.[]; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642	66	43	44	0	24	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	NOV 5	2013	7								726	10.3389/fnhum.2013.00726			11	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	245WK	WOS:000326494400001	24204337	DOAJ Gold, Green Published			2021-06-18	
J	Mihalik, JP; Lengas, E; Register-Mihalik, JK; Oyama, S; Begalle, RL; Guskiewicz, KM				Mihalik, Jason P.; Lengas, Eric; Register-Mihalik, Johna K.; Oyama, Sakiko; Begalle, Rebecca L.; Guskiewicz, Kevin M.			The Effects of Sleep Quality and Sleep Quantity on Concussion Baseline Assessment	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						assessment; baseline; college; concussion; student-athlete; traumatic brain injury	COGNITIVE PERFORMANCE; COLLEGE-STUDENTS; RECURRENT CONCUSSION; POSTURAL CONTROL; DEPRIVATION; PATTERNS; MOOD; ASSOCIATION; INJURY; HEALTH	Objective: Proper concussion assessment is imperative for properly caring for athletes who sustain traumatic brain injuries. Decreased sleep quality and sleep quantity affect cognition and may threaten the validity of clinical measures often used as a part of the concussion assessment. The purpose of this study was to determine if sleep quality or sleep quantity affects performance on clinical measures of concussion. Design: Prospective cohort design. Setting: Clinical research center. Participants: One hundred fifty-five college student-athletes (57 females, 98 males; age = 18.8 +/- 0.8 years; mass = 78.4 +/- 19.6 kg; height = 177.4 +/- 12.3 cm). Interventions: We performed preseason baseline testing by using a well-accepted and multifaceted protocol inclusive of neurocognition, balance performance, and symptom reporting. Information related to sleep quality and sleep quantity was also collected during preseason baseline testing. Main Outcome Measures: The CNS Vital Signs battery (computerized neurocognitive test), Sensory Organization Test (computerized dynamic posturography), and a Graded Symptom Checklist (symptom evaluation) were used. Results: Subjects with a low sleep quantity the night before baseline reported both a greater number of symptoms and higher total symptom severity score. No clinically significant effects for sleep quality were observed. Conclusions: Sleep-deprived athletes reporting for baseline testing should be rescheduled for testing after a normal night's sleep.	[Mihalik, Jason P.; Lengas, Eric; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Begalle, Rebecca L.; Guskiewicz, Kevin M.] Univ N Carolina, Sch Med, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Begalle, Rebecca L.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Allied Hlth Sci, Sch Med, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC USA; [Oyama, Sakiko] Univ Texas San Antonio, Dept Hlth & Kinesiol, San Antonio, TX USA	Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Register-Mihalik, Johna/0000-0002-4229-4743; Mihalik, Jason/0000-0001-6085-8322; Oyama, Sakiko/0000-0001-8263-9251; Guskiewicz, Kevin/0000-0002-8682-2130			Bougard C, 2011, EXP BRAIN RES, V209, P109, DOI 10.1007/s00221-010-2524-8; Buboltz WC, 2001, J AM COLL HEALTH, V50, P131, DOI 10.1080/07448480109596017; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Clanton NR, 2011, CANCER-AM CANCER SOC, V117, P2559, DOI 10.1002/cncr.25797; DEARY IJ, 1987, BRIT MED J, V295, P1513, DOI 10.1136/bmj.295.6612.1513; Fabbri M, 2006, NEUROPSYCHOLOGIA, V44, P2520, DOI 10.1016/j.neuropsychologia.2006.03.033; FITZPATRICK MF, 1991, THORAX, V46, P569, DOI 10.1136/thx.46.8.569; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gribble PA, 2004, PERCEPT MOTOR SKILL, V99, P1035, DOI 10.2466/PMS.99.7.1035-1045; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; JACQUES CHM, 1990, J FAM PRACTICE, V30, P223; Kelly WE, 2004, COLL STUD J, V35, P84; Kelman L, 2005, HEADACHE, V45, P904, DOI 10.1111/j.1526-4610.2005.05159.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lieberman HR, 2005, AVIAT SPACE ENVIR MD, V76, pC7; Lieberman HR, 2002, PSYCHOPHARMACOLOGY, V164, P250, DOI 10.1007/s00213-002-1217-9; Pilcher JJ, 1997, J PSYCHOSOM RES, V42, P583, DOI 10.1016/S0022-3999(97)00004-4; ROBBINS J, 1990, WESTERN J MED, V152, P82; Robillard R, 2011, CLIN NEUROPHYSIOL, V122, P1771, DOI 10.1016/j.clinph.2011.02.010; Trockel MT, 2000, J AM COLL HEALTH, V49, P125, DOI 10.1080/07448480009596294; Tsai LL, 2004, J PSYCHOSOM RES, V56, P231, DOI 10.1016/S0022-3999(03)00507-5; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Williamson AM, 2000, OCCUP ENVIRON MED, V57, P649, DOI 10.1136/oem.57.10.649	28	43	44	1	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2013	23	5					343	348		10.1097/JSM.0b013e318295a834			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	212YD	WOS:000324017900004	23917732				2021-06-18	
J	Reinke, SN; Walsh, BH; Boylan, GB; Sykes, BD; Kenny, LC; Murray, DM; Broadhurst, DI				Reinke, Stacey N.; Walsh, Brian H.; Boylan, Geraldine B.; Sykes, Brian D.; Kenny, Louise C.; Murray, Deirdre M.; Broadhurst, David I.			H-1 NMR Derived Metabolomic Profile of Neonatal Asphyxia in Umbilical Cord Serum: Implications for Hypoxic Ischemic Encephalopathy	JOURNAL OF PROTEOME RESEARCH			English	Article						asphyxia; hypoxic ischemic encephalopathy; nuclear magnetic resonance; cord serum; metabolomics; succinate; ketone; 3-hydroxybutryate	TRAUMATIC BRAIN-INJURY; ADAPTATION; EEG; HYPOTHERMIA; DISCOVERY; INFANTS; MODEL; NMR; HIF	Neonatal hypoxic ischemic encephalopathy (HIE) is a severe consequence of perinatal asphyxia (PA) that can result in life-long neurological disability. Disease mechanisms, including the role and interaction of individual metabolic pathways, remain unclear. As hypoxia is an acute condition, aerobic energy metabolism is central to global metabolic pathways, and these metabolites are detectable using H-1 NMR spectroscopy, we hypothesized that characterizing the NMR-derived umbilical cord serum metabolome would offer insight into the consequences of PA that lead to HIE. Fifty-nine at-risk infants were enrolled, together with 1:1 matched healthy controls, and stratified by disease severity (n = 25, HIE; n = 34, non HIE PA). Eighteen of 37 reproducibly detectable metabolites were significantly altered between study groups. Acetone, 3-hydroxybutyrate, succinate, and glycerol were significantly differentially altered in severe HIE. Multivariate data analysis revealed a metabolite profile associated with both asphyxia and HIE. Multiple-linear regression modeling using 4 metabolites (3-hydroxybutyrate, glycerol, O-phosphocholine, and succinate) predicted HIE severity with an adjusted R-2 of 0.4. Altered ketones. suggest that systemic metabolism may play a critical role in preventing neurological injury, while altered succinate provides a possible explanation for hypoxia-inducible factor 1-alpha (HIF-1 alpha) stabilization in HI injury.	[Reinke, Stacey N.; Broadhurst, David I.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Reinke, Stacey N.; Sykes, Brian D.] Univ Alberta, Dept Biochem, Edmonton, AB, Canada; [Walsh, Brian H.; Boylan, Geraldine B.; Murray, Deirdre M.] Natl Univ Ireland Univ Coll Cork, Neonatal Brain Res Grp, Dept Paediat & Child Hlth, Cork, Ireland; [Walsh, Brian H.; Boylan, Geraldine B.; Murray, Deirdre M.] Natl Univ Ireland Univ Coll Cork, Irish Ctr Fetal & Neonatal Translat Res INFANT, Cork, Ireland; Cork Univ Matern Hosp, Cork, Ireland; [Kenny, Louise C.] Natl Univ Ireland Univ Coll Cork, Dept Obstet & Gynaecol, Cork, Ireland	Broadhurst, DI (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.	dbroadhu@ualberta.ca	Kenny, Louise/X-6329-2019; Walsh, Brian/AAA-6421-2020; Kenny, Louise C/G-1112-2011	Kenny, Louise/0000-0002-9011-759X; Kenny, Louise C/0000-0002-9011-759X; Murray, Deirdre/0000-0002-2201-9912; Reinke, Stacey/0000-0002-0758-0330; Boylan, Geraldine/0000-0003-0920-5291; Broadhurst, David/0000-0003-0775-9581; Walsh, Brian/0000-0003-4665-6884	Alberta Innovates-Health Solutions (AIHS) studentship program; Molecular Medicines Ireland; Health Research Board Clinical Scientist Award [CSA/201240]; (Ireland) National Children's Research Centre (BASELINE); Canadian Institutes of Health Research (CIHR) (BDS)Canadian Institutes of Health Research (CIHR) [37769]; Pfizer CanadaPfizer	The authors wish to thank the nurses and clinical staff of the labour ward and neonatal intensive care unit for their help in identifying potential candidates for this study. S.N.R. was funded through the Alberta Innovates-Health Solutions (AIHS) studentship program. B.H.W. was funded through Molecular Medicines Ireland. This study was supported by grants from the Health Research Board Clinical Scientist Award (DMM and BiHiVE study, CSA/201240), the (Ireland) National Children's Research Centre (BASELINE), and Canadian Institutes of Health Research (CIHR) (BDS no. 37769). D.I.B. holds salary support from Pfizer Canada.	Amiel-Tison C, 2002, PEDIATR NEUROL, V27, P196, DOI 10.1016/S0887-8994(02)00436-8; Atzori L, 2010, J MATERN-FETAL NEO M, V23, P134, DOI 10.3109/14767058.2010.517033; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Beckstrom AC, 2011, J CHROMATOGR A, V1218, P1899, DOI 10.1016/j.chroma.2011.01.086; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Chen WQ, 2008, ACTA NEUROCHIR SUPPL, V102, P395, DOI 10.1007/978-3-211-85578-2_77; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dunn WB, 2012, BIOANALYSIS, V4, P2249, DOI [10.4155/bio.12.204, 10.4155/BIO.12.204]; Dunn WB, 2011, CHEM SOC REV, V40, P387, DOI 10.1039/b906712b; Fan X, 2009, BRAIN RES REV, V62, P99, DOI 10.1016/j.brainresrev.2009.09.006; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Hastie T., 2009, ELEMENTS STAT LEARNI, Vsecond, P745, DOI DOI 10.1007/978-0-387-84858-7; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Huang CC, 1999, NEW ENGL J MED, V341, P328, DOI 10.1056/NEJM199907293410504; Kanelakis KC, 2009, J BIOMOL SCREEN, V14, P627, DOI 10.1177/1087057109333976; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kirwan JA, 2013, ANAL BIOANAL CHEM, V405, P5147, DOI 10.1007/s00216-013-6856-7; Krzanowski W. J., 1988, PRINCIPLES MULTIVARI, P563; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; LEVENE MI, 1986, LANCET, V1, P67, DOI 10.1016/S0140-6736(86)90718-X; Liu J, 2011, J CEREBR BLOOD F MET, V31, P547, DOI 10.1038/jcbfm.2010.125; Locatelli A, 2008, EUR J OBSTET GYN R B, V139, P146, DOI 10.1016/j.ejogrb.2008.01.003; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; Murray DM, 2008, ARCH DIS CHILD-FETAL, V93, pF183, DOI 10.1136/adc.2006.100800; Murray DM, 2006, PEDIATRICS, V118, P41, DOI 10.1542/peds.2005-1524; Murray DM, 2009, PEDIATRICS, V124, pE459, DOI 10.1542/peds.2008-2190; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Peres-Neto PR, 2003, ECOLOGY, V84, P2347, DOI 10.1890/00-0634; Platt MW, 2005, SEMIN FETAL NEONAT M, V10, P341, DOI 10.1016/j.siny.2005.04.001; Pressler RM, 2001, CLIN NEUROPHYSIOL, V112, P31, DOI 10.1016/S1388-2457(00)00517-4; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Reinke SN, 2010, MOL GENET METAB, V100, P274, DOI 10.1016/j.ymgme.2010.03.013; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Solberg R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009606; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Suzuki Y, 2009, BRAIN RES, V1268, P17, DOI 10.1016/j.brainres.2009.02.074; Szeto SSW, 2010, J PROTEOME RES, V9, P6729, DOI 10.1021/pr100880y; US FDA, 2001, US FDA BIOAN METH VA; Veech RL, 2001, IUBMB LIFE, V51, P241; VOLPE JJ, 2001, NEUROLOGY NEWBORN, P912; Wallace DC, 2007, EMERY RIMOINS PRINCI, P194; Walsh BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050520; Xia JG, 2013, METABOLOMICS, V9, P280, DOI 10.1007/s11306-012-0482-9	54	43	45	0	19	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	SEP	2013	12	9					4230	4239		10.1021/pr400617m			10	Biochemical Research Methods	Biochemistry & Molecular Biology	295WT	WOS:000330147800036	23931672				2021-06-18	
J	Bradford, R; Choudhary, AK; Dias, MS				Bradford, Ray; Choudhary, Arabinda K.; Dias, Mark S.			Serial neuroimaging in infants with abusive head trauma: timing abusive injuries Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						abusive head trauma; shaken baby syndrome; infant; traumatic brain injury; magnetic resonance imaging; computed tomography	SHAKEN BABY SYNDROME; CRANIAL COMPUTED-TOMOGRAPHY; DIFFUSION-WEIGHTED MRI; CHILD-ABUSE; IMPACT SYNDROME; YOUNG-CHILDREN; SUBDURAL HEMATOMAS; BRAIN-DAMAGE; DIAGNOSIS; NEUROPATHOLOGY	Object. The appearance and evolution of neuroimaging abnormalities following abusive head trauma (AHT) is important for establishing the time frame over which these injuries might have occurred. From a legal perspective this frames the timing of the abuse and therefore identifies and excludes potential perpetrators. A previous pilot study involving 33 infants with AHT helped to refine the timing of these injuries but was limited by its small sample size. In the present study, the authors analyzed a larger group of 210 cases involving infants with AHT to chronicle the first appearance and evolution of radiological (CT, MRI) abnormalities. Methods. All children younger than 24 months admitted to the Penn State Hershey Medical Center with AHT over a 10-year period were identified from a medical record review; the time of injury was determined through an evaluation of the clinical records. All imaging studies were analyzed, and the appearance and evolution of abnormalities were chronicled on serial neuroimaging studies obtained in the days and weeks after injury. Results. One hundred five infants with specific injury dates and available imaging studies were identified; a subset of 43 children additionally had documented times of injury. In infants with homogeneously hyperdense subdural hematomas (SDHs) on initial CT scans, the first hypodense component appeared within the SDH between 0.3 and 16 days after injury, and the last hyperdense subdural component disappeared between 2 and 40 days after injury. In infants with mixed-density SDHs on initial scans, the last hyperdense component disappeared between 1 and 181 days. Parenchymal hypodensities appeared on CT scans performed as early as 1.2 hours, and all were visible within 27 hours after the injury. Rebleeding into SDHs was documented in 17 cases (16%) and was always asymptomatic. Magnetic resonance imaging of the brain was performed in 49 infants. Among those with SDH, 5 patterns were observed. Patterns I and II reflected homogeneous SDH; Pattern I (T1 hyperintensity and T2/FLAIR hypointensity, "early subacute") more commonly appeared on scans performed earlier after injury compared with Pattern II (T1 hyperintensity and T2/FLAIR hyperintensity, "late subacute"), although there was considerable overlap. Patterns III and IV reflected heterogeneous SDH; Pattern III contained relatively equal mixtures having different intensities, whereas Pattern IV had fluid that was predominantly T1 hypointense and T2/FLAIR hyperintense. Again, Pattern III more commonly appeared on scans performed earlier after injury compared with Pattern IV, although there was significant overlap. Conclusions. These data extend the preliminary data reported by Dias and colleagues and provide a framework upon which injuries in AHT can be timed as well as the limitations on such timing estimates.	[Bradford, Ray; Choudhary, Arabinda K.] Penn State Milton S Hershey Med Ctr, Penn State Coll Med, Dept Radiol, Hershey, PA USA; [Dias, Mark S.] Penn State Milton S Hershey Med Ctr, Penn State Coll Med, Dept Neurosurg, Hershey, PA USA	Dias, MS (corresponding author), Penn State Hershey Med Ctr, Dept Neurosurg EC110, 30 Hope Dr, Hershey, PA 17033 USA.	mdias@psu.edu	choudhary, arabinda/AAP-1220-2021	choudhary, arabinda/0000-0002-2338-5906	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Pennsylvania Department of Health; New York State Children and Family Trust Fund	Dr. Dias testifies as an expert witness in child abuse cases and reports receiving non-study related clinical or research support from the Centers for Disease Control, the Pennsylvania Department of Health, and the New York State Children and Family Trust Fund.	BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING, P107; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Brennan LK, 2009, J NEUROS-PEDIATR, V3, P232, DOI 10.3171/2008.11.PEDS0835; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; Fox RJ, 1996, NEUROSURGERY, V39, P84, DOI 10.1097/00006123-199607000-00017; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hymel Kent P, 2002, Child Maltreat, V7, P329, DOI 10.1177/107755902237263; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; Parizel PM, 2003, PEDIATR RADIOL, V33, P868, DOI 10.1007/s00247-003-1025-3; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Uscinski RH, 2006, NEUROL MED-CHIR, V46, P57, DOI 10.2176/nmc.46.57; Uscinski RH, 2008, NEUROL MED-CHIR, V48, P151, DOI 10.2176/nmc.48.151; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; Vinchon M, 2010, CHILD NERV SYST, V26, P637, DOI 10.1007/s00381-009-1048-7; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	39	43	43	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2013	12	2					110	119		10.3171/2013.4.PEDS12596			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	187CM	WOS:000322094500003	23799250	Bronze			2021-06-18	
J	Kahl, JE; Calvo, RY; Sise, MJ; Sise, CB; Thorndike, JF; Shackford, SR				Kahl, Jessica E.; Calvo, Richard Y.; Sise, Michael J.; Sise, C. Beth; Thorndike, Jonathan F.; Shackford, Steven R.			The changing nature of death on the trauma service	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Death; trauma center; innovations; elderly; aging patients	PRACTICE MANAGEMENT GUIDELINES; RESPIRATORY-DISTRESS-SYNDROME; LUNG-PROTECTIVE VENTILATION; EPIDEMIOLOGY; TRANSFUSION; OUTCOMES; SYSTEM; IMPACT; INJURY; RESUSCITATION	BACKGROUND: Recent innovations in care have improved survival following injury. Coincidentally, the population of elderly injured patients with preexisting comorbidities has increased. We hypothesized that this increase in elderly injured patients may have combined with recent care innovations to alter the causes of death after trauma. METHODS: We reviewed demographics, injury characteristics, and cause of death of in-hospital deaths of patients admitted to our Level I trauma service from 2000 through 2011. Cause of death was classified as acute hemorrhagic shock; severe traumatic brain injury or high spinal cord injury; complications of preexisting medical condition only (PM); survivable trauma combined with complications of preexisting medical condition(TCoM); multiple-organ failure, sepsis, or adult respiratory distress syndrome (MOF/S/ARDS), or trauma not otherwise categorized (e. g., asphyxiation). Major trauma care advances implemented on our service during the period were identified, and trends in the causes of death were analyzed. RESULTS: Of the 27,276 admissions, 819 (3%) eligible nonsurvivors were identified for the cause-of-death analyses. Causes of death were severe traumatic brain injury or high spinal cord injury at 44%, acute hemorrhagic shock at 28%, PM at 11%, TCoM at 10%, MOF/S/ARDS at 2%, and trauma not otherwise categorized at 5%. Mean age at death increased across the study interval (range, 47-57 years), while mean Injury Severity Score (ISS) decreased (range, 28-35). There was a significant increase in deaths because of TCoM(3.3-20.9%) and PM(6.7-16.4%), while deaths caused by MOF/S/ARDS decreased from 5% to 0% by 2007. Compared with year 2000, the annual adjusted mortality rate decreased consistently starting in 2009, after the 2002 to 2007 adoption of four major trauma practice guidelines. CONCLUSION: Mortality caused by preexisting medical conditions has increased, while markedly fewer deaths resulted from the complications of injury. Future improvements in outcomes will require improvement in the management of elderly trauma patients with comorbid conditions. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Kahl, Jessica E.; Calvo, Richard Y.; Sise, Michael J.; Sise, C. Beth; Thorndike, Jonathan F.; Shackford, Steven R.] Scripps Mercy Hosp, Trauma Serv, San Diego, CA 92103 USA	Sise, MJ (corresponding author), Scripps Mercy Hosp, Trauma Serv MER 62, 4077 5th Ave, San Diego, CA 92103 USA.	sise.mike@scrippshealth.org		Calvo, Richard/0000-0001-9147-2668	Haemonetics	Ernest E. Moore, Editor: PI, research grant, Haemonetics. Associate editors: David Hoyt, Ronald Maier, and Steven Shackford have nothing to disclose. Editorial staff: Jennifer Crebs, Jo Fields, and Angela Sauaia have nothing to disclose.	Alam HB, 2007, SURG CLIN N AM, V87, P55, DOI 10.1016/j.suc.2006.09.015; Bergeron E, 2006, J TRAUMA, V60, P268, DOI 10.1097/01.ta.0000197651.00482.c5; Bergeron E, 2004, J TRAUMA, V56, P760, DOI 10.1097/01.TA.0000119199.52226.C0; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clement ND, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-26; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x; Glance LG, 2012, ARCH SURG-CHICAGO, V147, P732, DOI 10.1001/archsurg.2012.1138; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Laudi S, 2007, INJURY, V38, P1052, DOI 10.1016/j.injury.2007.03.020; Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Plurad D, 2007, J TRAUMA, V63, P1, DOI 10.1097/TA.0b013e318068b1ed; Potenza BM, 2004, J TRAUMA, V56, P68, DOI 10.1097/01.TA.0000101490.32972.9F; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Rogers FB, 2001, J TRAUMA, V50, P604, DOI 10.1097/00005373-200104000-00003; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Sise CB, 2011, J TRAUMA, V70, P560, DOI 10.1097/TA.0b013e31820c7b79	25	43	44	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2013	75	2					195	201		10.1097/TA.0b013e3182997865			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300FL	WOS:000330449700002	23823614				2021-06-18	
J	Tan, T; Xie, JC; Liu, TT; Chen, XJ; Zheng, XB; Tong, ZQ; Tian, X				Tan, Tao; Xie, Jiacun; Liu, Tiaotiao; Chen, Xiaojia; Zheng, Xiaobo; Tong, Zhiqian; Tian, Xin			Low-frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) reverses A beta(1-42)-mediated memory deficits in rats	EXPERIMENTAL GERONTOLOGY			English	Article						Alzheimer's disease (AD); Repetitive transcranial magnetic stimulation (rTMS); Long-term potentiation (LTP); Nerve growth factor (NGF); Brain-derived neurotrophic factor (BDNF); NMDA receptor	LONG-TERM POTENTIATION; NERVE GROWTH-FACTOR; NONINVASIVE BRAIN-STIMULATION; SERUM BDNF LEVELS; NEUROTROPHIC FACTOR; NMDA RECEPTORS; MESSENGER-RNA; IN-VIVO; CORTICAL EXCITABILITY; SYNAPTIC PLASTICITY	Accumulating evidence shows the disruption of hippocampal neurotrophins secretion leads to memory deficits in Alzheimer's disease (AD) animal models. Invasive injection of exogenous neurotrophins into hippocampus reverses spatial memory deficits, but its clinical application is limited by traumatic brain injury during the injection procedure. Notably, recent studies have demonstrated that noninvasive repetitive transcranial magnetic stimulation (rTMS) increases endogenous neurotrophins contents in the brain of normal rats. Whether low-frequency rTMS can reverse A beta(1-42)-mediated decrease in hippocampal neurotrophins contents and spatial memory impairment is still unclear. Here, we reported that severe deficit in long-term potentiation (LTP) and spatial memory were observed in an A beta(1-42)-induced toxicity rat model. Furthermore, neurotrophins (NGF and BDNF) and NMDA-receptor levels were decreased after A beta injection. However, low-frequency rTMS markedly reversed the decrease in neurotrophins contents. And the rTMS-induced increment of neurotrophins up-regulated hippocampal NMDA-receptor expression. Moreover, low-frequency rTMS rescued deficits in LTP and spatial memory of rats with A beta-injection. These results indicate that low-frequency rTMS noninvasively and effectively increases hippocampal neurotrophins and NMDA-receptor contents in A beta(1-42)-induced toxicity model rats, which helps to enhance hippocampal LTP and reverses A beta(1-42)-mediated memory deficits. Crown Copyright (C) 2013 Published by Elsevier Inc. All rights reserved.	[Tan, Tao; Xie, Jiacun; Liu, Tiaotiao; Chen, Xiaojia; Zheng, Xiaobo; Tian, Xin] Tianjin Med Univ, Inst Biomed Engn, Tianjin 300070, Peoples R China; [Tan, Tao; Xie, Jiacun; Liu, Tiaotiao; Chen, Xiaojia; Zheng, Xiaobo; Tian, Xin] Tianjin Med Univ, Res Ctr Basic Med Sci, Lab Neural Engn, Tianjin 300070, Peoples R China; [Tian, Xin] Tianjin Neurol Inst, Tianjin 300070, Peoples R China; [Tong, Zhiqian] Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China	Tian, X (corresponding author), Tianjin Med Univ, Inst Biomed Engn, Tianjin 300070, Peoples R China.	tianx@tijmu.edu.cn	Tan, Tao/F-5535-2010	Tan, Tao/0000-0002-4571-3296	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61074131, 30770545]; Tianjin Medical University [2010GSI09]	We thank Prof. Rongqiao He for his expert help; Prof. Xiulan Zao for technical assistance and help on Immunohistochemistry staining and Ph.D. Zhiqian Tong for editing the manuscript. This study was supported by the National Natural Science Foundation of China (Nos. 61074131 and 30770545) and the "211 Project" Graduate Innovation Grant of Tianjin Medical University (No. 2010GSI09).	Abe K, 2009, PROG NEURO-PSYCHOPH, V33, P552, DOI 10.1016/j.pnpbp.2009.02.011; ADEY WR, 1981, PHYSIOL REV, V61, P435; Ahmed Z, 2006, BIOELECTROMAGNETICS, V27, P288, DOI 10.1002/bem.20211; Andersen P., 2007, SYNAPTIC PLASTICITY, P343; Angelucci F, 2004, NEUROREPORT, V15, P717, DOI 10.1097/00001756-200403220-00029; Arancibia S, 2008, NEUROBIOL DIS, V31, P316, DOI 10.1016/j.nbd.2008.05.012; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; BARKER AT, 1985, LANCET, V1, P1106; BARKER AT, 1994, J ROY SOC HEALTH, V114, P91, DOI 10.1177/146642409411400210; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Bentwich J, 2011, J NEURAL TRANSM, V118, P463, DOI 10.1007/s00702-010-0578-1; Bersani FS, 2013, NEUROCASE, V19, P451, DOI 10.1080/13554794.2012.690429; Bi H, 2002, J NEUROL SCI, V200, P11, DOI 10.1016/S0022-510X(02)00087-4; BLACKMAN CF, 1982, RADIAT RES, V92, P510, DOI 10.2307/3575923; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boroojerdi B, 2001, NEUROLOGY, V56, P526, DOI 10.1212/WNL.56.4.526; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Bruno MA, 2009, J NEUROPATH EXP NEUR, V68, P857, DOI 10.1097/NEN.0b013e3181aed9e6; Caldeira MV, 2007, MOL CELL NEUROSCI, V35, P208, DOI 10.1016/j.mcn.2007.02.019; Calon F, 2005, EUR J NEUROSCI, V22, P617, DOI 10.1111/j.1460-9568.2005.04253.x; Christensen R, 2008, EXP NEUROL, V210, P164, DOI 10.1016/j.expneurol.2007.10.009; Colaianna M, 2010, BRIT J PHARMACOL, V159, P1704, DOI 10.1111/j.1476-5381.2010.00669.x; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; Covaceuszach S, 2009, CURR ALZHEIMER RES, V6, P158, DOI 10.2174/156720509787602870; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; Danielyan A. A., 1999, Physiological Chemistry and Physics and Medical NMR, V31, P139; Filali M, 2011, NEUROPHARMACOLOGY, V60, P930, DOI 10.1016/j.neuropharm.2011.01.035; Foltys H, 2001, CLIN NEUROPHYSIOL, V112, P265, DOI 10.1016/S1388-2457(00)00539-3; Fregni Felipe, 2005, Curr Psychiatry Rep, V7, P381, DOI 10.1007/s11920-005-0041-4; Freitas C, 2011, EXP GERONTOL, V46, P611, DOI 10.1016/j.exger.2011.04.001; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; Gross M, 2007, ACTA PSYCHIAT SCAND, V116, P165, DOI 10.1111/j.1600-0447.2007.01049.x; Guerra Andrea, 2011, Int J Alzheimers Dis, V2011, P263817, DOI 10.4061/2011/263817; Haffen E, 2012, BRAIN STIMUL, V5, P264, DOI 10.1016/j.brs.2011.03.003; Harrison FE, 2009, PHARMACOL BIOCHEM BE, V93, P443, DOI 10.1016/j.pbb.2009.06.006; Hayashi T, 2004, ANN NEUROL, V56, P77, DOI 10.1002/ana.20151; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Jarvis CR, 1997, J NEUROPHYSIOL, V78, P2363; Kim DK, 2010, NEURAL REGEN RES, V5, P1365, DOI 10.3969/j.issn.1673-5374.2010.18.001; Lanctot KL, 2008, EXP NEUROL, V212, P251, DOI 10.1016/j.expneurol.2008.04.031; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; Levkovitz Y, 2001, NEUROPSYCHOPHARMACOL, V24, P608, DOI 10.1016/S0893-133X(00)00244-X; Liebetanz D, 2003, J PSYCHIATR RES, V37, P277, DOI 10.1016/S0022-3956(03)00017-7; Lu Y, 2008, NEUROBIOL LEARN MEM, V89, P312, DOI 10.1016/j.nlm.2007.08.018; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nilsson P, 2010, J CELL MOL MED, V14, P741, DOI 10.1111/j.1582-4934.2010.01038.x; Nomura I, 2012, J NEUROPHYSIOL, V107, P2526, DOI 10.1152/jn.00589.2011; O'Hare E, 1999, BRAIN RES, V815, P1, DOI 10.1016/S0006-8993(98)01002-6; Ogiue-Ikeda M, 2003, BRAIN RES, V993, P222, DOI 10.1016/j.brainres.2003.09.009; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Pennisi G, 2011, DEMENT GERIATR COGN, V31, P71, DOI 10.1159/000322798; Pilato F, 2012, MOL NEUROBIOL, V46, P563, DOI 10.1007/s12035-012-8302-9; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; Shankar GM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-48; Shin RW, 1997, J NEUROSCI, V17, P8187; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Spritzer MD, 2011, HORM BEHAV, V59, P484, DOI 10.1016/j.yhbeh.2011.01.009; [谭涛 TAN Tao], 2011, [生理学报, Acta Physiologica Sinica], V63, P225; Tang YP, 1999, NATURE, V401, P63; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Todd G, 2006, J APPL PHYSIOL, V101, P500, DOI 10.1152/japplphysiol.01399.2005; Tokay T, 2009, NEUROSCI LETT, V461, P150, DOI 10.1016/j.neulet.2009.06.032; Tong ZQ, 2013, AGE, V35, P583, DOI 10.1007/s11357-012-9388-8; Trippe J, 2009, EXP BRAIN RES, V199, P411, DOI 10.1007/s00221-009-1961-8; Tsang SWY, 2008, NEUROBIOL AGING, V29, P1524, DOI 10.1016/j.neurobiolaging.2007.03.014; Wang F, 2010, J MOL NEUROSCI, V41, P145, DOI 10.1007/s12031-009-9311-7; Wang HY, 2011, J NEUROSCI, V31, P11044, DOI 10.1523/JNEUROSCI.2125-11.2011; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wassermann EM, 2012, PHARMACOL THERAPEUT, V133, P98, DOI 10.1016/j.pharmthera.2011.09.003; WESKAMP G, 1987, J NEUROCHEM, V48, P1779, DOI 10.1111/j.1471-4159.1987.tb05736.x; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Wu AD, 2008, NEUROTHERAPEUTICS, V5, P345, DOI 10.1016/j.nurt.2008.02.002; Yukimasa T, 2006, PHARMACOPSYCHIATRY, V39, P52, DOI 10.1055/s-2006-931542; ZAFRA F, 1992, J NEUROSCI, V12, P4793; Zanardini R, 2006, J AFFECT DISORDERS, V91, P83, DOI 10.1016/j.jad.2005.12.029; Zhang XQ, 2007, J HUAZHONG U SCI-MED, V27, P415, DOI 10.1007/s11596-007-0416-3; Zhou JP, 2008, BRAIN RES, V1191, P12, DOI 10.1016/j.brainres.2007.10.097	82	43	49	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	AUG	2013	48	8					786	794		10.1016/j.exger.2013.05.001			9	Geriatrics & Gerontology	Geriatrics & Gerontology	181WI	WOS:000321700300013	23665072				2021-06-18	
J	Yeates, KO; Gerhardt, CA; Bigler, ED; Abildskov, T; Dennis, M; Rubin, KH; Stancin, T; Taylor, HG; Vannatta, K				Yeates, Keith Owen; Gerhardt, Cynthia A.; Bigler, Erin D.; Abildskov, Tracy; Dennis, Maureen; Rubin, Kenneth H.; Stancin, Terry; Taylor, H. Gerry; Vannatta, Kathryn			Peer Relationships of Children with Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Pediatric; Friendship; Victimization; Head; Trauma; Social competence; Sociometrics	VOXEL-BASED MORPHOMETRY; QUALITY-OF-LIFE; SOCIAL OUTCOMES; MODERATE; PSYCHOPATHOLOGY; ADOLESCENTS; COMPETENCE; ANTERIOR; TBI; MRI	This study examined peer relationships in children with traumatic brain injury (TBI) relative to children with orthopedic injuries (OI), and explored whether differences in peer relationships correlated with white matter volumes. Classroom procedures were used to elicit peer perceptions of social behavior, acceptance, and friendships for eighty-seven 8- to 13-year-old children, 15 with severe TBI, 40 with complicated mild/moderate TBI, and 32 with OI. Magnetic resonance imaging (MRI) and voxel-based morphometry (VBM) were used to investigate volumetric correlates of peer relationship measures. Children with severe TBI were rated higher in rejection-victimization than children with OI, and were less likely than children with OI to have a mutual friendship in their classroom (47% vs. 88%). Children with TBI without a mutual friend were rated lower than those with a mutual friend on sociability-popularity and prosocial behavior and higher on rejection-victimization, and had lower peer acceptance ratings. Mutual friendship ratings were related to white matter volumes in several posterior brain regions, but not to overall brain atrophy. Severe TBI in children is associated with detrimental peer relationships that are related to focal volumetric reductions in white matter within regions of the brain involved in social information-processing.	[Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen; Gerhardt, Cynthia A.; Vannatta, Kathryn] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Bigler, Erin D.; Abildskov, Tracy] Brigham Young Univ, Dept Psychol Sci, Provo, UT 84602 USA; [Bigler, Erin D.; Abildskov, Tracy] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Dennis, Maureen] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Rubin, Kenneth H.] Univ Maryland, Dept Human Dev, College Pk, MD 20742 USA; [Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Cleveland, OH USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Rubin, Kenneth H/M-5276-2018; Stancin, Terry/L-7993-2019; Vannatta, Kathryn/E-4237-2011; Gerhardt, Cynthia/E-3109-2011	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	The preparation of this study was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development to the first author. The authors do not have any conflicts of interest to declare.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; ASHER SR, 1979, DEV PSYCHOL, V15, P443, DOI 10.1037/0012-1649.15.4.443; Bendfeldt K, 2012, HUM BRAIN MAPP, V33, P1225, DOI 10.1002/hbm.21279; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bowker JCW, 2006, MERRILL PALMER QUART, V52, P671, DOI 10.1353/mpq.2006.0000; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Bukowski W. M., 1989, CONTRIBUTIONS PEER R, P15; Burt KB, 2008, CHILD DEV, V79, P359, DOI 10.1111/j.1467-8624.2007.01130.x; Cacioppo JT, 2002, PSYCHOSOM MED, V64, P407, DOI 10.1097/00006842-200205000-00005; DENNIS M, 2012, J INT NEUROPSYCH SOC, V19, P1; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FRANKEL F, 2005, PSYCHOSOCIAL TREATME, P693; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Hanten G., 2012, DEV SOCIAL NEUROSCIE, P254; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Howard I, 2005, ETHNIC DIS, V15, pS51; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Mars RB, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00189; Martinez W, 2011, J PEDIATR PSYCHOL, V36, P878, DOI 10.1093/jpepsy/jsr035; Masten AS, 2005, J CLIN CHILD ADOLESC, V34, P87, DOI 10.1207/s15374424jccp3401_8; MASTEN AS, 1985, DEV PSYCHOL, V21, P523, DOI 10.1037/0012-1649.21.3.523; Noll RB, 2007, AM J MED GENET A, V143A, P2261, DOI 10.1002/ajmg.a.31923; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Reiter-Purtill J., 2009, HDB PEDIAT PSYCHOL, P672; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Rubin K. H., 2006, SOCIAL EMOTIONAL PER, P571, DOI DOI 10.1002/9780470147658.CHPSY0310; Rubin K.H., 2012, DEV SOCIAL NEUROSCIE, P23; Rubin KH, 2006, J ABNORM CHILD PSYCH, V34, P143, DOI 10.1007/s10802-005-9017-4; Schnack HG, 2010, HUM BRAIN MAPP, V31, P1967, DOI 10.1002/hbm.20991; Segall JM, 2009, SCHIZOPHRENIA BULL, V35, P82, DOI 10.1093/schbul/sbn150; Sparrow S, 2005, VINELAND ADAPTIVE BE; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; Vannatta K, 2007, PEDIATR BLOOD CANCER, V49, P716, DOI 10.1002/pbc.21062; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeates K. O., 2010, PEDIAT NEUROPSYCHOLO, P112; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ziegler G, 2012, HUM BRAIN MAPP, V33, P2377, DOI 10.1002/hbm.21374	53	43	44	0	28	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2013	19	5					518	527		10.1017/S1355617712001531			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	136OB	WOS:000318370100004	23340166				2021-06-18	
J	Tian, CL; Wang, XW; Wang, XD; Wang, L; Wang, XG; Wu, SM; Wan, ZX				Tian, Chunlei; Wang, Xiongwei; Wang, Xiaodan; Wang, Lei; Wang, Xuguang; Wu, Shengmei; Wan, Zhixian			Autologous Bone Marrow Mesenchymal Stem Cell Therapy in the Subacute Stage of Traumatic Brain Injury by Lumbar Puncture	EXPERIMENTAL AND CLINICAL TRANSPLANTATION			English	Article						Cerebral lesion; Regenerative therapy; Transplant; Vegetative state; Motor	SPINAL-CORD-INJURY; TRANSPLANTATION; PROLIFERATION; DELIVERY; STROKE; EPIDEMIOLOGY; RECOVERY; SURVIVAL	Objectives: To explore the clinical therapeutic effects and safety of autologous bone marrow mesenchymal stem cell therapy for traumatic brain injury by lumbar puncture. Materials and Methods: A total of 97 patients (24 with persistent vegetative state and 73 with disturbance motor activity) who developed a complex cerebral lesion after traumatic brain injury received autologous bone marrow mesenchymal stem cell therapy voluntarily. The stem cells were isolated from the bone marrow of the patients and transplanted into the subarachnoid space by lumbar puncture. Results: Fourteen days after cell therapy, no serious complications or adverse events were reported. To a certain extent, 38 of 97 patients (39.2%) improved in the function of brain after transplant (P = .007). Eleven of 24 patients (45.8%) with persistent vegetative state showed posttherapeutic improvements in consciousness (P = .024). Twenty-seven of 73 patients (37.0%) with a motor disorder began to show improvements in motor functions (P = .025). The age of patients and the time elapsed between injury and therapy had effects on the outcomes of the cellular therapy (P < .05). No correlation was found between the number of cell injections and improvements (P>.05). Conclusions: This study suggests that the bone marrow stem cell therapy is safe and effective on patients with traumatic brain injury complications, such as persistent vegetative state and motor disorder, through lumbar puncture. Young patients improve more easily than older ones. The earlier the cellular therapy begins in the subacute stage of traumatic brain injury, the better the results.	[Tian, Chunlei; Wang, Xiongwei; Wang, Xiaodan; Wang, Lei; Wang, Xuguang; Wu, Shengmei; Wan, Zhixian] China Three Gorges Univ, Inst Neurol, Coll Clin Med Sci 1, Yichang 443003, Hubei, Peoples R China; [Tian, Chunlei; Wang, Xiongwei; Wang, Lei; Wang, Xuguang; Wu, Shengmei; Wan, Zhixian] Yichang Ctr Peoples Hosp, Dept Neurosurg, Yichang 443003, Hubei, Peoples R China	Wang, XW (corresponding author), China Three Gorges Univ, Inst Neurol, Coll Clin Med Sci 1, Yi Ling Da Dao 183, Yichang 443003, Hubei, Peoples R China.	xwwyc@yahoo.cn					Allers C, 2004, TRANSPLANTATION, V78, P503, DOI 10.1097/01.TP.0000128334.93343.B3; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Arango MF, 2007, EVIDENCE BASED NEURO, P142; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Curry Parichat, 2011, Int J Crit Illn Inj Sci, V1, P27, DOI 10.4103/2229-5151.79279; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Hilfiker A, 2011, LANGENBECK ARCH SURG, V396, P489, DOI 10.1007/s00423-011-0762-2; Jang DK, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/238409; Keimpema E, 2009, NEUROPATH APPL NEURO, V35, P89, DOI 10.1111/j.1365-2990.2008.00961.x; Kim HJ, 2005, BIOMATERIALS, V26, P4442, DOI 10.1016/j.biomaterials.2004.11.013; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Lerner AJ, 2006, DIAGNOSTIC CRITERIA, P69; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Meinel L, 2004, ANN BIOMED ENG, V32, P112, DOI 10.1023/B:ABME.0000007796.48329.b4; Meinel L, 2006, BIOMATERIALS, V27, P4993, DOI 10.1016/j.biomaterials.2006.05.021; Nicholl J, 2009, SEMIN NEUROL, V29, P247, DOI 10.1055/s-0029-1223878; Paul C, 2009, SPINE, V34, P328, DOI 10.1097/BRS.0b013e31819403ce; Pavlichenko N, 2008, BRAIN RES, V1233, P203, DOI 10.1016/j.brainres.2008.06.123; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Sykova E, 2007, CELL DEATH DIFFER, V14, P1336, DOI 10.1038/sj.cdd.4402140; Tolar J, 2006, BLOOD, V107, P4182, DOI 10.1182/blood-2005-08-3289; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Weiner Leslie P., 2008, V438, P3, DOI 10.1007/978-1-59745-133-8_1; Wilkinson L, 2005, ESSENTIAL NEUROLOGY, P55; Wislet-Gendebien S, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601560; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	34	43	44	0	6	BASKENT UNIV	ANKARA	TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY	1304-0855			EXP CLIN TRANSPLANT	Exp. Clin. Transplant.	APR	2013	11	2					176	181		10.6002/ect.2012.0053			6	Transplantation	Transplantation	137SQ	WOS:000318458100015	22891928				2021-06-18	
J	Luo, CL; Li, QQ; Chen, XP; Zhang, XM; Li, LL; Li, BX; Zhao, ZQ; Tao, LY				Luo, Cheng-Liang; Li, Qian-Qian; Chen, Xi-Ping; Zhang, Xin-Mu; Li, Li-Liang; Li, Bei-Xu; Zhao, Zi-Qin; Tao, Lu-Yang			Lipoxin A(4) attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury	BRAIN RESEARCH			English	Article						Lipoxin A(4); Traumatic brain injury; Blood-brain barrier; Brain edema; Pro-inflammatory cytokines; Mitogen-activated protein kinases	ASPIRIN-TRIGGERED LIPOXIN; FOCAL CEREBRAL-ISCHEMIA; INDUCED CELL-DEATH; NF-KAPPA-B; AQUAPORIN-4 EXPRESSION; NITRIC-OXIDE; IN-VIVO; RAT; RECEPTOR; EDEMA	The present study was designed to investigate the effects of lipoxin A(4) (LXA(4)) on traumatic brain injury (TBI) and to analyze the possible mechanism. Outcome parameters consist of blood-brain barrier (BBB) breakdown, brain edema and lesion volume. Using western blot and quantitative real-time PCR, we examined the levels of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6) and activation of mitogen-activated protein kinases (MAPKs) (including ERK, JNK, p38) following TBI. To investigate the cell types in which the LXA(4) receptor (ALXR) staining was localized, brain sections pulsed with ALXR were subjected to immunofluorescence staining with antibodies against cell type-specific antigens. Our findings show that LXA(4) decreases BBB permeability, attenuates brain edema, and reduces TBI-induced lesion volume. In addition, LXA(4) inhibits TBI-induced elevation of mRNA and protein levels of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6). In the injured cortex at 24 h post-TBI, the phosphorylated-ERK (p-ERK) and -JNK (p-JNK), but not -p38 (p-p38) levels were increased. The p-ERK and p-JNK production were attenuated by their respective inhibitors (PD98059 and SP600125), as well as LXA(4). Moreover, ALXR was found to label more GFAP positive cells, whereas few CD11b-positive cells were labeled by ALXR within the layers of the injured cortex at 24 h post-TBI. The activation of ALXR in astrocytes was partially enhanced by LXA(4) treatment. Taken together, these data indicate that TBI activates pro-inflammatory cytokines, the MAPK pathways together with ALXR in astrocytes, and these mechanisms may be exploited by pharmacological interventions. (C) 2013 Elsevier B.V. All rights reserved.	[Luo, Cheng-Liang; Li, Qian-Qian; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Luo, Cheng-Liang; Li, Li-Liang; Li, Bei-Xu; Zhao, Zi-Qin] Fudan Univ, Shanghai Med Coll, Dept Forens Med, Shanghai 200032, Peoples R China; [Li, Qian-Qian] Wannan Med Coll, Dept Forens Med, Wuhu, Peoples R China; [Zhang, Xin-Mu] Jilin Univ, Sch Pharm, Dept Biopharmaceut Sci, Changchun 130023, Peoples R China	Zhao, ZQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Forens Med, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	zqzhao@shmu.edu.cn; luyang.tao@163.com	Zhang, Xinmu/G-8128-2018; Li, Liliang/AAQ-9877-2020	Li, Liliang/0000-0002-1933-134X	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271379, 81172911, 81172897]; Shanghai Forensic Key Laboratory Foundation [KF1005]	This work was supported by the National Science Foundation of China (Nos. 81271379, 81172911, 81172897) and the Shanghai Forensic Key Laboratory Foundation (No. KF1005). We thank Dr. Jing Zhou in Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School for polishing our manuscript.	Auger G, 2011, CYTOKINE, V56, P290, DOI 10.1016/j.cyto.2011.06.015; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Jozsef L, 2002, P NATL ACAD SCI USA, V99, P13266, DOI 10.1073/pnas.202296999; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Marmarou A, 1980, Adv Neurol, V28, P345; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P404, DOI 10.1097/00005072-199207000-00003; Medeiros R, 2008, MOL PHARMACOL, V74, P154, DOI 10.1124/mol.108.046870; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Qin ZH, 1999, J NEUROSCI, V19, P4023; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sigala I, 2011, AM J PHYSIOL-REG I, V300, pR1152, DOI 10.1152/ajpregu.00376.2010; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Wu SH, 2007, PROSTAG LEUKOTR ESS, V76, P173, DOI 10.1016/j.plefa.2006.12.006; Wu Y, 2012, J MOL NEUROSCI, V46, P483, DOI 10.1007/s12031-011-9620-5; Wu Y, 2010, J MOL NEUROSCI, V42, P226, DOI 10.1007/s12031-010-9355-8; Ye XH, 2010, BRAIN RES, V1323, P174, DOI 10.1016/j.brainres.2010.01.079; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	39	43	45	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 28	2013	1502						1	10		10.1016/j.brainres.2013.01.037			10	Neurosciences	Neurosciences & Neurology	126SG	WOS:000317640900001	23370001				2021-06-18	
J	Babikian, T; McArthur, D; Asarnow, RF				Babikian, Talin; McArthur, David; Asarnow, Robert F.			Predictors of 1-Month and 1-Year Neurocognitive Functioning from the UCLA Longitudinal Mild, Uncomplicated, Pediatric Traumatic Brain Injury Study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Mild traumatic brain injury; Concussion; Pediatric; Neurocognition; Brain injury; Outcomes	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; CHILDREN; OUTCOMES; RECOVERY; BEHAVIOR	Although more severe brain injuries have long been associated with persisting neurocognitive deficits, an increasing body of literature has shown that children/adolescents with single, uncomplicated mild traumatic brain injury (mTBI) do not exhibit long-lasting neurocognitive impairments. Nonetheless, clinical experience and our previous report (Babikian, 2011) showed that a minority of children/adolescents exhibit persistent cognitive problems using performance based measures following what appear to be relatively mild injuries. Predictors of poor neurocognitive outcomes were evaluated in 76 mTBI and 79 Other Injury subjects to determine the relative contributions of indices of injury severity, clinical symptomatology, demographic factors, and premorbid functioning in predicting 1-month and 12-month neurocognitive impairment on computerized or paper and pencil measures. Injury severity indicators or type of injury (head vs. other body part) did not predict either 1-month or 12-month cognitive impairment status. Rather, premorbid variables that antedated the injury (parental education, premorbid behavior and/or learning problems, and school achievement) predicted cognitive impairments. When post-injury neurocognitive impairments are observed in survivors of mild injuries (head or other body part), a sound understanding of their etiology is critical in designing appropriate intervention plans. Clinical and research implications are discussed. (JINS, 2013, 19, 145-154)	[Babikian, Talin; Asarnow, Robert F.] UCLA Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [McArthur, David] UCLA Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	Babikian, T (corresponding author), UCLA Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90095 USA.	tbabikian@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801] Funding Source: NIH RePORTER	There are no conflicts of interest to report. This study was funded by NINDS R01NS026801 Neurobehavioral Sequelae of Mild Brain Injury in Children; and NICHD R01HD061504 Reconnection of Neural Networks and Cognitive Recovery After Pediatric TBI.	Achenbach T. M., 1991, CHILD BEHAV CHECKLIS; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Asarnow R, 1995, TRAUMATIC BRAIN INJU, P117; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; BIJUR PE, 1990, PEDIATRICS, V86, P337; Brier G.W., 1950, MONTHLY WEATHER REV, V78, P1, DOI 2.0.CO;2; Brooks BL, 2010, PSYCHOL ASSESSMENT, V22, P650, DOI 10.1037/a0019781; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P182, DOI 10.1093/arclin/acq005; Brun R, 2001, WATER RESOUR RES, V37, P1015, DOI 10.1029/2000WR900350; Dunn L., 1981, PEABODY PICTURE VOCA; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kundu S, 2011, EUR J EPIDEMIOL, V26, P261, DOI 10.1007/s10654-011-9567-4; Moos B.R., 1986, FAMILY ENV SCALE MAN; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; R Development Core Team, 2011, R LANG ENV STAT COMP; Reitan RM., 1985, HALSTEAD REITAN NEUR; SATZ P, 1989, PIN TEST PROFESSIONA; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Smith A., 1968, J LEARNING DISORDERS, V3, P83; Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	35	43	43	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	FEB	2013	19	2					145	154		10.1017/S135561771200104X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	085WV	WOS:000314645900004	23157821				2021-06-18	
J	Dreier, JP; Isele, T; Reiffurth, C; Offenhauser, N; Kirov, SA; Dahlem, MA; Herreras, O				Dreier, Jens P.; Isele, Thomas; Reiffurth, Clemens; Offenhauser, Nikolas; Kirov, Sergei A.; Dahlem, Markus A.; Herreras, Oscar			Is Spreading Depolarization Characterized by an Abrupt, Massive Release of Gibbs Free Energy from the Human Brain Cortex?	NEUROSCIENTIST			English	Article						spreading depression; stroke; subarachnoid hemorrhage; intracerebral hemorrhage; traumatic brain injury; epilepsy; migraine	LOW EXTRACELLULAR MAGNESIUM; FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; EPILEPTIFORM ACTIVITY; MIGRAINE AURA; IN-VIVO; CORTICAL ACTIVITY; ION HOMEOSTASIS; BLOOD-FLOW; DC SHIFTS	In the evolution of the cerebral cortex, the sophisticated organization in a steady state far away from thermodynamic equilibrium has produced the side effect of two fundamental pathological network events: ictal epileptic activity and spreading depolarization. Ictal epileptic activity describes the partial disruption, and spreading depolarization describes the near-complete disruption of the physiological double Gibbs-Donnan steady state. The occurrence of ictal epileptic activity in patients has been known for decades. Recently, unequivocal electrophysiological evidence has been found in patients that spreading depolarizations occur abundantly in stroke and brain trauma. The authors propose that the ion changes can be taken to estimate relative changes in Gibbs free energy from state to state. The calculations suggest that in transitions from the physiological state to ictal epileptic activity to spreading depolarization to death, the cortex releases Gibbs free energy in a stepwise fashion. Spreading depolarization thus appears as a twilight state close to death. Consistently, electrocorticographic recordings in the core of focal ischemia or after cardiac arrest display a smooth transition from the initial spreading depolarization component to the later ultraslow negative potential, which is assumed to reflect processes in cellular death.	[Dreier, Jens P.; Reiffurth, Clemens; Offenhauser, Nikolas] Charite, Ctr Stroke Res Berlin, D-10117 Berlin, Germany; [Dreier, Jens P.] Charite, Dept Neurol, D-10117 Berlin, Germany; [Dreier, Jens P.; Reiffurth, Clemens; Offenhauser, Nikolas] Charite, Dept Expt Neurol, D-10117 Berlin, Germany; [Isele, Thomas; Dahlem, Markus A.] Tech Univ Berlin, Inst Theoret Phys, Berlin, Germany; [Kirov, Sergei A.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA USA; [Herreras, Oscar] CSIC, Inst Cajal, Dept Syst Neurosci, E-28002 Madrid, Spain	Dreier, JP (corresponding author), Charite, Ctr Stroke Res, Campus Charite Mitte,Charitepl 1, D-10117 Berlin, Germany.	jens.dreier@charite.de	herreras, oscar/D-5256-2016; Dahlem, Markus/A-8805-2008; Herreras, Oscar/O-1711-2019	herreras, oscar/0000-0002-8210-3710; Dahlem, Markus/0000-0002-7532-0127; Herreras, Oscar/0000-0002-8210-3710; Dreier, Jens/0000-0001-7459-2828; Reiffurth, Clemens/0000-0002-1372-1240	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR 323/3-1, 323/5-1, 323/6-1]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, )Federal Ministry of Education & Research (BMBF) [01 EO 0801, 01GQ1001C B2]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057113]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057113] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by grants of the Deutsche Forschungsgemeinschaft (DFG DR 323/3-1, 323/5-1, 323/6-1), the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801, Bernstein Center for Computational Neuroscience Berlin 01GQ1001C B2 and Era-Net Neuron SDSVD) to Dr. Dreier and the National Institutes of Health, NS057113 to Dr. Kirov.	Alle H, 2009, SCIENCE, V325, P1405, DOI 10.1126/science.1174331; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Berger M, 2008, CEPHALALGIA, V28, P558, DOI 10.1111/j.1468-2982.2008.01556.x; BRANSTON NM, 1977, J NEUROL SCI, V32, P305, DOI 10.1016/0022-510X(77)90014-4; BURES J, 1957, PFLUG ARCH GES PHYS, V264, P325, DOI 10.1007/BF00364173; Canals S, 2005, J NEUROPHYSIOL, V94, P943, DOI 10.1152/jn.01145.2004; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Dalkara T, 2010, LANCET NEUROL, V9, P309, DOI 10.1016/S1474-4422(09)70358-8; DIETZEL I, 1989, GLIA, V2, P25, DOI 10.1002/glia.440020104; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Dreier JP, 2002, BRAIN, V125, P102, DOI 10.1093/brain/awf007; DREIER JP, 1991, EXP BRAIN RES, V87, P581; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Eikermann-Haerter K, 2012, CIRCULATION, V125, P335, DOI 10.1161/CIRCULATIONAHA.111.045096; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; Gerich FJ, 2006, J NEUROPHYSIOL, V96, P492, DOI 10.1152/jn.01015.2005; Gorji A, 2001, BRAIN RES, V906, P74, DOI 10.1016/S0006-8993(01)02557-4; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; HERRERA FC, 1992, COMP BIOCHEM PHYS A, V103, P29, DOI 10.1016/0300-9629(92)90238-L; HERRERAS O, 1993, BRAIN RES, V610, P283, DOI 10.1016/0006-8993(93)91412-L; HERRERAS O, 1994, J NEUROSCI, V14, P7087; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Kleeberg J, 2004, AM J PHYSIOL-HEART C, V286, pH1339, DOI 10.1152/ajpheart.00227.2003; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Kurth T, 2012, LANCET NEUROL, V11, P92, DOI 10.1016/S1474-4422(11)70266-6; LAMANNA JC, 1975, BRAIN RES, V88, P145, DOI 10.1016/0006-8993(75)90963-4; Largo C, 1996, J NEUROSCI, V16, P1219; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LEAF A, 1956, BIOCHEM J, V62, P241, DOI 10.1042/bj0620241; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; LEAO AAP, 1945, J NEUROPHYSIOL, V8, P33; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Makarova J, 2010, J NEUROPHYSIOL, V103, P2446, DOI 10.1152/jn.01045.2009; MARTINSFERREIRA H, 1974, J NEUROPHYSIOL, V37, P773; Maslarova A, 2011, STROKE, V42, P2917, DOI 10.1161/STROKEAHA.111.621581; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221, DOI 10.1097/00004647-199603000-00006; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MODY I, 1987, J NEUROPHYSIOL, V57, P869; Muller M, 2000, J NEUROPHYSIOL, V83, P735, DOI 10.1152/jn.2000.83.2.735; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Oliveira-Ferreira AI, 2012, FUTUR NEUROL, V7, P45, DOI 10.2217/FNL.11.69; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Shapiro BE, 2001, J COMPUT NEUROSCI, V10, P99, DOI 10.1023/A:1008924227961; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SOMJEN GG, 2004, IONS BRAIN; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891; TASAKI I, 1991, BIOCHEM BIOPH RES CO, V174, P293, DOI 10.1016/0006-291X(91)90519-D; Tidow H, 2010, TRENDS BIOCHEM SCI, V35, P653, DOI 10.1016/j.tibs.2010.05.004; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; VANHARREVELD A, 1965, J CELL BIOL, V25, P117, DOI 10.1083/jcb.25.1.117; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; Vorisek I, 1997, J CEREBR BLOOD F MET, V17, P191; Windmuller O, 2005, BRAIN, V128, P2042, DOI 10.1093/brain/awh545; Yanamoto H, 2005, STROKE, V36, P1544, DOI 10.1161/01.STR.0000169903.09253.c7	82	43	43	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	FEB	2013	19	1					25	42		10.1177/1073858412453340			18	Clinical Neurology; Neurosciences	Neurosciences & Neurology	057FZ	WOS:000312549600008	22829393	Green Published, Green Accepted			2021-06-18	
J	Kirov, II; Tal, A; Babb, JS; Lui, YW; Grossman, RI; Gonen, O				Kirov, Ivan I.; Tal, Assaf; Babb, James S.; Lui, Yvonne W.; Grossman, Robert I.; Gonen, Oded			Diffuse axonal injury in mild traumatic brain injury: a 3D multivoxel proton MR spectroscopy study	JOURNAL OF NEUROLOGY			English	Article						Brain injury; Diffuse axonal injury; Magnetic resonance spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; RELAXATION-TIMES; ADULT BRAIN; MATTER; DAMAGE; PREVALENCE; RECOVERY; TESLA	Since mild traumatic brain injury (mTBI) often leads to neurological symptoms even without clinical MRI findings, our goal was to test whether diffuse axonal injury is quantifiable with multivoxel proton MR spectroscopic imaging (H-1-MRSI). T1- and T2-weighted MRI images and three-dimensional H-1-MRSI (480 voxels over 360 cm(3), about 30 % of the brain) were acquired at 3 T from 26 mTBI patients (mean Glasgow Coma Scale score 14.7, 18-56 years old, 3-55 days after injury) and 13 healthy matched contemporaries as controls. The N-acetylaspartate (NAA), choline (Cho), creatine (Cr) and myo-inositol (mI) concentrations and gray-matter/white-matter (GM/WM) and cerebrospinal fluid fractions were obtained in each voxel. Global GM and WM absolute metabolic concentrations were estimated using linear regression, and patients were compared with controls using two-way analysis of variance. In patients, mean NAA, Cr, Cho and mI concentrations in GM (8.4 +/- A 0.7, 6.9 +/- A 0.6, 1.3 +/- A 0.2, 5.5 +/- A 0.6 mM) and Cr, Cho and mI in WM (4.8 +/- A 0.5, 1.4 +/- A 0.2, 4.6 +/- A 0.7 mM) were not different from the values in controls. The NAA concentrations in WM, however, were significantly lower in patients than in controls (7.2 +/- A 0.8 vs. 7.7 +/- A 0.6 mM, p = 0.0125). The Cho and Cr levels in WM of patients were positively correlated with time since mTBI. This H-1-MRSI approach allowed us to ascertain that early mTBI sequelae are (1) diffuse (not merely local), (2) neuronal (not glial), and (3) in the global WM (not GM). These findings support the hypothesis that, similar to more severe head trauma, mTBI also results in diffuse axonal injury, but that dysfunction rather than cell death dominates shortly after injury.	[Kirov, Ivan I.; Tal, Assaf; Babb, James S.; Lui, Yvonne W.; Grossman, Robert I.; Gonen, Oded] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA	Gonen, O (corresponding author), NYU, Dept Radiol, Sch Med, 660 1st Ave,4th Floor, New York, NY 10016 USA.	oded.gonen@med.nyu.edu	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Babb, James/0000-0003-1798-1186; Gonen, Oded/0000-0002-3148-2028; Tal, Assaf/0000-0001-6718-6522	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB01015, NS39135, NS29029, NS050520]; Human Frontiers Science Project; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050520, R01NS029029, R01NS039135, R37NS029029, R56NS050520] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants EB01015, NS39135, NS29029 and NS050520. Assaf Tal is also supported by the Human Frontiers Science Project. We thank Ms. Nissa Perry and Mr. Joseph Reaume for subject recruitment.	Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Baker EH, 2008, J MAGN RESON IMAGING, V27, P489, DOI 10.1002/jmri.21285; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FRAHM J, 1997, MAGNETIC RESONANCE S, P329; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2002, AM J NEURORADIOL, V23, P1327; Goelman G, 2006, MAGN RESON MED, V56, P34, DOI 10.1002/mrm.20942; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HU J, 1995, J MAGN RESON SER B, V108, P213, DOI 10.1006/jmrb.1995.1126; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JOHNSON VE, 2012, EXP NEUROL IN PRESS; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2008, MAGN RESON MED, V60, P790, DOI 10.1002/mrm.21715; Kirov II, 2012, MAGN RESON MED, V67, P27, DOI 10.1002/mrm.23001; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kreis R, 2005, MAGN RESON MED, V54, P761, DOI 10.1002/mrm.20673; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Son BC, 2000, ACT NEUR S, V76, P13; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Tal A, 2012, NMR BIOMED, V25, P1392, DOI 10.1002/nbm.2812; Tanelian T., 2008, INVISIBLE WOUNDS WAR, P305; TEASDALE G, 1974, LANCET, V2, P81; Traber F, 2004, J MAGN RESON IMAGING, V19, P537, DOI 10.1002/jmri.20053; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	49	43	45	0	25	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JAN	2013	260	1					242	252		10.1007/s00415-012-6626-z			11	Clinical Neurology	Neurosciences & Neurology	063NV	WOS:000313007600034	22886061	Green Accepted			2021-06-18	
J	MacGregor, AJ; Dougherty, AL; Tang, JJ; Galarneau, MR				MacGregor, Andrew J.; Dougherty, Amber L.; Tang, Janet J.; Galarneau, Michael R.			Postconcussive Symptom Reporting Among US Combat Veterans With Mild Traumatic Brain Injury From Operation Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						combat; concussion; depression; mild traumatic brain injury; military; posttraumatic stress disorder; PTSD	MENTAL-HEALTH PROBLEMS; AFGHANISTAN; DISORDER; DEPLOYMENT; OUTCOMES; RATES	Objective: To examine the association between postconcussive symptoms and mild traumatic brain injury (MTBI) among combat veterans while adjusting for posttraumatic stress disorder (PTSD) and depression. Patients: Military personnel with provider-diagnosed MTBI (n = 334) or nonhead injury (n = 658) were identified from the Expeditionary Medical Encounter Database. Main Outcome Measures: Post-Deployment Health Assessments and Re-Assessments were used to examine postconcussive symptoms and self-rated health. Results: Personnel with MTBI were more likely to report headache (odds ratio [OR] = 3.37; 95% confidence interval [CI] = 2.19-5.17), back pain (OR = 1.79; 95% CI = 1.23-2.60), memory problems (OR = 1.86; 95% CI = 1.20-2.88), tinnitus (OR = 1.63; 95% CI = 1.10-2.41), and dizziness (OR = 2.13; 95% CI = 1.06-4.29) compared with those with non-head injuries. Among those with MTBI, self-reported decline in health was associated with memory problems (OR = 5.07; 95% CI = 2.56-10.02) and dizziness (OR = 10.60; 95% CI = 3.48-32.27). Conclusions: Mild traumatic brain injury is associated with reports of negative health consequences among combat veterans even when accounting for co-occurring psychological morbidity. The identification of postconcussive symptoms related to declines in a service member's self-rated health may be important in targeting and prioritizing clinical interventions.	[MacGregor, Andrew J.; Dougherty, Amber L.; Tang, Janet J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA	Dougherty, AL (corresponding author), USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine under the Wounded, Ill and Injured/Psychological Health/Traumatic Brain Injury Program [60819]	This work was supported by the US Navy Bureau of Medicine under the Wounded, Ill and Injured/Psychological Health/Traumatic Brain Injury Program, Work Unit No. 60819.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; [Anonymous], 2005, POSTD HLTH REASS FOR; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Commission on Professional Hospital Activities, 1977, INT CLASS DIS; Deployment Health Clinical Center, 2003, POSTD HLTH ASS DD FO; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; MacGregor AJ, 2009, MIL MED, V174, P224, DOI 10.7205/MILMED-D-03-9107; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; McCrea M., 2008, OXFORD WORKSHOP SERI; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	42	43	43	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					59	67		10.1097/HTR.0b013e3182596382			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400007	22688214				2021-06-18	
J	Sajja, VSSS; Galloway, MP; Ghoddoussi, F; Thiruthalinathan, D; Kepsel, A; Hay, K; Bir, CA; VandeVord, PJ				Sajja, Venkata Siva Sai Sujith; Galloway, Matthew P.; Ghoddoussi, Farhad; Thiruthalinathan, Dhananjeyan; Kepsel, Andrea; Hay, Kathryn; Bir, Cynthia A.; VandeVord, Pamela J.			Blast-induced neurotrauma leads to neurochemical changes and neuronal degeneration in the rat hippocampus	NMR IN BIOMEDICINE			English	Article						neurotrauma; apoptosis; 1H MRS; blast; hippocampus	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; N-ACETYL ASPARTATE; MOUSE MODEL; INTRACRANIAL-PRESSURE; MAJOR DEPRESSION; TIME-COURSE; DYSFUNCTION; MECHANISMS; VETERANS	Blast-induced neurotrauma is a major concern because of the complex expression of neuropsychiatric disorders after exposure. Disruptions in neuronal function, proximal in time to blast exposure, may eventually contribute to the late emergence of clinical deficits. Using magic angle spinning 1H MRS and a rodent model of blast-induced neurotrauma, we found acute (2448 h) decreases in succinate, glutathione, glutamate, phosphorylethanolamine and ?-aminobutyric acid, no change in N-acetylaspartate and increased glycerophosphorylcholine, alterations consistent with mitochondrial distress, altered neurochemical transmission and increased membrane turnover. Increased levels of the apoptotic markers Bax and caspase-3 suggested active cell death, consistent with increased FluoroJade B staining in the hippocampus. Elevated levels of glial fibrillary acidic protein suggested ongoing inflammation without diffuse axonal injury measured by no change in beta-amyloid precursor protein. In conclusion, blast-induced neurotrauma induces a metabolic cascade associated with neuronal loss in the hippocampus in the acute period following exposure. Copyright (c) 2012 John Wiley & Sons, Ltd.	[Sajja, Venkata Siva Sai Sujith; Thiruthalinathan, Dhananjeyan; Kepsel, Andrea; Bir, Cynthia A.; VandeVord, Pamela J.] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA; [Galloway, Matthew P.; Ghoddoussi, Farhad] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Hay, Kathryn; VandeVord, Pamela J.] John D Dingell Vet Adm Med Ctr, Detroit, MI USA	VandeVord, PJ (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, 447 ICTAS Bldg,Stanger St, Blacksburg, VA 24060 USA.	pvord@vt.edu	Kepsel, Andrea/U-1596-2019; Sajja, Sujith/I-5289-2019	Kepsel, Andrea/0000-0002-9651-6700; Sajja, Sujith/0000-0002-1992-9501; Bir, Cynthia/0000-0002-0777-0951; Galloway, Matthew/0000-0002-7856-9606	United States Office of Naval ResearchOffice of Naval Research [N000140810585]; Joe Young Fund for Research in Psychiatry; Anesthesiology Fund for Medical Research; Wayne State University Rumble Graduate Fellowship	This research was supported in part by the United States Office of Naval Research Grant Award Number N000140810585 (CAB, PJV), The Joe Young Fund for Research in Psychiatry (MPG), The Anesthesiology Fund for Medical Research (MPG, FG) and a Wayne State University Rumble Graduate Fellowship (VSSSS).	Barker PB, 2001, ANN NEUROL, V49, P423, DOI 10.1002/ana.90.abs; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Bremner JD, 2006, ANN NY ACAD SCI, V1071, P80, DOI 10.1196/annals.1364.008; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Cavassila S, 2001, NMR BIOMED, V14, P278, DOI 10.1002/nbm.701; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cheng LL, 1997, P NATL ACAD SCI USA, V94, P6408, DOI 10.1073/pnas.94.12.6408; Cirstea CM, 2011, STROKE, V42, P1004, DOI 10.1161/STROKEAHA.110.601047; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Franklin KB, 2008, MOUSE BRAIN STEREOTA; Ghoddoussi F, 2010, J NEUROL SCI, V290, P41, DOI 10.1016/j.jns.2009.11.013; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Greco T, 2010, J ALZHEIMERS DIS, V20, pS427, DOI 10.3233/JAD-2010-100519; Haan C, 2007, J IMMUNOL METHODS, V318, P11, DOI 10.1016/j.jim.2006.07.027; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Keller JN, 1998, J NEUROSCI, V18, P4439; Kochanek PM, 2009, J NEUROTRAUM, V26, P813, DOI 10.1089/neu.2008.0893; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; MacQueen G, 2011, MOL PSYCHIATR, V16, P252, DOI 10.1038/mp.2010.80; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; MOFFET JR, 2006, N ACETYLASPARTATE UN; Moore GJ, 2000, PSYCHOPHARMACOL BULL, V36, P5; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rooney WD, 1998, NEUROLOGY, V50, P1800, DOI 10.1212/WNL.50.6.1800; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Salek RM, 2010, NEUROCHEM INT, V56, P937, DOI 10.1016/j.neuint.2010.04.001; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stanley JA, 2000, BIOL PSYCHIAT, V48, P357, DOI 10.1016/S0006-3223(00)00949-5; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90	54	43	45	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	DEC	2012	25	12					1331	1339		10.1002/nbm.2805			9	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	025ZR	WOS:000310237600004	22549883				2021-06-18	
J	Thompson, JW; Narayanan, SV; Perez-Pinzon, MA				Thompson, John W.; Narayanan, Srinivasan V.; Perez-Pinzon, Miguel A.			Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning	CURRENT NEUROPHARMACOLOGY			English	Article						Epsilon PKC; HIF; Ischemic preconditioning; Nrf2; Reactive oxygen species; Sirtuin; SIRT1; Reperfusion	PROTEIN-KINASE-C; HYPOXIA-INDUCIBLE FACTOR; FOCAL CEREBRAL-ISCHEMIA; CYSTATHIONINE BETA-SYNTHASE; NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL ELECTRON-TRANSPORT; ORGANOTYPIC HIPPOCAMPAL SLICE; HEME OXYGENASE-1 INDUCTION; ALCOHOL SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY	There is extensive evidence that the restoration of blood flow following cerebral ischemia contributes greatly to the pathophysiology of ischemia mediated brain injury. The initiating stimulus of reperfusion injury is believed to be the excessive production of reactive oxygen (ROS) and nitrogen (RNS) species by the mitochondria. ROS and RNS generation leads to mitochondrial protein, lipid and DNA oxidation which impedes normal mitochondrial physiology and initiates cellular death pathways. However not all ROS and RNS production is detrimental. It has been demonstrated that low levels of ROS production are protective and may serve as a trigger for activation of ischemic preconditioning. Ischemic preconditioning is a neuroprotective mechanism which is activated upon a brief sublethal ischemic exposure and is sufficient to provide protection against a subsequent lethal ischemic insult. Numerous proteins and signaling pathways have been implicated in the ischemic preconditioning neuroprotective response. In this review we examine the origin and mechanisms of ROS and RNS production following ischemic/reperfusion and the role of free radicals in modulating proteins associated with ischemic preconditioning neuroprotection.	[Thompson, John W.; Narayanan, Srinivasan V.; Perez-Pinzon, Miguel A.] Univ Miami, Miller Sch Med, Dept Neurol, Cerebral Vasc Dis Res Ctr, Miami, FL 33136 USA	Perez-Pinzon, MA (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, D4-5,POB 016960, Miami, FL 33101 USA.	perezpinzon@miami.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS45676-01, NS054147-01, NS34773]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054147, R01NS045676, R01NS034773, F31NS080344, R29NS034773] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants NS45676-01, NS054147-01 and NS34773.	Abe K, 1996, J NEUROSCI, V16, P1066; Abraham NG, 2005, FREE RADICAL BIO MED, V39, P1, DOI 10.1016/j.freeradbiomed.2005.03.010; Abraham P, 2009, CANCER CHEMOTH PHARM, V64, P279, DOI 10.1007/s00280-008-0868-6; Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a; Allen B.S., 2012, EUR J CARDIOTHORAC S; Altup S, 2001, EUR J PHARMACOL, V415, P239, DOI 10.1016/S0014-2999(01)00843-3; AMBROSIO G, 1995, J MOL CELL CARDIOL, V27, P1035, DOI 10.1016/0022-2828(95)90072-1; Ara J, 2011, NEUROBIOL DIS, V43, P473, DOI 10.1016/j.nbd.2011.04.021; AUCHAMPACH JA, 1991, J PHARMACOL EXP THER, V259, P961; AUCHAMPACH JA, 1993, AM J PHYSIOL, V264, pH1327; Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Ball KA, 2012, BIOCHEM BIOPH RES CO, V420, P727, DOI 10.1016/j.bbrc.2012.03.050; Beal MF, 1998, BRAIN RES, V783, P109, DOI 10.1016/S0006-8993(97)01192-X; Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5; Bell KF, 2011, P NATL ACAD SCI USA, V108, pE1, DOI 10.1073/pnas.1015229108; Bell KFS, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/689524; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.3.CO;2-#; Bertrand X, 2005, MED MALADIES INFECT, V35, P329, DOI 10.1016/j.medmal.2005.05.002; Blondeau N, 2000, NEUROSCIENCE, V100, P465, DOI 10.1016/S0306-4522(00)00304-3; Boyle EM, 1996, ANN THORAC SURG, V62, P1868, DOI 10.1016/S0003-4975(96)00950-2; Bright R, 2008, NEUROSCI LETT, V441, P120, DOI 10.1016/j.neulet.2008.05.080; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burwell LS, 2006, BIOCHEM J, V394, P627, DOI 10.1042/BJ20051435; Caito S, 2010, FASEB J, V24, P3145, DOI 10.1096/fj.09-151308; Calvert JW, 2010, CIRCULATION, V122, P11, DOI 10.1161/CIRCULATIONAHA.109.920991; Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919; Carroll R, 2001, CARDIOVASC RES, V51, P691, DOI 10.1016/S0008-6363(01)00330-3; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen R, 2011, J BIOL CHEM, V286, P13869, DOI 10.1074/jbc.M110.175414; CHEN W, 1995, CIRC RES, V77, P424, DOI 10.1161/01.RES.77.2.424; Chen W, 2011, FOOD CHEM TOXICOL, V49, P2439, DOI 10.1016/j.fct.2011.06.066; Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Csonka C, 2001, BIOCHEM BIOPH RES CO, V285, P1217, DOI 10.1006/bbrc.2001.5308; Das DK, 2003, ARCH BIOCHEM BIOPHYS, V420, P305, DOI 10.1016/j.abb.2003.09.023; De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226; Della-Morte D, 2011, NEUROSCI LETT, V487, P158, DOI 10.1016/j.neulet.2010.10.013; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Dong J, 2008, ANTIOXID REDOX SIGN, V10, P2023, DOI 10.1089/ars.2007.2019; Dreger H, 2009, CARDIOVASC RES, V83, P354, DOI 10.1093/cvr/cvp107; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fridovich I, 1979, Adv Neurol, V26, P255; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Girbovan C, 2012, BEHAV PHARMACOL, V23, P1, DOI 10.1097/FBP.0b013e32834eafa3; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223; Habeos IG, 2008, J MOL MED, V86, P1279, DOI 10.1007/s00109-008-0393-4; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hasegawa K, 2008, BIOCHEM BIOPH RES CO, V372, P51, DOI 10.1016/j.bbrc.2008.04.176; Hausenloy DJ, 2007, BASIC RES CARDIOL, V102, P445, DOI 10.1007/s00395-007-0656-1; Hausenloy DJ, 2011, NAT REV CARDIOL, V8, P619, DOI 10.1038/nrcardio.2011.85; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Hsu CP, 2010, CIRCULATION, V122, P2170, DOI 10.1161/CIRCULATIONAHA.110.958033; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Hwang I, 2012, DIABETES, V61, P728, DOI 10.2337/db11-0584; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; Jones SP, 2004, AM J PHYSIOL-HEART C, V286, pH276, DOI 10.1152/ajpheart.00129.2003; Kaspar J.W., 2012, J CELL SCI 4, V125, P1027; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Kikuchi N, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-31; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; KINUTA Y, 1989, J NEUROSURG, V71, P417, DOI 10.3171/jns.1989.71.3.0417; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kudin A.P., 2012, BIOCH BIOPHYS ACTA; Kumar A, 2011, MOL PHARMACOL, V80, P446, DOI 10.1124/mol.111.071126; Lange-Asschenfeldt C, 2004, J CEREBR BLOOD F MET, V24, P636, DOI 10.1097/01.WCB.0000121235.42748.BF; Lee BS, 2006, BIOCHEM BIOPH RES CO, V343, P965, DOI 10.1016/j.bbrc.2006.03.058; Li QF, 2012, BRAIN RES, V1451, P1, DOI 10.1016/j.brainres.2012.02.055; Liang HW, 2005, BRAIN RES, V1042, P169, DOI 10.1016/j.brainres.2005.02.031; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02; Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200; Liu Y, 2008, BASIC RES CARDIOL, V103, P54, DOI 10.1007/s00395-007-0683-y; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Liverman CS, 2004, MOL BRAIN RES, V126, P57, DOI 10.1016/j.molbrainres.2004.02.028; Luciano JA, 2008, CELL PHYSIOL BIOCHEM, V21, P421, DOI 10.1159/000129634; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; Maines MD, 2005, ANTIOXID REDOX SIGN, V7, P1761, DOI 10.1089/ars.2005.7.1761; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; McPherson BC, 2001, CIRCULATION, V103, P290; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Moreno DM, 2011, ARCH BIOCHEM BIOPHYS, V507, P304, DOI 10.1016/j.abb.2010.12.011; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nadtochiy SM, 2011, AM J PHYSIOL-HEART C, V301, pH1506, DOI 10.1152/ajpheart.00587.2011; Nadtochiy SM, 2011, CARDIOVASC RES, V89, P643, DOI 10.1093/cvr/cvq287; Nadtochiy SM, 2007, J MOL CELL CARDIOL, V42, P812, DOI 10.1016/j.yjmcc.2007.01.010; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Obata T, 2000, ARCH BIOCHEM BIOPHYS, V378, P195, DOI 10.1006/abbi.2000.1830; OHTSUKI T, 1992, BRAIN RES, V599, P246, DOI 10.1016/0006-8993(92)90398-S; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Oladipupo S, 2011, P NATL ACAD SCI USA, V108, P13264, DOI 10.1073/pnas.1101321108; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Palacios-Callender M, 2004, P NATL ACAD SCI USA, V101, P7630, DOI 10.1073/pnas.0401723101; Palmer LA, 2000, MOL PHARMACOL, V58, P1197; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Perez-Pinzon MA, 1999, J CEREBR BLOOD F MET, V19, P39, DOI 10.1097/00004647-199901000-00004; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; PHILIPSON KA, 1985, J STEROID BIOCHEM, V23, P1059, DOI 10.1016/0022-4731(85)90067-6; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; PIANTADOSI CA, 1987, J APPL PHYSIOL, V62, P1277; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Pugliese AM, 2003, BRIT J PHARMACOL, V140, P305, DOI 10.1038/sj.bjp.0705442; Puisieux F, 2004, BRAIN RES, V1027, P30, DOI 10.1016/j.brainres.2004.08.067; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Rao SM, 2011, DEV NEUROSCI-BASEL, V33, P288, DOI 10.1159/000327241; Raval AP, 2007, BRAIN RES, V1184, P345, DOI 10.1016/j.brainres.2007.09.073; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Raval AP, 2005, J CEREBR BLOOD F MET, V25, P730, DOI 10.1038/sj.jcbfm.9600071; Raval AP, 2003, J NEUROSCI, V23, P384; Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638; Ren JW, 2011, NEUROCHEM RES, V36, P2352, DOI 10.1007/s11064-011-0561-8; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Rosenthal M, 1997, ADV EXP MED BIOL, V428, P189; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; SALDIVA PHN, 1985, ACTA PHYSIOL PHARM L, V35, P109; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schildknecht S, 2011, J BIOL CHEM, V286, P4991, DOI 10.1074/jbc.M110.169565; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Schulke S, 2012, GENE, V500, P199, DOI 10.1016/j.gene.2012.03.019; Schultz JE, 1997, J MOL CELL CARDIOL, V29, P1055, DOI 10.1006/jmcc.1996.0358; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Siegel D, 1997, MOL PHARMACOL, V52, P300; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; Simao F, 2012, NEUROCHEM INT; Simao F., 2012, EUR J NEUROSCI; Singh S, 2009, J BIOL CHEM, V284, P22457, DOI 10.1074/jbc.M109.010868; Sivaraman V, 2009, J MOL CELL CARDIOL, V46, P758, DOI 10.1016/j.yjmcc.2009.02.013; Stevens JF, 2003, CHEM RES TOXICOL, V16, P1277, DOI 10.1021/tx020100d; Sugimoto K, 2003, CIRC J, V67, P295; Suliman HB, 2007, J CELL SCI, V120, P299, DOI 10.1242/jcs.03318; Sumbayev VV, 2003, FEBS LETT, V535, P106, DOI 10.1016/S0014-5793(02)03887-5; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Tritto I, 1997, CIRC RES, V80, P743, DOI 10.1161/01.RES.80.5.743; Um HC, 2011, NITRIC OXIDE-BIOL CH, V25, P161, DOI 10.1016/j.niox.2011.06.001; Usta E, 2011, J CARDIOVASC SURG, V52, P399; van der Kooij MA, 2009, NEUROSCI LETT, V451, P109, DOI 10.1016/j.neulet.2008.12.013; van der Veen RC, 1999, J NEUROIMMUNOL, V95, P1, DOI 10.1016/S0165-5728(98)00239-2; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Vlahakos D, 2012, ARTIF ORGANS, V36, P400, DOI 10.1111/j.1525-1594.2011.01385.x; VLESSIS AA, 1990, J NEUROCHEM, V54, P1412, DOI 10.1111/j.1471-4159.1990.tb01977.x; Walsh SR, 2008, EUR J CARDIO-THORAC, V34, P985, DOI 10.1016/j.ejcts.2008.07.062; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang B, 2011, STROKE, V42, P2605, DOI 10.1161/STROKEAHA.110.607101; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22; Xing YQ, 2009, BRAIN RES, V1291, P113, DOI 10.1016/j.brainres.2009.07.032; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027798; Yasinska IM, 2003, FEBS LETT, V549, P105, DOI 10.1016/S0014-5793(03)00807-X; YELLON DM, 1993, LANCET, V342, P276, DOI 10.1016/0140-6736(93)91819-8; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang Jian, 2007, Zhonghua Wai Ke Za Zhi, V45, P1253; Zhang JL, 2005, AM J PHYSIOL-CELL PH, V288, pC840, DOI 10.1152/ajpcell.00325.2004; Zhang Y, 2010, J MOL CELL CARDIOL, V49, P576, DOI 10.1016/j.yjmcc.2010.05.011; Zhao Y, 2010, CURR PHARM BIOTECHNO, V11, P868, DOI 10.2174/138920110793262105; Zhu H, 2007, CARDIOVASC TOXICOL, V7, P202, DOI 10.1007/s12012-007-9001-z; Zuckerbraun BS, 2007, FASEB J, V21, P1099, DOI 10.1096/fj.06-6644com	188	43	46	0	6	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X			CURR NEUROPHARMACOL	Curr. Neuropharmacol.	DEC	2012	10	4					354	369					16	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	048KH	WOS:000311909700008	23730259	Green Published			2021-06-18	
J	Harrison-Felix, C; Kolakowsky-Hayner, SA; Hammond, FM; Wang, R; Englander, J; Dams-O'Connor, K; Kreider, SED; Novack, TA; Diaz-Arrastia, R				Harrison-Felix, Cynthia; Kolakowsky-Hayner, Stephanie A.; Hammond, Flora M.; Wang, Roberta; Englander, Jeffrey; Dams-O'Connor, Kristen; Kreider, Scott E. D.; Novack, Thomas A.; Diaz-Arrastia, Ramon			Mortality After Surviving Traumatic Brain Injury: Risks Based on Age Groups	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; chronic; epidemiology; life expectancy; mortality; rehabilitation; vital statistics	LONG-TERM SURVIVAL; HEAD TRAUMA; POPULATION; REHABILITATION; INDIVIDUALS; TRENDS; COMA	Objective: To assess mortality, life expectancy, risk factors, and causes of death by age groups among persons who received inpatient traumatic brain injury (TBI) rehabilitation. Design: Prospective cohort study. Setting: The TBI Model Systems. Participants: 8573 individuals injured between 1988 and 2009, with survival status per December 31, 2009, determined. Interventions: Not applicable. Main Outcome Measures: Standardized mortality ratio, life expectancy, and cause of death. Results: Moderate-severe TBI increases risk of mortality compared with the general population in all age groups, with the exception of those 85 years or older at the time of injury. Teenagers to middle-aged adults are at particular risk. Risk factors for death varied by age group and included gender, marital and employment status, year and cause of injury, and level of disability. External causes of death predominate in younger groups. For the youngest male participants in the sample, longevity was reduced up to 16 years. Conclusion: Risk factors and causes of death varied considerably by age group for individuals with moderate-severe TBI who were receiving acute care rehabilitation. Moderate-severe TBI is a chronic health condition.	[Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; [Harrison-Felix, Cynthia; Kreider, Scott E. D.] Craig Hosp, Englewood, CO USA; [Hammond, Flora M.] Carolinas HealthCare Syst, Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA; [Novack, Thomas A.] Univ Alabama Birmingham, Birmingham, AL USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Kolakowsky-Hayner, SA (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	Stephanie.Hayner@hhs.sccgov.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Diaz-Arrastia, Ramon/0000-0001-6051-3594	National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education Services, Department of Education [H133A070038, HD133A020526, H133A070042, H133A070039, H133A070033, H133A110006, H133A070022]; Department of EducationUS Department of Education; NIDRR	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education Services, Department of Education grant numbers: H133A070038, HD133A020526, H133A070042, H133A070039, H133A070033, H133A110006, H133A070022. The contents of the study were developed under grants from the Department of Education, NIDRR, as specified under the Source of Funding section. However, those contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. The authors thank the research participants, research assistants, and all project staff for their assistance in the success of this endeavor. In addition, the authors acknowledge the continued support of the project officers and program manager at NIDRR.	ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; [Anonymous], 1997, GUID UN DAT SET MED; Baguley I, 2000, BRAIN INJURY, V14, P505; Betz ME, 2008, J AM GERIATR SOC, V56, P2267, DOI 10.1111/j.1532-5415.2008.02001.x; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, COMPR MORT FIL UND C; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hoff Clarissa J B, 2010, J La State Med Soc, V162, P352; Hoffman SW, 2010, NEUROREHABILITATION, V26, P257, DOI 10.3233/NRE-2010-0561; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Laing SP, 1999, DIABETIC MED, V16, P459, DOI 10.1046/j.1464-5491.1999.00075.x; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; *SAS I INC, SAS SYST WIND COMP P; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Solana R, SEMIN IMMUNOL, DOI [10.1016/j.bbr.2011.03.031, DOI 10.1016/J.BBR.2011.03.031]; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46	36	43	43	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E45	E56		10.1097/HTR.0b013e31827340ba			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200005	23131970				2021-06-18	
J	Semple, BD; Canchola, SA; Noble-Haeusslein, LJ				Semple, Bridgette D.; Canchola, Sandra A.; Noble-Haeusslein, Linda J.			Deficits in Social Behavior Emerge during Development after Pediatric Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; cognitive function; outcome measures; pediatric brain injury; social behavior	MORRIS WATER MAZE; SEX-DIFFERENCES; MOUSE MODEL; NEUROPSYCHOLOGICAL SEQUELAE; SOCIOEMOTIONAL BEHAVIOR; AGGRESSIVE-BEHAVIOR; PREFRONTAL CORTEX; ANIMAL-MODEL; HEAD-INJURY; SHORT-TERM	The pediatric brain may be particularly vulnerable to social deficits after traumatic brain injury (TBI) due to the protracted nature of psychosocial development through adolescence. However, the majority of pre-clinical studies fail to assess social outcomes in experimental pediatric TBI. The current study evaluated social behavior in mice subjected to TBI at postnatal day (p)21. Social behaviors were assessed by a partition test, resident-intruder, three-chamber, and tube dominance tasks during adolescence (p35-42) and again during early adulthood (p60-70), during encounters with unfamiliar, naive stimulus mice. Despite normal olfactory function and normal social behaviors during adolescence, brain-injured mice showed impaired social investigation by adulthood, evidenced by reduced ano-genital sniffing and reduced following of stimulus mice in the resident-intruder task, as well as a loss of preference for sociability in the three-chamber task. TBI mice also lacked a preference for social novelty, suggestive of a deficit in social recognition or memory. By adulthood, brain-injured mice exerted more frequent dominance in the tube task compared to sham-operated controls, a finding suggestive of aggressive tendencies. Together these findings reveal reduced social interaction and a tendency towards increased aggression, which evolves across development to adulthood. This emergence of aberrant social behavior, which parallels the development of other cognitive deficits in this model and behaviors seen in brain-injured children, is consistent with the hypothesis that the full extent of deficits is not realized until the associated skills reach maturity. Thus, efficacy of therapeutics for pediatric TBI should take into account the time-dependent emergence of abnormal behavioral patterns.	[Semple, Bridgette D.; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Canchola, Sandra A.; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA	Semple, BD (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 513 Parnassus Ave,Room HSE 722, San Francisco, CA 94143 USA.	Bridgette.Semple@ucsf.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159]; Core Exploratory Award from the UCSF Resource Allocation Program; Sir Keith Murdoch Fellowship from the American Australian Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R01NS077767] Funding Source: NIH RePORTER	This study was supported by an NIH/NINDS R01 grant (NS050159) and a Core Exploratory Award from the UCSF Resource Allocation Program. The research was conducted in the Neurobehavioral Core for Rehabilitation Research at UCSF. B.D. Semple was also supported by a Sir Keith Murdoch Fellowship from the American Australian Association.	Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Bachevalier J, 2001, BEHAV NEUROSCI, V115, P545, DOI 10.1037//0735-7044.115.3.545; Bannerman DM, 2002, EXP BRAIN RES, V142, P395, DOI 10.1007/s00221-001-0938-z; Barker LA, 2010, NEUROPSYCHOLOGIA, V48, P2550, DOI 10.1016/j.neuropsychologia.2010.05.001; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Braga LW, 2007, J CHILD NEUROL, V22, P1084, DOI 10.1177/0883073807306246; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Crawley JN, 2007, BRAIN PATHOL, V17, P448, DOI 10.1111/j.1750-3639.2007.00096.x; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duval J, 2008, J CHILD NEUROL, V23, P663, DOI 10.1177/0883073808314161; Duvoisin RM, 2011, BEHAV BRAIN RES, V221, P50, DOI 10.1016/j.bbr.2011.02.049; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Engelmann M, 2006, HORM BEHAV, V50, P496, DOI 10.1016/j.yhbeh.2006.04.009; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; Ferriero DM, 2010, J ANAT, V217, P429, DOI 10.1111/j.1469-7580.2010.01226.x; FILE SE, 1978, BRIT J PHARMACOL, V62, P19, DOI 10.1111/j.1476-5381.1978.tb07001.x; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Greve KW, 2001, BRAIN INJURY, V15, P255; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hsu YY, 2006, BIOL REV, V81, P33, DOI 10.1017/S146479310500686X; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jacobs R, 2011, CORTEX, V47, P808, DOI 10.1016/j.cortex.2010.06.002; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Kaidanovich-Beilin O., 2010, Journal of Visualized Experiments, V48, P2473, DOI [DOI 10.3791/2473, 10.3791/2473]; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kudryavtseva N N, 2003, Neurosci Behav Physiol, V33, P461, DOI 10.1023/A:1023411217051; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Maaswinkel H, 1996, PHYSIOL BEHAV, V60, P55, DOI 10.1016/0031-9384(95)02233-3; Malkova L, 2010, BEHAV NEUROSCI, V124, P742, DOI 10.1037/a0021622; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; Molina J, 2008, HUM MOL GENET, V17, P2486, DOI 10.1093/hmg/ddn148; Moy SS, 2008, BEHAV BRAIN RES, V191, P118, DOI 10.1016/j.bbr.2008.03.015; Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Pietropaolo S, 2004, PHYSIOL BEHAV, V81, P443, DOI 10.1016/j.physbeh.2004.02.022; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan BC, 2008, BEHAV BRAIN RES, V193, P235, DOI 10.1016/j.bbr.2008.06.002; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; Spencer CM, 2005, GENES BRAIN BEHAV, V4, P420, DOI 10.1111/j.1601-183X.2005.00123.x; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Terranova M.L., 2005, CURR PROT TOXICOL; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; VANDEPOLL NE, 1982, J COMP PHYSIOL PSYCH, V96, P893, DOI 10.1037/0735-7036.96.6.893; Verger K, 2001, BRAIN INJURY, V15, P211; Wang F, 2011, SCIENCE, V334, P693, DOI 10.1126/science.1209951; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Yang M, 2011, CURR PROT NEUROSCI, V8; Yang M, 2007, FRONT BEHAV NEUROSCI, V1, DOI [10.3389/neuro.08/001.2007, 10.3389/neuro.08.001.2007]; Yang Mu, 2009, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0824s48; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	77	43	44	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2672	2683		10.1089/neu.2012.2595			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400008	22888909	Green Published			2021-06-18	
J	Freire, MAM				Freire, M. A. M.			Pathophysiology of Neurodegeneration Following Traumatic Brain Injury	WEST INDIAN MEDICAL JOURNAL			English	Article						Acute neural injury; cell death; neurodegeneration; secondary damage	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURIES; NITRIC-OXIDE; OXIDATIVE STRESS; INFLAMMATORY RESPONSE; IN-VITRO; DEGENERATION; EXCITOTOXICITY; MECHANISMS; DISORDERS	Acute neuropathological conditions, including brain and spinal cord trauma, are leading causes of death and disabilities worldwide, especially in children and young adults. The causes of brain and spinal cord injuries include automobile accidents, accidents during recreational activities, falls and violent attacks. In the United States of America alone, around 1.7 million people each year seek medical care for some kind of head injury. About fifty-two thousand of these people will die, while the same number will present with permanent functional disability. Considering the high worldwide prevalence of these acute pathological conditions, research on the mechanisms underlying central nervous system damage is of extreme importance. Nowadays, a number of experimental models of acute neural disorders have been developed and the mechanisms of tissue loss have been investigated. These mechanisms include both primary and secondary pathological events contributing to tissue damage and functional impairment. The main secondary pathological mechanisms encompass excitotoxicity, ionic imbalances, inflammatory response, oxidative stress and apoptosis. The proper elucidation of how neural tissue is lost following brain and spinal cord trauma is fundamental to developing effective therapies to human diseases. The present review evaluates the main mechanisms of secondary tissue damage following traumatic brain and spinal cord injuries.	ELS IINN, BR-59066060 Natal, RN, Brazil	Freire, MAM (corresponding author), ELS IINN, Rua Prof Francisco Luciano de Oliveira 2460, BR-59066060 Natal, RN, Brazil.	freire.m@gmail.com	Freire, Marco Aurelio M./A-1450-2010	Freire, Marco Aurelio M./0000-0002-6483-0498	Associacao Alberto Santos Dumont para Apoio a Pesquisa (AASDAP) - Brazil	The author thanks Associacao Alberto Santos Dumont para Apoio a Pesquisa (AASDAP) - Brazil for its financial and logistical support. The author declares the inexistence of any financial interests or other dual commitments that represent potential conflicts of interest related to the present manuscript.	Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BELL MD, 1995, J NEUROCYTOL, V24, P695, DOI 10.1007/BF01179819; Burns SP, 2010, INJURY PREV, V16, P74, DOI 10.1136/ip.2008.021097; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Choi D, 1998, MT SINAI J MED, V65, P133; CHOI DW, 1994, PROG BRAIN RES, V100, P47; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crandon IW, 2007, W INDIAN MED J, V56, P223; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Freire MAM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027554; Freire MAM, 2009, FRONT NEUROSCI-SWITZ, V3, P175, DOI 10.3389/neuro.01.024.2009; Garthwaite J, 2008, EUR J NEUROSCI, V27, P2783, DOI 10.1111/j.1460-9568.2008.06285.x; Gomes-Leal W, 2004, EXP NEUROL, V190, P456, DOI 10.1016/j.expneurol.2004.06.028; Guimaraes JS, 2010, BRAIN RES, V1329, P182, DOI 10.1016/j.brainres.2010.03.007; Guimares JS, 2009, REV NEUROLOGIA, V48, P304, DOI 10.33588/rn.4806.2008512; Jackson AB, 2004, ARCH PHYS MED REHAB, V85, P1740, DOI 10.1016/j.apmr.2004.04.035; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Kraus J F, 1996, Inj Prev, V2, P212, DOI 10.1136/ip.2.3.212; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Love S, 1999, BRAIN PATHOL, V9, P119; Medina-Ceja L, 2007, REV NEUROLOGIA, V45, P341, DOI 10.33588/rn.4506.2005647; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Olney J W, 1990, Can Dis Wkly Rep, V16 Suppl 1E, P47; Olney JW, 1990, CAN DIS WKLY REP S1E, V16, P8; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Sanchez-Gomez M. V., 1996, INT J DEV BIOL S1, V1, p187S; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VNI: The Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Wink DA, 2000, SEMIN PERINATOL, V24, P20, DOI 10.1016/S0146-0005(00)80049-X; Yamaura I, 2002, SPINE, V27, P21, DOI 10.1097/00007632-200201010-00008; Yeleswarapu SP, 2010, PAEDIAT CHILD HLTH, V20, P9; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	54	43	45	0	9	UNIV WEST INDIES FACULTY MEDICAL SCIENCES	KINGSTON	MONA CAMPUS, KINGSTON 7, JAMAICA	0043-3144			W INDIAN MED J	West Ind. Med. J.	OCT	2012	61	7					751	755					5	Medicine, General & Internal	General & Internal Medicine	125OA	WOS:000317547900017	23620976				2021-06-18	
J	Chen, CJ; Wu, CH; Liao, YP; Hsu, HL; Tseng, YC; Liu, HL; Chiu, WT				Chen, Chi-Jen; Wu, Chih-Hsiung; Liao, Yen-Peng; Hsu, Hui-Ling; Tseng, Ying-Chi; Liu, Ho-Ling; Chiu, Wen-Ta			Working Memory in Patients with Mild Traumatic Brain Injury: Functional MR Imaging Analysis	RADIOLOGY			English	Article							HEAD-INJURY; COGNITIVE REHABILITATION; AXONAL INJURY; BLOOD-FLOW; FMRI; EPIDEMIOLOGY; PERFORMANCE; CONCUSSION; ACTIVATION; PARADIGM	Purpose: To analyze brain activation patterns in response to tests of working memory after a mild traumatic brain injury (MTBI). Materials and Methods: Research ethics committee approval and patient written informed consent were obtained. Brain activation patterns in response to n-back working memory tasks (n = 1, 2, 3) were assessed with functional magnetic resonance (MR) imaging in 20 patients with MTBI within 1 month after their injury and in 18 healthy control subjects. In n-back working memory tasks, participants monitored a series of number stimuli and were to indicate when the presented number was the same as that presented n back previously. Nine (45%) MTBI patients underwent follow-up functional MR imaging studies 6 weeks later. Digit span, a memory test for how many numbers a person can remember in sequence, and continuous performance test (CPT), a test that measures a person's sustained and selective attention and impulsivity, were also performed before functional MR imaging studies and outside the imager for each participant. Clinical data were analyzed by using t and chi(2) tests. Within-group, between-group, and initial and follow-up differences of functional MR imaging data were analyzed by using one-sample, two-sample, and paired t tests, respectively. Results: Groups were similar for sex (P = .75), years of education (P = .069), digit span (P = .37 for total score), CPT (P = .31, .27, and .43 for omission error, commission error, and hit reaction time, respectively), and accuracy of n-back working memory performance (P = .90, .11, and .39 for one-, two-, and three-back tasks, respectively). Brain activation patterns differed between MTBI patients and controls in response to increasing working memory loads (P < .01, uncorrected). Control subjects maintained their ability to increase activation in the working memory circuitry with each increase in working memory load. In contrast, MTBI patients were impaired in their ability to increase activation in working memory circuitry under both moderate and high working memory load conditions. However, MTBI patients did show cerebral plasticity, as evidenced by more activation in some areas outside and inside the working memory circuitry as compared with control subjects (P < .01, uncorrected). In the 6-week follow-up study, compared with baseline, MTBI patients showed an improvement of activation in response to increasing working memory loads (P < .05, uncorrected). Conclusion: MTBI-induced differences in working memory functional activity were observed even though differences in behavioral performance between MTBI patients and controls were absent, which suggests that this approach may increase sensitivity to MTBI compared with neuropsychological evaluation alone. (C) RSNA, 2012	[Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei 11031, Taiwan; [Chen, Chi-Jen; Liao, Yen-Peng; Hsu, Hui-Ling; Tseng, Ying-Chi] Taipei Med Univ, Shuang Ho Hosp, Dept Radiol, New Taipei City, Taiwan; [Wu, Chih-Hsiung] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, New Taipei City, Taiwan; [Liu, Ho-Ling] Chang Gung Univ, Sch Med, Dept Med Imaging & Radiol Sci, Tao Yuan, Taiwan	Chiu, WT (corresponding author), Taipei Med Univ, Grad Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 11031, Taiwan.	wtchiu@tmu.edu.tw	Liao, Yen-Peng/AAE-3575-2021	Liao, Yen-Peng/0000-0001-5721-0357	National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 98-2321-B-038-004-MY3, NSC-99-2811-B-038-024, NCS98-2321-B-038-003-MY3 (3-3), NCS98-2321-B-038-005-MY3 (3-3), NSC98-2314-B-038-012-MY3, NSC98-2314-B-038-011-MY3]; Taipei Medical University, Taiwan [TMU98-AE1-B15, 98YGH-TMU-04]	From the Departments of Radiology (C.J.C., Y.P.L., H. L. H., Y.C.T.) and Surgery (C. H. W.), Taipei Medical University/Shuang Ho Hospital, New Taipei City, Taiwan; Department of Medical Imaging and Radiological Sciences, Chang Gung University, School of Medicine, Guishan, Taoyuan, Taiwan (H. L. L.); and Graduate Institute of Injury Prevention and Control, Taipei Medical University, 250 Wu-Hsing St, Hsin-Yi District, Taipei 11031, Taiwan (W. T. C.). Received October 9, 2011; revision requested December 2; revision received February 10, 2012; accepted March 2; final version accepted March 30. Supported by grants NSC 98-2321-B-038-004-MY3, NSC-99-2811-B-038-024, NCS98-2321-B-038-003-MY3 (3-3), NCS98-2321-B-038-005-MY3 (3-3), NSC98-2314-B-038-012-MY3, and NSC98-2314-B-038-011-MY3 from the National Science Council, Taiwan, and grants TMU98-AE1-B15 and 98YGH-TMU-04 from Taipei Medical University, Taiwan.	Baddeley A. D., 1986, WORKING MEMORY; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Grady CL, 1999, COGNITIVE NEUROREHAB; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; LANGFITT TW, 1982, CLIN NEUR, V29, P353; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; Matthews PM, 2004, RESTOR NEUROL NEUROS, V22, P245; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1982, HEAD INJURY BASIC CL; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAYLOR AR, 1966, LANCET, V2, P178; Thermenos HW, 2005, SCHIZOPHR RES, V74, P179, DOI 10.1016/j.schres.2004.07.021; *US DEP HHS, 1989, INT HEAD INJ TASK FO; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; Wishart HA, 2006, AM J PSYCHIAT, V163, P1603, DOI 10.1176/appi.ajp.163.9.1603	34	43	44	0	22	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2012	264	3					844	851		10.1148/radiol.12112154			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	003XU	WOS:000308645500026	22829681				2021-06-18	
J	Hou, ZG; Luo, W; Sun, XJ; Hao, SY; Zhang, Y; Xu, FF; Wang, ZC; Liu, BY				Hou, Zonggang; Luo, Wei; Sun, Xuejun; Hao, Shuyu; Zhang, Ying; Xu, Feifan; Wang, Zhongcheng; Liu, Baiyun			Hydrogen-rich saline protects against oxidative damage and cognitive deficits after mild traumatic brain injury	BRAIN RESEARCH BULLETIN			English	Article						Hydrogen-rich saline; Traumatic brain injury; Hippocampus; Oxidative stress; Antioxidant; Neuroprotection	NEUROTROPHIC FACTOR; LIPID-PEROXIDATION; HEAD-INJURY; RAT MODEL; FAT DIET; STRESS; HIPPOCAMPUS; ANTIOXIDANT; HOMEOSTASIS; CONSUMPTION	Oxidative stress is the principal factor in traumatic brain injury (TB!) that initiates events that result in protracted neuronal dysfunction and remodeling. Importantly, antioxidants can protect the brain against oxidative damage and modulate the capacity of the brain to cope with synaptic dysfunction and cognitive impairment. However, no studies have investigated the effects of hydrogen-rich saline on cognitive deficits after TBI. In the present study, rats with fluid percussion injury (FPI) were used to investigate the protective effects of hydrogen-rich saline. The results showed that hydrogen-rich saline reduced the level of malondialdehyde (MDA) and elevated the level of silent information regulator 2 (Sir2). In addition, treatment with hydrogen-rich saline, which elevated the levels of molecules associated with brain-derived neurotropic factor (BDNF)-mediated synaptic plasticity, improved cognitive performance in the Morris water maze after mild TBI. These results suggest that hydrogen-rich saline can protect the brain against the deleterious effects of mild TBI on synaptic plasticity and cognition and that hydrogen-rich saline could be an effective therapeutic strategy for patients with cognitive deficits after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Hou, Zonggang; Wang, Zhongcheng] Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [Hou, Zonggang; Luo, Wei; Hao, Shuyu; Zhang, Ying; Xu, Feifan; Liu, Baiyun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Sun, Xuejun] Second Mil Med Univ, Fac Naval Med, Dept Diving Med, Shanghai 200433, Peoples R China; [Liu, Baiyun] Armed Police Force, Gen Hosp, Dept Nerve Trauma Surg, Beijing 100039, Peoples R China	Wang, ZC (corresponding author), Capital Med Univ, Beijing Neurosurg Inst, Tiantan Xili 6, Beijing 100050, Peoples R China.	wangzc1925@126.com; liubaiyun1964@163.com	sun, xuejun/C-2844-2013; sun, xuejun/A-5561-2010	sun, xuejun/0000-0003-2387-5531	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171144]; Beijing Municipal Education CommissionBeijing Municipal Commission of Education [KM 200910025019]; Special projects of Ministry of Health for public welfare fund industry research [200802093]; Health Technology Training Program of Beijing High-level Health Systems [2009-3-21]	This work was supported by research grants from the National Natural Science Foundation of China (No. 81171144); Project of Beijing Municipal Education Commission (KM 200910025019); Special projects of Ministry of Health for public welfare fund industry research (200802093); and the Health Technology Training Program of Beijing High-level Health Systems (2009-3-21).	Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Chen H, 2011, J SURG RES, V167, P316, DOI 10.1016/j.jss.2009.07.045; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Giese KP, 2011, BRAIN RES BULL, V85, P1, DOI 10.1016/j.brainresbull.2011.02.009; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Gu Y, 2010, J CLIN BIOCHEM NUTR, V46, P269, DOI 10.3164/jcbn.10-19; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Li J, 2010, BRAIN RES, V1328, P152, DOI 10.1016/j.brainres.2010.02.046; Mao YF, 2009, BIOCHEM BIOPH RES CO, V381, P602, DOI 10.1016/j.bbrc.2009.02.105; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Shen L, 2011, NEUROCHEM RES, V36, P1501, DOI 10.1007/s11064-011-0476-4; Shingu C, 2010, J ANESTH, V24, P569, DOI 10.1007/s00540-010-0942-1; Sun Q, 2009, EXP BIOL MED, V234, P1212, DOI 10.3181/0812-RM-349; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Zhou Y, 2012, NEUROSCIENCE, V209, P47, DOI 10.1016/j.neuroscience.2012.02.028	39	43	47	2	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	SEP 1	2012	88	6					560	565		10.1016/j.brainresbull.2012.06.006			6	Neurosciences	Neurosciences & Neurology	995XT	WOS:000308049300003	22742936				2021-06-18	
J	Stengel, D; Ottersbach, C; Matthes, G; Weigeldt, M; Grundei, S; Rademacher, G; Tittel, A; Mutze, S; Ekkernkamp, A; Frank, M; Schmucker, U; Seifert, J				Stengel, Dirk; Ottersbach, Caspar; Matthes, Gerrit; Weigeldt, Moritz; Grundei, Simon; Rademacher, Grit; Tittel, Anja; Mutze, Sven; Ekkernkamp, Axel; Frank, Matthias; Schmucker, Uli; Seifert, Julia			Accuracy of single-pass whole-body computed tomography for detection of injuries in patients with major blunt trauma	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							RADIOGRAPHY; ROUTINE; METAANALYSIS; SPINE	Background: Contrast-enhanced whole-body computed tomography (also called "pan-scanning") is considered to be a conclusive diagnostic tool for major trauma. We sought to determine the accuracy of this method, focusing on the reliability of negative results. Methods: Between July 2006 and December 2008, a total of 982 patients with suspected severe injuries underwent single-pass pan-scanning at a metropolitan trauma centre. The findings of the scan were independently evaluated by two reviewers who analyzed the injuries to five body regions and compared the results to a synopsis of hospital charts, subsequent imaging and interventional procedures. We calculated the sensitivity and specificity of the pan-scan for each body region, and we assessed the residual risk of missed injuries that required surgery or critical care. Results: A total of 1756 injuries were detected in the 982 patients scanned. Of these, 360 patients had an Injury Severity Score greater than 15. The median length of follow-up was 39 (interquartile range 7-490) days, and 474 patients underwent a definitive reference test. The sensitivity of the initial pan-scan was 84.6% for head and neck injuries, 79.6% for facial injuries, 86.7% for thoracic injuries, 85.7% for abdominal injuries and 86.2% for pelvic injuries. Specificity was 98.9% for head and neck injuries, 99.1% for facial injuries, 98.9% for thoracic injuries, 97.5% for abdominal injuries and 99.8% for pelvic injuries. In total, 62 patients had 70 missed injuries, indicating a residual risk of 6.3% (95% confidence interval 4.9%-8.0%). Interpretation: We found that the positive results of trauma pan-scans are conclusive but negative results require subsequent confirmation. The pan-scan algorithms reduce, but do not eliminate, the risk of missed injuries, and they should not replace close monitoring and clinical follow-up of patients with major trauma.	[Stengel, Dirk; Ottersbach, Caspar; Grundei, Simon] Unfallkrankenhaus Berlin, Clin Res Ctr, Berlin, Germany; [Matthes, Gerrit; Weigeldt, Moritz; Seifert, Julia] Unfallkrankenhaus Berlin, Dept Trauma & Orthopaed Surg, Berlin, Germany; [Rademacher, Grit; Tittel, Anja; Mutze, Sven] Unfallkrankenhaus Berlin, Dept Radiol, Berlin, Germany; [Stengel, Dirk; Ottersbach, Caspar; Ekkernkamp, Axel; Frank, Matthias; Schmucker, Uli; Seifert, Julia] Ernst Moritz Arndt Univ Greifswald, Dept Trauma & Reconstruct Surg, Med Ctr, Greifswald, Germany	Stengel, D (corresponding author), Unfallkrankenhaus Berlin, Clin Res Ctr, Berlin, Germany.	dirk.stengel@ukb.de	Stengel, Dirk/AAF-6470-2019	Weigeldt, Moritz/0000-0002-0052-9604	Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF); European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Johnson & Johnson MedicalJohnson & JohnsonJohnson & Johnson USA; Depuy; Medkon; Rehavital; German Advanced Trauma Life Support; NATONATO (North Atlantic Treaty Organisation)	Dirk Stengel is a board member of and a consultant for the German Trauma Association. He is a consultant, has provided expert testimony and received payment for lectures for the German Federal Statutory Accident Insurance, Biomet, DePuy, Stryker and the AO Foundation. He holds grants from these agencies, as well as from the Federal Ministry of Education and Research, and the European Commission. Gerrit Matthes is a board member and has received payment for providing lectures from the German Advanced Trauma Life Support. He has received compensation for travel expenses from NATO for providing a lecture on trauma management. Axel Ekkernkamp is a consultant for Pfizer, Stryker and Novo Nordisk. He has provided expert testimony for DePuy, Rehavital and Medkon, and he has received payment for lectures from Johnson & Johnson Medical, Depuy, Medkon and Rehavital. None declared for Caspar Ottersbach, Moritz Weigeldt, Simon Grundei, Grit Rademacher, Anja Tittel, Sven Mutze, Matthias Frank, Uli Schmucker and Julia Seifert.	Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Brink M, 2008, AM J ROENTGENOL, V190, P1591, DOI 10.2214/AJR.07.3277; Cameron PA, 2011, INJURY, V42, P10, DOI 10.1016/j.injury.2010.11.035; Canadian Institute for Health Information, 2011, NAT TRAUM REG 2011 R; Chen CW, 2011, ACCIDENT ANAL PREV, V43, P823, DOI 10.1016/j.aap.2010.11.001; Deunk J, 2009, J TRAUMA, V66, P1108, DOI 10.1097/TA.0b013e31817e55c3; Deutsche Gesellschaft fur Unfallchirurgie, 2011, DGU MITTEIL NACHR, V33, P1; Elmali M, 2007, DIAGN INTERV RADIOL, V13, P179; Gennarelli T.A., 2008, ABBREVIATED INJURY S; Hashem R, 2009, J TRAUMA, V66, P423, DOI 10.1097/TA.0b013e3181589fe5; Hilty MP, 2008, WORLD J EMERG SURG, V3, DOI 10.1186/1749-7922-3-11; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Hutter M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-73; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Lefering R., 2002, EUR J TRAUMA, V28, P52, DOI [10.1007/s00068-002-0170-y, DOI 10.1007/S00068-002-0170-Y]; Leidner B, 1998, EUR RADIOL, V8, P1630, DOI 10.1007/s003300050601; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; MUTZE S, 1999, EMERG RADIOL, V6, P77; Pfeifer R, 2008, PATIENT SAF SURG, V2, DOI 10.1186/1754-9493-2-20; Rutjes A W S, 2007, Health Technol Assess, V11, pix; Sierink JC, 2012, BRIT J SURG, V99, P52, DOI 10.1002/bjs.7760; Snyder GE, 2008, ANN EMERG MED, V52, P101, DOI 10.1016/j.annemergmed.2007.03.023; Stengel D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004446.pub2; Stengel D, 2005, RADIOLOGY, V236, P102, DOI 10.1148/radiol.2361040791; Stengel D, 2009, INJURY, V40, pS36, DOI 10.1016/j.injury.2009.10.035; Tillou A, 2009, J TRAUMA, V67, P779, DOI 10.1097/TA.0b013e3181b5f2eb; van Vugt R, 2011, EUR J TRAUMA EMERG S, V37, P185, DOI 10.1007/s00068-010-0042-9; van Vugt R, 2011, J TRAUMA	28	43	46	0	6	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	MAY 15	2012	184	8					869	876		10.1503/cmaj.111420			8	Medicine, General & Internal	General & Internal Medicine	001ZD	WOS:000308498400049	22392949	Bronze, Green Published			2021-06-18	
J	Lin, Y; Pan, YH; Shi, YF; Huang, XJ; Jia, NQ; Jiang, JY				Lin, Yong; Pan, Yaohua; Shi, Yinfeng; Huang, Xianjian; Jia, Nengqin; Jiang, Ji-yao			Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain	NANOTECHNOLOGY			English	Article							N-BUTYL CYANOACRYLATE; CEREBRAL ARTERIOVENOUS-MALFORMATIONS; BARRIER PERMEABILITY; EDEMA FORMATION; DRUG-DELIVERY; CORTICAL CONTUSION; N-BUTYL-2-CYANOACRYLATE; EMBOLIZATION; DISRUPTION; TRANSPORT	Poly(n-butyl-2-cyanoacrylate) (PBCA) nanoparticles have been successfully applied to deliver small-molecule drugs to the central nervous system (CNS). However, it is unclear whether PBCA nanoparticles can be used as the delivery system for large molecules to potentially treat traumatic brain injury (TBI). In this study, we tested the capacity of PBCA nanoparticles in passing through the blood-brain barrier (BBB) and transporting large molecules into normal and injured brains in the rat. We first synthesized PBCA nanoparticles by dispersion polymerization and then loaded the particles with either horseradish peroxidase (HRP, 44 kDa) or enhanced green fluorescent protein (EGFP, 29 kDa), which were further coated with polysorbate 80. Next, the polysorbate 80-coated HRP or EGFP-loaded PBCA nanoparticles were intravenously injected into the normal and brain-injured rats. We found that, at 45 min after injection, PBCA nanoparticle-delivered HRP or EGFP was hardly detected in the normal brains of the rats, but a small amount of EGFP carried by PBCA nanoparticles was noted in the normal brains 48 h after administration, which was further confirmed by immunolocalization with anti-EGFP antibodies. In contrast, at 4 h after TBI with a circulation time of 45 min, although the penetration of HRP or EGFP alone was hampered by the BBB, the PBCA nanoparticle-delivered HRP or EGFP was widely distributed near injured sites. Together, our findings provide histological evidence that PBCA nanoparticles can be used as an efficient delivery system for large molecules to overcome the barrier in the brain with TBI.	[Lin, Yong; Pan, Yaohua; Huang, Xianjian; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China; [Shi, Yinfeng; Jia, Nengqin] Shanghai Normal Univ, Dept Chem, Life & Environm Sci Coll, Shanghai 200234, Peoples R China	Lin, Y (corresponding author), Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiangjyb@online.sh.cn			National Science and Nature Committee of China [30973086]; National Health Ministry of China [200802093]; Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1409800]; Program for Shanghai Outstanding Medical Academic Leader	This work was excellently supported by grants from the National Science and Nature Committee of China (no. 30973086), the National Health Ministry of China (no. 200802093), the Shanghai Science and Technology Committee (no. 10JC1409800) and the Program for Shanghai Outstanding Medical Academic Leader.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adelson PD, 1998, ACT NEUR S, V71, P104; ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44; Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098; Amiel GE, 1999, J AM COLL SURGEONS, V189, P21, DOI 10.1016/S1072-7515(99)00068-X; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Behan N, 2001, BIOMATERIALS, V22, P1335, DOI 10.1016/S0142-9612(00)00286-6; Brown RC, 2004, BRAIN RES, V1014, P221, DOI 10.1016/j.brainres.2004.04.034; de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gilmore JL, 2008, J NEUROIMMUNE PHARM, V3, P83, DOI 10.1007/s11481-007-9099-6; Gulyaev AE, 1999, PHARM RES-DORDR, V16, P1564, DOI 10.1023/A:1018983904537; GUMERLOCK MK, 1992, J NEURO-ONCOL, V12, P33; Gupta R., 2006, NANOPARTICLE TECHNOL, P1; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; JAFAR JJ, 1993, J NEUROSURG, V78, P60, DOI 10.3171/jns.1993.78.1.0060; Jain KK, 2007, NEURODEGENER DIS, V4, P287, DOI 10.1159/000101884; Koffie RM, 2011, P NATL ACAD SCI USA, V108, P18837, DOI 10.1073/pnas.1111405108; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Mazal PR, 2006, PATHOLOGY, V38, P28, DOI 10.1080/00313020500455795; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NEUWELT EA, 1979, J CLIN INVEST, V64, P684, DOI 10.1172/JCI109509; Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Reimold I, 2008, EUR J PHARM BIOPHARM, V70, P627, DOI 10.1016/j.ejpb.2008.05.007; Reukov V, 2011, BIOTECHNOL BIOENG, V108, P243, DOI 10.1002/bit.22958; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; SOEHENDRA N, 1987, ENDOSCOPY, V19, P221, DOI 10.1055/s-2007-1018288; Starke RM, 2009, STROKE, V40, P2783, DOI 10.1161/STROKEAHA.108.539775; Suri Sarabjeet Singh, 2007, J Occup Med Toxicol, V2, P16, DOI 10.1186/1745-6673-2-16; Taira S, 2009, METHODS MOL BIOL, V544, P571, DOI 10.1007/978-1-59745-483-4_36; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8	44	43	44	0	33	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0957-4484	1361-6528		NANOTECHNOLOGY	Nanotechnology	APR 27	2012	23	16							165101	10.1088/0957-4484/23/16/165101			8	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Science & Technology - Other Topics; Materials Science; Physics	923SN	WOS:000302639500001	22460562				2021-06-18	
J	Zhou, HZ; Chen, L; Gao, X; Luo, BD; Chen, JH				Zhou, Hongzhen; Chen, Liang; Gao, Xiang; Luo, Bingde; Chen, Jinhui			Moderate Traumatic Brain Injury Triggers Rapid Necrotic Death of Immature Neurons in the Hippocampus	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Apoptosis; Cell death; Hippocampus; Mouse model; Necrosis; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; NEWLY GENERATED NEURONS; FLUORO-JADE-B; CELL-DEATH; COGNITIVE DEFICITS; DENTATE GYRUS; SUBUNIT COMPOSITION; ADULT NEUROGENESIS; NEWBORN NEURONS; NMDA RECEPTORS	Traumatic brain injury (TBI) causes cell death predominantly in the cerebral cortex, but there is additional secondary cell death in the hippocampus. We previously found that most of the dying cells in the mouse hippocampus are newborn immature granular neurons in a mouse model of lateral controlled cortical impact (CCI) injury with a moderate level of impact. It is not known how long this selective cell death in the hippocampal dentate gyrus lasts, and how it is induced. Using Fluoro-Jade B and immunohistochemistry, we show that most of the neuron death in the hippocampus occurs within 24 hours after TBI and that cell death continues at low level for at least another 2 weeks in this lateral CCI model. Most of the dying immature granular neurons did not exhibit morphologic characteristics of apoptosis, and only a small subpopulation of the dying cells was positive for apoptotic markers. In contrast, most of the dying cells coexpressed the receptor-interacting protein 1, a marker of necrosis, suggesting that immature neurons mainly died of necrosis. These results indicate that moderate TBI mainly triggers rapid necrotic death of immature neurons in the hippocampus in a mouse CCI model.	[Zhou, Hongzhen] So Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China; [Chen, Liang; Gao, Xiang; Chen, Jinhui] Indiana Univ, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Chen, Liang; Gao, Xiang; Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Chen, Liang; Gao, Xiang; Chen, Jinhui] Indiana Univ, Dept Neurosurg, Indianapolis, IN 46202 USA; [Luo, Bingde] So Med Univ, Sch Publ Hlth & Trop Med, Guangzhou, Guangdong, Peoples R China	Chen, JH (corresponding author), Indiana Univ, Sch Med, 980 W Walnut St,R3, Indianapolis, IN 46202 USA.	gw@fimmu.com; chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research; Ralph W. and Grace M. Showalter Research; Indiana University Biological Research; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RR025761, 1R21NS072631-01A]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported through funding from the Indiana Spinal Cord & Brain Injury Research Grants, the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, and National Institutes of Health Grants RR025761 and 1R21NS072631-01A.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; de Armentia ML, 2003, J NEUROSCI, V23, P6876; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golstein P, 2007, EMBO REP, V8, P829, DOI 10.1038/sj.embor.7401042; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kalai M, 2002, CELL DEATH DIFFER, V9, P981, DOI 10.1038/sj.cdd.4401051; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Ma YY, 2005, J BIOL CHEM, V280, P41827, DOI 10.1074/jbc.M510849200; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tovar KR, 1999, J NEUROSCI, V19, P4180; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanlangenakker N, 2008, CURR MOL MED, V8, P207, DOI 10.2174/156652408784221306; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vicini S, 2005, J NEUROPHYSIOL, V94, P3661, DOI 10.1152/jn.00753.2005; Wadiche LO, 2005, J NEUROPHYSIOL, V94, P4528, DOI 10.1152/jn.00633.2005; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Ye GL, 2005, DEV BRAIN RES, V155, P26, DOI 10.1016/j.devbrainres.2004.12.002; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	90	43	47	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	APR	2012	71	4					348	359		10.1097/NEN.0b013e31824ea078			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	917LR	WOS:000302178700007	22437344	Green Accepted, Bronze			2021-06-18	
J	Lee, P; Kim, J; Williams, R; Sandhir, R; Gregory, E; Brooks, WM; Berman, NEJ				Lee, Phil; Kim, Jieun; Williams, Rachel; Sandhir, Rajat; Gregory, Eugene; Brooks, William M.; Berman, Nancy E. J.			Effects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice	EXPERIMENTAL NEUROLOGY			English	Article						Controlled cortical impact; Traumatic brain injury; Aging; T1 mapping; Blood brain barrier; MMP-9; MMP-2; Occludin; ZO-1; Claudin-5	TIGHT JUNCTION PROTEINS; GENE KNOCK-OUT; CEREBRAL-ISCHEMIA; MICROGLIAL ACTIVATION; RAT-BRAIN; MEDIATED DISRUPTION; ENDOTHELIAL-CELLS; INJURY; EXPRESSION; MATRIX-METALLOPROTEINASE-9	Aging alters the ability of the brain to respond to injury. One of the major differences between the adult and aged brain is that comparable injuries lead to greater blood brain barrier disruption in the aged brain. The goals of these studies were to quantify the effects of age on BBB permeability using high field strength MRI T1 mapping and to determine whether activation of matrix metalloproteases, their inhibitors, or expression of blood brain barrier structural proteins, occludin, zonnula occludins-1 (ZO-1) and claudin-5 were altered following injury to the aged C57/BL6 mouse brain. T1 mapping studies revealed greater blood brain barrier permeability in the aged (21-24 months old) brain than in the adult (4-6 months old) following controlled cortical impact. The increased blood brain barrier permeability in the pericontusional region was confirmed with IgG immunohistochemistry. MMP-9 activity was increased following controlled cortical impact in the aged brain, and this was accompanied by increased MMP-9 gene expression. MMP-2 activity was higher in the uninjured aged brain than in the adult brain. Occludin and ZO-1 mRNA levels were unchanged following injury in either age group, but claudin-5 mRNA levels were lower in the aged than the adult brain following injury. These results demonstrate quantitative increases in blood brain barrier permeability in the aged brain following injury that are accompanied by increased MMP-9 activation and decreased blood brain barrier repair responses. (C) 2011 Published by Elsevier Inc.	[Lee, Phil; Brooks, William M.; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Lee, Phil; Kim, Jieun; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; [Williams, Rachel; Sandhir, Rajat; Gregory, Eugene; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	nberman@kumc.edu	Brooks, William/AAF-8299-2019	Brooks, William/0000-0001-6227-7636; Lee, Phil/0000-0002-2087-8887	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AG31140, P30 HD02528, P20 RR016475]; Hoglund Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031140] Funding Source: NIH RePORTER	Supported by NIH grant R01AG31140, P30 HD02528, P20 RR016475, and the Hoglund Family Foundation. We would like to thank Dr. Y.Y. He for assistance with surgery.	Adams DD, 2001, MECH AGEING DEV, V122, P173, DOI 10.1016/S0047-6374(00)00230-X; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Asahi M, 2001, J NEUROSCI, V21, P7724; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789; Boda E, 2009, J MOL NEUROSCI, V37, P238, DOI 10.1007/s12031-008-9128-9; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Burek M, 2009, MOL CELL ENDOCRINOL, V298, P19, DOI 10.1016/j.mce.2008.09.041; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.3.CO;2-V; del Zoppo GJ, 2007, STROKE, V38, P646, DOI 10.1161/01.STR.0000254477.34231.cb; Dobrogowska DH, 2004, J MOL HISTOL, V35, P529, DOI 10.1007/s10735-004-1318-3; Farrall AJ, 2009, NEUROBIOL AGING, V30, P337, DOI 10.1016/j.neurobiolaging.2007.07.015; Furuno T, 2002, PHARMACOGENETICS, V12, P529, DOI 10.1097/00008571-200210000-00004; Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herrera AJ, 2008, J NEUROCHEM, V105, P750, DOI 10.1111/j.1471-4159.2007.05170.x; Hirase T, 1997, J CELL SCI, V110, P1603; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kim J, 2011, NEUROIMAGE, V56, P1286, DOI 10.1016/j.neuroimage.2011.02.039; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Manaenko A, 2011, J NEUROSCI METH, V195, P206, DOI 10.1016/j.jneumeth.2010.12.013; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203; Nagaraja TN, 2011, NMR BIOMED, V24, P547, DOI 10.1002/nbm.1625; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pugh TD, 1999, CANCER RES, V59, P1642; Rao HV, 2007, J NEUROCHEM, V101, P498, DOI 10.1111/j.1471-4159.2006.04389.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rohatgi T, 2004, NEUROSCIENTIST, V10, P501, DOI 10.1177/1073858404269955; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sood R, 2007, J MAGN RESON IMAGING, V25, P39, DOI 10.1002/jmri.20802; Sood RR, 2008, J CEREBR BLOOD F MET, V28, P431, DOI 10.1038/sj.jcbfm.9600534; Stephens EB, 2003, AIDS RES HUM RETROV, V19, P837, DOI 10.1089/088922203322493003; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Strupp JP., 1996, NEUROIMAGE, V3, pS607, DOI DOI 10.1016/S1053-8119(96)80609-4; Stucky NL, 2011, HEADACHE, V51, P674, DOI 10.1111/j.1526-4610.2011.01882.x; Suo Z., 2004, Current Drug Targets - Inflammation and Allergy, V3, P105, DOI 10.2174/1568010043483953; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tavelin S, 2003, MOL PHARMACOL, V64, P1530, DOI 10.1124/mol.64.6.1530; Tejima E, 2007, J CEREBR BLOOD F MET, V27, P460, DOI 10.1038/sj.jcbfm.9600354; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI 10.1089/neu.2009.0959; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Van Itallie CM, 2009, MOL BIOL CELL, V20, P3930, DOI 10.1091/mbc.E09-04-0320; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yang Y, 2011, METHODS MOL BIOL, V762, P333, DOI 10.1007/978-1-61779-185-7_24; YURCHENCO PD, 1990, FASEB J, V4, P1577	72	43	47	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2012	234	1					50	61		10.1016/j.expneurol.2011.12.016			12	Neurosciences	Neurosciences & Neurology	910DN	WOS:000301617500007	22201549	Green Accepted			2021-06-18	
J	Reeves, TM; Smith, TL; Williamson, JC; Phillips, LL				Reeves, Thomas M.; Smith, Terry L.; Williamson, Judy C.; Phillips, Linda L.			Unmyelinated Axons Show Selective Rostrocaudal Pathology in the Corpus Callosum After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Corpus callosum; Stereology; Traumatic brain injury; Ultrastructure; Unmyelinated axons	INTRAAXONAL NEUROFILAMENT COMPACTION; MYELINATED NERVE-FIBERS; FLUID PERCUSSION INJURY; WHITE-MATTER; SPINAL-CORD; HEAD-INJURY; RAT; CALPAIN; DAMAGE; PROTEOLYSIS	Axonal injury is consistently observed after traumatic brain injury (TBI). Prior research has extensively characterized the post-TBI response in myelinated axons. Despite evidence that unmyelinated axons comprise a numerical majority of cerebral axons, pathologic changes in unmyelinated axons after TBI have not been systematically studied. To identify morphologic correlates of functional impairment of unmyelinated fibers after TBI, we assessed ultrastructural changes in corpus callosum axons. Adult rats received moderate fluid percussion TBI, which produced diffuse injury with no contusion. Cross-sectional areas of 13,797 unmyelinated and 3,278 intact myelinated axons were stereologically measured at survival intervals from 3 hours to 15 days after injury. The mean caliber of unmyelinated axons was significantly reduced at 3 to 7 days and recovered by 15 days, but the time course of this shrinkage varied among the genu, mid callosum, and splenium. Relatively large unmyelinated axons seemed to be particularly vulnerable. Injury-induced decreases in unmyelinated fiber density were also observed, but they were more variable than caliber reductions. By contrast, no significant morphometric changes were observed in myelinated axons. The finding of a preferential vulnerability in unmyelinated axons has implications for current concepts of axonal responses after TBI and for development of specifically targeted therapies.	[Reeves, Thomas M.; Smith, Terry L.; Williamson, Judy C.; Phillips, Linda L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Med Ctr, Richmond, VA 23298 USA	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Med Ctr, 1217 E Marshall St,Room 740,MCV Campus Box 980709, Richmond, VA 23298 USA.	tmreeves@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057758, NS056247, NS047463]; Virginia Commonwealth Neurotrauma Initiative [07-302F]; National Institutes of Health/National Institute of Neurological Disorders and Stroke CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS057758, R01NS056247] Funding Source: NIH RePORTER	Supported by the National Institutes of Health (Grants NS057758, NS056247, and NS047463) and Virginia Commonwealth Neurotrauma Initiative 07-302F. Microscopy was performed at Virginia Commonwealth University, Department of Anatomy and Neurobiology Microscopy Facility, which is supported, in part, with funding from National Institutes of Health/National Institute of Neurological Disorders and Stroke Center Core Grant NS047463.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAVEL C, 1990, J COMP NEUROL, V291, P147, DOI 10.1002/cne.902910110; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JURASKA JM, 1988, BRAIN RES, V450, P1, DOI 10.1016/0006-8993(88)91538-7; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim JHY, 1996, BRAIN RES, V740, P47, DOI 10.1016/S0006-8993(96)00637-3; Larsen JO, 1998, J NEUROSCI METH, V85, P107, DOI 10.1016/S0165-0270(98)00129-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MOUTON PR, 2002, PRINCIPLES PRACTICES; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Partadiredja G, 2003, J NEUROCYTOL, V32, P1165, DOI 10.1023/B:NEUR.0000021910.65920.41; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SEGGIE J, 1972, EXP NEUROL, V35, P215, DOI 10.1016/0014-4886(72)90148-3; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SMITH RS, 1970, AM J PHYSIOL, V219, P1256; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; WAXMAN SG, 1988, BRAIN RES, V453, P337, DOI 10.1016/0006-8993(88)90174-6; WAXMAN SG, 1976, EXP NEUROL, V53, P115, DOI 10.1016/0014-4886(76)90287-9; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x	62	43	43	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2012	71	3					198	210		10.1097/NEN.0b013e3182482590			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	897EM	WOS:000300627500002	22318124	Green Accepted, Bronze			2021-06-18	
J	Vincent, AS; Roebuck-Spencer, T; Gilliland, K; Schlegel, R				Vincent, Andrea S.; Roebuck-Spencer, Tresa; Gilliland, Kirby; Schlegel, Robert			Automated Neuropsychological Assessment Metrics (v4) Traumatic Brain Injury Battery: Military Normative Data	MILITARY MEDICINE			English	Article							SPORTS CONCUSSION; PERFORMANCE; TESTS; SAMPLE; ANAM; RECOVERY	The aim of the present study was to establish normative data for the Automated Neuropsychological Assessment Metrics (v4) Traumatic Brain Injury (ANAM4 TBI) battery in a military context. ANAM4 data from over 107,500 active duty service members ranging from 17 to 65 years of age were included in this study. The influence of the demographic variables of age and gender were also examined. These norms, stratified by age and gender, represent a more comprehensive set of norms than previously available and are provided as a representative set of norms for clinical practice. Additionally, base rates of below average performance in a normal population are provided to help inform clinical decision making.	[Vincent, Andrea S.; Roebuck-Spencer, Tresa; Gilliland, Kirby; Schlegel, Robert] Univ Oklahoma, Cognit Sci Res Ctr, Norman, OK 73072 USA	Vincent, AS (corresponding author), Univ Oklahoma, Cognit Sci Res Ctr, 3200 Marshall Ave,Suite 260, Norman, OK 73072 USA.				Cognitive Science Research Center at University of Oklahoma; U.S. Army Medical Research & Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC) at Fort Detrick, MD [W81XWH-07-2-0097]	This data analysis was conducted by the Cognitive Science Research Center (formerly C-SHOP) at the University of Oklahoma and is made possible by a DoD Grant awarded and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC) at Fort Detrick, MD, under contract number W81XWH-07-2-0097.	Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; C-SHOP ANAM4, 2007, C SHOP ANAM4 TB1 MIL; D'Agostino RB., 1986, GOODNESS OF FIT TECH; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Farmer K, 2001, HEADACHE, V41, P377, DOI 10.1046/j.1526-4610.2001.111006377.x; Farmer K., 2003, REDUCING BURDEN HEAD, P46; Friedl KE, 2007, ARCH CLIN NEUROPSYCH, V22, pS7, DOI 10.1016/j.acn.2006.10.002; Hamidovic A, 2008, J CLIN PSYCHOPHARM, V28, P45, DOI 10.1097/jcp.0b013e3181602fab; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P133; Harris WC, 2005, MIL PSYCHOL, V17, P115, DOI 10.1207/s15327876mp1702_4; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; Heaton RK, 2004, REVISED COMPREHENSIV; Helmick K, 2006, CLIN PRACTICE GUIDEL; HODDES E, 1972, PSYCHOPHYSIOLOGY, V9, P150; Holliday SL, 2003, LUPUS, V12, P697, DOI 10.1191/0961203303lu442oa; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kaminski TW, 2009, J CLIN EXP NEUROPSYC, V31, P689, DOI 10.1080/13803390802484771; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lowe M, 2007, ARCH CLIN NEUROPSYCH, V22, pS89, DOI 10.1016/j.acn.2006.10.010; Mitrushina M., 2005, HDB NORMATIVE DATA N; Olejnik S, 2003, PSYCHOL METHODS, V8, P434, DOI 10.1037/1082-989X.8.4.434; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Roebuck-Spencer TM, 2008, MIL PSYCHOL, V20, P187, DOI 10.1080/08995600802118825; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wilken JA, 2007, ARCH CLIN NEUROPSYCH, V22, pS127, DOI 10.1016/j.acn.2006.10.007	35	43	43	0	4	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAR	2012	177	3					256	269		10.7205/MILMED-D-11-00289			14	Medicine, General & Internal	General & Internal Medicine	906CW	WOS:000301323500004	22479912	Bronze			2021-06-18	
J	Zhang, W; Huguenard, JR; Buckmaster, PS				Zhang, Wei; Huguenard, John R.; Buckmaster, Paul S.			Increased Excitatory Synaptic Input to Granule Cells from Hilar and CA3 Regions in a Rat Model of Temporal Lobe Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article							PILOCARPINE-TREATED RATS; V PYRAMIDAL NEURONS; INJURED EPILEPTOGENIC NEOCORTEX; SEIZURE-INDUCED NEUROGENESIS; MOSSY FIBER REORGANIZATION; INDUCED STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; FASCIA-DENTATA; HIPPOCAMPAL SLICES	One potential mechanism of temporal lobe epilepsy is recurrent excitation of dentate granule cells through aberrant sprouting of their axons (mossy fibers), which is found in many patients and animal models. However, correlations between the extent of mossy fiber sprouting and seizure frequency are weak. Additional potential sources of granule cell recurrent excitation that would not have been detected by markers of mossy fiber sprouting in previous studies include surviving mossy cells and proximal CA3 pyramidal cells. To test those possibilities in hippocampal slices from epileptic pilocarpine-treated rats, laser-scanning glutamate uncaging was used to randomly and focally activate neurons in the granule cell layer, hilus, and proximal CA3 pyramidal cell layer while measuring evoked EPSCs in normotopic granule cells. Consistent with mossy fiber sprouting, a higher proportion of glutamate-uncaging spots in the granule cell layer evoked EPSCs in epileptic rats compared with controls. In addition, stimulation spots in the hilus and proximal CA3 pyramidal cell layer were more likely to evoke EPSCs in epileptic rats, despite significant neuron loss in those regions. Furthermore, synaptic strength of recurrent excitatory inputs to granule cells from CA3 pyramidal cells and other granule cells was increased in epileptic rats. These findings reveal substantial levels of excessive, recurrent, excitatory synaptic input to granule cells from neurons in the hilus and proximal CA3 field. The aberrant development of these additional positive-feedback circuits might contribute to epileptogenesis in temporal lobe epilepsy.	[Zhang, Wei; Buckmaster, Paul S.] Stanford Univ, Dept Comparat Med, Stanford, CA 94305 USA; [Huguenard, John R.; Buckmaster, Paul S.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Buckmaster, PS (corresponding author), Stanford Univ, Dept Comparat Med, 300 Pasteur Dr,R321 Edwards Bldg, Stanford, CA 94305 USA.	psb@stanford.edu	Huguenard, John/K-6429-2019; Huguenard, John/I-5016-2012	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191	National Institute of Neurological Disorders and Stroke-National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040276, P50NS012151, P01NS012151, R01NS034774] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke-National Institutes of Health. We are grateful to Dr. David Prince for providing access to equipment.	Babb TL, 1996, EPILEPSY RES, V26, P193, DOI 10.1016/S0920-1211(96)00053-8; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blumcke I, 2000, EPILEPSIA, V41, pS174, DOI 10.1111/j.1528-1157.2000.tb01577.x; Brill J, 2009, J NEUROSCI, V29, P7413, DOI 10.1523/JNEUROSCI.6098-08.2009; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Buckmaster PS, 2004, COMPARATIVE MED, V54, P473; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Buckmaster PS, 1996, J COMP NEUROL, V366, P271; Cameron MC, 2011, J COMP NEUROL, V519, P2175, DOI 10.1002/cne.22623; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; Del Turco D, 2003, HIPPOCAMPUS, V13, P685, DOI 10.1002/hipo.10118; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Fino E, 2009, FRONT NEURAL CIRCUIT, V3, DOI 10.3389/neuro.04.002.2009; FRANCK JE, 1995, EPILEPSIA, V36, P543, DOI 10.1111/j.1528-1157.1995.tb02566.x; Gabriel S, 2004, J NEUROSCI, V24, P10416, DOI 10.1523/JNEUROSCI.2074-04.2004; Golarai G, 2001, J NEUROSCI, V21, P8523; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Harvey BD, 2005, J COMP NEUROL, V488, P442, DOI 10.1002/cne.20594; HOUSER CR, 1990, J NEUROSCI, V10, P267; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Jung KH, 2004, EUR J NEUROSCI, V19, P3219, DOI 10.1111/j.0953-816X.2004.03412.x; Kadam SD, 2007, J COMP NEUROL, V505, P716, DOI 10.1002/cne.21533; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kron MM, 2010, J NEUROSCI, V30, P2051, DOI 10.1523/JNEUROSCI.5655-09.2010; Kumar SS, 2007, J NEUROSCI, V27, P1239, DOI 10.1523/JNEUROSCI.3182-06.2007; Larimer P, 2008, J NEUROSCI, V28, P12212, DOI 10.1523/JNEUROSCI.3612-08.2008; Lehmann TN, 2001, EUR J NEUROSCI, V14, P83, DOI 10.1046/j.0953-816x.2001.01632.x; LEMOS T, 1995, EXP BRAIN RES, V102, P423; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; Lynch M, 2000, J NEUROPHYSIOL, V83, P693; Lynd-Balta E, 2004, NEUROSCIENCE, V126, P105, DOI 10.1016/j.neuroscience.2004.03.004; MASUKAWA LM, 1992, BRAIN RES, V579, P119, DOI 10.1016/0006-8993(92)90750-4; Mathern GW, 1998, J NEUROSCI RES, V54, P734, DOI 10.1002/(SICI)1097-4547(19981215)54:6<734::AID-JNR2>3.0.CO;2-P; Mathern GW, 1997, NEUROSCIENCE, V77, P1003, DOI 10.1016/S0306-4522(96)00516-7; MATHERN GW, 1993, ELECTROEN CLIN NEURO, V87, P326, DOI 10.1016/0013-4694(93)90186-Y; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; Molnar P, 1999, J NEUROPHYSIOL, V82, P1883; Morgan RJ, 2008, P NATL ACAD SCI USA, V105, P6179, DOI 10.1073/pnas.0801372105; NADLER JV, 1980, BRAIN RES, V182, P1; Namgung U, 1997, P NATL ACAD SCI USA, V94, P11675, DOI 10.1073/pnas.94.21.11675; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699; Parent JM, 1997, J NEUROSCI, V17, P3727; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; Pierce JP, 2007, NEUROSCI LETT, V422, P136, DOI 10.1016/j.neulet.2007.06.016; Pierce JP, 2011, J COMP NEUROL, V519, P1196, DOI 10.1002/cne.22568; Pierce JP, 2005, EXP NEUROL, V196, P316, DOI 10.1016/j.expneurol.2005.08.007; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pitkanen A, 2000, EPILEPSIA, V41, pS24, DOI 10.1111/j.1528-1157.2000.tb01552.x; Prang P, 2003, BRAIN RES, V978, P205, DOI 10.1016/S0006-8993(03)02836-1; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rao MS, 2006, J NEUROSCI RES, V83, P1088, DOI 10.1002/jnr.20802; Raol YSH, 2003, ANN NEUROL, V53, P503, DOI 10.1002/ana.10490; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179; SCHARFMAN HE, 1994, J NEUROPHYSIOL, V72, P2167; Scharfman HE, 2007, PROG BRAIN RES, V163, P627, DOI 10.1016/S0079-6123(07)63034-9; Seress L, 2009, J NEUROSURG, V111, P1237, DOI 10.3171/2008.11.JNS08779; Shepherd GMG, 2003, NEURON, V38, P277, DOI 10.1016/S0896-6273(03)00152-1; Shetty AK, 2005, J NEUROSCI, V25, P8391, DOI 10.1523/JNEUROSCI.1538-05.2005; Siddiqui AH, 2005, BRAIN RES, V1066, P129, DOI 10.1016/j.brainres.2005.10.066; Sik A, 2006, J COMP NEUROL, V496, P229, DOI 10.1002/cne.20921; Simmons ML, 1997, J NEUROPHYSIOL, V78, P1860; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Spencer SS, 1999, EPILEPSIA, V40, P708, DOI 10.1111/j.1528-1157.1999.tb00767.x; Spigelman I, 1998, NEUROSCIENCE, V86, P109, DOI 10.1016/S0306-4522(98)00028-1; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Thind KK, 2008, J COMP NEUROL, V509, P190, DOI 10.1002/cne.21745; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Timofeeva OA, 1999, EPILEPSY RES, V33, P99, DOI 10.1016/S0920-1211(98)00078-3; vonCampe G, 1997, HIPPOCAMPUS, V7, P472; Wenzel HJ, 2000, EPILEPSIA, V41, pS70, DOI 10.1111/j.1528-1157.2000.tb01560.x; Wenzel HJ, 2000, HIPPOCAMPUS, V10, P244, DOI 10.1002/1098-1063(2000)10:3<244::AID-HIPO5>3.0.CO;2-7; Williams PA, 2004, EPILEPSIA, V45, P1210, DOI 10.1111/j.0013-9580.2004.60403.x; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Wong R K, 1986, Adv Neurol, V44, P583; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067; Zhan RZ, 2010, J NEUROPHYSIOL, V104, P3293, DOI 10.1152/jn.00663.2010; Zhang NH, 1999, J COMP NEUROL, V405, P472; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang X, 2002, J NEUROSCI, V22, P6052	104	43	43	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 25	2012	32	4					1183	1196		10.1523/JNEUROSCI.5342-11.2012			14	Neurosciences	Neurosciences & Neurology	885SM	WOS:000299801100005	22279204	Bronze, Green Accepted, Green Published			2021-06-18	
J	Larney, S; Topp, L; Indig, D; O'Driscoll, C; Greenberg, D				Larney, Sarah; Topp, Libby; Indig, Devon; O'Driscoll, Colman; Greenberg, David			A cross-sectional survey of prevalence and correlates of suicidal ideation and suicide attempts among prisoners in New South Wales, Australia	BMC PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; SELF-HARM; PSYCHIATRIC-DISORDERS; MENTAL-HEALTH; RISK-FACTORS; BEHAVIOR; WOMEN	Background: We aimed to estimate the prevalence of suicidal ideation and suicide attempt among prisoners in New South Wales, Australia; and, among prisoners reporting suicidal ideation, to identify factors associated with suicide attempt. Methods: A cross-sectional design was used. Participants were a random, stratified sample of 996 inmates who completed a telephone survey. The estimated population prevalence of suicidal ideation and suicide attempt were calculated and differences by sex and Aboriginality were tested using chi(2) tests. Correlates of suicidal ideation and suicide attempt were tested using logistic regression. Results: One-third of inmates reported lifetime suicidal ideation and one-fifth had attempted suicide. Women and Aboriginal participants were significantly more likely than men and non-Aboriginal participants, respectively, to report attempting suicide. Correlates of suicidal ideation included violent offending, traumatic brain injury, depression, self-harm, and psychiatric hospitalisation. Univariate correlates of suicide attempt among ideators were childhood out-of-home care, parental incarceration and psychiatric hospitalization; however, none of these remained significant in a multivariate model. Conclusions: Suicidal ideation and attempts are highly prevalent among prisoners compared to the general community. Assessment of suicide risk is a critical task for mental health clinicians in prisons. Attention should be given to ensuring assessments are gender-and culturally sensitive. Indicators of mental illness may not be accurate predictors of suicide attempt. Indicators of childhood trauma appear to be particularly relevant to risk of suicide attempt among prisoners and should be given attention as part of risk assessments.	[Larney, Sarah; Indig, Devon] Justice Hlth & Forens Mental Hlth Network, Ctr Hlth Res Criminal Justice, Sydney, NSW, Australia; [Larney, Sarah] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [Topp, Libby] Univ New S Wales, Kirby Inst, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; [Indig, Devon] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [O'Driscoll, Colman; Greenberg, David] Justice Hlth & Forens Mental Hlth Network, Statewide Forens Mental Hlth, Sydney, NSW, Australia; [O'Driscoll, Colman; Greenberg, David] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia	Larney, S (corresponding author), Justice Hlth & Forens Mental Hlth Network, Ctr Hlth Res Criminal Justice, Sydney, NSW, Australia.	s.larney@unsw.edu.au	Larney, Sarah L/B-1900-2008; Larney, Sarah/AAR-1372-2020	Larney, Sarah L/0000-0002-5602-4963; Larney, Sarah/0000-0002-5602-4963; Indig, Devon/0000-0002-6741-5062	Hunter New England Population Health; IHS investigator team; Corrective Services NSW; NSW Health and Justice Health; Inmate Health Survey	Thank you to the IHS Clinical Co-ordinator, Shalin Kumar; Belinda Border of Hunter New England Population Health; the IHS investigator team; and Corrective Services NSW for supporting the conduct of the IHS. The IHS was originally developed by Professor Tony Butler. Funding for the IHS was provided by NSW Health and Justice Health. The funding bodies had no role in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.; SL, DI and DG are current employees, and LT and CO are past employees, of Justice Health, which funded the Inmate Health Survey.	Australian Bureau of Statistics, 2010, CAUS DEATH 2008; Australian Bureau of Statistics, 2010, PRIS AUSTR; Australian Bureau of Statistics Australian Institute of Health and Welfare, 2008, HLTH WELF AUSTR AB T; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Baillargeon J, 2009, J AM ACAD PSYCHIATRY, V37, P188; Bebbington PE, 2010, EUR PSYCHIAT, V25, P427, DOI 10.1016/j.eurpsy.2009.12.004; Beck A. T., 1996, BECK DEPRESSION INVE; Blaauw E, 2005, SUICIDE LIFE-THREAT, V35, P63, DOI 10.1521/suli.35.1.63.59268; Borges G, 2010, CURR OPIN PSYCHIATR, V23, P195, DOI 10.1097/YCO.0b013e3283386322; Butler T, 2006, AUST NZ J PSYCHIAT, V40, P272, DOI 10.1111/j.1440-1614.2006.01785.x; Butler T, 2007, AUST NZ J PSYCHIAT, V41, P429, DOI 10.1080/00048670701261210; Clements-Nolle K, 2009, WOMEN HEALTH ISS, V19, P185, DOI 10.1016/j.whi.2009.02.002; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; Elliott-Farrelly T., 2004, ADV MENTAL HLTH, V3, P138, DOI DOI 10.5172/jamh.3.3.138; Fazel S, 2008, J CLIN PSYCHIAT, V69, P1721, DOI 10.4088/JCP.v69n1107; Fazel S, 2011, SOC PSYCH PSYCH EPID, V46, P191, DOI 10.1007/s00127-010-0184-4; Fruehwald S, 2004, BRIT J PSYCHIAT, V185, P494, DOI 10.1192/bjp.185.6.494; Hall G. J., 2006, PREVENTING SUICIDE O, P29; Hawton K, 2006, PSYCHOL MED, V36, P397, DOI 10.1017/S0033291705006914; Hunter Ernest, 2006, Arch Suicide Res, V10, P141, DOI 10.1080/13811110600556889; Indig D, 2010, 2009 INM HLTH SURV; Jenkins R, 2005, PSYCHOL MED, V35, P257, DOI 10.1017/S0033291704002958; Johnston AK, 2009, AUST NZ J PSYCHIAT, V43, P635, DOI 10.1080/00048670902970874; Joukamaa M, 1997, FORENSIC SCI INT, V89, P167, DOI 10.1016/S0379-0738(97)00119-9; Konrad N, 2007, CRISIS, V28, P113, DOI 10.1027/0227-5910.28.3.113; Lekka NP, 2006, EUR ARCH PSY CLIN N, V256, P87, DOI 10.1007/s00406-005-0606-6; Liebling A, 2006, PREVENTING SUICIDE O, P16; Marzano L, 2011, SOC SCI MED, V72, P874, DOI 10.1016/j.socscimed.2010.12.028; Marzano L, 2010, BRIT J PSYCHIAT, V197, P219, DOI 10.1192/bjp.bp.109.075424; Naud H, 2010, J PSYCHOPATHOL BEHAV, V32, P333, DOI 10.1007/s10862-009-9159-8; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Nock MK, 2000, INT HDB SUICIDE ATTE, P437, DOI 10.1002/9780470698976.ch24; O'Driscoll C, 2007, AUST NZ J PSYCHIAT, V41, P519, DOI 10.1080/00048670701341863; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Perkes I, 2011, BRAIN INJURY, V25, P131, DOI 10.3109/02699052.2010.536193; Perry AE, 2010, INT J OFFENDER THER, V54, P803, DOI 10.1177/0306624X09359757; SAS Institute, 2008, SAS 9 2; Shaw J, 2004, BRIT J PSYCHIAT, V184, P263, DOI 10.1192/bjp.184.3.263; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; *W AUSTR DEP JUST, 2002, SUIC PRIS	41	43	44	0	34	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2458		BMC PUBLIC HEALTH	BMC Public Health	JAN 6	2012	12								14	10.1186/1471-2458-12-14			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	892MG	WOS:000300289700001	22225627	DOAJ Gold, Green Published			2021-06-18	
J	Pogoda, TK; Hendricks, AM; Iverson, KM; Stolzmann, KL; Krengel, MH; Baker, E; Meterko, M; Lew, HL				Pogoda, Terri K.; Hendricks, Ann M.; Iverson, Katherine M.; Stolzmann, Kelly L.; Krengel, Maxine H.; Baker, Errol; Meterko, Mark; Lew, Henry L.			Multisensory impairment reported by veterans with and without mild traumatic brain injury history	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						Afghanistan; blast injuries; brain injuries; depression; hearing impairment; Iraq; multisensory impairment; nonblast injuries; posttraumatic stress disorder; vestibular impairment; veterans; vision impairment	POSTTRAUMATIC-STRESS-DISORDER; DUAL SENSORY IMPAIRMENT; PERSISTENT POSTCONCUSSIVE SYMPTOMS; POLYTRAUMA CLINICAL TRIAD; IRAQ WAR VETERANS; ENDURING FREEDOM; EVERYDAY COMPETENCE; BLAST; PREVALENCE; HEALTH	With the use of Veterans Health Administration and Department of Defense databases of veterans who completed a Department of Veterans Affairs comprehensive traumatic brain injury (TBI) evaluation, the objectives of this study were to (1) identify the co-occurrence of self-reported auditory, visual, and vestibular impairment, referred to as multisensory impairment (MSI), and (2) examine demographic, deployment-related, and mental health characteristics that were potentially predictive of MSI. Our sample included 13,746 veterans with either a history of deployment-related mild TBI (mTBI) (n = 9,998) or no history of TBI (n = 3,748). The percentage of MSI across the sample was 13.9%, but was 17.4% in a subsample with mTBI history that experienced both nonblast and blast injuries. The factors that were significantly predictive of reporting MSI were older age, being female, lower rank, and etiology of injury. Deployment-related mTBI history, posttraumatic stress disorder, and depression were also significantly predictive of reporting MSI, with mTBI history the most robust after adjusting for these conditions. A better comprehension of impairments incurred by deployed servicemembers is needed to fully understand the spectrum of blast and nonblast dysfunction and may allow for more targeted interventions to be developed to address these issues.	[Pogoda, Terri K.; Iverson, Katherine M.; Stolzmann, Kelly L.; Baker, Errol; Meterko, Mark] Dept Vet Affairs VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.; Hendricks, Ann M.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Hendricks, Ann M.] VA Boston Healthcare Syst, Hlth Care Financing & Econ, Boston, MA 02130 USA; [Iverson, Katherine M.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02130 USA; [Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Krengel, Maxine H.] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA; [Krengel, Maxine H.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA; [Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA USA	Pogoda, TK (corresponding author), VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, 150 S Huntington Ave 152M, Boston, MA 02130 USA.	terri.pogoda@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780; Krengel, Maxine/0000-0001-7632-590X	VA Office of Research and Development, Health Services Research and Development ServiceUS Department of Veterans Affairs [SDR 08-405]	This article was based on work supported by the VA Office of Research and Development, Health Services Research and Development Service (grant SDR 08-405).	Allison L, 1999, J NEUROL PHYS THER, V23, P13; Ari Adrienne B, 2006, Optometry, V77, P329, DOI 10.1016/j.optm.2006.03.015; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Brennan M, 2005, GERONTOLOGIST, V45, P337, DOI 10.1093/geront/45.3.337; Brennan M, 2006, J REHABIL RES DEV, V43, P777, DOI 10.1682/JRRD.2005.06.0109; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brewin B, 2010, NEXTGOV          JUN; Campbell V A, 1999, MMWR CDC Surveill Summ, V48, P131; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Castro CA, 2005, RTO HUM FACT MED PAN; Centers for Disease Control and Prevention, 2010, INJ PREV CONTR TRAUM; Centers for Disease Control and Prevention, 2008, BLAST INJ EAR BLAST; Chandler CW, 2006, ASHA LEADER; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823; Defense and Veterans Brain Injury Center, 2009, TBI FACTS; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2009, REP WHIT HOUS COUNC, P1; Department of Planning L, 2010, WATER SENSITIVE URBA, P1; Department of the Army, 2007, STAT INT 2007 2010, P1; Department of Veterans Affairs Department of Defens, 2009, VA DOD CLIN PRACT GU, P1; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harrell MC, 2007, ASSESSING ASSIGNMENT, P184; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Ladwig KH, 2001, PSYCHOSOMATICS, V42, P511, DOI 10.1176/appi.psy.42.6.511; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2011, J REHABIL RES DEV, V48, P913, DOI 10.1682/JRRD.2010.08.0140; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; National Center for Mental Health Statistics and the Centers for Medicare & Medicaid Services, 2008, INT CLASS DIS 9 REV; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Rustoen Tone, 2004, Pain Manag Nurs, V5, P105, DOI 10.1016/j.pmn.2004.01.004; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T, 2008, INVISIBLE WOUNDS WAR, P492; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tun C, 2009, HEAR J, V62, P24; U.S. General Accounting Office, 2008, GAO08794, P1; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; White House, 2011, STRENGTH OUR MIL FAM; Wijnhoven HAH, 2006, CLIN J PAIN, V22, P717, DOI 10.1097/01.ajp.0000210912.95664.53	80	43	43	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					971	983		10.1682/JRRD.2011.06.0099			13	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100003	23341273	Bronze			2021-06-18	
J	Soares, FMS; de Souza, NM; Schwarzbold, ML; Diaz, AP; Nunes, JC; Hohl, A; da Silva, PNA; Vieira, J; de Souza, RL; Bertotti, MM; Prediger, RDS; Linhares, MN; Bafica, A; Walz, R				Schneider Soares, Flavia Mahatma; de Souza, Nicole Menezes; Schwarzbold, Marcelo Liborio; Diaz, Alexandre Palm; Nunes, Jean Costa; Hohl, Alexandre; Abreu da Silva, Priscilla Nunes; Vieira, Juliana; de Souza, Rafael Lisboa; Bertotti, Melina More; Schoder Prediger, Rui Daniel; Linhares, Marcelo Neves; Bafica, Andre; Walz, Roger			Interleukin-10 Is an Independent Biomarker of Severe Traumatic Brain Injury Prognosis	NEUROIMMUNOMODULATION			English	Article						Cytokines; IL-10; TNF-alpha; Traumatic brain injury; Prognosis	CEREBROSPINAL-FLUID; PLASMA-LEVELS; IMPACT; IL-10; SERUM; INFLAMMATION; PARAMETERS; MORTALITY; ALPHA; PTX3	Background: Cytokines have been shown to be involved in traumatic brain injury (TBI). We investigated the independent association between serum levels of IL-10 and TNF-alpha and hospital mortality of patients with severe TBI. Methods: Serum IL-10 and TNF-alpha levels were determined after a median period (interquartile range (IQ) 25-75) of 10 h (IQ 5-18) after severe TBI in 93 consecutive patients and in randomly selected patients with mild (n = 18) and moderate (n = 16) TBI. In patients with severe TBI, additional blood samples were analyzed 30 h (IQ 22-37) and 68 h (IQ 55-78) after TBI. Age, gender, computed tomography findings, Glasgow Coma Scale score (GCS) and pupil reactions at admission, associated trauma and hospital mortality were collected. Results: Elevated serum levels of IL-10, but not TNF-alpha, correlated significantly with GCS severity (R-2 coefficient, p < 0.0001) and were found to be associated with hospital mortality in patients with severe TBI. Elevated IL-10 remained associated with mortality (p = 0.01) in a subset of patients with isolated severe TBI (n = 74). Multiple logistic regression analysis showed that higher IL-10 levels (>90 pg/ml) at 10 or 30 h after TBI were 6 times (odds ratio (OR) 6.2, 95% confidence interval (CI) 1.2-25.1, p = 0.03) and 5 times (OR 5.4, 95% CI 1.2-25.1, p = 0.03), respectively, more frequently associated with hospital mortality than lower levels (<50 pg/ml), independently of age, GCS as well as pupil reactions at admission and associated trauma. Conclusions: Serum IL-10 levels may be a useful marker for severe TBI prognosis. Copyright (C) 2012 S. Karger AG, Basel	[Walz, Roger] Univ Fed Santa Catarina, Univ Hosp, Dept Clin Med, BR-88040900 Florianopolis, SC, Brazil; [Schneider Soares, Flavia Mahatma; Schwarzbold, Marcelo Liborio; Diaz, Alexandre Palm; Nunes, Jean Costa; Hohl, Alexandre; Abreu da Silva, Priscilla Nunes; Vieira, Juliana; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas, BR-88040900 Florianopolis, SC, Brazil; [Linhares, Marcelo Neves] Univ Fed Santa Catarina, Dept Cirurgia, BR-88040900 Florianopolis, SC, Brazil; [de Souza, Nicole Menezes; Bafica, Andre] Univ Fed Santa Catarina, Lab Imunofarmacol & Doencas Infecciosas, BR-88040900 Florianopolis, SC, Brazil; [Schoder Prediger, Rui Daniel] Univ Fed Santa Catarina, Dept Farmacol, Lab Expt Doencas Neurodegenerat, BR-88040900 Florianopolis, SC, Brazil; [Linhares, Marcelo Neves] Hosp Governador Celso Ramos, Serv Neurocirurgia, Florianopolis, SC, Brazil; [de Souza, Rafael Lisboa] Hosp Governador Celso Ramos, Serv Terapia Intens, Florianopolis, SC, Brazil	Walz, R (corresponding author), Univ Fed Santa Catarina, Univ Hosp, Dept Clin Med, 3 Andar,Campus Univ 88-040-970, BR-88040900 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Neurociencia, Inct/I-1011-2013; Prediger, Rui D/C-4036-2013; Bafica, Andre/ABF-5986-2020; Prediger, Rui Daniel/AAV-3419-2020; Schwarzbold, Marcelo Liborio/J-8960-2014; Walz, Roger/K-9096-2013; Diaz, Alexandre Paim/AAD-8323-2019; Diaz, Alexandre Paim/J-9042-2014; Hohl, Alexandre/R-9269-2019	Prediger, Rui D/0000-0002-7547-6463; Bafica, Andre/0000-0002-5148-600X; Prediger, Rui Daniel/0000-0002-7547-6463; Walz, Roger/0000-0002-9875-6687; Diaz, Alexandre Paim/0000-0002-6591-6648; Hohl, Alexandre/0000-0002-8073-5837; Mahatma Schneider Soares, Flavia/0000-0001-5968-1312	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Programa de Apoio aos Nucleos de Excelencia; Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (Brazil); CNPq - BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This work was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, the Programa de Apoio aos Nucleos de Excelencia and the Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (all from Brazil). R.D.S.P., A.B. and R.W. are supported by research fellowships from CNPq - Brazil. The authors received technical support for the biological sample collection from the Laboratorio Biomedico (Florianopolis) under the supervision of Pharm. Saulo Correia de Mello. The authors thank all medical and nursing staff of the Servico de Terapia Intensiva (Hospital Governador Celso Ramos) for their kind cooperation during the study.	Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Thais MERD, 2012, CNS NEUROSCI THER, V18, P606, DOI 10.1111/j.1755-5949.2012.00346.x; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Doni A, 2006, J LEUKOCYTE BIOL, V79, P797, DOI 10.1189/jlb.0905493; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Gullo JD, 2011, NEUROCRIT CARE, V14, P194, DOI 10.1007/s12028-010-9462-y; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808	28	43	43	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2012	19	6					377	385		10.1159/000342141			9	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	033AK	WOS:000310764400007	23075771	Bronze			2021-06-18	
J	Ma, YH; Liu, WB; Wang, Y; Chao, XD; Qu, Y; Wang, K; Fei, Z				Ma, Yihui; Liu, Wenbo; Wang, Yuan; Chao, Xiaodong; Qu, Yan; Wang, Kai; Fei, Zhou			VEGF protects rat cortical neurons from mechanical trauma injury induced apoptosis via the MEK/ERK pathway	BRAIN RESEARCH BULLETIN			English	Article						VEGF; Neuroprotection; ERK; Neuron; Traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; BRAIN-INJURY; IN-VITRO; HIPPOCAMPAL-NEURONS; FACTOR RECEPTOR; CELL-DEATH; INHIBITION; NEUROGENESIS	Traumatic brain injury (TBI) is a serious insult that frequently leads to neurological dysfunction or death. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and vascular permeability. Recently, VEGF has been identified as a neurotrophic factor and has been implicated in the pathogenic mechanisms of TBI. However, the possible mechanisms of VEGF in primary or secondary injuries after TBI are largely unknown. The present study attempted to determine whether VEGF has a protective effect on primary cortical neurons against mechanical trauma injury, which is an in vitro insult mimicking traumatic brain injury. We found that pretreatment of primary cortical neurons in culture with VEGF decreased neuronal death in a concentration-dependent manner, and VEGF counteracted the mechanical trauma mediated apoptotic death of cultured cortical neurons. VEGF up-regulates the activity of ERK (extracellular signal-regulated kinase) in cultured cortical neurons and U0126 (a mitogen activated protein kinase kinase (MEK) inhibitor) suppressed VEGF induced activity of ERK. Furthermore, incubation of cells with U0126 attenuated the ability of VEGF to protect neurons against mechanical trauma-induced apoptosis. Therefore, the present study supports the notion that MEK/ERK pathway is involved in VEGF mediated neuroprotection against mechanical trauma injury. (C) 2011 Elsevier Inc. All rights reserved.	[Ma, Yihui; Liu, Wenbo; Wang, Yuan; Chao, Xiaodong; Qu, Yan; Wang, Kai; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China.	zhoufeifmmu@gmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093, 81070951, 30700255]	The National Natural Science Foundation of China (No. 30930093, No. 81070951 and No. 30700255) supported this research.	Carey RG, 2002, J NEUROSCI, V22, P1583, DOI 10.1523/JNEUROSCI.22-05-01583.2002; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Lee HT, 2010, J NEUROCHEM, V113, P79, DOI 10.1111/j.1471-4159.2010.06584.x; Lin JR, 2010, BRAIN RES BULL, V83, P284, DOI 10.1016/j.brainresbull.2010.08.002; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; LU KT, 2011, J NEUROTRAUMA; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Ma YH, 2011, J NEUROSCI RES, V89, P969, DOI 10.1002/jnr.22628; Matsuzaki H, 2001, FASEB J, V15, P1218; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Park EM, 2004, NEUROSCIENCE, V123, P147, DOI 10.1016/j.neuroscience.2003.08.023; Park EM, 2006, NEUROSCI LETT, V402, P190, DOI 10.1016/j.neulet.2006.04.004; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Payette DJ, 2008, INT J CLIN EXP PATHO, V1, P44; Shiote M, 2005, NEUROSCIENCE, V132, P175, DOI 10.1016/j.neuroscience.2004.12.031; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Sundberg LM, 2011, J NEUROTRAUM, V28, P565, DOI 10.1089/neu.2010.1533; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tolosa L, 2009, NEUROSCIENCE, V158, P1348, DOI 10.1016/j.neuroscience.2008.10.060; Tolosa L, 2008, J NEUROCHEM, V105, P1080, DOI 10.1111/j.1471-4159.2007.05206.x; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Xia Y, 2010, NEUROPHARMACOLOGY, V58, P330, DOI 10.1016/j.neuropharm.2009.10.009; Zheng XR, 2010, BRAIN RES BULL, V81, P372, DOI 10.1016/j.brainresbull.2009.11.012	38	43	46	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	NOV 25	2011	86	5-6					441	446		10.1016/j.brainresbull.2011.07.007			6	Neurosciences	Neurosciences & Neurology	871AZ	WOS:000298711300022	21801813				2021-06-18	
J	Susarla, BTS; Laing, ED; Yu, PP; Katagiri, Y; Geller, HM; Symes, AJ				Susarla, Bala T. S.; Laing, Eric D.; Yu, Panpan; Katagiri, Yasuhiro; Geller, Herbert M.; Symes, Aviva J.			Smad proteins differentially regulate transforming growth factor-beta-mediated induction of chondroitin sulfate proteoglycans	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; cell culture; glial scar; Smad3; Smad2; transforming growth factor-beta	MOLECULAR-CLONING; MESSENGER-RNA; RAT-BRAIN; FUNCTIONAL RECOVERY; INJURED BRAIN; CNS INJURY; EXPRESSION; REGENERATION; LOCALIZATION; INFLAMMATION	Traumatic injury to the CNS results in increased expression and deposition of chondroitin sulfate proteoglycans (CSPGs) that are inhibitory to axonal regeneration. Transforming growth factor-beta (TGF-beta) has been implicated as a major mediator of these changes, but the mechanisms through which TGF-beta regulates CSPG expression are not known. Using lentiviral expressed Smad-specific ShRNA we show that TGF-beta induction of CSPG expression in astrocytes is Smad-dependent. However, we find a differential dependence of the synthetic machinery on Smad2 and/or Smad3. TGF-beta induction of neurocan and xylosyl transferase 1 required both Smad2 and Smad3, whereas induction of phosphacan and chondroitin synthase 1 required Smad2 but not Smad3. Smad3 knockdown selectively reduced induction of chondroitin-4-sulfotransferase 1 and the amount of 4-sulfated CSPGs secreted by astrocytes. Additionally, Smad3 knockdown in astrocytes was more efficacious in promoting neurite outgrowth of neurons cultured on the TGF-beta-treated astrocytes. Our data implicate TGF-beta Smad3-mediated induction of 4-sulfation as a critical determinant of the permissiveness of astrocyte secreted CSPGs for axonal growth.	[Susarla, Bala T. S.; Laing, Eric D.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Yu, Panpan; Katagiri, Yasuhiro; Geller, Herbert M.] NHLBI, Dev Neurobiol Sect, Div Intramural Res, NIH, Bethesda, MD 20892 USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	asymes@usuhs.mil	Symes, Aviva J/S-7471-2016; Yu, Panpan/M-5718-2019; Yu, Panpan/A-4962-2013	Symes, Aviva J/0000-0003-2557-9939; Geller, Herbert/0000-0002-7048-6144; Laing, Eric/0000-0002-5574-2584	Maryland Spinal Cord Injury Research Board; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZIAHL006021] Funding Source: NIH RePORTER	This work was supported by a grant from the Maryland Spinal Cord Injury Research Board (AJS) and the Intramural Research Program of the National Heart, Lung and Blood Institute (PY, YK and HMG). We thank Dr Dours Zimmermann (Zurich, Switzerland) for the generous gift of neurocan antibody. We are grateful to past and present members of the Symes and Geller laboratories for their helpful comments and suggestions. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences or the US Department of Defense. The authors report no conflicts of interest.	Armstrong RC, 1998, METHODS, V16, P282, DOI 10.1006/meth.1998.0685; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Dobbertin A, 2003, MOL CELL NEUROSCI, V24, P951, DOI 10.1016/S1044-7431(03)00257-4; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Gris P, 2007, GLIA, V55, P1145, DOI 10.1002/glia.20537; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hamel MG, 2005, J NEUROCHEM, V93, P1533, DOI 10.1111/j.1471-4159.2005.03144.x; Hurtado A, 2008, BRAIN, V131, P2596, DOI 10.1093/brain/awn206; Ito Y, 2005, GLYCOBIOLOGY, V15, P593, DOI 10.1093/glycob/cwi036; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Logan A., 1999, CNS INJURIES CELLULA, P151; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; NICHOLS NR, 1991, J NEUROSCI RES, V28, P134, DOI 10.1002/jnr.490280114; Nomura M, 1998, NATURE, V393, P786; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Powell EM, 1997, MOL CELL NEUROSCI, V10, P27, DOI 10.1006/mcne.1997.0629; Prydz K, 2000, J CELL SCI, V113, P193; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Sherman LS, 2008, TRENDS NEUROSCI, V31, P44, DOI 10.1016/j.tins.2007.11.001; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wang H, 2008, J CELL SCI, V121, P3083, DOI 10.1242/jcs.032649; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Yamamoto Y, 1995, EUR J HISTOCHEM, V39, P265; Yin JR, 2009, BRAIN RES, V1263, P10, DOI 10.1016/j.brainres.2009.01.042; Zhang LJ, 2010, PROG MOL BIOL TRANSL, V93, P1, DOI 10.1016/S1877-1173(10)93001-9; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	51	43	44	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2011	119	4					868	878		10.1111/j.1471-4159.2011.07470.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	848AZ	WOS:000297020300019	21895657	Bronze, Green Accepted			2021-06-18	
J	Diedler, J; Zweifel, C; Budohoski, KP; Kasprowicz, M; Sorrentino, E; Haubrich, C; Brady, KM; Czosnyka, M; Pickard, JD; Smielewski, P				Diedler, Jennifer; Zweifel, Christian; Budohoski, Karol P.; Kasprowicz, Magdalena; Sorrentino, Enrico; Haubrich, Christina; Brady, Kenneth M.; Czosnyka, Marek; Pickard, John D.; Smielewski, Peter			The Limitations of Near-Infrared Spectroscopy to Assess Cerebrovascular Reactivity: The Role of Slow Frequency Oscillations	ANESTHESIA AND ANALGESIA			English	Article							CEREBRAL-BLOOD-FLOW; PRESSURE REACTIVITY; INTRACRANIAL-PRESSURE; AUTOREGULATION; OXYGENATION; TIME; HEMODYNAMICS; METABOLISM	BACKGROUND: A total hemoglobin reactivity index (THx) derived from near-infrared spectroscopy (NIRS) has recently been introduced to assess cerebrovascular reactivity noninvasively. Analogously to the pressure reactivity index (PRx), THx is calculated as correlation coefficient with arterial blood pressure (ABP). However, the reliability of THx in the injured brain is uncertain. Although slow oscillations have been described in NIRS signals, their significance for assessment of autoregulation remains unclear. In the current study, we investigated the role of slow oscillations of total hemoglobin for NIRS-based cerebrovascular reactivity monitoring. METHODS: This study was based on a retrospective analysis of data that were consecutively recorded for a different project published previously. Thirty-seven patients with traumatic brain injury and admitted to Addenbrooke's Neurosciences Critical Care Unit between June 2008 and June 2009 were included. After artifact removal, we performed spectral analysis of the tissue hemoglobin index (THI, a measure of oxy- and deoxygenated hemoglobin) and intracranial pressure (ICP) signal. PRx and THx were calculated as moving correlations between ICP and ABP, and THI and ABP, respectively. The agreement between PRx and THx as a function of normalized power of slow oscillations (0.015-0.055 Hz) contained in the input signals was assessed performing between-subject and within-subject correlation analyses. Furthermore, the correlation between the THx values derived from the right and left sides was analyzed. RESULTS: The agreement between PRx and THx depended on the power of slow oscillations in the input signals. Between-subject comparisons revealed a significant correlation between THx and PRx (r = 0.80, 95% confidence interval 0.53-0.92, P < 0.01) for patients with normalized slow wave activity > 0.4 in the THI signal, compared with r = 0.07 (95% confidence interval = 0.40 to 0.51, P = 0.79) in the remaining files. Furthermore, within-subject comparisons suggested that THx may be used as a substitute for PRx only when there is an at least moderate agreement (r = 0.36) between the THx values derived from the right and left sides. CONCLUSIONS: Our results suggest that the NIRS-based cerebrovascular reactivity index THx can be used as a noninvasive substitute for PRx, but only during phases with sufficient slow wave power in the input signal. Furthermore, a good agreement between the THx measures on both sides seems to be a prerequisite for comparison of a global (PRx) versus the more local (THx) index. Nevertheless, noninvasive assessment of cerebrovascular reactivity may be desirable in patients without ICP monitoring and help to guide ABP management in these patients. (Anesth Analg 2011;113:849-57)	[Diedler, Jennifer] Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany; [Diedler, Jennifer; Zweifel, Christian; Budohoski, Karol P.; Kasprowicz, Magdalena; Sorrentino, Enrico; Haubrich, Christina; Brady, Kenneth M.; Czosnyka, Marek; Pickard, John D.; Smielewski, Peter] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Brady, Kenneth M.] Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol & Pediat, Houston, TX 77030 USA; [Zweifel, Christian] Univ Basel, CH-4003 Basel, Switzerland; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, Wroclaw, Poland; [Sorrentino, Enrico] Univ Wroclaw, PL-50138 Wroclaw, Poland; [Haubrich, Christina] Univ Aachen, Aachen, Germany	Diedler, J (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	jennifer.diedler@med.uni-heidelberg.de		Smielewski, Peter/0000-0001-5096-3938; Kasprowicz, Magdalena/0000-0002-2271-7737	Medical Faculty, University of Heidelberg; National Institute of Health Research, Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; NIHRNational Institute for Health Research (NIHR); Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBBSP3-125550]; Hamamatsu Photonics, Welwyn Garden City, Hertfordshire, UK; Foundation for Polish ScienceFoundation for Polish ScienceEuropean Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	JD was supported by a scholarship from the Medical Faculty, University of Heidelberg. This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), NIHR Senior Investigator Awards (JDP), the Swiss National Science Foundation (PBBSP3-125550 to CZ, Bern, Switzerland, and the Foundation for Polish Science (MK). CZ received a travel grant from Hamamatsu Photonics, Welwyn Garden City, Hertfordshire, UK.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Calderon-Arnulphi M, 2009, NEUROL RES, V31, P605, DOI 10.1179/174313209X383286; Cheng OSK, 2002, ACTA NEUROCHIR SUPPL, V81, P135; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Einhaupl K, 1986, OSCILLATIONS ICP REL; Elwell CE, 1999, ADV EXP MED BIOL, V471, P57; FERRARI M, 1992, AM J PHYSIOL, V262, pH1908; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Li ZY, 2010, MICROVASC RES, V80, P142, DOI 10.1016/j.mvr.2010.02.004; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; Nissen P, 2009, NEUROCRIT CARE, V11, P235, DOI 10.1007/s12028-009-9226-8; Obrig H, 2000, NEUROIMAGE, V12, P623, DOI 10.1006/nimg.2000.0657; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P591, DOI 10.1089/neu.1995.12.591; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; VENES JL, 1979, CHILD BRAIN, V5, P352; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	32	43	43	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2011	113	4					849	857		10.1213/ANE.0b013e3182285dc0			9	Anesthesiology	Anesthesiology	824PT	WOS:000295215100028	21821514				2021-06-18	
J	Eckner, JT; Sabin, M; Kutcher, JS; Broglio, SP				Eckner, James T.; Sabin, Matthew; Kutcher, Jeffrey S.; Broglio, Steven P.			No Evidence for a Cumulative Impact Effect on Concussion Injury Threshold	JOURNAL OF NEUROTRAUMA			English	Article						acceleration; biomechanics; concussion; helmet; injury tolerance	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; HEAD IMPACTS; SPORTS; STATEMENT; MAGNITUDE; SEVERITY; LOCATION; HOCKEY	Recent studies using a helmet-based accelerometer system (Head Impact Telemetry System [HITS]) have demonstrated that concussions result from a wide range of head impact magnitudes. Variability in concussion thresholds has been proposed to result from the cumulative effect of non-concussive head impacts prior to injury. We used the HITS to collect biomechanical data representing > 100,000 head impacts in 95 high school football players over 4 years. The cumulative impact histories prior to 20 concussive impacts in 19 athletes were compared to the cumulative impact histories prior to the three largest magnitude non-concussive head impacts in the same athletes. No differences were present in any impact history variable between the concussive and non-concussive high magnitude impacts. These analyses included the number of head impacts, cumulative HIT severity profile value, cumulative linear acceleration, and cumulative rotational acceleration during the same practice or game session, as well as over the 30 min and 1 week preceding these impacts. Our data do not support the proposal that impact volume or intensity influence concussion threshold in high school football athletes.	[Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, Ann Arbor, MI 48109 USA; [Eckner, James T.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; [Sabin, Matthew] Eastern Kentucky Univ, Dept Exercise & Sport Sci, Richmond, KY 40475 USA	Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, 1402 Washington Hts, Ann Arbor, MI 48109 USA.	broglio@umich.edu			Unity Rockets football team (Tolono, IL); Rehabilitation Medicine Scientist Training Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	We thank Scott Hamilton and the Unity Rockets football team (Tolono, IL), John Storsved, and Susan Mantel, all of whose support made this project possible. We also thank James A. Ashton-Miller and James K. Richardson for their advice regarding our data analysis. Dr. Eckner also thanks the Rehabilitation Medicine Scientist Training Program for its support of his research.	Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gwin J. T., 2009, J ASTM INT, V6, P1; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	25	43	43	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2079	2090		10.1089/neu.2011.1910			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500009	21815783	Green Published			2021-06-18	
J	Readnower, RD; Pandya, JD; McEwen, ML; Pauly, JR; Springer, JE; Sullivan, PG				Readnower, Ryan D.; Pandya, Jignesh D.; McEwen, Melanie L.; Pauly, James R.; Springer, Joseph E.; Sullivan, Patrick G.			Post-Injury Administration of the Mitochondrial Permeability Transition Pore Inhibitor, NIM811, Is Neuroprotective and Improves Cognition after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; mitochondria; neurodegeneration; neuroprotection; TBI	SPINAL-CORD CONTUSION; CYCLOSPORINE-A ANALOG; CELL-DEATH; OXIDATIVE DAMAGE; SYNAPTIC MITOCHONDRIA; FREE-RADICALS; MOUSE MODEL; DYSFUNCTION; MEMBRANE; TISSUE	Mitochondrial dysfunction is known to play a pivotal role in cell death mechanisms following traumatic brain injury (TBI). N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclosporin A (CsA) analog, inhibits the mitochondrial permeability transition pore (mPTP) and has been shown to be neuroprotective following TBI in mice. However, the translation of the neuroprotective effects of mPTP inhibitors, including CsA and NIM811, into improved cognitive end points has yet to be fully investigated. Therefore, to build upon these results, a severe unilateral controlled cortical impact model of TBI was used in the present study to establish a dose-response curve for NIM811 in rats. The findings demonstrate that the neuroprotection afforded by NIM811 is dose dependent, with the 10 mg/kg dose being the most effective dose. Once the dose response was established, we evaluated the effect of the optimal dose of NIM811 on behavior, mitochondrial bioenergetics, and mitochondrial oxidative damage following TBI. For behavioral studies, rats were administered NIM811 at 15 min and 24 h post-injury, with cognitive testing beginning 10 days post-injury. Mitochondrial studies involved a single injection of NIM811 at 15 min post-injury followed by mitochondrial isolation at 6 h post-injury. The results revealed that the optimal dose of NIM811 improves cognition, improves mitochondrial functioning, and reduces oxidative damage following TBI.	[Sullivan, Patrick G.] Univ Kentucky, Chandler Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Readnower, Ryan D.; McEwen, Melanie L.; Springer, Joseph E.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [McEwen, Melanie L.; Springer, Joseph E.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Chandler Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 South Limestone,BBSRB 475, Lexington, KY 40536 USA.	patsull@email.uky.edu	springer, joe/B-2581-2014	springer, joe/0000-0001-9611-8107	National Institutes of Health, United States Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 NS48191, R01 NS062993, P30 NS051220, T32 DA022738]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062993, R01NS048191, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, United States Public Health Service grants R01 NS48191 (P.G.S.), R01 NS062993 (J.W.G, P.G.S.), P30 NS051220 (E.D.H), T32 DA022738 (E.D.H), and funding from the Kentucky Spinal Cord and Head Injury Research Trust.	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Giacomello M, 2007, CELL DEATH DIFFER, V14, P1267, DOI 10.1038/sj.cdd.4402147; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Jordan J, 2003, J PHYSIOL BIOCHEM, V59, P129, DOI 10.1007/BF03179878; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Komary Z, 2010, BBA-BIOENERGETICS, V1797, P922, DOI 10.1016/j.bbabio.2010.03.010; Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Ravikumar R, 2007, J NEUROTRAUM, V24, P1618, DOI 10.1089/neu.2007.0329; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	61	43	47	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1845	1853		10.1089/neu.2011.1755			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000015	21875332	Green Published			2021-06-18	
J	Babona-Pilipos, R; Droujinine, IA; Popovic, MR; Morshead, CM				Babona-Pilipos, Robart; Droujinine, Ilia A.; Popovic, Milos R.; Morshead, Cindi M.			Adult Subependymal Neural Precursors, but Not Differentiated Cells, Undergo Rapid Cathodal Migration in the Presence of Direct Current Electric Fields	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; PROGENITOR CELLS; STEM-CELLS; IN-VIVO; HIPPOCAMPAL-NEURONS; SUBVENTRICULAR ZONE; EPITHELIAL-CELLS; NERVOUS-SYSTEM; NEURITE GROWTH; MOUSE BRAIN	Background: The existence of neural stem and progenitor cells (together termed neural precursor cells) in the adult mammalian brain has sparked great interest in utilizing these cells for regenerative medicine strategies. Endogenous neural precursors within the adult forebrain subependyma can be activated following injury, resulting in their proliferation and migration toward lesion sites where they differentiate into neural cells. The administration of growth factors and immunomodulatory agents following injury augments this activation and has been shown to result in behavioural functional recovery following stroke. Methods and Findings: With the goal of enhancing neural precursor migration to facilitate the repair process we report that externally applied direct current electric fields induce rapid and directed cathodal migration of pure populations of undifferentiated adult subependyma-derived neural precursors. Using time-lapse imaging microscopy in vitro we performed an extensive single-cell kinematic analysis demonstrating that this galvanotactic phenomenon is a feature of undifferentiated precursors, and not differentiated phenotypes. Moreover, we have shown that the migratory response of the neural precursors is a direct effect of the electric field and not due to chemotactic gradients. We also identified that epidermal growth factor receptor (EGFR) signaling plays a role in the galvanotactic response as blocking EGFR significantly attenuates the migratory behaviour. Conclusions: These findings suggest direct current electric fields may be implemented in endogenous repair paradigms to promote migration and tissue repair following neurotrauma.	[Babona-Pilipos, Robart; Popovic, Milos R.; Morshead, Cindi M.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Droujinine, Ilia A.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Popovic, Milos R.] Toronto Rehabil Inst, Lyndhurst Ctr, Toronto, ON, Canada; [Morshead, Cindi M.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Morshead, Cindi M.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada	Babona-Pilipos, R (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.	cindi.morshead@utoronto.ca		Popovic, Milos R/0000-0002-2837-2346	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [249669, 482986]; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada [485508]	The authors thank the following sources of funding: Natural Sciences and Engineering Research Council of Canada (grant #249669, http://www.nserc-crsng.gc.ca/), Natural Sciences and Engineering Research Council of Canada (grant #482986, http://www.nserc-crsng.gc.ca/), Heart and Stroke Foundation of Canada (grant #485508, http://www.heartandstroke.com/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Ariza CA, 2010, STEM CELL REV REP, V6, P585, DOI 10.1007/s12015-010-9171-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BORGENS RB, 1995, DEV DYNAM, V203, P456, DOI 10.1002/aja.1002030408; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Craig CG, 1996, J NEUROSCI, V16, P2649; DAVENPORT RW, 1993, J NEUROBIOL, V24, P89, DOI 10.1002/neu.480240108; Erlandsson A, 2006, CURR OPIN MOL THER, V8, P331; Erlandsson A, 2011, EXP NEUROL, V230, P48, DOI 10.1016/j.expneurol.2010.05.018; Fang KS, 1999, J CELL SCI, V112, P1967; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; HOTARY KB, 1992, DEVELOPMENT, V114, P985; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Li L, 2008, STEM CELLS, V26, P2193, DOI 10.1634/stemcells.2007-1022; Matos MA, 2010, BIOTECHNOL PROGR, V26, P664, DOI 10.1002/btpr.389; MCCAIG CD, 1990, J CELL SCI, V95, P605; MCCAIG CD, 1986, J PHYSIOL-LONDON, V375, P55, DOI 10.1113/jphysiol.1986.sp016105; Meng XT, 2011, EXP NEUROL, V227, P210, DOI 10.1016/j.expneurol.2010.11.002; Moyer JD, 1997, CANCER RES, V57, P4838; Nishimura KY, 1996, J CELL SCI, V109, P199; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Pu J, 2007, J CELL SCI, V120, P3395, DOI 10.1242/jcs.002774; Rajnicek AM, 1998, DEV BIOL, V203, P412, DOI 10.1006/dbio.1998.9039; RAJNICEK AM, 1992, EXP PHYSIOL, V77, P229, DOI 10.1113/expphysiol.1992.sp003580; Rajnicek AM, 2006, J CELL SCI, V119, P1736, DOI 10.1242/jcs.02897; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rodgers EE, 2002, INT J DEV NEUROSCI, V20, P187, DOI 10.1016/S0736-5748(02)00047-3; Sato MJ, 2007, BIOSYSTEMS, V88, P261, DOI 10.1016/j.biosystems.2006.06.008; Sato MJ, 2009, P NATL ACAD SCI USA, V106, P6667, DOI 10.1073/pnas.0809974106; Song B, 2004, J CELL SCI, V117, P4681, DOI 10.1242/jcs.01341; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; SORENSEN E, 1978, SCAND J CLIN LAB INV, V38, P203, DOI 10.3109/00365517809108412; Yao L, 2008, J CELL PHYSIOL, V216, P527, DOI 10.1002/jcp.21431; Yao L, 2011, TISSUE ENG PART B-RE, V17, P143, DOI [10.1089/ten.teb.2010.0561, 10.1089/ten.TEB.2010.0561]; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 2002, FASEB J, V16, P857, DOI 10.1096/fj.01-0811fje; Zhao M, 2009, SEMIN CELL DEV BIOL, V20, P674, DOI 10.1016/j.semcdb.2008.12.009	46	43	43	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2011	6	8							e23808	10.1371/journal.pone.0023808			14	Multidisciplinary Sciences	Science & Technology - Other Topics	817NM	WOS:000294680800023	21909360	DOAJ Gold, Green Published			2021-06-18	
J	Cohen-Yeshurun, A; Trembovler, V; Alexandrovich, A; Ryberg, E; Greasley, PJ; Mechoulam, R; Shohami, E; Leker, RR				Cohen-Yeshurun, Ayelet; Trembovler, Victoria; Alexandrovich, Alexander; Ryberg, Erik; Greasley, Peter J.; Mechoulam, Raphael; Shohami, Esther; Leker, Ronen R.			N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; endocannabinoids; N-arachidonoyl-L-serine; neuroprotection; traumatic brain injury	CB2 RECEPTOR ACTIVATION; CANNABINOID RECEPTOR; K+ CHANNELS; RAT-BRAIN; IN-VIVO; CONSTITUENT; BAD; PHOSPHORYLATION; IDENTIFICATION; CANNABIDIOL	N-arachidonoyl-L-serine (AraS) is a brain component structurally related to the endocannabinoid family. We investigated the neuroprotective effects of AraS following closed head injury induced by weight drop onto the exposed fronto-parietal skull and the mechanisms involved. A single injection of AraS following injury led to a significant improvement in functional outcome, and to reduced edema and lesion volume compared with vehicle. Specific antagonists to CB2 receptors, transient receptor potential vanilloid 1 (TRPV1) or large conductance calcium-activated potassium (BK) channels reversed these effects. Specific binding assays did not indicate binding of AraS to the GPR55 cannabinoid receptor. N-arachidonoyl-L-serine blocked the attenuation in phosphorylated extracellular-signal-regulated kinase 1/2 (ERK) levels and led to an increase in pAkt in both the ipsilateral and contralateral cortices. Increased levels of the prosurvival factor Bcl-xL were evident 24 hours after injury in AraS-treated mice, followed by a 30% reduction in caspase-3 activity, measured 3 days after injury. Treatment with a CB2 antagonist, but not with a CB1 antagonist, reversed this effect. Our results suggest that administration of AraS leads to neuroprotection via ERK and Akt phosphorylation and induction of their downstream antiapoptotic pathways. These protective effects are related mostly to indirect signaling via the CB2R and TRPV1 channels but not through CB1 or GPR55 receptors. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1768-1777; doi:10.1038/jcbfm.2011.53; published online 20 April 2011	[Cohen-Yeshurun, Ayelet; Trembovler, Victoria; Alexandrovich, Alexander; Mechoulam, Raphael; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, Inst Drug Res, Fac Med, IL-91120 Jerusalem, Israel; [Cohen-Yeshurun, Ayelet; Leker, Ronen R.] Hadassah Hebrew Univ, Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Dept Neurol, IL-91120 Jerusalem, Israel; [Ryberg, Erik; Greasley, Peter J.] AstraZeneca R&D, Molndal, Sweden	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, Inst Drug Res, Fac Med, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il; leker@hadassah.org.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-9789]; Brettler Center for Research in Molecular Pharmacology and Therapeutics; HU School of Pharmacy; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; Sol Irwin Juni Trust; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER	This study was supported by NIH Grant No. DA-9789, a grant from the Brettler Center for Research in Molecular Pharmacology and Therapeutics, the HU School of Pharmacy, The Peritz and Chantal Scheinberg Cerebrovascular Research Fund, and the Sol Irwin Juni Trust Fund. ES is the incumbent of the Dr Leon and Mina Deutch Chair in Psychopharmacology at the Hebrew University.	Barna I, 2009, EUR NEUROPSYCHOPHARM, V19, P533, DOI 10.1016/j.euroneuro.2009.02.001; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XQ, 2005, J NEUROSCI RES, V79, P798, DOI 10.1002/jnr.20396; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Cudaback E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008702; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Fride E, 2005, NEUROPHARMACOLOGY, V48, P1117, DOI 10.1016/j.neuropharm.2005.01.023; Godlewski G, 2009, J PHARMACOL EXP THER, V328, P351, DOI 10.1124/jpet.108.144717; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; GOMEZ DP, 2000, BIOCHEM J, V347, P369; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Hayakawa K, 2007, J NEUROCHEM, V102, P1488, DOI 10.1111/j.1471-4159.2007.04565.x; Imlach WL, 2008, J PHARMACOL EXP THER, V327, P657, DOI 10.1124/jpet.108.143933; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Moranta D, 2007, J NEUROSCI RES, V85, P656, DOI 10.1002/jnr.21140; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Ozaita A, 2007, J NEUROCHEM, V102, P1105, DOI 10.1111/j.1471-4159.2007.04642.x; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang X, 2010, BRIT J PHARMACOL, V160, P1583, DOI 10.1111/j.1476-5381.2010.00841.x; Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893-04.2004	42	43	45	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2011	31	8					1768	1777		10.1038/jcbfm.2011.53			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	800EH	WOS:000293342100014	21505478	Bronze, Green Published			2021-06-18	
J	King, MD; McCracken, DJ; Wade, FM; Meiler, SE; Alleyne, CH; Dhandapani, KM				King, Melanie D.; McCracken, D. Jay; Wade, F. Marlene; Meiler, Steffen E.; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.			Attenuation of hematoma size and neurological injury with curcumin following intracerebral hemorrhage in mice	JOURNAL OF NEUROSURGERY			English	Article						hemorrhagic stroke; vasogenic edema; blood-brain barrier; hematoma; mouse; vascular disorders	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-BETA; BARRIER BREAKDOWN; VASOGENIC EDEMA; TRIAL; INTERLEUKIN-1-BETA; INFLAMMATION; ACTIVATION	Object. Intracerebral hemorrhage (ICH) is associated with significant morbidity and mortality. Acute hematoma enlargement is an important predictor of neurological injury and poor clinical prognosis; but neurosurgical clot evacuation may not be feasible in all patients and treatment options remain largely supportive. Thus, novel therapeutic approaches to promote hematoma resolution are needed. In the present study, the authors investigated whether the curry spice curcumin limited neurovascular injury following ICH in mice. Methods. Intracerebral hemorrhage was induced in adult male CD-1 mice by intracerebral administration of collagenase or autologous blood. Clinically relevant doses of curcumin (75-300 mg/kg) were administered up to 6 hours after ICH, and hematoma volume, inflammatory gene expression, blood-brain barrier permeability, and brain edema were assessed over the first 72 hours. Neurological assessments were performed to correlate neurovascular protection with functional outcomes. Results. Curcumin increased hematoma resolution at 72 hours post-ICH. This effect was associated with a significant reduction in the expression of the proinflammatory mediators, tumor necrosis factor a, interleukin-6, and interleukin-1 beta. Curcumin also reduced disruption of the blood-brain barrier and attenuated the formation of vasogenic edema following ICH. Consistent with the reduction in neuroinfiammation and neurovascular injury, curcumin significantly improved neurological outcome scores after ICH. Conclusions. Curcumin promoted hematoma resolution and limited neurological injury following ICH. These data may indicate clinical utility for curcumin as an adjunct therapy to reduce brain injury and improve patient outcome. (DOI: 10.3171/2011.2.JNS10784)	[King, Melanie D.; McCracken, D. Jay; Alleyne, Cargill H., Jr.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA 30809 USA; [Wade, F. Marlene; Meiler, Steffen E.] Georgia Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Augusta, GA 30809 USA	Dhandapani, KM (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, 1120 15th St, Augusta, GA 30809 USA.	kdhandapani@mcg.edu		McCracken, D. Jay/0000-0001-6305-707X; Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135]; Alpha Omega Alpha Carolyn L. Kuckein Research Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institutes of Health (no. NS065172) and American Heart Association (no. BGIA2300135) to Dr. Dhandapani, and by an Alpha Omega Alpha Carolyn L. Kuckein Research Fellowship to Mr. McCracken.	Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; BALLA G, 1992, J BIOL CHEM, V267, P18148; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Christoforidis GA, 2007, STROKE, V38, P1799, DOI 10.1161/STROKEAHA.106.472282; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x; Dhandapani KM, 2007, J NEUROSCI RES, V85, P1033, DOI 10.1002/jnr.21182; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Didier N, 2003, J NEUROCHEM, V86, P246, DOI 10.1046/j.1471-4159.2003.01829.x; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; FEWEL ME, 2003, NEUROSURG FOCUS, V15, pE1, DOI DOI 10.3171/F0C.2003.15.4.0; Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; Hua Y, 2006, NEUROSURGERY, V58, P542, DOI 10.1227/01.NEU.0000197333.55473.AD; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; Labovitz DL, 2001, CURR OPIN NEUROL, V14, P103, DOI 10.1097/00019052-200102000-00016; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Lu AG, 2006, J CEREBR BLOOD F MET, V26, P230, DOI 10.1038/sj.jcbfm.9600183; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Mendelow AD, 2003, ACT NEUR S, V86, P441; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Rynkowski MA, 2008, NAT PROTOC, V3, P122, DOI 10.1038/nprot.2007.513; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Wagner KR, 2006, ACTA NEUROCHIR SUPPL, V96, P177; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; WRIGHT JL, 1994, J NEURO-ONCOL, V20, P17, DOI 10.1007/BF01057957; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Zhao XR, 2007, J NEUROCHEM, V101, P652, DOI 10.1111/j.1471-4159.2006.04414.x	48	43	49	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2011	115	1					116	123		10.3171/2011.2.JNS10784			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	782JO	WOS:000292004700025	21417704	Green Accepted			2021-06-18	
J	Tsaousides, T; Cantor, JB; Gordon, WA				Tsaousides, Theodore; Cantor, Joshua B.; Gordon, Wayne A.			Suicidal Ideation Following Traumatic Brain Injury: Prevalence Rates and Correlates in Adults Living in the Community	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emotional distress; psychiatric functioning; psychosocial functioning; traumatic brain injury; suicidal ideation	QUALITY-OF-LIFE; STRUCTURED CLINICAL INTERVIEW; DSM-III-R; PROTECTIVE FACTORS; MAJOR DEPRESSION; PARTICIPATION; INDIVIDUALS; REHABILITATION; EMPLOYMENT; DISORDERS	Objective: To explore the rates of suicidal ideation (SI) in a sample of community-dwelling adults with traumatic brain injury (TBI) and to assess the relationship between SI and demographic and injury characteristics, pre- and postinjury psychiatric history, and psychosocial functioning. Participants: Data were collected from a cohort study focused on health, psychosocial functioning, and community integration post-TBI (N = 356). Participants were individuals with mild to severe TBI living in the community. Measures: The Beck Depression Inventory II (BDI-II) was used to assess SI. Psychiatric functioning was assessed using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) Axis I disorders (SCID-I), and psychosocial functioning was assessed using the Life-3, the Flanagan Scale of Unmet Needs, and the Bigelow Quality of Life Questionnaire. Results: There were no differences in SI endorsement based on gender, age, race, income, education, injury severity, or length of time since injury. Those whomet current criteria for a psychiatric diagnosis of depression, anxiety, or posttraumatic stress disorder reported SI more frequently. Those with SI reported significantly lower psychosocial functioning. Conclusion: Individuals with TBI from all demographic groups and with injuries of varying severity are at risk for SI and thus for emotional distress and suicidal behavior. Screening for SI is indicated in all individuals with TBI, particularly those with a history of premorbid substance misuse and concurrent mood and anxiety disorders. The importance of interventions to maximize social support and reduce social isolation is discussed.	[Tsaousides, Theodore; Cantor, Joshua B.; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Tsaousides, T (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.	theodore.tsaousides@mountsinai.org			National Institute on Disability and Rehabilitation Research [H133P050004, H133B040033, H133A070033]; US Department of EducationUS Department of Education; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	This project was funded by grants H133P050004, H133B040033, and H133A070033 from the National Institute on Disability and Rehabilitation Research, US Department of Education and grant 1R49CE001171-01 from the Centers for Disease Control and Prevention. The authors would like to extend their gratitude to Lisa Spielman, who aided in the design and analysis and to Vladimira Varbanova for her contribution in the preparation of the manuscript.	Andrews F. M., 1976, SOCIAL INDICATORS WE; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; BIGELOW DA, 1991, COMMUNITY MENT HLT J, V27, P43, DOI 10.1007/BF00752714; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; Booth BM, 1998, J PSYCHIAT RES, V32, P353, DOI 10.1016/S0022-3956(98)00031-4; Bowman ES, 2000, B MENNINGER CLIN, V64, P164; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bulinski L, 2010, MED SCI MONITOR, V16, pPH14; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Fach M, 2007, GEN HOSP PSYCHIAT, V29, P257, DOI 10.1016/j.genhosppsych.2007.01.016; First M., 1997, USERS GUIDE STRUCTUR; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hirsch JK, 2009, CRISIS, V30, P48, DOI 10.1027/0227-5910.30.1.48; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Kishi Y, 2001, J NERV MENT DIS, V189, P623, DOI 10.1097/00005053-200109000-00009; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEMAIRE CM, 2010, J AFFECT DISORDERS, V30, P231; Marty MA, 2010, AGING MENT HEALTH, V14, P1015, DOI 10.1080/13607863.2010.501068; Marzuk PM, 2005, ACTA PSYCHIAT SCAND, V112, P294, DOI 10.1111/j.1600-0447.2005.00585.x; Mascialino G, 2009, NEUROREHABILITATION, V24, P29, DOI 10.3233/NRE-2009-0451; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; Moscicki EK, 2001, CLIN NEUROSCI RES, V1, P310, DOI 10.1016/S1566-2772(01)00032-9; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SEGAL DL, 1994, COMPR PSYCHIAT, V35, P316, DOI 10.1016/0010-440X(94)90025-6; SHER L, 2010, QJM, V104, P455; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Simpson GK, 2007, MED J AUSTRALIA, V187, P229, DOI 10.5694/j.1326-5377.2007.tb01206.x; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013	56	43	44	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					265	275		10.1097/HTR.0b013e3182225271			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700004	21734510				2021-06-18	
J	Arun, P; Spadaro, J; John, J; Gharavi, RB; Bentley, TB; Nambiar, MP				Arun, Peethambaran; Spadaro, John; John, Jennifer; Gharavi, Robert B.; Bentley, Timothy B.; Nambiar, Madhusoodana P.			Studies on blast traumatic brain injury using in-vitro model with shock tube	NEUROREPORT			English	Article						biochemical analysis; blast injury; cellular effects; cellular injury; in-vitro model; neurobiological effects; neuropathology; shock tube; traumatic brain injury	ADULT-RAT BRAIN; LASTING IMPULSE NOISE; CYCLOPHILIN-A; INTRACRANIAL-PRESSURE; INDUCED NEUROTRAUMA; COGNITIVE FUNCTION; CELL-CULTURES; EXPOSURE; OVERPRESSURE; EXPRESSION	One of the major limitations in studying the mechanisms of blast-induced traumatic brain injury (bTBI) or screening therapeutics for protection is the lack of suitable laboratory model systems that can closely mimic the complex blast exposure. Although animal models of bTBI that use shock tubes to mimic blast exposure are available, no high throughput shock tube-based in-vitro models have been reported. Here, we report an in-vitro bTBI model using a compressed air-driven shock tube and mouse neuroblastoma/rat glioblastoma hybrid cells (NG108-15) or SH-SY5Y human neuroblastoma cells in tissue culture plates. Our data showed significant neurobiological effects with decreased adenosine triphosphate levels, increased cellular injury, lactate dehydrogenase release, and reactive oxygen species formation after blast exposure. NeuroReport 22:379-384 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.	[Arun, Peethambaran; Spadaro, John; John, Jennifer; Gharavi, Robert B.; Bentley, Timothy B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA	Nambiar, MP (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA.	Madhusoodana.nambiar@us.army.mil					Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Guy R J, 2000, J R Nav Med Serv, V86, P27; Kim SH, 2004, AM J PATHOL, V164, P1567, DOI 10.1016/S0002-9440(10)63715-7; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Monnet-Tschudi F, 2007, HUM EXP TOXICOL, V26, P339, DOI 10.1177/0960327107074589; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Seko Y, 2004, BIOCHEM BIOPH RES CO, V317, P162, DOI 10.1016/j.bbrc.2004.03.021; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Sinha R, 2010, CANCER EPIDEM BIOMAR, V19, P2332, DOI 10.1158/1055-9965.EPI-10-0253; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; VandeVord PJ, 2008, NEUROSCI LETT, V434, P247, DOI 10.1016/j.neulet.2008.01.056; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Yang H, 2005, J SURG RES, V123, P312, DOI 10.1016/j.jss.2004.08.026	25	43	43	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	JUN 11	2011	22	8					379	384		10.1097/WNR.0b013e328346b138			6	Neurosciences	Neurosciences & Neurology	756SY	WOS:000290036200004	21532394				2021-06-18	
J	Ryan, ML; Ogilvie, MP; Pereira, BMT; Gomez-Rodriguez, JC; Manning, RJ; Vargas, PA; Duncan, RC; Proctor, KG				Ryan, Mark L.; Ogilvie, Michael P.; Pereira, Bruno M. T.; Gomez-Rodriguez, Juan Carlos; Manning, Ronald J.; Vargas, Paola A.; Duncan, Robert C.; Proctor, Kenneth G.			Heart Rate Variability Is an Independent Predictor of Morbidity and Mortality in Hemodynamically Stable Trauma Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma		ECG; Traumatic brain injury; Computed axial tomography; Heart rate variability	ACUTE MYOCARDIAL-INFARCTION; BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PERIOD VARIABILITY; INTRACRANIAL HYPERTENSION; SYSTEMS; TRIAGE; DEATH; CT; PRESSURE	Background: Reduced heart rate variability (HRV) reflects autonomic dysfunction and can triage patients better than routine trauma criteria or vital signs. However, there is questionable specificity and no consensus measurement technique. The purpose of this study was to analyze whether factors that alter autonomic function affect the specificity of HRV for assessing traumatic injury. Methods: We evaluated 216 hemodynamically stable adults (3:1 M: F; 97:3 blunt: penetrating; age 49 years +/- 1 year, mean +/- standard error) undergoing computed axial tomography (CT) scan to rule out traumatic brain injury (TBI). All were prospectively instrumented with a Mars Holter system (GE Healthcare, Milwaukee, WI). HRV was determined offline using time domain (standard deviation of normal-normal intervals, root-mean-square successive difference) and frequency domain (very low frequency [VLF], LF, wideband frequency, high frequency [HF], low to HF index ratio) calculations from 15-minute electrocardiogram and correlated with routine vital signs, mortality, TBI, morbidity, length of stay (LOS), and comorbidities. Significance (p <= 0.05) was determined using nonparametric analysis, Student's t test, analysis of variance, or multiple logistic regression. Results: VLF alone predicted survival, severity of TBI, intensive care unit LOS, and hospital LOS (all p < 0.05). Beta-blockers or diabetes had no effect, whereas age, sedation, mechanical ventilation, spinal cord injury, and intoxication influenced one or more of the variables with age being the most powerful confounder (all p < 0.05). Except for the Glasgow Coma Scale, no other routine trauma or hemodynamic criteria correlated with any of these outcomes. Conclusions: Decreased VLF is an independent predictor of mortality and morbidity in hemodynamically stable trauma patients. Other time and other frequency domain variables correlated with some, but not all, outcomes. All were heavily influenced by factors that alter autonomic function, especially patient age.	[Proctor, Kenneth G.] Univ Miami, Miller Sch Med, Div Trauma, Dewitt Daughtry Family Dept Surg,Ryder Trauma Ctr, Miami, FL 33136 USA; [Duncan, Robert C.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Miller Sch Med, Div Trauma, Dewitt Daughtry Family Dept Surg,Ryder Trauma Ctr, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Pereira, Bruno M/D-4542-2015	Pereira, Bruno M/0000-0003-3763-1749			Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Batchinsky AI, 2007, CRIT CARE MED, V35, P519, DOI 10.1097/01.CCM.0000254065.44990.77; Batchinsky AI, 2010, J TRAUMA, V68, P1178, DOI 10.1097/TA.0b013e3181bb98a6; Batchinsky AI, 2009, SHOCK, V32, P565, DOI 10.1097/SHK.0b013e3181a993dc; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; BIGGER JT, 1993, CIRCULATION, V88, P927, DOI 10.1161/01.CIR.88.3.927; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; Cooke WH, 2006, AVIAT SPACE ENVIR MD, V77, P1107; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Fathizadeh P, 2004, CRIT CARE MED, V32, P1300, DOI 10.1097/01.CCM.0000127776.78490.E4; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grogan EL, 2005, J TRAUMA, V58, P7, DOI 10.1097/01.TA.0000151179.74839.98; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; Hon E. H., 1965, AM J OBSTET GYNECOL, V87, P814; Huikuri HV, 2009, EUR HEART J, V30, P689, DOI 10.1093/eurheartj/ehn537; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kasaoka S, 2010, J CRIT CARE, V25, P313, DOI 10.1016/j.jcrc.2009.06.047; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King DR, 2009, J TRAUMA, V67, P436, DOI 10.1097/TA.0b013e3181ad67de; LOWENSOHN RI, 1977, LANCET, V1, P626; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Morris JA, 2007, J AM COLL SURGEONS, V204, P885, DOI 10.1016/j.jamcollsurg.2007.01.019; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Novak V, 1997, CIRCULATION, V96, P1056; Perkiomaki JS, 2010, ANN NONINVAS ELECTRO, V15, P250, DOI 10.1111/j.1542-474X.2010.00372.x; Proctor KG, 2007, J TRAUMA, V63, P33, DOI 10.1097/01.ta.0000251593.32396.df; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; Rickards CA, 2010, CRIT CARE MED, V38, P1666, DOI 10.1097/CCM.0b013e3181e74cab; Ryan KL, 2010, SHOCK, V33, P583, DOI 10.1097/SHK.0b013e3181cd8cbe; Seely AJE, 2004, CRIT CARE, V8, pR367, DOI 10.1186/cc2948; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Signorini M G, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P3431; Sing RF, 2006, J TRAUMA, V60, P499; Takabatake N, 2001, AM J RESP CRIT CARE, V163, P1314, DOI 10.1164/ajrccm.163.6.2004175; Taylor JA, 1998, CIRCULATION, V98, P547, DOI 10.1161/01.CIR.98.6.547; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; Werdan K, 2009, CAN J PHYSIOL PHARM, V87, P266, DOI 10.1139/Y09-012; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	44	43	45	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2011	70	6					1371	1380		10.1097/TA.0b013e31821858e6			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	775QR	WOS:000291478500019	21817974				2021-06-18	
J	Goforth, PB; Ren, JH; Schwartz, BS; Satin, LS				Goforth, Paulette B.; Ren, Jianhua; Schwartz, Benjamin S.; Satin, Leslie S.			Excitatory synaptic transmission and network activity are depressed following mechanical injury in cortical neurons	JOURNAL OF NEUROPHYSIOLOGY			English	Article						traumatic brain injury; alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors; N-methyl-D-aspartate; oscillations	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; CA2+-PERMEABLE AMPA RECEPTORS; FLUID PERCUSSION INJURY; IMPROVES FUNCTIONAL RECOVERY; STRETCH-INDUCED ENHANCEMENT; D-ASPARTATE RECEPTORS; V PYRAMIDAL NEURONS; CLOSED-HEAD INJURY; IN-VITRO	Goforth PB, Ren J, Schwartz BS, Satin LS. Excitatory synaptic transmission and network activity are depressed following mechanical injury in cortical neurons. J Neurophysiol 105: 2350-2363, 2011. First published February 23, 2011; doi:10.1152/jn.00467.2010.-In vitro and in vivo traumatic brain injury (TBI) alter the function and expression of glutamate receptors, yet the combined effect of these alterations on cortical excitatory synaptic transmission is unclear. We examined the effect of in vitro mechanical injury on excitatory synaptic function in cultured cortical neurons by assaying synaptically driven intracellular free calcium ([ Ca(2+)](i)) oscillations in small neuronal networks as well as spontaneous and miniature excitatory postsynaptic currents (mEPSCs). We show that injury decreased the incidence and frequency of spontaneous neuronal [Ca(2+)](i) oscillations for at least 2 days post-injury. The amplitude of the oscillations was reduced immediately and 2 days post-injury, although a transient rebound at 4 h post-injury was observed due to increased activity of N-methyl-D-aspartate (NMDARs) and calcium-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (CP-AMPARs). Increased CP-AMPAR function was abolished by the inhibition of protein synthesis. In parallel, mEPSC amplitude decreased immediately, 4 h, and 2 days post-injury, with a transient increase in the contribution of synaptic CP-AMPARs observed at 4 h post-injury. Decreased mEPSC amplitude was evident after injury, even if NMDARs and CP-AMPARs were blocked pharmacologically, suggesting the decrease reflected alterations in synaptic Glur2-containing, calcium-impermeable AMPARs. Despite the transient increase in CP-AMPAR activity that we observed, the overriding effect of mechanical injury was long-term depression of excitatory neurotransmission that would be expected to contribute to the cognitive deficits of TBI.	[Satin, Leslie S.] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48105 USA	Satin, LS (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1000 Wall St, Ann Arbor, MI 48105 USA.	lsatin@umich.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS49519]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049519] Funding Source: NIH RePORTER	This work was supported by RO1 NS49519 from the National Institutes of Health (to L. Satin).	Ashman TA, 2006, MT SINAI J MED, V73, P999; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Calderone A, 2003, J NEUROSCI, V23, P2112; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; Cull-Candy Stuart G, 2004, Sci STKE, V2004, pre16, DOI 10.1126/stke.2552004re16; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Golarai G, 2001, J NEUROSCI, V21, P8523; Grosskreutz J, 2003, EUR J NEUROSCI, V17, P1173, DOI 10.1046/j.1460-9568.2003.02531.x; Guire ES, 2008, J NEUROSCI, V28, P6000, DOI 10.1523/JNEUROSCI.0384-08.2008; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Jones TL, 2004, J PHARMACOL EXP THER, V310, P223, DOI 10.1124/jpet.103.064741; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Koike M, 1997, NEUROSCI RES, V29, P27, DOI 10.1016/S0168-0102(97)00067-9; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lea PM, 2003, J NEUROTRAUM, V20, P1233, DOI 10.1089/089771503770802907; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Li G, 2003, BIOCHEMISTRY-US, V42, P12358, DOI 10.1021/bi0347961; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MURPHY TH, 1992, J NEUROSCI, V12, P4834; Nakanishi K, 1998, BRAIN RES, V795, P137, DOI 10.1016/S0006-8993(98)00283-2; Oh MC, 2005, NAT NEUROSCI, V8, P853, DOI 10.1038/nn1476; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBINSON HPC, 1993, J NEUROPHYSIOL, V70, P1606; Rogawski M A, 1999, Adv Neurol, V79, P947; Salin P, 1995, J NEUROSCI, V15, P8234; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santos SD, 2009, NEUROSCIENCE, V158, P105, DOI 10.1016/j.neuroscience.2008.02.037; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Seidenman KJ, 2003, J NEUROSCI, V23, P9220; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; Swanson GT, 1997, J NEUROSCI, V17, P58; Takazawa A, 1996, BRAIN RES, V706, P173, DOI 10.1016/0006-8993(95)01334-2; Terashima A, 2008, NEURON, V57, P872, DOI 10.1016/j.neuron.2008.01.028; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Vikman KS, 2008, J PHYSIOL-LONDON, V586, P515, DOI 10.1113/jphysiol.2007.145581; Wang XS, 1997, BRAIN RES, V767, P239, DOI 10.1016/S0006-8993(97)00585-4; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	72	43	43	0	11	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	MAY	2011	105	5					2350	2363		10.1152/jn.00467.2010			14	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	765MF	WOS:000290710300036	21346214	Green Published			2021-06-18	
J	Stein, DM; Lindell, A; Murdock, KR; Kufera, JA; Menaker, J; Keledjian, K; Bochicchio, GV; Aarabi, B; Scalea, TM				Stein, Deborah M.; Lindell, Allison; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Keledjian, Kaspar; Bochicchio, Grant V.; Aarabi, Bizhan; Scalea, Thomas M.			Relationship of Serum and Cerebrospinal Fluid Biomarkers With Intracranial Hypertension and Cerebral Hypoperfusion After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Biomarkers; Neuroinflammation; Intracranial hypertension; Cerebral hypoperfusion	TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; FRACTURE FIXATION; SECONDARY INSULTS; PROGNOSTIC VALUE; CARDIAC-ARREST; TNF-ALPHA; PRESSURE; PLASMA; INTERLEUKIN-8	Background: There is little that can be done to treat or reverse the primary injury that occurs at the time of a traumatic brain injury (TBI). Initial management of the patient with severe TBI focuses on prevention of subsequent secondary insults, namely, intracranial hypertension (ICH) and cerebral hypoperfusion (CH). Currently, there is no reliable way to predict which patients will develop ICH and CH other than clinical acumen; therefore, indicators of impending secondary intracranial insults may be useful in predicting these events and allowing for prevention and early intervention. This study was undertaken to investigate the relationship of cytokine levels with intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in patients with severe TBI. Methods: Patients at the R Adams Cowley Shock Trauma Center were prospectively enrolled for a 6-month period. Inclusion criteria were older than 17 years, admission within the first 6 hours after injury, Glasgow Coma Scale <9 on admission, and placement of a clinically indicated ICP monitor. Serum and cerebrospinal fluid, when available, were collected on admission and twice daily for 7 days. Cytokine levels of interleukin (IL)-1 beta, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-alpha were analyzed by multiplex bead array assays. Hourly values for ICP and CPP were recorded, and means, minimum (for CPP) or maximum (for ICP) values, percentage time ICP >20 mm Hg (% ICP20) and CPP <60 mm Hg (% CPP60), and cumulative Pressure Times Time Dose (PTD; mm Hg . h) for ICP >20 mm Hg (PTD ICP20) and CPP <60 mm Hg (PTD CPP60) were compared with the serum and cerebrospinal fluid levels that were drawn before 12-hour time periods (PRE) and after 12-hour time periods (POST) of monitoring. Results: Twenty-four patients were enrolled. In-hospital mortality was 12.5%, and good functional outcome was noted in 58%. Two hundred and seventy-five serum samples were taken and analyzed. IL-6 levels in the serum were found in the highest concentration of the cytokines measured. PTD ICP20 and PTD CPP60 were moderately correlated with increased PRE IL-8 levels (r = 0.34, p < 0.001; r = 0.53, p < 0.001). PTD ICP20 was also correlated with PRE TNF-alpha levels (r = 0.27, p < 0.001) as was PTD CPP60 (r = 0.25, p < 0.001). POST IL-8 levels were found to be correlated with PTD ICP20 (r = 0.46, p < 0.001) and PTD CPP60 (r = 0.54, p < 0.001). POST TNF-alpha was associated with PTD ICP20 (r = 0.45, p < 0.001). PTD CPP60 was also moderately correlated with POST TNF-alpha levels (r = 0.26, p < 0.001). When comparing patients with good versus poor outcome, median daily serum IL-8 levels were associated with poor outcome. Conclusions: IL-8 and, to a lesser extent, TNF-alpha demonstrated the most promise in this study to be candidate serum markers of impending ICH and CH. The clinical relevance of this is the suggestion that we may be able to predict impending secondary insults after TBI before the clinical manifestation of these events. Given the known morbidity of ICH and CH, early intervention and prevention may have a significant impact on outcome. This becomes even more important when decisions must be made about timing of interventions. Increased levels of IL-8 and TNF-alpha in the serum during episodes of ICH and CH imply there are significant systemic effects of these events. These serum biomarkers are promising as diagnostic targets. In addition, further study of the precise role of these molecules may have significant implications for inflammatory system manipulation in the management of severe TBI.	[Stein, Deborah M.] Univ Maryland, Div Crit Care, Program Trauma, R Adams Cowley Shock Trauma Ctr,Med Ctr,Sch Med, Baltimore, MD 21201 USA; [Stein, Deborah M.; Lindell, Allison; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Keledjian, Kaspar; Bochicchio, Grant V.; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Div Crit Care, Program Trauma, R Adams Cowley Shock Trauma Ctr,Med Ctr,Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963	US ArmyUnited States Department of Defense [W81XWH-07-2-0118]	Supported by W81XWH-07-2-0118, US Army.	Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; CHIARETTI A, 2005, CHILD NERV SYST, V32, P194; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FaberElman A, 1995, FASEB J, V9, P1605; FAN L, 1995, MOL BRAIN RES, V30, P125; Flierl MA, 2010, J ORTHOP TRAUMA, V24, P107, DOI 10.1097/BOT.0b013e3181b6bdfc; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Jawa Randeep S, 2006, J Intensive Care Med, V21, P63, DOI 10.1177/0885066605284325; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; KENNEDY CS, 2004, CLIN PEDIAT EMERG ME, V5, P224; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KRAUS JF, 1996, NEUROTRAUMA, P13; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOTZ M, 1993, CANCER INVEST, V11, P732, DOI 10.3109/07357909309046948; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; Scalea TM, 2008, J TRAUMA, V65, P253, DOI 10.1097/TA.0b013e31817fa475; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; TCHELINGERIAN JL, 1995, J NEUROCHEM, V65, P2377; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	69	43	44	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2011	70	5					1096	1103		10.1097/TA.0b013e318216930d			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	762LQ	WOS:000290480300028	21610426				2021-06-18	
J	Vas, AK; Chapman, SB; Cook, LG; Elliott, AC; Keebler, M				Vas, Asha K.; Chapman, Sandra B.; Cook, Lori G.; Elliott, Alan C.; Keebler, Molly			Higher-Order Reasoning Training Years After Traumatic Brain Injury in Adults	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adults; cognitive training; executive function; frontal lobe function; gist; reasoning; traumatic brain injury rehabilitation	COMMUNITY INTEGRATION QUESTIONNAIRE; FUNCTIONAL STATUS EXAMINATION; GLASGOW OUTCOME SCALE; CLOSED-HEAD-INJURY; FUZZY-TRACE THEORY; OF-THE-LITERATURE; COGNITIVE REHABILITATION; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; POSTTRAUMATIC AMNESIA	Objective: To conduct a feasibility study to compare the effects of top-down Strategic Memory and Reasoning Training (SMART) versus information-based Brain Health Workshop (BHW, control) on gist-reasoning (ie, abstracting novel meaning from complex information), memory, executive functions, and daily function in adults with traumatic brain injury. Participants: Twenty-eight participants (of the 35 recruited), 16 men & 12 women, aged 20 to 65 years (M = 43, SD = 11.34) at chronic stages posttraumatic brain injury (2 years or longer) completed the training. Fourteen participants that received SMART and 14 participants that completed BHW were assessed both pre- and posttraining. Thirteen of the SMART trained and 11 from BHW participated in a 6-month testing. Design: The study was a single blinded randomized control trial. Participants in both groups received a minimum of 15 hours of training over 8 weeks. Results: The SMART group significantly improved gist-reasoning as compared to the BHW group. Benefits of the SMART extended to untrained measures of working memory and participation in functional activities. Exploratory analyses suggested potential transfer effects of SMART on memory and executive functions. The benefits of the SMART program as compared to BHW were evident at immediately posttraining and 6 months posttraining. Conclusion: This study provides preliminary evidence that short-term intensive training in top-down modulation of information benefits gist-reasoning and generalizes to measures of executive function and real life function at chronic stages of post-TBI.	[Vas, Asha K.; Chapman, Sandra B.; Cook, Lori G.; Elliott, Alan C.; Keebler, Molly] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75235 USA	Chapman, SB (corresponding author), Univ Texas Dallas, Ctr BrainHlth, 2200 W Mockingbird Lane, Dallas, TX 75235 USA.	schapman@utdallas.edu			Dallas Foundation; Wood-Hayner-Yates TBI Research Fund; Julie and Ed Hawes, and the Dee Wyly Research fund	The authors thank the participants and their families for their interest and enthusiasm in taking part in the study. This research was supported by the Prothro-McDermott fund of the Dallas Foundation, Wood-Hayner-Yates TBI Research Fund, Julie and Ed Hawes, and the Dee Wyly Research fund. The authors also thank Kamini Krishnan, Michelle Kandalaft, and Nyaz Didehbani for their help with the assessments.	Adams C, 1997, J GERONTOL B-PSYCHOL, V52, pP187, DOI 10.1093/geronb/52B.4.P187; Ahmed S, 2000, BRAIN INJURY, V14, P765; Anand R, 2009, PERS NEUROPHYSIOL NE, V19, P117; Anand R, 2010, INT J GERIATR PSYCH, V25, P1; Beck A.T., 1996, MANUAL BECK DEPRESSI; Benton A., 1976, MULTILINGUAL APHASIA; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; Binder D, 2008, BRAIN HLTH WORKSH TO; Brainerd CJ, 2002, CURR DIR PSYCHOL SCI, V11, P164, DOI 10.1111/1467-8721.00192; BROWN JI, 1993, NELSONDENNY READING; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2002, ALZ DIS ASSOC DIS, V16, P177, DOI 10.1097/00002093-200207000-00008; Chapman SB, 1998, APHASIOLOGY, V12, P1081, DOI 10.1080/02687039808249473; Chapman SB, ADOLESCENT IN PRESS; Chapman SB, 1999, INT J SPEECH-LANG PA, V1, P19; Chapman SB., 2006, BRAIN IMPAIR, V7, P223, DOI [10.1375/brim.7.3.223, DOI 10.1375/BRIM.7.3.223]; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cook LG, 2007, CHILDRENS COMPREHENS, P218; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Delis DC, 2001, DELISKAPLAN EXECUTIV; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DZurilla T. J., 1982, ADV COGNITIVE BEHAV, V1, P201, DOI DOI 10.1016/B978-0-12-010601-1.50010-3; Fisk GD, 1998, BRAIN INJURY, V12, P683; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gabrieli John D E, 2004, Cerebrum, V6, P39; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gamino JF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00188; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Gamino JF, 2009, ADV ADHD, V3, P82; Gazzaley A, 2005, J COGNITIVE NEUROSCI, V17, P507, DOI 10.1162/0898929053279522; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JOANETTE Y, 1983, BRAIN LANG, V20, P217, DOI 10.1016/0093-934X(83)90043-3; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; Nichelli P, 1995, NEUROREPORT, V6, P2309, DOI 10.1097/00001756-199511270-00010; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Novakovic-Agopian T, 2010, J HEAD TRAUMA REHAB, V24, P436; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Plante E., 2006, LEARN DISABIL RES PR, V21, P61, DOI DOI 10.1111/J.1540-5826.2006.00207.X; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; REYNA VF, 1995, LEARN INDIVID DIFFER, V7, P1, DOI 10.1016/1041-6080(95)90031-4; Robertson DA, 2000, PSYCHOL SCI, V11, P255, DOI 10.1111/1467-9280.00251; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Schwartz DL, 1998, COGNITION INSTRUCT, V16, P475, DOI 10.1207/s1532690xci1604_4; Shores E A, 1995, Appl Neuropsychol, V2, P167; Simon D, 2001, REHABIL PSYCHOL, V46, P330; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; St George M, 1999, BRAIN, V122, P1317, DOI 10.1093/brain/122.7.1317; Stemmer B, 1999, BRAIN LANG, V68, P402, DOI 10.1006/brln.1999.2120; Stern L, 2009, VISUAL APPROACH SPSS; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Ulatowska HK, 1998, APHASIOLOGY, V12, P619, DOI 10.1080/02687039808249562; Uttl B, 2002, J CLIN EXP NEUROPSYC, V24, P1123, DOI 10.1076/jcen.24.8.1123.8375; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vas AK, 2010, BRAIN S CTR BRAINHEA; Von Cramon DY, 1992, NEUROPSYCHOL REHABIL, P203; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6	85	43	43	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2011	26	3					224	239		10.1097/HTR.0b013e318218dd3d			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	760CY	WOS:000290301800006	21552071				2021-06-18	
J	Sargin, D; El-Kordi, A; Agarwal, A; Muller, M; Wojcik, SM; Hassouna, I; Sperling, S; Nave, KA; Ehrenreich, H				Sargin, Derya; El-Kordi, Ahmed; Agarwal, Amit; Mueller, Michael; Wojcik, Sonja M.; Hassouna, Imam; Sperling, Swetlana; Nave, Klaus-Armin; Ehrenreich, Hannelore			Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice	BMC BIOLOGY			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; REACTION-TIME-TASK; PREFRONTAL CORTEX; TRANSGENIC MICE; NERVOUS-SYSTEM; SPREADING DEPRESSION; RAT HIPPOCAMPAL	Background: Erythropoietin (EPO) and its receptor (EPOR) are expressed in the developing brain and their transcription is upregulated in adult neurons and glia upon injury or neurodegeneration. We have shown neuroprotective effects and improved cognition in patients with neuropsychiatric diseases treated with EPO. However, the critical EPO targets in brain are unknown, and separation of direct and indirect effects has remained difficult, given the role of EPO in hematopoiesis and brain oxygen supply. Results: Here we demonstrate that mice with transgenic expression of a constitutively active EPOR isoform (cEPOR) in pyramidal neurons of cortex and hippocampus exhibit enhancement of spatial learning, cognitive flexibility, social memory, and attentional capacities, accompanied by increased impulsivity. Superior cognitive performance is associated with augmented long-term potentiation of cEPOR expressing neurons in hippocampal slices. Conclusions: Active EPOR stimulates neuronal plasticity independent of any hematopoietic effects and in addition to its neuroprotective actions. This property of EPOR signaling should be exploited for defining novel strategies to therapeutically enhance cognitive performance in disease conditions.	[El-Kordi, Ahmed; Mueller, Michael; Nave, Klaus-Armin; Ehrenreich, Hannelore] DFG Res Ctr Mol Physiol Brain CMPB, D-37073 Gottingen, Germany; [Sargin, Derya; El-Kordi, Ahmed; Hassouna, Imam; Sperling, Swetlana; Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Agarwal, Amit; Nave, Klaus-Armin] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; [Mueller, Michael] Univ Gottingen, Dept Neuro & Sensory Physiol, D-37073 Gottingen, Germany; [Wojcik, Sonja M.] Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany	Nave, KA (corresponding author), DFG Res Ctr Mol Physiol Brain CMPB, Humboldtallee 23, D-37073 Gottingen, Germany.	nave@em.mpg.de; ehrenreich@em.mpg.de	Agarwal, Amit/B-7735-2008; Muller, Michael/F-7222-2010	Agarwal, Amit/0000-0001-7948-4498; Ehrenreich, Hannelore/0000-0001-8371-5711; Muller, Michael/0000-0002-5863-1994	Max Planck SocietyMax Planck Society; DFG-Research Center for Molecular Physiology of the Brain (CMBP)German Research Foundation (DFG)	This study was supported by the Max Planck Society and the DFG-Research Center for Molecular Physiology of the Brain (CMBP). The authors thank Prof. Harvey F. Lodish, Cambridge, MA, for kindly providing the cEPOR construct. Belinda Hildebrandt and Anja Ronnenberg are acknowledged for their excellent technical help.	Adamcio B, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-37; Banks WA, 2004, EUR J PHARMACOL, V505, P93, DOI 10.1016/j.ejphar.2004.10.035; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Berridge KC, 2008, PSYCHOPHARMACOLOGY, V199, P457, DOI 10.1007/s00213-008-1099-6; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts N, 2008, CELL DEATH DIFFER, V15, P783, DOI 10.1038/cdd.2008.1; Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041; Chudasama Y, 2003, BEHAV BRAIN RES, V146, P105, DOI 10.1016/j.bbr.2003.09.020; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; Ehrenreich H, 2005, P NATL ACAD SCI USA, V102, P862, DOI 10.1073/pnas.0406008102; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Ehrenreich H, 2008, J RENAL NUTR, V18, P146, DOI 10.1053/j.jrn.2007.10.029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; El-Kordi A, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-37; Hepp S, 2005, J NEUROPHYSIOL, V94, P1091, DOI 10.1152/jn.00291.2005; Humby T, 1999, EUR J NEUROSCI, V11, P2813, DOI 10.1046/j.1460-9568.1999.00701.x; Humby Trevor, 2005, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0805hs31; Jelkmann W, 2005, CURR PHARM BIOTECHNO, V6, P65; JELKMANN W, 1992, PHYSIOL REV, V72, P449; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Kuroda M, 1998, PROG NEUROBIOL, V54, P417, DOI 10.1016/S0301-0082(97)00070-1; Liu C, 1996, P ASSOC AM PHYSICIAN, V108, P449; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; Miskowiak KW, 2009, PSYCHOPHARMACOLOGY, V207, P133, DOI 10.1007/s00213-009-1641-1; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Moucadel V, 2005, J BIOL CHEM, V280, P13364, DOI 10.1074/jbc.M407326200; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; Neubauer AP, 2010, ANN NEUROL, V67, P657, DOI 10.1002/ana.21977; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Rotaru DC, 2005, J COMP NEUROL, V490, P220, DOI 10.1002/cne.20661; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2009, NEUROTHERAPEUTICS, V6, P108, DOI 10.1016/j.nurt.2008.10.041; Sweatt JD, 1999, LEARN MEMORY, V6, P399, DOI 10.1101/lm.6.5.399; Takakusaki K, 2004, NEUROSCI RES, V50, P137, DOI 10.1016/j.neures.2004.06.015; Uylings HBM, 2003, BEHAV BRAIN RES, V146, P3, DOI 10.1016/j.bbr.2003.09.028; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wrenn CC, 2006, PHARMACOL BIOCHEM BE, V83, P428, DOI 10.1016/j.pbb.2006.03.003; Wustenberg T, 2011, MOL PSYCHIATR, V16, P26, DOI 10.1038/mp.2010.51; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	59	43	46	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7007			BMC BIOL	BMC Biol.	APR 28	2011	9								27	10.1186/1741-7007-9-27			16	Biology	Life Sciences & Biomedicine - Other Topics	781KX	WOS:000291932000001	21527022	DOAJ Gold, Green Published			2021-06-18	
J	Tokuda, S; Mahaffey, CL; Monks, B; Faulkner, CR; Birnbaum, MJ; Danzer, SC; Frankel, WN				Tokuda, Satoko; Mahaffey, Connie L.; Monks, Bobby; Faulkner, Christian R.; Birnbaum, Morris J.; Danzer, Steve C.; Frankel, Wayne N.			A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice	HUMAN MOLECULAR GENETICS			English	Article							TRAUMATIC BRAIN-INJURY; LHERMITTE-DUCLOS-DISEASE; INBRED MOUSE STRAINS; GLUCOSE-HOMEOSTASIS; SOMA SIZE; B-GAMMA; EPILEPSY; MODEL; PHOSPHORYLATION; GENE	In a phenotype-driven mutagenesis screen, a novel, dominant mouse mutation, Nmf350, caused low seizure threshold, sporadic tonic-clonic seizures, brain enlargement and ectopic neurons in the dentate hilus and molecular layer of the hippocampus. Genetic mapping implicated Akt3, one of four candidates within the critical interval. Sequencing analysis revealed that mutants have a missense mutation in Akt3 (encoding one of three AKT/protein kinase B molecules), leading to a non-synonymous amino acid substitution in the highly conserved protein kinase domain. Previous knockout studies showed that Akt3 is pivotal in postnatal brain development, including a smaller brain, although seizures were not observed. In contrast to Akt3(Nmf350), we find that Akt3 null mice exhibit an elevated seizure threshold. An in vitro kinase assay revealed that Akt3(Nmf350) confers higher enzymatic activity, suggesting that Akt3(Nmf350) might enhance AKT signaling in the brain. In the dentate gyrus of Akt3(Nmf350) homozygotes, we also observed a modest increase in immunoreactivity of phosphorylated ribosomal protein S6, an AKT pathway downstream target. Together these findings suggest that Akt3(Nmf350) confers an increase of AKT3 activity in specific neuronal populations in the brain, and a unique dominant phenotype. Akt3(Nmf350) mice provide a new tool for studying physiological roles of AKT signaling in the brain, and potentially novel mechanisms for epilepsy.	[Tokuda, Satoko; Mahaffey, Connie L.; Frankel, Wayne N.] Jackson Lab, Bar Harbor, ME 04609 USA; [Monks, Bobby; Birnbaum, Morris J.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA; [Faulkner, Christian R.; Danzer, Steve C.] Cincinnati Childrens Hosp, Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA	Frankel, WN (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	wayne.frankel@jax.org		Birnbaum, Morris/0000-0001-9972-8680	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA034196]; The Jackson Laboratory Neuroscience Mutagenesis Facility (NMF) [U01 NS41215]; Epilepsy Foundation; Jackson Laboratory Postdoctoral Fellowship; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS031348, NS041215, DK56886, NS-065020]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK056886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065020, R01NS031348, U01NS041215] Funding Source: NIH RePORTER	This work was subsidized by a cancer core center grant from the National Cancer Institute (grant CA034196). The initial part of this work was funded as part of The Jackson Laboratory Neuroscience Mutagenesis Facility (NMF), cooperative agreement U01 NS41215. S.T. was supported in part by an Epilepsy Foundation of America Fellowship and in part by a Jackson Laboratory Postdoctoral Fellowship. W.N.F. was funded by grants from the National Institutes of Health (grant numbers NS031348, NS041215). M.J.B. was funded by a grant from the National Institutes of Health (grant number DK56886). S.C.D. was funded by a grant from the National Institutes of Health (grant number NS-065020).	Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Boumil RM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001046; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Buchner DA, 2004, MAMM GENOME, V15, P344, DOI 10.1007/s00335-004-2332-1; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Ferraro TN, 2004, MAMM GENOME, V15, P239, DOI 10.1007/s00335-003-2270-3; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Frankel WN, 2001, GENOMICS, V74, P306, DOI 10.1006/geno.2001.6564; FRANKEL WN, 1994, GENETICS, V138, P481; Gardiner RM, 2000, J NEUROL, V247, P327, DOI 10.1007/s004150050598; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Jablonski MM, 2005, MOL VIS, V11, P569; Keays DA, 2007, CELL, V128, P45, DOI 10.1016/j.cell.2006.12.017; Kenedy AA, 2003, GENE, V303, P35, DOI 10.1016/S0378-1119(02)01141-1; Kermany MH, 2006, HEARING RES, V220, P76, DOI 10.1016/j.heares.2006.07.011; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Ljungberg MC, 2009, DIS MODEL MECH, V2, P389, DOI 10.1242/dmm.002386; Lucarini N, 2007, PEDIATR NEUROL, V37, P157, DOI 10.1016/j.pediatrneurol.2007.06.001; Meikle L, 2007, J NEUROSCI, V27, P5546, DOI 10.1523/JNEUROSCI.5540-06.2007; Neufeld TP, 2003, MECH DEVELOP, V120, P1283, DOI 10.1016/j.mod.2003.07.003; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Okado H, 2009, DEV BIOL, V331, P140, DOI 10.1016/j.ydbio.2009.04.030; Piermartiri TCB, 2009, NEUROTOX RES, V16, P106, DOI 10.1007/s12640-009-9057-6; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yang Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Zeng Ling-Hui, 2009, Mol Cell Pharmacol, V1, P124; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238	41	43	48	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	MAR 1	2011	20	5					988	999		10.1093/hmg/ddq544			12	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	716SJ	WOS:000286993500012	21159799	Green Published, Bronze			2021-06-18	
J	Woodrome, SE; Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M				Woodrome, Stacey E.; Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha			Coping Strategies as a Predictor of Post-concussive Symptoms in Children with Mild Traumatic Brain Injury versus Mild Orthopedic Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Children; Coping; Longitudinal study; Moderator variable; Post-concussive symptoms; Traumatic brain injury	POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; PSYCHOLOGICAL ADJUSTMENT; NEUROBEHAVIORAL SYMPTOMS; STRESS; ADOLESCENTS; CHILDHOOD; COMPLAINTS; MINORITY; VALIDITY	This study examined whether children's coping strategies are related to post-concussive symptoms following mild traumatic brain injury (TBI) versus orthopedic injury (OD. Participants were 8- to 15-year-old children with mild TB! (n = 167) or 01 (n = 84). They rated their current preferred coping strategies and post-injury symptoms at 2 weeks (baseline) and 1, 3, and 12 months post-injury. Children's reported use of coping strategies did not vary significantly over time, so their baseline coping ratings were examined as predictors of post-concussive symptoms across time. Self-ratings of symptoms were positively related to emotion-focused strategies and negatively related to problem-focused engagement after both mild TBI and OI. Higher problem-focused disengagement predicted larger group differences in children's ratings of symptoms, suggesting that problem-focused disengagement moderates the effects of mild TBI. Coping strategies collectively accounted for approximately 10-15% of the variance in children's post-concussive symptoms over time. The findings suggest that coping may play an important role in accounting for children's perceptions of post-concussive symptoms after mild TBI. (JINS, 2011, 17, 317-326)	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Woodrome, Stacey E.] Childrens Healthcare Atlanta, Dept Neuropsychol, Atlanta, GA USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The larger project from which the research was derived was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development to the second author. The authors have no conflicts of interest.	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Armstrong FD., 1993, CHILD HEALTH CARE, V22, P189, DOI [10.1207/s15326888chc2203_2, DOI 10.1207/S15326888CHC2203_2]; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bachanas PJ, 2001, J PEDIATR PSYCHOL, V26, P343, DOI 10.1093/jpepsy/26.6.343; BAND EB, 1988, DEV PSYCHOL, V24, P247, DOI 10.1037/0012-1649.24.2.247; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Campbell LK, 2009, J PEDIATR PSYCHOL, V34, P317, DOI 10.1093/jpepsy/jsn080; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casey R, 2000, REHABIL PSYCHOL, V45, P155, DOI 10.1037/0090-5550.45.2.155; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cauce AM, 1998, STUDYING MINORITY ADOLESCENTS, P147; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Compas BE, 2001, PSYCHOL BULL, V127, P87, DOI 10.1037//0033-2909.127.1.87; COMPAS BE, 1987, PSYCHOL BULL, V101, P393, DOI 10.1037/0033-2909.101.3.393; Compas BE, 2001, J DEV BEHAV PEDIATR, V22, P323, DOI 10.1097/00004703-200110000-00007; Compas BE, 2006, J CONSULT CLIN PSYCH, V74, P1132, DOI 10.1037/0022-006X.74.6.1132; Donaldson D, 2000, AM J ORTHOPSYCHIAT, V70, P351, DOI 10.1037/h0087689; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; George D., 2003, SPSS WINDOWS STEP ST, V4th; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Grey Margaret, 2004, Curr Diab Rep, V4, P126, DOI 10.1007/s11892-004-0068-7; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lazarus R.S., 1984, STRESS APPRAISAL COP; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Losoya S, 1998, INT J BEHAV DEV, V22, P287, DOI 10.1080/016502598384388; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; MCCALL RB, 1973, CHILD DEV, V44, P401; Miller KS, 2009, J PEDIATR PSYCHOL, V34, P1135, DOI 10.1093/jpepsy/jsp037; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Rollnik JD, 2001, HEADACHE, V41, P297, DOI 10.1046/j.1526-4610.2001.111006297.x; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RJ, 1993, J CONSULT CLIN PSYCH, V61, P468, DOI 10.1037/0022-006X.61.3.468; Tobin D. L., 1984, USERS MANUAL COPING; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yancey AK, 2006, ANNU REV PUBL HEALTH, V27, P1, DOI 10.1146/annurev.publhealth.27.021405.102113; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	65	43	43	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					317	326		10.1017/S1355617710001700			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900012	21241531	Green Accepted			2021-06-18	
J	Donkin, JJ; Cernak, I; Blumbergs, PC; Vink, R				Donkin, James J.; Cernak, Ibolja; Blumbergs, Peter C.; Vink, Robert			A Substance P Antagonist Reduces Axonal Injury and Improves Neurologic Outcome When Administered Up to 12 Hours after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						neurogenic inflammation; neuropeptides; neurotrauma; neurokinin 1 (NK1) antagonist	AMYLOID PRECURSOR PROTEIN; NEUROGENIC INFLAMMATION; FUNCTIONAL DEFICITS; THERAPEUTIC WINDOW; HEAD-INJURY; RATS; EDEMA; MEMORY; RECEPTOR; MODEL	Previous studies have demonstrated that the compound N-acetyl-L-tryptophan (NAT) reduces brain edema and improves functional outcome following traumatic brain injury (TBI). In this study we examined whether this effect was mediated via the neurokinin-1 receptor, and whether there was an effect on axonal injury. We also explored whether the compound was effective, even when administered at delayed time points. Male Sprague-Dawley rats were subject to acceleration-induced, diffuse TBI and administered NAT, its inactive D-enantiomer, or saline vehicle. In contrast to NAT (2.5 mg/kg), the inactive D-enantiomer was ineffective at improving rotarod motor performance after TBI. NAT also improved cognitive outcome as assessed by the Morris water maze and novel object recognition tests, and reduced axonal injury at 5 and 24 h after TBI as assessed by amyloid precursor protein immunohistochemistry. However, efficacy of the membrane-impermeable NAT was limited to administration within 5 h, whereas administration of a form of NAT, L-732,138 (47 mg/kg), in which a trifluoromethyl benzyl ester group has been added, making it highly lipid soluble and able to cross the intact blood-brain barrier, significantly improved motor outcome, even when administration was delayed by as much as 12 h. We conclude that the neuroprotective effects of NAT are receptor-mediated, and that administration of the membrane-permeable form of the compound can be effective even up to 12 h after TBI.	[Donkin, James J.; Blumbergs, Peter C.; Vink, Robert] Univ Adelaide, Discipline Anat & Pathol, Adelaide, SA 5005, Australia; [Blumbergs, Peter C.; Vink, Robert] Hanson Inst Ctr Neurol Dis, Adelaide, SA, Australia; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA	Vink, R (corresponding author), Univ Adelaide, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X	Neurosurgical Research Foundation (Adelaide); Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This work was supported in part by the Neurosurgical Research Foundation (Adelaide), and by a grant from the Australian National Health and Medical Research Council.	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Bellgowan PSF, 2009, LEARN MEMORY, V16, P433, DOI 10.1101/lm.1357309; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bracci-Laudiero L, 1999, NEUROSCI LETT, V275, P57, DOI 10.1016/S0304-3940(99)00737-5; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; MACLEOD M, 1994, J MED CHEM, V37, P1269, DOI 10.1021/jm00035a006; Marmarou A, 2003, ACT NEUR S, V86, P7; Mauler F, 2003, CNS DRUG REV, V9, P343; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Schable S, 2010, PEPTIDES, V31, P108, DOI 10.1016/j.peptides.2009.10.009; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Vink R, 2004, J AM COLL NUTR, V23, p538S, DOI 10.1080/07315724.2004.10719398; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; WOIE K, 1993, CIRC RES, V73, P839, DOI 10.1161/01.RES.73.5.839; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39	42	43	43	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					217	224		10.1089/neu.2010.1632			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700005	21175297				2021-06-18	
J	Loane, DJ; Washington, PM; Vardanian, L; Pocivavsek, A; Hoe, HS; Duff, KE; Cernak, I; Rebeck, GW; Faden, AI; Burns, MP				Loane, David J.; Washington, Patricia M.; Vardanian, Lilit; Pocivavsek, Ana; Hoe, Hyang-Sook; Duff, Karen E.; Cernak, Ibolja; Rebeck, G. William; Faden, Alan I.; Burns, Mark P.			Modulation of ABCA1 by an LXR Agonist Reduces Beta-Amyloid Levels and Improves Outcome after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						A beta clearance; amyloid precursor protein processing; beta-amyloid; liver X receptor; traumatic brain injury	LIVER-X-RECEPTORS; ALZHEIMERS-DISEASE PATHOLOGY; TRANSGENIC MOUSE MODEL; LONG-TERM ACCUMULATION; PRECURSOR PROTEIN; A-BETA; NEURONAL APOPTOSIS; INDUCED INCREASES; OXIDATIVE STRESS; APP23 MICE	Traumatic brain injury (TBI) increases brain beta-amyloid (A beta) in humans and animals. Although the role of A beta in the injury cascade is unknown, multiple preclinical studies have demonstrated a correlation between reduced A beta and improved outcome. Therefore, therapeutic strategies that enhance A beta clearance may be beneficial after TBI. Increased levels of ATP-binding cassette A1 (ABCA1) transporters can enhance A beta clearance through an apolipoprotein E (apoE)-mediated pathway. By measuring A beta and ABCA1 after experimental TBI in C57BL/6J mice, we found that A beta peaked early after injury (1-3 days), whereas ABCA1 had a delayed response (beginning at 3 days). As ABCA1 levels increased, A beta levels returned to baseline levels-consistent with the known role of ABCA1 in A beta clearance. To test if enhancing ABCA1 levels could block TBI-induced A beta, we treated TBI mice with the liver X-receptor (LXR) agonist T0901317. Pre- and post-injury treatment increased ABCA1 levels at 24 h post-injury, and reduced the TBI-induced increase in A beta. This reduction in A beta was not due to decreased amyloid precursor protein processing, or a shift in the solubility of A beta, indicating enhanced clearance. T0901317 also limited motor coordination deficits in injured mice and reduced brain lesion volume. These data indicate that activation of LXR can reduce A beta accumulation after TBI, and is accompanied by improved functional recovery.	[Washington, Patricia M.; Vardanian, Lilit; Pocivavsek, Ana; Hoe, Hyang-Sook; Rebeck, G. William; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; [Duff, Karen E.] Columbia Univ, Dept Pathol, Taub Inst Alzheimer Dis Res, Med Ctr, New York, NY USA; [Duff, Karen E.] Columbia Univ, Integrat Neurosci New York State Psychiat Inst, Med Ctr, New York, NY USA; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22A,3970 Reservoir Rd NW, Washington, DC 20007 USA.	mpb37@georgetown.edu	Pocivavsek, Ana/AAW-8923-2020; Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Loane, David/0000-0003-0393-3503; Burns, Mark P/0000-0003-4750-2000; Ibolja, Cernak/0000-0003-3214-698X; Pocivavsek, Ana/0000-0002-3817-3201	Wright Family;  [R03NS057635]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS057635] Funding Source: NIH RePORTER	This research was supported by grant no. R03NS057635 (to M.P.B.), and funding from the Wright Family through the Memory Disorders Program at Georgetown University (to M.P.B.). We would like to thank Marie Hanscom for technical support; the Small Animal Imaging Laboratory at Georgetown University; Dr. Guojon Bu (Washington University); and Dr. Paul Mathews (Nathan S. Kline Institute) for antibodies; and Dr. Yasuji Matsuoka for helpful comments and discussion.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Boyd-Kimball D, 2004, J ALZHEIMERS DIS, V6, P515; Brera B, 2000, NEUROBIOL DIS, V7, P395, DOI 10.1006/nbdi.2000.0313; Burns M, 2003, J NEUROSCI, V23, P5645; Burns MP, 2006, J NEUROCHEM, V98, P792, DOI 10.1111/j.1471-4159.2006.03925.x; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Combs CK, 2001, J NEUROSCI, V21, P1179; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Fitz NF, 2010, J NEUROSCI, V30, P6862, DOI 10.1523/JNEUROSCI.1051-10.2010; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hoe HS, 2007, J NEUROSCI, V27, P10895, DOI 10.1523/JNEUROSCI.3135-07.2007; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kobayashi S, 2010, NEUROCHEM INT, V56, P387, DOI 10.1016/j.neuint.2009.11.005; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Morales JR, 2008, CIRCULATION, V118, P1450, DOI 10.1161/CIRCULATIONAHA.108.782300; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Paterniti I, 2010, J NEUROCHEM, V112, P611, DOI 10.1111/j.1471-4159.2009.06471.x; Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823-07.2007; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sironi L, 2008, FEBS LETT, V582, P3396, DOI 10.1016/j.febslet.2008.08.035; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2008, J CLIN INVEST, V118, P671, DOI 10.1172/JCI33622; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zelcer N, 2007, P NATL ACAD SCI USA, V104, P10601, DOI 10.1073/pnas.0701096104; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200	53	43	43	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					225	236		10.1089/neu.2010.1595			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700006	21175399	Green Published			2021-06-18	
J	Chossegros, L; Hours, M; Charnay, P; Bernard, M; Fort, E; Boisson, D; Sancho, PO; Yao, SN; Laumon, B				Chossegros, Laetitia; Hours, Martine; Charnay, Pierrette; Bernard, Marlene; Fort, Emmanuel; Boisson, Dominique; Sancho, Pierre-Olivier; Yao, Sai Nan; Laumon, Bernard			Predictive factors of chronic post-traumatic stress disorder 6 months after a road traffic accident	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Post-traumatic stress disorder; Road traffic accident; Six-month follow-up; Two-wheel motor vehicle; Cohort study	TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; MAJOR TRAUMA; VICTIMS; SYMPTOMS; AMNESIA; PTSD; SEVERITY; IMPACT; RISK	Background: This study sets out to identify risk factors for post-traumatic stress disorder (PTSD) after a road traffic accident with a view to improving prevention. Methods: The study used a prospective cohort of road traffic accident casualties. All subjects over 15 years of age were recruited in the course of an interview conducted while they were receiving care in a hospital of the Rhone area administrative departement. Six months after their accident, they answered a self-administered postal questionnaire that included the Post-traumatic Check-List Scale (PCLS) in order to evaluate FTSD. Multivariate logistic regression analysis was conducted to compare those subjects with a PCLS score of 44 or over with those with a lower score, in order to identify factors that might be associated with PTSD. Results: 592 subjects (out of 1168) returned the 6-month questionnaire and 541 completed the PCLS test. One hundred subjects had a PCLS score >= 44, suggesting PTSD, and 441 subjects did not. The factors associated with FTSD were initial injury severity, post-traumatic amnesia, the feeling of not being responsible for their accident and persistent pain 6 months after it. A lower odds-ratio was associated with users of two-wheel than four-wheel motor vehicles (OR=0.4; 0.2-0.9). Conclusion: Besides predictive factors for PTSD (injury severity, post-traumatic amnesia and the feeling of not being responsible for their accident), our study suggested a reduced risk of PTSD among two-wheel motor vehicle users. (C) 2010 Elsevier Ltd. All rights reserved.	[Chossegros, Laetitia; Hours, Martine; Charnay, Pierrette; Bernard, Marlene; Fort, Emmanuel; Laumon, Bernard] Univ Lyon, Transport Work & Environm Epidemiol Res & Surveil, UMRESTTE, INRETS,UMR T9405, F-69500 Bron, France; [Boisson, Dominique; Sancho, Pierre-Olivier] Hosp Civils Lyon, Serv Med Phys & Readaptat, Hop Henry Gabrielle, F-69230 St Genis Laval, France; [Yao, Sai Nan] Ctr Hosp Vienne, Psychiat Serv, F-38209 Vienne, France	Chossegros, L (corresponding author), INRETS, UMRESTTE, 25 Ave Francois Mitterrand, F-69675 Bron, France.	laetitia.chossegros@inrets.fr; martine.hours@inrets.fr; pierrette.charnay@inrets.fr; marlene.bernard@ors-rhone-alpes.org; emmanuel.fort@recherche.univ-lyon1.fr; dominique.boisson@chu-lyon.fr; pierre-olivier.sancho@chu-lyon.fr; sn.yao@ch-vienne.fr; bernard.laumon@inrets.fr	Fort, Emmanuel/Q-4570-2019	Fort, Emmanuel/0000-0003-1419-9914			*AAAM, 1990, ABBR INJ SCAL 1990 R; BLANCHARD EB, 1995, BEHAV RES THER, V33, P471, DOI 10.1016/0005-7967(94)00064-Q; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Cousson F., 1996, PSYCHOL FRANCAISE, V41, P155; De Mey-Guillard C, 2005, ENCEPHALE, V31, P76; *DSM 4, 1996, MAN DIAGN STAT TROUB; Duckworth MP, 2005, CLIN J PAIN, V21, P251, DOI 10.1097/00002508-200505000-00008; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Feinstein A, 2002, J NEUROPSYCH CLIN N, V14, P25, DOI 10.1176/appi.neuropsych.14.1.25; Frommberger UH, 1998, EUR ARCH PSY CLIN N, V248, P316, DOI 10.1007/s004060050057; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Harris IA, 2008, ANZ J SURG, V78, P583, DOI 10.1111/j.1445-2197.2008.04578.x; Hickling EJ, 1999, J TRAUMA STRESS, V12, P345, DOI 10.1023/A:1024784711484; Hidalgo RB, 2000, J CLIN PSYCHIAT, V61, P5; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Laumon B, 2005, BRIT MED J, V331, P1371, DOI 10.1136/bmj.38648.617986.1F; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Malt U F, 1992, Psychiatr Med, V10, P117; Matthews LR, 2005, BEHAV RES THER, V43, P475, DOI 10.1016/j.brat.2004.03.008; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; MICHAELS AJ, 1999, INFECT CRITICAL CARE, V47, P466; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Norris FH, 2002, PSYCHIATRY, V65, P207, DOI 10.1521/psyc.65.3.207.20173; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osler T, 1997, J TRAUMA INJURY INFE, V143, P925; Peleg T, 2006, CNS SPECTRUMS, V11, P589, DOI 10.1017/S109285290001364X; ROBERTSON MD, 1994, ACCIDENT ANAL PREV, V26, P243, DOI 10.1016/0001-4575(94)90094-9; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Ursano RJ, 1999, AM J PSYCHIAT, V156, P1808; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Ventureyra VAG, 2002, PSYCHOTHER PSYCHOSOM, V71, P47, DOI 10.1159/000049343; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Whitaker Iveth Y, 2003, Annu Proc Assoc Adv Automot Med, V47, P301; Wrenger M, 2008, EUR PSYCHIAT, V23, P434, DOI 10.1016/j.eurpsy.2008.02.001; Yao SN, 2003, ENCEPHALE, V29, P232	44	43	47	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2011	43	1					471	477		10.1016/j.aap.2010.10.004			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	694CK	WOS:000285272400056	21094346				2021-06-18	
J	Gottshall, K				Gottshall, Kim			Vestibular rehabilitation after mild traumatic brain injury with vestibular pathology	NEUROREHABILITATION			English	Article						Vestibular; physical therapy; mild traumatic brain injury	GAZE STABILIZATION TEST; DYNAMIC POSTUROGRAPHY; DISORDERS; DIZZINESS; DYSFUNCTION; DIAGNOSIS	Vestibular complaints are the most frequent sequelae of mTBI. Vestibular physical therapy has been established as the most important treatment modality for this group of patients. Nevertheless there is little work objectively documenting the impact of vestibular physical therapy on this group of patients. Studies have been completed in the past examining clinical measures like the GCS on overall recovery pattern after TBI. But outcomes measures specifically aimed at examining the adequacy of vestibular tests to track vestibular recoveryhave remained lacking. Scherer and Schubert reinforced the need for best practice vestibular assessment for formulation of appropriate vestibular physical therapy treatment strategies. Now the application of vestibular testing and rehabilitation in this patient population is needed to provide information on objective outcome measures. Vestibular physical therapy is most effective when applied in a customized fashion. While we and others have developed vestibular physical therapy procedures that are applied in best practices for mTBI vestibular patients, these therapies must be customized for the patient entry level of function and expectation level of recovery. Knowledge of the patient's disability and diagnosis is critical to build the foundation for return to activity, work, or sport.	Vestibular Assessment & Rehabil, San Diego, CA USA	Gottshall, K (corresponding author), Vestibular Assessment & Rehabil, 34520 Bob Wilson Dr, San Diego, CA USA.	Kim.gottshall@med.navy.mil					Badaracco C, 2007, OTOL NEUROTOL, V28, P809, DOI 10.1097/MAO.0b013e3180cab73f; Goebel JA, 2007, OTOL NEUROTOL, V28, P68, DOI 10.1097/01.mao.0000244351.42201.a7; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Gottshall KR, 2005, OTOLARYNG HEAD NECK, V133, P326, DOI 10.1016/j.otohns.2005.06.001; Gottshall KR, 2003, LARYGNOSCOPE, V113, P1736; Herdman SJ, 1998, OTOLARYNG HEAD NECK, V119, P49, DOI 10.1016/S0194-5998(98)70195-0; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Mishra A, 2009, AM J AUDIOL, V18, P53, DOI 10.1044/1059-0889(2009/06-0024); Morris AE, 2009, INT J AUDIOL, V48, P24, DOI 10.1080/14992020802314905; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NORRE ME, 1994, CLIN OTOLARYNGOL, V19, P433, DOI 10.1111/j.1365-2273.1994.tb01264.x; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; POWELL LE, 1995, J GERONTOL A-BIOL, V50, P28, DOI DOI 10.1093/GERONA/50A.1.M28; Pritcher MR, 2008, OTOL NEUROTOL, V29, P982, DOI 10.1097/MAO.0b013e31818457fb; SCHERER MR, 2009, PHYS THER, V89, P1; Whitney SL, 2009, GAIT POSTURE, V29, P194, DOI 10.1016/j.gaitpost.2008.08.002; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906	22	43	44	0	24	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2011	29	2					167	171		10.3233/NRE-2011-0691			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	842IB	WOS:000296589600007	22027078				2021-06-18	
J	Meehan, WP; Taylor, AM; Proctor, M				Meehan, William P., III; Taylor, Alex M.; Proctor, Mark			The Pediatric Athlete: Younger Athletes with Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Mild traumatic brain injury; Head injury; Trauma; Injury; Sports	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; HIGH-SCHOOL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL PERFORMANCE; CEREBRAL CONCUSSION; CONTACT-SPORTS; 2ND IMPACT; RECOVERY	Although much of the lay media attention surrounding sport-related concussion (SRC) focuses on professional athletes, SRC is a common injury in pediatric sports. The anatomy, biomechanics, and response to injury of the developing pediatric brain differ from those of the adult. Similarly, the neurocognitive abilities of the child are developing more rapidly than in an adult. The effects of concussive brain injury on the life of a child are different from those of an adult. This article focuses on the aspects of SRC that are specific to the younger athletes.	[Meehan, William P., III; Taylor, Alex M.] Childrens Hosp Boston, Div Sports Med, Sports Concuss Clin, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [Taylor, Alex M.] Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA; [Proctor, Mark] Childrens Hosp Boston, Dept Neurosurg, Boston, MA 02115 USA	Meehan, WP (corresponding author), Childrens Hosp Boston, Div Sports Med, Sports Concuss Clin, Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This article was supported by the NIH through a T32 Award to Dr Meehan (T32 HD040128-06A1).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT., 1989, MILD HEAD INJURY, P257; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BERNEY J, 1994, CHILD NERV SYST, V10, P509, DOI 10.1007/BF00335073; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Bruce D A, 1982, Clin Sports Med, V1, P495; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; COLLINS M, 2004, CURR OPIN ORTHOP, V15, P100; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GRONWALL D, 1975, LANCET, V2, P995; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Holbourn AHS, 1943, LANCET, V2, P438; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2008, J INT NEUROPSYCHO S1, V14, pi; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 1999, SPORTS-RELATED CONCUSSION, P3; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P303; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Russo S, 2006, CURR OPIN PEDIATR, V18, P376; Sakas DE, 1997, NEUROSURGERY, V41, P661, DOI 10.1097/00006123-199709000-00031; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNITKER MT, 1949, J PEDIATR-US, V35, P557, DOI 10.1016/S0022-3476(49)80138-7; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Theye Fred, 2004, Clin Med Res, V2, P165; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Washington RL, 2001, PEDIATRICS, V107, P1205; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	94	43	43	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					133	+		10.1016/j.csm.2010.08.004			13	Sport Sciences	Sport Sciences	691XR	WOS:000285114800013	21074088	Green Accepted			2021-06-18	
J	van Velzen, JM; van Bennekom, CAM; van Dormolen, M; Sluiter, JK; Frings-Dresen, MHW				van Velzen, Judith M.; van Bennekom, Coen A. M.; van Dormolen, Max; Sluiter, Judith K.; Frings-Dresen, Monique H. W.			Factors influencing return to work experienced by people with acquired brain injury: a qualitative research study	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; stroke; acquired brain injury; return to work	SPINAL-CORD-INJURY; PERSONAL EXPERIENCES; PERSPECTIVE; CHALLENGES; DISABILITY; HEALTH; MILD	Purpose. To describe the factors experienced by adults with moderate-to-severe acquired brain injury (ABI) as either limiting or facilitating during the process of return to work (RTW) in order to give an advice about the vocational rehabilitation process. Methods. A qualitative study was performed. Twelve adults who were working before acquiring traumatic or non-traumatic brain injury (2-3 years earlier) participated. The experiences were gathered by semi-structured interviews. The International Classification of Functioning, Disability and Health was used as a theoretical framework for the interviews and the analysis. Results. The most common limiting factor was tiredness. The most common facilitating factors were the will to RTW, the ongoing recovery and the knowledge and support of the employer, colleagues, occupational physician and occupational specialist. Conclusions. Different aspects were experienced as being important during the process of RTW after ABI. These aspects should be kept in mind during the process of RTW to make the outcome as successful as possible. It is advised to pay special attention to the recovery opportunities of an individual, to inform the employer, colleagues, occupation physician and the occupational specialist about ABI, and to support people with ABI for long time periods. An important role can be played by the rehabilitation centre.	[van Velzen, Judith M.; Sluiter, Judith K.; Frings-Dresen, Monique H. W.] Univ Amsterdam, Acad Med Ctr, Dept Coronel Inst Occupat Hlth, NL-1100 DE Amsterdam, Netherlands; [van Velzen, Judith M.; van Bennekom, Coen A. M.; van Dormolen, Max] Heliomare Rehabil Ctr, Dept Res & Dev, Inst Vocat Assessment & Educ, Wijk Aan Zee, Netherlands	van Velzen, JM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Coronel Inst Occupat Hlth, POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.vanvelzen@amc.uva.nl					Boeije H., 2006, ANAL KWALITATIEF OND; CRISP R, 1990, J REHABIL, V56, P28; Dekkers-Sanchez PM, 2010, J REHABIL MED, V42, P544, DOI 10.2340/16501977-0544; Gamble D, 2003, J REHABIL, V69, P31; Gilworth G, 2009, WORK, V34, P95, DOI 10.3233/WOR-2009-0906; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kempers E., 1994, TOP STROKE REHABIL, V1, P65; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; Lerdal A, 2009, J PAIN SYMPTOM MANAG, V38, P928, DOI 10.1016/j.jpainsymman.2009.04.028; Lidal IB, 2007, DISABIL REHABIL, V29, P1341, DOI 10.1080/09638280701320839; Rubenson Camilla, 2007, Scand J Occup Ther, V14, P205, DOI 10.1080/11038120601110934; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Ten Katen K, 2011, DISABIL REHABIL, V33, P522, DOI 10.3109/09638288.2010.503257; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; van Veldhoven MJPM, 2009, INT ARCH OCC ENV HEA, V82, P1065, DOI 10.1007/s00420-009-0411-z; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Varekamp I, 2005, ARTHRIT RHEUM-ARTHR, V53, P965, DOI 10.1002/art.21592; WILKEN JP, 1994, MANUAL LABOUR CAPACI; World Health Organization, 2002, INT CLASS FUNCT DIS	24	43	44	2	22	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2011	33	23-24					2237	2246		10.3109/09638288.2011.563821			10	Rehabilitation	Rehabilitation	841GB	WOS:000296499500010	21446852				2021-06-18	
J	Kaen, A; Jimenez-Roldan, L; Alday, R; Gomez, PA; Lagares, A; Alen, JF; Lobato, RD				Kaen, Ariel; Jimenez-Roldan, Luis; Alday, Rafael; Gomez, Pedro A.; Lagares, Alfonso; Fernandez Alen, Jose; Lobato, Ramiro D.			Interhemispheric hygroma after decompressive craniectomy: does it predict posttraumatic hydrocephalus? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						head injury; decompressive craniectomy; hydrocephalus; subdural hygroma	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; EXTERNAL HYDROCEPHALUS; SUBDURAL HYGROMA; TOMOGRAPHY; HEMICRANIECTOMY; CLASSIFICATION; DIAGNOSIS; LESION	Object. The aim of this study was to determine the incidence of posttraumatic hydrocephalus in severely head-injured patients who required decompressive craniectomy (DC). Additional objectives were to determine the relationship between hydrocephalus and several clinical and radiological features, with special attention to subdural hygromas as a sign of distortion of the CSF circulation. Methods. The authors conducted a retrospective study of 73 patients with severe head injury who required DC. The patients were admitted to the authors' department between January 2000 and January 2006. Posttraumatic hydrocephalus was defined as: 1) modified frontal horn index greater than 33%, and 2) the presence of Gudeman CT criteria. Hygromas were diagnosed based on subdural fluid collection and classified according to location of the craniectomy. Results. Hydrocephalus was diagnosed in 20 patients (27.4%). After uni- and multivariate analysis, the presence of interhemispheric hygromas (IHHs) was the only independent prognostic factor for development of posttraumatic hydrocephalus (p < 0.0001). More than 80% of patients with IHHs developed hydrocephalus within the first 50 days of undergoing DC. In all cases the presence of hygromas preceded the diagnosis of hydrocephalus. The IHH predicts the development of hydrocephalus after DC with 94% sensitivity and 96% specificity. The presence of an IHH showed an area under the receiver-operator characteristic of 0.951 (95% CI 0.87-1.00; p < 0.0001). Conclusions. Hydrocephalus was observed in 27.4% of the patients with severe traumatic brain injury who required DC. The presence of IHHs was a predictive radiological sign of hydrocephalus development within the first 6 months of DC in patients with severe head injury. (DOI: 10.3171/2010.4.JNS10132)	[Kaen, Ariel] Hosp Univ Virgen del Rocio, Dept Neurosurg, Seville, Spain; [Jimenez-Roldan, Luis; Alday, Rafael; Gomez, Pedro A.; Lagares, Alfonso; Fernandez Alen, Jose; Lobato, Ramiro D.] Hosp 12 Octubre, Dept Neurosurg, E-28041 Madrid, Spain	Kaen, A (corresponding author), Hosp Virgen del Rocio, Dept Neurosurg, Avda Manuel Siurot S-N, Seville 41013, Spain.	kaenariel@hotmail.com	ALEN, JOSE A FERNANDEZ/G-4990-2018; kaen, ariel/G-3786-2015; KAEN, ARIEL/F-1338-2015; Lagares, Alfonso/B-2969-2011; Jimenez-Roldan, Luis/K-2298-2017; Gomez, Pedro/N-5051-2019	ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X; Lagares, Alfonso/0000-0003-3996-0554; Jimenez-Roldan, Luis/0000-0002-9864-0385; Gomez, Pedro/0000-0002-4185-5238			Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Cardoso ER, 1996, J NEUROSURG, V85, P1143, DOI 10.3171/jns.1996.85.6.1143; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Licata C, 2001, J Neurosurg Sci, V45, P141; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Miranda P, 2004, NEUROCIRUGIA, V15, P67; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	23	43	62	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2010	113	6					1287	1293		10.3171/2010.4.JNS10132			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	684QX	WOS:000284565500033	20486895				2021-06-18	
J	Zhang, YL; Xiong, Y; Mahmood, A; Meng, YL; Liu, ZW; Qu, CS; Chopp, M				Zhang, Yanlu; Xiong, Ye; Mahmood, Asim; Meng, Yuling; Liu, Zhongwu; Qu, Changsheng; Chopp, Michael			Sprouting of corticospinal tract axons from the contralateral hemisphere into the denervated side of the spinal cord is associated with functional recovery in adult rat after traumatic brain injury and erythropoietin treatment	BRAIN RESEARCH			English	Article						Axonal plasticity; Erythropoietin; Functional recovery; Rat; Traumatic brain injury	MARROW STROMAL CELL; ENHANCES NEUROGENESIS; STROKE; MODEL; NEUROPROTECTION; TRANSPLANTATION; REGENERATION; PLASTICITY; SYSTEM; VOLUME	Erythropoietin (EPO) promotes functional recovery after traumatic brain injury (TBI). This study was designed to investigate whether EPO treatment promotes contralateral corticospinal tract (CST) plasticity in the spinal cord in rats after TBI. Biotinylated dextran amine (BDA) was injected into the right sensorimotor cortex to anterogradely label the CST. TBI was induced by controlled cortical impact over the left parietal cortex immediately after BDA injections. EPO (5000 U/kg) or saline was administered intraperitoneally at Days 1, 2, and 3 post-injury. Neurological function was assessed using a modified neurological severity score (mNSS) and footfault tests. Animals were sacrificed 35 days after injury and brain sections stained for histological analysis. Compared to the saline treatment, 1:PO treatment significantly improved sensorimotor functional outcome (lower mNSS and reduced footfaults) from Days 7 to 35 post-injury. TBI alone significantly stimulated contralateral CST axon sprouting toward the denervated gray matter of the cervical and lumbar spinal cord; however, EPO treatment further significantly increased the axon sprouting in TBI rats although EPO treatment did not significantly affect axon sprouting in sham animals. The contralesional CST sprouting was highly and positively correlated with sensorimotor recovery after TBI. These data demonstrate that CST fibers originating from the contralesional intact cerebral hemisphere are capable of sprouting into the denervated spinal cord after TB! and EPO treatment, which may at least partially contribute to functional recovery. (C) 2010 Elsevier B.V. All rights reserved.	[Zhang, Yanlu; Xiong, Ye; Mahmood, Asim; Meng, Yuling; Qu, Changsheng] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Liu, Zhongwu; Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Xiong, Y (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS 62002, PO1 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS 62002 (YX) and PO1 NS42345 (MA and MC). Special thanks to Ms. Susan MacPhee-Gray for editorial assistance.	Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen Q, 2005, J NEUROSCI, V25, P281, DOI 10.1523/JNEUROSCI.3692-04.2005; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Daniels CML, 2009, NEUROSCI LETT, V450, P191, DOI 10.1016/j.neulet.2008.11.017; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Grasso G, 2009, NEUROSURGERY, V65, P763, DOI 10.1227/01.NEU.0000347475.73347.5F; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047; Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Martin JH, 2005, NEUROSCIENTIST, V11, P161, DOI 10.1177/1073858404270843; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Ramic M, 2006, BRAIN RES, V1111, P176, DOI 10.1016/j.brainres.2006.06.063; Ransome MI, 2008, MOL CELL NEUROSCI, V38, P537, DOI 10.1016/j.mcn.2008.05.002; Reiner A, 2000, J NEUROSCI METH, V103, P23, DOI 10.1016/S0165-0270(00)00293-4; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; STANFIELD BB, 1992, PROG NEUROBIOL, V38, P169, DOI 10.1016/0301-0082(92)90039-H; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Toth C, 2008, NEUROSCIENCE, V154, P767, DOI 10.1016/j.neuroscience.2008.03.052; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yin ZS, 2010, AM J NEURORADIOL, V31, P509, DOI 10.3174/ajnr.A1820; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	44	43	45	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 24	2010	1353						249	257		10.1016/j.brainres.2010.07.046			9	Neurosciences	Neurosciences & Neurology	657NN	WOS:000282419500026	20654589	Green Accepted			2021-06-18	
J	Fernandez-Espejo, D; Junque, C; Cruse, D; Bernabeu, M; Roig-Rovira, T; Fabregas, N; Rivas, E; Mercader, JM				Fernandez-Espejo, Davinia; Junque, Carme; Cruse, Damian; Bernabeu, Montserrat; Roig-Rovira, Teresa; Fabregas, Neus; Rivas, Eva; Mercader, Jose M.			Combination of diffusion tensor and functional magnetic resonance imaging during recovery from the vegetative state	BMC NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; MINIMALLY CONSCIOUS STATES; COLLEGE-OF-PHYSICIANS; CEREBRAL BLOOD-FLOW; DEFAULT NETWORK; AXONAL INJURY; RESTING STATE; HEAD-INJURY; BASE-LINE	Background: The rate of recovery from the vegetative state (VS) is low. Currently, little is known of the mechanisms and cerebral changes that accompany those relatively rare cases of good recovery. Here, we combined functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) to study the evolution of one VS patient at one month post-ictus and again twelve months later when he had recovered consciousness. Methods: fMRI was used to investigate cortical responses to passive language stimulation as well as task-induced deactivations related to the default-mode network. DTI was used to assess the integrity of the global white matter and the arcuate fasciculus. We also performed a neuropsychological assessment at the time of the second MRI examination in order to characterize the profile of cognitive deficits. Results: fMRI analysis revealed anatomically appropriate activation to speech in both the first and the second scans but a reduced pattern of task-induced deactivations in the first scan. In the second scan, following the recovery of consciousness, this pattern became more similar to that classically described for the default-mode network. DTI analysis revealed relative preservation of the arcuate fasciculus and of the global normal-appearing white matter at both time points. The neuropsychological assessment revealed recovery of receptive linguistic functioning by 12-months post-ictus. Conclusions: These results suggest that the combination of different structural and functional imaging modalities may provide a powerful means for assessing the mechanisms involved in the recovery from the VS.	[Fernandez-Espejo, Davinia; Junque, Carme] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain; [Fernandez-Espejo, Davinia; Junque, Carme] Inst Biomed Res August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Cruse, Damian] MRC Cognit & Brain Sci Unit, Cambridge, England; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain; [Roig-Rovira, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Fabregas, Neus; Rivas, Eva] Univ Barcelona, Dept Anesthesiol, Hosp Clin, Barcelona, Spain; [Mercader, Jose M.] Hosp Clin Barcelona, Ctr Diagnost Imatge Hosp Clin Barcelona CDIC, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain.	cjunque@ub.edu	Junque, Carme/B-4400-2011	Junque, Carme/0000-0002-6381-3063; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Rivas, Eva/0000-0002-5816-998X	Spanish Ministry of Science and InnovationSpanish Government [SAF2007-66077]; Generalitat de CatalunyaGeneralitat de Catalunya [2009SGR0941]; Spanish Ministry for Education [AP2006-00862]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [U.1055.01.002.00007.01]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559847] Funding Source: researchfish	This work was supported by grants SAF2007-66077 from the Spanish Ministry of Science and Innovation and 2009SGR0941 from the Generalitat de Catalunya to the Neuropsychology Research Group. D. Fernandez-Espejo was supported by a fellowship from the Spanish Ministry for Education (AP2006-00862). D. Cruse was supported by a Medical Research Council Translational Grant (U.1055.01.002.00007.01).	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Anton, 2002, 8 INT C FUNCT MAPP H, V16; Artiola-i-Fortuny L, 1999, MANUAL NORMAS PROCED; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bassetti C, 2000, LANCET, V356, P484, DOI 10.1016/S0140-6736(00)02561-7; Bates D, 2003, CLIN MED, V3, P249; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bekinschtein T, 2005, NEUROPSYCHOL REHABIL, V15, P307, DOI 10.1080/09602010443000443; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Canavero S, 2009, J NEUROL, V256, P834, DOI 10.1007/s00415-009-5019-4; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Fair DA, 2007, NEUROIMAGE, V35, P396, DOI 10.1016/j.neuroimage.2006.11.051; Fernandez-Espejo D, 2008, BRAIN INJURY, V22, P882, DOI 10.1080/02699050802403573; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FRISTON KJ, 1995, HUM BRAIN MAPP, V0003, P00165, DOI DOI 10.1002/HBM.460030303; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOODGLASS H, 1986, EVALUACION AFASIA TR, P2; GRAVES WW, CEREB CORTEX; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagen C, 1979, REHABILITATION HEAD; Harrison BJ, 2008, P NATL ACAD SCI USA, V105, P9781, DOI 10.1073/pnas.0711791105; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lezak M, 2004, NEUROPSYCHOLOGICAL A, P4; Maquet P, 2000, J SLEEP RES, V9, P207; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Moritz CH, 2001, MAGN RESON IMAGING, V19, P1129, DOI 10.1016/S0730-725X(01)00432-5; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Pena-Casanova J., 1991, PROGRAMA INTEGRADO E; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salek-Haddadi A, 2003, ANN NEUROL, V53, P663, DOI 10.1002/ana.10586; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166; Steriade M, 2001, ARCH ITAL BIOL, V139, P37; Stoeckel C, 2009, CORTEX, V45, P1091, DOI 10.1016/j.cortex.2008.12.004; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vigneau M, 2006, NEUROIMAGE, V30, P1414, DOI 10.1016/j.neuroimage.2005.11.002; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wechsler D., 1999, ESCALA INTELIGENCIA, V3; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	64	43	47	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	SEP 3	2010	10								77	10.1186/1471-2377-10-77			10	Clinical Neurology	Neurosciences & Neurology	667ZY	WOS:000283239200001	20815871	DOAJ Gold, Green Published			2021-06-18	
J	Yu, I; Inaji, M; Maeda, J; Okauchi, T; Nariai, T; Ohno, K; Higuchi, M; Suhara, T				Yu, Iwae; Inaji, Motoki; Maeda, Jun; Okauchi, Takashi; Nariai, Tadashi; Ohno, Kikuo; Higuchi, Makoto; Suhara, Tetsuya			Glial Cell-Mediated Deterioration and Repair of the Nervous System after Traumatic Brain Injury in a Rat Model as Assessed by Positron Emission Tomography	JOURNAL OF NEUROTRAUMA			English	Article						glial cell response to injury; head trauma; inflammation; models of injury; positron emission tomography scanning	PERIPHERAL BENZODIAZEPINE-RECEPTOR; FLUID-PERCUSSION MODEL; MOUSE MODEL; IN-VIVO; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; QUANTITATIVE ASSESSMENT; METABOLIC DEPRESSION; GLUCOSE-UTILIZATION; AXONAL INJURY	Traumatic brain injury (TBI) is one of the most acute degenerative pathologies in the central nervous system, and in vivo indices enabling an assessment of TBI on a mechanistic basis have yet to be established. The aim of this work was to pursue neuroinflammatory changes and their link to functional disruptions of traumatically-damaged neurons in a rat model of TBI by longitudinal positron emission tomographic (PET) assays. TBI was induced in the unilateral frontal cortex of craniotomied rats according to a lateral fluid percussion brain injury protocol. The use of [F-18] fluoroethyl-DAA1106 as a PET tracer for translocator protein (TSPO) permitted demonstration of the inflammatory response to the injury, peaking at 1 week after impact. This alteration was parallel to metabolic deficits assessed by PET with [F-18] fluorodeoxyglucose, but the difference in TSPO levels between impacted and non-impacted frontal cortices was more than threefold of the interlateral metabolic difference, indicating superiority of TSPO imaging for sensitive detection of post-traumatic pathologies. Comparative PET, autoradiographic. and immunohistochemical investigations illustrated the primary contribution of hypertrophic microglia and macrophages to acute TSPO signals in the vicinity of the impact. Astrocytes also formed a TSPO-positive glial scar encompassing necrotic inflammation, and were clustered with PET-detectable TSPO signals in the bilateral external and internal capsules at late stages, putatively reacting with diffuse axonal injury. These observations support the applicability of TSPO-PET as an imaging-based preclinical and clinical biomarker assay in TBI, and indicate its potential capability to clarify aggressive and protective roles of glial responses to injury when combined with emerging anti-inflammatory and immunomodulatory treatments.	[Higuchi, Makoto] Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, Chiba 2638555, Japan; [Yu, Iwae; Inaji, Motoki; Nariai, Tadashi; Ohno, Kikuo] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan	Higuchi, M (corresponding author), Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	mhiguchi@nirs.go.jp			Molecular Imaging Program and Scientific Research on Priority Areas, Research on Pathomechanisms of Brain DisordersMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20023036]; Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	The authors thank Mr. Takeharu Minamihisamatsu for technical assistance, and the staffs at the Cyclotron Unit and the Molecular Probe Group for the cyclotron operation and production of radiochemicals. This work was supported in part by Grants-in-Aid for the Molecular Imaging Program and Scientific Research on Priority Areas, Research on Pathomechanisms of Brain Disorders 20023036 (to M.H.), and from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We also thank Taisho Pharmaceutical (Tokyo, Japan) for providing DAA1123.	Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Cavus I, 2005, ANN NEUROL, V57, P226, DOI 10.1002/ana.20380; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen MK, 2004, BRAIN, V127, P1379, DOI 10.1093/brain/awh161; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; IP EY, 2003, J CEREB BLOOD FLOW M, V23, P300; Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maeda J, 2004, SYNAPSE, V52, P283, DOI 10.1002/syn.20027; Maeda J, 2007, J NEUROSCI, V27, P10957, DOI 10.1523/JNEUROSCI.0673-07.2007; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rojas S, 2007, J CEREBR BLOOD F MET, V27, P1975, DOI 10.1038/sj.jcbfm.9600500; Shen J, 1999, P NATL ACAD SCI USA, V96, P8235, DOI 10.1073/pnas.96.14.8235; Shimoji K, 2004, J NUCL MED, V45, P665; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Tai YC, 2005, J NUCL MED, V46, P455; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toyama H, 2004, J NUCL MED, V45, P1398; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Venneti S, 2009, NEUROBIOL AGING, V30, P1217, DOI 10.1016/j.neurobiolaging.2007.11.005; Wegman TD, 2002, APPL RADIAT ISOTOPES, V57, P505, DOI 10.1016/S0969-8043(02)00143-4; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; Yasuno F, 2008, BIOL PSYCHIAT, V64, P835, DOI 10.1016/j.biopsych.2008.04.021; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhang MR, 2004, J MED CHEM, V47, P2228, DOI 10.1021/jm0304919	47	43	46	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1463	1475		10.1089/neu.2009.1196			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900010	20504160				2021-06-18	
J	Fernandez-Espejo, D; Junque, C; Bernabeu, M; Roig-Rovira, T; Vendrell, P; Mercader, JM				Fernandez-Espejo, Davinia; Junque, Carme; Bernabeu, Montserrat; Roig-Rovira, Teresa; Vendrell, Pere; Mercader, Jose M.			Reductions of Thalamic Volume and Regional Shape Changes in the Vegetative and the Minimally Conscious States	JOURNAL OF NEUROTRAUMA			English	Article						disorders of consciousness; magnetic resonance imaging; shape analysis; traumatic brain injury; thalamus	TRAUMATIC BRAIN-INJURY; COLLEGE-OF-PHYSICIANS; BLUNT HEAD-INJURY; 1ST-EPISODE SCHIZOPHRENIA; NEUROPATHOLOGY; ABNORMALITIES; RECOVERY; AROUSAL; DISEASE; NUCLEI	The thalamus is known to play a key role in arousal regulation and support of human consciousness. Neuropathological studies have identified thalamic damage as one of the most common abnormalities present in the brains of patients who were in a vegetative state (VS) or a minimally-conscious state (MCS) state at the time of their deaths. Nonetheless, no in vivo studies of thalamic abnormalities in these patients have been conducted. Using high-resolution T1-weighted magnetic resonance images and a novel approach to shape analysis, we investigated thalamic global and regional changes in a sample of patients in a VS or an MCS. Group comparisons and correlations with clinical variables were performed for the total thalamic volume and for each surface vertex. Total thalamic volume was significantly lower in patients than in healthy volunteers. Shape analysis revealed significant bilateral regional atrophy in the dorso-medial body in patients compared to controls; this atrophy was more widespread in VS than in MCS patients. Lower thalamic volume was significantly correlated with worse Disability Rating Scale scores. Shape analysis suggested that the dorso-medial nucleus and the internal medullar lamina were the main regions responsible for this correlation. Our findings suggest that MCS and VS patients present different patterns of regional thalamic abnormalities, and that these differences partially explain their clinical profile.	[Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Inst Biomed Res August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain; [Roig-Rovira, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Mercader, Jose M.] Hosp Clin Barcelona, CDIC, Barcelona, Spain; [Mercader, Jose M.] Univ Barcelona, Dept Obstet & Gynaecol Pediat Radiol & Anat, E-08036 Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Vendrell, Pere/B-4392-2011; Junque, Carme/B-4400-2011	Vendrell, Pere/0000-0001-8918-5440; Junque, Carme/0000-0002-6381-3063; Fernandez-Espejo, Davinia/0000-0001-5941-7546	Spanish Ministry of Science and InnovationSpanish Government [SAF2007-66077]; Generalitat de CatalunyaGeneralitat de Catalunya [2009SGR0941]; Spanish Ministry for Education [AP2006-0082]	This work was supported by grant SAF2007-66077 from the Spanish Ministry of Science and Innovation, and grant 2009SGR0941 from the Generalitat de Catalunya. D. Fernandez-Espejo was supported by a fellowship from the Spanish Ministry for Education (AP2006-0082).	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Bates D, 2003, CLIN MED, V3, P249; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Coscia DM, 2009, HUM BRAIN MAPP, V30, P1236, DOI 10.1002/hbm.20595; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hagen C, 1979, REHABILITATION HEAD; Harms MP, 2007, J NEUROSCI, V27, P13835, DOI 10.1523/JNEUROSCI.2571-07.2007; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kang DH, 2008, NEUROREPORT, V19, P609, DOI 10.1097/WNR.0b013e3282fa6db9; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; McKeown MJ, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-8; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Patenaude B., 2007, THESIS U OXFORD; Qiu AQ, 2009, NEUROIMAGE, V47, P1163, DOI 10.1016/j.neuroimage.2009.04.027; Qiu AQ, 2009, NEUROIMAGE, V45, P656, DOI 10.1016/j.neuroimage.2009.01.013; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Tshibanda L, 2010, NEURORADIOLOGY, V52, P15, DOI 10.1007/s00234-009-0614-8; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001	29	43	44	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1187	1193		10.1089/neu.2010.1297			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100003	20392136				2021-06-18	
J	Hillary, FG; Genova, HM; Medaglia, JD; Fitzpatrick, NM; Chiou, KS; Wardecker, BM; Franklin, RG; Wang, JL; DeLuca, J				Hillary, Frank G.; Genova, Helen M.; Medaglia, John D.; Fitzpatrick, Neal M.; Chiou, Kathy S.; Wardecker, Britney M.; Franklin, Robert G., Jr.; Wang, Jianli; DeLuca, John			The Nature of Processing Speed Deficits in Traumatic Brain Injury: is Less Brain More?	BRAIN IMAGING AND BEHAVIOR			English	Article						TBI; fMRI; Reorganization; Working memory; Processing speed	DIFFUSE AXONAL INJURY; PREFRONTAL CORTICAL ACTIVITY; ADULT AGE-DIFFERENCES; WORKING-MEMORY LOAD; MULTIPLE-SCLEROSIS; FUNCTIONAL MRI; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE-CONTROL; QUANTIFIED MRI; MS PATIENTS	The cognitive constructs working memory (WM) and processing speed are fundamental components to general intellectual functioning in humans and highly susceptible to disruption following neurological insult. Much of the work to date examining speeded working memory deficits in clinical samples using functional imaging has demonstrated recruitment of network areas including prefrontal cortex (PFC) and anterior cingulate cortex (ACC). What remains unclear is the nature of this neural recruitment. The goal of this study was to isolate the neural networks distinct from those evident in healthy adults and to determine if reaction time (RT) reliably predicts observable between-group differences. The current data indicate that much of the neural recruitment in TBI during a speeded visual scanning task is positively correlated with RT. These data indicate that recruitment in PFC during tasks of rapid information processing are at least partially attributable to normal recruitment of PFC support resources during slowed task processing.	[Hillary, Frank G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Fitzpatrick, Neal M.; Wang, Jianli] Penn State Univ, Milton S Hershey Med Ctr, Dept Radiol, Hershey, PA 17033 USA; [Genova, Helen M.; DeLuca, John] Kessler Fdn Res Ctr, W Orange, NJ USA; [Hillary, Frank G.] Milton S Hershey Med Ctr, Dept Neurol, Hershey, PA USA; [Hillary, Frank G.; Medaglia, John D.; Chiou, Kathy S.; Wardecker, Britney M.; Franklin, Robert G., Jr.] Penn State Univ, Dept Psychol, State Coll, PA USA	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, 223 Moore Bldg, University Pk, PA 16802 USA.	fhillary@psu.edu	Hillary, Frank/AAN-8622-2021	Wardecker, Britney/0000-0003-2168-538X			Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BRADLEY VA, 1989, J NEUROL NEUROSUR PS, V52, P1228, DOI 10.1136/jnnp.52.11.1228; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Calhoun VD, 2004, NEUROIMAGE, V22, P252, DOI 10.1016/j.neuroimage.2003.12.029; Chang L, 2004, ANN NEUROL, V56, P259, DOI 10.1002/ana.20190; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Collette F, 1999, NEUROPSYCHOLOGIA, V37, P905, DOI 10.1016/S0028-3932(98)00148-1; Courtney Susan M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P501, DOI 10.3758/CABN.4.4.501; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Ernst T, 2003, NEUROIMAGE, V19, P1686, DOI 10.1016/S1053-8119(03)00232-5; Ernst T, 2002, NEUROLOGY, V59, P1343, DOI 10.1212/01.WNL.0000031811.45569.B0; Forn C, 2006, NEUROIMAGE, V31, P686, DOI 10.1016/j.neuroimage.2005.12.030; Forn C, 2007, HUM BRAIN MAPP, V28, P424, DOI 10.1002/hbm.20284; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; GENOVA HM, 2009, J INT NEUROPSYCHOLOG; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; [刘建兴 Liu Jianxing], 2005, [资源科学, Resources Science], V27, P33; Mainero C, 2004, NEUROIMAGE, V21, P858, DOI 10.1016/j.neuroimage.2003.10.004; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; MORRIS RG, 1988, J CLIN EXP NEUROPSYC, V10, P279, DOI 10.1080/01688638808408242; Mostofsky SH, 2003, COGNITIVE BRAIN RES, V17, P419, DOI 10.1016/S0926-6410(03)00144-7; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Penner IK, 2003, J NEUROL, V250, P461, DOI 10.1007/s00415-003-1025-0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rypma B, 2002, J COGNITIVE NEUROSCI, V14, P721, DOI 10.1162/08989290260138627; Rypma B, 2000, NAT NEUROSCI, V3, P509, DOI 10.1038/74889; Rypma B, 1999, NEUROIMAGE, V9, P216, DOI 10.1006/nimg.1998.0404; Rypma B, 2001, PSYCHOL AGING, V16, P371, DOI 10.1037//0882-7974.16.3.371; Rypma B, 2006, NEUROIMAGE, V33, P969, DOI 10.1016/j.neuroimage.2006.05.065; SALTHOUSE TA, 1992, MEM COGNITION, V20, P413, DOI 10.3758/BF03210925; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; SAYKIN AJ, 1994, ARCH GEN PSYCHIAT, V51, P124; SAYKIN AJ, 1991, ARCH GEN PSYCHIAT, V48, P618; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; SMITH A, 1997, SYMBOL DIGIT MODALIT; Smith A., 1973, SYMBOL DIGIT MODALIT; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Sweet LH, 2006, HUM BRAIN MAPP, V27, P28, DOI 10.1002/hbm.20163; TEASDALE G, 1974, LANCET, V2, P81; Trenerry MR., 1990, VISUAL SEARCH ATTENT; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42	71	43	43	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2010	4	2					141	154		10.1007/s11682-010-9094-z			14	Neuroimaging	Neurosciences & Neurology	606HJ	WOS:000278413200003	20502993				2021-06-18	
J	Jarlestedt, K; Rousset, CI; Faiz, M; Wilhelmsson, U; Stahlberg, A; Sourkova, H; Pekna, M; Mallard, C; Hagberg, H; Pekny, M				Jarlestedt, Katarina; Rousset, Catherine I.; Faiz, Maryam; Wilhelmsson, Ulrika; Stahlberg, Anders; Sourkova, Hana; Pekna, Marcela; Mallard, Carina; Hagberg, Henrik; Pekny, Milos			Attenuation of Reactive Gliosis Does Not Affect Infarct Volume in Neonatal Hypoxic-Ischemic Brain Injury in Mice	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; INTERMEDIATE-FILAMENTS; HYPOTONIC STRESS; ASTROCYTES; VIMENTIN; GFAP; REGENERATION; DEFICIENT; PCR; NEUROGENESIS	Background: Astroglial cells are activated following injury and up-regulate the expression of the intermediate filament proteins glial fibrillary acidic protein (GFAP) and vimentin. Adult mice lacking the intermediate filament proteins GFAP and vimentin (GFAP(-/-) Vim(-/-)) show attenuated reactive gliosis, reduced glial scar formation and improved regeneration of neuronal synapses after neurotrauma. GFAP(-/-) Vim(-/-) mice exhibit larger brain infarcts after middle cerebral artery occlusion suggesting protective role of reactive gliosis after adult focal brain ischemia. However, the role of astrocyte activation and reactive gliosis in the injured developing brain is unknown. Methodology/Principal Findings: We subjected GFAP(-/-) Vim(-/-) and wild-type mice to unilateral hypoxia-ischemia (HI) at postnatal day 9 (P9). Bromodeoxyuridine (BrdU; 25 mg/kg) was injected intraperitoneally twice daily from P9 to P12. On P12 and P31, the animals were perfused intracardially. Immunohistochemistry with MAP-2, BrdU, NeuN, and S100 antibodies was performed on coronal sections. We found no difference in the hemisphere or infarct volume between GFAP(-/-) Vim(-/-) and wild-type mice at P12 and P31, i.e. 3 and 22 days after HI. At P31, the number of NeuN(+) neurons in the ischemic and contralateral hemisphere was comparable between GFAP(-/-) Vim(-/-) and wild-type mice. In wild-type mice, the number of S100(+) astrocytes was lower in the ipsilateral compared to contralateral hemisphere (65.0 +/- 50.1 vs. 85.6 +/- 34.0, p<0.05). In the GFAP(-/-) Vim(-/-) mice, the number of S100(+) astrocytes did not differ between the ischemic and contralateral hemisphere at P31. At P31, GFAP(-/-) Vim(-/-) mice showed an increase in NeuN(+)BrdU(+) (surviving newly born) neurons in the ischemic cortex compared to wild-type mice (6.7 +/- 7.7; n = 29 versus 2.9 +/- 3.6; n = 28, respectively, p<0.05), but a comparable number of S100(+)BrdU(+) (surviving newly born) astrocytes. Conclusions/Significance: Our results suggest that attenuation of reactive gliosis in the developing brain does not affect the hemisphere or infarct volume after HI, but increases the number of surviving newborn neurons.	[Jarlestedt, Katarina; Mallard, Carina; Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Perinatal Ctr, Gothenburg, Sweden; [Rousset, Catherine I.; Hagberg, Henrik] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England; [Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Obstet & Gynecol, Gothenburg, Sweden; [Pekna, Marcela] Univ Gothenburg, Sahlgrenska Acad, Dept Med Chem & Cell Biol, Inst Biomed, Gothenburg, Sweden; [Faiz, Maryam; Wilhelmsson, Ulrika; Stahlberg, Anders; Sourkova, Hana; Pekny, Milos] Univ Gothenburg, Ctr Brain Repair & Rehabil, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Sahlgrenska Acad, Gothenburg, Sweden	Jarlestedt, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Perinatal Ctr, Gothenburg, Sweden.	Milos.Pekny@neuro.gu.se	Pekna, Marcela/AAM-3249-2021; Pekna, Marcela/AAM-3261-2021	Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237; Mallard, Carina/0000-0001-8953-919X; Hagberg, Henrik/0000-0003-3962-1448; Stahlberg, Anders/0000-0003-4243-0191	Swedish Research CouncilSwedish Research CouncilEuropean Commission [11548, 20116, 09455, 14185]; Medical Research Council (United Kingdom)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [P19381]; LUA/ALF Gothenburg; Region of Vastra Gotaland; Ragnar and Torsten Soderberg's Foundations; Hjarnfonden; Edith Jacobsson's Foundation; John and Brit Wennerstrom's Foundation; W. and M. Lundgren's Foundation; A. and U. Amlov's Foundation; Free Mason Foundation; Swedish Stroke Foundation;  [ALFGBG7592];  [ALFGBG11267];  [ALFGBG2863]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802853] Funding Source: researchfish; Action Medical Research [1764] Funding Source: researchfish	This study was supported by the Swedish Research Council, 11548 ( M. P.), 20116 ( M. P.), 09455 ( H. H.), 14185 ( C. M.), Medical Research Council (United Kingdom) contract: P19381 ( H. H.), LUA/ALF Gothenburg, ALFGBG7592 ( M. P.), ALFGBG11267 ( M. P.), ALFGBG2863 ( H. H.), The Region of Vastra Gotaland ( RUN), Ragnar and Torsten Soderberg's Foundations, Hjarnfonden, Edith Jacobsson's Foundation, John and Brit Wennerstrom's Foundation for Neurological Research, W. and M. Lundgren's Foundation, A. and U. Amlov's Foundation, The Free Mason Foundation and the Swedish Stroke Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderova M, 2001, GLIA, V35, P189, DOI 10.1002/glia.1084; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ding M, 1998, MOL BRAIN RES, V62, P77, DOI 10.1016/S0169-328X(98)00240-X; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Iwata-Ichikawa E, 1999, J NEUROCHEM, V72, P2334, DOI 10.1046/j.1471-4159.1999.0722334.x; Jing RF, 2007, J CELL SCI, V120, P1267, DOI 10.1242/jcs.03423; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; MCRAE A, 1995, DEV BRAIN RES, V84, P245, DOI 10.1016/0165-3806(94)00177-2; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2001, Prog Brain Res, V132, P23; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Sent E, 2006, MENT RETARD DEV D R, V12, P97, DOI 10.1002/mrdd.20106; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stahlberg A, 2005, EXPERT REV MOL DIAGN, V5, P221, DOI 10.1586/14737159.5.2.221; Sullivan SM, 2010, GLIA, V58, P181, DOI 10.1002/glia.20911; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Widestrand A, 2007, STEM CELLS, V25, P2619, DOI 10.1634/stemcells.2007-0122; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	32	43	43	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2010	5	4							e10397	10.1371/journal.pone.0010397			7	Multidisciplinary Sciences	Science & Technology - Other Topics	589MV	WOS:000277154200029	20442854	DOAJ Gold, Green Published			2021-06-18	
J	Rollnik, JD; Janosch, U				Rollnik, Jens D.; Janosch, Uwe			Current Trends in the Length of Stay in Neurological Early Rehabilitation	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Article							GERMANY; INJURY	Background: Neurological early rehabilitation (phase B) is an integral component of the phase model of the German Federal Rehabilitation Council (Bundesarbeits-gemeinschaft fur Rehabilitation, BAR). We studied the current trend in patients' length of stay. Methods: This study included 2060 cases of the BDH-Klinik Hessisch Oldendorf (a neurological rehabilitation clinic) from 2005 to 2008 that fulfilled the structural characteristics of item 8-552 of the German coding system for operations and procedures (Operationenund Prozedurenschlussel, OPS), which codes for neurological and neurosurgical early rehabilitation. We studied the parameters age, sex, length of stay, type of discharge, diagnoses, and morbidity. 75.7% of the collective carried a diagnosis of cerebral ischemia, traumatic brain injury, or intracerebral hemorrhage. Results: The mean length of stay over the entire period of the study was 44.6 days. A successive reduction of the mean length of stay from 2005 to 2008 was evident, from 46.8 days in 2005 to 37.5 in 2008 (p< 0.001). The morbidity, too, declined over the period of the study. 76.4% of the cases analyzed stayed in hospital for at least the minimum of 8 weeks proposed by the BAR. 39.5% of the patients improved to such an extent in phase B that they were able to be transferred to a further rehabilitation facility, while about one patient in five was transferred from early rehabilitation to a nursing facility. The mortality was 0.9%. Although the early rehabilitation procedure was correctly coded, a total of 60 different diagnosis-related groups (DRGs) were applied. Conclusion: These data support the BAR's recommendation for a minimum length of stay of 8 weeks in phase B. The observed shortening of the length of stay was found to be primarily the result of a reduction in morbidity during early rehabilitation. This, in turn, may well be due to a selection effect of the early rehabilitation procedure code 8-552.	[Rollnik, Jens D.] Hannover Med Sch, Akad Lehrkrankenhaus, BDH Klin Hessisch Oldendorf, D-31840 Hessisch Oldendorf, Germany	Rollnik, JD (corresponding author), Hannover Med Sch, Akad Lehrkrankenhaus, BDH Klin Hessisch Oldendorf, Greitstr 18-28, D-31840 Hessisch Oldendorf, Germany.						Bundesarbeitsgemeinschaft fur Rehabilitation, 1995, EMPF NEUR REH PAT SC; *G DRG, FALLP KAT G DRG VERS; Rollnik JD, 2009, AKTUEL NEUROL, V36, P368, DOI 10.1055/s-0029-1220390; Rollnilk JD, 2009, REHABILITATION, V48, P91, DOI 10.1055/s-0029-1202294; Schonle P W, 1995, Rehabilitation (Stuttg), V34, P69; Schonle PV, 1996, NERVENHEILKUNDE, V15, P220; Shen Q, 2006, ACTA NEUROL SCAND, V113, P114, DOI 10.1111/j.1600-0404.2005.00542.x; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; Stier-Jarmer M, 2002, PHYS MED REHAB KUROR, V12, P260, DOI 10.1055/s-2002-35154; VONWEDELPARLOW FK, 1999, NEUROREHABILITATION, P65; Wallesch CW, 2009, AKTUEL NEUROL, V36, P93, DOI 10.1055/s-0028-1090182	11	43	43	0	2	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	APR 23	2010	107	16					286	292		10.3238/arztebl.2010.0286			7	Medicine, General & Internal	General & Internal Medicine	592NW	WOS:000277387300003	20467554	Green Published			2021-06-18	
J	Lin, MR; Chiu, WT; Chen, YJ; Yu, WY; Huang, SJ; Tsai, MD				Lin, Mau-Roung; Chiu, Wen-Ta; Chen, Yi-Ju; Yu, Wen-Yu; Huang, Sheng-Jean; Tsai, Ming-Dar			Longitudinal Changes in the Health-Related Quality of Life During the First Year After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Depression; Quality of life; Rehabilitation; Social support; Taiwan	SOCIAL SUPPORT; RESPONSE-SHIFT; WHOQOL-BREF; SATISFACTION	Lin M-R, Chiu W-T, Chen Y-J, Yu W-Y, Huang S-J, Tsai M-D. Longitudinal changes in the health-related quality of life during the first year after traumatic brain injury. Arch Phys Med Rehabil 2010;91:474-80. Objective: To track the health-related quality of life (HRQL) at discharge and at 6 and 12 months after a traumatic brain injury (TBI) and examine factors associated with changes in each HRQL domain. Design: Longitudinal cohort study. Setting: Using codes of the International Classification of Diseases, eligible participants who had a newly diagnosed TBI were identified from discharge records of 4 hospitals in northern Taiwan. Information on the HRQL and injury-related characteristics at the initial and 2 follow-up assessments was collected by extracting medical records and conducting telephone interviews. Participants: Subjects (N=158) participated in the initial assessment, and 147 and 146, respectively, completed the follow-up assessments at 6 and 12 months after injury. Interventions: Not applicable. Main Outcome Measure: The brief version of the World Health Organization Quality of Life (WHOQOL-BREF) with 4 domains of physical capacity, psychologic well being, social relationships, and environment. Results: Scores on all WHOQOL-BREF domains except social relationships greatly improved over the first 6 months and showed continued improvement at 12 months after injury. The domain scores of the WHOQOL-BREF at discharge were significantly associated with the preinjury HRQL level, marital status, alcohol consumption at the time of injury, Glasgow Outcome Scale (GOS) level, cognition, activities of daily living, social support, and depressive status. However, after adjusting for these baseline differences, only the GOS level and depressive status significantly influenced longitudinal changes in the psychologic and social domains over the 12-month period. Changes in the physical and environmental domains were not significantly associated with any characteristics of the study. Conclusions: During the first year after a TBI, the magnitude of HRQL recovery differed across different HRQL domains. Many factors may have significant associations with the initial domain scores of HRQL after TBI; however, only a few factors can significantly influence longitudinal changes in the HRQL.	[Lin, Mau-Roung; Chiu, Wen-Ta] Taipei Med Univ, Coll Publ Hlth & Nutr, Inst Injury Prevent & Control, Shuang Ho Hosp, Taipei 11031, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Shuang Ho Hosp, Dept Neurosurg, Taipei 11031, Taiwan; [Chen, Yi-Ju] Cathay Gen Hosp, Dept Nursing, Taipei, Taiwan; [Yu, Wen-Yu] Taipei Med Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Tsai, Ming-Dar] Shin Kong Wu Ho Su Mem Hosp, Dept Neurosurg, Taipei, Taiwan	Chiu, WT (corresponding author), Taipei Med Univ, Coll Publ Hlth & Nutr, Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 11031, Taiwan.	wtchiu@tmu.edu.tw			National Science CouncilMinistry of Science and Technology, Taiwan [NSC97-2314-B-038-012-MY3]; National Health Research Institute, Taiwan, ROCNational Health Research Institutes - Taiwan [98TMU-SHH-07]	Supported by the National Science Council (grant no. NSC97-2314-B-038-012-MY3) and the National Health Research Institute (grant no. 98TMU-SHH-07), Taiwan, ROC.	Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CHESNUT RM, 1999, 2 AG HLTH CAR POL RE; Chiu W. T., 1996, NEUROTRAUMA, P905; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dawson DR, 2000, BRAIN COGNITION, V44, P35; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; JENNETT B, 1975, LANCET, V1, P480; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MACKENZIE EJ, 2001, INJURY CONTROL GUIDE; MAHONEY F I, 1965, Md State Med J, V14, P61; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; O'Shanick G J, 1986, Adv Psychosom Med, V16, P173; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Schipper H, 1996, QUAL LIFE PHARMACOEC, V2, P11; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; Sprangers MAG, 1996, CANCER TREAT REV, V22, P55, DOI 10.1016/S0305-7372(96)90064-X; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TENNSTEDT SL, 1992, AM J PUBLIC HEALTH, V82, P1541; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; World Health Organization, 1980, INT CLASS IMP DIS HA; Yao G, 2002, J FORMOS MED ASSOC, V101, P342	39	43	44	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2010	91	3					474	480		10.1016/j.apmr.2009.10.031			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	592YM	WOS:000277417900023	20298842				2021-06-18	
J	Schneiders, AG; Sullivan, SJ; Gray, AR; Hammond-Tooke, GD; McCrory, PR				Schneiders, Anthony G.; Sullivan, S. John; Gray, Andrew R.; Hammond-Tooke, Graeme D.; McCrory, Paul R.			Normative values for three clinical measures of motor performance used in the neurological assessment of sports concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Normal values; Postural balance; Coordination impairment; Reliability; Time	TO-NOSE TEST; POSTURAL STABILITY; STANDING BALANCE; TESTS; RELIABILITY; ADULTS; SCORES; AGE	Postural control and motor coordination are essential components of normal athletic activity. Tasks involving balance and coordination are used to determine neurological function in sports-related concussion. Determining normative values for these tasks is therefore essential to provide sports medicine professionals with a frame of reference with which to interpret clinical measures obtained from players suspected of sustaining a concussion. One hundred and seventytwo healthy subjects (16-37 yrs) performed three timed tests: Tandem Gait (TG); Finger-to-Nose (FTN); Single-Lee-Stance (SLS) on firm and foam surfaces. Unadjusted geometric means (+/- SD) for each measure were averaged across three trials. Time to complete TG was 11.2 +/- 1.2 s. FTN for the dominant and non-dominant arm were 2.9 +/- 1.1 s and 3.0 +/- 1.2 s, respectively. SLS values for dominant and non-dominant leg were 20.4 +/- 3.0 s (firm), 3.4 +/- 1.6 s (foam), and 21.0 +/- 2.9 s (firm), 3.3 +/- 1.6s (foam), respectively. For TG, there was an order effect (P<.001) but no age, sex or BMI effects. FTN demonstrated a dominant arm preference (P<.001), sex (P=.006), BM I (P=.043) and order effects (P<.001). SLS demonstrated an order effect on the firm surface (P=.009) and an order (P<.001) and BMI (P=.001) effect on foam. Intra-rater reliability, as measured by ICC (3,3), demonstrated that TG and FTN had excellent reliability compared to SLS. FIN and TG should continue to be used in test batteries to determine neurological function in sports-related concussion. (C) 2009 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Schneiders, Anthony G.; Sullivan, S. John] Univ Otago, Ctr Physiotherapy Res, Christchurch, New Zealand; [Gray, Andrew R.] Univ Otago, Dept Prevent & Social Med, Christchurch, New Zealand; [Hammond-Tooke, Graeme D.] Univ Otago, Dept Med & Surg Sci, Christchurch, New Zealand; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia	Schneiders, AG (corresponding author), Univ Otago, Ctr Physiotherapy Res, Christchurch, New Zealand.	tony.schneiders@otago.ac.nz	Gray, Andrew Robert/L-9161-2015; McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	Gray, Andrew Robert/0000-0003-4299-2194; McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879	New Zealand Society of Physiotherapists Scholarship Trust Fund; University of Otago Research Grant	Supported by the New Zealand Society of Physiotherapists Scholarship Trust Fund and a University of Otago Research Grant.	BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; BORNSTEIN RA, 1986, J CLIN EXP NEUROPSYC, V8, P12, DOI 10.1080/01688638608401293; Bressel E, 2007, J ATHL TRAINING, V42, P42; Brouwer B, 1998, SCAND J REHABIL MED, V30, P131; Cohen H, 1996, AGE AGEING, V25, P39, DOI 10.1093/ageing/25.1.39; Deliagina TG, 2006, PHYSIOLOGY, V21, P216, DOI 10.1152/physiol.00001.2006; DESROSIERS J, 1995, AGE AGEING, V24, P108, DOI 10.1093/ageing/24.2.108; Feys PG, 2003, ARCH PHYS MED REHAB, V84, P79, DOI 10.1053/apmr.2003.50068; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; Giorgetti M M, 1998, Physiother Res Int, V3, P274, DOI 10.1002/pri.150; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HAGEMAN PA, 1995, ARCH PHYS MED REHAB, V76, P961, DOI 10.1016/S0003-9993(95)80075-1; Haupstein T, 2000, Physiother Res Int, V5, P141, DOI 10.1002/pri.195; Isles RC, 2004, J AM GERIATR SOC, V52, P1367, DOI 10.1111/j.1532-5415.2004.52370.x; JOHNSTON K, 1998, CAN J NEUROL SCI, V25, pS98; Jonsson E, 2004, CLIN BIOMECH, V19, P688, DOI 10.1016/j.clinbiomech.2004.04.002; Kammerlind AS, 2005, EUR J PHYSIOTHER, V7, P96, DOI 10.1080/14038190510010403; Largo RH, 2001, DEV MED CHILD NEUROL, V43, P444, DOI 10.1017/S0012162201000822; Linnet K, 2000, CLIN CHEM, V46, P867; Madhavan S, 2005, EXP BRAIN RES, V164, P18, DOI 10.1007/s00221-004-2208-3; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Newton RA, 1997, ARCH PHYS MED REHAB, V78, P587, DOI 10.1016/S0003-9993(97)90423-8; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pendergrass TL, 2003, MIL MED, V168, P896; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneiders AG, 2008, BRIT J SPORT MED, V42, P1011, DOI 10.1136/bjsm.2007.041665; Shumway-cook A., 2006, MOTOR CONTROL TRANSL; Swaine BR, 2005, ARCH PHYS MED REHAB, V86, P1665, DOI 10.1016/j.apmr.2004.11.021; SWAINE BR, 1993, PHYS THER, V73, P71, DOI 10.1093/ptj/73.2.71; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Warren J, 2006, PHYS THER SPORT, V7, P185, DOI 10.1016/j.ptsp.2006.06.002	32	43	43	0	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAR	2010	13	2					196	201		10.1016/j.jsams.2009.05.004			6	Sport Sciences	Sport Sciences	577MR	WOS:000276228100002	19560971				2021-06-18	
J	Kozak, LR; Bango, M; Szabo, M; Rudas, G; Vidnyanszky, Z; Nagy, Z				Kozak, L. R.; Bango, M.; Szabo, M.; Rudas, G.; Vidnyanszky, Z.; Nagy, Z.			Using diffusion MRI for measuring the temperature of cerebrospinal fluid within the lateral ventricles	ACTA PAEDIATRICA			English	Article						Asphyxia; Diffusion; Magnetic resonance imaging; Temperature; Thermometry	MODERATE HYPOTHERMIA; HUMAN MUSCLE; BRAIN; THERMOMETRY; HYPERTHERMIA; SYSTEMS; INJURY	Aim: Hypothermia is often induced to reduce brain injury in newborns, following perinatal hypoxic-ischaemic events, and in adults following traumatic brain injury, stroke or cardiac arrest. We aimed to devise a method, based on diffusion-weighted MRI, to measure non-invasively the temperature of the cerebrospinal fluid in the lateral ventricles. Methods: The well-known temperature dependence of the water diffusion constant was used for the estimation of temperature. We carried out diffusion MRI measurements on a 3T Philips Achieva Scanner involving phantoms (filled with water or artificial cerebrospinal fluid while slowly cooling from 41 to 32 degrees C) and healthy adult volunteers. Results: The estimated temperature of water phantoms followed that measured using a mercury thermometer, but the estimates for artificial cerebrospinal fluid were 1.04 degrees C lower. After correcting for this systematic difference, the estimated temperature within the lateral ventricles of volunteers was 39.9 degrees C. Using diffusion directions less sensitive to cerebrospinal fluid flow, it was 37.7 degrees C, which was in agreement with the literature. Conclusion: Although further improvements are needed, measuring the temperature within the lateral ventricles using diffusion MRI is a viable method that may be useful for clinical applications. We introduced the method, identified sources of error and offered remedies for each.	[Kozak, L. R.; Bango, M.; Rudas, G.; Vidnyanszky, Z.] Semmelweis Univ, Szentagothai J Knowledge Ctr, MR Res Ctr, H-1083 Budapest, Hungary; [Bango, M.; Szabo, M.] Semmelweis Univ, Dept Pediat 1, H-1083 Budapest, Hungary; [Vidnyanszky, Z.] Semmelweis Univ, Pazmany Peter Catholic Univ, Hungarian Acad Sci, Neurob Res Grp, H-1083 Budapest, Hungary; [Nagy, Z.] UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Nagy, Z.] Karolinska Univ Hosp, Neonatal Unit, Dept Woman & Child Hlth, Stockholm, Sweden	Kozak, LR (corresponding author), Semmelweis Univ, Szentagothai J Knowledge Ctr, MR Res Ctr, Balassa U 6, H-1083 Budapest, Hungary.	lkozak@mrkk.sote.hu	Nagy, Zoltan/AAI-2485-2019; Kozak, Lajos R/B-4194-2011	Nagy, Zoltan/0000-0001-6611-6362; Kozak, Lajos R/0000-0003-0368-3663	Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [T048949]; Bolyai FellowshipHungarian Academy of Sciences; Wellcome Trust (UK)Wellcome Trust	The authors thank Dr Attila Ambrus, PhD, from the Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary and Dr Gabor Vass, PhD, from the Institute of Chemistry, Eotvos Lorand University, Budapest, Hungary for their kind assistance in the preparation of the artificial cerebrospinal fluid that was used in the phantom experiments. This study was supported by the Hungarian Scientific Research Fund (T048949) and by the Bolyai Fellowship to ZV. ZN enjoys support from the Wellcome Trust (UK).	BEERS MH, 1999, MERCK MANUAL DIAGNOS; Bevington PR., 2003, DATA REDUCTION ERROR; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CADY EB, 1995, MAGN RESON MED, V33, P862, DOI 10.1002/mrm.1910330620; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cheung Ka Wai, 2006, CJEM, V8, P329; Davson H, 1987, PHYSL PATHOPHYSIOLOG; den Hertog Heleen, 2007, Expert Rev Neurother, V7, P155, DOI 10.1586/14737175.7.2.155; DEPOORTER J, 1995, MAGNET RESON MED, V33, P74; Einstein A., 1956, INVESTIGATIONS THEOR; Il'yasov KA, 1998, J MAGN RESON IMAGING, V8, P1296; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kingsley PB, 2004, MAGNET RESON MED, V51, P996, DOI 10.1002/mrm.20059; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1989, RADIOLOGY, V171, P853, DOI 10.1148/radiology.171.3.2717764; Mcilvoy Laura, 2004, J Neurosci Nurs, V36, P23; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; MORVAN D, 1993, MAGNET RESON MED, V29, P371, DOI 10.1002/mrm.1910290313; Nagy Z, 2007, MAGN RESON MED, V58, P763, DOI 10.1002/mrm.21379; Rieke V, 2008, J MAGN RESON IMAGING, V27, P376, DOI 10.1002/jmri.21265; ROBERTSON NJ, 2007, P PEAD AC SOC C TOR; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Tofts PS, 2008, MAGN RESON MED, V59, P190, DOI 10.1002/mrm.21456; Tumani H, 2009, NEUROBIOL DIS, V35, P117, DOI 10.1016/j.nbd.2009.04.010; Whitelaw A, 2002, NEWBORN BRAIN: NEUROSCIENCE AND CLINICAL APPLICATIONS, P415; Xing D, 1997, MAGN RESON IMAGING, V15, P771, DOI 10.1016/S0730-725X(97)00037-4; Zougman A, 2008, J PROTEOME RES, V7, P386, DOI 10.1021/pr070501k	31	43	45	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253			ACTA PAEDIATR	Acta Paediatr.	FEB	2010	99	2					237	243		10.1111/j.1651-2227.2009.01528.x			7	Pediatrics	Pediatrics	541VS	WOS:000273449700018	19845565	Green Published			2021-06-18	
J	McKinlay, A; Kyonka, EGE; Grace, RC; Horwood, LJ; Fergusson, DM; MacFarlane, MR				McKinlay, A.; Kyonka, E. G. E.; Grace, R. C.; Horwood, L. J.; Fergusson, D. M.; MacFarlane, M. R.			An investigation of the pre-injury risk factors associated with children who experience traumatic brain injury	INJURY PREVENTION			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL FUNCTION; PSYCHOSOCIAL OUTCOMES; MATERNAL DEPRESSION; BEHAVIOR PROBLEMS; ADOLESCENTS; FAMILY; CHILDHOOD; PREDICTORS; ACCIDENTS	Background and Objective Traumatic brain injury (TBI) is a frequently occurring event in childhood that may have significant ongoing effects. Little is known about the child and family characteristics that predispose children to these injuries. A greater understanding of the risk factors associated with childhood TBI may provide an opportunity to prevent their occurrence. Methods Information provided by a large birth cohort study (n = 1265) was used to determine the child and family risk factors of TBI in children aged 0-15 years (n = 187). All information regarding child, family, and injury events were collected prospectively and unrelated to the injury event itself. Child variables included in the analysis were sex and the level of behavioural problems. Parental variables included were family socioeconomic status, mother's age, education level, depressive symptoms, number of adverse life events experienced by the family, and parenting style. Results The most important risk factors were sex, adverse life events, and parenting style. The results suggest evidence of modest increases in the rate of TBI for those in the highest risk categories (male, >= 4 life events per annum, high maternal punitiveness) compared to the lowest risk categories, with hazard ratios in the region of 1.4-1.6. Conclusions Overall characteristics of both the family and child predicted a TBI event. An increased understanding of risks associated with TBI in childhood will provide an avenue to prevent these injuries by targeting at-risk families and aiding the development of appropriate intervention strategies.	[McKinlay, A.; Kyonka, E. G. E.; Grace, R. C.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Kyonka, E. G. E.] W Virginia Univ, Morgantown, WV 26506 USA; [Horwood, L. J.; Fergusson, D. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand; [MacFarlane, M. R.] Christchurch Hosp, Dept Neurosurg, Christchurch, New Zealand	McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		Grace, Randolph/0000-0003-1115-6089; McKinlay, Audrey/0000-0001-9846-8514; Horwood, L./0000-0003-4881-1956; Fergusson, David/0000-0002-8117-017X; Kyonka, Elizabeth/0000-0001-7974-6080	Health Research Council of New ZealandHealth Research Council of New Zealand; National Child Health Research Foundation; Canterbury Medical Research Foundation; New Zealand Lottery Grants Board	The Christchurch Health and Development Study has been funded by grants from the Health Research Council of New Zealand, the National Child Health Research Foundation, the Canterbury Medical Research Foundation, and the New Zealand Lottery Grants Board. This research was funded by grants from the Canterbury Medical Research Foundation and the New Zealand Lottery Grants Board. The research was conducted during tenure of an ACC Post-Doctoral Research Career Development Award from the Health Research Council of New Zealand and the Accident Compensation Corporation.	BIJUR PE, 1990, PEDIATRICS, V86, P337; BRADLEY RH, 1977, AM J MENT DEF, V81, P417; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CASEY R, 1987, PEDIATRICS, V80, P159; CHESS S, 1966, J AMER ACAD CHILD PS, V5, P226, DOI 10.1016/S0002-7138(09)62054-9; Damashek A, 2009, J PEDIATR PSYCHOL, V34, P344, DOI 10.1093/jpepsy/jsn097; DAVIDSON LL, 1988, PEDIATRICS, V82, P644; Demellweek Colin, 2002, Pediatr Rehabil, V5, P81, DOI 10.1080/136384902320807194; EATON WO, 1986, PSYCHOL BULL, V100, P19, DOI 10.1037/0033-2909.100.1.19; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; Fergusson DM, 1998, J EMOT BEHAV DISORD, V6, P2, DOI 10.1177/106342669800600101; FERGUSSON DM, 1985, PEDIATRICS, V75, P30; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Horwood LJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e9; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LANGLEY J, 1980, AUST PAEDIATR J, V16, P244; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, BRAIN INJURY, V12, P41; McGraw MB, 1941, CHILD DEV, V12, P255; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MCKINLAY A, CHILD HLTH CARE DEV, DOI DOI 10.1111/J.1365-2214.2009.00947.X; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Morrongiello BA, 2004, INJURY PREV, V10, P114, DOI 10.1136/ip.2003.003459; O'Connor TG, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.5.e68; PILOWSKY I, 1969, BRIT J PSYCHIAT, V115, P937, DOI 10.1192/bjp.115.525.937; PLESS IB, 1989, AM J PUBLIC HEALTH, V79, P995, DOI 10.2105/AJPH.79.8.995; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schwebel DC, 2008, J PEDIATR PSYCHOL, V33, P1108, DOI 10.1093/jpepsy/jsn046; SILVA PA, 1996, DUNEDIN MULTIDISCIPL; Stratton G, 2007, OBESITY, V15, P1513, DOI 10.1038/oby.2007.179; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Uno D, 1998, J YOUTH ADOLESCENCE, V27, P585, DOI 10.1023/A:1022883023725	48	43	43	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	FEB	2010	16	1					31	35		10.1136/ip.2009.022483			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	569GQ	WOS:000275585000008	20179033				2021-06-18	
J	Saljo, A; Bolouri, H; Mayorga, M; Svensson, B; Hamberger, A				Saljo, Annette; Bolouri, Hayde; Mayorga, Maria; Svensson, Berndt; Hamberger, Anders			Low-Level Blast Raises Intracranial Pressure and Impairs Cognitive Function in Rats: Prophylaxis with Processed Cereal Feed	JOURNAL OF NEUROTRAUMA			English	Article						blast; intracranial pressure; cognitive function; traumatic brain injury treatment	TRAUMATIC BRAIN-INJURY; HUMAN CEREBROSPINAL-FLUID; CLOSED-HEAD INJURY; ATRIAL-NATRIURETIC-PEPTIDE; ANTISECRETORY FACTOR; KETOGENIC DIET; NA+/K+ PUMP; CELL-DEATH; MODEL; DEFICITS	There is increasing evidence that even low levels of blast cause brain injury, but little is known about their thresholds and mechanisms. Exposure of rats to 10-60 kPa blasts elevate intracranial pressure (ICP) in a dose-dependent manner and impair cognitive function. We have evaluated a prophylactic measure against these brain injuries in a rat animal model, consisting of feeding them processed cereal. This type of feed is known to ameliorate disturbances in secretion of body fluids and to have anti-inflammatory effects. In humans, intake of processed cereals is effective against intestinal diarrhea and also reduces the symptoms of Meniere's disease. Rats were given either standard laboratory feed or processed cereal feed for 2 weeks before exposure to blast in a shock tube. The ICP was monitored at different time points up to 1 week after exposure to a 60-kPa blast, and for up to 24 h after exposure to a 30-kPa blast. Maximal ICP elevation was reached at 10 h in both groups. In the group of rats on standard feed exposed to 60 kPa, an ICP increase of 145% was noted at 10 h, and the corresponding increase in the rats fed processed cereal feed was only 50%. In rats exposed to a 30-kPa blast, those fed standard feed and processed cereal feed demonstrated increases of ICP of 80% and 40%, respectively. Cognitive function as measured by the Morris water maze was assessed in other groups of rats at 2 days after exposure to 10- or 30-kPa blasts. Their performance was significantly impaired at both exposure levels in rats on standard feed, but no functional impairment was seen in rats fed processed cereal feed.	[Saljo, Annette] Univ Gothenburg, Inst Biomed, Sect Med Chem & Cell Biol, Sahlgren Acad,Dept Med Chem & Cell Biol, SE-40530 Gothenburg, Sweden	Saljo, A (corresponding author), Univ Gothenburg, Inst Biomed, Sect Med Chem & Cell Biol, Sahlgren Acad,Dept Med Chem & Cell Biol, Box 440, SE-40530 Gothenburg, Sweden.	annette.saljo@anatcell.gu.se			Swedish Armed ForcesFMV and Svenska Militarlakareforeningen	The authors want to express their gratitude to Svante Hojer, Samba Sensors AB, Vastra Frolunda, Sweden, for sharing with us his knowledge of pressure sensors and pressure recording; to Stefan Lange, Department of Infectious Medicine, Sahlgrenska Academy, Goteborg, Sweden; and Lantmannen AS-Faktor AB, Stockholm, Sweden, for providing advice and the cereal feed. This study was supported by grants from the Swedish Armed ForcesFMV and Svenska Militarlakareforeningen.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bjorck S, 2000, GUT, V46, P824, DOI 10.1136/gut.46.6.824; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLERICO A, 1992, CLIN CHEM, V38, P504; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; HALPERIN JA, 1985, LIFE SCI, V37, P561, DOI 10.1016/0024-3205(85)90469-2; HALPERIN JA, 1988, J BIOL CHEM, V263, P646; Hamberger A, 2003, NEUROCHEM RES, V28, P177, DOI 10.1023/A:1022364830421; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hanner P, 2004, HEARING RES, V190, P31, DOI 10.1016/S0378-5955(03)00368-X; HANNER P, 2009, ACTA OTO-LARYNGOL, P1; Hoane MR, 2008, MAGNESIUM RES, V21, P29; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; Jennische E, 2008, BRAIN RES, V1227, P189, DOI 10.1016/j.brainres.2008.05.083; JOHANSSON E, 1995, J BIOL CHEM, V270, P20615, DOI 10.1074/jbc.270.35.20615; Johansson E, 1997, BBA-MOL BASIS DIS, V1362, P177, DOI 10.1016/S0925-4439(97)00066-5; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Lange S, 2001, INT REV CYTOL, V210, P39; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LONNROTH I, 1988, COMP BIOCHEM PHYS A, V90, P611, DOI 10.1016/0300-9629(88)90675-5; LORENZO AV, 1989, Z KINDERCHIR, V44, P24; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYORGA MA, 2008, SPANISH J NEUROPSYCH, V10, P109; Mendelson WB, 1999, NEUROREPORT, V10, P3237, DOI 10.1097/00001756-199910190-00021; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NEWMAN LA, 2003, CARING OUR SOLDIERS, P10; Orban JC, 2007, ANN FR ANESTH, V26, P440, DOI 10.1016/j.annfar.2007.03.001; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; PRUSACZYK WK, 2008, ANN BATTL HEALTHC C; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; ROSENBERG GA, 1995, STROKE, V26, P874, DOI 10.1161/01.STR.26.5.874; SALJO A, 2009, J NEUROTRAUMA; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Westhout FD, 2008, SURG NEUROL, V70, P70, DOI 10.1016/j.surneu.2007.04.020; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099	61	43	43	1	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					383	389		10.1089/neu.2009.1053			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800011	19852583				2021-06-18	
J	Yasuda, H; Kuroda, S; Shichinohe, H; Kamei, S; Kawamura, R; Iwasaki, Y				Yasuda, Hiroshi; Kuroda, Satoshi; Shichinohe, Hideo; Kamei, Shintaro; Kawamura, Ryoichi; Iwasaki, Yoshinobu			Effect of biodegradable fibrin scaffold on survival, migration, and differentiation of transplanted bone marrow stromal cells after cortical injury in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						bone marrow stromal cell; transplantation; fibrin; scaffold; brain injury	TRAUMATIC BRAIN-INJURY; MICE CEREBRAL INFARCT; SPINAL-CORD-INJURY; STEM-CELLS; ACID RECEPTOR; HEART-TISSUE; ADULT; TRACKING; REPAIR; REGENERATION	Object. In this study the authors' aim was to assess whether fibrin matrix could act as an injectable, valuable scaffold in bone marrow stromal cell (BMSC) transplantation for injured CNS tissue. Methods. Both clotting time and 31) structure of fibrin matrix were analyzed with various concentrations of fibrinogen and CaCl2. The BMSCs were harvested from green fluorescent protein-transgenic mice and cultured. A cortical lesion was produced in rats by application of a very cold rod to the right cerebral hemisphere. The BMSCs, fibrin matrix, or BMSC-fibrin matrix complex was transplanted into the lesion though a small bur hole 7 days after the insult. Using immunohistochemical analysis, the authors evaluated the survival, migration, and differentiation of the transplanted cells 4 weeks after transplantation. Results. Based on in vitro observations, the concentrations of fibrinogen and CaCl2 were fixed at 2.5 mg/ml and 2 mu M in animal experiments, respectively. Fibrin matrix almost completely disappeared 4 weeks after transplantation. However, immunohistochemical analysis revealed that fibrin matrix exclusively enhanced the retention of the transplanted cells within the lesion. migration toward the lesion boundary zone, and differentiation into the neurons and perivascular cells. Conclusions. Injectable fibrin matrix enhanced the Survival, migration, and differentiation of the BMSCs transplanted into the cortical lesion in rats. The authors believe that it is one of the promising candidates for a potential, minimally invasive scaffold for CNS disorders. The present findings strongly suggest that such a strategy of tissue engineering could be a therapeutic option for CNS regeneration in patients with CNS injuries. (DOI: 10.3171/10.3171/2009.2.JNS08495)	[Kuroda, Satoshi] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Kamei, Shintaro; Kawamura, Ryoichi] Chemo Sero Therapeut Res Inst, Kumamoto, Japan	Kuroda, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012		Ministry of Education, Science and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [14370424, 15390426, 17390389, 18390387, 19390371]	This study was supported by Grants-in-Aid from the Ministry of Education, Science and Culture of Japan (Grant Nos. 14370424, 15390426, 17390389, 18390387, and 19390371). The authors report no other conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P330, DOI 10.3171/spi.2004.1.3.0330; Bretland AJ, 2001, CELL PROLIFERAT, V34, P199, DOI 10.1046/j.1365-2184.2001.00198.x; Christman KL, 2004, J AM COLL CARDIOL, V44, P654, DOI 10.1016/j.jacc.2004.04.040; Cox S, 2004, TISSUE ENG, V10, P942, DOI 10.1089/1076327041348392; de Haro J, 2005, NEUROSCI LETT, V377, P7, DOI 10.1016/j.neulet.2004.11.060; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Lacza Z, 2003, BRAIN RES PROTOC, V11, P145, DOI 10.1016/S1385-299X(03)00039-4; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Leor J, 2000, CIRCULATION, V102, P56; Lesny P, 2002, J CHEM NEUROANAT, V23, P243, DOI 10.1016/S0891-0618(02)00011-X; LI RK, 1999, CIRCULATION S, V100, P1163; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Ma W, 2004, EXP NEUROL, V190, P276, DOI 10.1016/j.expneurol.2003.10.016; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Masuda S, 2008, ADV DRUG DELIVER REV, V60, P277, DOI 10.1016/j.addr.2007.08.031; Novikova LN, 2006, J BIOMED MATER RES A, V77A, P242, DOI 10.1002/jbm.a.30603; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Ryu JH, 2005, BIOMATERIALS, V26, P319, DOI 10.1016/j.biomaterials.2004.02.058; Sawamura Y, 1999, NEUROSURGERY, V44, P332, DOI 10.1097/00006123-199902000-00048; Shi EY, 2006, ANN THORAC SURG, V81, P2227, DOI 10.1016/j.athoracsur.2005.12.056; Shichinohe H, 2004, BRAIN RES PROTOC, V13, P166, DOI 10.1016/j.brainresprot.2004.04.004; Shichinohe H, 2007, BRAIN RES, V1183, P138, DOI 10.1016/j.brainres.2007.08.091; Shichinohe H, 2006, J NUCL MED, V47, P486; Sykova E, 2005, ANN NY ACAD SCI, V1049, P146, DOI 10.1196/annals.1334.014; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Terasaka S, 2006, NEUROSURGERY, V58, P134, DOI 10.1227/01.NEU.0000193515.95039.49; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Yamada Y, 2003, J CRANIO MAXILL SURG, V31, P27, DOI 10.1016/S1010-5182(02)00143-9; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Yano S, 2005, J NEUROTRAUM, V22, P907, DOI 10.1089/neu.2005.22.907; Yano S, 2006, J NEUROTRAUM, V23, P1682, DOI 10.1089/neu.2006.23.1682; Zimmermann WH, 2004, BIOMATERIALS, V25, P1639, DOI 10.1016/S0142-9612(03)00521-0; Zimmermann WH, 2002, CIRCULATION, V106, pI151, DOI 10.1161/01.cir.0000032876.55215.10	39	43	45	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2010	112	2					336	344		10.3171/2009.2.JNS08495			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	550CX	WOS:000274107000020	19267524				2021-06-18	
J	Arun, P; Ariyannur, PS; Moffett, JR; Xing, GQ; Hamilton, K; Grunberg, NE; Ives, JA; Namboodiri, AMA				Arun, Peethambaran; Ariyannur, Prasanth S.; Moffett, John R.; Xing, Guoqiang; Hamilton, Kristen; Grunberg, Neil E.; Ives, John A.; Namboodiri, Aryan M. A.			Metabolic Acetate Therapy for the Treatment of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ATP; glyceryltriacetate; myelin synthesis; N-acetylaspartate	CONTROLLED CORTICAL IMPACT; N-ACETYLASPARTATE; MITOCHONDRIAL DYSFUNCTION; KETOGENIC DIET; RATS; SYNTHETASE; OXIDATION; SEVERITY; PROTEINS; JUVENILE	Patients suffering from traumatic brain injury (TBI) have decreased markers of energy metabolism, including N-acetylaspartate (NAA) and ATP. In the nervous system, NAA-derived acetate provides acetyl-CoA required for myelin lipid synthesis. Acetate can also be oxidized in mitochondria for the derivation of metabolic energy. In the current study, using the controlled cortical impact model of TBI in rats, we investigated the effects of the hydrophobic acetate precursor, glyceryltriacetate (GTA), as a method of delivering metabolizable acetate to the injured brain. We found that GTA administration significantly increased the levels of both NAA and ATP in the injured hemisphere 4 and 6 days after injury, and also resulted in significantly improved motor performance in rats 3 days after injury.	[Arun, Peethambaran; Ariyannur, Prasanth S.; Moffett, John R.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Neurosci Program, Bethesda, MD 20814 USA; [Arun, Peethambaran; Ariyannur, Prasanth S.; Moffett, John R.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Mol & Cell Biol Program, Bethesda, MD 20814 USA; [Xing, Guoqiang] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Hamilton, Kristen; Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Ives, John A.] Samueli Inst, Alexandria, VA USA	Namboodiri, AMA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	anamboodiri@usuhs.mil	Xing, Guoqiang/ABA-8450-2020; Messier, Claude/A-2322-2008; Ariyannur, Prasanth S./C-1280-2008; Hamilton, Kristen/B-8116-2015	Messier, Claude/0000-0002-4791-1763; Ariyannur, Prasanth S./0000-0003-0888-8094; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS RO1/R56, 039387]; Samueli Institute; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-2-0009]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039387] Funding Source: NIH RePORTER	This work was supported by grants from the NIH (NS RO1/R56; 039387) and the Samueli Institute (G170VR-under Award No. W81XWH-06-2-0009 from the U.S. Army Medical Research and Materiel Command).	Adibhatla RM, 2006, AAPS J, V8, pE314; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Arun P, 2008, J NEUROCHEM, V106, P1669, DOI 10.1111/j.1471-4159.2008.05524.x; BAILEY JW, 1991, JPEN-PARENTER ENTER, V15, P32, DOI 10.1177/014860719101500132; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Dash RR, 2009, J HAZARD MATER, V163, P1, DOI 10.1016/j.jhazmat.2008.06.051; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Madhavarao CN, 2009, J INHERIT METAB DIS, V32, P640, DOI 10.1007/s10545-009-1155-3; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Mathew R, 2005, J PHARMACOL EXP THER, V315, P297, DOI 10.1124/jpet.105.087536; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Nikolau BJ, 2000, BIOCHEM SOC T, V28, P591, DOI 10.1042/BST0280591; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	29	43	43	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					293	298		10.1089/neu.2009.0994			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200026	19803785	Green Published			2021-06-18	
J	Culley, C; Evans, JJ				Culley, Campbell; Evans, Jonathan J.			SMS text messaging as a means of increasing recall of therapy goals in brain injury rehabilitation: A single-blind within-subjects trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Goal-setting; Traumatic brain injury; Memory rehabilitation; External memory aid	MEMORY AID; PERFORMANCE	A single-blind within-subjects trial was used to test the efficacy of sending SMS text messages to patients with a traumatic brain injury as a means of improving their recall of rehabilitation goals. Eleven participants were recruited from two community-based rehabilitation centres and were sent text messages relating to three randomly selected goals from a selection of six current goals three times per day for 14 days. Participants' recall of their rehabilitation goals was assessed at baseline, seven days, and 14 days via free recall and cued recall procedures. Results showed that goals in the otexto condition were recalled better than goals in the ono texto condition. Practical applications and extensions are discussed.	[Culley, Campbell; Evans, Jonathan J.] Univ Glasgow, Fac Med, Sect Psychol Med, Glasgow G12 0XH, Lanark, Scotland	Evans, JJ (corresponding author), Univ Glasgow, Fac Med, Sect Psychol Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	Jonathan.evans@clinmed.gla.ac.uk			NHS Education for Scotland; Sackler Foundation	We are grateful to all of the participants who took part in this study and to staff at the Community Treatment Centre for Brain Injury, Glasgow and the Central Scotland Brain Injury Rehabilitation Centre, Wishaw for their assistance with this study. We are also grateful to two anonymous reviewers for their helpful suggestions for improvements to the manuscript, and to NHS Education for Scotland and the Sackler Foundation for financial support.	BARRACLOUGH C, 1986, BEHAV PHYSCHOTHERAPY, V14, P183; Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; Bryman A, 1990, QUANTITATIVE DATA AN; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; FUCHS LS, 1986, EXCEPT CHILDREN, V53, P199; Gauggel S., 1998, NEUROPSYCHOLOGICAL R; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Hole G., 2003, DESIGN REPORT EXPT; HOUTS PS, 1975, GOAL ATTAINMENT REV, V2, P33; Hurn J, 2006, CLIN REHABIL, V20, P756, DOI 10.1177/0269215506070793; KENNEDY P, 1991, PARAPLEGIA, V29, P197, DOI 10.1038/sc.1991.28; LAPORTE RE, 1976, J EDUC PSYCHOL, V68, P260, DOI 10.1037/0022-0663.68.3.260; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; LOCKE EA, 1981, PSYCHOL BULL, V90, P125, DOI 10.1037/0033-2909.90.1.125; McMillan TM, 1999, NEUROPSYCHOL REHABIL, V9, P241, DOI 10.1080/096020199389356; *MOB DAT ASS, 2008, Q1 2008 UK MOB TREND; Pijnenborg GHM, 2007, REHABIL PSYCHOL, V52, P236, DOI 10.1037/0090-5550.52.2.236; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Theodorakis Y, 1997, J SPORT REHABIL, V6, P355, DOI 10.1123/jsr.6.4.355; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WARD C, 1993, NEUROLOGICAL REHABIL, P13; Wechsler D., 2001, WECHSLER TEST ADULT; WILSON B, 1989, MODELS BRAIN INJURY, P117; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874	29	43	43	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	1					103	119	PII 911703432	10.1080/09602010902906926			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	530SB	WOS:000272611500006	19468962				2021-06-18	
J	Lyons, RA; Finch, CF; McClure, R; van Beeck, E; Macey, S				Lyons, Ronan A.; Finch, Caroline F.; McClure, Rod; van Beeck, Ed; Macey, Steven			The injury List Of All Deficits (LOAD) Framework - conceptualising the full range of deficits and adverse outcomes following injury and violence	INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION			English	Article						burden of injury; disability; injury outcomes	TRAUMATIC BRAIN-INJURY; PUBLIC-HEALTH IMPACT; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS; CHILDHOOD EXPERIENCES; TRAFFIC FATALITIES; MAJOR TRAUMA; RISK-FACTORS; HEAD-INJURY; DRUG-USE	Over recent years, there has been increasing recognition that the burden of injuries and violence includes more than just the direct and indirect monetary costs associated with their medical outcomes. However, quantification of the total burden has been seriously hampered by lack of a framework for considering the range of outcomes which comprise the burden, poor identification of the outcomes and their imprecise measurement. This article proposes a new conceptual framework, the List of All Deficits (or LOAD) Framework, that has been developed from extensive expert discussion and consensus meetings to facilitate the measurement of the full burden of injuries and violence. The LOAD Framework recognises the multidimensional nature of injury burden across individual, family and societal domains. This classification of potential consequences of injury was built on the International Classification of Functioning concept of disability. Examples of empirical support for each consequence were obtained from the scientific literature. Determining the multidimensional injury burden requires the assessment and combination of 20 domains of potential consequences. The resulting LOAD Framework classification and concept diagram describes 12 groups of injury consequences for individuals, three for family and close friends and five for wider society. Understanding the extent of the negative implications (or deficits) of injury, through application of the LOAD Framework, is needed to put existing burden of injury studies into context and to highlight the inter-relationship between the direct and indirect burden of injury relative to other conditions.	[Lyons, Ronan A.; Macey, Steven] Swansea Univ, Sch Med, Swansea SA2 8PP, W Glam, Wales; [Finch, Caroline F.] Univ Ballarat, Sch Human Movement & Sport Sci, Ballarat, Vic 3353, Australia; [McClure, Rod] Monash Univ, Accid Res Ctr, Clayton, Vic 3800, Australia; [van Beeck, Ed] Erasmus Univ, Med Ctr, Rotterdam, Netherlands	Lyons, RA (corresponding author), Swansea Univ, Sch Med, Swansea SA2 8PP, W Glam, Wales.	r.a.lyons@swansea.ac.uk	Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X; McClure, Roderick/0000-0002-9067-8282	Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/G007543/1] Funding Source: researchfish		Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4; Aoyagi K, 1998, J BONE MINER RES, V13, P1468, DOI 10.1359/jbmr.1998.13.9.1468; Australian Bureau of Statistics, 1999, DIS AG CAR SUMM FIND; Barnes PM, 2001, BRIT MED J, V323, P1034, DOI 10.1136/bmj.323.7320.1034; Barrett DH, 2002, PSYCHOSOMATICS, V43, P195, DOI 10.1176/appi.psy.43.3.195; Blandford JM, 2006, SEX TRANSM DIS, V33, pS117, DOI 10.1097/01.olq.0000235148.64274.2f; Boden LI, 1999, AM J IND MED, V36, P487, DOI 10.1002/(SICI)1097-0274(199911)36:5<487::AID-AJIM1>3.0.CO;2-2; Bonica JJ, 1990, MANAGEMENT PAIN; Boufous S, 2004, AUST NZ J PUBL HEAL, V28, P482, DOI 10.1111/j.1467-842X.2004.tb00032.x; Bradt DA, 2003, ACAD EMERG MED, V10, P650, DOI 10.1197/aemj.10.6.650; BURCHARDT T, 1999, EVOLUTION DISABILITY; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; Casanueva C, 2009, CHILD ABUSE NEGLECT, V33, P84, DOI 10.1016/j.chiabu.2007.04.017; Chang JJ, 2008, CHILD ABUSE NEGLECT, V32, P819, DOI 10.1016/j.chiabu.2007.11.003; Checchi F, 2008, PLOS MED, V5, P1025, DOI 10.1371/journal.pmed.0050146; Chu L. C., 2005, Hong Kong Medical Journal, V11, P391; Cumming RG, 2000, J GERONTOL A-BIOL, V55, pM299, DOI 10.1093/gerona/55.5.M299; Denavas-Walt C., 2007, INCOME POVERTY HLTH, P60; DISELEWIS JE, 2002, BRAINSTARS BRAIN INJ; Dube SR, 2003, PREV MED, V37, P268, DOI 10.1016/S0091-7435(03)00123-3; DUCLOS PJ, 1989, INT J EPIDEMIOL, V18, P213, DOI 10.1093/ije/18.1.213; Edwards RR, 2007, ARCH PHYS MED REHAB, V88, pS36, DOI 10.1016/j.apmr.2007.05.031; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Finch C, 2001, MED SCI SPORT EXER, V33, P778; Finch C, 2006, J SCI MED SPORT, V9, P490, DOI 10.1016/j.jsams.2006.03.002; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FINLEY MA, 2002, J NEUROLOGICAL PHYSI, V26, P21; FORD DV, 2007, EXPL EX DAT HLTH RES; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; GOODCHILD M, 2002, 4171 BERL DEP LAB; *GOV W AUSTR IND L, 2006, FAM CAR PHYS IMP CAR; Greenhalgh DG, 2003, J BURN CARE REHABIL, V24, P159, DOI 10.1097/01.BCR.0000054173.57871.61; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; HIMMELSTEIN DU, 2005, HLTH AFF MILLWOOD S; Hindmarsh DM, 2009, OSTEOPOROSIS INT, V20, P221, DOI 10.1007/s00198-008-0641-z; Holbrook TL, 2007, J TRAUMA, V62, P577, DOI 10.1097/TA.0b013e318031aa97; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Holtslag HR, 2007, INJURY, V38, P280, DOI 10.1016/j.injury.2006.10.026; Holtslag HR, 2008, B WORLD HEALTH ORGAN, V86, P111, DOI 10.2471/BLT.06.033803; Hubbard JR, 1996, AM J DRUG ALCOHOL AB, V22, P215, DOI 10.3109/00952999609001655; Ikossi DG, 2005, J AM COLL SURGEONS, V200, P49, DOI 10.1016/j.jamcollsurg.2004.09.016; *INJ EXP GROUP, 2009, GLOB BURD DIS; JAMISON DT, 1993, DIS CONTROL PRIORITI; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Karam EG, 2008, PLOS MED, V5, P579, DOI 10.1371/journal.pmed.0050061; KAUSAR R, 1999, ASIA PACIFIC DISABIL, V10, P58; Kitzmann KM, 2003, J CONSULT CLIN PSYCH, V71, P339, DOI 10.1037/0022-006X.71.2.339; KLEIN BP, 1984, J OCCUP ENVIRON MED, V26, P443, DOI 10.1097/00043764-198406000-00017; Kopits E, 2005, ACCIDENT ANAL PREV, V37, P169, DOI 10.1016/j.aap.2004.04.006; Kordi R, 2004, BRIT J SPORT MED, V38, P678, DOI 10.1136/bjsm.2004.011643; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kuterovac-Jagodic G, 2003, J CLIN PSYCHOL, V59, P9, DOI 10.1002/jclp.10114; Kvist J, 2005, KNEE SURG SPORT TR A, V13, P393, DOI 10.1007/s00167-004-0591-8; Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43; Lewis M, 2000, WHO IS PAYING HLTH C; Li L, 1998, AM J DRUG ALCOHOL AB, V24, P405, DOI 10.3109/00952999809016906; Lindqvist K, 2002, CROAT MED J, V43, P386; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Mahapatra P, 2002, NATL MED J INDIA, V15, P90; Mashrek SR, 2008, PUBLIC HEALTH, V122, P1418, DOI 10.1016/j.puhe.2008.06.007; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Meerding WJ, 2006, EUR J PUBLIC HEALTH, V16, P271, DOI 10.1093/eurpub/ckl006; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Miller TR, 2000, MED CARE, V38, P562, DOI 10.1097/00005650-200006000-00003; Mirzamani M, 2002, PSYCHOL REP, V90, P431, DOI 10.2466/pr0.2002.90.2.431; Morgan O, 2005, PLOS MED, V2, P491, DOI 10.1371/journal.pmed.0020184; Morgan OW, 2006, PLOS MED, V3, P809, DOI 10.1371/journal.pmed.0030195; Mulder S, 2002, INJURY PREV, V8, P74, DOI 10.1136/ip.8.1.74; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Nicholl JP, 2006, BMJ-BRIT MED J, V332, P1510, DOI 10.1136/bmj.332.7556.1510-a; North CS, 2002, J TRAUMA STRESS, V15, P171, DOI 10.1023/A:1015286909111; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; OLIVER JE, 1993, AM J PSYCHIAT, V150, P1315; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P1281; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Poudel-Tandukar K, 2004, JAMA-J AM MED ASSOC, V291, P2542, DOI 10.1001/jama.291.21.2542-a; Purtscher Katharina, 2005, Int J Inj Contr Saf Promot, V12, P119, DOI 10.1080/17457300500102955; RIVARA FP, 1995, ANN EMERG MED, V26, P609, DOI 10.1016/S0196-0644(95)70013-7; Rivara FP, 2008, ARCH SURG-CHICAGO, V143, P282, DOI 10.1001/archsurg.2007.61; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Rushby JF, 2001, HEALTH POLICY PLANN, V16, P326, DOI 10.1093/heapol/16.3.326; Sabri AA, 2006, PLOS MED, V3, P1452, DOI 10.1371/journal.pmed.0030382; Saxon L, 1999, SPORTS MED, V28, P123, DOI 10.2165/00007256-199928020-00005; Schaal S, 2006, J TRAUMA STRESS, V19, P95, DOI 10.1002/jts.20104; Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Stack S, 2003, J EPIDEMIOL COMMUN H, V57, P238, DOI 10.1136/jech.57.4.238; Thelin N, 2006, SCAND J MED SCI SPOR, V16, P329, DOI 10.1111/j.1600-0838.2005.00497.x; Thombs BD, 2008, J PSYCHOSOM RES, V64, P205, DOI 10.1016/j.jpsychores.2007.09.003; Thompson C, 2006, J Clin Forensic Med, V13, P186, DOI 10.1016/j.jcfm.2006.02.011; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; WANG JS, 1999, J TRANSPORTATION STA, V2, P19; WAUGH JH, 1994, MED J AUSTRALIA, V161, P594, DOI 10.5694/j.1326-5377.1994.tb127637.x; Weiss HB, 2008, ACCIDENT ANAL PREV, V40, P1088, DOI 10.1016/j.aap.2007.11.011; Wiebe DJ, 2006, INJURY PREV, V12, P347, DOI 10.1136/ip.2006.011494; Wilson HW, 2009, AM J PUBLIC HEALTH, V99, pS197, DOI 10.2105/AJPH.2007.131599; World Bank, 1993, WORLD DEV REP 1993 I; World Health Organization, 2001, INT CLASS FUNCT; World Health Organization (WHO), 2008, GLOB BURD DIS 2004 U; Zaloshnja E, 2004, ACCIDENT ANAL PREV, V36, P801, DOI 10.1016/j.aap.2003.07.006; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	109	43	43	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1745-7300	1745-7319		INT J INJ CONTROL SA	Int. J. Inj. Control Saf. Promot.		2010	17	3					145	159	PII 925130240	10.1080/17457300903453104			15	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	635EE	WOS:000280637600003	19946813				2021-06-18	
J	Naphade, SB; Kigerl, KA; Jakeman, LB; Kostyk, SK; Popovich, PG; Kuret, J				Naphade, Swati B.; Kigerl, Kristina A.; Jakeman, Lyn B.; Kostyk, Sandra K.; Popovich, Phillip G.; Kuret, Jeff			Progranulin expression is upregulated after spinal contusion in mice	ACTA NEUROPATHOLOGICA			English	Article						Progranulin; Spinal cord injury; Neurodegeneration; Neuroinflammation; Trauma	FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; CORD-INJURY; EPITHELIN PRECURSOR; INFLAMMATORY RESPONSE; GENETIC-VARIABILITY; MICROARRAY ANALYSIS; ALZHEIMER-DISEASE; GROWTH-FACTOR; BETA-TUBULIN	Progranulin (proepithelin) is a pleiotropic growth-factor associated with inflammation and wound repair in peripheral tissues. It also has been implicated in the response to acute traumatic brain injury as well as to chronic neurodegenerative diseases. To determine whether changes in progranulin expression also accompany acute spinal cord injury, C57BL/6 mice were subjected to mid-thoracic (T9 level) contusion spinal cord injury and analyzed by immunohistochemical and biochemical methods. Whereas spinal cord sections prepared from non-injured laminectomy control animals contained low basal levels of progranulin immunoreactivity in gray matter, sections from injured animals contained intense immunoreactivity throughout the injury epicenter that peaked 7-14 days post injury. Progranulin immunoreactivity colocalized with myeloid cell markers CD11b and CD68, indicating that expression increased primarily in activated microglia and macrophages. Immunoblot analysis confirmed that progranulin protein levels rose after injury. On the basis of quantitative polymerase chain reaction analysis, increased protein levels resulted from a tenfold rise in progranulin transcripts. These data demonstrate that progranulin is dramatically induced in myeloid cells after experimental spinal cord injury and is positioned appropriately both spatially and temporally to influence recovery after injury.	[Naphade, Swati B.; Kuret, Jeff] Ohio State Univ, Coll Med, Ctr Mol Neurobiol, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Kigerl, Kristina A.; Popovich, Phillip G.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Ctr Brain & Spinal Cord Repair, Coll Med, Columbus, OH 43210 USA; [Jakeman, Lyn B.] Ohio State Univ, Dept Cell Biol & Physiol, Ctr Brain & Spinal Cord Repair, Coll Med, Columbus, OH 43210 USA; [Kostyk, Sandra K.] Ohio State Univ, Dept Neurol, Ctr Brain & Spinal Cord Repair, Coll Med, Columbus, OH 43210 USA	Kuret, J (corresponding author), Ohio State Univ, Coll Med, Ctr Mol Neurobiol, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	kuret.3@osu.edu	Jakeman, Lyn/A-5094-2009	Kigerl, Kristina/0000-0002-1652-0882; Jakeman, Lyn/0000-0002-1760-8819; Kostyk, Sandra/0000-0002-3371-753X	Ohio State University Neuroscience Signature ProgramOhio State University; National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Neuroscience Core Center [NS045758]; Ohio State Center for Brain and Spinal Cord Repair; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043246, P30NS045758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG014452] Funding Source: NIH RePORTER	We thank Dr. Mariano Viapiano (Department of Neurosurgery) for guidance with imaging methods. This work was supported by The Ohio State University Neuroscience Signature Program (S.K.K., L.B.J., J.K.), National Institute for Neurological Disorders and Stroke (P.G.P.), Neuroscience Core Center (NS045758), and The Ohio State Center for Brain and Spinal Cord Repair.	Ahmed Z, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-7; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bhandari V, 1996, BIOCHEM J, V319, P441, DOI 10.1042/bj3190441; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Carmel JB, 2004, EXP NEUROL, V185, P81, DOI 10.1016/j.expneurol.2003.09.007; Chen-Plotkin AS, 2010, ACTA NEUROPATHOL, V119, P111, DOI 10.1007/s00401-009-0576-2; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Hanington PC, 2006, J BIOL CHEM, V281, P9963, DOI 10.1074/jbc.M600631200; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOLNESS CL, 1993, BLOOD, V81, P1607; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kojima Y, 2009, ATHEROSCLEROSIS, V206, P102, DOI 10.1016/j.atherosclerosis.2009.02.017; KRAMPS JA, 1983, SCAND J CLIN LAB INV, V43, P427; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Liu NK, 2006, J NEUROTRAUM, V23, P1794, DOI 10.1089/neu.2006.23.1794; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Mackenzie IRA, 2006, BRAIN, V129, P3081, DOI 10.1093/brain/awl271; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Mukherjee O, 2006, ANN NEUROL, V60, P314, DOI 10.1002/ana.20963; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Pereson S, 2009, J PATHOL, V219, P173, DOI 10.1002/path.2580; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Qin JW, 2005, BIOL REPROD, V73, P434, DOI 10.1095/biolreprod.105.040030; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Shankaran SS, 2008, J BIOL CHEM, V283, P1744, DOI 10.1074/jbc.M705115200; Sleegers K, 2008, NEUROLOGY, V71, P253, DOI 10.1212/01.wnl.0000289191.54852.75; Solovjov DA, 2005, J BIOL CHEM, V280, P1336, DOI 10.1074/jbc.M406968200; Sparro G, 1997, PROTEIN EXPRES PURIF, V10, P169, DOI 10.1006/prep.1997.0726; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; van der Zee J, 2007, HUM MUTAT, V28, P416, DOI 10.1002/humu.9484; Youn BS, 2009, DIABETES, V58, P627, DOI 10.2337/db08-1147; Young W, 2002, PROG BRAIN RES, V137, P231; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	62	43	45	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JAN	2010	119	1					123	133		10.1007/s00401-009-0616-y			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	538HE	WOS:000273174400010	19946692	Green Accepted			2021-06-18	
J	Ord, JS; Boettcher, AC; Greve, KW; Bianchini, KJ				Ord, Jonathan S.; Boettcher, Anneliese C.; Greve, Kevin W.; Bianchini, Kevin J.			Detection of malingering in mild traumatic brain injury with the Conners' Continuous Performance Test-II	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Response bias; Malingering; Traumatic brain injury; Neuropsychological assessment; Continuous performance task; Attention	VERBAL-LEARNING TEST; VISUAL MEMORY TEST; NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL EVALUATION; SPECIFICITY; SENSITIVITY; INDICATORS; VALIDATION; SCALES; MMPI-2	Classification accuracy for the detection of malingered neurocognitive dysfunction (MND) in mild traumatic brain injury (TBI) is examined for two selected measures from the Conners' Continuous Performance Test-II (CPT-II) using criterion-groups validation. Individual and joint classification accuracies are presented for Omissions and Hit Reaction Time Standard Error across a range of scores comparing mild TBI malingering (n = 27), mild TBI not-malingering (n = 31), and moderate-to-severe (M/S) TBI not-malingering (n = 24) groups. At cutoffs associated with at least 95% specificity in both mild and M/S TBI, sensitivity to MND in mild TBI was 30% for Omissions, 41% for Hit Reaction Time Standard Error, and 44% using both indicators. These results support the use of the CPT-II as a reliable indicator for the detection of malingering in TBI when used as part of a comprehensive diagnostic system.	[Greve, Kevin W.] Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; [Boettcher, Anneliese C.; Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone, 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Conners C., 2000, CONNERS CONTINUOUS P; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Gouvier WD, 1998, CRIT ISS NE, P55; Green P., 1996, MANUAL COMPUTERISED; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hennekens CH, 1987, EPIDEMIOLOGY MED; Henry GK, 2007, APPL NEUROPSYCHOL, V14, P267, DOI 10.1080/09084280701719245; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Larrabee G.J., 2007, ASSESSMENT MALINGERE; LARRABEE GJ, 2007, EVALUATION MALINGERI, P334; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MEYERS JE, 2002, APPL NEUROPSYCHOL, V7, P133; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Quinn CA, 2003, ARCH CLIN NEUROPSYCH, V18, P379, DOI 10.1016/S0887-6177(02)00150-6; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rogers R, 1997, CLIN ASSESSMENT MALI, P373; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D, 1997, WAIS 3 ADM SCORING M	40	43	44	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	4					380	387		10.1080/13803390903066881			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	589YV	WOS:000277191000005	19739010				2021-06-18	
J	Hu, ZG; Wang, HD; Jin, W; Yin, HX				Hu, Zhi Gang; Wang, Han Dong; Jin, Wei; Yin, Hong Xia			Ketogenic Diet Reduces Cytochrome c Release and Cellular Apoptosis Following Traumatic Brain Injury in Juvenile Rats	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article						traumatic brain injury; ketogenic diet; cytochrome c release; apoptosis; brain edema	FOCAL CEREBRAL-ISCHEMIA; D-BETA-HYDROXYBUTYRATE; KETONE-BODIES; CORTICAL CONTUSION; CASPASE ACTIVATION; DNA FRAGMENTATION; EXPRESSION; MITOCHONDRIAL; BCL-2; DEATH	Ketone bodies have been shown to be favorable alternative metabolic substrates and are protective under neuropathologies. At the same time, cytochrome c release has been reported following traumatic brain injury (TBI) and precipitates apoptosis via the mitochondrial pathway. The present study investigated the effects of a ketogenic diet (KD) on TBI. TBI was produced using the Feeney weight-drop model and the animals were fed either normal diet (ND) or KD. Brain edema was estimated by wet/dry weight ratio; cytochrome c was detected by Western blotting; cellular apoptosis in the penumbra area was examined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and active caspase-3 immunohistochemical staining. The results show that brain edema, cytochrome c release, and cellular apoptosis were induced after TBI and that KD reduced these changes dramatically. These findings suggest that KD has potential therapeutic benefit in TBI.	[Hu, Zhi Gang; Wang, Han Dong; Jin, Wei; Yin, Hong Xia] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020				Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Babu PP, 2000, NEUROSCI LETT, V291, P196, DOI 10.1016/S0304-3940(00)01404-X; Buki A, 2000, J NEUROSCI, V20, P2825; Cheng BH, 2007, AUTON NEUROSCI-BASIC, V134, P38, DOI 10.1016/j.autneu.2007.02.002; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Eun SH, 2006, BRAIN DEV-JPN, V28, P566, DOI 10.1016/j.braindev.2006.03.011; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; HAWKINS RA, 1979, SCIENCE, V205, P325, DOI 10.1126/science.451608; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; Kossoff EH, 2006, EPILEPSIA, V47, P421, DOI 10.1111/j.1528-1167.2006.00438.x; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li JY, 2006, NEUROSCIENCE, V142, P789, DOI 10.1016/j.neuroscience.2006.06.064; Li PA, 2001, BRAIN RES, V896, P69, DOI 10.1016/S0006-8993(01)01997-7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Papandreou D, 2006, BRIT J NUTR, V95, P5, DOI 10.1079/BJN20051591; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reger MA, 2004, NEUROBIOL AGING, V25, P311, DOI 10.1016/S0197-4580(03)00087-3; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; RINK A, 1995, AM J PATHOL, V147, P1575; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VanItallie TB, 2005, NEUROLOGY, V64, P728, DOI 10.1212/01.WNL.0000152046.11390.45; Veech RL, 2001, IUBMB LIFE, V51, P241; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wang XD, 2001, GENE DEV, V15, P2922; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	54	43	44	2	8	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	WIN	2009	39	1					76	83					8	Medical Laboratory Technology	Medical Laboratory Technology	405TP	WOS:000263247400012	19201746				2021-06-18	
J	Roozenbeek, B; Maas, AIR; Lingsma, HF; Butcher, I; Lu, J; Marmarou, A; McHugh, GS; Weir, J; Murray, GD; Steyerberg, EW				Roozenbeek, Bob; Maas, Andrew I. R.; Lingsma, Hester F.; Butcher, Isabella; Lu, Juan; Marmarou, Anthony; McHugh, Gillian S.; Weir, James; Murray, Gordon D.; Steyerberg, Ewout W.		IMPACT Study Grp	Baseline characteristics and statistical power in randomized controlled trials: Selection, prognostic targeting, or covariate adjustment?	CRITICAL CARE MEDICINE			English	Article						covariate adjustment; heterogeneity; randomized controlled trials; selection criteria; statistical power; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SAMPLE-SIZE REQUIREMENTS; CLINICAL-TRIALS; ADMISSION CHARACTERISTICS; MULTICENTER TRIAL; IMPACT; VALIDATION; EFFICACY; DESIGN	Objective. Heterogeneity of patients is a common problem in randomized controlled trials (RCTs) in various fields of clinical research. We aimed to investigate the potential benefits of different approaches for dealing with heterogeneity in a case study on traumatic brain injury (TBI). Design and Setting: Statistical modeling studies in three surveys and six randomized controlled trials. Patients: Individual patient data (n = 8033) from the IMPACT database. Interventions: We investigated the statistical power and efficiency of randomized controlled trials (RCTs) in relation to (1) selection according to baseline characteristics, (2) prognostic targeting (i.e., excluding those with a relatively extreme prognosis), and (3) covariate-adjusted analysis. Statistical power was expressed as the required sample size for obtaining 80% power and efficiency as the relative change in study duration, reflecting both gains in power and adverse effects on recruitment. Uniform and targeted treatment effects were simulated for 6 month unfavorable outcome. Results: For a uniform treatment effect, selection resulted in a sample size reduction of 33% in the surveys and 5% in the RCTs, but decreased recruitment by 65% and 41%, respectively. Hence, the relative study duration was prolonged (surveys: +95%; RCTs: +60%). Prognostic targeting resulted in sample size reductions of 28% and 17%, and increased relative study duration by +5% in surveys and +11% in the RCTs. Covariate adjustment reduced sample sizes by 30% and 16%, respectively, and did not affect recruitment. For a targeted treatment effect, the sample size reductions by selection (surveys: 47%; RCTs: 20%) and prognostic targeting (surveys: 49%; RCTs: 41%) were larger and adverse effects on recruitment smaller. Conclusions. The benefits of selection and prognostic targeting in terms of statistical power are reversed by adverse effects on recruitment. Covariate adjusted analysis in a broadly selected group of patients is advisable if a uniform treatment effect is assumed, since there is no decrease in recruitment. (Crit Care Med 2009; 37:2683-2690)	[Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Butcher, Isabella; McHugh, Gillian S.; Weir, James; Murray, Gordon D.] Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland	Steyerberg, EW (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands.	e.steyerberg@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-42691] Funding Source: Medline		Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; FOULKES AM, 1991, J NEUROSURG, V75, pS8; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; The European Study Group on Nimodipine in Severe Head Injury, 1994, J NEUROSURG, V80, P797; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yusuf S, 1999, BMJ-BRIT MED J, V319, P564, DOI 10.1136/bmj.319.7209.564	20	43	43	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2009	37	10					2683	2690		10.1097/CCM.0b013e3181ab85ec			8	Critical Care Medicine	General & Internal Medicine	499OU	WOS:000270234700001	19885979				2021-06-18	
J	Anderson, J; Sandhir, R; Hamilton, ES; Berman, NEJ				Anderson, Joshua; Sandhir, Rajat; Hamilton, Eric S.; Berman, Nancy E. J.			Impaired Expression of Neuroprotective Molecules in the HIF-1 alpha Pathway following Traumatic Brain Injury in Aged Mice	JOURNAL OF NEUROTRAUMA			English	Article						aging; erythropoietin; HIF-1 alpha; heme oxygenase-1; neuroprotection; traumatic brain injury; VEGF	HYPOXIA-INDUCIBLE FACTOR; CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; ENDOTHELIAL GROWTH-FACTOR; HEME OXYGENASE-1; FACTOR-I; INTRALUMINAL SUTURE; NEURONAL APOPTOSIS; UNITED-STATES; OLDER-ADULTS	Elderly traumatic brain injury (TBI) patients have higher rates of mortality and worse functional outcome than non-elderly TBI patients. The mechanisms involved in poor outcomes in the elderly are not well understood. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a basic helix-loop-helix transcription factor that modulates expression of key genes involved in neuroprotection. In this study, we studied the expression of HIF-1 alpha and its target survival genes, heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and erythropoietin (EPO) in the brains of adult versus aged mice following controlled cortical impact (CCI) injury. Adult (5-6 months) and aged (23-24 months) C57Bl/6 mice were injured using a CCI device. At 72 h post-injury, mice were sacrificed and the injured cortex was used for mRNA and protein analysis using real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting protocols. Following injury, HIF-1 alpha, HO-1, and VEGF showed upregulation in both the young and aged mice, but in the aged animals the increase in HIF-1 alpha and VEGF in response to injury was much lower than in the adult injured animals. EPO was upregulated in the adult injured brain, but not in the aged injured brain. These results support the hypothesis that reduced expression of genes in the HIF-1 alpha neuroprotective pathway in aging may contribute to poor prognosis in the elderly following TBI.	[Sandhir, Rajat; Hamilton, Eric S.; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Anderson, Joshua; Sandhir, Rajat; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Anderson, Joshua; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd,Mail Stop 3038, Kansas City, KS 66160 USA.	nberman@kumc.edu			Steve Palermo Endowment; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG026482, P30 NICHD HD 02528]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER	We acknowledge the assistance of Eugene Gregory in carrying out the work and Eileen Roach with processing of the images. Special thanks go to Dr. Y. Y. He for his help with controlled cortical impact injury. This study was supported in part by the Steve Palermo Endowment and the National Institutes of Health (AG026482 and research core support P30 NICHD HD 02528).	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Alam J, 2007, AM J RESP CELL MOL, V36, P166, DOI 10.1165/rcmb.2006-0340TR; Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; Chang EF, 2003, J NEUROSCI, V23, P3689; Chavez JC, 2003, ADV EXP MED BIOL, V510, P337; Chavez JC, 2002, J NEUROSCI, V22, P8922; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Frenkel-Denkberg G, 1999, FEBS LETT, V462, P341, DOI 10.1016/S0014-5793(99)01552-5; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; Geddes JF, 2004, FORENSIC SCI INT, V146, P83, DOI 10.1016/S0379-0738(03)00283-4; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Heiss WD, 1997, J CEREBR BLOOD F MET, V17, P388, DOI 10.1097/00004647-199704000-00004; Hwang ISS, 2007, J GERONTOL A-BIOL, V62, P41, DOI 10.1093/gerona/62.1.41; Ito Y, 2009, BIOGERONTOLOGY, V10, P173, DOI 10.1007/s10522-008-9164-4; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; LaManna JC, 2007, ESSAYS BIOCHEM, V43, P139; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leblanc N, 2006, BRAIN COGNITION, V60, P208; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liu Xin, 2004, J Bioinform Comput Biol, V2, P343, DOI 10.1142/S0219720004000594; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maes OC, 2008, MECH AGEING DEV, V129, P534, DOI 10.1016/j.mad.2008.05.004; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rapino C, 2005, AGING CELL, V4, P177, DOI 10.1111/j.1474-9726.2005.00161.x; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shan Y, 2007, GASTROENTEROLOGY, V133, P1166, DOI 10.1053/j.gastro.2007.08.002; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Sinor AD, 2000, NEUROSCI LETT, V290, P213, DOI 10.1016/S0304-3940(00)01361-6; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Stowe AM, 2008, J CEREBR BLOOD F MET, V28, P612, DOI 10.1038/sj.jcbfm.9600560; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thomas S, 2000, ACT NEUR S, V76, P397; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Unterberg AW, 1997, ACT NEUR S, V70, P106; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang XG, 2003, AM J PHYSIOL-HEART C, V284, pH613, DOI 10.1152/ajpheart.00449.2002; Williams BJ, 2006, PSYCHOPHARMACOLOGY, V188, P605, DOI 10.1007/s00213-006-0477-1; Xiaowei H, 2006, SPINAL CORD, V44, P35, DOI 10.1038/sj.sc.3101813; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhao WZ, 1997, J CEREBR BLOOD F MET, V17, P1281, DOI 10.1097/00004647-199712000-00003	68	43	45	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1557	1566		10.1089/neu.2008.0765			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200012	19203226	Green Published			2021-06-18	
J	Johnson, VE; Stewart, W; Graham, DI; Stewart, JE; Praestgaard, AH; Smith, DH				Johnson, Victoria E.; Stewart, William; Graham, David I.; Stewart, Janice E.; Praestgaard, Amy H.; Smith, Douglas H.			A Neprilysin Polymorphism and Amyloid-beta Plaques after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; human beta-amyloid; neprilysin; polymorphism; traumatic brain injury	SPORADIC ALZHEIMERS-DISEASE; LONG-TERM ACCUMULATION; DIFFUSE AXONAL INJURY; HEAD-INJURY; PROMOTER REGION; A-BETA; ASSOCIATION; GENE; DEPOSITION; PEPTIDE	Traumatic brain injury (TBI) induces the rapid formation of Alzheimer's disease (AD)-like amyloid-beta (AB) plaques in about 30% of patients. However, the mechanisms behind this selective plaque formation are unclear. We investigated a potential association between amyloid deposition acutely after TBI and a genetic polymorphism of the AB-degrading enzyme, neprilysin (n = 81). We found that the length of the GT repeats in AB-accumulators was longer than in non-accumulators. Specifically, there was an increased risk of AB plaques for patients with more than 41 total repeats (p < 0.0001; OR: 10.1). In addition, the presence of 22 repeats in at least one allele was independently associated with plaque deposition (p = 0.03; OR: 5.2). In contrast, the presence of 20GT repeats in one allele was independently associated with a reduced incidence of AB deposition (p = 0.003). These data suggest a genetically linked mechanism that determines which TBI patients will rapidly form AB plaques. Moreover, these findings provide a potential genetic screening test for individuals at high risk of TBI, such as participants in contact sports and military personnel.	[Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Praestgaard, Amy H.] Univ Penn, Biostat Anal Ctr, Sch Med, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Stewart, William; Graham, David I.; Stewart, Janice E.] So Gen Hosp NHS Trust, Inst Neurol Sci, Div Clin Neurosci, Acad Unit Neuropathol, Glasgow, Lanark, Scotland	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007	Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health (NS038104).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Comings DE, 1998, MOL PSYCHIATR, V3, P21, DOI 10.1038/sj.mp.4000289; Comings DE, 1999, NEUROREPORT, V10, P2283, DOI 10.1097/00001756-199908020-00011; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAOUAS H, 1995, BIOCHEM BIOPH RES CO, V207, P933, DOI 10.1006/bbrc.1995.1275; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Iwata N, 2005, PHARMACOL THERAPEUT, V108, P129, DOI 10.1016/j.pharmthera.2005.03.010; Iwata N, 2000, NAT MED, V6, P143; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; LI CW, 1995, GENE, V164, P363, DOI 10.1016/0378-1119(95)00464-H; Lilius L, 2003, NEUROSCI LETT, V337, P111, DOI 10.1016/S0304-3940(02)01300-9; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mohajeri MH, 2002, J BIOL CHEM, V277, P35460, DOI 10.1074/jbc.M202899200; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oda M, 2002, NEUROSCI LETT, V320, P105, DOI 10.1016/S0304-3940(02)00057-5; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sakai A, 2004, DEMENT GERIATR COGN, V17, P164, DOI 10.1159/000076351; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sodeyama N, 2001, J NEUROL NEUROSUR PS, V71, P817, DOI 10.1136/jnnp.71.6.817; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wood LS, 2007, NEUROSCI LETT, V427, P103, DOI 10.1016/j.neulet.2007.09.019; Yamada M, 2003, J NEUROL NEUROSUR PS, V74, P749, DOI 10.1136/jnnp.74.6.749; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X	39	43	43	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1197	1202		10.1089/neu.2008.0843			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900003	19326964	Green Published			2021-06-18	
J	Kasturi, BS; Stein, DG				Kasturi, Badrinarayanan S.; Stein, Donald G.			Traumatic Brain Injury Causes Long-Term Reduction in Serum Growth Hormone and Persistent Astrocytosis in the Cortico-Hypothalamo-Pituitary Axis of Adult Male Rats	JOURNAL OF NEUROTRAUMA			English	Article						anterior pituitary; growth hormone; hypopituitarism; hypothalamus; TBI	SPINAL-CORD-INJURY; GH DEFICIENCY; IGF-I; SUBARACHNOID HEMORRHAGE; INFLAMMATORY RESPONSE; PROGRESSIVE ATROPHY; HIGH-RISK; HYPOPITUITARISM; DYSFUNCTION; PROGESTERONE	In humans, traumatic brain injury (TBI) causes pathological changes in the hypothalamus (HT) and the pituitary. One consequence of TBI is hypopituitarism, with deficiency of single or multiple hormones of the anterior pituitary (AP), including growth hormone (GH). At present no animal model of TBI with ensuing hypopituitarism has been demonstrated. The main objective of this study was to investigate whether cortical contusion injury (CCI) could induce long-term reduction of serum GH in rats. We also tested the hypothesis that TBI to the medial frontal cortex (MFC) would induce inflammatory changes in the HT and AP. Methods: Nine young adult male rats were given sham surgery (n =4) or controlled impact contusions (n = 5) of the MFC. Two months post-injury they were killed, trunk blood collected and their brains and AP harvested. GH was measured in serum and AP using ELISA and Western blot respectively. Interleukin-1 beta (IL-1 beta) and glial fibrillary acidic protein (GFAP) were measured in the cortex (Cx), HT, and AP by Western blot. Results: Lesion rats had significantly (p< 0.05) lower levels of GH in the AP and serum, unaltered serum IGF-1, and significantly (p< 0.05) higher levels of IL-1 beta in the Cx and HT and GFAP in the Cx, HT, and AP compared to that of shams. Conclusion: CCI leads to a long-term depletion of serum GH in male rats. This chronic change in GH post-TBI is probably the result of systemic and persistent inflammatory changes observed at the level of HT and AP, the mechanism of which is not yet known.	[Kasturi, Badrinarayanan S.; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Kasturi, BS (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	bkastur@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS048451]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER	We gratefully acknowledge the assistance provided by Sneha Kemkar and Priya Gandhi in this study. This study was partly supported by funding from the NIH (grant no. 5R01NS048451).	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 1998, J ENDOCRINOL INVEST, V21, P506, DOI 10.1007/BF03347336; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2003, CLIN ENDOCRINOL, V59, P56, DOI 10.1046/j.1365-2265.2003.01794.x; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Bechmann I, 1997, HISTOCHEM CELL BIOL, V107, P391, DOI 10.1007/s004180050125; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jcem.76.6.7684744; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Gasco V, 2008, PITUITARY, V11, P121, DOI 10.1007/s11102-008-0110-x; GRANADA UL, 2000, EUROPEAN J ENDOCRINO, P243; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Horie H, 1997, NEUROREPORT, V8, P1955, DOI 10.1097/00001756-199705260-00032; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KASTURI BS, 2008, NAT NEUR SOC ANN M O; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KITA H, 1994, ACTA NEUROCHIR WIEN, V60, pS452; Koliatsos VE, 2004, P NATL ACAD SCI USA, V101, P14264, DOI 10.1073/pnas.0404364101; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lichtenwalner RJ, 2006, J NEUROSCI RES, V83, P199, DOI 10.1002/jnr.20719; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LIVI GP, 1991, J BIOL CHEM, V266, P15348; Lu G, 1997, NEUROCHEM INT, V30, P401, DOI 10.1016/S0197-0186(96)00075-7; McDonald A, 2008, J PEDIATR-US, V152, P590, DOI 10.1016/j.jpeds.2007.12.046; Mirzayan MJ, 2008, NEUROL RES, V30, P476, DOI 10.1179/174313208X276916; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; PAPADAKIS MA, 1995, J AM GERIATR SOC, V43, P1350, DOI 10.1111/j.1532-5415.1995.tb06613.x; PATEL HC, 2003, ANN NY ACAD SCI, V992, P1; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SARTORIO A, 1995, HORM RES, V44, P6, DOI 10.1159/000184582; Sartorio A, 1996, HORM RES, V45, P23, DOI 10.1159/000184754; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Sonntag WE, 2005, AGEING RES REV, V4, P195, DOI 10.1016/j.arr.2005.02.001; Sonntag WE, 2000, J ANAT, V197, P575, DOI 10.1046/j.1469-7580.2000.19740575.x; Sonntag WE, 1997, ENDOCRINOLOGY, V138, P3515, DOI 10.1210/en.138.8.3515; Sonntag WE, 2006, AM J PHYSIOL-ENDOC M, V291, pE604, DOI 10.1152/ajpendo.00012.2006; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; Vitellaro-Zuccarello L, 2008, NEUROSCIENCE, V151, P452, DOI 10.1016/j.neuroscience.2007.11.004; WARNER SJC, 1987, J IMMUNOL, V139, P1911	75	43	43	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1315	1324		10.1089/neu.2008.0751			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900014	19317601	Green Published			2021-06-18	
J	Tsaousides, T; Warshowsky, A; Ashman, TA; Cantor, JB; Spielman, L; Gordon, WA				Tsaousides, Theodore; Warshowsky, Adam; Ashman, Teresa A.; Cantor, Joshua B.; Spielman, Lisa; Gordon, Wayne A.			The Relationship Between Employment-Related Self-Efficacy and Quality of Life Following Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	84th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	OCT 03-07, 2007	Washington, DC	Amer Congress Rehabil Med		traumatic brain injury; employment; self-efficacy; quality of life	WORK; RETURN; SATISFACTION; INDIVIDUALS; DISABILITY; COMMUNITY; STABILITY; MODEL	Objectives: This study examines the relative contribution of employment-related and general self-efficacy to perceptions of quality of life (QoL) for individuals with traumatic brain injury. Design: Correlational. Setting: Community-based research and training center. Participants: 427 individuals with self-reported TBI under the age of 65 were included in analysis. Main Outcome Measure: Employment-related self-efficacy, general self-efficacy, perceived quality of life (PQoL), unmet important needs (UIN). Results: Significant correlations were found between income, injury severity, age at injury, and employment and the QoL variables. In addition, employment-related and general self-efficacy correlated positively with both PQoL and UIN. Employment-related and general self-efficacy accounted for 16% of the variance in PQoL and 9.5% of the variance in UIN, over and above other variables traditionally associated with QoL. Conclusions: These findings highlight the importance of including subjective appraisals of employment, such as perceived self-efficacy at the workplace, in assessing QoL and successful return to work following TBI.	[Tsaousides, Theodore; Warshowsky, Adam; Ashman, Teresa A.; Cantor, Joshua B.; Spielman, Lisa; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Tsaousides, T (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	theodore.tsaousides@mssm.edu	Ashman, Teresa/B-1621-2013				Andrews F. M., 1976, SOCIAL INDICATORS WE; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BIGELOW DA, 1991, COMMUNITY MENT HLT J, V27, P125, DOI 10.1007/BF00752815; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; FLANAGAN T, 1982, QUEENS QUART, V89, P596; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	34	43	44	1	5	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					299	305		10.1037/a0016807			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	488SW	WOS:000269371100007	19702428				2021-06-18	
J	Mahmood, A; Goussev, A; Kazmi, H; Qu, CS; Lu, DY; Chopp, M				Mahmood, Asim; Goussev, Anton; Kazmi, Humaira; Qu, Changsheng; Lu, Dunyue; Chopp, Michael			LONG-TERM BENEFITS AFTER TREATMENT OF TRAUMATIC BRAIN INJURY WITH SIMVASTATIN IN RATS	NEUROSURGERY			English	Article						Long term; Newly generated cells; Simvastatin; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; ENDOTHELIAL NITRIC-OXIDE; COA REDUCTASE INHIBITORS; PLASMINOGEN-ACTIVATOR; INTRACEREBRAL HEMORRHAGE; ISCHEMIC-STROKE; NERVOUS-SYSTEM; HEAD-INJURY; STATINS; ATORVASTATIN	OBJECTIVE: This study was designed to investigate the long-term effects of simvastatin treatment after traumatic brain injury (TBI) in rats. METHODS: Adult female Wistar rats (n = 24) were injured with controlled cortical impact and divided into 3 groups. The first 2 groups were treated with simvastatin (0.5 or 1.0 mg/kg) administered orally for 14 days starting 1 day after TBI. The third group (control) received phosphate-buffered saline orally for 14 days. Neurological functional outcome was measured with modified neurological severity scores performed I day before TBI; on days 1, 4, 7, 14 after TBI; and biweekly thereafter. All animals were sacrificed 3 months after TBI. Brain tissues of half of the animals were processed for preparation of paraffin-embedded sections for immunohistological studies. The remaining half were frozen for enzyme-linked immunosorbent assay studies for quantification of brain-derived neurotrophic factor (BDNF) in the hippocampus and cortex. RESULTS: The results showed that both doses of simvastatin significantly improved functional outcome compared with the control, with no difference between the 2 doses. Simvastatin treatment of 1.0 mg/kg increased the number of morphologically intact neurons in the hippocampus, but treatment of 0.5 mg/kg had no significant effect. Enzyme-linked immunosorbent assay studies showed that 0.5 mg/kg simvastatin significantly increased BDNF levels within the hippocampus, but 1.0 mg/kg had no significant effect. Neither dose had any effect on BDNF levels within the cortex. CONCLUSION: Simvastatin treatment provides long-lasting functional improvement after TBI in rats. It also enhances neuronal survival in the hippocampus and increases BDNF levels in the hippocampus secondary to simvastatin treatment.	[Mahmood, Asim; Goussev, Anton; Kazmi, Humaira; Qu, Changsheng] Henry Ford Hosp, Dept Neurosurg, Henry Ford Hlth Syst, Detroit, MI 48202 USA; [Lu, Dunyue] SUNY Hlth Sci Ctr, Dept Psychiat, Brooklyn, NY 11203 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, Henry Ford Hlth Syst, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5RO1 NS052280-04]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant 5RO1 NS052280-04. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Aoki T, 2008, STROKE, V39, P1276, DOI 10.1161/STROKEAHA.107.503086; Bang OY, 2007, NEUROLOGY, V68, P737, DOI 10.1212/01.wnl.0000252799.64165.d5; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Bourcier T, 2000, ARTERIOSCL THROM VAS, V20, P556, DOI 10.1161/01.ATV.20.2.556; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Day LB, 1999, ANIM BEHAV, V57, P393, DOI 10.1006/anbe.1998.1007; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dujovne CA, 2000, AM J CARDIOL, V85, P350, DOI 10.1016/S0002-9149(99)00745-6; Essig M, 1998, J AM SOC NEPHROL, V9, P1377; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; Harper CR, 2007, CURR OPIN LIPIDOL, V18, P401, DOI 10.1097/MOL.0b013e32825a6773; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hoglund K, 2005, DEMENT GERIATR COGN, V19, P256, DOI 10.1159/000084550; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laufs U, 2003, ARTERIOSCL THROM VAS, V23, P156, DOI 10.1161/01.ATV.0000051360.79309.4E; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Miida T, 2007, PHARMACOL THERAPEUT, V113, P378, DOI 10.1016/j.pharmthera.2006.09.003; Morikawa Shigeru, 2002, J Atheroscler Thromb, V9, P178; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Naval NS, 2008, NEUROCRIT CARE, V8, P6, DOI 10.1007/s12028-007-0080-2; Peterson DA, 1999, METHODS, V18, P493, DOI 10.1006/meth.1999.0818; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Shi JM, 2003, BLOOD COAGUL FIBRIN, V14, P575, DOI 10.1097/00001721-200309000-00010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sugawara T, 2008, J NEUROSCI METH, V167, P327, DOI 10.1016/j.jneumeth.2007.08.004; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; White CM, 1999, J CLIN PHARMACOL, V39, P111, DOI 10.1177/00912709922007642; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757	46	43	44	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2009	65	1					187	192		10.1227/01.NEU.0000343540.24780.D6			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	474EP	WOS:000268265600023	19574841	Green Accepted			2021-06-18	
J	Nagel, A; Graetz, D; Schink, T; Frieler, K; Sakowitz, O; Vajkoczy, P; Sarrafzadeh, A				Nagel, Alexandra; Graetz, Daniela; Schink, Tania; Frieler, Katja; Sakowitz, Oliver; Vajkoczy, Peter; Sarrafzadeh, Asita			Relevance of intracranial hypertension for cerebral metabolism in aneurysmal subarachnoid hemorrhage Clinical article	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; intracranial hypertension; microdialysis; cerebral metabolism; outcome	TRAUMATIC BRAIN-INJURY; MICRODIALYSIS; PRESSURE; ISCHEMIA; IMPAIRMENT; VASOSPASM; GLUTAMATE; COMA	Object. Intracranial hypertension, defined as intracranial pressure (ICP) >= 20 mm Hg, is a complication typically associated with head injury. Its impact on cerebral metabolism, ICP therapy, and outcome has rarely been studied in patients with aneurysmal subarachnoid hemorrhage (aSAH); such an assessment is the authors' goal in the present study. Methods. Cerebral metabolism was prospectively studied in 182 patients with aSAH. The database was retrospectively analyzed with respect to ICP. Patients were classified into 2 groups based on ICP. There were 164 with low ICP (< 20 mm Hg) and 18 with high ICP (>= 20 mm Hg, measured > 6 hours/day). Cerebral microdialysis parameters of energy metabolism, glycerol, and glutamate levels were analyzed hourly from the brain parenchyma of interest for 7 days. The 12-month outcome in these patients was evaluated. Results. In the high ICP group, extended ICP therapy including decompressive craniectomy was necessary in 7 patients (39%). Cerebral glycerol levels and the lactate/pyruvate ratio were pathologically increased on Days 1-7 after aSAH (p < 0.001). The excitotoxic neurotransmitter glutamate and glycerol, a marker of membrane degradation, further increased on Days 5-7, probably reflecting the development of secondary brain damage. An ICP a 20 mm Hg was shown to have a significant influence on the 12-month Glasgow Outcome Scale (GOS) score (p = 0.001) and was a strong predictor of mortality (OR = 24.6; p < 0.001). Glutamate (p = 0.012), the lactate/pyruvate ratio as a marker of anaerobic metabolism (p = 0.028), age (p < 0.001), and Fisher grade (p = 0.001) also influenced the GOS score at 12 months. Conclusions. The authors confirmed the relevance of intracranial hypertension as a severe complication in patients with aSAH. Because high ICP is associated with a severely deranged cerebral metabolism and poor outcome, future studies focusing on metabolism-guided, optimized ICP therapy could help minimize secondary brain damage and improve prognosis in patients with aSAH. (DOI: 10.3171/2009.1.JNS08587)	[Sarrafzadeh, Asita] Charite, Clin Neurosurg, Charite Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany; [Schink, Tania; Frieler, Katja] Charite Campus Mitte, Dept Med Stat & Clin Epidemiol, Berlin, Germany; [Sakowitz, Oliver] Heidelberg Univ, Dept Neurosurg, D-6900 Heidelberg, Germany	Sarrafzadeh, A (corresponding author), Charite, Clin Neurosurg, Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de	Schink, Tania/A-4585-2017	Schink, Tania/0000-0002-0224-1866; Frieler, Katja/0000-0003-4869-3013			Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Brunner E., 2002, NONPARAMETRIC ANAL L; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; DRAKE CG, 1988, J NEUROSURG, V68, P985; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fukuhara T, 1998, NEUROL MED-CHIR, V38, P710, DOI 10.2176/nmc.38.710; Gambardella G, 1998, ACT NEUR S, V71, P215; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAYASHI M, 1984, J NEUROSURG, V61, P30, DOI 10.3171/jns.1984.61.1.0030; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; JENNETT B, 1975, LANCET, V1, P480; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; LeRoux PD, 1996, NEUROSURGERY, V38, P887, DOI 10.1097/00006123-199605000-00006; Liu HL, 2005, EXP BRAIN RES, V167, P666, DOI 10.1007/s00221-005-0243-3; Mayer SA, 2002, NEUROLOGY, V59, P1750, DOI 10.1212/01.WNL.0000035748.91128.C2; McCullagh P., 1998, GEN LINEAR MODELS, V37; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; ROMNER B, 1991, British Journal of Neurosurgery, V5, P31, DOI 10.3109/02688699108998444; Sarrafzadeh AS, 2005, ACT NEUR S, V95, P89; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	30	43	45	1	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2009	111	1					94	101		10.3171/2009.1.JNS08587			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	462VA	WOS:000267383900021	19284237				2021-06-18	
J	Topjian, AA; Lin, R; Morris, MC; Ichord, R; Drott, H; Bayer, CR; Helfaer, MA; Nadkarni, V				Topjian, Alexis A.; Lin, Richard; Morris, Marilyn C.; Ichord, Rebecca; Drott, Henry; Bayer, Carey R.; Helfaer, Mark A.; Nadkarni, Vinay			Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						neuron-specific enolase; nerve tissue protein S-100; prognosis; heart arrest; biological markers; children	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; EUROPEAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; SERUM-LEVELS; REGAINING CONSCIOUSNESS; CEREBROSPINAL-FLUID	Objective: To characterize the pattern of serum biochemical markers of central nervous system injury (neuron-specific enolase [NSE], S-100B, plasminogen activator inhibitor-1 [PAI-1]) after pediatric cardiac arrest and determine whether there is an association between biomarker concentrations and neurologic outcome. Design: Prospective, observational study. Setting: Urban, tertiary care children's hospital. Patients: Cardiac arrest survivors, n = 35. Interventions: Serial blood sampling, pediatric cerebral performance category, and standardized neurologic examination. Measurements and Main Results: Serial serum NSE and S-100B concentrations over 96 hrs and PAI-1 at 24 hrs were measured in children (age < 18 yrs) who had return of spontaneous circulation following cardiac arrest. Neurologic outcome was prospectively categorized as poor if the change in pre- to postarrest pediatric cerebral performance category was >= 2. Biomarker concentrations were compared between outcome groups and between survival groups using longitudinal analysis correcting for multiple comparisons. Median levels (25th, 75th percentiles) are reported. Receiver operating characteristic analyses were performed at all time points. Biomarker concentrations showed statistically significant differences. Of the 35 patients, neurologic outcomes were poor in 19, with 15 deaths. Median NSE concentrations differed by outcome when measured at >= 48 hrs, and by survival at >= 24 hrs. S-100B concentrations were not significantly associated with neurologic outcome. S-100B levels were associated with survival outcome at >= 48 hrs. PAI-1 levels were not significantly associated with either neurologic or survival outcomes. Conclusions: The timing, intensity, and duration of serum NSE and S-100B biomarker concentration patterns are associated with neurologic and survival outcomes following pediatric cardiac arrest. Serum NSE concentrations at >= 48 hrs are associated with neurologic outcome, whereas serum S-100B levels at >= 48 hrs are associated with survival. Prospective analysis of these markers may help to predict outcomes and guide postresuscitative therapies. (Pediatr Crit Care Med 2009; 10:479-490)	[Topjian, Alexis A.; Lin, Richard; Helfaer, Mark A.; Nadkarni, Vinay] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Ichord, Rebecca] Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; [Morris, Marilyn C.] Childrens Hosp New York Presbyterian, Dept Pediat, New York, NY USA; [Drott, Henry] Childrens Hosp Philadelphia, Clin Lab, Philadelphia, PA 19104 USA; [Bayer, Carey R.] Morehouse Sch Med, Dept Pediat, Ctr Excellence Sexual Hlth, Atlanta, GA 30310 USA	Topjian, AA (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	topjian@email.chop.edu			Endowed Chair of Pediatric Critical Care Medicine; CTRC [M01-RR00240]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000240] Funding Source: NIH RePORTER	Supported, in part, by Endowed Chair of Pediatric Critical Care Medicine and CTRC grant M01-RR00240.	Akcan-Arikan A, 2007, KIDNEY INT, V71, P1028, DOI 10.1038/sj.ki.5002231; Balasa VV, 1999, THROMB HAEMOSTASIS, V81, P739; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger BW, 2001, CIRCULATION, V103, P2694; DALESSANDRO M, 1992, TUMOR BIOL, V13, P352, DOI 10.1159/000217786; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; Estelles A, 2001, THROMB HAEMOSTASIS, V86, P647; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GANDO S, 1995, CRIT CARE MED, V23, P1835, DOI 10.1097/00003246-199511000-00009; Gando S, 1997, THROMB HAEMOSTASIS, V77, P278; Geppert A, 2001, CRIT CARE MED, V29, P1670, DOI 10.1097/00003246-200109000-00003; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Hajnal BL, 1999, PEDIATR NEUROL, V21, P788, DOI 10.1016/S0887-8994(99)00101-0; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hu JR, 1997, J NEUROCHEM, V69, P2294; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Lindberg L, 1998, J THORAC CARDIOV SUR, V116, P281, DOI 10.1016/S0022-5223(98)70128-X; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Meaney PA, 2006, PEDIATRICS, V118, P2424, DOI 10.1542/peds.2006-1724; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MULLIE A, 1988, LANCET, V1, P137; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Nagdyman N, 2003, PEDIATR RES, V54, P270, DOI 10.1203/01.PDR.0000072518.98189.A0; Nsiri B, 1996, HEMATOL CELL THER, V38, P279, DOI 10.1007/s00282-996-0279-2; Palmio J, 2001, J NEUROL SCI, V183, P27, DOI 10.1016/S0022-510X(00)00478-0; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Prohl J, 2007, CRIT CARE MED, V35, P1230, DOI 10.1097/01.CCM.0000261892.10559.85; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Reisinger J, 2007, EUR HEART J, V28, P52, DOI 10.1093/eurheartj/ehl316; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Samson RA, 2006, NEW ENGL J MED, V354, P2328, DOI 10.1056/NEJMoa052917; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Shevell MI, 1999, PEDIATR NEUROL, V21, P776, DOI 10.1016/S0887-8994(99)00102-2; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Slonim AD, 1997, CRIT CARE MED, V25, P1951, DOI 10.1097/00003246-199712000-00008; Snyder-Ramos SA, 2004, ANAESTHESIA, V59, P344, DOI 10.1111/j.1365-2044.2004.03663.x; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Spinella Philip C, 2004, Pediatr Crit Care Med, V5, P53, DOI 10.1097/01.PCC.0000102221.98378.7D; Suzuki Y, 1999, NEUROLOGY, V53, P1761, DOI 10.1212/WNL.53.8.1761; Tekgul H, 2004, PEDIATR NEUROL, V31, P326, DOI 10.1016/j.pediatrneurol.2004.05.004; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; ZARITSKY A, 1995, PEDIATRICS, V96, P765; ZELTZER PM, 1986, CANCER, V57, P1230, DOI 10.1002/1097-0142(19860315)57:6<1230::AID-CNCR2820570628>3.0.CO;2-#; ZELTZER PM, 1983, LANCET, V2, P361; Zingler VC, 2003, EUR NEUROL, V49, P79, DOI 10.1159/000068503	66	43	44	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2009	10	4					479	490		10.1097/PCC.0b013e318198bdb5			12	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	468SI	WOS:000267840500008	19307814				2021-06-18	
J	Agoston, DV; Gyorgy, A; Eidelman, O; Pollard, HB				Agoston, Denes V.; Gyorgy, Andrea; Eidelman, Ofer; Pollard, Harvey B.			Proteomic Biomarkers for Blast Neurotrauma: Targeting Cerebral Edema, Inflammation, and Neuronal Death Cascades	JOURNAL OF NEUROTRAUMA			English	Article						antibody microarray; bioinformatics; blast; mass spectrometry; protein microarray; reverse-capture; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HUMAN CEREBROSPINAL-FLUID; CENTRAL-NERVOUS-SYSTEM; PROTEIN MICROARRAYS; GLIAL ACTIVATION; EXPRESSION; CYTOKINES; DISCOVERY; ASTROCYTE; HISTORY	Proteomics for blast traumatic brain injury (bTBI) research represents an exciting new approach that can greatly help to address the complex pathology of this condition. Antibody-based platforms, antibody microarrays (AbMA), and reverse capture protein microarrays (RCPM) can complement the classical methods based on 2D gel electrophoresis and mass spectrometry (2DGE/MS). These new technologies can address problematic issues, such as sample complexity, sensitivity, quantitation, reproducibility, and analysis time, which are typically associated with 2DGE/MS. Combined with bioinformatics analysis and interpretation of primary microarray data, these methods will generate a new level of understanding about bTBI at the level of systems biology. As biological and clinical knowledge and the availability of these systems become more widely established, we expect that AbMA and RCPM will be used routinely in clinical diagnostics, and also for following therapeutic progress. At the technical level, we anticipate that these platforms will evolve to accommodate comprehensive, high-speed, label-free analysis on a human proteome-wide scale.	[Agoston, Denes V.; Gyorgy, Andrea] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Eidelman, Ofer; Pollard, Harvey B.] Uniformed Serv Univ Hlth Sci, Ctr Med Prote, Bethesda, MD 20814 USA	Agoston, DV (corresponding author), Uniformed Serv Univ Sch Med, Dept Anat Physiol & Genet, Neurosurg Program Natl Capital Consortium, Program Neurosci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.mil					Alaiya AA, 2000, INT J CANCER, V86, P731, DOI 10.1002/(SICI)1097-0215(20000601)86:5<731::AID-IJC20>3.0.CO;2-A; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Baranzini SE, 2006, AUTOIMMUNITY, V39, P651, DOI 10.1080/08916930601061686; Breitling R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-100; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cahill DJ, 2001, J IMMUNOL METHODS, V250, P81, DOI 10.1016/S0022-1759(01)00325-8; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Davson H, 1966, Sci Basis Med Annu Rev, P238; Doherty NS, 1998, ELECTROPHORESIS, V19, P355, DOI 10.1002/elps.1150190234; EKINS RP, 1991, CLIN CHEM, V37, P1955; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Guy R J, 2000, J R Nav Med Serv, V86, P27; HARRIS EK, 1975, CLIN CHEM, V21, P1457; HARRIS EK, 1974, CLIN CHEM, V20, P1535; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; KAUR C, 1997, ANN ACAD MED SINGAP, V29, P27; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.3.CO;2-Y; Levison SW, 2000, GLIA, V32, P328, DOI 10.1002/1098-1136(200012)32:3<328::AID-GLIA110>3.0.CO;2-7; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mircean C, 2005, BIOINFORMATICS, V21, P1935, DOI 10.1093/bioinformatics/bti258; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oltvai ZN, 2002, SCIENCE, V298, P763, DOI 10.1126/science.1078563; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Pieroni E, 2008, PROTEOMICS, V8, P799, DOI 10.1002/pmic.200700767; Pollard HB, 2007, PROTEOM CLIN APPL, V1, P934, DOI 10.1002/prca.200700154; Pollard HB, 2006, MOL CELL PROTEOMICS, V5, P1628, DOI 10.1074/mcp.M600091-MCP200; Pollard HB, 2005, PROTEOMICS, V5, P2210, DOI 10.1002/pmic.200401120; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Ramaswamy Anitha, 2005, Proteome Sci, V3, P9, DOI 10.1186/1477-5956-3-9; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schweitzer B, 2002, CURR OPIN BIOTECH, V13, P14, DOI 10.1016/S0958-1669(02)00278-1; Soen Y, 2003, PLOS BIOL, V1, P429, DOI 10.1371/journal.pbio.0000065; Srivastava M, 2006, MOL GENET METAB, V87, P303, DOI 10.1016/j.ymgme.2005.10.021; Srivastava M, 2004, CLIN CANCER RES, V10, P2344, DOI 10.1158/1078-0432.CCR-03-0278; Srivastava M, 2007, INT J CANCER, V121, P2628, DOI 10.1002/ijc.23008; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; Sylvia FR, 2001, MIL MED, V166, P918; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, NEW ENGL J MED, V353, P633; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	66	43	44	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					901	911		10.1089/neu.2008.0724			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600008	19397421				2021-06-18	
J	Harris, OA; Muh, CR; Surles, MC; Pan, Y; Rozycki, G; Macleod, J; Easley, K				Harris, Odette A.; Muh, Carrie R.; Surles, Monique C.; Pan, Yi; Rozycki, Grace; Macleod, Jana; Easley, Kirk			Discrete cerebral hypothermia in the management of traumatic brain injury: a randomized controlled trial Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cooling helmet; hypothermia; trauma; traumatic brain injury	SEVERE HEAD-INJURIES; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA	Object. Hypothermia has been extensively evaluated in the management of traumatic brain injury (TBI), but no consensus as to its effectiveness has yet been reached. Explanatory hypotheses include a possible confounding effect of the neuroprotective benefits by adverse systemic effects. To minimize the systemic effects, the authors evaluated a selective cerebral cooling system, the CoolSystem Discrete Cerebral Hypothermia System (a "cooling cap"), in the management of TBI. Methods. A prospective randomized controlled clinical trial was conducted at Grady Memorial Hospital, a Level I trauma center. Adults admitted with severe TBI (Glasgow Coma Scale [GCS] score <= 8) were eligible. Patients assigned to the treatment group received the cooling cap, while those in the control group did not. Patients in the treatment group were treated with selective cerebral hypothermia for 24 hours, then rewarmed over 24 hours. Their intracranial and bladder temperatures. cranial-bladder temperature gradient, Glasgow Outcome Scale (GOS) and Functional Independence Measure (FIM) scores, and mortality rates were evaluated. The primary Outcome was to establish a cranial-bladder temperature gradient in those patients with the cooling cap. The secondary outcomes were mortality and morbidity per GOS and FIM scores. Results. The cohort comprised 25 patients (12 in the treatment group, 13 controls). There was no significant intergroup difference in demographic data or median GCS score at enrollment (treatment group 3.0, controls 3.0; p = 0.7). After the third hour of the study, the mean intracranial temperature of the treatment group was significantly lower than that of the controls at all time points except Hours 4 (p = 0.08) and 6 (p = 0.08). However, the target intracranial temperature of 33 degrees C was achieved in only 2 patients in the treatment group. The mean intracranial-bladder temperature gradient was not significant for the treatment group (p = 0.07) or the controls (p = 0.67). Six (50.0%) of 12 patients in the treatment group and 4 (30.8%) of 13 in the control group died (p = 0.43). The medians of the maximum change in GOS and FIM scores during the study period (28 days) for both groups were 0. There was no significant difference in complications between the groups (p value range 0.20-1.0). Conclusions. The cooling cap was not effective in establishing a statistically significant cranial-bladder temperature gradient or in reaching the target intracranial temperature in the majority of patients. No significant difference was achieved in mortality or morbidity between the 2 groups. As the technology Currently stands, the Discrete Cerebral Hypothermia System cooling cap is not beneficial for the management of TBI. Further refinement of the equipment available for the delivery of selective cranial cooling will be needed before any definite conclusions, regarding the efficacy of discrete cerebral hypothermia can be reached. (DOI: 10.3171/2009.1.JNS081320)	[Harris, Odette A.; Muh, Carrie R.; Surles, Monique C.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30303 USA; [Rozycki, Grace; Macleod, Jana] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30303 USA; [Pan, Yi; Easley, Kirk] Emory Univ, Dept Biostat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA	Harris, OA (corresponding author), Emory Univ, Sch Med, Grady Mem Hosp, Dept Neurosurg, 49 Jesse Hill Jr Dr SE,Fac Off Bldg,Room 339, Atlanta, GA 30303 USA.	oharris@emory.edu	Easley, Kirk/K-6910-2015	Easley, Kirk/0000-0003-4419-2617; Surles-Zeigler, Monique/0000-0002-2308-8813; Muh, Carrie/0000-0002-3764-4163	NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007056] Funding Source: NIH RePORTER		Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bell T E, 1998, J Cardiovasc Nurs, V13, P34; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; *CDC, 2006, MMWR-MORBID MORTAL W, V55, P201; *CDC, 2007, MMWR-MORBID MORTAL W, V56, P173; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Fay T, 1940, NY STATE J MED, V40, P1351; Gabbe BJ, 2007, J TRAUMA, V63, P1374, DOI 10.1097/01.ta.0000240481.55341.38; Guido RC, 2006, DIGIT SIGNAL PROCESS, V16, P24, DOI 10.1016/j.dsp.2005.04.002; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Maier C. M., 1995, Society for Neuroscience Abstracts, V21, P1030; MAIER CM, 1996, SOC NEUR ABS, V21, P1938; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MOURITZEN CV, 1966, J THORAC CARDIOV SUR, V51, P585, DOI 10.1016/S0022-5223(19)43326-6; Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stein S. C., 1996, NEUROTRAUMA, P31; STEINBERG GK, 1995, DELIBERATE HYPOTHERM; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; YOON EJ, 1994, SOC NEUR ABS, V20, P224; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	43	43	46	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2009	110	6					1256	1264		10.3171/2009.1.JNS081320			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451HH	WOS:000266460800023	19249933				2021-06-18	
J	Kenning, TJ; Gandhi, RH; German, JW				Kenning, Tyler J.; Gandhi, Ravi H.; German, John W.			A comparison of hinge craniotomy and decompressive craniectomy for the treatment of malignant intracranial hypertension: early clinical and radiographic analysis	NEUROSURGICAL FOCUS			English	Article						decompressive craniectomy; hinge craniotomy; cerebral decompression; intracranial hypertension	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY INFARCTION; HEMICRANIECTOMY; CHILDREN; EXPANSION	Object. Hinge craniotomy (HC) has recently been described as an alternative to decompressive craniectomy (DC). Although HC may obviate the need for cranial reconstruction, an analysis comparing HC to DC has not yet been published. Methods. A retrospective review was conducted of 50 patients who underwent cranial decompression (20 with HC, 30 with DC). Baseline demographics, neurological examination results, and underlying pathology were reviewed. Clinical outcome was assessed by length of ventilatory support, length of intensive care unit stay, and survival at discharge. Control of intracranial hypertension was assessed by average daily intracranial pressure (ICP) for the duration of ICP monitoring and an ICP therapeutic intensity index. Radiographic outcomes were assessed by comparing preoperative and postoperative CT scans for: 1) Rotterdam score; 2) postoperative volume of cerebral expansion; 3) presence of uncal herniation; 4) intracerebral hemorrhage; and 5) extraaxial hematoma. Postoperative CT scans were analyzed for the size of the craniotomy/craniectomy and magnitude of extracranial herniation. Results. No significant differences were identified in baseline demographics, neurological examination results, or Rotterdam score between the HC and DC groups. Both HC and DC resulted in adequate control of ICP, as reflected in the average ICP for each group of patients (HC = 12.0 +/- 5.6 mm Hg, DC = 12.7 +/- 4.4 mm Hg; p > 0.05) at the same average therapeutic intensity index (HC = 1.2 +/- 0.3, DC = 1.2 +/- 0.4; p > 0.05). The need for reoperation (3 [15%] of 20 patients in the HC group, 3 [10%] of 30 patients in the DC group; p > 0.05), hospital survival (15 [75%] of 20 in the HC group, 21 [70%] of 30 in the DC group; p > 0.05), and mean duration of both mechanical ventilation (9.0 +/- 7.2 days in the HC group, 11.7 +/- 12.0 days in the DC group; p > 0.05) and intensive care unit stay (11.6 +/- 7.7 days in the HC group, 15.6 +/- 15.3 days in the DC group; p > 0.05) were similar. The difference in operative time for the two procedures was not statistically significant (130.4 +/- 71.9 minutes in the HC group, 124.9 +/- 63.3 minutes in the DC group; p > 0.05). The size of the cranial defect was comparable between the 2 groups. Postoperative imaging characteristics, including Rotterdam score, also did not differ significantly. Although a smaller volume of cerebral expansion was associated with HC (77.5 +/- 54.1 ml) than DC (105.1 +/- 65.1 ml), this difference was not statistically significant. Conclusions. Hinge craniotomy appears to be at least as good as DC in providing postoperative ICP control and results in equivalent early clinical outcomes. (DOI: 10.3171/2009.4.FOCUS0960)	[Kenning, Tyler J.; Gandhi, Ravi H.; German, John W.] Albany Med Ctr, Div Neurosurg, Albany, NY 12208 USA	Kenning, TJ (corresponding author), Albany Med Ctr, Div Neurosurg, 47 New Scotland Ave,MC-10, Albany, NY 12208 USA.	kennint@mail.amc.edu					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Chen CC, 2007, J CLIN NEUROSCI, V14, P317, DOI 10.1016/j.jocn.2005.05.024; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Goettler CE, 2007, J TRAUMA, V62, P777, DOI 10.1097/TA.0b013e31802ee55e; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; KO K, 2007, NEUROSURGERY S2, V60; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Pillai A, 2007, J NEUROSURG, V106, P59, DOI 10.3171/jns.2007.106.1.59; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	20	43	45	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2009	26	6							E6	10.3171/2009.4.FOCUS0960			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451WK	WOS:000266501400006	19485719	Bronze			2021-06-18	
J	Ronner, HE; Ponten, SC; Stam, CJ; Uitdehaag, BMJ				Ronner, H. E.; Ponten, S. C.; Stam, C. J.; Uitdehaag, B. M. J.			Inter-observer variability of the EEG diagnosis of seizures in comatose patients	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Electroencephalogram; Coma; (Non-convulsive) status epilepticus; Intensive care unit; Seizure	INTENSIVE-CARE-UNIT; LATERALIZED EPILEPTIFORM DISCHARGES; NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CLINICAL-FEATURES; CRITICALLY-ILL; PROGNOSIS; PATTERNS	Objective: To assess the inter-observer agreement of the electroencephalogram (EEG) diagnosis of (non-convulsive) seizures in comatose patients. Design/setting/patients: Nine clinicians with different levels of experience in clinical neurophysiology were asked to evaluate in a strictly controlled way 90 epochs (10 s each) of 30 EEG's of 23 comatose patients admitted to the intensive care unit (ICU). For each EEG clinicians had to decide whether there was an electrographic seizure or not. Furthermore, Young's EEG criteria for (non-convulsive) seizures were scored in detail for all EEG's. Agreement was determined by calculating kappa values. Results: The inter-observer agreement of an EEG diagnosis of seizure was limited. The overall kappa score for the five experienced raters was 0.5, and the kappa score for less experienced raters was 0.29. Kappa values for the individual Young's criteria were highly variable, indicating discrepancies in the interpretation of specific phenomena. Especially, some types of periodic discharges gave rise to different interpretations. Conclusions: The EEG diagnosis of (non-convulsive) seizures in ICU patients is not very reliable, even when strict criteria such as proposed by Young are applied. There is a need for less ambiguous EEG criteria for (non-convulsive) seizures and status epilepticus. (C) 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Ronner, H. E.; Ponten, S. C.; Stam, C. J.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Neurophysiol, NL-1007 MB Amsterdam, Netherlands; [Uitdehaag, B. M. J.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Ronner, HE (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Neurophysiol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	HE.Ronner@vumc.nl; SC.Ponten@vumc.nl; CJ.Stam@vumc.nl; BMJ.Uitdehaag@vumc.nl			Dutch National Epilepsy Fund	The authors thank the observers: E. Vriens, C. de Langen, B. Jones, M. Laman, H. Hamburger, R. Strijers, R. Lazeron and E. Geiger for their participation in this study. S.C. Ponten was financially supported by the Dutch National Epilepsy Fund.	BRENNER RP, 1990, J CLIN NEUROPHYSIOL, V7, P249, DOI 10.1097/00004691-199004000-00007; Brenner RP, 2004, J CLIN NEUROPHYSIOL, V21, P319; Brenner RP, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.43.s.3.9.x; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; Garcia-Morales I, 2002, J CLIN NEUROPHYSIOL, V19, P172, DOI 10.1097/00004691-200203000-00009; Garzon E, 2001, NEUROLOGY, V57, P1175, DOI 10.1212/WNL.57.7.1175; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Stroink H, 2006, DEV MED CHILD NEUROL, V48, P374, DOI 10.1017/S0012162206000806; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Yemisci M, 2003, SEIZURE-EUR J EPILEP, V12, P465, DOI 10.1016/S1059-1311(02)00351-5; Young GB, 1996, NEUROLOGY, V47, P83	27	43	43	0	2	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311			SEIZURE-EUR J EPILEP	Seizure	MAY	2009	18	4					257	263		10.1016/j.seizure.2008.10.010			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	437CY	WOS:000265465000005	19046902				2021-06-18	
J	Chiesa, A; Duhaime, AC				Chiesa, Antonia; Duhaime, Ann-Christine			Abusive Head Trauma	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article						Child abuse; Abusive head trauma; Pediatric traumatic brain injury; Shaken baby syndrome; Nonaccidental trauma	SHAKEN BABY SYNDROME; PERMANENT BRAIN-DAMAGE; SUSPECTED CHILD-ABUSE; RETINAL HEMORRHAGES; CARDIOPULMONARY-RESUSCITATION; OPHTHALMOLOGIC FINDINGS; SUBDURAL HEMORRHAGES; CRANIAL INJURIES; YOUNG-CHILDREN; INFANTS	Child physical abuse that results in injury to the head or brain has been described using many terms, including battered child syndrome, whiplash injuries, shaken infant or shaken impact syndrome, and nonmechanistic terms such as abusive head trauma or nonaccidental trauma. These injuries sustained by child abuse victims are discussed in detail in this article, including information about diagnosis, management and outcomes. The use of forensics, the use imaging studies, and associated injuries are also detailed.	[Chiesa, Antonia] Childrens Hosp, Kempe Child Protect Team, Dept Pediat, Denver, CO 80045 USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Dept Pediat Neurosurg, Lebanon, NH 03756 USA	Chiesa, A (corresponding author), Childrens Hosp, Kempe Child Protect Team, Dept Pediat, 13123 E 16th Ave,Box 138, Denver, CO 80045 USA.	Chiesa.Antonia@tchden.org					ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; Boos SC, 2006, ABUSIVE HEAD TRAUMA, P191; BRENNAN LK, J NEUROSURG IN PRESS; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Butchart A, 2008, AM J PREV MED, V34, pS103, DOI 10.1016/j.amepre.2008.01.006; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CANTU RC, 1991, ATHLETIC INJURIES HE, P323; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; Demaerel P, 2002, EUR RADIOL, V12, P849, DOI 10.1007/s00330-001-1145-9; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUHAIME AC, 1998, GELLIS KAGANS CURREN, P436; Duhaime AC, 2007, PROG BRAIN RES, V161, P293, DOI 10.1016/S0079-6123(06)61020-0; DURFEE MJ, 1992, JAMA-J AM MED ASSOC, V267, P3172, DOI 10.1001/jama.267.23.3172; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fernando S, 2008, PEDIATR RADIOL, V38, P827, DOI 10.1007/s00247-007-0729-1; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Glick JC, 2007, PEDIATR NEUROSURG, V43, P436, DOI 10.1159/000106400; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; Gulino SP, 2006, ABUSIVE HEAD TRAUMA, P297; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hughes LA, 2006, J AAPOS, V10, P102, DOI 10.1016/j.jaapos.2005.12.005; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Jaspan T, 2008, PEDIATR RADIOL, V38, pS378, DOI 10.1007/s00247-008-0896-8; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jones R, 2008, PEDIATRICS, V122, P259, DOI 10.1542/peds.2007-2312; Judkins AR, 2004, AM J FOREN MED PATH, V25, P29, DOI 10.1097/01.paf.0000113811.85110.54; Kairys SW, 2001, PEDIATRICS, V108, P206; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; Kivlin JD, 2001, CURR OPIN OPHTHALMOL, V12, P158, DOI 10.1097/00055735-200106000-00002; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P237; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P285; Kleinman PL, 2004, RADIOLOGY, V233, P477, DOI 10.1148/radiol.2332031640; Labbe J, 2005, CHILD ABUSE NEGLECT, V29, P311, DOI 10.1016/j.chiabu.2005.03.002; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Salehi-Had H, 2006, PEDIATRICS, V117, pE1039, DOI 10.1542/peds.2005-0811; Sane SM, 2000, PEDIATRICS, V105, P1345; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shugerman RP, 1996, PEDIATRICS, V97, P664; SILVERMAN FN, 1953, AM J ROENTGENOL, V69, P413; SIROTNAK AP, 2006, ABUSIVE HEAD TRAUMA, P191; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; Starling SP, 2005, CHILD MALTREATMENT C, P37; Steinbok P, 2007, NEUROSURGERY, V60, P689, DOI 10.1227/01.NEU.0000255398.00410.6B; Swift DM, 2000, NEUROSURG CLIN N AM, V11, P439, DOI 10.1016/S1042-3680(18)30106-2; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9; YAIR M, 2004, J AAPOS, V8, P521; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	90	43	43	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	APR	2009	56	2					317	+		10.1016/j.pcl.2009.02.001			16	Pediatrics	Pediatrics	441CA	WOS:000265745700002	19358918				2021-06-18	
J	Clark, ME; Walker, RL; Gironda, RJ; Scholten, JD				Clark, Michael E.; Walker, Robyn L.; Gironda, Ronald J.; Scholten, Joel D.			Comparison of Pain and Emotional Symptoms in Soldiers with Polytrauma: Unique Aspects of Blast Exposure	PAIN MEDICINE			English	Article						Chronic Pain; Trauma; Posttraumatic Stress Syndrome; Psychosocial Factors	FUNCTIONAL INDEPENDENCE MEASURE; POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; IRAQI FREEDOM; PERSISTENT PAIN; MENTAL-ILLNESS; REHABILITATION; RELIABILITY	To compare the physical and emotional presentation and pain treatment outcomes of service members who sustained polytrauma secondary to blast with those of soldiers injured by other means. Retrospective medical record review. One of four Veterans Affairs multidisciplinary inpatient Polytrauma Rehabilitation Centers. One hundred twenty-eight Operation Enduring Freedom and Operation Iraqi Freedom military personnel with serious polytrauma injuries and concomitant pain categorized into three groups based on type of injuries: blast injuries, combat injuries other than blast, and noncombat, nonblast injuries. Intensive, interdisciplinary inpatient rehabilitation and pain treatment. Pain intensity ratings; Functional Independence Measure scores; Rancho Los Amigos levels; and opioid analgesic doses. Service members injured via blast demonstrated a broader spectrum of physical injuries, higher levels of admission and discharge opioid analgesic use, reduced improvement in pain intensity following treatment, and much higher rates of posttraumatic stress disorder and other psychiatric diagnoses than those injured via other means. Blast injury may be associated with differential physical, emotional, and pain-related symptoms that pose increased challenges for successful treatment.	[Clark, Michael E.; Walker, Robyn L.; Gironda, Ronald J.] James A Haley Vet Affairs Hosp, Chron Pain Rehabil Program, Tampa, FL USA; [Clark, Michael E.; Gironda, Ronald J.; Scholten, Joel D.] Univ S Florida, Tampa, FL USA; [Scholten, Joel D.] James A Haley Vet Affairs Hosp, Polytrauma Rehabil Ctr, Tampa, FL USA	Clark, ME (corresponding author), Chron Pain Rehabil Program 2CW, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Michael.Clark8@va.gov			Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [SDR-07-047]; University of South Florida or the Departments of Defense or Veterans Affairs	Support for preparation of this article was provided in part by the Department of Veterans Affairs Rehabilitation Research and Development grant SDR-07-047 to the first author. All opinions expressed herein are those of the authors and do not in any way represent those of the University of South Florida or the Departments of Defense or Veterans Affairs.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; BRAGANZA RJ, 2006, MANUAL PAIN MANAGEME, P231; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; CLARK ME, 2006, 2 ANN PAIN AW DAY C; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cohen SP, 2005, ANESTH ANALG, V101, P1098, DOI 10.1213/01.ane.0000169332.45209.cf; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Gatchel RJ, 1995, SPINE, V20, P2702, DOI 10.1097/00007632-199512150-00011; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hagen C., 1998, RANCHO LEVELS COGNIT; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HANDY K, 2007, FR0727 DEP DEF OFF S; Hanley M, 2004, DISABIL REHABIL, V26, P882, DOI 10.1080/09638280410001708896; Herbert J, 1997, BRIT MED J, V315, P530, DOI 10.1136/bmj.315.7107.530; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Jung BF, 2004, NEUROLOGY, V62, P1545, DOI 10.1212/01.WNL.0000123261.00004.29; Kalra R, 2008, FED PRACT, V25, P36; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Katz J, 2005, PAIN, V119, P16, DOI 10.1016/j.pain.2005.09.008; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Pflanz S, 2001, MIL MED, V166, P457; Roth RS, 2004, AM J PHYS MED REHAB, V83, P827, DOI 10.1097/01.PHM.0000140800.83146.FA; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seel RT, 2007, J HEAD TRAUMA REHAB, V22, P267, DOI 10.1097/01.HTR.0000290971.56130.c8; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Stojadinovic A, 2006, PAIN MED, V7, P330, DOI 10.1111/j.1526-4637.2006.00171.x	36	43	44	0	4	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1526-2375			PAIN MED	Pain Med.	APR	2009	10	3					447	455		10.1111/j.1526-4637.2009.00590.x			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	431QI	WOS:000265077500006	19416436				2021-06-18	
J	Koopmans, GC; Deumens, R; Buss, A; Geoghegan, L; Myint, AM; Honig, WHH; Kern, N; Joosten, EA; Noth, J; Brook, GA				Koopmans, Guido C.; Deumens, Ronald; Buss, Armin; Geoghegan, Liam; Myint, Aye Mu; Honig, Wiel H. H.; Kern, Nadine; Joosten, Elbert A.; Noth, Johannes; Brook, Gary A.			Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Spinal cord injury; Immunomodulation; Rolipram; Thalidomide; TNF-alpha; IL-1 beta; Cytokines; Functional recovery; Neuroprotection	TUMOR-NECROSIS-FACTOR; PHOSPHODIESTERASE INHIBITOR ROLIPRAM; ERYTHEMA-NODOSUM LEPROSUM; FUNCTIONAL RECOVERY; FACTOR-ALPHA; ADULT-RAT; SECONDARY INJURY; AXONAL REGENERATION; BRAIN-INJURY; TNF-ALPHA	Traumatic spinal cord injury (SCI) causes severe and permanent functional deficits due to the primary mechanical insult followed by secondary tissue degeneration. The cascade of secondary degenerative events constitutes a range of therapeutic targets which, if successfully treated, could significantly ameliorate functional loss after traumatic SCI. During the early hours after injury, potent pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) are synthesized and released, playing key roles in secondary tissue degeneration. In the present investigation, the ability of rolipram and thalidomide (FDA approved drugs) to reduce secondary tissue degeneration and improve motor function was assessed in an experimental model of spinal cord contusion injury. The combined acute single intraperitoneal administration of both drugs attenuated TNF-alpha and IL-1 beta production and improved white matter Sparing at the lesion epicenter. This was accompanied by a significant (2.6 point) improvement in the BBB locomotor score by 6 weeks. There is, at present, no widely accepted intervention strategy that is appropriate for the early treatment of human SCI. The present data suggest that clinical trials for the acute combined application of rolipram and thalidomide may be warranted. The use of such "established drugs" could facilitate the early initiation of trials. (C) 2009 Elsevier Inc. All rights reserved.	[Koopmans, Guido C.; Deumens, Ronald; Honig, Wiel H. H.; Joosten, Elbert A.] Acad Hosp Maastricht, Dept Anesthesiol, NL-6200 AZ Maastricht, Netherlands; [Buss, Armin; Kern, Nadine; Noth, Johannes; Brook, Gary A.] Aachen Univ Hosp, Rhein Westfal TH Aachen, Dept Neurol, D-52074 Aachen, Germany; [Geoghegan, Liam; Myint, Aye Mu] Univ Limburg, Acad Hosp Maastricht, Div Cellular Neurosci, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; [Brook, Gary A.] Aachen Univ Hosp, Rhein Westfal TH Aachen, Dept Neuropathol, D-52074 Aachen, Germany	Koopmans, GC (corresponding author), Spinal Cord Therapeut GmbH, Max Planck Str 15A, D-40699 Erkrath, Germany.	guido.koopmans@sctpx.com			Institutional Institute for Research in Paraplegia [P80/04]	This work was supported by a grant from the Institutional Institute for Research in Paraplegia (P80/04) and forms part of the doctoral thesis of Nadine Kern (D82, Diss. RWTH Aachen). The authors have no conflicting financial interests.	ANKENY DP, NEUROSCIENC IN PRESS, DOI DOI 10.1016/J.NEUROSCIENCE.2008.07.001; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; BARIOL C, 2002, J GASTROEN HEPATOL, V17, P233; Basso DM, 2004, J NEUROTRAUM, V21, P395, DOI 10.1089/089771504323004548; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; BUNGE RP, 1993, ADV NEUROL, V59, P75; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Buttini M, 1997, BRIT J PHARMACOL, V122, P1483, DOI 10.1038/sj.bjp.0701502; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; Fitch MT, 1999, J NEUROSCI, V19, P8182; FLEISCHHACKER WW, 1992, NEUROPSYCHOBIOLOGY, V26, P59, DOI 10.1159/000118897; Fujimaki K, 2000, NEUROPSYCHOPHARMACOL, V22, P42, DOI 10.1016/S0893-133X(99)00084-6; Genovese T, 2007, NEUROSCIENCE, V150, P168, DOI 10.1016/j.neuroscience.2007.06.059; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; George A, 2000, PAIN, V88, P267, DOI 10.1016/S0304-3959(00)00333-X; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Green B A, 1973, Surg Neurol, V1, P98; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Haslett PAJ, 2005, J INFECT DIS, V192, P2045, DOI 10.1086/498216; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Hunt GS, 2003, ANN EMERG MED, V42, pS40; Jordan LM, 1998, ANN NY ACAD SCI, V860, P83, DOI 10.1111/j.1749-6632.1998.tb09040.x; Kim YS, 2004, MOL CELLS, V17, P210; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koopmans GC, 2006, EUR J NEUROSCI, V23, P1035, DOI 10.1111/j.1460-9568.2006.04627.x; Koopmans GC, 2005, J NEUROTRAUM, V22, P214, DOI 10.1089/neu.2005.22.214; Laffitte Emmanuel, 2004, Expert Opin Drug Saf, V3, P47, DOI 10.1517/14740338.3.1.47; Lankhorst AJ, 1999, J NEUROTRAUM, V16, P323, DOI 10.1089/neu.1999.16.323; Lankhorst AJ, 2001, J NEUROTRAUM, V18, P203, DOI 10.1089/08977150150502622; Leskovar A, 2000, J EXP BIOL, V203, P1783; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Meierhofer C, 2003, CURR OPIN DRUG DISC, V6, P92; Mulcahy NJ, 2003, BRIT J PHARMACOL, V140, P471, DOI 10.1038/sj.bjp.0705462; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; O'Donnell JM, 2004, TRENDS PHARMACOL SCI, V25, P158, DOI 10.1016/j.tips.2004.01.003; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Penkowa M, 1999, GLIA, V25, P343; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Ribeiro RA, 2000, EUR J PHARMACOL, V391, P97, DOI 10.1016/S0014-2999(99)00918-8; Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Schwab ME, 1996, PHYSIOL REV, V76, P319; SCOTT AIF, 1991, EUR J CLIN PHARMACOL, V40, P127; SENTER HJ, 1978, J NEUROSURG, V49, P569, DOI 10.3171/jns.1978.49.4.0569; Settles B, 2001, CELL MOL BIOL, V47, P1105; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thome J, 2002, NERVENARZT, V73, P595, DOI 10.1007/s00115-002-1276-5; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Villahermosa LG, 2005, AM J TROP MED HYG, V72, P518, DOI 10.4269/ajtmh.2005.72.518; WACHTEL H, 1983, NEUROPHARMACOLOGY, V22, P267, DOI 10.1016/0028-3908(83)90239-3; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Whitaker CM, 2008, NEUROSCI LETT, V438, P200, DOI 10.1016/j.neulet.2008.03.087; Witkamp R, 2000, VET QUART, V22, P11, DOI 10.1080/01652176.2000.9695016; Wu JJ, 2005, BRIT J DERMATOL, V153, P254, DOI 10.1111/j.1365-2133.2005.06747.x; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; Yennurajalingam Sriram, 2004, Support Cancer Ther, V1, P97, DOI 10.3816/SCT.2004.n.003; Yoshikawa M, 1999, MULT SCLER J, V5, P126, DOI 10.1191/135245899678847194; YOUNG W, 1993, J EMERGENCY MED, V11, pS13; Zhu J, 2001, CNS DRUG REV, V7, P387	86	43	46	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2009	216	2					490	498		10.1016/j.expneurol.2009.01.005			9	Neurosciences	Neurosciences & Neurology	424ZK	WOS:000264606600031	19320007				2021-06-18	
J	Lagares, A; Ramos, A; Perez-Nunez, A; Ballenilla, F; Alday, R; Gomez, PA; Kaen, A; Lobato, RD				Lagares, Alfonso; Ramos, Ana; Perez-Nunez, Angel; Ballenilla, Federico; Alday, Rafael; Gomez, Pedro A.; Kaen, Ariel; Lobato, Ramiro D.			The role of MR imaging in assessing prognosis after severe and moderate head injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Head trauma; MRI; CT; Diffuse axonal injury; Prognosis	DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN-INJURY; COMA-DATA-BANK; MAGNETIC-RESONANCE; COMPUTERIZED-TOMOGRAPHY; VEGETATIVE STATE; SCALE SCORE; STEM INJURY; CT FINDINGS; FIELD MR	The objective of this work is two-fold: to determine the role of MRI findings in establishing the prognosis of patients with moderate and severe traumatic brain injury (TBI) admitted to our centre, measured with different outcome scales; and to determine in which patients the information given by MR findings adds prognostic information to that from traditional prognostic factors. One hundred patients suffering moderate or severe head injury in whom MRI had been performed in the first 30 days after trauma were included. The MRI was evaluated by two neuroradiologists who were not aware of the initial CT results or the clinical situation of the patients. Outcome was determined 6 months after head injury by means of the extended version of the Glasgow Outcome Scale. The prognostic capacity of the different factors related to outcome was compared by the analysis of receiver operating characteristic (ROC) curves and the area under the curve (AUC) for each factor. There exists a clear relation between the depth of the traumatic lesions shown on MRI, and their classification by the proposed scale, and the outcome of patients suffering traumatic brain injury determined by different scales 6 months after injury. The anatomical substrate of TBI depicted by MRI could be a useful prognostic tool in patients suffering moderate and severe head injury. Patients with a score of 4 or less on the motor subscale of the GCS scale are those who could benefit most from the prognostic information provided by MRI.	[Lagares, Alfonso; Perez-Nunez, Angel; Alday, Rafael; Gomez, Pedro A.; Kaen, Ariel; Lobato, Ramiro D.] Hosp 12 Octubre, Dept Neurosurg, Madrid 28041, Spain; [Ramos, Ana; Ballenilla, Federico] Hosp 12 Octubre, Dept Neuroradiol, Madrid 28041, Spain	Lagares, A (corresponding author), Hosp 12 Octubre, Dept Neurosurg, Crta Andalucia Km 5 4, Madrid 28041, Spain.	algadoc@yahoo.com	kaen, ariel/G-3786-2015; KAEN, ARIEL/F-1338-2015; Lagares, Alfonso/B-2969-2011; Gomez, Pedro/N-5051-2019; Perez-Nunez, Angel/AAG-4422-2020	Lagares, Alfonso/0000-0003-3996-0554; Gomez, Pedro/0000-0002-4185-5238; Perez-Nunez, Angel/0000-0002-2391-6586	Fundacion Mutua MadrilenaInstituto de Salud Carlos III	This study was supported by a grant from Fundacion Mutua Madrilena.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Aguas J, 2005, NEUROCIRUGIA, V16, P14; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Boto GR, 2004, NEUROCIRUGIA, V15, P233; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hoelper BM, 2000, ACT NEUR S, V76, P265; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kesler SR, 2000, BRAIN INJURY, V14, P851; Lagares A, 2006, NEUROCIRUGIA, V17, P105; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Marshall SB, 1991, J NEUROSURG S, V75, P14; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; SAHUQUILLO J, 1989, ACTA NEUROCHIR WIEN, V101, P762; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P37; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; Toschlog EA, 2003, AM SURGEON, V69, P491; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VILALTA J, 1984, REV NEUROLOGIA, V57, P133; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	62	43	47	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	APR	2009	151	4					341	356		10.1007/s00701-009-0194-8			16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	437OS	WOS:000265497400008	19224121				2021-06-18	
J	DiLeonardi, AM; Huh, JW; Rahupathi, R				DiLeonardi, Ann Mae; Huh, Jimmy W.; Rahupathi, Ramesh			Impaired axonal transport and neurofilament compaction occur in separate populations of injured axons following diffuse brain injury in the immature rat	BRAIN RESEARCH			English	Article						Traumatic axonal injury; Children; Mild traumatic brain injury; Closed head injury; NMDA; AMPA; White matter	LATERAL FLUID PERCUSSION; CLOSED-HEAD INJURY; AXOLEMMAL PERMEABILITY; COGNITIVE DEFICITS; NEONATAL PIG; PHOSPHORYLATION; ACCUMULATION; NEURODEGENERATION; PROTEOLYSIS; ANTAGONISTS	Diffuse brain injury is a leading cause of mortality in infants and children under 4 years of age and results in cognitive deficits in survivors. The anatomic basis for these behavioral deficits maybe traumatic axonal injury (TAI), which manifests as impaired axonal transport (IAT) and neurofilament compaction (NFC), and may occur as a result of glutamate receptor activation. The extent of IAT and NFC was evaluated at 6, 24 and 72 h following non-contusive brain trauma in the 17 day-old rat to examine the causal relationship between these two pathologic entities; in addition, the effect of antagonists to the ionotropic glutamate receptors on TAI was evaluated. At 6 h post-injury, NFC was observed primarily in the cingulum, and appeared as swollen axons and terminal bulbs. By 24 h, swollen axons were additionally present in the corpus callosum and lateral white matter tracts, and appeared to increase in diameter. At 72 h, the extent of axonal swellings exhibiting compacted neurofilaments appeared to decrease, and was accompanied by punctate immunoreactivity within axon tracts suggestive of axonal degeneration. Although NFC was present in the same anatomical locations where axonal accumulation of amyloid precursor protein (APP) has been observed, double-label immunohistochemistry revealed no evidence of colocalization of compacted neurofilament and APP. Pre-injury treatment with either the NMDA receptor antagonist, ifenprodil, or the AMPA receptor antagonist, NBQX, had no significant effect on the extent of TAI, suggesting that excitotoxicity may not be a primary mechanism underlying TAL Importantly, these data are indicative of the heterogeneity of mechanisms underlying TAI in the traumatically-injured immature brain. (C) 2009 Elsevier B.V. All rights reserved.	[Rahupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; [DiLeonardi, Ann Mae; Rahupathi, Ramesh] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19129 USA; [Huh, Jimmy W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Rahupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu		DiLeonardi, Ann Mae/0000-0002-1476-7726	University of Pennsylvania; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS053651, R01-NS41561]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, K08NS053651] Funding Source: NIH RePORTER	The authors acknowledge expert technical assistance from Ashley Widing (animal surgery), Ami Oristaglio-Wilson (blinded quantification) and Louise Bertrand (confocal microscopy). We are also grateful to Dr. John Q. Trojanowski (Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia PA) for the gift of the RM014 antibody. These studies were supported, in part, by The Endowed Chair of Critical Care Medicine, the Florence RC Murray grant from the Children's Hospital of Philadelphia (JWH, RR), a Research Foundation grant from the University of Pennsylvania (JWH, RR), and NINDS grants K08-NS053651 (JWH) and R01-NS41561 (RR).	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHEETZ AJ, 1994, FASEB J, V8, P745; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818	41	43	46	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 31	2009	1263						174	182		10.1016/j.brainres.2009.01.021			9	Neurosciences	Neurosciences & Neurology	431CV	WOS:000265039800019	19368848	Green Accepted			2021-06-18	
J	Bonilla, C; Zurita, M; Otero, L; Aguayo, C; Vaquero, J				Bonilla, Celia; Zurita, Mercedes; Otero, Laura; Aguayo, Concepcion; Vaquero, Jesus			Delayed intralesional transplantation of bone marrow stromal cells increases endogenous neurogenesis and promotes functional recovery after severe traumatic brain injury	BRAIN INJURY			English	Article						Stem cells; bone marrow stromal cells; brain trauma; cell therapy	MESENCHYMAL STEM-CELLS; SUBVENTRICULAR ZONE; NEURAL STEM; INTRACEREBRAL TRANSPLANTATION; NEURONAL DIFFERENTIATION; ADULT RATS; PROLIFERATION; THERAPY; STROKE; NEUROTROPHINS	Primary objective: To investigate the utility of delayed transplantation of bone marrow stromal cells (BMSC) to improve the neurological sequels after traumatic brain injury (TBI). Methods: Adult Wistar rats were subjected to weight-drop impact causing severe brain injury, and 2 months later, BMSC in saline, or saline alone, were injected into injured brain tissue. Both experimental groups were evaluated by means of rotarod and modified neurologic severity scores (mNSS) tests in the course of the two following months. At this time, the animal were sacrificed and their brains were studied by means of histological and immunohistochemical techniques. Results: Rotarod and mNSS tests showed progressive functional recovery in the BMSC- transplanted rats, compared with controls. Two months after transplantation, BMSC survived in the host tissue, and some of them showed expression of Neu-N or GFAP, suggesting neuronal and astroglial transdifferentiation. Furthermore, significant increase of endogenous neurogenesis was found in BMSC-transplanted rats, compared with controls. Conclusions: These findings suggest the utility of delayed intracerebral transplantation of BMSC for the treatment of established sequels after TBI.	[Vaquero, Jesus] Autonomous Univ Madrid, Hosp Puerta Hierro Majadahonda, Neurosci Res Unit, Madrid 28222, Spain; Autonomous Univ Madrid, Hosp Puerta Hierro Majadahonda, Mapfre UAM Chair Brain Injury Res, Madrid 28222, Spain	Vaquero, J (corresponding author), Autonomous Univ Madrid, Hosp Puerta Hierro Majadahonda, Neurosci Res Unit, Manuel Falla 1, Madrid 28222, Spain.	jvaqueroc@telefonica.net		Otero Ortega, Laura/0000-0001-8765-6341	Carlos III Institute, Ministry of Health, SpainInstituto de Salud Carlos III [FIS: PI 06/0650]	The present study was performed with financial support from Carlos III Institute, Ministry of Health (FIS: PI 06/0650), Spain.	Andres RH, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E15; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; GARCIACASTRO J, 2008, CELL THERAPY, P58; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, CELL TRANSPLANT, V10, P31; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Miles DK, 2006, PROG BRAIN RES, V157, P187, DOI 10.1016/S0079-6123(06)57012-8; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vaquero J, 2009, HISTOL HISTOPATHOL, V24, P107, DOI 10.14670/HH-24.107; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Zhang HB, 2006, NEUROL RES, V28, P104, DOI 10.1179/016164106X91960; Zimmet JM, 2005, BASIC RES CARDIOL, V100, P471, DOI 10.1007/s00395-005-0553-4; Zurita M, 2005, NEUROREPORT, V16, P505, DOI 10.1097/00001756-200504040-00017; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004; Zurita M, 2008, TRANSPLANTATION, V86, P845, DOI 10.1097/TP.0b013e318186198f; Zurita M, 2007, NEUROREPORT, V18, P1713, DOI 10.1097/WNR.0b013e3282f0d3b0; Zurita M, 2006, NEUROSCI LETT, V402, P51, DOI 10.1016/j.neulet.2006.03.069	44	43	45	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	9					760	769	PII 913448048	10.1080/02699050903133970			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	475UR	WOS:000268387600007	19637001				2021-06-18	
J	Catroppa, C; Anderson, VA; Muscara, F; Morse, SA; Haritou, F; Rosenfeld, JV; Heinrich, LM				Catroppa, Cathy; Anderson, Vicki A.; Muscara, Frank; Morse, Sue A.; Haritou, Flora; Rosenfeld, Jeffrey V.; Heinrich, Liesl M.			Educational skills: Long-term outcome and predictors following paediatric traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Head injury; Children; Literacy; Arithmetic; Recovery	CLOSED-HEAD INJURY; ACADEMIC-PERFORMANCE; CHILDREN; RECOVERY; CHILDHOOD; ADOLESCENTS; BEHAVIOR; TBI; ACHIEVEMENT; SCHOOL	Given that reading, spelling and arithmetic skills are acquired through childhood, their development may be compromised following a childhood traumatic brain injury (TBI). The present study examined educational skills (reading accuracy, spelling and arithmetic) at a mean follow-up interval of 6.8 years post-injury in children who had sustained a mild, moderate, or severe TBI at two ages: 'Young' (age at injury: 3-7 years, n = 48) and 'Old': (age at injury: 8-12 years, n = 36). Comparisons between the young and old TBI groups resulted in inconsistent findings. While a dose-response relationship for severity was evident for the young group, this was not always the case for the old group. Significant predictors of outcome included both severity and acute intellectual function.	[Catroppa, Cathy; Anderson, Vicki A.; Muscara, Frank; Heinrich, Liesl M.] Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.; Morse, Sue A.; Haritou, Flora] Royal Childrens Hosp, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.; Muscara, Frank] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011	Heinrich, Liesl/0000-0001-5813-7235	Research Foundation; Royal Children's Hospital; National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia	Financial support, via successful grants, was provided by the Research Foundation, Royal Children's Hospital and the National Health and Medical Research Council, Australia. No conflict of interest was associated with this research.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2000, BRIT J CANCER, V82, P255; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; CARNEY J, 1990, Pediatrician, V17, P222; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Daniel A. E., 1983, POWER PRIVILEGE PRES; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 2004, HANDBOOK OF PEDIATRIC PSYCHOLOGY IN SCHOOL SETTINGS, P313; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P, 1988, ICPS FAMILY FU UNPUB; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROWE JK, 1995, ROWE BEHAV RATING IN; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; SCHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; Sparrow S., 1984, VINELAND ADAPTIVE BE; STALINGS G, 1996, J INT NEUROPSYCHOLOG; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1997, MANUAL WECHSLER ADUL; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	50	43	44	0	10	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	5					716	732		10.1080/09602010902732868			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	539EK	WOS:000273236200006	19306233				2021-06-18	
J	Dichter, MA				Dichter, Marc A.			Posttraumatic epilepsy: The challenge of translating discoveries in the laboratory to pathways to a cure	EPILEPSIA			English	Article						Epileptogenesis; Antiepileptogenesis; Epilepsy prevention; Posttraumatic epilepsy	FLUID PERCUSSION INJURY; RAT; RECOVERY; SEIZURES	Translating laboratory discoveries into successful therapies for preventing epilepsy is a difficult task, but preventing epilepsy in those who are known to be at high risk needs to be one of our highest priorities. At present, we need to approach this task as a parallel set of research endeavors-one concentrating on laboratory experiments designed to learn how to prevent epilepsy after brain trauma and the other focusing on how to perform the appropriate clinical research in humans to demonstrate that whatever is discovered in the laboratory can be appropriately tested. It is too important to let the second process await conclusion of the first. Initially, we need to create a consortium of groups in trauma centers that are dedicated to antiepileptogenic studies and develop funding sources for long-term studies. We need to experiment with clinical protocols, making the studies as cost-effective as possible, while performing continuous data mining of outcomes and surrogate markers. The limitations of current technology to assist in antiepileptogenesis trials must be acknowledged: There is no currently available method for continuously monitoring electroencephalography (EEG) over prolonged periods, and there are no validated biomarkers for the process of epileptogenesis. As we learn more about the process of epileptogenesis and its underlying mechanisms, it is hoped that we will be able to prevent the development of epilepsy after traumatic brain injury (TBI) and after many other known epileptogenic lesions.	[Dichter, Marc A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	Dichter, MA (corresponding author), Univ Penn, Dept Neurol, Hosp Univ Penn, 3 W Gates,3400 Spruce St, Philadelphia, PA 19104 USA.	dichter@mail.med.upenn.edu					Blumenfeld H, 2008, EPILEPSIA, V49, P400, DOI 10.1111/j.1528-1167.2007.01458.x; Bragin A, 2004, EPILEPSIA, V45, P1017, DOI 10.1111/j.0013-9580.2004.17004.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dube C, 2004, ANN NEUROL, V56, P709, DOI 10.1002/ana.20266; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; Grohn O, 2007, EPILEPSIA, V48, P3, DOI 10.1111/j.1528-1167.2007.01236.x; Perna R, 2006, J HEAD TRAUMA REHAB, V21, P82, DOI 10.1097/00001199-200601000-00009; STEAD M, 2007, EPILEPSIA S6, V46; Temkin N R, 1998, Adv Neurol, V76, P179; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801	12	43	45	0	6	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						41	45		10.1111/j.1528-1167.2008.02009.x			5	Clinical Neurology	Neurosciences & Neurology	399VN	WOS:000262827500007	19187293	Bronze			2021-06-18	
J	Haas, B; Jurkovich, GJ; Wang, J; Rivara, FP; MacKenzie, EJ; Nathens, AB				Haas, Barbara; Jurkovich, Gregory J.; Wang, Jin; Rivara, Frederick P.; MacKenzie, Ellen J.; Nathens, Avery B.			Survival Advantage in Trauma Centers: Expeditious Intervention or Experience?	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							MULTIPLE IMPUTATION; CENTER DESIGNATION; CARE; IMPACT; MANAGEMENT; SURGEONS; MORBIDITY; MORTALITY; DEATHS; SYSTEM	BACKGROUND: Trauma patients who receive care at designated trauma centers have a decreased risk of death, but the processes of care that lead to improved outcomes are unknown. We set out to examine the relationship between trauma center care, rapidity of assessment and intervention, and mortality among trauma patients with indications for immediate operative intervention. STUDY DESIGN: Data were collected from a multicenter prospective cohort study of adult patients cared for in trauma centers (TC) and nondesignated centers (NTC). From this cohort, we identified patients with two patterns of injury: hypotensive penetrating trauma (PT) and blunt traumatic brain injury (TBI) with mass effect. Times from admission to relevant interventions were assessed, as were relative risks of in-hospital death in TC compared with NTC. Relative risks were adjusted for differences in case mix using propensity analysis. RESULTS: Among 1,331 patients who met inclusion criteria, 23.5% died in hospital. Relative risk of death was 0.61 (95% CI, 0.43 to 0.86) among patients managed at TC compared with those admitted to NTC. This survival advantage was greatest among patients in the PT group managed at TC (relative risk: 0.43; 95% CI, 0.19 to 0.94). Relative risk of death at TC among patients in the TBI group was 0.72 (95% CI, 0.50 to 1.0). Within the first 24 hours of admission, however, there was no statistically significant difference between median times to radiographic assessment or operative intervention at TC as compared with other hospitals. CONCLUSIONS: Risk of death is considerably lower among patients requiring early operative intervention if they are treated at a designated Level I trauma center. These outcomes are not a result of more rapid assessment and intervention alone, and emphasize the complex factors that contribute to the Survival benefit of trauma center care. (J Am Coll Surg 2009;208:28-36. (C) 2008 by the American College of Surgeons)	[Haas, Barbara; Nathens, Avery B.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Jurkovich, Gregory J.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Haas, B (corresponding author), St Michaels Hosp, Queen Wing, 3N-073,30 Bond St, Toronto, ON M5B 1W8, Canada.	barbara.haas@utoronto.ca			National Center for Injury Prevention and Control of the Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR316840]; National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01/AG20361]	Supported by a grant (R49/CCR316840) from the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention and a grant (R01/AG20361) from the National Institute on Aging of the National Institutes of Health. Dr Nathens has a Canada Research Chair in Systems of Trauma Care.	Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bulinski P, 2003, J TRAUMA, V54, P161, DOI 10.1097/00005373-200301000-00020; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; D'Agostino RB, 2007, JAMA-J AM MED ASSOC, V297, P314, DOI 10.1001/jama.297.3.314; Davenport DL, 2007, J AM COLL SURGEONS, V205, P778, DOI 10.1016/j.jamcollsurg.2007.07.039; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Esposito T, 2006, J TRAUMA, V61, P278; Fakhry SM, 2003, J TRAUMA, V54, P1, DOI 10.1097/00005373-200301000-00001; Haut ER, 2006, J TRAUMA, V61, P272, DOI 10.1097/01.ta.0000222939.51147.1c; Helling TS, 2003, J TRAUMA, V55, P20, DOI 10.1097/01.TA.0000071621.39088.7B; Kahn JM, 2007, QUAL SAF HEALTH CARE, V16, P329, DOI 10.1136/qshc.2007.022376; Khetarpal S, 1999, J TRAUMA, V47, P576, DOI 10.1097/00005373-199909000-00028; Luchette F, 1997, J TRAUMA, V42, P490, DOI 10.1097/00005373-199703000-00017; Lukan JK, 2001, J TRAUMA, V50, P1015, DOI 10.1097/00005373-200106000-00007; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Moore L, 2005, J TRAUMA, V59, P698, DOI 10.1097/01.ta.0000177700.54943.ee; Nathens AB, 2006, J TRAUMA, V60, P773, DOI 10.1097/01.ta.0000196669.74076.50; Nathens AB, 2004, J TRAUMA, V56, P173, DOI 10.1097/01.TA.0000056159.65396.7C; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; Newgard CD, 2006, ACAD EMERG MED, V13, P314, DOI 10.1197/j.aem.2005.09.011; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Raghunathan TL., 2001, SURV METHODOL, V27, P85; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Rubin DB., 1987, MULTIPLE IMPUTATION; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28	32	43	43	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	JAN	2009	208	1					28	36		10.1016/j.jamcollsurg.2008.09.004			9	Surgery	Surgery	392VO	WOS:000262330500004	19228499				2021-06-18	
S	Maiese, K; Chong, ZZ; Hou, JL; Shang, YC		Maiese, K		Maiese, Kenneth; Chong, Zhao Zhong; Hou, Jinling; Shang, Yan Chen			The "O" Class: Crafting Clinical Care with FoxO Transcription Factors	FORKHEAD TRANSCRIPTION FACTORS: VITAL ELEMENTS IN BIOLOGY AND MEDICINE	Advances in Experimental Medicine and Biology		English	Article; Book Chapter							INFLAMMATORY MICROGLIAL ACTIVATION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PROSTATE-CANCER CELLS; SMOOTH-MUSCLE-CELLS; NERVE GROWTH-FACTOR; REGULATORY T-CELLS; NF-KAPPA-B; OXIDATIVE-STRESS; PROTEIN-KINASE; LIFE-SPAN	Forkhead Transcription Factors: Vital Elements in Biology and Medicine provides a unique platform for the presentation of novel work and new insights into the vital role that fork-head transcription factors play in both cellular physiology as well as clinical medicine. Internationally recognized investigators provide their insights and perspectives for a number of forkhead genes and proteins that may have the greatest impact for the development of new strategies for a broad array of disorders that can involve aging, cancer, cardiac function, neurovascular integrity, fertility, stem cell differentiation, cellular metabolism, and immune system regulation. Yet, the work clearly sets a precedent for the necessity to understand the cellular and molecular function of forkhead proteins since this family of transcription factors can limit as wen as foster disease progression depending upon the cellular environment. With this in mind, our concluding chapter for Forkhead Transcription Factors: Vital Elements in Biology and Medicine offers to highlight both the diversity and complexity of the forkhead transcription family by focusing upon the mammalian forkhead transcription factors of the O class (FoxOs) that include FoxO1, FoxO3, FoxO4, and FoxO6. FoxO proteins are increasingly considered to represent unique cellular targets that can control numerous processes such as angiogenesis, cardiovascular development, vascular tone, oxidative stress, stem cell proliferation, fertility, and immune surveillance. Furthermore, FoxO transcription factors are exciting considerations for disorders such as cancer in light of their pro-apoptotic and inhibitory cell cycle effects as well as diabetes mellitus given the close association FoxOs hold with cellular metabolism. In addition, these transcription factors are closely integrated with several novel signal transduction pathways, such as erythropoietin and Writ proteins, that may influence the ability of FoxOs to lead to cell survival or cell injury. Further understanding of both the function and intricate nature of the forkhead transcription factor family, and in particular the FoxO proteins, should allow selective regulation of cellular development or cellular demise for the generation of successful future clinical strategies and patient well-being.	[Maiese, Kenneth] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Maiese, K (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA.	kmaiese@med.wayne.edu			NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30 ES006639, P30 ES06639] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS053946-04, R01 NS053946-05, R01 NS053946-06, R01 NS053946-05W1, R01 NS053946-02, R01 NS053946, R01 NS053946-01A2, R01 NS053946-03, R01 NS053946-03S1] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053946] Funding Source: NIH RePORTER		Abid MR, 2005, J BIOL CHEM, V280, P29864, DOI 10.1074/jbc.M502149200; Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a; Anitha M, 2006, J CLIN INVEST, V116, P344, DOI 10.1172/JCI26295; Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Bakker WJ, 2007, MOL CELL BIOL, V27, P3839, DOI 10.1128/MCB.01662-06; Balan V, 2008, J BIOL CHEM, V283, P27810, DOI 10.1074/jbc.M804681200; Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850; Barthelemy C, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-48; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Bosque A, 2007, BLOOD, V109, P1627, DOI 10.1182/blood-2006-05-022319; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Caporali A, 2008, CELL DEATH DIFFER, V15, P299, DOI 10.1038/sj.cdd.4402263; Cariou A, 2008, RESUSCITATION, V76, P397, DOI 10.1016/j.resuscitation.2007.10.003; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Chong ZZ, 2007, HISTOL HISTOPATHOL, V22, P1251, DOI 10.14670/HH-22.1251; Chong ZZ, 2007, BRIT J PHARMACOL, V150, P839, DOI 10.1038/sj.bjp.0707161; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; Chong ZZ, 2007, CURR NEUROVASC RES, V4, P194; Chong ZZ, 2007, CELL SIGNAL, V19, P1150, DOI 10.1016/j.cellsig.2006.12.009; Chong ZZ, 2007, INT J MOL MED, V19, P263; Chong ZZ, 2006, CURR NEUROVASC RES, V3, P107, DOI 10.2174/156720206776875830; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P387, DOI 10.2174/156720205774962683; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P197, DOI 10.2174/1567202054368317; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299; Chong ZZ, 2004, J CEREBR BLOOD F MET, V24, P728, DOI 10.1097/01.WCB.0000122746.72175.0E; Chong ZZ, 2004, ANTIOXID REDOX SIGN, V6, P277, DOI 10.1089/152308604322899341; Chong ZZ, 2003, CELL MOL NEUROBIOL, V23, P561, DOI 10.1023/A:1025158314016; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F; Chonga ZZ, 2004, EXP CELL RES, V296, P196, DOI 10.1016/j.yexcr.2004.01.021; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cools N, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/89195; Cornforth AN, 2008, ONCOGENE, V27, P4422, DOI 10.1038/onc.2008.80; Delpuech O, 2007, MOL CELL BIOL, V27, P4917, DOI 10.1128/MCB.01789-06; Donahoe SM, 2007, JAMA-J AM MED ASSOC, V298, P765, DOI 10.1001/jama.298.7.765; Ebert LM, 2008, CANCER RES, V68, P3001, DOI 10.1158/0008-5472.CAN-07-5664; Eddy SF, 2007, CANCER RES, V67, P9018, DOI 10.1158/0008-5472.CAN-07-1691; Emami KH, 2007, CANCER LETT, V253, P170, DOI 10.1016/j.canlet.2006.12.040; Evans-Anderson HJ, 2008, CIRC RES, V102, P686, DOI 10.1161/CIRCRESAHA.107.163428; Fabre S, 2008, J IMMUNOL, V181, P2980, DOI 10.4049/jimmunol.181.5.2980; Fallarino F, 2004, J EXP MED, V200, P1051, DOI 10.1084/jem.20040942; Ferrara N, 2008, REJUV RES, V11, P139, DOI 10.1089/rej.2007.0576; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Furuyama T, 2002, MICROSC RES TECHNIQ, V59, P331, DOI 10.1002/jemt.10213; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Goettsch W, 2008, J CELL PHYSIOL, V214, P491, DOI 10.1002/jcp.21229; Gomez-Gutierrez JG, 2006, CANCER BIOL THER, V5, P875, DOI 10.4161/cbt.5.7.2911; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Han CY, 2008, CARCINOGENESIS, V29, P1837, DOI 10.1093/carcin/bgn092; Hannenhalli S, 2006, CIRCULATION, V114, P1269, DOI 10.1161/CIRCULATIONAHA.106.632430; Hellwinkel OJC, 2008, BJU INT, V101, P1454, DOI 10.1111/j.1464-410X.2008.07540.x; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hockstra AV, 2008, GYNECOL ONCOL, V108, pS141; Hoekman MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI 10.1016/j.modgep.2005.07.003; Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jagani Z, 2008, BBA-REV CANCER, V1785, P63, DOI 10.1016/j.bbcan.2007.10.003; Jin CW, 1998, BIOCHEMISTRY-US, V37, P6179, DOI 10.1021/bi980031v; Jin GS, 2004, ACTA MED OKAYAMA, V58, P197; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Kaestner KH, 2000, GENE DEV, V14, P142; Kamagate A, 2008, CELL CYCLE, V7, P3162, DOI 10.4161/cc.7.20.6882; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kang JQ, 2003, J NEUROSCI RES, V74, P37, DOI 10.1002/jnr.10740; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Kerdiles YM, 2009, NAT IMMUNOL, V10, P176, DOI 10.1038/ni.1689; Kikuchi S, 2007, CANCER SCI, V98, P1949, DOI 10.1111/j.1349-7006.2007.00623.x; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kim HK, 2005, J GERONTOL A-BIOL, V60, P4, DOI 10.1093/gerona/60.1.4; Kim JR, 2006, OBESITY, V14, P188, DOI 10.1038/oby.2006.24; Kim JH, 2007, MODERN PATHOL, V20, P835, DOI 10.1038/modpathol.3800789; Kim KH, 2008, J PHARMACOL EXP THER, V324, P160, DOI 10.1124/jpet.107.125773; Kimura-Yoshida C, 2007, P NATL ACAD SCI USA, V104, P5919, DOI 10.1073/pnas.0607779104; Kono K, 2006, CANCER IMMUNOL IMMUN, V55, P1064, DOI 10.1007/s00262-005-0092-8; Kuo CC, 2007, MOL MED, V13, P561, DOI 10.2119/2007-00021.Kuo; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Larson ET, 2007, VIROLOGY, V368, P249, DOI 10.1016/j.virol.2007.06.040; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Li F, 2006, HISTOL HISTOPATHOL, V21, P103, DOI 10.14670/HH-21.103; Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Li FQ, 2005, CURR NEUROVASC RES, V2, P331, DOI 10.2174/156720205774322557; Li H, 2007, MOL CELL BIOL, V27, P2676, DOI 10.1128/MCB.01748-06; Li HH, 2007, J CLIN INVEST, V117, P3211, DOI 10.1172/JCI31757; Li MY, 2006, J BIOL CHEM, V281, P40429, DOI 10.1074/jbc.M606596200; Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Lin SH, 2001, J CEREBR BLOOD F MET, V21, P262, DOI 10.1097/00004647-200103000-00010; Liu CM, 2007, CANCER GENE THER, V14, P945, DOI 10.1038/sj.cgt.7701091; Liu L, 2007, DEVELOPMENT, V134, P199, DOI 10.1242/dev.02667; Liu P, 2008, ONCOGENE, V27, P4733, DOI 10.1038/onc.2008.104; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Ludikhuize J, 2007, ARTHRITIS RHEUM-US, V56, P2180, DOI 10.1002/art.22653; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; Maiese K, 2005, CURR NEUROVASC RES, V2, P425, DOI 10.2174/156720205774962692; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; MAIESE K, 2009, NEUROVASCULAR MED PU; Maiese Kenneth, 2008, Expert Rev Cardiovasc Ther, V6, P281, DOI 10.1586/14779072.6.3.281; Maiese K, 2008, CURR NEUROVASC RES, V5, P125, DOI 10.2174/156720208784310231; Maiese K, 2008, EXPERT OPIN THER TAR, V12, P905, DOI [10.1517/14728222.12.7.905, 10.1517/14728222.12.7.905 ]; Maiese K, 2008, PROG NEUROBIOL, V85, P194, DOI 10.1016/j.pneurobio.2008.02.002; Maiese K, 2008, TRENDS MOL MED, V14, P219, DOI 10.1016/j.molmed.2008.03.002; Maiese K, 2008, BIOMED PHARMACOTHER, V62, P218, DOI 10.1016/j.biopha.2008.01.009; Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004; Maiese K, 2007, CURR NEUROVASC RES, V4, P295, DOI 10.2174/156720207782446306; Maiese K, 2008, CYTOKINE GROWTH F R, V19, P145, DOI 10.1016/j.cytogfr.2008.01.004; Maiese K, 2007, CURR NEUROVASC RES, V4, P63, DOI 10.2174/156720207779940653; Maiese K, 2007, CURR MED CHEM, V14, P1729; Maiese K, 2009, MED RES REV, V29, P395, DOI 10.1002/med.20139; Maiese K, 2009, CLIN SCI, V116, P191, DOI 10.1042/CS20080113; Maiese K, 2008, CELL CYCLE, V7, P3829, DOI 10.4161/cc.7.24.7231; Marchetti V, 2006, DIABETES, V55, P2231, DOI 10.2337/db06-0369; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Morris JB, 2005, ENDOCRINOLOGY, V146, P4370, DOI 10.1210/en.2005-0162; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Munoz-Fontela C, 2007, J VIROL, V81, P1511, DOI 10.1128/JVI.01816-06; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2008, DIABETES, V57, P563, DOI 10.2337/db07-0698; Nakamura T, 2008, MOL CELL ENDOCRINOL, V281, P47, DOI 10.1016/j.mce.2007.10.007; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Ni YG, 2007, P NATL ACAD SCI USA, V104, P20517, DOI 10.1073/pnas.0610290104; Nowak K, 2007, BBA-GENE STRUCT EXPR, V1769, P244, DOI 10.1016/j.bbaexp.2007.04.001; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Pohl BS, 2001, MECH DEVELOP, V103, P93, DOI 10.1016/S0925-4773(01)00334-3; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Salvesen GS, 2008, ADV EXP MED BIOL, V615, P13, DOI 10.1007/978-1-4020-6554-5_2; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Sauvageot CM, 2007, NEUROL CLIN, V25, P891, DOI 10.1016/j.ncl.2007.07.014; Sedding DG, 2003, CIRCULATION, V108, P616, DOI 10.1161/01.CIR.0000079102.08464.E2; Sela U, 2006, EUR J IMMUNOL, V36, P2971, DOI 10.1002/eji.200636137; Shang YC, 2009, CURR NEUROVASC RES, V6, P20, DOI 10.2174/156720209787466064; Slomka M, 2008, ACTA NEUROBIOL EXP, V68, P1; Smith WW, 2005, J CELL BIOL, V169, P331, DOI 10.1083/jcb.200410041; Song JJ, 2008, CELL SIGNAL, V20, P892, DOI 10.1016/j.cellsig.2008.01.001; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Tajes M, 2009, MECH AGEING DEV, V130, P253, DOI 10.1016/j.mad.2008.12.006; Ticchioni M, 2007, ONCOGENE, V26, P7081, DOI 10.1038/sj.onc.1210519; Tomita H, 2007, CANCER RES, V67, P4079, DOI 10.1158/0008-5472.CAN-06-4025; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Van der Heide LP, 2005, BIOCHEM J, V391, P623, DOI 10.1042/BJ20050525; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Ward EC, 2008, ENDOCRINOLOGY, V149, P1942, DOI 10.1210/en.2007-0756; Watkins WJ, 2006, FERTIL STERIL, V86, P1518, DOI 10.1016/j.fertnstert.2006.03.054; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wijchers PJEC, 2006, BIOCHEM J, V397, P233, DOI 10.1042/BJ20060387; Won CK, 2006, NEUROSCI LETT, V398, P39, DOI 10.1016/j.neulet.2005.12.060; Xu HT, 2007, ANN SURG ONCOL, V14, P3251, DOI 10.1245/s10434-007-9555-9; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Zethelius B, 2008, NEW ENGL J MED, V358, P2107, DOI 10.1056/NEJMoa0707064; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	175	43	43	1	8	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	978-1-4419-1598-6	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2009	665						242	260			10.1007/978-1-4419-1599-3		19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	BMC36	WOS:000271833300018	20429429				2021-06-18	
J	Tashlykov, V; Katz, Y; Volkov, A; Gazit, V; Schreiber, S; Zohar, O; Pick, CG				Tashlykov, V.; Katz, Y.; Volkov, A.; Gazit, V.; Schreiber, S.; Zohar, O.; Pick, C. G.			Minimal Traumatic Brain Injury Induce Apoptotic Cell Death in Mice	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Apoptosis; H&E; C-jun; p53; Bcl-2; Minimal TBI; Mice	MINOR HEAD-INJURY; COGNITIVE DEFICITS; NERVOUS-SYSTEM; NEURONS; JUN; HIPPOCAMPUS; MODELS; MOUSE; BCL-2; RATS	In the United States, 1.4 million people suffer from traumatic brain injury (TBI) each year because of traffic, sports, or war-related injuries. The majority of TBI victims suffer mild to minimal TBI (mTBI), but most are released undiagnosed. Detailed pathologies are poorly understood. We characterized the microscopic changes of neurons of closed-head mTBI mice after increased unilateral trauma using hematoxylin and eosin (H&E) stain, and correlated it with the expression of the apoptotic proteins c-jun, p53, and BCL-2. Minimal damage to the brain increases the number of pyknotic appearing neurons and activates the apoptotic proteins in both hemispheres. Although minimal, increased impact was positively correlated with the increased number of damaged neurons. These results may explain the wide variety of behavioral and cognitive deficits closed-head mTBI causes in mice. Our cumulative results point to the pathological origin of post-concussion syndrome and may aid in the development of future neuroprotective strategies for the disease.	[Pick, C. G.] Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Schreiber, S.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; [Zohar, O.] Johns Hopkins Univ Montgomery Cty Campus, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; [Volkov, A.] Chaim Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel; [Katz, Y.] Rambam Med Ctr, Dept Anesthesiol, Haifa, Israel; [Tashlykov, V.] Chaim Sheba Med Ctr, Dept Neurol, Ramat Gan, Israel; [Tashlykov, V.; Katz, Y.; Gazit, V.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Lab Anesthesia Pain & Neural Res, IL-31096 Haifa, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Volkov, Alex/P-5220-2018; Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010	Volkov, Alex/0000-0002-3157-7422; Schreiber, Shaul/0000-0002-2189-0693			Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bogolepov N N, 2004, Neurosci Behav Physiol, V34, P611, DOI 10.1023/B:NEAB.0000028293.62205.5f; Bonny C, 2005, REV NEUROSCIENCE, V16, P57; BROWN AW, 1972, J NEUROL SCI, V16, P59, DOI 10.1016/0022-510X(72)90102-5; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Clark RSB, 1999, FASEB J, V13, P813; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Ooigawa H, 2006, ACTA NEUROPATHOL, V112, P471, DOI 10.1007/s00401-006-0108-2; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ozaki T, 1998, NEUROSCIENCE, V84, P1187, DOI 10.1016/S0306-4522(97)00536-8; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Ward NL, 2000, EUR J NEUROSCI, V12, P1867, DOI 10.1046/j.1460-9568.2000.00070.x; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	30	43	43	1	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	JAN	2009	37	1					16	24		10.1007/s12031-008-9094-2			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	387SE	WOS:000261971100003	18651249				2021-06-18	
J	Heskestad, B; Baardsen, R; Helseth, E; Ingebrigtsen, T				Heskestad, Ben; Baardsen, Roald; Helseth, Eirik; Ingebrigtsen, Tor			Guideline Compliance in Management of Minimal, Mild, and Moderate Head Injury: High Frequency of Noncompliance Among Individual Physicians Despite Strong Guideline Support From Clinical Leaders	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Guidelines; Physicians-compliance	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; IMPLEMENTATION; HOSPITALS; IMPACT; RULE	Background. The evidence-based Scandinavian Guidelines for the Initial Management of Minimal, Mild, and Moderate Head Injuries were developed to provide safe and cost-effective assessment of patients. A survey based on a questionnaire directed to clinical managers in all Norwegian hospitals indicated that the guidelines had influenced management practice significantly. However, implementation of guidelines and compliance from clinical leaders does not necessarily influence individual physicians decisions making. Methods: To evaluate physicians-compliance with the Scandinavian Guidelines in individual patients, we conducted a study (January 2003 to January 2004) that included all patients with minimal, mild, and moderate head injury who presented to the emergency department in a Norwegian university hospital. Guideline compliance was evaluated in the assessment and treatment of 508 patients. The management of each single patient was classified as compliant with the guidelines or not. Classification as compliant required correct use of computed tomography (CT) and hospital admission in accordance with the guideline. Results: The overall physicians-compliance with the Scandinavian Guidelines was 51%. A substantial overtriage with unnecessary CT examinations and hospital admissions was seen in patients with minimal and mild head injuries. Among patients with minimal head injury, 69% underwent overtriage, 18% with unnecessary hospital admission, 27% with unnecessary CT, and 24% with both. Among patients with mild head injury, 37% were subject to overtriage, all with admission for observation after a negative CT. All patients with moderate head injury were treated in accordance with the guideline. Conclusions Guidelines for assessment and treatment of minimal and mild head injuries may not have the intended degree of influence on clinical practice. Even in departments where clinical managers report that the practice is evidence based, physicians may not act in accordance with this in their daily practice. This causes significant unnecessary costs, estimated as USD 2,167.000 annually in Norway.	[Heskestad, Ben; Helseth, Eirik] Ullevaal Univ Hosp, Dept Neurosurg, N-0407 Oslo, Norway; [Ingebrigtsen, Tor] Univ Tromso, Inst Clin Med, Tromso, Norway; [Ingebrigtsen, Tor] Univ Hosp N Norway, Dept Neurosurg, Tromso, Norway; [Baardsen, Roald] Stavanger Univ Hosp, Dept Neurosurg, Stavanger, Norway	Heskestad, B (corresponding author), Ullevaal Univ Hosp, Dept Neurosurg, N-0407 Oslo, Norway.	ben.heskestad@ulleval.no	Helseth, Eirik/AAH-2466-2020	Ingebrigtsen, Tor/0000-0001-5966-9786			Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; *CENTR BANK NORW N, EXCH RAT 2007; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 2000, Tidsskr Nor Laegeforen, V120, P1985; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	15	43	43	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1309	1313		10.1097/TA.0b013e31815e40cd			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	383WV	WOS:000261706000022	19077619				2021-06-18	
J	Kirchhoff, C; Buhmann, S; Bogner, V; Stegmaier, J; Leidel, BA; Braunstein, V; Mutschler, W; Biberthaler, P				Kirchhoff, C.; Buhmann, S.; Bogner, V.; Stegmaier, J.; Leidel, B. A.; Braunstein, V.; Mutschler, W.; Biberthaler, P.			CEREBROSPINAL IL-10 CONCENTRATION IS ELEVATED IN NON-SURVIVORS AS COMPARED TO SURVIVORS AFTER SEVERE TRAUMATIC BRAIN INJURY	EUROPEAN JOURNAL OF MEDICAL RESEARCH			English	Article							SYSTEMIC INTERLEUKIN-10 RELEASE; CENTRAL-NERVOUS-SYSTEM; FLUID; ACTIVATION; EXPRESSION; CYTOKINES; SERUM; CELL; SUPPRESSES; PRESSURE	Objective: The intrathecal posttraumatic inflammation contributes to secondary brain damage as well as to the induction of neuroreparative mechanisms. In this context release of interleukin-10 (IL-10) has been reported to play a major role. However, initial IL-10 concentration in CSF remains incompletely characterized. Therefore, the aim was to analyze Il-10 in CSF and serum of patients early after TBI. Methods: For control, 10 Volunteers receiving spinal puncture were enrolled. In patients with severe TBI (GCS<8pts.), CSF and serum was drawn within 90 +/- 45min after intraventricular catheter insertion (0h), as well as 12h, 24h and 48h after TBI. Albumin for assessing Blood-Brain-Barrier (BBB) function and IL-10 (IMMULITE, DPC Biermann, Bad Nauheim, Germany) were analyzed. Results: 23 patients were enrolled. 15 survived and 8 deceased within 24h. In controls, CSF IL-10 was below detection limit (<5pg/ml). In contrast, IL-10 was elevated significantly in non-survivors at 0h vs. survivors and controls (30 +/- 6 vs. 9 +/- 1 vs. <5pg/mL). This was accompanied by a significant increase of serum If.-H in both groups at Oh vs. controls (survivors: 30 +/- 6pg/mL, non-survivors: 48 +/- 8pg/mL, controls: 10 +/- 7pg/mL, p <0.001). Survivors revealed signs of a mild BBB dysfunction during the entire observation period. In contrast, non-survivors presented a severe BBB breakage. Conclusions: We demonstrated an analysis of IL-10 CSF and serum concentration after TBI. These data Support an intrathecal IL-10 synthesis. Although the significant increase of IL-10 might indicate a bad outcome of TBI, responsible mechanisms still have to be elucidated.	[Kirchhoff, C.] Tech Univ Munich, Klinikum Rechts Isar, Abt Sportorthopad, D-80809 Munich, Germany; [Buhmann, S.] Univ Munich, Inst Klin Radiol, Munich, Germany; [Bogner, V.; Stegmaier, J.; Leidel, B. A.; Braunstein, V.; Mutschler, W.; Biberthaler, P.] Univ Munich, Chirurg Klin Innenstadt, Munich, Germany	Kirchhoff, C (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Abt Sportorthopad, Conollystr 32, D-80809 Munich, Germany.	chlodwig.kirchhoff@med.uni-muenchen.de		LEIDEL, Bernd A./0000-0002-5149-8764			Balasingam V, 1996, J NEUROSCI, V16, P2945; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; FREI K, 1994, J IMMUNOL, V152, P2720; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P339; LACKI JK, 1995, INFLAMM RES, V44, P24, DOI 10.1007/BF01630483; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maskin B, 2001, MEDICINA-BUENOS AIRE, V61, P573; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mussack T, 2005, EUR J MED RES, V10, P426; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Scott MJ, 2006, CYTOKINE, V33, P79, DOI 10.1016/j.cyto.2005.12.002; SEITZ M, 1995, EUR J IMMUNOL, V25, P1129, DOI 10.1002/eji.1830250443; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497; Woiciechowsky C, 2005, ACT NEUR S, V95, P373; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wu DF, 1999, P NATL ACAD SCI USA, V96, P254, DOI 10.1073/pnas.96.1.254	29	43	45	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0949-2321	2047-783X		EUR J MED RES	Eur. J. Med. Res.	OCT 27	2008	13	10					464	468					5	Medicine, Research & Experimental	Research & Experimental Medicine	370LJ	WOS:000260763400004	19008173				2021-06-18	
J	Moussaieff, A; Shein, NA; Tsenter, J; Grigoriadis, S; Simeonidou, C; Alexandrovich, AG; Trembovler, V; Ben-Neriah, Y; Schmitz, ML; Fiebich, BL; Munoz, E; Mechoulam, R; Shohami, E				Moussaieff, Arieh; Shein, Naama A.; Tsenter, Jeanna; Grigoriadis, Savvas; Simeonidou, Constantina; Alexandrovich, Alexander G.; Trembovler, Victoria; Ben-Neriah, Yinon; Schmitz, Michael L.; Fiebich, Bernd L.; Munoz, Eduardo; Mechoulam, Raphael; Shohami, Esther			Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Boswellia; cembranoids; incensole acetate; inflammation; neuroprotection; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; NECROSIS-FACTOR-ALPHA; FLUORO-JADE-B; NF-KAPPA-B; INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; NEURONAL INJURY; MOUSE MODEL; TNF-ALPHA	Boswellia resin has been used as a major anti-inflammatory agent and for the healing of wounds for centuries. Incensole acetate (IA), isolated from this resin, was shown to inhibit the activation of nuclear factor-kappa B, a key transcription factor in the inflammatory response. We now show that IA inhibits the production of inflammatory mediators in an in vitro model system of C6 glioma and human peripheral monocytes. Given the involvement of postinjury inflammation in the pathophysiology and outcome of traumatic brain injury, we examined the effect of IA on the inflammatory process and on the recovery of neurobehavioral and cognitive functions in a mouse model of closed head injury (CHI). In the brains of post-CHI mice, IA reduced glial activation, inhibited the expression of interleukin-1 beta, and tumor necrosis factor-alpha mRNAs, and induced cell death in macrophages at the area of trauma. A mild hypothermic effect was also noted. Subsequently, IA inhibited hippocampal neurodegeneration and exerted a beneficial effect on functional outcome after CHI, indicated by reduced neurological severity scores and improved cognitive ability in an object recognition test. This study attributes the anti-inflammatory activity of Boswellia resin to IA and related cembranoid diterpenes and suggests that they may serve as novel neuroprotective agents.	[Moussaieff, Arieh; Shein, Naama A.; Tsenter, Jeanna; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Moussaieff, Arieh; Mechoulam, Raphael] Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; [Tsenter, Jeanna] Hebrew Univ Jerusalem, Hadassah Med Ctr, Rehabil Ctr, IL-91120 Jerusalem, Israel; [Grigoriadis, Savvas] AHEPA Univ Hosp, Lab Expt Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Fac Med, Physiol Lab, GR-54006 Thessaloniki, Greece; [Ben-Neriah, Yinon] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; [Schmitz, Michael L.] Univ Giessen, Fac Med, Inst Biochem, Giessen, Germany; [Fiebich, Bernd L.] Univ Freiburg, Sch Med, Dept Psychiat, Freiburg, Germany; [Munoz, Eduardo] Univ Cordoba, Fac Med, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Ben-Neriah, Yinon/L-6285-2019; Schmitz, M. Lienhard/D-9328-2017; Munoz, Eduardo/I-5225-2012	Schmitz, M. Lienhard/0000-0002-6984-7192; Munoz, Eduardo/0000-0001-8478-5842			Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; CORSANO S, 1967, TETRAHEDRON, V23, P1977, DOI 10.1016/S0040-4020(01)82601-6; El Sayed KA, 2007, EXPERT OPIN INV DRUG, V16, P877, DOI 10.1517/13543784.16.6.877; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Hamm S, 2005, PHYTOCHEMISTRY, V66, P1499, DOI 10.1016/j.phytochem.2005.04.025; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; Marshall S., 2003, Pharmaceutical Journal, V271, P862; Moussaieff A, 2005, J ETHNOPHARMACOL, V101, P16, DOI 10.1016/j.jep.2005.03.028; Moussaieff A, 2007, MOL PHARMACOL, V72, P1657, DOI 10.1124/mol.107.038810; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Poeckel D, 2006, MOL PHARMACOL, V70, P1071, DOI 10.1124/mol.106.024836; Potts Mathew B, 2006, NeuroRx, V3, P143; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHUHMANN MU, 2005, J CEREB BLOOD FLOW M, V25, pS261; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Watt J. M., 1962, MED POISONOUS PLANTS, P151; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	39	43	43	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2008	28	7					1341	1352		10.1038/jcbfm.2008.28			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	318DZ	WOS:000257073100007	18414499	Bronze			2021-06-18	
J	Arango-Lasprilla, JC; Ketchum, JM; Williams, K; Kreutzer, JS; de la Plata, CAM; O'Neil-Pirozzi, TM; Wehman, P				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Williams, Kelli; Kreutzer, Jeffrey S.; de la Plata, Carlos A. Marquez; O'Neil-Pirozzi, Therese M.; Wehman, Paul			Racial differences in employment outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; outcomes research; race; rehabilitation	QUALITY-OF-LIFE; FUNCTIONAL OUTCOMES; WORK; RACE	Objective: To examine racial differences in employment status and occupational status I year after a traumatic brain injury (TBI). Design: Retrospective study. Setting: Longitudinal dataset of the Traumatic Brain Injury Model Systems national database. Participants: Subjects with primarily moderate to severe TBI (3468 whites vs 1791 minorities) hospitalized between 1989 and 2005. Interventions: Not applicable. Main Outcome Measures: Employment status (competitively employed or unemployed) and occupational status (professional/managerial, skilled, or manual labor) at 1 year postinjury. Results: Race and/or ethnicity has a significant effect on employment status at 1 year postinjury (chi(2)(1) = 58.23, P <.001), after adjusting for preinjury employment status, sex, Disability Rating Scale at discharge, marital status, cause of injury, age, and education. The adjusted odds of being unemployed versus competitively employed are 2.17 times (95% confidence interval, 1.78-2.65) greater for minorities than for whites. Race and ethnicity does not have a significant effect on occupational status at I year postinjury. Conclusions: With this empirical evidence supporting racial differences in employment outcomes between minorities and whites at I year postinjury, priority should be given to tailoring interventions to maximize minority survivors' work-related productivity.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA 23219 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23219 USA; [de la Plata, Carlos A. Marquez] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [de la Plata, Carlos A. Marquez] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Theater Row Bldg,730 Broad St, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education [H133A020516, H133B040011]	Supported by the National Institute on Disability and Rehabilitation Research. U.S. Department of Education (grant nos. H133A020516, H133B040011).	Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hosmer D. W., 2000, APPL LOGISTIC REGRES; INGE KJ, 2007, REAL WORK REAL PLAY, P117; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P69; RUTLANDBROWN W, 2003, J HEAD TRAUMA REHAB, V2, P544; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001	23	43	43	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					988	995		10.1016/j.apmr.2008.02.012			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900027	18452750				2021-06-18	
J	Ottens, AK; Golden, EC; Bustamante, L; Hayes, RL; Denslow, ND; Wang, KKW				Ottens, Andrew K.; Golden, Erin C.; Bustamante, Liliana; Hayes, Ronald L.; Denslow, Nancy D.; Wang, Kevin K. W.			Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry	JOURNAL OF NEUROCHEMISTRY			English	Article						biomarkers; mass spectrometry; myelin basic protein; neurotrauma; proteolysis; quantification	TRAUMATIC BRAIN-INJURY; SCLEROSIS; CALPAIN; DEMYELINATION; DEGRADATION; MECHANISM; QUANTIFICATION; IDENTIFICATION; INHIBITION; PROTEOMICS	Neurotrauma, as in the case of traumatic brain injury, promotes protease over-activation characterized by the select fragmentation of brain proteins. The resulting polypeptides are indicators of biochemical processes, which can be used to study post-injury dynamics and may also be developed into biomarkers. To this end, we devised a novel mass spectrometry approach to characterize post-injury calpain proteolytic processing of myelin basic protein (MBP), a biomarker of brain injury that denotes white matter damage and recovery. Our approach exceeds conventional immunological assays in its deconvolution of multiple protein isoforms, its absolute quantification of proteolytic fragments and its polypeptide selectivity. We quantified and characterized post-injury proteolytic processing of all MBP isoforms identified in adult rat cortex. Further, the translation of calpain-cleaved MBP into CSF was verified following brain injury. We ascertained that the exon-6 sequence of MBP resulted in a characteristic shift in gel migration for intact and fragmented protein alike. We also found evidence for a second post-TBI cleavage event within exon-2 and for the dimerization of the post-TBI 4.3 kDa fragment. Ultimately, the novel methodology described here can be used to study MBP dynamics and other similar proteolytic events of relevance to brain injury and other CNS processes.	[Ottens, Andrew K.; Bustamante, Liliana; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarker Res, Dept Psychiat, Gainesville, FL 32611 USA; [Ottens, Andrew K.; Bustamante, Liliana; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Psychiat, Gainesville, FL 32611 USA; [Ottens, Andrew K.; Golden, Erin C.; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32611 USA; [Ottens, Andrew K.; Golden, Erin C.; Hayes, Ronald L.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarker Res, Dept Neurosci, Gainesville, FL 32611 USA; [Denslow, Nancy D.] Univ Florida, McKnight Brain Inst, Ctr Neuroproteom & Biomarker Res, Dept Physiol Sci, Gainesville, FL 32611 USA; [Denslow, Nancy D.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Dept Physiol Sci, Gainesville, FL 32611 USA	Ottens, AK (corresponding author), POB 100256, Gainesville, FL 32610 USA.	aottens@mbi.ufl.edu	Ottens, Andrew/K-3352-2012	Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25NS055012] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25NS055012, K25 NS055012] Funding Source: Medline		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Arroyo EJ, 2000, HISTOCHEM CELL BIOL, V113, P1, DOI 10.1007/s004180050001; Banik NL, 2000, NEUROCHEM RES, V25, P1509, DOI 10.1023/A:1007684311023; Banik NL, 1997, BRAIN RES, V748, P205, DOI 10.1016/S0006-8993(96)01302-9; Barr JR, 1996, CLIN CHEM, V42, P1676; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Blackler AR, 2006, ANAL CHEM, V78, P1337, DOI 10.1021/ac051486a; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Boggs JM, 2000, BBA-BIOMEMBRANES, V1463, P81, DOI 10.1016/S0005-2736(99)00181-9; BOULIAS C, 1995, ARCH BIOCHEM BIOPHYS, V322, P174, DOI 10.1006/abbi.1995.1449; Capello E, 1997, ANN NEUROL, V41, P797, DOI 10.1002/ana.410410616; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Givogri MI, 2000, J NEUROSCI RES, V59, P153, DOI 10.1002/(SICI)1097-4547(20000115)59:2<153::AID-JNR1>3.3.CO;2-6; Godovac-Zimmermann J, 2005, PROTEOMICS, V5, P699, DOI 10.1002/pmic.200401051; Harauz G, 2004, MICRON, V35, P503, DOI 10.1016/j.micron.2004.04.005; Kimura M, 1998, BRAIN RES, V785, P245, DOI 10.1016/S0006-8993(97)01383-8; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOBEISSY FH, 2006, PROTOEMICS, V5, P1887; Kruger GM, 1999, J NEUROSCI RES, V56, P241; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Maatta JA, 1997, BIOCHEM BIOPH RES CO, V238, P498, DOI 10.1006/bbrc.1997.7318; Massaro AR, 1998, MULT SCLER J, V4, P1; Michalowska-Wender G, 2001, FOLIA NEUROPATHOL, V39, P1; NAKAJIMA K, 1993, J NEUROCHEM, V60, P1554, DOI 10.1111/j.1471-4159.1993.tb03321.x; Norton WT., 2013, MYELIN, V21, P147, DOI [10.1007/978-1-4757-1830-0_5, DOI 10.1007/978-1-4757-1830-0_5]; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; SATO S, 1984, ANN NEUROL, V15, P264, DOI 10.1002/ana.410150310; Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH ME, 1977, NEUROCHEM RES, V2, P233, DOI 10.1007/BF00969354; THOMAS D G T, 1978, Lancet, V1, P113; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; VOSKUHL RR, 1994, J IMMUNOL, V153, P4834; WOOD DD, 1989, J BIOL CHEM, V264, P5121; Yura K, 2006, GENE, V380, P63, DOI 10.1016/j.gene.2006.05.015	41	43	45	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2008	104	5					1404	1414		10.1111/j.1471-4159.2007.05086.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	264AI	WOS:000253257200023	18036155	Green Accepted			2021-06-18	
J	Kox, M; Pompe, JC; Pickkers, P; Hoedemaekers, CW; van Vugt, AB; van der Hoeven, JG				Kox, M.; Pompe, J. C.; Pickkers, P.; Hoedemaekers, C. W.; van Vugt, A. B.; van der Hoeven, J. G.			Increased vagal tone accounts for the observed immune paralysis in patients with traumatic brain injury	NEUROLOGY			English	Article							HEART-RATE-VARIABILITY; CHOLINERGIC ANTIINFLAMMATORY PATHWAY; VAGUS NERVE-STIMULATION; T-CELL FUNCTION; POWER SPECTRUM; ENDOTOXEMIA; SYSTEM; SUPPRESSION; IMPAIRMENT; ACTIVATION	Traumatic brain injury (TBI) is a leading cause of death and disability, especially in the younger population. In the acute phase after TBI, patients are more vulnerable to infection, associated with a decreased immune response in vitro. The cause of this immune paralysis is poorly understood. Apart from other neurologic dysfunction, TBI also results in an increase in vagal activity. Recently, the vagus nerve has been demonstrated to exert an anti-inflammatory effect, termed the cholinergic anti-inflammatory pathway. The anti-inflammatory effects of the vagus nerve are mediated by the alpha 7 nicotinic acetylcholine receptor present on macrophages and other cytokine-producing cells. From these observations, we hypothesize that the immune paralysis observed in patients with TBI may, at least in part, result from augmented vagal activity and subsequent sustained effects of the cholinergic anti-inflammatory pathway. This pathway may counteract systemic proinflammation caused by the release of endogenous compounds termed alarmins as a result of tissue trauma. However, sustained activity of this pathway may severely impair the body's ability to combat infection. Since the cholinergic anti-inflammatory pathway can be pharmacologically modulated in humans, it could represent a novel approach to prevent infections in patients with TBI.	[Kox, M.; Pompe, J. C.; Pickkers, P.; Hoedemaekers, C. W.; van der Hoeven, J. G.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands; [Pompe, J. C.; van Vugt, A. B.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Surg, Sect Traumotol, NL-6500 HB Nijmegen, Netherlands	Pickkers, P (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Intens Care Med, Geert Grooteplein 10, NL-6500 HB Nijmegen, Netherlands.	p.pickkers@ic.umcn.nl	Pickkers, P./H-8080-2014; Kox, Matthijs/L-4454-2015; Hoedemaekers, C.W.E./L-4375-2015; van der Hoeven, J.G./H-8048-2014	Pickkers, P./0000-0002-1104-4303; 			Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Borovikova LV, 2000, NATURE, V405, P458; Borovikova LV, 2000, AUTON NEUROSCI-BASIC, V85, P141, DOI 10.1016/S1566-0702(00)00233-2; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Cooke WH, 2006, J TRAUMA, V60, P363, DOI 10.1097/01.ta.0000196623.48952.0e; Corcoran C, 2005, NEUROIMMUNOMODULAT, V12, P307, DOI 10.1159/000087109; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Dempsey PW, 2003, CELL MOL LIFE SCI, V60, P2604, DOI 10.1007/s00018-003-3180-y; Freeman JV, 2006, PROG CARDIOVASC DIS, V48, P342, DOI 10.1016/j.pcad.2005.11.003; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Guyenet PG, 2006, NAT REV NEUROSCI, V7, P335, DOI 10.1038/nrn1902; Hamano R, 2006, SHOCK, V26, P358, DOI 10.1097/01.shk.0000228168.86845.60; HAUSER CJ, 1995, ARCH SURG-CHICAGO, V130, P1186; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; KAMATH MV, 1992, PACE, V15, P235, DOI 10.1111/j.1540-8159.1992.tb03067.x; Kawahara E, 2003, CIRC J, V67, P753; Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kessler W, 2006, LANGENBECK ARCH SURG, V391, P83, DOI 10.1007/s00423-006-0031-y; King ML, 1997, BRAIN INJURY, V11, P445; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; MATSUURA S, 1984, BRAIN RES, V305, P291, DOI 10.1016/0006-8993(84)90435-9; MILLER C H, 1991, Neurological Research, V13, P117; MONTANO N, 1994, CIRCULATION, V90, P1826, DOI 10.1161/01.CIR.90.4.1826; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Ori Z, 1992, Cardiol Clin, V10, P499; Pavlov VA, 2006, BIOCHEM SOC T, V34, P1037, DOI 10.1042/BST0341037; Pavlov VA, 2005, BRAIN BEHAV IMMUN, V19, P493, DOI 10.1016/j.bbi.2005.03.015; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Van Westerloo DJ, 2006, J THROMB HAEMOST, V4, P1997, DOI 10.1111/j.1538-7836.2006.02112.x; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Voldby B, 1988, Acta Neurochir Suppl (Wien), V45, P1; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; Winchell RJ, 1996, J SURG RES, V63, P11, DOI 10.1006/jsre.1996.0214; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806	59	43	46	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 5	2008	70	6					480	485		10.1212/01.wnl.0000279479.69502.3e			6	Clinical Neurology	Neurosciences & Neurology	258TS	WOS:000252893000011	18250293	Green Published			2021-06-18	
J	Howe, TJ				Howe, Tami J.			The ICF Contextual Factors related to speech-language pathology	INTERNATIONAL JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						ICF; World Health Organization; speech-language pathology; Contextual Factors; Environmental Factors; Personal Factors	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; COMMUNICATION DISORDERS; COMMUNITY INTEGRATION; ENVIRONMENTAL-FACTORS; STUTTERING TREATMENT; SPASMODIC DYSPHONIA; LATERAL-SCLEROSIS; CONTROLLED-TRIAL; VOICE PROBLEMS	The World Health Organization's International Classification of Functioning, Disability and Health (ICF) conceptualizes functioning and disability as a dynamic interaction between a person's health condition and their contextual factors. Contextual factors "represent the complete background of an individual's life and living" and comprise two components: Environmental Factors and Personal Factors. This review aims to: (1) discuss why contextual factors are important for speech-language pathologists to address in their clinical practice, (2) describe how, environmental factors are coded in the ICF, (3) identify environmental factors that are relevant for people with communication disorders, and (4) identify personal factors that are relevant for people with communication disorders. Research on environmental factors that can influence the functioning of individuals with various communication disorders is presented, in addition to studies on personal factors that are important for speech-language pathologists to consider. The paper concludes that speech-language pathologists need to address contextual factors routinely, in order to provide a holistic approach to intervention for their clients. Furthermore, although a number of contextual factors that are relevant for people with communication disorders have been reported in the literature, more research is needed in this area.	Univ Queensland, Sch Hlth & Rehabil Sci, Commun Disabil Ctr, Brisbane, Qld 4072, Australia	Howe, TJ (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Commun Disabil Ctr, Brisbane, Qld 4072, Australia.	t.howe@uq.edu.au					Adams S, 2006, J MED SPEECH-LANG PA, V14, P221; *AM SPEECH LANG HE, 2001, SCOP PRACT SPEECH LA; ASHTON C, APHASIOLOGY IN PRESS; Bailey RL, 2006, LANG SPEECH HEAR SER, V37, P50, DOI 10.1044/0161-1461(2006/006); Balandin S., 2004, AUGMENTATIVE ALTERNA, V20, P243, DOI DOI 10.1080/07434610400011646; Ball LJ, 2004, J COMMUN DISORD, V37, P197, DOI 10.1016/j.jcomdis.2003.09.002; Barr J, 2008, LANG SPEECH HEAR SER, V39, P21, DOI 10.1044/0161-1461(2008/003); Baylor CR, 2005, J COMMUN DISORD, V38, P395, DOI 10.1016/j.jcomdis.2005.03.003; Blood G. W., 2004, CONT ISSUES COMMUNIC, V31, P69, DOI [DOI 10.1044/CICSD_31_S_69, 10.1044/cicsd_31_S_69.]; Bornman J, 2004, DISABIL REHABIL, V26, P182, DOI 10.1080/09638280410001665218; Bothe AK, 2006, AM J SPEECH-LANG PAT, V15, P342, DOI 10.1044/1058-0360(2006/032); BOURGEOIS MS, 1992, J SPEECH HEAR RES, V35, P1344, DOI 10.1044/jshr.3506.1344; Brown K, 2006, APHASIOLOGY, V20, P595, DOI 10.1080/02687030600626256; Brundage SB, 2006, J FLUENCY DISORD, V31, P325, DOI 10.1016/j.jfludis.2006.08.003; Carr MM, 2000, OTOLARYNG HEAD NECK, V122, P39, DOI 10.1016/S0194-5998(00)70141-0; Cherney L. R., 2001, LANGUAGE INTERVENTIO, P148; CORRELL A, 2004, ACQUIRING KNOWLEDGE, V6, P93; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; Cox R M, 1999, J Am Acad Audiol, V10, P1; Crowe LK, 2004, J COMMUN DISORD, V37, P177, DOI 10.1016/j.jcomdis.2003.09.001; de Graeff A, 2000, HEAD NECK-J SCI SPEC, V22, P398, DOI 10.1002/1097-0347(200007)22:4<398::AID-HED14>3.0.CO;2-V; DePaul R, 2000, AM J SPEECH-LANG PAT, V9, P230, DOI 10.1044/1058-0360.0903.230; Drager K. D. R., 2004, AUGMENTATIVE ALTERNA, V20, P103, DOI [DOI 10.1080/07434610410001699681, 10.1080/07434610410001699681]; Eadie TL, 2003, AM J SPEECH-LANG PAT, V12, P189, DOI 10.1044/1058-0360(2003/065); Ebert KA, 1994, LANG SPEECH HEAR SER, V25, P211; Elman RJ, 2000, APHASIOLOGY, V14, P455, DOI 10.1080/026870300401234; Finn P, 2003, J COMMUN DISORD, V36, P153, DOI 10.1016/S0021-9924(03)00004-2; Fleming J, 1999, BRAIN INJURY, V13, P417; FLORANCE CL, 1980, CLIN APHASIOLOGY C P, V10, P285; Fox A, 2005, DISABIL REHABIL, V27, P1399, DOI 10.1080/09638280500052567; Garcia LJ, 2000, APHASIOLOGY, V14, P269, DOI 10.1080/026870300401478; Garcia LJ, 2002, J COMMUN DISORD, V35, P187, DOI 10.1016/S0021-9924(02)00064-3; GREENER J, 2001, COCHRANE DB SYST REV, V4; Gross J, 2004, ENVIRON BEHAV, V36, P424, DOI 10.1177/0013916503262536; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guest CM, 2006, J DEAF STUD DEAF EDU, V11, P252, DOI 10.1093/deafed/enj028; HO K, 2005, AUGMENTATIVE ALTERNA, V21, P218; Howe T., 2006, THESIS U QUEENSLAND; Howe TJ, 2004, APHASIOLOGY, V18, P1015, DOI 10.1080/02687030444000499; HOWE TJ, APHASIOLOGY IN PRESS; HUGHES D, 1985, LANGUAGE TREATMENT G; Hurst R, 2003, DISABIL REHABIL, V25, P572, DOI 10.1080/0963828031000137072; Hustad KC, 2003, AM J SPEECH-LANG PAT, V12, P198, DOI 10.1044/1058-0360(2003/066); Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Klasner ER, 2005, J MED SPEECH-LANG PA, V13, P127; Knox E, 2003, INT J LANG COMM DIS, V38, P1, DOI 10.1080/13682820304817; LaFrance C, 2007, J COMMUN DISORD, V40, P215, DOI 10.1016/j.jcomdis.2006.06.010; Lass N. J., 1992, LANG SPEECH HEAR SER, V23, P78, DOI DOI 10.1044/0161-1461.2301.73; LASSALETTA L, 2005, EUROPEAN ARCH OTO RH, V263, P267; Law J, 2005, DISABIL SOC, V20, P169, DOI 10.1080/09687590500059267; LeDorze G, 1996, DISABIL REHABIL, V18, P550; Legg C, 2005, APHASIOLOGY, V19, P559, DOI 10.1080/02687030544000029; McConachie H, 2007, J EVAL CLIN PRACT, V13, P120, DOI 10.1111/j.1365-2753.2006.00674.x; MELIN L, 1981, J APPL BEHAV ANAL, V14, P47, DOI 10.1901/jaba.1981.14-47; Muo R, 2005, DISABIL REHABIL, V27, P1405, DOI 10.1080/09638280500052542; Murphy J, 2006, HEALTH EXPECT, V9, P49, DOI 10.1111/j.1369-7625.2006.00366.x; MURPHY J, 2000, BRIT J THERAPY REHAB, V7, P454, DOI DOI 10.12968/BJTR.2000.7.11.13835; Murphy J., 2004, AUGMENTATIVE ALTERNA, V20, P259, DOI [10.1080/07434610400005663, DOI 10.1080/07434610400005663]; Nordehn G, 2006, TOP STROKE REHABIL, V13, P68, DOI 10.1310/5K2W-P6CD-EFDF-8HG4; O'Halloran R, 2008, INT J SPEECH-LANG PA, V10, P18, DOI 10.1080/14417040701772620; Orange J. B., 1995, DEMENTIA COMMUNICATI, P168; Owens JS, 2006, AUGMENT ALTERN COMM, V22, P196, DOI 10.1080/07434610600649971; OWENS RE, 2007, INTRO COMMUNICATION; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Parr S., 1997, TALKING APHASIA LIVI; Plexico L, 2005, J FLUENCY DISORD, V30, P1, DOI 10.1016/j.jfludis.2004.12.001; RICHARDSON J L, 1989, Health and Social Work, V14, P283; Rose TA, 2003, APHASIOLOGY, V17, P947, DOI 10.1080/02687030344000319; Roth CR, 2000, J MED SPEECH-LANG PA, V8, P365; Roy N, 2002, J SPEECH LANG HEAR R, V45, DOI 10.1044/1092-4388(2002/050); Schneidert M, 2003, DISABIL REHABIL, V25, P588, DOI 10.1080/0963828031000137090; Simmons-Mackie N, 2002, APHASIOLOGY, V16, P837, DOI 10.1080/02687030244000185; Simmons-Mackie N., 2000, NEUROGENIC COMMUNICA, P162; Smith E, 1998, J VOICE, V12, P480, DOI 10.1016/S0892-1997(98)80057-X; *SPEECH PATH AUSTR, 2002, SCOP PRACT SPEECH PA; Stephens D, 2001, AUDIOLOGY, V40, P294; Sullivan M. D., 1993, J MED SPEECH-LANG PA, V1, P73; Terrell JE, 2004, ARCH OTOLARYNGOL, V130, P401, DOI 10.1001/archotol.130.4.401; Thomas G, 2006, FOLIA PHONIATR LOGO, V58, P305, DOI 10.1159/000094566; THREATS T, 2000, FOLIA PHONIATR LOGO, V8, pR13; Threats T.T., 2004, ADV SPEECH LANG PATH, V6, P53, DOI [DOI 10.1080/14417040410001669426, 10.1080/14417040410001669426]; Threats T. T., 2003, SPEECH PATHOLOGY ONL; Threats T, 2007, APHASIOLOGY, V21, P67, DOI 10.1080/02687030600798303; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Townsend E, 2002, ENABLING OCCUPATION; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; VERDOLINIMARSTON K, 1994, J VOICE, V8, P30, DOI 10.1016/S0892-1997(05)80317-0; VOGEL D, 1995, EFFECTS DRUGS COMMUN; Vuorialho A, 2006, INT J AUDIOL, V45, P400, DOI 10.1080/14992020600625007; Waller A, 1998, INT J LANG COMM DIS, V33, P45, DOI 10.1080/136828298247929; Ward EC, 2003, FOLIA PHONIATR LOGO, V55, P39, DOI 10.1159/000068056; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; World Health Organization, 2001, INT CLASS FUNCT DIS; Yaruss JS, 2002, J FLUENCY DISORD, V27, P115; Zimmerman S, 1997, J SPEECH LANG HEAR R, V40, P1130, DOI 10.1044/jslhr.4005.1130; ZWIRNER P, 1991, J VOICE, V5, P78, DOI 10.1016/S0892-1997(05)80167-5	96	43	44	0	14	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	1754-9507			INT J SPEECH-LANG PA	Int. J. Speech-Lang. Pathol.	FEB-APR	2008	10	1-2					27	37		10.1080/14417040701774824			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	448JP	WOS:000266259200005					2021-06-18	
J	Kwok, FY; Lee, TMC; Leung, CHS; Poon, WS				Kwok, Florence Y.; Lee, Tatia M. C.; Leung, Clarence H. S.; Poon, Wai S.			Changes of cognitive functioning following mild traumatic brain injury over a 3-month period	BRAIN INJURY			English	Article						traumatic brain injury; attention; cognitive functions; mild TBI; neuropsychology	POSITRON-EMISSION-TOMOGRAPHY; MINOR HEAD-INJURY; ATTENTION; SYMPTOMS; DEFICITS; CONCUSSION; CHINESE; ADULTS	Primary objective: To examine the cognitive functioning in patients with complicated mild traumatic brain injury immediately post-injury and at 1 and 3 months post-injury. Research design, methods, and procedures: Between-group comparisons were adopted for this study. Specifically, both patients and healthy controls were administered neuropsychological assessments measuring attention, memory and executive functions at three time points. Results: Findings indicate that patients performed significantly more poorly in information processing and divided attention, sustained attention, verbal recognition and verbal fluency immediately post-injury. While the information processing and divided attention of mild TBI patients improved at 1 month and returned to normal at 3 months post-injury, their sustained attention remained significantly poorer over the 3-month period. Conclusions: Findings suggest that attention dysfunction is noticeable immediately following a mild TBI. Different attention functions appear to recover at a different pace over time, suggesting that the condition may have a differential impact on the different sub-types of attention.	[Kwok, Florence Y.; Lee, Tatia M. C.] Univ Hong Kong, Neuropsychol Lab, Hong Kong, Hong Kong, Peoples R China; [Lee, Tatia M. C.] MacLehose Med Rehabil Ctr, Inst Clin Neuropsychol, Hong Kong, Hong Kong, Peoples R China; [Leung, Clarence H. S.; Poon, Wai S.] Chinese Univ Hong Kong, Prince Wales Hosp, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China	Lee, TMC (corresponding author), Univ Hong Kong, Neuropsychol Lab, K610,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	tmclee@hkusua.hku.hk	Poon, Wai Sang/F-1558-2011; Lee, Tatia Mei Chun/D-4922-2009		The University of Hong KongUniversity of Hong Kong; Wai Lun Education Foundation Limited; S. K. Yee Medical Foundation	The project was supported by the University Development Fund and the Research Output Prize of The University of Hong Kong, the Wai Lun Education Foundation Limited and the S. K. Yee Medical Foundation.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Benton AL., 1974, REVISED VISUAL RETEN; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Brown L., 1997, TEST NONVERBAL INTEL; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fernandez-Duque D, 2001, J CLIN EXP NEUROPSYC, V23, P74, DOI 10.1076/jcen.23.1.74.1217; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gunstad J, 2006, ARCH CLIN NEUROPSYCH, V21, P645, DOI 10.1016/j.acn.2006.05.009; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lee TMC, 2002, J CLIN EXP NEUROPSYC, V24, P615, DOI 10.1076/jcen.24.5.615.1001; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWIS RF, 1992, DIG VIG TEST PROF US; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R.M., 1989, MILD HEAD INJURY, P176; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith A., 1982, SYMBOL DIGIT MODALIT; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; ZAKZANIS KK, 1999, MILD TRAUMATIC BRAIN	43	43	43	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	10					740	751		10.1080/02699050802336989			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400003	18787983				2021-06-18	
J	Ownsworth, T; Shum, D				Ownsworth, Tamara; Shum, David			Relationship between executive functions and productivity outcomes following stroke	DISABILITY AND REHABILITATION			English	Article						stroke; executive functions; employment; productivity	TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; SELF-AWARENESS; REHABILITATION; CONSEQUENCES; SENSITIVITY; MANAGEMENT; FREQUENCY; DEFICITS; FLUENCY	Purpose. Stroke occurs in many individuals of working age and can considerably disrupt their capacity for employment and other productive activities. Few studies have examined the relationship between loss of productivity and cognitive impairment, particularly deficits in executive function. The present study examined whether performance on tests of executive function is related to employment and productivity at 12-months follow-up. Method. Twenty-seven individuals (mean age = 47.3 years, SD = 10.7) on average 2.1 years (SD = 1.6) post-stroke were recruited from hospital and community rehabilitation services and administered a theory-driven battery of executive function tests (i.e. Health and Safety sub-test, FAS Test, Five-Point test, Key Search Test and Tinkertoy Test). A 12-month follow-up assessment of employment outcome ('employed' or 'unemployed') and productivity (measured by the Sydney Psychosocial Reintegration Scale) was conducted. Results. A series of between-group comparisons identified that a measure of purposive behaviour and self-regulation (i.e. the Tinkertoy Test) best distinguished between the employed and unemployed groups (p < 0.01) irrespective of time since injury and neglect. Level of post-stroke productivity was significantly correlated with measures of planning (p < 0.05), self-monitoring (p < 0.01) and self-regulation (p < 0.05), as well as time since injury (p < 0.05) and functional status (p < 0.01). Conclusions. These findings highlight the importance of routinely assessing executive functions to guide cognitive rehabilitation interventions following stroke.	[Ownsworth, Tamara; Shum, David] Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia; [Ownsworth, Tamara; Shum, David] Griffith Univ, Appl Cognitive Neurosci Res Ctr, Nathan, Qld 4111, Australia	Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262; Ownsworth, Tamara/0000-0003-1835-7094			Ashburn A, 2006, DISABIL REHABIL, V28, P809, DOI 10.1080/09638280500534689; Australian Institute of Health and Welfare, 2003, DIS PREV TRENDS; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BOGOUSSLAVSKY J, 1994, EUR NEUROL, V34, P306, DOI 10.1159/000117068; Cartoni A, 2005, NEUROPSYCHOL REHABIL, V15, P55, DOI 10.1080/09602010443000029; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Golding E., 1989, MIDDLESEX ELDERLY AS; Hartman-Maeir A, 2002, J REHABIL MED, V34, P158, DOI 10.1080/16501970213236; Jones F, 2006, DISABIL REHABIL, V28, P841, DOI 10.1080/09638280500534952; Kaplan E., 1988, CLIN NEUROPSYCHOLOGY, P125; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; Leeds L, 2001, AGE AGEING, V30, P251, DOI 10.1093/ageing/30.3.251; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Loeb P. A., 1996, INDEPENDENT LIVING S; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Pedersen PM, 1996, J NEUROL REHABIL, V10, P243; Pohjasvaara T, 2002, EUR J NEUROL, V9, P269, DOI 10.1046/j.1468-1331.2002.00396.x; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stemmer B, 2000, BRAIN COGNITION, V44, P25; Stephens S, 2004, INT J GERIATR PSYCH, V19, P1053, DOI 10.1002/gps.1209; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D.T., 1996, FRONTAL LOBES; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Teasdale TW, 2005, BRAIN INJURY, V19, P1049, DOI 10.1080/02699050500110421; TUPPER DE, 1989, ANN M NAT AC NEUR NO; VONCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516	42	43	43	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2008	30	7					531	540		10.1080/09638280701355694			10	Rehabilitation	Rehabilitation	279IL	WOS:000254348800007	17852299				2021-06-18	
J	You, ZR; Yang, JS; Takahashi, K; Yager, PH; Kim, HH; Qin, T; Stahl, GL; Alan, R; Ezekowitz, B; Carroll, MC; Whalen, MJ				You, Zerong; Yang, Jinsheng; Takahashi, Kazue; Yager, Phoebe H.; Kim, Hyung-Hwan; Qin, Tao; Stahl, Gregory L.; Alan, R.; Ezekowitz, B.; Carroll, Michael C.; Whalen, Michael J.			Reduced tissue damage and improved recovery of motor function after traumatic brain injury in mice deficient in complement component C4	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						complement; mice; behavior; traumatic brain injury; inflammation; genetics	CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; STREPTOCOCCAL INFECTION; CEREBROSPINAL-FLUID; REPERFUSION INJURY; FACTOR-B; RATS; RECEPTORS; C3; ACTIVATION	Complement component C4 mediates C3-dependent tissue damage after systemic ischemia reperfusion injury. Activation of C3 also contributes to the pathogenesis of experimental and human traumatic brain injury (TBI); however, few data exist regarding the specific pathways (classic, alternative, and lectin) involved. Using complement knockout mice and a controlled cortical impact (CCI) model, we tested the hypothesis that the classic pathway mediates secondary damage after TBI. After CCI, C4c and C3d immunostaining were detected in cortical vascular endothelial cells in wild-type (WT) mice; however, C4c and C3d immunostaining were also detected in C1q(-/-) mice, and C3d immunostaining was detected in C4(-/-) mice. After CCI, WT and C1q(-/-) mice had similar motor deficits, Morris water maze performance, and brain lesion size. Naive C4(-/-) and WT mice did not differ in baseline motor performance, but C4(-/-) mice had reduced postinjury motor deficits (days 1 to 7, P < 0.05) and decreased brain tissue damage (days 14 and 35, P < 0.05) versus WT. Reconstitution of C4(-/-) mice with human C4 (hC4) reversed their protection against postinjury motor deficits (P < 0.05 versus vehicle), but administration of hC4 did not impair postinjury motor performance (versus vehicle) in WT mice. The protective effects of C4(-/-) were functionally distinct from the classic pathway and terminal complement, as C1q(-/-) and C3(-/-) mice had postinjury tissue damage and motor dysfunction similar to WT. Thus, C4 contributes to motor deficits and brain tissue damage after CCI by mechanism(s) fundamentally different from those involved in experimental systemic ischemia-reperfusion injury.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med,Ctr Expt T, Boston, MA USA; Harvard Univ, Sch Med, CBR Inst Biomed Res Inc, Boston, MA USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02129 USA.	mwhalen@partners.org		Stahl, Gregory/0000-0002-4805-8119	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL052886, R29HL052886, R01HL056086, R56HL056086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI042788, R21AI042788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045776, R01NS047447] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL52886, HL56086] Funding Source: Medline; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI42788-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS47447, P30NS045776] Funding Source: Medline		Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; Boos LA, 2005, GLIA, V49, P158, DOI 10.1002/glia.20093; Botto M, 1998, EXP CLIN IMMUNOGENET, V15, P231, DOI 10.1159/000019076; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Chan RK, 2003, BRIT J SURG, V90, P1470, DOI 10.1002/bjs.4408; Chen ZB, 2000, J EXP MED, V192, P1339, DOI 10.1084/jem.192.9.1339; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; COOK HT, 2006, NAT MED, V5, P995; Fischer MB, 1996, J IMMUNOL, V157, P549; Hoffman KL, 2004, J NEUROSCI, V24, P1780, DOI 10.1523/JNEUROSCI.0887-03.2004; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KASUYA H, 1989, J NEUROSURG, V71, P741, DOI 10.3171/jns.1989.71.5.0741; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SCHWING C, 2002, KLINIKMANAG AKTUELL, V4, P8; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Taylor PR, 1998, J BIOL CHEM, V273, P1699, DOI 10.1074/jbc.273.3.1699; Ten VS, 2005, STROKE, V36, P2244, DOI 10.1161/01.STR.0000182237.20807.d0; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Williams JP, 1999, J APPL PHYSIOL, V86, P938; Yager P, 2005, J NEUROTRAUM, V22, P1250; Yang SX, 2006, J CEREBR BLOOD F MET, V26, P1490, DOI 10.1038/sj.jcbfm.9600305; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	37	43	43	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2007	27	12					1954	1964		10.1038/sj.jcbfm.9600497			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	231OB	WOS:000250957800007	17457366	Bronze			2021-06-18	
J	Bourgeois, MS; Lenius, K; Turkstra, L; Camp, C				Bourgeois, Michelle S.; Lenius, Kerry; Turkstra, Lyn; Camp, Cameron			The effects of cognitive teletherapy on reported everyday memory behaviours of persons with chronic traumatic brain injury	BRAIN INJURY			English	Article						memory; cognition; treatment; teletherapy	EXTERNAL AIDS; ERRORLESS; DEMENTIA; TBI; REHABILITATION; INTERVENTION; INDIVIDUALS; RELIABILITY; ACQUISITION; STRATEGIES	Primary objective: The purpose of this study was to evaluate the effects of an errorless training approach, Spaced Retrieval (SR) training delivered over the telephone, on the reported everyday memory problems of adults with chronic traumatic brain injury (TBI). Research design: The study was a randomized controlled clinical trial. Methods: Thirty-eight participants received either SR training or didactic strategy instruction (SI). Participants in both groups identified three memory-related goals and were paired to receive the same total telephone contact time. The main outcome measures were frequency of reported memory problems and perceived quality of life. Results: Participants in the SR group reported significantly more treatment goal mastery/strategy use than those in the Sl group, immediately and at 1-month post-training. Caregivers reported similarly significant between-groups differences in everyday use of treatment behaviours at 1 month. Both groups reported some generalized strategy use to other non-targeted behaviours and decreased frequency of reported memory problems, but there were no significant between-groups differences in participant or caregiver reports of generalized strategy use or reported memory problems at either time-point. There was no change in perceived quality of life in either group. Conclusions: SR treatment delivered by phone produced significantly more treatment goal mastery/strategy use and maintenance than SI; however, both treatments improved reported everyday memory functioning for persons with TBI without significant group differences on measures of generalized strategy use or perceived quality of life.	[Bourgeois, Michelle S.; Lenius, Kerry] Florida State Univ, Dept Commun Disorders, Tallahassee, FL 32306 USA; [Turkstra, Lyn] Univ Wisconsin, Dept Commun Disorders, Neurosci Training Program, Madison, WI 53706 USA; [Turkstra, Lyn] Univ Wisconsin, Neurosci Training Program, Dept Neurol Surg, Madison, WI 53706 USA; [Camp, Cameron] Menorah Pk Ctr Senior Living, Myers Res Inst, Beachwood, OH USA	Bourgeois, MS (corresponding author), Florida State Univ, Dept Commun Disorders, Tallahassee, FL 32306 USA.	michelle.bourgeois@comm.fsu.edu	Bourgeois, Michelle/F-9397-2015	Bourgeois, Michelle/0000-0003-1458-6842	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD046583] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03 HD046583] Funding Source: Medline		Abrahams Joel P., 1993, Clinical Gerontologist, V12, P57, DOI 10.1300/J018v12n03_06; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BIRD M, 1995, INT J GERIATR PSYCH, V10, P305, DOI 10.1002/gps.930100407; BOURGEOIS M, 2003, AM SPEECH LANG HEAR; Bourgeois MS, 2003, J COMMUN DISORD, V36, P361, DOI 10.1016/S0021-9924(03)00051-0; Brush JA, 1998, THERAPY TECHNIQUE IM; Camp C. J., 2006, GERIATRIC NEUROPSYCH, P275; Camp CJ, 1996, APPL COGNITIVE PSYCH, V10, P193, DOI 10.1002/(SICI)1099-0720(199606)10:3<193::AID-ACP374>3.0.CO;2-4; CAMP CJ, 1999, INNOVATIONS PRACTICE; CAMP CJ, 2000, COGNITIVE REHABILITA, P224; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHERRY KE, 1999, J CLIN GEROPSYCHOLOG, V5, P159, DOI DOI 10.1023/A:1022983131186; COELHO C, 1996, J SPEECH HEAR RES, V39, P5; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Ebbinghaus H., 1964, MEMORY CONTRIBUTION; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fogler J., 1988, IMPROVING YOUR MEMOR; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Hayden Claudia M., 1995, Clinical Gerontologist, V16, P80; Helm-Estabrooks N, 1991, BRIEF TEST HEAD INJU; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; Hopper T, 2005, J MED SPEECH-LANG PA, V13, pXXVII; Hunkin NM, 1998, NEUROPSYCHOL REHABIL, V8, P433, DOI 10.1080/713755581; Landauer T.K., 1978, PRACTICAL ASPECTS ME, P625; MCKITRICK LA, 1992, J GERONTOL, V47, P337, DOI DOI 10.1093/GERONJ/47.5.P337; McMahon C. M., 2003, CLIN PSYCHOL, V7, P50, DOI DOI 10.1080/13284200410001707483; McNair M, 1983, ASSESSMENT GERIATRIC, P137; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; NEUNDORFER MM, 2002, ANN M GER SOC AM BOS; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; *SPSS INC, 2005, SPSS 14 0 WIND; Squire Larry R., 1994, P203; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Sterns HL, 1998, APPL PSYCHOL-INT REV, V47, P175, DOI 10.1080/026999498377971; Sykes R.N, 1988, PRACTICAL ASPECTS ME, V1, P396; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Turkstra LS, 2005, J MED SPEECH-LANG PA, V13, P205; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; VANHALLE C, 1998, NEUORPHYSIOLOGY NEUR, P17; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	51	43	43	0	20	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2007	21	12					1245	1257		10.1080/02699050701727452			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	249HP	WOS:000252219200004	18236200				2021-06-18	
J	Hou, DJ; Tong, KA; Ashwal, S; Oyoyo, U; Joo, E; Shutter, L; Obenaus, A				Hou, Daniel J.; Tong, Karen A.; Ashwal, Stephan; Oyoyo, Udochukwu; Joo, Elliott; Shutter, Lori; Obenaus, Andre			Diffusion-weighted magnetic resonance Imaging improves outcome prediction in adult traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apparent diffusion coefficient; brain; diffuse axonal injury; gray matter; white matter	CLOSED-HEAD INJURY; GLASGOW COMA SCALE; AXONAL INJURY; CORPUS-CALLOSUM; ACUTE STROKE; MR; SEVERITY; EDEMA; COEFFICIENT; EXPERIENCE	In patients with traumatic brain injury TBI), diffuse axonal injury (DAI) accounts for a significant amount of parenchymal injury. Diffusion weighted magnetic resonance imaging (DWI) is known to be sensitive for detecting visible DAI lesions. We focused on detection of non-visible, quantifiable diffusion changes in specific normal-appearing brain regions, using apparent diffusion coefficient (ADC) maps. Thirty-seven adults with TBI were compared to 35 age-matched control patients. DWI was performed and ADC maps were generated. Thirty-one regions of interest (ROI) were manually drawn on ADC maps and ADC values extracted. Brain ROIs were categorized into five zones: peripheral gray matter, peripheral white matter, deep gray matter, deep white matter, and posterior fossa. ADC results were compared with the severity of injury based on the admission Glasgow Coma Scale (GCS 3-8; severe; GSC 9-15 mild/moderate) and with long-term outcome (6-12 months after injury) using the Glasgow Outcome Scale (GOS 1-3, unfavorable; GOS: 4-5, favorable) score. Mean ADC values in all five brain zones were significantly different between TBI subjects and controls (P <= 0.05). Patients with more severe injury (i.e., GCS 3-8) had significantly different mean ADC values than control patients (p :5 0.05) and patients with unfavorable outcomes had significantly higher mean deep gray and white matter ADC values compared to those with favorable outcomes and to controls (p :5 0.05). Thus, ADC maps can be used to detect non-visible DAI lesions. In addition, injuries in the deep gray and white matter may be useful to predict outcome in adult TBI patients.	Loma Linda Univ, Med Ctr, Dept Neuroradiol, Loma Linda, CA 92354 USA; Univ British Columbia, Fac Med, Vancouver, BC, Canada; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA 92354 USA; Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA	Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Neuroradiol, Schuman Pavil,Rm B623,112354 Anderson St, Loma Linda, CA 92354 USA.	ktong@llu.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bydder GM, 2001, CHILD NERV SYST, V17, P190, DOI 10.1007/s003810000280; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Galloway N, 2005, J NEUROTRAUM, V22, P1244; Gean A, 1994, IMAGING HEAD TRAUMA; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Helenius J, 2002, AM J NEURORADIOL, V23, P194; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Karibe H, 2000, J NEUROSURG, V92, P58, DOI 10.3171/jns.2000.92.1.0058; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mateo Magdalena A, 2003, Lippincotts Case Manag, V8, P203, DOI 10.1097/00129234-200309000-00005; McGraw P, 2002, AM J ROENTGENOL, V179, P1515, DOI 10.2214/ajr.179.6.1791515; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Prayer D, 2003, EUR J RADIOL, V45, P235, DOI 10.1016/S0720-048X(02)00312-1; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFFER P, 1998, 36 ANN M AM SOC NEUR; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	51	43	50	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2007	24	10					1558	1569		10.1089/neu.2007.0339			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227HZ	WOS:000250649100002	17970619				2021-06-18	
J	Schmittner, MD; Vajkoczy, SL; Horn, P; Bertsch, T; Ouintel, M; Vajkoczy, P; Muench, E				Schmittner, Marc D.; Vajkoczy, Susanne L.; Horn, Peter; Bertsch, Thomas; Ouintel, Michael; Vajkoczy, Peter; Muench, Elke			Effects of fentanyl and S(+)-ketamine on cerebral hemodynamics, gastrointestinal motility, and need of vasopressors in patients with intracranial pathologies - A pilot study	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						intracranial pressure; ketamine; fentanyl; bispectral index; gastrointestinal motility	BISPECTRAL INDEX; BLOOD-FLOW; KETAMINE ANESTHESIA; DRUG ABSORPTION; PRESSURE; SEDATION; PHARMACOLOGY; INHIBITION; SUFENTANIL; ALFENTANIL	In neurosurgical patients, opioids are administered to prevent secondary cerebral damage. Complications often related to the administration of opioids are a decrease in blood pressure affording the use of vasopressors and intestinal atonia. One alternative approach to opioids is the application of S(+)ketamine. However, owing to a suspected elevation of intracranial pressure (ICP), the administration of S(+)-ketamine has questioned for a long time. The aim of the present study was to evaluate ICP, gastrointestinal motility, and catecholamine consumption in neurosurgical patients undergoing 2 different protocols of anesthesia using fentanyl or S(+)-ketamine. Twenty-four patients sustaining traumatic brain injury or aneurysmal subarachnoid hemorrhage received methohexitone plus either fentanyl or S(+)-ketamine to establish a comparable level of sedation. To reach an adequate cerebral perfusion pressure (CPP), the norepinephrine dosage was adapted successively. Enteral nutrition and gastrointestinal stimulation were started directly after admission on the critical care unit. ICP, CPP, and norepinephrine dosage were recorded over 5 days and also the time intervals to full enteral nutrition and first defecation. There was no difference regarding ICP, CPP, and the time period until full enteral nutrition or first defecation between both groups. Patients who underwent analgesia with S(+)ketamine showed a trend to a lower demand of norepinephrine compared with the fentanyl group. Our results indicate that S(+)-ketamine does not increase ICP and that its use in neurosurgical patients should not be discouraged on the basis of ICP-related concerns.	Heidelberg Univ, Univ Hosp Mannheim, Dept Anesthesiol & Crit Care Med, D-6900 Heidelberg, Germany; Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, D-6900 Heidelberg, Germany; Univ Gottingen, Dept Anesthesiol & Crit Care Med, D-3400 Gottingen, Germany	Muench, E (corresponding author), Heidelberg Univ, Fac Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	elke.muench@t-online.de					Adams HA, 1997, ANAESTHESIST, V46, P1081, DOI 10.1007/s001010050510; Adams HA, 2001, ANASTH INTENSIV NOTF, V36, P417, DOI 10.1055/s-2001-15435; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Banki N, 2006, J NEUROSURG, V105, P15, DOI 10.3171/jns.2006.105.1.15; BENNETT MWR, 1994, ANAESTHESIA, V49, P155, DOI 10.1111/j.1365-2044.1994.tb03376.x; Botero CA, 2000, J CARDIOTHOR VASC AN, V14, P409, DOI 10.1053/jcan.2000.7933; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; *BRAIN TRAUM FDN, 2003, UPD NOT GUID MAN SEV; CHI OZ, 1994, ANESTH ANALG, V79, P860; Christ G, 1997, ANAESTH INTENS CARE, V25, P255, DOI 10.1177/0310057X9702500308; Citerio G, 2001, CRIT CARE MED, V29, P1466, DOI 10.1097/00003246-200107000-00027; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Deeren DH, 2005, INTENS CARE MED, V31, P1577, DOI 10.1007/s00134-005-2802-2; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279; FREYE E, 1994, ANAESTHESIST, V43, P87, DOI 10.1007/s001010050036; FRIESEN R, 1987, ANESTH ANALG, V66, P431, DOI 10.1213/00000539-198705000-00011; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GOODING JM, 1977, ANESTH ANALG, V56, P813; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; JENNETT B, 1975, LANCET, V1, P480; Kolbel CB, 2000, INTENS CARE MED, V26, P1421, DOI 10.1007/s001340000630; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; MAYBERG TS, 1993, ANESTHESIOLOGY, V79, pA204; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MCARTHUR CJ, 1995, INTENS CARE MED, V21, P573, DOI 10.1007/BF01700162; McDermott NB, 2003, ANESTH ANALG, V97, P39, DOI 10.1213/01.ANE.0000067402.02136.A2; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; NIMMO WS, 1984, BRIT J ANAESTH, V56, P29, DOI 10.1093/bja/56.1.29; PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267; PFENNINGER E, 1985, ACTA NEUROCHIR, V78, P113, DOI 10.1007/BF01808689; Proescholdt M, 2001, BRAIN RES, V904, P245, DOI 10.1016/S0006-8993(01)02465-9; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reeker W, 2000, CAN J ANAESTH, V47, P572, DOI 10.1007/BF03018950; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; TODD JG, 1983, BRIT J ANAESTH, V55, P1189, DOI 10.1093/bja/55.12.1189; Vereecke HEM, 2003, ANAESTHESIA, V58, P957, DOI 10.1046/j.1365-2044.2003.03403.x; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	46	43	47	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2007	19	4					257	262		10.1097/ANA.0b013e31811f3feb			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	213ZL	WOS:000249705700008	17893578				2021-06-18	
J	Tate, CC; Garcia, AJ; LaPlaca, MC				Tate, Ciara C.; Garcia, Andres J.; LaPlaca, Michelle C.			Plasma fibronectin is neuroprotective following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						fibronectin; traumatic brain injury; neurotraurna; neuroprotection; apoptosis; extracellular matrix; inflammation; controlled cortical impact	CONTROLLED CORTICAL IMPACT; EXTRACELLULAR-MATRIX PROTEINS; RAT; EXPRESSION; MOUSE; MACROPHAGES; CELLS; IMMUNOREACTIVITY; ANGIOGENESIS; ACTIVATION	Promotion of repair and regeneration following traumatic brain injury remains a challenging clinical problem. While significant efforts have been made to reduce inhibitory extracellular matrix expression following central nervous system injury, much less attention has been given to the role of endogenous reparative matrix proteins, such as fibronectin. Traumatic brain injury leads to increased levels of plasma-derived fibronectin in the brain tissue, though the specific function of this protein following neurotrauma was unknown. In this study, we utilized conditional plasma fibronectin (pFN) knockout mice to examine the role of fibronectin following a traumatic insult. Injured mice deficient in pFN performed significantly worse on both motor and cognitive tasks, had significantly increased lesion volume and apoptotic cell death, and had significantly less phagocytic cells in the injured cortex compared to injured mice with normal pFN levels. Moreover, intravenous injections of fibronectin prior to the injury restored the neural deficits seen in the pFN deficient mice to that of wild type injured mice. These results demonstrate that fibronectin is neuroprotective to the traumatically injured brain and identify a novel target for therapeutic interventions. (c) 2007 Elsevier Inc. All rights reserved.	Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Woodruff Sch Mech Engn, Atlanta, GA 30332 USA	LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu					DIXON CE, 1991, J NEUROSCI METH, V39, P253; EGAN RA, 1991, BRAIN RES, V568, P330, DOI 10.1016/0006-8993(91)91421-V; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; GAUPERAA T, 1985, ACTA CHIR SCAND, V151, P193; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gibson RM, 2005, MOL CELL NEUROSCI, V28, P588, DOI 10.1016/j.mcn.2004.11.004; GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206; Hoyte JS, 1997, INFLAMMATION, V21, P335, DOI 10.1023/A:1027354001187; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JONES TR, 1982, CANCER RES, V42, P168; KIENER JL, 1986, AM J PHYSIOL, V251, pR724; King VR, 2001, J NEUROCYTOL, V30, P243, DOI 10.1023/A:1012753808599; KRUM JM, 1991, EXP NEUROL, V111, P152, DOI 10.1016/0014-4886(91)90002-T; LANGLIOS JA, 2004, TRAUMATIC BRAIN INJU; Liao H, 2005, J BIOL CHEM, V280, P8316, DOI 10.1074/jbc.M412730200; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; MADDOX DE, 1982, P NATL ACAD SCI-BIOL, V79, P166, DOI 10.1073/pnas.79.1.166; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; MARTIN DE, 1988, ARCH DERMATOL, V124, P226, DOI 10.1001/archderm.124.2.226; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OWENS MR, 1982, BLOOD, V59, P1305; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; PENNELL NA, 1994, HISTOCHEMISTRY, V102, P483, DOI 10.1007/BF00269580; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.ne.14.030191.002531; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schwartz M, 2000, ANN NY ACAD SCI, V917, P341; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tate CC, 2007, J NEUROTRAUM, V24, P226, DOI 10.1089/neu.2006.0043; Yanaka K, 1996, J NEUROSURG, V85, P125, DOI 10.3171/jns.1996.85.1.0125; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhao LR, 2005, BRAIN RES, V1054, P1, DOI 10.1016/j.brainres.2005.04.056	39	43	45	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2007	207	1					13	22		10.1016/j.expneurol.2007.05.008			10	Neurosciences	Neurosciences & Neurology	210TB	WOS:000249477400003	17599836				2021-06-18	
J	Borekci, B; Aksoy, H; Al, RA; Demircan, B; Kadanali, S				Borekci, Bunyamin; Aksoy, Hulya; Al, Ragip Atakan; Demircan, Berna; Kadanali, Sedat			Maternal serum interleukin-10, interleukin-2 and interleukin-6 in pre-eclampsia and eclampsia	AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY			English	Article						convulsion; cytokines; eclampsia; IL-10; pre-eclampsia	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID; ANTIINFLAMMATORY CYTOKINES; RECEPTOR ANTAGONIST; PLASMA-LEVELS; WOMEN; IL-10; EPILEPSY; RELEASE	Problem The aim of the study was to investigate and compare the concentrations of interleukin (IL)-2, IL-6, and IL-10 in serum of women with mild pre-eclampsia, severe pre-eclampsia, eclampsia, and normotensive pregnancy. Method of study A total of 69 consecutive cases, 38 mild pre-eclampsia, 20 severe pre-eclampsia, 11 eclampsia, and 20 normotensive controls were included in this study. Serum IL-2, IL-6, and IL-10 levels were determined using enzyme-linked immunosorbent assay method. Results Gestational age (P = 0.210) and body mass index (P = 0.214) between the groups were similar. The mean concentration of serum IL-2 and IL-6 were not different between the groups (P = 0.261, P = 0.141 respectively). The median concentrations of serum IL-10 in patients with mild and severe pre-eclampsia were similar (P < 0.282) and was significantly lower than those of controls (P < 0.001) and patients with eclampsia (P < 0.001). In patients with eclampsia, the median concentration of IL-10 was significantly higher than that of all other groups (P < 0.001 for each comparison). Conclusion Pre-eclampsia is associated with a deficiency serum IL-10. High serum IL-10 is correlated with the presence of eclampsia.	Ataturk Univ, Sch Med, Dept Obstet & Gynecol, Erzurum, Turkey; Ataturk Univ, Sch Med, Dept Biochem, Erzurum, Turkey	Borekci, B (corresponding author), Atalar Mah Pasalar Cad,Pasalar Apt Kat 5,11, TR-25100 Erzurum, Turkey.	borekcib@gmail.com	al, ragip a/A-1177-2012	al, ragip a/0000-0003-2921-1891			Al-Othman S, 2001, GYNECOL OBSTET INVES, V52, P60, DOI 10.1159/000052943; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Azizieh F, 2005, AM J REPROD IMMUNOL, V54, P30, DOI 10.1111/j.1600-0897.2005.00278.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Benian A, 2002, OBSTET GYNECOL, V100, P327, DOI 10.1016/S0029-7844(02)02077-X; Benyo DF, 2001, J CLIN ENDOCR METAB, V86, P2505, DOI 10.1210/jc.86.6.2505; Bowen JM, 2002, PLACENTA, V23, P239, DOI 10.1053/plac.2001.0781; Conrad KP, 1998, AM J REPROD IMMUNOL, V40, P102; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cunningham FG, 2000, AM J OBSTET GYNECOL, V182, P94, DOI 10.1016/S0002-9378(00)70496-0; Cunningham GF, 2005, WILLIAMS OBSTET, P761; Darmochwal-Kolarz D, 1999, EUR J OBSTET GYN R B, V86, P165, DOI 10.1016/S0301-2115(99)00065-2; De Sarro Giovambattista, 1994, Neuroimmunomodulation, V1, P361, DOI 10.1159/000097189; Del Gobbo V, 2000, AM J REPROD IMMUNOL, V44, P214, DOI 10.1111/j.8755-8920.2000.440405.x; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; Eneroth E, 1998, ACTA OBSTET GYN SCAN, V77, P591, DOI 10.1034/j.1600-0412.1998.770602.x; Gant NF, 1996, INT J GYNECOL OBSTET, V53, P175; Gratacos E, 1998, OBSTET GYNECOL, V92, P849, DOI 10.1016/S0029-7844(98)00300-7; GREER IA, 1994, OBSTET GYNECOL, V84, P937; Hennessy A, 1999, J IMMUNOL, V163, P3491; Hulkkonen J, 2004, EPILEPSY RES, V59, P199, DOI 10.1016/j.eplepsyres.2004.04.007; Jonsson Y, 2004, AM J REPROD IMMUNOL, V51, P302, DOI 10.1111/j.1600-0897.2004.00161.x; Jonsson Y, 2006, J REPROD IMMUNOL, V70, P83, DOI 10.1016/j.jri.2005.10.007; Katz VL, 2000, AM J OBSTET GYNECOL, V182, P1389, DOI 10.1067/mob.2000.106178; Kaufmann P, 2003, BIOL REPROD, V69, P1, DOI 10.1095/biolreprod.102.014977; KAUMA SW, 1995, J SOC GYNECOL INVEST, V2, P614, DOI 10.1016/1071-5576(95)00007-2; Loureiro R, 2003, AM J OBSTET GYNECOL, V189, P1350, DOI 10.1067/S0002-9378(03)00651-3; Madazli R, 2003, ACTA OBSTET GYN SCAN, V82, P797, DOI 10.1034/j.1600-0412.2003.00206.x; Makris A, 2006, PLACENTA, V27, P445, DOI 10.1016/j.placenta.2005.05.003; Morriss MC, 1997, OBSTET GYNECOL, V89, P561; NISTICO G, 1991, ANN NY ACAD SCI, V621, P119; Olusi SO, 2000, ANN SAUDI MED, V20, P4, DOI 10.5144/0256-4947.2000.4; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Orange S, 2005, CYTOKINE, V29, P176, DOI 10.1016/j.cyto.2004.10.011; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; PACIFICI R, 1995, EPILEPSIA, V36, P384, DOI 10.1111/j.1528-1157.1995.tb01013.x; Pelidou SH, 1999, EUR J NEUROL, V6, P437, DOI 10.1046/j.1468-1331.1999.640437.x; Peltola J, 1998, EPILEPSY RES, V31, P129, DOI 10.1016/S0920-1211(98)00024-2; Peltola J, 2002, SEIZURE-EUR J EPILEP, V11, P44, DOI 10.1053/seiz.2001.0575; Peltola J, 2000, EPILEPSY RES, V41, P205, DOI 10.1016/S0920-1211(00)00140-6; Perini F, 2001, NEUROL SCI, V22, P289, DOI 10.1007/s10072-001-8170-y; Redmon D, 2003, DEVIANT BEHAV, V24, P27, DOI 10.1080/10639620390117174; Rein DT, 2003, CYTOKINE, V23, P119, DOI 10.1016/S1043-4666(03)00220-5; Rinehart BK, 1999, AM J OBSTET GYNECOL, V181, P915, DOI 10.1016/S0002-9378(99)70325-X; Schwartz RB, 2000, RADIOLOGY, V217, P371, DOI 10.1148/radiology.217.2.r00nv44371; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Straussberg R, 2001, PEDIATR NEUROL, V24, P49, DOI 10.1016/S0887-8994(00)00234-4; Takano T, 2002, PEDIATR NEUROL, V26, P71, DOI 10.1016/S0887-8994(01)00345-9; Takano T, 2001, ANN NEUROL, V49, P685, DOI 10.1002/ana.1043.abs; Tarkowski E, 1997, CLIN EXP IMMUNOL, V110, P492, DOI 10.1046/j.1365-2249.1997.4621483.x; Vatten LJ, 2004, BJOG-INT J OBSTET GY, V111, P298, DOI 10.1111/j.1471-0528.2004.00071.x; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vila N, 2003, STROKE, V34, P671, DOI 10.1161/01.STR.0000057976.53301.69; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Virta M, 2002, EPILEPSIA, V43, P920, DOI 10.1046/j.1528-1157.2002.02002.x; Zeeman GG, 2004, AM J OBSTET GYNECOL, V191, P1425, DOI 10.1016/j.ajog.2004.05.069; Zeeman GG, 2004, AM J OBSTET GYNECOL, V190, P714, DOI 10.1016/j.ajog.2003.09.015	59	43	44	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1046-7408	1600-0897		AM J REPROD IMMUNOL	Am. J. Reprod. Immunol.	JUL	2007	58	1					56	64		10.1111/j.1600-0897.2007.00491.x			9	Immunology; Reproductive Biology	Immunology; Reproductive Biology	178EX	WOS:000247205100007	17565548				2021-06-18	
J	Marcol, W; Kotulska, K; Larysz-Brysz, M; Kowalik, JL				Marcol, Wieslaw; Kotulska, Katarzyna; Larysz-Brysz, Magdalena; Kowalik, Joanna Lewin			BDNF contributes to animal model neuropathic pain after peripheral nerve transection	NEUROSURGICAL REVIEW			English	Article						autotomy behavior; neuropathic pain; BDNF; neuroma; regeneration	RAT SPINAL-CORD; NEUROTROPHIC FACTOR; SCIATIC-NERVES; MESSENGER-RNA; BRAIN; REGENERATION; INJURY; NEURONS; NGF; INHIBITION	The outcome of peripheral nerve injury is often impaired by neuropathic pain, which is resistant to most analgesics and presents a serious clinical problem. The mechanisms underlying post-traumatic neuropathic pain remain unclear, but they are likely associated with the regeneration processes. Brain-derived neurotrophic factor (BDNF) is known to enhance peripheral nerve regeneration and is also considered to be an endogenous modulator of nociceptive responses following spinal cord lesion. The aim of this work was to examine the local effect of BDNF in a neuropathic pain model. Sciatic nerves of adult male rats were transected and supplied with connective tissue chambers filled with (1) fibrin only, (2) fibrin with BDNF, or (3) fibrin with antibodies against BDNF. In control animals the nerve was transected and no chamber was applied. During follow-up, autotomy behavior was assessed. Seven weeks after the operation, the number of surviving and regenerating neurons in dorsal root ganglia was counted and the neuroma incidence was examined. We found that local inactivation of BDNF decreased the incidence as well as severity of autotomy and neuroma formation, but did not influence neuron regeneration into the chambers. These results indicate that BDNF plays a locally crucial role in neuropathic pain development after peripheral nerve injury.	L Warynski Silesian Med Acad, Dept Physiol, PL-40752 Katowice, Poland; Childrens Mem Hlth Inst, Dept Neurol, Warsaw, Poland	Marcol, W (corresponding author), L Warynski Silesian Med Acad, Dept Physiol, 18 Medykow St, PL-40752 Katowice, Poland.	Vie@alpha.net.pl		Kotulska-Jozwiak, Katarzyna/0000-0002-5015-250X			Al-Qattan MM, 1999, J HAND SURG-BRIT EUR, V24B, P547, DOI 10.1054/jhsb.1999.0222; Apfel SC, 1996, MOL CELL NEUROSCI, V7, P134, DOI 10.1006/mcne.1996.0010; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bennett DLH, 2001, NEUROSCIENTIST, V7, P13, DOI 10.1177/107385840100700105; Bowsher D, 2002, PAIN, V95, P187, DOI 10.1016/S0304-3959(01)00389-X; Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Eaton MJ, 2002, GENE THER, V9, P1387, DOI 10.1038/sj.gt.3301814; Fukuoka T, 2001, J NEUROSCI, V21, P4891, DOI 10.1523/JNEUROSCI.21-13-04891.2001; Kennedy JM, 2004, NEUROREPORT, V15, P807, DOI 10.1097/00001756-200404090-00013; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Kryger GS, 2001, J HAND SURG-AM, V26A, P635, DOI 10.1053/jhsu.2001.26035; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lewin-Kowalik Joanna, 2002, Med Sci Monit, V8, pBR414; Ljungberg C, 1999, NEUROSCI LETT, V262, P29, DOI 10.1016/S0304-3940(99)00040-3; Marcol W, 2003, J NEUROSCI RES, V72, P417, DOI 10.1002/jnr.10560; MARCOL W, 2002, J PHYSIOL PHARM S1, V53, P22; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Michael GJ, 1997, J NEUROSCI, V17, P8476; Midha R, 2003, J NEUROSURG, V99, P555, DOI 10.3171/jns.2003.99.3.0555; Miki K, 2000, NEUROSCI LETT, V278, P85, DOI 10.1016/S0304-3940(99)00908-8; Obata K, 2006, NEUROSCI RES, V55, P1, DOI 10.1016/j.neures.2006.01.005; Petersen A, 2001, BRAIN RES BULL, V56, P331, DOI 10.1016/S0361-9230(01)00580-9; Ro LS, 1996, NEUROSCI LETT, V218, P87; Sakai Y, 2005, J BIOMED MATER RES B, V73B, P355, DOI 10.1002/jbm.b.30219; Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693; SIUCIAK JA, 1995, EUR J NEUROSCI, V7, P663, DOI 10.1111/j.1460-9568.1995.tb00670.x; Stoll G, 1999, BRAIN PATHOL, V9, P313; Thompson SWN, 1999, P NATL ACAD SCI USA, V96, P7714, DOI 10.1073/pnas.96.14.7714; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2; WILLENBRING S, 1994, PAIN, V58, P135, DOI 10.1016/0304-3959(94)90194-5; Zhang JY, 2000, EUR J NEUROSCI, V12, P4171, DOI 10.1046/j.1460-9568.2000.01312.x; Zhou XF, 2000, EUR J NEUROSCI, V12, P100, DOI 10.1046/j.1460-9568.2000.00884.x; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6	34	43	48	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUL	2007	30	3					235	243		10.1007/s10143-007-0085-5			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	177XF	WOS:000247185100019	17530308				2021-06-18	
J	Catala-Temprano, A; Teruel, GC; Lasaosa, FJC; Odena, MP; Julian, AN; Rico, A				Catala-Temprano, Albert; Claret Teruel, Gemma; Cambra Lasaosa, Francisco Jose; Pons Odena, Marti; Noguera Julian, Antoni; Palomeque Rico, Antonio			Intracranial pressure and cerebral perfusion pressure as risk factors in children with traumatic brain injuries	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; intracranial pressure; cerebral perfusion pressure; pediatric neurosurgery	SEVERE HEAD-INJURIES; BLOOD-PRESSURE; MANAGEMENT; CARE	Object. The authors evaluated the initial intracranial pressure (ICP) and cerebral perfusion pressure (CPP) as prognostic factors in severe head injury in children and tried to determine the optimal CPP range. Methods. The authors performed a 9-year retrospective review of all patients with severe traumatic brain injuries (TBIs) who required invasive ICP monitoring and were admitted to the pediatric intensive care unit at their institution between January 1995 and December 2003. These patients had Glasgow Coma Scale scores lower than 8 and/or required ICP monitoring due to worsening neurological status or neuroimaging results suggestive of cerebral hypertension. Clinical summaries and imaging studies were reviewed. Data for 156 pediatric patients who ranged in age from I to 18 years were obtained. Half of these patients presented with normal initial ICPs (< 20 mm Hg), and a good outcome was achieved in 80% of these children. An unfavorable outcome was observed in more than 60% of patients with an initial CPP lower than 40 min Hg. The proportion of patients with an unfavorable Outcome decreased to 10% with initial CPPs higher than 60 min Hg, but patients with initial CPPs higher than 70 min Hg did not improve. Conclusions. Initial ICP and CPP measurements were useful as prognostic factors in pediatric patients with severe TBIs: patients with initial CPPs between 40 and 70 nim Hg were found to have a better neurological prognosis than those with CPPs either higher or lower than that range.	Univ Barcelona, Hosp Univ Sant Joan Deu, Integrated Unit Sant Joan Deu Clin, Pediat Intens Care Unit,Pediat Dept, Barcelona 7, Spain	Catala-Temprano, A (corresponding author), Passeig Sant Joan Deu, Barcelona 208950, Spain.	acatala@hsjdbcn.org	PONS-ODENA, MARTI/G-3982-2015; Odena, Marti Pons/K-3054-2019	PONS-ODENA, MARTI/0000-0002-1181-3547; CATALA, ALBERT/0000-0003-0133-1752; Noguera-Julian, Antoni/0000-0001-7485-0583; Cambra Lasaosa, Francisco Jose/0000-0002-3818-8032			BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Daley ML, 2004, STROKE, V35, P1952, DOI 10.1161/01.STR.0000133690.94288.c9; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; JENNETT B, 1975, LANCET, V1, P480; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Maidaun MVC, 2002, ARQ NEURO-PSIQUIAT, V60, P967, DOI 10.1590/S0004-282X2002000600015; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; RODRIQUEZ JO, 2001, MED INTENSIVA, V25, P8; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010	19	43	45	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2007	106	6		S			463	466		10.3171/ped.2007.106.6.463			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	174WH	WOS:000246973000008	17566403				2021-06-18	
J	Cater, HL; Gitterman, D; Davis, SM; Benham, CD; Morrison, B; Sundstrom, LE				Cater, Heather L.; Gitterman, Daniel; Davis, Susan M.; Benham, Christopher D.; Morrison, Barclay, III; Sundstrom, Lars E.			Stretch-induced injury in organotypic hippocampal slice cultures reproduces in vivo post-traumatic neurodegeneration: role of glutamate receptors and voltage-dependent calcium channels	JOURNAL OF NEUROCHEMISTRY			English	Article						calcium; electrophysiology; glutamate; immunohistochemistry; trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; LATERAL FLUID PERCUSSION; LONG-TERM POTENTIATION; AXONAL INJURY; VITRO MODEL; MECHANICAL INJURY; CORTICAL-NEURONS; HEAD-INJURY; DELAYED DEPOLARIZATION	The relationship between an initial mechanical event causing brain tissue deformation and delayed neurodegeneration in vivo is complex because of the multiplicity of factors involved. We have used a simplified brain surrogate based on rat hippocampal slices grown on deformable silicone membranes to study stretch-induced traumatic brain injury. Traumatic injury was induced by stretching the culture substrate, and the biological response characterized after 4 days. Morphological abnormalities consistent with traumatic injury in humans were widely observed in injured cultures. Synaptic function was significantly reduced after a severe injury. The N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 attenuated neuronal damage, prevented loss of microtubule-associated protein 2 immunoreactivity and attenuated reduction of synaptic function. In contrast, the NMDA receptor antagonists 3-[(R)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPP) and GYKI53655, were neuroprotective in a moderate but not a severe injury paradigm. Nifedipine, an L-type voltage-dependent calcium channel antagonist was protective only after a moderate injury, whereas omega-conotoxin attenuated damage following severe injury. These results indicate that the mechanism of damage following stretch injury is complex and varies depending on the severity of the insult. In conclusion, the pharmacological, morphological and electrophysiological responses of organotypic hippocampal slice cultures to stretch injury were similar to those observed in vivo. Our model provides an alternative to animal testing for understanding the mechanisms of post-traumatic delayed cell death and could be used as a high-content screen to discover neuroprotective compounds before advancing to in vivo models.	Univ Southampton, Div Clin Neurosci, Southampton, Hants, England; GlaxoSmithKline, Harlow, Essex, England; Columbia Univ, Dept Biomed Engn, New York, NY USA	Cater, HL (corresponding author), Capsant Neurotechnol Ltd, Biomed Sci Bldg,Bassett Crescent East, Southampton SO16 7PX, Hants, England.	hlcater@yahoo.co.uk	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864			Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Agrawal SK, 2000, NEUROSCIENCE, V99, P179, DOI 10.1016/S0306-4522(00)00165-2; Allen JW, 1999, FASEB J, V13, P1875; BANDAK FA, 1995, J NEUROTRAUM, V12, P635, DOI 10.1089/neu.1995.12.635; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Colak A, 2003, J NEUROSURG, V98, P275, DOI 10.3171/spi.2003.98.3.0275; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Golarai G, 2001, J NEUROSCI, V21, P8523; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Jennett B, 1979, Adv Neurol, V22, P137; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Koura SS, 1998, ACT NEUR S, V71, P244; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Leybaert L, 1996, EXP BRAIN RES, V112, P392, DOI 10.1007/BF00227945; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2004, J NEUROTRAUM, V21, P1273; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1999, J NEUROSCI, V19, P4263; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Toth Z, 1997, J NEUROSCI, V17, P8106; TROSSEILLE X, 1992, STAPP CAR CRASH J, V36, P235; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; Westenbroek RE, 1998, J NEUROSCI, V18, P2321; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Winkler T, 2003, ACTA NEUROCHIR SUPPL, V86, P425; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	78	43	44	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2007	101	2					434	447		10.1111/j.1471-4159.2006.04379.x			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	151TD	WOS:000245312800013	17250683	Bronze			2021-06-18	
J	Gao, WM; Chadha, MS; Berger, RP; Omenn, GS; Allen, DL; Pisano, M; Adelson, PD; Clark, RSB; Jenkins, LW; Kochanek, PM				Gao, Wei-Min; Chadha, Mandeep S.; Berger, Rachel P.; Omenn, Gilbert S.; Allen, David L.; Pisano, Michael; Adelson, P. David; Clark, Robert S. B.; Jenkins, Larry W.; Kochanek, Patrick M.			A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatric traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article							SHAKEN-BABY SYNDROME; PROSTAGLANDIN-D SYNTHASE; SEVERE HEAD-INJURY; YOUNG-CHILDREN; QUINOLINIC ACID; RAT-BRAIN; INFANTS; PROTEIN; EXPRESSION; APOPTOSIS	Traumatic brain injury (TBI) is the most common cause of traumatic death in infancy, and inflicted TBI (iTBI) is the predominant cause. Like other central nervous system pathologies, TBI changes the composition of cerebrospinal fluid (CSF), which may represent a unique clinical window on brain pathophysiology. Proteomic analysis, including two-dimensional (2-D) difference in gel electrophoresis (DIGE) combined with mass spectrometry (MS), was used to compare the CSF protein profile of two pooled samples from pediatric iTBI (n = 13) and non-inflicted TBI (nTBI; n = 13) patients with severe injury. CSF proteins from iTBI and nTBI were fluorescently labeled in triplicate using different fluorescent Cy dyes and separated by 2-D gel electrophoresis. Approximately 250 protein spots were found in CSF, with 90% between-gel reproducibility of the 2-D gel. Following in-gel digestion, the tryptic peptides were analyzed by MS for protein identification. The acute phase reactant, haptoglobin (HP) isoforms, showed an approximate fourfold increase in nTBI versus iTBI. In contrast, the levels of prostaglandin D-2 synthase (PGDS) and cystatin C (CC) were 12-fold and sevenfold higher in iTBI versus nTBI, respectively. The changes of HP, PGDS, and CC were confirmed by Western blot. These initial results with conventional gel-based proteomics show new protein changes that may ultimately help to understand pathophysiological differences between iTBI and nTBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Proteom Res Serv Inc, Ann Arbor, MI USA; Texas Tech Univ, Dept Environm Toxicol, Lubbock, TX 79409 USA; Texas Tech Univ, Inst Environm & Human Hlth, Lubbock, TX 79409 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 2323 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Omenn, Gilbert S./0000-0002-8976-6074	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, R01NS038087, R01NS042648, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [U54DA021519] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD043843, K23 HD 043843-01, HD 40686, T32 HD040686] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [U54 DA 021519, U54 DA021519] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38087, NS 30318, P01 NS030318, R01 NS038087, P50 NS030318, R01 NS042648, R01 NS042648-04, NS 42648] Funding Source: Medline		ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRED AR, 1995, COMP BIOCHEM PHYS B, V111, P1, DOI 10.1016/0305-0491(94)00229-N; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; CLAUSEN J, 1961, P SOC EXP BIOL MED, V107, P170; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Fliser D, 2001, AM J KIDNEY DIS, V37, P79, DOI 10.1053/ajkd.2001.20591; Freeman WM, 2004, NEUROCHEM RES, V29, P1065, DOI 10.1023/B:NERE.0000023594.21352.17; Gilliland MGF, 1998, J FORENSIC SCI, V43, P723; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Hochstrasser DF, 2002, PROTEOMICS, V2, P807, DOI 10.1002/1615-9861(200207)2:7<807::AID-PROT807>3.0.CO;2-4; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kingham PJ, 2001, J NEUROCHEM, V76, P1475, DOI 10.1046/j.1471-4159.2001.00146.x; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Odani N, 1996, J BIOL CHEM, V271, P16609, DOI 10.1074/jbc.271.28.16609; Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004; Olsson T, 2004, NEUROSCIENCE, V128, P65, DOI 10.1016/j.neuroscience.2004.06.024; Petersen HH, 2004, VET RES, V35, P163, DOI 10.1051/vetres:2004002; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Rohlff C, 2000, ELECTROPHORESIS, V21, P1227; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SPAIDE RF, 1990, AM FAM PHYSICIAN, V41, P1145; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; URADE Y, 1987, J BIOL CHEM, V262, P15132; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; Urade Yoshihiro, 2004, Nihon Yakurigaku Zasshi, V123, P5; Vejda S, 2002, MOL CELL PROTEOMICS, V1, P387, DOI 10.1074/mcp.M200004-MCP200; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Zheng PP, 2003, J NEUROPATH EXP NEUR, V62, P855, DOI 10.1093/jnen/62.8.855	46	43	45	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					43	53		10.1089/neu.2006.0061			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100005	17263669	Green Accepted			2021-06-18	
J	Mainio, A; Kyllonen, T; Viilo, K; Hakko, H; Sarkioja, T; Rasanen, P				Mainio, Arja; Kyllonen, Tiina; Viilo, Kaisa; Hakko, Helina; Sarkioja, Terttu; Rasanen, Pirkko			Traumatic brain injury, psychiatric disorders and suicide: A population-based study of suicide victims during the years 1988-2004 in Northern Finland	BRAIN INJURY			English	Article						traumatic brain injury; suicide; depression; alcohol abuse	RISK-FACTORS; HEAD-INJURY; AXIS-I; DEPRESSION; PREVENTION; MORTALITY; BEHAVIOR	Background: Depression and substance abuse are common among patients with traumatic brain injury (TBI). However, previous studies have not examined the temporal association between psychiatric disorders, TBI and suicide. Objective: To study the prevalence of TBI injury among suicide victims; to determine the association of suicide, psychiatric disorders and TBI severity; and to examine the effect of pre- and post-traumatic psychiatric disorders on their remaining life-time. Methods: This study examined all suicides (n = 1877) committed during a 16-year period in the province of Oulu, Finland. The information of suicide victims was extracted from the official death certificates and the National Hospital Discharge Registers. Results: TBI was found in 5.5% (n = 103) of the victims. Compared to the victims without TBI, those with TBI had significantly more hospital-treated psychiatric and alcohol disorders. If TBI subjects had comorbid psychiatric disorders, the time period between TBI and suicide was under 3 years in similar to 90% of victims in this suicide population. Conclusions: Seriousness of injury, male gender, older age, being unemployed and presence of psychiatric and alcohol disorders are important to identify as possible predictors for suicidal behaviour in TBI patients. Further studies are required to shed light on interventions aimed at better life management.	Univ Oulu, Dept Psychiat, Oulu, Finland; Univ Oulu, Dept Forens Med, Oulu, Finland	Mainio, A (corresponding author), Oulu Univ Hosp, Dept Psychiat, POB 26, FIN-90029 OYS, Finland.	arja.mainio@oulu.fi					ACHTE KA, 1971, ACTA PSYCHIAT SCAN S, V225, P1; Borges G, 2006, PSYCHOL MED, V36, P1747, DOI 10.1017/S0033291706008786; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kishi Y, 2001, J NERV MENT DIS, V189, P623, DOI 10.1097/00005053-200109000-00009; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Preti A, 1997, J AFFECT DISORDERS, V44, P123, DOI 10.1016/S0165-0327(97)00035-9; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2003, J HEAD TRAUMA REHAB, V18, P445, DOI 10.1097/00001199-200309000-00006; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Suokas J, 2001, ACTA PSYCHIAT SCAND, V104, P117, DOI 10.1034/j.1600-0447.2001.00243.x; Suominen K, 2004, SOC PSYCH PSYCH EPID, V39, P720, DOI 10.1007/s00127-004-0796-7; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tiihonen J, 2006, ARCH GEN PSYCHIAT, V63, P1358, DOI 10.1001/archpsyc.63.12.1358	22	43	43	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	8					851	855		10.1080/02699050701504265			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202YZ	WOS:000248942400006	17676442				2021-06-18	
J	Timofeev, I; Hutchinson, PJ				Timofeev, I.; Hutchinson, P. J.			Outcome after surgical decompression of severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						head injury; trauma; decompressive craniectomy; brain oedema; intracranial pressure; neurosurgery; neurological outcome; neuromonitoring; intensive care	SEVERE HEAD-INJURIES; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; CEREBRAL-ARTERY INFARCTION; ISCHEMIC-STROKE; EUROPEAN BRAIN; CRANIECTOMY; MANAGEMENT; EDEMA; CRANIOTOMY; PRESSURE	One of the factors that affects outcome following severe traumatic brain injury is development and progression of cerebral oedema with associated increase in intracranial pressure (ICP). Uncontrolled elevations of ICP may compromise energy metabolism of the injured brain and lead to secondary injury, affecting neurological outcome of the patient. Decompressive craniectomy has been used for over a century as a treatment of refractory brain swelling in a variety of neurological conditions. However, conclusive evidence of whether it has a beneficial or adverse affect on outcome is tacking. This article reviews the existing evidence on the role of decornpressive craniectomy in management of patients with traumatic brain injury and stresses the need for randomised controlled trials. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England	Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.	pjah2@cam.ac.uk	Timofeev, Ivan/AAE-7019-2019		Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390] Funding Source: Medline		Abdullah J, 2005, ACT NEUR S, V95, P311; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Ausman J I, 1976, Surg Neurol, V6, P97; Bor-Seng-Shu E, 2004, ARQ NEURO-PSIQUIAT, V62, P715, DOI 10.1590/S0004-282X2004000400028; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Cho DY, 2003, SURG NEUROL, V60, P227, DOI 10.1016/S0090-3019(03)00266-0; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DIERSSEN G, 1983, ACTA NEUROCHIR, V69, P53, DOI 10.1007/BF02055853; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fandino Y, 2004, SWISS MED WKLY, V134, P423; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; GAAB MR, 1990, ACT NEUR S, V51, P326; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Harrington ML, 1996, AM J VET RES, V57, P1659; Harscher S, 2006, ACTA NEUROCHIR, V148, P31, DOI 10.1007/s00701-005-0617-0; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Lu J, 2005, ACT NEUR S, V95, P281; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Meier U, 2005, ACT NEUR S, V95, P55; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mitchell P, 2004, ACTA NEUROCHIR, V146, P159, DOI 10.1007/s00701-003-0186-z; Munch E, 2000, NEUROSURGERY, V47, P315; Mussack T, 2005, J TRAUMA, V58, P1061, DOI 10.1097/01.TA.0000171989.63817.8c; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ong YK, 2002, CHILD NERV SYST, V18, P340, DOI 10.1007/s00381-002-0597-9; Oyelese AA, 2005, NEUROSURGERY, V57, P594, DOI 10.1227/01.NEU.0000170437.79760DF; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PEREIRA WC, 1977, ARQ NEURO-PSIQUIAT, V35, P99, DOI 10.1590/S0004-282X1977000200002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Reithmeier T, 2005, ACTA NEUROCHIR, V147, P947, DOI 10.1007/s00701-005-0543-1; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schneider GH, 2002, ACT NEUR S, V81, P77; Schwab S, 1998, NERVENARZT, V69, P896, DOI 10.1007/s001150050360; Strege RJ, 2003, NEUROL RES, V25, P510, DOI 10.1179/016164103101201742; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WHITFIELD P, 1995, STROKE, V26, P1125; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	60	43	50	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	DEC	2006	37	12					1125	1132		10.1016/j.injury.2006.07.031			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	123TQ	WOS:000243319200006	17081545				2021-06-18	
J	Gnagey, L; Clayton, HM; Lanovaz, JL				Gnagey, L.; Clayton, H. M.; Lanovaz, J. L.			Effect of standing tarsal angle on joint kinematics and kinetics	EQUINE VETERINARY JOURNAL			English	Article						horse; conformation; kinematics; kinetics; tarsal joint; hock joint	RISK-FACTORS; CONFORMATION; HORSES	Reasons for performing study: The tarsal joint is a frequent site of lameness, but little objective information is available regarding the effects of tarsal conformation on joint movements or forces. Objective: To compare tarsal kinematics and kinetics in horses with large, intermediate and small tarsal angles. Methods: Sagittal plane standing angle of the right tarsal joint was measured in 16 horses as they stood squarely with the hind hooves vertically beneath the hip joint. Tarsal angles were classified as small (< 155.5 degrees), intermediate (155.5-165.5 degrees) or large (> 165.5 degrees). Reflective markers, attached over the centres of joint rotation, were tracked during stance as the horses trotted across a force plate at a standardised speed. Joint angles and ground reaction forces were combined with morphometric data to calculate net joint moments and net joint powers across the tarsus using inverse dynamics. Results: In all horses, the tarsus flexed during the impact phase and extended in late. stance. Tarsal angles were stratified according to standing tarsal angle throughout stance. Horses with large standing angles showed less flexion and less energy absorption at the tarsus during the impact phase than those with intermediate or small angles and generated less vertical impulse than horses with small standing angles. Net extensor moment at the tarsus during stance was lower for horses with large standing angles. Conclusions: In horses with large tarsal angles, less concussion was absorbed during the impact phase, which may be a factor in the development of degenerative joint disease; and the smaller vertical impulse and extensor moment later in stance may limit propulsive ability. However, the smaller net joint moment may reduce the risk of plantar ligament desmitis. Clinical significance: The effects of conformation on kinematics and kinetics of the tarsal joint may influence both performance and soundness.	Michigan State Univ, Coll Vet Med, Mary Anne McPhail Equine Performance Ctr, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA	Clayton, HM (corresponding author), Michigan State Univ, Vet Med Ctr D202, Coll Vet Med, E Lansing, MI 48854 USA.			Lanovaz, Joel/0000-0001-7070-6648			Anderson TM, 2004, EQUINE VET J, V36, P571, DOI 10.2746/0425164044864462; Axelsson M, 2001, EQUINE VET J, V33, P84, DOI 10.2746/042516401776767502; BACK W, 1994, VET QUART, V16, pS91; BACK W, 1995, EQUINE VET J, V27, P39, DOI 10.1111/j.2042-3306.1995.tb03030.x; Back W, 1996, PFERDEHEILKUNDE, V12, P647; BLACK JB, 1992, P AM ASS EQUINE PRAC, V37, P393; Dolvik NI, 1999, ACTA AGR SCAND A-AN, V49, P156, DOI 10.1080/090647099424060; DREVEMO S, 1980, EQUINE VET J, V12, P60, DOI 10.1111/j.2042-3306.1980.tb02310.x; DYSON S, 2000, P AM ASS EQUINE PRAC, V46, P137; Eksell P, 1998, ACTA VET SCAND, V39, P339; HOLMSTROM M, 1995, EQUINE VET J, V27, P281, DOI 10.1111/j.2042-3306.1995.tb03078.x; HOLMSTROM M, 1990, EQUINE VET J, V22, P186, DOI 10.1111/j.2042-3306.1990.tb04245.x; HOLMSTROM M, 1993, LIVEST PROD SCI, V33, P293, DOI 10.1016/0301-6226(93)90009-7; HOLMSTROM M, 2000, P C EQ SPORT MED SCI, P45; Khumsap S, 2001, Equine Vet J Suppl, P21; MAGNUSSON LE, 1985, STUDIES CONFORMATION, P194; MARKS D, 2000, P AM ASS EQUINE PRAC, V46, P39; MCILWRAITH CW, 2003, P AM ASS EQUINE PRAC, V49, P59; MULLER J, 1976, ZUCHTERISCHE WEITERE, P105; RADIN EL, 1972, LANCET, V1, P519; STASHAK TS, 1987, ADAMS LAMENESS HORSE, P695	21	43	47	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	NOV	2006	38	7					628	633		10.2746/042516406X159043			6	Veterinary Sciences	Veterinary Sciences	128YT	WOS:000243696300008	17402467				2021-06-18	
J	Berger, RP; Kochanek, PM				Pardes Berger, Rachel; Kochanek, Patrick M.			Urinary S100B concentrations are increased after brain injury in children: A preliminary study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Society/Society-for-Pediatric-Research	MAY 14-17, 2005	Washington, DC	Pediat Acad Soc, Soc Pediat Res		S100B; urine; traumatic brain injury; hypoxemic brain injury; pediatrics	S-100 PROTEIN MEASUREMENTS; NEURON-SPECIFIC ENOLASE; INFLICTED HEAD-INJURY; FULL-TERM INFANTS; EARLY IDENTIFICATION; GESTATIONAL-AGE; CARDIAC-SURGERY; SERUM-LEVELS; DAMAGE; PRETERM	Objective: S100B is a renally excreted protein concentrated in glial cells of the nervous system. Increases in serum S100B concentrations reflect brain injury. However, increases in serum are rapid and transient and therefore may be of limited use in certain patients. Urinary S100B concentrations may be able to provide information about brain injury in this subgroup of patents. Design: Prospective, descriptive study. Setting: Level I trauma center. Patients: Fifteen children with acute traumatic or hypoxemic brain injury (subjects) and 14 healthy controls. Interventions: Urine and serum samples were collected from subjects and controls. Serial samples were collected in brain injury subjects up to every 12 hrs for 3 days. S100B concentrations were measured by enzyme-linked immunosorbent assay (Nanogen, San Diego CA). Outcome was assessed by Glasgow Outcome Scale score. Measurements and Main Results: Urinary S100B concentrations were detectable in 80% of subjects with increased serum S100B concentrations and 0% of controls. Peak urinary S100B concentrations occurred significantly later than peak serum S100B concentratons: 55.3 (29.8) (mean [SD]) vs. 14.6 (11.8) hrs after injury (p = .002). All subjects with an undetectable urinary S100B had a good outcome vs. only 20% of subjects with a detectable urinary S100B. Subjects with increased serum S100B were more likely to have a poor outcome than those with normal S100B (p = .01). Conclusions: Increases in urinary S100B are found in the majority of children with acute brain injury and an increased serum S100B. Urinary S100B concentrations peak later than serum concentrations, suggesting that measurement of urinary S100B may be helpful in subjects in whom early serum S100B is unavailable. Urinary and/or serum S100B concentrations may be useful to assist in the prediction of outcome after pediatric brain injury.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Child Advocacy Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Berger, RP (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD43843-01] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR323155-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER		Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Connolly ES, 2001, NEUROSURGERY, V49, P1076, DOI 10.1097/00006123-200111000-00010; Gazzolo D, 2005, PEDIATR RES, V58, P1170, DOI 10.1203/01.pdr.0000185131.22985.30; Gazzolo D, 2004, CRIT CARE MED, V32, P131, DOI 10.1097/01.CCM.0000104116.91462.CD; Gazzolo D, 2003, ARCH PEDIAT ADOL MED, V157, P1163, DOI 10.1001/archpedi.157.12.1163; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2001, CLIN CHEM, V47, P1132; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Gazzolo D, 2000, CLIN CHEM, V46, P998; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	30	43	45	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	NOV	2006	7	6					557	561		10.1097/01.PCC.0000244426.37793.23			5	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	103HY	WOS:000241877500007	17006387				2021-06-18	
J	Svendsen, HA; Teasdale, TW				Svendsen, Henriette Aaby; Teasdale, Thomas William			The influence of neuropsychological rehabilitation on symptomatology and quality of life following brain injury: A controlled long-term follow-up	BRAIN INJURY			English	Article						brain-injury; rehabilitation; follow-up	CLOSED HEAD-INJURY; COGNITIVE REHABILITATION; SUBJECTIVE EXPERIENCE; POPULATION; ADJUSTMENT; RELATIVES; TBI; NEUROREHABILITATION; OUTCOMES; TRAUMA	Primary objective: To establish whether, following acquired brain injury, intensive post-acute neuropsychological rehabilitation could have long-term beneficial effects. Methods and procedures: A group of 37 adults who had suffered cerebrovascular accidents or traumatic brain injuries and who had undergone a rehabilitation programme were followed up 12-22 years post-injury, together with a non-rehabilitated control group of 13 adults, matched for brain-injury and demographics characteristics. Both groups completed a set of questionnaires concerning broad aspects of psychological well-being. Significant others completed similar questionnaires. Main outcomes and results: The rehabilitation group showed significantly lower levels of brain injury symptoms and higher levels of competency at follow-up. They also rated internal locus of control and general self-efficacy as significantly higher than the control group. Anxiety and depression levels were significantly lower and quality of life significantly higher in the rehabilitation group for both the subjects themselves and for their significant others. Conclusions: Within methodological limitations this study suggests that post-acute neuropsychological rehabilitation can have long-term beneficial effects.	Univ Copenhagen, Ctr Rehabil Brain Injury, Dept Psychol, DK-2300 Copenhagen S, Denmark	Svendsen, HA (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Dept Psychol, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	henriette.svendsen@psy.ku.dk					*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CHRISTENSEN AL, 1988, NEUROPSYCHOL REHABIL, P115; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Diller L, 2003, NEURO S B C, P293; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Field A.P., 2005, DISCOVERING STAT USI; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HART T, 2000, PATIENT COMPETENCY R; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHANSEN LE, 2004, FOLLOW UP UNDERSOGEL; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Magnusson A, 2000, AM J PSYCHIAT, V157, P234, DOI 10.1176/appi.ajp.157.2.234; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Noerholm V, 2004, QUAL LIFE RES, V13, P531, DOI 10.1023/B:QURE.0000018485.05372.d6; Norholm V, 2001, NORD J PSYCHIAT, V55, P229; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schwarzer R, 1995, MEASURES HLTH PSYCHO, P35; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale T W, 1995, Appl Neuropsychol, V2, P116; Teasdale TW, 2005, BRAIN INJURY, V19, P1049, DOI 10.1080/02699050500110421; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TREXLER LE, 2000, INT HDB NEUROPSYCHOL, P137; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 2003, NEURO S B C, P329; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	43	43	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2006	20	12					1295	1306		10.1080/02699050601082123			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DF	WOS:000242357800008	17132552				2021-06-18	
J	Reeves, DL; Bleiberg, J; Roebuck-Spencer, T; Cernich, AN; Schwab, K; Ivins, B; Salazar, AM; Harvey, SC; Brown, FH; Warden, D				Reeves, Dennis L.; Bleiberg, Joseph; Roebuck-Spencer, Tresa; Cernich, Alison N.; Schwab, Karen; Ivins, Brian; Salazar, Andres M.; Harvey, Sally C.; Brown, Fred H., Jr.; Warden, Deborah			Reference values for performance on the Automated Neuropsychological Assessment Metrics V3.0 in an active duty military sample	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; REACTION-TIME	The Automated Neuropsychological Assessment Metrics (ANAM) is a computerized measure of processing speed, cognitive efficiency, and memory. This study describes performance and psychometric properties of ANAM in an active duty, healthy military sample (N = 2,371) composed primarily of young (18-46 years) adult males. Rarely have neuropsychological reference values for use with individuals in the military been derived from a large, active duty military population, and this is the first computerized neuropsychological test battery with military-specific reference values. Although these results do not provide demographically corrected, formal normative data, they provide reference points for neuropsychologists and other health care providers who are using ANAM data in research or clinical settings, with patients of comparable demographics to the present sample.	ClinVest Inc, Springfield, MO 65807 USA; Natl Rehabil Hosp, Ctr Cognit Neurosci, Washington, DC 20010 USA; Univ Maryland, Med Ctr, Dept Neurol, Baltimore, MD 21201 USA; Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20012 USA; Oncovir Inc, Washington, DC 20008 USA; 902nd Mil Intelligence Grp, Ft George G Meade, MD 20755 USA; Psychol Applicat Directorate, Special Operat Command, Ft Bragg, NC 28310 USA	Reeves, DL (corresponding author), ClinVest Inc, 3805 S Kansas Expressway, Springfield, MO 65807 USA.			Bleiberg, Joseph/0000-0003-0867-5494			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Farmer K, 2001, HEADACHE, V41, P377, DOI 10.1046/j.1526-4610.2001.111006377.x; GASTALDO E, 1997, ANAM NORMATIVE DATA; Gestaldo E, 2001, ARCH CLIN NEUROPSYCH, V16, P825; GOLDSTONE A, 1995, ANAM V3 11 GERIATRIC; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; KABAT MH, 2000, J INT NEUROPSYCH SOC, V6, P146; Kane R., 1997, NEUROPSYCHOLOGY HDB; LEVINSON DM, 1994, AUTOMATED NEUROPSYCH; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REEVES D, IN PRESS NEUROPSYCHO; REEVES DL, 1996, ANAM USMC NORMATIV 1; ROEBUCKSPENCER TM, IN PRESS NEUROPSYCHO; Salthouse TA, 2002, J CLIN EXP NEUROPSYC, V24, P858, DOI 10.1076/jcen.24.7.858.8392; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa	19	43	43	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2006	171	10					982	994		10.7205/MILMED.171.10.982			13	Medicine, General & Internal	General & Internal Medicine	096JH	WOS:000241372900012	17076451	Bronze			2021-06-18	
J	Wunderlich, MT; Wallesch, CW; Goertler, M				Wunderlich, M. T.; Wallesch, C. W.; Goertler, M.			Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						glial fibrillary acidic protein; outcome; sonography; stroke	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY STROKE; CEREBROSPINAL-FLUID; S-100 PROTEIN; NEUROBIOCHEMICAL MARKERS; INFARCTION; DAMAGE; BLOOD; SERUM; CLASSIFICATION	This study aimed at an analysis of glial fibrillary acidic protein (GFAP) in acute ischemic stroke, its association with the neurovascular status and its potential value as monitoring parameter. In 53 consecutive patients, serial venous blood samples were taken on admission, 6, 12, 18, 24, 48, 72, 96, and 120 h after stroke onset. The neurovascular status was assessed by repetitive extracranial and transcranial duplex sonography. Neurologic deficits were quantified by the National Institutes of Health stroke scale, and functional outcome was assessed with the modified Rankin Scale. Mean GFAP values were elevated from admission on with highest levels 48 h after stroke onset. GFAP release was highly correlated with severity of neurologic deficits and infarct volume. In patients with persistent middle cerebral artery occlusion, GFAP increased significantly compared with patients with normal sonographic findings (P = 0.019) and recanalization after thrombolysis resulted in a significant reduced increase (P = 0.038). GFAP concentrations were associated with the functional outcome after 3 months. Release kinetics of GFAP are associated with patients clinical deficits and infarct volume, depend on the neurovascular status on admission and on early recanalization after thrombolysis, and may be used as an additional predictor of the early course and functional outcome.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany	Wunderlich, MT (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	michael.wuderlich@medizin.uni-magdeburg.de					Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Burgin WS, 2000, STROKE, V31, P1128, DOI 10.1161/01.STR.31.5.1128; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Foerch C, 2003, J NEUROL NEUROSUR PS, V74, P322, DOI 10.1136/jnnp.74.3.322; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 1999, CLIN CHEM, V45, P138; Norgren N, 2004, NEUROLOGY, V63, P1586, DOI 10.1212/01.WNL.0000142988.49341.D1; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Schiemanck SK, 2005, RESTOR NEUROL NEUROS, V23, P257; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Verbeek MM, 2003, ANN CLIN BIOCHEM, V40, P25, DOI 10.1258/000456303321016141; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Yasuda Y, 2004, BRAIN RES, V1021, P20, DOI 10.1016/j.brainres.2004.06.015; ZANETTE EM, 1989, STROKE, V20, P899, DOI 10.1161/01.STR.20.7.899	28	43	51	1	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	OCT	2006	13	10					1118	1123		10.1111/j.1468-1331.2006.01435.x			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	085UY	WOS:000240631100016	16987165				2021-06-18	
J	Kim, E; Bijlani, M				Kim, Edward; Bijlani, Mona			A pilot study of quetiapine treatment of aggression due to traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							OVERT AGGRESSION; SCHIZOPHRENIA; RISPERIDONE; OLANZAPINE; REHABILITATION; HALOPERIDOL; CLOZAPINE; PSYCHOSIS; DISORDER	In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI) seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale - Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08855 USA; Bristol Myers Squibb Co, Plainsboro, NJ USA	Kim, E (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 671 Hoes Lane, Piscataway, NJ 08855 USA.	edward.kim@bms.com					Akdede BBK, 2005, PROG NEURO-PSYCHOPH, V29, P233, DOI 10.1016/j.pnpbp.2004.11.005; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Bilder RM, 2002, AM J PSYCHIAT, V159, P1018, DOI 10.1176/appi.ajp.159.6.1018; Burke JG, 1999, J PSYCHIATR NEUROSCI, V24, P456; Corson AH, 2004, J CLIN PSYCHIAT, V65, P1531, DOI 10.4088/JCP.v65n1115; EYSENCK MW, 1991, PERSPECTIVES COGNITI; Harvey PD, 2004, SCHIZOPHR RES, V66, P101, DOI 10.1016/j.schres.2003.07.009; Kraus J. F., 1999, REHABILITATION ADULT, P3; Krieger D, 2003, NEUROREHABILITATION, V18, P205; KRUETZER J, 1999, NEUROBEHAVIORAL FUNC; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Randolph C., 1998, RBANS REPEATABLE BAT; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; SANDEL ME, 1993, BRAIN INJURY, V7, P77, DOI 10.3109/02699059309008159; Scharre DW, 2002, ALZ DIS ASSOC DIS, V16, P128, DOI 10.1097/00002093-200204000-00011; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; Silver JM, 2005, TXB TRAUMATIC BRAIN, P259; Stanislav SW, 1997, BRAIN INJURY, V11, P335, DOI 10.1080/026990597123494; Temple M J, 2003, J R Army Med Corps, V149, P54; Volavka J, 2004, J CLIN PSYCHOPHARM, V24, P225, DOI 10.1097/01.jcp.0000117424.05703.29; Walker C, 2003, INT J OFFENDER THER, V47, P556, DOI 10.1177/0306624X03253027; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	24	43	43	0	6	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2006	18	4					547	549		10.1176/appi.neuropsych.18.4.547			3	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	103BX	WOS:000241861800012	17135382				2021-06-18	
J	Wilde, EA; Bigler, ED; Haider, JM; Chu, ZL; Levin, HS; Li, XQ; Hunter, JV				Wilde, Elisabeth A.; Bigler, Erin D.; Haider, Janelle M.; Chu, Zili; Levin, Harvey S.; Li, Xiaoqi; Hunter, Jill V.			Vulnerability of the anterior commissure in moderate to severe pediatric traumatic brain injury	JOURNAL OF CHILD NEUROLOGY			English	Article							CORPUS-CALLOSUM; FIBER TRACKING; HEAD-INJURY; TEMPORAL-LOBE; NUCLEUS; NEURONS; SIZE; PROJECTIONS; MORPHOLOGY; CORTEX	In relation to the adult brain, the immature brain might be more vulnerable to damage during and following traumatic brain iujury, particularly in white-matter tracts. Given well-established evidence of corpus callosum atrophy, we hypothesized that anterior commissure volume (using quantitative magnetic resonance imaging [MRI]) in this structure would be decreased in children with moderate to severe traumatic brain injury relative to typically developing children. Second, given the purported role of the anterior commissure in interhemispheric axon conveyance between temporal lobes, we hypothesized that temporal lobe white matter, temporal lesion volume, and injury severity (Glasgow Coma Scale score) would be predictive of decreased anterior commissure cross-sectional volume in patients with traumatic brain injury. Finally, we wished to establish the relationship between the anterior commissure and the temporal stem, a major white-matter tract into the temporal lobes, using diffusion tensor imaging fiber-tracking maps for each patient. We also hypothesized that children with traumatic brain injury would exhibit decreased fractional anisotropy in relation to typically developing children in a fiber system including the anterior commissure and the temporal lobes. Decreased anterior commissure cross-sectional volume was observed in patients with traumatic brain injury, and, as predicted, anterior commissure and temporal white-matter volumes were positively related to each other and to higher Glasgow Coma Scale scores. Lesion volume was not independently predictive of anterior commissure volume in the overall model. Diffusion tensor imaging fractional anisotropy values differed between the groups for the temporal stem-anterior commissure system, with the traumatic brain injury group exhibiting decreased fractional anisotropy. The anterior commissure, like the corpus callosum, appears to be highly vulnerable to white-matter degenerative changes resulting from mechanisms such as the direct impact of trauma, progressive axonal injury as tissue in other brain regions atrophies, or myelin degeneration. This is the first systematic examination of anterior commissure atrophy following traumatic brain injury using in vivo quantitative MRI and diffusion tensor imaging fiber tracking in pediatric subjects.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD 035476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALLEN LS, 1992, P NATL ACAD SCI USA, V89, P7199, DOI 10.1073/pnas.89.15.7199; Basser PJ, 2000, MAGNET RESON MED, V44, P41, DOI 10.1002/1522-2594(200007)44:1<41::AID-MRM8>3.0.CO;2-O; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BIGLER ED, 2005, NEUROPSYCHIATRY TRAU, P79; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Condes-Lara M, 2003, BRAIN RES, V982, P288, DOI 10.1016/S0006-8993(03)03054-3; DEMETER S, 1988, HUM NEUROBIOL, V6, P219; DEMETER S, 1990, J COMP NEUROL, V302, P29, DOI 10.1002/cne.903020104; Di Virgilio G, 1999, EXP BRAIN RES, V124, P1, DOI 10.1007/s002210050593; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HOOGENRAAD F, 2002, MULTICENTER EVALUATI; Jones HE, 1997, BRAIN RES BULL, V42, P341, DOI 10.1016/S0361-9230(96)00293-6; KLINGLER J, 1960, J COMP NEUROL, V115, P333, DOI 10.1002/cne.901150305; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LAMANTIA AS, 1994, J COMP NEUROL, V340, P328, DOI 10.1002/cne.903400304; Larriva-Sahd J, 1998, NEUROSCI LETT, V241, P119, DOI 10.1016/S0304-3940(98)00043-3; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Livy DJ, 2001, TERATOLOGY, V63, P15, DOI 10.1002/1096-9926(200101)63:1<15::AID-TERA1003>3.0.CO;2-Q; Martinez-Lorenzana G, 2004, NEUROSCI LETT, V366, P154, DOI 10.1016/j.neulet.2004.05.026; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Netsch T, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P718, DOI 10.1109/ICCV.2001.937595; Otake K, 2003, NEUROSCIENCE, V119, P623, DOI 10.1016/S0306-4522(03)00216-1; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Sandell JH, 2003, J COMP NEUROL, V466, P14, DOI 10.1002/cne.10859; Stieltjes B, 2001, NEUROIMAGE, V14, P723, DOI 10.1006/nimg.2001.0861; STURROCK RR, 1976, J ANAT, V122, P447; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092	41	43	43	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	SEP	2006	21	9					769	776		10.1177/08830738060210090201			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	102KV	WOS:000241810800010	16970884				2021-06-18	
J	Diaz-Arrastia, R; Baxter, VK				Diaz-Arrastia, Ramon; Baxter, Victoria K.			Genetic factors in outcome after traumatic brain injury - What the human genome project can teach us about brain trauma	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						apolipoprotein E4; genetics; Human Genome Project; outcomes; traumatic brain injury	INTERLEUKIN-1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN-E EPSILON-4; GLOBAL CEREBRAL-ISCHEMIA; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; APOE GENOTYPE; NEURONAL DAMAGE; E POLYMORPHISM; ANIMAL-MODELS	It is becoming increasingly clear that genetic factors modify outcome after traumatic brain injury (TBI). The best known example of this is the association between the apolipoprotein E4 allele (APOE 84) and poorer outcomes. However, our knowledge of the many other genes that might influence outcome is still in its infancy. This article will review the basic principles underlying recent advances in genetics, and then describe the current state of knowledge regarding the impact of genetic factors on TBI outcome. We conclude that although genetic advances have implications for prognosis, their biggest contribution will be to elucidate the pathophysiology of TBI,,potentially leading to new treatments.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA	Diaz-Arrastia, R (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652, R01 HD48179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BLAKEMORE AIF, 1994, ARTHRITIS RHEUM, V37, P1380, DOI 10.1002/art.1780370917; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Buttini M, 1999, J NEUROSCI, V19, P4867; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; CLEMENS JA, 1991, STROKE, V22, P1048, DOI 10.1161/01.STR.22.8.1048; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CRUSIUS JBA, 1995, LANCET, V346, P979, DOI 10.1016/S0140-6736(95)91607-5; delaConcha EG, 1997, J NEUROIMMUNOL, V80, P172, DOI 10.1016/S0165-5728(97)00153-7; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; Emahazion T, 1999, GENE, V238, P315, DOI 10.1016/S0378-1119(99)00330-3; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Goldstein DB, 2001, NAT GENET, V29, P109, DOI 10.1038/ng1001-109; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hartman RE, 2002, J NEUROSCI, V22, P10083; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Huang D, 1998, J NEUROIMMUNOL, V81, P76, DOI 10.1016/S0165-5728(97)00161-6; INMAN D, 1997, SOC NEUR ABSTR, V25, P899; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; Krzywkowski P, 1999, NEUROSCIENCE, V92, P1273, DOI 10.1016/S0306-4522(99)00061-5; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lanterna LA, 2005, NEUROLOGY, V64, P1238, DOI 10.1212/01.WNL.0000156523.77347.B4; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Overmyer M, 1999, DEMENT GERIATR COGN, V10, P252, DOI 10.1159/000017128; PALMER GC, 1995, J PHARMACOL EXP THER, V274, P991; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Perrier S, 1998, CLIN IMMUNOL IMMUNOP, V87, P309, DOI 10.1006/clin.1998.4520; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stroemer RP, 1997, J CEREBR BLOOD F MET, V17, P597; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tamaoka A, 2000, NEUROLOGY, V54, P2319, DOI 10.1212/WNL.54.12.2319; TARLOW JK, 1993, HUM GENET, V91, P403; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tourian A, 1983, METABOLIC BASIS INHE, P270; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Zhang Z., 1997, Society for Neuroscience Abstracts, V23, P899	90	43	45	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					361	374		10.1097/00001199-200607000-00007			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100007	16915011				2021-06-18	
J	Vos, PE; van Gils, M; Beems, T; Zimmerman, C; Verbeek, MM				Vos, P. E.; van Gils, M.; Beems, T.; Zimmerman, C.; Verbeek, M. M.			Increased GFAP and S100 beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						GFAP; NSE; coma; S100 beta; subarachnoid haemorrhage	NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID CSF; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN; CEREBRAL VASOSPASM; BLOOD; S100B; RELEASE; DAMAGE	Assessment of initial disease severity after subarachnoid haemorrhage (SAH) remains difficult. The objective of the study is to identify biochemical markers of brain damage in peripheral blood after SAH. Hospital admission S100 beta, glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) serum levels were analysed in 67 patients with SAH. Disease severity was determined by using the World Federation of Neurological Surgeons (WFNS) scale and the Fisher CT (computerized tomography) grading scale. Mean astroglial serum concentrations taken at hospital admission were increased (S100 beta 2.8-fold and GFAP 1.8-fold) compared with the upper limit of normal laboratory reference values (P95). The mean NSE concentration was within normal limits. S100 beta (P < 0.001) and GFAP (P =0.011) but not NSE levels were higher in patients who were in coma at the time of hospital admission compared with patients who were not. Similarly S100 beta and GFAP but not NSE serum levels increased with higher WFNS scores, raised intracranial pressure and higher CT Fisher grade scores. Concerning the location of the aneurysm, S100 beta and GFAP serum levels were within normal limits after a perimesencephalic type of haemorrhage and significantly increased after aneurysmal type SAH. Increased glial (S100 beta and GFAP) but not neuronal (NSE) protein serum concentrations are found after SAH, associated to the clinical severity of the initial injury.	Radboud Univ Nigmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nigmegen, Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; Radboud Univ Nigmegen, Med Ctr, Dept Intens Care, Nijmegen, Netherlands; Radboud Univ Nigmegen, Med Ctr, Lab Pediat & Neurol, Nijmegen, Netherlands	Vos, PE (corresponding author), Radboud Univ Nigmegen, Med Ctr, Dept Neurol, Hp 935,POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Verbeek, Marcel M/D-1971-2010	Verbeek, Marcel M/0000-0003-4635-7876			Anderson RE, 1999, ANN THORAC SURG, V67, P1721, DOI 10.1016/S0003-4975(99)00318-5; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P105; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Kay A, 2003, STROKE, V34, P637, DOI 10.1161/01.STR.0000057579.25430.16; KRUSE A, 1991, ACTA NEUROCHIR, V110, P106, DOI 10.1007/BF01400675; Lagares A, 2001, ACTA NEUROCHIR, V143, P665, DOI 10.1007/s007010170044; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; MABE H, 1991, SURG NEUROL, V36, P170, DOI 10.1016/0090-3019(91)90108-L; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Mees SMD, 2003, NEUROLOGY, V61, P1132, DOI 10.1212/01.WNL.0000090466.68866.02; Mussack T, 2003, EUR J MED RES, V8, P457; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Shore PM, 2004, J NEUROTRAUM, V21, P1113; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wallin A, 1996, DEMENTIA, V7, P267, DOI 10.1159/000106891; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 2004, NEUROSURG REV, V27, P178, DOI 10.1007/s10143-004-0341-x; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	41	43	52	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	JUN	2006	13	6					632	638		10.1111/j.1468-1331.2006.01332.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	050CY	WOS:000238066300010	16796588				2021-06-18	
J	Wilde, EA; Bigler, ED; Pedroza, C; Ryser, DK				Wilde, Elisabeth A.; Bigler, Erin D.; Pedroza, Claudia; Ryser, David K.			Post-traumatic amnesia predicts long-term cerebral atrophy in traumatic brain injury	BRAIN INJURY			English	Article						morphometry; neuroimaging; post-traumatic amnesia; traumatic brain injury; ventricle-to-brain ratio	CLOSED-HEAD-INJURY; PRACTICAL SCALE; REHABILITATION; SEVERITY; SEQUELAE; MILD; COMA; MRI	Primary objective: To examine post-traumatic amnesia (PTA) and its relation to long-term cerebral atrophy in persons with traumatic brain injury (TBI) using objective indicators of PTA duration and Quantitative Magnetic Resonance Imaging (QMRI). It was hypothesized that longer PTA would predict later generalized atrophy (increased ventricle-to-brain ratio (VBR)). As a guide in assessing patients with TBI, this study determined the probability of developing chronic cerebral atrophy based on PTA duration. Research design: Probability model using 60 adult patients with mild-to-severe TBI. Main outcomes and results: A logistic regression model with a cut-off determined by normative QMRI data confirmed that longer PTA duration predicts increased VBR. A probability model demonstrated a 6% increase in the odds of developing later atrophy on neuroimaging with each additional day of PTA. Conclusions: PTA has previously proven to be a good indicator of later cognitive recovery and functional outcome and also predicts long-term parenchymal change.	Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; LDS Hosp, Neuro Special Rehabil Unit, Salt Lake City, UT USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu		Pedroza, Claudia/0000-0003-4235-1282			Ahmed S, 2000, BRAIN INJURY, V14, P765; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BIGLER ED, 2005, NEUROPSYCHIATRY TRAU, P79; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GUISE E, 2005, BRAIN INJURY, V19, P1087; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; RYSER DK, 1996, INT PERSPECTIVES TRA, P79; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	29	43	43	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2006	20	7					695	699		10.1080/02699050600744079			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200003	16809201				2021-06-18	
J	Novack, TA; Banos, JH; Alderson, AL; Schneider, JJ; Weed, W; Blankenship, J; Salisbury, D				Novack, TA; Banos, JH; Alderson, AL; Schneider, JJ; Weed, W; Blankenship, J; Salisbury, D			UFOV performance and driving ability following traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; driving	HEAD-INJURY; ALZHEIMER-TYPE; COMPETENCE; DAMAGE; IMPAIRMENT; DEMENTIA; FITNESS; SAFETY; STROKE; RETURN	Primary objective: To investigate the relationship between performance on the Useful Field of View Test (UFOV) and driving performance following traumatic brain injury (TBI). Participants: Sixty people with TBI referred for driving evaluation. Measures: Useful Field of View Test, Global Rating Scale and Driver Assessment Scale. Results: Subject performance diminished as the complexity of the UFOV sub-tests increased. There was a significant relationship between UFOV performance, particularly on the second sub-test, and on-road driving performance. Subject age and Trail Making Test, Part B were also predictive of driving performance. Conclusions: The UFOV can be used as a screening measure to determine readiness to participate in an on-road driving assessment.	Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA	Novack, TA (corresponding author), Univ Alabama, Dept Phys Med & Rehabil, SRC 530,619 19th St S, Birmingham, AL 35249 USA.	novack@uab.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline		Ball K., 1992, J AM OPTOM ASSOC, V64, P71; Bieliauskas LA, 2005, BRAIN INJURY, V19, P221, DOI 10.1080/02699050400017213; Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; Fisk GD, 2002, ARCH PHYS MED REHAB, V83, P469, DOI 10.1053/apmr.2002.31179; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; Hunt LA, 1997, ARCH NEUROL-CHICAGO, V54, P707, DOI 10.1001/archneur.1997.00550180029008; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Whelihan WM, 2005, ARCH CLIN NEUROPSYCH, V20, P217, DOI 10.1016/j.acn.2004.07.002; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271	26	43	45	0	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2006	20	5					455	461		10.1080/02699050600664541			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800001	16716991				2021-06-18	
J	Ewing-Cobbs, L; Hasan, KM; Prasad, MR; Kramer, L; Bachevalier, J				Ewing-Cobbs, L; Hasan, KM; Prasad, MR; Kramer, L; Bachevalier, J			Corpus callosum diffusion anisotropy correlates with neuropsychological outcomes in twins disconcordant for traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	12th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine	MAY 15-21, 2004	Kyoto, JAPAN	Int Soc Magnet Resonance Med				Conventional and diffusion tensor MR imaging studies in twins sustaining severe pediatric traumatic brain injury identified reduction in fractional anisotropy (FA) in all regions of the corpus callosum, particularly the posterior body, rostral body, and genu, relative to healthy cotwins. FA from the rostrum, genu, anterior body, posterior body, and isthmus were correlated with measures of reading speed and comprehension; verbal working memory and math fact retrieval scores were correlated only with the rostral body FA.	Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Dept Intervent & Diagnost Imaging, Houston, TX 77030 USA; Emory Univ, Dept Psychol, Atlanta, GA 30322 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, 7000 Fannin UCT 2401, Houston, TX 77030 USA.		Hasan, Khader M./ABB-5767-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046308, R01 NS029462] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462, R01NS046308] Funding Source: NIH RePORTER		Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baumgardner TL, 1996, NEUROLOGY, V47, P477, DOI 10.1212/WNL.47.2.477; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Cohen J, 1998, STAT POWER ANAL BEHA; Constable RT, 2004, NEUROIMAGE, V22, P11, DOI 10.1016/j.neuroimage.2004.01.001; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; HASAN KM, 2004, P 12 INT SOC MAGN RE, P338; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Menon V, 2002, HUM BRAIN MAPP, V16, P119, DOI 10.1002/hbm.10035; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Simos PG, 2002, CEREB CORTEX, V12, P297, DOI 10.1093/cercor/12.3.297; STRICH SJ, 1970, PATHOLOGY TRAUMA, P166; Torgesen JK, 2009, TEST WORD READING EF; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Woodcock R.W., 2001, WOODCOCK JOHNSON 3 T	18	43	46	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2006	27	4					879	881					3	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	033BY	WOS:000236822500034	16611782				2021-06-18	
J	High, WM; Roebuck-Spencer, T; Sander, AM; Struchen, MA; Sherer, M				High, WM; Roebuck-Spencer, T; Sander, AM; Struchen, MA; Sherer, M			Early versus later admission to postacute rehabilitation: Impact on functional outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; treatment effectiveness; treatment outcome	DISABILITY RATING-SCALE; COMMUNITY INTEGRATION QUESTIONNAIRE; CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION; PREDICTION; RECOVERY; PROGRAM; COMA	Early versus later admission to postacute rehabilitation: impact on functional outcome after traumatic brain injury. Arch Phys Med Rehabil 2006;87:334-42. Objective: To examine the impact of participation in a postacute community reentry program on functional outcome after traumatic brain injury (TBI). Design: Cohort, nonrandomized, intervention study. Pretest-posttest, follow-up design. Setting: Nonprofit outpatient community reentry program affiliated with an inpatient rehabilitation hospital. Participants: Three groups of persons with moderate to severe TBI differing in length of time between injury and admission. The first group entered postacute rehabilitation within 6 months of injury (n= 115); the second group, between 6 and 12 months (n=23); and the third group, greater than 12 months (n=29). Interventions: Persons with TBI participated in a postacute community reentry program (average, 4.3mo) that emphasized (1) teaching compensatory strategies to address residual cognitive deficits; (2) arranging environmental supports to maximize functioning; (3) counseling and education to address personal and family adjustment and to improve accurate self-awareness; and (4) transition from simulated activities in the clinic to productive activities in the community. Main Outcome Measures: Disability Rating Scale, Supervision Rating Scale, and the Community Integration Questionnaire. Results: All groups showed improvements between admission and discharge on measures of overall disability, independence, home competency, and productivity, and these gains were maintained at follow-up. For the group beginning postacute rehabilitation the earliest (< 6mo postinjury) independence continued to improve after discharge. Community integration total score and home competency also continued to improve even after discharge. Conclusions: The results point toward the effectiveness of postacute rehabilitation in improving functional outcome after TBI even for persons who have reached stable neurologic recovery at 12 or more months postinjury.	Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Natl Rehabil Hosp, Washington, DC USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA	High, WM (corresponding author), Inst Rehabil & Res, Brain Injury Res Ctr, 1333 Moursund Ave, Houston, TX 77030 USA.	whigh@bcm.tmc.edu					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; HIGH WM, 2005, REHABILITATION TRAUM, P14; Johnson J, 2001, INT J PSYCHIAT CLIN, V5, P141, DOI 10.1080/136515001300374894; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; TEASDALE G, 1974, LANCET, V2, P81; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	32	43	43	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2006	87	3					334	342		10.1016/j.apmr.2005.11.028			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	021XZ	WOS:000236020500005	16500166				2021-06-18	
J	Ling, CY; Sandor, M; Suresh, M; Fabry, Z				Ling, CY; Sandor, M; Suresh, M; Fabry, Z			Traumatic injury and the presence of antigen differentially contribute to T-cell recruitment in the CNS	JOURNAL OF NEUROSCIENCE			English	Article						antigen specificity; CD8(+) T-cell homing; traumatic brain injury; neuroimmunology; ovalbumin antigen; intracerebral injection	CENTRAL-NERVOUS-SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE-SCLEROSIS LESIONS; FACIAL MOTONEURON LOSS; BLOOD-BRAIN-BARRIER; DENDRITIC CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; CD40-CD40L INTERACTION; HEMATOGENOUS CELLS; IMMUNE-RESPONSES	T-cell recruitment into the brain is critical in inflammatory and autoimmune diseases of the CNS. We use intracerebral antigen microinjection and tetramer technology to track antigen-specific CD8(+) T-cells in the CNS and to clarify the contribution of antigen deposition or traumatic injury to the accumulation of T-cells in the brain. We demonstrate that, after intracerebral microinjection of ovalbumin, ovalbumin-specific CD8(+) T-cells expand systemically and then migrate into the brain where they complete additional proliferation cycles. T-cells in the brain are activated and respond to in vitro secondary antigen challenge. CD8(+) T-cells accumulate and persist in sites of antigen in the brain without replenishment from the periphery. Persistent survival of CD8(+) T-cells at sites of cognate antigen is significantly reduced by blocking CD154 molecules. A small traumatic injury itself does not lead to recruitment of CD8(+) T-cells into the brain but attracts activated antigen-specific CD8(+) T-cells from cognate antigen injection sites. This process is presumably antigen independent and cannot be inhibited by blocking CD154 molecules. These data show that activated antigen-specific CD8(+) T-cells accumulate in the CNS at both cognate antigen-containing and traumatic injury sites after intracerebral antigen delivery. The accumulation of activated antigen-specific T-cells at traumatic injury sites, in addition to antigen-containing areas, could amplify local inflammatory processes in the CNS. Combination therapies in neuroinflammatory diseases to block both of these processes should be considered.	Univ Wisconsin, Madison Med Sch, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathol Sci, Madison, WI 53706 USA	Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol, 1300 Univ Ave,6130 Med Sci Ctr, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570, R01-NS 37570-01A2] Funding Source: Medline		Aktas O, 2005, NEURON, V46, P421, DOI 10.1016/j.neuron.2005.03.018; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Azukizawa H, 2003, EUR J IMMUNOL, V33, P1879, DOI 10.1002/eji.200323630; Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; BALZASCIA T, 2005, IMMUNITY, V22, P175; BOOSS J, 1983, J NEUROL SCI, V62, P219, DOI 10.1016/0022-510X(83)90201-0; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Brabb T, 2000, J EXP MED, V192, P871, DOI 10.1084/jem.192.6.871; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; CSERR HF, 1992, J NEUROIMMUNOL, V41, P195, DOI 10.1016/0165-5728(92)90070-2; Darabi K, 2004, J IMMUNOL, V173, P92, DOI 10.4049/jimmunol.173.1.92; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Fee DB, 2004, BRAIN RES, V1012, P52, DOI 10.1016/j.brainres.2004.03.028; FONTANA A, 1987, IMMUNOL REV, V100, P185, DOI 10.1111/j.1600-065X.1987.tb00532.x; Gay FW, 1997, BRAIN, V120, P1461, DOI 10.1093/brain/120.8.1461; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; HAYASHI T, 1988, ANN NEUROL, V24, P523, DOI 10.1002/ana.410240408; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hulshof S, 2002, GLIA, V38, P24, DOI 10.1002/glia.10050; Ingulli E, 2002, J IMMUNOL, V169, P2247, DOI 10.4049/jimmunol.169.5.2247; Irani DN, 1997, J IMMUNOL, V158, P2318; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; JUSTICIA C, 2005, IN PRESS J CEREB BLO; Karman J, 2004, IMMUNOL LETT, V92, P107, DOI 10.1016/j.imlet.2003.10.017; Karman J, 2004, J IMMUNOL, V173, P2353, DOI 10.4049/jimmunol.173.4.2353; KELLY JM, 1993, EUR J IMMUNOL, V23, P3318, DOI 10.1002/eji.1830231239; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ling CY, 2003, J NEUROIMMUNOL, V141, P90, DOI 10.1016/S0165-5728(03)00249-2; Liu JSH, 2001, AM J PATHOL, V158, P2057, DOI 10.1016/S0002-9440(10)64677-9; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; MATSUMOTO Y, 1993, IMMUNOLOGY, V79, P381; McGavern DB, 2004, J IMMUNOL, V173, P4779, DOI 10.4049/jimmunol.173.8.4779; McGavern DB, 2002, J INFECT DIS, V186, pS145, DOI 10.1086/344264; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mullins DW, 2003, J EXP MED, V198, P1023, DOI 10.1084/jem.20021348; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; Obst R, 2005, J EXP MED, V201, P1555, DOI 10.1084/jem.20042521; Qing Z, 2000, J NEUROIMMUNOL, V105, P169, DOI 10.1016/S0165-5728(99)00265-9; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reinhardt RL, 2003, J EXP MED, V197, P751, DOI 10.1084/jem.20021690; RODRIGUE.LA, 1968, J COMP NEUROL, V132, P109, DOI 10.1002/cne.901320106; Schwartz M, 2001, CELL MOL NEUROBIOL, V21, P617, DOI 10.1023/A:1015139718466; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 2003, BRAIN BEHAV IMMUN, V17, P393, DOI 10.1016/S0889-1591(03)00028-X; Serpe CJ, 1999, J NEUROSCI, V19; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Sorensen TL, 2002, J NEUROIMMUNOL, V127, P59, DOI 10.1016/S0165-5728(02)00097-8; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tan J, 2002, CURR OPIN PHARMACOL, V2, P445, DOI 10.1016/S1471-4892(02)00180-7; TRAUGOTT U, 1989, CELL IMMUNOL, V119, P114, DOI 10.1016/0008-8749(89)90228-1; VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433; Whitney LW, 1999, ANN NEUROL, V46, P425; Williams KC, 1995, CURR TOP MICROBIOL, V202, P221; WOODROOFE MN, 1986, J NEUROL SCI, V74, P135, DOI 10.1016/0022-510X(86)90100-0; Xiao BG, 1999, CELL MOL LIFE SCI, V56, P5, DOI 10.1007/s000180050002; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831	69	43	44	1	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JAN 18	2006	26	3					731	741		10.1523/JNEUROSCI.3502-05.2006			11	Neurosciences	Neurosciences & Neurology	003XG	WOS:000234715000004	16421293	Green Published, Bronze			2021-06-18	
J	Ciuffreda, KJ; Han, Y; Kapoor, N; Ficarra, AP				Ciuffreda, Kenneth J.; Han, Ying; Kapoor, Neera; Ficarra, Anthony P.			Oculomotor rehabilitation for reading in acquired brain injury	NEUROREHABILITATION			English	Article						acquired brain injury; oculomotor feedback; oculomotor rehabilitation; reading; saccadic adaptation; visual attention		The purpose of this study was to assess reading-related oculomotor rehabilitation in individuals with acquired brain injury. Adults with either stroke ( n = 5) or traumatic brain injury ( n = 9) participated. Training paradigms included single-line and multiple-line simulated reading, as well as basic versional tracking ( fixation, saccade, and pursuit), twice per week over an 8 week period. Training modes included normal internal oculomotor visual feedback either in isolation ( 4 weeks) or concurrent with external oculomotor auditory feedback ( 4 weeks). Training effects were assessed objectively using infrared eye movement recording technology for simulated and actual reading, with the assessments occurring before, midway, and after training. In addition, the individuals were assessed subjectively using a reading rating-scale questionnaire. All reported considerably improved reading ability, and this was confirmed by several of the objective oculomotor measures. There was a trend for improvement to be better with the combined visual and auditory oculomotor feedback. Reading-related oculomotor rehabilitation produced significant gains in both the subjective and objective domains. It is believed that rapid saccadic oculomotor adaptation, as well as the training of rhythmicity and automaticity, were involved in modifying eye movement behavior to produce a more systematic approach and resultant improved reading profile.	SUNY, State Coll Optomet, Dept Vis Sci, New York, NY 10036 USA; Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, New York, NY 10036 USA; Cincinnati VA Med Ctr, Optometry Serv, Cincinnati, OH 45220 USA	Ciuffreda, KJ (corresponding author), SUNY, State Coll Optomet, Dept Vis Sci, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu					ABRAMS SG, 1972, READ RES QUART, V8, P40, DOI 10.2307/746979; Carmichael L., 1947, READING VISUAL FATIG; CHEIMAN M, 1994, CLIN MANAGEMENT BINO; Ciuffreda K. J., 2001, DOWNEY DARLINGS PHYS, P241; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; Ciuffreda K. J., 1994, EYE MOVEMENTS READIN, P163; Ciuffreda KJ, 2002, MODELS VISUAL SYSTEM, P741; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Ciuffreda KJ, 1995, EYE MOVEMENT BASICS; Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241; Fayos B, 1998, J BEHAV OPTOMETRY, V9, P143; FLETCHER J, 1993, J LEARN DISABIL, V26, P683, DOI 10.1177/002221949302601006; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; GUR S, 1992, ISRAEL J MED SCI, V28, P622; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Jackowski MM, 1996, NEUROREHABILITATION, V6, P193, DOI 10.3233/NRE-1996-6305; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; KAPOOR N, 2005, TXB TRAUMATIC BRAIN, P405; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Koenig G S, 1997, J Am Optom Assoc, V68, P155; MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071; Rayner K., 1989, PSYCHOL READING; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; ROBINSON GM, 1977, J EXP PSYCHOL HUMAN, V3, P83; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Scheiman M, 2001, VISUAL VESTIBULAR CO, P89; SEMMLOW JL, 1989, J EXP PSYCHOL HUMAN, V15, P249, DOI 10.1037/0096-1523.15.2.249; Solan HA, 2001, J LEARN DISABIL-US, V34, P107, DOI 10.1177/002221940103400202; Suchoff IB, 2001, VISUAL VESTIBULAR CO; SUCHOFF IB, 2000, LIGHTHOUSE HDB VISIO, P517; Taylor EA., 1966, FUNDAMENTAL READING; ZIHL J, 1995, BRAIN, V118, P891, DOI 10.1093/brain/118.4.891; Zihl J., 2000, NEUROPSY REHABIL MOD; Zost MG, 2001, DIAGNOSIS MANAGEMENT, P75	35	43	43	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	1					9	21					13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045KY	WOS:000237742200003	16720933				2021-06-18	
J	Zhang, Z; Artelt, M; Burnet, M; Trautmann, K; Schluesener, HJ				Zhang, Z.; Artelt, M.; Burnet, M.; Trautmann, K.; Schluesener, H. J.			Early infiltration of CD8(+) macrophages/microglia to lesions of rat traumatic brain injury	NEUROSCIENCE			English	Article						traumatic brain injury; microglia; macrophages; weight-drop model; endothelial monocyte-activating polypeptide II	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEMATOGENOUS MACROPHAGES; P2X(4) RECEPTOR; EMAP-II; EXPRESSION; MICROGLIA; MONOCYTES; ACTIVATION; ACCUMULATION; RECRUITMENT	Local inflammatory responses play an important role in mediating secondary tissue damage in traumatic brain injury. Characterization of leukocytic subpopulations contributing to the early infiltration of the damaged tissue might aid in further understanding of lesion development and contribute to definition of cellular targets for selective immunotherapy. In a rat traumatic brain injury model, significant CD8(+) cell accumulation was observed 3 days post-injury. The CD8(+) cells were strictly distributed to the pannecrotic areas and around the pannecrotic perimeter. The morphology, time course of accumulation and distribution of CD8(+) cells were similar to that of reactive ED1(+) and enclothelial monocyteactivating polypepticle II+ microglia/macrophages, but different from W3/13(+) T cells. Further double-labeling experiments confirmed that the major cellular sources of CD8 were reactive macrophages/microglia. Both the location of these CD8(+) macrophages/microglia to the border of the pannecrosis and their co-expression of endothelial monocyte-activating polypeptide II and P2X(4) receptor suggest they might have a central role in lesion development and might thus be candidates fordevelopment of immunotherapeutic, anti-inflammatory strategies. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Synovo GmbH, D-72076 Tubingen, Germany	Zhang, Z (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	Burnet, Michael/AAB-2958-2019; Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Brabeck C, 2002, EXP NEUROL, V177, P341, DOI 10.1006/exnr.2002.7985; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Golarai G, 2001, J NEUROSCI, V21, P8523; Guo LH, 2005, NEUROSCIENCE, V134, P199, DOI 10.1016/j.neuroscience.2005.04.026; Hirji N, 1997, J IMMUNOL, V158, P1833; Hirji N, 1998, J IMMUNOL, V160, P6004; Hirji NS, 1999, INT ARCH ALLERGY IMM, V118, P180, DOI 10.1159/000024060; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Jander S, 2001, BRAIN PATHOL, V11, P27; KAFFENBERGER W, 1987, J LEUKOCYTE BIOL, V42, P181; Kato H, 2000, BRAIN PATHOL, V10, P137; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kostulas N, 2002, STROKE, V33, P1129, DOI 10.1161/hs0402.105379; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kubes P, 2000, BRAIN PATHOL, V10, P127; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Lehrmann E, 1997, J COMP NEUROL, V386, P461; Lin TJ, 2000, J IMMUNOL, V164, P1783, DOI 10.4049/jimmunol.164.4.1783; MCCALL MN, 1992, IMMUNOLOGY, V76, P310; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; Mueller CA, 2003, J NEUROIMMUNOL, V135, P1, DOI 10.1016/S0165-5728(02)00427-7; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schroeter M, 2003, AM J PATHOL, V163, P1517, DOI 10.1016/S0002-9440(10)63508-0; Schroeter M, 2001, ACTA NEUROPATHOL, V101, P440; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Scriba A, 1997, J LEUKOCYTE BIOL, V62, P741; Scriba A, 1998, SCAND J IMMUNOL, V47, P332; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Tam FWK, 1999, NEPHROL DIAL TRANSPL, V14, P1658, DOI 10.1093/ndt/14.7.1658; TORRESNAGEL N, 1992, EUR J IMMUNOL, V22, P2841, DOI 10.1002/eji.1830221113; WALKER DG, 1998, NEUROINFLAMMATION ME, P61; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x; Wu YP, 2001, J NEUROPATH EXP NEUR, V60, P1062, DOI 10.1093/jnen/60.11.1062; Zhang ZR, 2006, EXP NEUROL, V197, P252, DOI 10.1016/j.expneurol.2005.09.015	47	43	44	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	141	2					637	644		10.1016/j.neuroscience.2006.04.027			8	Neurosciences	Neurosciences & Neurology	072JA	WOS:000239668500008	16725271				2021-06-18	
J	Aimaretti, G; Ambrosio, MR; Di Somma, C; Gasperi, M; Cannavo, S; Scaroni, C; De Marinis, L; Baldelli, R; Bona, G; Giordano, G; Ghigo, E				Aimaretti, G; Ambrosio, MR; Di Somma, C; Gasperi, M; Cannavo, S; Scaroni, C; De Marinis, L; Baldelli, R; Bona, G; Giordano, G; Ghigo, E			Hypopituitarism induced by traumatic brain injury in the transition phase	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						traumatic brain injury; hypopituitarism; adolescence; transition phase	GROWTH-HORMONE DEFICIENCY; GH DEFICIENCY; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; STIMULATION TEST; HEAD TRAUMA; ADULTS; DIAGNOSIS; PREVALENCE	Traumatic brain injury (TBI) has been associated with hypopituitarism in general and GH deficiency (GHD) in particular; the consequences of this on growth and development are likely to be critical in children and adolescents in the so-called "transition phase". In order to verify the consequences of TBI on pituitary function in the transition phase, we studied a population of adolescents and young adults 3 and 12 months after brain injury [no. = 23, 9 females, 14 males; age: 16-25 yr; body mass index (BMI): 21.9 +/- 0.6 kg/m(2)]. At 3 months, hypopituitarism was present in 34.6%. Total, multiple and isolated deficits were present in 8.6, 4.3 and 21.7%, respectively. Diabetes insipidus (DI) was present in 8.6% patients and mild hyperprolactinemia in 4.3%. At 12 months, hypopituitarism was present in 30.3%. Total, multiple and isolated deficits were present in 8.6, 4.3 and 17.4%, respectively. DI was present in 4.3% of patients and mild hyperprolactinemia in 4.3%. Total hypopituitarism was always confirmed at retesting. Multiple and isolated hypopituitarism were confirmed in 0/1 and 2/5, respectively. Two/23 patients showed isolated hypopituitarism at 12 months only; 1 patient with isolated at 3 months showed multiple hypopituitarism at retesting. GHD and secondary hypogonadism were the most common acquired pituitary deficits. These results show the high risk of TBI-induced hypopituitarism also in the transition age. Thus it is recommended that pediatric endocrinologists follow-up pituitary function of children and adolescents after brain injuries.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Turin, Italy; Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, I-44100 Ferrara, Italy; Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy; Univ Pisa, Dept Endocrinol & Metab, Pisa, Italy; Univ Messina, Dept Med & Pharmacol, Endocrinol Sect, Messina, Italy; Univ Padua, Div Endocrinol, Dept Surg & Med Sci, Padua, Italy; Catholic Univ, Div Endocrinol, Rome, Italy; Univ Piemonte Orientale, Div Paediat, Novara, Italy	Aimaretti, G (corresponding author), Univ Turin, Dipartimento Med Interna, Div Endocrinol & Malattie Metab, C Dogliotti,14, I-10126 Turin, Italy.	gianluca.aimaretti@unito.it	Cannavo, Salvatore/D-7608-2013; Scaroni, Carla/G-3853-2017; Di Somma, Carolina/K-7772-2016	Cannavo, Salvatore/0000-0001-8779-7283; Scaroni, Carla/0000-0001-9396-3815; Di Somma, Carolina/0000-0002-5724-1951; ambrosio, maria rosaria/0000-0002-7911-9770			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Aimaretti G, 2003, CLIN ENDOCRINOL, V59, P56, DOI 10.1046/j.1365-2265.2003.01794.x; AIMARETTI G, 2005, IN PRESS J CLIN ENDO; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Clayton PE, 2005, EUR J ENDOCRINOL, V152, P165, DOI 10.1530/eje.1.01829; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Faglia G., 2001, ENDOCRINOL METAB, P73; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Goetz CG., 1999, TXB CLIN NEUROLOGY; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; THORNER MO, 1998, WILLIAMS TXB ENDOCRI, P165	29	43	44	0	2	EDITRICE KURTIS S R L	MILAN	VIA LUIGI ZOJA 30, 20153 MILAN, ITALY	0391-4097			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	DEC	2005	28	11					984	989		10.1007/BF03345336			6	Endocrinology & Metabolism	Endocrinology & Metabolism	006BO	WOS:000234870300005	16483176				2021-06-18	
J	Schultke, E; Kamencic, H; Zhao, M; Tian, GF; Baker, AJ; Griebel, RW; Juurlink, BHJ				Schultke, E; Kamencic, H; Zhao, M; Tian, GF; Baker, AJ; Griebel, RW; Juurlink, BHJ			Neuroprotection following fluid percussion brain trauma: A pilot study using quercetin	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; compound action potential; electrophysiology; fluid percussion model; glutathione; inflammation; oxidative stress	HYDROGEN-PEROXIDE; QUINONE REDUCTASE; AXONAL INJURY; KAPPA-B; FLAVONOID QUERCETIN; EPITHELIAL-CELLS; MARKER ENZYME; IN-VITRO; MYELOPEROXIDASE; RAT	Previously, we were able to demonstrate the neuroprotective effect of quercetin in an animal model of acute traumatic spinal cord injury. The objective of the present study was to determine whether any neuroprotective effect is seen when quercetin is administered in an animal model of traumatic brain injury. Twenty-six adult male Sprague-Dawley rats were submitted to moderate fluid percussion injury in the anterior midline position. Animals were divided into two experimental groups: one group received 25 mu mol/kg quercetin starting 1 h after injury, while animals in the second group received saline vehicle (n = 13 per group). Eight animals were used as uninjured healthy controls. Eight animals in each experimental group were sacrificed at 24 h, while five animals per group were allowed to recover for 72 h following injury. Compound action potential amplitudes (CAPAs) were recorded on 400-mu m vibrotome sections of the corpus callosum superfused with oxygenated artificial CSF (n = 3 per animal) in 20 experimental animals and five healthy controls. Three brains from animals in each experimental group and healthy controls were used for histological, immunocytochemical and biochemical analysis after sacrifice at 24 h. CAPAs in uninjured animals had a mean of 1.12 mV. This decreased to 0.55 mV in saline vehicle-treated injured animals by 24 h and changed little over the next 3 days. CAPAs were significantly better at 0.82 mV at 24 h and 0.76 mV at 3 days in quercetin-treated injured animals when compared to injured saline vehicle controls. Quercetin significantly prevented decrease of glutathione levels and decreased myeloperoxidase activity. We conclude that this dietary flavonoid has therapeutic potential following brain trauma.	Univ Saskatchewan, Dept Anat & Cell Biol, Div Neurosurg, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg, Div Neurosurg, Saskatoon, SK S7N 5E5, Canada; St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, Div Neurosurg, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	juurlink@duke.usask.ca	Schultke, Elisabeth/M-3959-2013				Arabbi PR, 2004, J AGR FOOD CHEM, V52, P1124, DOI 10.1021/jf0499525; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; BLACKBURN WD, 1987, BIOCHEM BIOPH RES CO, V144, P1229, DOI 10.1016/0006-291X(87)91442-2; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P801, DOI 10.1016/0091-6749(84)90450-0; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cheng IF, 2000, BIOMETALS, V13, P77, DOI 10.1023/A:1009229429250; Cho SY, 2003, MOL CELL BIOCHEM, V243, P153, DOI 10.1023/A:1021624520740; Christman JW, 2000, BRAIN PATHOL, V10, P153; CLARK RA, 1981, J IMMUNOL, V126, P1295; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Conquer JA, 1998, J NUTR, V128, P593; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; deVries JHM, 1997, CANCER LETT, V114, P141, DOI 10.1016/S0304-3835(97)04645-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Donnelly LE, 2004, AM J PHYSIOL-LUNG C, V287, pL774, DOI 10.1152/ajplung.00110.2004; Dugas AJ, 2000, J NAT PROD, V63, P327, DOI 10.1021/np990352n; Erlund I, 2003, EUR J CLIN NUTR, V57, P37, DOI 10.1038/sj.ejcn.1601513; Ferrali M, 1997, FEBS LETT, V416, P123, DOI 10.1016/S0014-5793(97)01182-4; Furtmuller PC, 2000, EUR J BIOCHEM, V267, P5858, DOI 10.1046/j.1432-1327.2000.01491.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hakkinen SH, 1999, J AGR FOOD CHEM, V47, P2274, DOI 10.1021/jf9811065; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7; HOLLMAN PCH, 1995, AM J CLIN NUTR, V62, P1276; Hollman PCH, 1996, FREE RADICAL BIO MED, V21, P703, DOI 10.1016/0891-5849(96)00129-3; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; IARC, 1999, IARC MON EV CARC RIS; Ishikawa Y, 1999, J AM SOC NEPHROL, V10, P2290; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kobuchi H, 1999, AM J PHYSIOL-CELL PH, V277, pC403; Lucisano-Valim YM, 2002, J PHARMACOL TOX MET, V47, P53, DOI 10.1016/S1056-8719(02)00206-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moon JH, 2000, AM J PHYSIOL-REG I, V279, pR461; Myhrstad MCW, 2002, FREE RADICAL BIO MED, V32, P386, DOI 10.1016/S0891-5849(01)00812-7; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; PAGONIS C, 1986, BIOCHEM PHARMACOL, V35, P237, DOI 10.1016/0006-2952(86)90520-4; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PINCEMAIL J, 1988, EXPERIENTIA, V44, P450, DOI 10.1007/BF01940544; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reiterer G, 2004, J NUTR, V134, P771; Rodrigues MR, 2002, BIOCHEM BIOPH RES CO, V292, P869, DOI 10.1006/bbrc.2002.6724; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schultke E, 2003, J NEUROTRAUM, V20, P583, DOI 10.1089/089771503767168500; Selloum L, 2001, ARCH BIOCHEM BIOPHYS, V395, P49, DOI 10.1006/abbi.2001.2562; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; THART BA, 1990, CHEM-BIOL INTERACT, V73, P323, DOI 10.1016/0009-2797(90)90012-C; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830; TORDERA M, 1994, Z NATURFORSCH C, V49, P235; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Uda Y, 1997, CANCER LETT, V120, P213, DOI 10.1016/S0304-3835(97)00311-X; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Valerio LG, 2001, TOXICOL LETT, V119, P49, DOI 10.1016/S0378-4274(00)00302-7; Wang LM, 2002, NEPHRON, V91, P142, DOI 10.1159/000057616; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Williamson G, 1996, CARCINOGENESIS, V17, P2385, DOI 10.1093/carcin/17.11.2385; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Yannai S, 1998, FOOD CHEM TOXICOL, V36, P623, DOI 10.1016/S0278-6915(98)00022-2; Yoshino M, 1998, ANAL BIOCHEM, V257, P40, DOI 10.1006/abio.1997.2522; Yoshizumi M, 2001, MOL PHARMACOL, V60, P656	77	43	47	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1475	1484		10.1089/neu.2005.22.1475			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500009	16379584				2021-06-18	
J	Davis, DP; Vadeboncoeur, TF; Ochs, M; Poste, JC; Vilke, GM; Hoyt, DB				Davis, DP; Vadeboncoeur, TF; Ochs, M; Poste, JC; Vilke, GM; Hoyt, DB			The association between field Glasgow Coma Scale score and outcome in patients undergoing paramedic rapid sequence intubation	JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 17, 2004	Orlando, FL	Soc Acad Emergency Med		Glasgow Coma Scale; paramedic; prehospital; EMS; Rapid Sequence Intubation; traumatic brain injury; head trauma	RESPIRATORY-DISTRESS-SYNDROME; SEVERE HEAD-INJURIES; INDUCED LUNG INJURY; ISCHEMIC BRAIN-DAMAGE; TRAUMA PATIENTS; MECHANICAL VENTILATION; ENDOTRACHEAL INTUBATION; INTRACRANIAL-PRESSURE; EMERGENCY-DEPARTMENT; HYPOTENSION	Early intubation is standard for treating severe traumatic brain injury (TBI). Aeromedical crews and select paramedic agencies use rapid sequence intubation (RSI) to facilitate intubation after TBI, with Glasgow Coma Scale (GCS) score commonly used as a screening tool. To explore the association between paramedic GCS and outcome in patients with TBI undergoing prehospital RSI, paramedics prospectively enrolled adult major trauma victims with GCS 3-8 and clinical suspicion for head trauma to undergo succinylcholine-assisted intubation as part of the San Diego Paramedic RSI Trial. The following data were abstracted from paramedic debriefing interviews and the county trauma registry: demographics, mechanism, vital signs including GCS score, clinical evidence of aspiration before RSI, arrival laboratory values, hospital course, and outcome. Paramedic GCS calculations were confirmed during debriefing interviews. Patients were stratified by GCS score, with chi-square and receiver-operator-curve (ROC) analysis used to explore the relationship between GCS and hypoxia, head injury severity, aspiration, intensive care unit (ICU) length of stay, and outcome. Cohort analysis was used to explore potential reasons for early extubation and discharge from the ICU in some patients. A total of 412 patients were included in this analysis. A total of 81 patients (20%) were extubated and discharged from the ICU in 48 h or less; these patients had higher pre-RSI oxygen saturation (SaO(2)) values and higher arrival serum ethanol levels. Paramedic and physician GCS calculations had high agreement (kappa = 0.995). A statistically significant relationship was observed between GCS score and Head Abbreviated Injury Score (AIS), survival, and pre-RSI SaO(2) values. However, ROC analysis revealed a limited ability of GCS to predict the presence of severe TBI, injury severity, desaturation, aspiration, ICU length of stay, or ultimate survival. In conclusion, paramedics seem to accurately calculate GCS values before prehospital RSI. Although a relationship between paramedic GCS and outcome exists, the ability to predict the severity of injury, airway-related complications, ICU length of stay, and overall survival is limited using this single variable. Other factors should be considered to screen TBI patients for prehospital RSI. (c) 2005 Elsevier Inc.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; San Diego Cty Emergency Med Serv, San Diego, CA USA; Univ Calif San Diego, John Muir Coll, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr 8676, San Diego, CA 92103 USA.						Amin AP, 2000, SURGERY, V127, P245, DOI 10.1067/msy.2000.104296; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; COTTRELL JE, 1983, ANESTH ANALG, V62, P1006; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, IN PRESS J TRAUMA; Doran J V, 1995, Prehosp Disaster Med, V10, P259; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MACIVER IN, 1958, LANCET, V1, P390; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MILLAR C, 1994, CAN J ANAESTH, V41, P281, DOI 10.1007/BF03009904; MODICA PA, 1992, CAN J ANAESTH, V39, P236, DOI 10.1007/BF03008783; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Spaite DW, 2003, ANN EMERG MED, V42, P729, DOI 10.1016/S0196-0644(03)00822-9; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, 1974, LANCET, V2, P81; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; VILKE GM, 2004, PREHOSP EMERG CARE, V8, P88; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; WANG H, 2004, PREHOSP EMERG CARE, V8, P84; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014	60	43	44	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	NOV	2005	29	4					391	397		10.1016/j.jemermed.2005.04.012			7	Emergency Medicine	Emergency Medicine	979QI	WOS:000232959500004	16243194				2021-06-18	
J	Xiong, Y; Shie, FS; Zhang, J; Lee, CP; Ho, YS				Xiong, Y; Shie, FS; Zhang, J; Lee, CP; Ho, YS			Prevention of mitochondrial dysfunction in post-traumatic mouse brain by superoxide dismutase	JOURNAL OF NEUROCHEMISTRY			English	Article						controlled cortical impact; oxidative phosphorylation; reactive oxygen species; transgenic and knockout mice	CONTROLLED CORTICAL IMPACT; CYTOCHROME-C RELEASE; LIPID-PEROXIDATION; CASPASE ACTIVATION; AMINO-ACIDS; INJURY; MICE; DAMAGE; COPPER; RAT	Reactive oxygen species (ROS) are known to be involved in the pathogenesis of traumatic brain injury (TBI). Previous studies have shown that the susceptibility of mice to TBI-induced formation of cortical lesion is determined by the expression levels of copper-zinc and manganese superoxide dismutase (CuZnSOD and MnSOD, respectively). However, the underlying biochemical mechanisms are not understood. In this study, we measured the efficiency of mitochondrial respiration in mouse brains with altered expression of these two enzymes. While controlled cortical impact injury (CCII) with a deformation depth of 2 mm caused a drastic decrease in NAD-linked bioenergetic capacity in brain mitochondria of wild-type mice, the functional decrease was not observed in brains of littermate transgenic mice overexpressing CuZnSOD or MnSOD. In addition, a 1 mm CCII greatly compromised brain mitochondrial function in mice deficient in CuZnSOD or MnSOD, but not wild-type mice. Inclusion of the calcium-chelating agent, EGTA, in the assay solution could completely prevent dysfunction of oxidative phosphorylation in all mitochondrial samples, suggesting that the observed impairment of mitochondrial function was a result of calcium overloading. In conclusion, our results imply that mitochondrial dysfunction induced by superoxide anion radical contributes to lesion formation in mouse brain following physical trauma.	Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Ho, YS (corresponding author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave,Room 4000, Detroit, MI 48201 USA.	yho@wayne.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL063317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES006639] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL63317, HL54321] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30 ES006639] Funding Source: Medline		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; BLOUGH NV, 1985, INORG CHEM, V24, P3502, DOI 10.1021/ic00216a003; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Boveris A, 1977, Adv Exp Med Biol, V78, P67; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Buki A, 2000, J NEUROSCI, V20, P2825; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; Crapo J D, 1978, Methods Enzymol, V53, P382; David M., 1965, METHOD ENZYMAT AN, P875; Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GELLER BL, 1982, J BIOL CHEM, V257, P8945; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; HOVDA DA, 1994, ACTA NEUROCHIR, P521; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KUO CF, 1987, J BIOL CHEM, V262, P4724; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee C. P., 1993, V2, P41; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LITTLE C, 1970, J BIOL CHEM, V245, P3632; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; Madsen K, 1996, ANAL BIOCHEM, V237, P37, DOI 10.1006/abio.1996.0197; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishikawa T, 2000, NATURE, V404, P787; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Ookawara T, 1998, AM J PHYSIOL-CELL PH, V275, pC840; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SLOT JW, 1986, LAB INVEST, V55, P363; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X	66	43	45	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2005	95	3					732	744		10.1111/j.1471-4159.2005.03412.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	972ZZ	WOS:000232493900013	16248885	Bronze			2021-06-18	
J	Beers, SR; Skold, A; Dixon, CE; Adelson, PD				Beers, SR; Skold, A; Dixon, CE; Adelson, PD			Neurobehavioral effects of amantadine after pediatric traumatic brain injury - A preliminary report	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						amantadine hydrochloride; behavior; Behavior Rating Inventory of Executive Function; executive function; neuropsychological tests; traumatic brain injury	DORSOLATERAL PREFRONTAL CORTEX; BEHAVIOR RATING INVENTORY; EXECUTIVE FUNCTION BRIEF; WATER MAZE PERFORMANCE; WORKING-MEMORY TASK; CLOSED-HEAD-INJURY; MILD HEAD; METHYLPHENIDATE TREATMENT; FUNCTIONAL-DEVELOPMENT; WORD FLUENCY	Objective: To investigate the safety and efficacy of a dopamine agonist, amantadine hydrochloride (AMH), in the treatment of neurobehavioral sequelae of pediatric TBI. Procedures: Age- and severity-matched traumatic brain injury groups, randomized to AMH (n = 17) or usual care (n = 10), completed behavior scales and neuropsychological tests. Effect sizes measured the treatment effect within subjects and between groups. Side effects were tracked over the 12-week study course. Results: Behavior improved in the AMH group, but only those 2 years or fewer postinjury showed a treatment effect on cognitive tests. Conclusions: After traumatic brain injury, a 12-week course of AMH was safe and, according to parent report, improved behavior. AMH may have the potential to improve cognition in more recently injured children.	Western Psychiat Inst & Clin, Traumat Brain Injury Program, Pittsburgh, PA 15213 USA; Pediat Neurotrauma Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Beers, SR (corresponding author), Western Psychiat Inst & Clin, Traumat Brain Injury Program, 3811 OHara St, Pittsburgh, PA 15213 USA.	beerssr@upmc.edu	Adelson, David/W-2083-2019		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD047976] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALEXANDER GE, 1978, BRAIN RES, V143, P233, DOI 10.1016/0006-8993(78)90566-8; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BEERS SR, 2004, P INT NEUR SOC 32 AN; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; Carter CS, 1998, AM J PSYCHIAT, V155, P1285, DOI 10.1176/ajp.155.9.1285; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; *CHOIC MED INC, 2001, AM HYDR; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; DESONNEVILLE LMJ, 1991, J CHILD PSYCHOL PSYC, V32, P285; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; EDBY K, 1995, CHILD NERV SYST, V11, P607, DOI 10.1007/BF00301001; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Fuster JM, 1980, PREFRONTAL CORTEX AN; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Golden C., 1978, STROOP COLOR WORD TE; GOLDMAN PS, 1970, EXP NEUROL, V27, P291, DOI 10.1016/0014-4886(70)90222-0; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAYDEN FG, 1983, ANTIMICROB AGENTS CH, V23, P458, DOI 10.1128/AAC.23.3.458; HEATON RK, 1993, WISCONSIN CART SORTI; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625; Hooper SR, 2002, J LEARN DISABIL-US, V35, P57, DOI 10.1177/002221940203500105; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; Isoardi RA, 1999, NEUROIMAGE, V9, P145, DOI 10.1006/nimg.1998.0392; King BH, 2001, J AM ACAD CHILD PSY, V40, P654, DOI 10.1097/00004583-200106000-00009; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Langlois JA, 2001, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Margo KL, 1998, AM FAM PHYSICIAN, V57, P1073; Masters KJ, 1997, J AM ACAD CHILD PSY, V36, P301, DOI 10.1097/00004583-199703000-00001; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mattes J, 1980, Psychopharmacol Bull, V16, P67; McEvoy LK, 1998, CEREB CORTEX, V8, P563, DOI 10.1093/cercor/8.7.563; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PORTER GE, 1993, PEDIATR INFECT DIS J, V12, P106; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; Romine CB, 2004, NEUROPSYCHOL REV, V14, P43, DOI 10.1023/B:NERV.0000026648.94811.32; Sailer M, 2000, PHARMACOPSYCHIATRY, V33, P28, DOI 10.1055/s-2000-7966; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Semel E. M., 1995, CLIN EVALUATION LANG; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thurman DJ, 2001, HEAD TRAUMA, P327; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 1991, WECHSLER INTELLIGENC; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; Zafonte RD, 1998, BRAIN INJURY, V12, P617	87	43	46	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					450	463		10.1097/00001199-200509000-00006			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600007	16170253				2021-06-18	
J	Ottens, AK; Kobeissy, FH; Wolper, RA; Haskins, WE; Hayes, RL; Denslow, ND; Wang, KKW				Ottens, AK; Kobeissy, FH; Wolper, RA; Haskins, WE; Hayes, RL; Denslow, ND; Wang, KKW			A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; SEPARATION METHOD; MESSENGER-RNA; BREAST-CANCER; PROTEINS; IDENTIFICATION; EXPRESSION; TECHNOLOGIES; PEPTIDES	Differential proteomic analysis has arisen as a large-scale means to discern proteome-wide changes upon treatment, injury, or disease. Tandem protein separation methods are required for large-scale differential proteomic analysis. Here, a novel multidimensional platform for resolving and differentially analyzing complex biological samples is presented. The platform, collectively termed CAX-PAGE/ RPLC-MSMS, combines biphasic ion-exchange chromatography with polyacrylamide gel electrophoresis for protein separation, quantification, and differential band targeting, followed by capillary reversed-phase liquid chromatography and data-dependent tandem mass spectrometry for quantitative and qualitative peptide analysis. CAX-PAGE provides high protein resolving power with a theoretical peak capacity of 3570, extendable to 7600, a wide protein mass range verified from 16 to 273 kDa, and reproducible differential sample comparison without the added expense of fluorescent dyes and imaging equipment. Demonstrated using a neuroproteomic model, CAX-PAGE revealed an increased number of differential proteins, 137, compared with 82 found by 2D difference gel electrophoresis. When combined with RPLC-MSMS for protein identification, an additional quantification step is performed for internal validation, confirming a 2-fold or greater change in 89% of identified differential targets.	Univ Florida, Ctr Neuroproteom & Biomarker Res, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; Univ Florida, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA	Ottens, AK (corresponding author), Univ Florida, Ctr Neuroproteom & Biomarker Res, Gainesville, FL 32610 USA.	aottens@mbi.ufl.edu	Ottens, Andrew/K-3352-2012; Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473			Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ahmed N, 2005, J CHROMATOGR B, V815, P39, DOI 10.1016/j.jchromb.2004.10.070; Alban A, 2003, PROTEOMICS, V3, P36, DOI 10.1002/pmic.200390006; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; BERGH GVD, 2003, ELECTROPHORESIS, V24, P1471; Chong BE, 2001, RAPID COMMUN MASS SP, V15, P291, DOI 10.1002/rcm.227; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; ELRASSI Z, 1986, J CHROMATOGR, V359, P255, DOI 10.1016/0021-9673(86)80079-6; Feng BB, 2001, RAPID COMMUN MASS SP, V15, P821, DOI 10.1002/rcm.276; Figeys D, 2003, ANAL CHEM, V75, P2891, DOI 10.1021/ac030142m; Fountoulakis M, 2004, MASS SPECTROM REV, V23, P231, DOI 10.1002/mas.10075; Fountoulakis M, 2001, AMINO ACIDS, V21, P363, DOI 10.1007/s007260170002; Freeman WM, 2004, NEUROCHEM RES, V29, P1065, DOI 10.1023/B:NERE.0000023594.21352.17; Gade D, 2003, J MOL MICROB BIOTECH, V5, P240, DOI 10.1159/000071076; GIDDINGS JC, 1991, UNIFIED SEPARATION S, P112; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Griffin TJ, 2001, J BIOL CHEM, V276, P45497, DOI 10.1074/jbc.R100014200; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hamler RL, 2004, PROTEOMICS, V4, P562, DOI 10.1002/pmic.200300606; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Haskins WE, 2001, ANAL CHEM, V73, P5005, DOI 10.1021/ac010774d; Hennessy TP, 2005, J CHROMATOGR B, V817, P127, DOI 10.1016/j.jchromb.2004.10.043; Herr AE, 2003, ANAL CHEM, V75, P1180, DOI 10.1021/ac026239a; Hoffmann P, 2001, PROTEOMICS, V1, P807, DOI 10.1002/1615-9861(200107)1:7<807::AID-PROT807>3.3.CO;2-Y; Hu S, 2004, ANAL CHEM, V76, P4044, DOI 10.1021/ac0498314; Issaq HJ, 2002, ELECTROPHORESIS, V23, P3048, DOI 10.1002/1522-2683(200209)23:17<3048::AID-ELPS3048>3.0.CO;2-L; Janini GM, 2003, J CHROMATOGR B, V787, P43, DOI 10.1016/S1570-0232(02)00616-5; Kim SI, 2004, NEUROCHEM RES, V29, P1317, DOI 10.1023/B:NERE.0000023618.35579.7c; Krapfenbauer K, 2003, ELECTROPHORESIS, V24, P1847, DOI 10.1002/elps.200305401; Krishnan Srinivasan, 2001, P575; LARMANN JP, 1993, ELECTROPHORESIS, V14, P439, DOI 10.1002/elps.1150140169; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Lubman DM, 2002, J CHROMATOGR B, V782, P183, DOI 10.1016/S1570-0232(02)00551-2; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; Meng FY, 2004, ANAL CHEM, V76, P2852, DOI 10.1021/ac0354903; Moritz RL, 2004, ANAL CHEM, V76, P4811, DOI 10.1021/ac049717l; Morrison RS, 2002, MOL CELL PROTEOMICS, V1, P553, DOI 10.1074/mcp.R200004-MCP200; Nishihara JC, 2002, ELECTROPHORESIS, V23, P2203, DOI 10.1002/1522-2683(200207)23:14<2203::AID-ELPS2203>3.0.CO;2-H; Opiteck GJ, 1998, ANAL BIOCHEM, V258, P349, DOI 10.1006/abio.1998.2588; Patton WF, 2002, J CHROMATOGR B, V771, P3, DOI 10.1016/S1570-0232(02)00043-0; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Rabilloud T, 2000, ANAL CHEM, V72, p48A, DOI 10.1021/ac002709u; REGNIER FE, 1987, SCIENCE, V238, P319, DOI 10.1126/science.3310233; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Shaw J, 2003, PROTEOMICS, V3, P1181, DOI 10.1002/pmic.200300439; Skold K, 2002, PROTEOMICS, V2, P447, DOI 10.1002/1615-9861(200204)2:4<447::AID-PROT447>3.0.CO;2-A; Steel LF, 2005, J CHROMATOGR B, V815, P275, DOI 10.1016/j.jchromb.2004.10.072; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tonge R, 2001, PROTEOMICS, V1, P377; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Voss T, 2000, ELECTROPHORESIS, V21, P3345, DOI 10.1002/1522-2683(20001001)21:16<3345::AID-ELPS3345>3.0.CO;2-Z; Wall DB, 2000, ANAL CHEM, V72, P1099, DOI 10.1021/ac991332t; Wang HX, 2004, PROTEOMICS, V4, P2476, DOI 10.1002/pmic.200300763; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wells DA, 2003, LC GC N AM, V21, P522; Zhang ZL, 2001, PROTEOMICS, V1, P1001, DOI 10.1002/1615-9861(200108)1:8<1001::AID-PROT1001>3.3.CO;2-8; Zheng SP, 2003, BIOTECHNIQUES, V35, P1202, DOI 10.2144/03356rr02; ZHU BY, 1992, J CHROMATOGR, V594, P75, DOI 10.1016/0021-9673(92)80314-K; Zhu K, 2004, J CHROMATOGR A, V1053, P133, DOI 10.1016/j.chroma.2004.08.080	67	43	47	0	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	AUG 1	2005	77	15					4836	4845		10.1021/ac050478r			10	Chemistry, Analytical	Chemistry	951HQ	WOS:000230920600030	16053296				2021-06-18	
J	Vlodavsky, E; Palzur, E; Feinsod, M; Soustiel, JF				Vlodavsky, E; Palzur, E; Feinsod, M; Soustiel, JF			Evaluation of the apoptosis-related proteins of the BCL-2 family in the traumatic penumbra area of the rat model of cerebral contusion, treated by hyperbaric oxygen therapy: a quantitative immunohistochemical study	ACTA NEUROPATHOLOGICA			English	Article						apoptosis; Bcl-2; hyperbaric oxygen; traumatic brain injury	BRAIN-INJURY; CELL-DEATH; NEURONAL DEATH; HEAD-INJURY; MECHANISMS; ISCHEMIA; BAX; EXPRESSION; PATHWAYS	The growth and progression of traumatic brain injury (TBI) lesions depend significantly on developments in the traumatic penumbra area, perilesional region, where delayed neuronal death occurs. Recent data supports the important role of apoptosis in delayed cell death in TBI. Previously we demonstrated a significant reduction of apoptosis in traumatic penumbra in animals treated by hyperbaric oxygen (HBO). In this study we evaluate the expression of apoptosis-related proteins of the Bcl-2 family (Bcl-2, Bax and Bcl-xL) in the traumatic penumbra area in correlation with the extent of apoptosis in the rat model of focal cerebral contusion, treated by HBO. Sprague-Dawley rats underwent cortical dynamic deformation, some with subsequent hypoxemia. A group of both hypoxemic and non-hypoxemic animals was treated by HBO. The pathological study was based on immunohistochemical staining of the brain sections for Bcl-2, Bax and Bcl-xL with quantitative evaluation of staining by image analysis. The expression of Bcl-2 in hypoxemic animals was lower than in non-hypoxemic animals, but a significant increase in Bcl-2 expression was seen in both groups after HBO treatment. Bcl-xL also demonstrated an increase after HBO treatment but less significant. Staining for Bax protein did not demonstrate significant change after treatment. These data correlate well with the reduction of TUNEL-positive cells in traumatic penumbra after HBO treatment. We concluded that the apoptotic mechanisms are important in delayed cell death in TBI and that post-traumatic hypoxemia increases the intensity of apoptosis, probably through a decrease in Bcl-2 and BclxL expression which normally repress apoptosis. The beneficial effect of HBO treatment in our model of brain contusion correlates well with the increased expression of anti-apoptotic proteins (Bcl-2 and Bcl-xL) following treatment and the appropriate decrease in the extent of apoptosis. In light of these results, the usage of HBO is justified as neuroprotective treament in TBI.	Rambam Med Ctr, Inst Pathol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Neurosurg, Haifa, Israel; Rambam Med Ctr, Acute Brain Res Lab, Haifa, Israel	Vlodavsky, E (corresponding author), Rambam Med Ctr, Inst Pathol, POB 9602, IL-31096 Haifa, Israel.	vlodavsky@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Barth M, 2000, ACTA NEUROCHIR SUPPL, V76, P121; Chen L, 2000, Fa Yi Xue Za Zhi, V16, P211; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Cregan SP, 1999, J NEUROSCI, V19, P7860; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kondo A, 1996, NEUROPATH APPL NEURO, V22, P350, DOI 10.1111/j.1365-2990.1996.tb01114.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Luo Chun, 2002, Chin J Traumatol, V5, P299; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Wada S, 2000, MAR BIOTECHNOL, V2, P285, DOI 10.1007/s101260000006; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55	25	43	59	0	4	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	AUG	2005	110	2					120	126		10.1007/s00401-004-0946-8			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	956VG	WOS:000231327400003	16001273				2021-06-18	
J	Guyton, MK; Wingrave, JM; Yallapragada, AV; Wilford, GG; Sribnick, EA; Matzelle, DD; Tyor, WR; Ray, SK; Banik, NL				Guyton, MK; Wingrave, JM; Yallapragada, AV; Wilford, GG; Sribnick, EA; Matzelle, DD; Tyor, WR; Ray, SK; Banik, NL			Upregulation of calpain correlates with increased neuro degeneration in acute experimental auto-immune encephalomyelitis	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						EAE; MS; calpain; Ca2+ influx; neurodegeneration	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; OPTIC NEURITIS; AXONAL-INJURY; PUTATIVE ROLE; INFLAMMATORY CELLS; NERVOUS-SYSTEM; CROSS-TALK	Although calpain up-regulation is well established in experimental auto-immune encephalomyelitis (EAE); a link between increased calpain expression and activity and neurodegeneration has not been examined. Therefore, spinal cord tissue from Lewis rats with EAE was examined to test the hypothesis that increased calpain expression in neurons would correlate with increased cell death and axonal damage in a time-dependent manner following EAE induction. We found that increased calpain expression in EAE corresponded to increased TUNEL-positive neurons and to increased expression of dephosphorylated neurofilament protein, markers of cell death and axonal degeneration, respectively. An increase in internucleosomal DNA fragmentation in EAE spinal cord suggested that cell death was, at least partially, due to apoptosis. Axonal damage was further demonstrated in EAE spinal cord compared with control via morphological analysis, revealing granular degeneration of filament and microtubule integrity, loss of myelin, and mitochondrial damage. Calcium (Ca2+) influx, which is required for calpain activation, was also increased in EAE spinal cord. From these findings, we conclude that increases in Ca2+-induced calpain activity may play a crucial role in neurodegeneration in acute EAE. (c) 2005 Wiley-Liss, Inc.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 96 Jonathan Lucus St, Charleston, SC 29425 USA.	baniknl@musc.edu	Sribnick, Eric/AAH-6693-2020				Ahmed Z, 2001, AM J PATHOL, V158, P2127, DOI 10.1016/S0002-9440(10)64684-6; Alcazar A, 1998, NEUROSCI LETT, V255, P75, DOI 10.1016/S0304-3940(98)00708-3; Banik N L, 1984, Prog Clin Biol Res, V146, P145; Banik NL, 2000, NEUROCHEM RES, V25, P1509, DOI 10.1023/A:1007684311023; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Banik NL, 1999, HISTOL HISTOPATHOL, V14, P649, DOI 10.14670/HH-14.649; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; CHAKRABARTI AK, 1989, NEUROCHEM RES, V14, P259, DOI 10.1007/BF00971321; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Craner MJ, 2004, BRAIN, V127, P294, DOI 10.1093/brain/awh032; Gold R, 2000, MOL MED TODAY, V6, P88, DOI 10.1016/S1357-4310(99)01639-1; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; GUYTON K, 2002, 33 ANN AM SOC NEUR M; Keegan BM, 2002, ANNU REV MED, V53, P285, DOI 10.1146/annurev.med.53.082901.103909; Kornek B, 2001, BRAIN, V124, P1114, DOI 10.1093/brain/124.6.1114; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; MATTSON MP, 1993, ANN NY ACAD SCI, V679, P1, DOI 10.1111/j.1749-6632.1993.tb18285.x; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meyer R, 2001, J NEUROSCI, V21, P6214; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; OGITA K, 1990, ADV SEC MESS PHOSPH, V24, P218; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Paschen W, 2000, BRAIN RES BULL, V53, P409, DOI 10.1016/S0361-9230(00)00369-5; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Piccoli F, 1979, Riv Neurol, V49, P253; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Ray SK, 2000, BRAIN RES PROTOC, V5, P305, DOI 10.1016/S1385-299X(00)00027-1; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schaecher K, 2002, J NEUROIMMUNOL, V129, P1, DOI 10.1016/S0165-5728(02)00142-X; Shields DC, 1998, EXP EYE RES, V67, P403, DOI 10.1006/exer.1998.0537; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shields DC, 1998, P NATL ACAD SCI USA, V95, P5768, DOI 10.1073/pnas.95.10.5768; Shields DC, 1999, J NEUROIMMUNOL, V99, P1, DOI 10.1016/S0165-5728(99)00043-0; Shields DC, 1998, BRAIN RES, V784, P299, DOI 10.1016/S0006-8993(97)01381-4; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Takuma H, 1999, ANN NEUROL, V46, P806, DOI 10.1002/1531-8249(199912)46:6<806::AID-ANA2>3.0.CO;2-S; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	56	43	45	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL 1	2005	81	1					53	61		10.1002/jnr.20470			9	Neurosciences	Neurosciences & Neurology	941LS	WOS:000230216900007	15952172				2021-06-18	
J	Urban, RJ; Harris, P; Masel, B				Urban, RJ; Harris, P; Masel, B			Anterior hypopituitarism following traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; head trauma; hypopituitarism; growth hormone deficiency	NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; POSTTRAUMATIC HYPOPITUITARISM; PITUITARY APOPLEXY; GH; INSUFFICIENCY; REPLACEMENT; DIAGNOSIS; SECONDARY; ANEURYSM	Primary objectives. To review evidence that there exists a substantial sub-population of patients with endocrine disorders as a result of traumatic brain injury (TBI) and to underscore the importance of screening patients with TBI considered most at risk for hypopituitarism with the goal of attaining beneficial effects in terms of morbidity and quality of life. Design and methods. Reviewed recent literature regarding the frequency of TBI-induced hypopituitarism. Main outcomes and results. Studies by Kelly DF, Gaw Gonzalo IT, Cohan P, et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: A preliminary report. Journal of Neurosurgery 2000; 93: 743-751, Lieberman SA, Oberoi AL, Gilkison CR, et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. Journal of Clinical Endocrinology and Metabolism 2001; 86: 2752-2756 and Aimaretti G, Ambrosio MR, Di Somma C, et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism. Screening study at 3 months after the brain injury, In press., found that about one-half to one-third of patients with TBI had anterior pituitary hormone deficiencies, including growth hormone (GH) deficiency in 15-21%, and subtle deficiencies in thyroid, adrenal and gonadal axes. One or more hormonal deficiencies produce diverse physical and psychological symptoms that may mimic symptoms attributed to brain trauma and may impair rehabilitation. A more general concern is the fact that hypopituitarism increases the risk of significant morbidity (e.g. ischaemic heart disease) and mortality (shortened life span). Conclusions. To attain maximal improvement in mental and physical functioning as well as in quality of life for victims of TBI, it is crucial that anterior pituitary hormonal function be assessed. Appropriate hormone replacement therapy for those patients with both TBI and TBI-induced pituitary function impairment could, for the first time, allow treatment and correction of underlying causes of TBI sequelae rather than merely symptomatic treatment.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77550 USA; Pfizer Ltd, Sandwich Labs, Clin Dev, Sandwich CT13 9NJ, Kent, England	Masel, B (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.	bmasel@tlc-galveston.org					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; AIMARETTI G, IN PRES TRAUMATIC BR; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; ARGYROPOULOU M, 1992, J PEDIATR-US, V120, P886, DOI 10.1016/S0022-3476(05)81955-9; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Barbeau C, 1998, ARCH PEDIATRIE, V5, P274, DOI 10.1016/S0929-693X(97)89368-2; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bontha S, 2000, ENDOCRINOLOGIST, V10, P277, DOI 10.1097/00019616-200010040-00010; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; *CDCP NAT CTR INJ, 2002, TRAUM BRAIN INJ FACT; Ceballos R, 1966, Ala J Med Sci, V3, P185; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANGELICA M, 1995, J TRAUMA, V39, P768, DOI 10.1097/00005373-199510000-00031; DANIEL PM, 1959, LANCET, V2, P927; EDWARDS OM, 1986, MEDICINE, V65, P281; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; Fellner F, 1998, Rontgenpraxis, V51, P243; FERNANDEZREAL JM, 1994, CLIN INVESTIGATOR, V72, P302; FUJITA K, 1992, EUR J PEDIATR, V151, P266, DOI 10.1007/BF02072226; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; GUPTA N, 2000, NEUROREVIEW; Hernandez A, 1998, EUR J NEUROL, V5, P499, DOI 10.1046/j.1468-1331.1998.550499.x; Hernberg-Stahl E, 2001, J CLIN ENDOCR METAB, V86, P5277, DOI 10.1210/jc.86.11.5277; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KLEIN MJ, 2002, EMED J          0415; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kusanagi Hiroaki, 2000, Journal of Nippon Medical School, V67, P130, DOI 10.1272/jnms.67.130; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDENBERG R, 1973, MEDICOLEGAL INVESTIG, P420; Mitchell A, 1997, Crit Care Nurse, V17, P34; MITCHELL A, 1997, CRITICAL CARE NURSE, V17, P53; MITCHELL A, 1997, CRITICAL CARE NURSE, V17, P46; MITCHELL A, 1997, CRITICAL CARE NURSE, V17, P40; Newman CB, 1998, ENDOCRINOLOGIST, V8, P178, DOI 10.1097/00019616-199805000-00009; OLIVER RM, 1991, BRIT J CLIN PRACT, V45, P150; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; SOULES MR, 1979, SOUTHERN MED J, V72, P1592, DOI 10.1097/00007611-197912000-00029; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Wettstein M, 1996, Conn Med, V60, P583; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	48	43	50	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2005	19	5					349	358		10.1080/02699050400004807			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	932JH	WOS:000229549500005	16094782				2021-06-18	
J	Nilsson, AL; Sunnerhagen, KS; Grimby, G				Nilsson, AL; Sunnerhagen, KS; Grimby, G			Scoring alternatives for FIM in neurological disorders applying Rasch analysis	ACTA NEUROLOGICA SCANDINAVICA			English	Article						stroke; traumatic brain injury; spinal cord injury; ordinal scale; latent trait analysis; Functional Independence Measure; Scandinavia	FUNCTIONAL INDEPENDENCE MEASURE; CROSS-CULTURAL VALIDITY; REHABILITATION; DISABILITY; STROKE; IMPAIRMENT; SCALES; MODEL	Objective - The Functional Independence Measure (FIMTM) is an internationally widely used outcome measure. The aim of this study was to evaluate the structural properties of FIMTM using the Rasch model, with regard to scoring within rehabilitation centres in Scandinavia. Materials and methods - FIMTM data from 1660 patients with stroke, traumatic brain injury and spinal cord injury were analysed. The best models with respect to person separation were determined, together with person reliability, item separation, disordered categories, distance of more than 1.4 logits between categories and item fit to the model. Results - Analysis showed disordering using seven categories in all three diagnoses. After collapsing of categories a four-category scale was the best solution. Conclusions - Decreasing the categories from seven to four may be one way of dealing with problems of disordered thresholds. Further studies are also needed in order to try the suggested scale in clinical settings and to compare it with the original FIMTM scale.	Gothenburg Univ, Inst Clin Neuro Sci, Gothenburg, Sweden	Nilsson, AL (corresponding author), Sahlgrens Univ Hosp, Inst Clin Neuro Sci, Guldhedsgatan 19, S-41345 Gothenburg, Sweden.	asa.lundgren-nilsson@rehab.gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020; Grimby, Gunnar/AAB-3178-2019	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400; 			Andrich D, 1988, RASCH MODELS MEASURE; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504; Claesson L, 2001, J REHABIL MED, V33, P137; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Deutsch A, 1996, CRIT REV PHYS REHABI, V8, P267; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; FISHER AG, 1992, AM J OCCUP THER, V46, P183, DOI 10.5014/ajot.46.2.183; FISHER AG, 1992, AM J OCCUP THER, V46, P278, DOI 10.5014/ajot.46.3.278; FISHER WP, 1993, AM J OCCUP THER, V47, P331, DOI 10.5014/ajot.47.4.331; Gosman-Hedstrom G, 2000, DISABIL REHABIL, V22, P702, DOI 10.1080/09638280050191972; Gosman-Hedstrom G, 2004, DISABIL REHABIL, V26, P410, DOI 10.1080/09638280410001662978; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Grimby G, 1996, ARCH PHYS MED REHAB, V77, P1109, DOI 10.1016/S0003-9993(96)90131-8; Haigh R, 2001, J REHABIL MED, V33, P273; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 2001, 1 WORLD C INT SOC PH; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kucukdeveci AA, 2001, CLIN REHABIL, V15, P311, DOI 10.1191/026921501676877265; Linacre J M, 1999, J Outcome Meas, V3, P103; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Linacre JM., 1995, RASCH MEAS T, V9, P450; LINACRE JM, 2002, WINSTEPS COMPUTER PR; Lundgren-Nilsson A, 2005, J REHABIL MED, V37, P23, DOI 10.1080/16501970410032696; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; Rasch G., 1980, PROBABILISTIC MODELS; Stone MH., 1979, BEST TEST DESIGN; Svensson E, 2001, J REHABIL MED, V33, P47, DOI 10.1080/165019701300006542; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Wright B, 1992, RASCH MEASUREMENT T, V6, P233; Wright B.D., 1982, RATING SCALE ANAL; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; Wright BD., 1994, RASCH MEASUREMENT T, V8, P370, DOI DOI 10.1177/01461672012710004	35	43	44	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	APR	2005	111	4					264	273		10.1111/j.1600-0404.2005.00404.x			10	Clinical Neurology	Neurosciences & Neurology	902HT	WOS:000227346200010	15740579				2021-06-18	
J	Hopkins, RO; Tate, DF; Bigler, ED				Hopkins, RO; Tate, DF; Bigler, ED			Anoxic versus traumatic brain injury: Amount of tissue loss, not etiology, alters cognitive and emotional function	NEUROPSYCHOLOGY			English	Article						anoxic brain injury (ABI); traumatic brain injury (TBI); brain imaging; cognitive function	DIFFUSE AXONAL INJURY; TEMPORAL-LOBE; HEAD-INJURY; MEMORY; VOLUME; DAMAGE; MR; PERFORMANCE; APOPTOSIS; ISCHEMIA	Research in neuropsychology suggests that the etiology of a neurologic injury determines the neuropathological and neuropsychological changes. This study compared neuropsychological outcome in subjects who had traumatic brain injury (TBI) with subjects who had anoxic brain injury (ABI), who were matched for age, gender, and ventricle-to-brain ratio. There were no group differences for morphologic or neuropsychological measures. Both groups exhibited impaired memory, attention, and executive function, as well as slowed mental processing speed. Intelligence Correlated with whole brain volume, and measures of memory correlated with hippocampal atrophy. There was no unique contribution of hippocampal atrophy on neuropsychological outcome between the groups. In the absence of localized lesions, the amount of neural tissue loss, rather than etiology, may be the critical factor in neuropsychological outcome.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Utah, Salt Lake City, UT 84112 USA	Hopkins, RO (corresponding author), Brigham Young Univ, Dept Psychol, 1122 Spence W Kimball Tower, Provo, UT 84602 USA.	mona_hopkins@byu.edu	Tate, David/G-5166-2011	Tate, David/0000-0003-0213-1920			Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BANDAK FA, 1996, TRAUMATIC BRAIN INJU; BARAT M, 1989, Annales de Readaptation et de Medecine Physique, V32, P657; Beck A.T., 1993; Beck A.T., 1987, BECK DEPRESSION INVE; Biagas Katherine, 1999, Current Opinion in Pediatrics, V11, P223, DOI 10.1097/00008480-199906000-00009; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P383, DOI 10.1016/0887-6177(88)90052-2; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2003, AM J NEURORADIOL, V24, P2066; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIGLER ED, IN PRESS NEUROREHABI; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Clarke E., 1996, ILLUSTRATED HIST BRA; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conti AC, 1998, J NEUROSCI, V18, P5663; Crawford JR, 2003, J INT NEUROPSYCH SOC, V9, P989, DOI 10.1017/S1355617703970032; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; Finger S., 1994, ORIGINS NEUROSCIENCE; FLOYD RA, 1990, FASEB J, V4, P2587; Gale SD, 1999, BRAIN INJURY, V13, P229, DOI 10.1080/026990599121601; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gale SD, 2004, J INT NEUROPSYCH SOC, V10, P60; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GRAFMAN J, 1986, J NEUROSCI, V6, P301; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2, P823; GROSS CG, 1964, FRONTAL GRANULAR COR, P74; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Hay PJ, 2002, J PSYCHOSOM RES, V53, P699, DOI 10.1016/S0022-3999(02)00424-5; HELFFENSTEIN D, 2000, CARBVON MONOXIDE TOX, P439; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN PAM, 2002, NEUROPSYCHIATRY CLIN, V14, P176; Hopkins R O, 1995, J Int Neuropsychol Soc, V1, P501; HOPKINS RO, TXB CLIN NEUROPSYCHO; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; IRLE E, 1987, BRAIN RES REV, V12, P307, DOI 10.1016/0165-0173(87)90003-8; Ives B, 2003, J LEARN DISABIL-US, V36, P490, DOI 10.1177/00222194030360060101; Johnson R.A., 2002, APPL MULTIVARIATE ST; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KASS IS, 1986, J PHYSIOL-LONDON, V378, P313, DOI 10.1113/jphysiol.1986.sp016221; Kesner RP, 2001, NEUROPSYCHOLOGY, V15, P58, DOI 10.1037/0894-4105.15.1.58; LASHLEY K, 1950, SOC EXPT BIOL S NO R, P478; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; LEZAK MD, 1995, NEUROPSYCHOLOGICALA; LURIA AR, 1966, HIGHERS CORTICAL FUN; LUTZ PL, 1994, BRAIN WITHOUT OXYGEN; Manns JR, 2003, NEURON, V38, P127, DOI 10.1016/S0896-6273(03)00146-6; Manns JR, 2003, NEURON, V37, P171, DOI 10.1016/S0896-6273(02)01147-9; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MIN SK, 1986, ACTA PSYCHIAT SCAND, V73, P80, DOI 10.1111/j.1600-0447.1986.tb02671.x; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; PARKER RS, 1990, TAUMATIC BRAIN INJUR; PARKIN AJ, 1987, CORTEX, V23, P655, DOI 10.1016/S0010-9452(87)80055-2; Raz N, 2003, BEHAV NEUROSCI, V117, P1169, DOI 10.1037/0735-7044.117.6.1169; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Reynolds CR, 1999, ARCH CLIN NEUROPSYCH, V14, P235, DOI 10.1016/S0887-6177(98)00018-3; ROBB R, 1995, ANALYZE 3 DIMENSIONA; Rosen AC, 2003, BEHAV NEUROSCI, V117, P1150, DOI 10.1037/0735-7044.117.6.1150; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; SCHURR A, 1992, HIPPOCAMPUS, V2, P221, DOI 10.1002/hipo.450020303; SIESJO BK, 1989, ANN NY ACAD SCI, V568, P234; Smith A., 1981, HDB CLIN NEUROPSYCHO, P175; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Spreen O, 1998, COMPRENDIUM NEUROPSY; Stevens J., 1996, APPL MULTIVARIATE ST; SWIERCINSKY DP, 1977, J CONSULT CLIN PSYCH, V45, P808, DOI 10.1037/0022-006X.45.5.808; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VICK NA, 1949, GRINKLERS NEUROLOGY; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767	82	43	43	0	6	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2005	19	2					233	242		10.1037/0894-4105.19.2.233			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	906DE	WOS:000227619900010	15769207				2021-06-18	
J	Himanen, L; Portin, R; Isoniemi, H; Helenius, H; Kurki, T; Tenovuo, O				Himanen, L; Portin, R; Isoniemi, H; Helenius, H; Kurki, T; Tenovuo, O			Cognitive functions in relation to MRI findings 30 years after traumatic brain injury	BRAIN INJURY			English	Article							ALZHEIMERS-DISEASE; TEMPORAL-LOBE; HIPPOCAMPAL VOLUMES; FRONTAL-LOBE; MEMORY SCALE; HEAD-INJURY; PERFORMANCE; RISK; DIAGNOSIS; EDUCATION	Objective: The aim of the study was to relate cognitive effects of a remote traumatic brain injury (TBI) to MRI findings and severity of injury. Method: Sixty-one patients were assessed on average 30 years after a TBI of variable severity. A comprehensive cognitive test battery was used to evaluate memory, executive functions and cognitive overall impairment. Multiple regression analyses were used to examine the relationships between cognitive variables and MRI volumetric findings (the volumes of the hippocampus and the lateral ventricles) and local contusions on MRI. Also, the effect of injury severity on cognitive outcome was evaluated. Results: Reductions in hippocampal volumes and lateral ventricular enlargement were significantly associated with impaired memory functions, memory complaints and executive functions. Of the MRI parameters used, the best predictor for cognitive outcome was the volume of the lateral ventricle. There was only a modest relationship between severity of injury and cognitive performance, Conclusions: The results show that long-term memory impairments after TBI are associated with MRI volumetric measures. This suggests that the degree of diffuse injury leading to atrophic changes is prognostically more important than the initial severity of TBI.	Turku Univ, Cent Hosp, Dept Neurol, FIN-20521 Turku, Finland; Turku Univ, Dept Biostat, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Radiol, FIN-20521 Turku, Finland	Himanen, L (corresponding author), Turku Univ, Cent Hosp, Dept Neurol, PL 52, FIN-20521 Turku, Finland.	ls.himanen@kolumbus.fi		Himanen, Leena/0000-0001-7261-8027; Kurki, Timo/0000-0001-5532-3534			Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BENTON AL, 1963, REVISED VISUAL RETEN; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Coffey CE, 2001, J NEUROPSYCH CLIN N, V13, P471, DOI 10.1176/appi.neuropsych.13.4.471; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Hackert VH, 2002, NEUROIMAGE, V17, P1365, DOI 10.1006/nimg.2002.1248; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; ICHISE M, 1994, J NUCL MED, V35, P217; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LAAKSO MP, 1995, J NEURAL TRANSM-PARK, V9, P73, DOI 10.1007/BF02252964; Laakso MP, 1996, NEUROLOGY, V46, P678, DOI 10.1212/WNL.46.3.678; LEHTOVIRTA M, 1995, NEUROSCIENCE, V67, P65, DOI 10.1016/0306-4522(95)00014-A; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Novack TA, 2000, BRAIN INJURY, V14, P987; Pihlajamaki M, 2000, ANN NEUROL, V47, P470, DOI 10.1002/1531-8249(200004)47:4<470::AID-ANA10>3.3.CO;2-D; PORTIN R, 1995, PSYCHOL MED, V25, P1295, DOI 10.1017/S0033291700033262; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; Reiman EM, 1998, ANN NEUROL, V44, P288, DOI 10.1002/ana.410440226; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Smith RJ, 1998, HUMAN BRAIN FUNCT, P135; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Ylikoski R, 2000, ACTA NEUROL SCAND, V101, P273, DOI 10.1034/j.1600-0404.2000.101004273.x	45	43	45	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					93	100		10.1080/02699050410001720031			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600003	15841753				2021-06-18	
J	Wong, LF; Ralph, GS; Walmsley, LE; Bienemann, AS; Parham, S; Kingsman, SM; Uney, JB; Mazarakis, ND				Wong, LF; Ralph, GS; Walmsley, LE; Bienemann, AS; Parham, S; Kingsman, SM; Uney, JB; Mazarakis, ND			Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus	MOLECULAR THERAPY			English	Article							ISCHEMIC BRAIN-INJURY; INDUCED NEURONAL DEATH; NEUROTROPHIC FACTOR; GENE-TRANSFER; IN-VIVO; TRANSGENE EXPRESSION; NERVOUS-SYSTEM; FLUORO-JADE; VECTOR; CALCIUM	Nutrient deprivation during ischemia leads to severe insult to neurons causing widespread excitotoxic damage in specific brain regions such as the hippocampus. One possible strategy for preventing neurodegeneration is to express therapeutic proteins in the brain to protect against excitotoxicity. We investigated the utility of equine infectious anemia virus (EIAV)-based vectors as genetic tools for delivery of therapeutic proteins in an in vivo excitotoxicity model. The efficacy of these vectors at preventing cellular loss in target brain areas following excitotoxic insult was also assessed. EIAV vectors generated to overexpress the human antiapoptotic Bcl-2 or growth factor glial-derived neurotrophic factor (GDNF) genes protected against glutamate-induced toxicity in cultured hippocampal neurons. In an in vivo excitotoxicity model, adult Wistar rats received a unilateral dose of the glutamate receptor agonist N-methyl-D-aspartate to the hippocampus that induced a large lesion in the CA1 region. Neuronal loss could not be protected by prior transduction of a control vector expressing beta-galactosidase. In contrast, EIAV-mediated expression of Bcl-2 and GDNF significantly reduced lesion size thus protecting the hippocampus from excitotoxic damage. These results demonstrate that EIAV vectors can be effectively used to deliver putative neuroprotective genes to target brain areas and prevent cellular loss in the event of a neurological insult. Therefore these lentiviral vectors provide potential therapeutic tools for use in cases of acute neurotrauma such as cerebral ischemia.	Oxford BioMed UK Ltd, Medawar Ctr, Oxford OX4 4GA, England; Univ Bristol, Henry Wellcome Labs Integrated Neurosci & Endocri, Bristol BS1 3NY, Avon, England	Wong, LF (corresponding author), Oxford BioMed UK Ltd, Medawar Ctr, Robert Robinson Ave,Oxford Sci Pk, Oxford OX4 4GA, England.	l.wong@oxfordbiomedica.co.uk			Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [GTH12528] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [069280] Funding Source: Medline		Azzouz M, 2002, J NEUROSCI, V22, P10302; Bienemann AS, 2003, MOL THER, V7, P588, DOI 10.1016/S1525-0016(03)00069-8; Bonde C, 2000, NEUROREPORT, V11, P4069, DOI 10.1097/00001756-200012180-00032; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Hermann DM, 2001, NEUROBIOL DIS, V8, P964, DOI 10.1006/nbdi.2001.0448; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kitagawa H, 1999, J CEREBR BLOOD F MET, V19, P1336, DOI 10.1097/00004647-199912000-00007; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lawrence MS, 1996, J NEUROSCI, V16, P486; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; Martin-Rendon E, 2002, MOL THER, V5, P566, DOI 10.1006/mthe.2002.0576; Mazarakis ND, 2001, HUM MOL GENET, V10, P2109, DOI 10.1093/hmg/10.19.2109; McMenamin MM, 1998, GENE THER, V5, P594, DOI 10.1038/sj.gt.3300639; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; MONAGHAN DT, 1983, NATURE, V306, P176, DOI 10.1038/306176a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; Ozawa CR, 2000, P NATL ACAD SCI USA, V97, P9270, DOI 10.1073/pnas.160503997; Perrelet D, 2002, NAT CELL BIOL, V4, P175, DOI 10.1038/ncb751; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Ralph GS, 2004, J CEREBR BLOOD F MET, V24, P245, DOI 10.1097/01.WCB.0000110532.48786.46; Rohll JB, 2002, METHOD ENZYMOL, V346, P466; Sarabi A, 2000, BRAIN RES, V877, P262, DOI 10.1016/S0006-8993(00)02682-2; Sawada H, 2000, J NEUROCHEM, V74, P1175; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHIMAZAKI K, 1994, NEUROSCI RES, V20, P95, DOI 10.1016/0168-0102(94)90026-4; Shimazaki K, 2000, GENE THER, V7, P1244, DOI 10.1038/sj.gt.3301211; Thomas CE, 2001, MOL THER, V3, P36, DOI 10.1006/mthe.2000.0224; Tsai TT, 2000, EXP NEUROL, V166, P266, DOI 10.1006/exnr.2000.7505; Wang Y, 2002, ANN NY ACAD SCI, V962, P423, DOI 10.1111/j.1749-6632.2002.tb04086.x; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; Yang GY, 2001, J CEREBR BLOOD F MET, V21, P722, DOI 10.1097/00004647-200106000-00010; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403	41	43	46	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-0016			MOL THER	Mol. Ther.	JAN	2005	11	1					89	95		10.1016/j.ymthe.2004.08.026			7	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	906BI	WOS:000227615100010	15585409	Other Gold			2021-06-18	
J	Hostetler, SG; Xiang, HY; Smith, GA				Hostetler, SG; Xiang, HY; Smith, GA			Characteristics of ice hockey-related injuries treated in US emergency departments, 2001-2002	PEDIATRICS			English	Article						ice hockey; athletic injuries; National Electronic Injury Surveillance System; United States	SPINAL-INJURIES; FACIAL INJURIES; NECK INJURIES; FACE MASKS; HEAD; JUNIOR; CONCUSSIONS; SPORTS; HELMETS; PLAYERS	Objective. Ice hockey, a popular sport in some regions, has potential for injury due to the velocities of players, pucks, and sticks. Previous studies conducted worldwide have shown that the rate of injury increases as the size and the speed of players increase, as well as when checking is allowed. However, national data about the annual number and types of injuries among ice hockey players are lacking. Data from previous studies were collected from regional tournaments, collegiate teams, local emergency departments (EDs), and different countries. The purpose of this article is to examine ice hockey injuries using a national US database to determine the age distribution of total injuries, injury types, and body regions injured, with a particular focus on ice hockey players <18 years old. Methods. Data regarding ice hockey-related injuries treated in US EDs between January 1, 2001, and December 31, 2002, were extracted from the National Electronic Injury Surveillance System (NEISS). Data considered included age, gender, race, injury diagnosis, and body region injured. Ice hockey-related injury cases were identified using the consumer product code for ice hockey and the narrative description of the incident in NEISS. Results. An estimated 32 750 individuals with ice hockey-related injuries were treated in US EDs in 2001 2002, including >18000 youths <18 years old. The number of injuries peak through adolescence (ages 12-17; 47% of all injuries). Males experienced 90% of all injuries. A very small percentage of individuals were hospitalized after injury (1.2% of individuals <18 years old; 0.5% of individuals greater than or equal to18 years old). The incidence of head injuries increased as age decreased, although the trend was not statistically significant. The upper extremity (44%) accounted for the highest total percentages of body regions injured for youths <18 years old, and trunk (14%) and facial injuries (10%) represented the smallest total percentages. Players >= 18 years old had significantly more lacerations than younger players (38% of injuries for 18- to 24-year-olds; 25% for 25- to 34-year-olds; 50% for 35- to 44-year-olds compared with 19% for 6- to 11-year-olds and 14% for 12- to 17-year-olds). Conclusions. Adolescents had the greatest number of ice hockey-related injuries treated in NEISS hospital EDs in 2001-2002; thus, ongoing efforts to develop injury prevention strategies should focus on this age group. Players <= 17 years old had a lower percentage of lacerations compared with all older players and a higher percentage of upper extremity injuries. The percentage of individuals hospitalized after injury was very low, yet youths <18 years old had twice the percentage of hospitalization after injury compared with individuals greater than or equal to18 years old. Males experienced the vast majority of all ice hockey-related injuries, with females representing a higher percentage of injuries among youths than among adults. Children and adults alike can reap the physical fitness and social benefits from ice hockey, when they are able to avoid predictable and preventable injuries.	Ohio State Univ, Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA	Xiang, HY (corresponding author), Ohio State Univ, Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	xiangh@pediatrics.ohiostate.edu	Xiang, Huiyun/E-4335-2011				Anderson AJ, 2000, PEDIATRICS, V105, P657; Baugh DK, 1998, HEALTH CARE FINANC R, V19, P129; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CASTALDI C R, 1991, Dental Clinics of North America, V35, P647; *CDCP, FACTS AD INJ; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Juhn MS, 2002, CLIN J SPORT MED, V12, P46, DOI 10.1097/00042752-200201000-00014; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Lee MA, 2003, J HEALTH CARE POOR U, V14, P436, DOI 10.1177/1049208903255801; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MCFAULL S, 2001, CHIRPP NEWS, V19, P1; Miller TR, 2000, FUTURE CHILD, V10, P137, DOI 10.2307/1602828; Molsa J, 2000, AM J SPORT MED, V28, P322; Molsa J, 2003, AM J SPORT MED, V31, P751; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MURRAY TM, 1995, PEDIATRICS, V95, P419; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; PASHBY TJ, 1988, INT OPHTHALMOL CLIN, V28, P228, DOI 10.1097/00004397-198802830-00013; Patel Dilip R, 2002, Adolesc Med, V13, P569; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; Reid SR, 1999, PEDIATR EMERG CARE, V15, P310, DOI 10.1097/00006565-199910000-00002; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; SCHWARTZ ML, 1998, OXFORD TXB SPORTS ME, P319; Sim F H, 1978, Am J Sports Med, V6, P378, DOI 10.1177/036354657800600612; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; STUART MJ, PREVENTION ICE HOCKE; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7; Tegner Y, 1991, Br J Sports Med, V25, P87; TOWNER EML, 1994, BRIT MED J, V308, P449, DOI 10.1136/bmj.308.6926.449; US Consumer Product Safety Commission, 2000, NAT EL INJ SURV SYST; *US HOCK INC, 2003, 2002 2003 OFF RUL IC; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596	49	43	44	0	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2004	114	6					E661	E666		10.1542/peds.2004-1565			6	Pediatrics	Pediatrics	875WN	WOS:000225453000052	15574599	Bronze			2021-06-18	
J	McNally, HA; Ben Borgens, R				McNally, HA; Ben Borgens, R			Three-dimensional imaging of living and dying neurons with atomic force microscopy	JOURNAL OF NEUROCYTOLOGY			English	Article							MAMMALIAN SPINAL-CORD; POLYETHYLENE-GLYCOL; GROWTH; REPAIR; MEMBRANES; RECOVERY; INJURY; CELLS	Atomic Force Microscopy (AFM) has been used to image the morphology of developing neurons and their processes. Additionally, AFM can physically interact with the cell under investigation in numerous ways. Here we use the AFM to both three-dimensionally image the neuron and to inflict a nano/micro-puncture to its membrane. Thus, the same instrument used as a tool to precisely penetrate/cut the membrane at the nanoscale level is employed to image the morphological responses to damage. These first high resolution AFM images of living chick dorsal root ganglion cells and cells of sympathetic ganglion and their growing processes provide confirmation of familiar morphologies. The increased resolution of the AFM revealed these structures to be significantly more complex and variable than anticipated. Moreover we describe novel, dynamic, and unreported architectures, particularly large dorsally projecting ridges, spines, and ribbons of cytoplasm that appear and disappear on the order of minutes. In addition, minute (ca. 100 nm) hair-like extensions of membrane along the walls of nerve processes that also shift in shape and density, appearing and disappearing over periods of minutes were seen. We also provide "real time'' images of the death of the neuron cell body after nano/micro scale damage to its membrane. These somas excreted their degraded cytoplasm, revealed as an enlarging pool beneath and around the cell. Conversely, identical injury, even repeated perforations and nanoslices, to the neurite's membrane do not lead to demise of the process. This experimental study not only provides unreported neurobiology and neurotrauma, but also emphasizes the unique versatility of AFM as an instrument that can ( 1) physically manipulate cells, ( 2) provide precise quantitative measurements of distance, surface area and volume at the nanoscale if required, ( 3) derive physiologically significant data such as membrane pressure and compliance, and ( 4) during the same period of study-provide unexcelled imaging of living samples.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Sch Engn, W Lafayette, IN 47907 USA	McNally, HA (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	mcnallyh@purdue.edu					BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; BORGENS RB, 2003, RESTORING FUNCTION I; Bray D., 1992, CELL MOVEMENTS; Colton RJ, 1997, CURR OPIN CHEM BIOL, V1, P370, DOI 10.1016/S1367-5931(97)80076-2; Defelipe J, 1988, CAJAL CEREBRAL CORTE; DIMITROV DS, 1984, BIOCHIM BIOPHYS ACTA, V779, P437, DOI 10.1016/0304-4157(84)90020-0; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Engel A, 1999, TRENDS CELL BIOL, V9, P77, DOI 10.1016/S0962-8924(98)01415-9; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; Jena BP, 1997, CELL BIOL INT, V21, P683, DOI 10.1006/cbir.1997.0212; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275; Lee T, 2000, J NANOPART RES, V2, P345, DOI 10.1023/A:1010053303142; LEMMON V, 1992, J NEUROSCI, V12, P818; MEYER G, 1988, APPL PHYS LETT, V53, P2400, DOI 10.1063/1.100425; Morris V. J., 1999, ATOMIC FORCE MICROSC; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Ricci D., 2004, GROWTH CONES LIVING, P125; SCHWISTER K, 1985, BIOCHIM BIOPHYS ACTA, V816, P332, DOI 10.1016/0005-2736(85)90501-2; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; SNYDER SR, 1992, ANAL CHEM, V64, pR116; Stoeckli ET, 1996, DEV BIOL, V177, P15, DOI 10.1006/dbio.1996.0141; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.3.CO;2-L; VALE RD, 1992, INTRO MOL NEUROBIOLO, P263; VENTIMIGLIA R, 1998, CULTURING NERVE CELL, P391	29	43	45	0	17	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	MAR	2004	33	2					251	258		10.1023/B:NEUR.0000030700.48612.0b			8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	827DO	WOS:000221879200008	15322383				2021-06-18	
J	Kline, AE; Massucci, JL; Dixon, CE; Zafonte, RD; Bolinger, BD				Kline, AE; Massucci, JL; Dixon, CE; Zafonte, RD; Bolinger, BD			The therapeutic efficacy conferred by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after experimental traumatic brain injury is not mediated by concomitant hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						8-OH-DPAT; controlled cortical impact (CCI); function; learning; memory; Morris water maze (MWM); recovery	BAY X 3702; VESICULAR ACETYLCHOLINE TRANSPORTER; WATER MAZE PERFORMANCE; MODERATE HYPOTHERMIA; COGNITIVE DEFICITS; GLUTAMATE RELEASE; RAT HIPPOCAMPUS; EVOKED RELEASE; IN-VITRO; MODEL	We recently reported that the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8OH-DPAT) attenuated traumatic brain injury (TBI)-induced cognitive deficits and histopathology. However, 8-OH-DPAT also produced mild hypothermia (Hypo), which may have contributed to the benefit. To clarify this issue, we conducted an experiment similar to the previous, but included an 8-OH-DPAT group that was maintained at 37 +/- 0.5degreesC (normothermia; Normo). Isoflurane-anesthetized rats received either a cortical impact (2.7-mm deformation at 4 m/sec) or sham injury and then were randomly assigned to two saline (Sham/Vehicle, n = 5; Injury/Vehicle, n = 10) or three 8-OH-DPAT (Sham/DPAT, n = 5; Injury/DPAT+Normo, n 10; Injury/DPAT+Hypo, n = 10) groups. 8-OH-DPAT (0.5 mg/kg) or a comparable volume of saline was administered intraperitoneally 15 min after cortical impact or sham injury. Core temperatures were taken prior to treatment and every 15 min thereafter for 2 h. Function was assessed by established motor and cognitive tasks on post-operative days 1-5 and 14-20, respectively. Hippocampal CA(1)/CA(3) cell survival and cortical lesion volume were quantified at 4 weeks. Both the Injury/DPAT+Normo and Injury/DPAT+Hypo groups exhibited enhanced cognitive performance (spatial acquisition and retention) and reduced histopathology (CA(3) cell loss and cortical lesion volume) versus the Injury/Vehicle group (P < 0.05), but did not differ from one another despite a rapid (15 min), mild (34.4-34.9degreesC), and transient (similar to1 h) hypothermic effect in the latter. These data confirm that a single systemic administration of 8-OH-DPAT confers neurological protection after TBI, and demonstrate that the beneficial effect is not mediated by concomitant hypothermia. The mechanisms for the protective effects of 8-OH-DPAT after TBI require further inquiry.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.	klineae@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD043851] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS033150] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER		Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Burger R, 2003, J NEUROTRAUM, V20, P543, DOI 10.1089/089771503767168474; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cryan JF, 1999, J PSYCHOPHARMACOL, V13, P278, DOI 10.1177/026988119901300310; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fujii T, 1997, BRAIN RES, V761, P244, DOI 10.1016/S0006-8993(97)00325-9; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HJORTH S, 1985, J NEURAL TRANSM, V61, P131, DOI 10.1007/BF01253058; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koyama T, 1999, NEUROSCI LETT, V265, P33, DOI 10.1016/S0304-3940(99)00200-1; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; MILLAN MJ, 1993, J PHARMACOL EXP THER, V264, P1364; Ohman J, 2001, J NEUROTRAUM, V18, P1313, DOI 10.1089/08977150152725614; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1981, ANNU REV PHARMACOL, V21, P323, DOI 10.1146/annurev.pa.21.040181.001543; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	56	43	45	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					175	185		10.1089/089771504322778631			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200005	15000758				2021-06-18	
J	Macciocchi, SN; Bowman, B; Coker, J; Apple, D; Leslie, D				Macciocchi, SN; Bowman, B; Coker, J; Apple, D; Leslie, D			Effect of co-morbid traumatic brain injury on functional outcome of persons with spinal cord injuries	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spinal cord injury; brain injury; functional outcomes; rehabilitation	CLOSED HEAD-INJURY; COGNITIVE DYSFUNCTION	Objective: This study was undertaken to determine if persons who sustain a spinal cord injury (SCI) and co-morbid brain injury (dual diagnosis [DDS]) evidence smaller functional gains and experience significantly longer rehabilitation lengths of stay than persons with only an SCI. Design: This retrospective comparison study was performed at a 100-bed rehabilitation hospital specializing in acute SCI and traumatic brain injury rehabilitation. Summary scale outcome data of persons who sustained an SCI were compared with outcome data of a group of persons with a DIDS. Comparisons were established by matching groups principally on level of SCI and admission Motor FIM(TM) score and secondarily on education, sex, and age. Outcome measures included admission Motor and Cognitive FIM score, discharge Motor and Cognitive FIM score, Motor and Cognitive FIM change, length of stay, and rehabilitation charges. Results: Persons with a DDS evidenced a significantly more impaired Cognitive FIM score at admission and discharge from rehabilitation. Persons with a DDS also achieved a significantly lower Motor FIM change than persons with SCI. There were no significant differences between DIDS and SCI groups regarding Cognitive FIM change, length of stay, or rehabilitation charges. Injury severity as defined by the Glasgow Coma Scale or intracranial lesions did not predict response to treatment in the DIDS group. Conclusion: Persons with a DIDS achieved smaller functional gains during rehabilitation than peers with SCI. Brain injuries seem to limit functional gains, although the relationship between brain injury severity and functional change is not linear. Prospective studies are needed to identify factors limiting functional gains in rehabilitation and assist in developing specific treatment programs for persons with SCI and brain injury.	Shepherd Ctr, Neuropsychol Div, Atlanta, GA 30309 USA; Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA	Macciocchi, SN (corresponding author), Shepherd Ctr, Neuropsychol Div, 2020 Peachtree Rd,NW, Atlanta, GA 30309 USA.						BLACK K, 1999, TOP SPINAL CORD INJ, V5, P47; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PAGNI CA, 1991, ACTA NEUROCHIR, V111, P1, DOI 10.1007/BF01402506; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0	16	43	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2004	83	1					22	26		10.1097/01.PHM.0000104661.86307.91			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	758FM	WOS:000187623100004	14709971				2021-06-18	
J	Queen, RM; Weinhold, PS; Kirkendall, DT; Yu, B				Queen, RM; Weinhold, PS; Kirkendall, DT; Yu, B			Theoretical study of the effect of ball properties on impact force in soccer heading	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						children; inflation pressure; ball size; mathematical modeling	TRAUMATIC BRAIN-INJURY; PLAYERS; CONCUSSION; PERFORMANCE; PROPORTIONS; STIFFNESS; FOOTBALL; MASS	Purpose: The objective of this study was to theoretically model, based on the Hertz contact theory, the impact force and contact time, as well as the linear and angular head accelerations during heading in children using two neck stiffness conditions (infinite and negligible stiffness). Methods: The following mathematical model inputs were obtained: elastic modulus and mass of size three, four, and five balls at inflation pressures of 10, 12, and 14 psi, head modulus, head mass, head length, head and trunk moment of inertia, and the precontact ball velocity. The model outputs consisted of linear and angular head acceleration, impact force, contact time between the ball and head, and head impact criteria (HIC) all at the point of impact. Head mass and length were obtained as a percentage of body weight and height, respectively, based on age, Results: With an increase in head mass, there is a decrease in the linear and angular head acceleration. With an increase in ball size, for the same head mass, there is an increase in the contact time between the head and the ball. Changing ball inflation pressure has little effect on the impact characteristics. Infinite neck stiffness decreased linear and angular head acceleration and HIC. Conclusion: Head mass and ball size have an effect on linear and angular head acceleration and contact time, respectively, whereas ball inflation pressure has a minimal effect on the impact characteristics. These results indicate that children should be restricted to using the appropriate ball for their age. Smaller head size within an age group is an underemphasized though important identifier of a player's injury risk.	Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Human Movement Sci, Div Phys Therapy, Chapel Hill, NC 27599 USA	Queen, RM (corresponding author), Univ N Carolina, Dept Biomed Engn, CB 7575,152 Macnider Bldg, Chapel Hill, NC 27599 USA.			Weinhold, Paul/0000-0002-7307-3580			ARMSTRONG CW, 1987, SCI FOOTBALL, P394; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; CHOU S, 1974, 740082 SAE, P197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; Ekblom B., 1994, FOOTBALL; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRESZCZUK LB, 1992, IMPACT DYNAMICS, P55; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; JENSEN RK, 1989, J BIOMECH, V22, P529, DOI 10.1016/0021-9290(89)90004-3; JENSEN RK, 1986, J BIOMECH, V19, P359, DOI 10.1016/0021-9290(86)90012-6; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; KHALIL TB, 1993, BIOMECHANICS IMPACT, P1107; LEVENDUSKY TA, 1987, SCI FOOTBALL, P385; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATSER JT, 1999, JAMA-J AM MED ASSOC, V28, P971; MCNAIR PJ, 1992, CLIN BIOMECH, V7, P131, DOI 10.1016/0268-0033(92)90027-2; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; PHEASANT S, 2001, BODYSPACE, P174; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; TIMOSHENKO S, 1951, THEORY ELASTICITY, P372; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WILSON GJ, 1991, INT J SPORTS MED, V12, P403, DOI 10.1055/s-2007-1024702	27	43	44	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2003	35	12					2069	2076		10.1249/01.MSS.0000099081.20125.A5			8	Sport Sciences	Sport Sciences	753QJ	WOS:000187241800018	14652504				2021-06-18	
J	Bruce, JM; Echemendia, RJ				Bruce, JM; Echemendia, RJ			Delayed-onset deficits in verbal encoding strategies among patients with mild traumatic brain injury	NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; SPORTS; ORGANIZATION; MEMORY	Knowledge obtained from longitudinal animal models was used to predict the course of verbal memory deficits in 19 concussed patients and 19 control patients who were given versions of the Hopkins Verbal Learning Test-Revised at 2 hr, 48 hr, and I week postconcussion. The physiological literature suggests that concussed patients should exhibit a decline in performance from 2 hr to 48 hr postconcussion on a measure of complex memory strategies. Consistent with this hypothesis, mixed-factor analysis of covariance revealed that concussed patients used less semantic clustering strategies than control patients at 48 hr postconcussion, whereas minimal differences were found at 2 hr postinjury. Furthermore, a chi-square analysis showed that a significant number of concussed patients experienced a decline in the number of semantic clusters they used from 2 hr to 48 hr. No differences were found between the groups at the 1-week testing session.	Penn State Univ, Coll Liberal Arts, Dept Psychol, University Pk, PA 16802 USA	Bruce, JM (corresponding author), Penn State Univ, Coll Liberal Arts, Dept Psychol, 429 Bruce V Moore Bldg, University Pk, PA 16802 USA.	jmb518@psu.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Delis DC, 1987, CALIFORNIA VERBAL LE; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, V1, P197; Gupta A, 1991, J PERS CLIN STUD, V7, P55; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; Hayes RL, 1989, MILD HEAD INJURY, P54; HODVA DA, 1995, J NEUROTRAUM, V12, P903; Johnson M. K., 1991, PERSPECTIVES COGNITI, P197; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kelly JP, 1997, NEUROLOGY, V48, P581; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; SARTER M, 1994, PSYCHOPHARMACOLOGY, V114, P539, DOI 10.1007/BF02244983; SHUELL TJ, 1969, PSYCHOL BULL, V72, P353, DOI 10.1037/h0028141; STUSS DT, 1987, FRONTAL LOBES REVIS; TRENNERY MR, 1989, STROOP NEUROPSYCHOLO	32	43	43	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2003	17	4					622	629		10.1037/0894-4105.17.4.622			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	740AP	WOS:000186378900009	14599275				2021-06-18	
J	Ivins, BJ; Schwab, KA; Warden, D; Harvey, S; Hoilien, MAJM; Powell, J; Johnson, EW; Salazar, AM				Ivins, BJ; Schwab, KA; Warden, D; Harvey, S; Hoilien, MAJM; Powell, J; Johnson, EW; Salazar, AM			Traumatic brain injury in US army paratroopers: Prevalence and character	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; brain injury; parachuting; US Army	HEAD-INJURY; UNITED-STATES; MILD; EPIDEMIOLOGY; FEATURES	Background: This study presents self-reported traumatic brain injury (TBI) prevalence rates for 2,337 active duty U.S. Army soldiers who underwent baseline testing as part of a larger study of military TBI. Methods: A computerized self-report questionnaire was administered to a convenience sample of 2,337 highly functioning active-duty soldiers at Fort Bragg, North Carolina, who underwent baseline testing during a 13-month period in 1999 and 2000 as part of a larger ongoing Institutional Review Board-approved study examining the consequences of brain injuries among paratroopers. Results: Approximately 23% of all of the soldiers surveyed reported sustaining a TBI after joining the Army. More than twice as many paratroopers reported sustaining TBI after joining the Army than did nonparatroopers (p < 0.001). Parachute-related TBI accounted for this difference. Nearly all of these injuries were mild. Less than 2% of paratroopers and no nonparatroopers reported loss of consciousness lasting more than 20 minutes. It was also shown that paratroopers with a history of TBI before joining the Army had a higher prevalence of TBI while serving in the Army (35%) than paratroopers without prior TBI (27.2%) (p = 0.002). Conclusion: This study demonstrates that parachuting appears to be a risk factor for mild TBI in the U.S. Army and that paratroopers with a history of TBI before joining the Army might be at somewhat increased risk of sustaining additional TBI while serving in the Army.	Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20012 USA; Def & Vet Head Injury Program, Ft Brag, NC USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Joint Special Operat Med Training Ctr, Ft Bragg, NC USA; USA, Aeromed Res Lab, Ft Rucker, AL USA; Landsthul Reg Med Ctr, Psychol Serv, Landsthul, Germany	Ivins, BJ (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, POB 59181, Washington, DC 20012 USA.	brian.ivins@na.amedd.army.mil					Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; Bar-Dayan Y, 1998, MIL MED, V163, P1; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Craig SC, 1997, MIL MED, V162, P162; CROVITZ HF, 1992, CORTEX, V28, P509, DOI 10.1016/S0010-9452(13)80160-8; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; MacKenzie E J, 1989, Md Med J, V38, P725; MCCARROL JE, 1990, ARMY NEUROEPIDEMIOL, V9, P296; MCCARROLL JE, 1989, NEUROEPIDEMIOLOGY, V8, P48, DOI 10.1159/000110165; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ryan L M, 1996, Appl Neuropsychol, V3, P49, DOI 10.1207/s15324826an0302_1; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Warren S, 1995, Alaska Med, V37, P11	25	43	43	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2003	55	4					617	621		10.1097/01.TA.0000052368.97573.D4			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	733GN	WOS:000185991700005	14566111				2021-06-18	
J	Kay, AD; Day, SP; Kerr, M; Nicoll, JAR; Packard, CJ; Caslake, MJ				Kay, AD; Day, SP; Kerr, M; Nicoll, JAR; Packard, CJ; Caslake, MJ			Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						APOE epsilon 4; cerebrospinal fluid; cholesterol; traumatic brain injury	APOLIPOPROTEIN-E POLYMORPHISM; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; HEAD-INJURY; E GENOTYPE; CEREBRAL-ISCHEMIA; HUMAN HIPPOCAMPUS; NEURONAL DAMAGE; GLOBAL-ISCHEMIA; ANIMAL-MODELS	The association between possession of the APOE epsilon4 allele and unfavourable outcome after traumatic brain injury (TBI) suggests that the apolipoprotein E protein (apoE) plays a key role in the response of the human brain to injury. ApoE is known to regulate cholesterol metabolism in the periphery through its action as a ligand for receptor mediated uptake of lipoprotein particles (Lps). Greater understanding of cholesterol metabolism in the human central nervous system may identify novel treatment strategies applicable to acute brain injury. We report findings from the analysis of lipoproteins in the cerebrospinal fluid (CSF) of patients with TBI and non-injured controls, testing the hypothesis that remodeling of CSF lipoproteins reflects the response of the brain to TBI. CSF Lps were isolated from the CSF of controls and patients with severe TBI by size exclusion chromatography, and the lipoprotein fractions analysed for cholesterol, phospholipid, apoAI, and apoE. There was a marked decrease in apoE containing Lps in the TBI CSF compared to controls (P = 0.002). After TBI there was no significant decrease in apoI containing CSF Lps (CSF LpAI), but the apoAI resided on smaller sized particles than in control CSF. There was a population of very small sized Lps in TBI CSF, which were associated with the increased cholesterol (P = 0.0001) and phospholipid (p = 0.040) seen after TBI. The dramatic loss of apoE containing Lps from the CSF, and the substantial increase in CSF cholesterol, support the concept that apoE and cholesterol metabolism are intimately linked in the context of acute brain injury. Treatment strategies targeting CNS lipid transport, required for neuronal sprouting and synaptogenesis, may be applicable to traumatic brain injury.	Univ Glasgow, Dept Neurosurg, Inst Neurol Sci, So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Dept Pathol Biochem, Glasgow, Lanark, Scotland; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Nursing Res, Pittsburgh, PA 15260 USA; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton SO9 5NH, Hants, England	Kay, AD (corresponding author), Univ Glasgow, Dept Neurosurg, Inst Neurol Sci, So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland.		Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246; Day, Stephen/0000-0003-4923-9373			Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; Carlin C, 2000, J NEUROPATH EXP NEUR, V59, P361, DOI 10.1093/jnen/59.5.361; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Demeester N, 2000, J LIPID RES, V41, P963; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X; Guyton JR, 1998, J NEUROCHEM, V70, P1235; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; Koch S, 2001, J LIPID RES, V42, P1143; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McColl BW, 2003, AM J PATHOL, V162, P273, DOI 10.1016/S0002-9440(10)63818-7; Montine KS, 1998, J LIPID RES, V39, P2443; Montine TJ, 1997, AM J PATHOL, V151, P1571; Nicoll JAR, 2001, NEUROREPORT, V12, P695, DOI 10.1097/00001756-200103260-00016; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Starck M, 2000, CELL BIOCHEM FUNCT, V18, P9, DOI 10.1002/(SICI)1099-0844(200001/03)18:1<9::AID-CBF841>3.0.CO;2-X; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655	38	43	43	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					717	723		10.1089/089771503767869953			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000003	12965051				2021-06-18	
J	Webbe, FM; Barth, JT				Webbe, FM; Barth, JT			Short-term and long-term outcome of athletic closed head injuries	CLINICS IN SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; SOCCER INJURIES; NEUROPSYCHOLOGICAL ASSESSMENT; GENDER-DIFFERENCES; NECK INJURIES; FOOTBALL; IMPACT; COLLEGIATE; PERFORMANCE	This article reviews the basic mechanisms of sport-related closed head injury, primary risk factors for differential outcome, and findings of neurocognitive deficit that characterize the immediate, short, and long-term aftermath of athletic head injury, and points toward known or theoretically sound mechanisms that might be candidates for clarifying differences.	Univ Virginia Hlth Syst, Dept Psychiat Med, Charlottesville, VA 22908 USA; Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA	Barth, JT (corresponding author), Univ Virginia Hlth Syst, Dept Psychiat Med, POB 800203, Charlottesville, VA 22908 USA.	jtb4y@virginia.edu	Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT., 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BROSHEK DK, 2002, 26 AN WILL TRAUM BRA; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Butterwick DJ, 2002, AM J SPORT MED, V30, P193, DOI 10.1177/03635465020300020801; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; ECHEMENDIA RJ, IN PRESS SPORTS NEUR; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; ERLANGER DM, 2002, CONCUSSION RESOLUTIO; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; FU K, 1992, J NEUROTRAUM, V9, P59; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GENTRY LR, 1994, RADIOLOGY, V191, P1; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P225; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holbourn AHS, 1943, LANCET, V2, P438; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jagoda A, 2000, EMERG MED CLIN N AM, V18, P355, DOI 10.1016/S0733-8627(05)70130-9; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kronisch RL, 2002, CLIN J SPORT MED, V12, P158, DOI 10.1097/00042752-200205000-00003; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LANDRY G, 1994, P MILD BRAIN INJURY; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; OCHS SR, IN PRESS BR J SPORTS; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; SYMONDS C, 1962, LANCET, V1, P1; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WITOL AD, IN PRESS ARCH CLIN N; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 2002, NCCA NEWS       0401, P10	82	43	44	1	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2003	22	3					577	+		10.1016/S0278-5919(02)00103-5			17	Sport Sciences	Sport Sciences	692LT	WOS:000183663100012	12852687				2021-06-18	
J	Denslow, N; Michel, ME; Temple, MD; Hsu, CY; Saatman, K; Hayes, RL				Denslow, N; Michel, ME; Temple, MD; Hsu, CY; Saatman, K; Hayes, RL			Application of proteomics technology to the field of neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; mass spectroscopy; proteomics; spinal cord trauma	2-DIMENSIONAL GEL-ELECTROPHORESIS; HUMAN GENES; PROTEIN; NEUROSCIENCE; SEQUENCE; NETWORK; DEATH	Near-completion of the Human Genome Project has stimulated scientists to begin looking for the next step in unraveling normal and abnormal functions within biological systems. Consequently, there is new focus on the role of proteins in these processes. Proteomics is a burgeoning field that may provide a valuable approach to evaluate the post-traumatic central nervous system (CNS). Although we cannot provide a comprehensive assessment of all methods for protein analysis, this report summarizes some of the newer proteomic technologies that have propelled this field into the limelight and that are available to most researchers in neurotrauma. Three technical approaches (two-dimensional gel electrophoresis, direct analysis by mass spectrometry, including two-dimensional chromatography coupled to mass spectrometry and isotope coded affinity tags, and antibody technologies) are reviewed, and their advantages and disadvantages presented. A discussion of proteomic technology in the context of brain and spinal cord trauma follows, addressing current and future challenges. Proteomics will likely be very useful for developing diagnostic predictors after CNS injury and for mapping changes in proteins after injury in order to identify new therapeutic targets. Neurotrauma results in complex alterations to the biological systems within the nervous system, and these changes evolve over time. Exploration of the "new nervous system" that follows injury will require methods that can both fully assess and simplify this complexity.	NINDS, Repair & Plast Program, Bethesda, MD 20982 USA; Univ Florida, Biotechnol Program, Gainesville, FL USA; Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL USA	Michel, ME (corresponding author), NINDS, Repair & Plast Program, 6001 Execut Blvd,Rm 2227, Bethesda, MD 20982 USA.			Hsu, Chung Y./0000-0002-5632-2733			AMESS B, 1995, ELECTROPHORESIS, V16, P1255, DOI 10.1002/elps.11501601207; Buonocore G, 1999, J NEUROCHEM, V73, P2139; CharriautMarlangue C, 1996, ELECTROPHORESIS, V17, P1781, DOI 10.1002/elps.1150171117; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; Grant SGN, 2001, TRENDS BIOTECHNOL, V19, pS49, DOI 10.1016/S0167-7799(01)01799-1; Grant SGN, 2001, J NEUROSCI, V21, P8315; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; KIRSCHENBAUM B, 1990, BRAIN RES, V12, P21; Leski ML, 1996, NEUROCHEM RES, V21, P681, DOI 10.1007/BF02527725; Patton WF, 2002, J CHROMATOGR B, V771, P3, DOI 10.1016/S1570-0232(02)00043-0; PERSIDIS A, 2001, PROTEOMICS NAT BIO S, V18, pIT45; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Shouse B, 2002, SCIENCE, V295, P1457; Tonge R, 2001, PROTEOMICS, V1, P377; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weir M, 2001, TRENDS BIOTECHNOL, V19, pS61, DOI 10.1016/S0167-7799(01)01794-2; Wojcik J, 2000, Brief Bioinform, V1, P250, DOI 10.1093/bib/1.3.250	20	43	48	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					401	407		10.1089/089771503765355487			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900001	12803973				2021-06-18	
J	Karmy-Jones, R; Hoffer, E; Meissner, M; Bloch, RD				Karmy-Jones, R; Hoffer, E; Meissner, M; Bloch, RD			Management of traumatic rupture of the thoracic aorta in pediatric patients	ANNALS OF THORACIC SURGERY			English	Article							ENDOVASCULAR STENT-GRAFTS; VASCULAR INJURIES; ANEURYSMS; REPAIR; PLACEMENT; CHILDREN; COARCTATION; DIAGNOSIS	Background. Traumatic rupture of the thoracic aorta (TRA) in the pediatric population is uncommon. Management of TRA in general has evolved to include selective nonoperative and endovascular stent graft approaches, although operative repair remains the standard. Methods. We conducted a retrospective chart review of patients younger than 16 years of age admitted to a single institution between March 1985 and February 2002. Results. Of 160 patients admitted with TRA, 11 were younger than 16 (11.9 +/- 3.5) years of age. Concomitant injuries included closed head injury (5 patients) and acute lung injury (6 patients). All were started on beta-blockers when the diagnosis was suspected. Laparotomy was required in 3 patients and orthopedic procedures in 5 patients. Six underwent operative repair (two primary repairs), with no mortality. Cross-clamp time was 30.4 +/- 2.6 minutes. One patient (operated on without bypass) was partially paralyzed. Two patients were managed nonoperatively, 1 with an intimal arch injury, who on subsequent follow-up has demonstrated healing, and 1 who died of head injury. Three patients were managed by endovascular stent grafts, 2 who died of closed head injury and 1 who at 1-year follow-up has fully recovered. The endovascular stent grafts were placed through the femoral artery in 2 patients and through an iliac conduit in 1 patient. No patient died of rupture. Conclusions. The approach to pediatric TRA should be identical to the adult, with early institution of beta-blockers. Depending on the clinical setting, a spectrum of options should be considered, including operation, nonoperation, and endovascular stent graft, although the choice of the latter must be tempered by the lack of long-term follow-up data. (C) 2003 by The Society of Thoracic Surgeons.	Univ Washington, Harborview Med Ctr, Div Cardiothorac Trauma, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Div Intervent Radiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Div Vasc Traums, Seattle, WA 98104 USA	Karmy-Jones, R (corresponding author), Univ Washington, Harborview Med Ctr, Div Cardiothorac Trauma, 325 9Th Ave,Box 359796, Seattle, WA 98104 USA.						Ahn SH, 2001, J TRAUMA, V50, P949, DOI 10.1097/00005373-200105000-00033; BERGMAN K, 1990, J TRAUMA, V30, P604, DOI 10.1097/00005373-199005000-00013; Bruninx G, 1999, CARDIOVASC INTER RAD, V22, P515, DOI 10.1007/s002709900442; Cox CS, 1998, J PEDIATR SURG, V33, P462, DOI 10.1016/S0022-3468(98)90089-6; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; Dake MD, 1998, J THORAC CARDIOV SUR, V116, P689, DOI 10.1016/S0022-5223(98)00455-3; DELEZO JS, 1995, AM HEART J, V129, P1002, DOI 10.1016/0002-8703(95)90123-X; Deshpande A, 1998, J ENDOVASC SURG, V5, P120, DOI 10.1583/1074-6218(1998)005<0120:TOTFAO>2.0.CO;2; Dorros G, 1996, J ENDOVASC SURG, V3, P270, DOI 10.1583/1074-6218(1996)003<0270:AITCAE>2.0.CO;2; Fink C, 2000, CARDIOL YOUNG, V10, P644; Grabenwoger M, 2000, ANN THORAC SURG, V69, P441, DOI 10.1016/S0003-4975(99)01291-6; HOFFER E, 2001, EMERG RADIOL, V8, P233; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Hormuth D, 1999, ARCH SURG-CHICAGO, V134, P759, DOI 10.1001/archsurg.134.7.759; Ishimaru S, 1998, J THORAC CARDIOV SUR, V115, P811, DOI 10.1016/S0022-5223(98)70360-5; Karmy-Jones R, 2001, AM SURGEON, V67, P61; Katayama Y, 2000, Jpn J Thorac Cardiovasc Surg, V48, P73; Katayama Y, 2000, JPN J THORAC CARDIOV, V48, P144; Kato N, 1997, RADIOLOGY, V205, P657, DOI 10.1148/radiology.205.3.9393517; Lowe LH, 1998, AM J ROENTGENOL, V170, P39, DOI 10.2214/ajr.170.1.9423595; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mattison R, 2001, J TRAUMA, V51, P326, DOI 10.1097/00005373-200108000-00016; Mattox K L, 2000, Chest Surg Clin N Am, V10, P167; PEZZELLA AT, 1978, AM SURGEON, V44, P699; Rousseau H, 1999, CIRCULATION, V99, P498, DOI 10.1161/01.CIR.99.4.498; Ruchat P, 2001, J CARDIOVASC SURG, V42, P77; Semba C P, 1997, Vasc Med, V2, P98; Semba CP, 1997, J VASC INTERV RADIOL, V8, P337, DOI 10.1016/S1051-0443(97)70568-2; SPOUGE AR, 1991, PEDIATR RADIOL, V21, P324, DOI 10.1007/BF02011477; STRIFFELER H, 1993, EUR J PEDIATR SURG, V3, P50, DOI 10.1055/s-2008-1063509; Temudom T, 2000, ANN VASC SURG, V14, P230, DOI 10.1007/s100169910040; Thompson CS, 2002, J VASC SURG, V35, P1163, DOI 10.1067/mva.2002.122885; Thompson CS, 2002, J TRAUMA, V52, P1173, DOI 10.1097/00005373-200206000-00025; Trachiotis GD, 1996, ANN THORAC SURG, V62, P724, DOI 10.1016/S0003-4975(96)00355-4; Weigand MA, 1998, ANESTHESIOLOGY, V89, P1037, DOI 10.1097/00000542-199810000-00035; Yamashita S, 2001, J TRAUMA, V51, P587, DOI 10.1097/00005373-200109000-00032	36	43	43	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	MAY	2003	75	5					1513	1517	PII S0003-4975(02)04838-5	10.1016/S0003-4975(02)04838-5			5	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	671YP	WOS:000182493400029	12735571				2021-06-18	
J	Vanderploeg, RD; Curtiss, G; Duchnick, JJ; Luis, CA				Vanderploeg, RD; Curtiss, G; Duchnick, JJ; Luis, CA			Demographic, medical, and psychiatric factors in work and marital status after mild head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						health status; marital status; mild head injury-minor; sequelae; work	TRAUMATIC BRAIN-INJURY; DIAGNOSTIC INTERVIEW SCHEDULE; COMMUNITY INTEGRATION; MENTAL-HEALTH; PREDICTION; REHABILITATION; MINORITY; SYMPTOMS; HISTORY; RETURN	Objective. To explore factors associated with long-term outcomes of work and marital status in individuals who had experienced a mild head injury (MHI), as well as those who had not. Design: Population-based study using logistical regression analyses to investigate the impact of preinjury characteristics on work and marital status. Participants: Two groups of Vietnam-era Army veterans: 626 who had experienced a MHI an average of 8 years before examination, and 3,896 who had not. Main outcome measures: Demographic characteristics, concurrent medical conditions, early life psychiatric problems, loss of consciousness (LOC), and interactions among these variables were used to predict current work and marital status. Results: Multiple variables were associated with work and marital status in the sample with MHI, accounting for approximately 23% and 17% of the variance in these two outcome variables, respectively. In contrast, the same factors accounted for significantly less variance in outcome in the sample without a head injury-13.3% and 9.4% for work and marital status, respectively. Conclusions: These findings suggest a more potent role for and increased vulnerability to the influence of demographic, medical, and psychiatric factors on outcomes after a MHI. That is, MHI itself moderates the influence of preinjury characteristics on work and marital status. In addition, in those who had a MHI, moderator relationships were found between education and LOC for both work and marital status. Similarly, complex moderator relationships among race, region of residence, and LOC were found for both work and marital status outcomes.	James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; Def & Vet Head Injury Program, Tampa, FL USA; Univ S Florida, Dept Psychiat & Behav Sci, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL USA; Mt Sinai Med Ctr, Miami Heart Inst, Wien Ctr Alzheimers Dis & Mem Disorders, Miami Beach, FL 33140 USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 1988, JAMA, V259, P2701; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; *CDC, 1989, HLTH STAT VIETN VET, V4; DeMaris A, 2002, SOCIOL METHOD RES, V31, P27, DOI 10.1177/0049124102031001002; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fleming J, 1999, BRAIN INJURY, V13, P417; FRANK RG, 1991, INT J LAW PSYCHIAT, V14, P377, DOI 10.1016/0160-2527(91)90016-G; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Gosling J, 1999, BRAIN INJURY, V13, P785; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; GUTMANN MC, 1982, CIRCULATION, V66, P33; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREIDER RM, 2001, P7080 US CENS BUR; Leonard KE, 1999, J STUD ALCOHOL, P139, DOI 10.15288/jsas.1999.s13.139; LUIS CA, 2001, ANN CONV AM PSYCH AS; MCKELVEY RD, 1975, J MATH SOCIOL, V4, P103, DOI 10.1080/0022250X.1975.9989847; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Panting A., 1972, REHABILITATION, V38, P33; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; STILWELL J, 1998, NATL TRAUMATIC BRAIN; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; Webster G, 1999, BRAIN INJURY, V13, P593; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	47	43	43	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					148	163		10.1097/00001199-200303000-00006			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600006	12802224				2021-06-18	
J	Hilton, GD; Nunez, JL; McCarthy, MM				Hilton, GD; Nunez, JL; McCarthy, MM			Sex differences in response to kainic acid and estradiol in the hippocampus of newborn rats	NEUROSCIENCE			English	Article						excitotoxicity; developmental; sex differentiation; estradiol	DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; ADULT FEMALE RATS; NEUROTROPHIC FACTOR; BINDING-SITES; KAINATE RECEPTORS; PYRAMIDAL CELLS; GLUTAMATE NEUROTOXICITY	Premature and full-term human infants are at considerable risk of excitotoxic-mediated brain damage due to hypoxia-ischemia, infection or other trauma. Glutamate receptor activation is a major source of excitoxicity in the adult and developing brain, and the hippocampus is particularly vulnerable to damage. The seven-day-old rat is a widely used model of pediatric brain damage, in large part due to the relative insensitivity of the brain to exogenous glutamate treatment prior to this age. We have reexamined the possible role of glutamate in pediatric brain damage in the newborn rat using kainic acid treatment and attending to the sex of the animal as well as the effects of pretreatment with the gonadal steroid estradiol. Consistent with previous studies, we found no evidence of damage 7 days posttreatment in the CA1 region of the hippocampus in males or females. There was also little to no damage in the CA2/3 or dentate gyrus of males. In females, however, kainic-acid treatment induced substantial damage in the dentate gyrus and moderate damage in CA2/3, as assessed by neuron number and regional volume. Pretreatment with estradiol was protective against kainic acid-induced damage in females but was permissive for damage in the dentate gyrus of males. Estradiol treatment in the absence of kainic acid treatment was also neuroprotective in females in that it increased neuron number and volume throughout the hippocampal formation, suggesting that the basis of the sex difference observed in hippocampal volume was hormonally mediated. There was no effect of exogenous estradiol given to males in the absence of kainic acid. We conclude that the newborn female rat brain, but not the male, is sensitive to glutamate-mediated toxicity and that gonadal steroids play a complex role in both naturally occurring sex differences in hippocampal volume and response to injury. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Hilton, GD (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.		McCarthy, Margaret/O-2059-2017	McCarthy, Margaret/0000-0003-2243-4726			ADAMS JA, 1997, PEDIATR RES, V41, P563; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Azcoitia I, 1999, J NEUROCYTOL, V28, P699, DOI 10.1023/A:1007025219044; BAHN S, 1994, J NEUROSCI, V14, P5525; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BENARI Y, 1984, DEV BRAIN RES, V14, P284, DOI 10.1016/0165-3806(84)90314-6; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Brake WG, 2001, ENDOCRINOLOGY, V142, P1284, DOI 10.1210/en.142.3.1284; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COOK TM, 1986, NEUROSCIENCE, V18, P79, DOI 10.1016/0306-4522(86)90180-6; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/S0006-8993(96)00298-3; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Edwards AD, 1997, PEDIATR RES, V42, P684, DOI 10.1203/00006450-199711000-00022; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FERKANY JW, 1983, J PHARMACOL EXP THER, V225, P399; Foy MR, 1999, J NEUROPHYSIOL, V81, P925; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5; GARCIALADONA FJ, 1993, NEUROSCI LETT, V151, P209, DOI 10.1016/0304-3940(93)90022-D; GERALL AA, 1992, HDB BEHAV NEUROBIOLO; GHO M, 1986, BRAIN RES, V385, P411, DOI 10.1016/0006-8993(86)91093-0; GOULD E, 1990, J NEUROSCI, V10, P1286; Gratacos E, 2001, J NEUROCHEM, V78, P1287, DOI 10.1046/j.1471-4159.2001.00538.x; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Gu Q, 1996, J NEUROSCI, V16, P3620; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Harukuni I, 2001, BRAIN RES, V900, P137, DOI 10.1016/S0006-8993(01)02278-8; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Ivanova T, 2001, J NEUROSCI RES, V66, P221, DOI 10.1002/jnr.1214; Katoh-Semba R, 1999, NEUROSCI RES, V35, P19, DOI 10.1016/S0168-0102(99)00059-0; Klau M, 2001, J NEUROSCI RES, V66, P327, DOI 10.1002/jnr.10007; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Lauterbach MD, 2001, NEUROPSYCHOLOGY, V15, P411, DOI 10.1037/0894-4105.15.3.411; Liu Z, 1996, DEV BRAIN RES, V97, P178, DOI 10.1016/S0165-3806(96)00141-1; Matsumoto A, 2000, SEXUAL DIFFERENTIATION OF THE BRAIN, P203; Mattson MP, 1997, NEUROREPORT, V8, P3817, DOI 10.1097/00001756-199712010-00031; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McGeer E G, 1981, Int Rev Neurobiol, V22, P173, DOI 10.1016/S0074-7742(08)60293-7; MILLER LP, 1990, NEUROSCIENCE, V35, P45, DOI 10.1016/0306-4522(90)90118-N; MILNER TA, 1982, BRAIN RES, V243, P180, DOI 10.1016/0006-8993(82)91136-2; Mong JA, 1999, J NEUROBIOL, V40, P602, DOI 10.1002/(SICI)1097-4695(19990915)40:4<602::AID-NEU14>3.0.CO;2-O; Moss RL, 1999, STEROIDS, V64, P14, DOI 10.1016/S0039-128X(98)00092-0; NUNEZ JL, 2001, SOC NEUR ABS, V27; OKEEFE JA, 1990, DEV BRAIN RES, V57, P119, DOI 10.1016/0165-3806(90)90191-Z; PAXINOS J, 1986, RAT BRAIN STEREOTAXI; Petersen A, 2001, BRAIN RES BULL, V56, P331, DOI 10.1016/S0361-9230(01)00580-9; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Schmitz D, 2001, P NATL ACAD SCI USA, V98, P11003, DOI 10.1073/pnas.191351498; Shughrue PJ, 2000, NEUROSCIENCE, V99, P605, DOI 10.1016/S0306-4522(00)00242-6; Sie LTL, 2000, NEUROPEDIATRICS, V31, P128, DOI 10.1055/s-2000-7496; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singh M, 1999, J NEUROSCI, V19, P1179; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Solum DT, 2002, J NEUROSCI, V22, P2650, DOI 10.1523/JNEUROSCI.22-07-02650.2002; Solum DT, 2001, DEV BRAIN RES, V128, P165, DOI 10.1016/S0165-3806(01)00171-7; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; Tandon P, 1999, NEUROSCIENCE, V91, P293, DOI 10.1016/S0306-4522(98)00609-5; ToranAllerand CD, 1996, J STEROID BIOCHEM, V56, P169, DOI 10.1016/0960-0760(95)00234-0; VANNUCCI RC, 1990, PEDIATR RES, V27, P317, DOI 10.1203/00006450-199004000-00001; Veliskova J, 2000, EPILEPSIA, V41, pS30, DOI 10.1111/j.1528-1157.2000.tb01553.x; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; WEILAND NG, 1992, ENDOCRINOLOGY, V131, P662, DOI 10.1210/en.131.2.662; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; WONG M, 1992, J NEUROSCI, V12, P3217; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Woolley CS, 1996, J COMP NEUROL, V373, P108; Woolley CS, 2000, EPILEPSIA, V41, P510, DOI 10.1111/j.1528-1157.2000.tb00203.x; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2002, J APPL PHYSIOL, V92, P195; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001	89	43	45	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2003	116	2					383	391		10.1016/S0306-4522(02)00716-9			9	Neurosciences	Neurosciences & Neurology	643MJ	WOS:000180864800008	12559094				2021-06-18	
J	Mohta, M; Sethi, AK; Tyagi, A; Mohta, A				Mohta, M; Sethi, AK; Tyagi, A; Mohta, A			Psychological care in trauma patients	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MOTOR-VEHICLE ACCIDENTS; BRAIN INJURY; HEAD-INJURY; EMOTIONAL SEQUELAE; TRAFFIC ACCIDENTS; MAJOR TRAUMA; SCALE; VICTIMS; CHILDREN	The clinician manages trauma patients in the emergency room, operation theatre, intensive care unit and trauma ward with an endeavour to provide best possible treatment for physical injuries. At the same time, it is equally important to give adequate attention to behavioural and psychological aspects associated with the event. Knowledge of the predisposing factors and their management helps the clinician to prevent or manage these psychological problems. Various causes of psychological disturbances in trauma patients have been highlighted. These include pain, the sudden and unexpected nature of events and the procedures and interventions necessary to resuscitate and stabilise the patient. The ICU and trauma ward environment, sleep and sensory deprivation, impact of injury on CNS, medications and associated pre-morbid conditions are also significant factors. Specific problems that concern the traumatised patients are helplessness, humiliation, threat to body image and mental symptoms. The patients react to these stressors by various defence mechanisms like conservation withdrawal, denial, regression, anger, anxiety and depression. Some of them develop delirium or even more severe problems like acute stress disorder or post-traumatic stress disorder. Physical, pharmacological or psychological interventions can be performed to prevent or minimise these problems in trauma patients. These include adequate pain relief, prevention of sensory and sleep deprivation, providing familiar surroundings, careful explanations and reassurance to the patient, psychotherapy and pharmacological treatment whenever required. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Coll Med Sci, Dept Anaesthesiol & Crit Care, Delhi 110095, India; GTB Hosp, Delhi 110095, India; Univ Coll Med Sci, Dept Surg, Delhi 110095, India	Mohta, M (corresponding author), 28-B,Pocket C,SFS Flats,Mayur Vihar Phase 3, Delhi 110096, India.		Mohta, Anup/AAE-1490-2020	TYAGI, ASHA/0000-0001-5331-6832; Mohta, Anup/0000-0003-1712-5750			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARCHER J, 1991, J ADV HLTH NURS CARE, V1, P9; Averill J.R., 1982, ANGER AGGRESSION ESS; Baker C F, 1984, CCQ, V6, P66; Blake D. D., 1990, BEHAV THER, V13, P187; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; Blumenfield M., 1993, P 20 INT C AUT LANG, P1; BRACKETT TO, 1984, JAMA-J AM MED ASSOC, V252, P793; BRESLAU N, 1982, AM J DIS CHILD, V136, P682, DOI 10.1001/archpedi.1982.03970440026007; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brewer M J, 1985, Crit Care Nurse, V5, P35; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; BROM D, 1993, J CLIN PSYCHOL, V49, P131, DOI 10.1002/1097-4679(199303)49:2<131::AID-JCLP2270490202>3.0.CO;2-2; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CHRISTIE J, 2000, TRAUMA CARE TEAM APP, P3; CIVETTA JM, 1981, CRIT CARE MED, V9, P763, DOI 10.1097/00003246-198111000-00001; Davidson JRT, 1997, INT CLIN PSYCHOPHARM, V12, P41, DOI 10.1097/00004850-199701000-00006; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; Derogatis L., 1982, BRIEF SYMPTOM INVENT; DUBOVSKY SL, 1981, UNDERSTANDING HUMAN, P90; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; ENGEL GL, 1956, J AM PSYCHOANAL ASS, V4, P428; Fitzpatrick MC, 1999, CLIN ORTHOP RELAT R, P98; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; GREGORIO MAP, 1992, INTENS CARE MED, V18, P278; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 1999, J TRAUMA STRESS, V12, P673, DOI 10.1023/A:1024773202939; HICKLING EJ, 1992, J ANXIETY DISORD, V6, P285, DOI 10.1016/0887-6185(92)90040-E; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jamerson PA, 1996, HEART LUNG, V25, P467, DOI 10.1016/S0147-9563(96)80049-5; JENNETT B, 1975, LANCET, V1, P480; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kennedy P, 2000, ARCH PHYS MED REHAB, V81, P932, DOI 10.1053/apmr.2000.5580; Kleck H G, 1984, CCQ, V6, P21; KORNFELD DS, 1969, BRIT MED J, V1, P108, DOI 10.1136/bmj.1.5636.108; Kubler-Ross E., 1969, DEATH DYING; KUCH K, 1985, CAN J PSYCHIAT, V30, P426, DOI 10.1177/070674378503000610; LIVINGSTON MG, 1986, BRIT MED J, V293, P742, DOI 10.1136/bmj.293.6549.742; Malt U F, 1992, Psychiatr Med, V10, P117; Malt U. F., 1993, European Psychiatry, V8, P227; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCCLELLAND P, 1987, TRAUMA CARE, V2, P198; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Mieszala P, 1978, CCQ, V1, P93; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; MUELLER AD, 1962, ARCH PHYSICAL MED RE, V43, P151; NAGLER B, 1950, AM J PSYCHIAT, V107, P49, DOI 10.1176/ajp.107.1.49; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PARKES CM, 1975, BRIT J PSYCHIAT, V127, P204, DOI 10.1192/bjp.127.3.204; PETERSON KC, 1991, POSTTRAUMATIC STRESS, P171; RIBBERS G, 1989, INT J REHABIL RES, V12, P175, DOI 10.1097/00004356-198906000-00006; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SCHMIDT CW, 1985, MANAGEMENT TRAUMA, P807; SCHNAPER N, 1975, J TRAUMA, V15, P94, DOI 10.1097/00005373-197502000-00002; SCHNAPER N, 1976, AM J PSYCHIAT, V133, P883; Schnyder U, 2000, CRIT CARE MED, V28, P86, DOI 10.1097/00003246-200001000-00014; Schnyder U, 1998, J PSYCHOSOM RES, V45, P419, DOI 10.1016/S0022-3999(98)00008-7; SHERMAN RS, 1988, J REHABIL RES DEV, V25, P7; Spitzer R.L., 1994, STRUCTURED CLIN INTE; STEDEFORD A, 1984, FACING DEATH PATIENT, P154; STEIN DJ, 2000, POSTTRAUMATIC STRESS, P131; Stein MB, 2000, BEHAV RES THER, V38, P619, DOI 10.1016/S0005-7967(99)00098-4; STRAIN JJ, 1978, PSYCHOL INTERVENTION; Strain JJ, 1975, PSYCHOL CARE MED ILL; Van Etten ML, 1998, CLIN PSYCHOL PSYCHOT, V5, P126, DOI 10.1002/(SICI)1099-0879(199809)5:3<126::AID-CPP153>3.3.CO;2-8; VREVEN DL, 1995, J TRAUMA STRESS, V8, P91, DOI 10.1007/BF02105409; Wallace-Barnhill George L., 1997, P89; WALLACEBARNHILL GL, 1989, TXB CRITICAL CARE, P1414; Wolman R. L., 1988, CONTEMP SURG S20, V3, P33; Yalom I.D., 1995, THEORY PRACTICE GROU	74	43	47	1	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JAN	2003	34	1					17	25	PII S0020-1383(02)00377-7	10.1016/S0020-1383(02)00377-7			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	640XP	WOS:000180714300004	12531372				2021-06-18	
J	van Geel, WJA; de Reus, HPM; Nijzing, H; Verbeek, MM; Vos, PE; Lamers, KJB				van Geel, WJA; de Reus, HPM; Nijzing, H; Verbeek, MM; Vos, PE; Lamers, KJB			Measurement of glial fibrillary acidic protein in blood: an analytical method	CLINICA CHIMICA ACTA			English	Article						glial fibrillary acidic protein; severe traumatic brain injury; blood values	CEREBROSPINAL-FLUID; ACUTE STROKE; S-100	Background: In the present study, a new assay for the measurement of glial fibrillary acidic protein (GFAP) in human blood is described. The aim of the study was to present the characteristics of a new GFAP assay for blood analysis. Methods: The method, a newly developed enzyme-linked immunosorbent assay (ELISA), was validated using blood samples from healthy blood donors and from patients with severe traumatic brain injury (TBI). Results: 22 out of 72 healthy blood donors had a detectable GFAP level. The reference values (percentiles) are as follows: P50 = 0.15 mug/l and P95 = 0.49 mug/l; range 0.15-0.76 mug/l. Conclusions: GFAP in blood might be a promising new marker for astrocyte involvement after acute brain damage. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Nijmegen, Ctr Med, Lab Pediat & Neurol, NL-6525 GC Nijmegen, Netherlands; Byk Nederland BV, Zwanenburg, Netherlands; Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands	van Geel, WJA (corresponding author), Univ Nijmegen, Ctr Med, Lab Pediat & Neurol, Reinier Postlaan 4, NL-6525 GC Nijmegen, Netherlands.		Vos, Pieter/A-6043-2012; Verbeek, Marcel M/D-1971-2010	Verbeek, Marcel M/0000-0003-4635-7876			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Duchen L. W, 1984, GREENFIELDS NEUROPAT, P1; ENDO T, 1981, J BIOL CHEM, V256, P2485; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Missler U, 1999, CLIN CHEM, V45, P138; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6	10	43	44	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981			CLIN CHIM ACTA	Clin. Chim. Acta	DEC	2002	326	1-2					151	154	PII S0009-8981(02)00330-3	10.1016/S0009-8981(02)00330-3			4	Medical Laboratory Technology	Medical Laboratory Technology	618TW	WOS:000179434200014	12417106				2021-06-18	
J	Knoblach, SM; Faden, AI				Knoblach, SM; Faden, AI			Administration of either anti-intercellular adhesion molecule-1 or a nonspecific control antibody improves recovery after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						antibody; anti-ICAM-1; CNS; expression; function; head injury; IgG	CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; ISCHEMIC CELL-DAMAGE; SPINAL-CORD-INJURY; NEUTROPHIL ACCUMULATION; MONOCLONAL-ANTIBODY; MICE DEFICIENT; UP-REGULATION; P-SELECTIN; ANTI-ICAM-1 ANTIBODY	Intercellular adhesion molecule-1 (ICAM-1) is an endothelial protein that facilitates invasion of leukocytes into the CNS in response to injury or inflammation. ICAM-1 expression correlates with the severity of clinical head injuries, but its importance in secondary injury events is not fully understood. Therefore, we evaluated ICAM-1 expression and the effect of anti-ICAM-1 treatment on motor recovery and neutrophil invasion after traumatic brain injury induced via the lateral fluid-percussion method in the rat. ICAM-1 was expressed in large and small blood vessels within the injured cortex at 10 and 24 h after injury. Repeated administration of anti-ICAM-1 antibody (clone 1A29) at 1, 10, and again at 24 h after injury significantly improved performance in two of three motor tests, compared to saline controls. Equal doses of nonspecific control antibody (IgG) also significantly improved motor test scores, compared to saline controls. Cortical myeloperoxidase activity, an indicator of neutrophil invasion, was significantly reduced 26 h after injury in animals treated with anti-ICAM-1. Animals treated with IgG showed a trend toward reduction that did not reach significance. These data suggest that ICAM-1 may be involved in neutrophil invasion and neurological dysfunction after TBI, but also implicate a role for a nonspecific antibody effect in improved functional outcome.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	knoblachs@giccs.georgetown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007459] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07459] Funding Source: Medline; ODCDC CDC HHS [R49CCR306634-07] Funding Source: Medline		BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BOWES MP, 1995, NEUROLOGY, V45, P815, DOI 10.1212/WNL.45.4.815; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Cole DJ, 1996, ANESTH ANALG, V83, P342, DOI 10.1097/00000539-199608000-00024; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Etienne S, 1998, J IMMUNOL, V161, P5755; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Isaksson J, 2000, J NEUROTRAUM, V17, P333, DOI 10.1089/neu.2000.17.333; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Lewczuk P, 1998, J NEUROIMMUNOL, V87, P156, DOI 10.1016/S0165-5728(98)00084-8; LUNDBLAD JL, 1986, REV INFECT DIS, V8, pS382; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/S0008-6363(96)00146-0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeating EG, 1998, BRIT J ANAESTH, V80, P77; McKeating EG, 1998, ACT NEUR S, V71, P200; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PALMER C, 1995, CLIN PERINATOL, V22, P481; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Schneider D, 1998, EUR NEUROL, V40, P78, DOI 10.1159/000007962; Seilhean D, 1997, NEUROPATH APPL NEURO, V23, P83, DOI 10.1111/j.1365-2990.1997.tb01190.x; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Shrikant P, 1996, J IMMUNOL, V157, P1819; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAMATANI T, 1993, INT IMMUNOL, V2, P166; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Vuorte J, 1999, J IMMUNOL, V162, P2353; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Worthington V., 1993, WORTHINGTON ENZYME M; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6	66	43	53	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1039	1050		10.1089/089771502760341956			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900005	12482117				2021-06-18	
J	McCullers, DL; Sullivan, PG; Scheff, SW; Herman, JP				McCullers, DL; Sullivan, PG; Scheff, SW; Herman, JP			Traumatic brain injury regulates adrenocorticosteroid receptor mRNA levels in rat hippocampus	BRAIN RESEARCH			English	Article						glucocorticoid; mineralocorticoid; cortical impact; spironolactone; RU486	GLUCOCORTICOID-RECEPTOR; GENE-TRANSCRIPTION; CORTICOSTERONE; TOXICITY; FACILITATION; EXPRESSION; BLOCKADE; CORTISOL; FEEDBACK; RHYTHM	Glucocorticoid activation of two types of adrenocorticosteroid receptors (ACRs), the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR), influences the vulnerability of hippocampal neurons to insult. To examine the potential impact of ACR activation following traumatic brain injury (TBI), the current study assesses regulation of MR and GR expression and glucocorticoid levels following controlled cortical impact (CCI). Male Sprague-Dawley rats were pretreated for 48 h with vehicle, the MR antagonist spironolactone, or the GR antagonist mifepristone (RU486). On day three, subjects were sham-operated or injured by unilateral CCI. In situ hybridization analysis determined that pretreatment with either MR antagonist spironolactone or GR antagonist RU486 increased 24-h hippocampal GR mRNA levels in sham-operated animals only, suggesting that MR and GR regulation of GR mRNA is suppressed following TBI. Injury decreased GR mRNA levels in the ipsilateral dentate gyrus of all pretreatment groups and bilaterally increased MR mRNA levels in CA3 of antagonist-pretreated animals. One day post-injury, plasma corticosterone levels were comparable in sham and injured animals pretreated with vehicle. A separate group of animals that did not receive pretreatment injections prior to sham operation or injury were included for a 24-h time course analysis of plasma ACTH and corticosterone levels. Injury increased hypothalamic-pituitary-adrenal (HPA) activation for approximately 6 h following injury. These results indicate that hippocampal ACR mRNA levels and HPA activation are altered by TBI. Regulation of MR and GR expression following TBI may influence hippocampal neuron viability by modulating glucocorticoid signaling after injury. (C) 2002 Published by Elsevier Science B.V.	Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Herman, JP (corresponding author), Univ Cincinnati, Dept Psychiat, POB 670559,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jpherman@psychiatry.uc.edu	Herman, James P/D-4960-2015	Herman, James P/0000-0003-3571-2406	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00242, AG10836, AG12965] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Cabral ALB, 2001, MOL CELL ENDOCRINOL, V175, P67, DOI 10.1016/S0303-7207(01)00396-3; CHABERT PR, 1984, J STEROID BIOCHEM, V20, P1253, DOI 10.1016/0022-4731(84)90154-7; Chao HM, 1998, ENDOCRINOLOGY, V139, P1810, DOI 10.1210/en.139.4.1810; DAGOSTINO J, 1982, ACTA ENDOCRINOL-COP, V100, P85, DOI 10.1530/acta.0.1000085; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Herman JP, 1998, J NEUROSCI, V18, P7462; HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/mend-3-11-1886; HERMAN JP, 1989, J NEUROSCI, V9, P3072; HERMAN JP, 1993, MOL CELL NEUROSCI, V4, P181, DOI 10.1006/mcne.1993.1022; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KWAK SP, 1992, NEUROENDOCRINOLOGY, V55, P74, DOI 10.1159/000126099; LEVINE RL, 1980, HORM RES, V13, P385, DOI 10.1159/000179306; Liu Z, 1997, NEUROREPORT, V8, P2019, DOI 10.1097/00001756-199705260-00043; LOWY MT, 1990, BRAIN RES, V533, P348, DOI 10.1016/0006-8993(90)91362-K; LOWY MT, 1992, J NEUROCHEM, V58, P1561, DOI 10.1111/j.1471-4159.1992.tb11379.x; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2001, J NEUROSCI RES, V64, P277; McIntosh LJ, 1996, NEUROTOXICOLOGY, V17, P873; MCINTOSH TK, 1981, J CLIN ENDOCR METAB, V53, P117, DOI 10.1210/jcem-53-1-117; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Ruhmann-Wennhold A, 1977, Ann N Y Acad Sci, V297, P498, DOI 10.1111/j.1749-6632.1977.tb41877.x; SAPOLSKY RM, 1988, BRAIN RES, V453, P367, DOI 10.1016/0006-8993(88)90180-1; SAPOLSKY RM, 1986, NEUROENDOCRINOLOGY, V43, P440, DOI 10.1159/000124561; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; Sarrieau A, 1996, NEUROSCI LETT, V206, P207, DOI 10.1016/S0304-3940(96)12454-X; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; SEROOGY KB, 1996, NEUROCHEMISTRY PRACT, P121; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; SPENCER RL, 1990, BRAIN RES, V514, P37, DOI 10.1016/0006-8993(90)90433-C; Spencer RL, 1998, ENDOCRINOLOGY, V139, P2718, DOI 10.1210/en.139.6.2718; vanHaarst AD, 1997, NEUROCHEM RES, V22, P1323, DOI 10.1023/A:1022010904600; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.ge.19.120185.001233; Yau JLW, 1999, NEUROSCI LETT, V277, P45, DOI 10.1016/S0304-3940(99)00858-7	43	43	44	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 23	2002	947	1					41	49	PII S0006-8993(02)02904-9	10.1016/S0006-8993(02)02904-9			9	Neurosciences	Neurosciences & Neurology	589PR	WOS:000177769400006	12144851				2021-06-18	
J	Brawanski, A; Faltermeier, R; Rothoerl, RD; Woertgen, C				Brawanski, A; Faltermeier, R; Rothoerl, RD; Woertgen, C			Comparison of near-infrared spectroscopy and tissue Po-2 time series in patients after severe head injury and aneurysmal subarachnoid hemorrhage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						near-infrared spectroscopy (NIRS); rSo(2); tissue Po-2 (tipo(2)); frequency analysis; multitaper analysis; modeling	CEREBRAL OXYGENATION; OXIMETRY; BULB	Monitoring of local oxygen pressure in brain white matter (tipo(2)) and of local hemoglobin oxygen saturation (rSo(2)) with near-infrared spectroscopy (NIRS) are increasingly employed techniques in neurosurgical intensive care units. Using frequency-based mathematical method,,, the authors sought to ascertain whether both techniques contained similar information. Twelve patient,,; treated in the intensive care unit were included (subarachnoid hemorrhage, n = 3 traumatic brain injury, n = 9). A tipo(2) probe and an NIRS sensor were positioned over the frontal lobe with the most pathologic changes on initial computed tomography scan. The authors calculated coherence of tipo(2) and rSo(2). its overall density distribution, its distribution per data set, and its time evolution. The authors identified a band of significantly correlated frequencies (from 0 to 1.3 x 10(3) Hz) in more than 90% of the data sets for coherence and overall density distribution. Time evolution showed slow but marked changes of significant coherence, By means of spectral analysis the authors show that tipo(2) and rSo(2) signals contain similar information. albeit using completely different registration methodologies.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany	Brawanski, A (corresponding author), Univ Regensburg, Dept Neurosurg, Germany Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	alexander.brawanski@klinik.uni-regensburg.de					BRILLINGER BR, 1981, TIME SERIES DATA ANA; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; GHIL M, 1996, DECADAL CLIMATE VARI, P445; Henson LC, 1998, ANESTHESIOLOGY, V88, P58, DOI 10.1097/00000542-199801000-00011; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KIRKPATRICK PJ, 1995, J NEUROSURG, V83, P963, DOI 10.3171/jns.1995.83.6.0963; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Meixensberger J, 1998, ACT NEUR S, V71, P260; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; PARK J, 1987, J GEOPHYS RES-SOLID, V92, P12675, DOI 10.1029/JB092iB12p12675; PURVES MJ, 1972, PHYSL CEREBRAL CIRCU; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Schreiber T., 1997, NONLINEAR TIME SERIE; Schwarz G, 1996, J NEUROSURG ANESTH, V8, P189, DOI 10.1097/00008506-199607000-00001; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Vinas FC, 1998, CRIT REV NEUROSURG, V8, P31, DOI 10.1007/s003290050058	18	43	48	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2002	22	5					605	611		10.1097/00004647-200205000-00012			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	548CN	WOS:000175371200012	11973433	Bronze			2021-06-18	
J	Brouwer, WH; Withaar, FK; Tant, MLM; van Zomeren, AH				Brouwer, WH; Withaar, FK; Tant, MLM; van Zomeren, AH			Attention and driving in traumatic brain injury: A question of coping with time-pressure	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive dysfunction; divided attention; driving skill; information processing; motor dysfunction; perceptual dysfunction; procedural knowledge	CLOSED-HEAD INJURY; FITNESS; DAMAGE	Background: Diffuse and focal traumatic brain injury (TBI) can result in perceptual, cognitive, and motor dysfunction possibly leading to activity limitations in driving. Characteristic dysfunctions for severe diffuse TBI are confronted with function requirements derived from the hierarchical task analysis of driving skill. Objective. Specifically, we focus on slow information processing, divided attention, and the development of procedural knowledge. Also the effects of a combination of diffuse and focal dysfunctions, specifically homonymous hemianopia and the dysexecutive syndrome, are discussed. Finally, we turn to problems and challenges with regard to assessment and rehabilitation methods in the areas of driving and fitness to drive.	Univ Groningen, Dept Psychol, NL-9712 TS Groningen, Netherlands; Acad Hosp, Dept Neurol, Groningen, Netherlands	Brouwer, WH (corresponding author), Univ Groningen, Acad Hosp, Neuropsychol & Gerontol Unit, Dept Psychol, Poortweg 4,POB 30001, NL-9700 RB Groningen, Netherlands.						Barer D. H., 1989, CLIN REHABIL, V3, P179; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BRUN A, 1999, SCI PRACT NEUROPSYCH, P349; Damasio A., 1994, DESCARTESERROR EMOTI; Evans, 1991, TRAFFIC SAFETY DRIVE; FITTS PM, 1964, CATEGORIES HUMAN LEA, P253; Groeger J.A., 2000, UNDERSTANDING DRIVIN; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; KINSBOURNE M, 1978, ATTENTION PERFORM, V7, P81; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; MICHON JA, 1971, PSYCHONOMIE ONDERWEG; Pincus J. H., 1998, SCI PRACT NEUROPSYCH, P547; RICHARDSON JTE, 1999, CLIN NEUROPSYCHOLOGI; SHORE D, 1980, ARCH PHYS MED REHAB, V65, P163; STRICH SJ, 1961, LANCET, V2, P443; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANBALEN HGG, 1990, P 5 EUR REG C REH; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5; WITHAAR FK, 2000, THESIS U GRONINGEN; 1995, REGELING EISEN RIJGE	28	43	45	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					1	15		10.1097/00001199-200202000-00003			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100004	11860325				2021-06-18	
J	Gerring, JP; Slomine, B; Vasa, RA; Grados, M; Chen, A; Rising, W; Christensen, JR; Denckla, MB; Ernst, M				Gerring, JP; Slomine, B; Vasa, RA; Grados, M; Chen, A; Rising, W; Christensen, JR; Denckla, MB; Ernst, M			Clinical predictors of posttraumatic stress disorder after closed head injury in children	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						posttraumatic stress disorder; posttraumatic stress symptoms; closed head injury	TRAUMATIC BRAIN INJURY; AMNESIA TEST; SYMPTOMATOLOGY; ADOLESCENTS; ORIENTATION; ACCIDENTS; SEQUELAE; SCALE; RISK	Objective: To describe injury, demographic, and neuropsychiatric characteristics of children who develop posttraumatic stress disorder (PTSD) and posttraumatic stress symptoms (PTSS) after closed head injury (CHI). Method: Ninety-five children with severe CHI and amnesia for the event were prospectively followed for 1 year. Structured interviews were administered twice to the parents: shortly after injury to cover the child's premorbid status, and 1 year after injury. The child was also interviewed twice: shortly after injury to cover current status, and 1 year after injury. Outcome measures were diagnostic status (PTSD by parent or child) and symptom severity (PTSS by parent or child). Results: Twelve children developed PTSD by 1 year after injury, 5 according to parent report, 5 according to child report, and 2 according to both parent and child report. Predictors of PTSD at 1 year post-CHI included female gender and early post-CHI anxiety symptoms. Predictors of PTSS at 1 year post-CHI were (1) premorbid psychosocial adversity, premorbid anxiety symptoms, and injury severity; and (2) early post-CHI depression symptoms and nonanxiety psychiatric diagnoses. Conclusions: PTSD developed in 13% of children with severe CHI accompanied by traumatic amnesia. Predictors of PTSD and PTSS after CHI, according to parent and child report, are consistent with predictors of PTSD and PTSS that develop after non-head injury trauma.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Duke Univ, Clin Res Inst, Durham, NC USA; NIMH, Mood & Anxiety Disorders Program, NIH, Bethesda, MD 20892 USA	Gerring, JP (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO-RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Asarnow J, 1999, J AM ACAD CHILD PSY, V38, P1016, DOI 10.1097/00004583-199908000-00018; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; EDELBROCK C, 1985, CHILD DEV, V56, P265, DOI 10.2307/1130193; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FOA EB, 1995, AM J PSYCHIAT, V152, P116; Foy DW, 1996, J SCHOOL PSYCHOL, V34, P133, DOI 10.1016/0022-4405(96)00003-9; FRICK PJ, 1994, PSYCHOL ASSESSMENT, V6, P372, DOI DOI 10.1037/1040-3590.6.4.372; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P1569, DOI 10.1097/00004583-199912000-00019; Klein D.N., 1993, BASIC ISSUES PSYCHOP, Vix; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LONIGAN CJ, 1994, J AM ACAD CHILD PSY, V33, P94, DOI 10.1097/00004583-199401000-00013; March JS, 1998, J AM ACAD CHILD PSY, V37, P585, DOI 10.1097/00004583-199806000-00008; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Sattler J. M., 1992, ASSESSMENT CHILDREN; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	35	43	43	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	FEB	2002	41	2					157	165		10.1097/00004583-200202000-00009			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	514PZ	WOS:000173451400009	11837405				2021-06-18	
J	Siegel, JH; Loo, G; Dischinger, PC; Burgess, AR; Wang, SC; Schneider, LW; Grossman, D; Rivara, F; Mock, C; Natarajan, GA; Hutchins, KD; Bents, FD; McCammon, L; Leibovich, E; Tenenbaum, N				Siegel, JH; Loo, G; Dischinger, PC; Burgess, AR; Wang, SC; Schneider, LW; Grossman, D; Rivara, F; Mock, C; Natarajan, GA; Hutchins, KD; Bents, FD; McCammon, L; Leibovich, E; Tenenbaum, N			Factors influencing the patterns of injuries and outcomes in car versus car crashes compared to sport utility, van, or pick-up truck versus car crashes: Crash injury research engineering network study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						motor vehicle crash (MVC); injury; trauma; airbags; MVC vehicle incompatibility; MVC vehicle mass ratio; MVC DELTA V; MVC side-impacts	MULTIPLE TRAUMA PATIENTS; MOTOR-VEHICLE CRASHES; IMPACT; DRIVERS; COSTS	Background. Data using crash dummies suggest that motor vehicle crashes (MVCs) involving passenger sedans (S) vs sport utility, vans, or light trucks (SUVTs) produce more severe injuries than those involving two sedans (SvS). However, no detailed data regarding pattern of injuries or force mechanisms involved have been presented in real patients. Methods: The relationship of injury patterns and severities with MVC reconstruction data were obtained in 412 MVC patients, drivers or front seat passengers. Crashes were examined with regard to impact direction, frontal (F) or lateral (L) crashes, vehicle mass ratio, ISS, DELTA V, seat belt use, and airbag deployment (AB). Results: In 309 F-MVC, AB reduced overall ISS (24.3 to 17.9) with a reduction in the mean severity of traumatic brain injury (TBI) GCS less than or equal to 12, from 48% to only 28%. This AB protection from TBI was preserved as DELTA V increased to > 30 mph even though non-AB protected body areas (thorax, lung, liver, and lower extremity injuries) all increased. When vehicles of incompatible size and mass (SUVT) had F-MVC with sedans the incidence of severe TBI rose as did face lacerations despite AB or belt use. In L-MVC between SUVT and sedans compared with SvS MVC, there was a cephalad shift in body injuries with increased thorax, but decreased lower extremity injuries. The incidence of TBI increased. Analysis of injury contact sites (hits) showed more hits and a wider distribution of contract sites in SUVT vs sedan MVC. These appeared due to the greater mass excess and larger mass ratio, hood height, and width in the F-SUVT vs S crashes. All of these factors plus the increased bumper height above the body frame side-door sill were injury causal factors in the L-SUVT vs S MVCs. Conclusion: Both F and L crashes between sedans and SUVT with a high mass ratio shift the pattern of injury cephalad with increased thorax and intrathoracic organ injuries, and more severe TBI. These data suggest that improved head and thorax side-impact buffering and design features which transmit MVC forces from the higher front end of the larger mass SUVT to the frame of the sedan may better protect sedan occupants from side-impacts.	UMDNJ, New Jersey Med Sch, Dept Anat Cell Biol & Injury Sci, Newark, NJ 07103 USA; UMDNJ, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; Univ Maryland, Charles McC Mathias Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; Univ Michigan, Trauma Burn Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Transportat Res Inst, Ann Arbor, MI 48109 USA; Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; Edwin H Albano Inst Forens Sci, Reg Med Examiner Off, Woodland Hills, CA USA; Dynam Sci Inc, Woodland Hills, CA USA	Siegel, JH (corresponding author), UMDNJ, New Jersey Med Sch, Dept Anat Cell Biol & Injury Sci, Med Sci Bldg G-609,185 S Orange Ave, Newark, NJ 07103 USA.			Mock, Charles/0000-0002-0564-568X			BLINCOE LJ, 1996, DOT PUBLICATION HS; CHIPMAN ML, 1993, P ASS ADV AUTOMOTIVE, V37, P329; DALMOTAS DJ, 1995, J TRAUMA, V38, P476, DOI 10.1097/00005373-199504000-00002; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; Dischinger PC, 1998, ACCIDENT ANAL PREV, V30, P831, DOI 10.1016/S0001-4575(98)00036-0; *DOT, 1998, DOT PUBL HS, P18; *DOT, 1997, DOT PUBL HS; EVANS L, 1993, ACCIDENT ANAL PREV, V25, P213, DOI 10.1016/0001-4575(93)90062-2; EVANS L, 1993, P ASS ADV AUT MED, V37, P313; *INS I HIGHW SAF, 1998, STATUS REPORT, V33, P1; JOLLY BT, 1996, P ASS ADV AUTOMOTIVE, V40, P519; Loo GT, 1996, J TRAUMA, V41, P935, DOI 10.1097/00005373-199612000-00001; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MCDERMUTT FJF, 1982, BRIT J SURG, V66, P518; McLellan BA, 1996, J TRAUMA, V41, P708, DOI 10.1097/00005373-199610000-00019; MILLER TR, 1989, ACCIDENT ANAL PREV, V21, P303, DOI 10.1016/0001-4575(89)90022-5; REATH DB, 1989, J TRAUMA, V29, P1173, DOI 10.1097/00005373-198908000-00018; SIEGEL JH, 1993, J TRAUMA, V34, P736, DOI 10.1097/00005373-199305000-00017; SIEGEL JH, 1993, J TRAUMA, V35, P920, DOI 10.1097/00005373-199312000-00019; SIEGEL JH, 1994, J TRAUMA, V37, P928, DOI 10.1097/00005373-199412000-00010; SIEGEL JH, 1992, DOT PUBLICATION, P51; SIEGEL JH, 1994, Patent No. 8358891; VIANO DC, 1990, ACCIDENT ANAL PREV, V22, P177, DOI 10.1016/0001-4575(90)90068-V	24	43	43	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2001	51	5					975	990		10.1097/00005373-200111000-00024			16	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	495QJ	WOS:000172351600030	11706349				2021-06-18	
J	Schwab, JM; Seid, K; Schluesener, HJ				Schwab, JM; Seid, K; Schluesener, HJ			Traumatic brain injury induces prolonged accumulation of cyclooxygenase-1 expressing microglia/brain macrophages in rats	JOURNAL OF NEUROTRAUMA			English	Article						bystander damage; inflammation; prostaglandin; tissue remodeling	SPINAL-CORD INJURY; CEREBRAL-ISCHEMIA; GENE DISRUPTION; EFFECTOR-CELLS; IN-VIVO; INFLAMMATION; COX-1; DIFFERENTIATION; DISEASE; GLIOMA	Inflammatory cellular responses to brain injury are promoted by proinflammatory messengers. Cyclooxygenases (prostaglandin endoperoxide H synthases [PGH]) are key enzymes in the conversion of arachidonic acid into prostanoids, which mediate immunomodulation, mitogenesis, apoptosis, blood flow, secondary injury (lipid peroxygenation), and inflammation. Here, we report COX-1 expression following brain injury. In control brains, COX-1 expression was localized rarely to brain microglia/macrophages. One to 5 days after injury, we observed a highly significant (P < 0.0001) increase in COX-1(+) microglia/macrophages at perilesional areas and in the developing core with a delayed culmination of cell accumulation at day 7, correlating with phagocytic activity. There, cell numbers remained persistently elevated up to 21 days following injury. Further, COX-1(+) cells were located in perivascular Virchow-Robin spaces also reaching maximal numbers at day 7. Lesion-confined COX-1(+) vessels increased in numbers from day 1, reaching the maximum at days 5-7. Double-labeling experiments confirmed coexpression of COX-1 by ED-1(+) and OX-42(+) microglia/ macrophages. Transiently after injury, most COX-1(+) microglia/macrophages coexpress the activation antigen OX-6 (MHC class II). However, the prolonged accumulation of COX-1(+), ED-1(+) microglia/macrophages in lesional areas enduring the acute postinjury inflammatory response points to a role of COX-1 in the pathophysiology of secondary injury. We have identified localized, accumulated COX-1 expression as a potential pharmacological target in the treatment of brain injury. Our results suggest that therapeutic approaches based on long-term blocking including COX-1, might be superior to selective COX-2 blocking to suppress the local synthesis of prostanoids.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany	Schwab, JM (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.			Schwab, Jan/0000-0001-6784-4919			Becher B, 1996, GLIA, V18, P1; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Deininger MH, 1999, J NEUROIMMUNOL, V95, P202, DOI 10.1016/S0165-5728(98)00257-4; Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dubois RN, 1998, FASEB J, V12, P1063; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GUILIAN D, 1993, GLIA, V7, P102; HALL ED, 1996, NEUROTRAUMA, P1405; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MALLAT M, 1994, J LEUKOCYTE BIOL, V56, P416; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nogawa S, 1997, J NEUROSCI, V17, P2746; Perry V H, 1992, Curr Opin Neurobiol, V2, P679, DOI 10.1016/0959-4388(92)90038-M; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Roller A, 1999, BIOCHEM BIOPH RES CO, V259, P600, DOI 10.1006/bbrc.1999.0825; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; SANDERS KM, 1978, AM J PHYSIOL, V234, pE209; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Shillabeer G, 1998, METABOLISM, V47, P461, DOI 10.1016/S0026-0495(98)90060-9; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; WILBERGER JE, 1996, NEUROTRAUMA, P1219; Williams CS, 1996, AM J PHYSIOL, V270, P393; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003	48	43	44	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2001	18	9					881	890		10.1089/089771501750451802			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	471TP	WOS:000170945000004	11565600				2021-06-18	
J	Schaefer, PW				Schaefer, PW			Applications of DWI in clinical neurology	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	4th Advanced Course on Magnetic Resonance Techniques in Multiple Sclerosis	MAY 18-20, 2000	MILIAN, ITALY			EP DWI; magnetic resonance; neurologic deficit	DIFFUSION-WEIGHTED MR; CREUTZFELDT-JAKOB-DISEASE; ACUTE CEREBRAL-ISCHEMIA; HIGH-RESOLUTION MEASUREMENT; TRAUMATIC BRAIN INJURY; TRACER BOLUS PASSAGES; MAGNETIC-RESONANCE; ACUTE STROKE; APPARENT DIFFUSION; SIGNAL INTENSITY	Echo planar diffusion-weighted imaging (EP DWI) provides information about the physiologic state of the brain that is not available on conventional magnetic resonance (MR) images. Specifically, it provides signal proportional to the molecular diffusion of water molecules. It has proven highly sensitive in the detection of acute infarction and it is reliable in differentiating acute stroke from other diseases that mimic acute stroke clinically and on conventional MR images. With perfusion imaging, diffusion-weighted imaging is useful in predicting final infarct size and patient outcome. Diffusion MR is also becoming increasingly useful in the evaluation of a wide variety of other disease processes including neoplasms, intracranial infections and traumatic brain injury. Because acute stroke is common in the differential diagnosis of the majority of patients who present with acute neurologic deficits, diffusion-weighted imaging has become an essential sequence. (C) 2001 Elsevier Science B.V. All rights reserved.	Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Neuroradiol, Boston, MA 02115 USA	Schaefer, PW (corresponding author), Massachusetts Gen Hosp, Div Neuroradiol, Fruit St,GRB 285, Boston, MA 02114 USA.		Schaefer, Pamela/AAA-1323-2019				Ay H, 1999, NEUROLOGY, V52, P1784, DOI 10.1212/WNL.52.9.1784; AY H, 1999, 24 AM HEART ASS INT; Bahn MM, 1997, ARCH NEUROL-CHICAGO, V54, P1411, DOI 10.1001/archneur.1997.00550230078021; Baird AE, 1997, ANN NEUROL, V41, P581, DOI 10.1002/ana.410410506; Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaulieu C, 1999, ANN NEUROL, V46, P568, DOI 10.1002/1531-8249(199910)46:4<568::AID-ANA4>3.0.CO;2-R; BEAULIEU CF, 1993, MAGNET RESON MED, V30, P201, DOI 10.1002/mrm.1910300208; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BRUNBERG JA, 1995, AM J NEURORADIOL, V16, P361; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; CHABRIAT H, 1999, REVERSIBLE DECREASE; Chenevert TL, 2000, JNCI-J NATL CANCER I, V92, P2029, DOI 10.1093/jnci/92.24.2029; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Connelly A, 1997, ARCH DIS CHILD, V77, P38, DOI 10.1136/adc.77.1.38; Corvol JC, 1998, STROKE, V29, P2649, DOI 10.1161/01.STR.29.12.2649; COWAN EM, 1994, NEUROPEDIATRICS, V25, P172, DOI 10.1055/s-2008-1073018; DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307; Demaerel P, 1999, NEUROLOGY, V52, P205, DOI 10.1212/WNL.52.1.205; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; Ebisu T, 1996, MAGN RESON IMAGING, V14, P1113, DOI 10.1016/S0730-725X(96)00237-8; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Everdingen KJ, 1998, STROKE, V29, P1783; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; GRANT P, 2001, IN PRESS RADIOLOGY; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HASEGAWA Y, 1994, NEUROLOGY, V44, P1484, DOI 10.1212/WNL.44.8.1484; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; KARONEN J, 2000, RADIOLOGY, V217, P668; Karonen JO, 1999, STROKE, V30, P1583, DOI 10.1161/01.STR.30.8.1583; KIDWELL C, 1999, 24 AM HEART ASS INT; Kim YJ, 1998, AM J ROENTGENOL, V171, P1487, DOI 10.2214/ajr.171.6.9843275; Kotsenas AL, 1999, PEDIATR RADIOL, V29, P524, DOI 10.1007/s002470050636; Krishnamoorthy KS, 2000, J CHILD NEUROL, V15, P592, DOI 10.1177/088307380001500905; KUCHARCZYK J, 1991, MAGNET RESON MED, V19, P311, DOI 10.1002/mrm.1910190220; KUCHARCZYK J, 1993, RADIOLOGY, V188, P711, DOI 10.1148/radiology.188.3.8351338; Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021; Lecouvet FE, 1999, NEUROLOGY, V52, P1085, DOI 10.1212/WNL.52.5.1085; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lovblad KO, 1997, ANN NEUROL, V42, P164; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; Lutsep HL, 1997, ANN NEUROL, V41, P574, DOI 10.1002/ana.410410505; MAEDA M, 1992, J COMPUT ASSIST TOMO, V16, P514, DOI 10.1097/00004728-199207000-00003; MARKS M, 1999, 24 AM HEART ASS INT; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; MATSUMOTO K, 1995, AM J NEURORADIOL, V16, P1107; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MINTOROVITCH J, 1994, J CEREBR BLOOD F MET, V14, P332, DOI 10.1038/jcbfm.1994.40; MOHR JP, 1995, STROKE, V26, P807, DOI 10.1161/01.STR.26.5.807; MOONEN CTW, 1991, MAGNET RESON MED, V19, P327, DOI 10.1002/mrm.1910190223; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; MULLER TB, 1995, STROKE, V26, P451, DOI 10.1161/01.STR.26.3.451; Nagesh V, 1998, STROKE, V29, P1778, DOI 10.1161/01.STR.29.9.1778; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Phillips MD, 1999, NEUROIMAG CLIN N AM, V9, P41; QUAST MJ, 1993, MAGN RESON IMAGING, V11, P465, DOI 10.1016/0730-725X(93)90465-P; Rordorf G, 1998, STROKE, V29, P939, DOI 10.1161/01.STR.29.5.939; ROSEN BR, 1991, MAGNET RESON MED, V19, P285, DOI 10.1002/mrm.1910190216; ROSEN BR, 1991, MAGNET RESON MED, V22, P293, DOI 10.1002/mrm.1910220227; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; Schaefer P, 1998, P 36 ANN M AM SOC NE; SCHAEFER P, 1999, P 37 ANN M AM SOC NE; SCHAEFER P, 1997, P 35 ANN M AM SOC NE; Schaper S, 1997, PROTEINS, V28, P1; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; SCHUIER G, 1995, 3 SCI M SOC MAGN RES; Schwamm LH, 1998, STROKE, V29, P2268, DOI 10.1161/01.STR.29.11.2268; Schwartz RB, 1998, AM J NEURORADIOL, V19, P859; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; SINGER M, 1998, P 36 ANN M AM SOC NE; Singer MB, 1998, STROKE, V29, P133, DOI 10.1161/01.STR.29.1.133; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Strupp M, 1998, ANN NEUROL, V43, P164, DOI 10.1002/ana.410430206; SYKOVA E, 1994, J CEREBR BLOOD F MET, V14, P301, DOI 10.1038/jcbfm.1994.37; Tatlisumak T, 1998, STROKE, V29, P850, DOI 10.1161/01.STR.29.4.850; TIEN RD, 1994, AM J ROENTGENOL, V162, P671, DOI 10.2214/ajr.162.3.8109520; Tong DC, 1998, NEUROLOGY, V50, P864, DOI 10.1212/WNL.50.4.864; TSURUDA JS, 1990, AM J NEURORADIOL, V11, P925; Tuor UI, 1998, EXP NEUROL, V150, P321, DOI 10.1006/exnr.1997.6766; Ueda T, 1999, AM J NEURORADIOL, V20, P983; vanderToorn A, 1996, MAGN RESON MED, V36, P914, DOI 10.1002/mrm.1910360614; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; WEISHMANN UC, 1997, LANCET, V350, P493; WICK M, 1995, STROKE, V26, P1930, DOI 10.1161/01.STR.26.10.1930	92	43	46	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAY 1	2001	186			1			S25	S35		10.1016/S0022-510X(01)00488-9			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	450FJ	WOS:000169730600005	11334987				2021-06-18	
J	Vibert, N; MacDougall, HG; de Waele, C; Gilchrist, DPD; Burgess, AM; Sidis, A; Migliaccio, A; Curthoys, IS; Vidal, PP				Vibert, N; MacDougall, HG; de Waele, C; Gilchrist, DPD; Burgess, AM; Sidis, A; Migliaccio, A; Curthoys, IS; Vidal, PP			Variability in the control of head movements in seated humans: a link with whiplash injuries?	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							RAPID POSTURAL RESPONSES; NECK MUSCLES; ACCIDENT MECHANISMS; RANDOM ROTATIONS; VERTICAL PLANE; STABILIZATION; PERTURBATIONS; PATTERNS; ACTIVATION; ORGANIZATION	1. The aim of this study was to determine how context and on-line sensory information are combined to control posture in seated subjects submitted to high-jerk, passive linear accelerations. Subjects were seated with eyes closed on a servo-controlled linear sled. They were asked to relax and received brief accelerations either sideways or in the fore-aft direction. The stimuli had an abrupt onset, comparable to the jerk experienced during a minor car collision. 2. notation and translation of the head and body were measured using an Optotrak system. In some of the subjects, surface electromyographic (EMG) responses of selected neck and/or back muscles were recorded simultaneously. For each subject, responses were highly stereotyped from the first trial, and showed little sign of habituation or sensitisation. 3. Comparable results were obtained with sideways and fore-aft accelerations. During each impulse, the head lagged behind the trunk for several tens of milliseconds. The subjects' head movement responses were distributed as a continuum in between two extreme categories. The 'stiff' subjects showed little rotation or translation of the head relative to the trunk for the whole duration of the impulse. In contrast, the 'floppy' subjects showed a large roll or pitch of the head relative to the trunk in the direction opposite to the sled movement. This response appeared as an exaggerated 'inertial' response to the impulse. 4. Surface EMG recordings showed that most of the stiff subjects were not contracting their superficial neck or back muscles. We think they relied on bilateral contractions of their deep, axial musculature to keep the head-neck ensemble in line with the trunk during the movement. 5. About half of the floppy subjects displayed reflex activation of the neck muscles on the side opposite to the direction of acceleration, which occurred before or during the head movement and tended to exaggerate it. The other floppy subjects seemed to rely on only the passive biomechanical properties of their head-neck ensemble to compensate for the perturbation. 6. In our study, proprioception was the sole source of sensory information as long as the head did not move. We therefore presume that the EMG responses and head movements we observed were mainly triggered by the activation of stretch receptors in the hips, trunk and/or neck. 7. The visualisation of an imaginary reference in space during sideways impulses significantly reduced the head roll exhibited by floppy subjects. This suggests that the adoption by the central nervous system of an extrinsic, 'allocentric' frame of reference instead of an intrinsic, 'egocentric' one may be instrumental for the selection of the stiff strategy. 8. The response of floppy subjects appeared to be maladaptive and likely to increase the risk of whiplash injury during motor vehicle accidents. Evolution of postural control may not have taken into account the implications of passive, high-acceleration perturbations affecting seated subjects.	CNRS, Lab Neurobiol Reseaux Sensorimoteurs, ESA 7060, F-75270 Paris 06, France; Univ Sydney, Dept Psychol, Vestibular Res Lab, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Eye & Ear Res Unit, Camperdown, NSW 2050, Australia	Vibert, N (corresponding author), CNRS, Lab Neurobiol Reseaux Sensorimoteurs, ESA 7060, 45 Rue St Peres, F-75270 Paris 06, France.		Migliaccio, Americo/A-5791-2013	Curthoys, Ian/0000-0002-9416-5038; MacDougall, Hamish/0000-0001-6201-1707; Migliaccio, Americo/0000-0001-8547-6590			ALLEN ME, 1994, SPINE, V19, P1285, DOI 10.1097/00007632-199405310-00017; Allum JHJ, 1998, EXP BRAIN RES, V121, P478, DOI 10.1007/s002210050484; Allum JHJ, 1997, J VESTIBUL RES-EQUIL, V7, P189; ALLUM JHJ, 1985, EXP BRAIN RES, V58, P82; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; AZZENA GB, 1978, ARCH ITAL BIOL, V116, P120; Buchanan JJ, 1999, J NEUROPHYSIOL, V81, P2325; Burleigh A, 1996, J NEUROPHYSIOL, V75, P1619; Castro W H, 1997, Eur Spine J, V6, P366, DOI 10.1007/BF01834062; COLLINS JJ, 1995, EXP BRAIN RES, V103, P151, DOI 10.1007/BF00241972; Corna S, 1996, J PHYSIOL-LONDON, V496, P589, DOI 10.1113/jphysiol.1996.sp021710; CREMIEUX J, 1994, PERCEPT MOTOR SKILL, V78, P67, DOI 10.2466/pms.1994.78.1.67; Davis CG, 1998, J MANIP PHYSIOL THER, V21, P629; DENG YC, 1989, ACCIDENT ANAL PREV, V21, P85, DOI 10.1016/0001-4575(89)90051-1; FORSSBERG H, 1994, EXP BRAIN RES, V97, P515; Freeman MD, 1999, SPINE, V24, P86, DOI 10.1097/00007632-199901010-00022; Fukushima K, 1997, EXP BRAIN RES, V117, P1, DOI 10.1007/PL00005786; Goldberg JM, 2000, EXP BRAIN RES, V130, P277, DOI 10.1007/s002210050033; Grauer JN, 1997, SPINE, V22, P2489, DOI 10.1097/00007632-199711010-00005; GRESTY M, 1989, MOVEMENT DISORD, V4, P233, DOI 10.1002/mds.870040305; GUITTON D, 1986, EXP BRAIN RES, V64, P59; Harm D L, 1993, J Vestib Res, V3, P297; Henry SM, 1998, J NEUROPHYSIOL, V80, P1939; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369; HUELKE DF, 1981, J NEUROSURG, V54, P316, DOI 10.3171/jns.1981.54.3.0316; Isableu B, 1997, EXP BRAIN RES, V114, P584, DOI 10.1007/PL00005667; Ito Y, 1997, EXP BRAIN RES, V117, P266, DOI 10.1007/s002210050221; Kanaya T, 1995, J PHYSIOL-LONDON, V489, P895, DOI 10.1113/jphysiol.1995.sp021102; Kaneoka K, 1999, SPINE, V24, P763, DOI 10.1097/00007632-199904150-00006; KESHNER EA, 1995, J NEUROPHYSIOL, V73, P2293; KESHNER EA, 1989, EXP BRAIN RES, V75, P335; KESHNER EA, 1995, J NEUROPHYSIOL, V73, P2302; Keshner EA, 2000, GAIT POSTURE, V11, P1, DOI 10.1016/S0966-6362(99)00046-6; KESHNER EA, 1988, EXP BRAIN RES, V71, P455, DOI 10.1007/BF00248739; KRAFFT M, 1998, P 16 INT TECHN C ENH; KULLGREN A, 1995, ACCIDENT ANAL PREV, V27, P717, DOI 10.1016/0001-4575(95)00025-U; Kuo AD, 1998, EXP BRAIN RES, V122, P185, DOI 10.1007/s002210050506; Luyat M, 1997, ACTA PSYCHOL, V95, P181, DOI 10.1016/S0001-6918(96)00015-7; Magnusson ML, 1999, EUR SPINE J, V8, P118, DOI 10.1007/s005860050140; MayouxBenhamou MA, 1997, EXP BRAIN RES, V113, P353, DOI 10.1007/BF02450333; MAZZINI L, 1992, ELECTROEN CLIN NEURO, V85, P183, DOI 10.1016/0168-5597(92)90131-T; MORRIS AP, 1996, P 40 STAPP CAR C; NASHNER LM, 1977, EXP BRAIN RES, V30, P13; Richter M, 1999, ORTHOPADE, V28, P414, DOI 10.1007/PL00003625; Runge CF, 1998, EXP BRAIN RES, V122, P403, DOI 10.1007/s002210050528; RYAN GA, 1993, MED J AUSTRALIA, V159, P651, DOI 10.5694/j.1326-5377.1993.tb138078.x; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; STURZENEGGER M, 1995, J NEUROL, V242, P443, DOI 10.1007/BF00873547; Thomson DB, 1996, EXP BRAIN RES, V110, P392; Versteegen G J, 1998, Eur Spine J, V7, P195, DOI 10.1007/s005860050055; VIDAL PP, 1982, AVIAT SPACE ENVIR MD, V53, P166; VIDAL PP, 1999, P INT C VIS VERS VES; VIVIANI P, 1975, BIOL CYBERN, V19, P19, DOI 10.1007/BF00319778; Wilson VJ, 1999, EXP BRAIN RES, V129, P483, DOI 10.1007/s002210050918; Winters J. M., 1990, MULTIPLE MUSCLE SYST, P461	56	43	43	0	6	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-9863 USA	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	MAY 1	2001	532	3					851	868		10.1111/j.1469-7793.2001.0851e.x			18	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	432ED	WOS:000168678500023	11313451	Bronze, Green Published			2021-06-18	
J	Maurino, J; Saposnik, G; Lepera, S; Rey, RC; Sica, RE				Maurino, J; Saposnik, G; Lepera, S; Rey, RC; Sica, RE			Multiple simultaneous intracerebral hemorrhages - Clinical features and outcome	ARCHIVES OF NEUROLOGY			English	Article							HEMATOMAS; MR	Background: The simultaneous occurrence of intracerebral hemorrhages in different arterial territories is an uncommon clinical event. Its predisposing factors and pathophysiological mechanisms are not clearly defined. Objective: To analyze the frequency, risk factors, clinical features, neuroimaging findings, and outcome of multiple simultaneous intracerebral hemorrhages (SIHs). Patients and Methods: We studied all patients with acute stroke admitted to our hospital from July 18, 1997, through December 18, 1999. Multiple SIHs were defined as the presence of 2 or more intracerebral hemorrhages affecting different arterial territories with identical computed tomographic density profiles. Patients with a history of traumatic brain injury were excluded from this study. Diagnostic investigation included routine blood and urine tests, coagulation studies, a chest radiograph, electrocardiogram, 2-dimensional transthoracic echocardiography, and computed tomography of the head without contrast medium. Disability was assessed using the National Institutes of Health Stroke Scale and Modified Rankin Scale. Results: Among 142 patients with hemorrhagic stroke, we found 4 (2.8%) with SIHs. All 4 patients had a history of uncontrolled arterial hypertension. We excluded other potential causes of multiple SIHs by using appropriate diagnostic tests. The most common clinical manifestations were headache and weakness. Localization of hematomas was supratentorial, except for one patient who had both infratentorial and supratentorial hemorrhages. The mean National Institutes of Health score an admission was 15 and the Modified Rankin Scale score was higher than 4 at 3 months. Conclusions: In our study, all patients with multiple SIHs had arterial hypertension and a poor outcome. Additional analytic studies, including new imaging techniques, can help to elucidate the association between arterial hypertension and multiple SIHs, rick factors, and underlying mechanisms of this clinical condition.	Univ Buenos Aires, Hosp JM Ramos Mejia, Dept Neurol, Stroke Serv, RA-1425 Buenos Aires, DF, Argentina	Maurino, J (corresponding author), Univ Buenos Aires, Hosp JM Ramos Mejia, Dept Neurol, Stroke Serv, Soler 4019,Sexto Piso, RA-1425 Buenos Aires, DF, Argentina.		Saposnik, Gustavo/M-3937-2017	Saposnik, Gustavo/0000-0002-5950-9886			BRODERICK JP, 1990, J NEUROSURG, V72, P195, DOI 10.3171/jns.1990.72.2.0195; Chan S, 1996, AM J NEURORADIOL, V17, P1821; DAMASIO H, 1983, ARCH NEUROL-CHICAGO, V40, P138, DOI 10.1001/archneur.1983.04050030032005; FREYTAG E, 1968, J NEUROL NEUROSUR PS, V31, P616, DOI 10.1136/jnnp.31.6.616; GILLES C, 1984, NEUROLOGY, V34, P730, DOI 10.1212/WNL.34.6.730; Guerrero A L, 1997, Neurologia, V12, P320; HICKEY WF, 1983, ARCH NEUROL-CHICAGO, V40, P519, DOI 10.1001/archneur.1983.04210070059016; KOMIYAMA M, 1995, NEURORADIOLOGY, V37, P129; Kwa VIH, 1998, ANN NEUROL, V44, P372, DOI 10.1002/ana.410440313; MCCORMICK WF, 1973, STROKE, V4, P946, DOI 10.1161/01.STR.4.6.946; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Seijo M, 1996, Rev Neurol, V24, P549; Tanikake T, 1983, No Shinkei Geka, V11, P1085; TANNO H, 1989, Neurological Surgery, V17, P223; UNO M, 1991, Neurological Surgery, V19, P933; VERSTICHEL P, 1991, REV NEUROL, V147, P671; WEISBERG L, 1981, NEUROLOGY, V31, P897, DOI 10.1212/WNL.31.7.897	17	43	50	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	APR	2001	58	4					629	632		10.1001/archneur.58.4.629			4	Clinical Neurology	Neurosciences & Neurology	419EG	WOS:000167935900013	11295994	Bronze			2021-06-18	
J	Gutierrez, E; Huang, YL; Haglid, K; Bao, F; Hansson, HA; Hamberger, A; Viano, D				Gutierrez, E; Huang, YL; Haglid, K; Bao, F; Hansson, HA; Hamberger, A; Viano, D			A new model for diffuse brain injury by rotational acceleration: I model, gross appearance, and astrocytosis	JOURNAL OF NEUROTRAUMA			English	Article						astrocytosis; biomechanics; head impact; rotational acceleration; subarachnoid hemorrhage; traumatic brain injury	AXONAL INJURY; BIOMECHANICS; DAMAGE; RATS	Rapid head rotation is a major cause of brain damage in automobile crashes and falls, This report details a new model for rotational acceleration about the center of mass of the rabbit head. This allows the study of brain injury without translational acceleration of the head. Impact from a pneumatic cylinder was transferred to the skull surface to cause a half-sine peak acceleration of 2.1 x 10(5) rad/s(2) and 0.96-ms pulse duration. Extensive subarachnoid hemorrhages and small focal bleedings were observed in the brain tissue. A pronounced reactive astrogliosis was found 8-14 days after trauma, both as networks around the focal hemorrhages and more diffusely in several brain regions. Astrocytosis was prominent in the gray matter of the cerebral cortex, layers II-V, and in the granule cell layer and around the axons of the pyramidal neurons in the hippocampus. The nuclei of cranial nerves, such as the hypoglossal and facial nerves, also showed intense astrocytosis. The new model allows study of brain injuries from head rotation in the absence of translational influences.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, Crash Safety Div, S-41296 Gothenburg, Sweden; Saab Automobile AB, Trollhattan, Sweden; China Med Univ, Brain Res Inst, Shenyang, Peoples R China	Hamberger, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.		Gutierrez-Farewik, Elena/G-6945-2012; Farewik, Elena M. Gutierrez/AAU-9832-2020; Farewik, Elena M Gutierrez/I-6842-2018	Gutierrez-Farewik, Elena/0000-0001-5417-5939; Farewik, Elena M. Gutierrez/0000-0001-5417-5939; Farewik, Elena M Gutierrez/0000-0001-5417-5939			Anderson R., 1997, P INT IRCOBI C BIOM, P181; CORETZ SC, 1989, BRAIN RES, V482, P271; Ding M, 2000, NEUROCHEM INT, V36, P313, DOI 10.1016/S0197-0186(99)00139-4; *ESTC, 1997, STRAT ROAD SAF PLAN; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goldsmith W, 1984, BIOMECHANICS IMPACT, P149; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; Holbourn AHS, 1943, LANCET, V2, P438; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; LIGTHLL JW, 1988, J NEUROTRAUM, V5, P1; LOWENHIELM P, 1978, J BIOENG, V2, P501; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1985, IRCOBI C GOT SWED; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Melvin J.W., 1993, ACCIDENTAL INJURY BI, P268; OMMAYA AK, 1984, BIOMECHANICS IMPACT, P117; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; PINCEMAILLE Y, 1989, STAPP CAR CRASH C, P177; POPESKI P, 1992, COLOUR ATLAS ANATOMY; ROSENGREN LE, 1986, BRIT J IND MED, V43, P291; SJOSTRAND J, 1965, Z ZELLFORSCH MIK ANA, V68, P481, DOI 10.1007/BF00347712; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; UNTERHARNSCHEIDT F, 1969, TEX REP BIOL MED, V27, P127; VIANO DC, 1997, THESIS KAROLINSKA I; VIANO DC, 1986, P 30 STAPP CAR CRASH, P269; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; 1971, FR, V36, P4600	32	43	46	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					247	257		10.1089/08977150151070874			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000003	11284546				2021-06-18	
J	Hausmann, R; Betz, P				Hausmann, R; Betz, P			The time course of the vascular response to human brain injury - an immunohistochemical study	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						brain injury; cortical contusion; vascular reaction; immunohistochemistry; wound age	HUMAN GLIOMA; TENASCIN-C; EXPRESSION; ASTROCYTOMAS; PROTEIN; VESSELS	In a total of 104 individuals who had sustained traumatic brain injury (TBI), the time-dependent vascular response was investigated at the injured cortical area during the first 30 weeks after the trauma. The immunohistochemical staining of the cerebral blood vessels was performed with antibodies against laminin, type IV collagen, tenascin, thrombomodulin and factor VIII associated antigen. Compared to the immunoreactivity in unaltered control tissue, a significantly increased vascular expression could be detected in cortical contusions after a postinfliction interval of at least 3 h for factor VIII, after 1.6 days for tenascin or after 6.8 days for thrombomodulin, whereas the immunostaining for laminin and type IV collagen was regularly positive even in the vascular endothelium of uninjured brain tissue.	Univ Erlangen Nurnberg, Dept Legal Med, D-91054 Erlangen, Germany	Hausmann, R (corresponding author), Univ Erlangen Nurnberg, Dept Legal Med, Univ Str 22, D-91054 Erlangen, Germany.						Alvarez-Dolado M, 1998, NEUROSCIENCE, V84, P309, DOI 10.1016/S0306-4522(97)00511-3; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Chintala SK, 1996, CANCER LETT, V101, P107, DOI 10.1016/0304-3835(96)04124-9; EISENMENGER W, 1977, THESIS MUNCHEN; Ferhat L, 1996, J NEUROCYTOL, V25, P535, DOI 10.1007/BF02284821; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; ISAKA T, 1994, ACTA NEUROPATHOL, V87, P81; MARUNO M, 1994, J NEURO-ONCOL, V19, P155, DOI 10.1007/BF01306457; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; ORITA T, 1989, ACTA NEUROPATHOL, V77, P397, DOI 10.1007/BF00687374; PETERS G, 1955, HDB SPEZIELLEN PATHO, V13, P84; Sasaki O, 1988, No To Shinkei, V40, P469; SELLIER K, 1963, ZBL VERKEHRSMED VERK, V9, P65; ZAGZAG D, 1995, CANCER RES, V55, P907	16	43	43	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	AUG	2000	113	5					288	292		10.1007/s004149900126			5	Medicine, Legal	Legal Medicine	350EV	WOS:000089088600008	11009065				2021-06-18	
J	Minnes, P; Graffi, S; Nolte, ML; Carlson, P; Harrick, L				Minnes, P; Graffi, S; Nolte, ML; Carlson, P; Harrick, L			Coping and stress in Canadian family caregivers of persons with traumatic brain injuries	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES VIEW	The purpose of this study was to document the stresses reported by Canadian caregivers of persons with brain injuries and to consider the factors which serve to mediate or moderate such stress. Highest stress scores on the Holroyd Questionnaire on Resources and Stress-Short Form (QRS) were associated with Lifespan Care and Personal Burden. Although overall burden as reported on the QRS by parents and spouses did not differ from other studies, it did differ somewhat for specific types of burden. Social Support and Spiritual Support, as measured by the F-COPES, fell within the medium use category, and scores for Reframing, Mobilizing and Passive Appraisal fell within the high use category. In multiple regression analyses, client competency as measured by the Patient Competency Rating Scale emerged as a major predictor of stress associated with Cognitive Impairment, Physical Limitations, Lifespan Care, Terminal Illness Stress, Limits on Family Opportunities, and Personal Burden. In contrast, other client characteristics (e.g. Time Since Injury) accounted for relatively little variance. The results also indicate that both Reframing and Seeking Spiritual Support as coping strategies can make an important contribution to stress reduction.	Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; Reg Community Brain Injury Serv, Kingston, ON, Canada	Minnes, P (corresponding author), Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BOND N, 1984, CLOSED HEAD INJURY P, P123; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DEPOMOEI R, 1991, HEAD INJURY FAMILY M, P100; FOLKMAN S, 1988, J PERS SOC PSYCHOL, V54, P466, DOI 10.1037/0022-3514.54.3.466; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HOLROYD J, 1979, J CLIN PSYCHOL, V325, P743; HOLROYD J, 1982, MANUAL QUESTIONNAIRE; Jackson A, 1991, COUNS PSYCHOL, V4, P355; KAY T, 1991, HEAD INJURY FAMILY M, P121; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCOLL MA, IN PRESS DISABILITY; McCubbin H. I., 1982, FAMILY STRESS COPING, P26; McCubbin H.I., 1987, FAMILY CRISIS ORIENT; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Minnes P., 1998, HDB MENTAL RETARDATI, P693; MINNES PM, 1988, AM J MENT RETARD, V93, P184; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; TAYLOR SE, 1983, AM PSYCHOL, V38, P1161, DOI 10.1037/0003-066X.38.11.1161; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WILTON K, 1986, J MENT DEFIC RES, V30, P163	35	43	46	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2000	14	8					737	748					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000007	10969892				2021-06-18	
J	Shields, DC; Schaecher, KE; Hogan, EL; Banik, NL				Shields, DC; Schaecher, KE; Hogan, EL; Banik, NL			Calpain activity and expression increased in activated glial and inflammatory cells in penumbra of spinal cord injury lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						calpain; calpastatin; spinal cord injury; calcium; neutral proteinase	PROTEOLYTIC-ENZYME; DEGRADATION; BRAIN; PROTEINS; DEMYELINATION; INHIBITOR; NEURONS; DISEASE	Following traumatic injury of the spinal cord, cells adjacent to the lesion are subject to ischemic cell death as a result of vascular disruption and secondary inflammatory responses. Proteases such as calcium-activated neutral proteinase (calpain) have been implicated in axon and myelin destruction following injury since they degrade structural proteins in the axon-myelin unit. To examine the role of calpain in cell death following spinal cord injury (SCI), calpain activity and translational expression were evaluated using Western blotting techniques. Calpain activity (as measured by specific substrate degradation) was significantly increased in and around the lesion site as early as 4 hr following injury with continued elevation at 48 hr compared to sham controls. Likewise, calpain expression was significantly increased in both the lesion site and penumbra at 4 and 48 hr after injury. Using double immunofluorescent labeling for calpain and cell-specific markers, this increase in calpain expression was found to be due in part to activated glial/inflammatory cells such as astrocytes, microglia, and infiltrating macrophages in these areas. Thus, since calpain degrades many myelin and axonal structural proteins, the increased activity and expression of this enzyme may be responsible for destruction of myelinated axons adjacent to the lesion site following SCI. (C) 2000 Wiley-Liss, Inc.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038146, R01NS031622] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31622, NS38146] Funding Source: Medline		Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BALENTINE JD, 1985, TRAUMA CENTRAL NERVO, P285; BANAYSCHWARTZ M, 1994, NEUROCHEM RES, V19, P563, DOI 10.1007/BF00971331; Banik N.L, 1999, CALPAIN PHARM TOXICO, P211; Banik Naren L., 1992, P571; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P92; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DESHPANDE RV, 1995, J NEUROSCI RES, V42, P259, DOI 10.1002/jnr.490420214; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HOGAN EL, 1985, HDB NEUROCHEMISTRY, V10, P285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELLGREN RL, 1987, FASEB J, V1, P110; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; NIXON RA, 1986, J NEUROSCI, V6, P1264; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1	35	43	44	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL 15	2000	61	2					146	150					5	Neurosciences	Neurosciences & Neurology	331AJ	WOS:000087994500005	10878587				2021-06-18	
J	Reeves, TM; Kao, CQ; Phillips, LL; Bullock, MR; Povlishock, JT				Reeves, TM; Kao, CQ; Phillips, LL; Bullock, MR; Povlishock, JT			Presynaptic excitability changes following traumatic brain injury in the rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; presynaptic volley; paired-pulse facilitation; hippocampus; rat	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; COMBINED FLUID PERCUSSION; EXCITATORY AMINO-ACIDS; HIPPOCAMPAL PYRAMIDAL CELLS; PAIRED-PULSE FACILITATION; EXTRACELLULAR POTASSIUM; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; DENTATE GYRUS	Pathological processes affecting presynaptic terminals may contribute to morbidity following traumatic brain injury (TBI). Posttraumatic widespread neuronal depolarization and elevated extracellular potassium and glutamate are predicted to alter the transduction of action potentials in terminals into reliable synaptic transmission and postsynaptic excitation. Evoked responses to orthodromic single- and paired-pulse stimulation were examined in the CA1 dendritic region of hippocampal slices removed from adult rats following fluid percussion TBI. The mean duration of the extracellularly recorded presynaptic volley (PV) increased from 1.08 msec in controls to 1.54 msec in slices prepared at 1 hr postinjury. There was a time-dependent recovery of this injury effect, and PV durations at 2 and 7 days postinjury were not different from controls. In slices removed at 1 hr postinjury, the initial slopes of field excitatory postsynaptic potentials (fEPSPs) were reduced to 36% of control values, and input/output plots revealed posttraumatic deficits in the transfer of excitation from pre- to postsynaptic elements. Manipulating potassium currents with 1.0 mM tetraethylammonium or elevating potassium ion concentration to 7.5 mM altered evoked responses but did not replicate the injury effects to PV duration. Paired-pulse facilitation of fEPSP slopes was significantly elevated at all postinjury survivals: 1 hr, 2 days, and 7 days. These results suggest two pathological processes with differing time courses: 1) a transient impairment of presynaptic terminal functioning affecting PV durations and the transduction of afferent activity in the terminals to reliable synaptic excitation and 2) a more protracted deficit to the plasticity mechanisms underlying paired-pulse facilitation. (C) 2000 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Sch Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Div Neurosurg, Richmond, VA 23298 USA	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Sch Med, Box 980709, Richmond, VA 23298 USA.	tmreeves@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Adams P R, 1986, Adv Neurol, V44, P137; AGHAJANIAN GK, 1989, SYNAPSE, V3, P331, DOI 10.1002/syn.890030406; ALREJA M, 1995, J NEUROSCI METH, V59, P67, DOI 10.1016/0165-0270(94)00195-M; ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; ANDERSEN P, 1978, BRAIN RES, V144, P11, DOI 10.1016/0006-8993(78)90431-6; ATTWELL PJE, 1995, BRAIN RES, V698, P155, DOI 10.1016/0006-8993(95)00886-U; BLISS TVP, 1983, J PHYSIOL-LONDON, V341, P617, DOI 10.1113/jphysiol.1983.sp014828; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1995, P 9 INT S ICP BRAIN, P64; CHOI DW, 1987, J NEUROSCI, V7, P369; Cochilla AJ, 1999, J NEUROSCI, V19, P193; COLBERT CM, 1992, J NEUROPHYSIOL, V68, P1; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dobrunz LE, 1997, P NATL ACAD SCI USA, V94, P14843, DOI 10.1073/pnas.94.26.14843; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Grover LM, 1998, J NEUROPHYSIOL, V79, P1167; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; HESS G, 1992, NEUROREPORT, V3, P361, DOI 10.1097/00001756-199204000-00018; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kamiya H, 1998, J PHYSIOL-LONDON, V509, P833, DOI 10.1111/j.1469-7793.1998.833bm.x; KAO CQ, 1998, J NEUROTRAUM, V15, P876; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWASAKI K, 1988, BRAIN RES, V457, P322, DOI 10.1016/0006-8993(88)90702-0; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; LAERUM H, 1994, BRAIN RES, V637, P349; LEUNG LS, 1994, BRAIN RES, V650, P75; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LOMO T, 1971, EXP BRAIN RES, V12, P46; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mattson MP, 1999, J NEUROSCI RES, V58, P2, DOI 10.1002/(SICI)1097-4547(19991001)58:1<2::AID-JNR2>3.3.CO;2-K; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Patel DR, 1997, EUR J PHARMACOL, V332, P143, DOI 10.1016/S0014-2999(97)01077-7; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; POOLOS NP, 1990, BRAIN RES, V508, P7, DOI 10.1016/0006-8993(90)91110-3; POOLOS NP, 1987, J NEUROPHYSIOL, V58, P404; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; RINGHAM GL, 1975, J PHYSIOL-LONDON, V251, P395, DOI 10.1113/jphysiol.1975.sp011100; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SILVER IA, 1990, J GEN PHYSIOL, V95, P837, DOI 10.1085/jgp.95.5.837; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STORM JF, 1990, PROG BRAIN RES, V83, P161; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	79	43	43	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2000	60	3					370	379		10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2			10	Neurosciences	Neurosciences & Neurology	308PM	WOS:000086722100012	10797540				2021-06-18	
J	O'Dell, DM; Gibson, CJ; Wilson, MS; DeFord, SM; Hamm, RJ				O'Dell, DM; Gibson, CJ; Wilson, MS; DeFord, SM; Hamm, RJ			Positive and negative modulation of the GABA(A) receptor and outcome after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; diazepam; bicuculline; cognition; (gamma)-aminobutyric acid; rat	GAMMA-AMINOBUTYRIC-ACID; EXCITATORY AMINO-ACIDS; CEREBRAL BLOOD-FLOW; CLOSED HEAD-INJURY; GLUTAMATE NEUROTOXICITY; POSTISCHEMIC DIAZEPAM; CEREBROSPINAL-FLUID; GERBIL HIPPOCAMPUS; NEURONAL INJURY; NERVOUS-SYSTEM	Glutamate-mediated excitotoxicity has been shown to contribute to cellular dysfunction following traumatic brain injury (TBI). Increasing inhibitory function through stimulation of gamma-aminobutyric acid (GABA(A)) receptors may attenuate excitotoxic effects and improve outcome. The present experiment examined the effects of diazepam, a positive modulator at the GABA(A) receptor, on survival and cognitive performance in traumatically brain-injured animals. In experiment 1, 15 min prior to central fluid percussion brain injury, rats (n = 8 per group) were injected (i.p.) with saline or diazepam (5 mg/kg or 10 mg/kg). Additional rats (n = 8) were surgically prepared but not injured (sham-injury). Rats pre-treated with the 5 mg/kg dose of diazepam had significantly lower mortality (0%) than injured, saline-treated rats (53%). Also, diazepam-treated (5 mg/kg) rats had significantly shorter latencies to reach the goal platform in the Morris water maze test performed 11-15 days post-injury. In experiment 2, at 15 min post-injury, rats were given either saline (n = 5) or 5 mg/kg diazepam (n = 6). Rats treated with diazepam did not differ in mortality from injured rats treated with vehicle. However, rats treated with diazepam at 15 min post-injury had significantly shorter latencies to reach the goal platform in the Morris water maze than injured, vehicle-treated rats. In experiment 3, the post-injury administration of bicuculline (1.5 mg/kg, n = 8), a GABA, antagonist, increased Morris water maze goal latencies compared to injured animals treated with saline (n = 8). These results suggest that enhancing inhibitory function during the acute: post-injury period produces beneficial effects on both survival and outcome following experimental TBI. (C) 2000 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA	Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Dept Psychol, POB 842018, Richmond, VA 23284 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; FOSTER NL, 1987, J CEREBR BLOOD F MET, V7, P415, DOI 10.1038/jcbfm.1987.84; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P1; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HOVDA DA, 1990, ACT NEUR S, V51, P331; Inglefield JR, 1995, HIPPOCAMPUS, V5, P460, DOI 10.1002/hipo.450050508; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOHANSEN FF, 1991, ACTA NEUROL SCAND, V84, P1; JOHANSEN J, 1985, P NATL ACAD SCI USA, V82, P3935, DOI 10.1073/pnas.82.11.3935; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Kanthasamy AG, 1995, BRAIN RES, V705, P97, DOI 10.1016/0006-8993(95)01147-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LOSCHER W, 1987, J NEUROCHEM, V49, P152, DOI 10.1111/j.1471-4159.1987.tb03407.x; LYDEN PD, 1994, STROKE, V25, P189, DOI 10.1161/01.STR.25.1.189; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MACDONALD RL, 1993, EPILIPSIA, V34, P1; MARK RJ, 1995, NEUROBIOL AGING, V16, P187, DOI 10.1016/0197-4580(94)00150-2; MATHEW RJ, 1985, BIOL PSYCHIAT, V20, P1109, DOI 10.1016/0006-3223(85)90010-1; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; ROALD OK, 1986, ACTA ANAESTH SCAND, V30, P341, DOI 10.1111/j.1399-6576.1986.tb02427.x; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHWARTZ RD, 1994, BRAIN RES, V647, P153, DOI 10.1016/0006-8993(94)91411-7; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; SHUAIB A, 1993, EXP NEUROL, V123, P284, DOI 10.1006/exnr.1993.1160; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; SMITH DH, 1993, J NEUROSCI, V13, P5383; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; STUDY RE, 1982, JAMA-J AM MED ASSOC, V247, P2147, DOI 10.1001/jama.247.15.2147; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VOLL CL, 1991, NEUROLOGY, V41, P423, DOI 10.1212/WNL.41.3.423; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YLINEN A, 1991, NEUROPEPTIDES, V19, P205, DOI 10.1016/0143-4179(91)90120-8; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	54	43	45	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 10	2000	861	2					325	332		10.1016/S0006-8993(00)02055-2			8	Neurosciences	Neurosciences & Neurology	303GL	WOS:000086414100013	10760494				2021-06-18	
J	Cheung, NS; Beart, PM; Pascoe, CJ; John, CA; Bernard, O				Cheung, NS; Beart, PM; Pascoe, CJ; John, CA; Bernard, O			Human Bcl-2 protects against AMPA receptor-mediated apoptosis	JOURNAL OF NEUROCHEMISTRY			English	Article						(S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate; Bcl-2; apoptosis; necrosis; glutamate; excitotoxicity	PROGRAMMED CELL-DEATH; INDUCED NEURONAL APOPTOSIS; PROTOONCOGENE BCL-2; HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; CORTICAL-NEURONS; KAINIC ACID; NEUROTOXICITY; SCHIZOPHRENIA; ACTIVATION	Dysfunctions of the (S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) subtype of ionotropic receptor for the brain's major excitatory neurotransmitter, L-glutamate, occur in various neurological conditions. We have previously demonstrated that AMPA receptor-mediated excitotoxicity occurs by apoptosis and here examined the influence of the expression of cell death repressor gene Bcl-2 on this excitotoxic insult. Using neuronal cortical cultures prepared from transgenic mice expressing the human Bcl-2 gene, the influence of Bcl-2 on AMPA receptor-mediated neuronal death was compared with that seen with staurosporine and H2O2. At day 6 cultures were exposed to AMPA (0.1-100 mu M), and cellular injury was analyzed 48 h after insult using phase-contrast microscopy, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide viability assay, and DNA staining with 4,6-diamidino-2-phenylindole and Sytox Green. AMPA produced a concentration-dependent increase in cell death that was significantly attenuated by human Bcl-2. AMPA (3 mu M) increased the number of apoptotic nuclei to 60% of control in wild-type cultures, and human Bcl-2 significantly decreased the number of apoptotic nuclei to 30% of AMPA-treated cultures. Human Bcl-2 only provided significant neuroprotection against neuronal injury induced by tow concentrations of staurosporine (1-10 nM) and H2O2 (0.1-30 mu M) and where neuronal death was by apoptosis, but not against H2O2-induced necrosis. Our findings indicate that overexpression of Bcl-2 in primary cultured neurons protects in an insult-dependent manner against AMPA receptor-mediated apoptosis, whereas protection was not seen against more traumatic insults. This study provides new insights into the molecular therapeutics of neurodegenerative conditions.	Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia	Beart, PM (corresponding author), Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia.	Phil.beart@med.monash.edu.au					AKBARIAN S, 1995, BRAIN RES, V699, P297, DOI 10.1016/0006-8993(95)00922-D; ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEHL C, 1993, BIOCHEM BIOPH RES CO, V197, P949, DOI 10.1006/bbrc.1993.2571; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cheung NS, 1998, NEUROPHARMACOLOGY, V37, P1419, DOI 10.1016/S0028-3908(98)00123-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COYLE JT, 1983, J NEUROCHEM, V41, P1; Eastwood SL, 1997, BIOL PSYCHIAT, V41, P636, DOI 10.1016/S0006-3223(96)00220-X; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gill R, 1997, INT REV NEUROBIOL, V40, P197; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Haugland R. P., 1996, HDB FLUORESCENT PROB, P149; Heaton MB, 1999, BRAIN RES, V817, P13, DOI 10.1016/S0006-8993(98)01173-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jacobson MD, 1998, CURR BIOL, V8, pR418, DOI 10.1016/S0960-9822(98)70267-2; Jia WWG, 1996, MOL BRAIN RES, V42, P350, DOI 10.1016/S0169-328X(96)00223-9; John CA, 1999, NEUROSCI LETT, V268, P9, DOI 10.1016/S0304-3940(99)00342-0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Nath R, 1998, J NEUROCHEM, V71, P186; Nicotera P, 1997, Adv Neurol, V72, P95; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Olney J, 1978, KAINIC ACID TOOL NEU, P95; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Simonian NA, 1996, NEUROSCIENCE, V75, P1047, DOI 10.1016/0306-4522(96)00326-0; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Williams TL, 1997, ANN NEUROL, V42, P200, DOI 10.1002/ana.410420211; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G	52	43	44	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2000	74	4					1613	1620		10.1046/j.1471-4159.2000.0741613.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	295DL	WOS:000085951400032	10737619				2021-06-18	
J	Bogner, JA; Corrigan, JD; Bode, RK; Heinemann, AW				Bogner, JA; Corrigan, JD; Bode, RK; Heinemann, AW			Rating scale analysis of the Agitated Behavior Scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Agitated Behavior Scale; agitation; anoxia; brain injury; dementia	BRAIN INJURY	Objective: Evaluate the measurement properties of the Agitated Behavior Scale (ADS) using rating scale analysis. Samples: Sample 1: 900 observations of 100 individuals with traumatic brain injury; Sample 2: 204 observations of 102 persons with dementia: Sample 3: 241 observations of 6 individuals with anuria. Results: The calibration indicated that the raring scale was used as intended. The hierarchies of item difficulty were similar across samples. Person and item separation values were within the acceptable range for the TBI sample, Generally, the items work well together, however 3 items misfit the measurement model moderately. Conclusions: Agitation as measured by the ABS is best represented as a unitary construct. Results provide additional support for the reliability and validity of the ABS.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA; Northwestern Univ, Sch Med, Rehabil Inst Chicago, Rehabil Serv Evaluat Serv, Chicago, IL USA	Bogner, JA (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; 			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; COHENMANSFIELD J, 1989, J GERONTOL, V44, P77; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1995, NEUROREHABILITATION, V5, P205, DOI 10.3233/NRE-1995-5303; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Corrigan JD, 1996, AM J ALZHEIMERS DIS, V11, P20; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; LINACRE JM, 1999, WINSTEPS PC COMPATIB; MALKMUS D, 1980, REHABILITATION HEAD; TERI L, 1992, ALZ DIS ASSOC DIS, V6, P77, DOI 10.1097/00002093-199206020-00003; Wright B. D., 1982, RATING SCALE ANAL RA	15	43	43	0	12	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2000	15	1					656	669		10.1097/00001199-200002000-00005			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	287MX	WOS:000085510800006	10745182				2021-06-18	
J	Brown, M; Gordon, WA; Haddad, L				Brown, M; Gordon, WA; Haddad, L			Models for predicting subjective quality of life in individuals with traumatic brain injury	BRAIN INJURY			English	Article							SPINAL-CORD INJURY; OF-LIFE; REHABILITATION OUTCOMES; SATISFACTION; DISABLEMENT; COMMUNITY; HANDICAP	The objective of this study was to compare the utility of ICIDH-based models and needs-based models for predicting subjective quality of life in individuals with traumatic brain injury (TBI). Using an existing data base of individuals with TBI living in the community, seven predictive models were tested using multiple regression analyses. In comparing adjusted R-2 associated With each of seven models, ic was concluded that needs-based models using subjective indicators clearly predict more variance in measures of life satisfaction, or subjective well-bring, than do either type of model relying on objective measures. It is suggested that, in documenting 'outcomes' of rehabilitation, the degree to which the focal individual's important needs are met defines more directly his/her Well-being than do measures of impairment, disability or handicap.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA	Gordon, WA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.		Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			ABBEY A, 1985, SOC INDIC RES, V16, P1, DOI 10.1007/BF00317657; ANDERSON TP, 1982, ARCH PHYSICAL MED RE, V63; Andrews F. M., 1976, SOCIAL INDICATORS WE; BECK A, 1987, BECK DEPRESSIONI INV; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; Brown M, 1999, MT SINAI J MED, V66, P160; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; BROWN M, 1999, UNPUB SUBJECTIVE QUA; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Campbell A., 1976, QUALITY AM LIFE PERC; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CREWE NM, 1980, MINN MED, V63, P586; deLateur BJ, 1997, ARCH PHYS MED REHAB, V78, P237, DOI 10.1016/S0003-9993(97)90026-5; DEMBO T, 1964, REHABIL LIT, V25, P231; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fayers PM, 1997, QUAL LIFE RES, V6, P393, DOI 10.1023/A:1018491512095; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GORDON WA, IN PRESS BRAIN INJUR; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEUBNER RA, 1998, J REHABILITATION OUT, V2, P8; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Krause JS, 1998, REHABIL PSYCHOL, V43, P282, DOI 10.1037/0090-5550.43.4.282; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LARSEN RJ, 1985, SOC INDIC RES, V17, P1, DOI 10.1007/BF00354108; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; LINDENBERG S, 1993, ACTA SOCIOL, V36, P191, DOI 10.1177/000169939303600304; Lindenberg S., 1986, PARADOXICAL EFFECTS; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; Maslow A. H, 1970, MOTIVATION PERSONALI; *MED OUTC TRUST, 1992, SF36 HLTH SURV; Murray H. A., 1938, EXPLORATIONS PERSONA; Ormel J, 1997, SOC SCI MED, V45, P1051, DOI 10.1016/S0277-9536(97)00032-4; Pieters L, 1995, PHYTOMEDICINE, V2, P17, DOI 10.1016/S0944-7113(11)80043-7; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; STIGLER GJ, 1977, AM ECON REV, V67, P76; TENNANT A, 1995, ANN RHEUM DIS, V54, P439, DOI 10.1136/ard.54.6.439; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITENECK GG, 1992, UNPUB COMMUNITY REEN; *WHO, 1997, ICIDH2 INT CLASS IMP; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; World Health Organization, 1980, INT CLASS IMP DIS HA; 1995, QUALITY LIFE INTERVI	54	43	44	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2000	14	1					5	19		10.1080/026990500120899			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200003	10670658				2021-06-18	
J	Shi, R; Pryor, JD				Shi, R; Pryor, JD			Temperature dependence of membrane sealing following transection in mammalian spinal cord axons	NEUROSCIENCE			English	Article						axon; temperature; membrane scaling; spinal cord injury; neurotrauma; nerve repair	CULTURED APLYSIA NEURONS; NERVE MYELINATED AXONS; CNS WHITE MATTER; MODERATE HYPOTHERMIA; IN-VITRO; NA+-CA2+ EXCHANGER; BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; DENDRITE TRANSECTION; NEURITE TRANSECTION	Using an in vitro sucrose-gap recording chamber, sealing of cut axone in isolated strips of white matter from guinea pig spinal cord was measured by recording the "compound membrane potential". This functional sealing was found to correlate well with anatomical resealing, measured by a horseradish peroxidase uptake assay. Near-complete functional and anatomical recovery of the axonal membrane occurred routinely within 60 min following transection at 37 degrees C in regular Krebs' solution. The rate of membrane potential recovery is exponential, with a time-constant of 20 +/- 5 min. The sealing process at 31 degrees C was similar to that at 37 degrees C, acid was effectively blocked at 25 degrees C, under which condition most axons continued to take up horseradish peroxidase for more than 1 h, and failed to substantially recover their membrane potential. Seventy-five percent of the cords transected at 40 degrees C had similar sealing behavior to those at 37 degrees C and 31 degrees C. The balance failed to seal the cut end. Two-dimensional morphometric analysis has shown that raising the temperature from 25 degrees C to above 31 degrees C significantly decreases axonal permeabilization to horseradish peroxidase (increases the sealing of transected ends) across all areas of a transverse section of spinal cord. Moreover, this enhancement of sealing exists across all axon calibers. Since severe cooling compromises membrane resealing, caution needs to be taken when hypothermic treatment (below 25 degrees C) is applied within the first 60 min following mechanical injury. In summary, we have found that at normal temperature (37 degrees C), nerve fibers repair their damaged membrane following physical injury with an hour. This is similar at mildly lower (31 degrees C) and relatively higher (40 degrees C) temperature, although some fibers tend to collapse under this febrile temperature. Moreover, severely low temperature (25 degrees C) hindered the repair of damaged membranes. Based on our study, caution is needed in treating spinal cord injury with low temperatures. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Shi, R (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA.						Agrawal SK, 1996, J NEUROSCI, V16, P545; AGUAYO AJ, 1983, BIRTH DEFECTS-ORIG, V19, P327; BENBASSAT D, 1994, EUR J NEUROSCI, V6, P1605, DOI 10.1111/j.1460-9568.1994.tb00551.x; Biagas Katherine V., 1998, Current Opinion in Pediatrics, V10, P271, DOI 10.1097/00008480-199806000-00009; BOENING JA, 1989, NEUROSCIENCE, V33, P263, DOI 10.1016/0306-4522(89)90205-4; Borgens R, 1989, ELECT FIELDS VERTEBR; BORGENS RB, 1980, P NATL ACAD SCI-BIOL, V77, P1209, DOI 10.1073/pnas.77.2.1209; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1981, SCIENCE, V213, P611, DOI 10.1126/science.7256258; BORGENS RB, 1977, J EXP ZOOL, V200, P403, DOI 10.1002/jez.1402000310; Bray GM, 1987, PROG BRAIN RES <D>, V71, P373; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; CAMPBELL G, 1992, J NEUROCYTOL, V21, P755, DOI 10.1007/BF01237903; CARLSTEDT T, 1985, BRAIN RES, V347, P188, DOI 10.1016/0006-8993(85)90911-4; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CROALL DE, 1991, PHYSIOL REV, V71, P813; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Ebmeyer U, 1998, J NEUROTRAUM, V15, P323, DOI 10.1089/neu.1998.15.323; GALLANT PE, 1988, J NEUROSCI, V8, P1479; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; GOLDBERG WJ, 1986, J NEUROSCI, V6, P3144; GROSS GW, 1983, J NEUROSCI, V3, P1979; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HAYES KC, 1993, PARAPLEGIA, V31, P730, DOI 10.1038/sc.1993.115; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; KEIRSTEAD HS, 1995, J NEUROSCI, V15, P6963; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; LAMPERT P, 1964, LAB INVEST, V13, P825; Lehning EJ, 1996, J NEUROCHEM, V66, P493; LOPACHIN RM, 1995, J NEUROSCI, V15, P6735; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS JH, 1994, J NEUROTRAUM, V11, P35, DOI 10.1089/neu.1994.11.35; LUCAS JH, 1987, BRAIN RES, V425, P384, DOI 10.1016/0006-8993(87)90526-9; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MEIRI H, 1981, SCIENCE, V211, P709, DOI 10.1126/science.7455707; NIGGLI V, 1987, J MEMBRANE BIOL, V100, P97, DOI 10.1007/BF02209144; Rosenberg LJ, 1996, BRAIN RES, V734, P349; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; SANGER JW, 1980, P NATL ACAD SCI-BIOL, V77, P5268, DOI 10.1073/pnas.77.9.5268; Shi R., 1996, Society for Neuroscience Abstracts, V22, P1185; Shi R., 1997, Society for Neuroscience Abstracts, V23, P270; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; SHI R, 1995, J NEUROTRAUM, V12, P996; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; SIMS TJ, 1994, EXP BRAIN RES, V99, P25; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; STYS PK, 1992, J NEUROSCI, V12, P430; Teng YD, 1997, J NEUROSCI, V17, P4359; Trescher WH, 1997, BRAIN DEV-JPN, V19, P326, DOI 10.1016/S0387-7604(97)00027-2; VINCENT C, 1990, MOL REPROD DEV, V26, P227, DOI 10.1002/mrd.1080260306; WANG OL, 1993, BIOCHEM J, V291, P803, DOI 10.1042/bj2910803; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; YAWO H, 1985, J NEUROSCI, V5, P1626; ZIV NE, 1993, EUR J NEUROSCI, V5, P657, DOI 10.1111/j.1460-9568.1993.tb00531.x	64	43	44	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	98	1					157	166		10.1016/S0306-4522(00)00096-8			10	Neurosciences	Neurosciences & Neurology	326NA	WOS:000087740600017	10858622				2021-06-18	
J	Murphy, LS; Teasdale, GM; Murray, GD; Miller, DJ; Pickard, JD; Shaw, MDM				Murphy, LS; Teasdale, GM; Murray, GD; Miller, DJ; Pickard, JD; Shaw, MDM			Head injuries in four British neurosurgical centres	BRITISH JOURNAL OF NEUROSURGERY			English	Article						case mix; clinical trials; head injury; intensive care; intracranial pressure monitoring	INTENSIVE-CARE; MANAGEMENT; SCALE	An issue in the design of trials in traumatic brain injury is whether variation amongst centres in 'conventional' management could mask the impact of a powerful new pharmacological agent. We report the results of an observational study of 988 patients admitted to one of four British neurosurgical units between 1986 and 1988 within 3 days of a severe head injury. The centres fell into two pairs on the basis of the 'intensity' of management. In Edinburgh and Southampton, more frequent use of intracranial pressure monitoring, ventilation and osmotic diuretics was made than in Glasgow and Liverpool. The odds ratio for an independent outcome at 6 months in Edinburgh or Southampton, relative to Glasgow or Liverpool, controlling for case mix, was 1.43 (95% CI, 1.03-1.98, p = 0.033). Thus, there is weak evidence of an association between the approach to management and clinical outcome at 6 months.	Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Glasgow, Dept Med & Therapeut, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Neurosurg, Glasgow G12 8QQ, Lanark, Scotland; Univ Cambridge, Dept Neurosurg, Cambridge CB2 1TN, England; Walton Ctr Neurol & Neurosurg NHS Trust, Liverpool, Merseyside, England	Murray, GD (corresponding author), Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			Murray, Gordon/0000-0001-9866-4734			Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bullock MR, 1996, J NEUROTRAUM, V13, P643; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; HARARI RJ, 1992, J NEUROSURG, V76, pA397; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; MASS AIR, 1983, J NEUROSURG, V58, P321; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	14	43	43	0	0	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	DEC	1999	13	6					564	569		10.1080/02688699943060			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	272YR	WOS:000084679500004	10715724				2021-06-18	
J	Pruneau, D; Chorny, I; Benkovitz, V; Artru, A; Roitblat, L; Shapira, Y				Pruneau, D; Chorny, I; Benkovitz, V; Artru, A; Roitblat, L; Shapira, Y			Effect of LF 16-0687MS, a new nonpeptide bradykinin B-2 receptor antagonist, in a rat model of closed head trauma	JOURNAL OF NEUROTRAUMA			English	Article						B-2 receptors; bradykinin; brain edema; closed head trauma; neurological status; nonpeptide antagonists; rat	VASOGENIC BRAIN EDEMA; KALLIKREIN-KININ SYSTEM; CEREBRAL ARTERIOLES; NEUROPEPTIDE-Y; SPINAL-CORD; ASTROCYTES; INJURY; PERMEABILITY; MEDIATOR; VESSELS	Bradykinin is an endogenous nonapeptide which potently dilates the cerebral vasculature and markedly increases vascular permeability. These effects are mediated by B-2 receptors located on the vascular endothelium. Previous experimental studies have shown that blockade of the kallikrein-kinin system, which mediates the formation of bradykinin, afforded a reduction of the brain edema that developed following a cryogenic cortical lesion. In the present study, we investigated the effect of LF 16-0687MS, a novel nonpeptide B-2 receptor antagonist, on cerebral edema and neurological severity score (NSS) after closed head injury to rats. LF 16-0687MS or its vehicle (NaCl 0.9%) was continuously infused at 10, 30, and 100 mu g/kg/min over 23 h starting 1 h after a focal trauma to the left hemisphere was induced using a weight-drop device. The extent of edema formation was evaluated 24 h after trauma from left and right hemispheres samples by measurement of specific gravity and water content. In a separate study, a neurological severity score based on scoring of behavioural and motor functions was evaluated 1 h and over 1 week after trauma. LF 16-0687MS at 100 mu g/kg/min markedly reduced the development of brain edema as indicated by a 68% increase in specific gravity (p < 0.05) and a 64% decrease of water content (p < 0.05) in the left hemisphere. In addition the recovery of neurological function was significantly improved by 100 mu g/kg/min LF 16-0687MS from day 3 to day 7 after CHT. In a separate experiment, we also showed that LF 16-0687MS at 100 mu g/kg/min given either 1 h before or 30 min after CHT did not affect mean arterial blood pressure. These results show that blockade of bradykinin B-2 receptors is an effective approach to reduce cerebral edema and to improve neurological outcome after a focal contusion to the cranium.	Fournier Labs, Res Ctr, F-21121 Daix, France; Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Beer Sheva, Israel; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	Pruneau, D (corresponding author), Fournier Labs, Res Ctr, 50 Rue Dijon, F-21121 Daix, France.	d.pruneau@fournier.fr					BHOOLA KD, 1992, PHARMACOL REV, V44, P1; DODEY P, 1998, 13 FRENCH JAP S MED; DODEY P, 1998, Patent No. 24783; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397; ELLIS EF, 1989, J NEUROSURG, V61, P97; FELETOU M, 1994, BRIT J PHARMACOL, V112, P683, DOI 10.1111/j.1476-5381.1994.tb13130.x; Gecse A, 1989, Adv Exp Med Biol, V247A, P249; Gorlach C, 1996, PEPTIDES, V17, P1373, DOI 10.1016/S0196-9781(96)00223-9; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOSLI E, 1993, NEUROREPORT, V4, P159; HOSLI L, 1992, NEUROSCI LETT, V148, P114, DOI 10.1016/0304-3940(92)90817-Q; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; KATUSIC ZS, 1993, STROKE, V24, P392, DOI 10.1161/01.STR.24.3.392; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mayhan WG, 1996, BRAIN RES, V738, P337, DOI 10.1016/S0006-8993(96)01000-1; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NAROTAM PK, 1995, J NEUROSURG, V82, pA350; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pruneau D, 1999, FUND CLIN PHARMACOL, V13, P75, DOI 10.1111/j.1472-8206.1999.tb00323.x; Pruneau D, 1998, BRIT J PHARMACOL, V125, P365, DOI 10.1038/sj.bjp.0702083; PRUNEAU D, 1999, IN PRESS IMMUNOPHARM; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; ROSENBLUM WI, 1986, STROKE, V17, P494, DOI 10.1161/01.STR.17.3.494; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; SCHILLING L, 1997, KIDNEY INT S59, V51, pS69; SCHULZ J, 1999, 11 INT S BRAIN OED M; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1989, PROSTAG LEUKOTR ESS, V36, P49, DOI 10.1016/0952-3278(89)90162-2; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; STEPHENS GJ, 1993, NEUROSCI LETT, V153, P223, DOI 10.1016/0304-3940(93)90327-H; STOVER J, 1999, 11 INT S BRAIN OED M; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x	47	43	43	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1057	1065		10.1089/neu.1999.16.1057			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500004	10595822				2021-06-18	
J	Cifu, DX; Huang, ME; Kolakowsky-Hayner, SA; Seel, RT				Cifu, DX; Huang, ME; Kolakowsky-Hayner, SA; Seel, RT			Age, outcome, and rehabilitation costs after paraplegia caused by traumatic injury of the thoracic spinal cord, conus medullaris, and cauda equina	JOURNAL OF NEUROTRAUMA			English	Article						age; costs; outcome; paraplegia; rehabilitation	BRAIN INJURY; OLDER ADULT	The object of this study was to investigate the relationships of age on neurologic and functional outcome, hospitalization length of stay (LOS), and hospital charges after spinal cord injury (SCI). At 20 medical centers, 2,169 consecutive adult patients with paraplegia SCI were assessed in acute care and inpatient rehabilitation. Outcome and treatment measures included the ASIA motor index score, functional independence measure, discharge to community ratio, LOS, and hospital charges. Age differences were examined by separating the sample into 11 age categories and conducting one-way analyses of variance on treatment, medical expense, and outcome measures that included the Functional Independence Measure (FIM) and ASIA motor index scores. Cramer's statistic was used to derive a chi-square value that indicated whether variables differed significantly in terms of age. Post-hoc Tukey tests were also performed. Age-related differences were found with multiple demographic variables. Significant differences between age categories were found with regard to the following treatment measures: ASIA motor index scores at acute-care admission and at discharge, rehabilitation LOS, inpatient rehabilitation hospitalization charges, total LOS, total hospitalization charges, FIM scores at inpatient rehabilitation admission and discharge, FIM change, and FIM efficiency. In conclusion, in patients with paraplegia, age appears to adversely affect functional outcome, rehabilitation LOS, and hospital costs. However, neurologic recovery as defined by the ASIA motor scores does not appear to be related to age.	Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Huang, ME (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B80029] Funding Source: Medline		ALANDER DH, 1994, SPINE, V19, P2299, DOI 10.1097/00007632-199410150-00008; *AM SPIN INJ ASS, 1996, INT STAND NEUR FUNCT; Bruning JL., 1997, COMPUTATIONAL HDB ST, V4th ed.; Burns SP, 1997, ARCH PHYS MED REHAB, V78, P1169, DOI 10.1016/S0003-9993(97)90326-9; CHARLES ED, 1978, PARAPLEGIA, V15, P302, DOI 10.1038/sc.1977.46; CHEN D, 1996, PHYSICAL MED REHABIL, P1149; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; CIFU DX, 1995, NEUROREHABILITATION, V5, P245, DOI 10.3233/NRE-1995-5307; CIFU DX, IN PRESS NEUROREHABI; DEVIVO MJ, 1990, ARCH NEUROL-CHICAGO, V47, P687, DOI 10.1001/archneur.1990.00530060101026; Ditunnio John F. Jr., 1995, P170; EISENBERG MG, 1985, PARAPLEGIA, V23, P335, DOI 10.1038/sc.1985.53; Go Bette K., 1995, P21; HALL JV, 1994, CONTEMP ECON POLICY, V12, P1, DOI 10.1111/j.1465-7287.1994.tb00441.x; Hays WL, 1994, STATISTICS; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KEITH RA, 1987, ADV CLIN REHABILITAT, V2, P6; KIWERSKI JE, 1992, INJURY, V23, P397, DOI 10.1016/0020-1383(92)90016-L; LEHMAN B, 1988, POSTGRAD GERIATR, V83, P140; McGlinchey-Berroth R, 1995, J Spinal Cord Med, V18, P183; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; Menter Robert R., 1995, P272; MEYERS AR, 1985, ARCH PHYS MED REHAB, V66, P704; *NAT SPIN CORD INJ, 1998, SPIN CORD INJ FACTS; Ota T, 1996, SPINAL CORD, V34, P531, DOI 10.1038/sc.1996.96; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; ROTH EJ, 1992, PARAPLEGIA, V30, P520, DOI 10.1038/sc.1992.109; Stover Samuel L., 1995, P317; WATERS RL, 1991, CLIN ORTHOP RELAT R, P14; Watson N, 1976, Paraplegia, V14, P36; YARKONY GM, 1988, J CLIN EPIDEMIOL, V41, P173, DOI 10.1016/0895-4356(88)90091-1	31	43	45	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					805	815		10.1089/neu.1999.16.805			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700006	10521140				2021-06-18	
J	Hellawell, DJ; Taylor, R; Pentland, B				Hellawell, DJ; Taylor, R; Pentland, B			Persisting symptoms and carers' views of outcome after subarachnoid haemorrhage	CLINICAL REHABILITATION			English	Article							BLUNT HEAD-INJURY; QUALITY-OF-LIFE; EARLY OPERATION; RELATIVES VIEW; HEMORRHAGE; DEFICITS; DEPRESSION; IMPAIRMENT; ADJUSTMENT; COGNITION	Objective: To report the outcome of aneurysmal subarachnoid haemorrhage (SAH) in terms of subjective symptoms and carers' perspective over a period of two years. Design: Forty-four consecutive patients admitted to a Regional Neurosurgical Unit and who survived aneurysmal SAH were invited for outpatient assessment at 6, 12 and 24 months post haemorrhage. Measures: The Glasgow Outcome Scale (GOS) was used to measure global outcome; the Hospital Anxiety and Depression Scale (HAD) to screen for affective symptoms; the Head Injury Symptom Checklist (HISC) to detect symptoms commonly reported after head trauma; and information was collected from a close friend or relative of the patient using the Relative's Questionnaire (RO). Results: GOS outcome was significantly related to the severity of the original haemorrhage, as classified by the World Federation of Neurological Surgeons (WFNS) Grading Scale, on admission to hospital. However, even in cases where patients had made a good recovery according to the GOS, a variety of problems were frequently reported by patients and relatives, and many of these persisted for the duration of the study. The three most common and persistent symptoms were tiredness (63%, 59% and 59% at 6, 12 and 24 months respectively), memory disturbance (50%, 52% and 56%) and passivity (61%, 47% and 46%). In contrast, the prevalence of disturbed mood, as reported using the HAD, was similar to that of the general population. Conclusions: Studies of outcome following SAH should address these subtle disturbances, and information pertaining to potential long-term problems should be provided to patients and relevant others.	Univ Edinburgh, Rehabil Studies Unit, Edinburgh, Midlothian, Scotland; Western Gen Hosp NHS Trust, Edinburgh, Midlothian, Scotland; Scottish Brain Injury Rehabil Serv, Edinburgh, Midlothian, Scotland	Pentland, B (corresponding author), Astley Ainslie Hosp, Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.						ANDERSON SI, 1994, CLIN REHABIL, V8, P301; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DRAKE CG, 1988, J NEUROSURG, V68, P985; GOLDBERG RJ, 1995, AM J MED, V98, P278, DOI 10.1016/S0002-9343(99)80375-1; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; HELLAWELL DJ, 1997, ADV NEUROTRAUMA RES, P115; Hop JW, 1998, STROKE, V29, P798, DOI 10.1161/01.STR.29.4.798; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; HUTTER BO, 1993, NEUROSURGERY, V33, P999; JENNETT B, 1975, LANCET, V1, P80; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LINDSAY K, 1991, NEUROLOGY NEUROSURGE; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; MCKENNA P, 1989, BRIT MED J, V299, P485, DOI 10.1136/bmj.299.6697.485; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; Ogden J. A., 1990, NEUROPSY NEUROPSY BE, V3, P260; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; OSullivan MG, 1996, BRIT J NEUROSURG, V10, P445, DOI 10.1080/02688699647069; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; SONESSON B, 1987, NEUROSURGERY, V21, P279, DOI 10.1227/00006123-198709000-00001; SORYAL I, 1992, CLIN REHABIL, V6, P103; VANGIJN J, 1994, STROKE, V25, P1623, DOI 10.1161/01.STR.25.8.1623; VILKKI J, 1990, NEUROSURGERY, V26, P579, DOI 10.1227/00006123-199004000-00004; Wade DT, 1992, MEASUREMENT NEUROLOG; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	43	43	0	3	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	AUG	1999	13	4					333	340		10.1191/026921599669500092			8	Rehabilitation	Rehabilitation	223NB	WOS:000081846200008	10460121				2021-06-18	
J	Hill-Felberg, SJ; McIntosh, TK; Oliver, DL; Raghupathi, R; Barbarese, E				Hill-Felberg, SJ; McIntosh, TK; Oliver, DL; Raghupathi, R; Barbarese, E			Concurrent loss and proliferation of astrocytes following lateral fluid percussion brain injury in the adult rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						proliferating cell nuclear antigen; Cajal's gold sublimate; glial fibrillary acidic protein; blood brain barrier; inflammation; macrophages	CELL NUCLEAR ANTIGEN; REACTIVE ASTROCYTES; EXPRESSION; IMMUNOHISTOCHEMISTRY; APOPTOSIS; PROTEIN; MOUSE	Astrocyte populations were analyzed over a period of 1 month in the hippocampus following lateral fluid percussion (FP) brain injury. Rats (n = 23) were subjected either to a brain injury of moderate severity, or to anesthesia and surgery without injury (n = 7), At 3 days, 1, 2, or 4 weeks postinjury, subgroups of animals were sacrificed and the brains removed and sectioned for histochemical analysis, The density of astrocytes, identified with gold sublimate staining, decreased significantly in the ipsilateral hippocampus of injured rats 3 days following injury, eventually falling to 64% of the total astrocyte population present in uninjured animals by 1 week postinjury, One month postinjury, the density of hippocampal astrocytes had returned to 85% of the total number of astrocytes observed in the hippocampus of uninjured animals. In order to characterize the post-traumatic formation of new astrocytes, immunohistochemistry was performed using antibodies to proliferating cell nuclear antigen (PCNA) and to glial fibriallary acidic protein (GFAP), Positive immunolabeling for both PCNA and GFAP was most abundant at 3 days following FP brain injury in regions where the blood brain barrier was compromised, and was not detectable by 1 month postinjury, These results indicate that astrocyte proliferation after injury may be evoked by mitogens released from vascular sources, and may be an attempt to compensate for some of the astrocytic cell loss observed after injury. J, Neurosci, Res, 57:271-279, 1999, (C) 1999 Wiley-Liss, Inc.	Univ Connecticut, Ctr Hlth, Dept Neurol, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Dept Anat, Farmington, CT USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Hill-Felberg, SJ (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.		Oliver, Douglas L./AAZ-2011-2020	Oliver, Douglas L./0000-0002-1176-4001	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS19943, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R01NS019943, P01NS008803] Funding Source: NIH RePORTER		ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; CAVANAGH JB, 1970, J ANAT, V106, P471; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GUILIAN D, 1988, J NEUROSCI, V8, P2485; GUILIAN D, 1985, SCIENCE, V228, P497; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HATTON JD, 1993, GLIA, V9, P18, DOI 10.1002/glia.440090104; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; KORR H, 1994, CELL TISSUE RES, V278, P85, DOI 10.1007/BF00305780; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MIYAKE T, 1992, BRAIN RES, V590, P300, DOI 10.1016/0006-8993(92)91109-R; POLVISHOCK JT, 1992, J NEUROTRAUMA S, V9, pS189; RINK A, 1995, AM J PATHOL, V147, P1575; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vaughn J E, 1971, UCLA Forum Med Sci, V14, P103; VAUGHN JE, 1969, J COMP NEUROL, V131, P143; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	37	43	45	1	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL 15	1999	57	2					271	279		10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z			9	Neurosciences	Neurosciences & Neurology	211JM	WOS:000081157500013	10398305				2021-06-18	
J	Carter, BG; Taylor, A; Butt, W				Carter, BG; Taylor, A; Butt, W			Severe brain injury in children: long-term outcome and its prediction using somatosensory evoked potentials (SEPs)	INTENSIVE CARE MEDICINE			English	Article						somatosensory evoked potentials; brain injury; outcome; outcome prediction; health state measure	SEVERE HEAD-INJURY; HYPOXIC-ISCHEMIC COMA; FOLLOW-UP; PROGNOSTIC UTILITY; TRAUMATIC COMA; CONDUCTION; SURVIVAL; DAMAGE; TIME	Objective: To evaluate the outcome of children 1 and 5 years after severe brain injury (Glasgow Coma Score < 8) using a functional measure [Glasgow Outcome Scale (GOS)] and a health status measure (the Torrance Health State (HUI:1)) and to determine the ability of somatosensory evoked potentials (SEPs) to predict these longterm outcomes. Design: Prospective study. Setting: A 16-bed paediatric intensive care unit in a tertiary children's hospital. Patients ann participants: 105 children with severe brain injury: Interventions: SEPs were recorded once in the first week after admission. Outcome was assessed 1 and 5 years after injury using the GOS and at 5 years after injury using HUI:1. Measurements and results: At 5 years, using the GOS, 46 (43.8%) children had a good outcome, 10 (9.5 %) were moderately disabled, 2 (1.9 %) severely disabled, 3 (2.9 %) vegetative and 44 (41.9 %) had died. At 5 years, 17 of 40 (42.5 %) survivors from 1 year had changed outcomes: 12 had improved, 3 had worsened and 2 had died. For a normal SEP, positive predictive power was 85.4 %, sensitivity 62.5 %, specificity 87.8 %, negative predictive power 67.2 % and the positive likelihood ratio was 5.1. For bilaterally absent responses, positive predictive power was 90.9 %, sensitivity 61.2 %, specificity 94.6 %, negative predictive Fewer 73.6 % and the positive likelihood ratio was 11.4. Outcomes using HUI:1 were: 30 (28.6 %) had a good quality of life, 21 (20.0 %) had a moderate quality of life, 7 (6.7 %) a poor quality, 44 died (41.9 %) and 3 (2.9 %) survived in a state deemed worse than death. For a normal SEP, positive predictive power was 85.4 %, sensitivity 68.6 %, specificity 88.9 %, negative predictive power 75.0 % and the positive likelihood ratio was 6.2. For bilaterally absent responses, positive predictive power was 93.9 %, sensitivity 57.4 %, specificity 96.1 %, negative predictive power 68.1 % and the positive likelihood ratio was 14.6. Conclusions: The outcome for children with severe brain injury should be assessed 5 years after injury because important changes occur between 1 year and 5 years. Differences exist between outcomes assessed using the GOS and HUI:1 as they measure slightly different aspects of function. Consideration should therefore be given to using both measures. SEPs are excellent predictors of long-term outcome measured by either the GOS or the HUI:1.	Royal Childrens Hosp, Paediat Intens Care Unit, Parkville, Vic 3052, Australia	Carter, BG (corresponding author), Royal Childrens Hosp, Paediat Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.						ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DEMEIRLEIR LJ, 1987, PEDIATR NEUROL, V3, P78, DOI 10.1016/0887-8994(87)90031-2; FACCO E, 1991, Brain Topography, V3, P447, DOI 10.1007/BF01129004; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GANES T, 1988, ELECTROEN CLIN NEURO, V69, P6, DOI 10.1016/0013-4694(88)90030-2; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRIEGER D, 1995, CRIT CARE MED, V23, P1123, DOI 10.1097/00003246-199506000-00020; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MCPHERSON RW, 1986, ANESTHESIOLOGY, V65, P584, DOI 10.1097/00000542-198612000-00004; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NEWLON PG, 1983, NEUROSURGERY, V12, P613, DOI 10.1227/00006123-198306000-00003; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; SACKETT DL, 1997, EVIDENCE BASED MED P, P118; SBORDONE RJ, 1995, BREAIN INJ, V9, P255; SLOAN TB, 1990, BRIT J ANAESTH, V64, P590, DOI 10.1093/bja/64.5.590; SUTTON LN, 1982, J NEUROSURG, V57, P178, DOI 10.3171/jns.1982.57.2.0178; SWAN PK, 1987, CRIT CARE MED, V15, P355, DOI 10.1097/00003246-198704000-00034; TAYLOR MJ, 1989, PEDIATR NEUROL, V5, P145, DOI 10.1016/0887-8994(89)90063-5; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TORRANCE GW, 1992, PROVISIONAL HLTH STA; YING Z, 1992, J NEUROL NEUROSUR PS, V55, P470, DOI 10.1136/jnnp.55.6.470	49	43	45	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	1999	25	7					722	728		10.1007/s001340050936			7	Critical Care Medicine	General & Internal Medicine	223TL	WOS:000081856900013	10470577				2021-06-18	
J	Dietrich, WD; Truettner, J; Zhao, WZ; Alonso, OF; Busto, R; Ginsberg, MD				Dietrich, WD; Truettner, J; Zhao, WZ; Alonso, OF; Busto, R; Ginsberg, MD			Sequential changes in glial fibrillary acidic protein and gene expression following parasagittal fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; glial fibrillary acidic protein (GFAP); gene expression; traumatic injury	GFAP-MESSENGER-RNA; MILD CORTICAL CONTUSION; NERVE GROWTH-FACTOR; HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; SPREADING DEPRESSION; CEREBRAL CONTUSION; ASTROCYTOMA-CELLS; NEURONAL-ACTIVITY; ASTROGLIAL CELLS	This study documents the regional and temporal patterns of glial fibrillary acidic protein (GFAP) RNA and protein expression after parasagittal fluid-percussion (F-P) brain injury (1.7 to 2.2 atm) in male Sprague-Dawley rats. In situ hybridization was conducted in 28 rats with a S-35-labeled antisense riboprobe to GFAP at 0.5, 2, and 6 hours and 1, 3, and 30 days after traumatic brain injury (TBI) or sham procedures. Immunocytochemical staining of GFAP was conducted in 20 rats at 1, 3, 7, and 30 days after TBI or sham procedures. At 0.5 and 2 hours after TBI, increased GFAP mRNA was restricted to superficial cortical areas underlying the impact site. At 24 hours, increased GFAP mRNA was observed throughout the traumatized hemisphere except within the histopathologically vulnerable lateral parietal cortex and external capsule. Contralateral expression within the hippocampus and cingulate and lateral cortices was also observed. Three days after TBI, GFAP mRNA expression was prominent overlying pial surfaces, in cortical regions surrounding the contusion, and within the hippocampus and lateral thalamus. Immunocytochemical visualization of GFAP at 1 and 3 days demonstrated reactive astrocytes overlying the pial surface, surrounding the cortical contusion, and within ipsilateral white matter tracts, hippocampus, and lateral thalamus. At 30 days, GFAP mRNA and protein expression were present within the deeper cortical layers of the lateral somatosensory cortex and lateral thalamus and throughout ipsilateral white matter tracts. These data demonstrate a complex pattern of GFAP mRNA and protein expression within gray and white matter tracts following F-P brain injury. Patterns of GFAP gene expression may be a sensitive molecular marker for evaluating the global response of the brain to focal injury in terms of progressive neurodegenerative as well as regenerative processes.	Univ Miami, Sch Med, Dept Neurol D4 5, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Antanitus DS, 1998, NEUROSCIENTIST, V4, P154, DOI 10.1177/107385849800400310; AQUINO DA, 1990, J NEUROCHEM, V54, P1398, DOI 10.1111/j.1471-4159.1990.tb01975.x; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, NEUROSCI RES COMMUN, V20, P157, DOI 10.1002/(SICI)1520-6769(199705)20:3<157::AID-NRC197>3.3.CO;2-Z; BARRES BA, 1990, ANNU REV NEUROSCI, V13, P441, DOI 10.1146/annurev.neuro.13.1.441; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; BOLOVENTA P, 1996, NEUROANALASTROCYTIC, P367; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1992, CAN J PHYSIOL PHARM, V70, pS206, DOI 10.1139/y92-264; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ENG LF, 1988, CURRENT ISSUES NEURA, P247; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Ginsberg MD, 1996, J NEUROSCI METH, V68, P225; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOMEZPINILLA F, 1994, NEUROREPORT, V1, P211; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAJOS F, 1990, GLIA, V3, P301, DOI 10.1002/glia.440030410; HANSEN A, 1991, J NEUROCHEM, V57, P1716, DOI 10.1111/j.1471-4159.1991.tb06372.x; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAIG RP, 1990, STROKE, V21, P184; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MAXWELL DS, 1965, J CELL BIOL, V25, P141, DOI 10.1083/jcb.25.2.141; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MUCKE L, 1991, NEW BIOL, V3, P465; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; Nathaniel EJ., 1981, ADV CELLULAR NEUROBI, P249, DOI [10.1016/B978-0-12-008302-2.50012-2, DOI 10.1016/B978-0-12-008302-2.50012-2]; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 1998, GLIA, V22, P390, DOI 10.1002/(SICI)1098-1136(199804)22:4<390::AID-GLIA8>3.3.CO;2-E; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; PETITO CK, 1982, ANN NEUROL, V11, P510, DOI 10.1002/ana.410110511; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Porter JT, 1996, J NEUROSCI, V16, P5073; PORTER T, 1995, IEEE MULTIMEDIA, V2, P101; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Rudge J. S., 1993, ASTROCYTES PHARM FUN, P267; RUTKA JT, 1993, CANCER RES, V53, P3624; SCHMIDTKASTNER R, 1993, INT J DEV NEUROSCI, V11, P157, DOI 10.1016/0736-5748(93)90076-P; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STEWARD O, 1990, NEUROL NEUR, V60, P71; STEWARD O, 1990, J NEUROSCI, V10, P2373; STEWARD O, 1991, P NATL ACAD SCI USA, V88, P6819, DOI 10.1073/pnas.88.15.6819; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; TORRE ER, 1993, BRAIN RES, V631, P256, DOI 10.1016/0006-8993(93)91543-2; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHAO WZ, 1993, IEEE T MED IMAGING, V12, P782, DOI 10.1109/42.251130; ZILLES L, 1985, CORTEX RAT STEREOTAX	95	43	45	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					567	581		10.1089/neu.1999.16.567			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700002	10447069				2021-06-18	
J	Abu-Judeh, HH; Parker, R; Singh, M; El-Zeftawy, H; Atay, S; Kumar, M; Naddaf, S; Aleksic, S; Abdel-Dayem, HM				Abu-Judeh, HH; Parker, R; Singh, M; El-Zeftawy, H; Atay, S; Kumar, M; Naddaf, S; Aleksic, S; Abdel-Dayem, HM			SPET brain perfusion imaging in mild traumatic brain injury without loss of consciousness and normal computed tomography	NUCLEAR MEDICINE COMMUNICATIONS			English	Article							CEREBRAL BLOOD-FLOW; LASER-DOPPLER FLOWMETRY; MINOR HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; ARTERIAL SPASM; TC-99(M)-HMPAO; HISTORY	We present SPET brain perfusion findings in 32 patients who suffered mild traumatic brain injury without loss of consciousness and normal computed tomography. None of the patients had previous traumatic brain injury, CVA, HIV, psychiatric disorders or a history of alcohol or drug abuse. Their ages ranged from 11 to 61 years (mean = 42). The study was performed in 20 patients (62%) within 3 months of the date of injury and in 12 (38%) patients more than 3 months post-injury. Nineteen patients (60%) were involved in a motor vehicle accident, 10 patients (31%) sustained a fall and three patients (9%) received a blow to the head. The most common complaints were headaches in 26 patients (81%), memory deficits in 15 (47%), dizziness in 13 (41%) and sleep disorders in eight (25%). The studies were acquired approximately 2 h after an intravenous injection of 740 MBq (20.0 mCi) of Tc-99(m)-HMPAO. All images were acquired on a triple-headed gamma camera. The data were displayed on a 10-grade colour scale, with 2-pixel thickness (7.4 mm), and were reviewed blind to the patient's history of symptoms. The cerebellum was used as the reference site (100% maximum value). Any decrease in cerebral perfusion in the cortex or basal ganglia less than 70%, or less than 50% in the medial temporal lobe, compared to the cerebellar reference was considered abnormal. The results show that 13 (41%) had normal studies and 19 (59%) were abnormal (13 studies performed within 3 months of the date of injury and six studies performed more than 3 months post-injury). Analysis of the abnormal studies revealed that 17 showed 48 focal lesions and two showed diffuse supratentorial hypoperfusion (one from each of the early and delayed imaging groups). The 12 abnormal studies performed early had 37 focal lesions and averaged 3.1 lesions per patient, whereas there was a reduction to an average of 2.2 lesions per patient in the five studies (total 11 lesions) performed more than 3 months post-injury. In the 17 abnormal studies with focal lesions, the following regions were involved in descending frequency: frontal lobes 58%, basal ganglia and thalami 47%, temporal lobes 26% and parietal lobes 16%. We conclude that: (1) SPET brain perfusion imaging is valuable and sensitive for the evaluation of cerebral perfusion changes following mild traumatic brain injury; (2) these changes fan occur without loss of consciousness; (3) SPET brain perfusion imaging is more sensitive than computed tomography in detecting brain lesions; and (4) the changes may explain a neurological component of the patient's symptoms in the absence of morphological abnormalities using other imaging modalities. ((C) 1999 Lippincott Williams & Wilkins).	New York Med Coll, Dept Radiol, Nucl Med Sect, St Vincent Hosp & Med Ctr, New York, NY 10011 USA	Abdel-Dayem, HM (corresponding author), New York Med Coll, Dept Radiol, Nucl Med Sect, St Vincent Hosp & Med Ctr, 153 W 11th St, New York, NY 10011 USA.						ABDELDAYEM HM, 1997, CLIN NUCL MED, V122, P345; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; BANDAK FA, 1996, J NEUROTRAUM, V12, P635; Chandler W. F., 1990, NEUROLOGICAL SURG, V4, P2367; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; COTE L, 1991, PRINCIPLES NEUROSCIE, P646; CROSSAON B, 1992, SUBCORTICAL FUNCTION, P78; DHARKER SR, 1993, NEUROSURGERY, V33, P863; FUMEYA H, 1990, ACT NEUR S, V51, P283; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Goshen E, 1996, NUCL MED COMMUN, V17, P418, DOI 10.1097/00006231-199605000-00011; GRAY BG, 1992, J NUCL MED, V33, P52; Heilman K. M., 1993, INT J CLIN NEUROPSYC, P141; HEILMAN KM, 1983, CLIN NEUROPSYCHOLOGY, P661; Jacobs A, 1996, J NUCL MED, V37, P1605; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KELLY JP, 1991, PRINCIPLES NEURAL SC, P283; KESTER N, 1993, BRAIN INJURY, V7, P469; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MASDEU CJ, 1995, J NEUROIMAGING, V5, pS53; Masdeu J C, 1994, J Neuroimaging, V4, P177; Miller J. D., 1986, CEREBRAL ARTERIAL SP, P476; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; *NAT I NEUR DIS ST, 1995, INT HEAD INJ TASK FO; Nordhoff L. S., 1996, MOTOR VEHICLE COLLIS, P1; PARKER R, 1995, J NEUROL ORTH MED S, V16, P118; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; PARKER RS, 1994, J NEUROL ORTH MED S, V15, P123; Reis D. J., 1996, PRIMER AUTONOMIC NER, P56; Robertson C. S., 1996, NEUROTRAUMA, P487; Robinson Robert G., 1994, P219; SYED GMS, 1992, NUCL MED COMMUN, V13, P811, DOI 10.1097/00006231-199211000-00007; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Tikofsky Ronald S., 1995, P171; Zasler Nathan D., 1994, P443; Zigmond Michael J., 1995, P45	41	43	44	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	JUN	1999	20	6					505	510		10.1097/00006231-199906000-00003			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	219UZ	WOS:000081626700003	10451861				2021-06-18	
J	Kim, SH; Manes, F; Kosier, T; Baruah, S; Robinson, RG				Kim, SH; Manes, F; Kosier, T; Baruah, S; Robinson, RG			Irritability following traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							HEAD-INJURY; STROKE PATIENTS; POSTCONCUSSION SYNDROME; LESION LOCATION; MOOD DISORDERS; DEPRESSION; SEQUELAE; MILD	This study was undertaken to identify the clinical and pathoanatomical correlates of irritability in patients with closed head injuries. A consecutive series of 66 patients was assessed in hospital and at 3, 6, 9, and 12-month follow-ups. Patients fulfilling criteria for irritability were divided into 2 groups based on the immediate or delayed onset of their irritability and compared with patients without irritability for background characteristics, impairment variables, and lesion characteristics. There were IZ patients (18.2%) with acute onset irritability and 10 (15.1%) with delayed onset irritability. Acute onset irritability patients had a higher frequency of left cortical lesions. Delayed onset irritability patients showed a strong association with poor social functioning and greater impairment in activities of daily Living. The findings suggest that post-brain injury irritability may have different causes and treatment in the acute and chronic stages.	Univ Iowa, Dept Psychiat, Coll Med, Iowa City, IA 52242 USA; Chosun Univ, Coll Med, Dept Psychiat, Kwangju 501759, South Korea	Robinson, RG (corresponding author), Univ Iowa, Dept Psychiat, Coll Med, 200 Hawkins Dr,2887 JPP, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 53592, MH 52879] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592, R01MH052879] Funding Source: NIH RePORTER		BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Caine T. M., 1967, MANUAL HOSTILITY DIR; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EVANS RW, 1992, NEUROL CLIN, V10, P815; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALBRAITH S, 1985, BRIT MED J, V291, P1668, DOI 10.1136/bmj.291.6510.1668; GUALTIERI CT, 1991, NEUROPSYCHIAT BEHAV; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LIDVALL HF, 1974, ACTA NEUROL SCAND, V50, P133; LONG CJ, 1995, NEUROPSYCHOLOGICAL A, P35; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCGINNIS GS, 1988, TRAUMA NURSING RESUS, P364; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Morris PLP, 1996, J NEUROPSYCH CLIN N, V8, P399; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Novaco R.W., 1975, ANGER CONTROL DEV EV; NOVACO RW, 1985, ANGER HOSTILITY CARD; Paradiso S, 1996, J NERV MENT DIS, V184, P746, DOI 10.1097/00005053-199612000-00005; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROHRBAUGH RM, 1988, J AM GERIATR SOC, V36, P736, DOI 10.1111/j.1532-5415.1988.tb07177.x; Sartorius N, 1974, MEASUREMENT CLASSIFI; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; Spitzer R, 1979, SCHEDULE AFFECTIVE D; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TAYLOR CA, 1994, NEUROPSYCHIATRY TRAU, P87; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	40	43	45	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	1999	187	6					327	335		10.1097/00005053-199906000-00001			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	205KN	WOS:000080820000001	10379719				2021-06-18	
J	Reinert, MM; Bullock, R				Reinert, MM; Bullock, R			Clinical trials in head injury	NEUROLOGICAL RESEARCH			English	Article						head injury; neuroprotection; trials; therapy; pathomechanism; secondary injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; SUBARACHNOID HEMORRHAGE; ARTERY OCCLUSION; FOCAL ISCHEMIA; FREE-RADICALS; AXONAL CHANGE; CALCIUM; NIMODIPINE; DAMAGE	Secondary brain damage, following severe head injury is considered to be a major cause for Dad outcome. Impressive reductions of the extent of brain damage in experimental studies have raised high expectations for cerebral neuroprotective treatment, in the clinic. Therefore multiple compounds were and are being evaluated in trials. In this review we discuss the pathomechanisms of traumatic brain damage, based upon their clinical importance. The role of hypothermia, mannitol, barbiturates, steroids, free radical scavengers, arachidonic acid inhibitors, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, and potassium channel blockers, will be discussed. The importance of a uniform strategic approach for evaluation of potentially interesting new compounds in clinical trials, to ameliorate outcome in patients with severe head injury, is proposed. To achieve this goal, two nonprofit organizations were founded: the European Brain injury Consortium (EBIC) and the American Brain Injury Consortium (ABIC). Their aim lies in conducting better clinical trials, which incorporate lessons learned from previous trials, such that the succession of negative, or incomplete studies, as performed in previous years, will cease.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Reinert, MM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.		Reinert, Michael/AAA-3929-2019	Reinert, Michael/0000-0002-0971-9543	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ALBERS GW, 1995, STROKE, V26, P254, DOI 10.1161/01.STR.26.2.254; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDINE P, 1992, J CEREBR BLOOD F MET, V12, P773, DOI 10.1038/jcbfm.1992.108; BAER P, 1993, CELL, V14, P293; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BULLOCK J, 1993, GLUTAMATE TRANSMITTE, P113; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COLD GE, 1990, NEUROSURGERY, V27, P660; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FAGG GE, 1988, EXCITATORY AMINO ACI, P63; FAUPEL G, 1976, DYNAMICS BRAIN EDEMA, P337; FISHER M, 1994, CEREBROVASC DIS, V4, P20, DOI 10.1159/000108547; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GERMANO IM, 1987, J NEUROSURG, V67, P81, DOI 10.3171/jns.1987.67.1.0081; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P89, DOI 10.1038/jcbfm.1990.11; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; JOHNSON J, 1988, EXCITATORY AMINO ACI, P109; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P153; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAZDA S, 1982, ARZNEIMITTEL-FORSCH, V32-1, P331; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lazorthes G, 1964, Clin Neurosurg, V12, P293; LEE MHK, 1993, BRAIN RES, V613, P156; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCLELLAN DR, 1986, COMA TRAMATIQUE, P165; Mendelow A D, 1984, Neurol Res, V6, P189; MOHAMED AA, 1985, ANN NEUROL, V18, P705, DOI 10.1002/ana.410180613; Muir KW, 1997, CLIN NEUROPHARMACOL, V20, P311, DOI 10.1097/00002826-199708000-00003; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; NOZAKI K, 1992, J CEREBR BLOOD F MET, V12, P400, DOI 10.1038/jcbfm.1992.57; OKONKWO D, 1998, J NEUROTRAUM, V15, P889; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PULSINELLI W, 1992, LANCET, V339, P533, DOI 10.1016/0140-6736(92)90347-6; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; Santos A. L. M., 1995, Journal of Neurotrauma, V12, P389; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; STEWART L, 1996, UNPUB 1 OBSERVATIONS; SYMON L, 1974, STROKE, V5, P355, DOI 10.1161/01.STR.5.3.355; TOWART R, 1981, CIRC RES, V48, P650, DOI 10.1161/01.RES.48.5.650; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	77	43	43	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1999	21	4					330	338		10.1080/01616412.1999.11740940			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	219FE	WOS:000081596600001	10406003				2021-06-18	
J	Vigue, B; Ract, C; Benayed, M; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B				Vigue, B; Ract, C; Benayed, M; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B			Early SjvO(2) monitoring in patients with severe brain trauma	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Societe-Francaise-d-Anesthesie-Reanimation	SEP, 1997	PARIS, FRANCE	Soc Francaise Anesthes Reanimat		SjvO(2); cerebral perfusion pressure; intracranial pressure	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; MANAGEMENT; DESATURATION; HYPOTENSION	Objective: To investigate early cerebral variables after minimal resuscitation and to compare the adequacy of a cerebral perfusion pressure (CPP) guideline above 70 mmHg, with jugular bulb venous oxygen saturation (SjvO(2)) monitoring in a patient with traumatic brain injury (TBI). Design: Prospective, observational study. Setting: Anesthesiological intensive care unit. Patients: 27 TBI patients with a postresuscitation Glasgow Coma Scale score less than 8. Intervention: After initial resuscitation, cerebral monitoring was performed and CPP increased to 70 mmHg by an increase in mean arterial pressure (MAP) with volume expansion and vasopressors as needed. Measurements and results: MAP, in tracranial pressure (ICP), CPP, and simultaneous arterial and venous blood gases were measured at baseline and after treatment. Before treatment, 37 % of patients had an SjvO(2) below 55 %, and SjvO(2) was significantly correlated with CPP (r = 0.73, p < 0.0001). After treatment, we observed a significant increase (p < 0,0001) in CPP (78 +/- 10 vs 53 +/- 15 mmHg), MAP (103 +/- 10 vs 79 +/- 9 mmHg) and SvjO(2) (72 +/- 7 vs 56 +/- 12), without a significant change in ICP (25 +/- 14 vs 25 +/- 11 mmHg). Conclusion: The present study shows that early cerebral monitoring with SjvO(2) is critical to assess cerebral ischemic risk and that MAP monitoring alone is not sensitive enough to determine the state of oxygenation of the brain. SjvO(2) monitoring permits the early identification of patients with low CPP and high risk of cerebral ischemia. In emergency situations it can be used alone when ICP monitoring is contraindicated or not readily available. However, ICP monitoring gives complementary information necessary to adapt treatment.	Hop Bicetre, Dept Anesthesiol, F-94275 Le Kremlin Bicetre, France; Univ Toronto, Dept Anesthesiol, Toronto, ON, Canada	Vigue, B (corresponding author), Hop Bicetre, Dept Anesthesiol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.						ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1993, NEUROSURGERY, V32, P547; Chesnut R M, 1995, New Horiz, V3, P366; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MYBURGH JA, 1996, YB INTENSIVE CARE EM, P716; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shapiro H, 1994, ANESTHESIA, P1897; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; WISNER DH, 1993, J TRAUMA, V35, P271, DOI 10.1097/00005373-199308000-00017	20	43	49	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAY	1999	25	5					445	451		10.1007/s001340050878			7	Critical Care Medicine	General & Internal Medicine	200JZ	WOS:000080537600005	10401936				2021-06-18	
J	Vaquero, J; Zurita, M; de Oya, S; Coca, S				Vaquero, J; Zurita, M; de Oya, S; Coca, S			Vascular endothelial growth permeability factor in spinal cord injury	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; vascular endothelial growth factor; vascular permeability factor	VASOGENIC BRAIN EDEMA; TUMOR ANGIOGENESIS; FACTOR EXPRESSION; MENINGIOMAS; BREAKDOWN; BARRIER	Object. Predicated on the hypothesis that this cytokine can contribute to the development of vascular hyperpermeability, leading to tissue edema after trauma, the purpose of this study was to determine the presence in tissue of vascular endothelial growth/permeability factor (VEG/PF) after experimental spinal cord injury. Methods. The presence of VEG/PF was studied at 8 hours and 2, 8, and 14 days after a traumatic injury in adult Wistar rats. Studies were conducted in which a monoclonal antibody to the VEG/PF was used. Strong VEG/PF immunoreactivity was detected in the walls of pial and intramedullary vessels and in reactive astrocytes 8 hours posttrauma and was unchanged on Days 2 and 8. By Day 14, immunoreactivity decreased, and most of the arterioles from the pia and gray matter showed no mural VEG/PF. Conclusions. The authors' present findings suggest a role for this cytokine in the development of tissue edema after spinal cord trauma and point to the possible usefulness of a therapeutic approach to spinal cord injury based on blocking the cell expression of VEG/PF or its physiological effects.	Autonomous Univ Madrid, Neurosurg Serv, Puerta De Hierro Clin, E-28049 Madrid, Spain; Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, E-28049 Madrid, Spain	Vaquero, J (corresponding author), Univ Madrid, Hosp Clin Puerta Hierro, Serv Neurocirugia, San Martin de Porres 4, Madrid, Spain.						BREIER G, 1992, DEVELOPMENT, V114, P521; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; Goldman CK, 1997, NEUROSURGERY, V40, P1269, DOI 10.1097/00006123-199706000-00029; HAGG T, 1994, NEUROBIOLOGY CENTRAL, P245; KALARIA RN, 1995, J CEREB BLOOD FLOW M, V15, pS599; Kalkanis SN, 1996, J NEUROSURG, V85, P1095, DOI 10.3171/jns.1996.85.6.1095; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Murata T, 1996, LAB INVEST, V74, P819; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Provias J, 1997, NEUROSURGERY, V40, P1016, DOI 10.1097/00006123-199705000-00027; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STRUGAR J, 1994, J NEUROSURG, V81, P560, DOI 10.3171/jns.1994.81.4.0560; STRUGAR JG, 1995, J NEUROSURG, V83, P682, DOI 10.3171/jns.1995.83.4.0682; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAQUEROCRESPO J, 1976, INVEST CLIN, V17, P115; VAQUEROCRESPO J, 1976, INVEST CLIN, V17, P150	19	43	45	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	APR	1999	90	4		S			220	223		10.3171/spi.1999.90.2.0220			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	181YT	WOS:000079471600008	10199251				2021-06-18	
J	Willer, B; Button, J; Rempel, R				Willer, B; Button, J; Rempel, R			Residential and home-based postacute rehabilitation of individuals with traumatic brain injury: A case control study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	74th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP 12-14, 1997	BOSTON, MASSACHUSETTS	Amer Congress Rehabil Med			COMMUNITY INTEGRATION QUESTIONNAIRE	Objectives: To compare the outcomes of severely brain-injured individuals treated in a postacute residential rehabilitation program with a matched sample of individuals receiving limited services in their homes or on an outpatient basis. Design: Controlled study using a matched design in a before-and-after trial and a 1-year follow-up trial. Setting: A postacute community-based residential rehabilitation program or in the homes of patients. Patients and Other Participants: The treatment group included all persons admitted consecutively for rehabilitation to the postacute residential program over a 3-year period (n = 23). All subjects had severe traumatic brain injury, The comparison group was selected from the roster of a support group on the basis of a systematic matching procedure. Matching variables included gender, age, length of coma, time since injury, and level of disability. Subjects of the two groups were matched on an individual basis. Main Outcome Measures: A functional assessment instrument (modified Health and Activity Limitations Survey [HALS]) and the Community Integration Questionnaire (CIQ). Results: Individuals with traumatic brain injury who received residential-based postacute rehabilitation displayed a statistically significant increase in functional abilities when compared with a traditional (home-based) service group. More specifically, treatment subjects showed significantly greater improvement in motor skills and cognitive abilities, Treatment subjects also showed greater improvement in community integration, although this may have been accounted for by initial,group differences. Conclusions: Postacute rehabilitation appears to be effective in improving function for individuals with severe brain injury. Residential-based services appear to produce greater functional improvement, whereas home-based services are more effective at maintaining community integration. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	SUNY Buffalo, Buffalo, NY 14214 USA; Ontario Brain Injury Assoc, St Catharines, ON, Canada; Anagram Rehabil Community, Niagara On The Lake, ON, Canada	Willer, B (corresponding author), SUNY Buffalo, 114 Farber Hall, Buffalo, NY 14214 USA.						Allen K, 1996, JAMA-J AM MED ASSOC, V275, P1001, DOI 10.1001/jama.275.13.1001; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Evans R W, 1991, J Insur Med, V23, P192; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FREDERICKSON M, 1995, ARCH PHYS MED REHAB, V76, pSC5; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; FURRIE AD, 1995, DISABIL REHABIL, V17, P344, DOI 10.3109/09638289509166720; HARRICK L, 1994, BRAIN INJURY, V8, P631; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; MCDOWELL I, 1988, DISABILITY SCORE HLT; MCMAHON BT, 1994, SHORTEST DISTANCE PU; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; *STAT CAN, 1989, HLTH ACT LIM SURV HA; Switzer S F, 1991, J Insur Med, V23, P239; Walker WC, 1996, BRAIN INJURY, V10, P65; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1994, BRAIN INJURY REHABIL, P355; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Wood R. L., 1987, BRAIN INJURY REHABIL; 1988, DISABILITY DATABASE	27	43	43	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1999	80	4					399	406		10.1016/S0003-9993(99)90276-9			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	184TG	WOS:000079629100007	10206601				2021-06-18	
J	Light, R; Asarnow, R; Satz, P; Zaucha, K; McCleary, C; Lewis, R				Light, R; Asarnow, R; Satz, P; Zaucha, K; McCleary, C; Lewis, R			Mild closed-head injury in children and adolescents: Behavior problems and academic outcomes	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							FOLLOW-UP; SEQUELAE; TRAUMA	The issue of whether mild head injuries (HIs) in children cause behavior problems and poor scholastic performance is controversial. This study included 119 children (range = 8-16 years old) with HI, 114 with other injuries, and 106 with no injury (NI). Behavioral functioning was assessed with the Child Behavior Checklist; academic functioning, with school grades and standardized testing. Higher T scores were found for both injury groups versus NI participants on preinjury behavioral status. All 3 groups' behavioral scores decreased relative to baseline at 1 year. HI and NI groups did not differ in school grades or achievement testing either pre- or postinjury. These results are consistent with the conclusion that head injury of the mildest type does not increase the probability of new overt behavioral or academic problems.	Daniel Freeman Mem Hosp, Rehabil Serv, Inglewood, CA 90301 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90089 USA; Pomona Coll, Dept Psychol, Claremont, CA 91711 USA	Light, R (corresponding author), Daniel Freeman Mem Hosp, Rehabil Serv, 333 N Prairie Ave, Inglewood, CA 90301 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS026801] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26801-04, P50 NS30308-02] Funding Source: Medline		Achenbach TM, 1983, MANUAL CHILD BEHAV C; ARSARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BIJUR PE, 1990, PEDIATRICS, V86, P337; BLACK P, 1971, HEAD INJURIES, P131; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BUTTERBAUGH G, 1993, J CLIN EXP NEUROPSYC, V15, P84; CASEY R, 1986, PEDIATRICS, V78, P497; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DENCKLA MB, 1995, TRAUMATIC HEAD INJUR, pR6; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Horowitz I, 1983, Int Rehabil Med, V5, P32; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KEWMAN DG, 1992, J CLIN EXPT NEUROPSY, V14, P100; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1994, J HEAD TRAUMA REHAB, V9, P106; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEAHY LF, 1987, J CLIN EXP NEUROPSYC, V9, P55; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Light R, 1987, J HEAD TRAUMA REHAB, V2, P11, DOI DOI 10.1097/00001199-198703000-00005; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; LYONS MJ, 1984, J PEDIATR PSYCHOL, V9, P485, DOI 10.1093/jpepsy/9.4.485; OGLES BM, 1996, ASSESSING OUTCOME CL; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SHAFFER D, 1995, TRAUMATIC HEAD INJUR, P117; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; Winogron H W, 1984, J Clin Neuropsychol, V6, P267	34	43	43	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	DEC	1998	66	6					1023	1029					7	Psychology, Clinical	Psychology	151DU	WOS:000077706100016	9874916				2021-06-18	
J	Gagnon, I; Forget, R; Sullivan, SJ; Friedman, D				Gagnon, I; Forget, R; Sullivan, SJ; Friedman, D			Motor performance following a mild traumatic brain injury in children: an exploratory study	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PROFICIENCY; ADOLESCENTS; ATTENTION; COHORT	Mild Traumatic Brain Injury (TBI) is a common occurrence in the paediatric population and, as the concept of motor performance has not been assessed specifically in this population, the purpose of this study was to determine if motor performance deficits are present and can be objectively identified in a sample of children having sustained a mild TBI (Glasgow Coma Scale score 13-15). Twenty-eight children aged between 5 and 15 years were recruited immediately post-trauma. Subjects were considered normal on standard neurological exam at the time of discharge. They were assessed 13-18 days post-trauma using the Bruininks-Oseretsky Test of Motor Proficiency, a norm referenced clinical standardized assessment tool. Compared to published norms, motor performance was significantly lower in domains of balance, response speed and running speed an agility (t-test p < 0.01), and significantly higher in domains of upper extremity coordination and visual motor control (t-test p < 0.01). Although excellent performance can be observed in domains requiring upper limb coordination, motor planning and execution of motor tasks, deficits in balance and response speed can be identified in a significant number of children even after mild TBI. More specific and sensitive evaluations are necessary to identify the exact nature of the problems and evaluate their functional impact on daily activities.	Montreal Childrens Hosp, Phys Therapy Dept, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Univ Otago, Sch Phys Therapy, Dunedin, New Zealand	Gagnon, I (corresponding author), Montreal Childrens Hosp, Phys Therapy Dept, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BAWDEN HN, 1991, BRAIN INJURY, V5, P339; Bruininks R. H., 1978, BRUININKS OSERETSKY; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; CONNOLLY BH, 1986, PHYS THER, V66, P344, DOI 10.1093/ptj/66.3.344; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Gabbard C, 1995, J GENET PSYCHOL, V156, P411, DOI 10.1080/00221325.1995.9914833; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; HATTIE J, 1987, BRIT J EDUC PSYCHOL, V57, P104, DOI 10.1111/j.2044-8279.1987.tb03065.x; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEVIN HS, 1979, CHILD BRAIN, V5, P281; McCordie W. R., 1988, CLIN NEUROPSYCHOL, V2, P198; Miller L, 1996, J COGNITIVE REHABILI, V15, P8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; PALISANO R J, 1989, Physical and Occupational Therapy in Pediatrics, V9, P79; PLIMPTON CE, 1992, PERCEPT MOTOR SKILL, V74, P399, DOI 10.2466/PMS.74.2.399-402; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Rodger S, 1994, AUSTR OCCUPATIONAL T, V41, P137; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81	34	43	43	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					843	853		10.1080/026990598122070			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100004	9783083				2021-06-18	
J	Tucker, FM; Hanlon, RE				Tucker, FM; Hanlon, RE			Effects of mild traumatic brain injury on narrative discourse production	BRAIN INJURY			English	Article							HEAD-INJURY; DEFICITS	Mild traumatic brain injury (MTBI) and postconcussive syndrome can result in difficult to document complaints regarding subtle language use. Narrative discourse production has been shown to be a sensitive index of linguistic and cognitive deficits in the more severe TBI population. The narrative discourse production of MTBI subjects was investigated to determine whether cognitive changes were reflected in linguistic production Eight MTBI, five moderate TBI, and five neurologically normal subjects were matched for age, education, and gender. The TBI subjects were matched on a number of neuropsychological measures. The subjects produced marratives about their correct picture sequences on five items from the Wechsler Adult Intelligenbce Scale-Revised picture arrangement subtest. The narratives were scored for correct arrangement, content: essential information, correct story, and implied meaning. Significant differences were found between the normal control group and both the TBI groups on accuracy of narrative description of the correct picture sequences. Although differences in generation of implied meaning failed to reach significance, a trend was noted for both the TBI groups to produce fewer implied meanings than the control group. The results suggest that cognitive disruptions associated with MTBI may affect the quality of narrative discourse.	So Illinois Univ, Dept Special Educ & Commun Disorders, Edwardsville, IL 62026 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Tucker, FM (corresponding author), So Illinois Univ, Dept Special Educ & Commun Disorders, Campus Box 1776, Edwardsville, IL 62026 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Cherney L., 1993, CLIN APHASIOLOGY, V21, P123; CICERONE K, 1995, J HEAT TRAUMA REHABI, V19, P1; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho C. A., 1994, DISCOURSE ANAL APPL, P95; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; GLOSSER G, 1993, DISCOURSE ABILITY BR, P191; HAGAN C, 1979, REHABILITATION HEAD, P87; Kaplan E., 1991, WAIS R NI MANUAL; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; Levin HS, 1989, MILD HEAD INJURY; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Myers PS, 1996, J SPEECH HEAR RES, V39, P870, DOI 10.1044/jshr.3904.870; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; ULATOWSKA HK, 1994, DISCOURSE ANAL APPL, P26; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	21	43	45	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					783	792		10.1080/026990598122179			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500006	9755369				2021-06-18	
J	Bicik, I; Radanov, BP; Schafer, N; Dvorak, J; Blum, B; Weber, B; Burger, C; von Schulthess, GK; Buck, A				Bicik, I; Radanov, BP; Schafer, N; Dvorak, J; Blum, B; Weber, B; Burger, C; von Schulthess, GK; Buck, A			PET with (18)fluorodeoxyglucose and hexamethylpropylene amine oxime SPECT in late whiplash syndrome	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; FOLLOW-UP; TECHNETIUM-99M-HMPAO SPECT; CEREBRAL SYMPTOMS; COMMON WHIPLASH; DYSFUNCTION; DEPRESSION; VALIDATION; DEFICITS; MRI	Background: Many patients have cognitive abnormalities and psychological problems after whiplash injury to the cervical spine. To our knowledge, neuroradiologic imaging has not depicted brain damage that explains the symptoms. Parietotemporo-occipital perfusion deficits on hexamethylpropylene amine oxime (HMPAO) SPECT studies have been described among patients who have sustained whiplash injury. Methods: Mie examined 13 patients with typical late whiplash syndrome (study group) using HMPAO SPECT, (18)fluorodeoxyglucose (FDG) PET, and MRI of the brain and compared the findings with those for 16 control subjects who underwent FDG PET. Results: In the study group, statistical parametric mapping revealed significantly decreased FDG uptake in the frontopolar and lateral temporal cortex and in the putamen. The frontopolar hypometabolism correlated significantly with scores of the Beck Depression Inventory. However, in individual cases, reliability in the depiction of hypometabolic areas was relatively low. No alterations were found in the parietotemporo-occipital area. In these areas, decreased uptake of HMPAO and FDG correlated with cortical mass. Conclusion: FDG PET did not allow reliable diagnosis of metabolic disturbances for individual patients. Therefore, we do not recommend FDG PET or HMPAO SPECT as a diagnostic tool in routine examinations of patients with late whiplash syndrome.	Univ Zurich, Dept Med Radiol, Div Nucl Med, CH-8006 Zurich, Switzerland; Univ Bern, Inselspital, Dept Psychiat, CH-3010 Berne, Switzerland; Schulthess Clin, Spine Unit, Dept Neurol, Zurich, Switzerland; Univ Zurich, Dept Neurol, CH-8006 Zurich, Switzerland	Buck, A (corresponding author), Univ Zurich Hosp, Dept Med Radiol, Div Nucl Med, Ramistr 100, CH-8091 Zurich, Switzerland.		Weber, Bruno/E-4400-2013	Schaefer, Niklaus/0000-0002-9732-7696			Beck A.T., 1987, BECK DEPRESSION INVE; BERSTAD JR, 1975, ACTA NEUROL SCAND, V51, P268; DOLAN RJ, 1994, PSYCHOL MED, V24, P849, DOI 10.1017/S0033291700028944; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; HARRIS GJ, 1994, AM J NEURORADIOL, V15, P225; HAUTZINGER M, 1992, DEPRESSIONS INVENTAR; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; KEIDEL M, 1992, NERVENARZT, V63, P731; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; KOHN MI, 1991, RADIOLOGY, V178, P115, DOI 10.1148/radiology.178.1.1984289; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; OMMAYA K, 1975, HDB CLIN NEUROLOGY, V24, P67; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; Otte A, 1997, J NUCL MED, V38, P1002; OTTE A, 1995, LANCET, V345, P8963; PIETRZYK U, 1994, J NUCL MED, V35, P2011; RADANOV BP, 1994, J NEUROL NEUROSUR PS, V57, P486, DOI 10.1136/jnnp.57.4.486; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; Radanov BP, 1996, PAIN, V64, P429, DOI 10.1016/0304-3959(95)00148-4; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; SPITZER WO, 1995, SPINE, V20, pS1; Talairach J., 1988, COPLANAR STEREOTAXIC; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; Zimmermann P., 1993, DEV ASSESSMENT REHAB, P3	28	43	43	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0028-3878			NEUROLOGY	Neurology	AUG	1998	51	2					345	350		10.1212/WNL.51.2.345			6	Clinical Neurology	Neurosciences & Neurology	110NN	WOS:000075387400009	9710001				2021-06-18	
J	Chendrasekhar, A; Moorman, DW; Timberlake, GA				Chendrasekhar, A; Moorman, DW; Timberlake, GA			An evaluation of the effects of semirigid cervical collars in patients with severe closed head injury	AMERICAN SURGEON			English	Article; Proceedings Paper	Midwest-Surgical-Association Meeting	AUG 10-13, 1997	HURON, OHIO	Midwest Surg Assoc			SPINE	The use of a semirigid cervical collar has been recommended to prevent further cervical spine injury in the management of trauma patients. These cervical collars are kept on obtunded patients for prolonged periods. We assessed the incidence of cervical collar related decubiti in patients with severe closed head injury (SCHI). We also assessed the utility of fluoroscopy in clearing the cervical spine of patients with SCHI, A retrospective chart review was performed on 52 consecutive patients with SCHI at a community hospital-based Level II trauma center over an 8-month period. Thirteen of 34 patients (38%) who survived >24 hours after admission developed decubiti related to the cervical collar. The patients who developed decubiti had a significantly greater duration of cervical collar placement (21.15 +/- 0.99 days) as compared with patients who did not develop decubiti (4.42 +/- 0.79 days; P = 0,001). Eight patients had their cervical spine assessed for ligamentous injury by bedside fluoroscopy. All eight patients had early collar removal; none of these patients developed decubiti, Patients with SCHI with semirigid cervical collars kept in place for prolonged periods of time are at risk for developing decubiti. Fluoroscopy in addition to standard radiographs may "clear" the cervical spine and allow early removal of these collars.	Iowa Methodist Med Ctr, Dept Surg Educ, Des Moines, IA USA	Chendrasekhar, A (corresponding author), 1221 Pleasant St,Suite 550, Des Moines, IA 50309 USA.						*AM COLL SURG SPIN, 1993, ADV TRAUM LIF SUPP I, P191; CLINE JR, 1985, J TRAUMA, V25, P649, DOI 10.1097/00005373-198507000-00013; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; GERRELTS BD, 1991, J TRAUMA, V31, P1622, DOI 10.1097/00005373-199112000-00010; GRADY MS, 1986, NEUROSURGERY, V18, P151; PLAISIER B, 1994, J TRAUMA, V37, P714, DOI 10.1097/00005373-199411000-00004; ROSEN PB, 1992, ANN EMERG MED, V21, P1189, DOI 10.1016/S0196-0644(05)81744-5; ROSS SE, 1987, J TRAUMA, V27, P1055, DOI 10.1097/00005373-198709000-00017	10	43	44	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	JUL	1998	64	7					604	606					3	Surgery	Surgery	ZW842	WOS:000074453800002	9655267				2021-06-18	
J	Rinker, CF; McMurry, FG; Groeneweg, VR; Bahnson, FF; Banks, KL; Gannon, DM				Rinker, CF; McMurry, FG; Groeneweg, VR; Bahnson, FF; Banks, KL; Gannon, DM			Emergency craniotomy in a rural Level III trauma center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 1997	WAIKOLOA, HAWAII	Amer Assoc Surg Trauma			ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; EPIDURAL HEMATOMA; TENTORIAL HERNIATION; EXTRADURAL HEMATOMA; COMATOSE PATIENTS; MANAGEMENT; MORTALITY; SURGERY; CARE	Patients with closed head injury and expanding epidural (EDH) or subdural (SDH) hematoma require urgent craniotomy for decompression and control of hemorrhage. In remote areas where neurosurgeons are not available, trauma surgeons may occasionally need to intervene to avert progressive neurologic injury and death. In 1990, a young man with rapidly deteriorating neurologic signs underwent emergency burr hole decompression of a combined EDH/SDH at our hospital, with complete recovery. In anticipation of future need, five surgeons at our rural, American College of Surgeons-verified Level III trauma center participated in a neurosurgeon-directed course in emergency craniotomy, Since January 1, 1991, 792 patients have been entered into the trauma registry, including 60 with closed head injury and Glasgow Coma Scale (GCS) score of 13 or less. All but seven were transferred to a regional Level II trauma center, which is a minimum flight time of 1 hour each way. All patients with EDH (5) and 2 of 14 with SDH were deemed too unstable for transport and underwent burr hole decompression followed by immediate transfer. All craniotomies were approved by the consulting neurosurgeon and were done for computed tomography-confirmed lesions combined with neurologic deterioration as demonstrated by (1) GCS score of 8 or less, (2) lateralizing signs (dilated pupil, hemiparesis), or (3) development of combined bradycardia and hypertension. One patient with a GCS score of 3 on arrival died. Seven survivors (mean follow-up, 3.9 years; range, 1-6.5 years), including the index case, function independently, although one survivor has moderate cognitive and motor impairment. We conclude that early craniotomy for expanding epidural and subdural hematomas by properly trained surgeons may save lives and reduce morbidity in properly selected cases when timely access to a neurosurgeon is not possible.	Montana State Univ, Bozeman, MT 59717 USA; Bozeman Deaconess Hosp, Bozeman, MT USA	Rinker, CF (corresponding author), Amer Coll Surg, 925 Highland Blvd, Bozeman, MT 59715 USA.						*AM COLL SURG, 1993, ADV TRAUM LIF SUPP P, P181; *AM COLL SURG, 1993, ADV TRAUM LIF SUPP P, P295; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BATTERSBY RDE, 1990, BRIT J HOSP MED, V44, P276; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Becker DP, 1989, TXB HEAD INJURY, P1; BULLOCK R, 1995, GUIDELINES MANAGEMEN, P12; Burton C, 1965, J Trauma, V5, P643, DOI 10.1097/00005373-196509000-00008; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Gudeman S. K., 1989, TXB HEAD INJURY, P138; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HOFF JT, 1978, WESTERN J MED, V128, P112; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; LOWE JG, 1996, NEUROLOGY TRAUMA, P140; MAHONEY BD, 1981, NEUROSURGERY, V8, P551, DOI 10.1227/00006123-198105000-00006; ORTLER M, 1993, UNFALLCHIRURG, V96, P628; OSULLIVAN MGJ, 1990, BRIT J SURG, V77, P1391, DOI 10.1002/bjs.1800771223; POON WS, 1991, INJURY, V22, P323, DOI 10.1016/0020-1383(91)90016-8; Reale F, 1984, J Neurosurg Sci, V28, P9; SCHECTER WP, 1985, ARCH SURG-CHICAGO, V120, P1163; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHARAR SR, 1988, J TRAUMA, V28, P794, DOI 10.1097/00005373-198806000-00012; SPRINGER MFB, 1988, AM J EMERG MED, V6, P640, DOI 10.1016/0735-6757(88)90110-6; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	27	43	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1998	44	6					984	989		10.1097/00005373-199806000-00009			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	ZU123	WOS:000074164600009	9637153				2021-06-18	
J	Katz, DI; Alexander, MP; Klein, RB				Katz, DI; Alexander, MP; Klein, RB			Recovery of arm function in patients with paresis after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; MOTOR RECOVERY; BASAL GANGLIA; FOLLOW-UP; STROKE; REHABILITATION; HEMORRHAGE; COMA	Objective: To characterize the frequency of recovery of arm paresis in patients with traumatic brain injury (TBI) admitted to rehabilitation. Design: Retrospective review identifying a cohort of patients with moderate or severe arm paresis after TBI followed at least 6 months postinjury. Setting: Freestanding acute rehabilitation hospital TBI unit. Patients and Methods: Forty-four patients with moderate to severe arm paresis were selected from 264 consecutive admissions and characterized by injury pathology subtype, injury severity (duration of unconsciousness [loss of consciousness, LOG] and posttraumatic amnesia [PTA]), age, and level of paresis according to Brunnstrom Stages of Recovery (BS 1 to 6). Patient groups with and without arm paresis were compared according to these variables (t tests and chi(2)). Main Outcome Measures: Recovery of arm paresis to isolated motor function (BS 5 or 6) and time to achieve recovery. Recovered and nonrecovered patients were compared (Mann-Whitney, t tests, and chi(2)) on injury severity, initial level of paresis, age, time to rehabilitation admission, and pathology subtype. Time to recovery was compared for patients at different levels of initial paresis, ranges of LOC, and pathology subtypes (Mann-Whitney and Kruskal-Wallis tests). Results: Forty-four patients (17%) had moderate (BS 3 to 4) or severe (BS 1 to 2) paresis at rehabilitation admission. They were more severely injured than nonparetic patients based on longer LOC (p < .002) and PTA (p < .009). Thirty-six patients (82%) recovered by 6 months; 72% of these recovered by 2 months. If still paretic at 2 months, only 56% recovered. Mean recovery time was 6.9 weeks (SD, 6.1) from injury. Time to recovery was best predicted by initial level of paresis and injury severity (r(2) = .48), but not age. Patients with diffuse injury tended towards a more protracted recovery (7.9 weeks, SD 6.5) than patients with focal injury (4.2 weeks, SD 3.9) (p = .08) and only those with diffuse injury showed further recovery after 3 months. Conclusions: Arm paresis after TBI is relatively infrequent. Most patients recover by 2 months but later recovery is possible, especially in patients with primarily diffuse brain damage. Recovery is highly related to initial impairment, injury severity, and distribution of brain injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Healths Braintree Hosp Rehabil Network, TBI Program, Braintree, MA 02185 USA; Healths Braintree Hosp Rehabil Network, Dept Neurol, Braintree, MA 02185 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Katz, DI (corresponding author), Healths Braintree Hosp Rehabil Network, TBI Program, 250 Pond St, Braintree, MA 02185 USA.			Katz, Douglas/0000-0002-7502-8505			ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BONITA R, 1988, STROKE, V19, P497; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BRUNNSTROM S, 1966, MOVEMENT THERAPY HEM, P34; Damasio H., 1989, LESION ANAL NEUROPSY; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; FAHY TJ, 1967, LANCET, V2, P475; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAY CS, 1990, AGE AGEING, V19, P179, DOI 10.1093/ageing/19.3.179; JORGENSEN HS, 1995, ANN NEUROL, V38, P45, DOI 10.1002/ana.410380110; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1983, ARCH NEUROL-CHICAGO, V40, P601, DOI 10.1001/archneur.1983.04050090037004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MacPherson Valerie, 1992, Brain Injury, V6, P489, DOI 10.3109/02699059209008146; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; Parker V M, 1986, Int Rehabil Med, V8, P69; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; REDDING MJ, 1988, STROKE, V19, P1354; SUNDERLAND A, 1989, J NEUROL NEUROSUR PS, V52, P1267, DOI 10.1136/jnnp.52.11.1267; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TALMAGE EW, 1983, PHYS THER, V12, P2010; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521	33	43	44	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					488	493		10.1016/S0003-9993(98)90060-0			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500002	9596386				2021-06-18	
J	Lin, VWH; Singh, H; Chitkara, RK; Perkash, I				Lin, VWH; Singh, H; Chitkara, RK; Perkash, I			Functional magnetic stimulation for restoring cough in patients with tetraplegia	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC QUADRIPLEGIA; CORD INJURY; DIAPHRAGM; NERVE; BRAIN	Objective: To evaluate the usefulness of functional magnetic stimulation (FMS) as a noninvasive method for assisting cough in patients with tetraplegia. Design: A prospective before-after trial. Setting: The functional magnetic stimulation laboratory of a spinal cord injury (SCI) service. Participants: Thirteen male SCI patients, with injury levels between C4 and C7. Intervention: A commercially available magnetic stimulator with a round magnetic coil (MC) was used. Expiratory muscle activation was achieved by placing the MC along the lower thoracic spine. Main Outcome Measure: The planned major outcome measures were the maximal expired pressure (MEP), expiratory reserve volume (ERV), and forced expiratory flow rate (FEF) by FMS compared with voluntary maximal efforts. Another outcome was the optimal MC placement and stimulation intensity that would result in highest expired pressure. Results: The mean (+/-SEM) MEP, ERV, and FEF generated by FMS were 66.40 +/- 6.69cmH(2)O, .77 +/- .14L, and 5.28 +/- .42L/sec, respectively. They were 118%, 169%, and 110% of voluntary maximum efforts. MC placement at the T10 to T11 spinous process and stimulation intensity at 80% produced the highest MEP and FEF. Conclusion: FMS of the expiratory muscles produced significant expired pressures, volumes, and flow rates when compared with voluntary maximum efforts; therefore, FMS can be used as an effective method to restore cough in tetraplegic patients. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Vet Adm Palo Alto Hlth Care Syst, Spinal Cord Injury Serv, Funct Magnet Simulat Lab, Stanford, CA 94305 USA; Vet Adm Palo Alto Hlth Care Syst, Pulm Dis Sect, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Funct Restorat, Div Phys Med & Rehabil, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Lin, VWH (corresponding author), Vet Adm Palo Alto Hlth Care Syst, Spinal Cord Injury Serv, Funct Magnet Simulat Lab, 3801 Miranda Ave, Stanford, CA 94305 USA.						BARKER AT, 1987, NEUROSURGERY, V20, P100; BELLAMY R, 1973, J NEUROSURG, V39, P596, DOI 10.3171/jns.1973.39.5.0596; BRAUN SR, 1984, AM J PHYS MED REHAB, V63, P1; CADWELL J, 1989, MAGNETIC STIMULATION, P16; CHOKROVERTY S, 1995, MUSCLE NERVE, V18, P987, DOI 10.1002/mus.880180910; DIMARCO AF, 1995, AM J RESP CRIT CARE, V151, P1466, DOI 10.1164/ajrccm.151.5.7735601; FISHBURN MJ, 1990, ARCH PHYS MED REHAB, V71, P197; FUGL-MEYER A R, 1971, Scandinavian Journal of Rehabilitation Medicine, V3, P141; JAEGER RJ, 1993, ARCH PHYS MED REHAB, V74, P1358, DOI 10.1016/0003-9993(93)90093-P; Kirby N A, 1966, Arch Phys Med Rehabil, V47, P705; LEDSOME JR, 1981, AM REV RESPIR DIS, V124, P41; Lin V W, 1997, J Spinal Cord Med, V20, P218; LIN VWH, 1997, AM J RESP CRIT CARE, V155, pA917; LIN VWH, 1993, ARCH PHYS MED REHAB, V74, P1237; LINDER SH, 1993, CHEST, V103, P166, DOI 10.1378/chest.103.1.166; LISSENS MA, 1994, J NEUROL SCI, V124, P204, DOI 10.1016/0022-510X(94)90327-1; MACABEE PJ, 1991, ELECTROEN CLIN NEURO, V81, P224; MCMICHAN JC, 1980, JAMA-J AM MED ASSOC, V243, P528, DOI 10.1001/jama.243.6.528; SIMILOWSKI T, 1989, J APPL PHYSIOL, V67, P1311; STONE DJ, 1963, AM REV RESPIR DIS, V88, P621; WRAGG S, 1994, EUR RESPIR J, V7, P1778; Zifko U, 1996, MUSCLE NERVE, V19, P614, DOI 10.1002/(SICI)1097-4598(199605)19:5<614::AID-MUS9>3.0.CO;2-E	22	43	51	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					517	522		10.1016/S0003-9993(98)90065-X			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500007	9596391				2021-06-18	
J	Nast-Kolb, D; Trupka, A; Ruchholtz, S; Schweiberer, L				Nast-Kolb, D; Trupka, A; Ruchholtz, S; Schweiberer, L			Abdominal trauma	UNFALLCHIRURG			German	Article						multitrauma; emergency therapy; abdominal diagnosis; laparoscopy; laparotomy	SEVERE HEPATIC-TRAUMA; SEVERE LIVER TRAUMA; STAB WOUNDS; NONOPERATIVE MANAGEMENT; BLUNT TRAUMA; INJURIES; TRANSPLANTATION; RESUSCITATION; LAPAROSCOPY; HEMORRHAGE	While a great part of the Anglo-American medical literature addresses the topic of penetrating trauma the German spreaking countries rather publish on blunt abdominal injury. The presented paper discusses the strategic principles of acute clinical management of abdominal trauma on the combined basis of own research results and a comprehensive review of the literature. Blunt abdominal injuries in most cases from a part in the pattern of multiple trauma. The early, first-hours mortality is most often caused by severe traumatic brain injury or abdominal trauma with massive hemorrhage. The prehospital management of penetrating injuries is characterized rather by the concept of 'load and go', whereas the on-scene stabilization of the patient with blunt abdominal injury should precede transport to the adequate hospital. On arrival in the accident and emergency room an immediate blood transfusion is recommended far hemodynamically unstable patients. If then a stabilization is not achieved, an emergency laparotomy should follow. Abdominal stab injuries should be explored by laparoscopy if an intraperitoneal lesion is suspected. If then the possibility of an intestinal lesion is present a laparotomy should be performed directly thereafter. Firearm injuries require open revision in almost all cases. The standard diagnostic technique in blunt abdominal trauma is sonography, assisted by computed tomography and, if indicated, angiography in hemodynamically stable patients. Isolated abdominal injuries without hemodynamic or coagulation disorders allow conservative treatment in the intensive care setting. In severe multiple trauma as well as in manifest shock even the smallest fluid detection should lead to laparotomy. The surgical treatment of splenic rupture is still a matter of discussion. Splenectomy is indicated in patients with severe concomitating injuries or shock whereas in the remainder of cases the total or partial preservation of the spleen should be pursued. Hepatic injuries offer a broad spectrum of operative interventions, ranging from superficial hemostatic measures over compression techniques like 'packing' and 'mesh-wrapping' to atypical and anatomical resections and to liver transplantation in exceptional cases. Lesions of tubular organs and the pancreas pose especially difficult diagnostical problems but regularly allow a rather easy operative treatment.	Univ Munich, Klinikum Innenstadt, Chirurg Klin & Poliklin, D-8000 Munich, Germany	Nast-Kolb, D (corresponding author), Chirurg Klin, Nussbaumstr 20, D-80336 Munich, Germany.						ANDERSSON R, 1986, ACTA CHIR SCAND, V152, P739; ANGSTADT J, 1989, J TRAUMA, V29, P606, DOI 10.1097/00005373-198905000-00012; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARDENHEUER M, 1995, UNFALLCHIRURG, V268, P269; BEAL SL, 1990, J TRAUMA, V30, P163, DOI 10.1097/00005373-199002000-00005; BEGER H, 1992, CHIRG OPERATIONSLEHR, V3, P75; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Branney SW, 1997, J TRAUMA, V42, P1086, DOI 10.1097/00005373-199706000-00017; BRUNET C, 1994, J TRAUMA, V37, P200, DOI 10.1097/00005373-199408000-00008; COGBILL TH, 1988, J TRAUMA, V28, P1433, DOI 10.1097/00005373-198810000-00004; CROCE MA, 1991, J TRAUMA, V31, P806, DOI 10.1097/00005373-199106000-00011; CUE JI, 1990, J TRAUMA, V30, P1007, DOI 10.1097/00005373-199008000-00010; DEMETRIADES D, 1986, BRIT J SURG, V73, P736, DOI 10.1002/bjs.1800730919; DEMETRIADES D, 1987, ANN SURG, V205, P129, DOI 10.1097/00000658-198702000-00005; DOCK W, 1988, UNFALLCHIRURG, V91, P185; DURHAM RM, 1992, AM J SURG, V164, P477, DOI 10.1016/S0002-9610(05)81184-5; ENDERSON BL, 1991, SURG CLIN N AM, V71, P399; Ertel W, 1996, UNFALLCHIRURG, V99, P288; ESQUIVEL CO, 1987, J TRAUMA, V27, P800, DOI 10.1097/00005373-198707000-00020; FABIAN TC, 1993, ANN SURG, V217, P557, DOI 10.1097/00000658-199305010-00017; FARNELL MB, 1988, SURGERY, V104, P748; FELICIANO DV, 1986, ANN SURG, V204, P438, DOI 10.1097/00000658-198610000-00012; FELICIANO DV, 1988, ANN SURG, V208, P362, DOI 10.1097/00000658-198809000-00014; FELICIANO PD, 1992, J TRAUMA, V33, P340, DOI 10.1097/00005373-199209000-00002; GOLDBERGER JH, 1982, J TRAUMA, V22, P476, DOI 10.1097/00005373-198206000-00006; HALLFELDT KKJ, 1998, IN PRESS SURG ENDOSC; HOLLANDS MJ, 1991, BRIT J SURG, V78, P968, DOI 10.1002/bjs.1800780824; IVATURY RR, 1993, J TRAUMA, V34, P822, DOI 10.1097/00005373-199306000-00013; KIRSCHNER P, 1974, THERAPIEWOCHE, V24, P4268; Kohlberger E J, 1989, Fortschr Med, V107, P244; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; KUDSK K, 1982, ABDOMINAL TRAUMA TRA; KUNIN JR, 1993, AM J ROENTGENOL, V160, P1221, DOI 10.2214/ajr.160.6.8498221; Matsuoka T, 1996, J TRAUMA, V41, P439, DOI 10.1097/00005373-199609000-00009; MCHENRY CR, 1994, AM J SURG, V168, P280, DOI 10.1016/S0002-9610(05)80202-8; MCINTYRE R, 1989, INJURY, V20, P355, DOI 10.1016/0020-1383(89)90013-2; MCKENNEY M, 1994, J TRAUMA, V37, P439, DOI 10.1097/00005373-199409000-00018; MEREDITH JW, 1994, J TRAUMA, V36, P529, DOI 10.1097/00005373-199404000-00012; MOORE EE, 1984, AM J SURG, V148, P712, DOI 10.1016/0002-9610(84)90422-7; NAGEL M, 1992, ZBL CHIR, V117, P453; NAGEL M, 1991, UNFALLCHIRURG, V94, P105; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; NASTKOLB D, 1997, LANGENBECKS ARCH C S, V2, P330; NASTKOLB D, 1993, CHIRURG, V64; OLDHAFER KJ, 1993, UNFALLCHIRURG, V96, P497; Patton JH, 1997, J TRAUMA, V43, P234, DOI 10.1097/00005373-199708000-00005; PEIPER HJ, 1987, CHIRURG, V58, P189; REED R, 1992, ANN SURG, V26, P524; RINGE B, 1991, SURGERY, V109, P792; ROSS SE, 1995, INJURY, V26, P393, DOI 10.1016/0020-1383(95)00058-H; ROSSI P, 1993, AM J SURG, V166, P707, DOI 10.1016/S0002-9610(05)80684-1; SCHMIDT U, 1994, UNFALLCHIRURG, V97, P54; SCHWEIBERER L, 1991, JB CHIRURG 1991, P19; SEUFERT R, 1992, CHIRURG ABDOMENS, V3, P127; SMITH JS, 1992, J TRAUMA, V33, P363, DOI 10.1097/00005373-199209000-00005	55	43	43	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0177-5537			UNFALLCHIRURG	Unfallchirurg	FEB	1998	101	2					82	91		10.1007/s001130050239			16	Emergency Medicine; Surgery	Emergency Medicine; Surgery	ZB289	WOS:000072456100002	9553475				2021-06-18	
J	Sherer, M; Oden, K; Bergloff, P; Levin, E; High, WM				Sherer, M; Oden, K; Bergloff, P; Levin, E; High, WM			Assessment and treatment of impaired awareness after brain injury: implications for community re-integration	NEUROREHABILITATION			English	Article						impaired awareness; traumatic brain injury; rehabilitation; treatment; community re-integration	HEAD-INJURY; BEHAVIORAL LIMITATIONS; RATING-SCALE; DEFICITS; ADULTS; REHABILITATION; UNAWARENESS; DYSFUNCTION; ANOSOGNOSIA; RECOVERY	Impaired self-awareness of deficits is a common finding in patients who have suffered traumatic brain injury. Impaired awareness can limit motivation for treatment and contribute to poor outcome. Consequently, it is important for brain injury rehabilitation professionals to understand this phenomenon and utilize treatment approaches that may improve patient awareness. The present article reviews the existing literature on measurement of impaired awareness, characteristics of impaired awareness, the relationship of impaired awareness to functional outcome, possible treatment approaches for impaired awareness and empirical investigations of interventions to improve awareness. The treatment strategies we use to address impaired awareness in our community re-integration program for brain injury survivors are described in detail. These approaches include: establishment of the therapeutic alliance, family interventions, peer feedback, education, roleplaying, videotape feedback, real world experiences, therapeutic milieu and psychotherapy. (C) 1998 Elsevier Science Ireland Ltd.	Inst Rehabil & Res, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA	Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						Alexy WD, 1983, COGNITIVE REHABILITA, V1, P8; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BABINSKI MJ, 1914, REV NEUROL, V12, P845; Barco P.P., 1991, COGNITIVE REHABILITA, P129; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Bloom B. S., 1956, CLASSIFICATION ED GO, V1; BUTLER RW, 1988, PROF PSYCHOL-RES PR, V19, P536, DOI 10.1037/0735-7028.19.5.536; Campodonico J. R., 1995, PSYCHOL ASSESSMENT M, P393; Chittum WR, 1996, BRAIN INJURY, V10, P763; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gasquoine PG, 1994, J HEAD TRAUMA REHAB, V9, P16, DOI DOI 10.1097/00001199-199412000-00004; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Graham D.I., 1993, HEAD INJURY, P91; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JOHNSON RP, 1987, CLIN REHABIL, V1, P319; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, UNPUB CLIN RATING SC; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P67; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Schank R.C., 1990, INTERACTIVE LEARNING, V1, P231; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; SHERER M, IN PRESS BRAIN INJ; SHERER M, UNPUB CHARACTERISTIC; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; SHERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; von Monakow A., 1885, ARCH PSYCHIAT, V16, P151, DOI [10.1007/BF02227304, DOI 10.1007/BF02227304]; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217	53	43	43	1	19	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	JAN	1998	10	1					25	37		10.1016/S1053-8135(97)00042-5			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YV946	WOS:000071880300004	24525814				2021-06-18	
J	Abe, K; Setoguchi, Y; Hayashi, T; Itoyama, Y				Abe, K; Setoguchi, Y; Hayashi, T; Itoyama, Y			In vivo adenovirus-mediated gene transfer and the expression in ischemic and reperfused rat brain	BRAIN RESEARCH			English	Article						gene transfer; lacZ gene; ischemia; brain	CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; IN-VIVO; NEURONAL DEATH; THERAPY; INVIVO; VECTORS; INDUCTION; DISEASE; CELLS	In an attempt to study whether ischemic brain could express a foreign gene in vivo, a replication-defective adenoviral vector containing the Escherichia coli lacZ gene was directly injected into the ischemic or reperfused cerebral cortex of rat, and temporal and spatial profiles of the exogenous gene expression were compared with that of the control brain. Right middle cerebral artery (MCA) of rat was continuously occluded by an insertion of nylon thread for 2 days, or only transiently occluded for 90 min and then the blood flow was restored for 21 days. The adenoviral vector was administered just after the MCA occlusion or reperfusion in the case of continuous ischemia and reperfusion, respectively. Adenoviral vector was transferred into the continuous ischemic brain, and the lacZ gene was expressed until 2 days of the occlusion in the cerebral cortex of the occluded MCA territory with the number of expressing cells smaller and the staining just weaker than that of the control brain. In contrast, expression of the lacZ gene was not or only minimally observed in the reperfused brain until 2 days. However, the expression dramatically exploded at 7 days of reperfusion at a level similar to that of the control, and the expression diminished by 21 days. A few neurons in the ipsilateral thalamus, hypothalamus, and basal ganglia, and in the contralateral cerebral cortex expressed the lacZ gene at 7 days after reperfusion, a phenomenon similar to the case of the control. The majority of brain cells that expressed the lacZ gene were neurons, and a part (5-10%) were astroglial cells. Traumatic injury and immunological response in the brain were minimal both in the cases of control and ischemia/reperfusion. The present study shows an effective gene transfer and the expression in neural cells of ischemic and reperfused brains in vivo, and suggests a great potential of the gene therapy for ischemic stroke patients in the future. (C) 1997 Elsevier Science B.V.	JUNTENDO UNIV,SCH MED,DEPT RESP MED,TOKYO 113,JAPAN	Abe, K (corresponding author), TOHOKU UNIV,SCH MED,DEPT NEUROL,AOBA KU,1-1 SEIRYO MACHI,SENDAI,MIYAGI 98077,JAPAN.		Setoguchi, Yasuhiro/AAE-1448-2021	Setoguchi, Yasuhiro/0000-0002-0892-6364			ABE K, 1991, NEUROSCI LETT, V123, P248, DOI 10.1016/0304-3940(91)90942-M; ABE K, 1995, NEUROSCI LETT, V199, P152, DOI 10.1016/0304-3940(95)12039-7; ABE K, 1987, BRAIN RES, V423, P221, DOI 10.1016/0006-8993(87)90843-2; ABE K, 1991, NEUROSCI LETT, V125, P166, DOI 10.1016/0304-3940(91)90018-O; ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; ABE K, 1988, J NEUROCHEM, V51, P1470, DOI 10.1111/j.1471-4159.1988.tb01113.x; ABE K, 1993, PROG BRAIN RES, V96, P221; AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BREAKEFIELD XO, 1993, NAT GENET, V3, P187, DOI 10.1038/ng0393-187; CULOTTA E, 1993, SCIENCE, V260, P914, DOI 10.1126/science.8493527; DANKO I, 1993, HUM MOL GENET, V2, P2055, DOI 10.1093/hmg/2.12.2055; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DECONINCK N, 1996, P NATL ACAD SCI USA, V93, P350; FELDMAN LJ, 1995, J AM COLL CARDIOL, V26, P826, DOI 10.1016/0735-1097(95)00235-V; FINK DJ, 1992, HUM GENE THER, V3, P11, DOI 10.1089/hum.1992.3.1-11; FINKEL T, 1995, FASEB J, V9, P843; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Heistad DD, 1996, STROKE, V27, P1688, DOI 10.1161/01.STR.27.9.1688; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; Karpati G, 1996, TRENDS NEUROSCI, V19, P49; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL EG, 1995, CIRCULATION, V91, P541, DOI 10.1161/01.CIR.91.2.541; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; Okada Y, 1996, AM J PATHOL, V149, P37; ONO T, 1990, NEUROSCI LETT, V117, P259, DOI 10.1016/0304-3940(90)90673-W; OOBOSHI H, 1995, CIRC RES, V77, P7, DOI 10.1161/01.RES.77.1.7; PALLELA TD, 1989, GENE, V80, P137; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SALLE GL, 1993, SCIENCE, V259, P988; SETOGUCHI Y, 1994, AM J RESP CELL MOL, V10, P369, DOI 10.1165/ajrcmb.10.4.8136153; SETOGUCHI Y, 1994, BLOOD, V84, P2946; SETOGUCHI Y, 1994, J INVEST DERMATOL, V102, P415, DOI 10.1111/1523-1747.ep12372181; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILLIAMS RS, 1993, AM J MED SCI, V306, P129, DOI 10.1097/00000441-199308000-00013; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379; Yang YP, 1996, HUM MOL GENET, V5, P1703, DOI 10.1093/hmg/5.11.1703	46	43	46	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 25	1997	763	2					191	201		10.1016/S0006-8993(97)00389-2			11	Neurosciences	Neurosciences & Neurology	XT038	WOS:A1997XT03800005	9296559				2021-06-18	
J	Max, JE; Lindgren, SD; Robin, DA; Smith, WL; Sato, Y; Mattheis, PJ; Castillo, CS; Stierwalt, JAG				Max, JE; Lindgren, SD; Robin, DA; Smith, WL; Sato, Y; Mattheis, PJ; Castillo, CS; Stierwalt, JAG			Traumatic brain injury in children and adolescents: Psychiatric disorders in the second three months	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							RELIABILITY; SCALE	Psychiatric disorders may be common after traumatic brain injury (TBI) in children, yet there is a dearth of prospective studies examining this problem. Fifty children aged 6 to 14, hospitalized after TBI, were assessed soon after TBI regarding preinjury psychiatric, behavioral, adaptive, and family functioning, family psychiatric history status and injury severity. The outcome measure was the presence of a ''novel'' psychiatric disorder (not present before the injury) during the second 3 months after the injury. Forty-two subjects were reassessed at 6 months. Severity of injury, family psychiatric history, and family function predicted a novel psychiatric disorder. Among children suffering a mild/moderate injury, those with preinjury lifetime psychiatric disorders were no longer (as they had been in the first 3 months) at higher risk than those without such a lifetime history. Thus, there appeared to be children, identifiable through clinical assessment, at increased risk for novel psychiatric disorders after TBI.	CEDAR CTR,CEDAR RAPIDS,IA	Max, JE (corresponding author), UNIV IOWA HOSP & CLIN,DEPT PSYCHIAT,1876 JPP,IOWA CITY,IA 52242, USA.		Robin, Donald/F-2109-2010; Mohamadifard, Mahtab/AAH-3843-2021	Sato, Yutaka/0000-0002-5245-232X			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Hoover H.D., 1986, MANUAL SCH ADM IOWA; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; MARSHALL LD, 1991, J NEUROSURG, V75, P514; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Sparrow S., 1984, VINELAND ADAPTIVE BE; *SPSS INC, 1993, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1991, WECHSLER INTELLIGENC	21	43	43	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	1997	185	6					394	401		10.1097/00005053-199706000-00006			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	XE747	WOS:A1997XE74700006	9205426				2021-06-18	
J	Peace, KA; Orme, SM; Sebastian, JP; Thompson, AR; Barnes, S; Ellis, A; Belchetz, PE				Peace, KA; Orme, SM; Sebastian, JP; Thompson, AR; Barnes, S; Ellis, A; Belchetz, PE			The effect of treatment variables on mood and social adjustment in adult patients with pituitary disease	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; HEAD-INJURY; SELF-REPORT	OBJECTIVE Studies of mood in hypopituitary adults have yielded inconsistent results. This investigation was carried out to investigate whether treatment characteristics may be responsible for the inconsistent results. DESIGN AND MEASUREMENTS We compared three groups of patients with a group of matched healthy controls on self-report measures of mood and social adjustment (Beck depression inventory, State-trait anxiety inventory, Social adjustment scale (modified)) and a measure of quality of life (Nottingham health profile, NHP). PATIENTS The patient groups were those treated with transfrontal surgery (n = 23), transsphenoidal surgery (n = 23) or medication only (n = 23), in addition, a close informant of each subject was asked to complete a social adjustment measure about the subject's lever of adjustment. RESULTS On the self-report mood and social adjustment measures and the emotion sub-scale of the NHP, the transsphenoidal and medication patient groups rated themselves as being more depressed, anxious and having poorer social adjustment than the transfrontal or control groups. The close informants, however, rated all three patient groups as having poorer social adjustment than the controls. Patients treated with surgery and without radiotherapy reported fewer symptoms of depression than those treated with radiotherapy. Realistic self-appraisal of social adjustment in surgical patients was found only in those treated with transsphenoidal surgery without radiotherapy. CONCLUSIONS Patients treated for pituitary tumour, excepting those treated with transfrontal surgery and to a lesser extent those treated with radiotherapy, suffer from mild mood disturbance and self-perceived decreased social adjustment. All patient groups are seen by others as having decreased social adjustment, raising the possibility that the transfrontal patients and possibly those who have had radiotherapy, lack insight. This may explain some of the discrepancies in the previous literature and needs to be taken into account when using self-report measures with these patients.	GEN INFIRM, DEPT ENDOCRINOL, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, DEPT CLIN PSYCHOL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; YORK UNIV, DEPT PSYCHOL, YORK, N YORKSHIRE, ENGLAND			Padayatty, Sebastian J/A-8581-2012	Padayatty, Sebastian J/0000-0001-8758-3170; Thompson, Andrew/0000-0001-6788-7222			BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; DEGERBLAD M, 1990, ACTA ENDOCRINOL-COP, V123, P185, DOI 10.1530/acta.0.1230185; DEPUY HJ, 1984, ASSESSMENT QUALITY L; DEYO RA, 1986, J CHRON DIS, V39, P897, DOI 10.1016/0021-9681(86)90038-X; FAHY TJ, 1967, LANCET, V2, P475; FAZZIO AF, 1977, VITAL HLTH STAT, V2; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HUNT SM, 1981, SOC SCI MED-MED SOC, V15, P221, DOI 10.1016/0271-7123(81)90005-5; JORGENSEN JOL, 1989, LANCET, V1, P1221; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MELMED S, 1990, NEW ENGL J MED, V323, P612; Olkin, 1960, CONTRIBUTIONS PROBAB, P278; Peace KA, 1997, J CLIN EXP NEUROPSYC, V19, P1, DOI 10.1080/01688639708403831; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; SAVILLE DJ, 1990, AM STAT, V44, P174, DOI 10.2307/2684163; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; *SPSS INC, 1994, SPSS WIND VERS 6 1; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WHITE JC, 1955, ARCH NEURO PSYCHIATR, V74, P383, DOI 10.1001/archneurpsyc.1955.02330160033006; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x	23	43	45	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	APR	1997	46	4					445	450		10.1046/j.1365-2265.1997.1600971.x			6	Endocrinology & Metabolism	Endocrinology & Metabolism	XA806	WOS:A1997XA80600011	9196607				2021-06-18	
J	Hamm, RJ; Temple, MD; Pike, BR; Ellis, EF				Hamm, RJ; Temple, MD; Pike, BR; Ellis, EF			The effect of postinjury administration of polyethylene glycol-conjugated superoxide dismutase (Pegorgotein, Dismutec(R)) or lidocaine on behavioral function following fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; motor; memory; PEG-SOD; lidocaine; rat; free radicals	CEREBRAL BLOOD-FLOW; RADICAL SCAVENGER; SCOPOLAMINE; IMPAIRMENT; MODEL; CATS	Previous studies in our laboratory have shown that polyethylene glycol-conjugated superoxide dismutase (PEG-SOD) or lidocaine treatment before experimental fluid-percussion brain injury in rats reduces the cortical hypoperfusion normally found in the early posttraumatic period, The purpose of the current study was to determine if posttreatment with PEG-SOD or lidocaine is also associated with changes in the trauma-induced suppression of motor and cognitive function that occurs following traumatic brain injury (TBI), Twenty-four hours after surgical preparation, rats were randomly assigned to a saline or drug posttreatment group, PEG-SOD (pegorgotein, Dismutec(R), 10,000 IU/kg) or lidocaine (2 mg/kg), which was injected iv 30 min after moderate injury, PEG-SOD completely prevented beam walk latency deficits on days 1-5 postinjury while lidocaine similarly prevented beam walk deficits on days 2 through 5 postinjury. Both drugs produced a statistically insignificant trend for a decrease in beam balance duration deficits on days 1-5 postinjury and had no effect on cognitive function, as assessed by the Morris water maze, on days 11 through 15 postinjury, The mechanism by which PEG-SOD and lidocaine reduce posttraumatic motor deficits may be related to their free radical scavenging effect or previously reported effects on posttraumatic cerebral blood flow, To our knowledge, this is the first report of the effectiveness of these two agents in laboratory animals when administered after traumatic injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [27214, 05274] Funding Source: Medline		BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; DAS KC, 1992, MOL CELL BIOCHEM, V115, P179; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIR JK, 1992, J NEUROTRAUM, V9, P394; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MURI JK, 1995, AM J PHYSIOL, V37, pH68; RASOOL N, 1990, STROKE, V21, P929, DOI 10.1161/01.STR.21.6.929; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	29	43	43	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1996	13	6					325	332		10.1089/neu.1996.13.325			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UZ052	WOS:A1996UZ05200005	8835800				2021-06-18	
J	Stablum, F; Mogentale, C; Umilta, C				Stablum, F; Mogentale, C; Umilta, C			Executive functioning following mild closed head injury	CORTEX			English	Article							REACTION-TIME; CONCUSSION; ATTENTION; SYMPTOMS; RECOVERY; LESIONS; BRAIN; CONSCIOUSNESS; ORGANIZATION; DISABILITY	This study was aimed to identify impaired attentional components in mild CHI patients. The CHI features taken into account were age (less than or equal to 30 vs. >30 years), loss of consciousness (yes vs. no), and time after injury (few days vs. some months). The groups tested were composed of 26 patients and 26 controls (matched for age, sex and education). Experiment 1 used a dual-task paradigm (Umilta et al., 1992), which taps executive functions. The double task-single task difference was greater for the CHI group, but only for patients older than 30 years and/or with consciousness loss. Two years after injury, some of these patients were retested: The results showed that this deficit was still present. Experiment 2 studied visual selective attention using the Navon (1977) paradigm. In this case, there were no differences between patients and controls. The results are discussed with reference to the anterior/posterior attention systems.		Stablum, F (corresponding author), UNIV PADUA,DIPARTIMENTO PSICOL GEN,VIA VENEZIA 8,I-35131 PADUA,ITALY.			Stablum, Franca/0000-0003-0123-5090			Allport A., 1989, FDN COGNITIVE SCI, P631; ALVISADOS B, 1982, CORTEX, V18, P5; BENYISHAY Y, 1983, REHABILITATION HEAD; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BIRREN JE, 1974, AM PSYCHOL, V29, P808, DOI 10.1037/h0037433; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BOOKS N, 1987, BRAIN INJURY, V1, P5; CERELLA J, 1991, J EXP PSYCHOL GEN, V120, P215, DOI 10.1037/0096-3445.120.2.215; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DOYON J, 1991, NEUROPSYCHOLOGIA, V29, P343, DOI 10.1016/0028-3932(91)90024-3; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HICKS L, 1970, PSYCHOL BULL, V74, P281; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LAMB MR, 1990, J EXP PSYCHOL LEARN, V16, P471, DOI 10.1037/0278-7393.16.3.471; LAMB MR, 1989, NEUROPSYCHOLOGIA, V27, P471, DOI 10.1016/0028-3932(89)90052-3; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARKER R, 1990, TRAUMATIC BRAIN INJU; PASHLER H, 1994, PSYCHOL BULL, V116, P220, DOI 10.1037/0033-2909.116.2.220; PASHLER H, 1989, Q J EXP PSYCHOL-A, V41, P19, DOI 10.1080/14640748908402351; POLICH J, 1990, ACTA PSYCHOL, V74, P47, DOI 10.1016/0001-6918(90)90034-D; POLSTER MR, 1994, CORTEX, V30, P487, DOI 10.1016/S0010-9452(13)80344-9; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Prigatano G., 1985, NEUROPSYCHOLOGICAL R; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; ROBERTSON LC, 1991, COGNITIVE PSYCHOL, V23, P299, DOI 10.1016/0010-0285(91)90012-D; ROBERTSON LC, 1986, NEUROPSYCHOLOGIA, V24, P363, DOI 10.1016/0028-3932(86)90021-7; ROBERTSON LC, 1991, NEUROPSYCHOLOGIA, V29, P959, DOI 10.1016/0028-3932(91)90060-L; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Salthouse T. A., 1985, THEORY COGNITIVE AGI; SHALLICE T, 1994, ATTENTION PERFORM, V15, P395; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; Umilta C, 1988, HDB NEUROPSYCHOLOGY, P175; Umilta C., 1988, CONSCIOUSNESS CONT S, P334; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; Wechsler D., 1974, WECHSLER ADULT INTEL; Welford Alan T., 1958, AGING HUMAN SKILL; WELFORD AT, 1981, HUM FACTORS, V23, P97; WELFORD AT, 1962, LANCET, V1, P335; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; ZANASI A, 1988, S FUNCTIONAL NEUROLO, V2, P185	77	43	43	0	8	MASSON DIVISIONE PERIODICI	MILAN	VIA STATUTO 2/4, 20121 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1996	32	2					261	278		10.1016/S0010-9452(96)80050-5			18	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	UT070	WOS:A1996UT07000004	8800614				2021-06-18	
J	Parker, RS				Parker, RS			The spectrum of emotional distress and personality changes after minor head injury incurred in a motor vehicle accident	BRAIN INJURY			English	Article								This is a systematic presentation of the emotional and personality disorders of 33 patients who incurred minor traumatic brain injury (MTBI) in a vehicular accident. A wide spectrum of disorders was observed: cerebral personality disorder, persistent altered consciousness, post-traumatic stress, psychodynamic reactions to impairment, and complex reactions expressing neurological, somatic, and psychological dysfunctions (sexuality and somatization). Examples of each category are offered to aid identification. A total of 31/33 patients suffered an additional psychiatric disorder. Unreported head trauma and loss of consciousness (LOC) elicited by detailed interviews helped to explain the extent of impairment. Emotional disorders, added to persistent cognitive loss and other neuropsychological symptoms, greatly impair the capacity to adapt after traumatic brain injury (TBI). Clinical procedures (interview; Rorschach; observation; figure drawings; checklists) are recommended to obtain detailed personality information needed for diagnosis, prognosis, and treatment. Behavioural outcome after TBI reflects disturbance in the processing of internal and external stimulation, and disturbance of pre-existing physiological and psychological processes. Emotional distress consistent with the accident and impairment adds to the credibility of patient complaints. There is an interaction between lesion effects and various emotional disturbances, which impacts employment, social relationships, and the enjoyment of life. Prompt and sympathetic treatment will contribute to more effective treatment, and may be anticipated to reduce or prevent some persistent symptoms after minor head injury.	NYU,MED CTR,NEW YORK,NY 10016							ADAMS JH, 1987, HEAD INJURY, P72; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; APPLEBY L, 1989, BRIT MED J, V298, P977; BANCAUD J, 1994, BRAIN, V117, P71, DOI 10.1093/brain/117.1.71; Bar-On D., 1990, J TRAUMA STRESS, V3, P415; BECKER ME, 1993, BRAIN INJURY, V7, P515, DOI 10.3109/02699059309008179; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; COVELLI V, 1994, NEUROIMMUNOMODULAT, P212; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; DAVIDOFF RA, 1995, MIGRAIN; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DEVINSKY O, 1993, NEUROL CLIN, V11, P127; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FEYEREISON P, 1991, HDB NEUROPSYCHOLOGY, V3, P271; Fuster J, 1989, PREFRONTAL CORTEX; GAINOTTI G, 1991, HDB NEUROPSYCHOLOGY, V3, P343; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GASS CS, 1991, J CLIN PSYCHOL, V47, P100, DOI 10.1002/1097-4679(199101)47:1<100::AID-JCLP2270470116>3.0.CO;2-H; Gean A, 1994, IMAGING HEAD TRAUMA; GRIGSBY J, 1991, PSYCHIATRY, V54, P39; GRIGSBY JP, 1989, PSYCHOL REP, V64, P527, DOI 10.2466/pr0.1989.64.2.527; HEILMAN KM, 1991, HDB NEUROPSYCHOLOGY, V3, P403; HENDLER N, 1990, NEUROLOGICAL SURG, V4, P3813; HIRSCH AD, 1968, 287 DEP NAV NAV SHIP, V19, P252; Janoff-Bulman R., 1985, TRAUMA ITS WAKE, V1, P15; JORJE RE, 1993, J NERV MENT DIS, V181, P91; KAPP B S, 1992, P229; KERR DS, 1991, J NEUROSCI, V11, P1316; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Kroening R. J., 1990, NEUROLOGICAL SURG, P3803; Kupfermann I, 1991, PRINCIPLES NEURAL SC, P735; LEDOUX J E, 1992, P339; MATARAZZO JD, 1984, J CONSULT CLIN PSYCH, V52, P631, DOI 10.1037/0022-006X.52.4.631; MCEWEN B, 1994, SEMIN NEUROSCI, V6, P195, DOI 10.1006/smns.1994.1025; MCLAURIN RL, 1990, NEUROLOGICAL SURG, V4, P2175; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; MIKAIL SF, 1994, CLIN PSYCHOL REV, V14, P1, DOI 10.1016/0272-7358(94)90045-0; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; Miller L., 1994, PSYCHOBIOLOGY AGGRES, V21, P91, DOI DOI 10.1300/J076; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Ommaya A. K., 1990, NEUROLOGICAL SURG, V3, P1877; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Pansky B., 1988, REV NEUROSCIENCE; PARKER R, 1990, TRAUMATIC BRAIN INJU; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; PARKER RS, 1983, SELF IMAGE PSYCHODYN; PARKER RS, IN PRESS J NEUROLOGI; PARKER RS, 1994, GUIDE ANAL UNDERSTAN, P79; PARKER RS, 1994, J NEUROL ORTH MED S, V15, P123; PARKER RS, 1968, J PROJECTIVE TECHNIQ, V32, P32; PARKER RS, 1994, GUIDE ANAL UNDERSTAN, P309; PARKER RS, IN PRESS J CLIN PSYC; PILOWSKY I, 1985, BRIT J PSYCHIAT, V147, P310, DOI 10.1192/bjp.147.3.310; PIOTROWSKI ZA, 1965, PERCEPTANALYSIS; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RADANOV BP, 1994, BRIT J RHEUMATOL, V33, P442; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; RON MA, 1994, J NEUROL NEUROSUR PS, V57, P1161, DOI 10.1136/jnnp.57.10.1161; ROSS ED, 1993, NEUROL CLIN, V11, P9; RYAN JJ, 1991, J CLIN PSYCHOL, V47, P104, DOI 10.1002/1097-4679(199101)47:1<104::AID-JCLP2270470117>3.0.CO;2-2; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Spiers PA, 1985, PRINCIPLES BEHAVIORA, P289; STRAUSS E, 1992, ARCH NEUROL-CHICAGO, V49, P391, DOI 10.1001/archneur.1992.00530280079026; TRIMBLE MR, 1995, NEUROLOGY GENERAL ME, P473; URSIN H, 1994, NEUROIMMUNOMODULAT, P204; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	69	43	44	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1996	10	4					287	302		10.1080/026990596124467			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UJ541	WOS:A1996UJ54100006	9044694				2021-06-18	
J	GOLDSTEIN, LB				GOLDSTEIN, LB			PRESCRIBING OF POTENTIALLY HARMFUL DRUGS TO PATIENTS ADMITTED TO HOSPITAL AFTER HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						HEAD TRAUMA; RECOVERY	VISUAL-CORTEX ABLATION; AMPHETAMINE-INDUCED RECOVERY; BINOCULAR DEPTH-PERCEPTION; CORTICAL HEMIPLEGIA; LOCOMOTOR FUNCTION; BRAIN INJURY; BEAM-WALKING; HALOPERIDOL; EXPERIENCE; PHENYTOIN	Fundamental studies in laboratory animals show that certain drugs influence behavioural recovery after brain injury. Although some drugs have the potential to enhance recovery, others may be detrimental. The purpose of the present study was to determine how often these potentially detrimental drugs are used in the management of patients with traumatic brain injury. The medical records of 100 patients with head trauma admitted to a university hospital during one year were reviewed and the frequencies of medication prescriptions during the stay in hospital were recorded. Only 14% of patients with head injury were taking medications at the time of injury. All of the patients were prescribed medications during their stay in hospital. Seventy two per cent of the patients received one or a combination of the drugs (neuroleptics and other central dopamine receptor antagonists, benzodiazepines, and the anticonvulsants phenytoin and phenobarbitone) that animal studies suggest may impair recovery. Until the true impact of these classes of drugs on the recovery process is better understood, care should be exercised in their use.	DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC 27710; VET AFFAIRS MED CTR,DURHAM,NC 27705	GOLDSTEIN, LB (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEUROL,BOX 3651,DURHAM,NC 27710, USA.						Barbay S., 1993, Society for Neuroscience Abstracts, V19, P1012; BARTH TM, 1990, STROKE, V21, P153; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; CHWEH AY, 1986, PHARMACOL BIOCHEM BE, V24, P1301, DOI 10.1016/0091-3057(86)90188-7; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DERYCK M, 1990, STROKE, V21, P158; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GOLDSTEIN LB, 1990, STROKE, V21, P139; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1988, NEUROLOGY, V38, P1806, DOI 10.1212/WNL.38.11.1806; GOLDSTEIN LB, 1989, ANN NEUROL, V26, P157; GOLDSTEIN LB, 1990, J NEURO REHAB, V4, P137; GOLDSTEIN LB, 1995, IN PRESS NEUROLOGY; GOLDSTEIN LB, 1989, CEREBROVASC DIS, P303; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAYES RL, 1985, J CEREB BLOOD FLO S1, V5, pS395; HERNANDEZ TD, 1994, BRAIN RES, V635, P300, DOI 10.1016/0006-8993(94)91451-6; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HOVDA DA, 1985, P W PHARMACOL SOC, V28, P209; JENNETT B, 1975, LANCET, V1, P480; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; Marshall L. F., 1985, CENTRAL NERVOUS SYST, P45; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; PORCH EE, 1986, CLIN APHASIOLOGY, V16, P309; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Saponjic R. M., 1993, Society for Neuroscience Abstracts, V19, P1012; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHALLERT T, 1992, PHYS MED REHABIL, V6, P375; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; STEPHENS J, 1986, ARCH PHYS MED REHAB, V67, P666; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WALKERBATSON D, 1992, RESTOR NEUROL NEUROS, V4, P47, DOI 10.3233/RNN-1992-4106	45	43	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1995	58	6					753	755		10.1136/jnnp.58.6.753			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	RC686	WOS:A1995RC68600026	7608684	Green Published, Bronze			2021-06-18	
J	CREMONAMETEYARD, SL; GEFFEN, GM				CREMONAMETEYARD, SL; GEFFEN, GM			PERSISTENT VISUOSPATIAL ATTENTION DEFICITS FOLLOWING MILD HEAD-INJURY IN AUSTRALIAN RULES FOOTBALL PLAYERS	NEUROPSYCHOLOGIA			English	Article							COVERT ORIENTATION; VISUAL-ATTENTION; NEUROPSYCHOLOGICAL DEFICITS; REACTION-TIME; SYMPTOMS; CONCUSSION; SEQUELAE; RECOVERY; LONG	The ability to direct visuospatial attention covertly was studied in two groups of Australian Rules football players who had sustained mild head injuries (MHI) during competition. Their performance was compared to 12 non-injured sportsmen using a cued reaction time (RT) task which measured the RT benefit of valid directional cueing and the RT cost of miscueing. In Experiment 1, nine footballers tested within 2 weeks of sustaining their injury showed the same cost as normals in speed of response to targets in the unexpected visual field. However, their responses to targets in the expected location (following valid cues) showed only a minor benefit compared to controls. Moderate to severely injured patients also show a normal cost but a reduced or absent benefit (CREMONA-METEYARD and GEFFEN, Neuropsychologia 30, 123-132, 1992). When subjects were retested 1 year later their pattern of performance had not altered but overall RT had improved. Experiment 2 replicated these findings in another eight footballers tested at least 1 year after sustaining their MHI. A persistent consequence of MHI might be an inability to take action quickly in response to expected events.	UNIV QUEENSLAND,DEPT PSYCHOL,COGNIT PSYCHOPHYSIOL LAB,ST LUCIA,QLD 4067,AUSTRALIA; UNIV QUEENSLAND,CLIN STUDIES UNIT,ST LUCIA,QLD 4067,AUSTRALIA; QUEENSLAND HLTH,BRISBANE,QLD 4072,AUSTRALIA							BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT., 1989, MILD HEAD INJURY, P257; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1987, ASSESSMENT BEHAVIOUR, P37; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Brooks N., 1984, CLOSED HEAD INJURY P; CASTIELLO U, 1988, RIV CULTURA SPORTIVA, V13, P28; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; CREMONAMETEYARD SL, IN PRESS BRAIN INJUR; DENCKER SJ, 1958, ACTA PSYCHIAT N S122, V33; DENCKER SJ, 1958, ACTA PSYCHIAT N S123, V33; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GANDY SE, 1984, NEUROLOGY, V16, P114; GEFFEN GM, 1991, J CLIN EXP NEUROPSYC, V13, P423; GEFFEN GM, UNPUB TEST RETEST RE; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GREENWOOD PM, 1993, NEUROPSYCHOLOGIA, V31, P471, DOI 10.1016/0028-3932(93)90061-4; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341; KEPPEL S, 1982, DESIGN ANAL RES HDB; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NOUGIER V, 1992, J EXP CHILD PSYCHOL, V54, P315, DOI 10.1016/0022-0965(92)90023-Y; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Posner M. I., 1978, MODES PERCEIVING PRO, P137; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1988, SCIENCE, V240, P1727; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P64; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	51	43	43	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUN	1994	32	6					649	662		10.1016/0028-3932(94)90026-4			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	NU235	WOS:A1994NU23500002	8084421				2021-06-18	
J	HAYES, RL; DIXON, CE				HAYES, RL; DIXON, CE			NEUROCHEMICAL CHANGES IN MILD HEAD-INJURY	SEMINARS IN NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; EXTRACELLULAR POTASSIUM; HORSERADISH-PEROXIDASE; SPINAL-INJURY; AMINO-ACIDS; NALOXONE; RAT; RESPONSES; HYPERTENSION; CONCUSSION	In this article, we review the present understanding of neurochemical changes associated with experimental mild head injury. The majority of these data are derived from recent laboratory studies primarily conducted in rodents. They indicate that excessive release of excitatory neurotransmitters, including acetylcholine (ACh) and excitatory amino acids (EAA), can importantly contribute to acute pathobiologic cascades that ultimately produce enduring neurologic deficits even at relatively low levels of traumatic brain injury (TBI). An ultimate loss of calcium homeostasis may be an important mediator of this acute excitotoxic cascade. Some studies have indicated that early changes in endogenous opiates may also mediate pathologic responses to mild head injury. Important findings from our own and other laboratories suggest that certain endogenous opiates can reduce neurologic deficits following mild TBI. Other data suggest that low levels of TBI may produce diffuse reductions in cerebral metabolic activity. The ultimate significance of these generalized depressions in energy metabolism is not completely understood. Mild TBI can also produce significant disruptions of the blood-brain barrier (BBB), which may have important consequences for acute responses to trauma. For example, excitatory neurotransmitters normally excluded from the brain can gain entry, thereby exacerbating acute, harmful, excitotoxic effects.	UNIV TEXAS,HLTH SCI CTR,HLTH SCI CTR,DEPT NEUROL,HOUSTON,TX 77225							BASKIN DS, 1982, LIFE SCI, V31, P2201, DOI 10.1016/0024-3205(82)90118-7; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT D S, 1988, Society for Neuroscience Abstracts, V14, P621; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; EISENBERG HM, 1989, MILD MODERATE HEAD I, P95; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLISON MD, 1986, J CEREBR BLOOD F MET, V6, P471, DOI 10.1038/jcbfm.1986.81; FADEN A I, 1983, Current Concepts of Cerebrovascular Disease and Stroke, V18, P27; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, STROKE, V14, P169, DOI 10.1161/01.STR.14.2.169; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRAHAM DI, 1989, MILD MODERATE HEAD I, P63; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAYES R, 1987, IEEE T SOFTWARE ENG, V13, P1254, DOI 10.1109/TSE.1987.232879; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1991, J NEUROTRAUM, V9, P173; HAYES RL, 1990, UNPUB NMDA RECEPTOR; HAYES RL, 1988, J NEUROTRAUM, V5, P287; Hayes RL, 1989, MILD HEAD INJURY, P54; Holaday JW, 1984, CENTRAL PERIPHERAL E, P237; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; JANE JA, 1989, MILD MODERATE HEAD I, P3; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENKINS LW, 1989, MICHIGAN S SERIES TR, V1, P47; JIANG JY, 1991, P SATELLITE S BRAIN, V91, P89; JOHANSSON B, 1970, ACTA NEUROPATHOL, V16, P117, DOI 10.1007/BF00687666; JULIAN FJ, 1962, J GEN PHYSIOL, V46, P297, DOI 10.1085/jgp.46.2.297; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1984, BRAIN RES, V296, P241, DOI 10.1016/0006-8993(84)90062-3; KAWAMATA T, 1990, Society for Neuroscience Abstracts, V16, P778; KAWAMATA T, 1990, 8TH P ANN M SOC NEUR; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1989, SOC NEUR ABS, V15, P113; LYETH BG, IN PRESS NEUROTRAUMA; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; NAGY Z, 1979, J COMP NEUROL, V185, P579, DOI 10.1002/cne.901850308; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RAPPORT SI, 1976, EXP NEUROL, V52, P467; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SMITH D H, 1990, Society for Neuroscience Abstracts, V16, P779; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; THOMPSON SM, 1985, J NEUROSCI, V5, P817; TORTELLA FC, 1987, INACTIVATION HYPERSE, P3; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZIMMERMAN R S, 1989, Society for Neuroscience Abstracts, V15, P131	75	43	43	0	2	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0271-8235			SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					25	31		10.1055/s-2008-1041055			7	Clinical Neurology	Neurosciences & Neurology	NE151	WOS:A1994NE15100006	7913245				2021-06-18	
J	PARK, CK; CHOI, KH; KIM, MC; KANG, JK; CHOI, CR				PARK, CK; CHOI, KH; KIM, MC; KANG, JK; CHOI, CR			SPONTANEOUS EVOLUTION OF POSTTRAUMATIC SUBDURAL HYGROMA INTO CHRONIC SUBDURAL-HEMATOMA	ACTA NEUROCHIRURGICA			English	Article						POSTTRAUMATIC SUBDURAL HYGROMA; CHRONIC SUBDURAL HEMATOMA; PATHOGENESIS; EVOLUTION	COMPUTERIZED TOMOGRAPHY; HEMATOMAS	Thirteen of 145 patients with Post-traumatic subdural hygroma (SDHy) developed chronic subdural haematoma (CSDH) at the involved site over a period of 6 years. CSDHs were found at the site of SDHys with no history of further head injury at a mean interval of 56 days. It appeared that these 13 patients did not have any distinguishing clinical features early on. Old age and brain atrophy on CT scans do not seem to be reasonable causative factors in the evolution of SDHy into CSDH. Initial enlargement of subdural accumulations at an early stage of SDHy and a subsequent increase in density at a later stage may point to the development of CSDH from SDHy in some instances. Ten of these 13 CSDH cases underwent surgical drainage, and the remaining 3 cases received no specific management. All resolved completely. The prognosis was good in all patients. The possible mechanism for the evolution of SDHy into CSDH is discussed.	CATHOLIC UNIV,COLL MED,DEPT NEUROSURG,SEOUL,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT RADIOL,SEOUL,SOUTH KOREA							DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; ECKLIN FA, 1956, JAMA-J AM MED ASSOC, V161, P1345; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; FRENCH BN, 1978, SURG NEUROL, V9, P145; FRENCH BN, 1977, SURG NEUROL, V7, P171; GUTIERREZ FA, 1974, AM J DIS CHILD, V128, P327, DOI 10.1001/archpedi.1974.02110280057007; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; ITO H, 1976, J NEUROSURG, V45, P26, DOI 10.3171/jns.1976.45.1.0026; ITO H, 1978, J NEUROSURG, V48, P197, DOI 10.3171/jns.1978.48.2.0197; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; MCLAURIN RL, 1961, J NEUROSURG, V18, P61, DOI 10.3171/jns.1961.18.1.0061; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; NAGANUMA H, 1986, NEUROSURGERY, V19, P794, DOI 10.1227/00006123-198611000-00013; NAKAMURA H, 1981, NEUROL MED CHIR, V21, P491; OKA H, 1972, ACTA NEUROCHIR, V26, P265, DOI 10.1007/BF01407072; Payr E, 1916, MED KLIN, V12, P841; ROSENBLUTH PR, 1962, JAMA-J AM MED ASSOC, V179, P759, DOI 10.1001/jama.1962.03050100013003; SCHNEIDER RC, 1969, CORRELATIVE NEUROSUR, P533; SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; TAGUCHI Y, 1982, Neurologia Medico-Chirurgica, V22, P276, DOI 10.2176/nmc.22.276; TAKAHASHI Y, 1982, NEUROSURGERY, V10, P281; THOMAS LM, 1973, NEUROLOGICAL SURGERY, V2, P960; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; WINESTOCK DP, 1975, RADIOLOGY, V115, P373, DOI 10.1148/115.2.373; YAMADA H, 1980, SURG NEUROL, V13, P441	29	43	49	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1994	127	1-2					41	47		10.1007/BF01808545			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NC941	WOS:A1994NC94100009	7942180				2021-06-18	
J	INGERSOLL, CD; ARMSTRONG, CW				INGERSOLL, CD; ARMSTRONG, CW			THE EFFECTS OF CLOSED-HEAD INJURY ON POSTURAL SWAY	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD INJURY; HEAD INJURY OUTCOME; POSTURE; POSTURAL SWAY; SENSORY INTEGRATION	COMPUTED-TOMOGRAPHY; FOOTBALL; BALANCE	The purpose of this study was to determine the effects of closed-head injury upon postural sway. Forty-eight subjects (26 males and 22 females) between the ages of 18 and 45 were equally divided into four groups corresponding to their level of head injury. Group 1 had not incurred a head injury, group 2 members incurred head injuries but did not lose consciousness, group 3 lost consciousness for less than 6 h, and group 4 lost consciousness for greater than 6 h. All subjects were at least 1 yr postinjury. Each subject performed three trials of six variations of the Romberg test. The center of pressure transmitted through the bottom of the feet was monitored during each 30-s trial. Total, anterior-posterior (AP), and medial-lateral (ML) sway was calculated from center of pressure data. The severely head-injured group generally evidenced greater AP sway than the other three experimental groups for all but one test condition. It was concluded that closed-head injury, particularly when associated with relatively long periods of unconsciousness, results in postural instability.	UNIV TOLEDO, DEPT HLTH PROMOT & HUMAN PERFORMANCE, APPL BIOMECH LAB, TOLEDO, OH 43606 USA	INGERSOLL, CD (corresponding author), INDIANA STATE UNIV, DEPT PHYS EDUC, SPORTS INJURY RES LAB, TERRE HAUTE, IN 47809 USA.		Ingersoll, Christopher/H-6474-2015	Ingersoll, Christopher/0000-0001-9157-6846			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ARCAN M, 1977, SCAND J REHABIL MED, V9, P165; BOHANNON RW, 1984, PHYS THER, V64, P1067, DOI 10.1093/ptj/64.7.1067; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; DICHGANS J, 1976, AGRESSOLOGIE, V17, P15; FREDRICKSON JM, 1966, EXP BRAIN RES, V2, P318; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; HAYES KC, 1983, SOC NEUR ABSTR, V13, P2115; Henriksson NG, 1967, ACTA OTO-LARYNGOL, V63, P272, DOI [10.3109/00016486709123592, DOI 10.3109/00016486709123592]; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; KELLY CR, 1981, ARCH PHYS MED REHAB, V62, P324; MITCHELL DE, 1973, LANCET, V2, P215; Mueller Frederick O, 1982, Phys Sportsmed, V10, P135, DOI 10.1080/00913847.1982.11947346; NASHNER LM, 1983, EXP BRAIN RES, V49, P393; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NJIOKIKTJIEN C, 1972, AGRESSOLOGIE, V13, P1; NJIOKIKTJIEN CJ, 1976, AGRESSOLOGIE, V17, P19; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; ROY S, 1983, SPORTS MED PREVENTIO, P141; SAHLSTRAND T, 1978, ACTA ORTHOP SCAND, V49, P354, DOI 10.3109/17453677809050088; SCHNEIDER RC, 1969, MED SCI SPORTS, V1, P115; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; SILFVERSKIOLD BP, 1969, ACTA NEUROL SCAND, V45, P292; STARR A, 1981, BRAIN, V104, P149, DOI 10.1093/brain/104.1.149; STRICH SJ, 1961, LANCET, V2, P443; TORG JC, 1982, ATHLETIC INJURIES HE, P15; VANPARYS JAP, 1976, AGRESSOLOGIE, V17, P95; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; 1986, SPSSX USERS GUIDE	35	43	43	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUL	1992	24	7					739	743					5	Sport Sciences	Sport Sciences	JC413	WOS:A1992JC41300001	1501556				2021-06-18	
J	SAAL, JA				SAAL, JA			COMMON AMERICAN FOOTBALL INJURIES	SPORTS MEDICINE			English	Article								As many as 1.5 million young men participate in American football in the United States. An estimated 1.2 million football-related injuries are sustained annually. Since the 1970s epidemiological studies have shown that the risk of injury is higher in older athletes and lower in teams with more experienced coaches and more assistant coaches. 51% of injuries occurred at training; contact sessions were 4.7 times more likely to produce injuries than controlled sessions. Injury rates were reduced by wearing shorter cleats and preseason conditioning. Overall, lower extremity injuries accounted for 50% of all injuries (with knee injuries accounting for up to 36%). Upper extremity injuries accounted for 30%. In general, sprains and strains account for 40% of injuries, contusions 25%, fractures 10%, concussions 5% and dislocations 15%. Cervical spine injuries have the potential to be catastrophic, but they declined dramatically in the decade 1975 to 1984, due to the impact of rule changes modifying tackling and blocking techniques and improved fitness, equipment and coaching. Appropriate diagnostic evaluation of cervical injuries is mandatory. The evidence supporting prophylactic knee bracing is not compelling and does not mandate compulsory or routine use. Return to play criteria include: full range of motion; normal strength; normal neurological evaluation; no joint swelling or instability; ability to run and sustain contact without pain; no intake of pain medication; player education about preventive measures and future risks. These criteria should be strictly observed. In addition to ankle and knee rehabilitation, lumbar spine injuries present a challenge for the physician. Repetitive flexion, extension and torsional stresses predispose the lumbar spine to injury. Rehabilitation consists of pain control and training. The training phase aims to eliminate repetitive injuries by minimising stress at the intervertebral joint. Football is a high risk sport. Coaches, players, trainers and physicians must all become aware of the proper means to prevent injuries.		SAAL, JA (corresponding author), SETON MED CTR,SAN FRANCISCO SPINE INST,1850 SULLIVAN AVE,SUITE 140,DALY CITY,CA 94015, USA.							0	43	43	1	18	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	AUG	1991	12	2					132	147		10.2165/00007256-199112020-00005			16	Sport Sciences	Sport Sciences	FZ359	WOS:A1991FZ35900005	1947533				2021-06-18	
J	DAVIDOFF, G; MORRIS, J; ROTH, E; BLEIBERG, J				DAVIDOFF, G; MORRIS, J; ROTH, E; BLEIBERG, J			CLOSED HEAD-INJURY IN SPINAL-CORD INJURED PATIENTS - RETROSPECTIVE STUDY OF LOSS OF CONSCIOUSNESS AND POST-TRAUMATIC AMNESIA	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT PHYS MED & REHABIL,CHICAGO,IL 60611							BLEIBERG J, 1983, ARCH PHYS MED REHAB, V64, P448; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DUBO H, 1983, P AM SPINAL INJURY A, P35; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GUTTMANN L, 1963, SPINAL INJURIES, P81; Harris P, 1968, Paraplegia, V5, P215; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Meinecke F W, 1968, Paraplegia, V5, P196; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHUENEMAN A, 1982, SCI DIG, V4, P35; Schueneman AL, 1982, SCI DIG, V4, P64; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; STRANG I, 1978, INJURY, V10, P154; WAGNER KA, 1983, P AM SPINAL INJURY A, P96; WILMOTT CB, 1983, P AM SPINAL INJURY A, P105; YOUNG JS, 1982, SPINAL CORD INJURY S, P34; 1980, 9 NW U MCG MED CTR M	27	43	44	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.		1985	66	1					41	43					3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AAF50	WOS:A1985AAF5000012	3966867				2021-06-18	
J	YASHON, D; JOHNSON, AB; JANE, JA				YASHON, D; JOHNSON, AB; JANE, JA			BILATERAL INTERNAL CAROTID ARTERY OCCLUSION SECONDARY TO CLOSED HEAD INJURIES	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																AMELI NO, 1949, LANCET, V257, P1078; Andrell PO, 1943, ACTA MED SCAND, V114, P336; Andreyev LA, 1935, ARCH NEURO PSYCHIATR, V34, P481, DOI 10.1001/archneurpsyc.1935.02250210002001; Blackwood W., 1963, GREENFIELDS NEUROPAT; BOYD RJ, 1962, ARCH SURG-CHICAGO, V84, P434, DOI 10.1001/archsurg.1962.01300220058009; BRASS K, 1957, Frankf Z Pathol, V68, P254; BULL JWD, 1962, BRIT J RADIOL, V35, P801, DOI 10.1259/0007-1285-35-420-801; CALDWELL HW, 1948, ANN INTERN MED, V28, P1132, DOI 10.7326/0003-4819-28-6-1132; Cooper A, 1836, GUYS HOSP REP, V1, P457; DONALD DE, 1961, NEUROLOGY, V11, P836, DOI 10.1212/WNL.11.9.836; DONIGER DE, 1963, NEUROLOGY, V13, P673, DOI 10.1212/WNL.13.8.673; ECKER AD, 1945, J NEUROSURG, V2, P479, DOI 10.3171/jns.1945.2.6.0479; ELVIDGE AR, 1951, AMA ARCH NEUROL PSY, V66, P752, DOI 10.1001/archneurpsyc.1951.02320120085011; FIELDS WS, 1961, ARCH NEUROL-CHICAGO, V4, P369, DOI 10.1001/archneur.1961.00450100017004; FOTOPULOS D, 1962, Zentralbl Neurochir, V22, P216; FROVIG AG, 1946, ACTA PSYCHIAT KBH  S, V39; Gardner MD, 1935, P SOC EXP BIOL MED, V32, P1034; GOSS CM, 1954, ANATOMY HUMAN BODY, P637; GRAY H, 1954, ANATOMY HUMAN BODY, P637; GRECO T, 1935, ARCH ITAL CHIR, V39, P757; GROCH SN, 1960, ARCH NEUROL-CHICAGO, V2, P130, DOI 10.1001/archneur.1960.03840080016003; GURDJIAN ES, 1958, HEAD INJURIES MECHAN; HIGAZI I, 1963, J NEUROSURG, V20, P354, DOI 10.3171/jns.1963.20.4.0354; HOCKADAY TDR, 1959, J NEUROL NEUROSUR PS, V22, P229, DOI 10.1136/jnnp.22.3.229; HOUCK WS, 1964, ANN SURG, V159, P219, DOI 10.1097/00000658-196402000-00006; HUMPHREY JG, 1960, BRAIN, V83, P565, DOI 10.1093/brain/83.4.565; JOHNSON HC, 1951, J NEUROSURG, V8, P631, DOI 10.3171/jns.1951.8.6.0631; KECHT B, 1937, ARCH OHR NAS KEHLKHE, V143, P3; LINZELL JL, 1957, J PHYSIOL-LONDON, V138, pP20; LOHR W, 1936, ZENTRALBLATT CHIR, V63, P2593; MURPHEY F, 1959, J NEUROSURG, V16, P24, DOI 10.3171/jns.1959.16.1.0024; MURRAY DS, 1957, BRIT J SURG, V44, P556, DOI 10.1002/bjs.18004418803; Northcroft GB, 1944, BRIT J SURG, V32, P105, DOI 10.1002/bjs.18003212518; SCHNEIDER RC, 1952, J NEUROSURG, V9, P495, DOI 10.3171/jns.1952.9.5.0495; SEDZIMIR CB, 1955, J NEUROL NEUROSUR PS, V18, P293, DOI 10.1136/jnnp.18.4.293; SILVERSTEIN A, 1963, NEUROLOGY, V13, P679, DOI 10.1212/WNL.13.8.679; SMITH MC, 1963, J NEUROSURG, V20, P46, DOI 10.3171/jns.1963.20.1.0046; VERBIEST H, 1959, Folia Psychiatr Neurol Neurochir Neerl, V62, P371; VERNEUIL, 1872, B ACAD MED PARIS, V1, P46	39	43	43	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1964	27	6					547	+		10.1136/jnnp.27.6.547			1	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	60255	WOS:A19646025500011	14249397	Bronze, Green Published			2021-06-18	
J	Jefferson, G				Jefferson, G			The nature of concussion	BRITISH MEDICAL JOURNAL			English	Article																BRESLAUER J, 1914, ARCH KLIN CHIR, V103, P478; BROWN DD, 1941, BRAIN, V64, P93; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; FISCHER H, 1870, SAMM KLIN VORTR, P119; Fulton JF, 1929, J NERV MENT DIS, V69, P1, DOI 10.1097/00005053-192901000-00001; Globus JH, 1940, ARCH NEURO PSYCHIATR, V43, P125, DOI 10.1001/archneurpsyc.1940.02280010133010; Greenfield J G, 1938, Proc R Soc Med, V32, P43; HARRISON J, 1940, HYPOTHALAMUS, V20, P635; Jefferson G, 1938, ARCH NEURO PSYCHIATR, V40, P857, DOI 10.1001/archneurpsyc.1938.02270110011001; Jefferson Geoffrey, 1942, Glasgow Med J, V138, P77; Kleitman N., 1939, SLEEP WAKEFULNESS; KNAUER A, 1922, J PSYCHOL NEUROL, V29, P1; KOCHER T, 1901, HIRNERCHUTTERUNG; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; PENFIELD W, 1941, EPILEPSY CEREBRAL LO, P143; RANSON S. W., 1939, ERGEBN PHYSIOL, V41, P56, DOI 10.1007/BF02084790; SYMONDS CP, 1940, INJURIES SKULL BRAIN; TROTTER W, 1932, CHOYCES SYSTEM SURG, V3, P363; von EC0N0M0 C., 1930, JOUR NERV & MENT DIS, V71, P249; VONECONOMO C, 1926, HDB NORMALEN PATHOLO, V17, P591; WHITE JC, 1940, HYPOTHALAMUS, V20, P855; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; WITKOWSKI L, 1877, VIRCHOWS ARCH, V69, P498	23	43	43	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN-JUN	1944	1944		1				1	5					5	Medicine, General & Internal	General & Internal Medicine	V07XP	WOS:000200534500001	20785201				2021-06-18	
J	Xie, BS; Wang, YQ; Lin, Y; Mao, Q; Feng, JF; Gao, GY; Jiang, JY				Xie, Bao-Shu; Wang, Yi-Qin; Lin, Yong; Mao, Qing; Feng, Jun-Feng; Gao, Guo-Yi; Jiang, Ji-Yao			Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						ferroptosis; iron accumulation; lipid ROS accumulation; traumatic brain injury (TBI)	HIPPOCAMPAL CELL-DEATH; NECROPTOSIS; HYPOTHERMIA; APOPTOSIS; STRESS	Aims Ferroptosis, a new form of iron-dependent programmed cell death, has been shown to be involved in a range of diseases. However, the role of ferroptosis in traumatic brain injury (TBI) has yet to be elucidated. We aimed to investigate whether ferroptosis is induced after TBI and whether the inhibition of ferroptosis would protect against traumatic brain injury in a controlled cortical impact injury (CCI) mouse model. Methods After establishing the TBI model in mice, we determined the biochemical and morphological changes associated with ferroptosis, including iron accumulation with Perl's staining, neuronal cell death with Fluoro-Jade B (FJB) staining, iron metabolism dysfunction with Western blotting, reactive oxygen species (ROS) accumulation with malondialdehyde (MDA) assays, and shrunken mitochondria with transmission electron microscopy. Furthermore, a specific inhibitor of ferroptosis, ferrostatin-1(fer-1), was administrated by cerebral ventricular injection after CCI. We used cresyl violet (CV) staining to assess lesion volume, along with the Morris water maze and beam walk test to evaluate long-term outcomes. Results TBI was followed by iron accumulation, dysfunctional iron metabolism, the upregulation of ferroptosis-related genes, reduced glutathione peroxidase (GPx) activity, and the accumulation of lipid-reactive oxygen species (ROS). Three days (d) after TBI, transmission electron microscopy (TEM) confirmed that the mitochondria had shrunk a typical characteristic of ferroptosis. Importantly, the administration of Fer-1 by cerebral ventricular injection significantly reduced iron deposition and neuronal degeneration while attenuating injury lesions and improving long-term motor and cognitive function. Conclusion This study demonstrated an effective method with which to treat TBI by targeting ferroptosis.	[Xie, Bao-Shu; Lin, Yong; Mao, Qing; Feng, Jun-Feng; Gao, Guo-Yi; Jiang, Ji-Yao] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Xie, Bao-Shu; Lin, Yong; Feng, Jun-Feng; Gao, Guo-Yi; Jiang, Ji-Yao] Shanghai Inst Head Trauma, Shanghai, Peoples R China; [Wang, Yi-Qin] Shanghai Jiao Tong Univ, Sch Med, Sino French Res Ctr Life Sci & Genom, State Key Lab Med Genom,Rui Jin Hosp, Shanghai, Peoples R China	Gao, GY; Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai, Peoples R China.	gao3@sina.com; jiyaojiang@126.com			Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine [BXJ201824]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772058, 81471856, 81471244, 81771317]	Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine, Grant/Award Number: BXJ201824; National Natural Science Foundation of China, Grant/Award Number: No.81772058, 81471856 and 81471244 and 81771317	Abou-Abbass H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005342; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Al Nimer F, 2011, BRAIN BEHAV IMMUN, V25, P981, DOI 10.1016/j.bbi.2010.10.017; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Do Van B, 2016, NEUROBIOL DIS, V94, P169, DOI 10.1016/j.nbd.2016.05.011; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Guiney SJ, 2017, NEUROCHEM INT, V104, P34, DOI 10.1016/j.neuint.2017.01.004; Hattori K, 2017, EMBO REP, V18, P2067, DOI 10.15252/embr.201744228; Imai H, 2017, CURR TOP MICROBIOL, V403, P143, DOI 10.1007/82_2016_508; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jin YC, 2015, J NEUROTRAUM, V32, P1090, DOI 10.1089/neu.2014.3649; Lachaier E, 2014, ANTICANCER RES, V34, P6417; Lee S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0544-4; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Lin Y, 2015, BIOMATERIALS, V69, P148, DOI 10.1016/j.biomaterials.2015.08.010; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Lu L., 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/470676; Ma S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.208; Maiorino M, 2018, ANTIOXID REDOX SIGN, V29, P61, DOI 10.1089/ars.2017.7115; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; Martin-Sanchez D, 2017, J AM SOC NEPHROL, V28, P218, DOI 10.1681/ASN.2015121376; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Muller T, 2017, CELL MOL LIFE SCI, V74, P3631, DOI 10.1007/s00018-017-2547-4; Potts Mathew B, 2006, NeuroRx, V3, P143; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sheng XH, 2017, PHYS CHEM CHEM PHYS, V19, P13153, DOI 10.1039/c7cp00804j; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Speer RE, 2013, FREE RADICAL BIO MED, V62, P26, DOI 10.1016/j.freeradbiomed.2013.01.026; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tuo QZ, 2017, MOL PSYCHIATR, V22, P1520, DOI 10.1038/mp.2017.171; Wang CF, 2016, SCI REP-UK, V6, DOI 10.1038/srep37063; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zhu S, 2017, CANCER RES, V77, P2064, DOI 10.1158/0008-5472.CAN-16-1979; Zille M, 2017, STROKE, V48, P1033, DOI 10.1161/STROKEAHA.116.015609	43	42	45	6	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	APR	2019	25	4					465	475		10.1111/cns.13069			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HP7WS	WOS:000461901900006	30264934	DOAJ Gold, Green Published			2021-06-18	
J	Tao, L; Li, D; Liu, HX; Jiang, F; Xu, YT; Cao, Y; Gao, R; Chen, G				Tao, Li; Li, Di; Liu, Huixiang; Jiang, Feng; Xu, Yitian; Cao, Ying; Gao, Rong; Chen, Gang			Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-kappa B and MAPK signaling pathway	BRAIN RESEARCH BULLETIN			English	Article						Metformin; Traumatic brain injury; Inflammation; Microglia activation	OXIDATIVE STRESS; SUBARACHNOID HEMORRHAGE; POSSIBLE INVOLVEMENT; CEREBRAL-ISCHEMIA; ACTIVATION; MICROGLIA; RESPONSES; MODULATION; DISEASE; OXYGEN	Traumatic brain injury (TBI) triggers a complex sequence of inflammatory responses that contribute to secondary injury. Metformin, a first-line drug used to treat type 2 diabetes, is reported to exhibit potent anti-inflammatory activity on diseases associated with the central nervous system (CNS). The aim of this study is to investigate the potential neuroprotective effects of metformin on acute brain injury after TBI and explore the underlying mechanisms. Male Sprague-Dawley (SD) rats were divided into four groups: sham group, TBI group, TBI + saline (NS) group and TBI + metformin group. A weight-dropping model was employed to induce TBI in rats. Modified neurological severity scores (mNSS) were employed to assess the short-term neurological deficits, neuronal degeneration and apoptosis in the brain tissues were assayed with Fluoro-Jade B and TUNEL staining, immunofluorescence was designed to investigate microglial activation. The mRNA and protein expression levels of pro-inflammatory cytokines such as necrosis factor-alpha (TNF-alpha), interleukin-beta (IL-1 beta) and nterleukin-6 (IL-6) were evaluated by real-time quantitative reverse transcriptase polymerase chain reaction (QPCR) and enzyme-linked immunosorbent assay (ELISA). Western blotting analysis was engaged to examine the expression of NF-kappa B p65 and phosphorylation of ERK1/2 and p38 MAPK. Our results showed that metformin significantly ameliorated neurological deficit, cerebral edema and neuronal apoptosis in rats following TBI. Moreover, metformin administration inhibited microglial activation and decreased the production of pro-inflammatory cytokines including TNF-alpha, IL-beta and IL-6. In addition, metformin inhibited the translocation of NF-kappa B p65 from cytoplasm into the nucleus, as well as the phosphorylation of ERK1/2 and p38 MAPK. This study suggests that metformin administration inhibits microglia activation-mediated inflammation via NF-kappa B and MAPK signaling pathway to improve neurobehavioral function following TBI, which provide a potential therapeutic benefit in treating brain injury.	[Tao, Li; Cao, Ying] Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Pharm, Suzhou, Peoples R China; [Tao, Li; Li, Di] Soochow Univ, Peoples Hosp Zhangjiagang 1, Translat Med Ctr, Suzhou, Peoples R China; [Li, Di; Liu, Huixiang; Jiang, Feng; Gao, Rong] Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Neurosurg, Suzhou, Peoples R China; [Xu, Yitian] Nanjing Med Univ, Sch Basic Med Sci, Nanjing 211166, Jiangsu, Peoples R China; [Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China	Cao, Y (corresponding author), Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Pharm, Suzhou, Peoples R China.; Gao, R (corresponding author), Soochow Univ, Peoples Hosp Zhangjiagang 1, Dept Neurosurg, Suzhou, Peoples R China.	caoyaoshi@126.com; lidi715@163.com	Xu, Yitian/AAH-9794-2019				Abd-Elsameea AA, 2014, EUR REV MED PHARMACO, V18, P2387; Asghari A, 2016, J PEDIATR UROL, V12, DOI 10.1016/j.jpurol.2016.06.017; Asghari A, 2016, ACTA CIR BRAS, V31, P411, DOI 10.1590/S0102-865020160060000008; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cahova M, 2015, AM J PHYSIOL-GASTR L, V309, pG100, DOI 10.1152/ajpgi.00329.2014; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Dang BQ, 2015, CRIT CARE MED, V43, pE369, DOI 10.1097/CCM.0000000000001146; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Furuyashiki T, 2012, J PHARMACOL SCI, V120, P63, DOI 10.1254/jphs.12R09CP; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Harada S, 2010, BRAIN RES, V1351, P254, DOI 10.1016/j.brainres.2010.06.052; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jiang T, 2014, BRIT J PHARMACOL, V171, P3146, DOI 10.1111/bph.12655; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nath N, 2009, J IMMUNOL, V182, P8005, DOI 10.4049/jimmunol.0803563; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Qi BX, 2017, NEUROCHEM RES, V42, P2912, DOI 10.1007/s11064-017-2322-9; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Schulte Joann M, 2014, N Engl J Med, V370, pe2, DOI 10.1056/NEJMclde1314028; Selvin E, 2008, ATHEROSCLEROSIS, V201, P425, DOI 10.1016/j.atherosclerosis.2008.02.002; Soraya H, 2012, PHARMACOL REP, V64, P1476, DOI 10.1016/S1734-1140(12)70945-3; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun XB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-157; Tao L, 2014, J PHARMACOL SCI, V125, P364, DOI 10.1254/jphs.14025FP; Wang Z, 2015, PROCEEDINGS OF THE 2014 INTERNATIONAL CONFERENCE ON MATERIALS SCIENCE AND ENERGY ENGINEERING (CMSEE 2014), P53; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu XC, 2015, MOL NEUROBIOL, V52, P375, DOI 10.1007/s12035-014-8866-7	41	42	44	1	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JUN	2018	140						154	161		10.1016/j.brainresbull.2018.04.008			8	Neurosciences	Neurosciences & Neurology	GO0ZR	WOS:000439675700020	29698747				2021-06-18	
J	Dong, WW; Yang, B; Wang, LL; Li, BX; Guo, XS; Zhang, M; Jiang, ZF; Fu, JQ; Pi, JB; Guan, DW; Zhao, R				Dong, Wenwen; Yang, Bei; Wang, Linlin; Li, Bingxuan; Guo, Xiangshen; Zhang, Miao; Jiang, Zhenfei; Fu, Jingqi; Pi, Jingbo; Guan, Dawei; Zhao, Rui			Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Traumatic brain injury (TBI); Curcumin; NF-E2-related factor (Nrf2); Antioxidant response; Inflammation; Apoptosis	TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; PROVIDES NEUROPROTECTION; ANTIOXIDANT RESPONSE; COUNTERACTS; MODULATION; EXPRESSION; INDUCTION; GENES; EDEMA	Traumatic brain injury (TBI), which leads to high mortality and morbidity, is a prominent public health problem worldwide with no effective treatment. Curcumin has been shown to be beneficial for neuroprotection in vivo and in vitro, but the underlying mechanism remains unclear. This study determined whether the neuroprotective role of curcumin in mouse TBI is dependent on the NF-E2-related factor (Nrf2) pathway. The Feeney weight-drop contusion model was used to mimic TBI. Curcumin was administered intraperitoneally 15 min after TBI induction, and brains were collected at 24 h after TBI. The levels of Nrf2 and its downstream genes (Hmox-1, Nqo1, Gclm, and Gclc) were detected by Western blot and qRT-PCR at 24 h after TBI. In addition, edema, oxidative damage, cell apoptosis and inflammatory reactions were evaluated in wild type (W7) and Nrf2-knockout (Nrf2-KO) mice to explore the role of Nrf2 signaling after curcumin treatment. In wild type mice, curcumin treatment resulted in reduced ipsilateral cortex injury, neutrophil infiltration, and microglia activation, improving neuron survival against TBI-induced apoptosis and degeneration. These effects were accompanied by increased expression and nuclear translocation of Nrf2, and enhanced expression of antioxidant enzymes. However, Nrf2 deletion attenuated the neuroprotective effects of curcumin in Nrf2-KO mice after TBI. These findings demonstrated that curcumin effects on TBI are associated with the activation the Nrf2 pathway, providing novel insights into the neuroprotective role of Nrf2 and the potential therapeutic use of curcumin for TBI.	[Dong, Wenwen; Wang, Linlin; Li, Bingxuan; Guo, Xiangshen; Zhang, Miao; Jiang, Zhenfei; Guan, Dawei; Zhao, Rui] China Med Univ, Sch Forens Med, Dept Forens Pathol, Shenyang 110122, Liaoning, Peoples R China; [Yang, Bei] China Med Univ, Coll Basic Med Sci, Dept Histol & Embryol, Shenyang 110122, Liaoning, Peoples R China; [Fu, Jingqi; Pi, Jingbo] China Med Univ, Sch Publ Hlth, Program Environm Toxicol, Shenyang 110122, Liaoning, Peoples R China	Guan, DW; Zhao, R (corresponding author), China Med Univ, Sch Forens Med, Dept Forens Pathol, Shenyang 110122, Liaoning, Peoples R China.	dwguan@cmu.edu.cn; rzhao@cmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81372943, 81772023, 81671862, 81602825]; Liaoning Provincial Department of Education Science Research Project [LJQ2015119]; Liaoning Natural science Foundation of China [201602882]; Science and Technology Research Program from Education Department of Liaoning Province, China [LK201658]	This work was partly supported by grants from the National Natural Science Foundation of China (81372943, 81772023, 81671862 and 81602825), the Liaoning Provincial Department of Education Science Research Project for outstanding young investigator (LJQ2015119), the Liaoning Natural science Foundation of China (201602882) and the Science and Technology Research Program from Education Department of Liaoning Province, China (LK201658).	Agarwal NB, 2011, PHYTOMEDICINE, V18, P756, DOI 10.1016/j.phymed.2010.11.007; Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cui XL, 2017, EXP THER MED, V14, P1512, DOI 10.3892/etm.2017.4683; Ding H, 2017, NEUROCHEM INT, V111, P32, DOI 10.1016/j.neuint.2017.04.016; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dressler Jan, 2009, Leg Med (Tokyo), V11 Suppl 1, pS54, DOI 10.1016/j.legalmed.2009.02.024; Gold R, 2012, CLIN IMMUNOL, V142, P44, DOI 10.1016/j.clim.2011.02.017; Gonzalez-Reyes S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/801418; Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Kaidery NA, 2013, ANTIOXID REDOX SIGN, V18, P139, DOI 10.1089/ars.2011.4491; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Lu XY, 2015, CELL MOL NEUROBIOL, V35, P713, DOI 10.1007/s10571-015-0167-9; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Nair S, 2008, BRIT J CANCER, V99, P2070, DOI 10.1038/sj.bjc.6604703; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Sakata H, 2012, J NEUROSCI, V32, P3462, DOI 10.1523/JNEUROSCI.5686-11.2012; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450; Shu LF, 2016, NEUROSCI LETT, V611, P74, DOI 10.1016/j.neulet.2015.11.012; Tu ZS, 2017, EUR J MED CHEM, V134, P72, DOI 10.1016/j.ejmech.2017.04.008; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao R, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/412576; Zhao R, 2011, ENVIRON HEALTH PERSP, V119, P56, DOI 10.1289/ehp.1002304; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	52	42	45	1	30	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	MAY 1	2018	346						28	36		10.1016/j.taap.2018.03.020			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	GC9XR	WOS:000430152600004	29571711				2021-06-18	
J	Bree, D; Levy, D				Bree, Dara; Levy, Dan			Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache	CEPHALALGIA			English	Article						Cephalic allodynia; conditioned place preference; sumatriptan; Anti-CGRP monoclonal antibody	TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; DURAL AFFERENTS; UP-REGULATION; SUMATRIPTAN; EFFICACY; SAFETY; PATHOPHYSIOLOGY	Background and objective Posttraumatic headache (PTH) is one of the most common, debilitating and difficult symptoms to manage after a mild traumatic brain injury, or concussion. However, the mechanisms underlying PTH remain elusive, in part due to the lack of a clinically relevant animal model. Here, we characterized for the first time, headache and pain-related behaviours in a rat model of concussion evoked by a mild closed head injury (mCHI) - the major type of military and civilian related trauma associated with PTH - and tested responses to current and novel headache therapies. Methods Concussion was induced in adult male rats using a weight-drop device. Characterization of headache and pain related behaviours included assessment of cutaneous tactile pain sensitivity, using von Frey monofilaments, and ongoing pain using the conditioned place preference or aversion (CPP/CPA) paradigms. Sensitivity to headache/migraine triggers was tested by exposing rats to low-dose glyceryl trinitrate (GTN). Treatments included acute systemic administration of sumatriptan and chronic systemic administration of a mouse anti-CGRP monoclonal antibody. Results Concussed rats developed cephalic tactile pain hypersensitivity that was resolved by two weeks post-injury and was ameliorated by treatment with sumatriptan or anti-CGRP monoclonal antibody. Sumatriptan also produced CPP seven days post mCHI, but not in sham animals. Following the resolution of the concussion-evoked cephalic hypersensitivity, administration of GTN produced a renewed and pronounced cephalic pain hypersensitivity that was inhibited by sumatriptan or anti-CGRP antibody treatment as well as a CGRP-dependent CPA. GTN had no effect in sham animals. Conclusions Concussion leads to the development of headache and pain-related behaviours, in particular sustained enhanced responses to GTN, that are mediated through a CGRP-dependent mechanism. Treatment with anti-CGRP antibodies may be a useful approach to treat PTH.	[Bree, Dara; Levy, Dan] Beth Israel Deaconess Med Ctr, Dept Anesthesia, Boston, MA 02215 USA; [Bree, Dara; Levy, Dan] Beth Israel Deaconess Med Ctr, Dept Crit Care, Boston, MA 02215 USA; [Bree, Dara; Levy, Dan] Beth Israel Deaconess Med Ctr, Dept Pain Med, Boston, MA 02215 USA; [Bree, Dara; Levy, Dan] Harvard Med Sch, Boston, MA USA	Levy, D (corresponding author), Dept Anesthesia Crit Care & Pain Med, 330 Brookline Ave DA 717, Boston, MA 02215 USA.	dlevy1@bidmc.harvard.edu	Levy, Dan/AAF-1871-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086830, R01NS078263, R21NS077882] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS078263, R01 NS086830, R21 NS077882] Funding Source: Medline		Abend NS, 2008, J CHILD NEUROL, V23, P438, DOI 10.1177/0883073807309772; Ashina M, 2000, BRAIN, V123, P1830, DOI 10.1093/brain/123.9.1830; Ashina M, 2004, CEPHALALGIA, V24, P967, DOI 10.1111/j.1468-2982.2004.00780.x; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Benromano T, 2015, EUR J PAIN, V19, P621, DOI 10.1002/ejp.583; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bigal ME, 2015, LANCET NEUROL, V14, P1081, DOI 10.1016/S1474-4422(15)00249-5; Bigal ME, 2015, LANCET NEUROL, V14, P1091, DOI 10.1016/S1474-4422(15)00245-8; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bree D, 2015, J PAIN, V16, P421, DOI 10.1016/j.jpain.2015.01.010; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Burstein R, 2004, ANN NEUROL, V55, P19, DOI 10.1002/ana.10786; Burstein R, 2004, ANN NEUROL, V55, P27, DOI 10.1002/ana.10785; Burstein R, 2001, PAIN, V89, P107, DOI 10.1016/S0304-3959(00)00478-4; DeFelice M, 2013, ANN NEUROL, V74, P257, DOI 10.1002/ana.23922; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Edelmayer RM, 2012, PAIN, V153, P1949, DOI 10.1016/j.pain.2012.06.012; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Ferrari LF, 2016, NEUROSCIENCE, V317, P121, DOI 10.1016/j.neuroscience.2016.01.005; Griggs RB, 2015, NEUROREPORT, V26, P522, DOI 10.1097/WNR.0000000000000382; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; IVERSEN HK, 1989, PAIN, V38, P17, DOI 10.1016/0304-3959(89)90067-5; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010; King MV, 2004, NEUROPHARMACOLOGY, V47, P195, DOI 10.1016/j.neuropharm.2004.03.012; Kopruszinski CM, 2017, CEPHALALGIA, V37, P560, DOI 10.1177/0333102416650702; Levy D, 2016, CEPHALALGIA, V36, P915, DOI 10.1177/0333102415617412; Levy D, 2012, BRAIN BEHAV IMMUN, V26, P311, DOI 10.1016/j.bbi.2011.09.016; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Macolino CM, 2014, J NEUROSCI METH, V226, P139, DOI 10.1016/j.jneumeth.2014.01.008; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mitsikostas DD, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0522-1; Moriarty O, 2016, BEHAV BRAIN RES, V303, P61, DOI 10.1016/j.bbr.2016.01.027; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Navratilova E, 2012, P NATL ACAD SCI USA, V109, P20709, DOI 10.1073/pnas.1214605109; OLESEN J, 1993, NEUROREPORT, V4, P1027, DOI 10.1097/00001756-199308000-00008; Oshinsky ML, 2007, HEADACHE, V47, P1026, DOI 10.1111/j.1526-4610.2007.00871.x; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Perry CJ, 2016, ANN NEUROL, V79, P1000, DOI 10.1002/ana.24665; Pietrobon D, 2013, ANNU REV PHYSIOL, V75, P365, DOI 10.1146/annurev-physiol-030212-183717; Pradhan AA, 2014, PAIN, V155, P269, DOI 10.1016/j.pain.2013.10.004; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Russo AF, 2015, ANNU REV PHARMACOL, V55, P533, DOI 10.1146/annurev-pharmtox-010814-124701; Sun H, 2016, LANCET NEUROL, V15, P382, DOI 10.1016/S1474-4422(16)00019-3; Tfelt-Hansen P, 1998, HEADACHE, V38, P748, DOI 10.1046/j.1526-4610.1998.3810748.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Vargas BB, 2012, CURR OPIN NEUROL, V25, P284, DOI 10.1097/WCO.0b013e3283535bf5; Visser WH, 1996, HEADACHE, V36, P471, DOI 10.1046/j.1526-4610.1996.3608471.x; VOS BP, 1994, J NEUROSCI, V14, P2708; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Winner P, 2003, MAYO CLIN PROC, V78, P1214, DOI 10.4065/78.10.1214; Yan J, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-6; Zhao J, 2014, PAIN, V155, P1392, DOI 10.1016/j.pain.2014.04.019	58	42	42	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	FEB	2018	38	2					246	258		10.1177/0333102416681571			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FW2QY	WOS:000425150600004	27899434	Green Accepted			2021-06-18	
J	Lilja, G; Nielsen, N; Bro-Jeppesen, J; Dunford, H; Friberg, H; Hofgren, C; Horn, J; Insorsi, A; Kjaergaard, J; Nilsson, F; Pelosi, P; Winters, T; Wise, MP; Cronberg, T				Lilja, Gisela; Nielsen, Niklas; Bro-Jeppesen, John; Dunford, Hannah; Friberg, Hans; Hofgren, Caisa; Horn, Janneke; Insorsi, Angelo; Kjaergaard, Jesper; Nilsson, Fredrik; Pelosi, Paolo; Winters, Tineke; Wise, Matt P.; Cronberg, Tobias			Return to Work and Participation in Society After Out-of-Hospital Cardiac Arrest	CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES			English	Article						cognitive dysfunction; depression; fatigue; sick leave; temperature; heart arrest	PORTLAND ADAPTABILITY INVENTORY; TARGET TEMPERATURE MANAGEMENT; TRAUMATIC BRAIN-INJURY; FOCUSED FOLLOW-UP; COGNITIVE FUNCTION; INTERNATIONAL-CLASSIFICATION; LIFE; SURVIVORS; FATIGUE; HEALTH	BACKGROUND: The aim of this study was to describe out-of-hospital cardiac arrest (OHCA) survivors' ability to participate in activities of everyday life and society, including return to work. The specific aim was to evaluate potential effects of cognitive impairment. METHODS AND RESULTS: Two hundred eighty-seven OHCA survivors included in the TTM trial (Target Temperature Management) and 119 matched control patients with ST-segment-elevation myocardial infarction participated in a follow-up 180 days post-event that included assessments of participation, return to work, emotional problems, and cognitive impairment. On the Mayo-Portland Adaptability Inventory-4 Participation Index, OHCA survivors (n=270) reported more restricted participation In everyday life and in society (47% versus 30%; P<0.001) compared with ST-segment-elevation myocardial infarction controls (n=118). Furthermore, 27% (n=36) of pre-event working OHCA survivors (n=135) compared with 7% (n=3) of pre-event working ST-segment-elevation myocardial infarction controls (n=45) were on sick leave (odds ratio, 4.9; 95% confidence interval, 1.4-16.8; P=0.01). Among the OHCA survivors assumed to return to work (n=135), those with cognitive impairment (n=55) were 3x more likely (odds ratio, 3.3; 95% confidence interval, 1.2-9.3; P=0.02) to be on sick leave compared with those without cognitive impairment (n=40; 36%, n=20, versus 15%, n=6). For OHCA survivors, the variables that were found most predictive for a lower participation were depression, restricted mobility, memory impairment, novel problem-solving difficulties, fatigue, and slower processing speed. CONCLUSIONS: OHCA survivors reported a more restricted societal participation 6 months post-arrest, and their return to work was lower compared with ST-segment-elevation myocardial infarction controls. Cognitive impairment was significantly associated with lower participation, together with the closely related symptoms of fatigue, depression, and restricted mobility. These predictive variables may be used during follow-up to identify OHCA survivors at risk of a less successful recovery that may benefit from further support and rehabilitation.	[Lilja, Gisela; Cronberg, Tobias] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden; [Nielsen, Niklas; Friberg, Hans] Lund Univ, Dept Clin Sci Anesthesiol & Intens Care Med, Skane Univ Hosp, Lund, Sweden; [Bro-Jeppesen, John; Kjaergaard, Jesper] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Heart Ctr, Copenhagen, Denmark; [Dunford, Hannah; Wise, Matt P.] Univ Hosp Wales, Adult Crit Care, Cardiff, S Glam, Wales; [Hofgren, Caisa] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Sect Hlth & Rehabil, Gothenburg, Sweden; [Horn, Janneke; Winters, Tineke] Acad Med Ctr, Intens Care, Amsterdam, Netherlands; [Insorsi, Angelo] IRCCS AOU San Martino IST, Anesthesia & Intens Care, Genoa, Italy; [Nilsson, Fredrik] Res & Dev Ctr Skane, Med Stat & Epidemiol, Lund, Sweden; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy	Lilja, G (corresponding author), Lund Univ, Skane Univ Hosp, Ctr Cardiac Arrest, Barngatan 2B 4th Floor, S-22185 Lund, Sweden.	gisela.lilja@med.lu.se	Nilsson, Fredrik/N-2771-2017	Nilsson, Fredrik/0000-0002-7526-6327; Pelosi, Paolo/0000-0001-5055-3023; Kjaergaard, Jesper/0000-0001-5244-0399	European Union Interreg IVA programme; Swedish Heart and Lung AssociationSwedish Heart-Lung Foundation; Skane University Hospital Foundations; Gyllenstierna-Krapperup Foundation; Academy of Caring Sciences at Skane University Hospital; Swedish National Health System (ALF); County Council of Skane; Swedish Society of Medicine; Koch Foundation; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; AFA Insurance Foundation; Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for medical research; Segerfalk Foundation; Tryg Foundation	This work was supported by The European Union Interreg IVA programme, The Swedish Heart and Lung Association, the Skane University Hospital Foundations, the Gyllenstierna-Krapperup Foundation, Academy of Caring Sciences at Skane University Hospital, the Swedish National Health System (ALF), the County Council of Skane, the Swedish Society of Medicine, the Koch Foundation, the Swedish Heart-Lung Foundation, AFA Insurance Foundation, the Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for medical research, the Segerfalk Foundation and the Tryg Foundation. The study sponsors have no involvement in the study design; in the collection, analysis, and interpretation of the data; in the writing of the manuscript, or in the decision to submit the manuscript for publication.	Alexander MP, 2011, J INT NEUROPSYCH SOC, V17, P364, DOI 10.1017/S1355617710001633; Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; Beesems SG, 2014, RESUSCITATION, V85, P1269, DOI 10.1016/j.resuscitation.2014.05.027; Boyce-van der Wal LW, 2015, RESUSCITATION, V93, P63, DOI 10.1016/j.resuscitation.2015.05.029; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Elliott VJ, 2011, RESUSCITATION, V82, P247, DOI 10.1016/j.resuscitation.2010.10.030; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kamphuis HCM, 2002, EUROPACE, V4, P417, DOI 10.1053/eupc.2002.0258; KELSEY SF, 1986, AM J EMERG MED, V4, P72; Kragholm K, 2015, CIRCULATION, V131, P1682, DOI 10.1161/CIRCULATIONAHA.114.011366; Ladwig KH, 1999, AM J PSYCHIAT, V156, P912, DOI 10.1176/ajp.156.6.912; Langa KM, 2014, JAMA-J AM MED ASSOC, V312, P2551, DOI 10.1001/jama.2014.13806; Larsson IM, 2014, RESUSCITATION, V85, P215, DOI 10.1016/j.resuscitation.2013.09.017; Lilja G, 2015, RESUSCITATION, V97, P68, DOI 10.1016/j.resuscitation.2015.09.389; Lilja G, 2015, CIRCULATION, V131, P1340, DOI 10.1161/CIRCULATIONAHA.114.014414; Lilja G, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-85; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Middelkamp W, 2007, CLIN REHABIL, V21, P425, DOI 10.1177/0269215507075307; Mollayeva T, 2014, NEUROSCI BIOBEHAV R, V47, P684, DOI 10.1016/j.neubiorev.2014.10.024; Moulaert VRM, 2016, RESUSCITATION, V106, P30, DOI 10.1016/j.resuscitation.2016.06.015; Moulaert VRM, 2015, INT J CARDIOL, V193, P8, DOI 10.1016/j.ijcard.2015.04.229; Moulaert VRMP, 2010, J REHABIL MED, V42, P553, DOI 10.2340/16501977-0547; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; O'Neil A, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-95; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; SAUVE MJ, 1995, HEART LUNG, V24, P133, DOI 10.1016/S0147-9563(05)80008-1; Sinha SS, 2016, CIRC-CARDIOVASC QUAL, V9, P749, DOI 10.1161/CIRCOUTCOMES.116.002916; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith K, 2015, CIRCULATION, V131, P174, DOI 10.1161/CIRCULATIONAHA.114.011200; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; World Health Organization ( WHO ), 2002, COMM LANG FUNCT DIS	39	42	42	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1941-7705	1941-7713		CIRC-CARDIOVASC QUAL	Circ.-Cardiovasc. Qual. Outcomes	JAN	2018	11	1							e003566	10.1161/CIRCOUTCOMES.117.003566			11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	FS9WB	WOS:000422768600003	29326145	Bronze			2021-06-18	
J	Sharma, A; Liaw, K; Sharma, R; Zhang, Z; Kannan, S; Kannan, RM				Sharma, Anjali; Liaw, Kevin; Sharma, Rishi; Zhang, Zhi; Kannan, Sujatha; Kannan, Rangaramanujam M.			Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics	THERANOSTICS			English	Article						Hydroxyl PAMAM dendrimer; mitochondria; activated microglia; sub-cellular targeting; oxidative stress; N-acetyl cysteine	TRAUMATIC BRAIN-INJURY; DRUG; SURFACE; NANOPARTICLES; ANTIOXIDANTS; MODEL; TRIPHENYLPHOSPHONIUM; NEUROPROTECTION; NANOCARRIERS; CONJUGATION	Mitochondrial oxidative stress is associated with many neurodegenerative diseases, such as traumatic brain injury (TBI). Targeted delivery of antioxidants to mitochondria has failed to translate into clinical success due to their nonspecific cellular localization, poor transport properties across multiple biological barriers, and associated side effects. These challenges, coupled with the complex function of the mitochondria, create the need for innovative delivery strategies. Methods: Neutral hydroxyl-terminated polyamidoamine (PAMAM) dendrimers have shown significant potential as nanocarriers in multiple brain injury models. N-acetyl cysteine (NAC) is a clinically used antioxidant and anti-inflammatory agent which has shown significant potency when delivered in a targeted manner. Here we present a mitochondrial targeting hydroxyl PAMAM dendrimer-drug construct (TPP-D-NAC) with triphenyl-phosphonium (TPP) for mitochondrial targeting and NAC for targeted delivery to mitochondria in injured glia. Co-localization and mitochondrial content of mitochondria-targeted and unmodified dendrimer were assessed in microglia and macrophages in vitro via immunohistochemistry and fluorescence quantification. Therapeutic improvements of TPP-D-NAC over dendrimer-NAC conjugate (D-NAC) and free NAC were evaluated in vitro in microglia under oxidative stress challenge. In vivo neuroinflammation targeting was confirmed in a rabbit model of TBI. Results: TPP-conjugated dendrimer co-localized significantly more with mitochondria than unmodified dendrimer without altering overall levels of cellular internalization. This targeting capability translated to significant improvements in the attenuation of oxidative stress by TPP-D-NAC compared to D-NAC and free NAC. Upon systemic administration in a rabbit TBI model, TPP-conjugated dendrimer co-localized specifically with mitochondria in activated microglia and macrophages in the white matter of the ipsilateral/injured hemisphere, confirming its BBB penetration and glial targeting capabilities. Conclusion: D-NAC has shown promising efficacy in many animal models of neurodegeneration, and this work provides evidence that modification for mitochondrial targeting can further enhance its therapeutic efficacy, particularly in diseases where oxidative stress-induced glial cell death plays a significant role in disease progression.	[Sharma, Anjali; Liaw, Kevin; Sharma, Rishi; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Ctr Nanomed, Dept Ophthalmol, Wilmer Eye Inst,Sch Med, Baltimore, MD 21231 USA; [Liaw, Kevin; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Zhang, Zhi; Kannan, Sujatha] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21287 USA; [Kannan, Sujatha; Kannan, Rangaramanujam M.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Baltimore, MD 21205 USA; [Kannan, Sujatha; Kannan, Rangaramanujam M.] Johns Hopkins Univ Cerebral Palsy Res Excellence, Kennedy Krieger Inst, Baltimore, MD 21218 USA	Kannan, RM (corresponding author), Wilmer Eye Inst, Ctr Nanomed, Ophthalmol, 400 North Broadway, Baltimore, MD 21231 USA.	krangar1@jhmi.edu		Zhang, Zhi/0000-0001-6256-9516; Sharma, Rishi/0000-0002-7069-7099; Sharma, Anjali/0000-0003-0748-3001	NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB01 8306]; Wilmer Core Grant for Vision Research, Microscopy and Imaging Core Module [EY001865]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB018306] Funding Source: NIH RePORTER	This study was funded by the NIBIB R01EB01 8306 (RM Kannan). We thank the Wilmer Core Grant for Vision Research, Microscopy and Imaging Core Module (Grant #EY001865) for access to the Zen LSM710 confocal microscope.	Battin EE, 2009, CELL BIOCHEM BIOPHYS, V55, P1, DOI 10.1007/s12013-009-9054-7; Bielski ER, 2015, MOL PHARMACEUT, V12, P3043, DOI 10.1021/acs.molpharmaceut.5b00320; Biswas S, 2012, BIOMATERIALS, V33, P4773, DOI 10.1016/j.biomaterials.2012.03.032; Chtistophe M, 2006, CURR PHARM DESIGN, V12, P739; Dai H, 2010, NANOMEDICINE-UK, V5, P1317, DOI [10.2217/nnm.10.89, 10.2217/NNM.10.89]; DIPIETRO V, 2017, SCI REP UK, V0007; Dobrovolskaia MA, 2017, CURR PHARM DESIGN, V23, P3134, DOI 10.2174/1381612823666170309151958; Dobrovolskaia MA, 2012, MOL PHARMACEUT, V9, P382, DOI 10.1021/mp200463e; Dupuis L, 2004, NEURODEGENER DIS, V1, P245, DOI 10.1159/000085063; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm JC, 2016, ANN THORAC SURG, V102, P743, DOI 10.1016/j.athoracsur.2016.02.077; Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009; He HJ, 2018, J AM CHEM SOC, V140, P1215, DOI 10.1021/jacs.7b11582; Heller A, 2012, EUR J PHARM BIOPHARM, V82, P1, DOI 10.1016/j.ejpb.2012.05.014; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hou RCW, 2005, ANN NY ACAD SCI, V1042, P279, DOI 10.1196/annals.1338.050; Hu QS, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0060-6; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kurtoglu YE, 2009, BIOMATERIALS, V30, P2112, DOI 10.1016/j.biomaterials.2008.12.054; Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045; Lesniak WG, 2013, MOL PHARM, V10; Li Y, 2017, RSC ADV, V7, P15475, DOI 10.1039/c7ra00713b; Liaw K, 2018, J NANOPART RES, V20, DOI 10.1007/s11051-018-4219-1; Lieven CJ, 2003, ANTIOXID REDOX SIGN, V5, P641, DOI 10.1089/152308603770310310; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu XS, 2013, LANGMUIR, V29, P9138, DOI 10.1021/la401556k; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mao PZ, 2010, BBA-MOL BASIS DIS, V1802, P66, DOI 10.1016/j.bbadis.2009.07.002; Marrache S, 2014, P NATL ACAD SCI USA, V111, P10444, DOI 10.1073/pnas.1405244111; Mignani S, 2017, PROG POLYM SCI, V64, P23, DOI 10.1016/j.progpolymsci.2016.09.006; Mignani S, 2013, ADV DRUG DELIVER REV, V65, P1316, DOI 10.1016/j.addr.2013.01.001; Mishra MK, 2014, ACS NANO, V8, P2134, DOI 10.1021/nn404872e; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Nance E, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1004-5; Nance E, 2016, BIOMATERIALS, V101, P96, DOI 10.1016/j.biomaterials.2016.05.044; Nance E, 2015, J CONTROL RELEASE, V214, P112, DOI 10.1016/j.jconrel.2015.07.009; Nemeth CL, 2017, NANOMED-NANOTECHNOL, V13, P2359, DOI 10.1016/j.nano.2017.06.014; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Saovapakhiran A, 2009, BIOCONJUGATE CHEM, V20, P693, DOI 10.1021/bc8002343; Sharma A, 2018, J CONTROL RELEASE, V283, P175, DOI 10.1016/j.jconrel.2018.06.003; Sharma A, 2014, ACS MACRO LETT, V3, P1079, DOI 10.1021/mz5006298; Sharma A, 2014, RSC ADV, V4, P19242, DOI 10.1039/c4ra02713b; Sharma A, 2012, BIOMACROMOLECULES, V13, P239, DOI 10.1021/bm201538j; Sharma A, 2011, MACROMOLECULES, V44, P521, DOI 10.1021/ma102354k; Sharma A, 2011, BIOMATERIALS, V32, P1419, DOI 10.1016/j.biomaterials.2010.10.025; Sharma R, 2018, BIOENG TRANSL MED, V3, P87, DOI 10.1002/btm2.10094; Sharma R, 2017, BIOCONJUGATE CHEM, V28, P2874, DOI 10.1021/acs.bioconjchem.7b00569; Sharma R, 2016, NANOSCALE, V8, P5106, DOI 10.1039/c5nr06757j; Sharma R, 2015, POLYM CHEM-UK, V6, P1436, DOI 10.1039/c4py01761g; Sharma R, 2014, CHEM COMMUN, V50, P13300, DOI 10.1039/c4cc06191h; Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007; Shi J, 2013, ACS NANO, V7, P10612, DOI 10.1021/nn403069n; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sliwka L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155772; Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010; Sorrentino V, 2018, ANNU REV PHARMACOL, V58, P353, DOI 10.1146/annurev-pharmtox-010716-104908; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thiagarajan G, 2013, EUR J PHARM BIOPHARM, V84, P330, DOI 10.1016/j.ejpb.2013.01.019; Vekaria HJ, 2017, NEUROCHEM INT, V109, P117, DOI 10.1016/j.neuint.2017.04.004; Wang CX, 2009, ANNU REV GENET, V43, P95, DOI 10.1146/annurev-genet-102108-134850; Yang G, 2018, NANO LETT; Yue YK, 2014, J OCUL PHARMACOL TH, V30, P657, DOI 10.1089/jop.2014.0022; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zhang F, 2015, BIOMATERIALS, V52, P507, DOI 10.1016/j.biomaterials.2015.02.053; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701	71	42	43	2	11	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2018	8	20					5529	5547		10.7150/thno.29039			19	Medicine, Research & Experimental	Research & Experimental Medicine	HA2DJ	WOS:000450042300002	30555562	DOAJ Gold, Green Published			2021-06-18	
J	Sun, MJ; Brady, RD; Wright, DK; Kim, HA; Zhang, SR; Sobey, CG; Johnstone, MR; O'Brien, TJ; Semple, BD; McDonald, SJ; Shultz, SR				Sun, Mujun; Brady, Rhys D.; Wright, David K.; Kim, Hyun Ah; Zhang, Shenpeng R.; Sobey, Christopher G.; Johnstone, Maddison R.; O'Brien, Terence J.; Semple, Bridgette D.; McDonald, Stuart J.; Shultz, Sandy R.			Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Fracture; Multitrauma; IL-beta; Neuroinflammation; MRI	CLOSED-HEAD INJURY; ANIMAL-MODEL; OVEREXPRESSION; OUTCOMES; IMPACT; MILD; INFLAMMATION; POLARIZATION; LIPOCALIN-2; ACTIVATION	Traumatic brain injury (TBI) and long bone fracture are common in polytrauma. This injury combination in mice results in elevated levels of the pro-inflammatory cytokine interleukin-1p (IL-18) and exacerbated neuropathology when compared to isolated-TBI. Here we examined the effect of treatment with an IL-1 receptor antagonist (IL-1ra) in mice given a TBI and a concomitant tibial fracture (i.e., poly trauma). Adult male C57BL/6 mice were given sham-injuries or polytrauma and treated with saline vehicle or IL-lra (100 mg/1<g). Treatments were subcutaneously injected at 1,6, and 24 h, and then once daily for one week post-injury. 7-8 mice/group were euthanized at 48 h post-injury. 12-16 mice/group underwent behavioral testing at 12 weeks post-injury and MRI at 14 weeks post-injury before being euthanized at 16 weeks post-injury. At 48 h post-injury, markers for activated microglia and astrocytes, as well as neutrophils and edema, were decreased in polytrauma mice treated with IL-lra compared to polytrauma mice treated with vehicle. At 14 weeks post-injury, MRI analysis demonstrated that IL-1 ra treatment after polytrauma reduced volumetric loss in the injured cortex and mitigated track weighted MRI markers for axonal injury. As IL-1 ra (Anakinra) is approved for human use, it may represent a promising therapy in polytrauma cases involving TBI and fracture. Crown Copyright (C) 2017 Published by Elsevier Inc. All rights reserved.	[Sun, Mujun; Brady, Rhys D.; O'Brien, Terence J.; Semple, Bridgette D.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia; [Brady, Rhys D.; Kim, Hyun Ah; Zhang, Shenpeng R.; Sobey, Christopher G.; Johnstone, Maddison R.; McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3083, Australia; [Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Zhang, Shenpeng R.] Monash Univ, Dept Pharmacol, Melbourne, Vic 3800, Australia; [Wright, David K.; O'Brien, Terence J.; Semple, Bridgette D.; Shultz, Sandy R.] Monash Univ, Dept Neurosci, Melbourne, Vic 3004, Australia; [Wright, David K.; O'Brien, Terence J.; Semple, Bridgette D.; Shultz, Sandy R.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia	Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr, Off 1-02, Parkville, Vic 3052, Australia.	sshultz@unimelb.edu.au	Sobey, Christopher G/A-2786-2008	Sobey, Christopher G/0000-0001-6525-9097; Wright, David/0000-0002-7535-8651; McDonald, Stuart/0000-0001-5190-3179; O'Brien, Terence/0000-0002-7198-8621; Sun, Mujun/0000-0002-9923-9913	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1062653]; La Trobe University; NHMRCNational Health and Medical Research Council of Australia	This work was supported by grants to SRS from the National Health and Medical Research Council (grant number 1062653) and to SJM from La Trobe University (RFA Understanding Disease), as well as fellowships to SRS and BDS from NHMRC. We acknowledge the scientific and technical assistance of the animal MRI facility at the Florey Institute of Neuroscience and Mental Health, a node of the National Imaging Facility.	Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brady RD, 2016, SCI REP-UK, V6, DOI 10.1038/srep34491; Brady RD, 2014, J ORTHOP RES, V32, P1277, DOI 10.1002/jor.22686; Brait VH, 2011, BRAIN RES, V1372, P169, DOI 10.1016/j.brainres.2010.11.087; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Connelly, 2010, P ISMRM, P1670; Diamond ML, 2015, EPILEPSIA, V56, P991, DOI 10.1111/epi.13100; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Franklin KBJ, 2007, MOUSE BRAIN STEREOTA; Greenhalgh AD, 2010, BRIT J PHARMACOL, V160, P153, DOI 10.1111/j.1476-5381.2010.00684.x; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Jin M, 2014, J CEREBR BLOOD F MET, V34, P1306, DOI 10.1038/jcbfm.2014.83; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Leitgeb J, 2013, ARCH ORTHOP TRAUM SU, V133, P659, DOI 10.1007/s00402-013-1710-0; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Masada T, 2001, J NEUROSURG, V95, P680, DOI 10.3171/jns.2001.95.4.0680; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McDonald SJ, 2011, J ORTHOP RES, V29, P740, DOI 10.1002/jor.21302; Minter MR, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0341-4; Morganti J.M., 2016, PLOS ONE; Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; Pape H.-C., 2010, DAMAGR CONTROL MANAG; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wright D, 2017, J NEUROTRAUM, DOI DOI 10.1089/neu.2017.5204; Wright D.K., 2016, CEREB CORTEX; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2	56	42	42	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2017	66						359	371		10.1016/j.bbi.2017.08.005			13	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FL4YE	WOS:000414236600034	28782716				2021-06-18	
J	Bennett, TD; DeWitt, PE; Greene, TH; Srivastava, R; Riva-Cambrin, J; Nance, ML; Bratton, SL; Runyan, DK; Dean, JM; Keenan, HT				Bennett, Tellen D.; DeWitt, Peter E.; Greene, Tom H.; Srivastava, Rajendu; Riva-Cambrin, Jay; Nance, Michael L.; Bratton, Susan L.; Runyan, Desmond K.; Dean, J. Michael; Keenan, Heather T.			Functional Outcome After Intracranial Pressure Monitoring for Children With Severe Traumatic Brain Injury	JAMA PEDIATRICS			English	Article							PROPENSITY SCORE; TRIAL; BIAS; CARE	IMPORTANCE Intracranial pressure (ICP) monitoring is a mainstay of therapy for children with traumatic brain injury (TBI), but its overall association with patient outcome is unclear. OBJECTIVE To test the hypothesis that ICP monitoring is associated with improved functional survival of children with severe TBI. DESIGN, SETTING, AND PARTICIPANTS A propensity-weighted effectiveness analysis was conducted using 2 linked national databases with data from 30 US children's hospitals from January 1, 2007, to December 31, 2012, on 3084 children with severe TBI. Clinical events including neurosurgical procedures were identified using validated computable phenotypes. Data analysis was conducted from September 1, 2016, to March 1, 2017. EXPOSURE Placement of an ICP monitor. MAIN OUTCOMES AND MEASURES A composite of hospital mortality, discharge to hospice, or survival with placement of new tracheostomy and gastrostomy tubes. RESULTS Of the 3084 children in the study (1128 girls and 1956 boys; mean [SD] age, 7.03 [5.44] years), 1002 (32.4%) underwent ICP monitoring, with substantial hospital variation (6% to 50% by hospital). Overall, 484 children (15.7%) experienced the primary composite outcome. A propensity approach using matching weights generated good covariate balance between those who did and those who did not undergo ICP monitoring. Using a propensity-weighted logistic regression model clustered by hospital, no statistically significant difference was found in functional survival between monitored and unmonitored patients (odds ratio of poor outcome among those who underwent ICP monitoring, 1.31; 95% CI, 0.99-1.74). In a prespecified secondary analysis, no difference in mortality was found (odds ratio, 1.16; 95% CI, 0.89-1.50). Prespecified subgroup analyses of children younger and older than 2 years of age and among those with unintentional and inflicted (intentional) injuries also showed no difference in outcome with ICP monitoring. CONCLUSIONS AND RELEVANCE With the use of linked national data and validated computable phenotypes, no evidence was found of a benefit from ICP monitoring on functional survival of children with severe TBI. Intracranial pressure monitoring is a widely but inconsistently used technology with incompletely demonstrated effectiveness. A large prospective cohort study or randomized trial is needed.	[Bennett, Tellen D.] Univ Colorado, Sch Med, Pediat Crit Care, 13199 E Montview Blvd,Ste 300,Campus Mail F443, Aurora, CO 80045 USA; [Bennett, Tellen D.] Childrens Hosp Colorado, Aurora, CO USA; [Bennett, Tellen D.] Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO 80045 USA; [DeWitt, Peter E.] Colorado Sch Publ Hlth, Bioinformat & Biostat, Aurora, CO USA; [Greene, Tom H.] Univ Utah, Sch Med, Div Biostat, Salt Lake City, UT USA; [Srivastava, Rajendu] Univ Utah, Sch Med, Pediat Inpatient Med, Salt Lake City, UT USA; [Srivastava, Rajendu] Intermt Healthcare, Res Off, Salt Lake City, UT USA; [Riva-Cambrin, Jay] Univ Calgary, Dept Clin Neurosci, Div Pediat Neurosurg, Calgary, AB, Canada; [Riva-Cambrin, Jay] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Nance, Michael L.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat Surg, Philadelphia, PA 19104 USA; [Bratton, Susan L.; Dean, J. Michael; Keenan, Heather T.] Univ Utah, Sch Med, Pediat Crit Care, Salt Lake City, UT USA; [Runyan, Desmond K.] Univ Colorado, Sch Med, Kempe Ctr, Dept Pediat, Aurora, CO 80045 USA	Bennett, TD (corresponding author), Univ Colorado, Sch Med, Pediat Crit Care, 13199 E Montview Blvd,Ste 300,Campus Mail F443, Aurora, CO 80045 USA.	tell.bennett@ucdenver.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029; Bratton, Susan/0000-0002-4605-8078; Greene, Tom/0000-0002-3706-7570; Bennett, Tellen/0000-0003-1483-4236	Eunice Kennedy Shriver National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620]; Colorado Clinical and Translational Science Institute from the National Center for Research Resources [UL1 TR001082]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620] Funding Source: NIH RePORTER	This work was supported by grant K23HD074620 from the Eunice Kennedy Shriver National Institute for Child Health and Human Development (Dr Bennett) and Colorado Clinical and Translational Science Institute grant UL1 TR001082 from the National Center for Research Resources.	Alali AS, 2015, J NEUROSURG-PEDIATR, V16, P523, DOI 10.3171/2015.3.PEDS14507; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allaire JJ, RMARKDOWN DYNAMIC DO; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bennett KS, 2017, PEDIATR CRIT CARE ME, V18, P54, DOI 10.1097/PCC.0000000000000948; Bennett TD, 2015, METHOD INFORM MED, V54, P328, DOI 10.3414/ME14-01-0093; Bennett TD, 2017, PEDIATR CRIT CARE ME, V18, P442, DOI 10.1097/PCC.0000000000001120; Bennett TD, 2016, PEDIATR CRIT CARE ME, V17, P1147, DOI 10.1097/PCC.0000000000000934; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FLURY BK, 1986, AM STAT, V40, P249, DOI 10.2307/2684560; Frieden T., 2014, REPORT C TRAUMATIC B; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kozar RA, 2014, J TRAUMA ACUTE CARE, V76, P634, DOI 10.1097/TA.0000000000000130; Li L, 2013, INT J BIOSTAT, V9, P215, DOI 10.1515/ijb-2012-0030; Lumley T, SURVEY; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; R Core Team, 2017, R LANG ENV STAT COMP; Ridgeway G, TWANG TOOLKIT WEIGHT, P3; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Sturmer T, 2010, AM J EPIDEMIOL, V172, P843, DOI 10.1093/aje/kwq198; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Van Cleve W, 2014, NEUROSURGERY, V74, pE156; Van Cleve W, 2013, NEUROSURGERY, V73, P746, DOI 10.1227/NEU.0000000000000097; VanderWeele TJ., 2015, EXPLANATION CAUSAL I; Wickham H., GGPLOT2 CREATE ELEGA; Xie Y, knitr: A General-Purpose Package for Dynamic Report Generation in R; Zhou Z, 2005, AM J EPIDEMIOL, V162, P1016, DOI 10.1093/aje/kwi307	37	42	43	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	OCT	2017	171	10					965	971		10.1001/jamapediatrics.2017.2127			7	Pediatrics	Pediatrics	FI7PV	WOS:000412190300014	28846763	Green Published			2021-06-18	
J	Gowrishankar, S; Wu, YM; Ferguson, SM				Gowrishankar, Swetha; Wu, Yumei; Ferguson, Shawn M.			Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology	JOURNAL OF CELL BIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SUBCELLULAR-LOCALIZATION; DEGENERATING NEURONS; RETROGRADE TRANSPORT; DYSTROPHIC NEURITES; HEAD TRAUMA; JIP3; PATHWAY	Lysosomes robustly accumulate within axonal swellings at Alzheimer's disease (AD) amyloid plaques. However, the underlying mechanisms and disease relevance of such lysosome accumulations are not well understood. Motivated by these problems, we identified JNK-interacting protein 3 (JIP3) as an important regulator of axonal lysosome transport and maturation. JIP3 knockout mouse neuron primary cultures accumulate lysosomes within focal axonal swellings that resemble the dystrophic axons at amyloid plaques. These swellings contain high levels of amyloid precursor protein processing enzymes (BACE1 and presenilin 2) and are accompanied by elevated A beta peptide levels. The in vivo importance of the JIP3-dependent regulation of axonal lysosomes was revealed by the worsening of the amyloid plaque pathology arising from JIP3 haploinsufficiency in a mouse model of AD. These results establish the critical role of JIP3-dependent axonal lysosome transport in regulating amyloidogenic amyloid precursor protein processing and support a model wherein A beta production is amplified by plaque-induced axonal lysosome transport defects.	[Gowrishankar, Swetha; Wu, Yumei; Ferguson, Shawn M.] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; [Gowrishankar, Swetha; Wu, Yumei; Ferguson, Shawn M.] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06520 USA	Ferguson, SM (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.; Ferguson, SM (corresponding author), Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06520 USA.	shawn.ferguson@yale.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM105718, AG047270]; Ellison Medical FoundationLawrence Ellison Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS036251, DK45735]; Yale University Program in Cellular Neuroscience, Neurodegeneration, and Repair imaging facility; BrightFocusBrightFocus Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK045735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM105718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036251, R37NS036251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG047270] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institutes of Health (NIH; GM105718 and AG047270) to S.M. Ferguson; S.M. Ferguson was also supported by the Ellison Medical Foundation. S. Gowrishankar is a recipient of a BrightFocus postdoctoral fellowship. Support for S. Gowrishankar and Y. Wu was also provided by grants to Pietro De Camilli from the NIH (NS036251 and DK45735). Microscopy studies were supported by the Yale University Program in Cellular Neuroscience, Neurodegeneration, and Repair imaging facility.	Allison R, 2017, J CELL BIOL, V216, P1337, DOI 10.1083/jcb.201609033; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Area-Gomez E, 2009, AM J PATHOL, V175, P1810, DOI 10.2353/ajpath.2009.090219; Arimoto M, 2011, J NEUROSCI, V31, P2216, DOI 10.1523/JNEUROSCI.2653-10.2011; Brown HM, 2009, DEV NEUROBIOL, V69, P174, DOI 10.1002/dneu.20690; Cai QA, 2010, NEURON, V68, P73, DOI 10.1016/j.neuron.2010.09.022; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Cheng XT, 2015, J CELL BIOL, V209, P377, DOI 10.1083/jcb.201412046; Condello C, 2011, SCI REP-UK, V1, DOI 10.1038/srep00019; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Das U, 2016, NAT NEUROSCI, V19, P55, DOI 10.1038/nn.4188; Dikranian K, 2012, INT J CLIN EXP PATHO, V5, P482; Drerup CM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003303; Edwards SL, 2013, GENETICS, V194, P143, DOI 10.1534/genetics.112.147348; Ewers M, 2008, BRAIN, V131, P1252, DOI 10.1093/brain/awn034; Farias GG, 2017, P NATL ACAD SCI USA, V114, pE2955, DOI 10.1073/pnas.1616363114; Fiala JC, 2007, ACTA NEUROPATHOL, V114, P551, DOI 10.1007/s00401-007-0284-8; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gowrishankar S, 2015, P NATL ACAD SCI USA, V112, pE3699, DOI 10.1073/pnas.1510329112; HOLLENBECK PJ, 1993, J CELL BIOL, V121, P305, DOI 10.1083/jcb.121.2.305; Huang SH, 2011, J NEUROSCI, V31, P10602, DOI 10.1523/JNEUROSCI.0436-11.2011; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Johnson DE, 2016, J CELL BIOL, V212, P677, DOI 10.1083/jcb.201507112; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; Kandalepas PC, 2013, ACTA NEUROPATHOL, V126, P329, DOI 10.1007/s00401-013-1152-3; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Maday S, 2014, DEV CELL, V30, P71, DOI 10.1016/j.devcel.2014.06.001; Maday S, 2012, J CELL BIOL, V196, P407, DOI 10.1083/jcb.201106120; Matsui T, 2012, J BIOL CHEM, V287, P28619, DOI 10.1074/jbc.M112.370544; Montagnac G, 2009, CURR BIOL, V19, P184, DOI 10.1016/j.cub.2008.12.043; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287; Pu J, 2015, DEV CELL, V33, P176, DOI 10.1016/j.devcel.2015.02.011; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rowland AA, 2014, CELL, V159, P1027, DOI 10.1016/j.cell.2014.10.023; Sannerud R, 2016, CELL, V166, P193, DOI 10.1016/j.cell.2016.05.020; Sato T, 2015, CELL DEATH DIFFER, V22, P1260, DOI 10.1038/cdd.2014.207; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; SU JH, 1993, BRAIN RES, V625, P228, DOI 10.1016/0006-8993(93)91063-X; Sun FN, 2011, EMBO J, V30, P3416, DOI 10.1038/emboj.2011.229; Teich AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055647; TERRY RD, 1964, AM J PATHOL, V44, P269; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang YM, 2016, J EXP MED, V213, P667, DOI 10.1084/jem.20151948; Wu Y, 2014, GLOB J ADV PURE APPL, V3, P1; Ye X, 2017, J NEUROSCI, V37, P2639, DOI 10.1523/JNEUROSCI.2851-16.2017; Yoon SY, 2013, NEUROPATH APPL NEURO, V39, P800, DOI 10.1111/nan.12032; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Yuan P, 2016, NEURON, V90, P724, DOI 10.1016/j.neuron.2016.05.003; Zhao J, 2007, J NEUROSCI, V27, P3639, DOI 10.1523/JNEUROSCI.4396-06.2007	63	42	42	0	5	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0021-9525	1540-8140		J CELL BIOL	J. Cell Biol.	OCT	2017	216	10					3291	3305		10.1083/jcb.201612148			15	Cell Biology	Cell Biology	FI4RS	WOS:000411962700026	28784610	Green Published, Bronze			2021-06-18	
J	Zhong, JJ; Jiang, L; Huang, ZJ; Zhang, HR; Cheng, CJ; Liu, H; He, JC; Wu, JC; Darwazeh, R; Wu, Y; Sun, XC				Zhong, Jianjun; Jiang, Li; Huang, Zhijian; Zhang, Hongrong; Cheng, Chongjie; Liu, Han; He, Junchi; Wu, Jingchuan; Darwazeh, Rami; Wu, Yue; Sun, Xiaochuan			The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Bexarotene; RXR; IncRNA; Neat1; Pidd1; TBI	NF-KAPPA-B; P53-INDUCED PROTEIN; EXPRESSION; DISEASE; PIDD; RXR; IDENTIFICATION; ACTIVATION; PLASTICITY; RECEPTORS	Objective: Bexarotene treatments exert neuroprotective effects on mice following traumatic brain injury (TBI). The present study aims to investigate the potential roles of the long noncoding RNA Neat1 in the neuroprotective effects of bexarotene. Materials and methods: Adult male C57BL/8J mice (n = 80) and newborn mice (within 24 h after birth) (n = 20) were used to generate a "controlled cortical impact" (CCI) model and harvest primary cortex neurons, respectively. The HT22 cell line and the BV2 cell line were cultured under "normal" or "oxygen/glucose-deprived" (OGD) conditions. The relationship between RXR-alpha and the Neat1 promoter was clarified using ChIP-qPCR and dual-luciferase reporter gene assays. The mRNA alterations induced by Neat1 knockdown were measured using next-generation RNA sequencing. Proteins were captured by Neat1, pulled down and subjected to mass spectrometry. The neurological severity score, rotarod test and water maze test were employed to measure the animals' motor and cognitive functions. Results: Bexarotene prominently up-regulated the Neat1 level in an RXR-alpha-dependent manner. Neat1 knockdown induced significant changes in mRNA expression, and the altered mRNAs were involved in many biological processes, including synapse formation and axon guidance. In primary neurons, Neat1 knockdown inhibited and Neat1 over-expression prompted axon elongation. Multiple proteins, including Pidd1, were captured by Neat1. Neat1 inhibited cell apoptosis and restricted inflammation by capturing Pidd1. The in vitro anti-apoptotic and anti-inflammatory effects of Neat1 were further confirmed in C57BL/6 mice, which resulted in better motor and cognitive function after TBI. Conclusion: Bexarotene up-regulates the IncRNA Neat1, which inhibits apoptosis and inflammation, thereby resulting in better functional recovery in mice after TBI. (C) 2017 Elsevier Inc. All rights reserved.	[Zhong, Jianjun; Jiang, Li; Huang, Zhijian; Zhang, Hongrong; Cheng, Chongjie; Liu, Han; He, Junchi; Wu, Jingchuan; Darwazeh, Rami; Wu, Yue; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China	Jiang, L; Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	156313147@qq.com; sunxch1445@qq.com	Darwazeh, Rami/AAT-7891-2020; Wu, Jingchuan/AAV-7799-2020; He, Junchi/AAD-8482-2019	Darwazeh, Rami/0000-0003-3099-8257; Wu, Jingchuan/0000-0002-1213-4888; sun, xiao chuan/0000-0001-6992-332X; Huang, Zhijian/0000-0002-8241-0761	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159, 81371319]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81601072]; Chongqing Graduate Innovation Project [40010200100417]	This work was supported by grants from the National Natural Science Foundation of China (grant nos. 81571159 and 81371319), National Natural Science Foundation for Youth of China (No. 81601072) and the Chongqing Graduate Innovation Project (grant no. 40010200100417). We express special gratitude to the "Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology" for providing the experimental platform.	Bali KK, 2014, TRENDS MOL MED, V20, P437, DOI 10.1016/j.molmed.2014.05.006; Barry G, 2014, MOL PSYCHIATR, V19, P410, DOI 10.1038/mp.2013.196; Barry G, 2017, SCI REP-UK, V7, DOI 10.1038/srep40127; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Bhat SA, 2016, MOL NEUROBIOL, V53, P6950, DOI 10.1007/s12035-015-9584-5; Bock FJ, 2012, ONCOGENE, V31, P4733, DOI 10.1038/onc.2011.639; Briggs JA, 2015, NEURON, V88, P861, DOI 10.1016/j.neuron.2015.09.045; Campos-Pires R, 2015, CRIT CARE MED, V43, P149, DOI 10.1097/CCM.0000000000000624; Choudhry H, 2015, ONCOGENE, V34, P4546, DOI 10.1038/onc.2014.431; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Das D, 2013, WORLD J GASTROENTERO, V19, P7374, DOI 10.3748/wjg.v19.i42.7374; Donofrio G, 2006, MICROBES INFECT, V8, P898, DOI 10.1016/j.micinf.2005.10.016; Dubovicky Michal, 2014, Interdiscip Toxicol, V7, P201, DOI 10.2478/intox-2014-0029; Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Guo J, 2016, MOL NEUROBIOL, V53, P3154, DOI 10.1007/s12035-015-9222-2; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Hung YH, 2016, MOL NEUROBIOL, V53, P793, DOI 10.1007/s12035-014-9046-5; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jalali S, 2015, BIOINFORMATICS, V31, P2241, DOI 10.1093/bioinformatics/btv148; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Joshi S, 2011, MOL CELL BIOL, V31, P3653, DOI 10.1128/MCB.05020-11; Kerin T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003479; Kim IR, 2009, APOPTOSIS, V14, P1039, DOI 10.1007/s10495-009-0375-1; Kour S, 2017, MOL NEUROBIOL, V54, P639, DOI 10.1007/s12035-015-9634-z; Kraus TFJ, 2017, MOL NEUROBIOL, V54, P2869, DOI 10.1007/s12035-016-9854-x; le Maire A, 2009, EMBO REP, V10, P367, DOI 10.1038/embor.2009.8; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Maden M, 2007, NAT REV NEUROSCI, V8, P755, DOI 10.1038/nrn2212; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Marin-Bejar O, 2015, METHODS MOL BIOL, V1206, P87, DOI 10.1007/978-1-4939-1369-5_8; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Modarresi F, 2012, NAT BIOTECHNOL, V30, P453, DOI 10.1038/nbt.2158; Mounier A, 2015, J NEUROSCI, V35, P11862, DOI 10.1523/JNEUROSCI.1001-15.2015; Nakagawa S, 2011, J CELL BIOL, V193, P31, DOI 10.1083/jcb.201011110; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Pajeau AK, 2001, CRIT CARE MED, V29, P675, DOI 10.1097/00003246-200103000-00043; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Ramos AD, 2013, CELL STEM CELL, V12, P616, DOI 10.1016/j.stem.2013.03.003; Salvi A, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5059043; Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200; Teng YC, 2013, MOL NEUROBIOL, V48, P281, DOI 10.1007/s12035-013-8492-9; Teng ZP, 2016, STROKE, V47, P196, DOI 10.1161/STROKEAHA.115.011701; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Zhang FF, 2016, J AUTOIMMUN, V75, P96, DOI 10.1016/j.jaut.2016.07.012; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhao XL, 2013, NAT NEUROSCI, V16, P1024, DOI 10.1038/nn.3438; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002	53	42	45	0	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2017	65						183	194		10.1016/j.bbi.2017.05.001			12	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FC6YD	WOS:000406986700018	28483659				2021-06-18	
